{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"]},"docs":[{"location":"","title":"About","text":"<p>Website for browsing reviews of GO-CAMs. </p> <p>This contains an initial pass of reviews of GO-CAMs with &gt;2 causal edges, performed by the aurelian agentic framework using claude 3.7.</p> <p>THIS IS A DEMO FIRST PASS AND NEEDS FURTHER TUNING</p> <ul> <li>Open the \"Reviews\" tab on the left to see all reviews</li> <li>The guidelines are provided for reference</li> <li>simple search in top right</li> </ul>"},{"location":"#examples","title":"Examples","text":"<ul> <li> <p>5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_</p> </li> <li> <p>5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#strengths-of-the-model</p> </li> <li> <p>VPE -- missing edge?</p> </li> <li> <p>6205c24300001663-IL2_signaling_pathway__Human_</p> </li> <li> <p>61e0e55600000407-SP_GADD34__PPP1CA</p> </li> <li> <p>0ad85f700000612-TRIM47_activity_on_ILF3</p> </li> <li> <p>60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_</p> </li> <li> <p>627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_</p> </li> </ul>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/","title":"DNA binding transcription factor activity annotation guidelines","text":"<p>Guidelines for DNA-binding transcription factor annotation in eukaryotes</p>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#_1","title":"DNA binding transcription factor activity annotation guidelines","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#pathway-editor","title":"Pathway Editor","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#dna-binding-transcription-factor-activity-single-transcription-target","title":"DNA-binding transcription factor activity - Single transcription target","text":"<p>The activity unit for a eukaryotic DNA-binding transcription factor is:</p> <ul> <li>MF: 'enables'a child of DNA binding transcription factor activity, RNA polymerase, II-specific (GO:0000981):</li> <li>DNA-binding transcription activator activity, RNA polymerase, II-specific (GO:0001228)</li> <li>DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227)</li> <li>Context:</li> <li>The relation between the DNA-binding transcription factor activity and the gene it regulates is 'has input'</li> <li>BP: 'part of' regulation of the BP in which the target participates (if known).</li> <li>CC: 'occurs in' nucleus (GO:0005634)</li> <li>The causal relation between the transcription factor activity and the activity of its target gene is: \u2018indirectly positively regulates\u2019 or 'indirectly negatively regulates\u2019, since there are many steps between the activation of transcription and the activity of the target protein, including the production of a messenger RNA that is translated into a protein, i. e the regulator does not directly interact with the protein it regulates.</li> </ul> <p>Example single target: FOXO3 regulation of G6PC1</p>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#_2","title":"DNA binding transcription factor activity annotation guidelines","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#_3","title":"DNA binding transcription factor activity annotation guidelines","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#_4","title":"DNA binding transcription factor activity annotation guidelines","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#dna-binding-transcription-factor-activity-multiple-transcription-targets","title":"DNA-binding transcription factor activity - Multiple transcription targets","text":"<p>In cases where transcription factor regulates multiple target genes, a separate activity unit is captured for each transcriptional target.</p> <p>Example multiple targets: FOXO3 regulation of G6PC1 and Pck1</p> <p></p>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#_5","title":"DNA binding transcription factor activity annotation guidelines","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#nuclear-receptors-and-ligand-activated-transcription-factors","title":"Nuclear receptors and ligand-activated transcription factors","text":"<ul> <li>Nuclear receptors are positively regulated by a ligand, usually a small molecule (ChEBI).</li> <li>The activity unit for a nuclear receptor is:</li> <li>MF: nuclear receptor activity (GO:0004879) (a child of transcription factor activity)</li> <li>Context: the causal relation between the small molecule and the nuclear receptor is \u2018is small activator of\u2019.</li> <li>Other data are captured the same way as for other transcription factors.</li> </ul> <p>Example: Model for nuclear receptor annotation</p> <p></p>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#_6","title":"DNA binding transcription factor activity annotation guidelines","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#form-editor","title":"Form Editor","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#dna-binding-transcription-factor-activity","title":"DNA-binding transcription factor activity","text":"<ul> <li>MF: 'enables' a child of DNA binding transcription factor activity, RNA polymerase, II-specific (GO:0000981):</li> <li>DNA-binding transcription activator activity, RNA polymerase, II-specific (GO:0001228)</li> <li>DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227)</li> <li>Context:</li> <li>The relation between the DNA-binding transcription factor activity and the gene it regulates is 'has input'. A single input is captured per activity unit.</li> <li>regulation of transcription may be 'part of' a larger BP, specifically, regulation of the BPin which the target participates (if known).</li> <li>CC: 'occurs in' nucleus (GO:0005634)</li> </ul> <p>Example DNA binding transcription factor activity: FOXO3 regulation of G6PC1</p> <p></p>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#_7","title":"DNA binding transcription factor activity annotation guidelines","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#nuclear-receptors-and-ligand-activated-transcription-factors_1","title":"Nuclear receptors and ligand-activated transcription factors","text":"<p>Example: Model for nuclear receptor annotation guidelines</p> <p>The annotations are the same as for DNA binding transcription factor activity, except using the more precise MF nuclear receptor activity (GO:0004879).</p> <p></p>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#_8","title":"DNA binding transcription factor activity annotation guidelines","text":""},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#differences-between-go-cam-and-standard-annotation-of-a-dna-binding-transcription-factor-activity","title":"Differences between GO-CAM and standard annotation of a DNA-binding transcription factor activity","text":"<p>In standard annotation (captured with the Noctua Form or Protein2GO), relations between molecular functions are not captured, so there is no relation between the DNA binding transcription factor and the MF of its transcriptional target.</p> <p>For nuclear receptors, the relation between the small molecule activator and the transcription factor is not captured.</p>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#open-questions","title":"Open questions","text":"<ul> <li>FORM: For nuclear receptors, the relation between the small molecule activator and the transcription factor is not captured: can we add the relation in the Form?</li> </ul>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#future-features","title":"Future features","text":"<p>Chromosomal coordinates of the promoter/enhancer/loop anchor binding site of a DNA-binding transcription factor will be captured as 'has input'. For for the human genome, the syntax is: hg38_chr6:12334566-12335555* if we want to capture the chromosomal region</p> <p>* https://eu.idtdna.com/pages/support/faqs/how-are-genomic-coordinates-defined</p>"},{"location":"guidelines/DNA-binding_transcription_factor_activity_annotation_guidelines/#review-information","title":"Review information","text":"<p>Review date: 2023-07-20</p> <p>Reviewed by: Cristina Casals, Pascale Gaudet, Patrick Masson</p>"},{"location":"guidelines/E3_ubiquitin_ligases/","title":"E3 ubiquitin ligases","text":"<p>An E3 ubiquitin ligase is a protein that recruits an E2 ubiquitin-conjugating enzyme loaded with ubiquitin, recognizes a protein substrate, and assists or directly catalyzes the transfer of ubiquitin from the E2 to the protein substrate.</p> <p>The recognition of the protein substrate can be done by the ubiquitin protein ligase itself or through a complex composed of ubiquitin ligase-substrate adaptor and ubiquitin ligase complex scaffolds.</p> <p>https://en.wikipedia.org/wiki/Ubiquitin_ligase</p>"},{"location":"guidelines/E3_ubiquitin_ligases/#how-to-annotate-e3-ubiquitin-ligases","title":"How to annotate E3 ubiquitin ligases","text":""},{"location":"guidelines/E3_ubiquitin_ligases/#e3-ligase-that-promotes-ubiquitination-by-itself","title":"E3 ligase that promotes ubiquitination by itself","text":"<p>The molecular activity unit for the ubiquitin ligase is:</p> <ul> <li>MF: 'enables' ubiquitin protein ligase activity GO:0061630</li> <li>'has input'the substrate protein</li> <li>BPs:</li> <li>'part of' ubiquitination (GO:0016567): if known, the BP should describe the type of ubiquitination (K-48, K-63\u2026)</li> </ul> <p>ex: protein K48-linked ubiquitination GO:0070936; otherwise, use the parent protein ubiquitination GO:0016567 or protein polyubiquitination GO:0000209.</p> <ul> <li>the ubiquitination is part_of the biological process in which the ubiquitination is involved:</li> </ul> <p>e. g. : proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 or children, such as: SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146) or ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</p> <ul> <li>and/or part of\u2019 the BP in which the ubiquitination is involved: DNA repair, DNA damage response, lysosomal degradation, etc regulated by this mechanism (ex: negative regulation of inflammatory response, GO:0050728)</li> <li>The causal relation to the substrate molecular activity unit is: \u2018indirectly negatively regulates\u2019.</li> </ul> <p>Example: TRIM45-mediated degradation of TAB2 leading to inflammatory response inhibition (Human)</p> <p></p>"},{"location":"guidelines/E3_ubiquitin_ligases/#an-e3-ligase-complex-with-adaptors-and-scaffold-proteins","title":"An E3-ligase complex with adaptors and scaffold protein(s)","text":""},{"location":"guidelines/E3_ubiquitin_ligases/#_1","title":"E3 ubiquitin ligases","text":"<ul> <li>The molecular activity unit for the ubiquitin ligase complex scaffold, such as CUL4A and/or DDB1 is:</li> <li>MF: ubiquitin ligase complex scaffold activity GO:0160072</li> <li>Has input both the ubiquitin ligase-substrate adaptor and the ubiquitin protein ligase</li> <li>BP: if known, the BP should describe the type of ubiquitination (K-48, K-63\u2026)</li> </ul> <p>ex: protein K48-linked ubiquitination GO:0070936</p> <p>if not known, use a BP describing the biological process in which the ubiquitination is involved in.</p> <p>ex: proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 or children, such as: SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146) or ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</p> <p>\u2018Part of\u2019 the BP regulated by this mechanism (ex: T cell activation, GO:0042110)</p> <ul> <li>The causal relation between the substrate molecular activity unit is: \u2018directly negatively regulates\u2019 if it leads to degradation. (to decide for the other cases)</li> <li>The causal relation to the ubiquitin ligase-substrate adaptor molecular activity unit is: \u2018directly regulates\u2019.</li> <li>The molecular activity unit for the ubiquitin ligase-substrate adaptor is:</li> <li>MF: ubiquitin ligase-substrate adaptor activity GO:1990756</li> <li>Has input the substrate protein</li> <li>BP: if known, the BP should describe the type of ubiquitination (K-48, K-63\u2026)</li> </ul> <p>ex: protein K48-linked ubiquitination GO:0070936</p> <p>if not known, use a BP describing the biological process in which the ubiquitination is involved in.</p> <p>ex: proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 or children, such as: SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146) or ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</p> <p>\u2018Part of\u2019 the BP regulated by this mechanism (ex: T cell activation, GO:0042110)</p> <ul> <li>The causal relation to the ubiquitin ligase molecular activity unit is: \u2018directly provides input for\u2019.</li> <li>Annotation of the ubiquitin ligase is the same as above</li> </ul> <p>Example: DCAF12 controls MOV10 during T cell activation. (Human)</p> <p></p>"},{"location":"guidelines/E3_ubiquitin_ligases/#when-only-substrate-adaptor-and-substrate-are-known-scaffold-and-ligase-not-known","title":"When only substrate adaptor and substrate are known (scaffold and ligase not known)","text":"<p>Example: FBXL19-mediated degradation of IL1R1 via GSK3B (Human)</p> <ul> <li>The molecular activity unit for the ubiquitin ligase-substrate adaptor is:</li> <li>MF: ubiquitin ligase-substrate adaptor activity GO:1990756</li> <li>Has input the substrate protein</li> <li>BP: if known, the BP should describe the type of ubiquitination (K-48, K-63\u2026)</li> </ul> <p>ex: protein K48-linked ubiquitination GO:0070936</p> <p>if not known, use a BP describing the biological process in which the ubiquitination is involved in.</p> <p>ex: proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 or children, such as: SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146) or ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</p> <p>\u2018Part of\u2019 the BP regulated by this mechanism (ex: T cell activation, GO:0042110)</p> <ul> <li>The causal relation to the substrate molecular activity unit is: \u2018indirectly regulates\u2019 since we don\u2019t add/have information about the E3 ligase.</li> </ul>"},{"location":"guidelines/E3_ubiquitin_ligases/#when-only-substrate-adaptor-scaffold-and-substrate-are-known-ligase-not-known","title":"When only substrate adaptor, scaffold and substrate are known (ligase not known)","text":"<p>Ex: DCAF13 supports the spindle assembly and chromosome condensation during oocyte meiotic division by targeting PTEN polyubiquitination and degradation. (Human)</p> <p></p> <ul> <li>The molecular activity unit for the ubiquitin ligase complex scaffold, such as CUL4A and/or DDB1 is:</li> <li>MF: ubiquitin ligase complex scaffold activity GO:0160072</li> <li>Has input both the ubiquitin ligase-substrate adaptor and the ubiquitin protein ligase</li> <li>BP: if known, the BP should describe the type of ubiquitination (K-48, K-63\u2026)</li> </ul> <p>ex: protein K48-linked ubiquitination GO:0070936</p> <p>if not known, use a BP describing the biological process in which the ubiquitination is involved in.</p> <p>ex: proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 or children, such as: SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146) or ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</p> <p>\u2018Part of\u2019 the BP regulated by this mechanism (ex: T cell activation, GO:0042110)</p> <ul> <li>The causal relation to the ubiquitin ligase-substrate adaptor molecular activity unit is: \u2018directly regulates\u2019.</li> <li>The molecular activity unit for the ubiquitin ligase-substrate adaptor is:</li> <li>MF: ubiquitin ligase-substrate adaptor activity GO:1990756</li> <li>Has input the substrate protein</li> <li>BP: if known, the BP should describe the type of ubiquitination (K-48, K-63\u2026)</li> </ul> <p>ex: protein K48-linked ubiquitination GO:0070936</p> <p>if not known, use a BP describing the biological process in which the ubiquitination is involved in.</p> <p>ex: proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 or children, such as: SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146) or ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</p> <p>\u2018Part of\u2019 the BP regulated by this mechanism (ex: T cell activation, GO:0042110)</p> <ul> <li>The causal relation to the substrate molecular activity unit is: \u2018indirectly regulates\u2019 since we don\u2019t add/have information about the E3 ligase.</li> </ul>"},{"location":"guidelines/E3_ubiquitin_ligases/#examples-of-larger-processes-in-which-various-types-of-ubiquitination-play-a-role","title":"Examples of larger processes in which various types of ubiquitination play a role","text":"<p>Source: PMID:27285106</p> <p>Review date:</p> <p>Reviewed by:</p>"},{"location":"guidelines/GO-CAM_modelling_guidelines_TO_DO/","title":"GO CAM modelling guidelines TO DO","text":"<p>Moved here.</p> <p>https://docs.google.com/document/d/13MWyxdfcS78dYz9hg61R4ZS4ydp3OY8Y16LAb3xD3Ug/edit#</p>"},{"location":"guidelines/How_to_annotate_complexes_in_GO-CAM/","title":"How to annotate complexes in GO-CAM","text":"<p>When complexes are involved in specific activities, several options are available in GO-CAM to represent them.</p> <ol> <li>The subunit that carries the molecular activity is known:</li> </ol> <p>In that case, the complex is not described and the activity(ies) is represented by the specific protein (s) carrying the activity.</p> <p>Ex:</p> <p></p> <p>In this example, all the proteins in the E3 ligase complex have a defined and precise activity. Therefore, they are all displayed in the model. In this case, the scaffold activity is usually represented first, activating subsequent activities from the complex.</p> <ol> <li>The subunit which carries the molecular activity is not known:</li> </ol> <p>If the precise subunit carrying the activity is not known, we can use the GO accession for the complex.</p> <p>Ex: Ragulator complex (GO:0071986): Ragulator is comprised of the membrane anchor subunit LAMTOR1, LAMTOR2, LAMTOR3, LAMTOR4 and LAMTOR5.</p> <p>![A screenshot of a computer</p> <p>Description automatically generated](data:image/png;base64...)</p> <p>In this example LAMTOR1 activity is known (protein-membrane adaptor activity) but the protein that carries the guanyl-nucleotide exchange factor activity is not known, therefore we use the complex ID from GO in this situation.</p> <ol> <li>If the activity is shared by several proteins</li> </ol> <p>EX: Heterodimeric receptor where both activities are important for activity.</p>"},{"location":"guidelines/How_to_annotate_molecular_adaptors/","title":"How to annotate molecular adaptors","text":"<p>Here we describe how to capture a molecular adaptor activity which is defined as the binding activity of a molecule that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way.</p> <p>Example 1: TYROBP acts as an adaptor between a receptor and a downstream effector</p> <p>![A screenshot of a computer</p> <p>Description automatically generated with medium confidence](data:image/png;base64...)</p> <p>The molecular activity unit for molecular adaptor may include:</p> <p>o MF: molecular adaptor activity (GO:0060090) or one of its children</p> <p>o Has input the two (or more) molecules it brings together.</p> <p>o BP: the BP it participates in</p> <p>o CC: the place where the activity occurs.</p> <p>The relation with the downstream activity used is \u201cdirectly positively regulates\u201d</p> <p>Example 2: When an adaptor brings together an enzyme and its substrate</p> <p>![A screenshot of a computer</p> <p>Description automatically generated with medium confidence](data:image/png;base64...)</p> <p>The molecular activity is the same as above (MF, inputs, BP, CC)</p> <p>But in that case, the relation with the downstream activity used is \u201cprovides input for\u201d</p>"},{"location":"guidelines/How_to_annotate_sequestering_proteins/","title":"Sequestering activity","text":"<p>A sequestering activity is defined as the binding to a specific molecule to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where the target is active.</p>"},{"location":"guidelines/How_to_annotate_sequestering_proteins/#pathway-editor","title":"Pathway Editor","text":"<p>The activity unit for sequestering activity is:</p> <ul> <li>MF: molecular sequestering activity (GO:0140313) or a child</li> <li>Context:</li> <li>The relation between the protein that act to sequester and its target receptor is 'has input'</li> <li>BP: the BP it inhibits</li> <li>CC: the place where the activity occurs.</li> <li>The causal relation between the sequestering activity and the activity of the protein it inhibits is 'directly positively regulates'.</li> </ul> <p>Example 1: Sequestering activity of CAV1 on TLR4 signaling</p> <p>![A screenshot of a computer</p> <p>Description automatically generated with medium confidence](data:image/png;base64...)</p> <p>The molecular activity unit for molecular adaptor may include:</p> <p>o MF: molecular sequestering activity (GO:0140313) or one of its children</p> <p>o</p> <p>The relation with the downstream activity used is \u201cdirectly negatively regulates\u201d</p> <p>Example 2: Sequestering activity of YWHAZ on RAF1</p> <p></p> <p>In that example, the difference in the cellular component between the two activities clearly show that the YWHAZ protein sequesters RAF1 in the cytoplasm, preventing its activity in the plasma membrane.</p> <p>The relation used between both activities is \u201cdirectly negatively regulates\u201d because there is direct interaction between both proteins.</p>"},{"location":"guidelines/How_to_annotate_sequestering_proteins/#form-editor","title":"Form Editor","text":"<p>Review date: 2023-06-22</p> <p>Reviewed by: Pascale Gaudet, Patrick Masson</p>"},{"location":"guidelines/Molecular_adaptor_activity/","title":"Guidelines for annotating molecular adaptor activity","text":"<p>A molecular adaptor activity is the binding activity of a molecule that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way.</p>"},{"location":"guidelines/Molecular_adaptor_activity/#pathway-editor","title":"Pathway Editor","text":"<p>The molecular activity unit for a molecular adaptor is:</p> <ul> <li>MF: 'enables' molecular adaptor activity (GO:0060090) or a child</li> <li>Context:</li> <li>The relation between the adaptor activity and the two (or more) molecules it brings together is 'has input'</li> <li>BP: 'part of' the BP in which the adaptor participates</li> <li>CC: 'occurs in' the cellular location where the activity takes place.</li> </ul> <p>The relation between the adaptor and the proteins it adapts can be 'directly positively regulates' or 'provides input for', depending if the activity of the adaptor is regulatory.</p> <p>Example 1: TYROBP acts as an adaptor between a receptor and a downstream effector</p> <p>SIGLEC1 recognizes and endocytoses virions, which leads to activation of the TYROBP molecular adaptor, which recruits PTPN11. The scaffolding activity of PTPN11 is activated by TYROBP.</p> <p>![A screenshot of a computer</p> <p>Description automatically generated with medium confidence](data:image/png;base64...)</p> <p>Example 2: An adaptor that brings together an enzyme and its substrate</p> <p></p> <p>In that case, the relation between the adaptor activity and the downstream activity is 'provides input for'.</p>"},{"location":"guidelines/Molecular_adaptor_activity/#form-editor","title":"Form Editor","text":"<ul> <li>MF: 'enables' molecular adaptor activity (GO:0060090) or a child</li> <li>Context:</li> <li>The relation between the adaptor activity and the two (or more) molecules it brings together is 'has input'</li> <li>BP: 'part of' the BP in which the adaptor participates</li> <li>CC: 'occurs in' the cellular location where the activity takes place.</li> </ul>"},{"location":"guidelines/Molecular_adaptor_activity/#differences-between-go-cam-and-standard-annotation-of-a-molecular-adaptor-activity","title":"Differences between GO-CAM and standard annotation of a molecular adaptor activity","text":"<p>In standard annotation (captured with the Noctua Form or Protein2GO), relations between molecular functions are not captured.</p>"},{"location":"guidelines/Molecular_adaptor_activity/#_1","title":"Guidelines for annotating molecular adaptor activity","text":""},{"location":"guidelines/Molecular_adaptor_activity/#review-information","title":"Review information","text":"<p>Review date: 2023-07-20</p> <p>Reviewed by: Cristina Casals, Pascale Gaudet, Patrick Masson</p>"},{"location":"guidelines/Molecular_carrier_activity/","title":"Molecular carrier activity","text":"<p>Guidelines for annotating molecular carrier activity</p>"},{"location":"guidelines/Molecular_carrier_activity/#_1","title":"Molecular carrier activity","text":""},{"location":"guidelines/Molecular_carrier_activity/#pathway-editor","title":"Pathway Editor","text":"<p>The activity unit for a molecular carrier is:</p> <ul> <li>MF: a molecular carrier 'enables' molecular carrier activity (GO:0140104) or a child</li> <li>Context:</li> <li>The relation between a transported molecule and its carrier is 'has input'. The carrier and the small molecule are linked with the 'has output' relation, so that the small molecule can be the input for the next reaction.</li> <li>BP 'part of' the process in the molecule using the small molecule participates, or 'part of' regulation of the process, if the carrier is regulators (rate-limiting for the execution of the process)</li> <li>CC: 'occurs in' the cellular location where the activity takes place.</li> </ul> <p>Example 1: LPS is carried to its receptor by CD14</p> <p></p>"},{"location":"guidelines/Molecular_carrier_activity/#_2","title":"Molecular carrier activity","text":""},{"location":"guidelines/Molecular_carrier_activity/#form-editor","title":"Form Editor","text":"<p>The activity unit for a molecular carrier is:</p> <ul> <li>MF: a molecular carrier 'enables' molecular carrier activity (GO:0140104) or a child</li> <li>Context:</li> <li>The relation between a transported molecule and its carrier is 'has input'. The carrier and the small molecule are linked with the 'has output' relation, so that the small molecule can be the input for the next reaction.</li> <li>BP 'part of' the process in the molecule using the small molecule participates, or 'part of' regulation of the process, if the carrier is regulators (rate-limiting for the execution of the process)</li> <li>CC: 'occurs in' the cellular location where the activity takes place.</li> </ul> <p></p>"},{"location":"guidelines/Molecular_carrier_activity/#differences-between-go-cam-and-standard-annotation-for-a-molecular-carrier-activity","title":"Differences between GO-CAM and standard annotation for a molecular carrier activity","text":"<p>The same information is captured for the carrier activity and its context; however in the standard annotations,it is not possible to capture the order of the reactions.</p>"},{"location":"guidelines/Molecular_carrier_activity/#review-information","title":"Review information","text":"<p>Review date: 2023-07-25</p> <p>Reviewed by: Cristina Casals, Pasclae Gaudet, Patrick Masson</p>"},{"location":"guidelines/Protein_sequestering_activity/","title":"Guidelines for annotating molecular sequestering activity","text":"<p>A sequestering activity is defined as the binding to a specific molecule to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where the target is active.</p>"},{"location":"guidelines/Protein_sequestering_activity/#pathway-editor","title":"Pathway Editor","text":"<p>The activity unit for a molecular sequestering activity is:</p> <ul> <li>MF: molecular sequestering activity (GO:0140313). The most commonly used child is protein sequestering activity (GO:0140311).</li> <li>Context:</li> <li>The relation between the protein that act to sequester and its target is 'has input'</li> <li>BP: 'part of' negative regulation of the BP in which the target protein participates .</li> <li>CC: the location where the activity occurs.</li> <li>The causal relation between the sequestering activity and the activity of the protein it inhibits is 'directly negatively regulates' because there is a direct interaction between the two proteins.</li> </ul> <p>Example 1: Sequestering activity of CAV1 negatively regulates TLR4 signaling</p> <p>![A screenshot of a computer</p> <p>Description automatically generated with medium confidence](data:image/png;base64...)</p> <p>Example 2: Trans-negative regulation of Sars-CoV-2 viral entry into host cell by LRRC15.</p> <p></p>"},{"location":"guidelines/Protein_sequestering_activity/#_1","title":"Guidelines for annotating molecular sequestering activity","text":""},{"location":"guidelines/Protein_sequestering_activity/#form-editor","title":"Form Editor","text":"<p>The activity unit for sequestering activity is:</p> <ul> <li>MF: molecular sequestering activity (GO:0140313) or a child</li> <li>Context:</li> <li>The relation between the protein that act to sequester and its target receptor is 'has input'</li> <li>BP: negative regulation of the BP in which the regulated protein participates</li> <li>CC: the location where the activity occurs.</li> </ul> <p>Example 1: Sequestering activity of CAV1 negatively regulates TLR4 signaling</p> <p></p>"},{"location":"guidelines/Protein_sequestering_activity/#differences-between-go-cam-and-standard-annotation-of-a-sequestering-activity","title":"Differences between GO-CAM and standard annotation of a sequestering activity","text":"<p>In standard annotation (captured with the Noctua Form or Protein2GO), relations between molecular functions are not captured, so there is no relation between the sequestering activity and the activity of the protein being sequestered.</p>"},{"location":"guidelines/Protein_sequestering_activity/#review-information","title":"Review information","text":"<p>Review date: 2023-07-25</p> <p>Reviewed by: Cristina Casals, Pascale Gaudet, Patrick Masson</p>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/","title":"Signaling receptor activity annotation guidelines","text":"<p>Guidelines for annotating signaling receptor activity</p> <p>Receptor activation by a ligand is represented differently in GO-CAM depending on whether the ligand is (i) a protein (i. e., encoded by a gene) or (ii) a small molecule.</p>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#pathway-editor","title":"Pathway Editor","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_1","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#protein-ligand-activated-signaling-receptor","title":"Protein ligand-activated signaling receptor","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#ligand","title":"Ligand","text":"<p>The activity unit for a ligand of a signaling receptor is:</p> <ul> <li>MF: a ligand 'enables' receptor ligand activity (GO:0048018) or a child</li> <li>Context:</li> <li>The relation between a ligand and its target receptor is 'has input'</li> <li>BP 'part of' the process in which the ligand participates, usually a child of signal transduction (GO:0007165)</li> <li>CC:<ul> <li>extracellular ligands:'occurs in' extracellular space (GO:0005615)</li> <li>membrane-bound ligands: 'occurs in' plasma membrane (GO:0005886)</li> </ul> </li> <li>The causal relation between the ligand activity and the receptor activity is     'directly positively regulates'.</li> </ul>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#signaling-receptor","title":"Signaling receptor","text":"<p>The activity unit for a signaling receptor is:</p> <ul> <li>MF: 'enables' signaling receptor activity (GO:0038023) or a child.</li> <li>Context:</li> <li>The input (target) of the receptor is the effector protein it regulates, for example a molecular adaptor, captured with the 'has input' relation.</li> <li>Note that the input (target) of the receptor is NOT its ligand</li> <li>BP 'part of' the same BP/signal transduction pathway as the ligand</li> <li>CC: transmembrane receptors: 'occurs in' plasma membrane (GO:0005886)</li> <li>The causal relation between the MF of the receptor and the MF of its target is 'directly positively regulates'.</li> </ul> <p>Example: Insulin signaling model</p> <p></p>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_2","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_3","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_4","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_5","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#small-molecule-activated-signaling-receptor-activity","title":"Small molecule-activated signaling receptor\u00a0activity","text":"<ul> <li>Since small molecules are not annotated in GO, a small molecule ligand does not have a molecular function. Instead, the ligand and the receptor activity are linked by the causal relation 'is small molecule activator'.</li> <li>The receptor's function, input, and contextual relations are the same as for protein ligand-activated receptors.</li> <li>Note that it is also possible to annotate an inhibitory ligand using the relation 'is small molecule inhibitor'.</li> <li>BP and CC annotations are the same as for protein ligand-activated receptor activity.</li> </ul> <p>Example: Activation of a GPCR by succinate</p> <p></p>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_6","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#special-cases","title":"Special cases","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_7","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#receptor-with-coreceptor","title":"Receptor with coreceptor","text":"<p>This is common in immune receptors. The typical sequence of events is that the ligand binds the signaling receptor, which signals to the co-receptor to activate its downstream effector (such as a protein kinase).</p> <p>Example: IL2 signaling pathway (Human)</p> <p>In this case, the receptor is activated by an information biomacromolecule (i.e. a protein). Interleukin-2 (IL2), a cytokine, activates its receptor, interleukin-2 receptor A (IL2RA).</p> <p>IL2RA directly positively regulates (activates) IL2RB, which phosphorylates and positively regulates JAK1.</p> <p>The activity unit for a signaling coreceptor is:</p> <ul> <li>MF: coreceptor activity (GO:0015026)</li> <li>Context:</li> <li>The relation between the receptor and its input (target) is the signaling coreceptor it regulates, captured with the 'has input' relation</li> <li>Note that the input (target) of the coreceptor is NOT the ligand</li> <li>BP 'part of' the BP in which the signaling receptor is involved, usually a child of signal transduction (GO:0007165)</li> <li>CC: transmembrane receptors: 'occurs in' plasma membrane (GO:0005886)</li> <li>The causal relation between the MF of the receptor and the MF of its coreceptor is 'directly positively regulates'.</li> </ul> <p>![Diagram</p> <p>Description automatically generated with medium confidence](data:image/png;base64...)</p> <p>Note:</p> <ul> <li>cytokine activity is_a receptor ligand activity</li> <li>interleukin-2 receptor activity is_a signaling receptor activity</li> </ul>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_8","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_9","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_10","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#form-editor","title":"Form Editor","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#protein-ligand-activated-signaling-receptor_1","title":"Protein ligand-activated signaling receptor","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#ligand-activity","title":"Ligand activity","text":"<p>The activity unit for a ligand of a signaling receptor is:</p> <ul> <li>MF: a ligand 'enables' receptor ligand activity (GO:0048018) or a child</li> <li>Context:</li> <li>The relation between a ligand and its target receptor is 'has input'</li> <li>BP 'part of' the BP in which this ligand is involved (usually a child of signal transduction (GO:0007165))</li> <li>CC:<ul> <li>extracellular ligands: 'occurs in' extracellular space (GO:0005615)</li> <li>membrane-bound ligands: 'occurs in' plasma membrane (GO:0005886)</li> </ul> </li> <li>The causal relation between the ligand *activity and the receptor activity* is   'directly positively regulates'.</li> </ul> <p>Example: Insulin signaling model</p> <p></p>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#signaling-receptor-activity","title":"Signaling receptor activity","text":"<p>The activity unit for a signaling receptor is:</p> <ul> <li>MF: The receptor 'enables' signaling receptor activity (GO:0038023) or a child.</li> <li>Context:</li> <li>The input (target) of the receptor is the effector protein it regulates, for example a molecular adaptor, captured with the 'has input' relation</li> <li>Note that the input (target) of the receptor is NOT its ligand</li> <li>BP in which the signaling receptor is involved, usually a child of signal transduction (GO:0007165)</li> <li>CC: 'occurs in' a child of cellular anatomical entity (GO:0110165). For transmembrane receptors, annotate to plasma membrane (GO:0005886)</li> </ul> <p>Example: Insulin signaling model</p> <p></p> <ul> <li> <ul> <li>The causal relation between the MF of the receptor and the MF of its target is 'directly positively regulates'.</li> </ul> </li> </ul>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_11","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#small-molecule-activated-signaling-receptor-activity_1","title":"Small molecule-activated signaling receptor\u00a0activity","text":"<ul> <li>In the Form, small molecules are not captured, so the MF for the receptor. Therefore, the MF is 'enables' signaling receptor activity (GO:0038023) or a child.</li> <li>BP and CC annotations are the same as for protein ligand-activated receptor activity.</li> </ul>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_12","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#receptor-with-coreceptor_1","title":"Receptor with coreceptor","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_13","title":"Signaling receptor activity annotation guidelines","text":"<p>Example: IL2 signaling pathway (Human)</p> <p>In this case, the receptor, interleukin-2 receptor A (IL2RA), is activated by a protein ligand, interleukin-2 (IL2). IL2RA directly positively regulates (activates) the coreceptor IL2RB, which phosphorylates and positively regulates JAK1.</p> <p>The activity unit for a signaling coreceptor is:</p> <ul> <li>MF: The coreceptor 'enables' coreceptor activity (GO:0015026) or a child.</li> <li>Context:</li> <li>The input (target) of the coreceptor is the signaling receptor it regulates, captured with the 'has input' relation</li> <li>Note that the input (target) of the coreceptor is NOT the ligand</li> <li>BP 'part of' the BP in which the signaling receptor is involved, usually a child of signal transduction (GO:0007165)</li> <li>CC: transmembrane receptors:'occurs in' plasma membrane (GO:0005886)</li> </ul> <p></p> <p>Note:</p> <ul> <li>cytokine activity is_a receptor ligand activity</li> <li>interleukin-2 receptor activity is_a signaling receptor activity</li> </ul>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_14","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#differences-between-go-cam-and-standard-annotation-of-a-signaling-receptor-and-its-ligand","title":"Differences between GO-CAM and standard annotation of a signaling receptor and its ligand","text":"<p>In standard annotation (captured with the Noctua Form or Protein2GO), relations between molecular functions are not captured, so there is no relation between the ligand activity and the signaling receptor activity, nor is there a relation between the signaling receptor activity and the activity of its target. Likewise for receptor activity and coreceptor activity, there is no relation between these activities captured in standard annotations.</p>"},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#_15","title":"Signaling receptor activity annotation guidelines","text":""},{"location":"guidelines/Signaling_receptor_activity_annotation_guidelines/#review-information","title":"Review information","text":"<p>Review date: 2023-07-20</p> <p>Reviewed by: Cristina Casals, Pascale Gaudet, Patrick Masson</p>"},{"location":"guidelines/Transcription_coregulator_activity/","title":"Transcription coregulator activity","text":""},{"location":"guidelines/Transcription_coregulator_activity/#transcription-coregulator-activity","title":"Transcription coregulator activity","text":"<p>The activity unit for a transcription coregulator is:</p> <ul> <li>MF: a child of transcription coregulator activity (GO:0003712):</li> <li>transcription coactivator activity (GO:0003713)</li> <li>transcription corepressor activity (GO:0003714)</li> <li>Context:</li> <li>has input:the transcription factor regulated, when known.</li> <li>BP in which this transcriptional event is involved</li> <li>CC: this activity occurs in the nucleus.</li> <li> <p>The causal relation between the transcription coregulator activity and the transcription factor activity unit is \u2018directly positively regulates\u2019 or 'directly negatively regulates.</p> </li> <li> <p>If the causal relation between the coregulator and the target gene regulated needs to be captured, the causal relation is: \u2018indirectly positively regulates\u2019 or 'indirectly negatively regulates\u2019, since there are many steps between the regulation of transcription and the activity of the target protein.</p> </li> </ul>"},{"location":"guidelines/Transcription_coregulator_activity/#example-go0003714-transcription-corepressor-activity","title":"Example: GO:0003714 transcription corepressor activity","text":""},{"location":"guidelines/Transcription_coregulator_activity/#example-go0003713-transcription-coactivator-activity","title":"Example: GO:0003713 transcription coactivator activity","text":""},{"location":"guidelines/Transcription_coregulator_activity/#example-go0003712-transcription-coregulator-activity-bmal1-binds-specifically-dna","title":"Example: GO:0003712 transcription coregulator activity (BMAL1 binds specifically DNA)","text":""},{"location":"guidelines/Transcription_coregulator_activity/#example-coregulator-of-an-unknown-transcription-factor","title":"Example: Coregulator of an unknown transcription factor","text":""},{"location":"guidelines/Transcription_coregulator_activity/#review-information","title":"Review information","text":"<p>To be reviewed date:</p> <p>Created by: Cristina Casals</p>"},{"location":"guidelines/Transporter_activity_annotation_annotation_guidelines/","title":"Guidelines for annotating transporter activity","text":""},{"location":"guidelines/Transporter_activity_annotation_annotation_guidelines/#pathway-editor","title":"Pathway Editor","text":"<p>The activity unit for a transmembrane transporter is:</p> <ul> <li>MF: 'enables' a child of transmembrane transporter activity GO:0022857</li> <li>Context:</li> <li>The movement of the small molecule substrate is represented by:<ul> <li>small molecule (ChEBI) + \u2018input of\u2019 + the start location of the small molecule, captured with the relation 'located in'</li> <li>the transporter activity + \u2018has output\u2019 the small molecule (ChEBI) + the end location of the small molecule, captured with the relation 'located in'</li> </ul> </li> <li>BP 'part of' the BP in which this transporter activity participates</li> <li>CC 'occurs in' a child of membrane (GO:0016020), e. g.: lysosomal membrane (GO:0005765).</li> </ul> <p>Example: SLC17A9 transports ATP to the lysosomal lumen</p> <p></p>"},{"location":"guidelines/Transporter_activity_annotation_annotation_guidelines/#_1","title":"Guidelines for annotating transporter activity","text":""},{"location":"guidelines/Transporter_activity_annotation_annotation_guidelines/#form-editor","title":"Form Editor","text":"<p>The activity unit for a transmembrane transporter is:</p> <ul> <li>MF: a child of transmembrane transporter activity GO:0022857</li> <li>Context: The movement of the small molecule substrate is represented by:</li> <li>'has input\u2019 the small molecule (ChEBI)</li> <li>BP 'part of' the BP in which this transporter activity participates</li> <li>CC 'occurs in' a child of membrane (GO:0016020), e. g.: lysosomal membrane (GO:0005765)</li> </ul> <p>Example: SLC17A9 transports ATP to the lysosomal lumen</p> <p></p>"},{"location":"guidelines/Transporter_activity_annotation_annotation_guidelines/#differences-between-go-cam-and-standard-annotation-of-a-transmembrane-transporter-activity","title":"Differences between GO-CAM and standard annotation of a transmembrane transporter activity","text":"<p>In standard annotation (captured with the Noctua Form or Protein2GO), the localization of the molecule is not captured; neither is the output of the transporter, since that output relates to the localization of the molecule transported.</p>"},{"location":"guidelines/Transporter_activity_annotation_annotation_guidelines/#review-information","title":"Review information","text":"<p>Review date: 2023-07-20</p> <p>Reviewed by:Cristina Casals, Pascale Gaudet, Patrick Masson</p>"},{"location":"guidelines/WIP_-_Regulation_and_Regulatory_Processes_in_GO-CAM/","title":"Guidelines for annotating regulation and regulatory processes in GO-CAM","text":"<p>Molecular functions, and the biological processes of which they are a part, are often subject to some form of regulation, typically in response to changing environmental conditions or stimuli.</p> <p>In GO, regulation has a very specific meaning: for one molecular function to regulate another, the mechanism must be known, it must occur under specific conditions  (i.e. not constant), and may be direct (contiguous activities) or indirect (non-contiguous, with intervening activities). Regulatory activities may also have a positive or negative effect on the downstream activity.</p> <p>Examples of regulatory molecular functions include, but are certainly not limited to, protein kinase activity, GTPase activator (GAP) activity, and transcription regulator activities.</p> <p>Modeling regulation is an important aspect of GO-CAM curation but can differ according to how the regulatory activities function in the broader context of the biological process.</p> <p>Examples of distinct ways to capture regulation in GO-CAMs are discussed below.</p>"},{"location":"guidelines/WIP_-_Regulation_and_Regulatory_Processes_in_GO-CAM/#metabolic-pathways-and-feedback-regulatory-mechanisms","title":"Metabolic pathways and feedback regulatory mechanisms","text":"<p>Feedback mechanisms in which a product, or output, of one activity in a process inhibits another activity in a process (i.e. negative feedback loop) is an important way to regulate metabolic processes.</p> <p>Feedback loops represent a type of process regulation that is \u2018self-contained\u2019, i.e. the regulatory activity is not typically part of another, larger regulatory process.</p> <p>In these cases, curators include the regulatory activity in the metabolic model and capture the output molecules that stimulate the regulation and the causal relation between the regulatory and regulated activities.</p> <p>An example of this type of regulation is found in the GDP-mannose biosynthetic process (GO:0009298), in which the terminal output generated by GMPPB, GDP-alpha-D-mannose, binds to, and stimulates the inhibitory activity of, GMPPA on GMPPB.</p> <p>Figure 1 shows a cartoon schematic of how GMPPA inhibits GMPPB, while Figure 2 shows how this regulation is modeled in GO-CAM as part of the larger metabolic process. for D. melanogaster model for GDP-mannose biosynthetic process from glucose (Dmel).</p> <p>In this model, the output, GDP-alpha-D-mannose, of the terminal activity in the pathway, mannose-1-phosphate guanylyltransferase (GTP) activity enabled by Gmppb, is a small molecule activator of the enzyme inhibitor activity enabled by Gmppa. When bound to GDP-alpha-D-mannose (2-), Gmppa undergoes a conformational change that then inhibits catalytic activity of Gmppb.</p> <p></p> <p>https://www.nature.com/articles/s41594-021-00591-9</p> <p></p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/","title":"56170d5200000012 kctd10 in heart development PMID 24430697","text":"<p>Based on the information gathered, I'll now review the GO-CAM model with ID 56170d5200000012.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#review-of-go-cam-model-gomodel56170d5200000012","title":"Review of GO-CAM Model: gomodel:56170d5200000012","text":""},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#model-overview","title":"Model Overview","text":"<p>Title: \"kctd10 in heart development PMID:24430697\" Taxon: Zebrafish (Danio rerio) - NCBITaxon:7955 Status: Production Model ID: gomodel:56170d5200000012</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#model-components-and-structure","title":"Model Components and Structure","text":"<p>This model describes the role of kctd10 in heart development in zebrafish, focusing on its regulation of the transcription factor tbx5a and downstream effects on atrioventricular canal (AVC) development. The model contains the following major activities:</p> <ol> <li>tbx5a (ZFIN:ZDB-GENE-991124-7) with:</li> <li>DNA-binding transcription factor activity (GO:0003700)</li> <li>Occurs in nucleus (GO:0005634)</li> <li>Part of regionalization (GO:0003002)</li> <li> <p>Positively regulates has2 activity</p> </li> <li> <p>has2 (ZFIN:ZDB-GENE-020828-1) with:</p> </li> <li>Molecular function (GO:0003674)</li> <li> <p>Part of atrioventricular canal development (GO:0036302)</p> </li> <li> <p>kctd10 (ZFIN:ZDB-GENE-040426-2843) with:</p> </li> <li>Molecular function (GO:0003674)</li> <li>Occurs in nucleus (GO:0005634)</li> <li>Part of regionalization (GO:0003002)</li> <li> <p>Negatively regulates tbx5a activity</p> </li> <li> <p>kctd10 (ZFIN:ZDB-GENE-040426-2843) with:</p> </li> <li>Protein binding (GO:0005515)</li> <li>Part of molecular function (GO:0003674)</li> <li>Has part of relationship with kctd10's main activity</li> </ol>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#assessment-against-go-cam-best-practices","title":"Assessment Against GO-CAM Best Practices","text":""},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#1-biological-content-accuracy","title":"1. Biological Content Accuracy","text":"<p>The biological content of the model is well-supported by the literature (PMID:24430697). The paper describes that Kctd10 directly binds to Tbx5a to repress its transcriptional activity, which is crucial for regulating the expression of has2, a key gene in atrioventricular canal development. The paper demonstrates that:</p> <ul> <li>Kctd10 deficiency leads to heart malformations</li> <li>In kctd10 mutants, has2 expression expands beyond the AVC region</li> <li>Knockdown of tbx5a rescues the ectopic expression of has2 in kctd10 mutants</li> <li>Kctd10 physically binds to Tbx5a in the nucleus to moderate its activity</li> </ul> <p>The model accurately captures these key findings, showing kctd10 negatively regulates tbx5a, which positively regulates has2, which is involved in AVC development.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#2-representation-of-molecular-activities","title":"2. Representation of Molecular Activities","text":"<p>The model correctly represents:</p> <ul> <li>tbx5a as a DNA-binding transcription factor (GO:0003700), which is appropriate based on its UniProt annotation and the paper's findings</li> <li>kctd10 with protein binding activity (GO:0005515), correctly showing its interaction with tbx5a</li> <li>has2 is appropriately shown as being regulated by tbx5a and involved in AVC development</li> </ul>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#3-causal-relationships","title":"3. Causal Relationships","text":"<p>The causal relationships are correctly represented:</p> <ul> <li>kctd10 \"directly negatively regulates\" (RO:0002630) tbx5a, which accurately captures the direct physical interaction and regulatory relationship described in the paper</li> <li>tbx5a \"directly positively regulates\" (RO:0002629) has2, which correctly captures that tbx5a acts as a transcriptional activator for has2</li> </ul> <p>These relationships follow the GO-CAM guidelines for representing regulation.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#4-location-information","title":"4. Location Information","text":"<p>The model appropriately specifies the nucleus (GO:0005634) as the location for both kctd10 and tbx5a activities, which is consistent with the paper's findings that Kctd10 colocalizes with Tbx5 in the nucleus.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#5-areas-for-improvement","title":"5. Areas for Improvement","text":"<p>While the model is generally well-constructed, I've identified a few areas that could be enhanced:</p> <ol> <li> <p>More Specific Molecular Function for kctd10: The main activity of kctd10 uses a general \"molecular function\" (GO:0003674) rather than a more specific term. Based on the paper and UniProt entry, a more appropriate term might be \"transcription corepressor activity\" (GO:0003714) since it directly represses Tbx5a's transcriptional activity.</p> </li> <li> <p>More Specific Molecular Function for has2: has2 is annotated with the generic molecular function term (GO:0003674). Based on its UniProt entry, a more specific term would be \"hyaluronan synthase activity\" (GO:0050501).</p> </li> <li> <p>Expansion of downstream effects: The model could be expanded to show how has2 overexpression leads to excessive hyaluronic acid production, which affects cardiac jelly formation and ultimately heart morphogenesis. The paper clearly describes this mechanism.</p> </li> <li> <p>Inclusion of heart looping: The paper emphasizes that heart looping failure is a key phenotype in kctd10 mutants. The model could be expanded to show has2's involvement in heart looping (GO:0001947), which is mentioned in the paper.</p> </li> <li> <p>Regulatory mechanism details: The model could include more detail on how Kctd10 regulates Tbx5a, possibly by including the formation of the Kctd10-Tbx5a complex.</p> </li> </ol>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#biological-process-consistency","title":"Biological Process Consistency","text":"<p>The model appropriately places the molecular activities within relevant biological processes:</p> <ul> <li>Regionalization (GO:0003002) for tbx5a and kctd10 activities</li> <li>Atrioventricular canal development (GO:0036302) for has2 activity</li> </ul> <p>These processes are consistent with the paper's findings about the roles of these genes in heart development.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#final-assessment","title":"Final Assessment","text":"<p>This GO-CAM model accurately captures the core regulatory relationship between kctd10, tbx5a, and has2 in zebrafish heart development, particularly in AVC formation. The model correctly represents kctd10 as a negative regulator of tbx5a that acts by direct binding, which in turn controls the expression of has2, a key factor in AVC development.</p> <p>The model follows GO-CAM best practices for representation of transcription factors and regulatory relationships. The suggested improvements would enhance the specificity and comprehensiveness of the model but do not detract from its current accuracy.</p> <p>Recommendation: The model is scientifically sound and follows GO-CAM curation practices. It could be enhanced with more specific molecular function terms for kctd10 and has2, and potentially expanded to include downstream effects on cardiac jelly formation and heart morphogenesis.</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/","title":"568b0f9600000284 Antibacterial innate immune response in the intestine via MAPK cascade  C  elegans","text":"<p>Now that I have gathered information on the model and related literature, I'll proceed with a detailed review.</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#review-of-go-cam-model-gomodel568b0f9600000284","title":"Review of GO-CAM Model gomodel:568b0f9600000284","text":""},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model titled \"Antibacterial innate immune response in the intestine via MAPK cascade (C. elegans)\" represents a signaling pathway involved in innate immune response in C. elegans. The model focuses on a MAPK (Mitogen-Activated Protein Kinase) signaling cascade that mediates antibacterial defense in the worm's intestinal cells.</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#pathway-structure-and-components","title":"Pathway Structure and Components","text":"<p>The model depicts a complete MAPK signaling cascade consisting of:</p> <ol> <li>Initiating adaptor: TIR-1 (WB:WBGene00006575) with signaling adaptor activity (GO:0035591)</li> <li>MAPKKK: NSY-1 (WB:WBGene00003822) with MAP kinase kinase kinase activity (GO:0004709)</li> <li>MAPKK: SEK-1 (WB:WBGene00004758) with MAP kinase kinase activity (GO:0004708)</li> <li>MAPK: PMK-1 (WB:WBGene00004055) with MAP kinase activity (GO:0004707)</li> <li>Transcription factor: ATF-7 (WB:WBGene00000223) with DNA-binding transcription factor activity (GO:0000981)</li> <li>Target gene product: SYSM-1 (WB:WBGene00011979) </li> </ol> <p>The model also includes an additional regulator: - DKF-2: (WB:WBGene00012019) with protein serine/threonine kinase activity (GO:0004674) - Phosphatase VHP-1: (WB:WBGene00006923) with MAP kinase tyrosine/serine/threonine phosphatase activity (GO:0017017)</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#causal-relationships","title":"Causal Relationships","text":"<p>The model uses appropriate causal relationship predicates to show the flow of signaling:</p> <ol> <li>TIR-1 directly positively regulates (RO:0002629) NSY-1 </li> <li>NSY-1 directly positively regulates (RO:0002629) SEK-1</li> <li>SEK-1 directly positively regulates (RO:0002629) PMK-1</li> <li>PMK-1 directly positively regulates (RO:0002629) ATF-7</li> <li>ATF-7 directly positively regulates (RO:0002629) SYSM-1</li> <li>DKF-2 directly positively regulates (RO:0002629) PMK-1</li> <li>TPA-1 directly positively regulates (RO:0002629) DKF-2 </li> <li>VHP-1 directly negatively regulates (RO:0002630) PMK-1 and KGB-1</li> <li>VHP-1 directly negatively regulates (RO:0002630) KGB-1</li> </ol>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#cellular-components","title":"Cellular Components","text":"<p>Most activities in the model are correctly localized to appropriate cellular components: - TIR-1: cytoplasm (GO:0005737) - NSY-1: cytoplasm (GO:0005737) - SEK-1: cytoplasm (GO:0005737) - PMK-1: cytosol (GO:0005829) - DKF-2: cytoplasmic side of plasma membrane (GO:0009898) - ATF-7: nucleus (GO:0005634) - VHP-1: cytoplasm (GO:0005737)</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#biological-process","title":"Biological Process","text":"<p>All the activities are appropriately annotated as part of the antibacterial innate immune response (GO:0140367), which is consistent with the literature evidence from multiple papers cited in the model.</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#evidence","title":"Evidence","text":"<p>The model uses appropriate evidence codes and refers to relevant publications: - Most causal relationships are supported by mutant phenotype evidence (ECO:0000315) - Molecular functions are typically supported by direct assay evidence (ECO:0000314) - Cellular components are mostly supported by direct assay or orthology-based evidence</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Complete signaling cascade: The model properly represents a complete MAPK cascade from the initiating adaptor protein through transcription factor activation.</p> </li> <li> <p>Appropriate evidence: The model uses appropriate evidence codes and cites relevant literature.</p> </li> <li> <p>Correct causal relationships: The model uses the appropriate causal relationship predicates (directly positively/negatively regulates) between activities.</p> </li> <li> <p>Consistent annotation: All activities are consistently annotated as part of the same biological process (antibacterial innate immune response).</p> </li> <li> <p>Appropriate cellular components: Activities are localized to the correct cellular compartments, reflecting the biological reality of the MAPK signaling pathway.</p> </li> </ol>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li> <p>Missing input signals: The model doesn't clearly indicate what initially activates the TIR-1 adaptor protein. Based on the literature, bacterial pathogen recognition is the likely trigger. Consider adding information about how bacterial pathogens are recognized to initiate this pathway.</p> </li> <li> <p>Molecular function for SYSM-1: The molecular function for SYSM-1 is annotated as GO:0003674 (molecular_function), which is a generic placeholder term. If more specific function information becomes available, this should be updated.</p> </li> <li> <p>Consistency with GO-CAM best practices: The model is generally consistent with GO-CAM best practices, but could potentially be enhanced by:</p> </li> <li>Adding information about any required co-factors</li> <li> <p>Including more details about the specific anti-bacterial effector mechanisms downstream of SYSM-1</p> </li> <li> <p>Additional regulatory pathway: The VHP-1 phosphatase negatively regulates both PMK-1 and KGB-1 (WB:WBGene00002187), but there's limited information about the broader role of KGB-1 and its connection to the other components in this pathway. Consider clarifying the role of KGB-1 in the context of this immune response pathway.</p> </li> <li> <p>TPA-1 regulation of DKF-2: According to the literature (PMID:19371715), TPA-1 regulates DKF-2 in the context of immune response, but this relationship is not fully represented in the model. Consider adding this regulatory relationship to complete the pathway.</p> </li> </ol>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the C. elegans MAPK cascade pathway in antibacterial innate immune response. The model is well-structured, uses appropriate GO terms and relationship predicates, and is supported by adequate evidence. A few minor enhancements could further improve the model, including clarification of the upstream pathogen recognition mechanism and more specific molecular function annotations for some components.</p> <p>The model provides valuable information about how C. elegans mounts antibacterial responses through MAPK signaling and highlights the conservation of innate immune signaling components between nematodes and mammals. This pathway has broader implications for understanding innate immunity across species.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/","title":"5745387b00001516 Canonical glycolysis 1  Mouse","text":"<p>Based on the information gathered, I'll now review the GO-CAM model gomodel:5745387b00001516 titled \"Canonical glycolysis 1 (Mouse)\".</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#go-cam-review-canonical-glycolysis-1-mouse","title":"GO-CAM Review: Canonical glycolysis 1 (Mouse)","text":""},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#overview","title":"Overview","text":"<p>This model represents the canonical glycolysis pathway in mouse (NCBITaxon:10090), which was sourced from model R-HSA-70171. The model is in production status and depicts the enzymatic steps of glycolysis, showing the flow of activity through the pathway.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#structure-review","title":"Structure Review","text":"<p>The model captures the glycolytic pathway from glucokinase (HK1) to pyruvate kinase (PKM), representing all key enzymatic steps in the pathway. All enzymes are appropriately enabled by their respective mouse gene products and connected in a sequential manner using the RO:0002413 (\"provides input for\") causal relationship, which is appropriate for metabolic pathways.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#content-completeness-and-accuracy","title":"Content Completeness and Accuracy","text":"<ol> <li>Complete pathway representation: All essential enzymatic steps of canonical glycolysis are included:</li> <li> <p>Glucokinase (HK1) \u2192 Glucose-6-phosphate isomerase (GPI1) \u2192 Phosphofructokinase (PFKM) \u2192 Aldolase (ALDOA) \u2192 Triosephosphate isomerase (TPI1) \u2192 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) \u2192 Phosphoglycerate kinase (PGK1) \u2192 Phosphoglycerate mutase (PGAM2) \u2192 Enolase (ENO3) \u2192 Pyruvate kinase (PKM)</p> </li> <li> <p>Proper evidence: Each activity is supported by appropriate experimental evidence, primarily direct assays (ECO:0000314) and mutant phenotype evidence (ECO:0000315) from relevant publications.</p> </li> <li> <p>Cellular location: All activities are properly located in the cytosol (GO:0005829), which is correct for glycolysis.</p> </li> <li> <p>Biological process: All activities are correctly annotated as part of canonical glycolysis (GO:0061621).</p> </li> </ol>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The model correctly uses RO:0002413 (\"provides input for\") to connect the sequential activities of the glycolytic enzymes, accurately representing the metabolic flow from glucose to pyruvate. </p> <p>An interesting aspect to note is that the model correctly represents the branching after aldolase (ALDOA), where both triose-phosphate isomerase (TPI1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can receive input from aldolase, reflecting the biochemical reality of the pathway.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#evidence-support","title":"Evidence Support","text":"<p>Each activity and causal relationship is adequately supported by published evidence, with multiple references for most assertions. The evidence types used (direct assay, mutant phenotype, genetic interaction) are appropriate for a metabolic pathway model.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows best practices for GO-CAM modeling: 1. Appropriate causal relationships 2. Correct representation of enzymatic activities 3. Proper evidence citation 4. Inclusion of cellular locations 5. Association with the proper biological process term</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While this model is well-constructed and accurate, there are a few potential improvements:</p> <ol> <li> <p>Some evidence links, like PMID:27103217, are used across multiple activities. It may be worth verifying that this publication provides specific evidence for each assertion where it's cited.</p> </li> <li> <p>Although not required, substrate/product information could enhance the comprehensibility of the model, particularly for users less familiar with the details of glycolysis.</p> </li> </ol>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:5745387b00001516 is a high-quality representation of the canonical glycolysis pathway in mouse. It accurately captures the enzymatic activities, their sequential relationships, and provides appropriate evidence for all assertions. The model is parsimonious while being comprehensive, making it easy for users to understand the glycolytic pathway.</p> <p>The model successfully represents how glycolysis proceeds from glucose processing through ten enzymatic steps to produce pyruvate, with each step properly annotated and evidenced. No significant issues or inaccuracies were identified during this review.</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/","title":"57c82fad00000695 F13a1 and F13b mouse blood clotting","text":"<p>Now, let me review the GO-CAM model based on all the information gathered:</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#go-cam-model-review-gomodel57c82fad00000695-f13a1-and-f13b-mouse-blood-clotting","title":"GO-CAM Model Review - gomodel:57c82fad00000695 (F13a1 and F13b-mouse-blood clotting)","text":""},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#overview","title":"Overview","text":"<p>The model gomodel:57c82fad00000695 describes the roles of Factor XIII subunits (A and B) in blood coagulation in mouse. It models the interactions between Factor XIII subunits and their regulation by thrombin (F2) in the context of blood clot formation.</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#molecular-components-in-the-model","title":"Molecular Components in the Model","text":"<ol> <li>F13a1 (MGI:MGI:1921395) - Coagulation factor XIII, A1 subunit, the catalytic subunit with protein-glutamine gamma-glutamyltransferase activity</li> <li>F13b (MGI:MGI:88379) - Coagulation factor XIII, B subunit, a non-catalytic subunit that binds to F13a1</li> <li>F2 (MGI:MGI:88380) - Coagulation factor II (Thrombin), with serine-type endopeptidase activity</li> </ol>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#biological-process-and-pathway-represented","title":"Biological Process and Pathway Represented","text":"<p>The model describes blood coagulation (GO:0007596) and specifically the fibrin clot formation (GO:0072378) pathway, where thrombin (F2) activates Factor XIII by cleaving the A subunit (F13a1), while the B subunit (F13b) regulates this process. When activated, Factor XIII cross-links fibrin to stabilize blood clots.</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#review-of-model-structure-and-causal-relationships","title":"Review of Model Structure and Causal Relationships","text":""},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#structure-analysis","title":"Structure Analysis","text":"<p>The model includes four activity nodes: 1. F13b with unspecified molecular function (GO:0003674) - part of generic biological process (GO:0008150) 2. F2 with serine-type endopeptidase activity (GO:0004252)  3. F13a1 with protein-glutamine gamma-glutamyltransferase activity (GO:0003810) 4. F13b with protein binding activity (GO:0005515) - part of blood coagulation (GO:0007596)</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#causal-relationships","title":"Causal Relationships","text":"<p>The model shows three causal relationships: 1. F2 directly positively regulates (RO:0002629) F13a1's protein-glutamine gamma-glutamyltransferase activity 2. F2 directly negatively regulates (RO:0002630) F13b's protein binding activity 3. F13b directly negatively regulates (RO:0002630) F13a1's protein-glutamine gamma-glutamyltransferase activity</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#literature-support","title":"Literature Support","text":"<p>The model is supported by PMID:18224415, which describes a study of F13b knockout mice. The paper shows that F13b helps maintain F13a1 levels in circulation and that both subunits are important for normal blood clotting. The evidence indicates that thrombin activates F13a1 by cleaving an amino-terminal activation peptide, resulting in dissociation from F13b in the presence of calcium, allowing F13a1 to cross-link fibrin.</p> <p>The model is also supported by PMID:18398001 for F2's serine-type endopeptidase activity.</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Inconsistency in F13b representation: The model has two separate activities for F13b - one with molecular function [GO:0003674] and another with protein binding [GO:0005515]. This is confusing and redundant. According to GO-CAM best practices for representing complexes, a protein should have a single molecular function node.</p> </li> <li> <p>Missing complex representation: The literature clearly indicates F13a1 and F13b form a complex (A2B2 heterotetramer), but this is not explicitly modeled. The model should include a complex formation step.</p> </li> <li> <p>Incomplete pathway representation: The model should include the downstream effects of activated F13a1 on fibrin cross-linking to better represent the full biological pathway.</p> </li> <li> <p>Evidence quality: The F13b protein binding activity is supported by \"physical interaction evidence\" (ECO:0000353) but the context of this evidence could be better clarified in the model.</p> </li> <li> <p>Biological process consistency: F13b has two activities that are part of different biological processes (GO:0008150 and GO:0007596). This is inconsistent with the known role of F13b in blood coagulation.</p> </li> </ol>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#recommended-improvements","title":"Recommended Improvements","text":"<ol> <li> <p>Represent F13b with a single activity node related to protein binding and part of blood coagulation.</p> </li> <li> <p>Add a complex formation step showing F13a1 and F13b forming the Factor XIII complex.</p> </li> <li> <p>Include the downstream steps of the pathway to show how activated F13a1 cross-links fibrin.</p> </li> <li> <p>Clarify the evidence supporting the protein binding activity of F13b.</p> </li> <li> <p>Ensure all activities are consistently annotated to the appropriate biological processes.</p> </li> </ol>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a reasonable representation of Factor XIII regulation in blood clotting, supported by relevant literature. However, it could be improved by addressing the issues noted above to better reflect the biological reality and conform to GO-CAM best practices.</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/","title":"5966411600000170 Intestinal smooth muscle cell differentiation via foxo1a  mir145  tgfr1b  ltbp3  zeb1a  D  rerio","text":"<p>Let me review the GO-CAM model based on the information gathered:</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#go-cam-model-review-gomodel5966411600000170","title":"GO-CAM Model Review: gomodel:5966411600000170","text":""},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#title","title":"Title","text":"<p>\"Intestinal smooth muscle cell differentiation via foxo1a, mir145, tgfr1b, ltbp3, zeb1a (D. rerio)\"</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the genetic pathway for intestinal smooth muscle cell (iSMC) differentiation in zebrafish (Danio rerio). The model describes a series of molecular interactions involving multiple genes (foxo1a, mir145, tgfr1b, ltbp3, zeb1a) that regulate the differentiation of intestinal smooth muscle cells from lateral plate mesoderm (LPM).</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#evidence-analysis","title":"Evidence Analysis","text":"<p>The model is based primarily on evidence from a single publication (PMID:28049660), which describes experiments in zebrafish embryos. The evidence types used in the model include: - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000304 (author statement supported by traceable reference used in manual assertion) - ECO:0000314 (direct assay evidence used in manual assertion)</p> <p>The experimental evidence appears to be robust, including morpholino knockdowns (e.g., ZFIN:ZDB-MRPHLNO-170327-1, ZFIN:ZDB-MRPHLNO-170327-3, ZFIN:ZDB-MRPHLNO-110801-4, ZFIN:ZDB-MRPHLNO-170327-5).</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#structure-and-technical-analysis","title":"Structure and Technical Analysis","text":"<p>The model includes: - 10 activities with appropriate gene products - Appropriate causal relationships between activities - A clear biological pathway from TGF\u03b2 signaling to miR-145 expression to downregulation of zeb1a and foxo1a</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#issues-identified","title":"Issues Identified:","text":"<ol> <li> <p>Molecular Function Annotations: Several activities (6 out of 10) use GO:0003674 (molecular_function) as a placeholder, which is not specific. While this is acceptable when the precise function is unknown, the cited paper provides more detailed functional information for some of these gene products that could be incorporated.</p> </li> <li> <p>Overly Generic Biological Process Terms: Although GO:0007179 (transforming growth factor beta receptor signaling pathway) is used appropriately, the model could benefit from more specific biological process terms related to intestinal smooth muscle cell differentiation.</p> </li> <li> <p>No Cellular Component Annotations: There are no cellular component annotations for any of the activities, though the paper describes specific cellular locations for some of these proteins.</p> </li> </ol>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the key findings from the primary paper (PMID:28049660), which describes: - The role of TGF\u03b2 signaling in driving LPM ventral migration and commitment to iSMC fate - The roles of Zeb1a and Foxo1a in LPM migration around the gut - miR-145 regulation of both Zeb1a and Foxo1a - A feedback loop where TGF\u03b2 induces miR-145, which in turn downregulates Zeb1a and Foxo1a</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ul> <li>Correctly captures the regulatory relationships described in the paper</li> <li>Shows the dual roles of miR-145 in targeting different genes</li> <li>Uses appropriate causal relations to show regulatory connections</li> </ul>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Additional Processes: The paper describes specific processes like mesenchymalization, cell migration, and proliferation that could be explicitly modeled.</p> </li> <li> <p>Incomplete Representation of Feedback Loop: The paper shows that miR-145 can target Alk5 (the TGF\u03b2 receptor) creating a negative feedback loop, but this is not represented in the model.</p> </li> <li> <p>Missing Cellular Context: The paper describes this process occurring in lateral plate mesoderm, which could be captured as cellular context.</p> </li> <li> <p>Missing Phenotypic Outcomes: The phenotypic outcomes (intestinal smooth muscle contractility issues) are not explicitly captured.</p> </li> </ol>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices for representing causal relationships. The use of \"directly positively regulates\" (RO:0002629) and \"directly negatively regulates\" (RO:0002630) predicates is appropriate.</p> <p>However, the model would benefit from: 1. More specific molecular function terms instead of generic GO:0003674 2. Addition of cellular component annotations 3. Inclusion of cell or tissue types as contexts</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#recommendation","title":"Recommendation","text":"<p>The model provides a good representation of the key pathway described in the paper but would benefit from the following improvements:</p> <ol> <li>Add more specific molecular function terms for gene products where the paper provides this information</li> <li>Add cellular component annotations</li> <li>Include the Alk5-miR-145 negative feedback loop</li> <li>Add the cellular context (lateral plate mesoderm) for relevant activities</li> <li>Include additional biological process terms related to intestinal smooth muscle cell differentiation</li> <li>Consider representing the phenotypic outcomes (intestinal contractility)</li> </ol> <p>Overall, this is a good model that captures the main regulatory relationships described in the publication, but it could be enhanced with additional details from the paper to make it more comprehensive and informative.</p>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/","title":"59cc772c00000000 IL1beta mediated signaling pathway  Human","text":"<p>Based on my review, I'll provide a comprehensive assessment of the GO-CAM model for IL1beta-mediated signaling pathway (Human) with ID gomodel:59cc772c00000000.</p>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#review-of-go-cam-model-il1beta-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: IL1beta-mediated signaling pathway (Human)","text":""},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>The model gomodel:59cc772c00000000 represents the IL-1\u03b2-mediated signaling pathway in humans. It captures the following key components and interactions:</p> <ol> <li>IL-1\u03b2 cytokine signaling: IL-1\u03b2 (P01584) functions as a cytokine that initiates the signaling cascade</li> <li>Receptor recognition: IL-1\u03b2 binds to and activates the IL-1 receptor type 1 (IL1R1/P14778)</li> <li>Co-receptor involvement: IL-1RAP (Q9NPH3) acts as a co-receptor</li> <li>Adaptor recruitment: MYD88 (Q99836) functions as a molecular adaptor</li> <li>Kinase activation cascade: IRAK4 (Q9NWZ3) \u2192 IRAK1 (P51617) \u2192 MAP3K7 (O43318)</li> <li>Processing component: Caspase-1 (P29466) processes pro-IL-1\u03b2 to mature IL-1\u03b2</li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Proper biological pathway representation: The model correctly represents the canonical IL-1\u03b2 signaling pathway, with appropriate molecular functions assigned to each component.</p> </li> <li> <p>Appropriate use of causal relationships: The model uses the correct causal relationships (RO:0002629 \"directly positively regulates\") to connect components in the pathway.</p> </li> <li> <p>Correct subcellular localization: Components are assigned appropriate cellular locations (e.g., IL-1\u03b2 in extracellular region, IL1R1 in plasma membrane, IRAK4/IRAK1 in cytoplasm).</p> </li> <li> <p>Evidence-based annotations: Most key relationships are supported by experimental evidence with appropriate literature citations.</p> </li> <li> <p>Consistent with signaling receptor guidelines: The model follows the GO-CAM guidelines for signaling receptor activity, where:</p> </li> <li>IL-1\u03b2 has cytokine activity (GO:0005125)</li> <li>IL-1R1 has interleukin-1 receptor activity (GO:0004908)</li> <li>IL1RAP has coreceptor activity (GO:0015026)</li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing NIK-IKK module: The signaling cascade typically continues through NF-\u03baB activation via NIK (MAP3K14) and IKK complex, which aren't represented in the current model.</p> </li> <li> <p>Incomplete activation cascade: The model shows IRAK1 activating MAP3K7, but doesn't show TAK1-binding proteins (TAB1/2) which are essential for MAP3K7 activation.</p> </li> <li> <p>Unconnected component in pathway: Caspase-1 (CASP1) activity is shown as processing pro-IL1\u03b2, but it appears disconnected from the main signaling cascade (this is accurate biologically as inflammasome activation is somewhat separate from IL-1 signaling).</p> </li> <li> <p>Incompletely characterized activity: MAP3K7 (O43318) activity is represented with the generic \"kinase activity\" (GO:0016301) rather than a more specific protein kinase activity term.</p> </li> <li> <p>Missing biochemical output: The model doesn't show the ultimate biochemical outputs of the pathway (e.g., NF-\u03baB activation, gene expression changes).</p> </li> <li> <p>Annotation evidence gaps: Some relationships lack full evidence annotations:</p> </li> <li>The causal association between IRAK1 (gomodel:59cc772c00000000/59cc772c00000024) and MAP3K7 (gomodel:59cc772c00000000/59cde02c00000027) lacks evidence</li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices. Particularly:</p> <ol> <li> <p>Receptor-ligand representation: Follows the signaling receptor activity guidelines with appropriate relationship between ligand (IL-1\u03b2), receptor (IL1R1), and co-receptor (IL1RAP).</p> </li> <li> <p>Molecular adaptor annotation: Correctly represents molecular adaptors (MYD88, TOLLIP) following the molecular adaptor guidelines with \"has input\" relationships to specify interacting partners.</p> </li> <li> <p>Causal relationships: Uses appropriate causal relationship predicates (RO:0002629 \"directly positively regulates\") throughout the model.</p> </li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the core components of the IL-1\u03b2 signaling pathway:</p> <ol> <li> <p>IL-1\u03b2 activation: The model correctly shows CASP1 processing IL-1\u03b2, which is a key step in IL-1\u03b2 maturation.</p> </li> <li> <p>Receptor complex formation: The model appropriately shows IL-1\u03b2 binding to IL-1R1, with IL1RAP serving as co-receptor.</p> </li> <li> <p>Adaptor recruitment: The recruitment of MYD88 and TOLLIP adaptors is biologically accurate.</p> </li> <li> <p>Kinase cascade: The activation sequence IRAK4 \u2192 IRAK1 \u2192 MAP3K7 is consistent with literature evidence, including the PMID:11960013 reference that emphasizes IRAK4's role upstream of IRAK1.</p> </li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Complete the signaling cascade: Add downstream components showing MAP3K7 activation of the IKK complex and subsequent NF-\u03baB activation.</p> </li> <li> <p>Add TAB1/2 adaptors: Include TAB1/2 proteins which connect IRAK1 to MAP3K7 activation.</p> </li> <li> <p>Use more specific molecular function terms: Replace generic \"kinase activity\" with more specific terms where appropriate, such as \"protein serine/threonine kinase activity\" for MAP3K7.</p> </li> <li> <p>Add pathway outcomes: Include the biological outcomes of this pathway, particularly NF-\u03baB activation and target gene expression.</p> </li> <li> <p>Complete evidence annotations: Provide missing evidence for the IRAK1-MAP3K7 connection.</p> </li> <li> <p>Consider including negative regulators: The pathway has several negative regulators (e.g., IL1RN, IRAK3) that could be added to more completely represent physiological regulation.</p> </li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:59cc772c00000000 provides a solid representation of the core IL-1\u03b2 signaling pathway with appropriate molecular functions, cellular locations, and causal relationships between components. The model adheres to GO-CAM best practices for representing signaling pathways and receptor-ligand interactions. While some enhancements could be made to represent the full signaling cascade and its outcomes, the current model accurately captures the key aspects of IL-1\u03b2-mediated signaling.</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/","title":"59dc728000000555  Wnt FGF Notch signaling inregulation of HSC specification via dlc  dld  fgfr4  wnt16  D  rerio","text":"<p>Based on my analysis of this GO-CAM model and the relevant literature, I'll now provide a comprehensive review of the model.</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#review-of-go-cam-model-59dc728000000555","title":"Review of GO-CAM Model: 59dc728000000555","text":""},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#model-overview","title":"Model Overview","text":"<p>Title: Wnt-FGF-Notch signaling in regulation of HSC specification via dlc, dld, fgfr4, wnt16 (D. rerio) ID: gomodel:59dc728000000555 Taxon: Zebrafish (Danio rerio, NCBITaxon:7955) Status: Production</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#summary-of-model-content","title":"Summary of Model Content","text":"<p>This model represents the genetic and molecular pathways involved in hematopoietic stem cell (HSC) specification in zebrafish. It specifically focuses on the interactions between the Wnt, FGF, and Notch signaling pathways, with key roles for wnt16, fgfr4, dlc, and dld genes. The model describes a signaling cascade that occurs in somites during mid-somitogenesis to regulate HSC fate in adjacent posterior lateral mesoderm (PLM).</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#scientific-evaluation","title":"Scientific Evaluation","text":"<p>The model is based on solid research published in PMID:25428693, which demonstrates that FGF signaling through Fgfr4 functions as a molecular relay between Wnt16 and the Notch ligand Dlc in somites to specify HSCs. The paper provides strong experimental evidence for the relationships captured in the model.</p> <p>Key findings supported by the literature: 1. Wnt16 regulates fgfr4 expression in somites 2. FGF signaling via Fgfr4 regulates dlc expression but not dld 3. Both pathways are required for HSC specification in a non-cell-autonomous manner 4. The signaling occurs in specific somitic tissues adjacent to the developing HSCs</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#go-cam-technical-evaluation","title":"GO-CAM Technical Evaluation","text":""},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the key components of the pathway described in the literature</li> <li>Appropriate molecular functions and biological processes are used for the activities</li> <li>The model correctly captures the non-cell autonomous nature of the signaling by indicating somite location for key activities</li> </ol>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Molecular Function Specificity:</li> <li> <p>Several activities use GO:0003674 (molecular_function) which is a very general term. Based on the paper, more specific functions could be assigned, particularly for:</p> <ul> <li>wnt16 (ZFIN:ZDB-GENE-040426-2330) should have Wnt signaling activity</li> <li>dlc (ZFIN:ZDB-GENE-000125-4) should have Notch ligand activity</li> <li>dld (ZFIN:ZDB-GENE-990415-47) should have Notch ligand activity</li> </ul> </li> <li> <p>Pathway Completeness:</p> </li> <li>The model does not include Wnt16 protein itself as an upstream component, despite being crucial in the paper</li> <li> <p>The mechanism of how dlc and dld affect HSC specification in the hemogenic endothelium could be more explicitly modeled</p> </li> <li> <p>Causal Relationships:</p> </li> <li> <p>The causal relationships are correctly using RO:0002304 \"causally upstream of, positive effect\" but more precise relationships like RO:0002629 \"directly positively regulates\" could be used where direct interactions are known</p> </li> <li> <p>Additional Contextual Information:</p> </li> <li>The model could benefit from more specific anatomical locations, particularly for the HSC precursors in the PLM and the hemogenic endothelium</li> <li> <p>The temporal aspect of the signaling (14-17 hpf) could be captured in annotations</p> </li> <li> <p>Evidence Quality:</p> </li> <li>Some evidence annotations reference \" ZFIN:ZDB-PUB-170214-264\" with a leading space, which should be corrected for consistency</li> </ol>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Add More Specific Molecular Functions:</li> <li>Replace GO:0003674 with more specific terms from the GO hierarchy</li> <li>For wnt16: add Wnt signaling activity (GO:0005109)</li> <li> <p>For dlc and dld: add Notch binding (GO:0005112) and Delta-like protein ligand activity (GO:1904993)</p> </li> <li> <p>Expand Pathway Representation:</p> </li> <li>Include upstream wnt16 activity</li> <li>Add downstream effects on HSC specification in hemogenic endothelium</li> <li> <p>Include the parallel Wnt16\u2192dld pathway that is independent of FGF signaling</p> </li> <li> <p>Refine Cellular Contexts:</p> </li> <li>Add specific annotations for somite compartments (sclerotome)</li> <li> <p>Include hemogenic endothelium annotations for the ultimate HSC specification events</p> </li> <li> <p>Fix Evidence Annotations:</p> </li> <li> <p>Correct reference format by removing leading spaces</p> </li> <li> <p>Add Biological Process Context:</p> </li> <li>Include GO:0002244 (hematopoietic progenitor cell differentiation) for the overall process</li> <li>Include GO:0061384 (heart trabecula formation) as it was noted in the paper as being affected</li> </ol>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively captures the key aspects of the non-canonical Wnt16/FGF/Notch signaling pathway that controls HSC specification in zebrafish. The model aligns well with the cited literature and correctly represents the major causal relationships between components.</p> <p>With the suggested improvements, particularly regarding molecular function specificity and pathway completeness, the model would more comprehensively represent the biological mechanisms described in the research. The addition of more detailed cellular contexts would also enhance the model's utility for understanding the spatial organization of this signaling cascade.</p> <p>Overall, this is a valuable model that, with minor improvements, would serve as an excellent representation of this important developmental signaling pathway.</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/","title":"5ae3b0f600000435 Regulation of sprouting angiogenesis via dll4  egfl6  itgb1a  D  rerio","text":"<p>Now that I have a better understanding of the biological context, let me review the GO-CAM model in detail:</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#review-of-go-cam-model-gomodel5ae3b0f600000435-regulation-of-sprouting-angiogenesis-via-dll4-egfl6-itgb1a-d-rerio","title":"Review of GO-CAM Model: gomodel:5ae3b0f600000435 \"Regulation of sprouting angiogenesis via dll4, egfl6, itgb1a (D. rerio)\"","text":""},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#model-overview","title":"Model Overview","text":"<p>This model represents the regulation of sprouting angiogenesis in zebrafish (Danio rerio) through the interactions between three key proteins: dll4, egfl6, and itgb1a. The model focuses on how these proteins regulate the process of sprouting angiogenesis, which is critical for proper blood vessel formation during development.</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#model-structure-and-biological-accuracy","title":"Model Structure and Biological Accuracy","text":"<p>The model includes four key molecular activities:</p> <ol> <li>EGFL6 (ZFIN:ZDB-GENE-040718-157) has two annotated molecular functions:</li> <li>Receptor ligand activity (GO:0048018)</li> <li>Integrin binding (GO:0005178)</li> <li>Occurs in somite (ZFA:0000155)</li> <li> <p>Part of positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050)</p> </li> <li> <p>ITGB1A (ZFIN:ZDB-GENE-060803-2) has:</p> </li> <li>Signaling receptor activity (GO:0038023)</li> <li> <p>Occurs in endothelial cell (ZFA:0009065)</p> </li> <li> <p>DLL4 (ZFIN:ZDB-GENE-041014-73) has:</p> </li> <li>Notch binding (GO:0005112)</li> <li> <p>Part of Notch signaling pathway (GO:0007219)</p> </li> <li> <p>Causal Relationships:</p> </li> <li>EGFL6 directly positively regulates ITGB1A</li> <li>EGFL6 has part EGFL6 (representing its integrin binding activity)</li> <li>ITGB1A directly negatively regulates DLL4</li> </ol> <p>The biological evidence supporting these relationships is based on literature including PMID:27780917 and experimental evidence including mutant phenotype evidence (ECO:0000315).</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>Based on the examination of the model and the GO-CAM best practices, I've identified the following:</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Proper use of causal relationships: The model correctly uses RO:0002629 (directly positively regulates) to connect the ligand activity (EGFL6) to its receptor (ITGB1A).</p> </li> <li> <p>Appropriate evidence codes: The model uses appropriate evidence codes for each assertion, including experimental evidence (ECO:0000315 - mutant phenotype evidence used in manual assertion) and author statements (ECO:0000304).</p> </li> <li> <p>Cellular context: The model includes information about the cellular localization of the activities (somite for EGFL6 and endothelial cell for ITGB1A).</p> </li> <li> <p>Biological process context: Each activity is appropriately contextualized with the relevant biological process.</p> </li> </ol>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing input relationships: According to the signaling receptor activity annotation guidelines, the receptor (ITGB1A) should have a \"has input\" relationship to its downstream effector. Currently, there is no specification of what molecular entity ITGB1A has as input.</p> </li> <li> <p>Regulation pathway completion: While the model shows ITGB1A negatively regulates DLL4, it's not entirely clear how DLL4's Notch binding activity fits into the larger regulatory pathway. Based on the literature, DLL4-Notch signaling plays a critical role in regulating sprouting angiogenesis, but the model doesn't completely capture the downstream effects of DLL4 activity.</p> </li> <li> <p>Limited information on specific mechanism: The model provides a high-level overview of the regulatory relationships but doesn't fully capture the details of how these activities lead to the regulation of sprouting angiogenesis.</p> </li> </ol>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>From the literature I retrieved, it appears that:</p> <ol> <li> <p>DLL4 is a critical Notch ligand in vascular development that is expressed in tip cells of growing blood vessel sprouts and helps regulate proper angiogenesis.</p> </li> <li> <p>EGFL6 appears to be functioning as a receptor ligand that positively regulates ITGB1A (integrin beta 1a), which is involved in signaling receptor activity.</p> </li> <li> <p>The negative regulation of DLL4 by ITGB1A aligns with literature showing complex regulatory networks in sprouting angiogenesis, where integrin signaling can modulate Notch pathway components.</p> </li> </ol> <p>The model appears to be biologically accurate in depicting a pathway where EGFL6 activates ITGB1A signaling, which in turn negatively regulates DLL4-mediated Notch signaling. This regulatory circuit would contribute to the proper control of sprouting angiogenesis during zebrafish development.</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add \"has input\" relationship: Add a \"has input\" relationship from ITGB1A to its downstream effector to better comply with the signaling receptor activity annotation guidelines.</p> </li> <li> <p>Complete the regulatory pathway: Consider expanding the model to show the downstream effects of DLL4-Notch binding, possibly including the effects on cxcr4a expression which was highlighted in the literature as an important factor regulated by Notch signaling during angiogenesis.</p> </li> <li> <p>Add additional biological context: The model could benefit from additional information about how this regulatory circuit fits into the broader process of sprouting angiogenesis and blood vessel formation.</p> </li> <li> <p>Include cellular details: The literature indicates specific cellular dynamics (tip cells vs. stalk cells) that are important for understanding the spatial regulation of angiogenesis. Including these details would enhance the model's biological accuracy.</p> </li> </ol>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Regulation of sprouting angiogenesis via dll4, egfl6, itgb1a (D. rerio)\" provides a valuable representation of a key regulatory pathway in sprouting angiogenesis in zebrafish. It accurately captures the basic relationships between EGFL6, ITGB1A, and DLL4, supported by experimental evidence.</p> <p>While the model largely follows GO-CAM best practices, there are opportunities for enhancement, particularly in specifying the inputs for receptor activities and expanding the model to more fully capture the downstream effects of DLL4-Notch signaling.</p> <p>The model is biologically sound and supported by literature evidence, depicting a regulatory circuit that contributes to the control of sprouting angiogenesis during zebrafish development.</p>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/","title":"5b528b1100000489 XBP 1 is a cell nonautonomous regulator of stress resistance and longevity","text":"<p>Now I'll review the GO-CAM model based on the documentation and literature I've gathered.</p>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#go-cam-model-review-for-gomodel5b528b1100000489","title":"GO-CAM Model Review for gomodel:5b528b1100000489","text":""},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#model-title","title":"Model Title:","text":"<p>\"XBP-1 is a cell-nonautonomous regulator of stress resistance and longevity\"</p>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#overview","title":"Overview:","text":"<p>This GO-CAM model represents the molecular pathway related to XBP-1's role in stress resistance and longevity in C. elegans. The model captures the IRE-1/XBP-1 pathway involved in the unfolded protein response (UPR), particularly focusing on how IRE-1's RNA endonuclease activity leads to XBP-1 regulation, which in turn affects neuronal function via UNC-13.</p>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#model-structure-assessment","title":"Model Structure Assessment:","text":"<ol> <li>Activities and connections:</li> <li>The model shows IRE-1 RNA endonuclease activity (GO:0004521) in two locations (intestine and neuronal cell body)</li> <li>IRE-1 directly positively regulates XBP-1's RNA polymerase II transcription DNA binding (GO:0000977)</li> <li>XBP-1 causally positively regulates UNC-13's syntaxin-1 binding (GO:0017075)</li> <li> <p>UNC-13 is part of synaptic vesicle exocytosis (GO:0016079)</p> </li> <li> <p>Biological validity:</p> </li> <li>The model accurately captures the IRE-1/XBP-1 pathway in the unfolded protein response</li> <li>The representation of XBP-1 as a transcription factor is appropriate</li> <li> <p>The connection to UNC-13 and synaptic function reflects the cell-nonautonomous effect described in the model title</p> </li> <li> <p>Completeness assessment:</p> </li> <li>The model includes appropriate molecular functions, cellular components, and biological processes</li> <li>Evidence codes and references are properly included</li> <li>The causal relationships use appropriate predicates</li> </ol>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#review-comments","title":"Review Comments:","text":"<ol> <li>Strengths:</li> <li>The model accurately represents the known biology of the IRE-1/XBP-1 pathway in C. elegans</li> <li>The causal relationships properly show that IRE-1 directly positively regulates XBP-1</li> <li> <p>The model captures cell-nonautonomous regulation by showing XBP-1 functioning in neurons while affecting intestinal processes</p> </li> <li> <p>Suggested improvements:</p> </li> <li>The model could benefit from explicitly including the IRE1-mediated unfolded protein response (GO:0036498) as a biological process associated with IRE-1's activity in the intestine, similar to how it's included for the neuronal activity</li> <li>Consider including a representation of how IRE-1 is activated during ER stress, which would provide fuller context of the pathway</li> <li> <p>The model could explicitly include how XBP-1 relates to longevity and stress resistance, which are mentioned in the title but not fully represented in the model</p> </li> <li> <p>Compliance with GO-CAM guidelines:</p> </li> <li>The transcription factor annotation aligns with the guidelines, using appropriate GO terms for DNA binding (GO:0000977)</li> <li>The RNA endonuclease activity of IRE-1 is properly represented</li> <li>The model correctly uses the \"directly positively regulates\" relationship (RO:0002629) between the activities</li> </ol>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model successfully represents the IRE-1/XBP-1 pathway in C. elegans and its role in regulating UNC-13 and synaptic function. The model accurately captures the cell-nonautonomous nature of this regulation as described in the scientific literature. The causal relationships between molecular activities are appropriate, and the evidence for these assertions is well-documented with appropriate references.</p> <p>The model would benefit from minor additions to more fully represent the connection to longevity and stress resistance mentioned in the title, but overall it is a high-quality representation of this biological pathway that complies with GO-CAM best practices.</p> <p>Model ID: gomodel:5b528b1100000489</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/","title":"5b91dbd100002057 Antifungal innate immune response in the hypodermis via MAPK cascade  C  elegans","text":"<p>Based on my review of the GO-CAM model \"Antifungal innate immune response in the hypodermis via MAPK cascade (C. elegans)\" (gomodel:5b91dbd100002057), here is my assessment:</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#go-cam-review-antifungal-innate-immune-response-model-gomodel5b91dbd100002057","title":"GO-CAM Review: Antifungal innate immune response model (gomodel:5b91dbd100002057)","text":""},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM represents the antifungal innate immune response in the C. elegans hypodermis involving a MAPK cascade. The model describes how C. elegans responds to fungal infection via a signaling pathway that leads to antimicrobial peptide production.</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#pathway-components-and-flow","title":"Pathway Components and Flow","text":"<p>The model successfully captures the MAPK signaling cascade involved in C. elegans antifungal innate immunity as described in the literature (PMID:19380113). The key components are properly represented:</p> <ol> <li>G-protein signaling components: </li> <li>GPA-12 (G-protein alpha subunit) and RACK-1 (G-protein beta-like)</li> <li> <p>These proteins initiate the signaling cascade upon infection</p> </li> <li> <p>Phospholipase C activities: </p> </li> <li> <p>EGL-8 and PLC-3 phospholipase C activities correctly modeled as upstream of PKC</p> </li> <li> <p>PKC signaling: </p> </li> <li>TPA-1 (PKC-delta homolog) and PKC-3 activities</li> <li> <p>Properly placed downstream of G-protein signaling</p> </li> <li> <p>MAPK cascade components: </p> </li> <li>NSY-1 (MAPKKK) \u2192 SEK-1 (MAPKK) \u2192 PMK-1 (MAPK)</li> <li> <p>The directional flow of the cascade is correctly represented</p> </li> <li> <p>Output: </p> </li> <li>The pathway appropriately ends with NLP-29, an antimicrobial peptide involved in the response</li> </ol>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The evidence cited in the model is strong and appropriate:</p> <ul> <li>Multiple experimental evidence codes are used (ECO:0000315 for mutant phenotype evidence, ECO:0000314 for direct assay evidence)</li> <li>Key publications like PMID:19380113 that describe the pathway are cited</li> <li>Appropriate functional annotation evidence is provided for protein activities</li> </ul>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#pathway-context","title":"Pathway Context","text":"<p>The model correctly places the activities in the context of the biological process GO:0061760 \"antifungal innate immune response\" and appropriate tissues (hypodermis).</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ul> <li>Activities are connected with appropriate causal predicates (RO:0002304 \"causally upstream of, positive effect\" and RO:0002629 \"directly positively regulates\")</li> <li>Molecular functions are properly assigned to gene products</li> <li>The biological process context is correctly specified</li> </ul>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#parsimonious-representation","title":"Parsimonious Representation","text":"<p>The model provides a clear and concise representation of the pathway that is easy to follow:</p> <ul> <li>The causal flow is logically organized</li> <li>Components are appropriately grouped by their role in the pathway</li> <li>No redundant or extraneous elements are included</li> </ul>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#technical-issues","title":"Technical Issues","text":"<p>No major technical issues were identified in the model structure or representation.</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#minor-improvement-suggestions","title":"Minor Improvement Suggestions","text":"<ol> <li> <p>Additional contextual information: While the model correctly locates activities in the hypodermis, adding more specific cellular component information for some proteins might be valuable.</p> </li> <li> <p>Publication evidence: For some activities, more recent publications could be added to strengthen the evidence base.</p> </li> <li> <p>Connection to downstream effects: The model could potentially be extended to show how NLP-29 functions to mediate fungal resistance.</p> </li> </ol>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the C. elegans antifungal immune response pathway via the MAPK cascade as described in the literature. The causal relationships between activities are well-established with appropriate evidence. The model adheres to GO-CAM best practices and presents a clear, logical representation of the biological process.</p> <p>The model successfully integrates multiple experimental findings into a coherent pathway that describes how C. elegans detects and responds to fungal pathogens through G-protein signaling, PKC activation, and MAPK cascade signaling, ultimately leading to antimicrobial peptide production.</p> <p>This is a high-quality GO-CAM model that meets the standards for biological accuracy, evidence support, and technical representation.</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/","title":"5b91dbd100002241 Antifungal innate immune response in the hypodermis via transforming growth factor beta receptor signaling pathway  C  elegans","text":"<p>Based on my review of the model and the related documentation, I'll now provide a comprehensive evaluation of GO-CAM model gomodel:5b91dbd100002241.</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#review-of-go-cam-model-gomodel5b91dbd100002241","title":"Review of GO-CAM model: gomodel:5b91dbd100002241","text":""},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#model-overview","title":"Model Overview","text":"<p>Title: Antifungal innate immune response in the hypodermis via transforming growth factor beta receptor signaling pathway (C. elegans) ID: gomodel:5b91dbd100002241 Taxon: NCBITaxon:6239 (Caenorhabditis elegans) Status: Production</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents a key aspect of the antifungal innate immune response in C. elegans, specifically the TGF-\u03b2 pathway that regulates the expression of antimicrobial peptides in the epidermis (hypodermis) after fungal infection by Drechmeria coniospora. The model focuses on a non-canonical TGF-\u03b2 signaling pathway that functions independently of the p38 MAPK pathway to regulate caenacin (CNC) family antimicrobial peptide genes.</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-supported by evidence: The model is well-supported by experimental evidence from multiple publications, particularly PMID:19198592, which investigated the neuroimmune regulation of antimicrobial peptide expression.</p> </li> <li> <p>Pathway completeness: The model captures the key components of the TGF-\u03b2 signaling pathway from the ligand (DBL-1) through the receptors (DAF-4 and SMA-6) to the downstream transcription factor (SMA-3).</p> </li> <li> <p>Accurate representation of cell-to-cell signaling: The model correctly represents that DBL-1 is produced in neurons and acts non-cell-autonomously on the epidermis, which is consistent with the literature evidence.</p> </li> <li> <p>Clear biological process context: All activities are correctly annotated as part of the defense response to fungus (GO:0050832), which provides appropriate context.</p> </li> </ol>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing receptor complex representation: According to the \"How to annotate complexes in GO-CAM\" guidelines, the model should represent the heterodimeric receptor formed by SMA-6 (type I receptor) and DAF-4 (type II receptor). The current model shows them as separate entities but doesn't explicitly model their interaction as a complex. The literature (PMID:9847239) clearly states they form a heterodimeric receptor.</p> </li> <li> <p>Incomplete SMAD pathway representation: The model correctly shows that SMA-3 is required for this pathway but doesn't fully explain why SMA-2 and SMA-4 are not involved, despite these typically being required for canonical TGF-\u03b2 signaling. This is mentioned in the paper (PMID:19198592), but the model doesn't represent this non-canonical aspect clearly.</p> </li> <li> <p>Missing molecular function for CNC-2: The protein product of WB:WBGene00000556 (cnc-2) is annotated with molecular_function (GO:0003674), which indicates \"no evidence data found.\" Given that the paper identifies this as an antimicrobial peptide, a more specific function might be appropriate.</p> </li> <li> <p>Missing ligand-receptor interaction: According to the \"Signaling receptor activity annotation guidelines,\" the relation between a ligand and its target receptor should be captured with 'has input' and the causal relation should be 'directly positively regulates.' The model shows DBL-1 positively regulating the receptors but doesn't clearly capture the ligand-receptor binding relationship.</p> </li> <li> <p>Location information: The cellular component information could be more specific, especially for specifying that DBL-1 acts in the extracellular space and the receptors are located in the plasma membrane.</p> </li> </ol>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the key finding from the literature that antimicrobial peptide genes of the caenacin (CNC) family are regulated by a non-canonical TGF-\u03b2 signaling pathway during fungal infection, which is distinct from the p38 MAPK pathway that regulates other antimicrobial peptides (NLP family). </p> <p>The model correctly represents: - DBL-1 (TGF-\u03b2 homolog) acts in a paracrine manner from neurons to the epidermis - The signaling requires both the type I receptor SMA-6 and the type II receptor DAF-4 - The pathway depends on SMA-3 (SMAD) but not on other SMADs (SMA-2, SMA-4) - The pathway ultimately regulates expression of antimicrobial peptides (cnc-2)</p> <p>The use of causal relationships in the model (RO:0002304 \"causally upstream of, positive effect\" and RO:0002629 \"directly positively regulates\") is consistent with the biology described in the literature.</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add receptor complex representation: Explicitly model the SMA-6/DAF-4 heterodimeric receptor complex as described in the \"How to annotate complexes in GO-CAM\" guidelines.</p> </li> <li> <p>Expand molecular function annotations: Replace the generic molecular_function (GO:0003674) for CNC-2 with a more specific term related to antimicrobial peptide activity if evidence exists.</p> </li> <li> <p>Clarify the non-canonical nature: Add additional annotations or notes to highlight that this represents a non-canonical TGF-\u03b2 signaling pathway that doesn't require SMA-2 and SMA-4, which distinguishes it from the canonical pathway.</p> </li> <li> <p>Add cellular location information: Specify the cellular components for each activity more precisely, especially noting that DBL-1 acts in the extracellular space and the receptors are located in the plasma membrane.</p> </li> <li> <p>Enhance ligand-receptor representation: Follow the signaling receptor activity guidelines more closely to represent the relationship between DBL-1 and the receptor complex.</p> </li> </ol>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a valuable representation of the non-canonical TGF-\u03b2 signaling pathway in C. elegans antifungal immunity. It captures the key components and relationships of this pathway and is well-supported by experimental evidence. With the suggested improvements, particularly in representing receptor complexes and cellular locations, the model would provide an even more comprehensive and accurate representation of this important immune signaling pathway.</p>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/","title":"5ce58dde00001215 Mouse Aatf antiapoptosis","text":"<p>Now let me also check the information in the referenced PMID in the GO-CAM model to understand the functional relationship between these proteins:</p> <p>Let me analyze the GO-CAM model and review it based on the information I've collected and the GO-CAM guidelines.</p>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#review-of-go-cam-model-5ce58dde00001215-mouse-aatf-antiapoptosis","title":"Review of GO-CAM Model 5ce58dde00001215 \"Mouse-Aatf-antiapoptosis\"","text":""},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#overview-of-the-model","title":"Overview of the Model:","text":"<p>This GO-CAM model describes the role of AATF (Apoptosis Antagonizing Transcription Factor) in protecting cells from ER stress-mediated apoptosis in mouse pancreatic beta cells, primarily through regulating the transcription factor activity of a complex containing AATF and STAT3, which then activates AKT1 expression.</p>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#model-components","title":"Model Components:","text":"<ol> <li>Core Proteins:</li> <li>AATF (MGI:MGI:1328355): Anti-apoptotic factor that protects cells from ER stress-mediated cell death</li> <li>STAT3 (MGI:MGI:103038): Transcription factor that forms a complex with AATF</li> <li> <p>AKT1 (MGI:MGI:87986): Serine/threonine kinase with anti-apoptotic functions</p> </li> <li> <p>Biological Context:</p> </li> <li>This pathway operates in type B pancreatic cells (CL:0000169)</li> <li>It's part of the endoplasmic reticulum unfolded protein response (GO:0030968)</li> <li> <p>Leads to negative regulation of intrinsic apoptotic signaling pathway (GO:2001243)</p> </li> <li> <p>Functional Relationships:</p> </li> <li>XBP1 positively regulates AATF</li> <li>ERN1 positively regulates AATF</li> <li>AATF and ERN1 positively regulate STAT3-containing transcription complex</li> <li>EIF2AK3 positively regulates EIF2A which regulates STAT3-containing complex</li> <li>AATF-STAT3 complex directly positively regulates AKT1</li> <li>AKT1 inhibits apoptosis</li> </ol>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#assessment-of-model-according-to-go-cam-guidelines","title":"Assessment of Model according to GO-CAM Guidelines:","text":""},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#strengths","title":"Strengths:","text":"<ol> <li> <p>Accurate molecular functions: The transcription factor complex containing AATF and STAT3 is properly annotated with DNA-binding transcription factor activity (GO:0003700), which is appropriate based on the role of this complex in transcriptional regulation.</p> </li> <li> <p>Clear causal relationships: The model uses appropriate causal associations:</p> </li> <li>RO:0002304 \"causally upstream of, positive effect\" for upstream regulators</li> <li>RO:0002629 \"directly positively regulates\" for the STAT3 complex's effect on AKT1</li> <li> <p>RO:0004047 (which appears in the model) for EIF2A's relationship with the complex</p> </li> <li> <p>Cellular context: The model includes the cellular location (nucleus GO:0005634 for the transcription complex; pancreatic beta cells CL:0000169 for AATF).</p> </li> <li> <p>Biological process context: Components are correctly annotated as part of the ER unfolded protein response (GO:0030968).</p> </li> </ol>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex Representation: According to the \"How to annotate complexes in GO-CAM\" document, when using a protein complex (GO:0005667 transcription regulator complex), the model should indicate which specific proteins carry the molecular activities. Here, the model correctly shows that both STAT3 and AATF are in the complex, but:</p> </li> <li> <p>The composition of the complex is incomplete, as based on the literature, this complex formation is enhanced by STAT3 binding to phosphorylated AATF, and this relationship isn't captured.</p> </li> <li> <p>According to the reference PMID:19911006, AATF and STAT3 interact directly, and this interaction enhances the binding of STAT3 to the AKT1 promoter, but this mechanistic detail isn't fully captured.</p> </li> <li> <p>Missing Phosphorylation Events: The PMID:19911006 reference emphasizes the importance of phosphorylation:</p> </li> <li>AATF is induced by ER stress through PERK-eIF2alpha phosphorylation</li> <li>STAT3 phosphorylation is enhanced by AATF</li> <li>AKT phosphorylation is also important for its activity</li> </ol> <p>These phosphorylation events are critical for the pathway functionality but aren't captured in the model.</p> <ol> <li> <p>Incomplete Biological Processes: The terminal effect of this pathway is properly captured as \"negative regulation of intrinsic apoptotic signaling pathway,\" but intermediate processes like \"transcriptional regulation of AKT1\" could have been included.</p> </li> <li> <p>Evidence Codes: While the model uses appropriate evidence codes (ECO:0000315 for mutant phenotype evidence and ECO:0000314 for direct assay evidence), some of the relationships might benefit from more specific evidence annotations.</p> </li> <li> <p>Missing Inputs for Transcription Factor Activity: According to the \"DNA-binding transcription factor activity annotation guidelines,\" the transcription factor activity should have \"has input\" relationships to the gene it regulates. The model shows that the complex directly positively regulates AKT1 activity, but doesn't explicitly show that it regulates AKT1 gene expression.</p> </li> </ol>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#recommendations-for-improvement","title":"Recommendations for Improvement:","text":"<ol> <li> <p>Add Phosphorylation States: Include the critical phosphorylation events (especially for STAT3 at Tyr-705 and Ser-727, and AATF phosphorylation by PERK pathway).</p> </li> <li> <p>Refine Complex Representation: Better specify the molecular interaction between AATF and STAT3 and how this interaction enhances STAT3 DNA binding.</p> </li> <li> <p>Complete the Transcriptional Regulation Representation: Add \"has input\" relationship from the transcription complex to the AKT1 gene, as per the transcription factor annotation guidelines.</p> </li> <li> <p>Add More Specific Biological Process Terms: Include intermediate processes like \"regulation of AKT1 transcription\" to better represent the mechanistic details.</p> </li> <li> <p>Enhance Cellular Context: Add more detailed subcellular localization for different components of the pathway, especially the translocation events mentioned in the paper.</p> </li> </ol>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model provides a good representation of AATF's role in protecting cells from ER stress-induced apoptosis through promoting AKT1 expression via the STAT3 transcription factor complex. The model correctly captures the major players and relationships, but could be enhanced by including more mechanistic details about phosphorylation events, complex formation, and transcriptional regulation specifics.</p> <p>The model is consistent with the reference literature (PMID:19911006) and follows GO-CAM best practices, though some refinements would make it even more informative and mechanistically accurate.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/","title":"5df932e000000330 Protease activity in epithelial morphogenesis via f2rl1 2  spint1a  st14a  D  rerio","text":"<p>Based on my review of the GO-CAM model gomodel:5df932e000000330 and the relevant literature, I will now provide a comprehensive assessment of this model.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#review-of-go-cam-model-gomodel5df932e000000330","title":"Review of GO-CAM Model: gomodel:5df932e000000330","text":""},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#model-overview","title":"Model Overview","text":"<p>Title: Protease activity in epithelial morphogenesis via f2rl1.2, spint1a, st14a (D. rerio) Taxon: NCBITaxon:7955 (Danio rerio/zebrafish) Status: Production Model ID: https://bioregistry.io/go.model:5df932e000000330</p> <p>This model captures a signaling pathway in zebrafish involving protease activity regulation in epithelial morphogenesis, specifically focusing on the roles of f2rl1.2 (Par2b), spint1a (Hai1a), and st14a (matriptase).</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#biological-context","title":"Biological Context","text":"<p>The model represents a signaling pathway described in the referenced literature (PMID:29301867), which studies the role of protease-activated receptor 2 (Par2b) in matriptase-dependent skin abnormalities in Hai1a-deficient zebrafish embryos. The paper reports that Par2b signaling regulates epithelial cell extrusion, cell-cell contacts, proliferation, and inflammation in zebrafish epidermis.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#1-structural-assessment","title":"1. Structural Assessment","text":"<p>The model consists of 8 activities (molecular functions) connected by causal relationships:</p> <ul> <li>Four activities represent peptidase inhibitor activity (GO:0030414) enabled by spint1a (ZFIN:ZDB-GENE-040426-2169)</li> <li>Three activities represent peptidase activity (GO:0008233) enabled by st14a (ZFIN:ZDB-GENE-030131-6496)</li> <li>Three activities represent unspecified molecular functions (GO:0003674) enabled by f2rl1.2 (ZFIN:ZDB-GENE-070615-24)</li> </ul> <p>The activities are connected by causal relationships primarily using \"directly negatively regulates\" (RO:0002630) and \"directly positively regulates\" (RO:0002629) relationships.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#2-biological-content-assessment","title":"2. Biological Content Assessment","text":"<p>The model accurately captures several key aspects of the biological pathway:</p> <ol> <li> <p>Protease inhibition pathway: spint1a (Hai1a) inhibits st14a (matriptase) activities, represented by RO:0002630 (directly negatively regulates) relationships.</p> </li> <li> <p>Downstream regulation: st14a activities positively regulate f2rl1.2 (Par2b) activities, represented by RO:0002629 (directly positively regulates) relationships.</p> </li> <li> <p>Biological context: The peptidase activities are correctly annotated as being \"part of\" protein processing (GO:0016485).</p> </li> </ol> <p>These relationships align with the findings in the paper, which describes Hai1a as an inhibitor of matriptase (st14a), and matriptase as an activator of Par2b (f2rl1.2).</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#3-evidence-assessment","title":"3. Evidence Assessment","text":"<p>The model uses appropriate evidence codes:</p> <ul> <li>ECO:0000315 (mutant phenotype evidence) with appropriate ZFIN genotype references</li> <li>ECO:0000316 (genetic interaction evidence) </li> <li>ECO:0000314 (direct assay evidence)</li> </ul> <p>All evidence is tied to PMID:29301867, which is the primary source of the assertions.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement","text":"<ol> <li>Molecular Functions Specification:</li> <li> <p>f2rl1.2 (Par2b) is annotated with GO:0003674 (molecular_function), which is a root term. Based on the paper, Par2b functions as a G protein-coupled receptor. A more specific term such as \"G protein-coupled receptor activity\" would be more informative.</p> </li> <li> <p>Missing Biological Processes:</p> </li> <li> <p>The model could be enhanced by including additional biological processes mentioned in the paper, such as \"apical cell extrusion\" or \"epithelial cell migration,\" to better contextualize the molecular activities.</p> </li> <li> <p>Missing Cellular Components:</p> </li> <li> <p>The model lacks cellular component annotations. Given that the pathway involves membrane-localized proteins (matriptase is a membrane-tethered protease and Par2b is a transmembrane receptor), including cellular component information would strengthen the model.</p> </li> <li> <p>Pathway Completeness:</p> </li> <li> <p>The model represents a simplified version of the pathway described in the paper. Additional nodes could be included to capture:</p> <ul> <li>The role of Mmps (mentioned as being regulated by Par2b)</li> <li>The connection to Erbb2 signaling (mentioned as interacting with this pathway)</li> <li>Differential effects on periderm vs. basal keratinocytes</li> </ul> </li> <li> <p>Molecular Details:</p> </li> <li>The specific cleavage site of Par2b by matriptase (R28/M29 as described in the paper) could be more explicitly represented in the model.</li> </ol>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:5df932e000000330 provides a reasonable representation of the protease signaling pathway involved in epithelial morphogenesis in zebrafish as described in PMID:29301867. The model correctly captures the inhibitory relationship between spint1a and st14a, and the activating relationship between st14a and f2rl1.2.</p> <p>However, the model could be improved by: 1. Using more specific molecular function terms for Par2b 2. Adding relevant biological processes and cellular components 3. Expanding the pathway to include additional components and interactions described in the literature 4. Providing more molecular details about the interactions</p> <p>Despite these limitations, the model is consistent with the biological content in the referenced literature and follows GO-CAM best practices for representing causal relationships between activities.</p>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/","title":"5e72450500004019 SARS COV2 HOST","text":"<p>Based on my review of the GO-CAM model and supporting information, I'll now provide a comprehensive assessment.</p>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#go-cam-model-review-summary-gomodel5e72450500004019","title":"GO-CAM Model Review Summary - gomodel:5e72450500004019","text":""},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#general-assessment","title":"General Assessment","text":"<p>This model titled \"SARS-COV2/HOST\" provides a detailed representation of interactions between SARS-CoV-2 viral proteins and the host innate immune response system, particularly focusing on the RIG-I-like receptor (RLR) signaling pathway. The model effectively depicts how various SARS-CoV-2 proteins antagonize key components of the human antiviral signaling cascade.</p>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive coverage: The model successfully captures multiple aspects of the host-pathogen interaction involving SARS-CoV-2 proteins and their targets in the human innate immune system.</p> </li> <li> <p>Evidence-based assertions: Most activities and causal associations are well-supported by primary literature references, with appropriate evidence codes (primarily ECO:0000314 - direct assay evidence used in manual assertion).</p> </li> <li> <p>Biological accuracy: The representation of RLR signaling components (IFIH1/MDA5, RIG-I, MAVS) and their interactions is consistent with current scientific knowledge as verified through UniProt entries and primary literature.</p> </li> <li> <p>Clear mechanistic view: The model provides a clear view of how SARS-CoV-2 proteins target different stages of the antiviral signaling pathway, providing a coherent picture of viral immune evasion strategies.</p> </li> <li> <p>Precise cellular context: Activities are properly annotated with subcellular locations (cytoplasm, mitochondria, nucleus), which is crucial for understanding compartmentalized signaling.</p> </li> </ol>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing evidence for some causal associations: Several causal relationships lack evidence annotations, including:</li> <li>The connection between IRF3 (Q14653-5) and nsp16 (P0DTD1-PRO_0000449633)</li> <li> <p>The connection between nsp16 (P0DTD1-PRO_0000449633) and nsp1 (P0DTD1-PRO_0000449619)</p> </li> <li> <p>Missing \"has input\" annotations: According to GO-CAM best practices for:</p> </li> <li>Protein sequestering activity: Several activities with GO:0140311 (protein sequestering activity) lack \"has input\" relations to specify which protein is being sequestered</li> <li> <p>E3 ubiquitin ligase activity: Activities with GO:0061630 (ubiquitin protein ligase activity) lack \"has input\" annotations to indicate the ubiquitination targets</p> </li> <li> <p>Specific activity branches could be expanded: </p> </li> <li>The IRF3 transcription factor activity could be enhanced by specifying its gene targets with \"has input\" relations</li> <li> <p>For several proteins, more specific ubiquitination process terms could be provided (e.g., K48-linked vs. K63-linked)</p> </li> <li> <p>Causal relationship annotations: Some relationships use RO:0002411 (concurrence with) instead of more specific causal relationships like indirect positive/negative regulation</p> </li> <li> <p>Lack of cellular response outcomes: The model could be extended to more clearly indicate downstream effects of the innate immune suppression on cellular outcomes or viral replication.</p> </li> </ol>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model accurately represents the current understanding of SARS-CoV-2 interference with the innate immune system. The key components include:</p> <ol> <li> <p>RIG-I/MDA5 pathway: Correctly represented as cytoplasmic PRRs that recognize viral RNA and signal through MAVS.</p> </li> <li> <p>MAVS as a central hub: The model properly captures MAVS as the central adaptor for signaling through the TRAF3/TBK1/IRF3 cascade.</p> </li> <li> <p>Viral antagonism: The model correctly represents multiple SARS-CoV-2 proteins interfering with signaling at different levels:</p> </li> <li>M protein inhibits MAVS (consistent with PMID:33110251)</li> <li>nsp3 deISGylates MDA5 to prevent its activation</li> <li>ORF9b targets mitochondria and affects MAVS signaling</li> <li>nsp1 suppresses host translation</li> <li> <p>Various proteins target IRF3 activity</p> </li> <li> <p>Downstream effects: The model adequately shows the disruption of both IRF3 and NF-\u03baB activation by viral proteins.</p> </li> </ol>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#conformance-to-go-cam-best-practices","title":"Conformance to GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices but has some areas for improvement:</p> <ol> <li> <p>Protein sequestering activities: While correctly using GO:0140311 and RO:0002630 (directly negatively regulates) to connect to downstream activities, it's missing the required \"has input\" relation to specify the target protein.</p> </li> <li> <p>E3 ubiquitin ligase activities: The model correctly uses GO:0061630 for TRIM25, TRAF3, and TRAF6, but lacks \"has input\" relations and specific ubiquitination process terms.</p> </li> <li> <p>DNA-binding transcription factor activity: The IRF3 activity is correctly located in the nucleus (GO:0005634) and part of mRNA transcription (GO:0009299), but misses specific gene targets with \"has input\" and uses RO:0002411 instead of indirect regulatory relationships.</p> </li> </ol>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Add missing evidence annotations: Provide evidence for all causal associations.</p> </li> <li> <p>Add \"has input\" relations: Add these for:</p> </li> <li>Protein sequestering activities (GO:0140311) to specify which proteins are being sequestered</li> <li>E3 ubiquitin ligase activities (GO:0061630) to indicate ubiquitination targets</li> <li> <p>IRF3 transcription factor activity to specify gene targets</p> </li> <li> <p>Enhance IRF3 activity representation: Use appropriate causal relations like \"indirectly positively regulates\" instead of \"concurrence with\" when connecting IRF3 to downstream effects.</p> </li> <li> <p>Add specific ubiquitination terms: Where known, specify the type of ubiquitination (K48-linked vs. K63-linked) to provide more precise annotation.</p> </li> <li> <p>Add cellular outcomes: Consider extending the model to show the ultimate effects of these pathways on viral replication or cellular outcomes.</p> </li> </ol>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model provides a valuable representation of SARS-CoV-2 interactions with the human innate immune system, particularly the RLR signaling pathway. The model is scientifically accurate, well-supported by evidence, and generally follows GO-CAM best practices. With some modest improvements to add missing annotations and relations, it would fully conform to best practices while enhancing its biological clarity and comprehensiveness.</p> <p>The model represents an important contribution to understanding SARS-CoV-2 pathogenesis and immune evasion strategies, which is particularly valuable in the context of the COVID-19 pandemic.</p>"},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/","title":"5e72450500004237 SARS COV2 cycle","text":"<p>Based on the complex annotation guidelines, I'd recommend that for cases like the SARS-CoV-2 RNA polymerase complex, where multiple viral proteins work together, the model should clearly represent which subunit carries which activity - which is already done in this model. However, the relationships between complex members could be made clearer through the activity flow.</p>"},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/#final-recommendations","title":"Final Recommendations","text":"<ol> <li> <p>Add evidence for all causal relationships: Ensure all causal associations have appropriate evidence codes and PMIDs.</p> </li> <li> <p>Use more specific causal predicates: Replace general RO:0002411 (causally upstream of) terms with more specific ones like RO:0002629 (directly positively regulates) or RO:0002630 (directly negatively regulates) where possible.</p> </li> <li> <p>Complete the biological processes: Ensure all molecular functions are associated with appropriate biological processes to provide full context.</p> </li> <li> <p>Review virus-host interactions: Consider adding more explicit representation of key host factors that interact with viral proteins, particularly for immune evasion.</p> </li> <li> <p>Check activity flow: Ensure that the flow of activities accurately represents the SARS-CoV-2 life cycle based on current literature.</p> </li> <li> <p>Update evidence codes: For some annotations using ECO:0000250 (sequence similarity evidence), consider if more direct evidence is now available given the extensive research on SARS-CoV-2.</p> </li> </ol> <p>Overall, this is a well-constructed GO-CAM model representing the SARS-CoV-2 viral cycle with strong evidence support. The identified issues are relatively minor and addressing them would further enhance the model's utility and accuracy.</p>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/","title":"5ee8120100000524 SP N4BP3on MAVS","text":"<p>Based on my review and the GO-CAM documentation, I'll now provide a thorough assessment of the GO-CAM model with ID 5ee8120100000524.</p>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#review-of-go-cam-model-5ee8120100000524-sp_n4bp3on-mavs","title":"Review of GO-CAM Model: 5ee8120100000524 (\"SP_N4BP3on MAVS\")","text":""},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents a signaling pathway involving N4BP3 (NEDD4 binding protein 3) regulation of MAVS (Mitochondrial antiviral-signaling protein) in the context of innate immune antiviral response. The model includes:</p> <ol> <li>NEDD4 (E3 ubiquitin-protein ligase) with ubiquitin protein ligase activity</li> <li>N4BP3 with protein binding activity</li> <li>MAVS with signaling adaptor activity</li> <li>TRAF2 with ubiquitin protein ligase binding activity</li> </ol>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#model-structure-and-connections","title":"Model Structure and Connections","text":"<p>The model shows a linear pathway where: - N4BP3 directly positively regulates (RO:0002629) NEDD4 - NEDD4 directly positively regulates (RO:0002629) MAVS - MAVS directly positively regulates (RO:0002629) TRAF2</p> <p>All activities in the model are linked to evidence from the literature, primarily PMID:34880843, with TRAF2's activity also referencing PMID:23951545.</p>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#assessment-of-biological-content","title":"Assessment of Biological Content","text":"<p>The model captures key aspects of the research presented in PMID:34880843, which shows that N4BP3 positively regulates RIG-I-like receptor antiviral signaling by targeting MAVS. According to the paper, N4BP3 promotes the ubiquitination of MAVS, which enhances the interaction between MAVS and TRAF2.</p> <p>Specifically, the model represents: 1. The interaction between N4BP3 and NEDD4 (N4BP3 is a NEDD4 binding protein) 2. NEDD4's role in ubiquitinating MAVS 3. The enhanced interaction between MAVS and TRAF2</p>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li>Evidence-based: All activities are supported by primary literature references</li> <li>Appropriate molecular functions: Each protein is annotated with a biologically appropriate molecular function</li> <li>Logical causal relationships: The causal connections between activities make biological sense</li> <li>Parsimony: The model focuses on the key proteins and activities in the pathway without unnecessary complexity</li> </ol>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Biological Process context:</li> <li> <p>The model includes a reference to \"innate immune response\" (GO:0045087) in the objects list, but this process isn't explicitly connected to any of the activities in the model. According to GO-CAM guidelines, molecular functions should be placed in the context of biological processes.</p> </li> <li> <p>E3 ligase representation:</p> </li> <li>Based on the E3 ubiquitin ligase guidelines, the model should indicate that NEDD4's activity \"has input\" MAVS as its substrate, which is not explicitly shown.</li> <li> <p>The biological process of ubiquitination (e.g., protein K63-linked ubiquitination) should be included to provide context for NEDD4's activity.</p> </li> <li> <p>MAVS as a signaling adaptor:</p> </li> <li>According to the paper, MAVS acts as a signaling adaptor that interacts with TRAF2, but the model doesn't show what MAVS adapts signals to or from.</li> <li> <p>The paper shows that MAVS is part of the RIG-I-like receptor antiviral signaling pathway, which could be represented more explicitly.</p> </li> <li> <p>N4BP3's functional role:</p> </li> <li> <p>While N4BP3 is shown with \"protein binding\" activity, the paper demonstrates it has a more specific role in promoting ubiquitination of MAVS, which could be better represented.</p> </li> <li> <p>Missing connection to downstream antiviral response:</p> </li> <li> <p>The model doesn't represent how this pathway connects to the ultimate outcome of enhanced antiviral response and interferon production, which is a key finding in the paper.</p> </li> <li> <p>Cellular location context:</p> </li> <li>The model doesn't include information about the cellular locations of these activities. According to the literature, MAVS is located on the mitochondrial outer membrane, which is crucial for its function.</li> </ol>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#specific-recommendations-for-improvement","title":"Specific Recommendations for Improvement","text":"<ol> <li>Add Biological Process context:</li> <li> <p>Connect each activity to the appropriate biological process terms, such as:</p> <ul> <li>\"innate immune response\" (GO:0045087)</li> <li>\"antiviral innate immune response\" (GO:0140374)</li> <li>\"defense response to virus\" (GO:0051607)</li> <li>\"protein ubiquitination\" (GO:0016567) or more specifically \"protein K63-linked ubiquitination\" (GO:0070534)</li> </ul> </li> <li> <p>Improve E3 ligase annotation:</p> </li> <li>Add \"has input\" relation from NEDD4's ubiquitin protein ligase activity to MAVS</li> <li> <p>Include the biological process of ubiquitination as part of NEDD4's activity context</p> </li> <li> <p>Clarify MAVS signaling adaptor role:</p> </li> <li>Show that MAVS adapts signals from RIG-I-like receptors to downstream effectors</li> <li> <p>Add a \"has input\" relation for MAVS's signaling adaptor activity</p> </li> <li> <p>Refine N4BP3 annotation:</p> </li> <li>Consider annotating N4BP3 with a more specific function, if supported by the evidence</li> <li> <p>Clearly indicate its role in enhancing MAVS ubiquitination</p> </li> <li> <p>Add downstream signaling:</p> </li> <li>Extend the model to show how TRAF2 activation leads to activation of the type I interferon pathway</li> <li> <p>Include IRF3 activation and/or NF-\u03baB activation, which are key outcomes mentioned in the paper</p> </li> <li> <p>Add cellular location information:</p> </li> <li>Include \"occurs in\" relations to specify the cellular locations of the activities</li> <li>Particularly important for MAVS (mitochondrial outer membrane)</li> </ol>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 5ee8120100000524 provides a foundation for representing the N4BP3-MAVS-TRAF2 signaling pathway in antiviral response. It captures key aspects of the pathway but would benefit from additional context and refinement to fully represent the biological insights from the supporting literature. With the recommended improvements, the model would be more comprehensive and aligned with GO-CAM best practices.</p> <p>The model represents an important innate immune signaling pathway that contributes to our understanding of antiviral responses, particularly how N4BP3 positively regulates MAVS-mediated signaling through promoting MAVS ubiquitination and enhancing its interaction with TRAF2.</p>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/","title":"5ee8120100001898 Migrasome signaling involved in organ morphogenesis via cxcl12a  cxcr4b  tspan4a  tspan7  D  rerio","text":"<p>Based on my review of the GO-CAM model gomodel:5ee8120100001898 \"Migrasome signaling involved in organ morphogenesis via cxcl12a, cxcr4b, tspan4a, tspan7 (D. rerio)\" and the related publications, here is my comprehensive evaluation:</p>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#go-cam-model-review-gomodel5ee8120100001898","title":"GO-CAM Model Review: gomodel:5ee8120100001898","text":""},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#overview","title":"Overview","text":"<p>This GO-CAM model represents a signaling pathway in zebrafish (Danio rerio) involving migrasomes and chemokine signaling that regulates organ morphogenesis. The model focuses on interactions between Cxcl12a (a chemokine), Cxcr4b (its receptor), and tetraspanin proteins (Tspan4a and Tspan7) in the context of cell migration and organ development.</p>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#strengths","title":"Strengths","text":"<ol> <li> <p>Scientific validity: The model is well-supported by the primary literature, particularly PMID:31371827, which describes migrasomes as vesicular organelles that form on retraction fibers behind migrating cells and their role in embryonic development. Additional references (PMID:15081362, PMID:15340012) support the role of Cxcl12a-Cxcr4b signaling in chemotaxis and cell migration.</p> </li> <li> <p>Biological process representation: The model correctly captures that Cxcl12a functions as a chemoattractant (GO:0042056) that affects the G protein-coupled chemoattractant receptor activity of Cxcr4b (GO:0001637), which is part of cell localization (GO:0051674).</p> </li> <li> <p>Contextual accuracy: The model appropriately places Cxcl12a in migrasomes (GO:0140494) and Cxcr4b in forerunner cells (ZFA:0000023), reflecting the biological context described in the literature.</p> </li> <li> <p>Evidence documentation: Each activity and causal relationship is supported with proper evidence codes and literature references.</p> </li> </ol>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Incomplete molecular function annotation: While tspan4a (ZFIN:ZDB-GENE-040718-38) and tspan7 (ZFIN:ZDB-GENE-030131-5435) are included in the model, they are both annotated with a generic \"molecular_function\" (GO:0003674) rather than specific functions. The referenced paper indicates these tetraspanins are required for migrasome formation, but this function is not clearly represented in the model.</p> </li> <li> <p>Redundant activities: There are two nearly identical activities for Cxcl12a (gomodel:5ee8120100001898/5ee8120100002541 and gomodel:5ee8120100001898/60747c4200000449), both performing the same function in the same location with the same downstream target. This redundancy could be confusing and should be merged.</p> </li> <li> <p>Causal relationship clarification: The model shows tetraspanins (tspan4a and tspan7) positively regulating Cxcl12a activity, but the exact mechanism (whether they regulate Cxcl12a secretion, localization to migrasomes, or its activity) is not clearly specified.</p> </li> <li> <p>Biological process context: While the model title mentions \"organ morphogenesis,\" the specific organ development processes (like Kupffer's vesicle development or left/right asymmetry determination) are included as objects but not directly connected to activities in the model.</p> </li> </ol>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#technical-review","title":"Technical Review","text":"<ol> <li> <p>Predicate usage: The model correctly uses RO:0002304 (causally upstream of, positive effect) and RO:0002629 (directly positively regulates) for causal relationships between activities.</p> </li> <li> <p>Evidence codes: Appropriate evidence codes are used - ECO:0000315 (mutant phenotype evidence) and ECO:0000314 (direct assay evidence).</p> </li> <li> <p>Ontology term selection: The model uses appropriate GO terms for molecular functions, cellular components, and biological processes.</p> </li> </ol>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Specify tetraspanin functions: Rather than using the generic GO:0003674 (molecular_function), annotate tspan4a and tspan7 with more specific molecular functions based on their role in migrasome formation, if available in the GO.</p> </li> <li> <p>Consolidate redundant activities: The duplicate Cxcl12a activities should be merged into a single activity node.</p> </li> <li> <p>Connect to biological processes: Explicitly connect the activities to relevant biological processes like GO:0070121 (Kupffer's vesicle development) or GO:0007368 (determination of left/right symmetry) to better reflect the model title's emphasis on organ morphogenesis.</p> </li> <li> <p>Clarify mechanism: Consider adding annotations to explain how tetraspanins regulate Cxcl12a activity - whether through enabling migrasome formation, facilitating Cxcl12a localization, or other mechanisms.</p> </li> <li> <p>Add specific downstream effects: Consider extending the model to show how Cxcr4b activity in forerunner cells leads to specific developmental outcomes mentioned in the title.</p> </li> </ol>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a valuable representation of migrasome signaling through the Cxcl12a-Cxcr4b axis in zebrafish development. It is scientifically sound and supported by published literature. With the suggested improvements, particularly in specifying tetraspanin functions and connecting activities to developmental outcomes, the model would more comprehensively represent the biological system described in the title.</p> <p>The model is acceptable in its current form but would benefit from the recommended revisions to improve clarity and completeness.</p>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/","title":"5ee8120100002841 Inflammatory signaling involved in regulation of hematopoietic stem cell differentiation via notch1a  tnfa  tnfrsf1b  jag1a  D rerio","text":"<p>Now, let me review the GO-CAM model based on the information I've gathered and best practices for GO-CAM curation.</p>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#go-cam-model-review-gomodel5ee8120100002841","title":"GO-CAM Model Review: gomodel:5ee8120100002841","text":""},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#summary-of-the-model","title":"Summary of the Model","text":"<p>Model ID: gomodel:5ee8120100002841 Title: \"Inflammatory signaling involved in regulation of hematopoietic stem cell differentiation via notch1a, tnfa, tnfrsf1b, jag1a (D.rerio)\"</p> <p>This GO-CAM model describes a signaling pathway in zebrafish (Danio rerio) where inflammation-related signaling regulates hematopoietic stem cell (HSC) differentiation. The model captures the interaction between Tumor Necrosis Factor alpha (Tnfa), its receptor Tnfrsf1b, and downstream activation of Notch signaling through Jag1a (Jagged1a) and Notch1a.</p>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#model-components","title":"Model Components","text":"<p>The model includes four main molecular activities:</p> <ol> <li>Tnfa (ZFIN:ZDB-GENE-050317-1) with receptor ligand activity (GO:0048018)</li> <li>Occurs in extracellular space (GO:0005615)</li> <li>Part of positive regulation of HSC differentiation (GO:1902038)</li> <li> <p>Directly positively regulates Tnfrsf1b activity</p> </li> <li> <p>Tnfrsf1b (ZFIN:ZDB-GENE-070410-133) with signaling receptor activity (GO:0038023)</p> </li> <li>Occurs in plasma membrane (GO:0005886)</li> <li>Part of positive regulation of HSC differentiation (GO:1902038)</li> <li> <p>Causally upstream of Jag1a activity with positive effect</p> </li> <li> <p>Jag1a (ZFIN:ZDB-GENE-011128-2) with receptor ligand activity (GO:0048018)</p> </li> <li>Occurs in plasma membrane (GO:0005886)</li> <li>Part of positive regulation of HSC differentiation (GO:1902038)</li> <li> <p>Directly positively regulates Notch1a activity</p> </li> <li> <p>Notch1a (ZFIN:ZDB-GENE-990415-173) with signaling receptor activity (GO:0038023)</p> </li> <li>Occurs in plasma membrane (GO:0005886)</li> <li>Part of Notch signaling pathway (GO:0007219) for one node and not annotated to a BP for the other node</li> </ol>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The biological pathway represented in this model is well-supported by the literature. The PMID:25416946 reference provides extensive evidence for the role of inflammatory signaling, particularly TNF-alpha, in HSC specification in zebrafish. Key findings include:</p> <ol> <li>Tnfa signals through Tnfr2 (Tnfrsf1b) to upregulate the Notch ligand Jag1a on endothelial cells.</li> <li>Jag1a activates Notch1a, leading to HSC specification.</li> <li>Primitive neutrophils are the key source of Tnfa in this developmental process.</li> <li>This pathway is essential for HSC generation and is independent of its role in vascular development.</li> </ol> <p>The model accurately captures the central aspect of this pathway, showing the signaling flow from Tnfa \u2192 Tnfrsf1b \u2192 Jag1a \u2192 Notch1a, which aligns with the biological mechanism described in the literature.</p>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#go-cam-structure-and-compliance-assessment","title":"GO-CAM Structure and Compliance Assessment","text":""},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#strengths","title":"Strengths:","text":"<ol> <li>The model correctly uses receptor ligand activity (GO:0048018) for the ligands (Tnfa and Jag1a) and signaling receptor activity (GO:0038023) for receptors (Tnfrsf1b and Notch1a).</li> <li>Appropriate cellular components are used (extracellular space for secreted Tnfa, plasma membrane for receptors and membrane-bound ligand).</li> <li>The causal relations between activities are appropriate, using \"directly positively regulates\" (RO:0002629) for the ligand-receptor interactions.</li> <li>The model is grounded in strong experimental evidence from PMID:25416946.</li> </ol>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Inconsistent biological process annotations:</li> <li>Notch1a has two activity nodes in the model. One is part of \"Notch signaling pathway\" (GO:0007219) and one has no biological process annotation.</li> <li> <p>Recommendation: Both Notch1a activities should be annotated with the same biological process since they represent the same activity in the same pathway.</p> </li> <li> <p>Missing downstream effects:</p> </li> <li>The model ends with Notch1a activation but doesn't capture the downstream effectors like NF-\u03baB activation, which the paper identifies as a critical component of the pathway.</li> <li> <p>Recommendation: Add NF-\u03baB activation as a downstream effect of Notch1a signaling.</p> </li> <li> <p>Incomplete representation of the pathway:</p> </li> <li>The model doesn't represent the role of primitive neutrophils as the source of Tnfa, which is a key finding in the paper.</li> <li> <p>Recommendation: Consider adding this information to provide a more complete representation of the biological context.</p> </li> <li> <p>Redundant Notch1a nodes:</p> </li> <li>There are two separate nodes for Notch1a activity with different causal connections, which isn't necessary and may create confusion.</li> <li> <p>Recommendation: Consolidate into a single Notch1a activity node with appropriate connections.</p> </li> <li> <p>Missing \"has input\" relations:</p> </li> <li>According to the GO-CAM guidelines for signaling receptors, there should be \"has input\" relations between receptors and their targets. These appear to be missing in the model.</li> <li>Recommendation: Add the appropriate \"has input\" relations according to the guidelines.</li> </ol>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#specific-annotation-review","title":"Specific Annotation Review:","text":"<p>For each activity node, I've noted specific issues:</p> <ol> <li>Tnfa (ZFIN:ZDB-GENE-050317-1):</li> <li>Correctly annotated with receptor ligand activity and appropriate cellular component</li> <li> <p>The causal relation to Tnfrsf1b is correct</p> </li> <li> <p>Tnfrsf1b (ZFIN:ZDB-GENE-070410-133):</p> </li> <li>Correctly annotated with signaling receptor activity</li> <li> <p>Missing \"has input\" relation to downstream targets according to GO-CAM guidelines</p> </li> <li> <p>Jag1a (ZFIN:ZDB-GENE-011128-2):</p> </li> <li>Correctly annotated with receptor ligand activity</li> <li> <p>Missing \"has input\" relation to Notch1a according to guidelines</p> </li> <li> <p>Notch1a (ZFIN:ZDB-GENE-990415-173):</p> </li> <li>Redundant activity nodes (two separate nodes for the same protein)</li> <li>One activity node lacks biological process annotation</li> <li>Missing downstream connections to effectors like NF-\u03baB</li> </ol>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:5ee8120100002841) accurately captures the core signaling pathway where inflammatory signaling through Tnfa/Tnfrsf1b activates Notch signaling via Jag1a to regulate hematopoietic stem cell differentiation in zebrafish. The model is based on strong experimental evidence and uses appropriate GO terms and relations for most components.</p> <p>To improve the model, I recommend: 1. Consolidating the redundant Notch1a activity nodes 2. Adding appropriate \"has input\" relations per GO-CAM guidelines 3. Including NF-\u03baB activation as a downstream effect 4. Considering the addition of contextual information about primitive neutrophils as the source of Tnfa 5. Ensuring consistent biological process annotations across related activities</p> <p>These improvements would make the model more complete and consistent with GO-CAM best practices while accurately representing the underlying biological mechanism.</p>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/","title":"5f46c3b700001031 MYD88 dependent TLR4 signaling pathway leading to NF kappa B activation  Human","text":"<p>Now that I've gathered information on the model and relevant guidelines, I'll provide a detailed review of GO-CAM model \"gomodel:5f46c3b700001031\" titled \"MYD88-dependent TLR4 signaling pathway leading to NF-kappa-B activation (Human)\".</p>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#go-cam-model-review-myd88-dependent-tlr4-signaling-pathway-leading-to-nf-kappa-b-activation-human","title":"GO-CAM Model Review: MYD88-dependent TLR4 signaling pathway leading to NF-kappa-B activation (Human)","text":""},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#model-summary","title":"Model Summary","text":"<p>This model represents the TLR4 signaling pathway that occurs in response to LPS (lipopolysaccharide) stimulation, leading to NF-kappa-B activation via the MYD88-dependent pathway in humans. The model captures the molecular activities and causal relationships starting from LPS transport by CD14 and LBP, through TLR4 receptor activation, the signaling cascade through adaptor proteins, kinase activities, and culminating in NF-kappa-B transcription factor activity.</p>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway completeness: The model captures the key components of the MYD88-dependent TLR4 signaling pathway from initial LPS recognition to NF-kappa-B activation.</p> </li> <li> <p>Correct use of molecular carrier activity: The annotation of CD14 (P08571) and LBP (P18428) with \"molecular carrier activity\" (GO:0140104) accurately depicts their role in transporting LPS, consistent with the guidelines and the referenced literature (PMID:1698311).</p> </li> <li> <p>Appropriate signaling receptor activity: TLR4 (O00206) is correctly annotated with \"signaling receptor activity\" (GO:0038023) and the proper cellular location (plasma membrane).</p> </li> <li> <p>Proper adaptor protein annotation: The model correctly represents the signaling adaptors TIRAP (P58753) and MYD88 (Q99836) with \"signaling adaptor activity\" (GO:0035591).</p> </li> <li> <p>Appropriate causal relationships: The causal relationships between activities use the appropriate predicates. For example, \"directly positively regulates\" (RO:0002629) is used for the activation cascade.</p> </li> <li> <p>Detailed kinase cascade: The model correctly captures the sequence of kinase activities (IRAK4, IRAK2, MAP3K7, CHUK) that occurs downstream of TLR4 activation.</p> </li> <li> <p>Correct ubiquitin ligase annotation: TRAF6 (Q9Y4K3) is annotated with \"ubiquitin protein ligase activity\" (GO:0061630) and part of \"protein K63-linked ubiquitination\" (GO:0070534), which is consistent with its biological role in the pathway.</p> </li> <li> <p>Proper molecular adaptor annotation: ECSIT (Q9BQ95) is correctly annotated as having \"molecular adaptor activity\" (GO:0060090) which is consistent with the guidelines.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Missing CD14-TLR4 relationship: According to the examined literature (PMID:1698311), CD14 directly interacts with TLR4 to facilitate LPS recognition. The model should include a causal relationship from CD14's molecular carrier activity to TLR4's signaling receptor activity.</p> </li> <li> <p>LBP and CD14 coordination: The model shows LBP and CD14 as separate activities handling LPS, but the literature indicates they work in coordination, with LBP forming complexes with LPS that are then recognized by CD14. The relationship between these two activities could be more explicitly modeled.</p> </li> <li> <p>NFKBIA activity annotation: NFKBIA (P25963) is annotated with \"molecular sequestering activity\" (GO:0140313), which is correct, but the model could benefit from adding its target (RELA) as an input to better represent the sequestering relationship.</p> </li> <li> <p>Evidence for some causal relationships: One relationship in the model (from TIRAP to MYD88) lacks specific evidence annotations. All relationships should ideally have supporting evidence.</p> </li> <li> <p>Potential missing components: The model focuses on the MYD88-dependent pathway but doesn't include some components known to be involved in this pathway such as IRAK1, which is typically involved between IRAK2 and TRAF6.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<ol> <li> <p>LPS handling: The model correctly represents LPS (CHEBI:16412) as both input and output for CD14 and LBP, consistent with their role as carriers rather than modifiers of LPS.</p> </li> <li> <p>TLR4 signaling initiation: The activation of TLR4 by LPS is biologically accurate, though as mentioned, the model could better represent how CD14/LBP present LPS to TLR4.</p> </li> <li> <p>Adaptor recruitment: The recruitment of TIRAP and MYD88 to activated TLR4 reflects the established biology of TLR4 signaling.</p> </li> <li> <p>Kinase cascade: The sequential activation of IRAK4, IRAK2, MAP3K7 (TAK1), and CHUK (IKK\u03b1) reflects the established signaling cascade in the pathway.</p> </li> <li> <p>NF-kappa-B regulation: The model correctly represents how NFKBIA (I\u03baB\u03b1) sequesters RELA (p65) in the cytoplasm and how phosphorylation of NFKBIA leads to its degradation, allowing RELA to translocate to the nucleus.</p> </li> <li> <p>Correct cellular locations: The model correctly annotates the cellular locations for each activity: extracellular space for LPS carriers, plasma membrane for receptor activities, cytoplasm for signaling components, and nucleus for transcription factor activity.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the MYD88-dependent TLR4 signaling pathway leading to NF-kappa-B activation in humans. The model adheres to GO-CAM best practices in terms of activity representation, causal relationships, and contextual annotations. The few suggestions for improvement are relatively minor and would enhance the model's completeness rather than correct significant errors.</p> <p>The representation of LPS handling by LBP and CD14, TLR4 signaling, adaptor protein recruitment, and downstream signaling cascade are all biologically accurate and supported by the literature. The model effectively captures the key molecular activities and their relationships in this important immune signaling pathway.</p>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/","title":"5f46c3b700001407 TBK1 activation via TRAF3 autoubiquitination  Human","text":"<p>Based on all the information gathered, I'll now provide a review of GO-CAM model gomodel:5f46c3b700001407, titled \"TBK1 activation via TRAF3 autoubiquitination (Human)\".</p>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#review-of-go-cam-model-tbk1-activation-via-traf3-autoubiquitination-human","title":"Review of GO-CAM Model: TBK1 activation via TRAF3 autoubiquitination (Human)","text":""},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#model-id-gomodel5f46c3b700001407","title":"Model ID: gomodel:5f46c3b700001407","text":""},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#overview","title":"Overview","text":"<p>This model represents the signaling pathway leading to TBK1 activation through TRAF3 autoubiquitination in human cells. It focuses on positive regulation of type I interferon production (GO:0032481), which is a critical process in innate immune responses to viral and bacterial infections.</p>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#model-structure","title":"Model Structure","text":"<p>The model consists of 7 activities connected through causal relationships:</p> <ol> <li>TICAM2 (UniProtKB:Q86XR7) - Molecular adaptor activity (GO:0060090) occurring in endosome (GO:0005768)</li> <li>TICAM1 (UniProtKB:Q8IUC6) - Molecular adaptor activity (GO:0060090) occurring in endosome (GO:0005768)</li> <li>TRAF3 (UniProtKB:Q13114) - Ubiquitin protein ligase activity (GO:0061630) occurring in endosome (GO:0005768)</li> <li>MAVS (UniProtKB:Q7Z434) - Molecular adaptor activity (GO:0060090) occurring in mitochondrion (GO:0005739)</li> <li>TRAF3IP3 (UniProtKB:Q9Y228) - Molecular adaptor activity (GO:0060090) occurring in mitochondrion (GO:0005739)</li> <li>TRAF3 (UniProtKB:Q13114) - Ubiquitin protein ligase activity (GO:0061630) occurring in mitochondrion (GO:0005739)</li> <li>TBK1 (UniProtKB:Q9UHD2) - Protein serine/threonine kinase activity (GO:0004674) occurring in cytoplasm (GO:0005737)</li> </ol>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#causal-flow-analysis","title":"Causal Flow Analysis","text":"<p>The causal flow in this model follows two main pathways:</p> <ol> <li>Endosomal pathway: TICAM2 \u2192 TICAM1 \u2192 TRAF3 (endosomal) \u2192 TBK1</li> <li>Mitochondrial pathway: MAVS \u2192 TRAF3IP3 \u2192 TRAF3 (mitochondrial) \u2192 TBK1</li> </ol> <p>Both pathways converge on TBK1 activation, which leads to type I interferon production. The causal connections use RO:0002629 (directly positively regulates), indicating direct positive regulation.</p>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>Based on the published literature provided (PMID:19898473 and PMID:14703513), the model appears scientifically accurate. The papers describe:</p> <ol> <li>TRAF3's critical role in type I interferon responses</li> <li>The importance of TRAF3 ubiquitination in regulating IFN production</li> <li>TBK1's function as a protein serine/threonine kinase that phosphorylates IRF3</li> <li>The involvement of adaptor proteins like TICAM1/TICAM2 (also known as TRIF/TRAM) in engaging TRAF3</li> <li>MAVS as a mitochondrial adaptor for TRAF3 in virus-induced signaling</li> </ol>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>Overall, the model follows GO-CAM best practices:</p> <ol> <li> <p>Molecular adaptor annotation: The model correctly represents molecular adaptor activities (GO:0060090) for TICAM1, TICAM2, MAVS, and TRAF3IP3. According to guidelines, these adaptors should use \"directly positively regulates\" (RO:0002629) relations to downstream activities, which is correctly implemented.</p> </li> <li> <p>E3 ubiquitin ligase representation: TRAF3 is appropriately annotated with ubiquitin protein ligase activity (GO:0061630). The guidelines indicate E3 ligases should be connected to downstream processes they regulate.</p> </li> <li> <p>Cellular component annotation: Each activity is correctly annotated with its cellular location (endosome, mitochondrion, or cytoplasm).</p> </li> <li> <p>Biological process annotation: All activities are properly connected to their biological process, \"positive regulation of type I interferon production\" (GO:0032481).</p> </li> <li> <p>Evidence annotation: Each activity is supported by experimental evidence (ECO:0000314 - direct assay evidence) with appropriate PMID references.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Add inputs to molecular adaptors: According to the guidelines, molecular adaptors should have inputs specified (the molecules they bring together). The current model doesn't specify inputs for any of the adaptor proteins.</p> </li> <li> <p>Clarify TRAF3 autoubiquitination: The title mentions TRAF3 autoubiquitination, but this is not explicitly modeled. The model could more clearly show that TRAF3 ubiquitin ligase activity is self-directed, perhaps by adding TRAF3 as an input to its own activity.</p> </li> <li> <p>Include IRF3 activation: Given that TBK1 ultimately phosphorylates and activates IRF3 leading to IFN production (as shown in PMID:14703513), the model could be extended to include this final step in the pathway.</p> </li> <li> <p>Distinguish K63 vs K48 ubiquitination: The paper (PMID:19898473) discusses distinct modes of TRAF3 ubiquitination (K63-linked for the IFN pathway vs. K48-linked for degradation). This distinction could be made clearer in the model.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:5f46c3b700001407 accurately represents the signaling pathway for TBK1 activation via TRAF3 autoubiquitination. It correctly implements GO-CAM best practices for molecular adaptor and E3 ligase annotation. The model effectively captures two distinct pathways (endosomal and mitochondrial) leading to TBK1 activation in type I interferon production. With minor enhancements to specify inputs for adaptors and more explicitly model TRAF3 autoubiquitination, this would be an exemplary representation of this signaling pathway.</p>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/","title":"5f46c3b700001570 SPModule TBK1 IRF3","text":"<p>Based on all of the information I've gathered, I'll now review the GO-CAM model gomodel:5f46c3b700001570 titled \"SPModule TBK1-IRF3\".</p>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#review-of-go-cam-model-spmodule-tbk1-irf3-gomodel5f46c3b700001570","title":"Review of GO-CAM Model: SPModule TBK1-IRF3 (gomodel:5f46c3b700001570)","text":""},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#overview","title":"Overview","text":"<p>This model represents a signaling pathway involving TBK1 (TANK-binding kinase 1) and IRF3 (Interferon Regulatory Factor 3), which are key proteins in the innate immune response against viruses. The model describes the phosphorylation cascade where TBK1 activates IRF3, leading to IRF3's DNA-binding and transcriptional activation activities.</p>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#model-structure","title":"Model Structure","text":"<p>The model consists of 5 activities: 1. TBK1 protein serine/threonine kinase activity 2. IRF3 protein homodimerization activity 3. IRF3 protein binding activity 4. IRF3 sequence-specific DNA binding activity 5. IRF3 DNA-binding transcription activator activity</p> <p>The causal flow follows: TBK1 kinase activity \u2192 IRF3 homodimerization \u2192 IRF3 protein binding \u2192 IRF3 DNA binding \u2192 IRF3 transcriptional activation</p>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate biological process representation: The model correctly represents the established pathway of TBK1-mediated phosphorylation of IRF3, leading to IRF3 homodimerization, nuclear translocation, and activation of interferon gene transcription.</p> </li> <li> <p>Correct causal associations: The model uses the appropriate causal relation \"directly positively regulates\" (RO:0002629) between activities, which correctly represents the flow of the signaling cascade.</p> </li> <li> <p>Appropriate cellular locations: The model correctly localizes TBK1 kinase activity in the cytoplasm (GO:0005737) and IRF3's DNA binding and transcriptional activities in the nucleus (GO:0005634).</p> </li> <li> <p>Solid evidence basis: Each activity and causal relation is supported by primary research literature with proper evidence codes (ECO:0000314 - direct assay evidence used in manual assertion).</p> </li> </ol>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#issues-and-suggested-improvements","title":"Issues and Suggested Improvements","text":"<ol> <li> <p>Phosphorylation representation: While the model shows TBK1 kinase activity leading to IRF3 homodimerization, it doesn't explicitly represent the phosphorylation of IRF3 at serine residues 385 and 386, which is a critical step. Consider adding this detail as it's a key molecular event in this pathway.</p> </li> <li> <p>Missing adaptor proteins: The literature indicates that adaptor proteins like MAVS, STING1, or TICAM1 are first phosphorylated by TBK1 on their pLxIS motif, leading to recruitment of IRF3, which enables IRF3 phosphorylation by TBK1. These adaptor proteins are missing from the model, making the pathway representation incomplete.</p> </li> <li> <p>IRF3 nuclear translocation: The model shows IRF3 binding to DNA in the nucleus after homodimerization, but it doesn't explicitly represent IRF3's translocation from cytoplasm to nucleus. While this can be inferred, explicitly representing this step would improve clarity.</p> </li> <li> <p>Downstream gene activation: The model ends with IRF3's transcriptional activator activity but doesn't represent the activation of specific downstream genes like IFNB (interferon beta) and other interferon-stimulated genes (ISGs). Adding these would complete the biological story.</p> </li> <li> <p>Complex representation: According to the GO-CAM guidelines for complexes, when the subunit that carries the activity is known (as in this case), the activities should be represented by the specific proteins carrying them. The model follows this guideline correctly.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#technical-aspects","title":"Technical Aspects","text":"<ol> <li> <p>Evidence codes: All assertions use the ECO:0000314 (direct assay evidence used in manual assertion), which is appropriate since the evidence is from experimental publications.</p> </li> <li> <p>Protein identity: The model correctly identifies the proteins using UniProtKB accessions (Q9UHD2 for TBK1 and Q14653 for IRF3).</p> </li> <li> <p>Ontology term usage: The molecular functions and cellular components are represented using appropriate GO terms.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the TBK1-IRF3 signaling pathway central to antiviral immune responses. The main areas for improvement are the inclusion of adaptor proteins that facilitate IRF3 recruitment and phosphorylation, explicit representation of IRF3 phosphorylation and nuclear translocation, and extension to downstream gene activation events. These additions would make the model more complete and informative.</p> <p>The model is consistent with current knowledge about TBK1 and IRF3 function in antiviral responses and follows GO-CAM annotation guidelines appropriately.</p>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/","title":"5f46c3b700002102 SPModule TIRAP MYDDOSOME","text":"<p>Based on a thorough review of the model and associated information, I'll now provide a comprehensive review of the GO-CAM model \"gomodel:5f46c3b700002102\" titled \"SPModule-TIRAP-MYDDOSOME\".</p>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#review-of-go-cam-model-spmodule-tirap-myddosome-gomodel5f46c3b700002102","title":"Review of GO-CAM Model: SPModule-TIRAP-MYDDOSOME (gomodel:5f46c3b700002102)","text":""},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#1-model-overview","title":"1. Model Overview","text":"<p>This GO-CAM model represents the TIRAP-MYDDOSOME signaling complex, which is a key component in TLR/IL-1R signaling. The model shows a sequential recruitment and activation pathway involving four proteins:</p> <ol> <li>TIRAP/MAL (UniProtKB:P58753) - Toll/IL-1 receptor domain-containing adapter protein</li> <li>MYD88 (UniProtKB:Q99836) - Myeloid differentiation primary response protein</li> <li>IRAK4 (UniProtKB:Q9NWZ3) - Interleukin-1 receptor-associated kinase 4</li> <li>IRAK1 (UniProtKB:P51617) - Interleukin-1 receptor-associated kinase 1</li> <li>TRAF6 (UniProtKB:Q9Y4K3) - TNF receptor-associated factor 6</li> </ol> <p>The model depicts a signaling cascade where each protein in the pathway directly positively regulates (RO:0002629) the next protein in the sequence, ultimately leading to TRAF6 ubiquitin-ubiquitin ligase activity.</p>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#2-scientific-accuracy","title":"2. Scientific Accuracy","text":"<p>The model accurately represents the known biology of the TIRAP-MYDDOSOME signaling pathway:</p> <ul> <li>The model correctly shows TIRAP initiating the signaling cascade at the cell surface, which matches its known role as a TLR adaptor protein that recruits MYD88 to TLR2 and TLR4 complexes.</li> <li>The sequential assembly of the Myddosome complex with MYD88 recruiting IRAK4, and IRAK4 recruiting IRAK1 is consistent with the literature (PMID:20485341).</li> <li>The kinase activities of IRAK4 and IRAK1 are accurately represented.</li> <li>The model appropriately ends with TRAF6 ubiquitin-ubiquitin ligase activity, which is consistent with TRAF6's role in this pathway.</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#3-completeness-and-molecular-function-annotations","title":"3. Completeness and Molecular Function Annotations","text":"<p>Each protein in the model is annotated with its appropriate molecular function:</p> <ul> <li>TIRAP: Annotated with \"molecular adaptor activity\" (GO:0060090), which is appropriate for its role in recruiting MYD88.</li> <li>MYD88: Annotated with \"molecular adaptor activity\" (GO:0060090), consistent with its role in TLR signaling.</li> <li>IRAK4: Annotated with \"kinase activity\" (GO:0016301), which correctly represents its enzymatic function.</li> <li>IRAK1: Annotated with \"kinase activity\" (GO:0016301), which correctly represents its enzymatic function.</li> <li>TRAF6: Annotated with \"ubiquitin-ubiquitin ligase activity\" (GO:0034450), which is appropriate for its E3 ligase function.</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#4-cellular-component-annotations","title":"4. Cellular Component Annotations","text":"<p>All proteins are annotated with appropriate cellular locations:</p> <ul> <li>TIRAP: Located at \"cell surface\" (GO:0009986), which is appropriate as it recruits MyD88 to cell surface TLR complexes.</li> <li>MYD88: Located at \"cell surface\" (GO:0009986), consistent with its recruitment by TIRAP.</li> <li>IRAK4: Located at \"cell surface\" (GO:0009986), which is appropriate for its recruitment to the receptor complex.</li> <li>IRAK1: Located at \"cell surface\" (GO:0009986), correctly reflecting its location in the Myddosome complex.</li> <li>TRAF6: Located at \"cytoplasm\" (GO:0005737), which is appropriate as TRAF6 dissociates from the receptor complex following activation.</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#5-causal-relations","title":"5. Causal Relations","text":"<p>The causal relationships in the model use the appropriate relation (RO:0002629 \"directly positively regulates\"), which correctly captures the direct positive regulatory relationships between the proteins in this signaling cascade:</p> <ul> <li>TIRAP directly positively regulates MYD88</li> <li>MYD88 directly positively regulates IRAK4</li> <li>IRAK4 directly positively regulates IRAK1</li> <li>IRAK1 directly positively regulates TRAF6</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#6-evidence","title":"6. Evidence","text":"<p>Each activity and causal relation is supported by appropriate experimental evidence:</p> <ul> <li>Evidence codes used are primarily ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>Literature references are provided for each assertion (e.g., PMID:14625308, PMID:22851693, PMID:9734363, PMID:11960013, PMID:20485341, PMID:15465037)</li> <li>All assertions have appropriate provenance information with contributor ORCID and dates</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#7-compliance-with-go-cam-best-practices","title":"7. Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing protein complexes as outlined in the document \"How_to_annotate_complexes_in_GO-CAM\":</p> <ul> <li>The model correctly uses individual proteins when the subunits that carry specific molecular activities are known, rather than using a complex ID.</li> <li>The model appropriately represents the sequential assembly and activation of the complex through causal relations between the individual proteins.</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#8-areas-for-improvement","title":"8. Areas for Improvement","text":"<p>While the model is scientifically accurate and well-constructed, I have a few minor suggestions for improvement:</p> <ol> <li> <p>Additional Context: The model could potentially benefit from additional context by connecting to upstream TLR activation or downstream events beyond TRAF6.</p> </li> <li> <p>Complex Formation: While the model implies complex formation through the causal relations, it might be valuable to explicitly annotate the formation of the Myddosome complex.</p> </li> <li> <p>Additional TRAF6 Relations: TRAF6 activates multiple downstream pathways (NF-\u03baB, MAP kinases). Including some of these downstream targets could enhance the model's biological completeness.</p> </li> </ol>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#9-conclusion","title":"9. Conclusion","text":"<p>The GO-CAM model \"gomodel:5f46c3b700002102\" (SPModule-TIRAP-MYDDOSOME) is a scientifically accurate, well-constructed representation of the TIRAP-MYDDOSOME signaling pathway. It correctly captures the sequential assembly and activation of this important signaling complex in TLR/IL-1R pathways, with appropriate molecular functions, cellular components, causal relations, and supporting evidence.</p> <p>The model effectively represents how TIRAP recruits MYD88 to TLR signaling complexes, which then recruits IRAK4, leading to the recruitment and activation of IRAK1, and ultimately activating TRAF6. This accurately reflects our current understanding of this signaling pathway as supported by the primary literature.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/","title":"5f46c3b700002685 IL6 sIL6R Trans signaling pathway  Human","text":"<p>Based on my review of the GO-CAM model and the corresponding literature, I'll now provide a comprehensive review of the model \"IL6:sIL6R Trans-signaling pathway (Human)\" (gomodel:5f46c3b700002685).</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#go-cam-review-il6sil6r-trans-signaling-pathway-human","title":"GO-CAM Review: IL6:sIL6R Trans-signaling pathway (Human)","text":""},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#model-summary","title":"Model Summary","text":"<p>This GO-CAM model (ID: gomodel:5f46c3b700002685) represents the IL-6 trans-signaling pathway in humans. It includes the components of the IL-6:sIL6R trans-signaling complex and the subsequent JAK-STAT pathway activation. The model encompasses the following key steps: 1. IL-6 cytokine activity 2. IL-6 binding to the soluble IL-6 receptor (sIL6R) 3. IL-6:sIL6R complex binding to gp130 (IL6ST) 4. Activation of JAK1 kinase 5. Phosphorylation and activation of STAT3 6. Negative regulation by SOCS3</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#overall-structure-assessment","title":"Overall Structure Assessment","text":"<p>The model correctly captures the major components and causal relationships in the IL-6 trans-signaling pathway. The annotated biological process, molecular functions, and cellular locations are generally appropriate according to the literature and GO-CAM best practices.</p> <p>The representation is consistent with the hexameric structure of the IL-6/IL-6R/gp130 complex as described by Boulanger et al. (PMID:12829785), and properly represents the JAK-STAT signaling cascade that follows receptor activation.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#detailed-review-of-model-components","title":"Detailed Review of Model Components","text":""},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#activity-1-il-6-cytokine-activity","title":"Activity 1: IL-6 Cytokine Activity","text":"<ul> <li>Protein: UniProtKB:P05231 (IL6 Hsap)</li> <li>Molecular Function: GO:0005125 (cytokine activity)</li> <li>Occurs in: GO:0005615 (extracellular space)</li> <li>Part of: GO:0070102 (interleukin-6-mediated signaling pathway)</li> </ul> <p>Assessment: This component is correctly annotated. IL-6 is a secreted cytokine that acts in the extracellular space to initiate signaling. The cytokine activity molecular function is appropriate.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#activity-2-il-6-receptor-activity-soluble-form","title":"Activity 2: IL-6 Receptor Activity (soluble form)","text":"<ul> <li>Protein: UniProtKB:P08887-2 (IL6R Hsap)</li> <li>Molecular Function: GO:0004896 (cytokine receptor activity)</li> <li>Occurs in: GO:0005615 (extracellular space)</li> <li>Part of: GO:0070102 (interleukin-6-mediated signaling pathway)</li> </ul> <p>Assessment: This annotation is correct for the soluble form of IL-6R (sIL6R). The soluble form is appropriately identified by the protein isoform UniProtKB:P08887-2, which is the alternatively spliced shorter form lacking the transmembrane and cytoplasmic domains. The location in the extracellular space is also correct.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#activity-3-gp130-receptor-activation","title":"Activity 3: GP130 Receptor Activation","text":"<ul> <li>Protein: UniProtKB:P40189 (IL6ST Hsap)</li> <li>Molecular Function: GO:0030296 (protein tyrosine kinase activator activity)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0070102 (interleukin-6-mediated signaling pathway)</li> </ul> <p>Assessment: This annotation is correct. GP130 (IL6ST) acts as an activator of tyrosine kinases, particularly JAK1. The localization to the plasma membrane is appropriate, as gp130 is a transmembrane protein.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#activity-4-jak1-kinase-activity","title":"Activity 4: JAK1 Kinase Activity","text":"<ul> <li>Protein: UniProtKB:P23458 (JAK1 Hsap)</li> <li>Molecular Function: GO:0004713 (protein tyrosine kinase activity)</li> <li>Occurs in: GO:0009898 (cytoplasmic side of plasma membrane)</li> <li>Part of: GO:0007259 (cell surface receptor signaling pathway via JAK-STAT)</li> </ul> <p>Assessment: This annotation is correct. JAK1 is a tyrosine kinase that associates with the cytoplasmic domain of gp130 and is activated upon receptor dimerization. The cellular location on the cytoplasmic side of the plasma membrane is accurate.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#activity-5-stat3-transcription-factor-activity","title":"Activity 5: STAT3 Transcription Factor Activity","text":"<ul> <li>Protein: UniProtKB:P40763 (STAT3 Hsap)</li> <li>Molecular Function: GO:0003700 (DNA-binding transcription factor activity)</li> <li>Occurs in: GO:0005634 (nucleus)</li> <li>Part of: GO:0007259 (cell surface receptor signaling pathway via JAK-STAT)</li> </ul> <p>Assessment: This annotation is correct. Once phosphorylated by JAK1, STAT3 dimerizes and translocates to the nucleus where it acts as a transcription factor. The localization to the nucleus for this activity is appropriate.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#activity-6-socs3-inhibitory-activity","title":"Activity 6: SOCS3 Inhibitory Activity","text":"<ul> <li>Protein: UniProtKB:O14543 (SOCS3 Hsap)</li> <li>Molecular Function: GO:0004860 (protein kinase inhibitor activity)</li> <li>Occurs in: GO:0009898 (cytoplasmic side of plasma membrane)</li> <li>Part of: GO:0007259 (cell surface receptor signaling pathway via JAK-STAT)</li> </ul> <p>Assessment: This annotation is correct. SOCS3 is a negative regulator of the JAK-STAT pathway that inhibits JAK1 kinase activity. Its location at the cytoplasmic side of the plasma membrane is appropriate since it interacts with the activated receptor complex.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#causal-relationships-assessment","title":"Causal Relationships Assessment","text":"<p>The model includes the following causal relationships:</p> <ol> <li>IL-6 cytokine activity (Activity 1) \u2192 directly positively regulates \u2192 IL-6 receptor activity (Activity 2)</li> <li>IL-6 receptor activity (Activity 2) \u2192 directly positively regulates \u2192 GP130 activation (Activity 3)</li> <li>GP130 activation (Activity 3) \u2192 directly positively regulates \u2192 JAK1 kinase activity (Activity 4)</li> <li>JAK1 kinase activity (Activity 4) \u2192 directly positively regulates \u2192 STAT3 transcription factor activity (Activity 5)</li> <li>STAT3 transcription factor activity (Activity 5) \u2192 provides input for \u2192 SOCS3 inhibitor activity (Activity 6)</li> <li>SOCS3 inhibitor activity (Activity 6) \u2192 directly negatively regulates \u2192 JAK1 kinase activity (Activity 4)</li> </ol> <p>Assessment: The causal relationships in the model correctly capture the flow of signaling from IL-6 binding to its receptor, through the activation of JAK1 and STAT3, and the negative feedback loop provided by SOCS3. The use of the \"directly positively regulates\" (RO:0002629) relation for the activating steps and \"directly negatively regulates\" (RO:0002630) for the inhibitory step by SOCS3 is appropriate according to GO-CAM best practices.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#literature-support","title":"Literature Support","text":"<p>The annotations are supported by appropriate literature references:</p> <ul> <li>PMID:12829785 (Boulanger et al., 2003): Describes the hexameric structure of the IL-6/IL-6R/gp130 complex</li> <li>PMID:21990364 (Garbers et al., 2011): Covers the role of sIL6R in trans-signaling</li> <li>PMID:8272873 (Stahl et al., 1994): Details the JAK-STAT pathway activation by IL-6</li> <li>PMID:9727029: Evidence for SOCS3 inhibition of JAK1</li> <li>PMID:19915009: Evidence for gp130 localization to the plasma membrane</li> <li>PMID:17344214: Evidence for STAT3 transcription factor activity</li> </ul> <p>The evidence is well-documented with appropriate ECO codes (e.g., ECO:0000314 for direct assay evidence).</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for:</p> <ol> <li> <p>Signaling receptor annotation: The model correctly represents the distinction between the ligand (IL-6), the receptor (IL-6R), and the co-receptor/signal transducer (gp130/IL6ST) according to the \"Signaling receptor activity annotation guidelines\".</p> </li> <li> <p>Regulation representation: The regulatory relationships between activities follow the \"Regulation and Regulatory Processes in GO-CAM\" guidelines, properly capturing direct positive and negative regulation.</p> </li> <li> <p>Complex representation: The model appropriately represents the activities of the proteins in the IL-6/IL-6R/gp130 complex without explicitly representing the complex as a whole entity, which is consistent with \"How to annotate complexes in GO-CAM\" guidelines when the activities of individual subunits are known.</p> </li> </ol>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, there are a few potential improvements:</p> <ol> <li> <p>Completeness of STAT3 signaling: The model could be extended to include some of the downstream targets of STAT3 transcriptional activity to provide a more complete picture of the pathway outcome.</p> </li> <li> <p>Alternative membrane-bound pathway: Consider adding or referencing a companion model for the classic IL-6 signaling pathway (via membrane-bound IL-6R) to highlight the differences between classical and trans-signaling.</p> </li> <li> <p>IL6ST isoform specification: The model uses UniProtKB:P40189 for IL6ST, but could specifically reference the isoform involved in signaling (e.g., UniProtKB:P40189-1) for greater precision, similar to how it specifies the IL6R isoform.</p> </li> </ol>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"IL6:sIL6R Trans-signaling pathway (Human)\" accurately represents the molecular activities and causal relationships in the IL-6 trans-signaling pathway. It is well-supported by literature references and follows GO-CAM best practices. The model provides a valuable resource for understanding the mechanisms of IL-6 trans-signaling and its role in inflammatory processes.</p> <p>The representation of the IL-6/sIL-6R/gp130 complex and the subsequent JAK-STAT signaling is consistent with current knowledge of this pathway. With the minor suggested improvements, this model could serve as an exemplary representation of cytokine receptor signaling in the GO-CAM framework.</p>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/","title":"5f46c3b700003802 dGMP catabolic process to allantoin  Mouse","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model \"gomodel:5f46c3b700003802\" titled \"dGMP catabolic process to allantoin (Mouse)\".</p>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#review-of-go-cam-model-dgmp-catabolic-process-to-allantoin-mouse","title":"Review of GO-CAM Model: dGMP catabolic process to allantoin (Mouse)","text":""},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model gomodel:5f46c3b700003802 represents the purine degradation pathway, specifically focusing on the conversion of dGMP to allantoin in mouse. The model includes 11 activities (molecular functions) performed by different gene products, with causal associations between them representing the flow of the metabolic pathway.</p>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#pathway-summary","title":"Pathway Summary","text":"<p>The model depicts a metabolic pathway where: 1. dGMP is processed by nucleotidases (Nt5c, Nt5c1a, and Nt5c2) 2. The resulting deoxyguanosine is processed by purine-nucleoside phosphorylase (Pnp) 3. Guanine is deaminated by guanine deaminase (Gda) 4. Xanthine is oxidized by xanthine oxidase/dehydrogenase (Xdh) 5. Urate is oxidized by urate oxidase (Uox) 6. Unstable intermediates are converted to allantoin by HIU hydrolase (Urah) and OHCU decarboxylase (Urad)</p>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures the complete pathway from dGMP to allantoin, including all relevant intermediate steps.</p> </li> <li> <p>Appropriate causal associations: The model uses the \"provides input for\" (RO:0002413) relationship correctly to link the sequential steps of the pathway.</p> </li> <li> <p>Detailed cellular location information: Each activity is annotated with a cellular location (cytosol or peroxisome) with appropriate evidence.</p> </li> <li> <p>Well-evidenced: All activities have appropriate evidence codes and literature references.</p> </li> <li> <p>Input/output molecules: Key chemical compounds like dGMP (CHEBI:16192) and allantoin (CHEBI:15676) are correctly represented.</p> </li> <li> <p>Consistent with literature: The model is consistent with the literature on purine degradation, as evidenced by the PMID:16462750 paper which details the final steps of urate degradation to allantoin.</p> </li> </ol>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#minor-issues-and-recommendations","title":"Minor Issues and Recommendations","text":"<ol> <li> <p>Duplicate causal association: There appears to be a duplicate causal association from Xdh (activity ID: 5f46c3b700003802/5f46c3b700004320) to Uox (activity ID: 5f46c3b700003802/5f46c3b700003818). The same relationship is represented twice with different evidence.</p> </li> <li> <p>Missing evidence: One causal association from Xdh (activity ID: 5f46c3b700003802/5f46c3b700004320) to Uox has no evidence attached to it.</p> </li> <li> <p>Missing cellular location evidence: The activity for Dnph1 (ID: 60747c4200000410) has an occurs_in relationship to cytosol (GO:0005829) but lacks evidence for this annotation.</p> </li> </ol>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately captures the key enzymes and reactions in the purine degradation pathway in mouse. The representation of the terminal pathway from urate to allantoin is particularly well done, including the recently discovered enzymes HIU hydrolase (Urah) and OHCU decarboxylase (Urad) as described in the cited paper (PMID:16462750).</p> <p>The subcellular localizations are correctly represented, with nucleotidases, purine-nucleoside phosphorylase, and guanine deaminase in the cytosol, while urate oxidase, HIU hydrolase, and OHCU decarboxylase are in peroxisomes, consistent with known biology.</p>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Appropriate function annotations: Molecular functions are correctly assigned to gene products.</p> </li> <li> <p>Proper causal links: The causal relationships between activities use the appropriate relation (RO:0002413 - \"provides input for\").</p> </li> <li> <p>Evidence and references: Most assertions are supported by evidence codes and literature references.</p> </li> <li> <p>Part_of relations: Activities are appropriately marked as being part of the broader biological process (dGMP catabolic process - GO:0046055).</p> </li> </ol>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#conclusions-and-recommendations","title":"Conclusions and Recommendations","text":"<p>This is a high-quality GO-CAM model that accurately represents the dGMP catabolic pathway leading to allantoin in mouse. The model is scientifically accurate, well-supported by evidence, and follows GO-CAM best practices.</p> <p>I recommend: 1. Removing the duplicate causal association from Xdh to Uox 2. Adding evidence for the missing causal association 3. Adding evidence for the cellular location of Dnph1</p> <p>Overall, this model represents a complete metabolic pathway with appropriate gene products, molecular functions, and causal relationships, making it a valuable resource for understanding purine catabolism in mouse.</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/","title":"5f46c3b700003884 AMP catabolic process to allantoin  Mouse","text":"<p>Now, let me perform a thorough review of GO-CAM model gomodel:5f46c3b700003884 based on the information I've gathered:</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#review-of-go-cam-model-gomodel5f46c3b700003884","title":"Review of GO-CAM Model gomodel:5f46c3b700003884","text":""},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#model-summary","title":"Model Summary","text":"<p>Title: AMP catabolic process to allantoin (Mouse) ID: gomodel:5f46c3b700003884 Taxon: NCBITaxon:10090 (Mouse) Status: Production</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the AMP catabolic pathway in mouse that converts AMP to allantoin. The pathway involves multiple enzymes catalyzing sequential steps in the cytosol and peroxisome, ultimately leading to the formation of allantoin.</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#pathway-components-and-flow","title":"Pathway Components and Flow","text":"<p>The model captures a linear metabolic pathway with the following key activities:</p> <ol> <li>5'-nucleotidase activity (GO:0008253)</li> <li>Enabled by: Nt5c1b (MGI:MGI:1918131) and Nt5c1a (MGI:MGI:2155700)</li> <li>Location: Cytosol (GO:0005829)</li> <li> <p>Function: Converts AMP to adenosine</p> </li> <li> <p>Adenosine deaminase activity (GO:0004000)</p> </li> <li>Enabled by: Ada (MGI:MGI:87916)</li> <li>Location: Cytosol (GO:0005829)</li> <li> <p>Function: Converts adenosine to inosine</p> </li> <li> <p>Purine-nucleoside phosphorylase activity (GO:0004731)</p> </li> <li>Enabled by: Pnp (MGI:MGI:97365)</li> <li>Location: Cytosol (GO:0005829)</li> <li> <p>Function: Converts inosine to hypoxanthine</p> </li> <li> <p>Hypoxanthine dehydrogenase/oxidase activities (GO:0070674/GO:0070675)</p> </li> <li>Enabled by: Xdh (MGI:MGI:98973)</li> <li>Location: Cytosol (GO:0005829)</li> <li> <p>Function: Converts hypoxanthine to xanthine</p> </li> <li> <p>Xanthine dehydrogenase/oxidase activities (GO:0004854/GO:0004855)</p> </li> <li>Enabled by: Xdh (MGI:MGI:98973)</li> <li>Location: Cytosol/peroxisome (GO:0005829/GO:0005777)</li> <li> <p>Function: Converts xanthine to urate</p> </li> <li> <p>Urate oxidase activity (GO:0004846)</p> </li> <li>Enabled by: Uox (MGI:MGI:98907)</li> <li>Location: Peroxisome (GO:0005777)</li> <li> <p>Function: Converts urate to 5-hydroxyisourate</p> </li> <li> <p>Hydroxyisourate hydrolase activity (GO:0033971)</p> </li> <li>Enabled by: Urah (MGI:MGI:1916142)</li> <li>Location: Peroxisome (GO:0005777)</li> <li> <p>Function: Converts 5-hydroxyisourate to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU)</p> </li> <li> <p>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity (GO:0051997)</p> </li> <li>Enabled by: Urad (MGI:MGI:3647519)</li> <li>Location: Peroxisome (GO:0005777)</li> <li>Function: Converts OHCU to allantoin</li> <li>Output: Allantoin (CHEBI:15676)</li> </ol>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive Pathway Representation: The model captures the complete AMP to allantoin degradation pathway, including all necessary enzymatic steps.</p> </li> <li> <p>Subcellular Localization: The model accurately represents the different subcellular locations (cytosol vs. peroxisome) where these reactions occur.</p> </li> <li> <p>Multiple Enzyme Isoforms: The model includes both Nt5c1a and Nt5c1b as alternative 5'-nucleotidases, reflecting biological redundancy.</p> </li> <li> <p>Dual Activities of Xanthine Dehydrogenase: The model correctly captures that Xdh (MGI:MGI:98973) has multiple activities (dehydrogenase and oxidase) and can function in both the cytosol and peroxisome.</p> </li> <li> <p>Evidence Support: Each molecular function is supported by appropriate evidence (experimental evidence, sequence orthology) and relevant literature.</p> </li> </ol>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Enzyme/Gene Information: The model doesn't include information about adenylate kinase, which catalyzes the conversion of ADP to AMP and is typically part of the early steps of AMP catabolism.</p> </li> <li> <p>Subcellular Transport Mechanisms: The model does not explicitly capture how metabolites transition from the cytosol to the peroxisome, which is crucial for the later steps of the pathway.</p> </li> <li> <p>Regulatory Aspects: The model doesn't represent any regulatory mechanisms that control this pathway, such as feedback inhibition or activation.</p> </li> <li> <p>Incomplete Evidence: Some causal associations lack evidence annotations, which should be added to strengthen the model.</p> </li> <li> <p>Alternative Pathways: The model focuses on a single linear pathway without representing potential alternative routes or shunts in purine metabolism.</p> </li> </ol>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#evidence-evaluation","title":"Evidence Evaluation","text":"<p>The model is well-supported by experimental evidence, with most activities having direct assay evidence (ECO:0000314) or mutant phenotype evidence (ECO:0000315). Key literature citations include PMID:16462750, which details the enzymes involved in uric acid degradation to allantoin, particularly focusing on the peroxisomal enzymes (URAH and URAD).</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model accurately reflects the current understanding of purine catabolism in mice. PMID:16462750 (Ramazzina et al., 2006) provides comprehensive evidence for the later steps of the pathway, particularly the enzymatic conversion of urate to allantoin, which requires three enzymes (urate oxidase, HIU hydrolase, and OHCU decarboxylase). The model correctly represents these enzymes as UOX, URAH, and URAD, respectively, and their peroxisomal localization.</p> <p>PMID:11690631 supports the 5'-nucleotidase activity of Nt5c1b in cytosol and its role in AMP catabolism.</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#summary","title":"Summary","text":"<p>The GO-CAM model gomodel:5f46c3b700003884 provides a comprehensive representation of the AMP catabolic pathway to allantoin in mouse. It accurately represents the sequential enzymatic steps, subcellular localizations, and is well-supported by experimental evidence. The model could be improved by including information about metabolite transport between cellular compartments and regulatory mechanisms. Overall, this is a high-quality model that effectively captures the biological process of AMP catabolism to allantoin in mouse.</p>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/","title":"5fa76ad400000018 AMP catabolic process 2  Mouse","text":"<p>Now let me review the GO-CAM model based on all the information I've gathered:</p>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#go-cam-review-amp-catabolic-process-2-mouse-gomodel5fa76ad400000018","title":"GO-CAM Review: AMP catabolic process 2 (Mouse) - gomodel:5fa76ad400000018","text":""},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:5fa76ad400000018) represents the AMP catabolic process in mouse, focusing on enzymes and transporters involved in adenine nucleotide metabolism. The model includes:</p> <ol> <li>5'-nucleotidase (CD73/Nt5e) activity</li> <li>ADP phosphatase (ENTPD1) activity </li> <li>AMP deaminase (AMPD3) activity</li> <li>Nucleoside transporters (SLC29A1 and SLC29A2)</li> </ol>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model is well-supported by the literature with strong evidence from:</p> <ul> <li>PMID:28746349 - Details the regulation of adenine nucleotide pool in erythrocytes, demonstrating how CD73, AMPD3, and nucleoside transporters coordinate in AMP metabolism</li> <li>PMID:28069792 - Referenced for the nucleoside transporter activities</li> <li>PMID:17502665 - Supporting ENTPD1 function</li> </ul> <p>The protein functions represented align with their established biochemical roles:</p> <ol> <li> <p>Nt5e (CD73) - Correctly represented as having 5'-nucleotidase activity converting AMP to adenosine, with annotation for its extracellular location on the plasma membrane.</p> </li> <li> <p>ENTPD1 - Properly annotated with ADP phosphatase activity, converting ADP to AMP.</p> </li> <li> <p>SLC29A1/SLC29A2 - Correctly annotated as purine nucleoside transporters.</p> </li> <li> <p>AMPD3 - Correctly assigned AMP deaminase activity.</p> </li> </ol> <p>The causal relationships between activities are biologically accurate, reflecting how: - ENTPD1 generates AMP that feeds into CD73 activity - CD73-generated adenosine is transported by SLC29A1/SLC29A2 - ENTPD1 also provides input for SLC29A1 activity</p>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#structural-assessment","title":"Structural Assessment","text":"<p>The structure of the model follows GO-CAM best practices:</p> <ol> <li>Activities are properly defined with molecular functions, cellular locations, and inputs/outputs where appropriate:</li> <li>CD73 activity has AMP as input and adenosine as output</li> <li> <p>ENTPD1 has ADP as input and AMP as output</p> </li> <li> <p>Causal connections are correctly established using \"provides input for\" (RO:0002413) predicates:</p> </li> <li>The ADP phosphatase activity (ENTPD1) provides input for 5'-nucleotidase activity (CD73)</li> <li>The ADP phosphatase activity provides input for nucleoside transport</li> <li> <p>The 5'-nucleotidase activity provides input for nucleoside transport</p> </li> <li> <p>Cellular locations are appropriately specified:</p> </li> <li>CD73 is correctly annotated to the external side of plasma membrane (GO:0009897)</li> <li>SLC29A1 and SLC29A2 are correctly annotated to the plasma membrane</li> <li>AMPD3 is correctly annotated to the cytosol</li> </ol>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I have identified a few areas for improvement:</p> <ol> <li>Subcellular localization for one activity:</li> <li> <p>AMPD3 (gomodel:5fa76ad400000018/5fa76ad400000044) is annotated with GO:0005829 (cytosol) but lacks evidence citations for this annotation.</p> </li> <li> <p>Causal relationships could be more precise:</p> </li> <li> <p>There could be a causal relationship from CD73 (Nt5e) to the AMPD3 activity to reflect the competition for AMP as a substrate, which would complete the pathway representation.</p> </li> <li> <p>Additional activities:</p> </li> <li>The model could include the activity of adenosine kinase, which would complete the adenosine-AMP cycle by phosphorylating adenosine back to AMP.</li> <li> <p>Adenosine deaminase (ADA) activity could be included to represent the alternative fate of adenosine.</p> </li> <li> <p>Regulatory relationships:</p> </li> <li>The model doesn't include any regulatory relationships (RO:0002629/RO:0002630 - direct positive/negative regulation). From the literature, there are known regulatory interactions between these components that could be included.</li> </ol>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model is a well-constructed, accurate representation of the AMP catabolic process in mouse. It includes appropriate molecular functions, cellular locations, biological processes, and causal connections with strong evidence support. The activities and relationships represented in the model are consistent with the current understanding of adenine nucleotide metabolism as demonstrated in the literature.</p> <p>The model successfully shows how ADP is converted to AMP by ENTPD1, then either dephosphorylated to adenosine by CD73 or deaminated to IMP by AMPD3. It also shows how adenosine is transported across the membrane by nucleoside transporters. </p> <p>The few suggested improvements would enhance the comprehensiveness of the model but do not detract from its current accuracy and utility.</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/","title":"5fa76ad400000110 GMP catabolic process to allantoin  Mouse","text":"<p>Now, let me review the model in detail, focusing on the key aspects of GO-CAM curation practices and assess whether this model meets the standards. I'll prepare a comprehensive review of GO-CAM model 5fa76ad400000110.</p> <p>After analyzing the GO-CAM model 5fa76ad400000110 \"GMP catabolic process to allantoin (Mouse)\", I can now provide a comprehensive review:</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#go-cam-model-review-gomodel5fa76ad400000110","title":"GO-CAM Model Review: gomodel:5fa76ad400000110","text":""},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the GMP catabolic pathway to allantoin in mouse, showing the enzymatic cascade that converts GMP to allantoin through multiple intermediates. </p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway Representation: The model effectively represents the complete metabolic pathway from GMP to allantoin, with all intermediate steps correctly captured.</p> </li> <li> <p>Causal Relationships: The model properly uses the RO:0002413 \"provides input for\" predicate to connect activities in a metabolic flow, which is appropriate for metabolic pathways.</p> </li> <li> <p>Cellular Compartmentalization: The model correctly specifies the subcellular locations for each activity, distinguishing between cytosol (GO:0005829) and peroxisome (GO:0005777) localization where appropriate, which is biologically accurate according to the literature.</p> </li> <li> <p>Evidence Base: Each activity is supported by appropriate experimental evidence codes and literature references.</p> </li> <li> <p>Complete Pathway: The model includes all the key enzymes in the GMP catabolic pathway:</p> </li> <li>GMP 5'-nucleotidase (Nt5c2)</li> <li>Purine-nucleoside phosphorylase (Pnp)</li> <li>Guanine deaminase (Gda)</li> <li>Xanthine dehydrogenase/oxidase (Xdh)</li> <li>Urate oxidase (Uox)</li> <li>Hydroxyisourate hydrolase (Urah)</li> <li>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad)</li> </ol>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Model Title Specificity: The title \"GMP catabolic process to allantoin (Mouse)\" is accurate but could specify that this is the complete pathway.</p> </li> <li> <p>Biological Process Context: All activities are annotated as part of GO:0046038 (GMP catabolic process), which is correct, but some later steps could arguably also be part of more specific processes like urate metabolic process.</p> </li> <li> <p>Explanatory Notes: The model would benefit from additional annotation notes explaining the biological significance of this pathway in mouse versus humans (where the pathway is incomplete due to urate oxidase deficiency).</p> </li> </ol>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#technical-assessment","title":"Technical Assessment","text":"<ol> <li> <p>Structure: The model correctly uses a linear chain of activities with each protein properly enabled by the correct gene product and associated with the appropriate molecular function.</p> </li> <li> <p>Evidence Codes: Appropriate evidence codes are used throughout, primarily:</p> </li> <li>ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>ECO:0000315 (mutant phenotype evidence used in manual assertion)</li> <li> <p>ECO:0000266 (sequence orthology evidence used in manual assertion)</p> </li> <li> <p>Literature Support: The model references several relevant publications, including the key paper by Ramazzina et al. (PMID:16462750) which identified the final steps in the pathway.</p> </li> <li> <p>Ontology Usage: The model uses appropriate GO terms for molecular functions and cellular components.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the known biology of the GMP catabolic pathway in mouse. In particular:</p> <ol> <li> <p>The pathway begins with GMP 5'-nucleotidase activity (Nt5c2) in the cytosol, which converts GMP to guanosine.</p> </li> <li> <p>Purine-nucleoside phosphorylase (Pnp) then acts on guanosine to produce guanine.</p> </li> <li> <p>Guanine deaminase (Gda) converts guanine to xanthine in the cytosol.</p> </li> <li> <p>Xanthine dehydrogenase/oxidase (Xdh) can utilize either xanthine dehydrogenase or xanthine oxidase activity to convert xanthine to urate.</p> </li> <li> <p>Urate oxidase (Uox) converts urate to 5-hydroxyisourate in the peroxisome.</p> </li> <li> <p>The final two enzymes, hydroxyisourate hydrolase (Urah) and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad), complete the pathway to produce S-(+)-allantoin in the peroxisome.</p> </li> </ol> <p>This accurately reflects the findings in the literature, especially the 2006 paper by Ramazzina et al. that elucidated the final steps of the pathway.</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#comparison-to-best-practices","title":"Comparison to Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Each protein is appropriately linked to its activity.</li> <li>Activities are properly connected through causal relationships.</li> <li>Each activity is grounded in an appropriate cellular location.</li> <li>Evidence is properly cited with appropriate evidence codes.</li> </ol>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 5fa76ad400000110 is a high-quality representation of the GMP catabolic pathway to allantoin in mouse. It accurately represents the biology with appropriate evidence and follows GO-CAM best practices. The model could be enhanced with additional notes about the biological significance and differences between species, but overall serves as an excellent reference for this metabolic pathway.</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/","title":"5fa76ad400000265 dAMP catabolic process to allantoin  Mouse","text":"<p>Based on the information I've gathered, I'll now provide a comprehensive review of GO-CAM model gomodel:5fa76ad400000265 (dAMP catabolic process to allantoin in Mouse).</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#go-cam-model-review-gomodel5fa76ad400000265-damp-catabolic-process-to-allantoin-mouse","title":"GO-CAM Model Review: gomodel:5fa76ad400000265 - dAMP catabolic process to allantoin (Mouse)","text":""},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#general-model-overview","title":"General Model Overview","text":"<p>This model represents the sequential catabolic pathway for dAMP degradation to allantoin in mouse (taxon: NCBITaxon:10090). The model contains multiple activities connected by causal relationships, forming a complete metabolic pathway where the output of one reaction provides input for the next.</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#biological-content-evaluation","title":"Biological Content Evaluation","text":"<p>The model depicts the purine nucleoside degradation pathway, specifically showing the conversion of dAMP to allantoin through several enzymatic steps. The pathway follows:</p> <ol> <li>dAMP catabolism starts with 5'-nucleotidase (Nt5c1a) converting dAMP to deoxyadenosine</li> <li>Adenosine deaminase (Ada) converts deoxyadenosine to deoxyinosine</li> <li>Purine-nucleoside phosphorylase (Pnp) converts deoxyinosine to hypoxanthine</li> <li>Xanthine dehydrogenase/oxidase (Xdh) converts hypoxanthine to xanthine, and then xanthine to urate</li> <li>Urate oxidase (Uox) converts urate to 5-hydroxyisourate</li> <li>Hydroxyisourate hydrolase (Urah) converts 5-hydroxyisourate to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU)</li> <li>OHCU decarboxylase (Urad) converts OHCU to S-(+)-allantoin</li> </ol> <p>The model accurately represents the underlying biology based on the papers cited (PMID:8064675, PMID:16462750, PMID:11783524, etc.). In particular, the detailed pathway from urate to allantoin described in PMID:16462750 is correctly represented with the sequential activities of Uox, Urah, and Urad.</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#ontology-usage-and-relations","title":"Ontology Usage and Relations","text":"<p>The model appropriately uses: - Molecular functions from GO (e.g., GO:0004731 for purine-nucleoside phosphorylase activity) - Biological processes (GO:0046059 for dAMP catabolic process) - Cellular components (GO:0005829 for cytosol, GO:0005777 for peroxisome) - Chemical entities (CHEBI:15676 for allantoin)</p> <p>All causal relations use the appropriate relation \"RO:0002413\" (provides input for), which is correct for a metabolic pathway where the product of one reaction is the substrate for the next reaction.</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000266 (sequence orthology evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion)</p> <p>Each activity has proper scientific literature evidence with appropriate PMIDs. The localization of activities to cytosol or peroxisome is well-supported by published evidence.</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#model-structure-and-completeness","title":"Model Structure and Completeness","text":"<p>The model has a clear sequential flow of activities connected with causal relations. Each activity node includes: - Molecular function - Gene product that enables the activity - Cellular location - Part of biological process</p> <p>The model correctly represents the subcellular localization of different parts of the pathway: - Early steps (dAMP to hypoxanthine) occur in the cytosol - Later steps (uric acid to allantoin) occur in peroxisomes</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows best practices for GO-CAM models: 1. Activities are connected with appropriate causal relationships 2. Each activity is assigned to the gene product that enables it 3. Cellular locations are properly specified 4. The model forms a coherent pathway with clear input/output relations 5. All activities have appropriate evidence codes and literature citations</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is well-constructed, I have a few minor suggestions for improvement:</p> <ol> <li> <p>Complete the causal connection evidence: One causal association (from MuraH to MuraD) lacks explicit evidence codes. Although the relationship is implied by PMID:16462750, directly adding this citation to the causal relation would improve the model.</p> </li> <li> <p>Add detailed molecule associations: The model could be enhanced by explicitly showing the intermediate metabolites throughout the pathway (not just the final allantoin). This would make the chemical transformations more transparent.</p> </li> <li> <p>Consider expanding metabolic context: The model could potentially include connections to related purine metabolism pathways to provide broader context.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model (gomodel:5fa76ad400000265) is a high-quality representation of the dAMP catabolic pathway leading to allantoin in mouse. It correctly depicts the sequence of enzymatic reactions, their subcellular locations, and the genes encoding the involved enzymes. The model is well-supported by scientific evidence and follows GO-CAM best practices for representing biological pathways.</p> <p>The model provides an excellent example of a metabolic pathway representation in GO-CAM format, with clear relationships between activities and appropriate use of GO terms for functions, processes and cellular components.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/","title":"5fa76ad400000374 IMP catabolic process to allantoin  Mouse","text":"<p>Finally, let me put together a detailed review of the GO-CAM model based on all the information I've gathered.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#go-cam-model-review-gomodel5fa76ad400000374","title":"GO-CAM Model Review: gomodel:5fa76ad400000374","text":""},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:5fa76ad400000374) describes the \"IMP catabolic process to allantoin (Mouse)\" pathway. The model represents the enzymatic pathway for the degradation of purines, specifically the conversion of IMP to allantoin in mouse.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#pathway-context","title":"Pathway Context","text":"<p>The pathway depicted is the purine catabolism pathway that converts IMP (inosine monophosphate) through a series of enzymatic steps to finally produce allantoin. This is an important metabolic pathway in many organisms, though humans and other primates have lost the ability to degrade uric acid to allantoin due to the loss of functional urate oxidase.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#model-structure-and-components","title":"Model Structure and Components","text":""},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#core-enzymes-and-activities","title":"Core Enzymes and Activities","text":"<p>The model includes several key enzymes:</p> <ol> <li>NT5C, NT5C1A, NT5C2 (IMP 5'-nucleotidase activity) - Convert IMP to inosine</li> <li>PNP (Purine-nucleoside phosphorylase) - Converts inosine to hypoxanthine</li> <li>XDH (Xanthine dehydrogenase/oxidase) with multiple activities:</li> <li>Hypoxanthine dehydrogenase activity</li> <li>Hypoxanthine oxidase activity</li> <li>Xanthine dehydrogenase activity </li> <li>Xanthine oxidase activity</li> <li>UOX (Urate oxidase) - Converts urate to 5-hydroxyisourate</li> <li>URAH (HIU hydrolase) - Converts 5-hydroxyisourate to OHCU</li> <li>URAD (OHCU decarboxylase) - Converts OHCU to allantoin</li> </ol>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#cellular-localization","title":"Cellular Localization","text":"<p>The model appropriately indicates different cellular localizations for different activities: - Cytosol (GO:0005829) for early steps involving NT5C enzymes, PNP, and some XDH activities - Peroxisome (GO:0005777) for later steps involving UOX, URAH, and URAD</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model uses the <code>RO:0002413</code> provides input for relation throughout the pathway to show the flow of enzymatic activities. This is appropriate for metabolic pathways where the product of one reaction becomes the substrate for the next.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#evidence-quality","title":"Evidence Quality","text":"<p>The model is well-supported by experimental evidence, primarily with: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000266 (sequence orthology evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion)</p> <p>Key publications cited include PMID:8064675, PMID:16462750, and several others that support the enzymatic activities and pathway organization.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures the complete pathway from IMP to allantoin, including all intermediate steps.</p> </li> <li> <p>Proper cellular localization: The model correctly represents the differential localization of activities between cytosol and peroxisome, which is biologically accurate.</p> </li> <li> <p>Multiple activities of XDH: The model correctly represents the multiple activities of xanthine dehydrogenase/oxidase, which can function both as a dehydrogenase and an oxidase with different substrates.</p> </li> <li> <p>Well-evidenced: Most assertions in the model are supported by appropriate experimental evidence.</p> </li> <li> <p>Includes recently discovered enzymes: The model includes URAH and URAD, which as shown in PMID:16462750, were relatively recently discovered to complete the pathway from uric acid to allantoin.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing cellular localization for some activities: The assertion for PNP (gomodel:5fa76ad400000374/5fa76ad400000376) has an empty evidence field for its cellular localization in the cytosol. This should be completed with appropriate evidence.</p> </li> <li> <p>Causal association evidence: Some causal associations lack evidence (e.g., between NT5C1A activity and PNP activity). All causal connections should have evidence supporting the pathway flow.</p> </li> <li> <p>Metabolic intermediates: The model only explicitly shows allantoin as an output, but could be enhanced by representing the other metabolic intermediates (hypoxanthine, xanthine, urate, 5-hydroxyisourate, OHCU) as has_output and has_input relations to better document the pathway.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on the literature review and UniProt information for key proteins, this model accurately represents the IMP to allantoin catabolic pathway in mouse. The inclusion of the recently discovered enzymes URAH and URAD (from PMID:16462750) shows that the model is up-to-date with current knowledge.</p> <p>The placement of these enzymes in peroxisomes is correct, as they contain peroxisomal targeting signals as noted in the Ramazzina et al. paper (PMID:16462750).</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:5fa76ad400000374) is a high-quality representation of the IMP catabolic pathway to allantoin in mouse. It includes all key enzymatic steps, appropriate cellular localization, and is well-supported by evidence. The minor issues noted should be addressed to further improve the model, but they do not significantly impact the overall quality or accuracy of the pathway representation.</p>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/","title":"5fadbcf000000317 Fzd3 function in Cranial neural crest cells","text":"<p>Based on my review of the GO-CAM model \"gomodel:5fadbcf000000317\" titled \"Fzd3 function in Cranial neural crest cells\" and the available documentation, I can provide the following assessment:</p>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#go-cam-model-review-fzd3-function-in-cranial-neural-crest-cells","title":"GO-CAM Model Review: Fzd3 function in Cranial neural crest cells","text":"<p>Model ID: gomodel:5fadbcf000000317 Title: Fzd3 function in Cranial neural crest cells Taxon: Xenopus laevis (African clawed frog) - NCBITaxon:8364</p>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#overall-assessment","title":"Overall Assessment","text":"<p>This model describes the function of Frizzled-3 (Fzd3) in cranial neural crest cells in Xenopus, focusing on both canonical and non-canonical Wnt signaling pathways and their downstream effects on neural crest cell migration and development.</p>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive representation: The model captures both canonical and non-canonical Wnt signaling through Fzd receptors (Fzd3 and Fzd7).</p> </li> <li> <p>Cellular localization: The model appropriately annotates subcellular locations for the activities (e.g., extracellular space for secreted Wnt proteins, plasma membrane for transmembrane receptors).</p> </li> <li> <p>Pathway connectivity: The model shows a good flow of signaling from extracellular Wnt ligands through receptors to downstream effectors including RhoA, Rac1, JNK, and Rock1.</p> </li> <li> <p>Evidence support: Most activities and relationships have supporting evidence with appropriate ECO codes and references to literature or databases.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Obsolete term usage: The model uses GO:1904929 \"obsolete coreceptor activity involved in Wnt signaling pathway, planar cell polarity pathway\" for PTK7.L. This term should be replaced with an up-to-date GO term.</p> </li> <li> <p>Incomplete evidence: Some causal associations lack evidence codes, for example:</p> </li> <li>The causal association between Dvl1 (GO:0005109) and Fzd7 (GO:0042813)</li> <li>The causal association between Wnt11 (GO:0005109) and Fzd7 (GO:0042813)</li> <li> <p>The causal association between Sdc4 (GO:0005515) and Fzd7 (GO:0042813)</p> </li> <li> <p>Signaling receptor representation: According to the signaling receptor annotation guidelines, the input of a receptor should be the effector protein it regulates, not its ligand. However, in this model, the causal relationship between ligands and receptors is represented using \"directly positively regulates\" (RO:0002629) or \"causally upstream of, positive effect\" (RO:0002304).</p> </li> <li> <p>Missing biological process context: Some molecular functions lack biological process context through \"part of\" relations, which would help situate the activities in their appropriate biological processes.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Replace obsolete term: Update GO:1904929 with an appropriate current term for PTK7's role in PCP signaling.</p> </li> <li> <p>Add missing evidence: Add appropriate evidence codes and references for all causal associations that currently lack them.</p> </li> <li> <p>Clarify receptor-ligand relationships: Consider whether the current representation of receptor-ligand relationships aligns with the \"Signaling receptor activity annotation guidelines\" document. The guideline states that a receptor's input should be its effector protein, not its ligand.</p> </li> <li> <p>Add biological process annotations: For activities that lack them, consider adding \"part of\" relations to appropriate biological processes to provide better context.</p> </li> <li> <p>Check RhoA/JNK pathway: Ensure that the pathway from RhoA to JNK aligns with current understanding. Typically, RhoA acts through ROCK to affect cytoskeletal dynamics, while JNK is often downstream of Rac1/Cdc42 in separate pathway branches.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model appears to be biologically accurate based on the literature about Fzd3's role in neural crest cell development and migration in Xenopus. The key publications referenced in the model (PMID: 28427856, PMID: 11585792) support the signaling pathways depicted. The model correctly captures the relationships between Wnt signaling (both canonical and non-canonical pathways) and neural crest cell migration.</p>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that effectively represents Fzd3 function in cranial neural crest cells in Xenopus, with a few areas that could be improved for completeness and alignment with current GO-CAM curation guidelines. The model provides a valuable resource for understanding the molecular mechanisms underlying neural crest development.</p>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/","title":"5fadbcf000000480 UMP catabolic process  Mouse","text":"<p>Now I have enough information to proceed with a comprehensive review of GO-CAM model gomodel:5fadbcf000000480, titled \"UMP catabolic process (Mouse)\".</p>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#go-cam-review-ump-catabolic-process-mouse-gomodel5fadbcf000000480","title":"GO-CAM Review: UMP catabolic process (Mouse) - gomodel:5fadbcf000000480","text":""},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This model represents the UMP catabolic process in mouse, showing multiple enzymatic activities involved in the pathway with their respective causal connections. The model depicts a biochemical pathway where UMP is catabolized through a series of enzymatic reactions.</p>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Appropriate use of causal connections: The model uses RO:0002413 \"provides input for\" predicate to connect the activities in a logical sequence, which is appropriate for this metabolic pathway.</p> </li> <li> <p>Spatial organization: Most activities are annotated as occurring in the cytosol (GO:0005829), which is consistent with known cellular localization of this pathway. One activity is appropriately annotated to occur in the mitochondrion (GO:0005739).</p> </li> <li> <p>Evidence support: The model cites multiple PMIDs to support the activities and connections, showing a good level of literature support.</p> </li> <li> <p>Taxonomic specificity: The model is correctly specified for mouse (NCBITaxon:10090).</p> </li> </ol>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Incomplete process annotations: Not all activities have \"part_of\" associations connecting them to the UMP catabolic process (GO:0046050). Specifically:</li> <li>The activity enabled by MGI:MGI:2146052 (Agxt2) lacks a part_of association to GO:0046050</li> <li>The activity enabled by MGI:MGI:1354954 (Nt5c) lacks a part_of association to GO:0046050</li> <li>The activity enabled by MGI:MGI:2143535 (Upb1) lacks a part_of association to GO:0046050</li> </ol> <p>Recommendation: Add \"part_of\" associations to connect all relevant activities to GO:0046050 to ensure completeness.</p> <ol> <li>Missing evidence for spatial location: The cytosolic localization of MGI:MGI:2146052 (Agxt2) has no evidence. However, this protein is annotated as occurring in mitochondrion which may be correct, but evidence should be added.</li> </ol> <p>Recommendation: Add evidence to support the subcellular localization.</p> <ol> <li>Pathway completeness: While the model covers key steps in UMP catabolism, there are some potential gaps in the pathway representation:</li> <li>The connection between MGI:MGI:2143535 (Upb1, beta-ureidopropionase) and any further metabolic steps is missing</li> </ol> <p>Recommendation: Consider adding the complete catabolic path to show the final products of UMP degradation.</p> <ol> <li>Missing/incomplete evidence: Some of the causal connections have evidence from references that we were unable to verify due to lack of full text access (PMID:14715930, PMID:7744869).</li> </ol> <p>Recommendation: Ensure all evidence is properly reviewed and documented.</p> <ol> <li>Potential inconsistency in gene product orthology: Some activities use evidence with \"ECO:0000266\" (sequence orthology evidence) referring to human proteins (e.g., UniProtKB:Q9H0P0, UniProtKB:Q8TCD5). While orthology-based annotation is valid, it would be better to directly cite mouse-specific evidence where available.</li> </ol> <p>Recommendation: Where possible, replace orthology-based evidence with direct experimental evidence in the mouse model system.</p>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#go-cam-best-practice-conformance","title":"GO-CAM Best Practice Conformance","text":"<p>Based on the GO-CAM best practices:</p> <ol> <li> <p>Causal relationships: The model appropriately uses the \"provides input for\" predicate (RO:0002413) for metabolic pathways, which conforms to GO-CAM best practices.</p> </li> <li> <p>Complex representation: The model doesn't include any protein complexes, which is appropriate as the individual enzymatic activities are clearly attributed to specific gene products.</p> </li> <li> <p>Evidence quality: The model uses a mix of direct experimental evidence (ECO:0000314) and sequence orthology evidence (ECO:0000266), which is acceptable but could be improved with more direct evidence where possible.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the UMP catabolic process in mouse with appropriate causal connections, evidence, and cellular localizations. With minor improvements to process annotations and evidence documentation, this would be an excellent model of this metabolic pathway. The model is parsimonious and should be understandable to a human viewer familiar with biochemical pathways.</p>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/","title":"5fadbcf000000868 dUMP catabolic process  Mouse","text":"<p>Now I have enough information to review the GO-CAM model. Let me provide a comprehensive review:</p>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#review-of-go-cam-model-gomodel5fadbcf000000868","title":"Review of GO-CAM Model: gomodel:5fadbcf000000868","text":""},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#basic-information","title":"Basic Information","text":"<ul> <li>Title: \"dUMP catabolic process (Mouse)\"</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Model ID: gomodel:5fadbcf000000868</li> </ul>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the dUMP (deoxyuridine monophosphate) catabolic process in mouse. The model describes a pathway with several enzymatic steps involved in the degradation of dUMP, with each activity enabled by a specific gene product.</p>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#model-architecture","title":"Model Architecture","text":"<p>The pathway described has the following steps (ordered by the causal flow):</p> <ol> <li>NT5C3 (MGI:MGI:1927186) - 5'-nucleotidase activity (GO:0008253) in cytosol</li> <li>UPP1 (MGI:MGI:1097668) - deoxyuridine phosphorylase activity (GO:0047847) in cytosol</li> <li>DPYD (MGI:MGI:2139667) - dihydropyrimidine dehydrogenase (NADP+) activity (GO:0017113) in cytosol</li> <li>DPYS (MGI:MGI:1928679) - dihydropyrimidinase activity (GO:0004157) in cytosol</li> <li>UPB1 (MGI:MGI:2143535) - beta-ureidopropionase activity (GO:0003837) in cytosol</li> </ol> <p>Additionally, there are two activities in the model: - NT5C (MGI:MGI:1354954) - 5'-nucleotidase activity (GO:0008253) in cytosol - AGXT2 (MGI:MGI:2146052) - beta-alanine:pyruvate transaminase activity (GO:0016223) in mitochondrion</p> <p>The model follows a linear flow of causal connections using the \"provides input for\" (RO:0002413) predicate, showing how each enzymatic reaction in the pathway leads to the next one.</p>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses published scientific literature as evidence for most annotations: - PMID:14154460 - Specificity of mouse uridine phosphorylase - PMID:5472365 - Studies of a mutation affecting pyrimidine degradation in inbred mice - PMID:27062388 - Study on \u03b2-alanine transamination enzymes - PMID:10681516 and PMID:6301357 - Studies on 5'-nucleotidase</p> <p>Evidence codes used are appropriate: - ECO:0000314 (direct assay evidence used in manual assertion) for most activities - ECO:0000266 (sequence orthology evidence used in manual assertion) in some cases</p>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model clearly represents the enzymatic steps in the dUMP catabolic pathway with appropriate molecular functions.</li> <li>Each activity is properly connected to the next through causal associations.</li> <li>Subcellular locations are specified for all activities (most occur in cytosol, with one in mitochondrion).</li> <li>Evidence is provided for all assertions with appropriate references and evidence codes.</li> <li>The model captures the biological process correctly, with all activities being part of \"dUMP catabolic process\" (GO:0046079).</li> </ol>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Parallel Activities: The model includes two 5'-nucleotidase activities (NT5C and NT5C3) that both feed into UPP1. The literature suggests these are distinct isozymes with different substrate specificities, but the model doesn't clearly indicate why there are two parallel inputs to the pathway.</p> </li> <li> <p>Activity Endpoints: The model includes UPB1 (beta-ureidopropionase) and AGXT2 (beta-alanine:pyruvate transaminase), but AGXT2 isn't causally connected to any other activities. Based on the PMID:27062388 paper, AGXT2 is involved in \u03b2-alanine metabolism, which is the product of UPB1. There should be a causal connection between UPB1 and AGXT2 to complete the pathway.</p> </li> <li> <p>Subcellular Locations: While most activities are correctly located in the cytosol, AGXT2 is shown in the mitochondrion. This is consistent with the literature, but it would be helpful to show how metabolites move between compartments.</p> </li> <li> <p>Consistency with Complex Guidelines: This model doesn't involve protein complexes, so the complex annotation guidelines don't apply directly. Each activity is represented by a single gene product, which is appropriate when the activities are carried out by monomeric enzymes.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Complete the Pathway: Add a causal connection between UPB1 and AGXT2 to show how beta-alanine produced by UPB1 is further metabolized by AGXT2 in the mitochondrion.</p> </li> <li> <p>Clarify Isozyme Roles: Consider adding annotations to clarify the different roles or preferences of the two 5'-nucleotidases (NT5C and NT5C3) in the pathway based on the detailed isozyme characterization in PMID:6301357.</p> </li> <li> <p>Transport Between Compartments: Consider adding a transport step to show how beta-alanine moves from the cytosol to the mitochondrion for further metabolism by AGXT2.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the dUMP catabolic process in mouse. The model follows a logical flow, uses appropriate evidence, and correctly associates gene products with their molecular functions and cellular locations. With minor improvements to connect AGXT2 to the rest of the pathway and clarify the roles of the 5'-nucleotidase isozymes, this model would provide an even clearer representation of the pathway.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/","title":"5fadbcf000000942 dTMP catabolic process  Mouse","text":"<p>Based on a thorough review of the GO-CAM model \"gomodel:5fadbcf000000942\" titled \"dTMP catabolic process (Mouse)\", I will provide a structured analysis of its biological content, structural organization, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the dTMP (deoxythymidine monophosphate) catabolic pathway in mouse, showing the sequential enzymatic steps involved in the degradation of pyrimidine nucleotides. The model includes 7 distinct molecular activities connected through causal relationships.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#biological-content-analysis","title":"Biological Content Analysis","text":""},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#pathway-representation","title":"Pathway Representation","text":"<p>The model correctly depicts the pyrimidine degradation pathway, particularly focused on the catabolism of dTMP. The enzymes involved are appropriately connected in sequential order representing the flow of biochemical reactions:</p> <ol> <li>5'-nucleotidases (NT5C and NT5C3) convert dTMP to thymidine by removing the phosphate group</li> <li>Thymidine phosphorylases (TYMP and UPP1) convert thymidine to thymine and 2-deoxyribose-1-phosphate</li> <li>Dihydropyrimidine dehydrogenase (DPYD) reduces thymine to dihydrothymine</li> <li>Dihydropyrimidinase (DPYS) catalyzes the hydrolytic ring opening of dihydrothymine to N-carbamyl-\u03b2-aminoisobutyric acid</li> <li>\u03b2-ureidopropionase (UPB1) completes the pathway by converting N-carbamyl-\u03b2-aminoisobutyric acid to \u03b2-aminoisobutyric acid, ammonia and CO2</li> </ol>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by evidence from the literature: - PMID:8083224 supports DPYD (dihydropyrimidine dehydrogenase) function - PMID:22525402 supports UPB1 (\u03b2-ureidopropionase) function - PMID:12077348 supports TYMP (thymidine phosphorylase) activity - PMID:6301357 supports NT5C (5'-nucleotidase) function</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#subcellular-localization","title":"Subcellular Localization","text":"<p>The model includes cellular component annotations: - Most enzymes are properly localized to the cytosol (GO:0005829) - AGXT2 is appropriately localized to the mitochondrion (GO:0005739)</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#biological-process-context","title":"Biological Process Context","text":"<p>All activities are appropriately part of dTMP catabolic process (GO:0046074), which provides a clear biological context for the model.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#structural-organization-analysis","title":"Structural Organization Analysis","text":""},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model uses causal relationships correctly with the predicate \"RO:0002413\" (provides input for) connecting sequential enzymatic activities, reflecting the flow of metabolites through the pathway. This correctly shows how the product of one enzyme becomes the substrate for the next enzyme.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#activity-representation","title":"Activity Representation","text":"<p>Each activity has: - A molecular function term (e.g., GO:0004157 for dihydropyrimidinase activity) - An enabled_by relationship to the gene product performing the activity (e.g., MGI:MGI:1928679 for Dpys) - In most cases, a subcellular location (occurs_in) - A biological process context (part_of)</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#causal-flow","title":"Causal Flow","text":"<p>The activities flow as follows: 1. NT5C (5'-nucleotidase) \u2192 TYMP/UPP1 (thymidine phosphorylases) 2. TYMP/UPP1 \u2192 DPYD (dihydropyrimidine dehydrogenase) 3. DPYD \u2192 DPYS (dihydropyrimidinase) 4. DPYS \u2192 UPB1 (\u03b2-ureidopropionase)</p> <p>This accurately reflects the actual flow of metabolites in the pyrimidine degradation pathway.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":""},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#use-of-evidence-codes","title":"Use of Evidence Codes","text":"<p>The model uses appropriate evidence codes: - ECO:0000266 (sequence orthology evidence) for orthology-based annotations - ECO:0000314 (direct assay evidence) for experimentally confirmed activities - ECO:0000315 (mutant phenotype evidence) for activities confirmed by mutation studies</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#completeness","title":"Completeness","text":"<p>The model is quite comprehensive, including all major enzymatic steps in the dTMP catabolic pathway.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#complex-representation","title":"Complex Representation","text":"<p>The model follows best practices for representing protein functions: - Each enzyme is represented as an individual activity rather than using complex IDs - This is appropriate since the specific activities of each component are known</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#gene-product-usage","title":"Gene Product Usage","text":"<p>The model uses MGI identifiers for mouse gene products consistently and appropriately.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#minor-issues-identified","title":"Minor Issues Identified","text":"<ol> <li> <p>Missing Occurs_in Annotation: A few activities (NT5C3 and UPB1) are missing subcellular location information, though this is not crucial since the default location for these enzymes is the cytosol.</p> </li> <li> <p>No Molecular Complex Representation: Though DPYD functions as a homodimer and UPB1 as homotetramer/homooctamer according to UniProt data, these are represented as monomeric activities. This is acceptable according to GO-CAM guidelines when the specific subunits carrying the activities are known.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"gomodel:5fadbcf000000942\" is a well-constructed representation of the dTMP catabolic pathway in mouse. It accurately represents the sequential enzymatic steps, includes appropriate gene products, and follows GO-CAM best practices for causal connections, evidence attribution, and cellular location. The model provides a clear and biologically accurate view of the pathway that aligns well with current biochemical knowledge.</p> <p>The biological content is robust and supported by literature evidence. The activities are connected in a way that is consistent with the known biochemical flow in this pathway. Overall, this model serves as a good example of how metabolic pathways should be represented in GO-CAM format.</p>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/","title":"5fadbcf000001101 SPModule IFIH1 MAVS","text":"<p>Now that I have all the necessary information, I can review the GO-CAM model gomodel:5fadbcf000001101 titled \"SPModule IFIH1-MAVS\".</p>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#go-cam-review-for-gomodel5fadbcf000001101-spmodule-ifih1-mavs","title":"GO-CAM Review for gomodel:5fadbcf000001101 (SPModule IFIH1-MAVS)","text":""},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#overview-of-the-model","title":"Overview of the Model","text":"<p>The model gomodel:5fadbcf000001101 describes interactions between: - IFIH1 (MDA5, UniProtKB:Q9BYX4) - MAVS (UniProtKB:Q7Z434)  - PPP1CA (PP1-alpha, UniProtKB:P62136)</p> <p>The model represents pathways involved in antiviral innate immune signaling, specifically how these proteins work together in virus sensing and signal transduction.</p>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#model-structure-analysis","title":"Model Structure Analysis","text":"<p>The model consists of five activities:</p> <ol> <li>IFIH1 pattern recognition receptor activity (GO:0038187)</li> <li>Enabled by IFIH1/MDA5 (Q9BYX4)</li> <li> <p>Provides input for PPP1CA phosphatase activity</p> </li> <li> <p>PPP1CA phosphatase activity (GO:0016791)</p> </li> <li>Enabled by PPP1CA (P62136)</li> <li>Occurs in cytoplasm (GO:0005737)</li> <li> <p>Directly positively regulates IFIH1 identical protein binding activity</p> </li> <li> <p>IFIH1 identical protein binding activity (GO:0042802)</p> </li> <li>Enabled by IFIH1/MDA5 (Q9BYX4)</li> <li>Has input ATP (CHEBI:15422)</li> <li>Occurs in cytoplasm (GO:0005737)</li> <li> <p>Directly positively regulates MAVS identical protein binding activity</p> </li> <li> <p>MAVS identical protein binding activity (GO:0042802)</p> </li> <li>Enabled by MAVS (Q7Z434)</li> <li>Occurs in mitochondrial outer membrane (GO:0005741)</li> <li> <p>Directly positively regulates MAVS signaling adaptor activity</p> </li> <li> <p>MAVS signaling adaptor activity (GO:0035591)</p> </li> <li>Enabled by MAVS (Q7Z434)</li> <li>Occurs in mitochondrial outer membrane (GO:0005741)</li> </ol>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model correctly represents the core components of the MDA5-MAVS signaling pathway.</li> <li>The model uses appropriate causal relationships between activities.</li> <li>The model correctly places the activities in their appropriate cellular compartments.</li> <li>The model includes the role of PPP1CA (PP1-alpha) in dephosphorylating MDA5, which is supported by the literature.</li> <li>The evidence cited for the activities is appropriate and well-documented with PMID references.</li> </ol>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Missing Interaction Details:</li> <li>The model doesn't explicitly show that PPP1CA dephosphorylates MDA5 at Ser-88, which is a key regulatory mechanism according to the PMID:23499489 paper.</li> <li> <p>Recommendation: Consider adding this detail by including a has_output relationship from the PPP1CA activity.</p> </li> <li> <p>Missing ATP Hydrolysis Step: </p> </li> <li>According to the literature, IFIH1/MDA5 has ATP hydrolysis activity, which is important for its function.</li> <li> <p>Recommendation: Consider representing this more explicitly with GO:0016887 (ATP hydrolysis activity) instead of just showing ATP as an input.</p> </li> <li> <p>Missing Other Key Components:</p> </li> <li>The model doesn't represent the role of viral dsRNA as an input for IFIH1/MDA5.</li> <li> <p>Recommendation: Add CHEBI:67208 (double-stranded RNA) as an input for the IFIH1 pattern recognition receptor activity.</p> </li> <li> <p>Incomplete Representation of MAVS Signaling:</p> </li> <li>The downstream effects of MAVS activation (activation of TBK1, IKK, IRF3, NF-\u03baB) are not shown.</li> <li> <p>Recommendation: Consider extending the model to include these downstream effects.</p> </li> <li> <p>Missing Molecular Adaptor Function:</p> </li> <li>According to the annotation guidelines, MAVS functions as a molecular adaptor bringing together proteins, but this is not explicitly represented.</li> <li> <p>Recommendation: Consider using GO:0060090 (molecular adaptor activity) or adding inputs that MAVS brings together.</p> </li> <li> <p>IFIH1 Identical Protein Binding:</p> </li> <li>The model correctly represents that IFIH1 forms oligomers (identical protein binding), but doesn't fully capture that this oligomerization is a result of dephosphorylation.</li> <li>Recommendation: Consider adding more detail about how dephosphorylation enables oligomerization.</li> </ol>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<ol> <li>Complex Representation:</li> <li> <p>The model follows GO-CAM guidelines for representing activities carried out by specific proteins rather than complexes, which is appropriate since the individual activities of each protein are known.</p> </li> <li> <p>Causal Relationships:</p> </li> <li>The model appropriately uses \"directly positively regulates\" (RO:0002629) to show regulation between activities.</li> <li> <p>The use of \"provides input for\" (RO:0002413) between IFIH1 pattern recognition and PPP1CA activity is appropriate.</p> </li> <li> <p>Subcellular Localization:</p> </li> <li> <p>The model correctly represents the subcellular locations: IFIH1 and PPP1CA in cytoplasm, and MAVS at the mitochondrial outer membrane.</p> </li> <li> <p>Evidence and Provenance:</p> </li> <li>The model includes appropriate evidence codes and PMID references for most activities.</li> </ol>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#overall-assessment","title":"Overall Assessment","text":"<p>The GO-CAM model represents the core MDA5-MAVS signaling pathway and includes the important role of PPP1CA in regulating MDA5 activity. The model is consistent with GO-CAM best practices and is supported by scientific literature.</p> <p>The model would benefit from some additional details about the mechanism of MDA5 activation (dephosphorylation at Ser-88, viral RNA binding) and more explicit representation of the downstream effects of MAVS activation. These additions would make the model more comprehensive and better aligned with the current understanding of this signaling pathway.</p> <p>Despite these minor issues, the model provides a useful representation of this important antiviral signaling pathway.</p>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/","title":"5fadbcf000001646 SP SIK2 actvity on P300","text":"<p>Now, let me analyze the specific model content in detail:</p>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#model-overview","title":"Model Overview","text":"<p>The model \"SP_SIK2-actvity-on-P300\" (gomodel:5fadbcf000001646) depicts the regulatory pathway where SIK2 (Salt-inducible kinase 2) regulates transcription through phosphorylation of P300 (histone acetyltransferase), which in turn affects ChREBP/MLXIPL (carbohydrate-responsive element-binding protein) transcriptional activity.</p>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#model-components","title":"Model Components:","text":"<ol> <li>SIK2 (UniProtKB:Q9H0K1) - protein serine/threonine kinase activity (GO:0004674)</li> <li>P300/EP300 (UniProtKB:Q09472) - acetyltransferase activity (GO:0016407) and protein binding (GO:0005515)</li> <li>MLXIPL/ChREBP (UniProtKB:Q9NP71) - DNA-binding transcription activator activity (GO:0001216) and DNA-binding transcription factor binding (GO:0140297)</li> <li>PPARA (UniProtKB:Q07869) - DNA-binding transcription activator activity (GO:0001216)</li> </ol>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#causal-relationships-in-the-model","title":"Causal Relationships in the Model:","text":"<ul> <li>SIK2 directly negatively regulates P300's acetyltransferase activity</li> <li>SIK2 directly negatively regulates P300's protein binding activity</li> <li>P300 directly positively regulates MLXIPL's transcription factor binding</li> <li>MLXIPL's transcription factor binding directly positively regulates its DNA-binding transcription activator activity</li> <li>P300 directly positively regulates PPARA's DNA-binding transcription activator activity</li> </ul>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#evaluation-based-on-literature","title":"Evaluation Based on Literature:","text":"<p>Based on the literature I reviewed (PMID:21084751 and PMID:26983400), the model accurately represents:</p> <ol> <li>The key role of SIK2 in phosphorylating P300 at Ser89, which inhibits P300's HAT activity</li> <li>P300's role in acetylating ChREBP/MLXIPL, which enhances its transcriptional activity</li> <li>The relationship between SIK2, P300, and transcription factors (ChREBP and PPARA)</li> </ol> <p>The PMID:21084751 paper specifically supports the connection between SIK2, P300, and ChREBP in regulating lipogenesis, while PMID:26983400 supports the connection between SIK2, P300, and PPARA in ketogenesis.</p>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices:","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li>Appropriate molecular functions are assigned to each protein</li> <li>Causal relationships are correctly represented using the appropriate predicates</li> <li>Evidence is provided for each assertion with appropriate PMIDs</li> <li>Cellular context is included (chromatin - GO:0000785)</li> <li>Biological process context is included (lipid biosynthetic process - GO:0008610)</li> </ol>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Biological Process Context: While the model includes \"lipid biosynthetic process\" for ChREBP/MLXIPL activity, it could benefit from adding biological process context for the other activities, particularly for PPARA (which typically regulates fatty acid oxidation/ketogenesis as shown in PMID:26983400).</p> </li> <li> <p>Tissue Context: The model doesn't specify the tissue context (such as liver - UBERON:0002107) where these interactions primarily occur. Both papers discuss these interactions in liver, and the model would be more complete with this information.</p> </li> <li> <p>Incomplete Pathways: The model captures the regulatory effects but doesn't show the downstream targets of ChREBP/MLXIPL and PPARA, which would provide a more complete picture of the biological impact of this pathway.</p> </li> <li> <p>Molecular Mechanism Details: The model could provide more details on the specific mechanism, such as indicating that SIK2 phosphorylates P300 at Ser89 (this is mentioned in the referenced papers but not explicit in the model).</p> </li> </ol>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#scientific-accuracy","title":"Scientific Accuracy:","text":"<p>The model is scientifically accurate and supported by the literature. It correctly represents that:</p> <ol> <li>SIK2 negatively regulates P300 activity through phosphorylation</li> <li>P300 positively regulates the transcriptional activity of both ChREBP/MLXIPL and PPARA</li> <li>This occurs in the context of lipid metabolism regulation</li> </ol> <p>The referenced papers show that SIK2 plays a dual role by regulating lipogenesis (through ChREBP) and ketogenesis (through PPARA), both via P300 regulation.</p>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#summary-and-recommendations","title":"Summary and Recommendations:","text":"<p>The GO-CAM model \"SP_SIK2-actvity-on-P300\" (gomodel:5fadbcf000001646) provides an accurate representation of the regulatory pathway involving SIK2, P300, and the transcription factors ChREBP/MLXIPL and PPARA. It aligns with the literature and follows GO-CAM best practices.</p> <p>To improve the model, I would recommend: 1. Adding liver (UBERON:0002107) as a cellular context 2. Including biological process context for PPARA activity (e.g., fatty acid oxidation process) 3. Expanding the model to include some downstream targets of ChREBP and PPARA 4. Explicitly indicating the Ser89 phosphorylation of P300 by SIK2</p> <p>Overall, this is a well-constructed model that captures an important regulatory pathway in metabolism, supported by experimental evidence from the literature.</p>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/","title":"5fadbcf000001962 T helper 17 cell lineage commitment by IL6 cluster  Human","text":"<p>Now, let me review the GO-CAM model based on the guidelines and best practices.</p>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#go-cam-model-review-t-helper-17-cell-lineage-commitment-by-il6-cluster-human-gomodel5fadbcf000001962","title":"GO-CAM Model Review: \"T-helper 17 cell lineage commitment by IL6 cluster (Human)\" (gomodel:5fadbcf000001962)","text":""},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#overview","title":"Overview","text":"<p>This model represents the IL-6 signaling pathway leading to T-helper 17 cell lineage commitment in humans. It shows how IL-6 signaling through its receptor complex activates the JAK-STAT pathway, culminating in STAT3 activation and subsequent gene regulation, with feedback inhibition by SOCS3.</p>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<ol> <li>Pathway Flow: </li> <li>The model correctly represents the IL-6 signaling cascade:<ul> <li>IL-6 (P05231) \u2192 IL-6R (P08887-2) \u2192 gp130/IL6ST (P40189-2) \u2192 JAK1 (P23458) \u2192 STAT3 (P40763)</li> <li>STAT3 regulates SOCS3 (O14543), which provides negative feedback to JAK1</li> </ul> </li> <li> <p>This is consistent with established knowledge of IL-6 signaling and the JAK-STAT pathway.</p> </li> <li> <p>Molecular Functions:</p> </li> <li>IL-6: cytokine activity (GO:0005125) - correctly assigned</li> <li>IL-6R: cytokine receptor activity (GO:0004896) - correctly assigned</li> <li>IL-6ST/gp130: protein tyrosine kinase activator activity (GO:0030296) - correctly assigned for its role in activating JAK1</li> <li>JAK1: protein tyrosine kinase activity (GO:0004713) - correctly assigned</li> <li>STAT3: DNA-binding transcription factor activity (GO:0003700) - correctly assigned</li> <li> <p>SOCS3: kinase inhibitor activity (GO:0019210) - correctly assigned for feedback inhibition</p> </li> <li> <p>Cellular Localization:</p> </li> <li>IL-6: extracellular space (GO:0005615) - correct</li> <li>IL-6R: plasma membrane (GO:0005886) - correct</li> <li>IL-6ST: plasma membrane (GO:0005886) - correct</li> <li>JAK1: cytoplasmic side of plasma membrane (GO:0009898) - correct</li> <li>STAT3: nucleus (GO:0005634) - correct for activated STAT3</li> <li>SOCS3: cytosol (GO:0005829) - correct</li> </ol>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li>Signaling Pathway Representation:</li> <li> <p>The model follows the signaling receptor annotation guidelines:</p> <ul> <li>Ligand (IL-6) has cytokine activity and occurs in extracellular space</li> <li>Receptor components are properly located at the plasma membrane</li> <li>Causal relationships use appropriate relations (RO:0002629 \"directly positively regulates\")</li> </ul> </li> <li> <p>Transcription Factor Annotation:</p> </li> <li>STAT3 is correctly annotated as a DNA-binding transcription factor in the nucleus</li> <li> <p>The causal relationship between JAK1 and STAT3 is appropriate</p> </li> <li> <p>Biological Process Context:</p> </li> <li> <p>Activities are properly placed in biological processes:</p> <ul> <li>IL-6 signaling components in \"interleukin-6-mediated signaling pathway\" (GO:0070102)</li> <li>JAK1, STAT3, and SOCS3 in \"cell surface receptor signaling pathway via JAK-STAT\" (GO:0007259)</li> </ul> </li> <li> <p>Causal Relationships:</p> </li> <li>The model uses appropriate causal relations between activities:<ul> <li>\"Directly positively regulates\" (RO:0002629) for activation steps</li> <li>\"Directly negatively regulates\" (RO:0002630) for SOCS3 inhibition of JAK1</li> <li>\"Contributes to\" (RO:0002407) for STAT3's regulation of SOCS3</li> </ul> </li> </ol>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#evidence-support","title":"Evidence Support","text":"<p>The model cites multiple PMIDs with appropriate evidence codes: - PMID:12829785 - For IL-6 receptor signaling - PMID:8272873 - For JAK-STAT pathway components - PMID:19915009 - For IL6R-gp130 interactions - PMID:12754505 - For SOCS3 feedback inhibition</p>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#issues-identified","title":"Issues Identified","text":"<ol> <li>Minor Ontology Term Issue:</li> <li> <p>The model contains a comment noting an automated term replacement: \"GO:0005887 replaced by GO:0005886\" (integral component of plasma membrane replaced by plasma membrane), which is appropriate.</p> </li> <li> <p>Evidence for STAT3-SOCS3 Relationship:</p> </li> <li> <p>The causal association between STAT3 and SOCS3 uses ECO:0000250 (sequence similarity evidence) with PMID:10359822. It would be preferable to have direct experimental evidence (ECO:0000314) for this specific human interaction.</p> </li> <li> <p>SOCS3 Pathway Placement:</p> </li> <li> <p>SOCS3's inhibition of JAK1 is supported by evidence from mouse (O35718), while it would be better to have human-specific evidence where possible.</p> </li> <li> <p>Missing Model Components:</p> </li> <li>The model doesn't explicitly show the endpoint - T-helper 17 cell lineage commitment (GO:0072540) is in the model title but not clearly represented as the outcome of the pathway.</li> </ol>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Include T-helper 17 cell lineage commitment:</li> <li> <p>Add the biological process GO:0072540 (T-helper 17 cell lineage commitment) as a downstream process influenced by STAT3 transcription factor activity.</p> </li> <li> <p>Strengthen Evidence:</p> </li> <li> <p>Replace sequence similarity evidence (ECO:0000250) with direct experimental evidence (ECO:0000314) for human STAT3-SOCS3 relationship if available.</p> </li> <li> <p>Complete the Pathway:</p> </li> <li> <p>Consider adding STAT3 target genes specific to Th17 differentiation (e.g., RORC, IL17A) if this level of detail is desired.</p> </li> <li> <p>Update Evidence:</p> </li> <li>Include more recent literature supporting the role of this pathway in Th17 differentiation if available.</li> </ol>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#summary","title":"Summary","text":"<p>The GO-CAM model \"T-helper 17 cell lineage commitment by IL6 cluster (Human)\" (gomodel:5fadbcf000001962) is a well-constructed model that accurately represents the IL-6 signaling pathway leading to STAT3 activation. It follows GO-CAM best practices for signaling pathways and transcription factor annotation. The model has strong evidence support from the literature.</p> <p>The main improvements would be to explicitly represent the connection to T-helper 17 cell lineage commitment and possibly strengthen some of the evidence with human-specific data. Overall, this is a high-quality model that provides valuable information about IL-6 signaling in the context of T-helper 17 cell development.</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/","title":"5fadbcf000002042 CMP catabolic process  Mouse","text":"<p>Now that I have reviewed the GO-CAM model and related information, I'll provide a comprehensive review of GO-CAM model 5fadbcf000002042 \"CMP catabolic process (Mouse)\".</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#go-cam-model-review-gomodel5fadbcf000002042-cmp-catabolic-process-in-mouse","title":"GO-CAM Model Review: gomodel:5fadbcf000002042 (CMP catabolic process in Mouse)","text":""},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: CMP catabolic process (Mouse) ID: gomodel:5fadbcf000002042 Taxon: Mouse (NCBITaxon:10090) Status: Production Curator: ORCID:0000-0001-7476-6306  </p> <p>This model represents the CMP catabolic process pathway in mouse, showing the enzymatic steps involved in the breakdown of cytidine monophosphate (CMP).</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#pathway-structure-and-causality","title":"Pathway Structure and Causality","text":"<p>The model presents a clear, linear pathway of CMP catabolism with the following activities connected by causal associations using <code>RO:0002413</code> (provides input for):</p> <ol> <li>Initial step: Cytidine deaminase (Cda, MGI:MGI:1919519) deaminates CMP to UMP</li> <li>Branch point: UMP can be processed by either:</li> <li>Uridine phosphorylase 1 (Upp1, MGI:MGI:1097668)</li> <li>Uridine phosphorylase 2 (Upp2, MGI:MGI:1923904)</li> <li>Convergence: Both phosphorylase activities feed into dihydropyrimidine dehydrogenase (Dpyd, MGI:MGI:2139667)</li> <li>Late steps: The pathway continues through:</li> <li>Dihydropyrimidinase (Dpys, MGI:MGI:1928679)</li> <li>Beta-ureidopropionase (Upb1, MGI:MGI:2143535)</li> </ol> <p>The causal relationships accurately represent the flow of metabolites through the catabolic pathway, with each enzyme acting on the product of the previous reaction.</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#evidence-and-annotations","title":"Evidence and Annotations","text":"<p>The model includes appropriate evidence codes and references: - Most activities are supported by <code>ECO:0000314</code> (direct assay evidence) with appropriate PMID references - Some activities use <code>ECO:0000266</code> (sequence orthology evidence) with UniProt accessions - All activities are appropriately annotated with molecular functions (GO MF terms) - Most activities are properly annotated as part of the CMP catabolic process (GO:0006248) - Cellular locations are provided where known (cytosol, GO:0005829)</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Pathway completeness: The model captures the full CMP catabolic pathway from initial deamination to final breakdown products</li> <li>Clear causality: The causal relationships clearly show the flow of metabolites through the pathway</li> <li>Evidence quality: The annotations are supported by appropriate experimental evidence</li> <li>Subcellular localization: Where known, the cellular locations of activities are included</li> <li>Branched pathway representation: The model correctly shows the alternative processing paths for UMP</li> </ol>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Missing terminal process annotation: The final activity (beta-ureidopropionase) lacks a \"part_of\" relationship to the CMP catabolic process (GO:0006248) that should be added for consistency.</p> </li> <li> <p>Potential missing input: The initial cytidine deaminase activity has inputs from 5'-nucleotidase (Nt5c3), but the original source of CMP isn't explicitly modeled. Consider adding the source of CMP if known.</p> </li> <li> <p>Evidence gaps: Some causal associations lack direct evidence annotations. It would strengthen the model to add specific evidence for each causal link where possible.</p> </li> <li> <p>Cellular location annotations: Some activities are annotated with cellular locations while others aren't. For consistency, consider adding location information for all activities if available.</p> </li> <li> <p>Unclear reaction products: While the causal relationships show which activities provide input for others, the specific metabolic intermediates aren't explicitly represented. Adding annotations about the specific products might enhance clarity.</p> </li> </ol>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model generally follows GO-CAM best practices: - Activities are properly connected with appropriate causal relationships - Gene products are correctly enabled by the appropriate mouse gene identifiers - Evidence is properly documented with appropriate ECO codes and references - The cellular component annotations are correctly used - The \"part_of\" relationships to the broader biological process are properly included</p> <p>The model doesn't include any complexes, so the complex annotation guidelines aren't applicable here.</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the CMP catabolic pathway according to published literature: - The enzyme activities match their known molecular functions - The pathway organization reflects the known sequential steps in pyrimidine degradation - The localization information is consistent with what's known about these enzymes</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model provides a clear, well-structured representation of the CMP catabolic process in mouse. The model successfully captures the enzymatic steps involved and their causal relationships. With a few minor additions and clarifications as suggested above, the model would be even more comprehensive and informative.</p> <p>The model should be approved for continued production status with consideration of the minor suggested improvements.</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/","title":"5fadbcf000002129 Sphingomyelin phosphodiesterase activity involved in viral entry  Human Sars Cov 2","text":"<p>Based on all the information I've gathered, let me now provide a detailed review of the GO-CAM model gomodel:5fadbcf000002129.</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#review-of-go-cam-model-gomodel5fadbcf000002129","title":"Review of GO-CAM Model: gomodel:5fadbcf000002129","text":""},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#model-information","title":"Model Information","text":"<ul> <li>Title: Sphingomyelin phosphodiesterase activity involved in viral entry (Human-Sars-Cov-2)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#model-overview","title":"Model Overview","text":"<p>This model describes the role of acid sphingomyelinase (encoded by SMPD1) and its product ceramide in facilitating SARS-CoV-2 entry into host cells, as well as the involvement of NPC2 in cholesterol transport and ACE2 as the viral receptor. The model captures a specific molecular pathway involving:</p> <ol> <li>SMPD1's sphingomyelin phosphodiesterase activity</li> <li>NPC2's cholesterol transfer activity </li> <li>ACE2's virus receptor activity for SARS-CoV-2</li> </ol>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#pathway-biology-accuracy","title":"Pathway Biology Accuracy","text":"<p>The model accurately represents a pathway where:</p> <ol> <li>SMPD1 (P17405) hydrolyzes sphingomyelin to produce ceramide in different cellular compartments (lysosome and extracellular space)</li> <li>SMPD1 activity directly positively regulates NPC2 (P61916) cholesterol transfer activity</li> <li>ACE2 (Q9BYF1) functions as a SARS-CoV-2 receptor, facilitating viral entry</li> <li>ACE2 activity directly positively regulates SMPD1 activity</li> </ol> <p>This pathway is well-supported by the literature, particularly the Carpinteiro et al. (2020) PMID:33163980 paper, which demonstrates that: - SARS-CoV-2 infection activates acid sphingomyelinase (SMPD1) - This activation triggers ceramide release on the cell surface - Ceramide in the plasma membrane facilitates viral entry - Inhibition of SMPD1 prevents SARS-CoV-2 infection</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#evidence-support","title":"Evidence Support","text":"<p>The model is well supported by evidence, with all assertions properly tied to the primary literature:</p> <ol> <li>SMPD1 activity is supported by PMID:33163980, showing its role in SARS-CoV-2 infection</li> <li>The relationship between SMPD1 and NPC2 is supported by PMID:25339683</li> <li>ACE2's role as a SARS-CoV-2 receptor is supported by PMID:33163980</li> </ol> <p>The evidence codes used (ECO:0000314 - direct assay evidence used in manual assertion) are appropriate for the experimental evidence provided in the cited papers.</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#go-cam-structure-and-best-practices","title":"GO-CAM Structure and Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Molecular Functions (MF): The model properly represents three key molecular functions:</li> <li>GO:0004767 (sphingomyelin phosphodiesterase activity) for SMPD1</li> <li>GO:0120020 (cholesterol transfer activity) for NPC2</li> <li> <p>GO:0001618 (virus receptor activity) for ACE2</p> </li> <li> <p>Cellular Components (CC): Each activity is appropriately localized:</p> </li> <li>SMPD1 activity in GO:0005764 (lysosome) and GO:0005615 (extracellular space)</li> <li>NPC2 activity in GO:0005764 (lysosome)</li> <li> <p>ACE2 activity in GO:0005886 (plasma membrane)</p> </li> <li> <p>Biological Processes (BP): Activities are correctly associated with relevant processes:</p> </li> <li>SMPD1 with GO:0046513 (ceramide biosynthetic process)</li> <li>NPC2 with GO:0033344 (cholesterol efflux)</li> <li> <p>ACE2 with GO:0046718 (symbiont entry into host cell)</p> </li> <li> <p>Causal Relations: The model correctly uses causal relations:</p> </li> <li>RO:0002413 (provides input for) between SMPD1 activities</li> <li>RO:0002629 (directly positively regulates) from SMPD1 to NPC2</li> <li>RO:0002629 (directly positively regulates) from ACE2 to SMPD1</li> </ol>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#annotation-quality","title":"Annotation Quality","text":"<p>The annotations are precise and accurate: - All proteins are correctly identified with UniProt IDs - All GO terms are appropriately used - Causal relations follow proper GO-CAM conventions - Annotations are properly scoped with appropriate evidence</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#recommendations","title":"Recommendations","text":"<p>While the model is scientifically accurate and technically sound, I have a few suggestions for improvement:</p> <ol> <li> <p>Consider adding tissue context: The research indicates that SMPD1 is particularly important in nasal epithelial cells for SARS-CoV-2 infection. Adding this tissue context would enhance the model's specificity.</p> </li> <li> <p>Expand the ceramide pathway: The model could benefit from including downstream effects of ceramide formation, such as its role in reorganizing membrane domains that facilitate viral entry, as described in the literature.</p> </li> <li> <p>Include inhibitory relationships: The literature cited describes how antidepressants functionally inhibit SMPD1 activity, preventing SARS-CoV-2 infection. Including this inhibitory relationship could enhance the model's utility.</p> </li> <li> <p>Link to related models: If there are GO-CAM models describing other aspects of SARS-CoV-2 infection, establishing connections to those models would provide a more comprehensive view.</p> </li> </ol>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:5fadbcf000002129 is a high-quality representation of sphingomyelin phosphodiesterase activity involved in SARS-CoV-2 entry into host cells. The model accurately captures the roles of SMPD1, NPC2, and ACE2, with proper evidence support and logical causal relationships. The model adheres to GO-CAM best practices and effectively communicates an important molecular pathway in SARS-CoV-2 infection.</p> <p>The model is scientifically sound, with all assertions backed by experimental evidence. It provides valuable insights into the mechanism of SARS-CoV-2 entry and highlights potential therapeutic targets (particularly SMPD1) for preventing infection, as supported by the cited literature.</p>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/","title":"5fadbcf000002236 dCMP catabolic process  Mouse","text":"<p>Based on my review of the provided GO-CAM model (gomodel:5fadbcf000002236) and associated references, I'll provide a comprehensive assessment of this model.</p>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#go-cam-model-review-dcmp-catabolic-process-mouse","title":"GO-CAM Model Review: \"dCMP catabolic process (Mouse)\"","text":"<p>Model ID: gomodel:5fadbcf000002236 Title: dCMP catabolic process (Mouse) Taxon: NCBITaxon:10090 (Mouse) Status: Production</p>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the dCMP (deoxycytidine monophosphate) catabolic pathway in mouse, showing the sequence of enzymatic activities that lead to the breakdown of dCMP. The model connects multiple gene products and their molecular functions in a causal chain, representing the flow of metabolites through this catabolic pathway.</p>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#model-structure-analysis","title":"Model Structure Analysis","text":""},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#key-components-and-activities","title":"Key Components and Activities","text":"<p>The model consists of 7 activities, each performed by a different mouse protein:</p> <ol> <li>Cda (MGI:MGI:1919519) - Cytidine deaminase activity (GO:0019239)</li> <li>Input: 2'-deoxycytidine (CHEBI:15698)</li> <li>Part of dCMP catabolic process (GO:0006249)</li> <li> <p>Occurs in cytosol (GO:0005829)</p> </li> <li> <p>Upp1 (MGI:MGI:1097668) - Deoxyuridine phosphorylase activity (GO:0047847)</p> </li> <li>Part of dCMP catabolic process (GO:0006249)</li> <li> <p>Occurs in cytosol (GO:0005829)</p> </li> <li> <p>Dpyd (MGI:MGI:2139667) - Dihydropyrimidine dehydrogenase (NADP+) activity (GO:0017113)</p> </li> <li>Part of dCMP catabolic process (GO:0006249)</li> <li> <p>Occurs in cytosol (GO:0005829)</p> </li> <li> <p>Nt5c3 (MGI:MGI:1927186) - 5'-nucleotidase activity (GO:0008253)</p> </li> <li>Part of dCMP catabolic process (GO:0006249)</li> <li> <p>Occurs in cytosol (GO:0005829)</p> </li> <li> <p>Nt5c (MGI:MGI:1354954) - 5'-nucleotidase activity (GO:0008253)</p> </li> <li>Part of dCMP catabolic process (GO:0006249)</li> <li> <p>Occurs in cytosol (GO:0005829)</p> </li> <li> <p>Dpys (MGI:MGI:1928679) - Dihydropyrimidinase activity (GO:0004157)</p> </li> <li>Part of dCMP catabolic process (GO:0006249)</li> <li> <p>Occurs in cytosol (GO:0005829)</p> </li> <li> <p>Upp2 (MGI:MGI:1923904) - Deoxyuridine phosphorylase activity (GO:0047847)</p> </li> <li>Part of dCMP catabolic process (GO:0006249)</li> <li> <p>Occurs in cytosol (GO:0005829)</p> </li> <li> <p>Upb1 (MGI:MGI:2143535) - Beta-ureidopropionase activity (GO:0003837)</p> </li> <li>Occurs in cytosol (GO:0005829)</li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model shows the following causal relationships (all using RO:0002413 \"provides input for\"):</p> <ol> <li>Cytidine deaminase (Cda) \u2192 Deoxyuridine phosphorylase (Upp1)</li> <li>Cytidine deaminase (Cda) \u2192 Deoxyuridine phosphorylase (Upp2)</li> <li>Deoxyuridine phosphorylase (Upp1) \u2192 Dihydropyrimidine dehydrogenase (Dpyd)</li> <li>Deoxyuridine phosphorylase (Upp2) \u2192 Dihydropyrimidine dehydrogenase (Dpyd)</li> <li>Dihydropyrimidine dehydrogenase (Dpyd) \u2192 Dihydropyrimidinase (Dpys)</li> <li>Dihydropyrimidinase (Dpys) \u2192 Beta-ureidopropionase (Upb1)</li> <li>5'-nucleotidase (Nt5c3) \u2192 Cytidine deaminase (Cda)</li> <li>5'-nucleotidase (Nt5c) \u2192 Cytidine deaminase (Cda)</li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#literature-support","title":"Literature Support","text":"<p>The model is well-supported by literature evidence with multiple references for most activities and causal connections:</p> <ul> <li>Cytidine deaminase (Cda) function is supported by PMID:7923172, demonstrating that this enzyme can deaminate 2'-deoxycytidine</li> <li>The role of Upp1/Upp2 (uridine phosphorylases) in nucleoside metabolism is supported by PMID:12849978, which specifically identified UPP2 as a novel uridine phosphorylase with broad substrate specificity</li> <li>The overall pathway structure is supported by references including PMID:7744869, PMID:5472365, and PMID:6301357</li> </ul>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#evaluation","title":"Evaluation","text":""},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Biological Accuracy: The model correctly represents the dCMP catabolic pathway with appropriate enzymes and their activities. The UniProt entries for human cytidine deaminase (P32320) and uridine phosphorylase 2 (O95045) confirm that the activities and substrates represented in the model are accurate.</p> </li> <li> <p>Pathway Completeness: The model captures the complete catabolic pathway from dCMP to final breakdown products, with each step represented by the appropriate enzyme activity.</p> </li> <li> <p>Evidence and References: The model incorporates appropriate literature evidence for each assertion, with multiple references provided for key activities and causal connections.</p> </li> <li> <p>Correct Causal Relationships: The causal connections use the appropriate predicate (RO:0002413 \"provides input for\") to show metabolic flow through the pathway.</p> </li> <li> <p>Proper Cellular Context: All activities are correctly localized to the cytosol, which is the appropriate cellular compartment for these enzymes.</p> </li> <li> <p>Parallel Pathways: The model correctly represents alternative paths in the pathway, showing that both Upp1 and Upp2 can act on the product of Cda, with both ultimately feeding into Dpyd.</p> </li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#minor-issues","title":"Minor Issues","text":"<ol> <li> <p>Part_of Annotations: All molecular activities are annotated as part of the dCMP catabolic process (GO:0006249), which is appropriate. However, Upb1 does not have this annotation, which would be expected for consistency.</p> </li> <li> <p>Input/Output Specification: While Cda has an explicit has_input annotation for 2'-deoxycytidine (CHEBI:15698), the inputs and outputs for other enzymes in the pathway are not explicitly stated, though they can be inferred from the causal connections and the known activities of the enzymes.</p> </li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#recommendations","title":"Recommendations","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the dCMP catabolic pathway in mouse. My recommendations for minor improvements include:</p> <ol> <li> <p>Add a part_of annotation to Upb1 to indicate it is part of the dCMP catabolic process (GO:0006249), consistent with other enzymes in the pathway.</p> </li> <li> <p>Consider adding explicit has_input and has_output annotations for each enzyme to make the metabolic flow more transparent, though this is not strictly necessary as the enzyme activities and causal connections already imply these relationships.</p> </li> <li> <p>The model appropriately uses orthology evidence in some cases (ECO:0000266), which is suitable when direct evidence for mouse proteins is limited. This approach is consistent with GO-CAM best practices.</p> </li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for the dCMP catabolic process in mouse (gomodel:5fadbcf000002236) is biologically accurate, well-supported by evidence, and properly structured according to GO-CAM best practices. The model provides a clear representation of the metabolic pathway and the causal relationships between the enzymatic activities involved. It effectively combines experimental evidence from multiple sources to build a comprehensive representation of this biological process.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/","title":"5fb9cc0600000156 circadian rhythm and hematopoiesis via ezh2  per1b  cry1a etc   D  rerio","text":"<p>Based on my review of the GO-CAM model, related publications, and the knowledge about best practices, I'll now provide a comprehensive review of this GO-CAM model.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#review-of-go-cam-model-gomodel5fb9cc0600000156","title":"Review of GO-CAM Model: gomodel:5fb9cc0600000156","text":""},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the relationships between circadian rhythm and hematopoiesis in zebrafish, mediated by proteins such as Ezh2, Per1b, Cry1a, and the CLOCK-BMAL transcription complex. The model is based primarily on the research published in PMID:29447387, which demonstrated that Ezh2 promotes clock function and hematopoiesis independent of its histone methyltransferase activity in zebrafish.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#model-title-and-focus","title":"Model Title and Focus","text":"<ul> <li>Title: \"circadian rhythm and hematopoiesis via ezh2, per1b, cry1a etc. (D. rerio)\"</li> <li>Taxon: Danio rerio (zebrafish)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological accuracy: The model accurately captures key findings from the primary literature (PMID:29447387), showing how Ezh2 functions in both circadian regulation and hematopoiesis.</p> </li> <li> <p>Complex representation: The CLOCK-BMAL transcription complex (GO:1990513) is appropriately represented with its member proteins (clocka and bmal1b), following GO-CAM best practices.</p> </li> <li> <p>Appropriate use of causal relationships: The model uses appropriate causal relationships such as \"directly positively regulates\" (RO:0002629) and \"directly negatively regulates\" (RO:0002630) to show the regulatory interactions between proteins.</p> </li> <li> <p>Cellular context representation: The model includes biological processes like \"circadian regulation of gene expression\" (GO:0032922) and \"hemopoiesis\" (GO:0030097), providing important cellular context.</p> </li> <li> <p>Evidence quality: The model uses appropriate evidence codes, with experimental evidence from the primary publication.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#issues-and-recommendations","title":"Issues and Recommendations","text":""},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#1-activity-flow-inconsistencies","title":"1. Activity Flow Inconsistencies","text":"<p>Some activities in the model appear disconnected or have unclear relationships. For example: - Activity node 5fb9cc0600000185 (Ezh2 with transcription coregulator activity) doesn't have any downstream causal associations. - Several activities (e.g., 5fb9cc0600000205, Per1b with molecular function) are shown as endpoints without further connections, which doesn't fully represent their role in the pathway.</p> <p>Recommendation: Review the activities that appear as endpoints and connect them to downstream processes where appropriate, based on the literature.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#2-redundant-annotations","title":"2. Redundant Annotations","text":"<p>There are multiple instances of the same protein being annotated with similar functions in slightly different contexts: - Ezh2 is represented multiple times with transcription coactivator activity (GO:0003713) in different nodes - Similar redundancy exists for Cry1a and the CLOCK-BMAL complex</p> <p>Recommendation: Consider consolidating redundant activities to simplify the model and improve readability while maintaining biological accuracy.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#3-evidence-documentation","title":"3. Evidence Documentation","text":"<p>While the model cites appropriate evidence, some activity nodes lack specific evidence codes, showing only empty evidence arrays.</p> <p>Recommendation: Add appropriate evidence codes and references for all activity nodes to increase the model's credibility and traceability.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#4-molecular-function-annotations","title":"4. Molecular Function Annotations","text":"<p>Some nodes use the generic \"molecular_function\" term (GO:0003674) where more specific functions could be used: - Node 5fb9cc0600000205 (Per1b) is annotated with GO:0003674 - Node 60747c4200000570 (lck) is also annotated with GO:0003674</p> <p>Recommendation: Replace generic GO:0003674 annotations with more specific molecular functions based on the literature. For Per1b, a more appropriate term might be related to its role in circadian regulation.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#5-part-of-relationships","title":"5. Part-of Relationships","text":"<p>Not all activities have appropriate \"part_of\" relationships to biological processes, which reduces the contextual information available in the model.</p> <p>Recommendation: Ensure each activity is associated with the appropriate biological process through \"part_of\" relationships.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#specific-literature-consistency-check","title":"Specific Literature Consistency Check","text":"<p>The primary findings from PMID:29447387 that are well-captured in the model include:</p> <ol> <li>Ezh2 regulation by the circadian clock via E-box and RORE motifs</li> <li>Ezh2's role in positively regulating key circadian clock genes</li> <li>Involvement of Ezh2 in hematopoiesis through regulating genes like cmyb and lck</li> <li>The interaction between Ezh2 and the Clock-Bmal1 complex</li> </ol> <p>These aspects are reasonably represented in the model's structure, though some connections could be strengthened as noted above.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a good quality GO-CAM model that captures important relationships between circadian rhythm and hematopoiesis in zebrafish. The model would benefit from some refinements to improve its clarity, comprehensiveness, and evidential support. The connections between activities could be optimized to better represent the pathway flow as described in the literature.</p> <p>The model successfully integrates findings from the primary research paper and represents complex biological relationships in a structured manner that aligns with GO-CAM best practices, particularly in the representation of protein complexes.</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/","title":"5fb9cc0600000627 Regulation of macrophage differntiation via irf2bp2b  cebpa  spi1b  D  rerio","text":"<p>Based on my review of the GO-CAM model and the relevant documentation, I'll now provide a detailed assessment of the model \"gomodel:5fb9cc0600000627\" titled \"Regulation of macrophage differntiation via irf2bp2b, cebpa, spi1b (D. rerio)\":</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#go-cam-review-regulation-of-macrophage-differentiation-via-irf2bp2b-cebpa-spi1b-d-rerio","title":"GO-CAM Review: Regulation of macrophage differentiation via irf2bp2b, cebpa, spi1b (D. rerio)","text":"<p>Model ID: gomodel:5fb9cc0600000627</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#summary","title":"Summary","text":"<p>This model represents the regulation of macrophage differentiation in zebrafish (Danio rerio), focusing on the roles of three transcription factors: cebpa, irf2bp2b, and spi1b. The model describes how these transcription factors interact to regulate macrophage differentiation through their transcriptional regulatory activities.</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#overview-of-biological-process","title":"Overview of Biological Process","text":"<p>Based on the model and literature, irf2bp2b (interferon regulatory factor 2 binding protein 2b) serves as a negative regulator of macrophage differentiation. The model represents how cebpa (CCAAT enhancer binding protein alpha) positively regulates irf2bp2b, which in turn negatively regulates the differentiation of macrophages involving spi1b.</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Appropriate molecular functions: The model correctly uses GO:0000978 (RNA polymerase II cis-regulatory region sequence-specific DNA binding) and the specific transcription factor activities (GO:0001228 and GO:0001227) for the transcription factors.</p> </li> <li> <p>Evidence support: Evidence codes are appropriately used with the primary reference PMID:31123027.</p> </li> <li> <p>Structure: The model follows the causal flow from cebpa to irf2bp2b to the regulation of macrophage differentiation.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Incomplete gene function annotation: </li> <li>spi1b (ZFIN:ZDB-GENE-980526-164) is annotated with GO:0003674 (molecular_function), which is a root term indicating that the specific molecular function is unknown. Based on the literature, spi1b is a known transcription factor involved in macrophage differentiation and should be annotated with a more specific transcription factor activity term.</li> </ol> <p>Recommendation: Update the molecular function of spi1b to either GO:0001228 (DNA-binding transcription activator activity) or a more specific term based on the literature evidence.</p> <ol> <li>Causal connection issues:</li> <li>The model shows cebpa activity being part_of (BFO:0000050) its downstream activity rather than causally regulating it. According to GO-CAM guidelines for transcription factors, the causal relation should be \"indirectly positively regulates\" or \"indirectly negatively regulates.\"</li> </ol> <p>Recommendation: Change the relation from BFO:0000050 (part_of) to RO:0002407 (indirectly positively regulates) between cebpa's DNA binding and its downstream transcription activity.</p> <ol> <li>Missing cellular location:</li> <li>According to the transcription factor annotation guidelines, these activities should include \"occurs in\" nucleus (GO:0005634), which is missing from the model.</li> </ol> <p>Recommendation: Add the cellular location \"nucleus\" to each transcription factor activity.</p> <ol> <li>Incomplete representation of spi1b:</li> <li>The role of spi1b in macrophage differentiation is not fully represented in the model. Based on the literature, spi1b is a key driver of macrophage differentiation, but its specific regulatory role is not clearly defined in the model.</li> </ol> <p>Recommendation: Clarify the specific molecular function of spi1b and its causal relationships in the regulation of macrophage differentiation.</p> <ol> <li>Spelling error in the title:</li> <li>The title contains a spelling error: \"differntiation\" should be \"differentiation\".</li> </ol> <p>Recommendation: Correct the spelling in the title.</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#biological-content-assessment","title":"Biological Content Assessment","text":"<ol> <li>Consistency with literature:</li> <li> <p>The model is generally consistent with the literature on irf2bp2b's role as a negative regulator of macrophage differentiation in zebrafish. According to the paper (PMID:31123027), depletion of irf2bp2b results in a bias toward macrophage fate at the expense of neutrophils during definitive myelopoiesis.</p> </li> <li> <p>The paper indicates that irf2bp2b is under the control of C/ebp\u03b1 (cebpa), which is correctly represented in the model.</p> </li> <li> <p>Missing biological details:</p> </li> <li>The model does not capture the neutrophil versus macrophage fate decision aspect mentioned in the paper's title. The paper discusses how irf2bp2b regulates the balance between neutrophil and macrophage differentiation, but the model only represents the macrophage differentiation side.</li> </ol> <p>Recommendation: Consider expanding the model to represent both sides of the cell fate decision (neutrophil vs. macrophage differentiation).</p> <ol> <li>Pathway completeness:</li> <li>The model represents a simplified version of the regulatory network. According to the literature, pu.1 (spi1b) expression is inhibited by irf2bp2b, which is represented in the model, but the downstream effects of this regulation on other targets and pathways are not included.</li> </ol> <p>Recommendation: Consider adding additional downstream targets and effects if well-supported by evidence.</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good foundation for representing the regulation of macrophage differentiation in zebrafish via transcription factors. The model correctly captures the core regulatory relationship between cebpa, irf2bp2b, and macrophage differentiation. However, it needs several technical improvements to fully adhere to GO-CAM best practices for transcription factor annotation, and could be expanded to better represent the biological complexity of neutrophil versus macrophage fate decisions.</p> <p>The most critical improvements needed are: 1. Providing a specific molecular function for spi1b 2. Correcting the causal relationships between activities 3. Adding cellular compartment information 4. Expanding the biological scope to include the neutrophil fate decision</p> <p>With these improvements, the model would provide a more complete and accurate representation of this important regulatory pathway in zebrafish myelopoiesis.</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/","title":"5fb9cc0600000727 Triacyl lipopetide activation of TLR1 TLR2 complex  Human","text":"<p>Now, let me prepare a thorough review of the GO-CAM model:</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#review-of-go-cam-model-gomodel5fb9cc0600000727","title":"Review of GO-CAM Model: gomodel:5fb9cc0600000727","text":""},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Triacyl lipopeptide activation of TLR1-TLR2 complex (Human) Model ID: gomodel:5fb9cc0600000727 Species: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents the molecular pathway involving triacylated lipopeptide recognition and signaling through the TLR1-TLR2 heterodimer in humans. The model captures:</p> <ol> <li>The roles of lipopolysaccharide-binding protein (LBP) and CD14 in capturing and transporting triacyl lipopeptide to the TLR1-TLR2 complex</li> <li>The activation of the TLR1-TLR2 receptor complex </li> <li>The involvement of TIRAP (MyD88 adapter-like protein) as an adaptor molecule in the signaling cascade</li> </ol>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#detailed-evaluation","title":"Detailed Evaluation","text":""},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#model-structure-and-connections","title":"Model Structure and Connections","text":"<p>The model consists of four key activities properly connected via causal relations:</p> <ol> <li>LBP (P18428) with molecular carrier activity (GO:0140104), having triacyl lipopeptide (CHEBI:60192) as input, providing input for TLR1-TLR2 complex activity</li> <li>CD14 (P08571) with molecular carrier activity (GO:0140104), having triacyl lipopeptide (CHEBI:60192) as input, providing input for TLR1-TLR2 complex activity</li> <li>TLR1-TLR2 complex (GO:0035354) enabled by TLR1 (Q15399) and TLR2 (O60603) proteins with transmembrane signaling receptor activity (GO:0004888), directly positively regulates TIRAP activity</li> <li>TIRAP (P58753) with protein-macromolecule adaptor activity (GO:0030674)</li> </ol> <p>The causal relationships in the model use appropriate relation types: - \"provides input for\" (RO:0002413) connects the carrier activities to the receptor complex - \"directly positively regulates\" (RO:0002629) connects the receptor complex to TIRAP</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on the literature and protein information examined:</p> <ol> <li> <p>LBP and CD14 functions: The model correctly represents LBP and CD14 as proteins that recognize and transport bacterial lipopeptides. LBP binds to lipid A moiety of bacterial lipopolysaccharides and facilitates its transfer to CD14, which then presents it to the TLR1-TLR2 complex. This is consistent with their molecular carrier activity.</p> </li> <li> <p>TLR1-TLR2 complex: The model correctly represents that TLR1 and TLR2 form a heterodimer that specifically recognizes triacylated lipopeptides. TLR1 and TLR2 are shown to pre-exist as heterodimers before stimulation and are recruited to lipid rafts upon ligand binding, as supported by PMID:16880211.</p> </li> <li> <p>TIRAP role: The model correctly includes TIRAP as an adaptor molecule that links TLR1-TLR2 receptor activation to downstream signaling. The research (PMID:17322885) confirms TIRAP interacts with TLR2 and mediates the activation of NF-kappa-B and cytokine production.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#cellular-locations","title":"Cellular Locations","text":"<p>The model includes appropriate cellular locations for the activities:</p> <ul> <li>LBP and CD14 activities occur in extracellular space (GO:0005615)</li> <li>TLR1-TLR2 activity occurs in plasma membrane raft (GO:0044853)</li> <li>TIRAP activity occurs at the plasma membrane (GO:0005886)</li> </ul> <p>These locations are consistent with the literature reviewed, particularly PMID:16880211 which describes how TLR1-TLR2 heterodimers are recruited to lipid rafts upon ligand binding.</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#literature-support","title":"Literature Support","text":"<p>Each association in the model is supported by primary literature: - LBP and CD14 activities with triacyl lipopeptide are supported by PMID:23430250 and PMID:15294986 - TLR1-TLR2 receptor activity is supported by PMID:16880211 - TIRAP's role as an adaptor is supported by PMID:17322885</p> <p>All of these papers are relevant to the model content and provide appropriate evidence.</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>Based on the molecular carrier activity guidelines, the model correctly: - Uses \"has input\" to connect the transported molecule (triacyl lipopeptide) to the carriers (LBP and CD14) - Uses \"provides input for\" to connect the carriers to the next activity (TLR1-TLR2 complex) - Specifies the cellular locations where these activities occur</p> <p>For the TLR1-TLR2 receptor complex, the model correctly: - Shows the complex enabled by both TLR1 and TLR2 proteins - Shows the receptor activity occurring in the plasma membrane raft - Uses \"directly positively regulates\" to connect to its downstream adaptor TIRAP</p> <p>The adaptor protein TIRAP is correctly represented with: - Protein-macromolecule adaptor activity - Appropriate cellular location at the plasma membrane</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complete Signaling Pathway: The model could be extended to include additional downstream components of the TLR1-TLR2 signaling pathway beyond TIRAP, such as MyD88, IRAK1/4, TRAF6, and NF-\u03baB activation.</p> </li> <li> <p>Biological Process Context: While the model includes molecular functions and cellular components, it could benefit from explicit annotation of biological processes for some activities. For example, TLR1-TLR2 activity is correctly annotated as part of \"toll-like receptor TLR1:TLR2 signaling pathway\" (GO:0038123), but other activities could be similarly contextualized.</p> </li> <li> <p>Missing Elements: The model doesn't capture the homo-oligomerization of TIRAP that occurs upon recruitment or the interaction between TIRAP and MyD88, which could be relevant for the complete signaling picture.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:5fb9cc0600000727 accurately represents the molecular pathway for triacyl lipopeptide recognition and initial signaling through the TLR1-TLR2 complex in humans. The model is well-structured, biologically accurate, and supported by appropriate literature. It adheres to GO-CAM best practices for representing molecular carrier activities, receptor complexes, and adaptor proteins.</p> <p>The model provides a clear representation of how bacterial lipopeptides are recognized by carrier proteins LBP and CD14, which then present them to the TLR1-TLR2 complex, leading to TIRAP recruitment and the initiation of signaling. While the model could be extended to include more of the downstream signaling components, it serves as an excellent representation of the initial steps in this important innate immune pathway.</p>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/","title":"5fce9b7300000367 BMP2 SMAD signaling mouse","text":"<p>Now that I have gathered all the necessary information, I'll review the GO-CAM model, focusing on its biological content, connections, and adherence to GO-CAM guidelines.</p>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#go-cam-model-review-for-gomodel5fce9b7300000367-bmp2-smad-signaling-mouse","title":"GO-CAM Model Review for gomodel:5fce9b7300000367 - \"BMP2-SMAD signaling mouse\"","text":""},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#summary","title":"Summary","text":"<p>This GO-CAM model represents BMP2-SMAD signaling in mouse, focusing on two BMP receptors (BMPR1A and BMPR2) and their downstream signaling through SMAD1 activation. The model depicts a canonical bone morphogenetic protein (BMP) signaling pathway which is critical for bone and cartilage development.</p>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#biological-content-review","title":"Biological Content Review","text":""},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#molecules-and-their-roles","title":"Molecules and their roles:","text":"<ol> <li> <p>BMP2 (MGI:88177): Correctly annotated as performing receptor ligand activity (GO:0048018), occurring at the plasma membrane, and being part of the BMP signaling pathway. BMP2 directly positively regulates BMPR2.</p> </li> <li> <p>BMPR2 (MGI:1095407): Annotated as having BMP receptor activity (GO:0098821), occurring at the plasma membrane, and being part of the BMP signaling pathway. BMPR2 directly positively regulates BMPR1A, showing the correct order of signaling events.</p> </li> <li> <p>BMPR1A (MGI:1338938): Annotated as having BMP receptor activity and protein serine/threonine kinase activity, which is biologically accurate. BMPR1A is correctly shown to be part of the BMP signaling pathway.</p> </li> <li> <p>SMAD1 (MGI:109452): Correctly shown as a transcription factor (GO:0000981) in the nucleus, functioning in the BMP signaling pathway.</p> </li> <li> <p>Eps15l1 (MGI:104582): Annotated as being involved in clathrin-dependent endocytosis, which is consistent with its role in regulating receptor trafficking.</p> </li> </ol>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#pathway-logic","title":"Pathway Logic:","text":"<p>The model correctly represents the canonical BMP signaling cascade, where: 1. BMP2 binds to and activates BMPR2 2. BMPR2 activates BMPR1A 3. BMPR1A has protein serine/threonine kinase activity, which would phosphorylate downstream effectors 4. SMAD1 functions as a transcription factor in the nucleus</p> <p>This reflects the well-established mechanism of BMP signaling.</p>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#go-cam-guidelines-and-model-structure-review","title":"GO-CAM Guidelines and Model Structure Review","text":"<ol> <li> <p>Molecular Activities: Each molecule has appropriate molecular functions assigned (receptor ligand activity, receptor activities, kinase activity, transcription factor activity).</p> </li> <li> <p>Cellular Context: Cellular locations are correctly specified for each activity (plasma membrane for receptors, nucleus for transcription factor).</p> </li> <li> <p>Biological Process Context: All activities are correctly part of the BMP signaling pathway (GO:0030509).</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal relations:</p> </li> <li>BMP2 directly positively regulates BMPR2 (RO:0002629) - correct for ligand-receptor interaction</li> <li>BMPR2 directly positively regulates BMPR1A (RO:0002629) - correct for type II to type I receptor signaling</li> <li>BMPR1A has protein binding and protein serine/threonine kinase activity - correctly represented</li> <li> <p>BMPR1A is shown to have direct protein binding with Eps15l1 in a clathrin-coated pit, potentially representing receptor internalization</p> </li> <li> <p>Evidence: The model includes appropriate evidence codes and literature references, with PMIDs supporting the annotations:</p> </li> <li>PMID:10564272 (Fujii et al., 1999) - Studies BMP type I receptors and Smad proteins in osteoblast differentiation</li> <li>PMID:11714695 - Could not retrieve text but likely provides additional evidence</li> <li>PMID:16923969 - Could not retrieve text but likely provides additional evidence</li> <li>PMID:21976273 (Schwaerzer et al., 2012) - Investigates BMP signaling and receptor interactions</li> <li>PMID:23041979 - Could not retrieve text but likely supports localization annotations</li> </ol>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological Accuracy: The model correctly represents the key components and interactions of the BMP2 signaling pathway.</p> </li> <li> <p>Annotation Detail: The model includes detailed annotations for molecular functions, cellular locations, and biological processes.</p> </li> <li> <p>Evidence Base: The model is supported by literature references, providing evidence for the annotations.</p> </li> <li> <p>Pathway Completeness: The model captures the core BMP signaling pathway from ligand binding to transcription factor activation.</p> </li> </ol>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Downstream Targets: The model could benefit from including downstream targets of SMAD1, showing which genes are regulated by this transcription factor.</p> </li> <li> <p>Receptor Complexes: According to the \"How to annotate complexes in GO-CAM\" document, when specific activities are known for different components of a complex (as is the case for BMPR1A and BMPR2), they should be represented separately, which is correctly done in this model. However, the representation might be improved by explicitly showing that these receptors function together in a complex.</p> </li> <li> <p>Feedback Mechanisms: The model could include feedback mechanisms that regulate BMP signaling, such as inhibitory SMADs (SMAD6/7) or extracellular antagonists like Noggin, which are important for fine-tuning the pathway.</p> </li> <li> <p>Non-canonical Signaling: While the model focuses on canonical SMAD-dependent signaling, it might be enhanced by including non-canonical signaling pathways activated by BMPs, such as p38 MAPK pathways.</p> </li> <li> <p>Receptor Specificity: The model correctly shows BMPR1A and BMPR2, but it could also include alternative type I receptors (like BMPR1B) that can also mediate BMP signaling with different affinities and specificities.</p> </li> </ol>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:5fce9b7300000367 is a well-constructed representation of the BMP2-SMAD signaling pathway in mouse. It accurately depicts the key molecular components, their locations, and their interactions in accordance with GO-CAM guidelines and current biological knowledge. The model is supported by appropriate evidence from the literature.</p> <p>While the model correctly captures the core signaling pathway, it could be enhanced by including downstream targets, feedback mechanisms, and non-canonical signaling pathways to provide a more comprehensive view of BMP signaling. Overall, this is a high-quality model that effectively represents our current understanding of BMP2 signaling.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/","title":"5fce9b7300000434 BMP2 MAPK signaling mouse","text":"<p>Now I understand I need to review this GO-CAM model and provide detailed feedback. Based on my analysis of the model, related literature, and GO-CAM guidelines, I'll provide a comprehensive review.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#go-cam-model-review-gomodel5fce9b7300000434-bmp2-mapk-signaling-mouse","title":"GO-CAM Model Review: gomodel:5fce9b7300000434 (BMP2-MAPK signaling mouse)","text":""},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#summary","title":"Summary","text":"<p>The model gomodel:5fce9b7300000434 represents BMP2-MAPK signaling in mouse. It illustrates the signaling pathway from BMP2 (as a ligand) through BMP receptors, leading to MAPK cascade activation and subsequently affecting transcription factors and other proteins involved in osteoblast differentiation and bone development.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Appropriate pathway representation: The model correctly depicts the BMP signaling pathway starting with BMP2 (MGI:MGI:88177) as a receptor ligand, properly activating BMP receptors (BMPR1A, BMPR1B, BMPR2), and leading to downstream activation of MAPK components.</p> </li> <li> <p>Evidence-based annotations: Most causal relationships are supported by experimental evidence (primarily ECO:0000314 - direct assay evidence) and have appropriate literature references.</p> </li> <li> <p>Proper cellular localization: The model includes appropriate cellular compartments (extracellular region for BMP2, cytosol for MAPK components).</p> </li> <li> <p>Biological process associations: Activities are correctly placed within relevant biological processes (BMP signaling pathway, MAPK cascade, osteoblast differentiation).</p> </li> </ol>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#issues-and-recommendations-for-improvement","title":"Issues and Recommendations for Improvement","text":""},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#1-missing-bmp-receptor-complex-formation-and-structure","title":"1. Missing BMP Receptor Complex Formation and Structure","text":"<p>According to the \"How to annotate complexes in GO-CAM\" document, when modeling receptor complexes where different subunits have different activities, each component should be represented with its specific activity. The current model represents BMPR1A (MGI:MGI:1338938), BMPR1B (MGI:MGI:107191), and BMPR2 (MGI:MGI:1095407) correctly with their respective activities, but does not clearly represent their functioning as a complex.</p> <p>Recommendation: Consider using BFO:0000051 (has_part) relations between receptor components to better represent the BMP receptor complex formation.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#2-conformance-with-signaling-receptor-annotation-guidelines","title":"2. Conformance with Signaling Receptor Annotation Guidelines","text":"<p>Based on the \"Signaling receptor activity annotation guidelines,\" the model correctly shows: - BMP2 enabling receptor ligand activity (GO:0048018) - BMP receptors (BMPR1A/B) with \"BMP receptor activity\" (GO:0098821) - Appropriate causal relations with RO:0002629 (directly positively regulates)</p> <p>However, there are some deviations:</p> <p>a. Receptor inputs: According to the guidelines, \"The input (target) of the receptor is the effector protein it regulates... Note that the input (target) of the receptor is NOT its ligand.\" The current model doesn't explicitly capture this using input relations.</p> <p>Recommendation: Add has_input relations from the BMP receptors to their downstream effectors (Map3k7).</p> <p>b. BMP binding activities: Both BMPR1A and BMPR1B are shown with \"BMP binding\" (GO:0036122) activity, but these should be considered as part of their receptor function rather than separate activities.</p> <p>Recommendation: Consider removing the separate BMP binding activities or clarify their role in the signaling process.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#3-missing-evidence-for-some-annotations","title":"3. Missing Evidence for Some Annotations","text":"<p>Several activities and causal associations lack evidence codes: - Activity gomodel:5fce9b7300000434/5fce9b7300000840 (Bglap with structural constituent of bone activity) - Activity gomodel:5fce9b7300000434/5fce9b7300000795 (BMPR1A with protein serine/threonine kinase activity) - Several causal associations (e.g., between gomodel:5fce9b7300000434/5fce9b7300000830 and gomodel:5fce9b7300000434/5fce9b7300000840)</p> <p>Recommendation: Add appropriate evidence codes and references for these annotations.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#4-pathway-flow-consistency","title":"4. Pathway Flow Consistency","text":"<p>The model depicts the BMP signaling pathway leading to activation of transcription factors (Runx2, Sp7) and ultimately to bone-related proteins (Ibsp, Bglap). However, some of the causal relationships could be clarified:</p> <p>a. Jumping connections: The causal relationship from Runx2 (GO:0003700) directly to structural constituent of bone activity (GO:0008147) skips intermediate steps.</p> <p>Recommendation: Consider adding intermediate steps that explain how Runx2 regulates Bglap expression.</p> <p>b. Redundant connections: BMPR1A and BMPR1B both activate Map3k7, but the pathways could be more clearly delineated.</p> <p>Recommendation: Consider revising the connections to better represent the specificity of signaling pathways.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#5-feedback-mechanisms","title":"5. Feedback Mechanisms","text":"<p>Based on the literature reviewed (particularly PMID:21976273), BMP signaling includes feedback mechanisms involving noggin, which is not represented in the model.</p> <p>Recommendation: Consider adding relevant feedback mechanisms to provide a more complete representation of the pathway regulation.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#scientific-content-verification","title":"Scientific Content Verification","text":"<p>The scientific content aligns well with current knowledge of BMP-MAPK signaling:</p> <ol> <li> <p>The paper by Schwaerzer et al. (PMID:21976273) confirms the role of BMP2 in activating Smad and non-Smad (p38 MAPK) signaling pathways, which is correctly represented in the model.</p> </li> <li> <p>The involvement of MAPK components (Map3k7, Map2k6, Mapk11, Mapk14) in mediating BMP signaling to transcription factors is supported by the literature.</p> </li> <li> <p>The downstream effects on osteoblast differentiation and bone development proteins (Alpl, Sp7, Ibsp, Bglap) are consistent with the known roles of BMP signaling in bone development.</p> </li> </ol>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:5fce9b7300000434 provides a good representation of BMP2-MAPK signaling in mouse, capturing key molecular functions, cellular components, and biological processes. The model is well-supported by experimental evidence and literature references.</p> <p>The main recommendations for improvement include: 1. Better representation of receptor complex formation 2. More consistent application of signaling receptor annotation guidelines 3. Adding missing evidence codes 4. Clarifying some causal relationships 5. Including feedback mechanisms</p> <p>With these improvements, the model would provide an even more comprehensive and accurate representation of BMP2-MAPK signaling.</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/","title":"5fce9b7300001590 SPModule PGLYRP1 HSP701A","text":"<p>Now I'll review the GO-CAM model with ID gomodel:5fce9b7300001590 based on the information obtained. This model appears to focus on the interactions between HSPA1A (Heat shock 70 kDa protein 1A), HSPBP1 (HSP70-binding protein 1), PGLYRP1 (Peptidoglycan recognition protein 1), and TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A).</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#go-cam-model-review-gomodel5fce9b7300001590-spmodule-pglyrp1hsp701a","title":"GO-CAM Model Review: gomodel:5fce9b7300001590 (SPModule-PGLYRP1/HSP701A)","text":""},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#summary-of-model-components","title":"Summary of Model Components:","text":"<p>This GO-CAM model represents molecular interactions between heat shock proteins and their regulatory partners, particularly focusing on HSPA1A (HSP70) and its interactions with HSPBP1 and PGLYRP1, ultimately affecting TNFRSF1A signaling.</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#activities-and-causal-associations","title":"Activities and Causal Associations:","text":"<ol> <li>HSPA1A (P0DMV8) has \"receptor ligand activity\" (GO:0048018) that occurs in \"extracellular space\" (GO:0005615)</li> <li> <p>This activity directly positively regulates (RO:0002629) TNFRSF1A's \"tumor necrosis factor receptor activity\" (GO:0005031)</p> </li> <li> <p>HSPBP1 (Q9NZL4) has \"molecular sequestering activity\" (GO:0140313) that occurs in \"extracellular space\" (GO:0005615)</p> </li> <li> <p>This activity directly negatively regulates (RO:0002630) PGLYRP1's \"Hsp70 protein binding\" (GO:0030544)</p> </li> <li> <p>PGLYRP1 (O75594) has \"Hsp70 protein binding\" (GO:0030544) that occurs in \"extracellular space\" (GO:0005615)</p> </li> <li> <p>This activity directly positively regulates (RO:0002629) HSPA1A's \"receptor ligand activity\" (GO:0048018)</p> </li> <li> <p>TNFRSF1A (P19438-1) has \"tumor necrosis factor receptor activity\" (GO:0005031) that occurs on \"cell surface\" (GO:0009986)</p> </li> </ol>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li>The model correctly represents the established interactions between these proteins based on the literature.</li> <li>The causal relationships between activities follow the proper direction of regulatory flow.</li> <li>The model uses appropriate molecular function terms for each protein and includes proper cellular component annotations.</li> <li>Evidence citations are properly included, with relevant PMIDs for each assertion.</li> </ol>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing Mechanism Details: The model doesn't completely capture the mechanism by which HSPBP1 inhibits PGLYRP1-HSPA1A interaction as described in PMID:21247889. According to this reference, HSPBP1 protects cells against the cytotoxic action of the PGLYRP1-HSPA1A complex.</p> </li> <li> <p>Incomplete Process Context: The biological context of this regulatory module could be better represented. The literature indicates that this pathway relates to tumor cell cytotoxicity, which isn't captured in the model.</p> </li> <li> <p>Potential Missing Activities:</p> </li> <li>HSPA1A's chaperone activity isn't represented, though it's central to its function</li> <li> <p>TNFRSF1A's signaling activities downstream of activation could be included</p> </li> <li> <p>Complex Representation: According to the \"How to annotate complexes in GO-CAM\" guidelines, the PGLYRP1-HSPA1A complex could be more explicitly modeled since it appears to function as a unit to activate TNFRSF1A.</p> </li> </ol>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#biological-consistency","title":"Biological Consistency:","text":"<p>The model is consistent with the literature findings that: - PGLYRP1 (Tag7) forms a complex with HSPA1A (Hsp70) - This complex can induce cytotoxic processes in tumor cells via TNFRSF1A (TNFR1) - HSPBP1 can inhibit the activity of the PGLYRP1-HSPA1A complex</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#parsimony-and-clarity","title":"Parsimony and Clarity:","text":"<p>The model is relatively parsimonious, focusing on the core interactions without unnecessary complexity. However, the biological context and downstream effects could be more clearly represented to help users understand the functional significance of these interactions.</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#recommendations-for-improvement","title":"Recommendations for Improvement:","text":"<ol> <li>Consider adding the PGLYRP1-HSPA1A complex as a distinct entity or clarifying their joint action</li> <li>Include the biological context (tumor cell cytotoxicity) as part of the model</li> <li>Add potential downstream effects of TNFRSF1A activation</li> <li>Consider including HSPA1A's chaperone activity which may be relevant to the overall mechanism</li> </ol>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#overall-assessment","title":"Overall Assessment:","text":"<p>This GO-CAM model provides a valid representation of the molecular interactions between HSPA1A, HSPBP1, PGLYRP1, and TNFRSF1A. It captures the core regulatory relationships described in the literature, though it could be enhanced by including more mechanistic details and biological context. The model uses appropriate GO terms and relationship types to represent the causal flow of activities, making it a useful resource for understanding this signaling module.</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/","title":"5fce9b7300001616 SPModule PGRP1 S100A4","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model (gomodel:5fce9b7300001616) titled \"SPModule-PGRP1-S100A4\".</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#review-of-go-cam-model-gomodel5fce9b7300001616","title":"Review of GO-CAM Model: gomodel:5fce9b7300001616","text":""},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model describes the interaction between PGLYRP1 (Tag7/PGRP-S), S100A4 (Mts1), and two chemokine receptors (CCR5 and CXCR3) in the context of immune cell migration. The model captures how PGLYRP1 and S100A4 form a complex that acts as a chemoattractant, stimulating lymphocyte migration via CCR5 and CXCR3 receptors.</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#model-components","title":"Model Components","text":"<p>The model consists of four key activities: 1. PGLYRP1 (UniProtKB:O75594) with molecular adaptor activity (GO:0060090) 2. S100A4 (UniProtKB:P26447) with chemoattractant activity (GO:0042056) 3. CCR5 (UniProtKB:P51681) with C-C chemokine receptor activity (GO:0016493) 4. CXCR3 (UniProtKB:P49682) with C-C chemokine receptor activity (GO:0016493)</p> <p>The causal relationships show: - PGLYRP1 directly positively regulates (RO:0002629) S100A4's chemoattractant activity - S100A4 directly positively regulates (RO:0002629) both CCR5 and CXCR3 activities</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#scientific-accuracy-and-evidence","title":"Scientific Accuracy and Evidence","text":"<p>The model is well-supported by the cited literature, particularly PMID:26654597 and PMID:30713770, which describe how the Tag7-Mts1 (PGLYRP1-S100A4) complex induces lymphocyte migration through CCR5 and CXCR3 receptors. Key scientific points from the publications that align with the model:</p> <ol> <li>The Tag7-Mts1 complex acts as a chemoattractant, while neither protein individually has this activity</li> <li>The complex signals through CCR5 and CXCR3 receptors to induce lymphocyte movement</li> <li>Mts1 (S100A4) can bind to the receptors but requires Tag7 (PGLYRP1) to activate them effectively</li> <li>The complex has higher affinity for CCR5 than CXCR3</li> </ol> <p>The model correctly captures these cellular location annotations: - PGLYRP1 and S100A4 are in the extracellular space (GO:0005615) - CCR5 and CXCR3 are on the cell surface (GO:0009986)</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#model-structure-and-go-cam-practices","title":"Model Structure and GO-CAM Practices","text":"<p>The model follows GO-CAM best practices for representing protein interactions and causal relationships:</p> <ol> <li> <p>Appropriate molecular functions: The molecular adaptor activity for PGLYRP1 is appropriate since it mediates the interaction with S100A4, enabling the complex to function as a chemoattractant.</p> </li> <li> <p>Causal relationships: The model uses the correct relationship \"directly positively regulates\" (RO:0002629) to show how PGLYRP1 enables S100A4's chemoattractant activity, and how S100A4 then activates the receptors.</p> </li> <li> <p>Cellular locations: All entities have appropriate cellular component annotations.</p> </li> <li> <p>Evidence: Each association and causal relationship is appropriately evidenced with references to published literature.</p> </li> <li> <p>Complex representation: The model follows the GO-CAM guidelines for representing complexes by showing the individual proteins and their specific activities rather than representing the complex as a single entity, which is appropriate since the specific roles of PGLYRP1 and S100A4 in the complex are known.</p> </li> </ol>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<p>While the model is scientifically accurate and well-structured, a few minor improvements could be considered:</p> <ol> <li> <p>Pathway completeness: The model could potentially be extended to include downstream signaling events following receptor activation, such as G-protein activation, calcium signaling, or cytoskeletal reorganization required for cell migration.</p> </li> <li> <p>Receptor specificity: According to the literature, CCR5 has a stronger interaction with the Tag7-Mts1 complex than CXCR3 does. This difference in affinity isn't captured in the current model.</p> </li> <li> <p>Molecular details: The literature mentions specific regions of homology between S100A4, PGLYRP1, and MIP1alpha (a natural ligand of CCR5) that may be important for receptor binding. These structural details aren't captured in the current model.</p> </li> </ol>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:5fce9b7300001616 is a scientifically accurate and well-structured representation of how the PGLYRP1-S100A4 complex induces lymphocyte migration through chemokine receptors. The model follows GO-CAM best practices and is supported by the cited literature. It effectively captures the key molecular and cellular components of this pathway, making it a valuable resource for understanding this aspect of immune cell migration.</p> <p>The model could potentially be enhanced by extending it to include downstream signaling events or by capturing the differences in affinity between the receptors, but these are minor suggestions for what is already a high-quality model.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/","title":"5fce9b7300001742 Strap in alternative splicing mouse","text":"<p>Now that I have a better understanding of the model and the relevant best practices, let me conduct a comprehensive review of this GO-CAM model.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#review-of-go-cam-model-gomodel5fce9b7300001742-strap-in-alternative-splicing-mouse","title":"Review of GO-CAM Model: gomodel:5fce9b7300001742 (Strap in alternative splicing-mouse)","text":""},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:5fce9b7300001742) describes the role of STRAP (Serine-threonine kinase receptor-associated protein, MGI:MGI:1329037) in mouse alternative splicing and its effect on retinoic acid signaling pathways via transcription factors.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model contains several key components: 1. STRAP protein (MGI:MGI:1329037) with multiple molecular functions:    - U2 snRNP binding (GO:1990447)    - mRNA binding (GO:0003729)    - An unspecified molecular function (GO:0003674) that negatively regulates transcription factors</p> <ol> <li>Transcription factors:</li> <li>KLF9 (Klf9 Mmus, MGI:MGI:1333856) - DNA-binding transcription factor activity</li> <li> <p>SP1 (Sp1 Mmus, MGI:MGI:98372) - DNA-binding transcription factor activity</p> </li> <li> <p>Downstream target:</p> </li> <li>CYP26A1 (Cyp26a1 Mmus, MGI:MGI:1096359) - retinoic acid 4-hydroxylase activity</li> </ol>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model is well-supported by experimental evidence, citing relevant PMIDs (29781215, 33230114, 9250660).</li> <li>The model correctly connects the molecular functions of STRAP to biological processes (alternative mRNA splicing, protein-RNA complex assembly).</li> <li>The causal relationships between STRAP's activities and downstream transcription factors are clear, using appropriate relationship predicates (RO:0002630 - directly negatively regulates).</li> <li>The flow from transcription factors to the downstream target (CYP26A1) is logically consistent, using appropriate positive regulation relationships (RO:0002629 - directly positively regulates).</li> </ol>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#issues-and-recommendations","title":"Issues and Recommendations","text":""},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#1-incomplete-molecular-function-annotation","title":"1. Incomplete Molecular Function Annotation","text":"<p>STRAP is annotated with one unspecified molecular function (GO:0003674). According to best practices, generic molecular function terms should be avoided when more specific functions are known.</p> <p>Recommendation: Replace GO:0003674 with a more specific molecular function term that explains how STRAP negatively regulates transcription factors. Based on literature, this could be related to its scaffolding function or protein binding activity.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#2-missing-biological-context","title":"2. Missing Biological Context","text":"<p>The model includes individual molecular functions but doesn't fully capture the larger biological context of how STRAP affects retinoic acid signaling in development.</p> <p>Recommendation: Add a higher-level biological process that connects these activities to embryonic stem cell differentiation or neural development, which is mentioned in the paper (PMID:29781215).</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#3-complex-representation","title":"3. Complex Representation","text":"<p>If STRAP functions as part of the SMN complex (as suggested by UniProt information found in search), this aspect is not represented in the model.</p> <p>Recommendation: According to \"How to annotate complexes in GO-CAM\" document, if STRAP is part of a complex where its activity is known, the complex should be represented properly. Consider adding this information if supported by the evidence.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#4-transcription-factor-annotation","title":"4. Transcription Factor Annotation","text":"<p>The transcription factors (KLF9 and SP1) are connected directly to the retinoic acid 4-hydroxylase activity, but according to the DNA-binding transcription factor annotation guidelines, there should be a specification of whether these are activators or repressors.</p> <p>Recommendation: Use more specific terms for the transcription factor activities: - DNA-binding transcription activator activity (GO:0001228) instead of the generic GO:0003700, if they are activators - DNA-binding transcription repressor activity (GO:0001227) if they are repressors</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#5-spatial-context","title":"5. Spatial Context","text":"<p>While one STRAP activity occurs in the nucleus (GO:0005634), other activities lack cellular location.</p> <p>Recommendation: Add cellular component annotations for all activities where the location is known.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (5fce9b7300001742) provides a good representation of STRAP's roles in alternative splicing and regulation of retinoic acid metabolism in mouse. The model correctly uses appropriate causal relationships to represent the regulatory pathways.</p> <p>With the suggested improvements, particularly specifying the molecular function of STRAP that regulates transcription factors and using more specific terms for transcription factor activities, the model would better adhere to GO-CAM best practices and provide a more complete representation of the underlying biology.</p> <p>The model is scientifically accurate according to the cited literature, but could benefit from additional context to improve its utility for users trying to understand the role of STRAP in development and retinoic acid signaling.</p>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/","title":"5fce9b7300002336 SPModule TREM1 DAP12","text":"<p>Based on my review of the GO-CAM model and relevant information, here's my assessment of gomodel:5fce9b7300002336 (SPModule-TREM1-DAP12):</p>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#go-cam-review-gomodel5fce9b7300002336-spmodule-trem1-dap12","title":"GO-CAM Review: gomodel:5fce9b7300002336 (SPModule-TREM1-DAP12)","text":""},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#overview","title":"Overview","text":"<p>This model represents the signaling pathway involving TREM1 (Triggering receptor expressed on myeloid cells 1) and its adaptor protein DAP12 (TYROBP). The model shows how TREM1 activation leads to downstream signaling through DAP12, ultimately resulting in SYK kinase activity.</p>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate molecular relationships: The model correctly depicts TREM1 as a transmembrane signaling receptor that associates with DAP12, which acts as a molecular adaptor. This is consistent with the literature (PMID:10799849, PMID:9490415).</p> </li> <li> <p>Appropriate causal associations: The model uses the correct causal association predicate (RO:0002629 - directly positively regulates) to show how TREM1 receptor signaling activates DAP12's adaptor activity, which then activates SYK kinase activity.</p> </li> <li> <p>Cellular localization: The model correctly annotates the activities with appropriate cellular locations - TREM1 at the cell surface (GO:0009986) and ligands in the extracellular space (GO:0005615).</p> </li> <li> <p>Multiple ligands: The model appropriately shows multiple ligands (PGLYRP1, HMGB1, HSPA1A) that can activate TREM1, which is supported by evidence in the literature (PMID:25595774, PMID:17568691).</p> </li> <li> <p>Includes decoy receptor activity: The model includes the important regulatory mechanism of the soluble isoform of TREM1 (TREM1-2) acting as a receptor decoy (GO:0140319) that negatively regulates TREM1 signaling.</p> </li> </ol>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex representation: According to the GO-CAM guidance on representing complexes, in cases where specific subunits carry known activities, each should be explicitly shown. In this model, both TREM1 and DAP12 have specific known functions (receptor activity and adaptor activity respectively), which is correctly represented. However, there should be a clearer indication that these two proteins form a functional complex together.</p> </li> <li> <p>Evidence details: While the model includes PMID references for the assertions, it might benefit from more specific evidence statements describing exactly what observations from each paper support the stated relationships.</p> </li> <li> <p>Additional downstream effects: The model shows signaling only as far as SYK kinase activity, but the literature indicates further downstream effects such as calcium mobilization, ERK1/2 phosphorylation, and activation of PLC-\u03b3 (as seen in PMID:10799849). These could be added to make the model more comprehensive.</p> </li> </ol>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#technical-review","title":"Technical Review","text":"<ol> <li>Molecular functions: All activities are annotated with appropriate GO terms:</li> <li>TREM1: GO:0004888 (transmembrane signaling receptor activity)</li> <li>DAP12: GO:0060090 (molecular adaptor activity)</li> <li>SYK: GO:0016301 (kinase activity)</li> <li>TREM1-2: GO:0140319 (receptor decoy activity)</li> <li> <p>Ligands: GO:0048018 (receptor ligand activity)</p> </li> <li> <p>Causal relationships: The causal relationships use the correct relationship predicates:</p> </li> <li>Ligands directly positively regulate TREM1 (RO:0002629)</li> <li>TREM1 directly positively regulates DAP12 (RO:0002629)</li> <li>DAP12 directly positively regulates SYK (RO:0002629)</li> <li> <p>TREM1-2 directly negatively regulates TREM1 (RO:0002630)</p> </li> <li> <p>Cellular context: Appropriate cellular locations are provided:</p> </li> <li>TREM1 and DAP12 at cell surface (GO:0009986)</li> <li>Ligands in extracellular space (GO:0005615)</li> </ol>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#conclusion","title":"Conclusion","text":"<p>The model gomodel:5fce9b7300002336 accurately represents the TREM1-DAP12 signaling pathway with appropriate molecular functions, causal relationships, and cellular contexts. It follows GO-CAM best practices for representation of activities and their relationships. </p> <p>The model could be enhanced by: 1. Making the TREM1-DAP12 complex relationship more explicit 2. Adding more downstream signaling events beyond SYK activation 3. Providing more detailed evidence statements</p> <p>Overall, this is a well-constructed GO-CAM model that effectively captures the essential aspects of TREM1-DAP12 signaling.</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/","title":"5fce9b7300002436 TREM2 activated by APP","text":"<p>Now I'll review the GO-CAM model with ID gomodel:5fce9b7300002436.</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#review-of-go-cam-model-gomodel5fce9b7300002436","title":"Review of GO-CAM Model (gomodel:5fce9b7300002436)","text":""},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#model-overview","title":"Model Overview","text":"<p>This model titled \"TREM2 activated by APP\" describes a signaling pathway involving TREM2 (Triggering Receptor Expressed on Myeloid cells 2), its adaptor protein DAP12 (TYROBP), and downstream tyrosine kinase SYK in human cells (NCBITaxon:9606).</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#components-and-structure","title":"Components and Structure","text":"<p>The model contains four main molecular activities:</p> <ol> <li>APP (UniProtKB:P05067) with receptor ligand activity (GO:0048018) occurring in extracellular space (GO:0005615), part of cellular response to amyloid-beta (GO:1904646)</li> <li>TREM2 (UniProtKB:Q9NZC2) with transmembrane signaling receptor activity (GO:0004888) occurring in plasma membrane (GO:0005886), part of cellular response to amyloid-beta (GO:1904646)</li> <li>TYROBP/DAP12 (UniProtKB:O43914) with protein-macromolecule adaptor activity (GO:0030674) occurring in plasma membrane (GO:0005886), part of cellular response to amyloid-beta (GO:1904646)</li> <li>SYK (UniProtKB:P43405) with protein tyrosine kinase activity (GO:0004713) occurring in cytoplasm (GO:0005737), part of cellular response to amyloid-beta (GO:1904646)</li> </ol>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#causal-relationships","title":"Causal Relationships","text":"<p>The model represents the following causal flow: - APP directly positively regulates (RO:0002629) TREM2 - TREM2 directly positively regulates (RO:0002629) TYROBP/DAP12 - TYROBP/DAP12 directly positively regulates (RO:0002629) SYK</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#evidence","title":"Evidence","text":"<p>Each activity and causal relationship is supported by experimental evidence from peer-reviewed literature (ECO:0000314 - direct assay evidence used in manual assertion), primarily from PMID:29518356 for most connections and additional PMID:24078628 for TREM2 localization and PMID:23459077 for TYROBP/DAP12 activity and localization.</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#assessment-and-recommendations","title":"Assessment and Recommendations","text":""},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#strengths-of-the-model","title":"Strengths of the model:","text":"<ul> <li>The model accurately captures the molecular function of each protein</li> <li>The causal relationships are appropriately represented with the correct relationship types</li> <li>All activities are properly classified as part of the same biological process</li> <li>Evidence is well-documented for each assertion</li> <li>The model aligns with current literature showing TREM2 as a receptor for amyloid-beta (supported by PMID:29518356)</li> </ul>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#areas-for-improvement","title":"Areas for improvement:","text":"<ol> <li>Complex representation:</li> <li> <p>The model currently doesn't indicate that TREM2 and DAP12/TYROBP form a complex, which is critical for signaling. According to GO-CAM complex guidelines, this should be represented since they function together to transmit the signal to SYK.</p> </li> <li> <p>Physical interactions:</p> </li> <li> <p>The direct physical interaction between TREM2 and its adaptor DAP12/TYROBP should be more explicitly represented, as this binding is crucial for signal transduction.</p> </li> <li> <p>Additional downstream effects:</p> </li> <li> <p>The model could be extended to include downstream effects after SYK activation, such as phosphorylation of specific targets and activation of inflammatory responses.</p> </li> <li> <p>Specificity of cellular context:</p> </li> <li> <p>While the model indicates that TREM2 is in the plasma membrane, it would be useful to specify that this is occurring specifically in microglial cells (or other myeloid cells), which is the primary cell type expressing TREM2 in the brain.</p> </li> <li> <p>Additional evidence:</p> </li> <li>The model could benefit from including more recent publications that further support the interactions between A\u03b2, TREM2, and downstream signaling.</li> </ol>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#suggested-updates","title":"Suggested Updates","text":"<ol> <li> <p>Add a relationship indicating that TREM2 and DAP12/TYROBP form a functional complex through their physical association.</p> </li> <li> <p>Consider adding details about the specific molecular mechanisms of activation, such as:</p> </li> <li>Phosphorylation of ITAM domains in DAP12/TYROBP following ligand binding to TREM2</li> <li> <p>Recruitment of SYK to phosphorylated ITAM domains</p> </li> <li> <p>Include more specific cellular context information about the pathway occurring in microglia.</p> </li> <li> <p>Extend the model to capture downstream effects of SYK activation in the context of amyloid-beta response.</p> </li> </ol>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#conclusion","title":"Conclusion","text":"<p>Overall, the model gomodel:5fce9b7300002436 provides a solid representation of the TREM2 signaling pathway activated by APP/amyloid-beta, which is consistent with current literature. The model accurately captures the main molecular players in the pathway and their causal relationships. The suggested improvements would enhance the model's completeness and provide a more comprehensive view of the biological mechanisms involved in TREM2-mediated responses to amyloid-beta, which is relevant for understanding microglial function in Alzheimer's disease.</p> <p>The model correctly follows GO-CAM best practices in terms of evidence documentation and causal relationship representation. The suggested addition of complex information would further align the model with GO-CAM guidelines for representing protein complexes in signaling pathways.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/","title":"600ced8500002343 BMP9 signaling pathway  Human","text":"<p>After researching the GO-CAM model and relevant documentation, I'm now ready to provide a comprehensive review of the GO-CAM model with ID \"600ced8500002343\" titled \"BMP9 signaling pathway (Human)\".</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#review-of-go-cam-model-bmp9-signaling-pathway-human","title":"Review of GO-CAM Model: BMP9 signaling pathway (Human)","text":"<p>Model ID: gomodel:600ced8500002343</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents the BMP9 signaling pathway in humans, showing how BMP9 (GDF2) activates its receptors and triggers downstream signaling. The pathway includes:</p> <ol> <li>BMP9/GDF2 (UniProtKB:Q9UK05) acting as a growth factor</li> <li>Type II receptors: ACVR2B (UniProtKB:Q13705) and BMPR2 (UniProtKB:Q13873)</li> <li>Type I receptor: ACVRL1/ALK1 (UniProtKB:P37023)</li> <li>Downstream effector: SMAD1 (UniProtKB:Q15797)</li> </ol>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Accurate representation of pathway components: The model correctly includes the main components of the BMP9 signaling pathway.</li> <li>Proper cellular localization: The model appropriately places components in their correct cellular locations (BMP9 in extracellular space, receptors in plasma membrane).</li> <li>Correct pathway association: All activities are properly associated with the BMP signaling pathway (GO:0030509).</li> <li>Evidence support: Each activity and relationship is supported by evidence from peer-reviewed literature.</li> <li>Directionality of signaling: The model correctly shows the flow of information from ligand to downstream effector.</li> </ol>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement","text":""},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#1-relationship-between-gdf2-and-its-receptors","title":"1. Relationship between GDF2 and its receptors","text":"<p>The model shows GDF2 directly positively regulating both ACVR2B and BMPR2. According to the \"Signaling receptor activity annotation guidelines\", the relationship between a ligand and its receptors should be represented using the predicate \"directly positively regulates\". This is correctly implemented in the model.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#2-relationship-between-type-ii-and-type-i-receptors","title":"2. Relationship between type II and type I receptors","text":"<p>The model shows both type II receptors (ACVR2B and BMPR2) directly positively regulating the type I receptor ACVRL1, which is consistent with the known mechanism where type II receptors phosphorylate and activate type I receptors in the BMP signaling pathway.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#3-missing-parts-of-the-signaling-pathway","title":"3. Missing parts of the signaling pathway","text":"<p>While the model captures the main components, I recommend adding:</p> <ul> <li>The formation of the receptor complex between type I and type II receptors upon BMP9 binding</li> <li>The SMAD1 transcription factor activity leads to transcriptional regulation of target genes</li> <li>The model could benefit from depicting additional SMAD proteins (SMAD4, SMAD5) that form complexes with SMAD1</li> </ul>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#4-missing-input-relationships","title":"4. Missing input relationships","text":"<p>According to the guidelines, receptors should have their downstream targets identified via \"has input\" relationships. While the causal associations are correct, the explicit input relationships could be made clearer.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#5-other-bmps-and-their-signaling","title":"5. Other BMPs and their signaling","text":"<p>The model focuses exclusively on BMP9/GDF2, but other BMPs (like BMP10) can also signal through these receptors. Consider mentioning this in a note or expanding the model to include alternative ligands.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#verification-with-literature","title":"Verification with Literature","text":"<p>The model is well-supported by literature evidence. I've verified key aspects:</p> <ol> <li>PMID:7664647 and PMID:19366699 support GDF2/BMP9 as activating BMPR2 and ACVR2B receptors</li> <li>PMID:8622651 and PMID:8395525 support ACVR2B function in this pathway</li> <li>PMID:22718755 confirms ACVRL1/ALK1 as the type I receptor in this cascade</li> <li>PMID:8653785 supports SMAD1's role as a downstream effector</li> </ol> <p>This is consistent with current understanding of the BMP9 signaling pathway, where BMP9 binds to type II receptors (ACVR2B or BMPR2), which then phosphorylate and activate the type I receptor ACVRL1/ALK1, which in turn phosphorylates and activates SMAD1 to regulate gene expression.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"600ced8500002343\" accurately represents the core BMP9 signaling pathway in humans, with proper molecular functions, cellular locations, and causal relationships. The model follows GO-CAM best practices for representing signaling pathways.</p> <p>Recommendations for improvement: 1. Consider adding additional downstream components (e.g., SMAD4 complex formation)  2. Clarify the input relationships for the receptors 3. Add more detail about the transcriptional targets regulated by SMAD1 4. Consider including notes about alternative ligands (like BMP10) that can act through the same pathway</p> <p>Overall, this is a well-constructed model that provides a clear representation of the BMP9 signaling pathway.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/","title":"60418ffa00000327 Xanthine catabolic process  Mouse","text":"<p>Based on my review of the provided GO-CAM model and related literature, I'll now provide a comprehensive review of gomodel:60418ffa00000327 (Xanthine catabolic process in Mouse).</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#review-of-go-cam-model-60418ffa00000327-xanthine-catabolic-process-mouse","title":"Review of GO-CAM Model: 60418ffa00000327 - Xanthine catabolic process (Mouse)","text":""},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:60418ffa00000327) represents the xanthine catabolic process in mouse (Mus musculus, NCBI Taxon: 10090). The model depicts the pathway for the degradation of purines into allantoin, focusing on the conversion of xanthine to uric acid and its subsequent metabolism.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#pathway-structure-and-model-accuracy","title":"Pathway Structure and Model Accuracy","text":"<p>The model correctly represents the purine catabolism pathway in mice, showing:</p> <ol> <li>Initial conversion of xanthine by xanthine dehydrogenase/oxidase (Xdh) activity </li> <li>Oxidation of uric acid by urate oxidase (Uox)</li> <li>Subsequent processing by hydroxyisourate hydrolase (Urah)</li> <li>Final conversion to allantoin by 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad)</li> </ol> <p>The flow of activities follows the correct biochemical sequence as supported by the references, particularly PMID:16462750, which describes the complete uric acid degradation pathway.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model properly uses the causal relation RO:0002413 (provides input for) to connect the molecular activities, indicating that the product of one reaction serves as the substrate for the next. The causal connections accurately reflect the metabolic flow:</p> <ul> <li>Xanthine oxidase/dehydrogenase activities (3 instances) \u2192 urate oxidase activity</li> <li>Urate oxidase activity \u2192 hydroxyisourate hydrolase activity</li> <li>Hydroxyisourate hydrolase activity \u2192 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity</li> </ul>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#cellular-locations","title":"Cellular Locations","text":"<p>The model appropriately represents the cellular locations where these reactions occur: - Xanthine dehydrogenase activity is shown in both cytosol (GO:0005829) and peroxisome (GO:0005777) - Urate oxidase, hydroxyisourate hydrolase, and OHCU decarboxylase activities are all shown in peroxisome (GO:0005777)</p> <p>This is accurate according to the literature, particularly the peroxisomal localization of the later steps in this pathway.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by primary literature: - PMID:16462750 (Ramazzina et al., 2006) is used extensively and appropriately, as it describes the complete pathway - PMID:1590774 (Terao et al., 1992) correctly supports the xanthine dehydrogenase aspects - PMID:4207016 (Lee, 1973) supports the developmental aspects of these enzymes in mice</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#gene-products-and-molecular-functions","title":"Gene Products and Molecular Functions","text":"<p>The gene products and their molecular functions are correctly associated: - MGI:MGI:98973 (Xdh) with xanthine dehydrogenase (GO:0004854) and xanthine oxidase (GO:0004855) activities - MGI:MGI:98907 (Uox) with urate oxidase activity (GO:0004846) - MGI:MGI:1916142 (Urah) with hydroxyisourate hydrolase activity (GO:0033971) - MGI:MGI:3647519 (Urad) with 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity (GO:0051997)</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#output-representation","title":"Output Representation","text":"<p>The model correctly shows allantoin (CHEBI:15676) as the final product of this pathway, which is the output of the Urad activity.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>I've reviewed the GO-CAM complex annotation document, and this model follows the best practices:</p> <ol> <li>The activities are properly enabled by the relevant gene products</li> <li>Causal relations use the appropriate RO terms</li> <li>Cellular locations are accurately represented</li> <li>Evidence is properly cited with ECO codes and PMIDs</li> <li>The biological process context is correctly provided (GO:0009115 - xanthine catabolic process)</li> </ol>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<p>While the model is generally well-constructed, there are a few potential improvements:</p> <ol> <li> <p>Completeness of pathway: The model could include the earlier steps in purine catabolism (hypoxanthine \u2192 xanthine) for a more complete representation.</p> </li> <li> <p>Substrate representation: While the model shows allantoin as the output, it could explicitly represent uric acid and other intermediates as inputs to their respective reactions.</p> </li> <li> <p>Regulatory aspects: The model doesn't capture regulatory aspects of this pathway, such as the conversion between xanthine dehydrogenase and oxidase forms, which is mentioned in the UniProt entry for Xdh.</p> </li> </ol>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60418ffa00000327 accurately represents the xanthine catabolic pathway in mouse. It is well-structured, with appropriate causal connections, correct subcellular localizations, and strong supporting evidence. The model successfully represents the conversion of xanthine to allantoin through a series of enzymatic reactions, consistent with current biological knowledge.</p> <p>This model serves as a good example of a metabolic pathway represented in GO-CAM format, with clear activity flow and proper evidence attribution. The minor suggested improvements would enhance the model but do not detract from its current accuracy and utility.</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/","title":"60418ffa00000414 Adenosine catabolic process  Mouse","text":"<p>Now I'll review the GO-CAM model in detail based on the information I've collected:</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#go-cam-model-review-gomodel60418ffa00000414","title":"GO-CAM Model Review: gomodel:60418ffa00000414","text":""},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model describes the \"Adenosine catabolic process (Mouse)\" pathway. It illustrates the enzymatic steps involved in adenosine degradation through to allantoin, with a focus on xanthine metabolism in mouse.</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":""},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#activities-and-molecular-functions","title":"Activities and Molecular Functions","text":"<p>The model contains 10 distinct molecular activities connected in a pathway:</p> <ol> <li>Adenosine deaminase activity (GO:0004000) - Enabled by Ada (MGI:MGI:87916)</li> <li> <p>Located in cytosol (GO:0005829)</p> </li> <li> <p>Purine-nucleoside phosphorylase activity (GO:0004731) - Enabled by Pnp (MGI:MGI:97365)</p> </li> <li>Located in cytosol (GO:0005829)</li> <li> <p>Part of adenosine catabolic process (GO:0006154)</p> </li> <li> <p>Hypoxanthine dehydrogenase activity (GO:0070674) - Enabled by Xdh (MGI:MGI:98973)</p> </li> <li>Located in cytosol (GO:0005829)</li> <li> <p>Part of adenosine catabolic process (GO:0006154)</p> </li> <li> <p>Hypoxanthine oxidase activity (GO:0070675) - Enabled by Xdh (MGI:MGI:98973)</p> </li> <li>Located in cytosol (GO:0005829)</li> <li> <p>Part of adenosine catabolic process (GO:0006154)</p> </li> <li> <p>Xanthine dehydrogenase activity (GO:0004854) - Enabled by Xdh (MGI:MGI:98973)</p> </li> <li>Located in cytosol (GO:0005829)</li> <li> <p>Part of adenosine catabolic process (GO:0006154)</p> </li> <li> <p>Xanthine oxidase activity (GO:0004855) - Enabled by Xdh (MGI:MGI:98973)</p> </li> <li>Located in peroxisome (GO:0005777)</li> <li> <p>Part of adenosine catabolic process (GO:0006154)</p> </li> <li> <p>Urate oxidase activity (GO:0004846) - Enabled by Uox (MGI:MGI:98907)</p> </li> <li>Located in peroxisome (GO:0005777)</li> <li> <p>Part of adenosine catabolic process (GO:0006154)</p> </li> <li> <p>Hydroxyisourate hydrolase activity (GO:0033971) - Enabled by Urah (MGI:MGI:1916142)</p> </li> <li>Located in peroxisome (GO:0005777)</li> <li> <p>Part of adenosine catabolic process (GO:0006154)</p> </li> <li> <p>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity (GO:0051997) - Enabled by Urad (MGI:MGI:3647519)</p> </li> <li>Located in peroxisome (GO:0005777)</li> <li>Has output allantoin (CHEBI:15676)</li> </ol>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model uses the \"provides input for\" (RO:0002413) relationship to connect activities in a linear pathway:</p> <ol> <li>Ada (adenosine deaminase) \u2192 Pnp (purine-nucleoside phosphorylase)</li> <li>Pnp \u2192 Xdh (hypoxanthine dehydrogenase activity) and Xdh (hypoxanthine oxidase activity)</li> <li>Xdh (hypoxanthine oxidase activity) \u2192 Xdh (xanthine oxidase activity) and Xdh (xanthine dehydrogenase activity)</li> <li>Xdh (hypoxanthine dehydrogenase activity) \u2192 Xdh (xanthine dehydrogenase activity)</li> <li>Xdh (xanthine dehydrogenase activity) \u2192 Uox (urate oxidase)</li> <li>Xdh (xanthine oxidase activity) \u2192 Uox (urate oxidase)</li> <li>Uox \u2192 Urah (hydroxyisourate hydrolase)</li> <li>Urah \u2192 Urad (OHCU decarboxylase)</li> </ol>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#model-evidence","title":"Model Evidence","text":"<p>Each activity and connection is supported by literature evidence, primarily using direct assay evidence (ECO:0000314) and mutant phenotype evidence (ECO:0000315). The papers referenced include:</p> <ol> <li>PMID:8064675 - Information about adenosine deaminase and purine-nucleoside phosphorylase activities</li> <li>PMID:16462750 - Information about the later steps of the pathway, particularly the conversion from uric acid to allantoin</li> <li>PMID:30936145 - Recent paper providing evidence about xanthine oxidoreductase activities</li> <li>PMID:1590774, PMID:8226898, PMID:29895374 - Additional evidence for Xdh functions</li> </ol>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the adenosine catabolic pathway through purine degradation.</li> <li>Activities are properly connected with causal relationships, showing the flow of the pathway.</li> <li>The placement of activities in appropriate cellular locations (cytosol vs. peroxisome) is biologically accurate.</li> <li>The model is supported by multiple literature references for each activity and causal connection.</li> <li>The model correctly shows Xdh as having multiple enzymatic activities (oxidase and dehydrogenase forms).</li> <li>The final output (allantoin) is correctly identified as the end product.</li> </ol>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Substrate and Product Specification: While the final output (allantoin) is specified, the model could be enhanced by specifying more intermediates as input/output of each reaction.</p> </li> <li> <p>Activity Compartments: There seems to be a discrepancy with Xdh having xanthine oxidase activity in peroxisomes and xanthine dehydrogenase activity in cytosol. While this may be biologically accurate, it would be helpful to clarify if these represent the same enzyme in different cellular locations.</p> </li> <li> <p>Ada Activity: The first step (adenosine deaminase) isn't explicitly connected to the biological process (GO:0006154), unlike other activities in the pathway.</p> </li> <li> <p>Missing Output Annotations: Some activities could benefit from having explicit output annotations to show the flow of metabolites more clearly.</p> </li> </ol>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#biological-accuracy-review","title":"Biological Accuracy Review","text":"<p>The model accurately represents the adenosine catabolic pathway from literature:</p> <ol> <li>Adenosine is first deaminated to inosine by Ada.</li> <li>Inosine is converted to hypoxanthine by Pnp.</li> <li>Hypoxanthine is oxidized to xanthine by Xdh.</li> <li>Xanthine is further oxidized to uric acid by Xdh.</li> <li>In mice (unlike humans), uric acid is converted to allantoin through a series of enzymatic steps involving Uox, Urah, and Urad.</li> </ol> <p>The model correctly shows that Xdh can function both as a dehydrogenase and an oxidase, with different activities in different cellular locations. The final steps converting uric acid to allantoin via 5-hydroxyisourate (HIU) and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) are accurately represented.</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a high-quality GO-CAM model that accurately represents the adenosine catabolic pathway in mouse. The model is well-supported by literature evidence and correctly shows the enzymatic activities, their cellular locations, and the flow of metabolites through the pathway. </p> <p>The minor improvements suggested above would enhance the clarity and completeness of the model, but overall it meets the standards for GO-CAM best practices and provides an accurate representation of the biological process.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/","title":"60418ffa00000811 Inosine catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model and related information, I'll now provide a comprehensive assessment of the model.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#review-of-go-cam-model-gomodel60418ffa00000811-inosine-catabolic-process-in-mouse","title":"Review of GO-CAM Model: gomodel:60418ffa00000811 (Inosine catabolic process in Mouse)","text":""},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:60418ffa00000811) represents the inosine catabolic pathway in mouse. The model captures the enzymatic conversion of inosine to allantoin through a series of reactions involving multiple enzymes, occurring primarily in cytosol and peroxisomes.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model correctly represents the purine degradation pathway, specifically focusing on inosine catabolism. It shows the progression from inosine through hypoxanthine, xanthine, urate, 5-hydroxyisourate (HIU), 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU), and finally to allantoin.</p> <p>The key enzymes represented include: 1. Purine-nucleoside phosphorylase (Pnp, MGI:MGI:97365) 2. Xanthine dehydrogenase/oxidase (Xdh, MGI:MGI:98973) with various activities 3. Urate oxidase (Uox, MGI:MGI:98907) 4. OHCU decarboxylase (Urad, MGI:MGI:3647519) 5. HIU hydrolase (Urah, MGI:MGI:1916142)</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is well-supported by the literature cited. The PMID:30936145 paper confirms the role of xanthine oxidoreductase in uric acid metabolism in mice. PMID:16462750 provides detailed information about the enzymatic steps that convert uric acid into allantoin, particularly highlighting the roles of HIU hydrolase and OHCU decarboxylase.</p> <p>The cited literature (PMID:16462750) clarifies why complete enzymatic degradation of uric acid to allantoin requires multiple enzymes rather than just urate oxidase - it helps produce the correct stereoisomer (S-(+)-allantoin) and prevents accumulation of reactive intermediates.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#protein-functions","title":"Protein Functions","text":"<p>The functions assigned to the proteins in the model match what's known from UniProt and the literature: - Xanthine dehydrogenase/oxidase (Xdh) correctly shows multiple activities including hypoxanthine dehydrogenase, hypoxanthine oxidase, xanthine dehydrogenase, and xanthine oxidase activities - The model appropriately captures the subcellular localization of activities (cytosol vs. peroxisome) - The causal relationships between activities follow the expected metabolic flow</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#go-cam-best-practice-assessment","title":"GO-CAM Best Practice Assessment","text":""},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#model-structure","title":"Model Structure","text":"<p>The model follows GO-CAM best practices by: 1. Using appropriate molecular function terms for each enzyme 2. Providing cellular component information for activities 3. Using the \"provides input for\" (RO:0002413) causal relationship to connect activities in a metabolic pathway 4. Including the biological process context (inosine catabolic process, GO:0006148)</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#evidence-and-provenance","title":"Evidence and Provenance","text":"<p>Each assertion is well documented with: - Appropriate evidence codes (ECO terms) - Primary literature citations (PMIDs) - Provenance information (contributor ORCID and dates)</p> <p>The model uses a variety of evidence types, including: - ECO:0000314 (direct assay evidence) - ECO:0000315 (mutant phenotype evidence) - ECO:0000266 (sequence orthology evidence)</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#complex-representation","title":"Complex Representation","text":"<p>The model does not involve protein complexes, so the complex annotation guidelines are not applicable in this case. Each protein is correctly annotated with its specific activity.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Output molecules: While the model includes an output molecule for allantoin (CHEBI:15676) from URAD activity, it would be more complete to include the intermediate metabolites as outputs for each enzymatic step in the pathway.</p> </li> <li> <p>Regulatory aspects: The model focuses on the core catalytic pathway but does not include any regulatory aspects. If literature evidence exists, adding known regulatory mechanisms affecting these enzymes would enhance the model.</p> </li> <li> <p>Alternative isoforms: The model could potentially include the alternative transcripts of HIU hydrolase (Urah) mentioned in PMID:16462750, which lack the peroxisomal targeting signal and might function in different cellular locations.</p> </li> </ol>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the inosine catabolic pathway in mouse. It is consistent with the literature, follows GO-CAM best practices, and is supported by appropriate evidence. The model effectively captures both the enzymatic activities and their subcellular localization, providing a clear representation of this metabolic pathway.</p> <p>The model is particularly valuable for showing the complete enzymatic pathway from inosine to allantoin, including the recently elucidated steps involving HIU hydrolase and OHCU decarboxylase that ensure efficient conversion of uric acid to the correct stereoisomer of allantoin.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/","title":"60418ffa00001019 NLRP3 inflammasome in pyroptosis via nlrp3  caspa  caspb etc   D  rerio","text":"<p>Based on my review of the GO-CAM model (gomodel:60418ffa00001019), the relevant literature, and the complex annotation guidelines, I will now provide a comprehensive assessment of this model:</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#review-of-go-cam-model-60418ffa00001019","title":"Review of GO-CAM Model: 60418ffa00001019","text":""},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#model-overview","title":"Model Overview","text":"<p>Model ID: gomodel:60418ffa00001019 Title: \"NLRP3 inflammasome in pyroptosis via nlrp3, caspa, caspb etc. (D. rerio)\" Taxon: Danio rerio (zebrafish) Status: Production  </p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#summary","title":"Summary","text":"<p>This model describes the NLRP3 inflammasome in zebrafish (Danio rerio) and its role in pyroptosis. The model captures the activities of key components including NLRP3, ASC (not explicitly shown in the model), caspases (caspa and caspb), and gasdermin proteins that are involved in the pyroptotic inflammatory response pathway.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#strengths","title":"Strengths","text":"<ol> <li>The model is supported by direct experimental evidence from the cited literature (PMID:31852739).</li> <li>It captures the key molecular components of the NLRP3 inflammasome in zebrafish.</li> <li>The model includes both the molecular functions and biological processes involved.</li> <li>The causal relationships between components are represented correctly.</li> </ol>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#issues-and-recommendations","title":"Issues and Recommendations","text":""},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#1-missing-components","title":"1. Missing Components","text":"<p>ASC (Adaptor Protein) Representation: - The literature (PMID:31852739) clearly demonstrates that ASC (pycard) is a critical adaptor protein in the NLRP3 inflammasome, connecting NLRP3 to caspases. - While ZFIN:ZDB-GENE-000511-2 (pycard) is mentioned in the objects list, it's not actively represented in the model activities. - Recommendation: Explicitly include pycard (ASC) in the model, showing how it connects NLRP3 to caspases.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#2-inflammasome-complex-representation","title":"2. Inflammasome Complex Representation","text":"<p>Inconsistent Complex Annotation: - The model includes the NLRP3 inflammasome complex (GO:0072559) enabled activities, but doesn't show its members. - According to the \"How to annotate complexes in GO-CAM\" guidelines, if the subunits carrying specific activities are known (which they are from the literature), they should be represented. - Recommendation: The complex should include NLRP3 and ASC as its members. The complex representation should follow the pattern shown in the guidelines.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#3-causal-relationships","title":"3. Causal Relationships","text":"<p>Incomplete Pyroptosis Pathway: - The paper describes a two-step mechanism where: 1) NLRP3-ASC inflammasome activates caspases in an ASC-dependent manner, and 2) NLRP3 directly activates caspase B in an ASC-independent manner to cleave GSDME. - The model shows some but not all of these relationships. - Recommendation: Complete the causal links to show both ASC-dependent and ASC-independent pathways.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#4-molecular-functions","title":"4. Molecular Functions","text":"<p>Non-specific Molecular Functions: - Several activities in the model use GO:0003674 (molecular_function) which is a very general term.  - For example, NLRP3 (ZFIN:ZDB-GENE-070424-110) has a more specific function described in the paper. - Recommendation: Use more specific molecular function terms where possible, such as:   - For NLRP3: inflammasome complex assembly function   - For gasdermin: pore-forming activity</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#5-evidence-codes","title":"5. Evidence Codes","text":"<p>Appropriate Evidence Codes: - The model uses ECO:0000314 (direct assay evidence) and ECO:0000315 (mutant phenotype evidence) appropriately. - This is consistent with the experimental approach in the primary literature.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model correctly captures the overall mechanism of NLRP3 inflammasome function in zebrafish pyroptosis as described in PMID:31852739, but with some simplifications. The paper describes:</p> <ol> <li>DrNLRP3 can trigger the assembly of a classical inflammasome structure (DrNLRP3-DrASC inflammasome) in an ASC-dependent manner.</li> <li>This inflammasome activates DrCaspase-A/B by self-cleavage, which then cleaves pro-IL-1\u03b2.</li> <li>DrNLRP3 can also directly recruit and activate DrCaspase-B (without ASC) to cleave GSDME and induce pyroptosis.</li> </ol> <p>The model captures aspects of these relationships but could be more explicit in representing these dual pathways.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a solid foundation for representing the NLRP3 inflammasome in zebrafish and its role in pyroptosis. The key improvements needed are:</p> <ol> <li>Include ASC (pycard) as an explicit component in the model activities</li> <li>Better represent the inflammasome complex with its members</li> <li>Complete the causal relationships to show both ASC-dependent and ASC-independent pathways</li> <li>Use more specific molecular function terms where appropriate</li> </ol> <p>With these improvements, the model would more accurately capture the complex biology of the NLRP3 inflammasome as described in the literature.</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/","title":"60418ffa00001124 Hypoxanthine catabolic process  Mouse","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model gomodel:60418ffa00001124 - \"Hypoxanthine catabolic process (Mouse)\".</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#go-cam-review-hypoxanthine-catabolic-process-mouse-gomodel60418ffa00001124","title":"GO-CAM Review: Hypoxanthine catabolic process (Mouse) - gomodel:60418ffa00001124","text":""},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This model represents the hypoxanthine catabolic pathway in mouse, focusing on the conversion of hypoxanthine to allantoin. The model describes the sequence of enzymatic activities involved in this purine degradation pathway, with an emphasis on the role of Xanthine dehydrogenase/oxidase (Xdh) and subsequent enzymes.</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#biological-accuracy-and-literature-support","title":"Biological Accuracy and Literature Support","text":"<p>The model accurately represents the hypoxanthine catabolic process as supported by the literature. Specifically:</p> <ol> <li> <p>Pathway flow: The model correctly represents the conversion of hypoxanthine to xanthine, then uric acid, and ultimately to allantoin through several enzymatic steps.</p> </li> <li> <p>Key enzymes: The model includes all critical enzymes in this pathway:</p> </li> <li>Xanthine dehydrogenase/oxidase (Xdh) - MGI:MGI:98973</li> <li>Urate oxidase (Uox) - MGI:MGI:98907</li> <li>Hydroxyisourate hydrolase (Urah) - MGI:MGI:1916142</li> <li> <p>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad) - MGI:MGI:3647519</p> </li> <li> <p>Enzymatic activities: The model correctly represents multiple enzymatic activities of Xdh, including:</p> </li> <li>Hypoxanthine dehydrogenase activity (GO:0070674)</li> <li>Hypoxanthine oxidase activity (GO:0070675)</li> <li>Xanthine dehydrogenase activity (GO:0004854)</li> <li> <p>Xanthine oxidase activity (GO:0004855)</p> </li> <li> <p>Cellular locations: The model appropriately captures the subcellular locations of these activities:</p> </li> <li>Cytosol (GO:0005829) for the early steps involving Xdh</li> <li> <p>Peroxisome (GO:0005777) for the later steps involving Uox, Urah, and Urad</p> </li> <li> <p>Evidence: The model uses appropriate evidence codes and references, including experimental evidence from primary literature.</p> </li> </ol>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#go-cam-structure-and-format","title":"GO-CAM Structure and Format","text":"<ol> <li> <p>Causal relations: The model correctly uses RO:0002413 (provides input for) to connect activities in the pathway, which is appropriate for a metabolic pathway.</p> </li> <li> <p>Activity connections: The activities are connected in a biologically meaningful way that reflects the flow of this pathway:</p> </li> <li> <p>Hypoxanthine \u2192 Xanthine \u2192 Uric acid \u2192 5-hydroxyisourate \u2192 OHCU \u2192 Allantoin</p> </li> <li> <p>Molecular functions: Each activity has an appropriate molecular function term assigned.</p> </li> <li> <p>Process associations: All activities are correctly associated with the biological process \"hypoxanthine catabolic process\" (GO:0009114).</p> </li> </ol>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures the complete pathway from hypoxanthine to allantoin with all intermediary steps.</p> </li> <li> <p>Multiple forms of Xdh: The model correctly represents the different activities of Xdh (dehydrogenase vs. oxidase), which is biologically important.</p> </li> <li> <p>Parsimony: Despite representing a complex pathway, the model remains clear and focused.</p> </li> <li> <p>Strong evidence base: The model is supported by multiple scientific references, including PMID:16462750, which specifically describes the complete uric acid degradation pathway through Urah and Urad.</p> </li> </ol>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Molecular entities as inputs/outputs: While the model does include allantoin (CHEBI:15676) as an output of the final reaction, it would be beneficial to explicitly represent other chemical intermediates (hypoxanthine, xanthine, uric acid, etc.) as inputs/outputs for each reaction.</p> </li> <li> <p>Connection to upstream pathways: The model could be enhanced by connecting to upstream purine catabolism pathways that generate hypoxanthine.</p> </li> <li> <p>Regulation: The model doesn't include regulatory aspects of this pathway, such as the regulation of Xdh activity (which can be modified by proteolysis or oxidation of sulfhydryl groups as noted in the UniProt entry).</p> </li> </ol>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60418ffa00001124 on hypoxanthine catabolic process in mouse is an accurate, well-structured representation of this metabolic pathway. It follows GO-CAM best practices regarding the representation of enzymatic activities and their connections. The model is consistent with the scientific literature, including recent research on the complete uric acid degradation pathway.</p> <p>The model correctly uses molecular function terms, biological process associations, and cellular component annotations, and it employs appropriate causal relations between activities. It successfully captures the complexity of the Xdh enzyme, which has multiple activities in this pathway.</p> <p>This model is a good example of a GO-CAM representation of a metabolic pathway, with a clear flow of activities that corresponds to the biological reality.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/","title":"60418ffa00001200 Guanine catabolic process  Mouse","text":"<p>Based on my review, I'll now provide a comprehensive assessment of the GO-CAM model with ID 60418ffa00001200.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#review-of-go-cam-model-gomodel60418ffa00001200","title":"Review of GO-CAM Model: gomodel:60418ffa00001200","text":""},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>The model gomodel:60418ffa00001200 titled \"Guanine catabolic process (Mouse)\" represents the purine degradation pathway, specifically the uric acid degradation pathway in mouse. This model captures the enzymatic activities and molecular functions involved in converting guanine to allantoin.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#model-structure-analysis","title":"Model Structure Analysis","text":""},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#pathway-described","title":"Pathway Described","text":"<p>The model describes the multi-step enzymatic process by which guanine is catabolized to allantoin in mouse (NCBITaxon:10090). The pathway involves multiple enzymes that catalyze sequential reactions:</p> <ol> <li>Guanine deaminase (Gda) - converts guanine to xanthine</li> <li>Xanthine dehydrogenase/oxidase (Xdh) - oxidizes xanthine to uric acid</li> <li>Urate oxidase (Uox) - oxidizes uric acid to 5-hydroxyisourate</li> <li>Hydroxyisourate hydrolase (Urah) - hydrolyzes 5-hydroxyisourate to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU)</li> <li>OHCU decarboxylase (Urad) - decarboxylates OHCU to allantoin</li> </ol>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#causal-associations","title":"Causal Associations","text":"<p>The model correctly uses the causal association predicate \"RO:0002413\" (provides input for) to link the sequential molecular functions, representing the flow of chemical transformations from guanine to allantoin.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#cellular-compartmentalization","title":"Cellular Compartmentalization","text":"<p>The model appropriately captures the cellular compartmentalization of the different enzymatic activities:</p> <ul> <li>Guanine deaminase activity occurs in the cytosol (GO:0005829)</li> <li>Xanthine dehydrogenase/oxidase activities occur in both cytosol (GO:0005829) and peroxisome (GO:0005777)</li> <li>The subsequent enzymes in the pathway (Uox, Urah, Urad) function in the peroxisome (GO:0005777)</li> </ul> <p>This compartmentalization is biologically accurate based on the literature evidence.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by experimental evidence from multiple publications:</p> <ul> <li>PMID:1590774 - Establishes the role of xanthine dehydrogenase in mouse liver</li> <li>PMID:16462750 - Provides evidence for the complete uric acid degradation pathway</li> <li>PMID:8064675 - Supports the role of guanine deaminase</li> <li>PMID:31659168 - Recent paper on xanthine oxidoreductase with additional evidence for pathway components</li> </ul> <p>The evidence codes used (ECO:0000314 - direct assay evidence used in manual assertion, ECO:0000266 - sequence orthology evidence) are appropriate for the assertions made.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#protein-functionality-assessment","title":"Protein Functionality Assessment","text":"<p>The model correctly represents the dual functions of Xanthine Dehydrogenase/Oxidase (XDH/XO):</p> <ol> <li>Xanthine dehydrogenase activity (GO:0004854) - uses NAD+ as an electron acceptor</li> <li>Xanthine oxidase activity (GO:0004855) - uses molecular oxygen as an electron acceptor</li> </ol> <p>This is important as the literature reveals that XDH can be converted to XO by oxidation of sulfhydryl groups or proteolysis, producing reactive oxygen species that have physiological implications.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The pathway representation aligns with current understanding of purine catabolism in mammals. The literature supports that, unlike in humans (where the pathway stops at uric acid due to loss of urate oxidase), mice possess the complete pathway to convert uric acid to allantoin, making it more soluble for excretion.</p> <p>The model correctly captures the specific role of each enzyme and reflects the two-step process discovered relatively recently (16462750) for converting 5-hydroxyisourate to allantoin via the OHCU intermediate.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li>Using appropriate causal relationships between activities (RO:0002413 - provides input for)</li> <li>Properly connecting molecular functions to biological processes (part_of relationships)</li> <li>Correctly specifying cellular locations (occurs_in relationships)</li> <li>Including appropriate evidence for each assertion</li> </ol> <p>The placement of molecular functions within the broader biological process (GO:0006147 - guanine catabolic process) is correct, and the directional flow of the pathway is well-represented.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<ol> <li> <p>Additional molecular context: The model could potentially include more details about the regulation of these enzymatic activities, especially since xanthine oxidase activity is known to be regulated by environmental factors as described in the literature.</p> </li> <li> <p>Outputs of final reaction: The model includes CHEBI:15676 (allantoin) as the output of the final step, but could be enhanced by specifying that this is specifically the S-(+)-allantoin form, as mentioned in PMID:16462750.</p> </li> <li> <p>Biological role context: The model could benefit from connections to broader physiological processes that the guanine catabolic pathway impacts, such as purine homeostasis or responses to oxidative stress.</p> </li> </ol>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:60418ffa00001200) is a scientifically accurate and well-constructed representation of the guanine catabolic process in mouse. It effectively captures the enzymatic activities, their cellular locations, and the sequential flow of the pathway according to current knowledge. The model includes appropriate evidence for all assertions and follows GO-CAM best practices for representing biochemical pathways.</p> <p>The representation of this pathway is particularly valuable as it highlights important metabolic differences between mice and humans in purine metabolism, which has implications for studies of diseases like gout and kidney stones, as well as for the use of mice as model organisms for purine metabolism disorders.</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/","title":"60418ffa00001258 Deoxyadenosine catabolic process  Mouse","text":"<p>Based on the materials I've gathered and reviewed, I'll now provide a comprehensive review of the GO-CAM model gomodel:60418ffa00001258 \"Deoxyadenosine catabolic process (Mouse)\".</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#go-cam-model-review-deoxyadenosine-catabolic-process-mouse","title":"GO-CAM Model Review: Deoxyadenosine catabolic process (Mouse)","text":"<p>Model ID: gomodel:60418ffa00001258</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the deoxyadenosine catabolic process in mouse. The model depicts a metabolic pathway involving the degradation of deoxyadenosine through multiple enzymatic steps ultimately leading to the production of allantoin. The model is based on the purine degradation pathway, which is conserved in many organisms, though some organisms (like humans) have lost some enzymatic activities in this pathway during evolution.</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#model-components","title":"Model Components","text":"<p>The model includes 8 activities representing the following proteins:</p> <ol> <li>Ada (Adenosine deaminase) - MGI:MGI:87916</li> <li>Function: 2'-deoxyadenosine deaminase activity (GO:0046936)</li> <li> <p>Location: cytosol (GO:0005829)</p> </li> <li> <p>Pnp (Purine-nucleoside phosphorylase) - MGI:MGI:97365</p> </li> <li>Function: purine-nucleoside phosphorylase activity (GO:0004731)</li> <li> <p>Location: cytosol (GO:0005829)</p> </li> <li> <p>Xdh (Xanthine dehydrogenase) - MGI:MGI:98973</p> </li> <li>Multiple functions represented: <ul> <li>hypoxanthine dehydrogenase activity (GO:0070674)</li> <li>hypoxanthine oxidase activity (GO:0070675)</li> <li>xanthine dehydrogenase activity (GO:0004854)</li> <li>xanthine oxidase activity (GO:0004855)</li> </ul> </li> <li> <p>Location: cytosol (GO:0005829) and peroxisome (GO:0005777)</p> </li> <li> <p>Uox (Urate oxidase) - MGI:MGI:98907</p> </li> <li>Function: urate oxidase activity (GO:0004846)</li> <li> <p>Location: peroxisome (GO:0005777)</p> </li> <li> <p>Urah (Hydroxyisourate hydrolase) - MGI:MGI:1916142</p> </li> <li>Function: hydroxyisourate hydrolase activity (GO:0033971)</li> <li> <p>Location: peroxisome (GO:0005777)</p> </li> <li> <p>Urad (2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase) - MGI:MGI:3647519</p> </li> <li>Function: 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity (GO:0051997)</li> <li>Location: peroxisome (GO:0005777)</li> <li>Has output: allantoin (CHEBI:15676)</li> </ol>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#model-analysis","title":"Model Analysis","text":""},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#1-pathway-flow-and-connectivity","title":"1. Pathway Flow and Connectivity","text":"<p>The model presents a well-connected linear pathway for deoxyadenosine catabolism:</p> <ol> <li>The pathway begins with Ada (adenosine deaminase) converting deoxyadenosine to deoxyinosine</li> <li>Pnp (purine-nucleoside phosphorylase) then provides input for both hypoxanthine dehydrogenase and hypoxanthine oxidase activities of Xdh</li> <li>Multiple activities of Xdh (xanthine dehydrogenase/oxidase) provide input for Uox</li> <li>Uox (urate oxidase) provides input for Urah</li> <li>Urah (hydroxyisourate hydrolase) provides input for Urad</li> <li>Urad (OHCU decarboxylase) produces allantoin as the final product</li> </ol> <p>All causal associations use the \"provides input for\" (RO:0002413) relationship, which is appropriate for a metabolic pathway.</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#2-evidence-and-annotations","title":"2. Evidence and Annotations","text":"<p>The model is well supported by experimental evidence: - Mostly direct assay evidence (ECO:0000314) and mutant phenotype evidence (ECO:0000315) - Evidence comes from multiple publications (PMID:10720488, PMID:11783524, PMID:16462750, PMID:8064675, etc.) - Appropriate use of with_objects fields to provide additional evidence support (e.g., UniProtKB:P00491)</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#3-cellular-locations","title":"3. Cellular Locations","text":"<p>The model correctly represents the dual localization of the pathway: - The initial steps (Ada, Pnp, some Xdh activities) occur in the cytosol (GO:0005829) - The later steps (Uox, Urah, Urad) occur in peroxisomes (GO:0005777) - This is consistent with the known biology of purine degradation, where initial degradation occurs in the cytosol followed by final processing in peroxisomes</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#4-biological-accuracy","title":"4. Biological Accuracy","text":"<p>The model is consistent with the known biochemistry of deoxyadenosine degradation: - The degradation pathway from deoxyadenosine \u2192 deoxyinosine \u2192 hypoxanthine \u2192 xanthine \u2192 uric acid \u2192 hydroxyisourate \u2192 OHCU \u2192 allantoin is well established - The identification of Urah and Urad is consistent with recent research (PMID:16462750) that identified these enzymes as completing the uric acid degradation pathway - The allocation of multiple functions to Xdh correctly represents its ability to function both as a dehydrogenase and as an oxidase</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#5-species-considerations","title":"5. Species Considerations","text":"<p>The model correctly represents the mouse pathway, where: - Mice retain a functional urate oxidase, unlike humans who have lost this enzyme - The pathway proceeds all the way to allantoin in mice, whereas in humans the pathway stops at uric acid - All genes indicated are valid mouse genes with appropriate MGI identifiers</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#model-improvements","title":"Model Improvements","text":"<p>While this model is generally well-constructed, a few aspects could be enhanced:</p> <ol> <li> <p>Part_of relationships: Some activities include \"part_of\" annotations to the biological process \"deoxyadenosine catabolic process\" (GO:0006157), but this is inconsistently applied across all activities. This relationship could be added for all activities for completeness.</p> </li> <li> <p>Has_input relationships: The model would benefit from more explicit representation of metabolic inputs and outputs. While Urad has allantoin as an output, the other intermediate metabolites are not explicitly represented.</p> </li> <li> <p>Detailed Evidence Documentation: For some causal associations, evidence codes are provided without supporting references. All evidence should include a reference.</p> </li> </ol>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60418ffa00001258 accurately represents the deoxyadenosine catabolic pathway in mice, with appropriate gene products, molecular functions, cellular locations, and pathway connectivity. The model is well-supported by experimental evidence from the literature and correctly represents the biological process from the initial deamination by Ada to the final production of allantoin.</p> <p>The model is particularly noteworthy for including the recently characterized enzymes Urah and Urad, which complete the uric acid degradation pathway. This representation is consistent with current scientific understanding of purine catabolism in mice and represents a complete pathway from substrate to final product.</p> <p>Overall, this is a high-quality GO-CAM model that effectively captures the deoxyadenosine catabolic process in mice.</p>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/","title":"60418ffa00001536 Deoxyguanosine catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model 60418ffa00001536 \"Deoxyguanosine catabolic process (Mouse)\" and the available references, I will now provide a comprehensive review of the model:</p>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#go-cam-model-review-gomodel60418ffa00001536","title":"GO-CAM Model Review: gomodel:60418ffa00001536","text":""},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This model represents the deoxyguanosine catabolic process in mouse. It shows the enzymatic pathway for degrading deoxyguanosine through several molecular activities connected by causal relationships. The model was created by contributor ORCID:0000-0001-7476-6306 on March 25, 2021.</p>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the deoxyguanosine catabolic pathway in mouse with the following key activities:</p> <ol> <li>Purine-nucleoside phosphorylase activity (GO:0004731) by PNP (MGI:MGI:97365) in the cytosol</li> <li>Guanine deaminase activity (GO:0008892) by Gda (MGI:MGI:95678) in the cytosol</li> <li>Xanthine dehydrogenase activity (GO:0004854) and xanthine oxidase activity (GO:0004855) by Xdh (MGI:MGI:98973) in cytosol and peroxisome</li> <li>Urate oxidase activity (GO:0004846) by Uox (MGI:MGI:98907) in peroxisome</li> <li>Hydroxyisourate hydrolase activity (GO:0033971) by Urah (MGI:MGI:1916142) in peroxisome</li> <li>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity (GO:0051997) by Urad (MGI:MGI:3647519) in peroxisome</li> </ol>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the enzymatic steps in purine degradation from deoxyguanosine to allantoin as documented in the literature.</li> <li>The enzymatic activities are properly connected with causal relationships (RO:0002413 \"provides input for\").</li> <li>Cellular locations are correctly specified (cytosol and peroxisome).</li> <li>Each activity has appropriate literature evidence (primarily from PMID:16462750, PMID:8226898, and others).</li> <li>The model shows the correct branching of activities, particularly with xanthine dehydrogenase/oxidase having two functions.</li> </ol>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#go-cam-best-practices-evaluation","title":"GO-CAM Best Practices Evaluation","text":""},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#model-structure","title":"Model Structure:","text":"<ol> <li>Activities and causal connections: The model correctly uses the \"provides input for\" (RO:0002413) predicate to connect the sequential enzymatic activities in the pathway.</li> <li>Evidence: Each assertion is properly supported with evidence references.</li> <li>Cellular components: The model correctly specifies the cellular locations of each activity (peroxisome or cytosol).</li> <li>Biological process: Activities are appropriately included in the \"deoxyguanosine catabolic process\" (GO:0006161).</li> </ol>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement:","text":"<ol> <li> <p>Pathway context: While the model correctly shows the enzymatic steps, it could benefit from adding a connection to the broader purine metabolism context. Consider adding the relationship to purine nucleoside degradation.</p> </li> <li> <p>Input/Output molecules: The model shows enzyme activities but doesn't explicitly show the chemical transformations. Consider adding the input and output molecules for each enzymatic activity to make the pathway clearer (e.g., deoxyguanosine \u2192 guanine \u2192 xanthine \u2192 urate \u2192 hydroxyisourate \u2192 OHCU \u2192 allantoin).</p> </li> <li> <p>Completeness of xanthine oxidase representation: The model correctly shows the dual role of Xdh gene product (xanthine dehydrogenase and xanthine oxidase activities), but it might be worth adding a note that these are two forms of the same enzyme with different cofactor preferences (NAD+ vs. O2), as supported by PMID:29895374.</p> </li> <li> <p>Peroxisomal targeting: According to PMID:16462750, the peroxisomal location of the later enzymes in the pathway (Uox, Urah, Urad) involves peroxisomal targeting sequences. This detail could be added to provide more biological context about the organization of the pathway.</p> </li> <li> <p>Stereochemistry: PMID:16462750 mentions the importance of the final enzymes in generating dextrorotatory allantoin (S-(+)-allantoin) rather than racemic allantoin. This stereochemical detail could be mentioned as it's an important aspect of the biological versus non-enzymatic conversion.</p> </li> </ol>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 60418ffa00001536 is a scientifically accurate representation of the deoxyguanosine catabolic pathway in mouse. The model follows GO-CAM best practices with appropriate activity connections, evidence, and cellular locations. The model could be enhanced by adding input/output molecules and more context about the broader metabolic pathway, but these are minor suggestions for an already well-constructed model.</p> <p>The main strength of this model is the accurate representation of the final steps of urate degradation to allantoin, which involves multiple enzyme activities (Uox, Urah, Urad) as elucidated in PMID:16462750. This pathway is particularly interesting since humans lack this ability to convert uric acid to allantoin due to the loss of functional urate oxidase, which is correctly represented as a mouse-specific pathway in this model.</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/","title":"60418ffa00001643 Deoxyinosine catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model, the protein information, and the relevant literature, I'll now provide a comprehensive assessment of gomodel:60418ffa00001643 - \"Deoxyinosine catabolic process (Mouse)\".</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#go-cam-model-review-deoxyinosine-catabolic-process-mouse","title":"GO-CAM Model Review: Deoxyinosine catabolic process (Mouse)","text":""},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This model represents the deoxyinosine catabolic process in mouse, focusing on the enzymatic pathway that degrades deoxyinosine through a series of oxidation steps leading ultimately to allantoin. The model includes key enzymes like xanthine dehydrogenase/oxidase (Xdh), urate oxidase (Uox), hydroxyisourate hydrolase (Urah), and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad), along with purine-nucleoside phosphorylase (Pnp).</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model correctly represents the purine degradation pathway in mice, which differs from humans (humans lack functional urate oxidase). The pathway accurately shows:</p> <ol> <li>Conversion of deoxyinosine to hypoxanthine (mediated by Pnp)</li> <li>Oxidation of hypoxanthine to xanthine (via Xdh with hypoxanthine dehydrogenase/oxidase activities)</li> <li>Oxidation of xanthine to uric acid (via Xdh with xanthine dehydrogenase/oxidase activities)</li> <li>Conversion of uric acid to 5-hydroxyisourate (via Uox)</li> <li>Further metabolism to allantoin (via Urah and Urad)</li> </ol> <p>This is consistent with established purine metabolism pathways in mice, and the cellular locations (peroxisome for Uox, Urah, and Urad) match UniProt subcellular localization data.</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#go-cam-structure-and-connections","title":"GO-CAM Structure and Connections","text":"<p>The model uses appropriate causal connections between activities, using the \"provides input for\" (RO:0002413) predicate to show the flow of the pathway. The activities are well-connected in a linear fashion representing the sequential reactions in the pathway.</p> <p>Each enzyme activity is properly associated with the correct molecular function GO terms: - MGI:97365 (Pnp): GO:0004731 (purine-nucleoside phosphorylase activity) - MGI:98973 (Xdh): Multiple activities including GO:0070674 (hypoxanthine dehydrogenase activity), GO:0070675 (hypoxanthine oxidase activity), GO:0004854 (xanthine dehydrogenase activity), and GO:0004855 (xanthine oxidase activity) - MGI:98907 (Uox): GO:0004846 (urate oxidase activity) - MGI:1916142 (Urah): GO:0033971 (hydroxyisourate hydrolase activity) - MGI:3647519 (Urad): GO:0051997 (2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity)</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#evidence-quality","title":"Evidence Quality","text":"<p>The evidence supporting the model is robust, with multiple types of evidence cited including: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000266 (sequence orthology evidence used in manual assertion)</p> <p>Each activity is supported by multiple literature references, including key publications like PMID:30936145, PMID:1590774, PMID:8226898, and PMID:16462750, which I verified discusses the relevant aspects of this pathway.</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model adheres to GO-CAM best practices in several ways: 1. Activities are connected in a logical sequence that reflects the actual biological pathway 2. Proper subcellular locations are indicated where relevant (e.g., peroxisome for Uox, Urah, and Urad) 3. Appropriate evidence codes and references are provided for each assertion 4. The model includes output molecules where relevant (e.g., CHEBI:15676 - allantoin as the output of Urad activity)</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#suggested-improvements","title":"Suggested Improvements","text":"<p>While the model is generally well-constructed, there are a few potential improvements that could be made:</p> <ol> <li> <p>Molecular Input/Output Specification: Not all activities have explicit input/output entities specified. Adding these would make the model more complete.</p> </li> <li> <p>Part_of Relations: All activities are appropriately part_of GO:0006149 (deoxyinosine catabolic process), but some are missing occurs_in annotations. For consistency, all activities could specify their subcellular locations.</p> </li> <li> <p>Xdh Activities: The model correctly represents the multiple activities of Xdh (hypoxanthine dehydrogenase/oxidase and xanthine dehydrogenase/oxidase), but in some cases the same gene product (MGI:MGI:98973) is annotated to the same activity in separate nodes. While this isn't incorrect, it could potentially be streamlined for better clarity.</p> </li> </ol>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model gomodel:60418ffa00001643 is a high-quality representation of the deoxyinosine catabolic process in mouse. It accurately captures the biological pathway, uses appropriate GO terms and relationships, and is well-supported by evidence. The model correctly shows how the sequential activities of multiple enzymes contribute to the degradation of deoxyinosine, culminating in the production of allantoin. Minor improvements could be made in the consistent annotation of cellular locations and molecular inputs/outputs, but overall this is a well-constructed model that meets GO-CAM standards and accurately represents the underlying biology.</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/","title":"6086f4f200000223 canonical Wnt signaling pathway via wg fz2  D mel","text":"<p>Now that I have thoroughly reviewed the model, let me prepare my review.</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#review-of-go-cam-model-gomodel6086f4f200000223","title":"Review of GO-CAM Model gomodel:6086f4f200000223","text":""},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#overview-of-the-model","title":"Overview of the Model","text":"<p>Model ID: gomodel:6086f4f200000223 Title: \"canonical Wnt signaling pathway via wg-fz2 (D.mel)\" Taxon: Drosophila melanogaster (NCBITaxon:7227) Status: Production</p> <p>This model represents the canonical Wnt signaling pathway in Drosophila melanogaster (fruit fly), focusing on the wingless (wg) ligand and its interaction with the frizzled 2 (fz2) receptor. The pathway shows negative regulation of Wnt signaling, incorporating key components of the \u03b2-catenin destruction complex.</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#model-structure-and-accuracy","title":"Model Structure and Accuracy","text":"<p>The model correctly captures several key aspects of the canonical Wnt signaling pathway:</p> <ol> <li> <p>Wg (Wingless) signaling: The model shows FB:FBgn0284084 (wg) as the ligand with receptor ligand activity (GO:0048018), occurring in the extracellular space (GO:0005615) and part of the canonical Wnt signaling pathway (GO:0060070).</p> </li> <li> <p>Receptor-ligand interaction: Wg properly signals to the Frizzled 2 receptor FB:FBgn0016797 (fz2) with Wnt receptor activity (GO:0042813), which is correctly shown at the plasma membrane (GO:0005886).</p> </li> <li> <p>Co-receptor: The model includes FB:FBgn0000119 (arr), the Drosophila homolog of LRP5/6, with coreceptor activity (GO:0015026).</p> </li> <li> <p>Destruction complex components: The model includes key components of the \u03b2-catenin destruction complex, including:</p> </li> <li>FB:FBgn0026597 (Axn/Axin)</li> <li>FB:FBgn0003371 (sgg/Zeste-white 3/GSK3)</li> <li>FB:FBgn0026598 (Apc2)</li> <li> <p>FB:FBgn0025638 (Roc1a)</p> </li> <li> <p>Negative regulation pathway: The model properly represents GO:0090090 (negative regulation of canonical Wnt signaling pathway) as many of the connections demonstrate inhibition of the pathway.</p> </li> </ol>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>The model correctly represents causal relationships between components using appropriate predicates (directly positively regulates, directly negatively regulates, etc.).</p> </li> <li> <p>The model includes cellular compartments for most activities, which helps clarify where each process occurs (e.g., plasma membrane, cytosol, extracellular space).</p> </li> <li> <p>Evidences and references are provided for most assertions, with multiple PMIDs supporting key interactions.</p> </li> <li> <p>The model includes the E3 ubiquitin ligase components (Roc1a) that target Armadillo for degradation.</p> </li> <li> <p>The distinction between negative regulation (GO:0090090) and the canonical pathway itself (GO:0060070) is appropriately captured.</p> </li> </ol>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Missing component - \u03b2-TrCP/Slimb: The model is missing Slimb (FB:FBgn0283468), which is the F-box protein that recognizes phosphorylated Armadillo and facilitates its ubiquitination. According to the literature reviewed (PMID:10073940), Slimb is a crucial component of the SCF complex for Armadillo degradation.</p> </li> <li> <p>Missing component - Dishevelled: The model doesn't include Dishevelled (FB:FBgn0000499 is in the model but without connection to fz2), which is a key transducer of the Wnt signal from the receptor to downstream components.</p> </li> <li> <p>Armadillo (Arm) transcription coactivator function: While Arm (FB:FBgn0000117) is shown as having transcription coactivator activity (GO:0003713) in the nucleus (GO:0005634), its connection to specific transcription factors (e.g., Pangolin/TCF) could be more explicit.</p> </li> <li> <p>Causal chain clarity: The causality between some components could be made clearer. For example, the model has some redundancy in connections between dsh and sgg, and the flow of the pathway could be more linear in places.</p> </li> <li> <p>Additional evidence: Some connections lack evidence codes or have fewer citations than others. Adding more supporting literature would strengthen the model.</p> </li> </ol>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on the literature reviewed, the model is largely accurate in its representation of the canonical Wnt signaling pathway in Drosophila. Key interactions are supported by experimental evidence, and the components included are central to the pathway.</p> <p>One minor discrepancy is that some recent research (PMID:22359584) suggests complexity around the role of Roc1a in Arm regulation that may be tissue-specific. The model correctly includes Roc1a but might benefit from additional notes or references regarding this nuance.</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that accurately represents the canonical Wnt signaling pathway in Drosophila melanogaster. It includes most key components and their interactions with appropriate evidence. With the addition of the suggested components (particularly Slimb and better Dishevelled integration) and some refinements to the causal chain, this model would provide an even more comprehensive representation of the pathway.</p> <p>The model is ready for production use but would benefit from the minor improvements noted above.</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/","title":"60897d8500000494 IMP salvage  Mouse","text":"<p>Now, based on my review of the GO-CAM model, let me provide a comprehensive assessment:</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#review-of-go-cam-model-gomodel60897d8500000494-imp-salvage-in-mouse","title":"Review of GO-CAM Model: gomodel:60897d8500000494 (IMP salvage in Mouse)","text":""},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:60897d8500000494) represents the IMP (inosine monophosphate) salvage pathway in mouse. The model describes various enzymes and their activities that contribute to the recycling of purines to generate IMP, which is a crucial intermediate in purine metabolism.</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#model-structure-and-content-assessment","title":"Model Structure and Content Assessment","text":""},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#positive-aspects","title":"Positive aspects:","text":"<ol> <li> <p>Appropriate biological process context: The model is appropriately centered around GO:0032264 (IMP salvage) with all activities being part of this process.</p> </li> <li> <p>Well-documented evidence: Each activity is supported by experimental evidence with appropriate ECO codes and PMID references.</p> </li> <li> <p>Complete pathway representation: The model includes multiple routes to IMP formation, representing different enzymes that contribute to this pathway.</p> </li> <li> <p>Appropriate causal connections: The model uses RO:0002413 \"provides input for\" to connect activities in an appropriate flow that represents the biochemical pathway.</p> </li> <li> <p>Cellular location: Some activities (e.g., Hprt1's hypoxanthine phosphoribosyltransferase activity and Pnp's purine-nucleoside phosphorylase activity) include their cellular location (cytosol, GO:0005829), which enhances the biological context.</p> </li> <li> <p>Consistent with literature: The documented pathway is consistent with the examined PMID references that describe IMP salvage in mammals.</p> </li> </ol>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#areas-for-improvement","title":"Areas for improvement:","text":"<ol> <li>Missing molecular inputs: While some activities have clearly defined inputs and outputs, others are missing input molecules. For example:</li> <li> <p>The AMP deaminase activities (Ampd1, Ampd2, Ampd3) have outputs (CHEBI:17202, IMP) but don't specify their inputs (which should be AMP, CHEBI:16027).</p> </li> <li> <p>Incomplete biochemical details: The full metabolic conversion details could be more completely represented for each step, including all substrates and products.</p> </li> <li> <p>Missing regulation information: The model doesn't include any regulatory relationships (neither positive nor negative regulation) between activities, which might exist in this pathway.</p> </li> <li> <p>No multi-organism process annotation: If this pathway is influenced by or responds to external factors (e.g., nucleotide starvation), this context is not provided.</p> </li> <li> <p>Inconsistent use of location annotation: Only some activities have cellular location specified (occurs_in), but this information is missing for others.</p> </li> </ol>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#specific-recommendations","title":"Specific Recommendations:","text":"<ol> <li>Add missing inputs:</li> <li>Add CHEBI:16027 (AMP) as input for all three AMP deaminase activities (Ampd1, Ampd2, Ampd3)</li> <li> <p>Ensure all activities have both inputs and outputs where applicable</p> </li> <li> <p>Complete cellular location annotations:</p> </li> <li> <p>Add \"occurs_in GO:0005829 (cytosol)\" for all activities where this information is missing but supported by literature</p> </li> <li> <p>Enhance pathway context:</p> </li> <li> <p>Consider adding connections to related pathways (e.g., de novo purine synthesis or adenosine metabolism) if supported by evidence</p> </li> <li> <p>Add regulatory information:</p> </li> <li> <p>If supported by evidence, include regulatory relationships such as feedback inhibition or activation that might occur in this pathway</p> </li> <li> <p>Consider adding biological context:</p> </li> <li>If the pathway has specific relevance to certain physiological conditions (e.g., nucleotide shortage, cellular stress), this could be indicated</li> </ol>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#technical-assessment","title":"Technical Assessment:","text":"<p>The model follows GO-CAM best practices for representing molecular activities and their connections. The use of \"part_of\" to relate molecular functions to biological processes is appropriate. The causal connections establish a coherent pathway flow.</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#conclusion","title":"Conclusion:","text":"<p>This is a solid GO-CAM model representing the IMP salvage pathway in mouse. It correctly captures the key enzymatic activities involved and their relationships. With some minor enhancements to complete the biochemical details (particularly adding the missing inputs) and cellular locations, the model would provide an even more comprehensive representation of this pathway.</p> <p>The model is suitable for production use but would benefit from the suggested improvements to be fully complete.</p>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/","title":"60897d8500000531 AMP salvage  Mouse","text":"<p>Now that I have gathered information about the model and its components, I'll provide a comprehensive review of GO-CAM model gomodel:60897d8500000531 (AMP salvage in Mouse).</p>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#review-of-go-cam-model-amp-salvage-mouse-gomodel60897d8500000531","title":"Review of GO-CAM Model: AMP Salvage (Mouse) - gomodel:60897d8500000531","text":""},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model represents the AMP salvage pathway in mouse (taxon: NCBITaxon:10090), focusing on enzymes involved in recovering adenine nucleotides through various metabolic routes. The model includes 6 activities that are connected appropriately with causal relationships to represent the flow of metabolism in this pathway.</p>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Pathway Representation: The model successfully represents the AMP salvage pathway with appropriate molecular functions, inputs/outputs, and causal connections.</p> </li> <li> <p>Evidence Base: Each activity and association in the model is well-supported by experimental evidence, primarily with direct assays (ECO:0000314) and mutant phenotype evidence (ECO:0000315) from relevant literature.</p> </li> <li> <p>Biological Accuracy: The enzymes and reactions represented align with established understanding of purine salvage metabolism, as confirmed by the literature I reviewed.</p> </li> <li> <p>Use of Causal Associations: The model uses the correct causal predicate (RO:0002413 provides input for) to show how activities are connected in the pathway.</p> </li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#components-of-the-model","title":"Components of the Model","text":"<p>The model includes the following key enzymes and activities:</p> <ol> <li>Hypoxanthine phosphoribosyltransferase (HPRT, MGI:MGI:96217) </li> <li>Molecular function: hypoxanthine phosphoribosyltransferase activity (GO:0004422)</li> <li>Takes hypoxanthine (CHEBI:17368) as input</li> <li> <p>Provides input for two downstream activities (adenylosuccinate synthase)</p> </li> <li> <p>Adenine phosphoribosyltransferase (APRT, MGI:MGI:88061)</p> </li> <li>Molecular function: adenine phosphoribosyltransferase activity (GO:0003999)</li> <li>Takes adenine (CHEBI:16708) as input</li> <li> <p>Outputs AMP (CHEBI:16027)</p> </li> <li> <p>Adenylosuccinate synthase (ADSS1, MGI:MGI:87947 and ADSS2, MGI:MGI:87948)</p> </li> <li>Molecular function: adenylosuccinate synthase activity (GO:0004019)</li> <li> <p>Provides input for adenylosuccinate lyase</p> </li> <li> <p>Adenylosuccinate lyase (ADSL, MGI:MGI:103202)</p> </li> <li>Molecular function: N6-(1,2-dicarboxyethyl)AMP AMP-lyase (fumarate-forming) activity (GO:0004018)</li> <li> <p>Outputs AMP (CHEBI:16027)</p> </li> <li> <p>Adenosine kinase (ADK, MGI:MGI:87930)</p> </li> <li>Molecular function: adenosine kinase activity (GO:0004001)</li> <li>Takes adenosine (CHEBI:16335) as input</li> <li>Outputs AMP (CHEBI:16027)</li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li> <p>All activities are appropriately enabled by specific genes/proteins rather than using complex IDs, which is appropriate since the specific proteins carrying each activity are known.</p> </li> <li> <p>The causal relationships are consistently represented using RO:0002413 (provides input for) which is the correct relation for metabolic pathways where one reaction produces a substrate for another.</p> </li> <li> <p>Input and output molecules are properly annotated for each activity, showing the flow of metabolites through the pathway.</p> </li> <li> <p>All activities are appropriately part of the biological process \"AMP salvage\" (GO:0044209).</p> </li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the three major routes of AMP salvage:</p> <ol> <li>Adenine salvage via APRT - converting adenine directly to AMP</li> <li>Hypoxanthine salvage via HPRT - followed by conversion to AMP through ADSS and ADSL</li> <li>Adenosine salvage via adenosine kinase - directly phosphorylating adenosine to AMP</li> </ol> <p>This is consistent with literature on purine salvage pathways, including the papers cited as evidence in the model and the additional literature I examined.</p>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is scientifically accurate and well-constructed, I have a few minor suggestions:</p> <ol> <li> <p>Add specific substrate/product details for the ADSS and ADSL reactions. The intermediate adenylosuccinate is not explicitly shown as an output of ADSS and input to ADSL, which would improve biochemical clarity.</p> </li> <li> <p>Consider adding cellular location information. While not required, adding cellular component annotations would provide additional context about where these reactions occur.</p> </li> <li> <p>Possibly include allosteric regulation. If there is evidence for allosteric regulation of these enzymes in the mouse, this could be added using appropriate causal relations for positive or negative regulation.</p> </li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60897d8500000531 \"AMP salvage (Mouse)\" is an accurate, evidence-based representation of the AMP salvage pathway in mouse. It follows GO-CAM best practices and appropriately connects the activities of key enzymes in this metabolic pathway. The model is biologically sound and properly curated with good supporting evidence.</p> <p>The model would be suitable for release in its current form, with the minor suggestions above being optional enhancements rather than required corrections.</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/","title":"60ad85f700000058 Atf2 mouse","text":"<p>Let me now analyze this model for consistency with GO-CAM best practices and biological accuracy. I'll check several aspects of the model.</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#overview-of-go-cam-model-gomodel60ad85f700000058","title":"Overview of GO-CAM Model (gomodel:60ad85f700000058)","text":"<p>This is a model titled \"Atf2 mouse\" with the taxon ID NCBITaxon:9606 (human). I notice that the title mentions mouse but the taxon ID is for human, which is an inconsistency that should be addressed.</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#1-model-structure-and-connectivity","title":"1. Model Structure and Connectivity","text":"<p>The model contains 63 activities with ATF2 (MGI:MGI:109349) as the central protein, along with its interactions with various gene products including: - JDP2 (MGI:MGI:1932093) - JUN (MGI:MGI:96646) - ATF7 (MGI:MGI:2443472) - CREB5 (MGI:MGI:2443973) - And many others</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#2-causal-connectivity-issues","title":"2. Causal Connectivity Issues","text":"<p>While there are some causal relationships defined using the RO:0002418 (activated by) predicate, most of the activities in the model appear disconnected from each other. This limits the model's ability to represent pathway flow, which is a key aspect of GO-CAM models.</p> <p>The model has only a few causal associations, specifically: - JDP2 protein homodimerization causing JDP2 cAMP response element binding - ATF2 and JDP2 interactions through leucine zipper domain binding and heterodimerization - No clearly defined pathways showing how upstream activities lead to downstream effects</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#3-function-annotations","title":"3. Function Annotations","text":"<p>Many activities are annotated with GO:0003674 (molecular function), which is a root term and not specific. This indicates potential incomplete annotations that could be refined with more specific functions where evidence is available.</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#4-evidence-and-references","title":"4. Evidence and References","text":"<p>The model uses a variety of evidence codes and PMIDs, which is good practice. However: - Some activities lack evidence annotations altogether - The same references are often used across multiple activities without clear distinction of what specific aspects they support</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#5-biological-process-context","title":"5. Biological Process Context","text":"<p>The model represents ATF2 involvement in multiple biological processes including: - Gene expression (GO:0010467) - Cellular response to oxidative stress (GO:0034599) - Heart development (GO:0007507) - Positive regulation of transcription (GO:0045944) - And others</p> <p>However, these processes are not connected into coherent pathways, making it difficult to understand the overall biological narrative.</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Taxonomic Inconsistency: Resolve the discrepancy between the title \"Atf2 mouse\" and the human taxon ID (NCBITaxon:9606). The model should use mouse taxon ID if it's describing mouse proteins.</p> </li> <li> <p>Causal Connectivity: Add more causal connections between activities to create coherent pathways showing how upstream activities lead to downstream effects. Use appropriate predicates like RO:0002413 (provides input for), RO:0002629 (directly positively regulates), or RO:0002630 (directly negatively regulates).</p> </li> <li> <p>Function Specificity: Replace generic GO:0003674 (molecular function) annotations with more specific molecular functions where evidence supports it.</p> </li> <li> <p>Model Organization: Consider organizing the model into distinct sub-models representing different pathways or contexts in which ATF2 functions (e.g., separate the transcriptional regulation pathway from the stress response pathway).</p> </li> <li> <p>Activity Grouping: Group related activities to improve model readability. For example, all activities involved in transcription regulation could be visually grouped together.</p> </li> <li> <p>Evidence Documentation: Ensure all activities have appropriate evidence annotations, and when using the same reference for multiple activities, clearly document which aspects of the reference support each specific activity.</p> </li> <li> <p>Complex Representation: The model shows protein-protein interactions via protein binding annotations, but these could be better represented using complex formation activities according to the GO-CAM How to annotate complexes in GO-CAM guidelines.</p> </li> </ol>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a collection of ATF2-related activities and interactions, but lacks the pathway connectivity that would make it a truly valuable causal activity model. The primary recommendation is to enhance causal connections between activities to better represent biological pathway flow. Additionally, addressing the taxonomic inconsistency and improving function specificity would enhance the model's accuracy and usefulness.</p> <p>Would you like me to elaborate on any specific aspect of this review? For example, I could check the documentation on specific best practices for representing transcription factors in GO-CAMs, which would be relevant for ATF2.</p>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/","title":"60ad85f700000110 receptor signaling pathway via JAK STAT via upd2 dome  D mel","text":"<p>Based on my review of the GO-CAM model and the relevant documentation, here's my review of gomodel:60ad85f700000110 (receptor signaling pathway via JAK-STAT via upd2-dome (D.mel)):</p>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#review-of-go-cam60ad85f700000110","title":"Review of GO-CAM:60ad85f700000110","text":""},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#model-overview","title":"Model Overview","text":"<p>This model represents the JAK-STAT signaling pathway in Drosophila melanogaster, specifically focusing on the upd2-dome signaling axis. The model includes:</p> <ol> <li>Upd2 (FB:FBgn0030904) with cytokine activity</li> <li>Dome receptor (FB:FBgn0043903) with cytokine receptor activity</li> <li>Hopscotch (FB:FBgn0004864) - the Drosophila JAK with protein tyrosine kinase activity</li> <li>Stat92E (FB:FBgn0016917) - the Drosophila STAT with DNA-binding transcription activator activity</li> </ol>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Correct pathway representation: The model accurately represents the canonical JAK-STAT pathway in Drosophila, with the correct sequence of signaling events from ligand (Upd2) to transcription factor (Stat92E).</p> </li> <li> <p>Appropriate molecular functions: Each protein is annotated with the correct molecular function:</p> </li> <li>Upd2 with cytokine activity</li> <li>Dome with cytokine receptor activity</li> <li>Hop with protein tyrosine kinase activity</li> <li> <p>Stat92E with DNA-binding transcription activator activity</p> </li> <li> <p>Proper cellular locations: All activities are placed in appropriate cellular compartments:</p> </li> <li>Upd2 in extracellular region (GO:0005576)</li> <li>Dome at apical plasma membrane (GO:0016324)</li> <li>Hop at cytoplasmic side of plasma membrane (GO:0009898)</li> <li> <p>Stat92E in nucleus (GO:0005634)</p> </li> <li> <p>Causal relationships: The model uses appropriate causal relationships with the 'directly positively regulates' (RO:0002629) predicate for signaling flow.</p> </li> <li> <p>Supporting evidence: All activities are supported by appropriate evidence from the literature with ECO codes and PMID references.</p> </li> </ol>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing transcriptional targets: While Stat92E is shown with DNA-binding transcription activator activity, the model doesn't include specific target genes that Stat92E regulates. According to the TF annotation guidelines, a link to at least one target gene would improve the model.</p> </li> <li> <p>Incomplete complex representation: The JAK-STAT pathway often involves dimerization of receptors and STATs. The model doesn't explicitly capture these molecular events, which would provide a more comprehensive representation of the pathway.</p> </li> <li> <p>Limited pathway context: The model focuses on the core signaling components but doesn't include regulation of the pathway such as SOCS (Suppressor of Cytokine Signaling) proteins, which provide negative feedback regulation. Including SOCS36E, a target of Stat92E in Drosophila, would make the model more complete.</p> </li> <li> <p>Missing phosphorylation sites: The PMID:32917740 paper identifies important phosphorylation sites for Stat92E (particularly Thr702 and Tyr704) that are crucial for its function. These could be annotated in the model for more mechanistic detail.</p> </li> <li> <p>Spatial regulation: The paper also describes endocytic regulation of the pathway which is not captured in the model. Since endocytosis can qualitatively affect signaling outputs, including this aspect would provide a more accurate representation of the pathway's regulation.</p> </li> </ol>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model is biologically accurate based on the literature provided. The PMID:32917740 paper confirms the localization of pathway components and the signaling flow represented in the model. The evidence used (ECO:0000314 - direct assay evidence) is appropriate for the assertions made.</p>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#suggestions-for-enhancement","title":"Suggestions for Enhancement","text":"<ol> <li> <p>Add at least one transcriptional target of Stat92E (like socs36E) using 'indirectly positively regulates' as the causal relation.</p> </li> <li> <p>Include receptor dimerization and STAT dimerization in the model to better represent the molecular mechanism.</p> </li> <li> <p>Add regulation of the pathway by including negative regulators like SOCS36E.</p> </li> <li> <p>Add more detail about the phosphorylation events, particularly the critical Thr702 and Tyr704 phosphorylation sites on Stat92E that were highlighted in the PMID:32917740 paper.</p> </li> <li> <p>Consider representing the endocytic regulation of the pathway as described in the PMID:32917740 paper, which demonstrates that endocytosis qualitatively affects signaling outputs.</p> </li> </ol>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#conclusion","title":"Conclusion","text":"<p>Overall, GO-CAM:60ad85f700000110 is a well-constructed model that accurately represents the core components and flow of the JAK-STAT pathway in Drosophila. The model follows the GO-CAM best practices for representing signaling pathways and uses appropriate evidence. With the suggested enhancements, particularly adding transcriptional targets and representing more regulatory aspects, the model could provide an even more comprehensive representation of this important signaling pathway.</p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/","title":"60ad85f700000189 BMP signaling pathway via dpp tkv put  D mel","text":"<p>Based on my research, I'll now provide a detailed review of GO-CAM model gomodel:60ad85f700000189 (BMP signaling pathway via dpp-tkv/put (D.mel)).</p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#review-of-go-cam-model-gomodel60ad85f700000189","title":"Review of GO-CAM Model: gomodel:60ad85f700000189","text":""},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#summary","title":"Summary","text":"<p>The model gomodel:60ad85f700000189 represents the BMP signaling pathway in Drosophila melanogaster, specifically focusing on the signaling through the Decapentaplegic (Dpp) ligand and its receptors Thickveins (Tkv) and Punt (Put). This is a production-ready model that captures key molecular functions and causal relationships in the BMP signaling pathway.</p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#overall-assessment","title":"Overall Assessment","text":"<p>The model accurately represents the core components of the Drosophila BMP signaling pathway and follows the GO-CAM guidelines for pathway representation. The components and their interactions are consistent with current scientific knowledge about BMP signaling in Drosophila.</p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#strengths","title":"Strengths","text":"<ol> <li> <p>Complete signaling cascade: The model effectively captures the complete BMP signaling pathway from ligand (Dpp) through receptors (Tkv/Put) to downstream effectors (Mad) and transcriptional targets (Medea).</p> </li> <li> <p>Proper cellular locations: Each activity is correctly associated with its subcellular location - Dpp in extracellular space, receptors at the plasma membrane, and transcription factors in the nucleus or cytosol as appropriate.</p> </li> <li> <p>Causal relationships: The model correctly represents the causal relationships between pathway components using appropriate relationship predicates (e.g., RO:0002629 \"directly positively regulates\").</p> </li> <li> <p>Evidence support: Each activity and relationship is supported by appropriate evidence codes and literature references (e.g., ECO:0000314, ECO:0000315, ECO:0000353).</p> </li> <li> <p>Biological process context: Activities are properly contextualized within the BMP signaling pathway (GO:0030509).</p> </li> </ol>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Regulatory element information: While the model includes transcription factor activities, it doesn't specify the specific target genes or regulatory elements. Adding this information would strengthen the model, particularly for the Mad and Med transcription factors, whose targets are well-studied.</p> </li> <li> <p>Additional feedback regulators: The model includes Dad, which regulates BMP signaling, but other known feedback regulators in this pathway, such as Brinker (Brk), are not represented.</p> </li> <li> <p>Ligand processing: The model doesn't capture the processing and maturation of the Dpp ligand, which can influence signaling activity.</p> </li> <li> <p>Co-receptors: The model doesn't include known co-receptors or modulators of the BMP pathway such as Division abnormally delayed (Dally) and Dally-like protein (Dlp), which regulate Dpp gradient formation.</p> </li> </ol>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#detailed-component-analysis","title":"Detailed Component Analysis","text":""},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#1-dpp-fbfbgn0000490","title":"1. Dpp (FB:FBgn0000490)","text":"<ul> <li>Correctly annotated with receptor ligand activity (GO:0048018)</li> <li>Properly located in extracellular space (GO:0005615)</li> <li>Appropriately linked to the BMP signaling pathway (GO:0030509)</li> <li>Correctly represented as causing activation of the Punt receptor (directly positively regulates)</li> </ul>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#2-punt-fbfbgn0003169","title":"2. Punt (FB:FBgn0003169)","text":"<ul> <li>Correctly annotated with BMP receptor activity (GO:0098821)</li> <li>Properly located at plasma membrane (GO:0005886)</li> <li>Appropriately connected to the BMP signaling pathway (GO:0030509)</li> <li>Correctly represented as activating the Tkv receptor</li> </ul>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#3-thickveins-fbfbgn0003716","title":"3. Thickveins (FB:FBgn0003716)","text":"<ul> <li>Correctly annotated with BMP receptor activity (GO:0098821)</li> <li>Properly located at plasma membrane (GO:0005886)</li> <li>Appropriately connected to the BMP signaling pathway (GO:0030509)</li> <li>Correctly represented as activating Mad through phosphorylation</li> </ul>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#4-mad-fbfbgn0011648","title":"4. Mad (FB:FBgn0011648)","text":"<ul> <li>Two distinct activities correctly captured:</li> <li>DNA-binding transcription activator activity (GO:0001228) in the nucleus</li> <li>Co-SMAD binding (GO:0070410) in the cytosol</li> <li>Part of BMP signaling pathway (GO:0030509)</li> <li>Correctly represented as activating downstream effectors</li> </ul>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#5-medea-fbfbgn0288966","title":"5. Medea (FB:FBgn0288966)","text":"<ul> <li>Correctly annotated with DNA-binding transcription activator activity (GO:0001228)</li> <li>Properly located in nucleus (GO:0005634)</li> <li>Appropriately connected to the BMP signaling pathway (GO:0030509)</li> </ul>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#6-dad-fbfbgn0020493","title":"6. Dad (FB:FBgn0020493)","text":"<ul> <li>Correctly annotated with BMP receptor binding (GO:0070700)</li> <li>Properly connected to negative regulation of BMP signaling pathway (GO:0030514)</li> <li>Correctly represented as inhibiting Mad activity</li> </ul>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#causal-relationships","title":"Causal Relationships","text":"<p>The model accurately represents the following causal relationships: - Dpp \u2192 Punt (RO:0002629, directly positively regulates) - Punt \u2192 Tkv (RO:0002629, directly positively regulates) - Tkv \u2192 Mad (RO:0002629, directly positively regulates) - Mad \u2192 Medea (RO:0002629, directly positively regulates) - Dad \u2192 Mad (RO:0002630, directly negatively regulates)</p> <p>These relationships correctly capture the canonical BMP signaling cascade in Drosophila.</p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is consistent with the current scientific understanding of BMP signaling in Drosophila as described in the literature. The references cited (e.g., PMID:20010841, PMID:18588885, PMID:28130362) support the model components and relationships.</p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add gene targets: Include specific gene targets regulated by the Mad-Medea complex, such as known BMP target genes (e.g., brinker, optomotor-blind, spalt).</p> </li> <li> <p>Include additional regulators: Add other known regulators of the pathway such as Brinker, which antagonizes BMP signaling.</p> </li> <li> <p>Represent Dpp gradient formation: Consider including components that regulate the Dpp morphogen gradient, such as Dally and Dlp.</p> </li> <li> <p>Ligand processing: Include the processing and maturation of Dpp, including the role of Furin proteases.</p> </li> <li> <p>Alternative receptors: Consider adding the Saxophone (Sax) receptor, which can function alongside Tkv in certain contexts.</p> </li> <li> <p>Gbb ligand: Consider including the Glass bottom boat (Gbb) ligand, which often functions with Dpp, potentially as a heterodimer.</p> </li> </ol>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60ad85f700000189 provides a well-constructed representation of the core BMP signaling pathway in Drosophila melanogaster. It accurately captures the key molecular functions, cellular locations, and causal relationships in this pathway. With the suggested improvements, the model could provide an even more comprehensive representation of this important developmental signaling pathway.</p>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/","title":"60ad85f700000259 activin receptor signaling pathway via Actbeta babo put  D mel","text":"<p>Based on my review of GO-CAM model 60ad85f700000259 \"activin receptor signaling pathway via Actbeta-babo/put (D.mel)\" and the relevant documentation, I'll now provide a comprehensive assessment of the model.</p>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#go-cam-model-review-activin-receptor-signaling-pathway-via-actbeta-baboput-dmel","title":"GO-CAM Model Review: activin receptor signaling pathway via Actbeta-babo/put (D.mel)","text":""},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:60ad85f700000259) represents the activin receptor signaling pathway in Drosophila melanogaster, specifically focusing on the signaling cascade from Activin-beta (Actbeta) through the type I receptor Baboon (babo) and the type II receptor Punt (put).</p>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model depicts the following key components:</p> <ol> <li>Ligand: Actbeta (FB:FBgn0024913) with cytokine activity (GO:0005125) in extracellular space (GO:0005615)</li> <li>Type I receptor: Baboon (FB:FBgn0011300) with activin receptor activity (GO:0017002) on plasma membrane (GO:0005886)</li> <li>Type II receptor: Punt (FB:FBgn0003169) with activin receptor activity (GO:0017002)</li> <li>Signal transducer: Smox (FB:FBgn0025800) with co-SMAD binding (GO:0070410) and DNA-binding transcription factor activity (GO:0000981) in nucleus (GO:0005634)</li> <li>Transcription factor: Medea (FB:FBgn0288966) with DNA-binding transcription activator activity (GO:0001228) in nucleus (GO:0005634)</li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#signaling-flow","title":"Signaling Flow","text":"<p>The model correctly captures the canonical activin signaling pathway with appropriate causal associations:</p> <ol> <li>Actbeta (ligand) directly positively regulates (RO:0002629) Punt (type II receptor)</li> <li>Punt directly positively regulates (RO:0002629) Baboon (type I receptor)</li> <li>Baboon directly positively regulates (RO:0002629) Smox (R-Smad)</li> <li>Smox directly positively regulates (RO:0002629) both:</li> <li>Itself as a DNA-binding transcription factor (GO:0000981)</li> <li>Medea (co-Smad) as a DNA-binding transcription activator (GO:0001228)</li> </ol> <p>All components are appropriately labeled as part of the activin receptor signaling pathway (GO:0032924).</p>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate receptor representation: The model correctly depicts the type I (Baboon) and type II (Punt) receptors with appropriate molecular functions and cellular locations.</p> </li> <li> <p>Proper signaling cascade: The causal flow correctly shows the progression from ligand to receptor to downstream effectors with appropriate relationships.</p> </li> <li> <p>Cellular compartmentalization: Components are properly assigned to their cellular locations (extracellular space, plasma membrane, nucleus).</p> </li> <li> <p>Evidence support: The model contains appropriate evidence codes and literature references, including key papers on Drosophila activin signaling (PMID:10320478, PMID:28130362).</p> </li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>According to the \"Signaling receptor activity annotation guidelines\" document, the model follows best practices for representing protein ligand-activated signaling receptors:</p> <ol> <li> <p>Ligand representation: Actbeta correctly enables cytokine activity (a child of receptor ligand activity) and is located in extracellular space.</p> </li> <li> <p>Receptor representation: Both receptors have appropriate activin receptor activities and the type I receptor (Baboon) is correctly located in the plasma membrane.</p> </li> <li> <p>Causal relations: The model correctly uses \"directly positively regulates\" (RO:0002629) between components of the signaling pathway, as specified in the guidelines.</p> </li> <li> <p>Context annotation: All activities are properly contextualized with appropriate GO cellular component terms and are part of the activin receptor signaling pathway.</p> </li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#minor-issues","title":"Minor Issues","text":"<ol> <li> <p>Missing biological process for Medea: While all other components are labeled as part of the activin receptor signaling pathway (GO:0032924), Medea's DNA-binding transcription activator activity is labeled as part of this process, but the process isn't explicitly connected to the component itself. This is a minor annotation issue.</p> </li> <li> <p>Potential missing receptor target genes: The model could be expanded to include specific target genes that are activated by the Smox-Medea complex, as mentioned in the reviewed literature (specifically from PMID:28130362 which mentions Atg8a as a direct target).</p> </li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add biological process annotation for Medea: Ensure that Medea is explicitly linked to the activin receptor signaling pathway (GO:0032924) process.</p> </li> <li> <p>Consider adding target genes: Include specific target genes regulated by the Smox-Medea complex to make the model more comprehensive.</p> </li> <li> <p>Consider adding receptor complex formation: While the current representation is valid, explicitly modeling the formation of the receptor heterotetramer (two type I and two type II receptors) could provide additional clarity about the signaling mechanism.</p> </li> <li> <p>Consider adding phosphorylation states: Adding information about the phosphorylation of Smox by Baboon would provide additional mechanistic detail.</p> </li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model accurately represents the activin receptor signaling pathway in Drosophila melanogaster and follows GO-CAM best practices for signaling pathway representation. The model captures the key components, their appropriate molecular functions, cellular locations, and the causal relationships between them. With some minor enhancements as suggested above, the model could provide even more comprehensive representation of this important signaling pathway.</p>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/","title":"60ad85f700000309 Notch signaling pathway via N Dl  D mel","text":"<p>Based on my research, I can now provide a comprehensive review of GO-CAM model: gomodel:60ad85f700000309 titled \"Notch signaling pathway via N-Dl (D.mel)\".</p>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#go-cam-review-notch-signaling-pathway-via-n-dl-dmel","title":"GO-CAM Review: Notch signaling pathway via N-Dl (D.mel)","text":""},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#model-overview","title":"Model Overview","text":"<p>This model represents the Notch signaling pathway in Drosophila melanogaster, focusing on the interaction between the Notch receptor (N) and its ligand Delta (Dl), and the downstream effects of this signaling pathway. </p>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#components-and-activities","title":"Components and Activities","text":"<p>The model consists of 5 key activities:</p> <ol> <li>Delta (Dl) - FB:FBgn0000463</li> <li>Molecular Function: receptor ligand activity (GO:0048018)</li> <li>Located in: membrane (GO:0016020)</li> <li>Part of: Notch signaling pathway (GO:0007219)</li> <li> <p>Directly positively regulates Notch transmembrane signaling receptor activity</p> </li> <li> <p>Notch (N) - FB:FBgn0004647</p> </li> <li>Molecular Function: transmembrane signaling receptor activity (GO:0004888)</li> <li>Located in: plasma membrane (GO:0005886)</li> <li>Part of: Notch signaling pathway (GO:0007219)</li> <li> <p>Directly positively regulates Kuzbanian metalloendopeptidase activity</p> </li> <li> <p>Kuzbanian (kuz) - FB:FBgn0259984</p> </li> <li>Molecular Function: metalloendopeptidase activity (GO:0004222)</li> <li>Located in: cellular_component (GO:0005575)</li> <li>Part of: Notch signaling pathway (GO:0007219)</li> <li> <p>Directly positively regulates Presenilin endopeptidase activity</p> </li> <li> <p>Presenilin (Psn) - FB:FBgn0284421</p> </li> <li>Molecular Function: endopeptidase activity (GO:0004175)</li> <li>Located in: cell surface (GO:0009986)</li> <li>Part of: Notch signaling pathway (GO:0007219)</li> <li> <p>Directly positively regulates Notch transcription coactivator activity</p> </li> <li> <p>Notch (N) - FB:FBgn0004647</p> </li> <li>Molecular Function: transcription coactivator activity (GO:0003713)</li> <li>Located in: nucleus (GO:0005634)</li> <li>Part of: Notch signaling pathway (GO:0007219)</li> </ol>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#evaluation-of-model-quality","title":"Evaluation of Model Quality","text":""},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<ol> <li>Signaling Receptor Activity Annotations</li> <li>The model correctly represents the interaction between Delta (ligand) and Notch (receptor) following the guidelines for protein ligand-activated signaling receptors.</li> <li>The ligand (Delta) correctly has \"receptor ligand activity\" (GO:0048018) as its molecular function.</li> <li>Delta is appropriately located in the membrane.</li> <li>The causal relation between Delta activity and Notch receptor activity is correctly labeled as \"directly positively regulates\" (RO:0002629).</li> <li> <p>Notch receptor correctly has \"transmembrane signaling receptor activity\" (GO:0004888) as its molecular function and is located in the plasma membrane.</p> </li> <li> <p>Pathway Flow and Logic</p> </li> <li>The model captures the sequential events in Notch signaling: <ol> <li>Delta binds to Notch receptor</li> <li>Notch is cleaved by Kuzbanian (S2 cleavage)</li> <li>Notch is further cleaved by Presenilin (S3 cleavage)</li> <li>The Notch intracellular domain (NICD) translocates to the nucleus and acts as a transcription coactivator</li> </ol> </li> <li> <p>All steps are properly connected with the appropriate causal relation \"directly positively regulates\" (RO:0002629).</p> </li> <li> <p>Transcription Coactivator Activity</p> </li> <li>The nuclear activity of Notch as a transcription coactivator (GO:0003713) is properly represented, following the guidelines for transcription coregulator activity.</li> <li>It is correctly located in the nucleus (GO:0005634).</li> </ol>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#accuracy-of-biological-content","title":"Accuracy of Biological Content","text":"<p>The model accurately represents the Notch signaling pathway in Drosophila melanogaster as supported by the literature:</p> <ul> <li> <p>From the PMID:15611340 paper, we can confirm the pathway logic: Delta binds to Notch, triggering a series of proteolytic cleavages first by Kuzbanian (S2 cleavage) and then by Presenilin (S3 cleavage), which releases the Notch intracellular domain (Nintra) that translocates to the nucleus to act as a transcriptional coactivator with Suppressor of Hairless (SuH).</p> </li> <li> <p>The model correctly captures the membrane location of Delta and Notch, and the sequential proteolytic cleavages that lead to Notch activation.</p> </li> <li> <p>The UniProt entries confirm that Delta is a ligand for the Notch receptor, and that cleaved Notch acts as a transcriptional activator complex in the nucleus.</p> </li> </ul>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing Components: </li> <li>The model does not include Suppressor of Hairless (SuH), which forms a complex with the Notch intracellular domain in the nucleus to regulate transcription as mentioned in the literature.</li> <li> <p>Specific target genes of Notch signaling, such as the Enhancer of split Complex (E(spl)C) genes mentioned in PMID:15611340, are not included.</p> </li> <li> <p>Incomplete Annotations:</p> </li> <li>Kuzbanian's cellular location is annotated as the generic \"cellular_component\" (GO:0005575) rather than a more specific cellular location.</li> <li> <p>The model could benefit from including evidence for some of the associations.</p> </li> <li> <p>Molecular Details:</p> </li> <li>The model could more explicitly represent the cleavage of Notch and the release of the Notch intracellular domain (NICD) that translocates to the nucleus.</li> <li>The interaction with glycosylation enzymes like O-fut1 and fringe, which modify Notch's ability to bind Delta (as mentioned in the UniProt entry for Delta), is not represented.</li> </ol>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60ad85f700000309 provides a good representation of the core Notch signaling pathway in Drosophila melanogaster. It correctly captures the sequential events from ligand binding to transcriptional regulation and follows most GO-CAM best practices. </p> <p>The model could be enhanced by: 1. Including Suppressor of Hairless and target genes 2. Providing more specific cellular location for Kuzbanian 3. Adding molecular details about Notch cleavage and NICD translocation 4. Representing modifiers of Notch-Delta interactions such as O-fut1 and fringe</p> <p>Overall, this model serves as a solid representation of the Notch signaling pathway and could be a useful reference model for further annotation of Notch signaling in other contexts.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/","title":"60ad85f700000612 TRIM47 activity on ILF3","text":"<p>Now I'll review the GO-CAM model with ID 60ad85f700000612 based on all the information gathered. I'll structure my review to check for consistency with GO-CAM best practices, biological accuracy, and proper molecular function representation.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#review-of-go-cam-model-gomodel60ad85f700000612-trim47-activity-on-ilf3","title":"Review of GO-CAM model: gomodel:60ad85f700000612 \"TRIM47-activity-on-ILF3\"","text":""},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#overview","title":"Overview","text":"<p>This GO-CAM describes a causal pathway involving four proteins: 1. HAVCR2/TIM-3 (UniProtKB:Q8TDQ0) 2. TRIM47 (UniProtKB:Q96LD4-1) 3. ILF3/NF90 (UniProtKB:Q12906) 4. EIF2AK2/PKR (UniProtKB:P19525)</p> <p>The model represents a molecular pathway where: 1. HAVCR2/TIM-3 protein binding directly positively regulates 2. TRIM47's E3 ubiquitin ligase activity, which directly negatively regulates 3. ILF3/NF90's virus receptor activity, which is also regulated by 4. EIF2AK2/PKR's kinase activity that directly positively regulates ILF3/NF90</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":""},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#representation-of-protein-complex-activities","title":"Representation of Protein Complex Activities","text":"<p>According to the \"How to annotate complexes in GO-CAM\" document, the model correctly follows the practice of representing the individual protein activities when the specific activity-carrying subunits are known. The model doesn't include a complex term but instead shows the individual proteins and their activities, which is appropriate when the specific roles of individual proteins are being modeled.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#causal-associations","title":"Causal Associations","text":"<p>The model uses appropriate causal predicates: - RO:0002629 (directly positively regulates) between HAVCR2 and TRIM47  - RO:0002630 (directly negatively regulates) between TRIM47 and ILF3 - RO:0002629 (directly positively regulates) between EIF2AK2 and ILF3</p> <p>These are appropriate predicates for describing direct regulatory relationships between molecular activities.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#evidence-support","title":"Evidence Support","text":"<p>All molecular functions and causal associations are supported by experimental evidence: - ECO:0000314 (direct assay evidence used in manual assertion) - From PMIDs: 34110282 and 21123651</p> <p>The use of direct experimental evidence is appropriate and well-documented.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#biological-content-review","title":"Biological Content Review","text":"<p>The model is based primarily on findings from two papers:</p> <ol> <li>PMID:34110282 (Dou et al., 2021): \"Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity\"</li> <li>PMID:21123651 (Harashima et al., 2010): \"Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase PKR constitutes a novel mechanism of translational regulation and cellular defense\"</li> </ol> <p>The model accurately represents the key findings from these papers:</p> <ol> <li>TIM-3 (HAVCR2) interacts with and promotes TRIM47 E3 ubiquitin ligase activity</li> <li>TRIM47 ubiquitinates ILF3/NF90 at Lys297, leading to its degradation</li> <li>This degradation inhibits ILF3's antiviral function</li> <li>PKR (EIF2AK2) phosphorylates ILF3/NF90, which activates its antiviral function</li> </ol> <p>The GO-CAM accurately captures the opposing regulatory effects of TIM-3/TRIM47 (negative) versus PKR (positive) on ILF3's function.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#biological-issues","title":"Biological Issues","text":"<ol> <li> <p>Annotation of ILF3 activity: ILF3 is annotated with GO:0001618 (virus receptor activity). This seems questionable as the primary function of ILF3 in the context described is as an antiviral protein that recognizes viral RNAs. The papers describe it as an RNA-binding protein involved in antiviral responses. A more appropriate term might be GO:0003723 (RNA binding) or GO:0003725 (double-stranded RNA binding) since that's its activity that mediates antiviral response.</p> </li> <li> <p>EIF2AK2/PKR occurs_in GO:0005737 (cytoplasm): While this is correctly annotated as per the literature (PKR is primarily cytoplasmic), the model would be more complete if it noted that according to Harashima et al., PKR's phosphorylation of ILF3 causes it to be retained in the cytoplasm where it can bind viral RNAs.</p> </li> </ol>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#technical-aspects","title":"Technical Aspects","text":"<ol> <li> <p>Evidential Support: All activities are supported by appropriate experimental evidence from the literature, which is properly cited.</p> </li> <li> <p>Connectivity: The model shows good connectivity between activities, representing a coherent causal pathway.</p> </li> <li> <p>Enables_by annotations: Each activity is properly annotated with the protein that enables it.</p> </li> </ol>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Re-evaluate the molecular function assigned to ILF3/NF90: Consider changing from \"virus receptor activity\" (GO:0001618) to a more specific function like \"double-stranded RNA binding\" (GO:0003725), which better reflects its antiviral mechanism described in the papers.</p> </li> <li> <p>Add spatial context: Consider adding occurs_in annotations for ILF3, noting that phosphorylated ILF3 is retained in the cytoplasm according to Harashima et al.</p> </li> <li> <p>Consider adding more detailed information about the ubiquitination site: The model could note that TRIM47 specifically targets Lys297 of ILF3 for ubiquitination as mentioned in the Dou et al. paper.</p> </li> <li> <p>Consider expanding the model to include downstream effects: The papers discuss how this pathway affects viral replication and innate immune response, which could be included to make the model more complete.</p> </li> </ol>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:60ad85f700000612) provides a well-structured representation of the regulatory relationship between HAVCR2, TRIM47, ILF3, and EIF2AK2 in the context of antiviral innate immunity. The model follows GO-CAM best practices and is supported by direct experimental evidence from the literature.</p> <p>The main issue is the molecular function assigned to ILF3, which should be reconsidered to better reflect its RNA-binding role in antiviral defense rather than as a virus receptor. With this adjustment and some additional contextual information, the model would provide an even more accurate representation of the biological pathway.</p>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/","title":"60ad85f700001873 epidermal growth factor receptor signaling pathway via spi Egfr  D mel","text":"<p>Based on my review of the GO-CAM model and relevant guidelines, here is my assessment of the \"epidermal growth factor receptor signaling pathway via spi-Egfr (D.mel)\" model (model ID: gomodel:60ad85f700001873):</p>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#model-review","title":"Model Review","text":""},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Pathway Completeness: The model captures the entire EGFR signaling pathway in Drosophila, from the ligand (Spi) through the receptor (Egfr) and downstream signaling cascade involving adaptor proteins (Drk, Shc, Csw), GEF (Sos), G-protein (Ras85D), and the MAPK cascade (Raf \u2192 Dsor1 \u2192 Rl/MAPK), ultimately affecting transcriptional regulation.</p> </li> <li> <p>Proper Causal Relationships: The model appropriately uses RO:0002629 (directly positively regulates) to connect activities in the signaling cascade, following the proper directional flow.</p> </li> <li> <p>Cellular Compartmentalization: Appropriate cellular locations are specified for the different components (e.g., extracellular space for the ligand, plasma membrane for the receptor, cytoplasm/cytosol for adaptor proteins, nucleus for transcription factors).</p> </li> <li> <p>Evidence Base: Each activity and relationship is supported by evidence from the literature with appropriate ECO codes and PMIDs, demonstrating strong literature support.</p> </li> <li> <p>Transcriptional Outcomes: The model includes both activation and repression outcomes of the pathway, showing how MAPK (Rl) regulates transcription factors (Pnt positively, Aop, Cic, and Gro negatively).</p> </li> </ol>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Receptor-Ligand Relationship: According to the signaling receptor guidelines, the causal relation between the ligand activity (Spi) and receptor activity (Egfr) should be \"directly positively regulates.\" This relationship is correctly modeled.</p> </li> <li> <p>Missing Input Relationships: The guidelines indicate that relationships between components should be captured with 'has input' relations, but these don't appear to be explicitly modeled. For example, in the model, adaptor proteins like Drk, Shc, and Csw should have 'has input' relationships to their targets.</p> </li> <li> <p>Complex Representation: The model doesn't explicitly represent any protein complexes. If there are known complexes in this pathway (e.g., receptor-adaptor complexes), these could be added according to the complex annotation guidelines.</p> </li> <li> <p>Model Organization: While the pathway flow is clear, the organization could be improved to make the linear cascade more visually apparent.</p> </li> <li> <p>Missing Components: The model doesn't explicitly include any scaffolding proteins or feedback loops that might be present in the EGFR signaling pathway, if those are known to be important in Drosophila.</p> </li> </ol>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#suggested-improvements","title":"Suggested Improvements:","text":"<ol> <li> <p>Add Input Relationships: Consider adding 'has input' relationships between components where appropriate according to the signaling receptor guidelines.</p> </li> <li> <p>Review Complex Formation: Check the literature to see if any of the interactions involve stable complexes that should be represented according to the complex annotation guidelines.</p> </li> <li> <p>Consider Feedback Loops: EGFR signaling often includes feedback regulation mechanisms; if these are documented in Drosophila, they could be included to provide a more complete picture.</p> </li> <li> <p>Update Annotations: The model has several automated changes noted (2022-2023), suggesting some terms have been updated. Ensure all terms are current.</p> </li> <li> <p>Cross-reference with UniProt: Consider checking the UniProt entries for key proteins to ensure all known functions and interactions are represented.</p> </li> </ol>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a comprehensive representation of the EGFR signaling pathway in Drosophila melanogaster, from ligand binding through transcriptional regulation. The model follows most GO-CAM best practices and is well-supported by evidence. The primary areas for potential improvement relate to explicitly modeling input relationships and considering complex formation. Overall, this is a high-quality model that effectively captures the biology of EGFR signaling in Drosophila.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/","title":"60ad85f700002694  de novo  AMP biosynthetic process  Mouse","text":"<p>Now, I'll review the model in detail:</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#go-cam-model-review-de-novo-amp-biosynthetic-process-mouse","title":"GO-CAM Model Review: \"de novo AMP biosynthetic process (Mouse)\"","text":"<p>Model ID: gomodel:60ad85f700002694</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#general-overview","title":"General Overview","text":"<p>This model represents the 'de novo' AMP biosynthetic process in mouse (taxon: NCBITaxon:10090). It was sourced from gomodel:R-HSA-73817 and is currently in production status.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#structure-analysis","title":"Structure Analysis","text":"<p>The model depicts a linear pathway of the de novo AMP biosynthesis process (GO:0044208) with multiple enzymatic activities connected by causal relations using the \"provides input for\" (RO:0002413) predicate. The pathway flows through the following activities in sequence:</p> <ol> <li>Ppat (MGI:MGI:2387203) - amidophosphoribosyltransferase activity (GO:0004044)</li> <li>Gart (MGI:MGI:95654) with multiple functions:</li> <li>phosphoribosylamine-glycine ligase activity (GO:0004637)</li> <li>phosphoribosylglycinamide formyltransferase activity (GO:0004644)</li> <li>phosphoribosylformylglycinamidine cyclo-ligase activity (GO:0004641)</li> <li>Pfas (MGI:MGI:2684864) - phosphoribosylformylglycinamidine synthase activity (GO:0004642)</li> <li>Paics (MGI:MGI:1914304) with two functions:</li> <li>phosphoribosylaminoimidazole carboxylase activity (GO:0004638)</li> <li>phosphoribosylaminoimidazolesuccinocarboxamide synthase activity (GO:0004639)</li> <li>Adsl (MGI:MGI:103202) with two functions:</li> <li>(S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido) succinate lyase activity (GO:0070626)</li> <li>N6-(1,2-dicarboxyethyl)AMP AMP-lyase activity (GO:0004018)</li> <li>Atic (MGI:MGI:1351352) with two functions:</li> <li>phosphoribosylaminoimidazolecarboxamide formyltransferase activity (GO:0004643)</li> <li>IMP cyclohydrolase activity (GO:0003937)</li> <li>Adss2 (MGI:MGI:87948) - adenylosuccinate synthase activity (GO:0004019)</li> </ol>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<ul> <li>The model uses various evidence codes, predominantly:</li> <li>ECO:0000266 (sequence orthology evidence)</li> <li>ECO:0000314 (direct assay evidence)</li> <li>ECO:0000315 (mutant phenotype evidence)</li> <li>The evidence is supported by appropriate references to scientific literature (PMIDs)</li> <li>There are appropriate \"with\" references to UniProtKB entries for orthology evidence</li> </ul>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#cellular-location","title":"Cellular Location","text":"<ul> <li>Some activities (those of Gart protein) are annotated as occurring in the cytosol (GO:0005829)</li> <li>Other activities lack cellular location annotation</li> </ul>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model clearly represents the sequential nature of the AMP biosynthetic pathway</li> <li>Each activity is appropriately connected to the biological process (GO:0044208)</li> <li>Appropriate molecular function terms are used for each enzyme</li> <li>Evidence is well documented with appropriate references</li> </ol>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#improvement-opportunities","title":"Improvement Opportunities","text":"<ol> <li> <p>Cellular location annotation: Only Gart activities have cellular location (GO:0005829). For consistency and completeness, all activities should have cellular location annotations.</p> </li> <li> <p>Causal chain completion: The final activity (Adss2 with GO:0004018) doesn't have any outgoing causal associations. This makes the pathway appear incomplete.</p> </li> <li> <p>GART multifunctionality representation: The Gart protein (MGI:MGI:95654) is represented with three separate activities. According to the complexes document, if these are activities of a single protein, they should be properly linked to show how they relate to each other within the pathway.</p> </li> <li> <p>Evidence consistency: While most activities have multiple evidence entries, some (like GO:0004018) have fewer. Strengthening the evidence base for these activities would improve the model.</p> </li> <li> <p>Missing substrates and products: The model focuses on the enzymatic activities but doesn't explicitly represent the small molecule substrates and products of each reaction, which would make the model more informative.</p> </li> </ol>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The represented pathway follows the established steps of de novo AMP biosynthesis, with the appropriate enzymes and activities. The evidence provided supports the biological accuracy of the model.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good representation of the de novo AMP biosynthetic process in mouse with a clear sequential pathway of enzymatic activities. The main recommendations for improvement are to complete the cellular location annotations for all activities, ensure the causal chain is complete through to the final product, and consider adding the molecular substrates and products to make the model more informative about the actual biochemical transformations occurring in the pathway.</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/","title":"60ad85f700002947  de novo  IMP biosynthetic process  Mouse","text":"<p>Now let me review the GO-CAM model for 'de novo' IMP biosynthetic process (Mouse) with ID gomodel:60ad85f700002947 based on all the information I've gathered.</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#go-cam-model-review-de-novo-imp-biosynthetic-process-mouse","title":"GO-CAM Model Review: 'de novo' IMP biosynthetic process (Mouse)","text":""},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#model-summary","title":"Model Summary","text":"<ul> <li>Model ID: gomodel:60ad85f700002947</li> <li>Title: 'de novo' IMP biosynthetic process (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Sourced from: gomodel:R-HSA-73817</li> </ul>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#review-of-biological-content","title":"Review of Biological Content","text":"<p>This GO-CAM model represents the 'de novo' IMP (inosine monophosphate) biosynthetic process in mouse. The model depicts the pathway for purine biosynthesis, specifically focusing on the enzymatic steps leading to IMP production.</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#pathway-representation","title":"Pathway Representation","text":"<p>The model correctly captures the sequence of enzymatic reactions in the 'de novo' IMP biosynthetic pathway. Each enzyme is properly annotated with its molecular function and is shown to participate in the GO:0006189 ('de novo' IMP biosynthetic process). The causal connections between activities use the appropriate predicate \"RO:0002413\" (provides input for), showing the sequential nature of the pathway.</p> <p>The pathway includes the following key enzymes: 1. Ppat (amidophosphoribosyltransferase activity) 2. Gart (phosphoribosylamine-glycine ligase, phosphoribosylglycinamide formyltransferase, and phosphoribosylformylglycinamidine cyclo-ligase activities) 3. Pfas (phosphoribosylformylglycinamidine synthase activity) 4. Paics (phosphoribosylaminoimidazolesuccinocarboxamide synthase activity) 5. Adsl (adenylosuccinate lyase activity) 6. Atic (phosphoribosylaminoimidazolecarboxamide formyltransferase and IMP cyclohydrolase activities)</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#evidence-quality","title":"Evidence Quality","text":"<p>The model uses appropriate evidence codes for the assertions: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000266 (sequence orthology evidence used in manual assertion)</p> <p>All assertions are supported by literature references, primarily from the following publications: - PMID:6480832 - Studies on adenylosuccinate lyase and muscle function - PMID:26588576 - Referenced for orthology-based assertions - PMID:26144885 - Evidence for ATIC function - PMID:6327016 - Evidence for amidophosphoribosyltransferase - PMID:8299947 - Evidence for GART activity - PMID:27590927 - Evidence for PFAS and PAICS functions - PMID:2183217 - Evidence for GART function</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#molecular-functions-and-biological-process","title":"Molecular Functions and Biological Process","text":"<p>All entities in the model are correctly annotated with appropriate molecular function terms: - GO:0004044 - amidophosphoribosyltransferase activity - GO:0004637 - phosphoribosylamine-glycine ligase activity - GO:0004644 - phosphoribosylglycinamide formyltransferase activity - GO:0004641 - phosphoribosylformylglycinamidine cyclo-ligase activity - GO:0004642 - phosphoribosylformylglycinamidine synthase activity - GO:0004639 - phosphoribosylaminoimidazolesuccinocarboxamide synthase activity - GO:0070626 - (S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido) succinate lyase (fumarate-forming) activity - GO:0004643 - phosphoribosylaminoimidazolecarboxamide formyltransferase activity - GO:0003937 - IMP cyclohydrolase activity</p> <p>All activities are properly connected to the biological process GO:0006189 ('de novo' IMP biosynthetic process).</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#technical-quality-assessment","title":"Technical Quality Assessment","text":""},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#model-structure","title":"Model Structure","text":"<ol> <li> <p>Activity Flow: The model correctly represents the sequential flow of enzymatic activities with appropriate causal connections using \"RO:0002413\" (provides input for).</p> </li> <li> <p>Cellular Location: Two of the enzymes (Gart activities) are correctly annotated with the cellular location GO:0005829 (cytosol), which is consistent with what is known about this pathway.</p> </li> <li> <p>Gene Products: The model uses the correct MGI IDs for the mouse gene products:</p> </li> <li>MGI:MGI:2387203 (Ppat)</li> <li>MGI:MGI:95654 (Gart)</li> <li>MGI:MGI:2684864 (Pfas)</li> <li>MGI:MGI:1914304 (Paics)</li> <li>MGI:MGI:103202 (Adsl)</li> <li> <p>MGI:MGI:1351352 (Atic)</p> </li> <li> <p>Bifunctional Enzymes: The model correctly represents bifunctional enzymes. Particularly noteworthy is the representation of Atic, which has two distinct molecular functions (phosphoribosylaminoimidazolecarboxamide formyltransferase and IMP cyclohydrolase activities) that catalyze the last two steps of the pathway.</p> </li> <li> <p>Causal Relationships: All causal relationships between activities are properly represented with the appropriate predicate \"RO:0002413\" (provides input for).</p> </li> </ol>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li>Using appropriate molecular function terms for each enzyme</li> <li>Connecting all molecular functions to the relevant biological process</li> <li>Using appropriate evidence codes and citations</li> <li>Properly representing spatial information where known (cytosol location)</li> <li>Correctly handling multi-functional enzymes</li> </ol>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is already of high quality, there are a few minor suggestions for potential improvement:</p> <ol> <li> <p>Additional Cellular Locations: Consider annotating all enzymes with their subcellular locations if this information is available.</p> </li> <li> <p>Chemical Entities: The model could be enhanced by including the chemical entities (substrates and products) for each reaction step, which would make the pathway more understandable to users.</p> </li> <li> <p>Regulation Information: If known, regulatory information about how this pathway is controlled could be added using appropriate causal predicates like \"RO:0002629\" (directly positively regulates) or \"RO:0002630\" (directly negatively regulates).</p> </li> </ol>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60ad85f700002947 accurately represents the 'de novo' IMP biosynthetic process in mouse. The model correctly depicts the sequential enzymatic steps in this pathway, with appropriate molecular functions, biological process annotations, and causal connections. The evidence provided supports the assertions in the model, and the model complies with GO-CAM best practices. The model is clear, scientifically accurate, and provides a useful representation of this important metabolic pathway.</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/","title":"60ad85f700003015  de novo  GMP biosynthetic process  Mouse","text":"<p>Based on my review of GO-CAM model 60ad85f700003015 \"'de novo' GMP biosynthetic process (Mouse)\", I can provide the following assessment:</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#go-cam-model-review-de-novo-gmp-biosynthetic-process-mouse","title":"GO-CAM Model Review: 'de novo' GMP biosynthetic process (Mouse)","text":""},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#gomodel60ad85f700003015","title":"gomodel:60ad85f700003015","text":""},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the 'de novo' GMP biosynthetic process in mouse (NCBITaxon:10090). It's a comprehensive pathway model that depicts the sequential enzymatic steps involved in GMP biosynthesis from the beginning of purine synthesis.</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive pathway representation: The model successfully captures the multi-step process of de novo GMP biosynthesis, including all key enzymatic steps from the beginning of purine synthesis through to the final GMP production.</p> </li> <li> <p>Causal connections: The model correctly uses the \"provides input for\" (RO:0002413) predicate to show the sequential flow of enzymatic reactions through the pathway.</p> </li> <li> <p>Evidence quality: Each activity in the model is supported by appropriate evidence codes and literature references (PMIDs), providing solid support for the annotations.</p> </li> <li> <p>Cellular location: Some activities appropriately specify cellular location (e.g., cytosol/GO:0005829), which enhances the biological accuracy of the model.</p> </li> <li> <p>Species specificity: The model is properly specified for mouse with mouse gene identifiers (MGI IDs).</p> </li> </ol>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Input/output molecules: While the causal flow of activities is well represented, the model would benefit from explicitly stating the input and output molecules for each activity. This would make the model more informative for users who may not be familiar with these enzymatic activities.</p> </li> <li> <p>Visualization organization: The pathway flow would be easier to follow if the activities were organized in a linear or branched representation that visually matches the pathway's biological progression.</p> </li> <li> <p>Complex representation: For any steps where the enzymatic activity is carried out by protein complexes, the model should follow GO-CAM best practices for representing complexes. The current model doesn't indicate whether any of these activities involve complexes.</p> </li> <li> <p>Regulatory information: The model could be enhanced by including regulatory information about how this pathway is controlled (e.g., feedback inhibition by end products).</p> </li> </ol>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the de novo GMP biosynthetic pathway: - It begins with amidophosphoribosyltransferase (GO:0004044) by PPAT (MGI:MGI:2387203) - Proceeds through phosphoribosylamine-glycine ligase (GO:0004637) by GART (MGI:MGI:95654) - Includes key steps like phosphoribosylglycinamide formyltransferase (GO:0004644), phosphoribosylformylglycinamidine synthase (GO:0004642), and others - Shows the branching to GMP synthesis via IMP dehydrogenase activity (GO:0003938) and GMP synthase activity (GO:0003922)</p> <p>The evidence cited from the literature supports these activities and their connections.</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This appears to be a well-constructed GO-CAM model that accurately represents the de novo GMP biosynthetic process in mouse. The model is supported by appropriate evidence and follows the GO-CAM modeling guidelines. The suggested improvements would make the model more informative and easier to interpret, but the basic biological content and relationships are sound.</p> <p>The model would be valuable for researchers studying purine biosynthesis in mouse models and could serve as a reference for understanding how this fundamental metabolic pathway is organized.</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/","title":"60ad85f700003288  de novo  UMP biosynthetic process  Mouse","text":"<p>Let me review the specific GO-CAM model 60ad85f700003288. Based on the model information I've retrieved, this GO-CAM represents the \"'de novo' UMP biosynthetic process\" in mouse (NCBITaxon:10090). The model describes several molecular functions carried out by different proteins that are part of this biosynthetic pathway.</p> <p>Here's my review of the model:</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#go-cam-model-review-gomodel60ad85f700003288","title":"GO-CAM Model Review: gomodel:60ad85f700003288","text":""},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#basic-information","title":"Basic Information","text":"<ul> <li>Title: \"'de novo' UMP biosynthetic process (Mouse)\"</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> <li>Comments: Sourced from gomodel:R-HSA-500753</li> </ul>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#pathway-overview","title":"Pathway Overview","text":"<p>This model represents the de novo UMP biosynthetic pathway in mouse, where several enzymes catalyze sequential reactions leading to UMP synthesis.</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#model-structure","title":"Model Structure","text":"<p>The model includes three key proteins: 1. MGI:MGI:1916969 (Cad) - multifunctional protein with three activities:    - Carbamoyl-phosphate synthase (GO:0004088)    - Aspartate carbamoyltransferase (GO:0004070)    - Dihydroorotase (GO:0004151)</p> <ol> <li>MGI:MGI:1928378 (Dhodh) - with activity:</li> <li> <p>Dihydroorotate dehydrogenase (GO:0004152)</p> </li> <li> <p>MGI:MGI:1298388 (Umps) - with two activities:</p> </li> <li>Orotate phosphoribosyltransferase (GO:0004588)</li> <li>Orotidine-5'-phosphate decarboxylase (GO:0004590)</li> </ol>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#pathway-flow","title":"Pathway Flow","text":"<p>The causal flow in the model is: 1. Cad carbamoyl-phosphate synthase \u2192 Cad aspartate carbamoyltransferase \u2192 Cad dihydroorotase \u2192 Dhodh dihydroorotate dehydrogenase \u2192 Umps orotate phosphoribosyltransferase \u2192 Umps orotidine-5'-phosphate decarboxylase</p> <p>All causal connections use the predicate RO:0002413 \"provides input for\", which correctly represents the sequential enzymatic reactions in a biosynthetic pathway.</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#evidence","title":"Evidence","text":"<p>The model includes appropriate evidence for each assertion: - Evidence from direct assays (ECO:0000314)  - Mutant phenotype evidence (ECO:0000315) - Sequence orthology evidence (ECO:0000266)</p> <p>Each assertion is backed by PMIDs, indicating proper literature support.</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly represents the known enzymatic activities in the de novo UMP biosynthetic pathway</li> <li>The causal connections accurately reflect the flow of intermediates in the pathway</li> <li>All activities are appropriately linked to the overall process (GO:0044205)</li> <li>The model uses appropriate evidence codes with literature references</li> <li>The use of multifunctional proteins (Cad, Umps) accurately reflects the biology</li> </ol>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#potential-issues","title":"Potential Issues","text":"<ol> <li>There's a \"part_of\" relationship from GO:0004151 to GO:0004152 in one of the activities which seems incorrect - dihydroorotase activity shouldn't be part of dihydroorotate dehydrogenase activity as these are distinct enzymatic functions</li> <li>There's a BFO:0000050 causal association which is inconsistent with the rest of the causal associations that use RO:0002413 - this should be standardized</li> <li>One evidence reference has a space before the PMID (\" PMID:6154574\"), which should be fixed</li> </ol>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model provides a good representation of the UMP biosynthetic pathway in mouse with appropriate proteins, activities, and causal connections. The few minor issues identified should be addressed for complete consistency, but they don't detract from the biological accuracy of the model.</p> <p>The model is parsimonious, focused on the essential activities of the pathway, and maintains a clear linear flow that is easily interpretable. The evidence citations are appropriate and support the assertions made in the model.</p>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/","title":"60d5209a00000233 tumor necrosis factor mediated signaling pathway via grnd egr  D mel","text":"<p>Based on my review of the GO-CAM model gomodel:60d5209a00000233 and the relevant best practice documents, I'll now provide a comprehensive evaluation of this model.</p>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#go-cam-model-review-gomodel60d5209a00000233","title":"GO-CAM Model Review: gomodel:60d5209a00000233","text":""},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#model-overview","title":"Model Overview","text":"<p>Title: tumor necrosis factor-mediated signaling pathway via grnd-egr (D.mel) Taxon: NCBITaxon:7227 (Drosophila melanogaster) Status: production</p> <p>This model represents the tumor necrosis factor (TNF) signaling pathway in Drosophila melanogaster, specifically the signaling cascade involving the TNF ligand Eiger (Egr) and the TNF receptor Grindelwald (Grnd).</p>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Clear Signaling Pathway Representation: The model clearly depicts the TNF signaling pathway, starting with the ligand Egr (FB:FBgn0033483), through the receptor Grnd (FB:FBgn0032682), and downstream to the JNK signaling cascade.</p> </li> <li> <p>Appropriate Molecular Functions: Each gene product is annotated with appropriate molecular functions that align with their known biological roles:</p> </li> <li>Egr with receptor ligand activity (GO:0048018)</li> <li>Grnd with TNF receptor activity (GO:0005031)</li> <li>Traf6 with TNF receptor binding (GO:0032813)</li> <li> <p>Downstream kinases with appropriate kinase activities</p> </li> <li> <p>Proper Cellular Locations: The model includes appropriate cellular component annotations:</p> </li> <li>Egr in extracellular space (GO:0005615)</li> <li>Grnd in plasma membrane (GO:0005886)</li> <li> <p>Cytoplasmic components in cytoplasm/cytosol (GO:0005737/GO:0005829)</p> </li> <li> <p>Consistent Causal Relationships: The causal connections use \"directly positively regulates\" (RO:0002629) appropriately to show the flow of signal transduction.</p> </li> <li> <p>Evidence Support: All associations have evidence codes with appropriate references.</p> </li> </ol>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Input Relationship for Grnd: According to the \"Signaling receptor activity annotation guidelines\", the input (target) of a receptor should be the effector protein it regulates, not its ligand. In this model, there is no explicit \"has input\" relationship between Grnd and its downstream effector.</p> </li> <li> <p>Missing Complex Information: If any of the components function as part of complexes, this should be indicated in the model. The JNK pathway often involves multiprotein complexes, but these are not explicitly represented.</p> </li> <li> <p>Veli PDZ-domain Interaction: Based on the provided literature (Andersen et al., 2015), Grnd interacts with Veli (Lin-7) through its PDZ domain. This interaction is important for coupling Crb activity with JNK signaling, but it's not represented in the model.</p> </li> <li> <p>Additional Pathway Context: The model focuses on the core TNF-JNK pathway but could be enhanced by including the connection to cell polarity determinants like Crumbs (Crb), which was highlighted in the Andersen et al. paper as an important context for Grnd function.</p> </li> </ol>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#technical-evaluation","title":"Technical Evaluation","text":"<ol> <li> <p>Predicate Usage: The model correctly uses RO:0002629 (directly positively regulates) for causal associations between pathway components, which is appropriate for direct signal transduction.</p> </li> <li> <p>Part_of Relations: All activities are appropriately indicated as part_of the TNF-mediated signaling pathway (GO:0033209).</p> </li> <li> <p>Evidence Consistency: The model uses a mix of evidence types (ECO:0000304, ECO:0000314, ECO:0000315, etc.) with appropriate references, showing good evidence diversity.</p> </li> </ol>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately captures the core TNF signaling pathway in Drosophila as described in the literature:</p> <ol> <li> <p>Egr-Grnd Interaction: The model correctly shows Egr as the TNF ligand that activates the Grnd receptor, consistent with the findings in Andersen et al. (2015).</p> </li> <li> <p>JNK Cascade: The model appropriately represents the downstream JNK kinase cascade (msn \u2192 Tak1 \u2192 hep \u2192 bsk), which is a well-established pathway activated by TNF receptors.</p> </li> <li> <p>Adapter Proteins: The inclusion of Tab2 and Traf6 as adapter proteins in the signal transduction cascade is consistent with their known roles in the TNF pathway.</p> </li> </ol>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model provides a clear and accurate representation of the Drosophila TNF-mediated signaling pathway via the Egr-Grnd axis. The model follows most GO-CAM best practices and captures the essential components of the pathway with appropriate molecular functions, cellular locations, and causal relationships.</p>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add \"has input\" relationships: For the Grnd receptor, explicitly indicate its input relationship with its downstream effector (likely Traf6).</p> </li> <li> <p>Add Crb-Grnd connection: Consider expanding the model to include the relationship between Grnd and the cell polarity determinant Crumbs, as this is an important context for Grnd function described in the literature.</p> </li> <li> <p>Include Veli interaction: Add the interaction between Grnd and Veli, which is important for coupling Crb activity with JNK signaling.</p> </li> <li> <p>Consider complex annotations: If any components function as part of complexes, explicitly represent these using the appropriate complex annotation guidelines.</p> </li> <li> <p>Add biological outcomes: Consider extending the model to include the biological outcomes of pathway activation (e.g., apoptosis, cell migration, or growth) to provide a more complete picture of the pathway's function.</p> </li> </ol> <p>In conclusion, gomodel:60d5209a00000233 is a high-quality GO-CAM model that accurately represents the TNF signaling pathway in Drosophila, with a few opportunities for enhancement to provide additional biological context and conform more fully to GO-CAM annotation guidelines.</p>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/","title":"60d5209a00000521 torso signaling pathway  D mel","text":"<p>Now I'll review the GO-CAM model in detail based on the guidelines I've consulted.</p>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#go-cam-model-review-gomodel60d5209a00000521-torso-signaling-pathway-dmel","title":"GO-CAM Model Review: gomodel:60d5209a00000521 \"torso signaling pathway (D.mel)\"","text":""},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the torso signaling pathway in Drosophila melanogaster (fruit fly). The model shows a signaling cascade initiated by ligands, receptor activation, and downstream signaling events leading to transcriptional regulation.</p>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures multiple components of the torso signaling pathway, from extracellular ligands to nuclear transcription factors.</p> </li> <li> <p>Appropriate predicate usage: The model correctly uses RO:0002629 (directly positively regulates) to connect activities in the cascade.</p> </li> <li> <p>Cellular location annotations: Most activities have appropriate cellular component annotations (e.g., extracellular space for ligands, plasma membrane for receptors).</p> </li> <li> <p>Evidence codes and references: Most activities include evidence codes and PMIDs supporting the annotations.</p> </li> <li> <p>Standard signaling pathway structure: The model follows the canonical structure for RTK signaling pathways from ligand \u2192 receptor \u2192 adaptor \u2192 GEF \u2192 small G protein \u2192 kinase cascade \u2192 nuclear targets.</p> </li> </ol>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Unknown molecular functions: Several activities (enabled by FB:FBgn0003867, FB:FBgn0261016, FB:FBgn0005390, FB:FBgn0004650) have molecular function GO:0003674 (\"molecular_function\"), indicating unknown functions. This is not ideal for a production model.</li> <li> <p>Recommendation: If possible, update these with more specific molecular functions based on literature.</p> </li> <li> <p>Incomplete documentation of ligand-receptor interaction: The model shows several putative ligands (tsl, clos, fs1M3, fs1N) acting on the receptor tor, but the mechanism of activation is unclear.</p> </li> <li> <p>Recommendation: Based on the signaling receptor guidelines, clarify if these are direct ligands or cofactors for receptor activation.</p> </li> <li> <p>Multiple redundant causal associations: There are some duplicate causal relations, for example:    <pre><code>rl (FB:FBgn0003256) --RO:0002630--&gt; gro (FB:FBgn0001139)\n</code></pre>    appears twice with the same evidence.</p> </li> <li> <p>Recommendation: Remove duplicate causal associations.</p> </li> <li> <p>Incomplete transcription factor connections: The transcription repressor activity of cic (FB:FBgn0262582) is shown to be regulated by rl (FB:FBgn0003256), but its downstream targets are not specified.</p> </li> <li> <p>Recommendation: According to the DNA-binding transcription factor guidelines, each transcription factor should indicate its target gene(s) with \"has input\" relations.</p> </li> <li> <p>Potential missing complex representation: If any of the activities involve protein complexes, these should be represented according to the complex annotation guidelines.</p> </li> <li>Recommendation: Review literature to determine if any complexes should be explicitly modeled.</li> </ol>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model correctly represents the Torso RTK signaling pathway in Drosophila, showing the canonical activation sequence: 1. Extracellular ligands (trk and others) \u2192  2. Receptor (tor) \u2192 3. Adaptor proteins (Shc, csw, drk) \u2192  4. GEF (Sos) \u2192  5. Small G protein (Ras85D) \u2192  6. MAPK cascade (Raf \u2192 Dsor1 \u2192 rl) \u2192  7. Transcriptional regulators (cic, gro)</p> <p>This is consistent with known RTK signaling mechanisms and specifically the torso pathway in Drosophila development.</p>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#summary","title":"Summary","text":"<p>The GO-CAM model effectively represents the torso signaling pathway in Drosophila melanogaster. While generally well-constructed and biologically accurate, the model could be improved by:</p> <ol> <li>Specifying molecular functions for the activities currently annotated with the generic \"molecular_function\" term</li> <li>Clarifying the precise mechanism of receptor activation by the putative ligands</li> <li>Removing duplicate causal relations</li> <li>Completing the transcription factor target annotations</li> <li>Explicitly modeling any relevant protein complexes</li> </ol> <p>Overall, this is a good production model that provides useful information about the torso signaling pathway, though with some areas for potential refinement.</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/","title":"60d5209a00001406  de novo  XMP biosynthetic process  Mouse","text":"<p>Now, let's review the GO-CAM model \"gomodel:60d5209a00001406\" titled \"'de novo' XMP biosynthetic process (Mouse)\". This is a production-status model for the mouse (NCBITaxon:10090).</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM represents the 'de novo' XMP biosynthetic process in mouse, detailing the enzymatic activities and molecular functions involved in this pathway. The model was sourced from gomodel:R-HSA-73817 and was created/contributed by ORCID:0000-0001-7476-6306 on July 7, 2021.</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#pathway-structure-and-connectivity","title":"Pathway Structure and Connectivity","text":"<p>The model accurately represents the 'de novo' XMP biosynthetic pathway with: - 11 distinct activities representing different enzymatic steps - All activities are properly connected via causal associations using the appropriate \"RO:0002413\" predicate (provides input for) - The activities form a coherent, linear pathway where each enzymatic step feeds into the next</p> <p>The pathway flow appears to be: 1. PPAT (amidophosphoribosyltransferase) \u2192  2. GART (phosphoribosylamine-glycine ligase) \u2192  3. GART (phosphoribosylglycinamide formyltransferase) \u2192  4. PFAS (phosphoribosylformylglycinamidine synthase) \u2192  5. GART (phosphoribosylformylglycinamidine cyclo-ligase) \u2192  6. PAICS (phosphoribosylaminoimidazole carboxylase) \u2192  7. PAICS (phosphoribosylaminoimidazolesuccinocarboxamide synthase) \u2192  8. ADSL ((S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido) succinate lyase) \u2192  9. ATIC (phosphoribosylaminoimidazolecarboxamide formyltransferase) \u2192  10. ATIC (IMP cyclohydrolase) \u2192  11. IMPDH1/IMPDH2 (IMP dehydrogenase)</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model includes appropriate evidence codes with references: - ECO:0000314 (direct assay evidence) - ECO:0000315 (mutant phenotype evidence) - ECO:0000266 (sequence orthology evidence)</p> <p>Each activity is supported by at least one reference, primarily from peer-reviewed publications (PMIDs).</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The activities are properly placed in the context of the biological process \"GO:0097294\" ('de novo' XMP biosynthetic process)</li> <li>Appropriate molecular functions are assigned to each gene product</li> <li>The causal connections between activities form a coherent pathway</li> <li>Subcellular localization (cytosol) is specified where relevant</li> <li>Multi-functional proteins (like GART with three distinct activities) are properly represented</li> </ol>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#conformance-to-go-cam-best-practices","title":"Conformance to GO-CAM Best Practices","text":"<p>The model appears to follow GO-CAM best practices: - Each activity is properly enabled by a specific gene product - The correct causal relationship predicate (RO:0002413 \"provides input for\") is used throughout - Each connection has appropriate evidence - The activities accurately represent the known enzymatic steps in this pathway</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#potential-issues-and-recommendations","title":"Potential Issues and Recommendations","text":"<p>I did not identify any significant issues with the model. It represents a well-characterized metabolic pathway and adheres to GO-CAM best practices. The pathway is complete from the initial steps through to XMP production.</p> <p>For additional thoroughness, the curator might consider: 1. Checking if any newer literature has emerged since 2021 that might further validate or refine this pathway 2. Ensuring that all relevant cellular compartments are correctly specified for each activity (currently only cytosol is mentioned for some activities)</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a high-quality GO-CAM model that accurately represents the 'de novo' XMP biosynthetic process in mouse. The activities are properly connected, each with appropriate evidence, and the model provides a clear illustration of this metabolic pathway. No significant revisions appear necessary.</p> <p>You can view this model at: https://bioregistry.io/go.model:60d5209a00001406</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/","title":"60e7989d00000165 dTMP biosynthetic process1A  Mouse","text":"<p>Now I'll review the model based on the information gathered. Let me analyze whether it follows best practices and if the biological content is consistent with literature.</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#go-cam-model-review-dtmp-biosynthetic-process-gomodel60e7989d00000165","title":"GO-CAM Model Review: dTMP Biosynthetic Process (gomodel:60e7989d00000165)","text":""},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the dTMP (deoxythymidine monophosphate) biosynthetic process in mouse (Mus musculus). The model describes a pathway essential for DNA synthesis, showing how various enzymes function together to produce dTMP, a critical nucleotide precursor.</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#model-structure-and-connectivity","title":"Model Structure and Connectivity","text":"<p>The model contains 9 activities connected by causal relationships using the \"provides input for\" (RO:0002413) predicate, creating a coherent pathway flow. The model shows:</p> <ol> <li>The ribonucleoside-diphosphate reductase complex (GO:0005971) initiates the pathway by converting UDP to dUDP</li> <li>Multiple nucleoside diphosphate kinase activities (Nme1, Nme2, Nme3) convert dUDP to dUTP</li> <li>dUTP diphosphatase (Dut) converts dUTP to dUMP</li> <li>Thymidylate synthase (Tyms) converts dUMP to dTMP</li> <li>Two parallel paths involving serine hydroxymethyltransferase activities (Shmt1, Shmt2) and dihydrofolate reductase (Dhfr) support the thymidylate synthase reaction</li> </ol>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Compartmentalization accuracy: The model correctly places the activities in the nucleus, which is consistent with the literature (PMID:19513116) that demonstrates nuclear de novo thymidylate biosynthesis.</p> </li> <li> <p>Species specificity: The model properly uses mouse-specific gene products (MGI identifiers) and reflects mouse biology.</p> </li> <li> <p>Evidence quality: The model incorporates appropriate evidence codes and literature references supporting each assertion.</p> </li> <li> <p>Pathway completeness: The model captures all key steps in the dTMP biosynthetic pathway.</p> </li> <li> <p>Redundancy representation: The model correctly represents the functional redundancy between Shmt1 and Shmt2 in nuclear folate metabolism, as demonstrated in the literature.</p> </li> </ol>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex representation: The ribonucleoside-diphosphate reductase complex (GO:0005971) is represented without specifying its members. According to the GO-CAM best practices for annotating complexes, if the subunits carrying specific activities are known, they should be individually represented.</p> </li> <li> <p>Missing SUMO modification details: The literature (PMID:19513116) emphasizes that SHMT1, DHFR, and TYMS undergo SUMOylation for nuclear localization during S and G2/M phases. This post-translational modification, which is important for nuclear localization, is not captured in the model.</p> </li> <li> <p>Missing cell cycle context: The literature indicates that the nuclear localization of these enzymes is cell cycle-dependent (occurring during S and G2/M phases), which is not represented in the model.</p> </li> <li> <p>Molecular details: Some intermediate molecular steps in folate metabolism could be more explicitly modeled to show how one-carbon units from serine are utilized for thymidylate biosynthesis.</p> </li> </ol>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is well-supported by the literature evidence provided:</p> <ul> <li>PMID:19513116 provides strong experimental evidence for nuclear thymidylate biosynthesis and the roles of SHMT1 and SHMT2 in this process</li> <li>The molecular functions assigned to each protein are consistent with their known activities</li> <li>The subcellular localization of activities in the nucleus is correct and experimentally validated</li> </ul> <p>The model correctly captures the finding that both SHMT1 and SHMT2 (specifically SHMT2alpha) contribute to nuclear de novo thymidylate biosynthesis, with SHMT2alpha providing redundancy that may account for the viability of Shmt1-/- mice.</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#recommendation","title":"Recommendation","text":"<p>This model is scientifically accurate and follows most GO-CAM best practices. I recommend accepting the model with minor suggested improvements:</p> <ol> <li>Consider specifying the members of the ribonucleoside-diphosphate reductase complex (GO:0005971) if known</li> <li>Add context about the cell cycle-dependence of this pathway</li> <li>Consider representing the SUMOylation of SHMT1, DHFR, and TYMS as this post-translational modification is critical for their nuclear localization</li> </ol> <p>Overall, this is a high-quality GO-CAM model that effectively represents the current understanding of the dTMP biosynthetic process in mice.</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/","title":"60e7989d00000281 UDP biosynthetic process  Mouse","text":"<p>Now I'll review the model based on all the information I've gathered.</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#review-of-go-cam-model-gomodel60e7989d00000281","title":"Review of GO-CAM Model gomodel:60e7989d00000281","text":""},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#overview-summary","title":"Overview Summary","text":"<p>This GO-CAM model (ID: gomodel:60e7989d00000281) titled \"UDP biosynthetic process (Mouse)\" represents the pathway for UDP biosynthesis in mouse (NCBITaxon:10090). The model includes 7 molecular activities that are part of the UDP biosynthetic process (GO:0006225), with clear causal relationships between them.</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#pathway-components-and-structure","title":"Pathway Components and Structure","text":"<p>The model captures the following key enzymatic activities:</p> <ol> <li>Dihydroorotate dehydrogenase activity (GO:0004152)</li> <li>Enabled by Dhodh (MGI:MGI:1928378)</li> <li>Part of UDP biosynthetic process (GO:0006225)</li> <li> <p>Provides input for orotate phosphoribosyltransferase activity</p> </li> <li> <p>Orotate phosphoribosyltransferase activity (GO:0004588)</p> </li> <li>Enabled by Umps (MGI:MGI:1298388)</li> <li>Part of UDP biosynthetic process (GO:0006225)</li> <li> <p>Provides input for orotidine-5'-phosphate decarboxylase activity</p> </li> <li> <p>Orotidine-5'-phosphate decarboxylase activity (GO:0004590)</p> </li> <li>Enabled by Umps (MGI:MGI:1298388)</li> <li>Part of UDP biosynthetic process (GO:0006225)</li> <li> <p>Provides input for UMP kinase activity</p> </li> <li> <p>UMP kinase activity (GO:0033862)</p> </li> <li>Enabled by Cmpk1 (MGI:MGI:1913838)</li> <li> <p>Part of UDP biosynthetic process (GO:0006225)</p> </li> <li> <p>Dihydroorotase activity (GO:0004151)</p> </li> <li>Enabled by Cad (MGI:MGI:1916969)</li> <li>Part of UDP biosynthetic process (GO:0006225)</li> <li> <p>Provides input for dihydroorotate dehydrogenase activity</p> </li> <li> <p>Aspartate carbamoyltransferase activity (GO:0004070)</p> </li> <li>Enabled by Cad (MGI:MGI:1916969)</li> <li>Part of UDP biosynthetic process (GO:0006225)</li> <li> <p>Provides input for dihydroorotase activity</p> </li> <li> <p>Carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity (GO:0004088)</p> </li> <li>Enabled by Cad (MGI:MGI:1916969)</li> <li>Part of UDP biosynthetic process (GO:0006225)</li> <li>Provides input for aspartate carbamoyltransferase activity</li> </ol>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model has strong evidential support with: - Multiple evidence types (ECO:0000315 - mutant phenotype evidence, ECO:0000314 - direct assay evidence, ECO:0000266 - sequence orthology evidence) - References to published literature (including PMID:6249586, PMID:20413687, PMID:965379, PMID:30449682, etc.) - Consistent contributor documentation (ORCID:0000-0001-7476-6306) - Appropriate dating of evidence (2021-07-13)</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#evaluation-of-pathway-completeness-and-biological-accuracy","title":"Evaluation of Pathway Completeness and Biological Accuracy","text":"<p>Based on the literature and database information reviewed:</p> <ol> <li>The pathway correctly captures the core enzymes involved in UDP biosynthesis</li> <li>The pathway flow is biologically accurate, starting with carbamoyl-phosphate synthesis and proceeding through the expected enzymatic steps to UDP production</li> <li>The causal connections (RO:0002413 \"provides input for\") are appropriate for representing the substrate-product relationships between these enzymes</li> <li>The model properly attributes each activity to the correct gene products based on established knowledge of the UDP biosynthetic pathway</li> </ol>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#technical-quality-assessment","title":"Technical Quality Assessment","text":"<p>The model follows GO-CAM best practices: - Each activity is properly enabled by the correct gene product - All activities are appropriately placed within the UDP biosynthetic process - Causal connections are properly utilized - Evidence codes are correctly applied with appropriate citations</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#model-strengths","title":"Model Strengths","text":"<ol> <li>Comprehensive representation of the UDP biosynthetic pathway</li> <li>Appropriate use of causal relationships to show the flow of reactions</li> <li>Strong evidential support from multiple literature sources</li> <li>Correct annotation of the gene products that enable each activity</li> <li>Proper taxonomic context (mouse-specific)</li> </ol>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Minor concern: The model could potentially benefit from including additional molecular details about the substrates and products of each reaction, though this is not strictly required by GO-CAM standards</li> </ol>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model representing the UDP biosynthetic process in mouse is biologically accurate, technically sound, and well-supported by evidence. It effectively captures the key enzymatic activities and their relationships in this metabolic pathway. The model is in a production-ready state and accurately reflects current biological knowledge about UDP biosynthesis.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/","title":"60e7989d00001485 Tetrahydrofolate interconversion 1a  Mouse","text":"<p>Based on all this information, I'll now provide a comprehensive review of the GO-CAM model gomodel:60e7989d00001485.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#review-of-go-cam-model-gomodel60e7989d00001485","title":"Review of GO-CAM Model gomodel:60e7989d00001485","text":""},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: Tetrahydrofolate interconversion 1a (Mouse) Taxon: NCBITaxon:10090 (Mouse) Status: Production Source: gomodel:R-HSA-196757 Model ID: gomodel:60e7989d00001485</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#model-content-analysis","title":"Model Content Analysis","text":"<p>This GO-CAM model represents the tetrahydrofolate interconversion pathway in mouse, with a focus on four key enzymes participating in this interconnected metabolic network:</p> <ol> <li>Dihydrofolate reductase (DHFR) - MGI:MGI:94890 (Dhfr)</li> <li>Serine hydroxymethyltransferase 1, cytosolic (SHMT1) - MGI:MGI:98299 (Shmt1)</li> <li>Serine hydroxymethyltransferase 2, mitochondrial (SHMT2) - MGI:MGI:1277989 (Shmt2)</li> <li>Thymidylate synthase (TYMS) - MGI:MGI:98878 (Tyms)</li> </ol> <p>The model shows these enzymes operating in the nucleus (all have <code>occurs_in: GO:0005634</code>), which is consistent with the literature finding that folate-dependent nuclear dTMP synthesis occurs in the liver, with the required enzymes localizing to the nucleus during S-phase and G2/M phases of the cell cycle (as supported by PMID:19513116).</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model correctly represents the flow of metabolites through the tetrahydrofolate interconversion pathway using the <code>RO:0002413</code> \"provides input for\" relationship. The causal connections depicted are:</p> <ol> <li>DHFR (MGI:94890) with dihydrofolate reductase activity (<code>GO:0004146</code>) provides input for both:</li> <li>SHMT1 (MGI:98299) with glycine hydroxymethyltransferase activity (<code>GO:0004372</code>)</li> <li> <p>SHMT2 (MGI:1277989) with glycine hydroxymethyltransferase activity (<code>GO:0004372</code>)</p> </li> <li> <p>SHMT1 (MGI:98299) provides input for:</p> </li> <li> <p>TYMS (MGI:98878) with thymidylate synthase activity (<code>GO:0004799</code>)</p> </li> <li> <p>SHMT2 (MGI:1277989) provides input for:</p> </li> <li> <p>TYMS (MGI:98878) with thymidylate synthase activity (<code>GO:0004799</code>)</p> </li> <li> <p>TYMS (MGI:98878) provides input for:</p> </li> <li>DHFR (MGI:94890) with dihydrofolate reductase activity (<code>GO:0004146</code>)</li> </ol> <p>This creates a cycle that accurately represents how DHFR regenerates tetrahydrofolate, which is then used by SHMT1/SHMT2 to produce 5,10-methylenetetrahydrofolate, which is in turn used by TYMS to convert dUMP to dTMP while generating dihydrofolate that returns to DHFR.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model uses appropriate evidence codes and references:</p> <ul> <li>ECO:0000315 (mutant phenotype evidence used in manual assertion) with PMID:19513116</li> <li>ECO:0000314 (direct assay evidence used in manual assertion) with PMID:360074 and PMID:22057276</li> </ul> <p>These references, particularly PMID:19513116, strongly support the nuclear localization of these enzymes and their roles in nuclear thymidylate biosynthesis.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#biological-context","title":"Biological Context","text":"<p>This model accurately represents a critical pathway in one-carbon metabolism necessary for DNA synthesis and cellular division. As described in PMID:19513116, these enzymes are SUMOylated and translocate to the nucleus during S-phase, where they form a metabolically coupled complex for de novo thymidylate synthesis directly at the replication fork, ensuring proper DNA synthesis.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#assessment-of-model-accuracy","title":"Assessment of Model Accuracy","text":"<p>The model adheres well to the biological understanding of tetrahydrofolate interconversion:</p> <ol> <li> <p>Appropriate molecular functions: Each protein is annotated with its correct enzymatic activity.</p> </li> <li> <p>Subcellular localization: The nuclear localization is supported by the cited literature.</p> </li> <li> <p>Proper process annotation: All activities are correctly indicated as part of tetrahydrofolate interconversion (<code>GO:0035999</code>).</p> </li> <li> <p>Causal relationships: The \"provides input for\" relationships accurately represent the metabolic flow in this pathway.</p> </li> </ol>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<p>While the model is scientifically sound, there are some aspects that could be enhanced:</p> <ol> <li> <p>More detailed process context: The model could potentially benefit from indicating these activities are specifically involved in dTMP biosynthesis, in addition to general tetrahydrofolate interconversion.</p> </li> <li> <p>Consideration of cytoplasmic versus nuclear roles: The literature indicates that these enzymes function both in the cytoplasm and nucleus, with specific nuclear translocation during S-phase. The model focuses only on the nuclear aspect, which is valid but could be noted as specific to certain cell cycle phases.</p> </li> <li> <p>Inclusion of metabolites: While GO-CAM focuses on activity flow rather than metabolites, a note about the key metabolites (tetrahydrofolate, 5,10-methylenetetrahydrofolate, etc.) could provide additional context.</p> </li> </ol>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60e7989d00001485 accurately represents the tetrahydrofolate interconversion pathway in mouse, with a focus on the nuclear localization of these activities as supported by the scientific literature. The model adheres to GO-CAM best practices and provides a coherent representation of this metabolic process.</p> <p>The model effectively captures the key findings from PMID:19513116 which demonstrated that these enzymes localize to the nucleus during specific cell cycle phases to support nuclear thymidylate biosynthesis, contributing to proper DNA replication. The cycle of reactions is represented appropriately with causal relationships that reflect the metabolic dependencies between these enzymes.</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/","title":"60ff660000000882 GMP salvage 2a  from adenosine  Mouse","text":"<p>Based on my review of the model and the GO-CAM documentation, here's my assessment of GO-CAM model 60ff660000000882 \"GMP salvage 2a, from adenosine (Mouse)\":</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#go-cam-review-for-model-gomodel60ff660000000882","title":"GO-CAM Review for Model gomodel:60ff660000000882","text":""},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the GMP salvage pathway in mouse (taxon NCBITaxon:10090), showing how adenosine is converted to GMP through a series of enzymatic reactions. The model was sourced from Reactome pathways R-HSA-73817 and R-HSA-74217.</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#molecular-activities-and-causal-flow","title":"Molecular Activities and Causal Flow","text":"<p>The model includes the following activities: 1. Ada (MGI:MGI:87916) - adenosine deaminase activity (GO:0004000) 2. Pnp (MGI:MGI:97365) - purine-nucleoside phosphorylase activity (GO:0004731) 3. Hprt1 (MGI:MGI:96217) - hypoxanthine phosphoribosyltransferase activity (GO:0004422) 4. Impdh1 (MGI:MGI:96567) - IMP dehydrogenase activity (GO:0003938) 5. Impdh2 (MGI:MGI:109367) - IMP dehydrogenase activity (GO:0003938) 6. Gmps (MGI:MGI:2448526) - GMP synthase (glutamine-hydrolyzing) activity (GO:0003922)</p> <p>The causal flow is represented using RO:0002413 (provides input for) relations, following a logical pathway from adenosine \u2192 hypoxanthine \u2192 IMP \u2192 XMP \u2192 GMP.</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well supported by experimental evidence: - Most activities have direct assay evidence (ECO:0000314) or mutant phenotype evidence (ECO:0000315) - Key publications such as PMID:718989 support the connections between activities - The evidence aligns with the literature about purine metabolism, including the biochemical study I examined (PMID:718989) which shows details of purine metabolism and nucleotide pools in neuroblastoma cells</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>Pathway Integrity: The model correctly represents the sequence of biochemical reactions in the GMP salvage pathway</li> <li>Evidence Quality: Uses appropriate evidence codes with specific PMIDs for each activity</li> <li>Biological Accuracy: The enzymatic activities align with known functions of these proteins</li> <li>Completeness: All essential enzymes for this pathway are included</li> <li>Alternative Pathways: Correctly represents that both Impdh1 and Impdh2 can catalyze the same reaction step (IMP \u2192 XMP)</li> </ol>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Biological Process Annotation: While most activities have part_of relations to GO:0032263 (GMP salvage), Ada (adenosine deaminase) is missing this annotation</li> <li>Missing Evidence: The causal association between Ada and Pnp has no evidence associated with it</li> <li>Cellular Component: No cellular component annotations are provided, which would add contextual information</li> <li>Additional Context: The model could benefit from information about regulation, especially since the literature indicates this pathway is subject to regulatory processes</li> </ol>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM guidelines for representing metabolic pathways: - Uses appropriate causal relations (RO:0002413 - provides input for) - Represents each functional entity with its molecular function - Correctly links activities to specific gene products</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li>Add the \"part of\" relation to link Ada (adenosine deaminase) activity to GO:0032263 (GMP salvage)</li> <li>Add evidence to support the causal relationship between Ada and Pnp</li> <li>Include cellular component annotations for each activity</li> <li>Consider adding regulatory elements if supported by evidence, as purine metabolism is known to be highly regulated</li> </ol>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed model of the GMP salvage pathway in mouse with accurate representation of the enzymatic activities and their causal connections. The minor improvements suggested above would enhance the model's completeness and adherence to GO-CAM best practices but don't affect the overall validity of the biological content.</p> <p>The model is consistent with experimental evidence and textbook knowledge of purine metabolism, as confirmed by the literature review. The activities are correctly connected in a way that represents the actual flow of the GMP salvage pathway from adenosine.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/","title":"60ff660000000897 GMP salvage 2b  from adenosine  Mouse","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model \"GMP salvage 2b, from adenosine (Mouse)\" (gomodel:60ff660000000897).</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#go-cam-review-gmp-salvage-2b-from-adenosine-mouse","title":"GO-CAM Review: GMP salvage 2b, from adenosine (Mouse)","text":""},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the GMP salvage pathway in mouse, starting from adenosine. The pathway shows how adenosine is converted through multiple steps to eventually produce GMP. The model focuses on the activities of several enzymes involved in this purine salvage pathway.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#structure-analysis","title":"Structure Analysis","text":"<p>The model contains 7 activities connected in a causal pathway:</p> <ol> <li>Adenosine Kinase activity (GO:0004001) - Enabled by Adk (MGI:MGI:87930)</li> <li>Converts adenosine to AMP</li> <li> <p>Provides input for three downstream activities (AMP deaminase)</p> </li> <li> <p>AMP deaminase activity (GO:0003876) - Enabled by three different genes:</p> </li> <li>Ampd1 (MGI:MGI:88015)</li> <li>Ampd2 (MGI:MGI:88016)</li> <li>Ampd3 (MGI:MGI:1096344)</li> <li> <p>These activities convert AMP to IMP</p> </li> <li> <p>IMP dehydrogenase activity (GO:0003938) - Enabled by two genes:</p> </li> <li>Impdh1 (MGI:MGI:96567)</li> <li>Impdh2 (MGI:MGI:109367)</li> <li> <p>These convert IMP to XMP</p> </li> <li> <p>GMP synthase (glutamine-hydrolyzing) activity (GO:0003922) - Enabled by Gmps (MGI:MGI:2448526)</p> </li> <li>Final step converting XMP to GMP</li> </ol>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by multiple pieces of evidence: - Direct assay evidence (ECO:0000314) - Mutant phenotype evidence (ECO:0000315) - Sequence orthology evidence (ECO:0000266) - Author statements (ECO:0000304)</p> <p>Each activity is supported by multiple evidence codes with associated PMID references, demonstrating good scientific support for the pathway.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#biological-process-context","title":"Biological Process Context","text":"<p>The model appropriately places most activities within the \"GMP salvage\" (GO:0032263) biological process, which is consistent with the pathway being modeled.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal connections between activities use the appropriate relation \"provides input for\" (RO:0002413), which correctly represents the substrate-product relationships in an enzymatic pathway. The flow from one enzyme to the next follows the expected metabolic progression in purine salvage.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive coverage: The model includes multiple isoforms of enzymes (e.g., AMPD1, AMPD2, AMPD3, and IMPDH1, IMPDH2) that can catalyze the same reaction, accurately representing the biological redundancy.</p> </li> <li> <p>Well-evidenced: Each activity and relationship is supported by multiple published references.</p> </li> <li> <p>Clear pathway representation: The model shows a clear linear progression from adenosine to GMP through the expected intermediates.</p> </li> <li> <p>Appropriate use of GO terms: The molecular functions, biological processes, and relationships are correctly applied.</p> </li> </ol>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Metabolites not explicitly shown: While the causal connections between enzymatic activities are present, the actual metabolites (adenosine, AMP, IMP, XMP, GMP) are not explicitly represented in the model. Adding the chemical entities would improve clarity.</p> </li> <li> <p>Cellular compartment information: The model does not specify the cellular locations where these reactions occur. Adding cellular component annotations would enhance the completeness of the model.</p> </li> <li> <p>Visual organization: The branching of the pathway with multiple AMPD and IMPDH enzymes could be organized more clearly to distinguish parallel pathways vs. alternative isoforms.</p> </li> </ol>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#consistency-with-literature-and-go-cam-practices","title":"Consistency with Literature and GO-CAM Practices","text":"<p>The model is consistent with: - Known purine metabolism pathways as described in literature - GO-CAM best practices for representing enzyme activities and causal relationships - The appropriate use of evidence codes and references</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"GMP salvage 2b, from adenosine (Mouse)\" (gomodel:60ff660000000897) is a well-constructed representation of the GMP salvage pathway. It accurately captures the enzymatic activities, their causal relationships, and provides appropriate evidence for the assertions. The model would benefit from minor enhancements such as explicit representation of metabolites and cellular compartment information, but overall, it is a high-quality GO-CAM that meets the standards for production status.</p> <p>The model successfully represents the conversion of adenosine to GMP through the sequential activities of adenosine kinase, AMP deaminase, IMP dehydrogenase, and GMP synthase, with appropriate documentation of the alternative enzyme isoforms that can catalyze key steps in the pathway.</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/","title":"60ff660000000917 GMP salvage 3  from adenine  Mouse","text":"<p>Based on all the information gathered, let me now provide a detailed review of the GO-CAM model (gomodel:60ff660000000917):</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#go-cam-model-review-gmp-salvage-3-from-adenine-mouse","title":"GO-CAM Model Review: GMP Salvage 3, from Adenine (Mouse)","text":""},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#model-summary","title":"Model Summary","text":"<ul> <li>ID: gomodel:60ff660000000917</li> <li>Title: GMP salvage 3, from adenine (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Comments: Sourced from: R-HSA-73817 and R-HSA-74217 (Reactome pathways)</li> </ul>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model represents the GMP salvage pathway in mouse, specifically focusing on the conversion of adenine to GMP. The model captures the key enzymatic activities involved in this process with appropriate causal relationships.</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#biological-content-review","title":"Biological Content Review","text":"<p>The model accurately represents the GMP salvage pathway, which is an important pathway for recycling purine bases to maintain nucleotide pools without the high energy cost of de novo synthesis. The model shows:</p> <ol> <li>The initial step with adenine phosphoribosyltransferase (APRT) converting adenine to AMP</li> <li>Multiple routes of AMP deamination by three different AMP deaminases (AMPD1, AMPD2, AMPD3) to form IMP</li> <li>Conversion of IMP to XMP by two IMP dehydrogenases (IMPDH1, IMPDH2)</li> <li>Final conversion of XMP to GMP by GMP synthase (GMPS)</li> </ol> <p>This pathway is consistent with established biochemical knowledge about purine nucleotide metabolism and the GMP salvage pathway.</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#technical-compliance-assessment","title":"Technical Compliance Assessment","text":""},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#1-activity-flow-and-causal-relationships","title":"1. Activity Flow and Causal Relationships","text":"<p>The model uses the \"provides input for\" (RO:0002413) relationship consistently to connect activities in the pathway: - APRT provides input for multiple AMPD enzymes - AMPD enzymes provide input for IMPDH enzymes - IMPDH enzymes provide input for GMP synthase</p> <p>This is correct for a metabolic pathway, where each enzyme converts a substrate to a product that serves as the substrate for the next enzyme.</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#2-gene-product-annotations","title":"2. Gene Product Annotations","text":"<p>Each activity is properly enabled by a specific gene product: - MGI:MGI:88061 (Aprt) - Adenine phosphoribosyltransferase activity - MGI:MGI:88015 (Ampd1) - AMP deaminase activity - MGI:MGI:88016 (Ampd2) - AMP deaminase activity - MGI:MGI:1096344 (Ampd3) - AMP deaminase activity - MGI:MGI:96567 (Impdh1) - IMP dehydrogenase activity - MGI:MGI:109367 (Impdh2) - IMP dehydrogenase activity - MGI:MGI:2448526 (Gmps) - GMP synthase activity</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#3-biological-process-context","title":"3. Biological Process Context","text":"<p>All relevant activities are correctly placed within the biological process context of \"GMP salvage\" (GO:0032263).</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#4-evidence-quality","title":"4. Evidence Quality","text":"<p>The model uses appropriate evidence codes for the annotations: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000304 (author statement supported by traceable reference used in manual assertion)</p> <p>Each activity is supported by at least one literature reference (PMID).</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#5-complex-representation","title":"5. Complex Representation","text":"<p>The model does not appear to include protein complexes. According to the UniProt information for IMPDH2, this enzyme can form homotetramers, but since the molecular function is directly associated with the gene product rather than a complex, this representation is appropriate according to the GO-CAM guidelines for annotating complexes (the subunit that carries the activity is known).</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Process Annotations: Some activities don't have explicit \"part_of\" process annotations, which would be beneficial for completeness.</p> </li> <li> <p>Evidence for Causal Relationships: Some causal associations lack evidence annotations. Adding evidence to support all causal claims would strengthen the model.</p> </li> <li> <p>Complete Pathway Context: While the model focuses on the GMP salvage pathway, it could benefit from placing this pathway in the broader context of purine metabolism by connecting it to related pathways.</p> </li> </ol>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#literature-consistency","title":"Literature Consistency","text":"<p>The model is consistent with current understanding of the GMP salvage pathway as described in the literature. The key enzymes, their activities, and the pathway flow are accurately represented.</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:60ff660000000917) represents a biologically accurate and technically sound representation of the GMP salvage pathway from adenine in mouse. The model follows GO-CAM best practices for the most part, with only minor improvements suggested. The causal relationships between activities are appropriate, and the model is supported by published literature. This model is suitable for production use and provides a valuable resource for understanding GMP salvage metabolism.</p>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/","title":"60ff660000001341 AMP salvage 2b  from adenosine  Mouse","text":"<p>Based on my comprehensive review of GO-CAM model 60ff660000001341 titled \"AMP salvage 2b, from adenosine (Mouse)\", I can provide the following assessment:</p>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#review-of-go-cam-model-amp-salvage-2b-from-adenosine-mouse","title":"Review of GO-CAM Model: AMP salvage 2b, from adenosine (Mouse)","text":"<p>Model ID: gomodel:60ff660000001341</p>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#overview","title":"Overview","text":"<p>This model represents the AMP salvage pathway in mouse, specifically focusing on the conversion of adenosine to AMP. It includes five molecular activities that form a connected pathway through causal relationships using the \"provides input for\" predicate (RO:0002413).</p>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Appropriate biological pathway representation: The model correctly captures the AMP salvage pathway, which is well-supported by literature evidence, particularly PMID:25681585 which specifically discusses AMP salvage in the context of nucleotide metabolism.</p> </li> <li> <p>Well-documented evidence: Each activity in the model is supported by appropriate experimental evidence (ECO:0000314 - direct assay evidence) and specific literature references.</p> </li> <li> <p>Proper use of causal relationships: The model uses the \"provides input for\" (RO:0002413) relationship appropriately to connect molecular functions in the sequence of the pathway.</p> </li> <li> <p>Proper gene product assignments: Each molecular function is correctly enabled by the appropriate gene product based on the UniProt entries I reviewed.</p> </li> <li> <p>Biological process context: Multiple activities in the model are appropriately placed in the context of the \"AMP salvage\" (GO:0044209) biological process.</p> </li> </ol>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#components-assessment","title":"Components Assessment","text":"<ol> <li>Adenosine Deaminase (Ada) activity:</li> <li>Correctly represented as GO:0004000 (adenosine deaminase activity)</li> <li>Appropriately enabled by MGI:MGI:87916 (Ada)</li> <li>Evidence from PMID:8064675 and PMID:6771472</li> <li> <p>This corresponds to the conversion of adenosine to inosine</p> </li> <li> <p>Purine-nucleoside Phosphorylase (Pnp) activity:</p> </li> <li>Correctly represented as GO:0004731 (purine-nucleoside phosphorylase activity)</li> <li>Appropriately enabled by MGI:MGI:97365 (Pnp)</li> <li>Evidence from PMID:8064675 and PMID:6771472</li> <li>Correctly placed in AMP salvage biological process</li> <li> <p>This corresponds to the conversion of inosine to hypoxanthine</p> </li> <li> <p>Hypoxanthine Phosphoribosyltransferase (Hprt1) activity:</p> </li> <li>Correctly represented as GO:0004422 (hypoxanthine phosphoribosyltransferase activity)</li> <li>Appropriately enabled by MGI:MGI:96217 (Hprt1)</li> <li>Evidence from PMID:8064675</li> <li>Correctly placed in AMP salvage biological process</li> <li> <p>This corresponds to the conversion of hypoxanthine to IMP</p> </li> <li> <p>Adenylosuccinate Synthase (Adss1) activity:</p> </li> <li>Correctly represented as GO:0004019 (adenylosuccinate synthase activity)</li> <li>Appropriately enabled by MGI:MGI:87947 (Adss1)</li> <li>Evidence from PMID:1939273 and PMID:11560929</li> <li>Correctly placed in AMP salvage biological process</li> <li> <p>This corresponds to the conversion of IMP to adenylosuccinate</p> </li> <li> <p>Adenylosuccinate Lyase (Adsl) activity:</p> </li> <li>Correctly represented as GO:0004018 (N6-(1,2-dicarboxyethyl)AMP AMP-lyase (fumarate-forming) activity)</li> <li>Appropriately enabled by MGI:MGI:103202 (Adsl)</li> <li>Evidence from PMID:5891253</li> <li>This corresponds to the conversion of adenylosuccinate to AMP</li> </ol>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#pathway-flow-assessment","title":"Pathway Flow Assessment","text":"<p>The model correctly represents the flow of the AMP salvage pathway from adenosine:</p> <ol> <li>Adenosine \u2192 Inosine (by Ada)</li> <li>Inosine \u2192 Hypoxanthine + Ribose-1-P (by Pnp)</li> <li>Hypoxanthine + PRPP \u2192 IMP (by Hprt1)</li> <li>IMP + Aspartate + GTP \u2192 Adenylosuccinate (by Adss1)</li> <li>Adenylosuccinate \u2192 AMP + Fumarate (by Adsl)</li> </ol>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Complete biological process context: While three of the five activities are placed in the context of \"AMP salvage\" biological process, the adenosine deaminase and adenylosuccinate lyase activities could also be tagged with this biological process to provide complete context.</p> </li> <li> <p>Consider adding additional evidence: For some of the reactions, additional evidence exists from research papers like PMID:25681585, which specifically discusses this pathway in mouse hearts. This could strengthen the evidentiary basis for the model.</p> </li> <li> <p>Consider including regulation information: The model focuses on the enzymatic activities but doesn't capture any regulatory aspects of the pathway. If such information is available from the literature, it could enhance the model.</p> </li> </ol>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the AMP salvage pathway in mouse. The model uses appropriate molecular function terms, connects them with correct causal relationships, and provides good evidence for the assertions. The recommended improvements are minor and would only enhance what is already a high-quality model.</p> <p>The model effectively achieves its goal of representing how adenosine is salvaged to regenerate AMP through a series of enzymatic reactions in mouse cells, which is important for maintaining the adenine nucleotide pool during conditions of metabolic stress.</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/","title":"61283a3000000217 cobalamin metabolic process 1  adenosylation of cobalamin  Mouse","text":"<p>Now I'll review the GO-CAM model with ID 61283a3000000217 based on GO-CAM best practices and scientific literature.</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#review-of-go-cam-model-gomodel61283a3000000217","title":"Review of GO-CAM Model: gomodel:61283a3000000217","text":""},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model titled \"Cobalamin metabolic process 1, adenosylation of cobalamin (Mouse)\" represents the pathway of cobalamin (vitamin B12) metabolism in mouse, specifically focusing on the adenosylation of cobalamin. The model is sourced from Reactome pathways R-HSA-196741 and R-HSA-3149560.</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#overall-structure-and-composition","title":"Overall Structure and Composition","text":"<p>The model consists of 6 activities representing proteins involved in cobalamin processing:</p> <ol> <li>MMACHC (MGI:MGI:1914346) - Functions in two distinct roles:</li> <li>Oxidoreductase activity (GO:0016491)</li> <li> <p>Cyanocobalamin reductase activity (GO:0033787)</p> </li> <li> <p>MMADHC (MGI:MGI:1923786) - Molecular carrier activity (GO:0140104)</p> </li> <li> <p>MMAB (MGI:MGI:1924947) - Corrinoid adenosyltransferase activity (GO:0008817)</p> </li> <li> <p>MMAA (MGI:MGI:1923805) - Molecular carrier activity (GO:0140104)</p> </li> <li> <p>MMUT (MGI:MGI:97239) - Methylmalonyl-CoA mutase activity (GO:0004494)</p> </li> </ol> <p>These activities are connected in a pathway that represents the processing of cobalamin to adenosylcobalamin and its subsequent use.</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#pathway-flow-analysis","title":"Pathway Flow Analysis","text":"<p>The model represents a linear process flow:</p> <ol> <li>MMACHC (oxidoreductase) \u2192 MMADHC</li> <li>MMACHC (cyanocobalamin reductase) \u2192 MMADHC</li> <li>MMADHC \u2192 MMAB (positively regulates)</li> <li>MMAB \u2192 MMAA</li> <li>MMAA (with input from cobamamide) \u2192 MMUT</li> </ol> <p>This pathway correctly represents the known steps in cobalamin metabolism where: - MMACHC processes incoming cobalamin forms (removes the upper axial ligand) - MMADHC works with MMACHC to direct cobalamin toward adenosylation - MMAB functions as adenosyltransferase to create adenosylcobalamin - MMAA acts as a molecular carrier/chaperone - MMUT uses adenosylcobalamin as a cofactor</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#cellular-localization-accuracy","title":"Cellular Localization Accuracy","text":"<p>The cellular localizations are accurate: - MMACHC is correctly annotated to occur in the cytosol (GO:0005829) - MMAB, MMAA, and MMUT are correctly annotated to the mitochondrial matrix (GO:0005759)</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#evidence-and-literature-support","title":"Evidence and Literature Support","text":"<p>The model uses appropriate evidence codes: - Orthology evidence (ECO:0000266) from human studies is appropriately used - Direct assay evidence (ECO:0000314) is used for MMUT - Curator inferences (ECO:0000305) are properly applied</p> <p>The evidence is supported by PMIDs that match the functions described, including key papers on MMACHC (PMID:21697092, PMID:22642810) that describe its dual roles.</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway Completeness: The model captures the key enzymes involved in the adenosylation pathway of cobalamin.</p> </li> <li> <p>Accurate Molecular Functions: The molecular functions are correctly assigned to each protein, especially the dual functions of MMACHC.</p> </li> <li> <p>Proper Use of Molecular Carrier Activity: The model correctly uses GO:0140104 (molecular carrier activity) for proteins that function as carriers/chaperones (MMADHC and MMAA).</p> </li> <li> <p>Appropriate Causal Relations: The causal relationships (RO:0002413 \"provides input for\" and RO:0002304 \"causally upstream of, positive effect\") are used correctly.</p> </li> <li> <p>Chemical Inputs/Outputs: The model correctly includes cobamamide (CHEBI:18408) as an input for MMAA.</p> </li> </ol>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Small Molecules: While cobamamide is included, some intermediate forms of cobalamin (such as cob(I)alamin) are not explicitly represented in the pathway.</p> </li> <li> <p>Evidence Gaps: Some causal associations lack evidence codes, which would strengthen the model.</p> </li> <li> <p>Molecular Context Completeness: For MMACHC, glutathione is an important cofactor for its dealkylation activity but is not represented in the model.</p> </li> <li> <p>Process Context: While individual activities are annotated to \"cobalamin metabolic process\" (GO:0009235), the specific subprocesses (e.g., \"adenosylcobalamin biosynthetic process\") could be more precisely annotated.</p> </li> </ol>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#conformance-to-go-cam-best-practices","title":"Conformance to GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Molecular Carrier Activity: The model correctly uses GO:0140104 as specified in the \"Molecular carrier activity\" guidelines document.</p> </li> <li> <p>Activity Flow: The pathway is represented as a linear flow with appropriate causal relations.</p> </li> <li> <p>Cellular Context: The activities are appropriately annotated with cellular locations.</p> </li> <li> <p>Evidence: The model uses appropriate evidence codes and references.</p> </li> </ol>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The biological process represented is accurate according to current understanding of cobalamin metabolism:</p> <ol> <li> <p>MMACHC functions as both an oxidoreductase and a cyanocobalamin reductase, processing various forms of cobalamin.</p> </li> <li> <p>MMADHC interacts with MMACHC and directs processed cobalamin toward adenosylation pathways.</p> </li> <li> <p>MMAB functions as a corrinoid adenosyltransferase, converting cob(I)alamin to adenosylcobalamin.</p> </li> <li> <p>MMAA acts as a carrier/chaperone for adenosylcobalamin.</p> </li> <li> <p>MMUT uses adenosylcobalamin as a cofactor for methylmalonyl-CoA mutase activity.</p> </li> </ol>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:61283a3000000217) accurately represents the adenosylation pathway of cobalamin metabolism in mouse. It captures the key proteins, their molecular functions, cellular locations, and the pathway flow according to current scientific knowledge. The model is well-evidenced and follows GO-CAM best practices. </p> <p>Minor improvements could be made by including additional small molecule intermediates and more specific process annotations, but overall, this model provides a clear and accurate representation of the biological pathway.</p>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/","title":"613aae0000000011 SP ANN SEC14L1","text":"<p>Let me analyze the GO-CAM model with the information I've gathered:</p> <p>Based on my review of GO-CAM model 613aae0000000011 (titled \"SP-ANN-SEC14L1\"), I can now provide a comprehensive assessment of the model. This model involves four molecular activities from three different proteins:</p> <ol> <li>RIG-I (UniProtKB:O95786) with activity:</li> <li>Pattern recognition receptor activity (GO:0038187)</li> <li> <p>Located in cytoplasm (GO:0005737)</p> </li> <li> <p>MAVS (UniProtKB:Q7Z434) with two activities:</p> </li> <li>RIG-I binding (GO:0039552) - located in mitochondrial membrane (GO:0031966)</li> <li> <p>Molecular adaptor activity (GO:0060090) - located in mitochondrial membrane (GO:0031966)</p> </li> <li> <p>SEC14L1 (UniProtKB:Q92503) with activity:</p> </li> <li>Protein sequestering activity (GO:0140311)</li> <li>Located in cytoplasm (GO:0005737)</li> </ol> <p>The model represents antiviral innate immune response signaling through the RIG-I/MAVS pathway, with SEC14L1 acting as a negative regulator. </p>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#assessment-of-the-model","title":"Assessment of the Model:","text":"<ol> <li>Overall Structure:     The model correctly depicts the RIG-I \u2192 MAVS signaling pathway with appropriate causal relationships:</li> <li>RIG-I pattern recognition receptor activity directly positively regulates MAVS RIG-I binding</li> <li>MAVS RIG-I binding directly positively regulates MAVS molecular adaptor activity</li> <li> <p>SEC14L1 protein sequestering activity directly negatively regulates MAVS RIG-I binding</p> </li> <li> <p>Molecular Functions:</p> </li> <li>The molecular functions are appropriately assigned to each protein based on their known biological roles</li> <li>RIG-I's pattern recognition receptor activity correctly represents its role in viral RNA detection</li> <li>MAVS's dual role as both binding RIG-I and acting as a molecular adaptor is properly represented</li> <li> <p>SEC14L1's protein sequestering activity accurately reflects its negative regulatory role in RIG-I signaling</p> </li> <li> <p>Cellular Components:</p> </li> <li>The cellular localization of each activity is appropriate:</li> <li>RIG-I in cytoplasm</li> <li>MAVS on mitochondrial membrane</li> <li> <p>SEC14L1 in cytoplasm</p> </li> <li> <p>Causal Relationships:</p> </li> <li>The causal relationships use appropriate predicates:</li> <li>\"RO:0002629\" (directly positively regulates) for activation steps</li> <li> <p>\"RO:0002630\" (directly negatively regulates) for inhibition by SEC14L1</p> </li> <li> <p>Annotation Evidence:</p> </li> <li>Each activity is supported by appropriate evidence codes (ECO:0000314 - direct assay evidence)</li> <li>Each activity references relevant literature (PMIDs)</li> <li>All activities have appropriate contributor information and dates</li> </ol>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines:","text":"<ol> <li>Molecular Adaptor Activity Guidelines:</li> <li>MAVS is correctly represented as an adaptor protein</li> <li>The relationship between its RIG-I binding and adaptor activity follows guidelines</li> <li> <p>The \"directly positively regulates\" relationship is appropriate for this regulatory interaction</p> </li> <li> <p>Protein Sequestering Activity Guidelines:</p> </li> <li>SEC14L1's protein sequestering activity correctly uses the \"directly negatively regulates\" relationship</li> <li> <p>This follows the guidelines for representing a sequestering activity that prevents an interaction</p> </li> <li> <p>Complex Annotation Guidelines:</p> </li> <li>The model doesn't explicitly represent complexes, which is appropriate since the individual molecular activities of each protein are known and represented</li> <li>The activities are connected through causal relationships rather than complex formation</li> </ol>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#biological-accuracy","title":"Biological Accuracy:","text":"<p>The model accurately captures the established biology of the RIG-I/MAVS antiviral signaling pathway: - RIG-I functions as a cytoplasmic sensor for viral RNA - Upon activation, RIG-I interacts with MAVS at the mitochondrial membrane - MAVS acts as an adaptor to propagate the signal - SEC14L1 negatively regulates this pathway by sequestering MAVS, preventing its interaction with RIG-I</p> <p>The causal flow of the model is consistent with the direction of signal transduction in the actual biological pathway.</p>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#conclusion","title":"Conclusion:","text":"<p>The GO-CAM model 613aae0000000011 is well-constructed, biologically accurate, and follows GO-CAM best practices. It correctly represents the molecular activities, cellular locations, and causal relationships between the proteins involved in the RIG-I/MAVS signaling pathway and its negative regulation by SEC14L1.</p> <p>The evidence and references provided for each activity are appropriate, and the model effectively communicates the biological knowledge about this pathway in a clear and standardized way.</p>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/","title":"613aae0000000040 cGAS Sting pathway  Drosophila","text":"<p>After reviewing all the information, I will now provide a comprehensive review of GO-CAM model 613aae0000000040 (cGAS-Sting pathway in Drosophila):</p>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#review-of-go-cam-model-cgas-sting-pathway-drosophila","title":"Review of GO-CAM Model: cGAS-Sting pathway (Drosophila)","text":""},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#model-overview","title":"Model Overview","text":"<ul> <li>Model ID: gomodel:613aae0000000040</li> <li>Title: cGAS-Sting pathway (Drosophila)</li> <li>Taxon: Drosophila melanogaster (NCBITaxon:7227)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#model-content-overview","title":"Model Content Overview","text":"<p>This model represents the cGAS-STING pathway in Drosophila, focusing on antiviral immunity. It includes:</p> <ol> <li>Two cGAS-like receptors (cGLR1 and cGLR2) that sense RNA and produce cyclic dinucleotides</li> <li>STING protein that binds these cyclic dinucleotides</li> <li>Downstream signaling leading to activation of the Rel transcription factor (NF-\u03baB homolog)</li> <li>All activities are part of the \"defense response to virus\" (GO:0051607) biological process</li> </ol>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#key-activities-and-causal-associations","title":"Key Activities and Causal Associations","text":"<p>The model includes the following core activities: 1. cGLR2 (FB:FBgn0050424) has two activities:    - 2',3'-cyclic GMP-AMP synthase activity (GO:0061501)    - 3',2'-cyclic GMP-AMP synthase activity (GO:0140700)    - Both provide input to STING protein (RO:0002413)</p> <ol> <li>cGLR1 (FB:FBgn0034047) has two activities:</li> <li>Double-stranded RNA binding (GO:0003725)</li> <li>3',2'-cyclic GMP-AMP synthase activity (GO:0140700)</li> <li> <p>Both directly positively regulate STING (RO:0002629 and RO:0002413)</p> </li> <li> <p>STING (FB:FBgn0033453) has two binding activities:</p> </li> <li>2',3'-cyclic GMP-AMP binding (GO:0061507)</li> <li>3',2'-cyclic GMP-AMP binding (GO:0140704)</li> <li> <p>Both directly positively regulate Rel (RO:0002629)</p> </li> <li> <p>Rel (FB:FBgn0014018) has transcription factor activity (GO:0000981)</p> </li> <li>Part of defense response to virus (GO:0051607)</li> </ol>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by recent primary literature: - PMID:34261128 (2021) - Two cGAS-like receptors induce antiviral immunity in Drosophila - PMID:34261127 (2021) - Related to cGAS-like receptors and RNA sensing - PMID:33262294 (2020) - Related to STING activation - PMID:19135474 (2009) - Related to Rel transcription factor activity - PMID:30119996 (2018) - Related to antiviral response</p>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#strengths","title":"Strengths","text":"<ol> <li> <p>Good representation of the current literature: The model accurately captures the latest findings about the cGAS-STING pathway in Drosophila, where cGAS-like receptors (cGLRs) detect RNA and produce cyclic dinucleotides to activate STING.</p> </li> <li> <p>Appropriate causal relationships: The model uses appropriate relationship predicates:</p> </li> <li>\"provides input for\" (RO:0002413) for substrate-product relationships</li> <li> <p>\"directly positively regulates\" (RO:0002629) for regulatory relationships</p> </li> <li> <p>Consistent biological process annotation: All activities are appropriately annotated as part of the defense response to virus (GO:0051607).</p> </li> <li> <p>Logical flow: The pathway representation follows a clear sequence from sensor proteins (cGLRs) to effector (Rel transcription factor).</p> </li> </ol>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Upstream signal representation: The model could be improved by including the upstream viral RNA that triggers the pathway. The model starts with the cGLR activities but does not explicitly represent what activates these proteins.</p> </li> <li> <p>Molecular details: While the model shows the cyclic dinucleotide synthase and binding activities, it would be beneficial to include the specific molecules involved (e.g., dsRNA, 2',3'-cGAMP, 3',2'-cGAMP) as chemical entities within the model.</p> </li> <li> <p>Downstream targets: The model represents Rel transcription factor activity but doesn't include any downstream target genes. Including key antiviral genes regulated by Rel would complete the signaling pathway.</p> </li> <li> <p>Alternative pathways: The literature suggests that the two cGLRs may have somewhat distinct roles. The model could potentially clarify if there are any pathway-specific differences between cGLR1 and cGLR2 signaling.</p> </li> </ol>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Activity representation: Each activity is appropriately enabled by a specific gene product.</p> </li> <li> <p>Process context: All activities are correctly placed within a biological process context.</p> </li> <li> <p>Causal relationships: The model uses appropriate causal relationships between activities.</p> </li> <li> <p>Evidence: Each assertion is supported by evidence from the literature.</p> </li> </ol>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add upstream stimulus: Include viral RNA as a trigger for cGLRs to provide more complete context.</p> </li> <li> <p>Include molecular participants: Add the cyclic dinucleotides as participants in the model.</p> </li> <li> <p>Expand downstream effects: Include key antiviral genes regulated by Rel transcription factor.</p> </li> <li> <p>Consider adding complex representation: If the cGLRs or STING function as part of larger complexes, these could be represented following GO-CAM complex guidelines.</p> </li> <li> <p>Clarify specific roles: Provide more detail on any distinct roles of cGLR1 versus cGLR2 if indicated by the literature.</p> </li> </ol>"},{"location":"reviews/613aae0000000040-cGAS_Sting_pathway__Drosophila_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the cGAS-STING pathway in Drosophila as described in recent literature. It captures the core signaling pathway from RNA sensing by cGAS-like receptors through cyclic dinucleotide production, STING activation, and downstream Rel transcription factor activity. While generally well-constructed, the model could be enhanced by including upstream stimuli, molecular participants, and downstream targets to provide a more complete representation of the pathway.</p>"},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/","title":"613aae0000000341 cobalamin transport 2  distribution to tissues  Mouse","text":"<p>Now I'm going to analyze the GO-CAM model based on the information I've gathered. First, let me check if there are any relevant documents on how to annotate molecular carrier activity, since this appears to be an important part of the model.</p>"},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#go-cam-model-review-gomodel613aae0000000341","title":"GO-CAM Model Review: gomodel:613aae0000000341","text":""},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#model-overview","title":"Model Overview","text":"<p>GO-CAM model 613aae0000000341 represents \"cobalamin transport 2, distribution to tissues (Mouse)\" in mouse (Mus musculus, NCBITaxon:10090). This model describes the process of cobalamin (vitamin B12) transport from the intestine to tissues through the bloodstream via cobalamin-binding proteins.</p>"},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#key-components","title":"Key Components","text":"<p>The model includes four main proteins and their activities:</p> <ol> <li>Abcc1/MRP1 (MGI:MGI:102676) - Enables ABC-type vitamin B12 transporter activity (GO:0015420)</li> <li>Tcn2 (MGI:MGI:98534) - Enables both:</li> <li>Molecular carrier activity (GO:0140104)</li> <li>Cargo receptor ligand activity (GO:0140355)</li> <li>Cobalamin binding (GO:0031419)</li> <li>Cd320 (MGI:MGI:1860083) - Enables cargo receptor activity (GO:0038024)</li> </ol>"},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#model-structure-and-causal-flow","title":"Model Structure and Causal Flow","text":"<p>The model represents a sequential process of cobalamin transport with the following causal associations:</p> <ol> <li> <p>Abcc1/MRP1 with ABC-type vitamin B12 transporter activity (GO:0015420) in the basal plasma membrane (GO:0009925) provides input for Tcn2's molecular carrier activity (GO:0140104) in extracellular space (GO:0005615).</p> </li> <li> <p>Tcn2 with molecular carrier activity (GO:0140104) in extracellular space (GO:0005615) directly positively regulates Tcn2's cargo receptor ligand activity (GO:0140355) on the external side of plasma membrane (GO:0009897).</p> </li> <li> <p>Tcn2 with cargo receptor ligand activity (GO:0140355) on the external side of plasma membrane (GO:0009897) directly positively regulates Cd320's cargo receptor activity (GO:0038024) on the plasma membrane (GO:0005886).</p> </li> <li> <p>The molecular carrier activity of Tcn2 includes a nested activity of cobalamin binding (GO:0031419), connected through a BFO:0000051 relation (has_part).</p> </li> </ol>"},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#evidence","title":"Evidence","text":"<p>The model is supported by several published studies: - PMID:19897579 - Identification of MRP1/ABCC1 as the transporter responsible for cellular export of cobalamin - PMID:23430977 - Transcobalamin receptor (Cd320) knockout mouse study - PMID:21655200 - Mouse transcobalamin features compared to human transcobalamin and haptocorrin - PMID:237480 - Transport of vitamin B12 into mouse leukemia cells</p>"},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#qc-assessment","title":"QC Assessment","text":""},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>Biological accuracy: The model correctly represents the current understanding of cobalamin transport in mice, especially regarding:</li> <li>The role of MRP1/ABCC1 in exporting cobalamin from cells</li> <li>Tcn2 as the primary cobalamin binding protein in mouse (unlike humans who have both transcobalamin and haptocorrin)</li> <li> <p>Cd320 as the receptor for Tcn2-cobalamin complex</p> </li> <li> <p>Causal flow: The model has appropriate directional flow showing how cobalamin moves from cells to extracellular space and then is taken up by other cells.</p> </li> <li> <p>Cell locations: Each activity is properly annotated with the appropriate cellular location.</p> </li> <li> <p>Evidence base: All activities are supported by experimental evidence from mouse studies.</p> </li> </ol>"},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#issuessuggestions-for-improvement","title":"Issues/Suggestions for Improvement","text":"<ol> <li> <p>Molecular carrier activity representation: According to the \"Molecular_carrier_activity\" guidelines, the relation between a transported molecule (cobalamin) and its carrier (Tcn2) should be \"has input\" and \"has output\". While the model properly represents Tcn2's cobalamin binding activity as part of its molecular carrier activity, it might benefit from explicitly representing the cobalamin molecule as input and output.</p> </li> <li> <p>Complete pathway representation: The model starts with the export of cobalamin from cells (via MRP1) but doesn't represent the initial uptake of dietary cobalamin. Consider expanding the model to include the intestinal absorption of cobalamin.</p> </li> <li> <p>Part_of biological process annotation: All activities are appropriately annotated as part_of the cobalamin transport process (GO:0015889), which is correct.</p> </li> </ol>"},{"location":"reviews/613aae0000000341-cobalamin_transport_2__distribution_to_tissues__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, GO-CAM model 613aae0000000341 is a well-constructed representation of cobalamin transport in mice. It accurately captures the molecular mechanisms of how cobalamin is exported from cells, bound by transcobalamin (Tcn2) in the extracellular space, and subsequently taken up by other cells through the Cd320 receptor.</p> <p>The model effectively integrates information from several primary research papers and correctly represents the differences between mouse and human cobalamin transport (particularly that mice have Tcn2 but no haptocorrin). The causal connections between activities create a coherent biological story.</p> <p>The only minor suggestion would be to consider explicitly representing the cobalamin molecule as input and output in the carrier activity, as recommended in the molecular carrier activity guidelines. However, this doesn't detract from the overall quality and accuracy of the model.</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/","title":"613aae0000000500 cobalamin metabolic process 3  methylation of cobalamin  Mouse","text":"<p>Based on all the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model gomodel:613aae0000000500 \"cobalamin metabolic process 3, methylation of cobalamin (Mouse)\".</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#review-of-go-cam-model-cobalamin-metabolic-process-3-methylation-of-cobalamin-mouse","title":"Review of GO-CAM Model: Cobalamin Metabolic Process 3, Methylation of Cobalamin (Mouse)","text":""},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:613aae0000000500) represents the \"cobalamin metabolic process 3, methylation of cobalamin\" pathway in mouse. It models the conversion of cobalamin (vitamin B12) to its active methylcobalamin form and its subsequent use in methionine synthesis.</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#model-structure-analysis","title":"Model Structure Analysis","text":"<p>The model includes five activities with the following gene products: 1. MMACHC (MGI:MGI:1914346) - oxidoreductase activity 2. MMADHC (MGI:MGI:1923786) - molecular carrier activity 3. MTRR (MGI:MGI:1891037) - [methionine synthase] reductase (NADPH) activity 4. MTR (MGI:MGI:894292) - methionine synthase activity 5. A second MTR activity with output CHEBI:16304 (cob(II)alamin)</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#causal-flow-analysis","title":"Causal flow analysis","text":"<p>The causal flow of the model appears to be: - MMACHC (oxidoreductase) \u2192 MMADHC (molecular carrier) - MMADHC \u2192 MTR (methionine synthase) AND MTR (with cob(II)alamin output) - MTR (with cob(II)alamin output) \u2192 MTRR (methionine synthase reductase) - MTRR \u2192 MTR (methionine synthase)</p> <p>This represents a circular pathway where MTR activity produces cob(II)alamin, which is then a substrate for MTRR, which in turn produces methylcobalamin (CHEBI:28115) that enables the methionine synthase activity of MTR again.</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#evaluation-against-go-cam-best-practices","title":"Evaluation Against GO-CAM Best Practices","text":""},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#1-biological-accuracy","title":"1. Biological accuracy","text":"<p>The model accurately represents the current understanding of the methylcobalamin pathway: - MMACHC acts as an oxidoreductase to prepare cobalamin for further processing - MMADHC functions as a molecular carrier to deliver cobalamin to the appropriate enzymes - MTR uses methylcobalamin as a cofactor for methionine synthesis - MTRR regenerates the active methylcobalamin form when MTR's cobalamin cofactor becomes oxidized to cob(II)alamin</p> <p>The molecular species (CHEBI:28115, methylcobalamin; CHEBI:16304, cob(II)alamin) are appropriately included.</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#2-appropriate-use-of-causal-relations","title":"2. Appropriate use of causal relations","text":"<p>The model uses the appropriate causal relations: - \"RO:0002413\" (provides input for) is used consistently to link activities in the pathway - The relations accurately reflect that each protein's activity provides input for the downstream protein's activity</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#3-cellular-component-annotations","title":"3. Cellular component annotations","text":"<p>The model includes \"GO:0005829\" (cytosol) as the location for MMACHC and MMADHC activities, which is correct based on their known subcellular localization.</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#4-use-of-evidence-codes","title":"4. Use of evidence codes","text":"<p>The model uses appropriate evidence codes: - ECO:0000266 (sequence orthology evidence used in manual assertion) - correctly used with human Uniprot IDs as with_objects - ECO:0000315 (mutant phenotype evidence used in manual assertion) - appropriately used with mouse genes</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#5-completeness-of-the-model","title":"5. Completeness of the model","text":"<p>The model appears to include all the essential components of the methylcobalamin metabolic pathway. It correctly represents: - Initial processing of cobalamin by MMACHC/MMADHC - The role of methionine synthase (MTR) - The regeneration of the active methylcobalamin form by MTRR</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is generally well-constructed, I recommend the following improvements:</p> <ol> <li> <p>Add cellular component annotation for MTRR and MTR: Both activities should have \"occurs_in\" relationships with the cytosol (GO:0005829) as they are cytosolic proteins.</p> </li> <li> <p>Clarify input/output relationships: Add explicit \"has_input\" and \"has_output\" annotations for MMACHC to show what form of cobalamin it processes.</p> </li> <li> <p>Complete molecular details: Consider adding the \"has_input\" relationship for MMADHC that would show it receives cobalamin from MMACHC.</p> </li> <li> <p>Add homocysteine and methionine molecules: The model would benefit from including homocysteine as input and methionine as output for the MTR activity to complete the biochemical context.</p> </li> <li> <p>Consider using a complex representation: Since MMACHC and MMADHC are known to form a functional complex, as per the document \"How to annotate complexes in GO-CAM\", this interaction could be represented.</p> </li> <li> <p>Add additional evidence: Some of the causal associations lack evidence annotations. Adding evidence for these relationships would strengthen the model.</p> </li> </ol>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"cobalamin metabolic process 3, methylation of cobalamin (Mouse)\" (gomodel:613aae0000000500) is a well-constructed representation of vitamin B12 metabolism. It accurately captures the key activities and relationships in the methylcobalamin pathway and uses appropriate ontology terms and evidence codes.</p> <p>The model is biologically accurate, following the known pathway where cobalamin is processed by MMACHC, transported by MMADHC, utilized by methionine synthase (MTR), and regenerated by methionine synthase reductase (MTRR). The circular nature of the pathway is correctly represented through the causal flow of activities.</p> <p>With the suggested minor improvements, particularly regarding cellular components and molecular inputs/outputs, the model would provide an even more comprehensive representation of this important metabolic pathway.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/","title":"613aae0000000579 SP ANN TPPP","text":"<p>Now I have sufficient information to review the GO-CAM model. Let me analyze the model and provide a comprehensive assessment.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#review-of-go-cam-model-gomodel613aae0000000579","title":"Review of GO-CAM Model gomodel:613aae0000000579","text":""},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#model-overview","title":"Model Overview","text":"<p>This model (GO-CAM ID: gomodel:613aae0000000579) titled \"SP-ANN-TPPP\" represents interactions between various S100 calcium-binding proteins (S100B, S100A6, S100A2) and the Tubulin Polymerization Promoting Protein (TPPP/p25), focusing on their role in regulating microtubule dynamics and organization.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model represents a regulatory pathway where multiple S100 proteins (S100B, S100A6, and S100A2) interact with TPPP/p25 to inhibit its dimerization activity, which in turn affects microtubule nucleation. The model includes:</p> <ol> <li>Three S100 proteins (S100B, S100A6, S100A2) with protein binding activity (GO:0005515)</li> <li>TPPP/p25 with protein dimerization activity (GO:0046983) and microtubule nucleator activity (GO:0140490)</li> <li>Causal relationships where S100 proteins negatively regulate (RO:0002630, \"directly negatively regulates\") TPPP's dimerization activity</li> <li>TPPP's dimerization activity positively regulates (RO:0002629, \"directly positively regulates\") its own microtubule nucleator activity</li> <li>The microtubule nucleator activity occurs in the Golgi apparatus (GO:0005794)</li> </ol> <p>This pathway accurately represents the findings from the literature, particularly from the 2021 paper by Doi et al. (PMID: 33831707) which demonstrated that S100 proteins regulate TPPP activity by inhibiting its dimerization.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model cites appropriate evidence for its assertions:</p> <ul> <li>TPPP's protein dimerization activity: ECO:0000314 (direct assay) from PMID:22484033</li> <li>TPPP's microtubule nucleator activity: ECO:0000314 (direct assay) from PMID:31522887</li> <li>S100 proteins' inhibition of TPPP dimerization: ECO:0000314 (direct assay) from PMID:33831707</li> <li>TPPP's dimerization promoting microtubule nucleation: ECO:0000314 (direct assay) from PMID:22484033</li> </ul> <p>The evidence aligns with current scientific understanding:</p> <ol> <li>Olah et al. (2012) demonstrated that TPPP forms dimers that promote microtubule assembly</li> <li>Fu et al. (2019) showed that TPPP acts as a microtubule nucleator at Golgi outposts</li> <li>Doi et al. (2021) established that S100 proteins (S100B, S100A6, S100A2) directly bind to TPPP and inhibit its dimerization</li> </ol>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Correct causal relationships: The model appropriately uses \"directly negatively regulates\" (RO:0002630) for inhibitory relationships and \"directly positively regulates\" (RO:0002629) for activating relationships.</p> </li> <li> <p>Proper molecular function annotation: The model correctly annotates TPPP with protein dimerization activity (GO:0046983) and microtubule nucleator activity (GO:0140490), and S100 proteins with protein binding activity (GO:0005515).</p> </li> <li> <p>Cellular location specification: The model includes location information for the microtubule nucleator activity (Golgi apparatus).</p> </li> <li> <p>Evidence provenance: All assertions include appropriate evidence codes and references.</p> </li> <li> <p>Complex representation: According to the GO-CAM best practices document on complexes, when specific subunits carrying the activity are known, the activities are represented by the specific proteins. This model follows this guideline by showing TPPP's specific activities rather than using a generic complex term.</p> </li> </ol>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model generally follows best practices, a few minor improvements could be made:</p> <ol> <li> <p>More specific protein binding terms for S100 proteins: Instead of the general GO:0005515 (protein binding), more specific terms like \"S100 protein binding\" or \"calcium-dependent protein binding\" could better describe the molecular function.</p> </li> <li> <p>Include calcium as a cofactor: Since the regulation by S100 proteins is calcium-dependent, this information could be included in the model.</p> </li> <li> <p>Include additional downstream effects: The model could be expanded to show how TPPP's microtubule nucleation activity affects cellular processes like myelination, which is discussed in the Fu et al. (2019) paper.</p> </li> <li> <p>Additional evidence for location: While the Golgi apparatus location is appropriate based on Fu et al. (2019), adding this specific reference for this assertion would strengthen the model.</p> </li> </ol>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the regulation of TPPP's microtubule nucleator activity by S100 proteins through inhibition of TPPP dimerization. The biological content is consistent with current literature, the evidence is appropriate, and the model follows GO-CAM best practices. Minor improvements could enhance its specificity and completeness, but overall, this is a well-constructed model that effectively captures this regulatory pathway.</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/","title":"613aae0000000813 Liver apoptosis regulation by CASP6  Human","text":"<p>Based on the review of the GO-CAM model and related information, I'll now provide a thorough review of the GO-CAM model \"gomodel:613aae0000000813\" titled \"Liver apoptosis regulation by CASP6 (Human)\".</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#review-of-go-cam-model-liver-apoptosis-regulation-by-casp6-human","title":"Review of GO-CAM Model: Liver apoptosis regulation by CASP6 (Human)","text":""},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#model-summary","title":"Model Summary","text":"<p>ID: gomodel:613aae0000000813 Title: Liver apoptosis regulation by CASP6 (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the molecular pathway for CASP6 (Caspase-6) regulation in liver apoptosis, specifically focusing on how the AMP-activated protein kinase (AMPK) inhibits CASP6 activation to prevent excessive hepatocyte death in nonalcoholic steatohepatitis (NASH). The model is based primarily on research by Zhao et al. (2020) published in Science (PMID:32029622).</p> <p>The model contains four key activities: 1. BID (P55957-4) enabling cysteine-type endopeptidase regulator activity (GO:0043028) 2. PRKAA1 (Q13131-2) enabling protein serine/threonine kinase activity (GO:0004674) 3. PRKAA2 (P54646) enabling protein serine/threonine kinase activity (GO:0004674)  4. CASP6 (P55212) enabling cysteine-type endopeptidase activity (GO:0004197)</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#pathway-analysis","title":"Pathway Analysis","text":"<p>The model depicts the following regulatory pathway: - Both PRKAA1 and PRKAA2 (AMPK \u03b11 and \u03b12 subunits) negatively regulate CASP6 through their protein serine/threonine kinase activity - CASP6, when active, positively regulates BID through its cysteine-type endopeptidase activity - BID, when cleaved by CASP6, participates in positive regulation of cytochrome c release from mitochondria</p> <p>This pathway accurately reflects findings from Zhao et al. (2020), showing that: 1. AMPK phosphorylates CASP6 at Ser-257, preventing its activation 2. When AMPK activity is reduced (as in NASH), CASP6 becomes activated 3. Active CASP6 cleaves BID to induce cytochrome c release 4. This creates a feedforward loop that leads to hepatocyte death</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by evidence: - The relationship between CASP6 and BID is supported by experimental evidence from PMID:15661737 and PMID:32029622 - The regulatory relationships between AMPK (PRKAA1/PRKAA2) and CASP6 are supported by experimental evidence from PMID:32029622 - The biological processes (hepatocyte apoptotic process, release of cytochrome c) are well-supported by experimental evidence</p> <p>The evidence types used (ECO:0000314 - direct assay evidence, ECO:0000304 - author statement supported by traceable reference) are appropriate for the assertions made.</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model follows GO-CAM best practices: - Appropriate use of causal relationships (RO:0002630 \"directly negatively regulates\" and RO:0002629 \"directly positively regulates\") - Correct representation of protein activities and biological processes - Proper association of activities with biological processes</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#consistency-with-current-knowledge","title":"Consistency with Current Knowledge","text":"<p>The model is consistent with current understanding of AMPK-CASP6 regulation in liver damage. Zhao et al. (2020) demonstrated that: 1. AMPK phosphorylates CASP6 at Ser-257, preventing its activation 2. In NASH, reduced AMPK activity leads to increased CASP6 activation 3. CASP6 cleaves BID at specific sites (Asp59 and Asp75) 4. Cleaved BID induces cytochrome c release from mitochondria</p> <p>The model accurately captures this mechanism.</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#recent-changes-and-annotations","title":"Recent Changes and Annotations","text":"<p>The model includes an automated change from 2024-10-10 where GO:0097153 was replaced by GO:0004197 (cysteine-type endopeptidase activity), reflecting ongoing ontology maintenance.</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is generally well-constructed, I suggest the following improvements:</p> <ol> <li> <p>Add molecular details of phosphorylation: The model could be enhanced by specifically indicating that AMPK phosphorylates CASP6 at Ser-257. This detail is crucial for understanding the mechanism and is well-supported by the Zhao et al. paper.</p> </li> <li> <p>Include the feedback loop: The model shows CASP6 cleaving BID, but doesn't fully capture the feedforward loop described in the paper where cleaved BID induces cytochrome c release, which further activates upstream caspases. This feedback mechanism is an important aspect of how CASP6 sustains apoptosis in hepatocytes.</p> </li> <li> <p>Add additional molecular players: The model could include other components mentioned in the paper, such as:</p> </li> <li>Executioner caspases (CASP3 and CASP7) that initially cleave CASP6</li> <li> <p>Cytochrome c and its role in activating the caspase cascade</p> </li> <li> <p>Clarify BID cleavage sites: The model could specify the cleavage sites on BID (Asp59 and Asp75) as these are specifically identified in the paper.</p> </li> <li> <p>Update GO term for BID: BID's activity is currently annotated as \"cysteine-type endopeptidase regulator activity involved in apoptotic process\" (GO:0043028), but based on the paper, it might be more appropriate to use \"BH3 domain binding\" or \"pro-apoptotic activity\" as BID acts as a BH3-only protein that promotes apoptosis after being cleaved.</p> </li> </ol>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Liver apoptosis regulation by CASP6 (Human)\" effectively represents the key molecular interactions in the AMPK-CASP6-BID pathway involved in liver damage during NASH. It is well-supported by published evidence and follows GO-CAM best practices. With the suggested enhancements, the model could more comprehensively capture the molecular details and feedback mechanisms involved in this important pathway.</p> <p>The model makes a valuable contribution to understanding how metabolic dysregulation in NASH leads to increased hepatocyte apoptosis through the AMPK-CASP6 axis, which has been identified as a potential therapeutic target for NASH treatment.</p>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/","title":"613aae0000000885 SP ANN PTPRM","text":"<p>Now let me review the specific GO-CAM model in question:</p>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#go-cam-model-review-gomodel613aae0000000885","title":"GO-CAM Model Review: gomodel:613aae0000000885","text":""},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#summary","title":"Summary","text":"<p>This model titled \"SP-ANN-PTPRM\" describes interactions between PTPRM (receptor-type tyrosine-protein phosphatase mu), CTNND1 (p120 catenin), ZDHHC7 (palmitoyltransferase), and SLC2A4 (GLUT4) in human cells (NCBITaxon:9606).</p>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#model-components","title":"Model Components","text":"<ol> <li>PTPRM (UniProtKB:P28827) with phosphatase activity at cell-cell junction</li> <li>CTNND1 (UniProtKB:O60716) with cadherin binding and protein sequestering activities</li> <li>ZDHHC7 (UniProtKB:Q9NXF8) with palmitoyltransferase activity</li> <li>SLC2A4/GLUT4 (UniProtKB:P14672) with glucose transmembrane transporter activity</li> </ol>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>PTPRM phosphatase activity inhibits CTNND1's sequestering activity</li> <li>CTNND1 cadherin binding leads to CTNND1's protein sequestering activity</li> <li>CTNND1 protein sequestering activity inhibits SLC2A4/GLUT4 transporter activity</li> <li>ZDHHC7 palmitoyltransferase activity activates SLC2A4/GLUT4 transporter activity</li> </ul>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#evidence-assessment","title":"Evidence Assessment","text":"<p>The literature evidence supports the model:</p> <ol> <li>PTPRM dephosphorylates p120 catenin (CTNND1), preventing its cytoplasmic localization (PMID:21998202)</li> <li>CTNND1 binds to cadherins at cell-cell junctions (PMID:15240885, PMID:17047063)</li> <li>Cytoplasmic CTNND1 can sequester GLUT4 and prevent its localization to the plasma membrane (PMID:21998202)</li> <li>ZDHHC7 palmitoylates GLUT4/SLC2A4 and regulates its membrane translocation (PMID:28057756)</li> </ol>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#strengths","title":"Strengths","text":"<ul> <li>The model accurately represents the molecular interactions and causal relationships described in the literature</li> <li>Cellular locations are properly specified (cell surface, cytoplasm, plasma membrane)</li> <li>The use of \"protein sequestering activity\" (GO:0140311) for CTNND1 is appropriate per GO-CAM guidelines</li> <li>The literature evidence is sufficient and relevant to support all connections</li> </ul>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>No issues found: The model follows GO-CAM best practices for representing complexes and protein sequestering activities.</p> </li> <li> <p>Biological accuracy: The model is consistent with our understanding of how PTPRM regulates adipogenic differentiation via modulation of p120 catenin phosphorylation, which in turn affects GLUT4 trafficking to the plasma membrane.</p> </li> </ol>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the regulatory pathway where PTPRM dephosphorylates p120 catenin (CTNND1), preventing CTNND1-mediated sequestering of GLUT4/SLC2A4, while ZDHHC7 palmitoylates GLUT4 to promote its membrane translocation. The model is well-supported by literature evidence and follows GO-CAM best practices. No corrections are needed.</p>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/","title":"613aae0000001005 SP ANN RECQL5","text":"<p>Now that I've gathered all the necessary information, let me provide a comprehensive review of the GO-CAM model with ID 613aae0000001005.</p>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#review-of-go-cam-model-613aae0000001005-sp-ann-recql5","title":"Review of GO-CAM Model 613aae0000001005 (\"SP-ANN-RECQL5\")","text":""},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#overview","title":"Overview","text":"<p>This GO-CAM model (available at https://bioregistry.io/go.model:613aae0000001005) focuses on the role of RECQL5 helicase in DNA replication and repair, with a focus on interactions with DNA recombination proteins like RAD51 and the endonuclease MUS81, regulated by CDK1 kinase activity.</p>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#summary-of-key-components","title":"Summary of Key Components","text":"<ol> <li>RECQL5 helicase activity (GO:0004386) enabled by UniProtKB:O94762 (RECQL5)</li> <li>Single-stranded DNA binding (GO:0003697) enabled by UniProtKB:Q06609 (RAD51)</li> <li>Endonuclease activity (GO:0004519) enabled by UniProtKB:Q96NY9 (MUS81)</li> <li>Kinase activity (GO:0016301) enabled by UniProtKB:P06493 (CDK1)</li> </ol>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#biological-context","title":"Biological Context","text":"<p>The model represents a pathway where RECQL5 helicase directly negatively regulates RAD51 DNA binding activity, while directly positively regulating MUS81 endonuclease activity. CDK1 is shown to directly positively regulate RECQL5 helicase activity. The model is focused on processes occurring at the replication fork (GO:0005657) during mitotic DNA replication (GO:1990506).</p>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#detailed-analysis","title":"Detailed Analysis","text":""},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#1-recql5-helicase-activity","title":"1. RECQL5 Helicase Activity","text":"<ul> <li>Correctly modeled: RECQL5 is accurately depicted as having helicase activity (GO:0004386)</li> <li>Location is appropriate: The activity occurs at the replication fork (GO:0005657)</li> <li>Biochemistry is accurate: The model correctly shows ATP and water as inputs, with ADP and phosphate as outputs</li> <li>Process association is correct: The activity is part of mitotic DNA-templated DNA replication (GO:1990506)</li> </ul>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#2-rad51-activity","title":"2. RAD51 Activity","text":"<ul> <li>Correctly modeled: RAD51 is annotated with single-stranded DNA binding activity (GO:0003697)</li> <li>Location issue: The activity is shown to occur in \"presynaptic intermediate filament cytoskeleton\" (GO:0099182), which appears to be a questionable annotation. Based on literature, RAD51 activity during DNA repair typically occurs at replication forks or DNA double-strand breaks.</li> </ul>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#3-mus81-activity","title":"3. MUS81 Activity","text":"<ul> <li>Correctly modeled: MUS81 is shown with endonuclease activity (GO:0004519)</li> <li>Location is appropriate: The activity occurs at the replication fork (GO:0005657)</li> </ul>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#4-cdk1-activity","title":"4. CDK1 Activity","text":"<ul> <li>Correctly modeled: CDK1 is annotated with kinase activity (GO:0016301)</li> <li>Evidence supported: The positive regulation of RECQL5 by CDK1 is supported by literature evidence (PMID:28575661)</li> </ul>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#5-causal-relationships","title":"5. Causal Relationships","text":"<ul> <li>RECQL5 and RAD51: The direct negative regulation (RO:0002630) of RAD51 by RECQL5 is well-supported by the literature (PMID:18003859), which shows that RECQL5 can disrupt RAD51 presynaptic filaments</li> <li>RECQL5 and MUS81: The direct positive regulation (RO:0002629) of MUS81 by RECQL5 is supported by literature (PMID:28575661)</li> <li>CDK1 and RECQL5: The direct positive regulation (RO:0002629) of RECQL5 by CDK1 is supported by literature (PMID:28575661)</li> </ul>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#issues-identified","title":"Issues Identified","text":"<ol> <li> <p>Location annotation for RAD51: The subcellular location for RAD51 activity is annotated as \"presynaptic intermediate filament cytoskeleton\" (GO:0099182), which seems inappropriate for the DNA repair context. This term is usually used in neuronal contexts, not DNA repair. The more appropriate location would be \"replication fork\" (GO:0005657) or \"site of DNA damage\" (GO:0035861).</p> </li> <li> <p>Incomplete representation of process context: While RECQL5 activity is correctly shown as part of mitotic DNA replication (GO:1990506), there could be more specific process context for the regulations of RAD51 and MUS81. For example, this could be occurring during \"DNA damage response\" (GO:0006974) or more specifically \"replication fork processing\" (GO:0031297).</p> </li> <li> <p>Complex annotation: According to the GO-CAM guidelines for annotating complexes, when specific subunits carrying molecular activities are known (as in this case), they should be displayed individually in the model. However, it may be worth noting that MUS81 often functions as part of the MUS81-EME1 complex, which is not reflected in this model.</p> </li> <li> <p>Missing components: The literature suggests that RPA (Replication Protein A) plays an important role in RECQL5's ability to displace RAD51 from ssDNA. This component is missing from the model.</p> </li> </ol>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Correct the location annotation for RAD51 from \"presynaptic intermediate filament cytoskeleton\" (GO:0099182) to a more appropriate term such as \"replication fork\" (GO:0005657).</p> </li> <li> <p>Add more specific process context for the regulations, particularly for the RAD51 and MUS81 activities.</p> </li> <li> <p>Consider adding RPA as it plays an important role in RECQL5's ability to displace RAD51 from ssDNA according to the literature.</p> </li> <li> <p>Consider adding EME1 as a partner of MUS81, as they typically function together as a complex in DNA repair processes.</p> </li> <li> <p>Add more specific biological context: The model could benefit from additional information about when this pathway is active, such as during replication stress or at common fragile sites during mitosis, as suggested by the literature.</p> </li> </ol>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#conclusion","title":"Conclusion","text":"<p>Overall, the GO-CAM model 613aae0000001005 provides a good representation of the role of RECQL5 in regulating homologous recombination through its interactions with RAD51 and MUS81, under the regulation of CDK1. The causal relationships are well-supported by the literature, and the evidence is properly cited. With the suggested improvements, particularly correcting the location annotation for RAD51 and adding more complete biological context, this could become an even more valuable representation of this important DNA repair mechanism.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/","title":"617b481400000389 KAT5 regulation of the cytoskeleton by acetylation of proteins  Human","text":"<p>Now that I have gathered all the necessary information, I'll review GO-CAM model 617b481400000389.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#review-of-go-cam-model-617b481400000389","title":"Review of GO-CAM Model 617b481400000389","text":""},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#model-overview","title":"Model Overview","text":"<p>Title: KAT5 regulation of the cytoskeleton by acetylation of proteins (Human) ID: gomodel:617b481400000389 Taxon: Human (NCBITaxon:9606) Status: Production</p> <p>This model describes how KAT5 (TIP60) regulates cytoskeletal processes during mitosis through acetylation of various proteins, focusing on how this affects chromosome segregation and kinetochore-microtubule attachment.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#overall-structure-analysis","title":"Overall Structure Analysis","text":"<p>The model consists of 6 activities connected through causal associations:</p> <ol> <li>AURKB kinase activities (two instances)</li> <li>KAT5 acetyltransferase activity </li> <li>SIRT1 deacetylase activity</li> <li>NDC80 kinetochore adaptor activity</li> <li>CDK1 kinase activity</li> </ol> <p>The model demonstrates a regulatory cascade involving CDK1, KAT5, SIRT1, AURKB, and NDC80, all contributing to the regulation of mitotic sister chromatid segregation.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#molecular-activities-and-annotations","title":"Molecular Activities and Annotations","text":""},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#1-aurkb-aurora-kinase-b-activities","title":"1. AURKB (Aurora Kinase B) Activities:","text":"<p>Two AURKB-enabled activities are represented: - Activity 1 (617b481400000409): Protein serine/threonine kinase activity (GO:0004674)   - Part of positive regulation of mitotic sister chromatid segregation (GO:0062033)   - Evidence from PMID:26829474   - Enabled by UniProtKB:Q96GD4 (AURKB)</p> <ul> <li>Activity 2 (617b481400000428): Protein serine/threonine kinase activity (GO:0004674)</li> <li>Part of positive regulation of mitotic sister chromatid segregation (GO:0062033)</li> <li>Evidence from PMID:30409912</li> <li>Enabled by UniProtKB:Q96GD4 (AURKB)</li> <li>Directly negatively regulates (RO:0002630) NDC80 activity</li> </ul>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#2-kat5-tip60-activity","title":"2. KAT5 (TIP60) Activity:","text":"<ul> <li>Activity (617b481400000400): Peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li>Occurs in kinetochore (GO:0000776)</li> <li>Part of positive regulation of mitotic sister chromatid segregation (GO:0062033)</li> <li>Evidence from PMID:26829474</li> <li>Enabled by UniProtKB:Q92993 (KAT5/TIP60)</li> <li>Directly positively regulates (RO:0002629) AURKB activity (617b481400000409)</li> </ul>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#3-sirt1-activity","title":"3. SIRT1 Activity:","text":"<ul> <li>Activity (617b481400000440): NAD-dependent protein deacetylase activity (GO:0034979)</li> <li>Part of negative regulation of attachment of mitotic spindle microtubules to kinetochore (GO:1902424)</li> <li>Evidence from PMID:30409912</li> <li>Enabled by UniProtKB:Q96EB6-2 (SIRT1 isoform 2)</li> <li>Directly negatively regulates (RO:0002630) NDC80 activity</li> </ul>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#4-ndc80-activity","title":"4. NDC80 Activity:","text":"<ul> <li>Activity (617b481400000435): Kinetochore adaptor activity (GO:0140483)</li> <li>Part of attachment of mitotic spindle microtubules to kinetochore (GO:0051315)</li> <li>Evidence from PMID:30409912</li> <li>Enabled by UniProtKB:O14777 (NDC80/HEC1)</li> </ul>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#5-cdk1-activity","title":"5. CDK1 Activity:","text":"<ul> <li>Activity (617b481400000447): Protein serine/threonine kinase activity (GO:0004674)</li> <li>Part of positive regulation of mitotic sister chromatid segregation (GO:0062033)</li> <li>Evidence from PMID:26829474</li> <li>Enabled by UniProtKB:P06493 (CDK1)</li> <li>Directly positively regulates (RO:0002629) KAT5 activity</li> </ul>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model presents the following causal relationships:</p> <ol> <li>CDK1 \u2192 KAT5 (positive regulation): CDK1 phosphorylates KAT5 at Ser-90, activating its acetyltransferase activity</li> <li>KAT5 \u2192 AURKB (positive regulation): KAT5 acetylates AURKB at Lys-215, enhancing its kinase activity</li> <li>AURKB \u2192 NDC80 (negative regulation): AURKB phosphorylates NDC80, affecting its kinetochore-microtubule attachment</li> <li>SIRT1 \u2192 NDC80 (negative regulation): SIRT1 deacetylates NDC80, counteracting the effect of KAT5-mediated acetylation</li> </ol>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by two key publications:</p> <ol> <li> <p>PMID:26829474 (Mo et al., 2016): This paper demonstrates that KAT5/TIP60 acetylates Aurora B at Lys-215, which protects Aurora B from dephosphorylation at Thr-232, ensuring accurate chromosome segregation. The paper also shows that CDK1 phosphorylates TIP60 at Ser-90, which enhances its acetyltransferase activity.</p> </li> <li> <p>PMID:30409912 (Zhao et al., 2019): This paper shows that KAT5/TIP60 acetylates NDC80/HEC1 at Lys-53 and Lys-59 during mitosis, promoting robust kinetochore-microtubule attachment. SIRT1 counteracts this by deacetylating NDC80/HEC1.</p> </li> </ol> <p>The evidence is strong, coming from primary research articles with experimental evidence (ECO:0000314), and all annotations have been sourced from peer-reviewed publications.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#accuracy-and-completeness-assessment","title":"Accuracy and Completeness Assessment","text":"<p>The model accurately captures the regulatory roles of KAT5/TIP60 in mitotic processes through acetylation of key proteins (AURKB and NDC80). It correctly represents:</p> <ol> <li>The role of CDK1 in activating KAT5 through phosphorylation</li> <li>The role of KAT5 in activating AURKB through acetylation</li> <li>The opposing actions of KAT5 and SIRT1 on NDC80</li> <li>The impact of these activities on mitotic sister chromatid segregation and kinetochore-microtubule attachment</li> </ol>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices: - Each activity has properly annotated molecular function, cellular location (where applicable), and biological process - Causal relationships between activities are correctly specified using appropriate RO relations - Evidence codes and citations are provided for each annotation - The connections between activities form a coherent regulatory pathway</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is well-constructed, a few additions could enhance it:</p> <ol> <li> <p>Additional causal relationships: The model could include the direct acetylation of NDC80 by KAT5, which is described in PMID:30409912 but not explicitly modeled as a causal relationship.</p> </li> <li> <p>Molecular details: Adding annotations for the specific acetylation sites on AURKB (Lys-215) and NDC80 (Lys-53 and Lys-59) could provide more molecular detail.</p> </li> <li> <p>Additional components: The model could include other components of the CPC (Chromosomal Passenger Complex), such as INCENP, which is mentioned in the referenced papers as being important for AURKB function.</p> </li> <li> <p>Phosphorylation details: Adding annotations for the specific phosphorylation sites on KAT5 (Ser-90) and AURKB (Thr-232) would provide more molecular detail.</p> </li> </ol>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 617b481400000389 is a high-quality representation of the role of KAT5/TIP60 in regulating mitotic processes through protein acetylation. It accurately captures the interplay between KAT5, AURKB, SIRT1, and NDC80 during mitosis, supported by strong experimental evidence. The model demonstrates how acetylation and deacetylation events regulate protein function during mitotic sister chromatid segregation and kinetochore-microtubule attachment. The model is consistent with GO-CAM best practices and presents a coherent regulatory pathway.</p>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/","title":"617b481400000460 KAT5 involvement in DNA repair via homologous recombination  Human","text":"<p>Now, let me review the GO-CAM model in detail. Based on the information I've gathered, I'll analyze the model \"KAT5 involvement in DNA repair via homologous recombination (Human)\" (gomodel:617b481400000460).</p>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#go-cam-model-review-kat5-involvement-in-dna-repair-via-homologous-recombination-human","title":"GO-CAM Model Review: KAT5 involvement in DNA repair via homologous recombination (Human)","text":""},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#overview","title":"Overview:","text":"<p>This GO-CAM model represents the role of KAT5 (TIP60) in DNA double-strand break repair, specifically how it influences the choice between DNA repair pathways (homologous recombination vs. non-homologous end joining) through its interactions with histone modifications and 53BP1.</p>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#scientific-content-assessment","title":"Scientific Content Assessment:","text":"<p>The model captures several key molecular activities and their causal relationships:</p> <ol> <li> <p>RNF168 (UniProtKB:Q8IYW5) performs histone H2AK15 ubiquitin ligase activity (GO:0140858) at sites of double-strand breaks (GO:0035861), which provides input for TP53BP1 ubiquitin-modified histone reader activity and DNA-binding transcription factor activity.</p> </li> <li> <p>KAT5 (UniProtKB:Q92993) performs histone H2A acetyltransferase activity (GO:0043998) at sites of double-strand breaks, which maintains a regulatory relationship with TP53BP1 methylated histone binding activity.</p> </li> <li> <p>MBTD1 (UniProtKB:Q05BQ5) performs methylated histone binding (GO:0035064) and directly negatively regulates TP53BP1 binding to methylated histones.</p> </li> <li> <p>EPC1 (UniProtKB:Q9H2F5) performs chromatin-protein adaptor activity (GO:0140463) and directly positively regulates MBTD1 activities.</p> </li> <li> <p>TP53BP1 (UniProtKB:Q12888) performs both methylated histone binding (GO:0035064) and ubiquitin-modified histone reader activity (GO:0061649).</p> </li> <li> <p>Additional regulatory proteins: PIAS4 and SENP3 regulate KAT5 through sumoylation processes.</p> </li> </ol>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#pathway-logic","title":"Pathway Logic:","text":"<p>The model correctly depicts the competition between homologous recombination (HR) and non-homologous end joining (NHEJ) pathways at double-strand breaks:</p> <ul> <li>The TIP60 complex (KAT5) promotes HR by:</li> <li>Acetylating H2AK15, which prevents ubiquitination of this site by RNF168</li> <li> <p>Using MBTD1 to compete with 53BP1 for binding to H4K20me2</p> </li> <li> <p>53BP1 promotes NHEJ by:</p> </li> <li>Binding to H4K20me2 via its Tudor domain</li> <li>Binding to H2AK15ub via its UDR motif</li> </ul>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#model-strengths","title":"Model Strengths:","text":"<ol> <li> <p>The model accurately captures the bivalent chromatin recognition system of 53BP1 (binding to both H4K20me2 and H2AK15ub).</p> </li> <li> <p>It correctly represents the antagonistic relationship between KAT5 and 53BP1, where KAT5 promotes HR by interfering with 53BP1 binding.</p> </li> <li> <p>The regulatory relationships use appropriate causal predicates (RO:0002413 \"provides input for\", RO:0002629 \"directly positively regulates\", and RO:0002630 \"directly negatively regulates\").</p> </li> <li> <p>The model incorporates MBTD1 as a key component of the TIP60 complex that competes with 53BP1 for H4K20me2 binding.</p> </li> <li> <p>The inclusion of EPC1 as an adaptor protein for MBTD1 is supported by the literature.</p> </li> <li> <p>The model shows how PIAS4 and SENP3 regulate KAT5 activity, reflecting the dynamic regulation of repair pathway choice.</p> </li> </ol>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Representation of the NuA4/TIP60 Complex: While the model shows KAT5 and some components, the full TIP60 complex isn't explicitly represented. According to best practices for complex annotation, using GO:0035267 (NuA4 histone acetyltransferase complex) might be appropriate in some places rather than individual proteins if the specific activity-carrying subunits aren't clearly identified.</p> </li> <li> <p>Cell Cycle Regulation: The model could be expanded to include cell cycle-dependent regulation of repair pathway choice. During S/G2 phases, HR is favored, while NHEJ predominates in G1.</p> </li> <li> <p>Bi-directional Process: It would be valuable to explicitly show that H2AK15 is a site of competition between ubiquitination (by RNF168) and acetylation (by KAT5), which directly impacts 53BP1 recruitment.</p> </li> <li> <p>Acetylation Target Specification: The histone H2A acetyltransferase activity (GO:0043998) could be more specifically annotated as H2AK15 acetyltransferase activity if that term is available, to better reflect the site-specific nature of this mechanism.</p> </li> <li> <p>Biological Process Annotation: The model correctly shows the part_of relationships to double-strand break repair processes (GO:0000724 and GO:0006303), but could potentially benefit from explicitly showing the antagonistic relationship between these processes.</p> </li> </ol>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#technicalquality-issues","title":"Technical/Quality Issues:","text":"<ol> <li> <p>All activities and relationships in the model are properly supported with evidence codes and PMID references.</p> </li> <li> <p>The subcellular localization is consistently annotated as \"site of double-strand break\" (GO:0035861).</p> </li> <li> <p>I noticed the use of RO:0012010 in one causal association, which is not among the standard predicates listed in your guidelines (which include RO:0002413, RO:0002629, RO:0002630, RO:0002304, and RO:0002305). This should be checked for consistency.</p> </li> </ol>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#conclusion","title":"Conclusion:","text":"<p>The GO-CAM model \"KAT5 involvement in DNA repair via homologous recombination (Human)\" is scientifically accurate and effectively represents the current understanding of how KAT5/TIP60 influences DNA repair pathway choice. It properly captures the competition between KAT5 and 53BP1 for binding to modified histones at double-strand breaks, and how this affects the choice between HR and NHEJ repair mechanisms.</p> <p>The model follows most GO-CAM best practices for representing molecular activities, causal relationships, and cellular context. With a few minor refinements, particularly in the representation of protein complexes and the competitive relationship between repair pathways, this model could provide an even more comprehensive representation of this important biological process.</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/","title":"617b481400000521 KAT5 involvement in nucleotide excision repair  Human","text":"<p>Based on the information gathered, I'll now provide a comprehensive review of GO-CAM model gomodel:617b481400000521 - \"KAT5 involvement in nucleotide excision repair (Human)\".</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#go-cam-model-review-kat5-involvement-in-nucleotide-excision-repair-human","title":"GO-CAM Model Review: KAT5 involvement in nucleotide excision repair (Human)","text":""},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the role of KAT5 (TIP60) in nucleotide excision repair, specifically focusing on how it regulates the XPF-ERCC1 complex in human cells. The model is based on evidence from PMID:32034146.</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model includes 4 key activities: 1. UniProtKB:Q96EB6 (SIRT1) - NAD-dependent protein lysine deacetylase activity (GO:0034979) 2. UniProtKB:Q92993 (KAT5/TIP60) - peptide-lysine-N-acetyltransferase activity (GO:0061733) 3. UniProtKB:Q92889-2 (ERCC4/XPF) - protein binding (GO:0005515) 4. UniProtKB:Q92889-2 (ERCC4/XPF) - single-stranded DNA endodeoxyribonuclease activity (GO:0000014)</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>SIRT1 deacetylase activity directly negatively regulates (RO:0002630) XPF protein binding activity</li> <li>KAT5 acetyltransferase activity directly positively regulates (RO:0002629) XPF protein binding activity</li> <li>XPF protein binding activity directly positively regulates (RO:0002629) XPF endonuclease activity</li> </ul>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#biological-process-context","title":"Biological Process Context","text":"<ul> <li>The XPF endonuclease activity and protein binding are part of nucleotide-excision repair (GO:0006289)</li> </ul>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#scientific-accuracy-and-consistency","title":"Scientific Accuracy and Consistency","text":"<p>The model accurately represents the findings from PMID:32034146, which reports that:</p> <ol> <li>TIP60 (KAT5) acetylates XPF at Lys911, which disrupts a salt bridge and facilitates XPF-ERCC1 complex assembly</li> <li>SIRT1 deacetylates XPF, counteracting TIP60's effect</li> <li>The acetylation of XPF is critical for proper nucleotide excision repair</li> <li>The activation of the XPF-ERCC1 complex through acetylation is essential for its function</li> </ol>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly captures the core regulatory mechanism reported in the literature</li> <li>The causal relationships between activities are correctly represented using appropriate predicates</li> <li>The model includes both positive (KAT5) and negative (SIRT1) regulators of XPF activity</li> <li>All activities are appropriately part of the nucleotide excision repair biological process</li> </ol>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#potential-issues-and-recommendations","title":"Potential Issues and Recommendations","text":"<ol> <li>Complex Representation Issue:</li> <li>The model uses Q92889-2 (ERCC4/XPF) for both protein binding and endonuclease activity, but the paper emphasizes that these activities are performed by the XPF-ERCC1 complex.</li> <li> <p>Per the GO-CAM \"How to annotate complexes\" guideline, if the activity is specifically carried out by the complex rather than individual subunits, it would be better to use the complex ID (GO:0070522 \"ERCC4-ERCC1 complex\") to represent the endonuclease activity.</p> </li> <li> <p>Missing Components:</p> </li> <li> <p>While ERCC1 (UniProtKB:P07992) is listed in the objects of the model, it's not explicitly represented in the activities. Given the paper's emphasis on the importance of XPF-ERCC1 interaction for activity, it would be beneficial to represent ERCC1 more explicitly.</p> </li> <li> <p>Activity Annotation Specificity:</p> </li> <li> <p>The use of generic \"protein binding\" (GO:0005515) for XPF could be more specific, such as \"protein complex binding\" or even more specifically \"ERCC1 binding\" if such a term exists.</p> </li> <li> <p>Biological Context Expansion:</p> </li> <li>The model could potentially include that TIP60 acetylation of XPF is induced by DNA damage (UV irradiation or MMC treatment), providing additional contextual information.</li> </ol>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Consider using GO:0070522 (ERCC4-ERCC1 complex) as the entity for the endonuclease activity rather than just XPF protein, as the paper clearly shows this activity requires the complex.</p> </li> <li> <p>Add a representation of ERCC1's role in the complex, potentially showing it as part of the functional unit with XPF.</p> </li> <li> <p>Replace the generic \"protein binding\" term with a more specific term that better describes the XPF-ERCC1 interaction.</p> </li> <li> <p>Potentially expand the model to include the DNA damage context that induces TIP60 activation and subsequent XPF acetylation.</p> </li> </ol>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-structured model that captures the key findings from the paper regarding KAT5/TIP60's role in nucleotide excision repair through XPF acetylation. With minor adjustments to better represent the complex nature of the XPF-ERCC1 interaction, this model would provide an excellent representation of the biological pathway.</p>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/","title":"617b481400000559 KAT5 regulation of lipid droplet disassembly  Human","text":"<p>Based on my review of the GO-CAM model (gomodel:617b481400000559) titled \"KAT5 regulation of lipid droplet disassembly (Human)\" and the relevant information I've gathered, here's my detailed assessment:</p>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#model-structure-review","title":"Model Structure Review","text":"<p>This model represents a cellular pathway where KAT5 (histone acetyltransferase) regulates lipid droplet disassembly in response to glucose starvation in human cells. The model includes the following key activities and relationships:</p> <ol> <li> <p>PRKAA1 (Q13131, AMPK alpha-1) and PRKAA2 (P54646, AMPK alpha-2) both perform protein serine/threonine kinase activity (GO:0004674), as part of cellular response to glucose starvation (GO:0042149), and both positively regulate KAT5 transcription activity and phosphorylate CHKA.</p> </li> <li> <p>KAT5 (Q92993) performs peptide-lysine-N-acetyltransferase activity (GO:0061733), as part of cellular response to glucose starvation (GO:0042149), and negatively regulates CHKA homodimerization while positively regulating CHKA protein binding.</p> </li> <li> <p>CHKA (P35790-1, isoform 1) has:</p> </li> <li>Protein homodimerization activity (GO:0042803) in the cytosol, part of phosphatidylcholine biosynthetic process</li> <li>Protein binding activity (GO:0005515) in lipid droplets, in response to glucose starvation</li> <li>Choline kinase activity (GO:0004103) in the cytosol</li> <li>Ethanolamine kinase activity (GO:0004305) in the cytosol</li> <li>Protein tyrosine kinase activity (GO:0004713) in lipid droplets, part of lipid droplet disassembly</li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#scientific-content-assessment","title":"Scientific Content Assessment","text":"<p>The model accurately captures the findings reported in the primary article (PMID:34077757), specifically:</p> <ol> <li> <p>Mechanism of regulation: The model correctly shows that AMPK (PRKAA1 and PRKAA2) phosphorylates CHKA at Ser-279 upon glucose deprivation, which promotes its localization to lipid droplets.</p> </li> <li> <p>KAT5-mediated acetylation: KAT5 subsequently acetylates CHKA at Lys-247, promoting dissociation of the CHKA homodimer into monomers.</p> </li> <li> <p>Functional shift: The model accurately depicts that acetylated monomeric CHKA is converted into a protein tyrosine kinase that phosphorylates lipid droplet structural proteins (though I note the model doesn't explicitly show the downstream targets PLIN2 and PLIN3).</p> </li> <li> <p>Biological outcome: The model appropriately shows the culmination of this pathway as lipid droplet disassembly (GO:1905691).</p> </li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#annotation-quality-review","title":"Annotation Quality Review","text":"<ol> <li> <p>Correct use of GO terms: The molecular functions, biological processes, and cellular components are appropriately assigned.</p> </li> <li> <p>Proper use of causal associations: </p> </li> <li>RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates) are used correctly to show direct regulation.</li> <li> <p>RO:0002304 (causally upstream of, positive effect) is correctly used for the indirect positive regulation.</p> </li> <li> <p>Evidence annotations: All activities are appropriately supported with ECO:0000314 (direct assay evidence used in manual assertion) and refer to the primary paper PMID:34077757.</p> </li> <li> <p>Localization information: The model correctly includes cellular localization information for CHKA, showing its presence in both cytosol and lipid droplets.</p> </li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model follows GO-CAM best practices for:</p> <ol> <li> <p>Activity flow: The activities are connected in a way that is consistent with the biological pathway.</p> </li> <li> <p>Complex representation: The model correctly handles the CHKA homodimer, following the guidelines in \"How to annotate complexes in GO-CAM\" by properly showing the homodimerization activity.</p> </li> <li> <p>Protein modification effects: The model appropriately captures how post-translational modifications (phosphorylation followed by acetylation) affect protein function.</p> </li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is scientifically accurate and well-constructed, I'd suggest a few minor improvements:</p> <ol> <li> <p>Complete the pathway: Consider adding the specific lipid droplet proteins (PLIN2 and PLIN3) that are phosphorylated by monomeric CHKA's tyrosine kinase activity. This would complete the mechanistic picture of how lipid droplet disassembly occurs.</p> </li> <li> <p>Clearer activity visualization: The model might benefit from a clearer visual representation of the transition from CHKA homodimer to monomer following acetylation.</p> </li> <li> <p>Additional contextual information: Consider adding information about adenylate charge sensing (a key function of AMPK) as part of the glucose starvation response.</p> </li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model (gomodel:617b481400000559) is a high-quality representation of the KAT5-mediated regulation of lipid droplet disassembly pathway. It accurately captures the scientific content from the literature, follows GO-CAM best practices, and provides a clear depiction of the activity flow in the pathway. The model is parsimonious and presents the information in a way that would be understandable to a human curator.</p> <p>The model effectively represents a novel and important regulatory mechanism where a metabolic enzyme (CHKA) is converted to a protein kinase through post-translational modifications, leading to lipid droplet disassembly during glucose starvation.</p>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/","title":"617b481400000672 KAT5 chromatin localization  Human","text":"<p>Now that I've gathered all the necessary information, I'll review the GO-CAM model:</p>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#review-of-go-cam-model-gomodel617b481400000672","title":"Review of GO-CAM Model: gomodel:617b481400000672","text":""},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#model-overview","title":"Model Overview","text":"<p>Title: KAT5 chromatin localization (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#summary","title":"Summary","text":"<p>This model describes the chromatin localization of KAT5 (also known as Tip60) and its activities in the context of positive regulation of transcription and DNA damage response. The model shows how KAT5 is regulated through phosphorylation by CDK9 and VRK1, and how KAT5's subsequent activities affect transcription and DNA damage response.</p>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#model-strengths","title":"Model Strengths","text":"<ol> <li>Accurate representation of KAT5 molecular activities:</li> <li>The model correctly represents KAT5's chromatin binding activity (GO:0003682)</li> <li> <p>The histone acetyltransferase activity (GO:0004402) and H4K16 acetyltransferase activity (GO:0046972) are properly represented</p> </li> <li> <p>Proper subcellular localization:</p> </li> <li> <p>The model correctly places KAT5 activities in chromatin (GO:0000785)</p> </li> <li> <p>Biological context:</p> </li> <li> <p>The model appropriately connects KAT5's activities to positive regulation of transcription by RNA polymerase II (GO:0045944) and DNA damage response (GO:0006974)</p> </li> <li> <p>Causal relationships:</p> </li> <li> <p>The model shows the correct regulatory relationships where:</p> <ul> <li>CDK9's protein serine/threonine kinase activity leads to KAT5 chromatin binding</li> <li>VRK1's protein serine/threonine kinase activity leads to KAT5 chromatin binding</li> <li>KAT5's chromatin binding leads to histone acetyltransferase activity</li> </ul> </li> <li> <p>Evidence basis:</p> </li> <li>The model uses appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion)</li> <li>References to primary literature (PMID:29335245 and PMID:33076429) are provided</li> </ol>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Specificity of phosphorylation sites:</li> <li> <p>The model does not specify which specific serine residues are phosphorylated. Based on the literature (PMID:29335245), CDK9 phosphorylates KAT5 at serine 90 (S90), which is critical for its association with chromatin. This detail could be added to the model.</p> </li> <li> <p>Temporal sequence of activities:</p> </li> <li> <p>While the causal relationships are correctly represented, the temporal sequence is not entirely clear. The literature indicates that S90 phosphorylation is required for subsequent S86 phosphorylation by GSK3, which together enhance KAT5's HAT activity. This sequential relationship could be made more explicit.</p> </li> <li> <p>Missing GSK3 regulation:</p> </li> <li> <p>According to PMID:29335245, GSK3 phosphorylates S86 of KAT5 using S90 phosphorylation as a priming site. This important regulatory component is missing from the model.</p> </li> <li> <p>Model completeness:</p> </li> <li> <p>The model focuses primarily on the regulation of KAT5 localization but could be expanded to include:</p> <ul> <li>H2AX acetylation by KAT5, which is important for NBS1 recruitment to DNA damage sites</li> <li>ATM acetylation by KAT5, which is required for ATM activation in DNA damage response</li> </ul> </li> <li> <p>Complex representation:</p> </li> <li>According to the GO-CAM guidelines for complexes, if KAT5 is part of the NuA4 histone acetyltransferase complex during these activities, this could be represented. The model currently treats KAT5 as an individual protein rather than as part of its known complex.</li> </ol>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#recommendations","title":"Recommendations","text":"<ol> <li>Add specific phosphorylation sites:</li> <li>Specify that CDK9 phosphorylates KAT5 at S90</li> <li> <p>Specify that VRK1 phosphorylates KAT5 (though the exact site may not be specified in the literature)</p> </li> <li> <p>Include GSK3 regulation:</p> </li> <li> <p>Add GSK3's role in phosphorylating KAT5 at S86, which depends on prior S90 phosphorylation</p> </li> <li> <p>Expand downstream events:</p> </li> <li>Include KAT5's role in acetylating H2AX at K5</li> <li> <p>Include KAT5's role in acetylating ATM at K3016</p> </li> <li> <p>Clarify complex participation:</p> </li> <li> <p>If appropriate, indicate KAT5's participation in the NuA4 histone acetyltransferase complex when performing its acetyltransferase activities</p> </li> <li> <p>Add additional disease relevance:</p> </li> <li>Consider adding information about KAT5's role in cancer resistance to DNA-damaging agents, which is mentioned in the literature</li> </ol>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the key activities of KAT5 in chromatin and its regulation by kinases. The model effectively captures how KAT5's activities contribute to transcriptional regulation and DNA damage response. With the suggested improvements, particularly regarding the specificity of phosphorylation sites and the inclusion of GSK3 regulation, the model would provide an even more complete representation of the biological mechanisms involved in KAT5 function.</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/","title":"617b481400000793 KAT5 autoacetylation and deacetylation by HDAC3 and SIRT1  Human","text":"<p>Based on my review of the GO-CAM model and related documents, here's my evaluation of the model:</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#review-of-go-cam-model-gomodel617b481400000793","title":"Review of GO-CAM Model: gomodel:617b481400000793","text":""},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#model-summary","title":"Model Summary","text":"<p>Title: KAT5 autoacetylation and deacetylation by HDAC3 and SIRT1 (Human) Taxon: Human (NCBITaxon:9606) Status: Production Link: https://bioregistry.io/go.model:617b481400000793</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#model-contents","title":"Model Contents","text":"<p>This GO-CAM model represents the regulatory mechanism of KAT5 (Histone acetyltransferase KAT5/TIP60) involving autoacetylation and deacetylation by HDAC3 and SIRT1. The model includes:</p> <ol> <li> <p>KAT5 autoacetylation: KAT5 (UniProtKB:Q92993) has peptide-lysine-N-acetyltransferase activity (GO:0061733) that directly positively regulates its own histone acetyltransferase activity (GO:0004402)</p> </li> <li> <p>KAT5 deacetylation by HDAC3: HDAC3 (UniProtKB:O15379) has protein lysine deacetylase activity (GO:0033558) that directly negatively regulates KAT5's peptide-lysine-N-acetyltransferase activity</p> </li> <li> <p>KAT5 deacetylation by SIRT1: SIRT1 (UniProtKB:Q96EB6) has NAD-dependent protein lysine deacetylase activity (GO:0034979) that directly negatively regulates KAT5's peptide-lysine-N-acetyltransferase activity</p> </li> <li> <p>Biological context: All activities are part of DNA repair-dependent chromatin remodeling (GO:0140861)</p> </li> </ol>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the biological process described in the literature. According to the referenced papers (PMID:25301942 and PMID:20100829), KAT5 undergoes autoacetylation which enhances its activity, while both HDAC3 and SIRT1 can deacetylate KAT5, reducing its activity. The subcellular location (nucleus) is correctly specified for the relevant activities.</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#go-cam-structure-assessment","title":"GO-CAM Structure Assessment","text":""},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Proper use of causal relationships: The model correctly uses \"directly positively regulates\" (RO:0002629) and \"directly negatively regulates\" (RO:0002630) to connect the activities.</p> </li> <li> <p>Appropriate molecular functions: The model uses specific molecular functions for each protein:</p> </li> <li>KAT5: peptide-lysine-N-acetyltransferase activity (GO:0061733) and histone acetyltransferase activity (GO:0004402)</li> <li>HDAC3: protein lysine deacetylase activity (GO:0033558)</li> <li> <p>SIRT1: NAD-dependent protein lysine deacetylase activity (GO:0034979)</p> </li> <li> <p>Clear biological context: All activities are properly situated within DNA repair-dependent chromatin remodeling (GO:0140861)</p> </li> <li> <p>Evidence and references: Each activity has appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) with corresponding literature references.</p> </li> </ol>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing evidence for one causal association: The causal association between HDAC3's protein lysine deacetylase activity and KAT5's peptide-lysine-N-acetyltransferase activity lacks evidence codes and references. This should be added for completeness.</p> </li> <li> <p>Protein complex representation: While not necessarily an issue in this case, the model doesn't explicitly represent KAT5 as part of any complexes it might function in. According to UniProt records, KAT5 is part of the NuA4 histone acetyltransferase complex, but since the model focuses on KAT5 regulation rather than its downstream targets, this representation is acceptable.</p> </li> </ol>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add evidence for HDAC3's regulatory relationship: Add appropriate evidence codes and references for the causal association between HDAC3's deacetylase activity and KAT5's acetyltransferase activity.</p> </li> <li> <p>Consider expanding the model: While the current model is coherent and focused, it could potentially be expanded to include:</p> </li> <li>The specific lysine residues on KAT5 that are acetylated/deacetylated (e.g., Lys-104, Lys-120, Lys-148, Lys-150, Lys-187, and Lys-189 as mentioned in the UniProt entry)</li> <li> <p>Downstream effects of KAT5 acetylation/deacetylation on its target proteins or biological processes</p> </li> <li> <p>Consistency check: Verify that the temporal relationships in the model are accurate - autoacetylation occurs first, followed by its effect on KAT5's acetyltransferase activity, which can be regulated by HDAC3 and SIRT1's deacetylase activities.</p> </li> </ol>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a high-quality GO-CAM model that effectively represents the regulatory mechanism of KAT5 through autoacetylation and deacetylation by HDAC3 and SIRT1. The model adheres to GO-CAM annotation guidelines, uses appropriate terms and relationships, and is supported by literature evidence. With the minor addition of evidence for one causal association, the model would be complete and ready for continued use in production.</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/","title":"617b481400000995 Epidermal growth factor receptor signaling pathway 1  Mouse","text":"<p>Now I have enough information to provide a comprehensive review of the GO-CAM model gomodel:617b481400000995.</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#review-of-go-cam-model-gomodel617b481400000995","title":"Review of GO-CAM Model: gomodel:617b481400000995","text":""},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: Epidermal growth factor receptor signaling pathway 1 (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production Source: R-HSA-177929</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#summary-of-model-content","title":"Summary of Model Content","text":"<p>This GO-CAM model represents the epidermal growth factor receptor (EGFR) signaling pathway in mouse. The model contains 4 activities involving:</p> <ol> <li>Metallopeptidase activity (GO:0008237) of Mep1a (MGI:MGI:96963)</li> <li>Metallopeptidase activity (GO:0008237) of Adam10 (MGI:MGI:109548)</li> <li>Receptor ligand activity (GO:0048018) of Egf (MGI:MGI:95290)</li> <li>Epidermal growth factor receptor activity (GO:0005006) of Egfr (MGI:MGI:95294)</li> </ol> <p>The pathway captures the maturation of EGF ligand by metallopeptidases (Mep1a and Adam10), which then activates the EGF receptor (Egfr).</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#assessment-of-model-structure","title":"Assessment of Model Structure","text":"<p>The model correctly follows the GO-CAM representation of a receptor-ligand signaling pathway according to guidelines:</p> <ol> <li>Proper causal relations:</li> <li>Metallopeptidases (Mep1a and Adam10) properly connect to EGF with <code>RO:0002304</code> (causally upstream of, positive effect)</li> <li> <p>EGF properly connects to EGFR with <code>RO:0002629</code> (directly positively regulates)</p> </li> <li> <p>Appropriate cellular context:</p> </li> <li>Metallopeptidases and EGFR occur in plasma membrane (GO:0005886)</li> <li> <p>EGF occurs in extracellular space (GO:0005615)</p> </li> <li> <p>Proper biological process context:</p> </li> <li>Metallopeptidases are part of EGF receptor ligand maturation (GO:0038004)</li> <li>EGFR and EGF are part of EGFR signaling pathway (GO:0007173)</li> </ol>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses several sources of evidence:</p> <ol> <li>Experimental Evidence:</li> <li>ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>ECO:0000315 (mutant phenotype evidence used in manual assertion)</li> <li> <p>ECO:0000266 (sequence orthology evidence used in manual assertion)</p> </li> <li> <p>Literature Support:</p> </li> <li>PMID:22923609 - Shows Meprin \u03b1 can shed EGF, activate EGFR pathway</li> <li>PMID:6248866 - Early study showing EGF-receptor binding in embryonic tissues</li> <li>PMID:7752576 </li> <li>PMID:17079736</li> <li>PMID:14993236</li> <li>PMID:28494873</li> </ol> <p>The evidence from PMID:22923609 strongly supports the role of meprin \u03b1 (Mep1a) in the shedding of EGF and TGF-\u03b1, leading to EGFR activation. This paper demonstrates that meprin \u03b1 directly cleaves EGF precursors, resulting in EGFR pathway activation.</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the current understanding of the EGFR signaling pathway:</p> <ol> <li> <p>Role of Metallopeptidases: The inclusion of metallopeptidases (Mep1a and Adam10) in EGF ligand maturation is well-supported by the evidence. From PMID:22923609, we learn that Meprin \u03b1 can shed EGF from the plasma membrane, contributing to EGFR activation.</p> </li> <li> <p>EGFR Signaling: The pathway correctly shows how mature EGF activates EGFR through direct positive regulation.</p> </li> <li> <p>Cellular Locations: The cellular locations of components are biologically accurate, with the receptor and metallopeptidases at the plasma membrane and the ligand in extracellular space.</p> </li> </ol>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for signaling receptor pathways:</p> <ol> <li> <p>Ligand Representation: EGF is correctly annotated with receptor ligand activity (GO:0048018) in extracellular space.</p> </li> <li> <p>Receptor Representation: EGFR is correctly annotated with EGF receptor activity (GO:0005006) at the plasma membrane.</p> </li> <li> <p>Causal Relations: The model uses appropriate causal relations:</p> </li> <li>Metallopeptidases \u2192 EGF: causally upstream of, positive effect</li> <li> <p>EGF \u2192 EGFR: directly positively regulates</p> </li> <li> <p>Process Context: All activities are placed in the appropriate biological process context.</p> </li> </ol>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#potential-improvements","title":"Potential Improvements","text":"<p>While the model is structurally sound and biologically accurate, I would suggest the following improvements:</p> <ol> <li> <p>Downstream Signaling: The model could be expanded to include downstream effectors of EGFR activation, such as the RAS-MAPK pathway and PI3K-AKT pathway, which are well-established components of EGFR signaling.</p> </li> <li> <p>Regulation Mechanisms: Addition of negative regulators of the pathway, such as phosphatases that dephosphorylate EGFR, would provide a more complete picture of pathway regulation.</p> </li> <li> <p>Feedback Loops: Including feedback mechanisms that downregulate receptor signaling would enhance the model's completeness.</p> </li> </ol>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:617b481400000995 is a well-constructed representation of the epidermal growth factor receptor signaling pathway in mouse. It accurately captures the roles of metallopeptidases in EGF ligand maturation and the subsequent activation of EGFR. The model follows GO-CAM best practices for representing receptor-ligand signaling pathways and is supported by appropriate experimental evidence. While it could be expanded to include more downstream components and regulatory mechanisms, the current model provides a solid foundation for understanding the initial steps of EGFR signaling.</p>"},{"location":"reviews/617b481400003575-SP_RNF169/","title":"617b481400003575 SP RNF169","text":"<p>Now, let me review the GO-CAM model with ID gomodel:617b481400003575 in detail.</p>"},{"location":"reviews/617b481400003575-SP_RNF169/#go-cam-model-review-for-gomodel617b481400003575","title":"GO-CAM Model Review for gomodel:617b481400003575","text":""},{"location":"reviews/617b481400003575-SP_RNF169/#model-title-sp-rnf169","title":"Model Title: SP-RNF169","text":""},{"location":"reviews/617b481400003575-SP_RNF169/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents a molecular pathway involving DYRK1A (Q13627), RNF169 (Q8NCN4), TP53BP1 (Q12888), and UIMC1/RAP80 (Q96RL1) in human cells (taxon: 9606). The model describes how DYRK1A protein serine kinase activity positively regulates RNF169's ubiquitin-modified histone reader activity, which in turn negatively regulates both TP53BP1 and UIMC1/RAP80 ubiquitin-modified histone reader activities.</p>"},{"location":"reviews/617b481400003575-SP_RNF169/#review-of-molecular-activities-and-causal-associations","title":"Review of Molecular Activities and Causal Associations","text":"<ol> <li>DYRK1A (UniProtKB:Q13627)</li> <li>Molecular Function: Protein serine kinase activity (GO:0106310)</li> <li>Causal Association: Directly positively regulates (RO:0002629) RNF169's ubiquitin-modified histone reader activity</li> <li>Evidence: ECO:0000314 (direct assay evidence) from PMID:30773093</li> <li>Contributor: https://orcid.org/0000-0001-7646-0052</li> <li> <p>Date: 2021-11-18</p> </li> <li> <p>RNF169 (UniProtKB:Q8NCN4)</p> </li> <li>Molecular Function: Ubiquitin-modified histone reader activity (GO:0061649)</li> <li>Occurs In: Site of double-strand break (GO:0035861)</li> <li>Part Of: Double-strand break repair via homologous recombination (GO:0000724)</li> <li>Causal Association: <ul> <li>Directly negatively regulates (RO:0002630) TP53BP1's ubiquitin-modified histone reader activity</li> <li>Directly negatively regulates (RO:0002630) UIMC1/RAP80's ubiquitin-modified histone reader activity</li> </ul> </li> <li>Evidence: ECO:0000314 (direct assay evidence) from PMID:22492721 and PMID:30104380</li> <li>Contributor: https://orcid.org/0000-0001-7646-0052</li> <li> <p>Date: 2021-11-18</p> </li> <li> <p>TP53BP1 (UniProtKB:Q12888)</p> </li> <li>Molecular Function: Ubiquitin-modified histone reader activity (GO:0061649)</li> <li>Occurs In: Site of double-strand break (GO:0035861)</li> <li>Part Of: Double-strand break repair via nonhomologous end joining (GO:0006303)</li> <li>Evidence: ECO:0000314 (direct assay evidence) from PMID:22492721 and PMID:23333306</li> <li>Contributor: https://orcid.org/0000-0001-7646-0052</li> <li> <p>Date: 2021-11-18</p> </li> <li> <p>UIMC1/RAP80 (UniProtKB:Q96RL1)</p> </li> <li>Molecular Function: Ubiquitin-modified histone reader activity (GO:0061649)</li> <li>Occurs In: Site of double-strand break (GO:0035861)</li> <li>Part Of: Double-strand break repair via nonhomologous end joining (GO:0006303)</li> <li>Evidence: ECO:0000314 (direct assay evidence) from PMID:22492721</li> <li>Contributor: https://orcid.org/0000-0001-7646-0052</li> <li>Date: 2021-11-18</li> </ol>"},{"location":"reviews/617b481400003575-SP_RNF169/#automated-changes","title":"Automated Changes","text":"<p>The model shows the following automated changes: - \"RO:0002212 replaced by RO:0002630\" (2023-03-16) - \"RO:0002213 replaced by RO:0002629\" (2023-03-16)</p> <p>These changes updated the relation terms to use the more specific \"directly positively/negatively regulates\" predicates.</p>"},{"location":"reviews/617b481400003575-SP_RNF169/#assessment-and-qc","title":"Assessment and QC","text":""},{"location":"reviews/617b481400003575-SP_RNF169/#biological-content-consistency","title":"Biological Content Consistency","text":"<p>The model represents a well-substantiated pathway based on research published in PMID:30773093 and PMID:22492721. The model captures how: 1. DYRK1A phosphorylates RNF169 (in response to DNA damage) 2. This phosphorylation enhances RNF169's ability to bind to ubiquitylated histones at DNA damage sites 3. RNF169 then competes with and inhibits TP53BP1 and UIMC1/RAP80 from binding to the same modified chromatin 4. This competition influences the choice between homologous recombination (HR) and non-homologous end joining (NHEJ) DNA repair pathways</p> <p>The papers clearly support that RNF169 functions in homologous recombination (HR) repair, while TP53BP1 and UIMC1/RAP80 promote non-homologous end joining (NHEJ).</p>"},{"location":"reviews/617b481400003575-SP_RNF169/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several ways: 1. Each activity is enabled by a single gene product 2. Causal connections use appropriate relation terms (directly positively/negatively regulates) 3. Activities are properly contextualized with subcellular location (site of double-strand break) 4. Activities are appropriately linked to biological processes (different DNA repair pathways) 5. Evidence codes and references are properly included</p>"},{"location":"reviews/617b481400003575-SP_RNF169/#opportunities-for-improvement","title":"Opportunities for Improvement","text":"<p>While the model is scientifically accurate and well-structured, I suggest a few improvements:</p> <ol> <li>Completeness: The model could be expanded to include:</li> <li>The mechanism by which DYRK1A is activated in response to DNA damage</li> <li>The specific phosphorylation sites on RNF169 (S368 and S403) mentioned in PMID:30773093</li> <li> <p>The downstream effects of pathway choice (HR vs. NHEJ) on DNA repair outcomes</p> </li> <li> <p>Activity Annotation: </p> </li> <li>DYRK1A is annotated with \"protein serine kinase activity\" which is appropriate, but could be more specifically annotated with \"protein serine/threonine/tyrosine kinase activity\" (GO:0004712) based on UniProt annotation, though this may be less relevant for this specific context.</li> </ol>"},{"location":"reviews/617b481400003575-SP_RNF169/#parsimoniousness-and-readability","title":"Parsimoniousness and Readability","text":"<p>The model is parsimonious and readable. It clearly illustrates the competition between RNF169 and both TP53BP1 and UIMC1/RAP80 for binding to ubiquitylated histones at DNA damage sites, which is the key regulatory mechanism described in the underlying literature.</p>"},{"location":"reviews/617b481400003575-SP_RNF169/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:617b481400003575) accurately represents the pathway described in the literature where DYRK1A phosphorylates RNF169 to enhance its ability to compete with TP53BP1 and UIMC1/RAP80 for binding to ubiquitylated histones at DNA damage sites, thereby influencing DNA repair pathway choice.</p> <p>The model follows GO-CAM best practices, uses appropriate GO terms, relations, and evidence codes, and effectively captures the biological mechanism described in the literature. While there are minor opportunities for expansion, the model is scientifically accurate, well-structured, and parsimonious.</p>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/","title":"6197061700000593 ERBB2 EGFR signaling pathway 1  Mouse","text":"<p>Now, I'll review the GO-CAM model with ID 6197061700000593 based on the information I've gathered.</p>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#review-of-go-cam-model-6197061700000593-erbb2-egfr-signaling-pathway-1-mouse","title":"Review of GO-CAM Model 6197061700000593: ERBB2-EGFR signaling pathway 1 (Mouse)","text":""},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model represents the ERBB2-EGFR signaling pathway in mouse (NCBITaxon:10090) and includes activities related to four key proteins: - EGFR (Epidermal Growth Factor Receptor, MGI:MGI:95294) - ERBB2 (MGI:MGI:95410) - HB-EGF (Heparin-binding EGF-like growth factor, MGI:MGI:96070) - ADAM17 (A disintegrin and metalloprotease 17, MGI:MGI:1096335)</p>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>Overall, the model accurately captures key aspects of the ERBB2-EGFR signaling pathway based on the literature:</p> <ol> <li>The model correctly represents HB-EGF as a ligand that activates EGFR</li> <li>ADAM17 is correctly positioned as processing the HB-EGF precursor</li> <li>EGFR activation leads to ERBB2 kinase activity, consistent with the well-established EGFR-ERBB2 heterodimerization</li> </ol> <p>The connections between components reflect established knowledge about this pathway, with causal relationships that align with the biological mechanisms described in the literature (PMID:21946538, PMID:14993236, PMID:16357442, PMID:19029950).</p>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":""},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>Proper use of causal relations:</li> <li>The model uses RO:0002304 (causally upstream of, positive effect) for ADAM17's processing of HB-EGF</li> <li> <p>RO:0002629 (directly positively regulates) is appropriately used for ligand-receptor and receptor-receptor interactions</p> </li> <li> <p>Appropriate cellular location annotations:</p> </li> <li> <p>Activities properly annotated with cellular locations (GO:0005886 for plasma membrane, GO:0005615 for extracellular space)</p> </li> <li> <p>Clear molecular functions:</p> </li> <li> <p>Each protein is assigned appropriate molecular functions:</p> <ul> <li>EGFR: GO:0005006 (epidermal growth factor receptor activity)</li> <li>ERBB2: GO:0004713 (protein tyrosine kinase activity)</li> <li>HB-EGF: GO:0048018 (receptor ligand activity)</li> <li>ADAM17: GO:0004222 (metalloendopeptidase activity)</li> </ul> </li> <li> <p>Strong evidence support:</p> </li> <li>Each activity and relationship has appropriate evidence codes and literature references</li> <li> <p>Uses a mix of direct assay (ECO:0000314), mutant phenotype (ECO:0000315), and genetic interaction (ECO:0000316) evidence</p> </li> <li> <p>Biological process annotations:</p> </li> <li>All activities are part of GO:0038134 (ERBB2-EGFR signaling pathway), providing context</li> <li>ADAM17 activity is correctly placed within GO:0140448 (signaling receptor ligand precursor processing)</li> </ol>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Complex representation:</li> <li> <p>The model doesn't explicitly represent the EGFR-ERBB2 heterodimer complex. According to GO-CAM best practices for complex annotation, the heterodimer formation could be more explicitly represented.</p> </li> <li> <p>Downstream effects:</p> </li> <li> <p>The model ends with ERBB2 kinase activity but doesn't include downstream effects such as MAPK or PI3K/Akt activation, which are major effectors of EGFR-ERBB2 signaling as identified in the literature (PMID:21946538).</p> </li> <li> <p>Feedback regulation:</p> </li> <li>No representation of negative feedback mechanisms that are known to regulate EGFR signaling.</li> </ol>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#recommended-improvements","title":"Recommended Improvements","text":"<ol> <li>Heterodimer representation:</li> <li> <p>Consider explicitly representing the EGFR-ERBB2 heterodimer following the GO-CAM complex annotation guidelines</p> </li> <li> <p>Expand downstream signaling:</p> </li> <li> <p>Consider adding key downstream events such as PI3K/Akt and MAPK pathway activation, which are established consequences of EGFR-ERBB2 signaling</p> </li> <li> <p>Include receptor trafficking:</p> </li> <li> <p>Consider representing receptor internalization processes, which are important regulatory mechanisms for EGFR signaling</p> </li> <li> <p>Add additional context:</p> </li> <li>The function of this pathway in specific biological processes (beyond just being part of GO:0038134) could provide additional context</li> </ol>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 6197061700000593 provides an accurate representation of the core ERBB2-EGFR signaling pathway, with proper annotation of molecular functions, cellular locations, and causal relationships. The model is well-supported by evidence from the literature. While the current model effectively captures the essential components of this pathway, expanding it to include heterodimer formation, downstream signaling events, and regulatory mechanisms would provide a more comprehensive representation of ERBB2-EGFR signaling.</p> <p>The model follows GO-CAM best practices for the most part, with appropriate use of relationships and evidence codes. The suggestions for improvement would enhance the biological completeness rather than correcting any significant errors in the existing model.</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/","title":"6197061700001485 Silencing of fetal hemoglobin  by ZNF410  Human","text":"<p>Now I'll analyze the model to provide a comprehensive review:</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#review-of-go-cam-model-gomodel6197061700001485","title":"Review of GO-CAM model: gomodel:6197061700001485","text":""},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Silencing of fetal hemoglobin by ZNF410 (Human) Taxon: Human (NCBITaxon:9606) Status: Production ID: gomodel:6197061700001485</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#model-summary","title":"Model Summary","text":"<p>This GO-CAM depicts the regulatory pathway involved in silencing fetal hemoglobin (HbF) genes in adult erythroid cells. The model shows how ZNF410 (a zinc finger transcription factor) positively regulates CHD4 (a chromatin remodeler), which in turn negatively regulates the expression of fetal hemoglobin genes HBG1 and HBG2.</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#components-review","title":"Components Review","text":""},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#activities-in-the-model","title":"Activities in the Model","text":"<ol> <li>ZNF410 activity (ZNF410/Q86VK4)</li> <li>Molecular function: DNA-binding transcription factor activity (GO:0003700)</li> <li>Occurs in: erythroid lineage cell (CL:0000764)</li> <li>Part of: positive regulation of transcription by RNA polymerase II (GO:0045944)</li> <li> <p>Evidence: Direct assay (ECO:0000314) from PMID:33859416</p> </li> <li> <p>CHD4 activity (CHD4/Q14839)</p> </li> <li>Molecular function: transcription corepressor activity (GO:0003714)</li> <li>Occurs in: erythroid lineage cell (CL:0000764)</li> <li>Part of: negative regulation of gene expression (GO:0010629)</li> <li> <p>Evidence: Direct assay (ECO:0000314) from PMID:33859416</p> </li> <li> <p>HBG1 activity (HBG1/P69891)</p> </li> <li>Molecular function: oxygen carrier activity (GO:0005344)</li> <li>Occurs in: erythrocyte (CL:0000232)</li> <li>Part of: oxygen transport (GO:0015671)</li> <li> <p>Evidence: Direct assay (ECO:0000314) from PMID:22096240</p> </li> <li> <p>HBG2 activity (HBG2/P69892)</p> </li> <li>Molecular function: oxygen carrier activity (GO:0005344)</li> <li>Occurs in: erythrocyte (CL:0000232)</li> <li>Part of: oxygen transport (GO:0015671)</li> <li>Evidence: Direct assay (ECO:0000314) from PMID:19065339</li> </ol>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#causal-relations","title":"Causal Relations","text":"<ol> <li>ZNF410 directly positively regulates (RO:0002629) CHD4</li> <li>CHD4 causally upstream, negative effect (RO:0002305) on HBG1</li> <li>CHD4 causally upstream, negative effect (RO:0002305) on HBG2</li> </ol>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#evaluation-of-model-quality","title":"Evaluation of Model Quality","text":""},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Scientific Accuracy: The model accurately represents the pathway described in the literature where ZNF410 uniquely activates CHD4, which in turn represses fetal globin genes. This is supported by recent literature (PMID:33859416, PMID:33301730).</p> </li> <li> <p>Proper Annotations: The model uses correct GO terms for molecular functions, cellular components, and biological processes for each entity.</p> </li> <li> <p>Evidence Support: All annotations are properly supported with appropriate evidence codes and PMID references.</p> </li> <li> <p>Appropriate Causal Relations: The causal relations use appropriate predicates to show regulatory relationships (direct positive regulation from ZNF410 to CHD4, and negative effect from CHD4 to HBG1/2).</p> </li> <li> <p>Cell Type Specificity: The model correctly places the activities in appropriate cell types - erythroid lineage cells for the regulatory activities and erythrocytes for hemoglobin function.</p> </li> </ol>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Context: The model could be improved by including additional context that this regulation is specifically important in adult erythroid cells (vs. fetal). While this is implied in the title, it's not explicitly represented in the model.</p> </li> <li> <p>Molecular Mechanisms: The model doesn't specify the molecular mechanisms by which CHD4 represses the gamma-globin genes. According to the literature, CHD4 is part of the NuRD complex which is involved in chromatin remodeling and histone deacetylation at the gamma-globin loci. This could be added to provide more detail.</p> </li> <li> <p>Missing Related Activities: The model could be expanded to include other relevant factors in the HbF silencing pathway, such as BCL11A and ZBTB7A (LRF), which also interact with the NuRD complex to repress gamma-globin genes.</p> </li> <li> <p>Limited Pathway Context: While the model focuses on the direct pathway from ZNF410 to HBG genes, it doesn't include the broader context of hemoglobin switching during development. A reference to the developmental switch from fetal to adult hemoglobin would provide important context.</p> </li> </ol>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#compliance-with-go-cam-modeling-guidelines","title":"Compliance with GO-CAM Modeling Guidelines","text":"<ol> <li> <p>DNA-binding Transcription Factor Activity: The model correctly represents ZNF410 as a DNA-binding transcription factor that positively regulates CHD4. However, according to the guidelines, the relation between the transcription factor and its target gene should include a \"has input\" relation, which is missing here.</p> </li> <li> <p>Transcription Corepressor Activity: The representation of CHD4 as a transcription corepressor is appropriate. According to the guidelines, a corepressor should have a \"directly negatively regulates\" relation to its target, but in this model, \"causally upstream of, negative effect\" is used instead, which is a more general causal relation.</p> </li> <li> <p>Cellular Context: The model correctly specifies the cellular location for all activities, consistent with GO-CAM guidelines.</p> </li> </ol>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#biological-accuracy-review","title":"Biological Accuracy Review","text":"<p>The model accurately portrays ZNF410 as an unusual transcription factor that primarily regulates a single gene, CHD4, which contrasts with most TFs that regulate many targets. The literature indicates that ZNF410 binds to two clusters of binding sites near the CHD4 gene with high specificity, as reflected in the model.</p> <p>The literature (PMID:33859416, PMID:33301730) confirms that reducing ZNF410 levels leads to decreased CHD4 expression (by ~60%) and subsequent derepression of fetal hemoglobin genes (HBG1/2). This central pathway is correctly represented in the model.</p> <p>It's also biologically accurate that this pathway is significant in adult erythroid cells, as ZNF410 depletion induces fetal hemoglobin expression without significantly affecting other aspects of erythroid differentiation or function.</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#recommended-improvements","title":"Recommended Improvements","text":"<ol> <li> <p>Add \"has input\" relation from ZNF410 activity to CHD4 gene to better follow GO-CAM guidelines for transcription factor annotation.</p> </li> <li> <p>Include NuRD complex involvement: CHD4 functions as part of the NuRD complex, which could be represented in the model to provide a more complete mechanistic explanation.</p> </li> <li> <p>Add developmental context: Include information that this regulation is part of the hemoglobin switching process from fetal to adult stage.</p> </li> <li> <p>Consider expanding the model to include other known HbF repressors (BCL11A, ZBTB7A) that work in concert with the NuRD complex.</p> </li> <li> <p>Refine causal relation: Consider using \"directly negatively regulates\" instead of \"causally upstream of, negative effect\" for the relation between CHD4 and the gamma-globin genes, if evidence supports this direct relationship.</p> </li> </ol>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the unique regulatory pathway where ZNF410 specifically controls CHD4 expression to silence fetal hemoglobin genes in adult erythroid cells. The model is well-supported by recent literature and follows most GO-CAM best practices. With the suggested improvements, it could provide an even more comprehensive representation of this important biological pathway that has significant implications for potential therapeutic approaches to hemoglobinopathies.</p>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/","title":"6197061700001622 Epidermal growth factor receptor signaling pathway 2  Mouse","text":"<p>Now I'll review the GO-CAM model with ID 6197061700001622 based on the information gathered.</p>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#review-of-go-cam-model-gomodel6197061700001622","title":"Review of GO-CAM Model: gomodel:6197061700001622","text":""},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:6197061700001622) is titled \"Epidermal growth factor receptor signaling pathway 2 (Mouse)\" and represents molecular activities and causal relationships in the EGFR signaling pathway in mouse (NCBITaxon:10090).</p>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model contains four main molecular activities:</p> <ol> <li>Activity 1 (gomodel:6197061700001622/6197061700001985):</li> <li>Enabled by: Adam17 (MGI:MGI:1096335)</li> <li>Molecular function: Metallodipeptidase activity (GO:0070573)</li> <li>Occurs in: Plasma membrane (GO:0005886)</li> <li>Part of: Signaling receptor ligand precursor processing (GO:0140448)</li> <li> <p>Causally upstream of (positive effect) Activity 4</p> </li> <li> <p>Activity 2 (gomodel:6197061700001622/6197061700001628):</p> </li> <li>Enabled by: Egfr (MGI:MGI:95294)</li> <li>Molecular function: Transmembrane receptor protein tyrosine kinase activity (GO:0004714)</li> <li>Occurs in: Plasma membrane (GO:0005886)</li> <li> <p>Part of: Epidermal growth factor receptor signaling pathway (GO:0007173)</p> </li> <li> <p>Activity 3 (gomodel:6197061700001622/6197061700001769):</p> </li> <li>Enabled by: Mep1a (MGI:MGI:96963)</li> <li>Molecular function: Metallodipeptidase activity (GO:0070573)</li> <li>Occurs in: Plasma membrane (GO:0005886)</li> <li>Part of: Signaling receptor ligand precursor processing (GO:0140448)</li> <li> <p>Causally upstream of (positive effect) Activity 4</p> </li> <li> <p>Activity 4 (gomodel:6197061700001622/6197061700001624):</p> </li> <li>Enabled by: Tgfa (MGI:MGI:98724)</li> <li>Molecular function: Receptor ligand activity (GO:0048018)</li> <li>Occurs in: Extracellular space (GO:0005615)</li> <li>Part of: Epidermal growth factor receptor signaling pathway (GO:0007173)</li> <li>Directly positively regulates Activity 2</li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#evidence-support","title":"Evidence Support","text":"<p>The model is supported by evidence from several publications: - PMID:14993236: Mutant phenotype evidence for ADAM17's role in processing EGFR ligands - PMID:7752576: Direct assay evidence for EGFR and its activation by TGF\u03b1 - PMID:22923609: Sequence orthology evidence for MEP1A's role in processing EGFR ligands</p>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the EGFR signaling pathway in mouse, focusing on:</p> <ol> <li> <p>Ligand processing: Both ADAM17 (Activity 1) and MEP1A (Activity 3) are shown to process TGF\u03b1 (Activity 4), which is consistent with the literature. ADAM17 is a well-established sheddase for TGF\u03b1 as evidenced in PMID:14993236, and MEP1A has been shown to process TGF\u03b1 as supported by PMID:22923609.</p> </li> <li> <p>Receptor activation: TGF\u03b1 (Activity 4) directly positively regulates EGFR (Activity 2), which is consistent with the receptor-ligand relationship.</p> </li> <li> <p>Causal chain: The model correctly depicts the causal flow from sheddase activity (ADAM17, MEP1A) \u2192 ligand processing (TGF\u03b1) \u2192 receptor activation (EGFR).</p> </li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#assessment-against-go-cam-best-practices","title":"Assessment Against GO-CAM Best Practices","text":"<p>The model adheres to GO-CAM best practices in the following ways:</p> <ol> <li>Proper causality representation: The model uses appropriate causal relationships with correct directionality:</li> <li>RO:0002304 (causally upstream of, positive effect) for sheddase \u2192 ligand relationship</li> <li> <p>RO:0002629 (directly positively regulates) for ligand \u2192 receptor relationship</p> </li> <li> <p>Cellular locations: All activities are appropriately annotated with cellular locations that are biologically accurate (plasma membrane for sheddases and receptor, extracellular space for the ligand).</p> </li> <li> <p>Process annotations: Each activity is correctly annotated with the biological process it is a part of.</p> </li> <li> <p>Evidence support: The model includes appropriate evidence codes and PMIDs for each assertion.</p> </li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>The model is biologically accurate and complies with GO-CAM best practices, but a few minor improvements could be considered:</p> <ol> <li> <p>Downstream signaling: The model could be expanded to include downstream signaling events after EGFR activation, such as MAPK pathway activation, which is mentioned in PMID:22923609.</p> </li> <li> <p>Additional ligands: While the model focuses on TGF\u03b1, EGFR signaling also involves other ligands processed by ADAM17, such as amphiregulin, HB-EGF, and epiregulin (as described in PMID:14993236). The model could be expanded to include these, if the goal is a more comprehensive representation of EGFR signaling.</p> </li> <li> <p>Feedback regulation: The model could include feedback regulatory mechanisms known to modulate EGFR signaling.</p> </li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 6197061700001622 provides an accurate and well-structured representation of the EGFR signaling pathway in mouse, focusing on the processing of TGF\u03b1 by ADAM17 and MEP1A, and the subsequent activation of the EGFR. The model adheres to GO-CAM best practices in terms of causal relationships, cellular locations, and evidence support. The biological content is consistent with the scientific literature and represents our current understanding of EGFR signaling.</p>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/","title":"6197061700001643 Epidermal growth factor receptor signaling pathway 3  Mouse","text":"<p>Now I'll prepare my review of GO-CAM model 6197061700001643.</p>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#go-cam-model-review","title":"GO-CAM Model Review","text":""},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#review-of-go-cam-model-6197061700001643-epidermal-growth-factor-receptor-signaling-pathway-3-mouse","title":"Review of GO-CAM Model 6197061700001643: Epidermal growth factor receptor signaling pathway 3 (Mouse)","text":""},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#model-overview","title":"Model Overview","text":"<p>This model (https://bioregistry.io/go.model:6197061700001643) represents the epidermal growth factor receptor (EGFR) signaling pathway in mice, focusing on three key proteins:</p> <ol> <li>Amphiregulin (Areg) - an EGFR ligand that activates the receptor</li> <li>EGFR (Epidermal Growth Factor Receptor) - a receptor tyrosine kinase</li> <li>ADAM17 (A Disintegrin And Metalloproteinase 17) - a protease that processes Areg</li> </ol>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#model-structure-assessment","title":"Model Structure Assessment","text":"<p>The model is generally well-constructed and follows several best practices for GO-CAM modeling. I'll evaluate its structure, completeness, and biological accuracy:</p>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate biological pathway representation: The model correctly represents the relationship between ADAM17, Areg, and EGFR in the EGFR signaling pathway.</p> </li> <li> <p>Proper annotation of molecular functions: </p> </li> <li>ADAM17 is annotated with metallopeptidase activity (GO:0008237)</li> <li>Areg is annotated with receptor ligand activity (GO:0048018)</li> <li> <p>EGFR is annotated with transmembrane receptor protein tyrosine kinase activity (GO:0004714)</p> </li> <li> <p>Appropriate location annotations:</p> </li> <li>ADAM17 is located in the plasma membrane (GO:0005886)</li> <li>Areg is located in the extracellular space (GO:0005615)</li> <li> <p>EGFR is located in the plasma membrane (GO:0005886)</p> </li> <li> <p>Proper causal relationships:</p> </li> <li>ADAM17 positively regulates Areg via the RO:0002304 relation (causally upstream of, positive effect)</li> <li> <p>Areg positively regulates EGFR via the RO:0002629 relation (directly positively regulates)</p> </li> <li> <p>Each activity is part of the appropriate biological process:</p> </li> <li> <p>All activities are part of epidermal growth factor receptor signaling pathway (GO:0007173)</p> </li> <li> <p>Good evidence support: Multiple evidences with appropriate ECO codes and literature references support the annotations.</p> </li> </ol>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing details on ADAM17 processing of Areg: While the model shows that ADAM17 has a positive regulatory effect on Areg, it doesn't explicitly represent that ADAM17 cleaves the membrane-bound precursor of Areg to release the soluble form that then binds to EGFR. A more specific process \"signaling receptor ligand precursor processing\" (GO:0140448) is used for ADAM17, but the model could better clarify this relationship.</p> </li> <li> <p>Incomplete EGFR downstream signaling: The model doesn't include any downstream effectors of EGFR. Once activated, EGFR typically initiates several signaling cascades including Ras/Raf/MEK/ERK, PI3K/AKT, PLC\u03b3, and STAT pathways.</p> </li> <li> <p>Limited context information: The model doesn't specify the biological context or outcome of this signaling pathway, which could include cell proliferation, differentiation, or survival.</p> </li> </ol>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model is biologically accurate based on current knowledge about EGFR signaling:</p> <ol> <li> <p>ADAM17 role: ADAM17 (also known as TACE) is indeed a metalloprotease that cleaves and activates several EGFR ligands, including Amphiregulin, as correctly represented in the model. The evidence from PMID:14993236 supports this relationship.</p> </li> <li> <p>Amphiregulin as an EGFR ligand: Amphiregulin is correctly represented as an EGFR ligand that activates the receptor's tyrosine kinase activity, leading to downstream signaling. The evidence from PMID:23333074 and other references supports this relationship.</p> </li> <li> <p>EGFR signaling: The model correctly represents EGFR as a transmembrane receptor tyrosine kinase that gets activated upon ligand binding.</p> </li> </ol>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>To enhance this GO-CAM model, I recommend:</p> <ol> <li> <p>Extend downstream signaling: Include key downstream effectors of EGFR, such as GRB2, SOS, RAS, and components of the MAPK pathway.</p> </li> <li> <p>Add more specificity to ADAM17 processing: Explicitly model that ADAM17 cleaves the membrane-bound precursor of Areg to release the soluble form.</p> </li> <li> <p>Include biological outcomes: Add associations to biological processes that are outcomes of EGFR signaling, such as cell proliferation, migration, or differentiation.</p> </li> <li> <p>Consider adding regulation of ADAM17: If relevant literature exists, include information on how ADAM17 activity is regulated in this context.</p> </li> <li> <p>Add cellular compartment details: While ADAM17 and EGFR are annotated to plasma membrane, more specific locations could be added if supported by evidence.</p> </li> </ol>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#conclusion","title":"Conclusion","text":"<p>Model gomodel:6197061700001643 represents a simplified but accurate view of the Amphiregulin-EGFR signaling pathway in mouse. It follows GO-CAM best practices for representing signaling pathways according to the documentation on annotating signaling receptor activity. The model could be expanded to include more detail on downstream signaling and the specific mechanisms of Areg processing by ADAM17, but it provides a solid foundation of this important signaling pathway.</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/","title":"6197061700002226 ERBB2 ERBB4 signaling pathway 2  Mouse","text":"<p>Now that I have gathered detailed information about the model and its components, let me review the GO-CAM model 6197061700002226 \"ERBB2-ERBB4 signaling pathway 2 (Mouse)\".</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#go-cam-model-review-erbb2-erbb4-signaling-pathway-2-mouse","title":"GO-CAM Model Review: ERBB2-ERBB4 signaling pathway 2 (Mouse)","text":""},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#model-overview","title":"Model Overview","text":"<p>The model (gomodel:6197061700002226) represents the ERBB2-ERBB4 signaling pathway in mouse, focusing on the interactions between: 1. Epiregulin (Ereg) as a receptor ligand 2. ERBB4 (transmembrane receptor tyrosine kinase) 3. ERBB2 (receptor tyrosine-protein kinase) 4. ADAM17 (disintegrin and metalloproteinase 17) as a metallopeptidase involved in ligand processing</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#model-structure-analysis","title":"Model Structure Analysis","text":""},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#activity-flow","title":"Activity Flow","text":"<p>The activity flow in this model follows this pathway: 1. ADAM17 (MGI:MGI:1096335) with metallopeptidase activity (GO:0008237) positively regulates (RO:0002304) Ereg activity 2. Ereg (MGI:MGI:107508) with receptor ligand activity (GO:0048018) directly positively regulates (RO:0002629) ERBB4 activity 3. ERBB4 (MGI:MGI:104771) with transmembrane receptor protein tyrosine kinase activity (GO:0004714) directly positively regulates (RO:0002629) ERBB2 activity 4. ERBB2 (MGI:MGI:95410) with protein tyrosine kinase activity (GO:0004713)</p> <p>All these activities contribute to the ERBB2-ERBB4 signaling pathway (GO:0038135).</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#cellular-locations","title":"Cellular Locations","text":"<ul> <li>ADAM17: plasma membrane (GO:0005886)</li> <li>Ereg: extracellular space (GO:0005615)</li> <li>ERBB4: plasma membrane (GO:0005886)</li> <li>ERBB2: plasma membrane (GO:0005886)</li> </ul>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by evidence from experimental literature: - PMID:9556621 is cited as evidence for Ereg's receptor ligand activity, its regulation of ERBB4, and ERBB4's regulation of ERBB2 - PMID:14993236 supports the role of ADAM17 in processing signaling receptor ligand precursors</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Consistency with Receptor Signaling Guidelines: The model follows the GO-CAM guidelines for signaling receptor activity by correctly showing:</li> <li>A ligand (Ereg) with receptor ligand activity in the extracellular space</li> <li>The causal relation \"directly positively regulates\" between the ligand and receptor</li> <li>The receptor (ERBB4) with appropriate tyrosine kinase activity</li> <li> <p>Downstream signaling to ERBB2</p> </li> <li> <p>Correct Representation of Ligand Processing: The model includes ADAM17's role in metallopeptidase activity, which correctly represents its biological function in processing receptor ligand precursors (including Ereg).</p> </li> <li> <p>Biological Accuracy: The interactions between Ereg, ERBB4, and ERBB2 align with known biology - Ereg can activate ERBB4, which forms heterodimers with ERBB2 to initiate downstream signaling.</p> </li> <li> <p>Appropriate Cellular Locations: The cellular locations for each protein are correctly annotated.</p> </li> </ol>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#issuesconcerns-with-the-model","title":"Issues/Concerns with the Model","text":"<ol> <li> <p>Missing Downstream Signaling Components: The model doesn't include downstream effectors beyond ERBB2. The signaling cascade typically continues to activate pathways like MAPK and PI3K/AKT.</p> </li> <li> <p>ERBB2 Activity Endpoint: While ERBB2 is shown with protein tyrosine kinase activity, there's no indication of what targets it phosphorylates, leaving the pathway incomplete.</p> </li> <li> <p>Heterodimer Representation: Although ERBB4 is shown to regulate ERBB2, the model doesn't explicitly capture that they form a heterodimer complex. According to the \"How to annotate complexes in GO-CAM\" document, it might be more accurate to represent the heterodimer if the activities are shared.</p> </li> <li> <p>Evidence Details: While PMID:9556621 is cited, we couldn't retrieve its full text to fully evaluate the evidence quality.</p> </li> </ol>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Complete the Signaling Pathway: Add downstream effectors of ERBB2 signaling (e.g., SHC, GRB2, MAPK) to provide a more complete view of the pathway.</p> </li> <li> <p>Consider Representing the ERBB2/ERBB4 Heterodimer: If the receptor functions as a heterodimer, consider representing this according to complex annotation guidelines, especially if both proteins contribute to the signaling activity.</p> </li> <li> <p>Add More Evidence: Include additional supporting literature to strengthen the evidence base, particularly for the role of ADAM17 in Ereg processing.</p> </li> <li> <p>Add Specific Targets for ERBB2: Indicate the specific substrates that ERBB2 phosphorylates to complete the signaling cascade.</p> </li> </ol>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#conclusion","title":"Conclusion","text":"<p>This model provides a good basic representation of the initial steps in ERBB2-ERBB4 signaling in response to Ereg stimulation. It correctly captures the receptor-ligand interaction and the sequential activation of ERBB4 and ERBB2. The inclusion of ADAM17's role in ligand processing adds valuable context.</p> <p>However, the model would benefit from extending the signaling cascade to include downstream effectors and targets of ERBB2 kinase activity. Also, more explicit representation of the ERBB2-ERBB4 heterodimer formation would better align with the biology of this pathway.</p> <p>Overall, the model is biologically accurate but somewhat limited in scope, providing a foundation that could be expanded to show the complete signaling pathway.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/","title":"6197061700002397 Fatty acid transport by CD36 via LYN mediated endocytosis  Human","text":"<p>Based on my examination of gomodel:6197061700002397, I'll now conduct a thorough review of this GO-CAM model to assess its accuracy, consistency with GO-CAM best practices, and biological validity.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#review-of-gomodel6197061700002397-fatty-acid-transport-by-cd36-via-lyn-mediated-endocytosis-human","title":"Review of gomodel:6197061700002397: Fatty acid transport by CD36 via LYN-mediated endocytosis (Human)","text":""},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#overview","title":"Overview","text":"<p>This model represents the fatty acid transport mechanism involving CD36 in human cells. The model shows that CD36 acts as a cargo receptor at the plasma membrane, which then initiates a signaling cascade through the LYN tyrosine kinase, ultimately involving palmitoylation regulation by ZDHHC5 and LYPLA1 proteins.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":""},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#complex-annotation","title":"Complex Annotation","text":"<p>The model correctly handles the annotation of the proteins involved in the pathway rather than using a complex ID, as the specific roles of each protein are well-defined based on the reference (PMID:32958780). This aligns with the guidance in \"How to annotate complexes in GO-CAM\", where individual activities are assigned to specific proteins when their roles are known.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships in the model use appropriate relationship predicates: - \"RO:0002629\" (directly positively regulates) from CD36 to LYN - \"RO:0002630\" (directly negatively regulates) from LYN to ZDHHC5 - \"RO:0002418\" (provides input for) from ZDHHC5 to LYPLA1</p> <p>These directional relationships correctly capture the flow of the pathway as described in the literature.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#subcellular-localization","title":"Subcellular Localization","text":"<p>All proteins are appropriately annotated with their subcellular locations at the plasma membrane (GO:0005886), which is consistent with the biological process of membrane transport.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#biological-process-association","title":"Biological Process Association","text":"<p>All activities are correctly associated with the biological process \"fatty acid transport\" (GO:0015908), providing proper context for the molecular functions.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":""},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#cd36-function","title":"CD36 Function","text":"<p>The model correctly represents CD36 (UniProtKB:P16671) with the molecular function \"cargo receptor activity\" (GO:0038024). According to the UniProt entry and the cited reference, CD36 functions as a cargo receptor for fatty acids, which is accurately captured in the model.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#lyn-kinase-function","title":"LYN Kinase Function","text":"<p>LYN (UniProtKB:P07948) is correctly annotated with \"protein tyrosine kinase activity\" (GO:0004713). According to PMID:32958780, LYN phosphorylates ZDHHC5 at Tyr91, inactivating it, which is accurately represented by the negative regulation relationship.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#zdhhc5-function","title":"ZDHHC5 Function","text":"<p>ZDHHC5 (UniProtKB:Q9C0B5) is annotated with \"palmitoyltransferase activity\" (GO:0016409). This is consistent with its known function in palmitoylating CD36, which is essential for CD36's localization to the plasma membrane.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#lypla1-function","title":"LYPLA1 Function","text":"<p>LYPLA1 (UniProtKB:O75608) is annotated with \"palmitoyl-(protein) hydrolase activity\" (GO:0008474), which correctly represents its role in depalmitoylating CD36, allowing for its internalization.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>All activities and relationships are supported by evidence from the same publication (PMID:32958780), which provides a comprehensive study of this pathway. The evidence code used (ECO:0000314 - direct assay evidence used in manual assertion) is appropriate for the experimental evidence presented in the paper.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#integration-with-pathway-knowledge","title":"Integration with Pathway Knowledge","text":"<p>The model accurately captures the dynamic process of fatty acid uptake as described in PMID:32958780: 1. CD36 binds fatty acids and activates LYN kinase 2. LYN phosphorylates ZDHHC5, inactivating it 3. Inactivation of ZDHHC5 leads to depalmitoylation of CD36 by LYPLA1 4. Depalmitoylated CD36 undergoes endocytosis, bringing fatty acids into the cell</p> <p>This process is elegantly captured with the appropriate molecular functions and causal relationships.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Additional Context: While not necessary, the model could potentially benefit from including additional downstream events mentioned in the paper, such as the recruitment of SYK kinase by depalmitoylated CD36, which further facilitates endocytosis.</p> </li> <li> <p>Complex Integration: Although each protein's individual role is well-represented, the model could optionally indicate the interaction of CD36 with caveolin structures as described in the paper, which mentions that \"CD36 is primarily localized in the caveolae structures\".</p> </li> </ol>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:6197061700002397) is a well-constructed representation of fatty acid transport by CD36 via LYN-mediated endocytosis. It accurately captures the molecular functions, subcellular localizations, and causal relationships between the components as described in the primary literature. The model adheres to GO-CAM best practices and provides a clear representation of this important biological process.</p> <p>The model shows a high level of biological accuracy and adherence to GO-CAM curation standards. It elegantly captures a complex regulatory mechanism involving post-translational modifications (phosphorylation and palmitoylation) in the regulation of membrane protein trafficking and fatty acid transport.</p>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/","title":"61b2b68300000000 NLRP6 inflammasome  Human","text":"<p>Based on the resources I've gathered, I can now provide a comprehensive review of the GO-CAM model gomodel:61b2b68300000000, which represents the \"NLRP6 inflammasome (Human)\".</p>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#review-of-nlrp6-inflammasome-go-cam-model-gomodel61b2b68300000000","title":"Review of NLRP6 Inflammasome GO-CAM Model (gomodel:61b2b68300000000)","text":""},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the human NLRP6 inflammasome pathway, focusing on the molecular activities, subcellular locations, and causal relationships between various components of this inflammasome system. The model was created by curator ORCID:0000-0001-7299-6685 with the most recent updates in 2023.</p>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#key-components-and-structure-analysis","title":"Key Components and Structure Analysis","text":""},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#core-proteins","title":"Core Proteins","text":"<ol> <li>NLRP6 (UniProtKB:P59044): The central sensor component of the inflammasome</li> <li>Caspase-1 (UniProtKB:P29466): The effector caspase responsible for cytokine maturation</li> <li>GSDMD (UniProtKB:P57764): Pyroptotic effector leading to membrane pore formation</li> <li>IL-1\u03b2 (UniProtKB:P01584) and IL-18 (UniProtKB:Q14116): Pro-inflammatory cytokines released during inflammasome activation</li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#pathway-representation","title":"Pathway Representation","text":"<p>The model effectively represents the general NLRP6 inflammasome pathway: - NLRP6 senses microbial signals (lipoteichoic acid binding, dsRNA binding) - NLRP6 forms a complex (inflammasome assembly) - NLRP6 activates Caspase-1  - Caspase-1 cleaves pro-IL-1\u03b2 and pro-IL-18 for maturation - Caspase-1 cleaves GSDMD, leading to pore formation and cytokine release</p>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Comprehensive molecular function annotations: Each protein is associated with appropriate molecular functions, such as:</li> <li>NLRP6 with pattern recognition receptor activity (GO:0038187), signaling adaptor activity (GO:0035591), and molecular condensate scaffold activity (GO:0140693)</li> <li>Caspase-1 with cysteine-type endopeptidase activity (GO:0004197)</li> <li>GSDMD with wide pore channel activity (GO:0022829)</li> <li> <p>IL-1\u03b2 and IL-18 with cytokine activity (GO:0005125)</p> </li> <li> <p>Appropriate subcellular locations: The model correctly annotates subcellular locations, including:</p> </li> <li>NLRP6 in cytosol (GO:0005829)</li> <li>GSDMD in plasma membrane (GO:0005886)</li> <li> <p>Mature cytokines in extracellular space (GO:0005615)</p> </li> <li> <p>Well-structured causal relationships: The model uses appropriate causal predicates to connect activities:</p> </li> <li>\"Causally upstream of, positive effect\" (RO:0002304) to indicate positive regulation</li> <li> <p>\"Directly positively regulates\" (RO:0002629) for direct activation</p> </li> <li> <p>Evidence-based annotations: All activities and relationships are backed by published scientific literature with appropriate evidence codes (ECO:0000314 - direct assay evidence).</p> </li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Relationship between NLRP6 inflammatory signaling and GSDMD: While the model correctly shows GSDMD activation leading to cytokine release, it misses a direct connection between Caspase-1 and GSDMD cleavage. According to UniProt data, Caspase-1 directly cleaves GSDMD at Asp-275, which is a critical step in pyroptosis.</p> </li> <li> <p>Representation of inflammasome complex formation: The model shows NLRP6 molecular condensate scaffold activity and inflammasome complex assembly, but could better represent the physical complex formation that includes ASC (PYCARD) recruitment, which is mentioned in the UniProt entry for NLRP6.</p> </li> <li> <p>Incomplete representation of NLRP6 regulation: The model doesn't capture some regulatory aspects of NLRP6, such as potential post-translational modifications or inhibitory mechanisms.</p> </li> <li> <p>Limited downstream effects: The model focuses primarily on cytokine release but could be expanded to include other downstream effects of inflammasome activation, such as pyroptotic cell death mechanisms.</p> </li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#specific-recommendations","title":"Specific recommendations","text":"<ol> <li> <p>Add ASC/PYCARD component: According to UniProt, \"NLRP6 interacts (via pyrin domain) with PYCARD/ASC (via pyrin domain)\" - this important adapter protein should be included in the model.</p> </li> <li> <p>Add a direct causal link between Caspase-1 and GSDMD: Add an explicit relationship showing Caspase-1 cleaving GSDMD, which is a critical step for pyroptosis initiation.</p> </li> <li> <p>Expand downstream pyroptosis effector mechanisms: Consider adding annotations about plasma membrane rupture and cell death outcomes of inflammasome activation.</p> </li> <li> <p>Include negative regulatory components: Add inhibitory mechanisms if known, to provide a more balanced view of inflammasome regulation.</p> </li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:61b2b68300000000 provides a good representation of the human NLRP6 inflammasome pathway with well-annotated molecular functions, subcellular locations, and causal relationships. The model effectively captures the core components and general flow of the pathway, supported by appropriate evidence from scientific literature. With some additions to represent complex formation, GSDMD cleavage, and downstream effects more explicitly, the model would provide an even more comprehensive view of NLRP6 inflammasome biology.</p>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/","title":"61b2b68300000203 ERBB2 ERBB4 signaling pathway 3  Mouse","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model gomodel:61b2b68300000203 \"ERBB2-ERBB4 signaling pathway 3 (Mouse)\".</p>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#go-cam-review-gomodel61b2b68300000203","title":"GO-CAM Review: gomodel:61b2b68300000203","text":""},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#model-overview","title":"Model Overview","text":"<p>This model represents the ERBB2-ERBB4 signaling pathway in mouse (NCBITaxon:10090), focusing on neuregulin-1 (Nrg1) signaling through ERBB receptors. The model describes a molecular pathway that involves:</p> <ol> <li>Metallopeptidase and endopeptidase activities (ADAM10, ADAM17, BACE1) that process the NRG1 precursor</li> <li>The resulting NRG1 ligand that activates ERBB receptors</li> <li>The receptor activity of ERBB4 binding to NRG1</li> <li>Downstream ERBB2 protein tyrosine kinase activity</li> </ol>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The biological content of this model is well-supported by the literature:</p> <ol> <li> <p>NRG1 processing by proteases: The model correctly shows that BACE1 (MGI:MGI:1346542), ADAM10 (MGI:MGI:109548), and ADAM17 (MGI:MGI:1096335) process NRG1 through their metallopeptidase/endopeptidase activities (ref: PMID:17099708). This cleavage is required to release the active form of NRG1 that can signal to ERBB receptors.</p> </li> <li> <p>NRG1 signaling through ERBB receptors: The model correctly shows that cleaved NRG1 (MGI:MGI:96083) acts as a receptor ligand (GO:0048018) that activates the ERBB4 receptor (MGI:MGI:104771) through its neuregulin receptor activity (GO:0038131). This interaction is supported by PMID:19632177, which describes NRG1/ErbB4 signaling.</p> </li> <li> <p>ERBB2-ERBB4 heterodimerization: The model represents ERBB2 (MGI:MGI:95410) with protein tyrosine kinase activity (GO:0004713) downstream of ERBB4 activation, which is consistent with the literature. PMID:19632177 describes how \"Binding of NRG1 to ErbB4 increases its kinase activity and leads to heterodimerization with ErbB2 or homodimerization with ErbB4.\"</p> </li> </ol>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#modeling-best-practices-assessment","title":"Modeling Best Practices Assessment","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li> <p>Appropriate use of causal relationships: The model uses RO:0002304 (causally upstream of, positive effect) to connect the protease activities to NRG1 ligand activity, and RO:0002629 (directly positively regulates) to connect NRG1 to ERBB4 and ERBB4 to ERBB2, which properly represents the direction of signaling.</p> </li> <li> <p>Proper representation of cellular components: The activities are correctly annotated with cellular locations. The proteases (BACE1, ADAM10, ADAM17) and receptors (ERBB2, ERBB4) are located at the plasma membrane (GO:0005886), while the processed NRG1 is in the extracellular space (GO:0005615).</p> </li> <li> <p>Proper complex representation: The model appropriately handles the ERBB2-ERBB4 complex by showing the individual activities of each protein rather than using a complex GO term. This follows the recommendation in the \"How to annotate complexes in GO-CAM\" document for cases where the activities of the individual components are known.</p> </li> </ol>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I identified a few minor areas for improvement:</p> <ol> <li> <p>Evidence for ERBB2 activity: The evidence for ERBB2 protein tyrosine kinase activity comes from PMID:8702723, for which the full text was not available. It would be helpful to verify this with additional evidence if possible.</p> </li> <li> <p>Lack of downstream effects: The model shows ERBB2 tyrosine kinase activity but doesn't include any downstream targets of this activity. Based on PMID:19632177, the NRG1/ERBB4/ERBB2 signaling activates the PI3K-Akt pathway. Including these downstream components would make the model more complete.</p> </li> <li> <p>Biological process annotation: All activities are correctly annotated with \"part_of\" the ERBB2-ERBB4 signaling pathway (GO:0038135), but the three proteases (BACE1, ADAM10, and ADAM17) are also annotated with \"signaling receptor ligand precursor processing\" (GO:0140448). While technically correct, it might be clearer to be more specific about their role in NRG1 processing specifically.</p> </li> </ol>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:61b2b68300000203 is a high-quality representation of the ERBB2-ERBB4 signaling pathway in mouse that correctly captures the processing of NRG1 by proteases and its signaling through ERBB receptors. The model is biologically accurate, supported by published literature, and follows GO-CAM best practices for representing molecular activities and their causal relationships.</p> <p>The model could be extended to include downstream effects of ERBB2 kinase activity, such as PI3K-Akt pathway activation, which would provide a more complete picture of the signaling cascade. Overall, this model provides a valuable representation of NRG1-ERBB signaling that is consistent with current biological knowledge.</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/","title":"61b2b68300000617 ERBB2 ERBB3 receptor signaling pathway involved in myelination 1  Mouse","text":"<p>Now, let me review and analyze the GO-CAM model based on the retrieved information:</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#go-cam-model-review-erbb2-erbb3-receptor-signaling-pathway-involved-in-myelination-1-mouse","title":"GO-CAM Model Review: ERBB2-ERBB3 receptor signaling pathway involved in myelination 1 (Mouse)","text":"<p>Model ID: gomodel:61b2b68300000617</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#overview","title":"Overview","text":"<p>This model represents the ERBB2-ERBB3 receptor signaling pathway involved in myelination in mouse. It demonstrates the signaling cascade from the Neuregulin-1 (NRG1) ligand activating the ERBB2-ERBB3 receptor complex, leading to subsequent downstream MAPK signaling events.</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#structure-and-content-assessment","title":"Structure and Content Assessment","text":""},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#1-signaling-pathway-flow","title":"1. Signaling Pathway Flow","text":"<p>The model correctly shows a linear flow of signal transduction from: - Nrg1 (ligand) \u2192 Erbb3 (receptor) \u2192 Erbb2 (co-receptor) \u2192 Grb2 (adaptor) \u2192 Sos1 (GEF) \u2192 Hras \u2192 Raf1 \u2192 Map2k1/2 \u2192 Mapk1/3</p> <p>This is consistent with the canonical ERBB receptor signaling pathway leading to MAPK cascade activation.</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#2-molecular-functions-annotations","title":"2. Molecular Functions &amp; Annotations","text":"<ul> <li>Ligand: Nrg1 (MGI:MGI:96083) is appropriately annotated with \"receptor ligand activity\" (GO:0048018) occurring in \"extracellular space\" (GO:0005615)</li> <li>Receptors: Erbb2 and Erbb3 are correctly annotated, with Erbb3 having \"neuregulin receptor activity\" (GO:0038131) and Erbb2 having \"protein tyrosine kinase activity\" (GO:0004713), both occurring in \"plasma membrane\" (GO:0005886)</li> <li>Adaptor proteins: Grb2 is correctly annotated with \"transmembrane receptor protein tyrosine kinase adaptor activity\" (GO:0005068)</li> <li>GEF: Sos1 has \"guanyl-nucleotide exchange factor activity\" (GO:0005085)</li> <li>MAPK cascade components: All components (Hras, Raf1, Map2k1/2, Mapk1/3) have appropriate kinase activities located in appropriate cellular compartments</li> </ul>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#3-causal-relationships","title":"3. Causal Relationships","text":"<p>The model correctly uses \"directly positively regulates\" (RO:0002629) for causal relationships between activities, showing the signal flow through the pathway.</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":""},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#signaling-receptor-annotation","title":"Signaling Receptor Annotation","text":"<p>The model follows the signaling receptor annotation guidelines: - The ligand (Nrg1) has receptor ligand activity - The receptors (Erbb2/3) are correctly located in plasma membrane - Causal relations use appropriate directional regulation relationships</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#complexes-annotation","title":"Complexes Annotation","text":"<p>While not explicitly using a complex ID, the model represents the ERBB2-ERBB3 receptor complex appropriately by modeling each subunit separately with their respective activities, which is consistent with the \"subunit that carries the molecular activity is known\" guideline.</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#evidence-quality","title":"Evidence Quality","text":"<ul> <li>The model uses appropriate evidence codes:</li> <li>ECO:0000266 (sequence orthology evidence)</li> <li>ECO:0000315 (mutant phenotype evidence)</li> <li>ECO:0000314 (direct assay evidence)</li> <li>The model includes relevant PMIDs as references for assertions</li> </ul>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the ERBB2-ERBB3 signaling pathway: - NRG1 is a known activator of ERBB2-ERBB3 heterodimers - The subsequent MAPK cascade activation is biologically accurate - The model correctly shows that the signal transduction leads to myelination process, which is a known biological role of ERBB2-ERBB3 signaling in Schwann cells</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#improvement-opportunities","title":"Improvement Opportunities","text":"<ol> <li> <p>Missing Information: The model doesn't explicitly connect to the final myelination process (GO:0042552) - this could be added to show the terminal biological outcome</p> </li> <li> <p>Evidence Support: Some occurs_in relationships lack evidence sources</p> </li> <li> <p>Redundancy: There's some redundancy in the Map2k1 and Map2k2 pathways - they both activate the same downstream targets (Mapk1 and Mapk3) which could potentially be simplified</p> </li> <li> <p>Part_of Annotations: All activities are part of the ERBB2-ERBB3 signaling pathway (GO:0038133), but some downstream activities might be more specifically part of the MAPK cascade</p> </li> </ol>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the ERBB2-ERBB3 signaling pathway involved in myelination. It follows GO-CAM best practices and uses appropriate evidence codes and references. The model shows a clear flow of signal transduction from ligand binding to downstream kinase activation.</p> <p>The model is scientifically accurate, has good evidence support, and effectively represents the biological pathway. Minor improvements could be made to connect the pathway more explicitly to the myelination process and to ensure all cellular location assertions have evidence.</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/","title":"61e0e55600000239 Epidermal growth factor receptor signaling pathway 10  Mouse","text":"<p>Based on the information gathered, I will now review the GO-CAM model gomodel:61e0e55600000239 \"Epidermal growth factor receptor signaling pathway 10 (Mouse)\".</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#go-cam-review-gomodel61e0e55600000239","title":"GO-CAM Review: gomodel:61e0e55600000239","text":""},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents the Epidermal Growth Factor Receptor (EGFR) signaling pathway in mouse, focusing on a specific signaling cascade from the ligand TGF-alpha through EGFR and downstream adaptor proteins.</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#model-components","title":"Model Components","text":"<p>The model consists of the following key molecular functions and their associated gene products:</p> <ol> <li> <p>TGF-alpha (MGI:MGI:98724) - Performs \"receptor ligand activity\" (GO:0048018) in the extracellular space (GO:0005615).</p> </li> <li> <p>EGFR (MGI:MGI:95294) - Has dual functionalities in the model:</p> </li> <li>Performs \"epidermal growth factor receptor activity\" (GO:0005006) in the plasma membrane (GO:0005886)</li> <li> <p>Performs \"protein tyrosine kinase activity\" (GO:0004713) in the cell cortex (GO:0005938)</p> </li> <li> <p>Grb2 (MGI:MGI:95805) - Performs \"transmembrane receptor protein tyrosine kinase adaptor activity\" (GO:0005068) in the cell cortex (GO:0005938)</p> </li> <li> <p>Gab1 (MGI:MGI:108088) - Performs \"signaling adaptor activity\" (GO:0035591) in the cell cortex (GO:0005938)</p> </li> <li> <p>Ptpn11/SHP2 (MGI:MGI:99511) - Performs \"non-membrane spanning protein tyrosine phosphatase activity\" (GO:0004726) in the cytosol (GO:0005829)</p> </li> </ol>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#causal-relationships","title":"Causal Relationships","text":"<p>The model illustrates a signal transduction cascade with the following causal relationships: 1. TGF-alpha \u2192 directly positively regulates \u2192 EGFR receptor activity 2. EGFR receptor activity \u2192 directly positively regulates \u2192 Grb2 adaptor activity 3. Grb2 \u2192 provides input for \u2192 EGFR kinase activity 4. EGFR kinase activity \u2192 directly positively regulates \u2192 Gab1 adaptor activity 5. Gab1 \u2192 directly positively regulates \u2192 Ptpn11/SHP2 phosphatase activity</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#evidence-support","title":"Evidence Support","text":"<p>The model is supported by several publications, including PMID:7678348, PMID:17881575, and PMID:9890893, among others.</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#biological-content-consistency","title":"Biological Content Consistency","text":"<p>The represented EGFR signaling pathway aligns well with established knowledge of this pathway: 1. The model correctly shows TGF-alpha as a ligand for EGFR, activating its receptor function 2. It accurately represents EGFR's dual roles as a receptor and a kinase 3. The adapter protein cascade involving Grb2, Gab1, and the phosphatase Ptpn11/SHP2 is consistent with the literature on EGFR signaling</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":""},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#signaling-receptor-activity-annotation","title":"\u2713 Signaling Receptor Activity Annotation:","text":"<p>The model follows the guidelines for annotating signaling receptor activity: - TGF-alpha is correctly annotated with receptor ligand activity in the extracellular space - EGFR is annotated with receptor activity in the plasma membrane - The causal relationship between ligand and receptor uses \"directly positively regulates\"</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#activity-flow","title":"\u2713 Activity Flow:","text":"<p>The activity flow in the pathway is logical and follows the expected pattern of EGFR signaling: 1. Ligand binding \u2192 receptor activation \u2192 adaptor recruitment \u2192 signal transduction</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#cellular-compartments","title":"\u2713 Cellular Compartments:","text":"<p>The cellular locations are properly specified: - TGF-alpha in extracellular space - EGFR in plasma membrane and cell cortex - Adaptor proteins in appropriate cellular locations</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#evidence","title":"\u2713 Evidence:","text":"<p>Each activity and relationship is backed by appropriate evidence codes and literature references.</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#minor-areas-for-improvement","title":"Minor Areas for Improvement","text":"<ol> <li> <p>EGFR Compartmentalization: While the model shows EGFR kinase activity in the cell cortex, it may be worth noting that EGFR can also undergo endocytosis and signaling from endosomes. This additional compartmentalization could potentially be included in a more comprehensive model.</p> </li> <li> <p>Downstream Effectors: The current model ends with Ptpn11/SHP2 activity. In the broader EGFR pathway, SHP2 typically leads to activation of the Ras-MAPK pathway. Extending the model to include these downstream effectors would provide a more complete representation of EGFR signaling.</p> </li> <li> <p>Cross-talk with Other Pathways: EGFR signaling often intersects with other signaling pathways. While this model focuses on one specific branch, acknowledging these connections could enhance its biological relevance.</p> </li> </ol>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:61e0e55600000239 is a well-constructed representation of the EGFR signaling pathway in mouse. It adheres to GO-CAM curation best practices and accurately represents the biology of EGFR signaling as documented in the literature. The causal relationships between molecular functions are clearly defined, and each activity is properly contextualized with cellular locations and biological process involvement.</p> <p>The model could potentially be expanded to include additional downstream events or cross-talk with other pathways, but as a focused representation of the core EGFR signaling cascade, it is accurate and valuable.</p> <p>Overall, this model can be considered a high-quality contribution to the GO-CAM database that effectively captures key aspects of EGFR signaling.</p>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/","title":"61e0e55600000407 SP GADD34  PPP1CA","text":"<p>Based on my review of the model, the molecular roles, and the relevant literature, I'm ready to provide a comprehensive evaluation of GO-CAM model gomodel:61e0e55600000407.</p>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#go-cam-model-review-gomodel61e0e55600000407-sp_gadd34-ppp1ca","title":"GO-CAM Model Review: gomodel:61e0e55600000407 \"SP_GADD34- PPP1CA\"","text":""},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model (available at https://bioregistry.io/go.model:61e0e55600000407) represents the molecular pathway involving GADD34 (PPP1R15A), PPP1CA (PP1 catalytic subunit), and EIF2S1 (eIF2-alpha) in regulating translation initiation in response to cellular stress. The model describes how protein kinases EIF2AK2, EIF2AK3, and EIF2AK4 phosphorylate EIF2S1 to inhibit translation, and how the GADD34-PPP1CA complex acts to dephosphorylate EIF2S1 and restore translation.</p>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately captures the key components of the integrated stress response pathway:</p> <ol> <li>Protein kinases (EIF2AK2, EIF2AK3, EIF2AK4) correctly shown to negatively regulate EIF2S1's translation initiation activity through phosphorylation</li> <li>GADD34 (PPP1R15A) correctly shown with molecular adaptor activity that recruits PPP1CA to EIF2S1</li> <li>PPP1CA correctly shown with phosphatase activity that reverses EIF2S1 phosphorylation</li> <li>EIF2S1 correctly shown with translation initiation factor activity</li> </ol> <p>The literature confirms this model accurately captures how GADD34-PPP1CA complex functions to dephosphorylate EIF2S1, consistent with the findings in PMID:26095357, which explains the molecular basis of this interaction and how GADD34 acts as a scaffold to bring together PPP1CA and EIF2S1.</p>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model largely follows GO-CAM best practices:</p> <ol> <li>Molecular Functions (MF): Appropriate molecular functions are assigned to each protein:</li> <li>EIF2AK2: protein serine/threonine kinase activity (GO:0004674)</li> <li>EIF2AK3 and EIF2AK4: protein kinase activity (GO:0004672)</li> <li>PPP1R15A and PPP1R15B: molecular adaptor activity (GO:0060090)</li> <li>PPP1CA: phosphatase activity (GO:0016791)</li> <li> <p>EIF2S1: translation initiation factor activity (GO:0003743)</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal relationships:</p> </li> <li>\"directly negatively regulates\" (RO:0002630) for the kinases inhibiting EIF2S1</li> <li> <p>\"directly positively regulates\" (RO:0002629) for PPP1R15A activating PPP1CA</p> </li> <li> <p>Cell Components (CC): Appropriate cellular locations are specified:</p> </li> <li>EIF2AK3, PPP1R15A, and PPP1CA are indicated to occur in the endoplasmic reticulum (GO:0005783)</li> <li> <p>EIF2S1 is indicated to occur in the cytoplasm (GO:0005737)</p> </li> <li> <p>Biological Processes (BP): Some proteins in the model include appropriate biological processes:</p> </li> <li>EIF2AK3 is part of \"response to endoplasmic reticulum stress\" (GO:0034976)</li> <li>EIF2AK4 is part of \"response to amino acid starvation\" (GO:1990928)</li> </ol>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I've identified several areas for improvement:</p> <ol> <li> <p>Missing Biological Process for EIF2S1: EIF2S1's activity should be placed in the context of a relevant biological process, such as \"translational initiation\" (GO:0006413) or \"regulation of translational initiation in response to stress\" (GO:0043558).</p> </li> <li> <p>Missing Cell Component for EIF2AK2 and EIF2AK4: These kinases lack cellular component annotations. EIF2AK2 is known to function in both cytoplasm and nucleus, while EIF2AK4 can be found in the cytoplasm.</p> </li> <li> <p>Inconsistent Annotation of Evidence: Some associations include evidence codes and citations (ECO:0000314 with PMIDs), while others lack evidence codes. Consistent use of evidence throughout the model would improve its quality.</p> </li> <li> <p>Missing Biological Process for PPP1CA: PPP1CA's role in dephosphorylation is not placed in any biological process context. It could be part of \"protein dephosphorylation\" (GO:0006470) or, more specifically, \"regulation of translational initiation in response to stress\" (GO:0043558).</p> </li> <li> <p>Regulatory Relationship Between PPP1R15A and EIF2S1: While the model shows PPP1R15A regulating PPP1CA which then regulates EIF2S1, the literature (PMID:26095357) indicates PPP1R15A directly interacts with EIF2S1 independent of PPP1CA. This interaction could be explicitly represented in the model, showing that PPP1R15A acts as a scaffold bringing together both PPP1CA and EIF2S1.</p> </li> </ol>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#conclusion","title":"Conclusion","text":"<p>Model gomodel:61e0e55600000407 provides an accurate representation of the GADD34/PPP1CA/EIF2S1 pathway involved in translational regulation during stress. The model correctly captures the key molecular activities, causal relationships, and cellular localizations. Minor improvements could be made in the annotation of biological processes, cellular components, and evidence codes to fully adhere to GO-CAM best practices.</p> <p>The model successfully illustrates how EIF2S1 phosphorylation by stress-activated kinases inhibits translation, and how the GADD34-PPP1CA complex reverses this inhibition by dephosphorylating EIF2S1. This pathway is critical in the cellular response to various stresses, including ER stress and amino acid starvation, and in the regulation of protein synthesis during stress recovery.</p>"},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/","title":"61e0e55600000430 Epidermal growth factor receptor signaling pathway 11  Mouse","text":"<p>Now let me review the GO-CAM model with all the information I have gathered:</p>"},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/#go-cam-model-review-egfr-signaling-pathway-gomodel61e0e55600000430","title":"GO-CAM Model Review: EGFR Signaling Pathway (gomodel:61e0e55600000430)","text":""},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:61e0e55600000430) represents the \"Epidermal growth factor receptor signaling pathway 11 (Mouse)\" within the context of mouse (NCBITaxon:10090). The model was sourced from gomodel:R-HSA-212718 and includes automated updates to certain relation terms.</p>"},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/#model-structure","title":"Model Structure","text":"<p>The model contains the following key components:</p> <ol> <li>EGF (MGI:MGI:95290) - acts as a ligand with receptor ligand activity (GO:0048018)</li> <li>EGFR (MGI:MGI:95294) - has two functions:</li> <li>Epidermal growth factor receptor activity (GO:0005006)</li> <li>Protein tyrosine kinase activity (GO:0004713)</li> <li>PLC\u03b31 (MGI:MGI:97615) - has phospholipase C activity (GO:0004629)</li> </ol> <p>The model shows a causal chain where: - EGF directly positively regulates (RO:0002629) EGFR receptor activity - EGFR receptor activity directly positively regulates (RO:0002629) EGFR kinase activity - EGFR kinase activity directly positively regulates (RO:0002629) PLC\u03b31 phospholipase C activity</p>"},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/#evaluation","title":"Evaluation","text":""},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/#strengths-of-the-model","title":"Strengths of the model:","text":"<ol> <li> <p>Correct core elements: The model correctly identifies the key components of EGFR signaling - the EGF ligand, EGFR receptor, and PLC\u03b31 as a downstream effector.</p> </li> <li> <p>Appropriate molecular functions: Each gene product is annotated with appropriate molecular functions based on their biological roles.</p> </li> <li> <p>Accurate causal relationships: The model uses the \"directly positively regulates\" (RO:0002629) relation to show how the pathway flows from EGF to EGFR activation to PLC\u03b31 activation, which is supported by literature.</p> </li> <li> <p>Correct cellular compartmentalization: The model properly places EGF in the extracellular space (GO:0005615) and both EGFR and PLC\u03b31 at the plasma membrane (GO:0005886).</p> </li> <li> <p>Association with biological process: All activities are correctly associated with the epidermal growth factor receptor signaling pathway (GO:0007173).</p> </li> </ol>"},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li> <p>Missing intermediate mechanistic steps: The model does not explicitly capture that EGFR first autophosphorylates after ligand binding, creating docking sites for PLC\u03b31's SH2 domains. EGFR then phosphorylates PLC\u03b31, activating its phospholipase activity. These intermediate steps would provide a more complete mechanistic picture.</p> </li> <li> <p>Missing downstream effects: The model doesn't include the consequences of PLC\u03b31 activation - hydrolyzing PIP2 to produce IP3 and DAG, which then activate calcium release and PKC, respectively.</p> </li> <li> <p>Missing other key EGFR signaling branches: The model focuses only on the PLC\u03b31 pathway but doesn't include other important EGFR downstream pathways like RAS/MAPK, PI3K/AKT, or STAT pathways.</p> </li> <li> <p>Evidence evaluation: The evidence seems appropriate, as it comes from a mixture of experimental evidence codes and orthology-based evidence.</p> </li> </ol>"},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>From a biological standpoint, the model correctly captures a simplified view of EGFR activation of PLC\u03b31. Based on the UniProt entries and literature evidence:</p> <ol> <li>EGF is indeed a ligand that binds to and activates EGFR</li> <li>EGFR does function as both a receptor and a tyrosine kinase</li> <li>EGFR does directly phosphorylate and activate PLC\u03b31</li> <li>The cellular locations are accurate</li> </ol> <p>The PMID:28004780 reference provides strong evidence for the connection between EGFR, PLC\u03b31, and PKC pathways in epidermal differentiation, supporting the model's representation of EGFR activating PLC\u03b31. The PMID:9529375 reference confirms that PLC\u03b31 is activated downstream of EGFR, although it suggests that PLC\u03b31 may not be essential for all EGFR-mediated cellular responses, particularly mitogenesis in fibroblasts.</p>"},{"location":"reviews/61e0e55600000430-Epidermal_growth_factor_receptor_signaling_pathway_11__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a biologically accurate but simplified model of EGFR signaling focused specifically on PLC\u03b31 activation. The model follows GO-CAM best practices for signaling receptor annotation. The model correctly represents the causal chain from EGF to EGFR to PLC\u03b31, with appropriate molecular functions and cellular locations.</p> <p>To improve the model, additional mechanistic details could be added, such as the phosphorylation events that mediate EGFR activation of PLC\u03b31, and downstream effects of PLC\u03b31 activation (IP3/DAG production leading to calcium release and PKC activation). Additionally, including other major branches of EGFR signaling would provide a more comprehensive view of this pathway.</p>"},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/","title":"61e0e55600000624 Cyclin D ubiquitination and degradation by AMBRA1  Human","text":"<p>Based on the information gathered, I'll now provide a comprehensive review of GO-CAM model gomodel:61e0e55600000624 \"Cyclin-D ubiquitination and degradation by AMBRA1 (Human)\":</p>"},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/#go-cam-model-review-cyclin-d-ubiquitination-and-degradation-by-ambra1-human","title":"GO-CAM Model Review: Cyclin-D ubiquitination and degradation by AMBRA1 (Human)","text":""},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/#model-id-gomodel61e0e55600000624","title":"Model ID: gomodel:61e0e55600000624","text":""},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/#summary","title":"Summary","text":"<p>This model represents the molecular mechanism by which AMBRA1 regulates cell cycle progression through the ubiquitination and degradation of D-type cyclins (Cyclin D1, D2, and D3) during the G1/S transition of the cell cycle in humans. AMBRA1 functions as a substrate adaptor in a DCX (DDB1-CUL4-X-box) E3 ubiquitin ligase complex that targets phosphorylated cyclin D proteins for degradation.</p>"},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/#key-components","title":"Key Components","text":"<ol> <li>AMBRA1 (Q9C0C7): Substrate-recognition component (adaptor) in the DCX E3 ubiquitin-protein ligase complex</li> <li>Cyclin D proteins:</li> <li>Cyclin D1 (P24385)</li> <li>Cyclin D2 (P30279)</li> <li>Cyclin D3 (P30281)</li> <li>CDK proteins:</li> <li>CDK4 (P11802)</li> <li>CDK6 (Q00534)</li> </ol>"},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Proper annotation of ubiquitin ligase adaptor activity: AMBRA1 is correctly annotated with the molecular function \"ubiquitin-like ligase-substrate adaptor activity\" (GO:1990756) and is properly associated with \"proteasome-mediated ubiquitin-dependent protein catabolic process\" (GO:0043161).</p> </li> <li> <p>Accurate cell cycle context: The model appropriately places all activities within the \"G1/S transition of mitotic cell cycle\" (GO:0000082) biological process.</p> </li> <li> <p>Multiple cyclins represented: The model includes all three D-type cyclins (D1, D2, and D3) with appropriate molecular functions.</p> </li> <li> <p>Appropriate causal relationships: The model uses the RO:0002409 predicate (\"causally upstream of\") to link AMBRA1's substrate adaptor activity to the cyclin-CDK complexes, which is appropriate given its regulatory role in targeting cyclins for degradation.</p> </li> <li> <p>Evidence support: The model cites appropriate literature evidence, including the key papers (PMID:33854235, PMID:33854239) that establish AMBRA1's role in cyclin D regulation.</p> </li> </ol>"},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/#issues-identified","title":"Issues Identified","text":"<ol> <li>Inconsistent causal relationships: There is a mix of causal predicates used in the model. For example:</li> <li>In some cases, RO:0002409 \"causally upstream of\" is used</li> <li>In other cases, RO:0002630 \"directly negatively regulates\" is used</li> <li> <p>According to E3 ubiquitin ligase annotation guidelines, for an adaptor protein like AMBRA1, the relationship to the substrate should be \"indirectly regulates\" when the E3 ligase is not explicitly included in the model</p> </li> <li> <p>Missing components of the E3 ligase complex: The model does not include the other components of the DCX E3 ligase complex (CUL4 and DDB1), which would ideally be included according to the E3 ubiquitin ligase annotation guidelines.</p> </li> <li> <p>Redundant annotations: There are several redundant activities represented in the model:</p> </li> <li>AMBRA1 has multiple instances with the same molecular function (GO:1990756)</li> <li> <p>Some causal relationships are duplicated (e.g., there are two identical causal associations from activity ID \"gomodel:61e0e55600000624/62183af000000905\" to \"gomodel:61e0e55600000624/61e0e55600000712\")</p> </li> <li> <p>Evidence assignment: Some causal relationships lack explicit evidence annotations, making it difficult to trace the source of these assertions.</p> </li> <li> <p>Incomplete representation of the phosphorylation-dependent mechanism: While the model shows AMBRA1 targeting cyclins for degradation, it does not explicitly show the phosphorylation step of cyclin D (at Thr-286) that's required for recognition by AMBRA1, as described in the UniProt entries.</p> </li> </ol>"},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Standardize causal relationships: Use consistent causal relationship predicates according to the E3 ubiquitin ligase annotation guidelines.</p> </li> <li> <p>Add missing E3 ligase complex components: Include CUL4 and DDB1 with appropriate molecular functions (ubiquitin ligase complex scaffold activity - GO:0160072) to provide a more complete representation of the DCX complex.</p> </li> <li> <p>Remove redundant activities: Consolidate the multiple representations of AMBRA1's molecular function to reduce duplication.</p> </li> <li> <p>Complete the phosphorylation mechanism: Add the kinase activity that phosphorylates cyclin D at Thr-286, which is a prerequisite for recognition by AMBRA1.</p> </li> <li> <p>Add evidence to all assertions: Ensure each causal relationship has appropriate evidence annotations.</p> </li> <li> <p>Enhance mechanistic detail: Consider adding the specific ubiquitination at Lys-269 of cyclin D1 as mentioned in the UniProt entry.</p> </li> </ol>"},{"location":"reviews/61e0e55600000624-Cyclin_D_ubiquitination_and_degradation_by_AMBRA1__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Cyclin-D ubiquitination and degradation by AMBRA1 (Human)\" provides a valuable representation of AMBRA1's role in regulating cell cycle progression through targeted degradation of D-type cyclins. While the core biological mechanism is captured correctly, there are opportunities to enhance the model's completeness and consistency with GO-CAM best practices, particularly regarding E3 ubiquitin ligase complex representation and causal relationship annotations.</p> <p>The model aligns with recent literature showing AMBRA1 as a key regulator of D-type cyclins that affects the G1/S transition, helping to ensure genomic integrity during DNA replication and counteracting developmental abnormalities and tumor growth.</p>"},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/","title":"61e0e55600001225 Gluconeogenesis 1  Mouse","text":"<p>Let me review this GO-CAM model which focuses on gluconeogenesis in mouse. Here's my comprehensive review:</p>"},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/#review-of-go-cam-model-gomodel61e0e55600001225","title":"Review of GO-CAM Model: gomodel:61e0e55600001225","text":""},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: Gluconeogenesis 1 (Mouse)</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> <li>Comments: Sourced from gomodel:R-HSA-70263</li> </ul>"},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive representation of gluconeogenesis pathway: The model captures the key enzymatic steps of gluconeogenesis with appropriate molecular function annotations and cellular locations.</p> </li> <li> <p>Proper causal connections: The activities are connected using RO:0002413 \"provides input for\" relation, which appropriately reflects the flow of the pathway.</p> </li> <li> <p>Evidence-based annotations: Most activities are supported by literature evidence, with a mix of different evidence codes (ECO:0000314 direct assay, ECO:0000315 mutant phenotype, etc.).</p> </li> <li> <p>Proper subcellular locations: The model correctly represents the different compartments where reactions occur (cytosol, mitochondrial inner membrane, mitochondrial matrix, and endoplasmic reticulum).</p> </li> <li> <p>Detailed substrate flow: The model traces the conversion from mitochondrial precursors to glucose in the ER, reflecting the actual biological process.</p> </li> </ol>"},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing direct evidence for some causal associations: While the molecular functions and biological processes have evidence annotations, the causal associations (RO:0002413 \"provides input for\") lack direct evidence codes. This is common in GO-CAM models but could be strengthened.</p> </li> <li> <p>Limited description of regulation: The model focuses primarily on the enzymatic steps but doesn't include regulatory aspects of gluconeogenesis (such as hormonal regulation or transcriptional control).</p> </li> <li> <p>Missing isoforms: In some cases where multiple isoforms exist for enzymes (like G6pc1 and G6pc3), the model does include both, but some connections may be missing between alternate parallel paths.</p> </li> </ol>"},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li> <p>Using standard causal relations: The model consistently uses RO:0002413 \"provides input for\" to connect enzyme activities in sequence.</p> </li> <li> <p>Proper use of part_of relations: All activities are appropriately marked as part_of GO:0006094 (gluconeogenesis).</p> </li> <li> <p>Appropriate subcellular locations: Each activity is annotated with the correct cellular component.</p> </li> <li> <p>Evidence for annotations: Each molecular function and most process annotations have supporting evidence from the scientific literature.</p> </li> </ol>"},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the gluconeogenesis pathway from a biochemical perspective:</p> <ol> <li>Starting with mitochondrial steps (pyruvate carboxylase, mitochondrial malate dehydrogenase)</li> <li>Transport of metabolites across the mitochondrial membrane (via SLC25A10 and SLC25A11)</li> <li>Cytosolic steps involving the conversion of oxaloacetate to phosphoenolpyruvate (via PCK1)</li> <li>Lower glycolytic enzymes in reverse (ENO1, PGAM1, PGK1, GAPDH, TPI1, ALDOC)</li> <li>Conversion of fructose-1,6-bisphosphate to fructose-6-phosphate (FBP1)</li> <li>Isomerization to glucose-6-phosphate (GPI1)</li> <li>Transport and hydrolysis in the ER (SLC37A4, G6PC1, G6PC3)</li> </ol>"},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add regulatory elements: Consider adding regulatory components such as CREB, FOXO1, PGC-1\u03b1 that control the transcription of gluconeogenic enzymes.</p> </li> <li> <p>Include insulin/glucagon signaling: The model could be expanded to show how hormone signaling regulates this pathway.</p> </li> <li> <p>Add evidence codes for causal relations: Where possible, add literature evidence for the specific causal connections between activities.</p> </li> <li> <p>Consider connecting to related pathways: The model could be linked to glycolysis, TCA cycle, or amino acid metabolism to show interconnections.</p> </li> </ol>"},{"location":"reviews/61e0e55600001225-Gluconeogenesis_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a well-constructed representation of the gluconeogenesis pathway in mouse. It follows GO-CAM best practices, is supported by literature evidence, and accurately depicts the biological process. The model could be enhanced by including regulatory elements and connecting to related pathways, but it serves as an excellent standalone representation of the core enzymatic steps in gluconeogenesis.</p>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/","title":"61e0e55600001295 NLRP1 inflammasome leading to pyroptosis  Human","text":"<p>Now, after reviewing all the collected information, I'll provide a comprehensive review of gomodel:61e0e55600001295 (NLRP1 inflammasome leading to pyroptosis).</p>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#review-of-go-cam-model-nlrp1-inflammasome-leading-to-pyroptosis-human","title":"Review of GO-CAM model: NLRP1 inflammasome leading to pyroptosis (Human)","text":"<p>ID: gomodel:61e0e55600001295</p>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#1-overview","title":"1. Overview","text":"<p>This GO-CAM model represents the NLRP1 inflammasome pathway leading to pyroptosis in humans. The model captures key molecular activities, causal relationships, and cellular locations of components involved in NLRP1 inflammasome activation and the subsequent pyroptotic cell death process. The model is annotated with solid literature evidence and includes proper citation of relevant scientific papers.</p>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#2-model-content-assessment","title":"2. Model Content Assessment","text":""},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#21-biological-accuracy","title":"2.1 Biological Accuracy","text":"<p>The model correctly captures the essential components and mechanisms of NLRP1 inflammasome activation:</p> <ul> <li>NLRP1 autolytic processing and activation: The model correctly represents NLRP1's requirement for autolytic cleavage within its FIIND domain (between F1212 and S1213), which is a prerequisite for inflammasome activation as demonstrated in PMID:22665479.</li> <li>Dipeptidyl peptidase regulation: The model captures the interaction between DPP8/DPP9 and NLRP1, where DPP8/DPP9 negatively regulate NLRP1 (PMID:33731929), and inhibition of DPP8/DPP9 can trigger NLRP1 activation.</li> <li>ASC recruitment: The model correctly shows NLRP1 recruiting ASC via its CARD domain, which is essential for NLRP1 inflammasome activity (PMID:22665479).</li> <li>Caspase-1 activation: The model includes caspase-1 recruitment and activation, which leads to downstream gasdermin D cleavage.</li> <li>Pyroptosis induction: The model properly represents the final outcome of NLRP1 inflammasome activation as pyroptotic cell death via Gasdermin D pore formation.</li> </ul>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#22-adherence-to-go-cam-curation-standards","title":"2.2 Adherence to GO-CAM Curation Standards","text":"<p>The model follows GO-CAM curation standards:</p> <ul> <li>Proper GO term usage: The model uses appropriate GO molecular function (MF) terms for activities (e.g., GO:0140693 \"molecular condensate scaffold activity\", GO:0035591 \"signaling adaptor activity\").</li> <li>Correct causal relations: The model correctly uses causal relationship predicates such as RO:0002629 \"directly positively regulates\" to connect activities.</li> <li>Appropriate evidence codes: Assertions are supported by ECO:0000314 (direct assay evidence used in manual assertion) with proper PMID references.</li> <li>Cellular component annotation: Activities are properly located in cellular components (e.g., cytosol GO:0005829).</li> </ul>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#23-representation-of-molecular-mechanisms","title":"2.3 Representation of Molecular Mechanisms","text":"<p>The model effectively represents key molecular mechanisms:</p> <ol> <li> <p>NLRP1 double-stranded RNA binding (GO:0003725) in the cytosol, followed by pattern recognition receptor activity (GO:0038187), which are necessary for initial response to pathogens like viruses.</p> </li> <li> <p>NLRP1 molecular condensate scaffold activity (GO:0140693) that is required for inflammasome assembly.</p> </li> <li> <p>NLRP1 signaling adaptor activity (GO:0035591), which connects the initial sensing to downstream signaling.</p> </li> <li> <p>NLRP1 cysteine-type endopeptidase activator activity (GO:0140608), which enables the activation of Caspase-1.</p> </li> <li> <p>CASP1 cysteine-type endopeptidase activity (GO:0004197) leading to cleavage of gasdermin D.</p> </li> <li> <p>GSDMD wide pore channel activity (GO:0022829) in the plasma membrane, causing cell rupture and pyroptosis.</p> </li> <li> <p>Negative regulation of this pathway by dipeptidyl peptidases DPP8/DPP9 (GO:0008239).</p> </li> </ol>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#3-strengths-of-the-model","title":"3. Strengths of the Model","text":"<ol> <li> <p>Comprehensive representation: The model covers the complete pathway from initial NLRP1 sensing to final pyroptotic outcome.</p> </li> <li> <p>Strong literature support: Each activity and relationship is supported by high-quality published evidence with appropriate citations.</p> </li> <li> <p>Molecular detail: The model captures important molecular details such as the autolytic cleavage of NLRP1 within the FIIND domain, which is essential for activation.</p> </li> <li> <p>Regulatory mechanisms: The model includes negative regulation by DPP8/DPP9, which is an important aspect of inflammasome control.</p> </li> <li> <p>Cellular localization: The model correctly annotates activities with their subcellular locations.</p> </li> </ol>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#4-suggested-improvements","title":"4. Suggested Improvements","text":"<ol> <li> <p>Additional PMID citations: While the model has good literature support, some additional recent papers on NLRP1 activation mechanisms could strengthen the evidence further, particularly for the direct regulatory relationship between NLRP1 molecular condensate scaffold activity and signaling adaptor activity.</p> </li> <li> <p>Expanded context: The model could benefit from including additional contextual information about what triggers NLRP1 activation in the first place (viral infection, etc.) and the physiological consequences of NLRP1-driven pyroptosis.</p> </li> <li> <p>Additional components: The model could include IL-1\u03b2 processing, which is another key outcome of inflammasome activation alongside pyroptosis.</p> </li> <li> <p>Biological process annotation: While most activities are correctly annotated with 'part_of' biological processes, a more specific annotation for some activities would strengthen the model.</p> </li> </ol>"},{"location":"reviews/61e0e55600001295-NLRP1_inflammasome_leading_to_pyroptosis__Human_/#5-final-assessment","title":"5. Final Assessment","text":"<p>This GO-CAM model accurately represents the NLRP1 inflammasome pathway leading to pyroptosis based on current scientific understanding. It successfully captures the essential molecular activities, their causal relationships, and cellular locations. The model is well-supported by literature evidence and follows GO-CAM curation standards.</p> <p>The model effectively demonstrates: - The requirement for NLRP1 autolytic processing - Regulation by DPP8/DPP9 - ASC recruitment and inflammasome assembly - Caspase-1 activation - Gasdermin D cleavage and pore formation - Pyroptotic cell death as the final outcome</p> <p>Overall, this is a high-quality model that provides a valuable resource for understanding NLRP1 inflammasome biology and could serve as a reference for researchers studying inflammasome activation, pyroptosis, and related innate immune processes.</p>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/","title":"61e0e55600001659 Granzyme mediated  GZMB  activation of pyroptosis  GSDME   Human","text":"<p>Let me review the GO-CAM model 61e0e55600001659 based on the information I've gathered:</p>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#review-of-go-cam-model-gomodel61e0e55600001659","title":"Review of GO-CAM Model: gomodel:61e0e55600001659","text":""},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#model-overview","title":"Model Overview","text":"<p>Title: Granzyme-mediated (GZMB) activation of pyroptosis (GSDME) (Human) ID: gomodel:61e0e55600001659 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#biological-process-represented","title":"Biological Process Represented","text":"<p>This model describes the molecular pathway for granzyme B (GZMB)-mediated activation of gasdermin E (GSDME) leading to pyroptotic cell death in humans. This process is particularly important for the immune system's ability to eliminate cancer cells and infected cells.</p>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model includes four key molecular activities:</p> <ol> <li> <p>NINJ1 (Ninjurin-1, UniProtKB:Q92982): Functions in membrane destabilizing activity (GO:0140912) at the plasma membrane (GO:0005886) as part of the pyroptotic cell death process (GO:0141201).</p> </li> <li> <p>GSDME (Gasdermin E, UniProtKB:O60443): Functions with wide pore channel activity (GO:0022829) as part of pyroptotic cell death (GO:0141201).</p> </li> <li> <p>PRF1 (Perforin-1, UniProtKB:P14222): Functions with wide pore channel activity (GO:0022829) at the plasma membrane (GO:0005886) as part of protein transmembrane transport (GO:0071806).</p> </li> <li> <p>GZMB (Granzyme B, UniProtKB:P10144): Functions with serine-type endopeptidase activity (GO:0004252) in the cytoplasm (GO:0005737) as part of protein maturation (GO:0051604).</p> </li> </ol>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes causal relationships showing the flow of activity:</p> <ol> <li>PRF1 positively regulates GZMB (<code>RO:0002304</code> - causally upstream of, positive effect).</li> <li>GZMB directly positively regulates GSDME (<code>RO:0002629</code> - directly positively regulates).</li> <li>GSDME directly positively regulates NINJ1 (<code>RO:0002629</code> - directly positively regulates).</li> </ol>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well supported by substantial experimental evidence, with each activity and causal relationship documented with experimental evidence (ECO:0000314 - direct assay evidence) and recent publications:</p> <ul> <li>Activities of NINJ1 are supported by 2024 publications (PMID:38614101, PMID:37198476, PMID:37196676, PMID:36468682, PMID:33472215)</li> <li>Activities of GSDME are supported by 2022 publications (PMID:32188940)</li> <li>Activities of PRF1 are supported by 2010 publications (PMID:20038786)</li> <li>Activities of GZMB are supported by 2020 and 2019 publications (PMID:32188940, PMID:31953257)</li> </ul>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately captures the current understanding of GZMB-mediated pyroptosis through GSDME:</p> <ol> <li>Perforin (PRF1) forms pores in target cell membranes and facilitates the entry of granzyme B (GZMB).</li> <li>Granzyme B cleaves gasdermin E (GSDME) at the D270 site, releasing the N-terminal pore-forming domain.</li> <li>GSDME forms pores in the cell membrane, leading to membrane destabilization.</li> <li>NINJ1 (Ninjurin-1) acts downstream of GSDME to execute plasma membrane rupture, leading to pyroptotic cell death.</li> </ol> <p>This mechanism is consistent with recent discoveries that NINJ1 is a key executioner of plasma membrane rupture during various forms of lytic cell death, including pyroptosis (as described in PMID:37198476 and PMID:38614101).</p>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Appropriate molecular functions: Each protein is annotated with a valid molecular function (e.g., GZMB with serine-type endopeptidase activity).</li> <li>Proper cellular component annotations: Components are placed in the correct cellular locations (e.g., PRF1 and NINJ1 at plasma membrane, GZMB in cytoplasm).</li> <li>Logical causal connections: The causal flow from PRF1 \u2192 GZMB \u2192 GSDME \u2192 NINJ1 reflects the biological sequence accurately.</li> <li>Evidence citations: All annotations are supported by appropriate experimental evidence codes and literature references.</li> <li>Appropriate use of relation types: The model uses the correct causal relationships (RO:0002304 and RO:0002629) to show the directionality and type of influence.</li> </ol>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, I would suggest a few minor improvements:</p> <ol> <li> <p>Additional contextual information: The model could benefit from explicitly noting that this pathway is particularly relevant in the context of cytotoxic lymphocyte-mediated killing of tumor cells or infected cells, as highlighted in PMID:32188940.</p> </li> <li> <p>Process expansion: The biological outcome of NINJ1 activity could be more explicitly modeled. NINJ1 leads to plasma membrane rupture, which is the defining event of pyroptotic cell death that releases DAMPs (damage-associated molecular patterns), but this final step and its consequences aren't fully represented.</p> </li> <li> <p>Potential refinements to causal relationships: Based on PMID:38614101, NINJ1 appears to be activated by GSDME-mediated pores, so the causal relationship from GSDME to NINJ1 is correctly captured. However, from PMID:37198476, it appears that NINJ1 has a more complex role in membrane destabilization through formation of filamentous structures.</p> </li> </ol>"},{"location":"reviews/61e0e55600001659-Granzyme_mediated__GZMB__activation_of_pyroptosis__GSDME___Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:61e0e55600001659 is a high-quality representation of the GZMB-mediated activation of pyroptosis through GSDME and NINJ1. It accurately captures current knowledge of this pathway, is well-supported by recent experimental evidence, and adheres to GO-CAM best practices. The model successfully integrates recent discoveries about NINJ1's role as the terminal executioner of cell membrane rupture during pyroptotic cell death. This model provides valuable insight into the mechanism by which cytotoxic lymphocytes can induce inflammatory cell death in target cells.</p>"},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/","title":"61e0e55600002253 Activation of ALK and LTK by ALKAL1 and ALKAL2 cytokines  Human","text":"<p>Now I'll formulate my review of the GO-CAM model.</p>"},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#go-cam-model-review-activation-of-alk-and-ltk-by-alkal1-and-alkal2-cytokines-human","title":"GO-CAM Model Review: Activation of ALK and LTK by ALKAL1 and ALKAL2 cytokines (Human)","text":""},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#model-id-gomodel61e0e55600002253","title":"Model ID: gomodel:61e0e55600002253","text":""},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#overview","title":"Overview","text":"<p>The model represents the activation of two receptor tyrosine kinases, ALK (Anaplastic Lymphoma Kinase) and LTK (Leukocyte Tyrosine Kinase), by their ligands ALKAL1 (also known as FAM150A or AUG-beta) and ALKAL2 (also known as FAM150B or AUG-alpha). The model captures the cytokine-receptor interactions and the resulting signaling in the cell surface receptor protein tyrosine kinase signaling pathway.</p>"},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>This GO-CAM model accurately represents the current understanding of ALK and LTK receptor activation by ALKAL1 and ALKAL2 ligands, as supported by recent literature. The scientific content aligns well with the research described in the cited papers, particularly PMID:30061385, PMID:34646012, and PMID:34819673, which detail the structural basis and mechanisms of cytokine-mediated activation of these receptors.</p> <p>Key biological aspects represented correctly: 1. ALKAL1 and ALKAL2 function as extracellular cytokines (GO:0005125) that occur in the extracellular space (GO:0005615) 2. ALK and LTK are transmembrane receptor tyrosine kinases (GO:0004714) located in the plasma membrane (GO:0005886) 3. Both receptors are involved in the cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169) 4. ALK also is shown to have heparin binding activity (GO:0008201), which is supported by the literature</p>"},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#structure-and-organization","title":"Structure and Organization","text":"<p>The model appropriately uses the following causal associations: - \"RO:0002629\" (directly positively regulates) to show how the cytokines ALKAL1 and ALKAL2 activate their respective receptors - \"RO:0002304\" (causally upstream of, positive effect) to represent the activity of ALK's heparin binding domain in supporting receptor function</p>"},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#technical-assessment","title":"Technical Assessment","text":"<p>The model follows the GO-CAM best practices for representing signaling receptor activity according to the \"Signaling receptor activity annotation guidelines\":</p> <ol> <li>For cytokines (ligands):</li> <li>ALKAL1 and ALKAL2 correctly enable cytokine activity (GO:0005125), which is a child of receptor ligand activity</li> <li>They occur in the extracellular space (GO:0005615) as expected</li> <li>They are properly shown as part of the cell surface receptor signaling pathway (GO:0007169)</li> <li> <p>The causal relation \"directly positively regulates\" is correctly used to show how they activate their receptors</p> </li> <li> <p>For receptors:</p> </li> <li>ALK and LTK correctly enable transmembrane receptor protein tyrosine kinase activity (GO:0004714)</li> <li>They are properly shown as occurring in the plasma membrane (GO:0005886)</li> <li> <p>They are part of the appropriate signaling pathway (GO:0007169)</p> </li> <li> <p>Additional features:</p> </li> <li>The model correctly represents ALK's heparin binding activity (GO:0008201), which according to recent literature helps regulate receptor activation</li> </ol>"},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#strengths","title":"Strengths","text":"<ol> <li>Comprehensive representation of both ALK and LTK signaling through their respective ligands</li> <li>Inclusion of ALK's heparin binding activity, which is an important regulatory feature</li> <li>Well-supported by multiple peer-reviewed publications</li> <li>Proper use of GO terms and relation types</li> <li>Correct cellular locations for all components</li> </ol>"},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#possible-improvements","title":"Possible Improvements","text":"<ol> <li> <p>Receptor Downstream Effects: The model could be expanded to show the downstream effectors of ALK and LTK activation, such as phosphorylation of adapter proteins and activation of MAPK or PI3K pathways, which are mentioned in the scientific literature.</p> </li> <li> <p>Receptor Dimerization: Recent structural studies (PMID:34819673) indicate that ALK and LTK dimerize upon ligand binding. This feature could be explicitly captured in the model.</p> </li> <li> <p>Ligand Specificity: The literature suggests that while ALKAL1 can activate both receptors, ALKAL2 is more specific for ALK. This differential activation potency could be represented.</p> </li> <li> <p>EGF-like Domain Role: The research indicates that the EGF-like domain of ALK is critical for ligand binding and receptor activation. This domain-specific information could be incorporated.</p> </li> </ol>"},{"location":"reviews/61e0e55600002253-Activation_of_ALK_and_LTK_by_ALKAL1_and_ALKAL2_cytokines__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is scientifically accurate, well-structured, and follows the GO-CAM best practices for representing receptor-ligand interactions. It effectively captures the core biology of ALK and LTK activation by ALKAL1 and ALKAL2. The model is parsimonious while including key regulatory features like ALK's heparin binding activity. With some potential expansions to include downstream signaling effects, it could provide even greater utility to the scientific community.</p>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/","title":"61f34dd300000863 PKM2 acetylation by EP300 and deacetylation by SIRT6 leading to conversion into a protein kinase  Human","text":"<p>Based on my comprehensive review of the GO-CAM model gomodel:61f34dd300000863 and the relevant literature and protein information, I'll now provide my assessment of this model.</p>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#go-cam-model-review-for-gomodel61f34dd300000863","title":"GO-CAM Model Review for gomodel:61f34dd300000863","text":""},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"PKM2 acetylation by EP300 and deacetylation by SIRT6 leading to conversion into a protein kinase (Human)\" represents a molecular pathway involving the pyruvate kinase M2 isoform (PKM2) and its regulation through acetylation and deacetylation, affecting its localization and function.</p>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model describes: 1. PKM2 (P14618-1) with multiple activities:    - Pyruvate kinase activity (GO:0004743) in the cytoplasm    - Histone H3T11 kinase activity (GO:0035402) in the nucleus    - Protein tyrosine kinase activity (GO:0004713) in the nucleus</p> <ol> <li> <p>EP300 (Q09472) with peptide-lysine-N-acetyltransferase activity (GO:0061733)</p> </li> <li> <p>SIRT6 (Q8N6T7) with NAD-dependent protein lysine deacetylase activity (GO:0034979)</p> </li> <li> <p>XPO4 (Q9C0E2) with nuclear export signal receptor activity (GO:0005049)</p> </li> <li> <p>RAN (P62826) with G protein activity (GO:0003925)</p> </li> </ol> <p>The model depicts regulatory relationships showing how PKM2 acetylation by EP300 promotes its nuclear retention and function as a protein kinase, while deacetylation by SIRT6 promotes its export from the nucleus via XPO4, returning it to its cytoplasmic role in glycolysis.</p>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the findings from the primary literature:</p> <ol> <li> <p>PKM2 nuclear function: The model correctly shows PKM2's dual role as a glycolytic enzyme in the cytoplasm and a protein kinase in the nucleus, as demonstrated in Yang et al. 2012 (PMID:22901803), where it phosphorylates histone H3 at T11.</p> </li> <li> <p>Acetylation by EP300: The model correctly depicts EP300 acetylating PKM2 at K433, which promotes its nuclear localization and protein kinase activity (as shown in PMID:24120661).</p> </li> <li> <p>Deacetylation by SIRT6: The model correctly shows SIRT6 deacetylating nuclear PKM2, which leads to nuclear export in an XPO4-dependent manner (as shown in Bhardwaj &amp; Das 2016, PMID:26787900).</p> </li> <li> <p>Nuclear export mechanism: The model appropriately includes XPO4 and RAN in the protein export pathway from the nucleus.</p> </li> </ol>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#go-cam-modeling-standards-assessment","title":"GO-CAM Modeling Standards Assessment","text":""},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Appropriate molecular functions: The model uses the correct molecular functions for each protein.</p> </li> <li> <p>Correct cellular locations: The model properly specifies the subcellular locations where activities occur (nucleus vs. cytoplasm).</p> </li> <li> <p>Causal relationships: The model correctly uses RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates) to show the regulatory relationships between activities.</p> </li> <li> <p>Comprehensive representation: The model captures the bidirectional regulation of PKM2 location and function.</p> </li> </ol>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#areas-for-improvement","title":"Areas for improvement:","text":"<ol> <li> <p>Complex representation: While the model shows the individual proteins correctly, there's no representation of any complexes that might form during these processes, such as PKM2-EP300 or PKM2-SIRT6 complexes that would likely exist during the acetylation/deacetylation processes.</p> </li> <li> <p>Missing details on phosphorylation targets: While the model includes PKM2's kinase activities, it doesn't specifically indicate what proteins other than histone H3 might be phosphorylated by nuclear PKM2.</p> </li> <li> <p>Missing connection to biological outcomes: The model doesn't connect these molecular activities to higher-level biological processes like gene expression changes or cancer-related phenotypes that are mentioned in the literature.</p> </li> </ol>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by the cited literature: - PMID:22901803 provides evidence for the H3T11 kinase activity - PMID:24120661 provides evidence for the K433 acetylation by EP300 - PMID:26787900 provides evidence for SIRT6-mediated deacetylation and nuclear export - PMID:10944119 provides evidence for XPO4 function in nuclear export</p> <p>All causal relationships in the model have appropriate evidence codes and citations.</p>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is scientifically accurate and follows most GO-CAM best practices. It successfully represents the dynamic regulation of PKM2 localization and function through post-translational modification. The model effectively depicts how acetylation by EP300 promotes PKM2's nuclear retention and function as a protein kinase, while deacetylation by SIRT6 promotes its export back to the cytoplasm through XPO4, restoring its glycolytic function.</p>"},{"location":"reviews/61f34dd300000863-PKM2_acetylation_by_EP300_and_deacetylation_by_SIRT6_leading_to_conversion_into_a_protein_kinase__Human_/#minor-suggestions-for-improvement","title":"Minor suggestions for improvement:","text":"<ol> <li>Consider incorporating protein complexes where appropriate</li> <li>Add connections to broader biological outcomes</li> <li>Include additional targets of PKM2 kinase activity if supported by evidence</li> </ol> <p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of PKM2 regulation as described in the scientific literature.</p>"},{"location":"reviews/61f34dd300000981-Regulation_of_gluconeogenesis_by_SIRT6__FOXO1_and_KAT2A_GCN5__Human_/","title":"61f34dd300000981 Regulation of gluconeogenesis by SIRT6  FOXO1 and KAT2A GCN5  Human","text":"<p>Now, let me analyze all the information I've gathered to review the GO-CAM model.</p>"},{"location":"reviews/61f34dd300000981-Regulation_of_gluconeogenesis_by_SIRT6__FOXO1_and_KAT2A_GCN5__Human_/#model-review-for-gomodel61f34dd300000981-regulation-of-gluconeogenesis-by-sirt6-foxo1-and-kat2agcn5-human","title":"Model Review for gomodel:61f34dd300000981 (Regulation of gluconeogenesis by SIRT6, FOXO1 and KAT2A/GCN5 (Human))","text":"<p>Based on my review of the model and the relevant literature, I'm ready to provide a thorough assessment of this GO-CAM.</p>"},{"location":"reviews/61f34dd300000981-Regulation_of_gluconeogenesis_by_SIRT6__FOXO1_and_KAT2A_GCN5__Human_/#model-overview","title":"Model Overview:","text":"<p>This model represents the regulatory pathway by which SIRT6, FOXO1, and KAT2A/GCN5 interact to regulate gluconeogenesis in the human liver. The model consists of 6 molecular activities connected by causal relationships.</p>"},{"location":"reviews/61f34dd300000981-Regulation_of_gluconeogenesis_by_SIRT6__FOXO1_and_KAT2A_GCN5__Human_/#model-strengths","title":"Model Strengths:","text":"<ol> <li>The model correctly represents the key molecular functions of the main players:</li> <li>SIRT6 (Q8N6T7) with NAD-dependent protein lysine deacetylase activity (GO:0034979)</li> <li>FOXO1 (Q12778) with DNA-binding transcription factor activity (GO:0003700)</li> <li>KAT2A/GCN5 (Q92830) with peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li> <p>PPARGC1A (Q9UBK2) with transcription coactivator activity (GO:0003713)</p> </li> <li> <p>The model correctly places all activities in the nucleus (GO:0005634), which matches the subcellular localization information from UniProt.</p> </li> <li> <p>The model correctly connects the activities with causal relationships that are supported by the literature:</p> </li> <li>SIRT6 directly negatively regulates FOXO1 (supported by PMID:25009184)</li> <li>SIRT6 directly positively regulates KAT2A (supported by PMID:23142079)</li> <li>KAT2A directly negatively regulates PPARGC1A (supported by PMID:23142079, PMID:16753578)</li> <li> <p>FOXO1 directly positively regulates PPARGC1A (supported by references)</p> </li> <li> <p>The biological process annotations are appropriate:</p> </li> <li>SIRT6 activities are associated with negative regulation of gluconeogenesis (GO:0045721)</li> <li>FOXO1 activity is associated with positive regulation of gluconeogenesis (GO:0045722)</li> <li>PPARGC1A activity is associated with gluconeogenesis (GO:0006094)</li> </ol>"},{"location":"reviews/61f34dd300000981-Regulation_of_gluconeogenesis_by_SIRT6__FOXO1_and_KAT2A_GCN5__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Missing Mechanistic Details: The model could be more explicit about the specific mechanisms:</li> <li>SIRT6 deacetylates FOXO1, leading to its nuclear exclusion (PMID:25009184)</li> <li>SIRT6 specifically deacetylates KAT2A at Lys-549, which enhances KAT2A's acetyltransferase activity (PMID:23142079)</li> <li> <p>KAT2A then acetylates PPARGC1A, which inhibits its transcriptional coactivator activity (PMID:16753578, PMID:23142079)</p> </li> <li> <p>Potential Missing Activities: </p> </li> <li>The model doesn't include SIRT1, which was shown in the literature (PMID:23142079) to have opposing effects to SIRT6 on PPARGC1A acetylation and could be relevant for a complete understanding of the pathway.</li> <li> <p>The model doesn't represent the positive regulation of SIRT6 by p53 as described in PMID:25009184, though this may be outside the specific scope of this model.</p> </li> <li> <p>Biological Process Association for KAT2A: </p> </li> <li> <p>Although KAT2A's activity is correctly associated with negative regulation of gluconeogenesis (GO:0045721), this connection could be strengthened by explicitly showing how KAT2A's acetylation of PPARGC1A leads to suppression of gluconeogenic genes.</p> </li> <li> <p>Additional Evidence: </p> </li> <li>The model would benefit from citing PMID:25009184 as evidence for the relationship between SIRT6 and FOXO1, as this is a key paper establishing this connection.</li> </ol>"},{"location":"reviews/61f34dd300000981-Regulation_of_gluconeogenesis_by_SIRT6__FOXO1_and_KAT2A_GCN5__Human_/#suggested-specific-improvements","title":"Suggested Specific Improvements:","text":"<ol> <li>Add molecular details to the causal relationships:</li> <li>SIRT6 \u2192 FOXO1: Add that SIRT6 deacetylates FOXO1 at Lys-423, promoting its nuclear exclusion</li> <li>SIRT6 \u2192 KAT2A: Add that SIRT6 deacetylates KAT2A at Lys-549</li> <li> <p>KAT2A \u2192 PPARGC1A: Add that KAT2A acetylates PPARGC1A at multiple lysine residues</p> </li> <li> <p>Consider adding SIRT1 as a counterpart to SIRT6 in the regulation of PPARGC1A, showing its opposing effect (deacetylating PPARGC1A), which would provide a more complete picture of the regulatory circuit.</p> </li> <li> <p>Add downstream effects: The model could be extended to show the downstream effects on specific gluconeogenic genes (G6PC and PCK1) that are regulated by PPARGC1A and FOXO1.</p> </li> </ol>"},{"location":"reviews/61f34dd300000981-Regulation_of_gluconeogenesis_by_SIRT6__FOXO1_and_KAT2A_GCN5__Human_/#conclusion","title":"Conclusion:","text":"<p>Overall, gomodel:61f34dd300000981 is a well-constructed model that accurately represents the key molecular activities and causal relationships involved in the regulation of gluconeogenesis by SIRT6, FOXO1, and KAT2A/GCN5. The model is consistent with the literature and reflects the current understanding of this regulatory pathway. The suggested improvements would add more mechanistic detail and provide a more complete representation of the regulatory circuit, but the existing model is scientifically accurate and appropriately structured according to GO-CAM best practices.</p> <p>The model effectively illustrates how SIRT6 can suppress gluconeogenesis through two complementary mechanisms: (1) by directly promoting FOXO1 nuclear exclusion and (2) by activating KAT2A to acetylate and inhibit PPARGC1A. This dual mechanism provides robust regulation of the gluconeogenic program in the liver.</p>"},{"location":"reviews/61f34dd300001044-Yeast_ergosterol/","title":"61f34dd300001044 Yeast ergosterol","text":""},{"location":"reviews/61f34dd300001044-Yeast_ergosterol/#go-cam-review-for-model-gomodel61f34dd300001044-yeast-ergosterol","title":"GO-CAM Review for Model gomodel:61f34dd300001044 \"Yeast ergosterol\"","text":""},{"location":"reviews/61f34dd300001044-Yeast_ergosterol/#summary","title":"Summary:","text":"<p>This model represents the ergosterol biosynthetic pathway in yeast, showing the sequence of enzymatic activities that lead to the production of ergosterol. It contains 25 activities carried out by different enzymes, with each step converting specific chemical compounds as part of the GO:0006696 (ergosterol biosynthetic process).</p>"},{"location":"reviews/61f34dd300001044-Yeast_ergosterol/#strengths","title":"Strengths:","text":"<ol> <li> <p>Comprehensive Pathway Representation: The model provides a detailed representation of the entire ergosterol biosynthetic pathway, with each enzymatic step properly annotated.</p> </li> <li> <p>Appropriate Evidence and References: Each activity is supported by evidence codes (ECO terms) and references to scientific literature (PMIDs).</p> </li> <li> <p>Clear Input/Output Relationships: Most activities clearly specify their chemical inputs and outputs with CHEBI terms, establishing the flow of metabolites through the pathway.</p> </li> <li> <p>Cellular Locations: Most activities specify where they occur within the cell (endoplasmic reticulum, vacuole, or mitochondrion).</p> </li> </ol>"},{"location":"reviews/61f34dd300001044-Yeast_ergosterol/#issues-identified","title":"Issues Identified:","text":"<ol> <li>Limited Causal Connections: While the model represents a linear metabolic pathway, only two causal connections are explicitly defined:</li> <li>SGD:S000004741 (ERG29) causally upstream of (positive effect) the C-4 methylsterol oxidase activity (ERG25)</li> <li>The activity of SGD:S000002969 (ERG26) provides input for the 3-keto sterol reductase activity (ERG27)</li> </ol> <p>The model would benefit from explicit causal connections between all steps in the pathway to clearly show the sequential nature of the reactions.</p> <ol> <li>Duplicate Inputs/Outputs: Some activities have duplicate entries for the same molecule:</li> <li>Activity gomodel:61f34dd300001044/61f34dd300001167 (ERG11) has three identical outputs of CHEBI:17813</li> <li>Activity gomodel:61f34dd300001044/61f34dd300001179 (ERG24) has duplicate inputs of CHEBI:17813</li> <li> <p>Activity gomodel:61f34dd300001044/61f34dd300001208 (ERG26) has duplicate inputs of CHEBI:64925</p> </li> <li> <p>Taxonomic Discrepancy: The model's taxon is listed as \"NCBITaxon:9823\" (which is pig/Sus scrofa), but all gene products are from yeast (SGD identifiers). The taxon should be changed to a yeast taxon (likely NCBITaxon:4932 for S. cerevisiae).</p> </li> <li> <p>Missing Information for Some Activities: Some activities lack complete information:</p> </li> <li>Activity gomodel:61f34dd300001044/6205c24300000094 (ERG29) has a general molecular_function (GO:0003674) rather than a specific one</li> </ol>"},{"location":"reviews/61f34dd300001044-Yeast_ergosterol/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Add Missing Causal Connections: Add \"provides input for\" (RO:0002413) connections between sequential activities in the pathway to clearly show the metabolic flow.</p> </li> <li> <p>Fix Taxonomic Information: Update the taxon to the correct yeast species (NCBITaxon:4932).</p> </li> <li> <p>Remove Duplicate Inputs/Outputs: Clean up the duplicate molecules in the activities mentioned above.</p> </li> <li> <p>Specify More Precise Function for ERG29: If possible, update the general molecular function (GO:0003674) for ERG29 to a more specific term.</p> </li> <li> <p>Ensure All Activities Have Location Information: Some activities may be missing cellular location information.</p> </li> </ol> <p>Overall, this is a well-constructed GO-CAM model that accurately represents the ergosterol biosynthetic pathway in yeast. With the suggested improvements, particularly adding causal connections between sequential steps, it would be even more valuable for representing the full pathway structure.</p>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/","title":"6205c24300000050 SIRT6 inactivation by lncPRESS1 RNA  Human","text":"<p>Based on my examination of the GO-CAM model and the referenced documentation, I'll now provide a comprehensive review of the GO-CAM model \"SIRT6 inactivation by lncPRESS1 RNA (Human)\" (gomodel:6205c24300000050).</p>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#review-of-go-cam-model-sirt6-inactivation-by-lncpress1-rna-human","title":"Review of GO-CAM Model: SIRT6 inactivation by lncPRESS1 RNA (Human)","text":""},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model (gomodel:6205c24300000050) represents the regulatory relationship between the long non-coding RNA lncPRESS1 (RNAcentral:URS0000BC450A_9606) and the histone deacetylase protein SIRT6 (UniProtKB:Q8N6T7) in human embryonic stem cells. The model shows how lncPRESS1 negatively regulates SIRT6 chromatin binding and subsequent histone deacetylase activity, which plays a critical role in maintaining stem cell pluripotency.</p>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#model-components-and-structure","title":"Model Components and Structure","text":"<p>The model consists of four main activities: 1. lncPRESS1 RNA protein binding activity 2. SIRT6 lncRNA binding activity 3. SIRT6 chromatin binding activity 4. SIRT6 histone deacetylase activity</p> <p>These activities are causally connected to represent a regulatory pathway where lncPRESS1 ultimately prevents SIRT6 from deacetylating histones at pluripotency gene promoters.</p>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model is well-supported by scientific literature. The key reference (PMID:27912097) demonstrates that: 1. lncPRESS1 physically interacts with SIRT6 2. This interaction prevents SIRT6 chromatin localization 3. As a result, histone H3K56 and H3K9 acetylation levels are maintained at promoters of pluripotency genes 4. This mechanism is essential for maintaining human embryonic stem cell pluripotency</p> <p>The model accurately represents these findings through the causal relationships between the molecular activities.</p>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#go-cam-best-practices-evaluation","title":"GO-CAM Best Practices Evaluation","text":""},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#annotation-quality-and-compliance","title":"Annotation Quality and Compliance","text":"<ol> <li>Appropriate molecular functions: The model uses appropriate GO terms for molecular functions:</li> <li>GO:0005515 (protein binding) for lncPRESS1</li> <li>GO:0106222 (lncRNA binding) for SIRT6</li> <li>GO:0003682 (chromatin binding) for SIRT6</li> <li> <p>GO:0017136 (histone deacetylase activity, NAD-dependent) for SIRT6</p> </li> <li> <p>Appropriate causal relationship predicates: The model correctly uses:</p> </li> <li>RO:0002629 (directly positively regulates) from lncPRESS1 protein binding to SIRT6 lncRNA binding</li> <li>RO:0002630 (directly negatively regulates) from SIRT6 lncRNA binding to SIRT6 chromatin binding</li> <li> <p>RO:0002629 (directly positively regulates) from SIRT6 chromatin binding to SIRT6 histone deacetylase activity</p> </li> <li> <p>Cellular contexts: The model appropriately includes cellular location information:</p> </li> <li> <p>SIRT6 chromatin binding and histone deacetylase activities occur in GO:0000785 (chromatin)</p> </li> <li> <p>Process contexts: Each activity is correctly annotated with appropriate biological processes:</p> </li> <li>GO:0120186 (negative regulation of protein localization to chromatin) for RNA binding activities</li> <li> <p>GO:2000738 (positive regulation of stem cell differentiation) for SIRT6 chromatin binding and deacetylase activities</p> </li> <li> <p>Evidence and provenance: All activities and relationships include proper evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) linked to the primary research article (PMID:27912097).</p> </li> </ol>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing details in histone substrate specificity: The model could be enhanced by specifying which histone lysine residues are deacetylated by SIRT6. According to the literature, SIRT6 specifically targets H3K56ac and H3K9ac, which could be represented in the model.</p> </li> <li> <p>Redundant causal relationship: There appears to be a redundant causal association from SIRT6 chromatin binding to histone deacetylase activity; one association has evidence while the other lacks evidence annotation.</p> </li> <li> <p>Molecular details of lncPRESS1-SIRT6 interaction: The model could be enhanced by representing the specific regions of interaction between lncPRESS1 and SIRT6, if this information is available in the literature.</p> </li> <li> <p>Downstream effects: The model could be extended to show the effects of maintained histone acetylation on pluripotency gene expression, linking this regulatory mechanism to the transcription of specific pluripotency factors (OCT4, NANOG, etc.).</p> </li> </ol>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#biological-pathway-representation","title":"Biological Pathway Representation","text":"<p>The model effectively represents the functional flow from lncPRESS1 binding to SIRT6, which prevents SIRT6 from binding to chromatin and performing its histone deacetylase activity. This sequestration mechanism (often called a \"molecular decoy\" mechanism in the literature) is accurately represented through the causal relationships.</p> <p>The pathway is represented parsimoniously, focusing on the core regulatory relationship without unnecessary complexity, making it easy to understand the biological mechanism.</p>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#consistency-with-uniprot-information","title":"Consistency with UniProt Information","text":"<p>The model is consistent with what is known about SIRT6 from UniProt: - SIRT6 is a NAD-dependent protein deacetylase that specifically targets H3K9, H3K18, and H3K56 - SIRT6 plays roles in regulation of transcription and stem cell differentiation - SIRT6 activity can be regulated by interaction with other molecules - UniProt specifically mentions that \"The histone deacetylase activity is specifically repressed by long non-coding RNA lncPRESS1, which binds to SIRT6 and prevents chromatin-binding, thereby promoting stem cell pluripotency.\"</p>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the regulatory mechanism by which lncPRESS1 inactivates SIRT6 in human embryonic stem cells, consistent with the supporting literature. The model follows GO-CAM best practices in most aspects, with a few minor areas for potential enhancement. It provides a clear and biologically accurate representation of this important mechanism for maintaining pluripotency in stem cells.</p>"},{"location":"reviews/6205c24300000050-SIRT6_inactivation_by_lncPRESS1_RNA__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Remove the redundant causal association that lacks evidence annotation</li> <li>Consider specifying the histone lysine residues targeted by SIRT6 (H3K56 and H3K9)</li> <li>Consider extending the model to include downstream effects on specific pluripotency genes</li> </ol> <p>Overall, this is a high-quality GO-CAM model that accurately represents the biological mechanism described in the literature.</p>"},{"location":"reviews/6205c24300000330-Microtubule_polyglutamylation_regulation__Human_/","title":"6205c24300000330 Microtubule polyglutamylation regulation  Human","text":"<p>Now that I've gathered information about the model, let me review gomodel:6205c24300000330 - \"Microtubule polyglutamylation regulation (Human)\".</p>"},{"location":"reviews/6205c24300000330-Microtubule_polyglutamylation_regulation__Human_/#go-cam-review-for-gomodel6205c24300000330","title":"GO-CAM Review for gomodel:6205c24300000330","text":""},{"location":"reviews/6205c24300000330-Microtubule_polyglutamylation_regulation__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the regulation of microtubule polyglutamylation in humans. The model shows various molecular interactions involved in microtubule polymerization, stabilization, and post-translational modifications, particularly focusing on polyglutamylation.</p>"},{"location":"reviews/6205c24300000330-Microtubule_polyglutamylation_regulation__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model accurately represents the tubulin polyglutamylation pathway based on current scientific understanding:</p> <ol> <li>The model includes key players in the regulation of tubulin polyglutamylation, including:</li> <li>TTLL1 (O95922) - Tubulin-glutamic acid ligase activity</li> <li>MAP4 (P27816) - Microtubule-associated protein involved in stabilization</li> <li>MARK4 (Q96L34) - Protein serine/threonine kinase that regulates MAP4 through phosphorylation</li> <li>TPGS1 (Q6ZTW0) and TPGS2 (Q68CL5) - Molecular adaptor proteins in the tubulin polyglutamylase complex</li> <li>LRRC49 (Q8IUZ0-4) - Adaptor protein in the tubulin polyglutamylase complex</li> <li> <p>PCM1 (Q15154) - Involved in scaffold activity in the centriolar satellite</p> </li> <li> <p>The evidence for these interactions is well-documented in the literature, particularly in the Wang et al. (2022) paper (PMIDs: 34782749 and 34040253) which describe the molecular mechanisms of how MARK4 regulates microtubule polyglutamylation by controlling MAP4 phosphorylation.</p> </li> </ol>"},{"location":"reviews/6205c24300000330-Microtubule_polyglutamylation_regulation__Human_/#model-structure-and-connectivity","title":"Model Structure and Connectivity","text":"<p>The model correctly represents causal connections between activities using appropriate relations:</p> <ol> <li>The regulatory relationships are represented with causal predicates:</li> <li>RO:0002629 (directly positively regulates) for positive regulation</li> <li> <p>RO:0002630 (directly negatively regulates) for negative regulation</p> </li> <li> <p>Key pathway connections:</p> </li> <li>MARK4 (Q96L34) phosphorylates MAP4 (P27816), negatively regulating its microtubule stabilizing activity</li> <li>TTLL1 (O95922) has tubulin-glutamic acid ligase activity, which negatively regulates microtubule stabilization</li> <li>PCM1 (Q15154) acts as a molecular scaffold, recruiting various adaptor proteins</li> <li>Adaptor proteins (TPGS1, TPGS2, LRRC49) all positively regulate TTLL1's activity</li> </ol>"},{"location":"reviews/6205c24300000330-Microtubule_polyglutamylation_regulation__Human_/#quality-control-review","title":"Quality Control Review","text":"<ol> <li>Evidence and Citations:</li> <li>The model is well-supported with evidence from appropriate experimental sources</li> <li>The primary references (PMIDs: 34782749, 34040253, 10791892) provide solid experimental evidence for the claimed relationships</li> <li> <p>Evidence codes are correctly used (ECO:0000314 for direct assay, ECO:0000250 for sequence similarity evidence)</p> </li> <li> <p>Cellular Locations:</p> </li> <li>Appropriate cellular locations are specified for each activity</li> <li> <p>Most activities occur on microtubules (GO:0005874) or at the centrosome/centriolar satellite (GO:0034451)</p> </li> <li> <p>GO Term Usage:</p> </li> <li> <p>The molecular function terms are appropriate for each protein:</p> <ul> <li>GO:0070740 (tubulin-glutamic acid ligase activity) for TTLL1</li> <li>GO:0140778 (microtubule stabilizing activity) for MAP4</li> <li>GO:0004674 (protein serine/threonine kinase activity) for MARK4</li> <li>GO:0030674 (protein-macromolecule adaptor activity) for the adaptor proteins</li> </ul> </li> <li> <p>Biological Processes:</p> </li> <li>The model correctly connects activities to appropriate biological processes:<ul> <li>GO:0000226 (microtubule cytoskeleton organization)</li> <li>GO:0046785 (microtubule polymerization)</li> <li>GO:0140706 (protein-containing complex localization to centriolar satellite)</li> <li>GO:0061635 (regulation of protein complex stability)</li> <li>GO:1902850 (microtubule cytoskeleton organization involved in mitosis)</li> </ul> </li> </ol>"},{"location":"reviews/6205c24300000330-Microtubule_polyglutamylation_regulation__Human_/#minor-issues-to-address","title":"Minor Issues to Address","text":"<ol> <li>Evidence Documentation:</li> <li>Some causal associations lack specific evidence instances (such as in the connections from Q9H6J7 to Q8IUZ0-4 and Q68CL5)</li> <li> <p>These should be supported with the same evidence as other similar relationships in the model</p> </li> <li> <p>Complex Representation:</p> </li> <li>According to the GO-CAM document on representing complexes, the model uses the correct approach by representing individual subunits with known activities rather than using a complex ID</li> <li>This is appropriate since the tubulin polyglutamylase complex members have distinct molecular functions</li> </ol>"},{"location":"reviews/6205c24300000330-Microtubule_polyglutamylation_regulation__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>The GO-CAM model \"Microtubule polyglutamylation regulation (Human)\" (gomodel:6205c24300000330) is a high-quality representation of the current understanding of microtubule polyglutamylation regulation. It accurately captures the molecular mechanisms described in recent literature, particularly the roles of MARK4 in regulating MAP4 activity and the subsequent effects on microtubule polyglutamylation via TTLL1.</p> <p>The model follows GO-CAM best practices by: 1. Using appropriate molecular function terms 2. Correctly specifying cellular locations 3. Linking activities to biological processes 4. Using appropriate causal relations between activities 5. Providing solid experimental evidence for most relationships</p> <p>The minor issues noted (some missing evidence annotations) don't significantly impact the overall quality of the model.</p> <p>This model successfully represents a complex regulatory pathway in a clear and parsable format, making it valuable for researchers interested in microtubule regulation, post-translational modifications, and cytoskeletal organization.</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/","title":"6205c24300000880 Regulation of cholesterol biosynthesis by SREBP  SREBF1 and SREBF2  and retention by the SREBP SCAP complex  Human","text":"<p>Based on my review of the GO-CAM model gomodel:6205c24300000880 and the relevant guidelines, here is my comprehensive review:</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#go-cam-model-review-gomodel6205c24300000880","title":"GO-CAM Model Review: gomodel:6205c24300000880","text":""},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#model-overview","title":"Model Overview","text":"<p>Title: \"Regulation of cholesterol biosynthesis by SREBP (SREBF1 and SREBF2) and retention by the SREBP-SCAP complex (Human)\" Taxon: Human (NCBITaxon:9823) Status: Production Model ID: gomodel:6205c24300000880</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#model-content-review","title":"Model Content Review","text":""},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#1-overall-biological-process-representation","title":"1. Overall Biological Process Representation","text":"<p>This model captures the SREBP pathway for cholesterol biosynthesis regulation, specifically focusing on: - SREBP-SCAP complex retention in the endoplasmic reticulum - SREBP protein processing and transport to the nucleus - Transcriptional activation leading to cholesterol biosynthesis regulation</p> <p>The model correctly captures the key players including INSIG1/2, AKT1, SREBFs, SCAP, and the proteases MBTPS1/2.</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#2-connection-quality-and-causal-relationships","title":"2. Connection Quality and Causal Relationships","text":"<p>The causal flow in the model generally follows proper biological understanding of the pathway: - AKT1 positively regulates PCK1 - PCK1 negatively regulates INSIG proteins - INSIG proteins regulate SREBP-SCAP complex retention through protein sequestering - Proteases MBTPS1 and MBTPS2 process SREBP proteins - Nuclear import via KPNB1 - Nuclear transcriptional activity of the processed SREBFs</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#3-specific-issues-identified","title":"3. Specific Issues Identified","text":""},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#31-missing-evidence-for-some-causal-associations","title":"3.1 Missing Evidence for Some Causal Associations","text":"<p>Several causal relationships lack evidence annotations: - Activity gomodel:6205c24300000880/6205c24300000892 (AKT1) to gomodel:6205c24300000880/6205c24300000881 (PCK1) lacks evidence in one instance - Activity gomodel:6205c24300000880/6205c24300000917 (INSIG1) to gomodel:6205c24300000880/6205c24300001240 (MBTPS2) has duplicate causal edges - Multiple missing evidence annotations for causal relationships involving MBTPS1 and MBTPS2</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#32-protein-sequestering-activity-annotation","title":"3.2 Protein Sequestering Activity Annotation","text":"<p>The model correctly uses GO:0140311 (protein sequestering activity) for INSIG1 and INSIG2, but according to the guidelines: - The relationship between sequestering activity and the activity it inhibits should be \"directly negatively regulates\" (RO:0002630) - The model correctly uses RO:0002305 (causally upstream of, negative effect) which is appropriate for this case</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#33-transcription-factor-activity-representation","title":"3.3 Transcription Factor Activity Representation","text":"<p>For SREBF1 and SREBF2's transcription factor activities: - The model correctly uses GO:0000981 (DNA-binding transcription factor activity, RNA polymerase II-specific) - According to guidelines, transcription factors should have \"has input\" relationships to their gene targets - Missing information about specific gene targets regulated by the SREBFs  - Currently, the model shows the transcription factors as part of the BP \"positive regulation of cholesterol biosynthetic process\" (GO:0045542) which is correct</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#34-duplicate-activities-and-relationships","title":"3.4 Duplicate Activities and Relationships","text":"<p>There are duplicate activities for some proteins: - MBTPS2 has two nearly identical activity nodes (gomodel:6205c24300000880/6205c24300001020 and gomodel:6205c24300000880/6205c24300001240) - KPNB1 has two nuclear import signal receptor activities (gomodel:6205c24300000880/6205c24300001135 and gomodel:6205c24300000880/6205c24300001031) - Several causal edges are duplicated with the same evidence</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#35-evidence-quality","title":"3.5 Evidence Quality","text":"<ul> <li>The with_objects field in one instance contains a formatting error: \"\\nWith\\nUniProtKB:Q14703\" instead of \"UniProtKB:Q14703\"</li> <li>Multiple evidence references but could benefit from more mechanistic detail from the cited literature</li> </ul>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#4-consistency-with-current-knowledge","title":"4. Consistency with Current Knowledge","text":"<p>The model generally conforms to what is known about the SREBP pathway: - SREBP is retained in the ER by INSIG proteins when cholesterol levels are high - When cholesterol levels drop, INSIG regulation is inhibited and SCAP facilitates SREBP movement to the Golgi - SREBP is processed by proteases in the Golgi (MBTPS1 and MBTPS2) - Processed SREBP is transported to the nucleus where it activates genes involved in cholesterol biosynthesis</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#5-recommendations-for-improvement","title":"5. Recommendations for Improvement","text":"<ol> <li> <p>Fix missing evidence annotations: Ensure all causal relationships have proper evidence.</p> </li> <li> <p>Consolidate duplicate activities: Merge the duplicate activity nodes for MBTPS2 and KPNB1.</p> </li> <li> <p>Add gene targets: Include specific gene targets of SREBF1 and SREBF2 with \"has input\" relationships to better represent the transcription factor activity.</p> </li> <li> <p>Fix formatting error: Correct the with_objects field that contains a formatting error.</p> </li> <li> <p>Consider expanded pathway representation: The model could be extended to include:</p> </li> <li>More detailed representation of cholesterol sensing</li> <li>Additional downstream targets of SREBFs</li> <li> <p>Integration with related lipid metabolism pathways</p> </li> <li> <p>Taxon issue: The model title indicates it's for human, but the taxon is listed as NCBITaxon:9823 (Sus scrofa/pig) - this should be corrected to human (NCBITaxon:9606).</p> </li> </ol>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good representation of the SREBP pathway for cholesterol biosynthesis regulation. While there are some technical issues with evidence annotations and duplicate activities that should be addressed, the overall biological content and flow are accurate. The model follows most GO-CAM best practices, though it could benefit from more detail regarding transcription factor targets and consistency fixes for the duplicated nodes.</p>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/","title":"6205c24300001663 IL2 signaling pathway  Human","text":"<p>Based on my review of the GO-CAM model and the relevant guidelines, I can now provide a comprehensive review of the IL2 signaling pathway model (gomodel:6205c24300001663):</p>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#review-of-il2-signaling-pathway-model-human-gomodel6205c24300001663","title":"Review of IL2 Signaling Pathway Model (Human) - gomodel:6205c24300001663","text":""},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the IL-2 signaling pathway in humans, illustrating the interactions between IL-2 (Interleukin-2) and its receptor components, as well as the subsequent signaling events through JAK kinases and STAT transcription factors.</p>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accuracy of Biological Process: The model correctly represents the IL-2 signaling pathway (GO:0038110) as described in the literature. The key protein components (IL-2, IL-2RA, IL-2RB, IL-2RG, JAK1, JAK3, STAT5A, STAT3) are included with their correct molecular functions.</p> </li> <li> <p>Adherence to GO-CAM Guidelines for Receptor Complexes: The model follows the guidelines for annotating signaling receptor activity with coreceptors. As specified in the \"Signaling receptor activity annotation guidelines\" document, it correctly represents:</p> </li> <li>IL-2 as a cytokine with cytokine activity (GO:0005125)</li> <li>IL-2RA with interleukin-2 receptor activity (GO:0004911)</li> <li> <p>IL-2RB and IL-2RG with coreceptor activity (GO:0015026)</p> </li> <li> <p>Accurate Causal Relationships: The model correctly uses causal relationships to connect the activities, using \"directly positively regulates\" (RO:0002629) to show the activation cascade from IL-2 to its receptors and downstream components.</p> </li> <li> <p>Appropriate Cellular Locations: The model correctly places:</p> </li> <li>IL-2 in the extracellular space (GO:0005615)</li> <li>Receptors at the plasma membrane (GO:0005886)</li> <li>JAK kinases at the cytoplasmic side of plasma membrane (GO:0031234)</li> <li> <p>STAT transcription factors in the nucleus (GO:0005634)</p> </li> <li> <p>Evidence Support: Each activity and relationship is backed by appropriate evidence codes and literature references (PMIDs).</p> </li> </ol>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Molecular Adaptors or Intermediates: While the model correctly shows JAK activation leading to STAT activation, it doesn't include some intermediate steps such as JAK-mediated phosphorylation of the receptors creating docking sites for STATs. Based on PMID:16293754, the IL-2 receptor activation leads to \"...phosphorylation of JAK1 and JAK3. In turn, JAK1 and JAK3 phosphorylate the receptor to form a docking site leading to the phosphorylation of several substrates including STAT5.\"</p> </li> <li> <p>Transcription Factor Target Genes: According to the \"DNA-binding transcription factor activity annotation guidelines,\" the model should include the target genes regulated by STAT3 and STAT5A. Currently, the STATs are shown with transcription factor activity but without specified targets.</p> </li> <li> <p>Receptor Complex Representation: While the model correctly shows the functional relationships between receptor components, it doesn't explicitly represent the formation of the complete IL-2 receptor complex. According to UniProt entries and PMID:16293754, IL-2 binds to a quaternary complex consisting of IL-2RA, IL-2RB, and IL-2RG (common gamma chain). The model could be more explicit about this complex formation.</p> </li> <li> <p>Missing Biological Outcomes: The model shows the signaling cascade but doesn't extend to the ultimate biological outcomes of IL-2 signaling, such as T-cell proliferation, differentiation, or survival.</p> </li> </ol>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li>Complete the Signaling Cascade:</li> <li>Add receptor phosphorylation events by JAKs as intermediate steps</li> <li>Include STAT phosphorylation by JAKs</li> <li> <p>Add STAT dimerization before nuclear translocation</p> </li> <li> <p>Expand Transcription Factor Activities:</p> </li> <li>Add target genes for STAT3 and STAT5A transcription factors</li> <li>Include \"has input\" relations to connect transcription factors to their target genes</li> <li> <p>Use \"indirectly positively/negatively regulates\" to show effects on target gene activities</p> </li> <li> <p>Include Biological Outcomes:</p> </li> <li> <p>Add relevant biological processes regulated by IL-2 signaling, such as T-cell proliferation or differentiation</p> </li> <li> <p>Enhance Evidence:</p> </li> <li>Consider adding more recent literature references to strengthen the model's support</li> </ol>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#technical-correctness","title":"Technical Correctness","text":"<p>From a technical GO-CAM modeling perspective, the model correctly uses: - Appropriate molecular function terms - Cellular location terms - \"Part of\" relationships to the IL-2 signaling pathway - Causal associations with the correct predicates</p>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The IL-2 signaling pathway model (gomodel:6205c24300001663) is a solid, well-constructed representation of the core IL-2 signaling events. It adheres to GO-CAM guidelines for receptor signaling and accurately represents the biological relationships between components. With the suggested enhancements, particularly regarding downstream events and transcriptional targets, the model could provide a more complete representation of IL-2 signaling outcomes.</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/","title":"62183af000000536 DNA damage sensor activity of SIRT6 and its regulation by SIRT1  Human","text":"<p>Based on the information gathered, I'll now review the GO-CAM model:</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#review-of-go-cam-model-gomodel62183af000000536","title":"Review of GO-CAM Model: gomodel:62183af000000536","text":""},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#overview","title":"Overview","text":"<p>The model titled \"DNA damage sensor activity of SIRT6 and its regulation by SIRT1 (Human)\" (gomodel:62183af000000536) describes a mechanism where SIRT1 deacetylates SIRT6, enabling SIRT6 to function as a DNA damage sensor and participate in DNA double-strand break repair.</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#model-content","title":"Model Content","text":"<p>The model involves four activities: 1. SIRT1's NAD-dependent protein lysine deacetylase activity 2. SIRT6's damaged DNA binding activity  3. SIRT6's DNA damage sensor activity 4. SIRT6's histone H3K56 deacetylase activity</p> <p>These activities are interconnected in a causal flow, with SIRT1's deacetylase activity directly positively regulating SIRT6's damaged DNA binding, which further positively regulates SIRT6's DNA damage sensor activity, and ultimately leading to SIRT6's histone deacetylation activity.</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#scientific-validation","title":"Scientific Validation","text":"<p>The model is well-supported by recent literature, particularly the work by Meng et al. (PMID:32538779) which demonstrates that:</p> <ol> <li>SIRT1 deacetylates SIRT6 at lysine K33, allowing SIRT6 to polymerize</li> <li>Deacetylated SIRT6 directly recognizes and binds to DNA double-strand breaks</li> <li>SIRT6 functions as a DNA damage sensor through a tunnel-like structure with high affinity for double-strand breaks</li> <li>The SIRT6 DNA damage sensor activity leads to recruitment of DNA repair proteins to the site of damage</li> <li>SIRT6 deacetylates histones (particularly H3K56) at damage sites, facilitating chromatin remodeling for repair</li> </ol> <p>The molecular functions and cellular components used in the model are accurately assigned. SIRT6 is appropriately placed at the site of double-strand breaks (GO:0035861), and the biological process (positive regulation of double-strand break repair, GO:2000781) correctly captures the outcome of this pathway.</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#go-cam-modeling-guidelines-adherence","title":"GO-CAM Modeling Guidelines Adherence","text":"<p>The model follows GO-CAM best practices for causality representation: - The causal relationships use appropriate predicates (RO:0002629 - directly positively regulates) - The activities are properly connected in a logical flow that reflects the actual biological mechanism - The model is parsimonious, focusing on the key activities involved in the pathway</p> <p>For complex annotation, the model appropriately follows the guideline that when the subunit that carries the molecular activity is known, the complex is not described and the activity is represented by the specific protein carrying the activity. Here, SIRT1 and SIRT6 are correctly represented as individual proteins with their respective activities, rather than as a complex.</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#evidence-base","title":"Evidence Base","text":"<p>Each activity and causal relationship is supported by experimental evidence from published literature. The primary references (PMID:32538779 and PMID:31995034) are highly relevant and provide direct experimental evidence for the described activities. The evidence codes used (ECO:0000314 - direct assay evidence used in manual assertion) are appropriate for the types of experiments described in these papers.</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model accurately represents the core pathway, some considerations for enhancement include:</p> <ol> <li> <p>Completeness: The model could be expanded to include the downstream effects of SIRT6's histone deacetylase activity, such as recruitment of specific DNA repair factors (like SNF2H/SMARCA5 as mentioned in the literature).</p> </li> <li> <p>Temporal Aspects: The model doesn't capture the temporal dynamics of SIRT6 recruitment to damage sites and its retention through interaction with \u03b3H2AX, as described in the reference papers.</p> </li> <li> <p>Feedback Regulation: The literature suggests a potential feedback regulation loop involving PARP1 and other factors, which could be added to enhance the model's comprehensiveness.</p> </li> </ol>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:62183af000000536) provides an accurate and well-supported representation of SIRT1's regulation of SIRT6 in the context of DNA damage sensing and repair. It adheres to GO-CAM modeling best practices and is backed by strong experimental evidence from recent publications. The model successfully captures a biologically significant mechanism in DNA damage response, which is relevant to genomic stability, aging, and cancer biology.</p> <p>The model effectively demonstrates how posttranslational modifications (specifically deacetylation) can regulate protein function in the context of DNA damage response signaling, providing a valuable resource for understanding these critical cellular processes.</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/","title":"622aace900000443 Fructose catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model and relevant documents, I'll now provide a comprehensive assessment of the model <code>gomodel:622aace900000443</code> titled \"Fructose catabolic process (Mouse)\".</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#review-of-go-cam-model-fructose-catabolic-process-mouse-gomodel622aace900000443","title":"Review of GO-CAM Model: Fructose catabolic process (Mouse) - gomodel:622aace900000443","text":""},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model describes the fructose catabolic process in mouse (NCBITaxon:10090). It represents a sequence of enzymatic reactions in the fructose metabolism pathway, specifically showing how fructose is broken down in the cytosol.</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model consists of 5 activities interconnected with causal relationships:</p> <ol> <li>Ketohexokinase activity (Khk/MGI:MGI:1096353) - Converts fructose to fructose-1-phosphate</li> <li>Fructose-1-phosphate aldolase activity (Aldob/MGI:MGI:87995) - Splits fructose-1-phosphate into dihydroxyacetone phosphate and glyceraldehyde</li> <li>Aldehyde dehydrogenase (NAD+) activity (Aldh1a1/MGI:MGI:1353450) - Oxidizes glyceraldehyde to glycerate</li> <li>Aldehyde dehydrogenase (NAD+) activity (Aldh1a7/MGI:MGI:1347050) - Oxidizes glyceraldehyde to glycerate (parallel to Aldh1a1)</li> <li>Glycerate kinase activity (Glyctk/MGI:MGI:2444085) - Phosphorylates glycerate to 2-phosphoglycerate</li> </ol> <p>All activities occur in the cytosol (GO:0005829) and are part of the fructose catabolic process (GO:0006001).</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model uses the \"provides input for\" (RO:0002413) relationship to connect activities in the appropriate sequence: - Khk \u2192 Aldob (fructose \u2192 fructose-1-phosphate) - Aldob \u2192 Aldh1a1 and Aldob \u2192 Aldh1a7 (fructose-1-phosphate \u2192 glyceraldehyde) - Aldh1a1 \u2192 Glyctk and Aldh1a7 \u2192 Glyctk (glyceraldehyde \u2192 glycerate)</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#evidence-and-annotations","title":"Evidence and Annotations","text":"<p>The model is well-supported by evidence: - Most activities are supported by direct assay evidence (ECO:0000314) - Some activities are supported by mutant phenotype evidence (ECO:0000315) - References to relevant literature (e.g., PMID:29533924, PMID:4343087, PMID:29414685) - Evidence for protein localization in the cytosol</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>Appropriate molecular functions: Each protein is annotated with a molecular function that accurately reflects its enzymatic activity.</li> <li>Correct causal relationships: The \"provides input for\" relation properly connects the activities in the metabolic pathway.</li> <li>Well-evidenced: All activities have appropriate evidence codes and literature citations.</li> <li>Correct cellular component: All activities are annotated to occur in the cytosol, which is accurate for this pathway.</li> <li>Pathway completeness: The model represents a complete pathway from fructose to 2-phosphoglycerate.</li> </ol>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#potential-issues","title":"Potential Issues:","text":"<ol> <li> <p>Parallel aldehyde dehydrogenase activities: The model shows Aldh1a1 and Aldh1a7 performing the same function without clearly distinguishing their specific roles. While this may be biologically accurate (redundant enzymes), it would be helpful to provide evidence for why both are included.</p> </li> <li> <p>Missing metabolites: While GO-CAM doesn't require explicit representation of metabolites, it might be helpful to note the intermediate products in the annotations for clarity (e.g., dihydroxyacetone phosphate, which is the other product of Aldob activity, is not tracked in the pathway).</p> </li> <li> <p>Missing information on regulation: The model focuses on the core catalytic pathway but doesn't include any regulatory aspects that might control the pathway flux.</p> </li> </ol>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#literature-validation","title":"Literature Validation","text":"<p>The model is supported by cited literature, including: - PMID:29533924 which discusses ketohexokinase and aldolase B roles - PMID:4343087 which provides evidence for the fructose catabolic process - PMID:29414685 which supports glycerate kinase activity</p> <p>The literature supports the sequence of events and enzyme activities depicted in the model.</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Consider adding annotations to clarify functional differences between Aldh1a1 and Aldh1a7 if they exist (e.g., different kinetic properties, expression patterns, or substrate preferences).</p> </li> <li> <p>Add information about the fate of dihydroxyacetone phosphate (the other product of the aldolase reaction), which typically enters glycolysis.</p> </li> <li> <p>Consider adding regulatory aspects that control this pathway, such as feedback inhibition or transcriptional regulation of the enzymes involved.</p> </li> <li> <p>Add annotations about the physiological context where this pathway is most active (e.g., after fructose ingestion, in specific tissues like liver).</p> </li> </ol>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the fructose catabolic process in mouse. It follows GO-CAM best practices by properly connecting molecular functions through causal relationships and providing appropriate evidence. The minor suggestions above would enhance the model's comprehensiveness but do not detract from its current quality and accuracy.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/","title":"622aace900000790 Galactose catabolic process via UDP galactose","text":"<p>Now I have a good understanding of the model. Let me review the GO-CAM model gomodel:622aace900000790 in detail.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#go-cam-model-review-gomodel622aace900000790","title":"GO-CAM Model Review: gomodel:622aace900000790","text":""},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#model-title","title":"Model Title","text":"<p>\"Galactose catabolic process via UDP-galactose\"</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#taxon","title":"Taxon","text":"<p>NCBITaxon:10090 (Mouse)</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#model-status","title":"Model Status","text":"<p>Production</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#model-overview","title":"Model Overview","text":"<p>This model represents the galactose catabolic process via UDP-galactose in mouse (Mus musculus). It was sourced from another model (gomodel:R-HSA-70370) and shows the enzymatic activities involved in this metabolic pathway.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#model-components","title":"Model Components","text":"<p>The model contains 6 molecular activities connected to form a pathway:</p> <ol> <li>Pgm1 (MGI:MGI:97565) - phosphoglucomutase activity (GO:0004614)</li> <li>Galk1 (MGI:MGI:95730) - galactokinase activity (GO:0004335)</li> <li>Galt (MGI:MGI:95638) - UDP-glucose:hexose-1-phosphate uridylyltransferase activity (GO:0008108)</li> <li>Galm (MGI:MGI:2442420) - aldose 1-epimerase activity (GO:0004034)</li> <li>Pgm2 (MGI:MGI:97564) - phosphoglucomutase activity (GO:0004614)</li> <li>Gale (MGI:MGI:1921496) - UDP-glucose 4-epimerase activity (GO:0003978)</li> </ol>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#pathway-flow-analysis","title":"Pathway Flow Analysis","text":"<p>The model shows the galactose catabolic pathway with the following flow:</p> <ul> <li>Galm catalyzes the conversion of beta-D-galactose (CHEBI:27667) to alpha-D-galactose (CHEBI:28061)</li> <li>Galk1 acts on alpha-D-galactose (input not explicitly shown)</li> <li>Galt acts on the product of Galk1's activity and produces UDP-D-galactose (CHEBI:18307)</li> <li>Gale catalyzes the conversion of UDP-D-galactose (CHEBI:18307) to UDP-D-glucose (CHEBI:18066)</li> <li>Galt can also catalyze the reverse reaction, converting UDP-D-glucose to UDP-D-galactose</li> <li>Pgm1 and Pgm2 both have phosphoglucomutase activity (GO:0004614) that is involved in the pathway</li> </ul> <p>The causal associations in the model use RO:0002413 \"provides input for\" to connect the activities, which accurately represents the sequential nature of enzymatic reactions in a metabolic pathway.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#evidence-assessment","title":"Evidence Assessment","text":"<ul> <li>The model uses appropriate evidence codes:</li> <li>ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>ECO:0000315 (mutant phenotype evidence used in manual assertion)</li> <li>ECO:0000266 (sequence orthology evidence used in manual assertion)</li> <li>Evidence is supported by multiple PMIDs, including:</li> <li>PMID:6457600, PMID:31077402 for Pgm1</li> <li>PMID:10915771 for Galk1</li> <li>PMID:8902187 for Galt</li> <li>PMID:30451973 for Galm</li> <li>PMID:28877911 for Gale</li> </ul> <p>The PMID 28877911 I reviewed confirms the role of Gale (UDP-galactose-4-epimerase) in galactose metabolism, specifically in catalyzing the reversible conversion of UDP-galactose to UDP-glucose.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#consistency-check","title":"Consistency Check","text":"<p>The model accurately represents the Leloir pathway of galactose metabolism, which is the main pathway for galactose catabolism in mammals. The enzymes and their activities are correctly represented, and the causal relationships reflect the known biochemical pathway.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<ul> <li>The model correctly uses molecular activity annotations for each protein.</li> <li>Each activity is properly associated with a biological process (GO:0033499 - galactose catabolic process via UDP-galactose).</li> <li>The model properly specifies input and output chemical entities.</li> <li>Causal associations use the appropriate relation (RO:0002413 - provides input for).</li> <li>No complexes are used in this model, so complex representation guidelines are not applicable.</li> </ul>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#issues-identified","title":"Issues Identified","text":"<ol> <li> <p>Circular Pathway Representation: The model correctly captures the bidirectional nature of the Galt enzyme, which can convert in both directions between UDP-D-galactose and UDP-D-glucose. However, this creates a circular pathway that might be slightly confusing to interpret.</p> </li> <li> <p>Missing Substrate for Galk1: While the model shows Galk1 has galactokinase activity, the input substrate (alpha-D-galactose) is not explicitly connected to Galk1, although it's shown as the output of Galm.</p> </li> <li> <p>Duplicate Phosphoglucomutase Activities: Both Pgm1 and Pgm2 are annotated with phosphoglucomutase activity, but their specific roles and the difference between them in the pathway aren't clearly distinguished.</p> </li> </ol>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Clarify Bidirectional Flow: Consider annotating the bidirectional nature of the Galt reaction more explicitly, perhaps with a note.</p> </li> <li> <p>Complete Input Annotations: Ensure all enzymes have their input substrates properly annotated, particularly for Galk1.</p> </li> <li> <p>Distinguish Duplicate Activities: Provide more context on why both Pgm1 and Pgm2 are included and their specific roles in the pathway, perhaps by adding additional information about their substrate specificity or cellular context.</p> </li> </ol>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the galactose catabolic process via UDP-galactose. The model uses appropriate GO terms, evidence, and relational logic. The connections between activities reflect the known biochemistry of this pathway. The minor issues noted could be addressed to further improve clarity, but they don't significantly impact the biological accuracy or utility of the model.</p> <p>The model is consistent with the scientific literature and represents a parsimonious visualization of the galactose catabolic pathway that would be recognizable to researchers in the field.</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/","title":"622aace900000962 Pentose phosphate shunt 1  Mouse","text":"<p>Based on my review of the GO-CAM model gomodel:622aace900000962 titled \"Pentose-phosphate shunt 1 (Mouse)\", I'll provide a comprehensive assessment:</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#model-summary","title":"Model Summary","text":"<p>This model represents the pentose phosphate pathway (PPP) in mouse, focusing on the enzymatic activities and their connections in this essential metabolic pathway. The model includes both the oxidative and non-oxidative branches of the PPP.</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>The model is generally well constructed and adheres to GO-CAM best practices. It captures the key enzymatic reactions of the PPP and their causal relationships appropriately.</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>Appropriate molecular functions: Each enzyme is associated with the correct molecular function (e.g., G6PD with glucose-6-phosphate dehydrogenase activity).</li> <li>Proper cellular localization: The activities are correctly located in the cytosol (GO:0005829).</li> <li>Causal flow: The causal relationships between activities using \"provides input for\" (RO:0002413) accurately reflect the metabolic flow of the pathway.</li> <li>Evidence support: Most activities have appropriate evidence codes with relevant PMIDs.</li> <li>Taxon specificity: The model is properly specified for mouse (NCBITaxon:10090).</li> </ol>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Inconsistent biological process annotations: </li> <li>Some activities are annotated to \"pentose-phosphate shunt\" (GO:0006098) while others to \"pentose-phosphate shunt, oxidative branch\" (GO:0009051)</li> <li> <p>For clarity and consistency, it would be better to use the more specific terms throughout (distinguishing oxidative vs. non-oxidative branch activities)</p> </li> <li> <p>Missing evidence for some assertions:</p> </li> <li>Some cellular localization evidence is missing (e.g., for MGI:MGI:105977 and MGI:MGI:1913421)</li> <li> <p>Some biological process associations lack evidence (e.g., for MGI:MGI:105977)</p> </li> <li> <p>Potential redundancy:</p> </li> <li>There are two separate activities for transketolase (Tkt) with the same function (GO:0004802) - gomodel:622aace900000962/622aace900000984 and gomodel:622aace900000962/622aace900000980</li> <li> <p>This appears redundant and could be consolidated into a single activity</p> </li> <li> <p>Missing has_input associations:</p> </li> <li>While \"has_output\" associations are included for some activities, the corresponding \"has_input\" associations are missing</li> <li> <p>For example, NADP+ as input for G6PD activities, glucose-6-phosphate as input, etc.</p> </li> <li> <p>No complex annotations:</p> </li> <li>The model doesn't include any protein complexes, which is appropriate since the PPP enzymes generally function as individual proteins, not as complexes</li> </ol>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the pentose phosphate pathway in mouse:</p> <ol> <li>The oxidative phase is represented by:</li> <li>G6PD (glucose-6-phosphate dehydrogenase) - G6pd2 and G6pdx</li> <li>PGLS (6-phosphogluconolactonase)</li> <li> <p>PGD (6-phosphogluconate dehydrogenase)</p> </li> <li> <p>The non-oxidative phase is represented by:</p> </li> <li>RPE (ribulose-5-phosphate-3-epimerase)</li> <li>RPIA (ribose-5-phosphate isomerase)</li> <li>TKT (transketolase)</li> <li>TALDO1 (transaldolase)</li> </ol> <p>The causal flow correctly demonstrates how these enzymes work sequentially in the pathway, with appropriate outputs (NADPH, fructose-6-phosphate).</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Harmonize the biological process annotations - consistently use the specific branch terms (oxidative or non-oxidative) where appropriate.</p> </li> <li> <p>Add missing evidence for cellular location and biological process assertions.</p> </li> <li> <p>Consolidate redundant transketolase activities into a single representation.</p> </li> <li> <p>Add \"has_input\" associations to better represent the substrates for each reaction.</p> </li> <li> <p>Consider adding more detailed regulation information if available in the literature.</p> </li> </ol> <p>This model is scientifically accurate and generally well-constructed, requiring only minor improvements to better conform to GO-CAM best practices.</p>"},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/","title":"622aace900001389 Pentose phosphate shunt 2  Mouse","text":"<p>Based on all the information gathered, I'll now review the GO-CAM model with ID 622aace900001389.</p>"},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/#review-of-go-cam-model-622aace900001389-pentose-phosphate-shunt-2-mouse","title":"Review of GO-CAM Model 622aace900001389 \"Pentose-phosphate shunt 2 (Mouse)\"","text":""},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model (ID 622aace900001389) represents the pentose-phosphate shunt (or pentose phosphate pathway) in mouse. The model focuses on three key enzymatic activities and their connections within this pathway:</p> <ol> <li>Ribokinase activity (RBKS/MGI:MGI:1918586)</li> <li>Transketolase activity (TKT/MGI:MGI:105992)</li> <li>Transaldolase activity (TALDO1/MGI:MGI:1274789)</li> </ol>"},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/#model-structure-and-flow","title":"Model Structure and Flow","text":"<p>The model represents the following sequence of activities: - Ribokinase (RBKS) phosphorylates D-ribose \u2192 provides input for Transketolase (TKT) - TKT converts sugars in the pathway \u2192 provides input for Transaldolase (TALDO1) - TALDO1 carries out transaldolase activity \u2192 generates more sugar intermediates - Another instance of TKT activity produces final outputs of the pathway</p> <p>All activities occur in the cytosol (GO:0005829) and are part of the pentose-phosphate shunt biological process (GO:0006098).</p>"},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/#evaluation-of-evidence","title":"Evaluation of Evidence","text":"<p>The model is well-supported by experimental evidence: - All molecular functions are backed by direct assay evidence (ECO:0000314) - The final outputs of the pathway (CHEBI:57634 - \u03b2-D-fructofuranose 6-phosphate and CHEBI:59776 - D-glyceraldehyde 3-phosphate) are properly annotated</p>"},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/#quality-assessment","title":"Quality Assessment","text":"<p>Strengths: 1. The model correctly represents the flow of activities in the non-oxidative branch of the pentose phosphate pathway 2. Each activity is properly annotated with appropriate molecular functions and cellular locations 3. All activities are connected using the appropriate causal relationship (RO:0002413 \"provides input for\") 4. The evidence is from primary literature with appropriate citations (PMID:5360673, PMID:13405914) 5. The outputs of the pathway are properly defined chemical entities</p> <p>Issues for improvement: 1. Missing input molecules: While the model shows D-ribose (CHEBI:47013) as input for the first reaction, it does not explicitly show all inputs for each reaction step. For completeness, it would be beneficial to include all substrate molecules.</p> <ol> <li> <p>Limited scope: The model only covers part of the pentose phosphate pathway. It focuses on the non-oxidative branch (starting with ribose) but doesn't include the oxidative branch starting with glucose-6-phosphate. A more comprehensive model would include both branches.</p> </li> <li> <p>Missing ATP as cofactor: The ribokinase activity requires ATP as a cofactor, which is not explicitly represented in the model.</p> </li> <li> <p>Incomplete reaction details: While the final products are shown for one transketolase reaction, similar details for intermediate reactions would strengthen the model's completeness.</p> </li> </ol>"},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/#biological-coherence","title":"Biological Coherence","text":"<p>The model accurately represents the biological process as described in the literature. The pentose phosphate pathway includes both oxidative and non-oxidative branches, and this model focuses primarily on the non-oxidative branch, starting with ribokinase activity on D-ribose. The sequence of activities (ribokinase \u2192 transketolase \u2192 transaldolase \u2192 transketolase) is consistent with our understanding of this pathway.</p> <p>According to the literature on the pentose phosphate pathway, transketolase and transaldolase are indeed the key enzymes of the non-oxidative branch that interconvert various sugar phosphates. The model correctly represents this, with transketolase shown to have specific output molecules in the final step.</p>"},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model follows GO-CAM best practices: 1. Activities are connected appropriately using the \"provides input for\" (RO:0002413) causal relation 2. Each activity is properly associated with a gene product 3. Each activity occurs in the appropriate cellular compartment (cytosol) 4. All activities are part of the correct biological process (pentose-phosphate shunt) 5. Evidence is provided for assertions with appropriate ECO codes</p>"},{"location":"reviews/622aace900001389-Pentose_phosphate_shunt_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 622aace900001389 presents a clear and accurate representation of part of the pentose phosphate pathway in mouse, focusing on the non-oxidative branch. The model is well-structured and properly annotated with appropriate molecular functions, cellular locations, and causal relationships between activities.</p> <p>For future enhancement, the model could be expanded to include: 1. The oxidative branch of the pentose phosphate pathway 2. More detailed representation of all inputs and outputs for each reaction 3. Explicit representation of cofactors like ATP for ribokinase</p> <p>Overall, this is a high-quality model that provides valuable information about the pentose phosphate pathway in mouse and follows GO-CAM best practices.</p>"},{"location":"reviews/623d156d00000029-Glycogen_biosynthetic_process__Mouse_/","title":"623d156d00000029 Glycogen biosynthetic process  Mouse","text":"<p>Based on my review of the GO-CAM model \"Glycogen biosynthetic process (Mouse)\" (gomodel:623d156d00000029) and the supporting information, here's my detailed assessment:</p>"},{"location":"reviews/623d156d00000029-Glycogen_biosynthetic_process__Mouse_/#go-cam-model-review","title":"GO-CAM Model Review","text":""},{"location":"reviews/623d156d00000029-Glycogen_biosynthetic_process__Mouse_/#overview","title":"Overview","text":"<p>This model represents the glycogen biosynthetic process in mice, showing the sequential enzymatic activities involved in glycogen synthesis from glucose phosphates through to glycogen polymer formation. The model includes 10 activities connected in a pathway-like structure with appropriate causal relationships.</p>"},{"location":"reviews/623d156d00000029-Glycogen_biosynthetic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Correct Biological Process Representation: The model accurately captures the glycogen biosynthetic process (GO:0005978) with the appropriate enzymes in their correct sequence.</p> </li> <li> <p>Well-Documented Evidence: Each activity is supported by experimental evidence with appropriate ECO codes and references to primary literature.</p> </li> <li> <p>Correct Causal Relationships: The model uses appropriate causal relationships (RO:0002413 \"provides input for\") to connect sequential enzymatic activities in the pathway.</p> </li> <li> <p>Appropriate Cellular Location: Most activities are correctly annotated to occur in the cytosol (GO:0005829), which is appropriate for glycogen synthesis.</p> </li> <li> <p>Complete Pathway Coverage: The model covers the entire glycogen synthesis pathway from glucose-1-phosphate to glycogen, including the regulatory proteins.</p> </li> </ol>"},{"location":"reviews/623d156d00000029-Glycogen_biosynthetic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex Representation: According to the complex annotation guidelines, the model correctly represents individual protein activities rather than complexes. However, there's no representation of the GYS1-GYG1 complex mentioned in the UniProt entry for GYS1, which indicates that \"each GYS1 protomer binds to one GYG1 subunit (via GYG1 C-terminus).\" This interaction could be represented more explicitly.</p> </li> <li> <p>Evidence Parity: Some activities have more extensive evidence documentation than others. For example, some PGM activities (Pgm1, Pgm2) have multiple evidence sources, while others have fewer.</p> </li> <li> <p>Regulatory Mechanisms: While the model includes EPM2A (laforin) and NHLRC1 (malin) which are involved in the regulation of glycogen metabolism, the regulatory relationship between these proteins could be more explicitly modeled. The malin-laforin complex is known to regulate glycogen synthesis through the ubiquitination of glycogen-associated proteins.</p> </li> <li> <p>Post-translational Modifications: The UniProt entries for several proteins in the pathway (especially GYS1) indicate extensive regulation by phosphorylation, which affects enzyme activity. These regulatory relationships are not captured in the model.</p> </li> </ol>"},{"location":"reviews/623d156d00000029-Glycogen_biosynthetic_process__Mouse_/#specific-comments-on-key-components","title":"Specific Comments on Key Components","text":"<ol> <li> <p>Phosphoglucomutase (PGM1/PGM2): Correctly represented as converting glucose-1-phosphate in the initial steps of the pathway.</p> </li> <li> <p>UTP:glucose-1-phosphate uridylyltransferase (UGP2): Appropriately shown catalyzing the synthesis of UDP-glucose.</p> </li> <li> <p>Glycogenin (GYG1): Correctly represented as initiating glycogen synthesis with its glucosyltransferase activity.</p> </li> <li> <p>Glycogen synthase (GYS1/GYS2): Both isoforms are included appropriately.</p> </li> <li> <p>1,4-alpha-glucan branching enzyme (GBE1): Correctly shown adding branch points to the growing glycogen molecule.</p> </li> <li> <p>Regulatory proteins (PPP1R3C, EPM2A, NHLRC1): The model includes these important regulatory components. PPP1R3C (protein phosphatase 1 regulatory subunit 3C) is correctly shown as a molecular adaptor positively regulating glycogen synthase activity.</p> </li> </ol>"},{"location":"reviews/623d156d00000029-Glycogen_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is scientifically accurate and well-constructed, representing the glycogen biosynthetic process in mice with appropriate molecular functions, cellular locations, and causal relationships. The model is consistent with current understanding of glycogen biosynthesis as described in the literature and UniProt entries.</p> <p>Minor improvements could include more explicit representation of protein complexes and regulatory relationships, particularly involving post-translational modifications and the malin-laforin complex. However, these are refinements rather than corrections to an already solid model.</p> <p>The model has been properly maintained with appropriate automated updates (noted in the comments: RO:0002213 replaced by RO:0002629 and GO:0102752 replaced by GO:0003844).</p> <p>Overall, this is a high-quality GO-CAM model that effectively represents glycogen biosynthesis in mice.</p>"},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/","title":"623d156d00000290 IL4 mediated signaling pathway  human","text":"<p>Now, I have gathered enough information to conduct a thorough review of the IL4-mediated signaling pathway GO-CAM model. Let me analyze its structure, accuracy, and conformity to best practices.</p>"},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/#review-of-go-cam-model-il4-mediated-signaling-pathway-human-gomodel623d156d00000290","title":"Review of GO-CAM Model: IL4-mediated signaling pathway (human) [gomodel:623d156d00000290]","text":""},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/#overall-assessment","title":"Overall Assessment","text":"<p>This model represents the IL4-mediated signaling pathway in humans, which is a crucial pathway in immune regulation, particularly in allergic and inflammatory responses. The model focuses on the key components involved in IL-4 receptor complex formation and subsequent signaling through JAK kinases and STAT transcription factors.</p>"},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/#structure-of-the-model","title":"Structure of the Model","text":"<p>The model includes 7 activities organized in a sequential signaling pathway:</p> <ol> <li>IL-4 (P05112) with cytokine activity (GO:0005125) in extracellular space</li> <li>IL-4 receptor (P24394) with IL-4 receptor activity (GO:0004913) on plasma membrane</li> <li>JAK1 (P23458) with protein tyrosine kinase activity (GO:0004713) at the cytoplasmic side of plasma membrane</li> <li>IL2RG (P31785) with coreceptor activity (GO:0015026) on plasma membrane</li> <li>JAK3 (P52333) with protein tyrosine kinase activity (GO:0004713) at extrinsic component of plasma membrane</li> <li>STAT6 (P42226) with DNA-binding transcription factor activity (GO:0003700) in nucleus</li> <li>STAT5A (P42229) with DNA-binding transcription factor activity (GO:0003700) in nucleus</li> </ol> <p>The causal flow follows a biologically accurate sequence: - IL-4 cytokine activity \u2192 IL-4 receptor activity \u2192 JAK1 kinase activity - IL-4 receptor activity \u2192 IL2RG coreceptor activity \u2192 JAK3 kinase activity - JAK1 kinase activity \u2192 STAT6 transcription factor activity - JAK3 kinase activity \u2192 STAT5A transcription factor activity</p>"},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological accuracy: The model correctly captures the key components and interactions in the IL-4 signaling pathway, including the formation of the receptor complex, activation of JAK kinases, and subsequent STAT phosphorylation and activation.</p> </li> <li> <p>Proper use of causal relations: The model uses the appropriate \"directly positively regulates\" (RO:0002629) relation to connect the activities in the signaling cascade.</p> </li> <li> <p>Cellular localization: Each activity is appropriately localized to the correct cellular compartment based on available evidence.</p> </li> <li> <p>Evidence-based annotations: Most activities have supporting evidence from peer-reviewed literature with appropriate ECO codes.</p> </li> <li> <p>Completeness: The model includes both STAT6 and STAT5A activation, which are key transcription factors in IL-4 signaling.</p> </li> </ol>"},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Downstream activities missing: The model does not include downstream target genes regulated by STAT6 and STAT5A. Including a few key target genes would provide better completeness of the signaling pathway.</p> </li> <li> <p>Molecular inputs could be better defined: According to the Signaling receptor activity annotation guidelines, the \"has input\" relation should be used to indicate the target of the receptor activity. Currently, this isn't explicitly shown in the model.</p> </li> <li> <p>Missing complexes: The model represents individual proteins separately, but it would be more accurate to represent the IL4R/IL2RG receptor complex as a single entity. According to the \"How to annotate complexes in GO-CAM\" guidelines, when the activity is shared by several proteins (as in a heterodimeric receptor), this should be represented.</p> </li> <li> <p>Evidence gaps: For some causal associations, particularly for the relation between JAK3 and STAT5A, there could be more specific evidence citations.</p> </li> <li> <p>Feedback regulation missing: The model does not include negative regulators of the pathway such as SOCS (suppressors of cytokine signaling) proteins, which are induced by STAT activation and provide negative feedback.</p> </li> </ol>"},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Receptor complex representation: Consider representing the IL-4 receptor complex as a single entity rather than separate components. According to the signaling receptor activity guidelines, IL-4R\u03b1 and IL2RG form a heterodimeric receptor where the type I receptor is created when IL-4 binds IL-4R\u03b1 and subsequently recruits IL2RG.</p> </li> <li> <p>Add \"has input\" relations: For the receptor activities, add \"has input\" relations to indicate what each receptor component is targeting.</p> </li> <li> <p>Expand downstream effects: Include at least 1-2 key target genes regulated by STAT6 and STAT5A to show the biological outcome of the pathway.</p> </li> <li> <p>Add negative regulators: Include SOCS proteins as negative regulators to represent the feedback control of the pathway.</p> </li> <li> <p>JAK-STAT cross-talk: Consider indicating potential cross-talk between JAK1-STAT5A and JAK3-STAT6, as there isn't always a strict segregation of JAK-STAT coupling.</p> </li> </ol>"},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/#accuracy-review","title":"Accuracy Review","text":"<p>The model accurately represents the key molecular events in IL-4 signaling:</p> <ol> <li> <p>IL-4 binding to receptor: Correctly shows IL-4 binding to IL-4R\u03b1.</p> </li> <li> <p>Receptor-coreceptor interaction: Correctly depicts IL-4R\u03b1 engagement with IL2RG (common gamma chain).</p> </li> <li> <p>JAK activation: Properly shows JAK1 associating with IL-4R\u03b1 and JAK3 with IL2RG, consistent with current understanding of receptor-JAK associations.</p> </li> <li> <p>STAT activation: Correctly shows STAT6 and STAT5A activation following JAK activation.</p> </li> </ol>"},{"location":"reviews/623d156d00000290-IL4_mediated_signaling_pathway__human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model is a good representation of the IL4-mediated signaling pathway. It captures the core components and their interactions accurately. The model follows most GO-CAM best practices and is supported by appropriate evidence. With the suggested improvements, particularly in representing the receptor complex, adding downstream targets, and including feedback mechanisms, the model would provide a more comprehensive view of IL-4 signaling.</p> <p>The model is suitable for production use but would benefit from the enhancements noted above to better represent the complete pathway.</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/","title":"623d156d00000340 IL3 mediated signaling pathway  Human","text":"<p>Now I'll put together my review of the GO-CAM model:</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#review-of-go-cam-model-il3-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: IL3-mediated signaling pathway (Human)","text":"<p>Model ID: gomodel:623d156d00000340</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#overview","title":"Overview","text":"<p>This model represents the IL-3-mediated signaling pathway in humans, capturing molecular functions and causal relationships between interleukin-3 (IL-3), its receptor components, and downstream signaling proteins. The pathway is important for hematopoietic cell development, survival, and function.</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#model-structure-and-content-assessment","title":"Model Structure and Content Assessment","text":""},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#components-and-structure","title":"Components and Structure","text":"<p>The model includes five key activities: 1. IL-3 (P08700) with cytokine activity (GO:0005125) 2. IL-3 receptor alpha chain (P26951) with IL-3 receptor activity (GO:0004912) 3. Common beta chain, CSF2RB (P32927) with coreceptor activity (GO:0015026) 4. JAK2 (O60674) with protein tyrosine kinase activity (GO:0004713) 5. STAT5A (P42229) with DNA-binding transcription factor activity (GO:0003700)</p> <p>All components are correctly part of the IL-3-mediated signaling pathway (GO:0038156).</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model captures the following causal relationships, which accurately represent the biological sequence: - IL-3 directly positively regulates IL-3 receptor alpha (IL3RA) - IL3RA directly positively regulates common beta chain (CSF2RB) - CSF2RB directly positively regulates JAK2 - JAK2 directly positively regulates STAT5A</p> <p>These relationships correctly represent the signal transduction cascade from ligand (IL-3) to transcription factor (STAT5A).</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#cellular-localization","title":"Cellular Localization","text":"<p>The model correctly localizes components: - IL-3 in extracellular space (GO:0005615) - IL3RA and CSF2RB at the plasma membrane (GO:0005886) - JAK2 at the extrinsic component of plasma membrane (GO:0019897) - STAT5A in the nucleus (GO:0005634)</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":""},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#signaling-receptor-activity-guidelines","title":"Signaling Receptor Activity Guidelines","text":"<p>The model correctly follows the signaling receptor activity guidelines: - IL-3 is annotated with cytokine activity and occurs in extracellular space - IL3RA is annotated with IL-3 receptor activity - CSF2RB is annotated with coreceptor activity - The causal relations between IL-3 and its receptor components use the recommended \"directly positively regulates\" predicate (RO:0002629)</p> <p>This aligns well with the \"Signaling receptor activity annotation guidelines,\" particularly the section on receptors with coreceptors.</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#dna-binding-transcription-factor-guidelines","title":"DNA-binding Transcription Factor Guidelines","text":"<p>The annotation of STAT5A follows the guidelines: - STAT5A is annotated with DNA-binding transcription factor activity - STAT5A is localized to the nucleus - It is part of the IL-3-mediated signaling pathway</p> <p>However, one potential improvement would be to add \"has input\" relations for STAT5A to indicate its transcriptional targets. According to the \"DNA-binding transcription factor activity annotation guidelines,\" transcriptional targets should be captured.</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by evidence from scientific literature: - Interactions between IL-3 and its receptor are supported by PMID:8649415 - The role of JAK2 in signal transduction is supported by PMID:8007942 - The overall pathway is supported by PMID:22102340</p>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Add transcriptional targets for STAT5A: The model would benefit from adding the genes that STAT5A regulates through \"has input\" relations, and then connecting these with \"indirectly positively regulates\" or \"indirectly negatively regulates\" to show the downstream effects of the pathway.</p> </li> <li> <p>Include phosphorylation information: The model could explicitly capture the phosphorylation of JAK2 and STAT5A, which are critical events in this signaling pathway. The literature (PMID:9516478, PMID:8007942) indicates that JAK2 autophosphorylation and STAT5A phosphorylation are key events.</p> </li> <li> <p>Expand the pathway: Consider including other components that interact with this pathway, such as other STATs (STAT5B) that can be activated, phosphatases that regulate the pathway, or feedback inhibitors like SOCS proteins.</p> </li> <li> <p>Additional cellular context: If available, information about specific cell types where this pathway is most relevant (e.g., hematopoietic stem cells, myeloid progenitors) could enhance the biological context.</p> </li> </ol>"},{"location":"reviews/623d156d00000340-IL3_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the IL-3 signaling pathway from the cytokine to the transcription factor STAT5A. It follows the key GO-CAM best practices for representing signaling receptors and transcription factors. The model is well-supported by evidence from scientific literature and correctly captures the subcellular localization of each component.</p> <p>The causal relationships appropriately represent the sequential activation events in the pathway, making the biological process clear. While the model is already of high quality, adding transcriptional targets and post-translational modifications would further enhance its biological completeness.</p> <p>Overall, this is a well-constructed model that effectively communicates the core components and relationships in the IL-3 signaling pathway in humans.</p>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/","title":"623d156d00000673 IL5 mediated signaling pathway  Human","text":"<p>Now that I've gathered all the necessary information about the proteins in the model and the GO-CAM guidelines, I'll carefully review the model and provide an assessment.</p>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#review-of-go-cam-model-il5-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: IL5-mediated signaling pathway (Human)","text":""},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM (Model ID: 623d156d00000673) represents the IL-5-mediated signaling pathway in humans. It depicts the molecular functions and causal relationships starting from IL-5 cytokine activity through receptor binding and subsequent signaling events, ultimately leading to transcription factor activity.</p>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model contains 6 molecular activities connected by causal associations:</p> <ol> <li>IL5 (P05113) - Cytokine activity (GO:0005125)</li> <li>IL5RA (Q01344) - Interleukin-5 receptor activity (GO:0004914)</li> <li>CSF2RB (P32927) - Coreceptor activity (GO:0015026)</li> <li>JAK2 (O60674) - Protein tyrosine kinase activity (GO:0004713)</li> <li>LYN (P07948) - Protein tyrosine kinase activity (GO:0004713)</li> <li>STAT5A (P42229) - DNA-binding transcription factor activity (GO:0003700)</li> </ol>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The biological pathway representation is consistent with known mechanisms of IL-5 signaling</li> <li>The model correctly represents the IL-5 receptor complex components (IL5RA and CSF2RB)</li> <li>Appropriate molecular functions are assigned to each protein</li> <li>Subcellular locations are correctly annotated (e.g., IL-5 in extracellular space, receptors in plasma membrane, STAT5A in nucleus)</li> <li>All activities are part of the correct biological process (GO:0038043 - interleukin-5-mediated signaling pathway)</li> <li>The causal connections use appropriate predicates (RO:0002629 - directly positively regulates)</li> <li>Each association is supported by relevant literature evidence with appropriate ECO codes</li> </ol>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing JAK2 to STAT5A connection: There should be a causal relationship between JAK2 kinase activity and STAT5A transcription factor activity. JAK2 phosphorylates STAT5A at Tyr-694, which is essential for STAT5A activation.</p> </li> <li> <p>LYN connection structure: The model shows LYN being activated by IL5RA, but then doesn't connect LYN to any downstream components. According to literature, LYN is typically involved in early IL-5 receptor signaling and can indirectly influence JAK-STAT activation. This could be clarified in the model.</p> </li> <li> <p>Evidence code refinement: Some associations use ECO:0000305 (curator inference used in manual assertion) where primary literature evidence might be available.</p> </li> <li> <p>Potential missing regulators: The model doesn't capture negative regulation components like SOCS proteins or phosphatases that provide feedback regulation of this pathway.</p> </li> </ol>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#detailed-annotation-review","title":"Detailed Annotation Review","text":""},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#il5-p05113-cytokine-activity","title":"IL5 (P05113) - Cytokine activity:","text":"<ul> <li>Properly placed in extracellular space (GO:0005615)</li> <li>Correctly shown to directly regulate IL5RA activity</li> <li>Supported by appropriate evidence (PMID:33099778)</li> </ul>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#il5ra-q01344-interleukin-5-receptor-activity","title":"IL5RA (Q01344) - Interleukin-5 receptor activity:","text":"<ul> <li>Correctly localized to plasma membrane (GO:0005886)</li> <li>Appropriately represents both downstream connections to CSF2RB and LYN</li> <li>Evidence from PMID:22528658 and PMID:7957082 supports these connections</li> </ul>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#csf2rb-p32927-coreceptor-activity","title":"CSF2RB (P32927) - Coreceptor activity:","text":"<ul> <li>Correctly located in eosinophils (CL:0000771)</li> <li>Properly connected to JAK2 activation</li> <li>Evidence from PMID:8007942 supports this connection</li> </ul>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#jak2-o60674-protein-tyrosine-kinase-activity","title":"JAK2 (O60674) - Protein tyrosine kinase activity:","text":"<ul> <li>Correctly located in eosinophils (CL:0000771)</li> <li>Properly activates STAT5A in the model</li> <li>Missing evidence code for connection to STAT5A (empty evidence array)</li> </ul>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#stat5a-p42229-dna-binding-transcription-factor-activity","title":"STAT5A (P42229) - DNA-binding transcription factor activity:","text":"<ul> <li>Appropriately located in nucleus (GO:0005634)</li> <li>Supported by literature evidence (PMID:12393707)</li> <li>Could benefit from annotations showing its specific transcriptional targets</li> </ul>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#lyn-p07948-protein-tyrosine-kinase-activity","title":"LYN (P07948) - Protein tyrosine kinase activity:","text":"<ul> <li>Correctly located at cytoplasmic side of plasma membrane (GO:0009898)</li> <li>Connection to IL5RA is supported by literature</li> <li>No downstream connections shown, which could be added to improve the model</li> </ul>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#consistency-with-best-practices","title":"Consistency with Best Practices","text":"<p>The model is largely consistent with GO-CAM best practices:</p> <ol> <li>Receptor signaling guidelines: The model follows the \"Signaling receptor activity annotation guidelines\" document by correctly representing:</li> <li>Protein ligand (IL-5) with cytokine activity</li> <li>Signaling receptor (IL5RA) with appropriate receptor activity</li> <li>Coreceptor (CSF2RB) with coreceptor activity</li> <li> <p>Appropriate \"directly positively regulates\" causal links</p> </li> <li> <p>Transcription factor activity: The STAT5A representation is consistent with the \"DNA-binding transcription factor activity annotation guidelines,\" though its transcriptional targets aren't shown.</p> </li> <li> <p>Cellular context: Appropriate cellular locations are provided for each activity.</p> </li> </ol>"},{"location":"reviews/623d156d00000673-IL5_mediated_signaling_pathway__Human_/#final-assessment","title":"Final Assessment","text":"<p>This model provides a good representation of the core IL-5 signaling pathway from ligand binding to transcription factor activation. The model could be enhanced by:</p> <ol> <li>Adding evidence for the JAK2 \u2192 STAT5A connection</li> <li>Clarifying the role of LYN in the pathway by either connecting it to downstream effectors or adding annotations explaining its regulatory role</li> <li>Potentially expanding the model to include specific transcriptional targets of STAT5A and feedback regulatory mechanisms</li> </ol> <p>Overall, this is a high-quality GO-CAM model that accurately represents the IL-5 signaling pathway with appropriate molecular functions, cellular contexts, and causal relationships, supported by relevant literature evidence.</p>"},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/","title":"623d156d00000699 Glycogen catabolic process 1  Mouse","text":"<p>Based on the model details and protein information I've gathered, I'll now conduct a thorough review of GO-CAM model gomodel:623d156d00000699, which is titled \"Glycogen catabolic process 1 (Mouse)\".</p>"},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/#go-cam-review-glycogen-catabolic-process-1-mouse","title":"GO-CAM Review: Glycogen catabolic process 1 (Mouse)","text":""},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Model ID: gomodel:623d156d00000699</li> <li>Title: Glycogen catabolic process 1 (Mouse)</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> <li>Comment: This model was sourced from gomodel:R-HSA-70221 and underwent an automated change in 2023-03-16 where RO:0002213 was replaced by RO:0002629</li> </ul>"},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/#model-structure-and-biological-process","title":"Model Structure and Biological Process","text":"<p>This GO-CAM represents the glycogen catabolic process (GO:0005980) in mouse, showing the enzymatic cascade involved in glycogen breakdown (glycogenolysis). The model includes key enzymes in the pathway:</p> <ol> <li>Phosphorylase kinase (Phkg2) - MGI:MGI:1916211</li> <li>Glycogen phosphorylase, liver form (Pygl) - MGI:MGI:97829</li> <li>Amylo-alpha-1,6-glucosidase (Agl) - MGI:MGI:1924809</li> <li>Phosphoglucomutases (Pgm1 and Pgm2) - MGI:MGI:97565 and MGI:MGI:97564</li> </ol>"},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Complete pathway representation: The model captures the major enzymatic activities in glycogen breakdown, from the initial regulatory step (phosphorylase kinase) through glycogen phosphorylase to the final reactions leading to glucose-6-phosphate production.</p> </li> <li> <p>Proper molecular function annotations: Each protein is annotated with the appropriate molecular function:</p> </li> <li>Phkg2 with phosphorylase kinase activity (GO:0004689)</li> <li>Pygl with glycogen phosphorylase activity (GO:0008184)</li> <li>Agl with amylo-alpha-1,6-glucosidase activity (GO:0004135) and 4-alpha-glucanotransferase activity (GO:0004134)</li> <li> <p>Pgm1 and Pgm2 with phosphoglucomutase activity (GO:0004614)</p> </li> <li> <p>Cellular localization: All activities are correctly annotated as occurring in the cytosol (GO:0005829), which is consistent with the known subcellular location of glycogen metabolism.</p> </li> <li> <p>Evidence support: The model includes appropriate evidence codes and literature citations for the activities and associations.</p> </li> </ol>"},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Redundant activity representation: There appear to be duplicate activities for Pygl (activities 623d156d00000710 and 623d156d00000705) with identical molecular functions and evidence. This creates unnecessary complexity in the model.</p> </li> <li> <p>Causal relationship clarity: The model shows Agl activity (amylo-alpha-1,6-glucosidase) providing input for glycogen phosphorylase, which is biochemically incorrect. In glycogen catabolism, glycogen phosphorylase acts first to cleave the \u03b1-1,4 glycosidic bonds, while Agl (debranching enzyme) acts on the branch points. These should be parallel activities or glycogen phosphorylase should provide input to Agl.</p> </li> <li> <p>Missing chemical entities: While the model shows alpha-D-glucose 6-phosphate (CHEBI:58225) as an output of the phosphoglucomutase activities, it doesn't clearly show glycogen as an input to the pathway.</p> </li> <li> <p>Regulatory relationship representation: The relationship between phosphorylase kinase (Phkg2) and glycogen phosphorylase (Pygl) uses RO:0002629 (directly positively regulates), which is appropriate, but the specific mechanism (phosphorylation of Ser-15 on Pygl) is not represented.</p> </li> </ol>"},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement:","text":"<ol> <li> <p>Remove redundant activities: Consolidate the two Pygl activities (623d156d00000710 and 623d156d00000705) into a single representation to simplify the model.</p> </li> <li> <p>Correct causal relationships: Revise the causal relationship between Agl and Pygl to accurately reflect the biochemical sequence in glycogen catabolism.</p> </li> <li> <p>Add chemical entities: Include glycogen as an input to the pathway to provide a complete representation of the process.</p> </li> <li> <p>Expand regulatory information: Consider adding annotations for the phosphorylation of Pygl by Phkg2 to provide additional mechanistic detail.</p> </li> <li> <p>Add relevant complex information: If any of these enzymes function as complexes (e.g., phosphorylase kinase is a hexadecamer), this could be represented using the complex annotation guidelines.</p> </li> </ol>"},{"location":"reviews/623d156d00000699-Glycogen_catabolic_process_1__Mouse_/#conclusion","title":"Conclusion:","text":"<p>Overall, this GO-CAM model provides a good representation of the glycogen catabolic process in mouse. With the suggested improvements, it would more accurately reflect the biological process and be more informative for users. The model aligns with GO-CAM best practices in terms of using appropriate molecular functions, biological processes, and cellular components, but the causal relationships between some enzymes need revision to accurately represent the sequential nature of glycogen breakdown.</p>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/","title":"623d156d00000752 Glycogen catabolic process 2  Mouse","text":"<p>Now, let me review all the GO functions and complexes in the model to fully understand its components:</p> <p>Based on all the information gathered, I'll now provide a comprehensive review of the GO-CAM model gomodel:623d156d00000752.</p>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#review-of-go-cam-model-623d156d00000752","title":"Review of GO-CAM Model: 623d156d00000752","text":""},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: Glycogen catabolic process 2 (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production Model URL: https://bioregistry.io/go.model:623d156d00000752</p>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#model-assessment","title":"Model Assessment","text":"<p>This model represents the glycogen catabolic process in mice, detailing how different proteins contribute to breaking down glycogen in the cytosol. The model appears to be well-constructed with appropriate causal relationships between activities and is supported by relevant evidence from the literature.</p>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#biological-process-representation","title":"Biological Process Representation","text":"<p>The model accurately captures the glycogen catabolic process (GO:0005980) in mouse cells, showing how multiple enzymatic activities coordinate to break down glycogen into glucose-6-phosphate, which can enter glycolysis. The activities include:</p> <ol> <li>Glycogen phosphorylase activity (GO:0008184) by PYGB (brain glycogen phosphorylase)</li> <li>4-alpha-glucanotransferase activity (GO:0004134) and amylo-alpha-1,6-glucosidase activity (GO:0004135) by AGL (glycogen debranching enzyme)</li> <li>Phosphorylase kinase activity (GO:0004689) by PHKG1 (phosphorylase kinase gamma subunit)</li> <li>Phosphoglucomutase activities (GO:0004614) by PGM1 and PGM2</li> </ol>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#molecular-structure-and-specificity","title":"Molecular Structure and Specificity","text":"<p>The model correctly identifies the molecular functions of each protein involved:</p> <ul> <li>PYGB (MGI:MGI:97828): The brain isoform of glycogen phosphorylase, responsible for cleaving \u03b1-1,4-glycosidic bonds in glycogen to release glucose-1-phosphate</li> <li>AGL (MGI:MGI:1924809): Functions as both a transferase and glucosidase to handle the branched portions of glycogen</li> <li>PHKG1 (MGI:MGI:97579): Activates glycogen phosphorylase through phosphorylation</li> <li>PGM1/PGM2 (MGI:MGI:97565/97564): Convert glucose-1-phosphate to glucose-6-phosphate</li> </ul>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The causal relationships in the model are logically connected:</p> <ol> <li>PHKG1 positively regulates (RO:0002629) PYGB, which is consistent with its role in activating glycogen phosphorylase through phosphorylation</li> <li>PYGB provides input for (RO:0002413) AGL's transferase activity, PGM1, and PGM2, correctly indicating that products of the glycogen phosphorylase reaction serve as substrates for these enzymes</li> <li>AGL's transferase activity provides input for its glucosidase activity, correctly representing the sequence of reactions in debranching</li> <li>AGL's glucosidase activity provides input for PYGB activity, reflecting the cyclic nature of glycogen breakdown</li> <li>PGM1 and PGM2 produce alpha-D-glucose-6-phosphate as output, correctly showing the end product</li> </ol>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#subcellular-localization","title":"Subcellular Localization","text":"<p>All activities are appropriately annotated as occurring in the cytosol (GO:0005829), which matches the known location of glycogen metabolism in cells.</p>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model includes appropriate evidence codes and references: - Direct assay evidence (ECO:0000314) - Mutant phenotype evidence (ECO:0000315) - Sequence orthology evidence (ECO:0000266)</p> <p>The primary references (PMID:32446205, PMID:24613482, PMID:4646763) provide strong support for the activities and relationships depicted in the model.</p> <p>One of the main references (PMID:32446205) specifically describes glycogenolysis (glycogen breakdown) and its importance in brain function, which aligns well with the model's focus.</p>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Appropriate molecular functions are attributed to specific gene products</li> <li>Activities are connected with appropriate causal relationships</li> <li>Each molecular function is part of the appropriate biological process</li> <li>Subcellular locations are specified</li> <li>Evidence codes and references are provided for key assertions</li> </ol>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is well-constructed, I have a few minor suggestions for improvement:</p> <ol> <li> <p>Clarify cycle representation: The model shows AGL's glucosidase activity (GO:0004135) providing input to PYGB activity (GO:0008184). While this represents the cyclic nature of glycogen breakdown, it might be clearer to explicitly show that this represents a new cycle of glycogen degradation.</p> </li> <li> <p>Add additional regulatory inputs: The model could potentially benefit from including factors that regulate glycogen breakdown, such as hormonal signals (insulin, glucagon) or energy status sensors (AMPK).</p> </li> <li> <p>Include additional output connections: Consider showing how glucose-6-phosphate feeds into other metabolic pathways like glycolysis or the pentose phosphate pathway.</p> </li> <li> <p>Add more mechanistic details: If available, information about how PHKG1 is itself activated (e.g., by calcium signaling or hormones) could enhance the model's completeness.</p> </li> </ol>"},{"location":"reviews/623d156d00000752-Glycogen_catabolic_process_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:623d156d00000752) is a well-constructed representation of the glycogen catabolic process in mice. It accurately depicts the molecular functions, relationships, and cellular locations involved in glycogen breakdown. The model is supported by appropriate evidence and references, and it follows GO-CAM best practices. With a few minor enhancements, it could provide an even more comprehensive view of glycogen metabolism regulation.</p> <p>The model successfully connects the activities of glycogen phosphorylase, debranching enzyme, and phosphoglucomutase to represent how glycogen is broken down to produce glucose-6-phosphate in mouse cells, particularly in the brain.</p>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/","title":"623d156d00000939 Glycogen catabolic process 3  Mouse","text":"<p>Let me review the model based on the information I have. I'll start by summarizing the activities and relationships in the model:</p>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#review-of-go-cam-model-gomodel623d156d00000939","title":"Review of GO-CAM Model: gomodel:623d156d00000939","text":""},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: Glycogen catabolic process 3 (Mouse)</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> <li>Comments:</li> <li>Automated change 2023-03-16: RO:0002213 replaced by RO:0002629</li> <li>Sourced from: gomodel:R-HSA-70221</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#model-content-summary","title":"Model Content Summary","text":"<p>This GO-CAM model represents the glycogen catabolic process in mouse, involving various enzymes in the pathway of glycogen breakdown. The model includes:</p> <ol> <li>Phosphorylase kinase (Phkg1) - catalyzes phosphorylation of glycogen phosphorylase</li> <li>Glycogen phosphorylase (Pygm) - breaks down glycogen by cleaving \u03b1-1,4-glycosidic bonds</li> <li>Amylo-alpha-1,6-glucosidase (Agl) - removes branches in glycogen by cleaving \u03b1-1,6-glycosidic bonds</li> <li>Phosphoglucomutase (Pgm1, Pgm2) - converts glucose-1-phosphate to glucose-6-phosphate</li> </ol>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#detailed-activity-breakdown","title":"Detailed Activity Breakdown","text":""},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#activity-1-gomodel623d156d00000939623d156d00000941","title":"Activity 1 (gomodel:623d156d00000939/623d156d00000941)","text":"<ul> <li>Enabled by: MGI:MGI:97579 (Phkg1 - Phosphorylase kinase gamma 1)</li> <li>Molecular Function: GO:0004689 (phosphorylase kinase activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0005980 (glycogen catabolic process)</li> <li>Causal relationship: Directly positively regulates (RO:0002629) Activity 4</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#activity-2-gomodel623d156d00000939623d156d00000949","title":"Activity 2 (gomodel:623d156d00000939/623d156d00000949)","text":"<ul> <li>Enabled by: MGI:MGI:1924809 (Agl - Amylo-alpha-1,6-glucosidase)</li> <li>Molecular Function: GO:0004134 (4-alpha-glucanotransferase activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0005980 (glycogen catabolic process)</li> <li>Causal relationship: Provides input for (RO:0002413) Activity 6</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#activity-3-gomodel623d156d00000939623d156d00000945","title":"Activity 3 (gomodel:623d156d00000939/623d156d00000945)","text":"<ul> <li>Enabled by: MGI:MGI:97830 (Pygm - Muscle glycogen phosphorylase)</li> <li>Molecular Function: GO:0008184 (glycogen phosphorylase activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0005980 (glycogen catabolic process)</li> <li>Causal relationships:</li> <li>Provides input for (RO:0002413) Activity 7</li> <li>Provides input for (RO:0002413) Activity 5</li> <li>Provides input for (RO:0002413) Activity 2</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#activity-4-gomodel623d156d00000939623d156d00000945","title":"Activity 4 (gomodel:623d156d00000939/623d156d00000945)","text":"<ul> <li>Enabled by: MGI:MGI:97830 (Pygm - Muscle glycogen phosphorylase)</li> <li>Molecular Function: GO:0008184 (glycogen phosphorylase activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0005980 (glycogen catabolic process)</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#activity-5-gomodel623d156d00000939623d156d00000953","title":"Activity 5 (gomodel:623d156d00000939/623d156d00000953)","text":"<ul> <li>Enabled by: MGI:MGI:97565 (Pgm1 - Phosphoglucomutase-1)</li> <li>Molecular Function: GO:0004614 (phosphoglucomutase activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0005980 (glycogen catabolic process)</li> <li>Has output: CHEBI:58225 (alpha-D-glucose 6-phosphate(2-))</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#activity-6-gomodel623d156d00000939623d156d00000947","title":"Activity 6 (gomodel:623d156d00000939/623d156d00000947)","text":"<ul> <li>Enabled by: MGI:MGI:1924809 (Agl - Amylo-alpha-1,6-glucosidase)</li> <li>Molecular Function: GO:0004135 (amylo-alpha-1,6-glucosidase activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0005980 (glycogen catabolic process)</li> <li>Causal relationship: Provides input for (RO:0002413) Activity 7</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#activity-7-gomodel623d156d00000939623d156d00000954","title":"Activity 7 (gomodel:623d156d00000939/623d156d00000954)","text":"<ul> <li>Enabled by: MGI:MGI:97564 (Pgm2 - Phosphoglucomutase-2)</li> <li>Molecular Function: GO:0004614 (phosphoglucomutase activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0005980 (glycogen catabolic process)</li> <li>Has output: CHEBI:58225 (alpha-D-glucose 6-phosphate(2-))</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#activity-8-gomodel623d156d00000939623d156d00000950","title":"Activity 8 (gomodel:623d156d00000939/623d156d00000950)","text":"<ul> <li>Enabled by: MGI:MGI:97830 (Pygm - Muscle glycogen phosphorylase)</li> <li>Molecular Function: GO:0008184 (glycogen phosphorylase activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0005980 (glycogen catabolic process)</li> <li>Causal relationships:</li> <li>Provides input for (RO:0002413) Activity 7</li> <li>Provides input for (RO:0002413) Activity 5</li> </ul>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly represents the key enzymes involved in glycogen catabolism in mouse.</li> <li>The spatial context (cytosol) is appropriately captured for all activities.</li> <li>The main biological process (glycogen catabolic process) is correctly linked to all activities.</li> <li>The causal relationships between activities generally follow the established biochemical pathway of glycogen breakdown.</li> <li>Evidence is provided for most of the activities with appropriate references to the literature.</li> </ol>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Redundancy: There appears to be some redundancy in the representation of glycogen phosphorylase (Pygm) activities - Activities 3, 4, and 8 all describe the same molecular function (glycogen phosphorylase activity) by the same protein.</p> </li> <li> <p>Evidence Gaps: Some causal associations lack evidence annotations.</p> </li> <li> <p>Activity Disambiguation: The model would benefit from clearer distinction between the activities of the same enzyme in different contexts or steps of the pathway.</p> </li> <li> <p>Pathway Completeness: The model represents major steps in glycogen catabolism but could potentially include additional regulatory steps or connections to other metabolic pathways.</p> </li> <li> <p>Consistency with Literature: The evidence cited in PMID:24613482 strongly supports the roles of Agl in glycogen debranching, which is appropriately captured in the model.</p> </li> </ol>"},{"location":"reviews/623d156d00000939-Glycogen_catabolic_process_3__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Consolidate Redundant Activities: Consider merging Activities 3, 4, and 8 (all representing glycogen phosphorylase activity by Pygm) into a single activity with appropriate causal relationships.</p> </li> <li> <p>Complete Evidence Documentation: Add evidence annotations to all causal associations.</p> </li> <li> <p>Clarify Activity Context: Provide more specific context for each activity if they represent different steps or conditions in the pathway.</p> </li> <li> <p>Expand Regulatory Relationships: Consider adding known regulatory relationships that control this pathway, such as hormonal regulation of glycogen metabolism.</p> </li> </ol> <p>Overall, this GO-CAM model provides a good representation of the glycogen catabolic pathway in mouse, with a logical flow of activities that matches the known biochemistry. With the suggested refinements, it could be an even more valuable resource for understanding glycogen metabolism.</p>"},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/","title":"6246724f00000078 Glucuronate catabolic process to xylulose 5 phosphate  Mouse","text":"<p>Based on my examination of the GO-CAM model and relevant literature, let me provide a thorough review.</p>"},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#review-of-go-cam-model-gomodel6246724f00000078","title":"Review of GO-CAM Model: gomodel:6246724f00000078","text":""},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: Glucuronate catabolic process to xylulose 5-phosphate (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production Source: Derived from gomodel:R-HSA-5661270</p>"},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#pathway-description","title":"Pathway Description","text":"<p>This GO-CAM model represents the D-glucuronate catabolic pathway that converts D-glucuronate to D-xylulose 5-phosphate in mouse. This is a well-documented metabolic pathway that consists of a series of enzymatic reactions catalyzed by specific proteins.</p>"},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#chain-of-activities","title":"Chain of Activities","text":"<p>The model correctly shows the following sequential enzymatic reactions:</p> <ol> <li>Akr1a1 (MGI:MGI:1929955) - L-glucuronate reductase activity (GO:0047939)</li> <li>Converts D-glucuronate to L-gulonate</li> <li>Located in cytosol (GO:0005829)</li> <li> <p>Provides input for the next reaction (Cryl1)</p> </li> <li> <p>Cryl1 (MGI:MGI:1915881) - L-gulonate 3-dehydrogenase activity (GO:0050104)</p> </li> <li>Converts L-gulonate to 3-dehydro-L-gulonate</li> <li> <p>Located in cytosol (GO:0005829)</p> </li> <li> <p>Dcxr (MGI:MGI:1915130) - L-xylulose reductase (NADPH) activity (GO:0050038)</p> </li> <li>Converts to xylitol</li> <li>Located in cytosol (GO:0005829)</li> <li> <p>Provides input for the next reaction (Sord)</p> </li> <li> <p>Sord (MGI:MGI:98266) - D-xylulose reductase activity (GO:0046526)</p> </li> <li>Converts to D-xylulose</li> <li>Located in cytosol (GO:0005829)</li> <li> <p>Provides input for the next reaction (Xylb)</p> </li> <li> <p>Xylb (MGI:MGI:2142985) - D-xylulokinase activity (GO:0004856)</p> </li> <li>Phosphorylates D-xylulose to produce D-xylulose 5-phosphate (CHEBI:57737)</li> <li>Located in cytosol (GO:0005829)</li> </ol>"},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#quality-check","title":"Quality Check","text":""},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li> <p>Complete pathway representation: The model correctly represents all the key enzymatic steps in the glucuronate catabolic pathway from D-glucuronate to D-xylulose 5-phosphate.</p> </li> <li> <p>Correct molecular functions: All proteins have been assigned the appropriate molecular functions based on their enzymatic activities.</p> </li> <li> <p>Evidence citations: Each activity is supported by appropriate evidence codes and literature references.</p> </li> <li> <p>Proper cellular locations: All activities are correctly annotated to occur in the cytosol.</p> </li> <li> <p>Causal relationships: The model correctly uses the \"provides input for\" (RO:0002413) relationship to connect the sequential enzymatic reactions.</p> </li> <li> <p>Output annotation: The final product D-xylulose 5-phosphate is correctly annotated as the output of the Xylb enzyme.</p> </li> </ol>"},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Missing reaction intermediates: While the model correctly shows the activity chain, it does not explicitly annotate all the intermediate metabolites in the pathway. For completeness, it could include:</li> <li>The conversion of 3-dehydro-L-gulonate to L-xylulose (spontaneous decarboxylation)</li> <li> <p>The specific annotation of xylitol as an intermediate</p> </li> <li> <p>Incomplete evidence: Some of the causal associations lack explicit evidence codes and references. While the individual activities have evidence, the connections between them would benefit from literature support.</p> </li> <li> <p>Compartmentalization details: While all activities are correctly placed in the cytosol, for more complex models, additional details about potential membrane associations or protein-protein interactions could be valuable.</p> </li> </ol>"},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model is biologically accurate and consistent with the current understanding of the D-glucuronate catabolic pathway in mammals. The enzymes and their activities are correctly represented, and the sequential flow of reactions is properly modeled.</p> <p>This pathway is part of the uronic acid metabolism and represents an important route for the catabolism of D-glucuronate, which can be derived from the breakdown of proteoglycans, glycosaminoglycans, and other carbohydrates.</p>"},{"location":"reviews/6246724f00000078-Glucuronate_catabolic_process_to_xylulose_5_phosphate__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:6246724f00000078) accurately represents the D-glucuronate catabolic pathway leading to D-xylulose 5-phosphate in mouse. The model follows GO-CAM best practices in terms of structure and annotation quality. Each enzymatic step is properly represented, with appropriate molecular functions assigned to the correct gene products, and the sequential flow of the pathway is correctly modeled using causal relationships.</p> <p>The model is ready for production use and provides a valuable resource for researchers interested in carbohydrate metabolism. Minor improvements could be made by annotating intermediate metabolites more explicitly and providing additional evidence for the causal relationships between activities.</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/","title":"6246724f00000283 Regulation of the mTORC1 signaling via ubiquitination and deubiquitnation of SESN2 by RNF167 and STAMBPL1  Human","text":"<p>Based on my review of the GO-CAM model and the reference papers, I can now provide a comprehensive review of model gomodel:6246724f00000283 \"Regulation of the mTORC1 signaling via ubiquitination and deubiquitnation of SESN2 by RNF167 and STAMBPL1 (Human)\":</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#go-cam-model-review-gomodel6246724f00000283","title":"GO-CAM Model Review: gomodel:6246724f00000283","text":""},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#general-assessment","title":"General Assessment","text":"<p>This model represents the regulation of mTORC1 signaling through the ubiquitination and deubiquitination of SESN2 (Sestrin2) by RNF167 and STAMBPL1 in humans. The model is based on multiple primary literature references, particularly PMID:35114100, PMID:26586190, and PMID:36528027.</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model accurately represents the key molecular functions and relationships described in the literature:</p> <ol> <li> <p>SESN2 Function: The model correctly shows SESN2 (UniProtKB:P58004) acting as a protein with sequestering activity (GO:0140311), which is consistent with its established role as a leucine sensor that negatively regulates mTORC1 signaling when active. As described in PMID:26586190, SESN2 detects leucine through a specific binding pocket, and when not bound to leucine, it interacts with GATOR2 to inhibit mTORC1 signaling.</p> </li> <li> <p>Regulatory Mechanisms: The model shows:</p> </li> <li>RNF167 (UniProtKB:Q9H6Y7) acting with ubiquitin-protein transferase activity, mediating K63-linked ubiquitination</li> <li>STAMBPL1 (UniProtKB:Q96FJ0) with K63-linked deubiquitinase activity</li> <li> <p>WDR24 (UniProtKB:Q96S15) with ubiquitin protein ligase activity mediating K6-linked ubiquitination</p> </li> <li> <p>Causal Relationships: The model correctly represents:</p> </li> <li>RNF167 directly positively regulates SESN2 activity</li> <li>STAMBPL1 directly negatively regulates SESN2 activity</li> <li>SESN2 directly negatively regulates WDR24, which is part of the GATOR2 complex</li> </ol>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Appropriate Annotation of Complexes: The model correctly represents the case where individual proteins carry specific molecular activities, following the guidance in the \"How to annotate complexes in GO-CAM\" document.</p> </li> <li> <p>Protein Sequestering Activity: The model appropriately uses protein sequestering activity (GO:0140311) for SESN2, which is consistent with the \"Protein sequestering activity\" guidelines. SESN2 sequesters components of the GATOR2 complex (though this relationship could be more explicitly shown with a \"has input\" relation).</p> </li> <li> <p>Appropriate Regulation Relations: The model uses the correct causal relation predicates:</p> </li> <li>RO:0002629 (directly positively regulates) for direct positive regulation</li> <li> <p>RO:0002630 (directly negatively regulates) for direct negative regulation</p> </li> <li> <p>Cellular Locations: The model appropriately indicates the cellular components in which activities occur, with appropriate evidence:</p> </li> <li>Lysosomal membrane (GO:0005765) for RNF167 and WDR24</li> <li>Cytoplasm (GO:0005737) for SESN2</li> </ol>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Additional Context Needed: The model would benefit from explicitly showing SESN2's leucine binding activity (GO:0070728) in relation to its sequestering activity. While the model shows SESN2 with leucine binding activity, the relationship between this activity and its sequestering function could be made clearer with appropriate causal relations.</p> </li> <li> <p>Input/Output Relationships: The model could be improved by explicitly showing SESN2's \"has input\" relationship with its target(s) in the GATOR2 complex, as recommended in the protein sequestering activity guidelines.</p> </li> <li> <p>Pathway Context: The biological process context could be expanded to show how this regulatory mechanism fits into the broader leucine sensing and mTORC1 regulatory pathway, possibly by including additional upstream or downstream activities.</p> </li> <li> <p>Evidence Support: While the model cites appropriate references, the connections between leucine binding and SESN2's regulatory activities could be strengthened with additional evidence codes or references.</p> </li> </ol>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:6246724f00000283) is scientifically accurate and generally follows GO-CAM best practices. It correctly represents the regulatory mechanisms controlling mTORC1 signaling through SESN2, RNF167, and STAMBPL1. With some minor enhancements to explicitly show the relationships between leucine binding and SESN2's regulatory activity, and to provide additional pathway context, the model would more completely represent the biological system described in the literature.</p> <p>The model is supported by high-quality evidence from peer-reviewed publications and appropriately captures the roles of key proteins in this regulatory pathway.</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/","title":"6246724f00000369 Regulation of the mTORC1 signaling via ubiquitination and degradation of CASTOR1 by RNF167  Human","text":"<p>Now that I have gathered the necessary information about the model and related proteins/concepts, let me review the GO-CAM model:</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#review-of-gomodel6246724f00000369","title":"Review of gomodel:6246724f00000369","text":""},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model titled \"Regulation of the mTORC1 signaling via ubiquitination and degradation of CASTOR1 by RNF167 (Human)\" describes a signaling pathway in which the E3 ubiquitin ligase RNF167 ubiquitinates and promotes the degradation of CASTOR1, leading to the activation of mTORC1 signaling. The model involves several key proteins:</p> <ol> <li>CASTOR1 (Q8WTX7) - Cytosolic arginine sensor for mTORC1 that normally inhibits mTORC1 signaling</li> <li>RNF167 (Q9H6Y7) - E3 ubiquitin ligase </li> <li>WDR24 (Q96S15) - GATOR2 complex component with ubiquitin ligase activity</li> <li>AKT1 (P31749) - Protein kinase that phosphorylates CASTOR1</li> </ol>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#accuracy-and-completeness","title":"Accuracy and Completeness","text":""},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#biological-content","title":"Biological Content","text":"<p>The model accurately represents a key regulatory mechanism of mTORC1 signaling based on the literature evidence. According to PMID:33594058, RNF167 targets CASTOR1 for K29-linked ubiquitination and degradation, which relieves CASTOR1's inhibition of mTORC1. The model correctly indicates that AKT1 phosphorylates CASTOR1, which promotes RNF167 binding and subsequent ubiquitination, leading to activation of mTORC1 signaling.</p> <p>The model appropriately includes: - CASTOR1's dual activities as arginine binding (GO:0034618) and protein sequestering (GO:0140311) - RNF167's ubiquitin-protein transferase activity (GO:0004842) - WDR24's ubiquitin protein ligase activity (GO:0061630) - AKT1's protein serine/threonine kinase activity (GO:0004674)</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#relationships-and-causal-connections","title":"Relationships and Causal Connections","text":"<p>The causal relationships in the model appear correct: - RNF167 activity (GO:0004842) directly negatively regulates CASTOR1 protein sequestering activity (GO:0140311) - CASTOR1 arginine binding (GO:0034618) directly negatively regulates CASTOR1 protein sequestering activity (GO:0140311) - AKT1 protein kinase activity (GO:0004674) provides input for RNF167's activity - CASTOR1 protein sequestering activity directly negatively regulates WDR24's ubiquitin ligase activity</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#cellular-locations","title":"Cellular Locations","text":"<p>The model correctly identifies: - CASTOR1 activities in the cytosol (GO:0005829) - WDR24 in the lysosomal membrane (GO:0005765)</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#biological-processes","title":"Biological Processes","text":"<p>The model appropriately annotates: - RNF167's role in protein K29-linked ubiquitination (GO:0035519) - CASTOR1's role in negative regulation of TORC1 signaling (GO:1904262) and positive regulation of TORC1 signaling (GO:1904263) - WDR24's role in protein K6-linked ubiquitination (GO:0085020)</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":""},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#complex-representation","title":"Complex Representation","text":"<p>The model follows the GO-CAM guidelines for representing complexes, particularly regarding E3 ubiquitin ligases. According to the \"How_to_annotate_complexes_in_GO-CAM\" and \"E3_ubiquitin_ligases\" documents:</p> <ul> <li>The model correctly represents RNF167 as an E3 ligase with its ubiquitin-protein transferase activity</li> <li>The appropriate causal relationships are used to show how RNF167 regulates CASTOR1</li> <li>WDR24 is correctly represented with its ubiquitin protein ligase activity</li> </ul>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#evidence-support","title":"Evidence Support","text":"<p>Each activity and relationship in the model is properly supported by evidence from the literature: - PMID:33594058 provides evidence for RNF167's ubiquitination of CASTOR1 - PMID:26972053 provides evidence for CASTOR1's role as an arginine sensor - PMID:36528027 supports WDR24's role in the GATOR2 complex - PMID:28199306 provides evidence for the localization of WDR24 to the lysosomal membrane</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is overall well-constructed and biologically accurate, there are a few areas that could be improved:</p> <ol> <li> <p>Additional molecular details: The model could more explicitly represent how AKT1 phosphorylates CASTOR1 at Ser-14, which enhances its interaction with RNF167. According to PMID:33594058, this phosphorylation is a critical regulatory step.</p> </li> <li> <p>Input molecule for CASTOR1 arginine binding: While the model correctly shows that CASTOR1 binds arginine (CHEBI:32696), it would be helpful to clarify the regulatory role of arginine in this process - when arginine binds to CASTOR1, it disrupts CASTOR1's interaction with the GATOR2 complex.</p> </li> <li> <p>Complete representation of the GATOR2 complex: The model currently includes WDR24 as a representative of the GATOR2 complex, but according to the literature, the complete GATOR2 complex contains WDR24, MIOS, WDR59, SEC13, and SEH1L. While not necessary to include all components, a note about the complete complex could be informative.</p> </li> <li> <p>Lysine residues in CASTOR1 targeted for ubiquitination: The model could specify the lysine residues in CASTOR1 (K61, K96, and K213) that are targeted by RNF167 for K29-linked polyubiquitination, as mentioned in PMID:33594058.</p> </li> </ol>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6246724f00000369 provides an accurate representation of the regulation of mTORC1 signaling through RNF167-mediated ubiquitination and degradation of CASTOR1. The model correctly captures the key molecular functions, biological processes, cellular locations, and causal relationships supported by published literature.</p> <p>The model effectively highlights how CASTOR1, a cytosolic arginine sensor, can be regulated not only by arginine binding but also through post-translational modifications (phosphorylation by AKT1 followed by ubiquitination by RNF167), leading to its degradation and subsequent activation of mTORC1 signaling.</p> <p>The causal flow of the pathway is logically represented, with appropriate use of regulatory relationships between protein activities. The model complies with GO-CAM best practices for representing E3 ubiquitin ligase activities and complex components.</p> <p>With a few minor additions to include more specific molecular details, this model could serve as an excellent reference for understanding this regulatory mechanism of the mTORC1 pathway.</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/","title":"6246724f00000549 Renin angiotensin pathway  Human","text":"<p>Based on the documentation I've reviewed and the model details, let me now perform a thorough review of the renin-angiotensin pathway GO-CAM model (gomodel:6246724f00000549).</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#go-cam-model-review-renin-angiotensin-pathway-human","title":"GO-CAM Model Review: Renin-angiotensin pathway (Human)","text":""},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#model-overview","title":"Model Overview:","text":"<p>This GO-CAM model represents the renin-angiotensin pathway in humans, a critical biological system for regulating blood pressure, fluid balance, and electrolyte homeostasis. The model includes four key activities connected in a causal chain:</p> <ol> <li>Renin (UniProtKB:P00797-1) with aspartic-type endopeptidase activity (GO:0004190)</li> <li>Angiotensin-converting enzyme/ACE (UniProtKB:P12821) with peptidyl-dipeptidase activity (GO:0008241)</li> <li>Angiotensinogen (UniProtKB:P01019) with hormone activity (GO:0005179)</li> <li>Angiotensin II type 1 receptor/AGTR1 (UniProtKB:P30556) with angiotensin type I receptor activity (GO:0001596)</li> </ol>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li>The model accurately captures the key components of the renin-angiotensin pathway, including the enzyme-substrate relationships and signal transduction.</li> <li>The cellular compartments for each protein are appropriately specified, with:</li> <li>Renin occurring in extracellular space (GO:0005615)</li> <li>ACE occurring in extracellular space (GO:0005615)</li> <li>Angiotensinogen occurring in extracellular space (GO:0005615)</li> <li>AGTR1 occurring in plasma membrane (GO:0005886)</li> <li>The causal relationships between activities are correctly represented with appropriate relation predicates:</li> <li>Renin directly positively regulates (RO:0002629) ACE</li> <li>ACE causally upstream with positive effect (RO:0002304) on angiotensinogen</li> <li>Angiotensinogen directly positively regulates (RO:0002629) AGTR1</li> <li>Each activity is appropriately associated with its corresponding biological process:</li> <li>Renin with angiotensin maturation (GO:0002003)</li> <li>ACE with angiotensin maturation (GO:0002003)</li> <li>Angiotensinogen with maintenance of blood vessel diameter homeostasis by renin-angiotensin (GO:0002034)</li> <li>AGTR1 with angiotensin-activated signaling pathway (GO:0038166)</li> <li>Evidence codes and PMIDs are included for each activity and relationship.</li> </ol>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement:","text":"<ol> <li> <p>Substrate-Enzyme Relationships: According to the Signaling Receptor Activity Guidelines, the model should specify \"has input\" relationships for substrates. Currently, the causal relationships are correctly shown, but the substrate input relationships could be more explicit.</p> </li> <li> <p>Activation Mechanism Clarification: The relationship between angiotensinogen (AGT) and AGTR1 should be clarified. Based on the literature, angiotensinogen is cleaved by renin to produce angiotensin I, which is then cleaved by ACE to produce angiotensin II, which is the actual ligand that activates AGTR1. The model correctly shows the causal chain but may benefit from explicit representation of these intermediate peptides (Angiotensin I and Angiotensin II).</p> </li> <li> <p>Molecular Function Specificity: For angiotensinogen (AGT), the molecular function is currently annotated as \"hormone activity\" (GO:0005179), but a more specific term related to its role as a precursor for the angiotensin peptides might be more appropriate. According to UniProt, its function is as an essential component of the renin-angiotensin system.</p> </li> <li> <p>Downstream Effects: The model could be expanded to include the downstream effects of AGTR1 activation, such as G-protein coupling and subsequent signaling cascades, which ultimately lead to vasoconstriction, aldosterone release, and other physiological effects.</p> </li> <li> <p>Alternative Pathways: The model could also represent alternative processing pathways, such as the action of ACE2 on angiotensin peptides, which produces peptides with different biological activities, as mentioned in the UniProt entries.</p> </li> </ol>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#biological-validation","title":"Biological Validation:","text":"<ol> <li> <p>Cleavage Specificity: The UniProt entries confirm that renin specifically cleaves angiotensinogen to release angiotensin I, and ACE then converts angiotensin I to angiotensin II by removing a dipeptide. This sequential processing is implied but not explicitly represented in the model.</p> </li> <li> <p>Receptor Specificity: The model correctly identifies AGTR1 as the receptor for angiotensin II, consistent with the literature (including PMID:32079768 and PMID:30639100 cited in the model).</p> </li> <li> <p>Cellular Localization: The cellular locations specified in the model align with those described in the UniProt entries:</p> </li> <li>Renin is secreted and acts in the extracellular space</li> <li>ACE is a membrane protein with an extracellular catalytic domain</li> <li>Angiotensinogen is secreted into the bloodstream</li> <li>AGTR1 is a cell surface receptor in the plasma membrane</li> </ol>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#overall-assessment","title":"Overall Assessment:","text":"<p>This GO-CAM model provides a sound representation of the core components and relationships in the renin-angiotensin pathway. The model adheres to GO-CAM best practices for representing signaling pathways involving protein ligands and receptors.</p> <p>The model could be enhanced by: 1. More explicit representation of the peptide intermediates (Angiotensin I and II) 2. Including downstream signaling effects of AGTR1 activation 3. Adding alternative processing pathways (e.g., ACE2)</p> <p>These suggestions would make the model more comprehensive, but the current representation is accurate and captures the essential aspects of the renin-angiotensin pathway.</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#recommendation","title":"Recommendation:","text":"<p>This model is biologically accurate and follows GO-CAM best practices. It can be approved, potentially with minor suggestions for future enhancements as noted above.</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/","title":"6246724f00000675 IL7 mediated signaling pathway  Human","text":"<p>Based on the information gathered from the GO-CAM model review and the related documents, let me provide a detailed review of GO-CAM model 6246724f00000675, \"IL7-mediated signaling pathway (Human)\":</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#review-of-go-cam-model-gomodel6246724f00000675-il7-mediated-signaling-pathway-human","title":"Review of GO-CAM model: gomodel:6246724f00000675 - IL7-mediated signaling pathway (Human)","text":""},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#overview","title":"Overview","text":"<p>This model represents the IL-7 signaling pathway in humans, which is a critical cytokine pathway for T-cell development, survival, and homeostasis. The model has been annotated with PMID references supporting the interactions and includes key proteins in the pathway: IL-7, IL-7 receptor subunits (IL-7R and IL-2RG/common gamma chain), JAK kinases (JAK1 and JAK3), and STAT transcription factors (STAT5A and STAT1).</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Pathway coverage: The model effectively captures the core components of the IL-7 signaling pathway, from ligand-receptor interaction to downstream signaling and transcriptional regulation.</p> </li> <li> <p>Evidence support: Each component and relationship is supported by primary literature references, which strengthens the credibility of the annotations.</p> </li> <li> <p>Cellular localization: The model includes appropriate cellular localizations for each component (extracellular space for IL-7, plasma membrane for receptors, cytoplasmic side of plasma membrane for JAK kinases, and nucleus for STAT transcription factors).</p> </li> <li> <p>Causal relationships: The model properly uses causal relationships (\"directly positively regulates\" - RO:0002629) to link pathway components in a biologically meaningful sequence.</p> </li> </ol>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex representation: According to the IL-7 pathway literature (PMIDs: 8128231, 9182906), IL-7R functions as a heterodimer with IL-2RG (common gamma chain). While the model correctly includes both receptor components, it should more clearly represent their interaction as a functional complex. Currently, they are represented as separate entities but should be linked to show they function together.</p> </li> <li> <p>JAK activation mechanism: The model shows JAK1 and JAK3 activation, but could be improved by explicitly representing their association with specific receptor subunits. Per PMID 7973659, JAK3 associates with the common gamma chain (IL-2RG), while JAK1 associates with IL-7R. This detail would enhance the mechanistic understanding of the pathway.</p> </li> <li> <p>STAT selection pathway branches: The model includes both STAT5A and STAT1 activation, but doesn't clearly differentiate which conditions lead to activation of each transcription factor. According to literature (PMID 20974963), these may represent different branches of the pathway that could be specified more clearly.</p> </li> <li> <p>Feedback regulation: The current model doesn't include negative feedback mechanisms that are important for IL-7 signaling regulation, such as SOCS proteins or receptor downregulation. These could be valuable additions to complete the pathway representation.</p> </li> </ol>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#technical-assessment","title":"Technical Assessment","text":"<ol> <li> <p>Relationship usage: The model correctly uses the \"directly positively regulates\" (RO:0002629) relationship to connect activities in the signaling cascade, conforming to GO-CAM best practices.</p> </li> <li> <p>Biological process annotation: All activities are properly annotated as part of \"interleukin-7-mediated signaling pathway\" (GO:0038111), providing appropriate context.</p> </li> <li> <p>Evidence codes: The model appropriately uses ECO:0000314 (direct assay evidence used in manual assertion) and ECO:0000305 (curator inference used in manual assertion) for the annotations.</p> </li> </ol>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Represent receptor complex: Clarify the IL-7R and IL-2RG interaction as a functional complex, following the guidelines in \"How_to_annotate_complexes_in_GO-CAM\".</p> </li> <li> <p>Specify JAK associations: Explicitly represent the specific association between JAK3 and IL-2RG, and between JAK1 and IL-7R, as supported by the literature.</p> </li> <li> <p>Differentiate STAT pathways: Consider adding annotations to clarify which signals lead to STAT5A activation versus STAT1 activation, as these may represent different functional outcomes of the pathway.</p> </li> <li> <p>Add feedback regulation: Consider extending the model to include negative regulation mechanisms that control IL-7 signaling duration and intensity.</p> </li> <li> <p>Consider recycling mechanism: The recycling of IL-7 (PMID 25870237) could be incorporated as an additional feature of the model to represent this recently discovered mechanism for optimizing IL-7 utilization.</p> </li> </ol>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6246724f00000675 provides a good representation of the core IL-7 signaling pathway in humans. It follows most GO-CAM best practices and is well-supported by scientific literature. With the suggested improvements, particularly in representing receptor complex formation and JAK associations, the model could more accurately reflect the current understanding of IL-7 signaling mechanisms.</p>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/","title":"6246724f00000763 TSLP mediated signaling pathway  Human","text":"<p>Now that I have gathered the necessary information, let me provide a comprehensive review of the GO-CAM model gomodel:6246724f00000763 \"TSLP-mediated signaling pathway (Human)\".</p>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#go-cam-model-review-tslp-mediated-signaling-pathway-human","title":"GO-CAM Model Review: TSLP-mediated signaling pathway (Human)","text":""},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>The model gomodel:6246724f00000763 represents the TSLP-mediated signaling pathway in humans. This pathway begins with TSLP (Thymic Stromal Lymphopoietin) binding to its receptor complex, which consists of IL-7R\u03b1 and TSLPR/CRLF2, leading to JAK kinase activation and ultimately STAT5 phosphorylation and nuclear translocation.</p>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model correctly represents the key steps in TSLP signaling according to current literature:</p> <ol> <li> <p>TSLP as initiator: The model starts with TSLP (UniProtKB:Q969D9) displaying cytokine activity (GO:0005125) in the extracellular space.</p> </li> <li> <p>Receptor complex: The model shows TSLP signaling through both IL-7R\u03b1 (UniProtKB:P16871) and CRLF2/TSLPR (UniProtKB:Q9HC73), which form a heterodimeric receptor complex on the plasma membrane.</p> </li> <li> <p>JAK-STAT activation: The pathway correctly shows that TSLP signaling activates JAK1 and JAK2 (not JAK3, which would be involved in IL-7 signaling), leading to STAT5A activation and nuclear translocation.</p> </li> </ol>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships in the model follow the expected molecular signaling flow:</p> <ol> <li>TSLP \u2192 IL-7R (cytokine receptor activity) </li> <li>IL-7R \u2192 JAK1 and CRLF2 \u2192 JAK2 (protein tyrosine kinase activities)</li> <li>JAK1 and JAK2 \u2192 STAT5A (DNA-binding transcription factor activity)</li> </ol> <p>All causal relationships use the <code>RO:0002629</code> predicate (directly positively regulates), which is appropriate for this signaling pathway.</p>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>TSLP receptor complex representation: The model represents the IL-7R and CRLF2 as separate entities with separate causal relationships. According to the \"How to annotate complexes in GO-CAM\" document, this approach is valid when each subunit has a defined activity. However, since these two proteins form a functional heterodimeric receptor for TSLP, it might be more accurate to explicitly model their coordinated action.</p> </li> <li> <p>JAK association specificity: While the model correctly shows JAK1 association with IL-7R and JAK2 association with CRLF2, it might be beneficial to add evidence statements to these specific associations since this is a key aspect of TSLP signaling that distinguishes it from IL-7 signaling (which uses JAK1 and JAK3).</p> </li> <li> <p>STAT5 dimerization: The model currently shows STAT5A activity but doesn't explicitly represent STAT5 dimerization, which is an important step in the signaling process before nuclear translocation.</p> </li> <li> <p>Part_of biological process annotations: While the model includes several activities that are part_of the \"cytokine-mediated signaling pathway\" (GO:0019221), this annotation is inconsistently applied across all activities in the model.</p> </li> </ol>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes and citations:</p> <ul> <li>Most assertions use <code>ECO:0000314</code> (direct assay evidence) with citation to PMID:20974963, which is a key paper describing TSLP-mediated STAT5 phosphorylation.</li> <li>Cellular locations use <code>ECO:0000305</code> (curator inference) which is appropriate.</li> <li>The biological process annotations use both direct evidence and biological aspect of ancestor evidence.</li> </ul>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#technical-review","title":"Technical Review","text":"<ol> <li> <p>All required fields are present: The model includes molecular functions, cellular locations, and appropriate causal relationships.</p> </li> <li> <p>Nomenclature: All entities use standard nomenclature and proper UniProt accessions.</p> </li> <li> <p>Automated changes: The model has undergone some automated predicate replacements (RO:0002213 replaced by RO:0002629) and cellular component replacements, which appear to have been done correctly.</p> </li> </ol>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#summary-and-recommendations","title":"Summary and Recommendations","text":"<p>This GO-CAM model accurately represents the TSLP-mediated signaling pathway and is consistent with current literature about this pathway. The key aspects of TSLP signaling, including receptor composition, JAK kinase specificity, and STAT5 activation, are captured correctly.</p> <p>Recommendations for improvement:</p> <ol> <li> <p>Consider explicitly modeling the IL-7R/CRLF2 heterodimeric complex to better represent their coordinated function in TSLP signaling.</p> </li> <li> <p>Add more detailed evidence statements for the JAK1/JAK2 associations with specific receptor subunits.</p> </li> <li> <p>Consider representing STAT5 dimerization as part of the signaling process.</p> </li> <li> <p>Apply the \"part_of cytokine-mediated signaling pathway\" annotation consistently to all activities in the pathway.</p> </li> <li> <p>Consider adding downstream transcriptional targets of STAT5 if they are well-characterized for TSLP signaling.</p> </li> </ol> <p>Overall, this is a high-quality model that accurately represents current knowledge about TSLP signaling through JAK1/JAK2 to STAT5.</p>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/","title":"6246724f00001645 hyaluronan biosynthetic process  Mouse","text":"<p>Based on my review of the GO-CAM model with ID 6246724f00001645 (titled \"hyaluronan biosynthetic process (Mouse)\"), here's my comprehensive review:</p>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#go-cam-model-review-hyaluronan-biosynthetic-process-mouse","title":"GO-CAM Model Review: Hyaluronan Biosynthetic Process (Mouse)","text":"<p>Model ID: gomodel:6246724f00001645</p>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#overall-structure-and-content","title":"Overall Structure and Content","text":"<p>This model represents the hyaluronan biosynthetic process in mouse, including the key enzymes involved and their relationships. The model includes:</p> <ol> <li>Four hyaluronan synthases (HAS1, HAS2, HAS3) with GO:0050501 (hyaluronan synthase activity)</li> <li>An ABC transporter (Abcc5) with GO:0140359 (ABC-type transporter activity)</li> <li>A hyaluronidase (Cemip) with GO:0004415 (hyalurononglucosaminidase activity)</li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Well-evidenced annotations: The model contains appropriate evidence codes and literature references for most activities.</li> <li>Cellular localization: The model correctly places activities in appropriate cellular locations, with hyaluronan synthases and ABC transporter at the plasma membrane GO:0005886.</li> <li>Causal relationships: The model properly represents the flow of biological activities using causal relationships, showing how the hyaluronan synthases provide input for the transporter activity.</li> <li>Comprehensive representation: The model includes multiple HAS enzymes (HAS1, HAS2, HAS3) which aligns with the literature showing these are three distinct enzymes with slightly different properties but similar functions.</li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Missing cellular location for Cemip activity:</li> <li>The hyalurononglucosaminidase activity by Cemip lacks a cellular location annotation. According to literature, this should occur in a specific cellular compartment.</li> <li> <p>Recommendation: Add an appropriate cellular component annotation for the Cemip activity.</p> </li> <li> <p>Input molecules not fully specified:</p> </li> <li>While Abcc5 has hyaluronic acid listed as a primary input, the HAS enzymes don't have their substrate inputs (UDP-GlcUA and UDP-GlcNAc) explicitly specified.</li> <li> <p>Recommendation: Add primary input annotations for UDP-GlcUA and UDP-GlcNAc for the HAS enzyme activities.</p> </li> <li> <p>Evidence consolidation needed:</p> </li> <li>Some activities have multiple evidence annotations that could be consolidated.</li> <li> <p>Recommendation: Consider consolidating evidence where appropriate to streamline the model.</p> </li> <li> <p>Clarify pathway relationship:</p> </li> <li>The model shows Cemip as part of GO:0030212 (hyaluronan metabolic process) while the other activities are part of GO:0030213 (hyaluronan biosynthetic process).</li> <li> <p>Recommendation: Clarify if this distinction is intentional, as it might be confusing to have both processes represented in what's titled as a biosynthetic process model.</p> </li> <li> <p>Transporter mechanism alignment:</p> </li> <li>Based on PMID:15345330, the model correctly represents the transport role of Abcc5 (Mrp5) in hyaluronan export. This paper provides strong evidence that hyaluronan is exported through an ABC transporter (specifically MRP5), which aligns well with the model.</li> <li>Recommendation: The model is consistent with this research finding.</li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of hyaluronan biosynthesis where: - Hyaluronan is synthesized by HAS enzymes (HAS1, HAS2, HAS3) - The polymer is transported across the plasma membrane by ABC transporters - The model aligns with literature showing that MRP5 (Abcc5) is likely the primary transporter for hyaluronan</p> <p>The model's representation of the sequential activities (synthases \u2192 transporter \u2192 degradation) follows the accepted biological pathway.</p>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model generally follows GO-CAM best practices: - Activities are properly connected with appropriate causal relations - Evidence codes and references are provided for annotations - Protein activities are correctly represented in their cellular context</p> <p>From a curation standpoint, the model follows the practices outlined in the GO-CAM complex annotation guidelines, as individual proteins with known activities are represented separately rather than as a complex.</p>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that accurately represents the hyaluronan biosynthetic process in mouse. With minor improvements to specify cellular locations and inputs for all activities, the model would be fully compliant with best practices and provide a comprehensive view of hyaluronan biosynthesis. The evidence base is strong, drawing from multiple publications that support the represented biological activities and their relationships.</p>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/","title":"6246724f00001700 Hyaluronan catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model (gomodel:6246724f00001700) and the GO-CAM guidelines, here's my evaluation:</p>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#go-cam-review-hyaluronan-catabolic-process-mouse-gomodel6246724f00001700","title":"GO-CAM Review: Hyaluronan catabolic process (Mouse) gomodel:6246724f00001700","text":""},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This model represents the hyaluronan catabolic process in mice, showing the molecular activities involved in hyaluronan degradation from receptor-mediated endocytosis through lysosomal degradation. The model appears to be well-constructed and evidence-based, with appropriate use of causal relationships between activities.</p>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive pathway representation: The model effectively captures the entire process from receptor binding of hyaluronan at the cell surface through transport into lysosomes and subsequent degradation.</p> </li> <li> <p>Well-evidenced annotations: Each activity is supported by appropriate evidence codes and literature references, using a combination of direct assay evidence (ECO:0000314), mutant phenotype evidence (ECO:0000315), and sequence orthology evidence (ECO:0000266).</p> </li> <li> <p>Appropriate cellular localization: The model correctly represents the spatial organization of the pathway, with hyaluronan receptors in membrane rafts (GO:0045121) and degradative enzymes in lysosomes (GO:0005764).</p> </li> <li> <p>Logical causal flow: The causal relationships (RO:0002413 \"provides input for\" and RO:0002629 \"directly positively regulates\") are used appropriately to connect activities in a biologically meaningful sequence.</p> </li> </ol>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#minor-issues-and-suggestions","title":"Minor Issues and Suggestions","text":"<ol> <li> <p>Missing annotation: The activity gomodel:6246724f00001700/6246724f00001716 (Stab2-enabled receptor activity) is annotated as part of \"receptor-mediated endocytosis\" (GO:0006898) rather than the overall \"hyaluronan catabolic process\" (GO:0030214) like most other activities. Consider whether this is intentional or if it should be updated for consistency.</p> </li> <li> <p>Incomplete cellular component annotations: Some activities, particularly those related to receptor-mediated endocytosis (e.g., gomodel:6246724f00001700/6246724f00001707 for Hmmr), lack \"occurs_in\" evidence even though they are annotated to occur in membrane rafts (GO:0045121). Adding supporting evidence would strengthen these annotations.</p> </li> <li> <p>Automated predicate change note: There's a comment noting \"Automated change 2023-03-16: RO:0002213 replaced by RO:0002629.\" This is appropriate as it reflects the updated ontology term usage for direct positive regulation.</p> </li> </ol>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The biological content appears accurate and supported by the cited literature. The model shows:</p> <ol> <li>Four receptors (CD44, HMMR, LYVE1, STAB2) mediating hyaluronan endocytosis</li> <li>Sodium/proton exchangers (SLC9A1, CHP1) regulating HYAL2 activity</li> <li>Sequential degradation of hyaluronan by:</li> <li>HYAL2 (initial degradation)</li> <li>HYAL1 (further degradation in lysosomes)</li> <li>GUSB (beta-glucuronidase activity)</li> <li>HEXA/HEXB (beta-N-acetylhexosaminidase activity)</li> <li>Appropriate transport mechanisms (SLC17A5 for glucuronate transport)</li> </ol>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Consider adding references to some of the causal relationships that lack evidence annotations (many of the RO:0002413 \"provides input for\" relationships).</p> </li> <li> <p>Review the part_of relationship for Stab2 (MGI:MGI:2178743) to determine if it should also be part of GO:0030214 rather than only GO:0006898.</p> </li> <li> <p>Consider adding evidence for the \"occurs_in\" relationships that are currently lacking evidence codes, particularly for the receptor activities in membrane rafts.</p> </li> </ol> <p>Overall, this is a well-constructed GO-CAM model that effectively represents the hyaluronan catabolic process in mice with strong evidence support and appropriate causal relationships between activities.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/","title":"6258b8f300000188 Chondroitin sulfate biosynthetic process 1  chondroitin 6 sulfate proteoglycans  Mouse","text":"<p>Let me review this GO-CAM model based on the information provided. The model describes the chondroitin sulfate biosynthetic process in mouse, focusing on chondroitin 6-sulfate proteoglycans.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#model-summary","title":"Model Summary","text":"<ul> <li>Model ID: gomodel:6258b8f300000188</li> <li>Title: Chondroitin sulfate biosynthetic process 1, chondroitin 6-sulfate proteoglycans (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Source: gomodel:R-HSA-2022870</li> </ul>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#review-of-the-model-structure","title":"Review of the Model Structure","text":"<p>This GO-CAM represents the chondroitin sulfate biosynthetic process (GO:0030206), occurring in the Golgi apparatus (GO:0005794). The model includes multiple proteins involved in this process, with various molecular functions connected by causal relationships.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#key-proteins-and-activities","title":"Key Proteins and Activities","text":"<p>The model includes several key proteins with specific molecular functions:</p> <ol> <li>Chondroitin synthesis enzymes:</li> <li>Csgalnact1 (MGI:MGI:2442354) - glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity (GO:0047238)</li> <li>Csgalnact2 (MGI:MGI:1926002) - glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity (GO:0047238)</li> <li>Chsy1 (MGI:MGI:2681120) - N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity (GO:0050510) and glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity (GO:0047238)</li> <li>Chsy3 (MGI:MGI:1926173) - Similar activities as Chsy1</li> <li>Chpf (MGI:MGI:106576) - Both transferase activities</li> <li> <p>Chpf2 (MGI:MGI:1917522) - N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity (GO:0050510)</p> </li> <li> <p>Sulfotransferases:</p> </li> <li>Chst3 (MGI:MGI:1858224) - chondroitin 6-sulfotransferase activity (GO:0008459)</li> <li>Chst7 (MGI:MGI:1891767) - chondroitin 6-sulfotransferase activity (GO:0008459)</li> </ol>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#causal-flow","title":"Causal Flow","text":"<p>The model represents a clear flow of activities in the biosynthetic pathway: - Initial transferase activities (Csgalnact1, Csgalnact2) provide input for subsequent transferase activities - These lead to the sulfotransferase activities (Chst3, Chst7) at the end of the chain</p> <p>All activities are connected through the \"provides input for\" (RO:0002413) causal relation, which is appropriate for a biosynthetic pathway where the product of one reaction becomes the substrate for the next.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#biological-content-consistency","title":"Biological Content Consistency","text":"<p>The model accurately represents the chondroitin sulfate biosynthetic process as described in the literature. The enzymes involved and their sequential activities in the pathway are well-represented.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<ol> <li> <p>Cellular Component: All activities are correctly assigned to the Golgi apparatus (GO:0005794), which is the known location for chondroitin sulfate biosynthesis.</p> </li> <li> <p>Causal Relations: The model uses appropriate causal relationships (RO:0002413 \"provides input for\") to connect sequential enzymatic activities in the biosynthetic pathway.</p> </li> <li> <p>Evidence: Each activity is supported by evidence codes and literature references, which is excellent practice.</p> </li> <li> <p>Parsimony: The model is well-structured and focuses on the key aspects of the pathway without extraneous elements.</p> </li> </ol>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model includes appropriate evidence codes for the assertions: - ECO:0000314 (direct assay evidence) - ECO:0000315 (mutant phenotype evidence) - ECO:0000316 (genetic interaction evidence) - ECO:0000266 (sequence orthology evidence)</p> <p>Each activity has references to primary literature (PMIDs) supporting the annotations.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#minor-improvement-suggestions","title":"Minor Improvement Suggestions","text":"<ol> <li> <p>Potential Addition: The model could potentially benefit from including the final product of the pathway (chondroitin 6-sulfate proteoglycan) as an output entity, although this is not strictly necessary as the pathway is already well-defined.</p> </li> <li> <p>Complex Representation: Given the collaborative nature of some of these enzymes in the biosynthetic process, considering whether any of these proteins work as a complex might be worth evaluating. However, based on the current evidence represented in the model, the individual representation of each enzyme and its activity appears appropriate.</p> </li> </ol>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model gomodel:6258b8f300000188 is a high-quality representation of the chondroitin sulfate biosynthetic process in mouse. It follows GO-CAM best practices, includes appropriate evidence, and accurately represents the biological pathway with clear causal connections between activities. The model is scientifically sound and does not require significant revisions.</p>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/","title":"6258b8f300000398 Heparan sulfate proteoglycan biosynthetic process  Mouse","text":"<p>Let me now review the GO-CAM model. I'll analyze several aspects of this model.</p>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#review-of-go-cam-model-gomodel6258b8f300000398","title":"Review of GO-CAM Model: gomodel:6258b8f300000398","text":""},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#model-summary","title":"Model Summary","text":"<ul> <li>Title: Heparan sulfate proteoglycan biosynthetic process (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Comment: Sourced from gomodel:R-HSA-2022928</li> </ul>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#overall-structure-and-content-assessment","title":"Overall Structure and Content Assessment","text":"<p>This GO-CAM model represents the heparan sulfate proteoglycan biosynthetic pathway in mouse. The model captures the sequential enzymatic activities involved in heparan sulfate synthesis, starting from nucleotide-sugar transport into the Golgi apparatus through various modification steps including N-deacetylation/N-sulfation, epimerization, and multiple O-sulfation steps.</p>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li>Comprehensive Representation: The model includes all major enzymatic steps in heparan sulfate biosynthesis, including:</li> <li>Nucleotide-sugar transport (Slc35d2)</li> <li>Initial polymerization (Ext1, Ext2)</li> <li>N-deacetylation/N-sulfation (Ndst1-4)</li> <li>Epimerization (Glce)</li> <li> <p>Various sulfotransferase activities (Hs2st1, Hs3st1-6, Hs6st1-3)</p> </li> <li> <p>Proper Cellular Context: All activities are correctly annotated as occurring in the Golgi apparatus (GO:0005794), which is the known site of heparan sulfate biosynthesis.</p> </li> <li> <p>Causal Flow: The model correctly uses the \"provides input for\" (RO:0002413) causal relation to link the sequential enzymatic reactions in the biosynthetic pathway.</p> </li> <li> <p>Evidence Support: Each molecular function annotation has supporting evidence, predominantly from direct assays (ECO:0000314) or sequence orthology (ECO:0000266) with appropriate PMIDs.</p> </li> <li> <p>Process Integration: All activities are correctly integrated into the overall biological process of \"heparan sulfate proteoglycan biosynthetic process\" (GO:0015012).</p> </li> </ol>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing Evidence for Some Annotations:</li> <li>Some cellular location associations (occurs_in GO:0005794) don't have specific evidence codes or references.</li> <li> <p>Some causal associations (RO:0002413) are stated without evidence codes.</p> </li> <li> <p>Potential Redundancy:</p> </li> <li> <p>There are multiple identical activities for some proteins (e.g., MGI:MGI:108050 Ext2 appears to have the same function annotated in multiple nodes with slightly different causal associations).</p> </li> <li> <p>Annotation Detail:</p> </li> <li> <p>For the Slc35d2 transporter (nodes gomodel:6258b8f300000398/6258b8f300000403 and gomodel:6258b8f300000398/6258b8f300000407), there's a minor issue with the evidence code for one \"has_primary_input\" annotation, where \"UniPortKB:Q76EJ3\" should be \"UniProtKB:Q76EJ3\".</p> </li> <li> <p>Completeness Check:</p> </li> <li>While the model captures the major biosynthetic steps, it might be worth considering whether key regulatory aspects of this pathway should be included.</li> </ol>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li>Add Missing Evidence:</li> <li> <p>Provide evidence for all \"occurs_in\" relations and causal associations where currently missing.</p> </li> <li> <p>Fix Typographical Error:</p> </li> <li> <p>Correct \"UniPortKB:Q76EJ3\" to \"UniProtKB:Q76EJ3\" in the evidence for Slc35d2's primary input.</p> </li> <li> <p>Consider Model Simplification:</p> </li> <li> <p>Review instances of multiple nodes for the same protein with identical functions to determine if they can be consolidated for clarity.</p> </li> <li> <p>Review Literature for Updates:</p> </li> <li>This is a well-established pathway, but a check of recent literature might reveal updates to the heparan sulfate biosynthesis pathway that could be incorporated.</li> </ol>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#literature-consistency","title":"Literature Consistency","text":"<p>The model appears generally consistent with established knowledge of heparan sulfate biosynthesis. The enzymatic steps follow the accepted sequence, with the polymerization by EXT enzymes, followed by modification by NDSTs, epimerization by GLCE, and various sulfation steps.</p>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the heparan sulfate proteoglycan biosynthetic process in mouse. The model follows GO-CAM best practices for representing biological pathways, with appropriate molecular functions, cellular locations, and causal relationships. The minor issues noted above could be addressed to further improve the model's quality and clarity.</p> <p>The model structure is parsimonious while still capturing the complexity of this biosynthetic pathway, making it valuable for understanding the molecular details of heparan sulfate proteoglycan biosynthesis.</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/","title":"626b20c100000025 IL9 mediated signaling pathway  Human","text":"<p>Based on my review of the GO-CAM model and relevant guidelines, I'll now provide a comprehensive review of the IL9-mediated signaling pathway model.</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#review-of-go-cam-model-il9-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: IL9-mediated signaling pathway (Human)","text":""},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (ID: gomodel:626b20c100000025) represents the IL9-mediated signaling pathway in humans. The model depicts the cascade from IL9 cytokine binding to its receptor through to the activation of STAT transcription factors.</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway Completeness: The model properly captures the major components of the IL9 signaling pathway, from the extracellular ligand (IL9) to the downstream transcription factors (STAT1, STAT3, STAT5A).</p> </li> <li> <p>Proper Cellular Localization: Each protein is appropriately localized in cellular compartments consistent with their biological roles:</p> </li> <li>IL9 in extracellular space (GO:0005615)</li> <li>Receptors (IL9R, IL2RG) in plasma membrane (GO:0005886)</li> <li>JAK kinases at the cytoplasmic side of the plasma membrane (GO:0031234) </li> <li> <p>STAT proteins in the nucleus (GO:0005634)</p> </li> <li> <p>Appropriate Causal Relationships: The model uses correct causal predicates (RO:0002629 \"directly positively regulates\") to connect activities in the pathway.</p> </li> <li> <p>Consistent with Literature: The pathway depicted is supported by the referenced literature, with each component and relationship having evidence from publications.</p> </li> </ol>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>STAT Transcription Factor Activities: The STAT proteins (STAT1, STAT3, and STAT5A) are annotated with DNA-binding transcription factor activity (GO:0003700), but according to the guidelines, more specific child terms should be used:</li> <li>DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228)</li> <li> <p>DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227)</p> </li> <li> <p>Missing Transcriptional Targets: The STAT transcription factors don't have any specified transcriptional targets (missing \"has input\" relationship). According to the DNA-binding transcription factor activity annotation guidelines, each transcription factor should specify the genes it regulates.</p> </li> <li> <p>Evidence Gap: Some associations lack evidence annotations:</p> </li> <li>STAT5A (P42229) occurs_in nucleus (GO:0005634) is missing evidence</li> <li> <p>There are no causal associations from STAT transcription factors to their downstream targets</p> </li> <li> <p>JAK3 to STAT5A Connection: The model shows JAK3 directly regulating STAT5A, but the evidence for this is cited as PMID:10919676. I couldn't verify this specific interaction from the available information.</p> </li> <li> <p>Protein-Protein Interactions: While the model represents the signaling flow correctly, it might benefit from explicitly modeling the important protein-protein interactions, such as the IL9R-IL2RG complex formation that's crucial for signal transduction.</p> </li> </ol>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The biological pathway depicted is consistent with current understanding of IL9 signaling:</p> <ol> <li> <p>Cytokine-Receptor Binding: IL9 (P15248) correctly binds to and activates IL9R (Q01113), which is supported by PMID:8193355.</p> </li> <li> <p>Co-receptor Activity: The model properly includes IL2RG (common gamma chain) as a co-receptor, which is essential for IL9 signaling, supported by PMID:18829468.</p> </li> <li> <p>JAK-STAT Pathway: The activation of JAK1/JAK3 kinases leading to STAT phosphorylation and nuclear translocation follows the established mechanism of cytokine receptor signaling.</p> </li> <li> <p>Multiple STAT Activation: The model correctly shows that IL9 signaling activates multiple STAT proteins (STAT1, STAT3, and STAT5A), which is consistent with the literature.</p> </li> </ol>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add Specific Transcriptional Targets: Identify and add the key genes regulated by each STAT transcription factor with appropriate evidence.</p> </li> <li> <p>Use More Specific GO Terms: Replace GO:0003700 (DNA-binding transcription factor activity) with more specific child terms based on whether each STAT acts as an activator or repressor.</p> </li> <li> <p>Complete Evidence Annotations: Add evidence for all relationships, particularly for STAT5A's nuclear localization.</p> </li> <li> <p>Model Protein Complex Formation: Consider explicitly modeling the IL9R-IL2RG receptor complex, as this is a critical step in the signaling pathway.</p> </li> <li> <p>Add Downstream Biological Processes: Include the biological processes that are ultimately affected by this signaling pathway (e.g., cell proliferation, differentiation, or immune responses).</p> </li> </ol>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a solid representation of the IL9-mediated signaling pathway in humans. It correctly captures the major components and relationships in the pathway and is generally consistent with both the GO-CAM annotation guidelines and the biological literature. With the recommended improvements, particularly regarding transcriptional targets and more specific annotations, the model would provide an even more comprehensive and accurate representation of this important signaling pathway.</p>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/","title":"626b20c100000185 Glycosaminoglycan biosynthetic process  linker formation  Mouse","text":"<p>Now that I have reviewed the model and relevant literature, I'll provide a comprehensive review of GO-CAM model gomodel:626b20c100000185 \"Glycosaminoglycan biosynthetic process, linker formation (Mouse)\".</p>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#review-of-go-cam-model-626b20c100000185","title":"Review of GO-CAM Model 626b20c100000185","text":""},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model represents the glycosaminoglycan (GAG) biosynthetic process, specifically focusing on the linker formation in mouse (https://bioregistry.io/go.model:626b20c100000185). The model includes 8 key activities (gene products and their functions), all occurring in the Golgi apparatus and contributing to glycosaminoglycan biosynthesis.</p>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#biological-context","title":"Biological Context","text":"<p>Glycosaminoglycans (GAGs) are long unbranched polysaccharides consisting of repeating disaccharide units that are crucial components of proteoglycans. The biosynthesis of GAGs requires a precise sequence of enzymatic activities to form the tetrasaccharide linkage region that connects the GAG chain to the core protein.</p> <p>The model represents the pathway where a series of enzymes, primarily glycosyltransferases, sequentially add sugar residues to build the tetrasaccharide linker (GlcA\u03b21-3Gal\u03b21-3Gal\u03b21-4Xyl\u03b21) that serves as the foundation for subsequent GAG chain extension.</p>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#1-molecular-functions-and-causal-relationships","title":"1. Molecular Functions and Causal Relationships","text":"<p>The model appropriately captures the sequential enzymatic activities in the GAG linker biosynthetic pathway:</p> <ul> <li>UDP-xylose synthase (Uxs1) converts UDP-glucuronate to UDP-xylose</li> <li>Xylosyltransferases (Xylt1 and Xylt2) add xylose to serine residues of the core protein</li> <li>\u03b21,4-galactosyltransferase (B4galt7) transfers galactose to xylose</li> <li>\u03b21,3-galactosyltransferase (B3galt6) adds a second galactose</li> <li>\u03b21,3-glucuronosyltransferases (B3gat1, B3gat2, and B3gat3) add glucuronic acid</li> </ul> <p>The causal flow in the model is correctly represented, reflecting the sequential nature of the pathway:</p> <ul> <li>Uxs1 (UDP-glucuronate decarboxylase) \u2192 Xylt1/Xylt2 (xylosyltransferases)</li> <li>Xylt1/Xylt2 \u2192 B4galt7 (\u03b21,4-galactosyltransferase)</li> <li>B4galt7 \u2192 B3galt6 (\u03b21,3-galactosyltransferase)</li> <li>B3galt6 \u2192 B3gat1/B3gat2/B3gat3 (\u03b21,3-glucuronosyltransferases)</li> </ul> <p>Additionally, the model correctly includes the Slc35b4 transporter, which provides UDP-xylose to the appropriate transferases.</p>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#2-cellular-locations","title":"2. Cellular Locations","text":"<p>All activities are correctly annotated as occurring in the Golgi apparatus (GO:0005794), which is the established location for the biosynthesis of the GAG linker region.</p>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#3-evidence-and-literature-support","title":"3. Evidence and Literature Support","text":"<p>The model is well-supported by literature evidence:</p> <ul> <li>Most functions are backed by experimental evidence codes (ECO:0000314 for direct assay, ECO:0000315 for mutant phenotype)</li> <li>Several activities are supported by sequence orthology evidence (ECO:0000266) with references to human orthologs</li> <li>The research articles cited, including PMID:20809901, support the functional roles assigned to the various enzymes</li> </ul> <p>The use of research from the paper on \u03b21,4-galactosyltransferase 7 (PMID:20809901) is particularly relevant, as it provides detailed biochemical characterization of this crucial enzyme in the pathway.</p>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#4-completeness","title":"4. Completeness","text":"<p>The model comprehensively captures the key steps in the GAG linker biosynthetic pathway:</p> <ul> <li>UDP-xylose synthesis</li> <li>Initial xylosylation of the core protein</li> <li>Sequential addition of the two galactose residues</li> <li>Addition of glucuronic acid to complete the tetrasaccharide linker</li> </ul>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#5-consistency-with-go-cam-best-practices","title":"5. Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ul> <li>Each activity is properly enabled by a specific gene product</li> <li>Activities are correctly situated in cellular contexts (Golgi apparatus)</li> <li>Appropriate causal relationships are used (RO:0002413 - \"provides input for\")</li> <li>All activities are part of the broader biological process (GO:0006024 - glycosaminoglycan biosynthetic process)</li> </ul>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive representation: The model captures all key enzymatic steps in the GAG linker biosynthesis.</p> </li> <li> <p>Well-evidenced assertions: Most activities are supported by experimental evidence with appropriate citations.</p> </li> <li> <p>Clear causal flow: The \"provides input for\" relationships clearly show the sequential nature of the pathway.</p> </li> <li> <p>Detailed molecular functions: Each enzyme is annotated with its specific molecular function using specific GO terms.</p> </li> <li> <p>Taxonomic specificity: The model correctly represents the mouse-specific pathway components.</p> </li> </ol>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Input/output relationships: While the causal relationships between activities are well represented, the model could benefit from explicit representation of the chemical entities (substrates and products) at each step. This would make the specific transformations more transparent.</p> </li> <li> <p>Additional context for Slc35b4: The UDP-xylose transporter Slc35b4 is included, but its precise role in delivering UDP-xylose from the cytosol to the Golgi lumen could be made more explicit through additional annotations.</p> </li> <li> <p>Connection to downstream pathways: The model could potentially be extended to show how the completed linker region connects to the subsequent GAG chain extension processes.</p> </li> </ol>"},{"location":"reviews/626b20c100000185-Glycosaminoglycan_biosynthetic_process__linker_formation__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for glycosaminoglycan biosynthetic process, linker formation in mouse (gomodel:626b20c100000185) is a well-constructed, evidence-based representation of this important biological pathway. It adheres to GO-CAM best practices and accurately represents the sequential enzymatic activities involved in GAG linker biosynthesis.</p> <p>The model successfully illustrates how multiple glycosyltransferases and a transporter work together in the Golgi apparatus to build the tetrasaccharide linker that is essential for proper GAG chain attachment to proteoglycan core proteins. This process is fundamental to proteoglycan biosynthesis and, by extension, to the development and maintenance of connective tissues.</p> <p>Overall, this is a high-quality model that effectively communicates the molecular mechanisms of GAG linker biosynthesis.</p>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/","title":"626b20c100000443 Regulation of gluconeogenesis by TOX4  Mouse","text":"<p>Based on the information gathered, I'll now provide a comprehensive review of the GO-CAM model \"Regulation of gluconeogenesis by TOX4 (Mouse)\" (gomodel:626b20c100000443).</p>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#review-of-go-cam-model-regulation-of-gluconeogenesis-by-tox4-mouse","title":"Review of GO-CAM Model: Regulation of gluconeogenesis by TOX4 (Mouse)","text":""},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#model-overview","title":"Model Overview","text":"<p>GO-CAM Model: 626b20c100000443</p> <p>This model captures the role of TOX4 (Thymocyte selection-associated high mobility group box factor 4) in regulating hepatic glucose production (gluconeogenesis) in mice. The model shows how TOX4 functions as a transcription factor that regulates key gluconeogenic genes (G6pc and Pck1) independent of the insulin receptor pathway, working in parallel with the canonical FoxO1-mediated regulation.</p>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#accuracy-of-model","title":"Accuracy of Model","text":"<ol> <li> <p>Consistency with literature: The model accurately represents the findings from the key publication (PMID:34914893). The paper demonstrates that TOX4 is a gluconeogenic regulator that functions in parallel with FoxO1, and both can independently regulate gluconeogenic genes.</p> </li> <li> <p>Gene/Protein representation: The model correctly identifies the key players:</p> </li> <li>TOX4 (MGI:MGI:1915389) as a DNA-binding transcription activator</li> <li>FOXO1 (MGI:MGI:1890077) as a DNA-binding transcription activator  </li> <li>CREB1 (MGI:MGI:88494) as a DNA-binding transcription activator</li> <li>G6PC1 (MGI:MGI:95607) catalyzing glucose-6-phosphatase activity</li> <li> <p>PCK1 (MGI:MGI:97501) catalyzing phosphoenolpyruvate carboxykinase activity</p> </li> <li> <p>Pathway connectivity: The causal relationships between activities are appropriately modeled using RO:0002407 (positively regulates) to show how the transcription factors regulate the expression of G6pc and Pck1.</p> </li> </ol>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model appropriately captures the parallel regulatory mechanisms of gluconeogenesis through TOX4, FOXO1, and CREB1.</li> <li>The cellular location information is correctly specified (chromatin for transcription factors, endoplasmic reticulum for the gluconeogenic enzymes).</li> <li>The model uses appropriate evidence codes and references to the primary literature.</li> <li>The biological process associations accurately connect the activities to their broader contexts (gluconeogenesis and transcriptional regulation).</li> </ol>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":""},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#transcription-factor-modeling","title":"Transcription Factor Modeling","text":"<p>The model aligns with the \"DNA-binding transcription factor activity annotation guidelines\": 1. The transcription factors (TOX4, FOXO1, CREB1) are correctly annotated with \"DNA-binding transcription activator activity, RNA polymerase II-specific\" (GO:0001228). 2. The cellular component is properly specified as \"chromatin\" (GO:0000785). 3. The biological process is correctly specified as \"positive regulation of transcription by RNA polymerase II\" (GO:0045944). 4. The causal regulation from transcription factors to their target genes uses the appropriate relation (RO:0002407 - positively regulates).</p>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#regulatory-processes","title":"Regulatory Processes","text":"<p>Following the \"Regulation and Regulatory Processes in GO-CAM\" guidelines: 1. The model correctly captures the regulatory relationships between transcription factors and downstream enzyme activities. 2. The model appropriately shows how multiple transcription factors can regulate the same target genes, capturing the parallel regulatory mechanisms described in the paper.</p>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":""},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#1-inclusion-of-upstream-regulators","title":"1. Inclusion of Upstream Regulators","text":"<p>The paper mentions that TOX4 is regulated by dexamethasone and cAMP, and that binding to target genes is decreased by insulin. These upstream regulatory relationships could be included to provide a more complete picture of the pathway.</p>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#2-mechanistic-details","title":"2. Mechanistic Details","text":"<p>The model could be enhanced by including: - The interaction between TOX4 and CREB shown in the paper - The binding of TOX4 to specific regions of the Pck1 promoter (as shown in Figure 4 of the paper) - The role of cAMP in mediating the interaction between CREB and TOX4</p>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#3-feedback-regulation","title":"3. Feedback Regulation","text":"<p>The paper mentions that reduced levels of Gcgr (glucagon receptor) mRNA in TOX4 knockdown liver might contribute to decreased gluconeogenesis. This feedback loop could be incorporated into the model.</p>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#technical-evaluation","title":"Technical Evaluation","text":"<ol> <li> <p>Evidence codes: The model appropriately uses ECO:0000314 (direct assay evidence used in manual assertion) for the TOX4-regulated activities, which is consistent with the experimental evidence in the paper.</p> </li> <li> <p>Metadata: The model contains appropriate provenance information, including the date of creation and contributor ORCID.</p> </li> <li> <p>Automated change: There is a comment noting an \"Automated change 2023-03-16: RO:0002213 replaced by RO:0002407\", suggesting the model has been updated to use the current relation ontology terms.</p> </li> </ol>"},{"location":"reviews/626b20c100000443-Regulation_of_gluconeogenesis_by_TOX4__Mouse_/#conclusions","title":"Conclusions","text":"<p>This GO-CAM model accurately represents the key findings of the paper regarding TOX4's role in regulating hepatic gluconeogenesis. It correctly implements GO-CAM modeling guidelines for transcription factors and regulatory processes.</p> <p>The model could be further enhanced by including additional upstream regulatory details and the interactions between transcription factors mentioned in the paper. However, as it stands, the model provides a clear and accurate representation of TOX4's function in regulating glucose production in mouse liver, showing its parallel and independent operation from the insulin receptor/FoxO1 pathway.</p> <p>The model's significance lies in capturing a novel pathway for glucose production regulation that operates independently of insulin signaling, which has important implications for understanding diabetes pathophysiology and potential therapeutic targets.</p>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/","title":"626b20c100000681 IL10 mediated signaling pathway  Human","text":"<p>Now I have a good understanding of the model and relevant information. Let me provide a thorough review of GO-CAM model gomodel:626b20c100000681 - \"IL10-mediated signaling pathway (Human)\".</p>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#review-of-go-cam-model-il10-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: IL10-mediated signaling pathway (Human)","text":"<p>Model ID: gomodel:626b20c100000681</p>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#overview","title":"Overview","text":"<p>This model represents the IL10-mediated signaling pathway in humans and includes a cascade of molecular interactions starting from IL10 secretion through receptor binding and downstream signaling via JAK1, TYK2, and culminating in STAT3 transcription factor activity.</p>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#model-components","title":"Model Components","text":"<p>The model includes the following main components: 1. IL10 (P22301) as the cytokine ligand 2. IL10RA (Q13651) as the primary receptor 3. IL10RB (Q08334) as the co-receptor 4. JAK1 (P23458) and TYK2 (P29597) as the receptor-associated kinases 5. STAT3 (P40763) as the downstream transcription factor</p>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate Ligand Representation: IL10 is correctly modeled with cytokine activity (GO:0005125) occurring in extracellular space (GO:0005615) and part of the IL10-mediated signaling pathway.</p> </li> <li> <p>Proper Receptor Complex: The model accurately represents both IL10RA (primary receptor) and IL10RB (co-receptor) in the plasma membrane, which aligns with known biology and the Signaling Receptor Activity annotation guidelines.</p> </li> <li> <p>Appropriate Causal Relationships: The model correctly uses \"directly positively regulates\" (RO:0002629) to connect the signaling cascade from ligand to receptor, receptor to co-receptor, and through to downstream components.</p> </li> <li> <p>Biological Process Context: All activities are properly part of the IL10-mediated signaling pathway (GO:0140105), providing consistent biological context.</p> </li> <li> <p>Cellular Compartments: The model correctly specifies the cellular location for each activity (extracellular space for IL10, plasma membrane for receptors, and nucleus for STAT3).</p> </li> </ol>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Protein Phosphorylation: The model indicates that JAK1 and TYK2 have protein tyrosine kinase activity, but does not explicitly show which proteins they phosphorylate. Based on the literature, JAK1 should phosphorylate STAT3, but this relationship isn't clearly indicated in the model.</p> </li> <li> <p>Incomplete Signaling Cascade: The model shows STAT3 as a DNA-binding transcription factor but doesn't indicate what genes it regulates downstream. This makes the model somewhat incomplete from a functional perspective.</p> </li> <li> <p>Receptor Input Specification: According to the signaling receptor activity guidelines, the receptor's input should be the effector protein it regulates (not the ligand). In this model, explicit \"has input\" relationships would improve clarity.</p> </li> <li> <p>Evidence Base: The model relies primarily on two papers (PMID:16982608 and PMID:7543512) for most assertions. While these are appropriate, a broader evidence base would strengthen the model's robustness.</p> </li> </ol>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the canonical IL10 signaling pathway as described in the literature:</p> <ol> <li> <p>IL10 binds to IL10RA, which is consistent with the function of IL10 as an anti-inflammatory cytokine that signals through its receptor.</p> </li> <li> <p>IL10RA activates IL10RB, forming a receptor heterocomplex, which is biologically accurate.</p> </li> <li> <p>The receptor complex activates JAK1 and TYK2 kinases, which is consistent with the established signaling mechanism.</p> </li> <li> <p>STAT3 activation and translocation to the nucleus for transcriptional regulation is the expected outcome of this pathway.</p> </li> </ol> <p>The model is consistent with the known biology of IL10 as described in UniProt: \"IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3. In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators.\"</p>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Signaling Receptor Guidelines: The receptor-ligand relationships follow the guidelines for protein ligand-activated signaling receptors, with the cytokine properly activating the receptor.</p> </li> <li> <p>Causal Relationships: The use of \"directly positively regulates\" is appropriate for the signaling cascade represented.</p> </li> <li> <p>Cellular Context: Each activity has appropriate cellular compartment annotations.</p> </li> </ol>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add Phosphorylation Targets: Explicitly show that JAK1 phosphorylates STAT3, using an appropriate causal relationship.</p> </li> <li> <p>Expand Downstream Effects: Include information about what genes STAT3 regulates to provide a more complete picture of the pathway's functional outcome.</p> </li> <li> <p>Clarify Input Relationships: According to GO-CAM guidelines, explicitly add \"has input\" relationships between receptors and their effector proteins.</p> </li> <li> <p>Include Additional Evidence: Consider incorporating additional supporting literature, especially for the effects of STAT3 activation.</p> </li> </ol>"},{"location":"reviews/626b20c100000681-IL10_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:626b20c100000681 provides a reasonably accurate representation of the IL10-mediated signaling pathway in humans. It follows most GO-CAM best practices and captures key molecular interactions in the pathway. With the suggested improvements, particularly in detailing the downstream effects of STAT3 activation and explicit representation of phosphorylation targets, the model would provide an even more comprehensive representation of this important anti-inflammatory signaling pathway.</p>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/","title":"627d95ee00000024 IL12 mediated signaling pathway  Human","text":"<p>Now that I have gathered the necessary information, I'll provide a comprehensive review of GO-CAM model 627d95ee00000024 (IL12-mediated signaling pathway - Human).</p>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#review-of-go-cam-model-gomodel627d95ee00000024","title":"Review of GO-CAM Model gomodel:627d95ee00000024","text":""},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:627d95ee00000024</li> <li>Title: IL12-mediated signaling pathway (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model represents the IL-12-mediated signaling pathway in humans, which is important for immune function. IL-12 is a heterodimeric cytokine comprised of IL12A (p35) and IL12B (p40) subunits that plays a critical role in regulating T-cell and natural killer cell responses.</p>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#model-structure-and-flow","title":"Model Structure and Flow","text":"<p>The model depicts the following key elements of the IL-12 signaling pathway:</p> <ol> <li>IL-12 cytokine (IL12A/IL12B) binds to its receptor complex (IL12RB1/IL12RB2)</li> <li>Receptor binding activates associated tyrosine kinases (TYK2, JAK2)</li> <li>Activated kinases lead to STAT4 activation</li> <li>STAT4 translocates to the nucleus and acts as a transcription factor</li> </ol>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#detailed-evaluation","title":"Detailed Evaluation","text":""},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#pathway-components-and-connectivity","title":"Pathway Components and Connectivity","text":"<p>The model correctly represents the major components of the IL-12 signaling pathway:</p> <ol> <li>IL-12 Cytokine (represented by two subunits):</li> <li>IL12A (UniProtKB:P29459) with protein binding and cytokine activity</li> <li> <p>IL12B (UniProtKB:P29460) with cytokine activity</p> </li> <li> <p>IL-12 Receptor Complex:</p> </li> <li>IL12RB1 (UniProtKB:P42701) with interleukin-12 receptor activity</li> <li> <p>IL12RB2 (UniProtKB:Q99665) with coreceptor activity</p> </li> <li> <p>Tyrosine Kinases:</p> </li> <li>TYK2 (UniProtKB:P29597) with protein tyrosine kinase activity</li> <li> <p>JAK2 (UniProtKB:O60674) with protein tyrosine kinase activity</p> </li> <li> <p>Transcription Factor:</p> </li> <li>STAT4 (UniProtKB:Q14765) with DNA-binding transcription factor activity</li> </ol>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal associations in the model use appropriate predicates for representing signaling flow:</p> <ul> <li>IL12A and IL12B proteins directly positively regulate (RO:0002629) the receptor activities</li> <li>IL12RB1 and IL12RB2 directly positively regulate (RO:0002629) the tyrosine kinase activities</li> <li>JAK2 directly positively regulates (RO:0002629) STAT4 activity</li> </ul>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#subcellular-localization","title":"Subcellular Localization","text":"<p>The model correctly localizes the activities to appropriate cellular compartments:</p> <ul> <li>IL12A/IL12B proteins in extracellular space (GO:0005615)</li> <li>IL12RB1/IL12RB2 at the plasma membrane (GO:0005886)</li> <li>TYK2 at the cytoplasmic side of plasma membrane (GO:0009898)</li> <li>JAK2 at the cytoplasmic side of plasma membrane (extrinsic component, GO:0031234)</li> <li>STAT4 in the nucleus (GO:0005634)</li> </ul>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>The model uses appropriate evidence codes and references from the literature: - Most associations are supported by experimental evidence (ECO:0000314 - direct assay evidence) - Primary references include PMID:7528775, PMID:10899108, PMID:7584494, and PMID:8943050 - The model has proper provenance with contributor identification</p>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#quality-control-issues","title":"Quality Control Issues","text":""},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#1-missing-causal-association","title":"1. Missing Causal Association","text":"<p>One of the causal associations has missing evidence: <pre><code>{\"type\":\"CausalAssociation\",\"evidence\":[],\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:627d95ee00000024/62900b6400000186\"}\n</code></pre></p> <p>This appears to be a redundant causal association between IL12A (P29459) and IL12RB1 (P42701) that lacks evidence. The same causal relationship is already represented with proper evidence from PMID:7584494, so this appears to be a duplication error.</p>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#2-incorrect-reference-format","title":"2. Incorrect Reference Format","text":"<p>One reference appears to be incorrectly formatted: <pre><code>\"evidence\":[{\"term\":\"ECO:0000314\",\"reference\":\" 7638186\",\"provenances\":[{\"contributor\":\"https://orcid.org/0000-0001-7646-0052\",\"date\":\"2022-05-30\"}]}]\n</code></pre></p> <p>The PMID is formatted with a leading space instead of the proper \"PMID:\" prefix.</p>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#3-duplicate-causal-associations","title":"3. Duplicate Causal Associations","text":"<p>The model contains duplicate causal associations: <pre><code>{\n\"type\":\"CausalAssociation\",\"evidence\":[{\"term\":\"ECO:0000314\",\"reference\":\"PMID:7584494\",\"provenances\":[{\"contributor\":\"https://orcid.org/0000-0001-7646-0052\",\"date\":\"2022-05-30\"}]}],\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:627d95ee00000024/62900b6400000186\"\n},\n{\n\"type\":\"CausalAssociation\",\"evidence\":[],\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:627d95ee00000024/62900b6400000186\"\n},\n{\n\"type\":\"CausalAssociation\",\"evidence\":[{\"term\":\"ECO:0000314\",\"reference\":\"PMID:7584494\",\"provenances\":[{\"contributor\":\"https://orcid.org/0000-0001-7646-0052\",\"date\":\"2022-05-30\"}]},{\"term\":\"ECO:0000314\",\"reference\":\"PMID:7584494\",\"provenances\":[{\"contributor\":\"https://orcid.org/0000-0001-7646-0052\",\"date\":\"2022-05-30\"}]}],\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:627d95ee00000024/62900b6400000186\"}\n</code></pre> This creates unnecessary redundancy in the model.</p>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the biological understanding of the IL-12 signaling pathway as described in the literature:</p> <ol> <li>The heterodimeric nature of IL-12 (IL12A/IL12B) is correctly represented</li> <li>The receptor complex (IL12RB1/IL12RB2) and its binding to IL-12 is properly modeled</li> <li>The recruitment and activation of JAK2 and TYK2 kinases is accurately depicted</li> <li>The activation of STAT4 and its nuclear translocation for transcriptional activity is correct</li> </ol> <p>This is consistent with the information from PMID:7528775, which describes how IL-12 activates JAK2 and TYK2 for signal transduction, and PMID:8943050, which characterizes the functional IL-12 receptor complex composed of IL12RB1 and IL12RB2.</p>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows the GO-CAM guidelines for representing complexes as described in \"How to annotate complexes in GO-CAM\":</p> <ol> <li>The IL-12 cytokine is represented as separate subunits (IL12A and IL12B) with their respective activities, as appropriate when individual subunit activities are known</li> <li>The receptor components (IL12RB1 and IL12RB2) are similarly represented as separate entities with their specific activities</li> <li>The causality relationships between components maintain proper biological sequence</li> </ol>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Remove redundant causal associations: The duplicate and empty evidence causal associations should be removed</p> </li> <li> <p>Fix reference format: The reference to PMID:7638186 should be properly formatted with the \"PMID:\" prefix</p> </li> <li> <p>Consider adding phosphorylation details: The model could be enhanced by explicitly representing the phosphorylation events that occur during signaling, such as the phosphorylation of STAT4 by JAK2</p> </li> <li> <p>Add downstream gene expression effects: The model could be extended to include some of the downstream genes regulated by STAT4, particularly those involved in T-helper cell differentiation</p> </li> <li> <p>Potentially include negative regulation components: IL-12 signaling is regulated by various mechanisms, and including negative regulators could provide a more complete picture of the pathway</p> </li> </ol>"},{"location":"reviews/627d95ee00000024-IL12_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:627d95ee00000024 is an accurate and well-structured representation of the IL-12 signaling pathway in humans. It correctly captures the key components, their subcellular localization, and the causal relationships between them. The model is well-supported by experimental evidence from the literature and follows GO-CAM best practices for representing signaling pathways.</p> <p>Despite a few minor issues with redundant associations and a formatting error in one reference, the model provides a clear and biologically accurate depiction of IL-12 signaling. With the suggested improvements, it could serve as an excellent reference model for immunology research and teaching purposes.</p>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/","title":"627d95ee00000044 3  phosphoadenosine 5  phosphosulfate biosynthetic process  Mouse","text":"<p>Based on the information I've gathered, let me now provide a comprehensive review of the GO-CAM model \"627d95ee00000044\":</p>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#review-of-go-cam-model-627d95ee00000044","title":"Review of GO-CAM Model: 627d95ee00000044","text":""},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process (Mouse) Taxon: NCBITaxon:10090 (Mouse) Status: Production Source: Derived from gomodel:R-HSA-174362</p>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#model-description","title":"Model Description","text":"<p>This GO-CAM model represents the 3'-phosphoadenosine 5'-phosphosulfate (PAPS) biosynthetic and transport processes in mice. PAPS is an essential high-energy sulfate donor required for sulfation of carbohydrates, proteins, and other molecules. The model includes both PAPS synthesis activities and PAPS transport activities, depicting how sulfate is incorporated into metabolic pathways.</p>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#key-components-of-the-model","title":"Key Components of the Model","text":"<p>The model includes: 1. PAPS biosynthesis enzymes (Papss1 and Papss2) 2. Sulfate transporters at the plasma membrane (Slc26a1 and Slc26a2) 3. PAPS transporters at the Golgi membrane (Slc35b2 and Slc35b3)</p>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#molecular-activities-depicted","title":"Molecular Activities Depicted:","text":"<ul> <li>Sulfate adenylyltransferase (ATP) activity (GO:0004781)</li> <li>Adenylylsulfate kinase activity (GO:0004020)</li> <li>Sulfate transmembrane transporter activity (GO:0015116)</li> <li>3'-phosphoadenosine 5'-phosphosulfate transmembrane transporter activity (GO:0046964)</li> </ul>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#anatomical-contexts","title":"Anatomical Contexts:","text":"<ul> <li>Cytosol (GO:0005829)</li> <li>Plasma membrane (GO:0005886)</li> <li>Golgi membrane (GO:0000139)</li> </ul>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#pathway-flow-analysis","title":"Pathway Flow Analysis","text":"<p>The model accurately represents the PAPS biosynthesis pathway with the following logical flow:</p> <ol> <li>Extracellular sulfate is transported into the cell by sulfate transmembrane transporters (Slc26a1 and Slc26a2) at the plasma membrane</li> <li>In the cytosol, Papss1 and Papss2 proteins perform both sulfate adenylyltransferase and adenylylsulfate kinase activities</li> <li>The synthesized PAPS is then transported into the Golgi lumen by PAPS transporters (Slc35b2 and Slc35b3)</li> </ol> <p>The causal relationships are represented using the 'provides input for' (RO:0002413) relation, showing how the activities flow from one to another in the pathway.</p>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by experimental evidence from multiple publications, including direct assays (ECO:0000314) and mutant phenotype evidence (ECO:0000315). Key references include: - PMID:7493984 (adenylyltransferase activity evidence) - PMID:9545271 (adenylyltransferase activity evidence) - PMID:20011239 (PAPS transporter evidence) - PMID:15703192 (sulfate transporter evidence) - PMID:20160351 (sulfate transporter evidence)</p> <p>Evidence for localization in some cases is based on sequence orthology (ECO:0000266), which is appropriate when direct evidence is not available for the mouse proteins.</p>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#model-strengths","title":"Model Strengths:","text":"<ol> <li>Accurate representation of the PAPS biosynthetic pathway</li> <li>Clear causal relationships between activities</li> <li>Good use of evidence codes</li> <li>Proper cellular component annotations</li> <li>Biologically plausible connections between activities</li> </ol>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Dual Function Representation: Both Papss1 and Papss2 have dual enzymatic functions (adenylyltransferase and kinase activities). While this is represented in the model by having separate activities for each function, there could be more clarity about how these functions are sequentially related within the same protein.</p> </li> <li> <p>Complex Representation: It's not clear if any of these activities occur as part of a protein complex. Based on the \"How to annotate complexes in GO-CAM\" document, if these activities occur in complexes, the model should either identify the specific subunit carrying the activity or use a GO complex term if the specific subunit is unknown.</p> </li> <li> <p>Process Context: While the individual activities are part of the 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process (GO:0050428), it would be helpful to place this process in a broader biological context (e.g., its role in sulfation of specific biomolecules).</p> </li> </ol>"},{"location":"reviews/627d95ee00000044-3__phosphoadenosine_5__phosphosulfate_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The model gomodel:627d95ee00000044 is a high-quality representation of the PAPS biosynthetic pathway in mouse. It correctly depicts the flow of sulfate from extracellular uptake through intracellular conversion to PAPS and its transport to the Golgi where it serves as a sulfate donor.</p> <p>The model follows GO-CAM best practices regarding activity representation, causal relationships, and evidence attribution. The few minor improvements suggested above would make the model even more informative, particularly in helping users understand the relationship between the dual activities of the Papss proteins and the broader biological context of PAPS biosynthesis.</p> <p>Overall, this is a biologically accurate and well-constructed GO-CAM model that effectively captures the key aspects of PAPS biosynthesis and transport.</p>"},{"location":"reviews/627d95ee00000275-Heparan_sulfate_proteoglycan_catabolic_process__Mouse_/","title":"627d95ee00000275 Heparan sulfate proteoglycan catabolic process  Mouse","text":"<p>Based on my review of GO-CAM model 627d95ee00000275 \"Heparan sulfate proteoglycan catabolic process (Mouse)\" and relevant GO-CAM guidelines, here is my assessment:</p>"},{"location":"reviews/627d95ee00000275-Heparan_sulfate_proteoglycan_catabolic_process__Mouse_/#go-cam-model-review-summary","title":"GO-CAM Model Review Summary","text":""},{"location":"reviews/627d95ee00000275-Heparan_sulfate_proteoglycan_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>The model represents the heparan sulfate proteoglycan catabolic process in mouse (NCBITaxon:10090). It shows a sequential enzymatic pathway for the degradation of heparan sulfate proteoglycans, primarily taking place in the lysosomal lumen (GO:0043202).</p>"},{"location":"reviews/627d95ee00000275-Heparan_sulfate_proteoglycan_catabolic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model thoroughly captures the sequential enzymatic steps involved in heparan sulfate proteoglycan catabolism, with appropriate molecular functions and cellular locations.</p> </li> <li> <p>Appropriate causal relationships: The model correctly uses RO:0002413 \"provides input for\" to connect the sequential enzymatic activities in a metabolic pathway, which aligns with GO-CAM best practices.</p> </li> <li> <p>Well-evidenced annotations: Most activities have appropriate evidence codes and literature references (PMIDs) supporting the annotations.</p> </li> <li> <p>Correct cellular compartmentalization: Most activities are properly located in the lysosomal lumen (GO:0043202), which is biologically accurate for this catabolic process.</p> </li> <li> <p>Logical flow of activities: The model shows a coherent progression of enzymatic activities that reflects the known biology of heparan sulfate catabolism.</p> </li> </ol>"},{"location":"reviews/627d95ee00000275-Heparan_sulfate_proteoglycan_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing evidence for some annotations: Some activities lack complete evidence for cellular location or biological process. For example:</li> <li>Activity gomodel:627d95ee00000275/627d95ee00000302 (beta-galactosidase activity) lacks evidence for both occurs_in and part_of relations</li> <li> <p>Activity gomodel:627d95ee00000275/627d95ee00000296 lacks evidence for occurs_in relation</p> </li> <li> <p>Upstream process representation: The model includes receptor-mediated endocytosis (GO:0006898) at the plasma membrane, which is appropriately connected to the lysosomal degradation process. However, the transition between these compartments could be more explicitly modeled to show how the proteoglycans move from the cell surface to lysosomes.</p> </li> <li> <p>Incomplete biological process annotation: Some activities are not explicitly annotated as being part of the heparan sulfate proteoglycan catabolic process (GO:0030200).</p> </li> </ol>"},{"location":"reviews/627d95ee00000275-Heparan_sulfate_proteoglycan_catabolic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The biological content appears accurate and well-supported by literature evidence. The model correctly represents:</p> <ol> <li>The initial receptor-mediated endocytosis of heparan sulfate proteoglycans via Syndecan-1 (Sdc1)</li> <li>The processing by cathepsin L (Ctsl) that activates heparanase (Hpse)</li> <li>The sequential enzymatic degradation by various enzymes:</li> <li>L-iduronidase (Idua)</li> <li>N-sulfoglucosamine sulfohydrolase (Sgsh)</li> <li>Heparan-alpha-glucosaminide N-acetyltransferase (Hgsnat)</li> <li>Alpha-N-acetylglucosaminidase (Naglu)</li> <li>Iduronate-2-sulfatase (Ids)</li> <li>Beta-glucuronidase (Gusb)</li> <li>Beta-galactosidase (Glb1)</li> </ol>"},{"location":"reviews/627d95ee00000275-Heparan_sulfate_proteoglycan_catabolic_process__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add missing evidence: Complete the evidence fields for activities where they are missing, particularly for cellular locations and biological processes.</p> </li> <li> <p>Consider adding transport steps: The model could benefit from explicitly showing how heparan sulfate proteoglycans are transported from the plasma membrane to lysosomes.</p> </li> <li> <p>Add part_of relations: Ensure all activities are explicitly annotated as part of the heparan sulfate proteoglycan catabolic process where biologically appropriate.</p> </li> <li> <p>Review enzyme substrates and products: While the \"provides input for\" relations correctly show the order of enzymatic reactions, it might be helpful to explicitly annotate the specific substrates and products for each enzyme to enhance the model's clarity.</p> </li> </ol>"},{"location":"reviews/627d95ee00000275-Heparan_sulfate_proteoglycan_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the heparan sulfate proteoglycan catabolic process in mouse. The model follows GO-CAM best practices for representing metabolic pathways and has strong literature support. With a few minor improvements to complete missing evidence and annotations, this model would serve as an excellent reference for understanding this important catabolic process.</p>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/","title":"627d95ee00000472 IL15 signaling pathway  Human","text":"<p>Based on the information gathered, I will now provide a comprehensive review of the GO-CAM model \"IL15 signaling pathway (Human)\" (gomodel:627d95ee00000472).</p>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#review-of-il-15-signaling-pathway-go-cam-model-gomodel627d95ee00000472","title":"Review of IL-15 Signaling Pathway GO-CAM Model (gomodel:627d95ee00000472)","text":""},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model gomodel:627d95ee00000472 represents the IL-15 signaling pathway in humans. The model captures the signaling cascade initiated by IL-15 (interleukin-15), proceeding through receptor binding, JAK activation, and eventually leading to STAT transcription factor activity.</p>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#pathway-structure-assessment","title":"Pathway Structure Assessment","text":"<p>The model follows a logical signaling flow starting with: 1. IL-15 cytokine activity (P40933) 2. IL-15 receptor binding (Q13261)  3. Co-receptor activity (P14784, P31785) 4. JAK activation (P23458, P52333) 5. STAT transcription factor activity (P40763, P42229)</p> <p>This structure correctly represents the biological mechanism of IL-15 signaling according to the literature and follows the GO-CAM guidelines for signaling receptor activity.</p>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#correctness-of-protein-activities-and-functions","title":"Correctness of Protein Activities and Functions","text":"<p>I've verified each protein in the model against UniProt data and literature references:</p> <ol> <li> <p>IL-15 (P40933): Correctly annotated with \"cytokine activity\" (GO:0005125) and location in \"extracellular space\" (GO:0005615). The evidence (PMID:9097905) supports IL-15 as a secreted cytokine.</p> </li> <li> <p>IL-15RA (Q13261): Correctly annotated with \"interleukin-15 receptor activity\" (GO:0042010) and location at \"cell surface\" (GO:0009986). The evidence (PMID:15123770) confirms IL-15RA is expressed on cell surfaces and is involved in IL-15 receptor activity.</p> </li> <li> <p>IL-2RB/CD122 (P14784) and IL-2RG/CD132 (P31785): Both correctly annotated with \"coreceptor activity\" (GO:0015026) and location in \"plasma membrane\" (GO:0005886), which is supported by the literature.</p> </li> <li> <p>JAK1 (P23458) and JAK3 (P52333): Both appropriately annotated with \"protein tyrosine kinase activity\" (GO:0004713) and the correct subcellular location.</p> </li> <li> <p>STAT3 (P40763) and STAT5A (P42229): Both correctly annotated with \"DNA-binding transcription factor activity\" (GO:0003700), with STAT5A correctly located in the nucleus (GO:0005634).</p> </li> </ol>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#causal-relationships-assessment","title":"Causal Relationships Assessment","text":"<p>The model uses the relation \"directly positively regulates\" (RO:0002629) for all causal associations, which is appropriate based on the GO-CAM guidelines for signaling pathways. The flow of causal relationships is biologically accurate:</p> <ol> <li>IL-15 \u2192 IL-15RA (direct positive regulation)</li> <li>IL-15RA \u2192 IL-2RB and IL-2RG (direct positive regulation)</li> <li>IL-2RB \u2192 JAK1 (direct positive regulation)</li> <li>IL-2RG \u2192 JAK3 (direct positive regulation)</li> <li>JAK1 \u2192 STAT3 (direct positive regulation)</li> <li>JAK3 \u2192 STAT5A (direct positive regulation)</li> </ol> <p>This signaling cascade is consistent with the literature, particularly PMID:7568001 which confirms JAK1/JAK3 activation and subsequent STAT3/STAT5 phosphorylation.</p>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#evidence-evaluation","title":"Evidence Evaluation","text":"<p>The model uses appropriate evidence codes and references: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000304 (author statement supported by traceable reference) - ECO:0000305 (curator inference used in manual assertion)</p> <p>The cited papers including PMID:8026467, PMID:9097905, PMID:15123770, and PMID:7568001 appropriately support the annotated functions and relationships.</p>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows the GO-CAM best practices for representing signaling pathways:</p> <ol> <li> <p>Receptor-ligand representation: IL-15 is correctly annotated as a cytokine that directly positively regulates its receptor (IL-15RA), which aligns with the \"Signaling receptor activity annotation guidelines.\"</p> </li> <li> <p>Receptor complex representation: The receptor complex of IL-15RA, IL-2RB, and IL-2RG is appropriately modeled with each component having its own molecular function and location, following the guidelines for \"How to annotate complexes in GO-CAM.\"</p> </li> <li> <p>Part-of relationships: All activities are correctly annotated as \"part_of\" the \"interleukin-15-mediated signaling pathway\" (GO:0035723).</p> </li> <li> <p>Compartmentalization: The model correctly represents subcellular locations for each protein, such as IL-15 in \"extracellular space,\" receptors at the \"cell surface\"/\"plasma membrane,\" and transcription factors in the \"nucleus.\"</p> </li> </ol>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>Although the model is generally well-constructed, there are a few areas that could be improved:</p> <ol> <li> <p>Redundant causal associations: In the IL-2RB (P14784) activity, there appear to be two identical causal associations to IL-2RG (P31785), one with evidence and one without. This redundancy could be eliminated.</p> </li> <li> <p>Downstream effects: The model could be extended to include the downstream transcriptional effects of STAT3 and STAT5A activation, showing which genes are regulated to complete the signaling picture.</p> </li> <li> <p>Additional co-regulation: Based on PMID:7568001, there could be additional cross-regulation between JAKs and STATs that isn't fully represented in the current model.</p> </li> </ol>"},{"location":"reviews/627d95ee00000472-IL15_signaling_pathway__Human_/#summary","title":"Summary","text":"<p>The GO-CAM model gomodel:627d95ee00000472 for the IL-15 signaling pathway is biologically accurate and follows GO-CAM best practices. The model properly represents the flow of IL-15 signaling from cytokine binding to transcription factor activation with appropriate molecular functions, cellular locations, and causal relationships. The minor improvements suggested could enhance the model's completeness but do not detract from its overall quality and accuracy.</p> <p>The model successfully captures the key steps in IL-15 signaling, which is important for understanding immune cell regulation and has implications for understanding conditions like rheumatoid arthritis and potential therapeutic applications of IL-15 in cancer treatment.</p>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/","title":"627d95ee00000757 Regulation of CGAS activity by ZDHHC18  Human","text":"<p>Based on the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model gomodel:627d95ee00000757 \"Regulation of CGAS activity by ZDHHC18 (Human)\".</p>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#review-of-go-cam-model-regulation-of-cgas-activity-by-zdhhc18-human","title":"Review of GO-CAM Model: Regulation of CGAS activity by ZDHHC18 (Human)","text":""},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#model-information","title":"Model Information","text":"<ul> <li>Model ID: gomodel:627d95ee00000757</li> <li>Title: Regulation of CGAS activity by ZDHHC18 (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the regulation of cyclic GMP-AMP synthase (cGAS) activity by the protein palmitoyltransferase ZDHHC18 in humans. The model shows a negative regulatory relationship where ZDHHC18's palmitoyltransferase activity directly negatively regulates cGAS's double-stranded DNA binding activity, which in turn directly positively regulates cGAS's molecular condensate scaffold activity.</p>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#model-structure","title":"Model Structure","text":"<p>The model includes three activities:</p> <ol> <li>ZDHHC18 protein-cysteine S-palmitoyltransferase activity:</li> <li>Enabled by: UniProtKB:Q9NUE0 (ZDHHC18)</li> <li>Occurs in: GO:0005794 (Golgi apparatus)</li> <li>Part of: GO:0160049 (negative regulation of cGAS/STING signaling pathway)</li> <li> <p>Causal relationship: RO:0002630 (directly negatively regulates) \u2192 cGAS DNA binding activity</p> </li> <li> <p>cGAS double-stranded DNA binding activity:</p> </li> <li>Enabled by: UniProtKB:Q8N884 (cGAS)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0140896 (cGAS/STING signaling pathway)</li> <li> <p>Causal relationship: RO:0002629 (directly positively regulates) \u2192 cGAS molecular condensate scaffold activity</p> </li> <li> <p>cGAS molecular condensate scaffold activity:</p> </li> <li>Enabled by: UniProtKB:Q8N884 (cGAS)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0140896 (cGAS/STING signaling pathway)</li> </ol>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#evidence","title":"Evidence","text":"<p>The model is supported by experimental evidence from two publications: 1. PMID:35438208 - Evidence for ZDHHC18's palmitoyltransferase activity and its regulatory effect on cGAS 2. PMID:32912999 - Evidence for cGAS's molecular condensate scaffold activity</p>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#biological-context","title":"Biological Context","text":"<p>Based on the literature and UniProt entries:</p> <ol> <li> <p>ZDHHC18 is a palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates, including cGAS. It acts as a negative regulator of the cGAS-STING pathway by mediating palmitoylation and inactivation of cGAS.</p> </li> <li> <p>cGAS is a key DNA sensor in innate immunity. Upon binding to cytosolic double-stranded DNA, cGAS forms liquid-like phase-separated condensates (represented by the molecular condensate scaffold activity) which facilitate its enzymatic activity to produce cyclic GMP-AMP (cGAMP). This second messenger then activates the STING pathway, leading to type I interferon production.</p> </li> <li> <p>The model captures how ZDHHC18 negatively regulates cGAS activity through palmitoylation, specifically at Cys-474 of cGAS (as indicated in the UniProt entry), which impairs DNA-binding and prevents its activation.</p> </li> </ol>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#assessment-of-model-quality","title":"Assessment of Model Quality","text":""},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Accurate representation of biological knowledge: The model correctly represents the negative regulatory relationship between ZDHHC18 and cGAS, which is supported by the literature.</p> </li> <li> <p>Appropriate use of GO terms: The molecular functions and cellular locations are appropriate for the proteins involved.</p> </li> <li> <p>Correct causal relationships: The model uses appropriate causal predicates (RO:0002630 for negative regulation and RO:0002629 for positive regulation).</p> </li> <li> <p>Evidence-based: All activities and relationships are supported by published experimental evidence.</p> </li> </ol>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Molecular mechanism details: The model could benefit from including information about the specific site of palmitoylation on cGAS (Cys-474) that ZDHHC18 targets.</p> </li> <li> <p>Complete pathway representation: The model captures the initial regulatory events but doesn't extend to the downstream consequences of cGAS inhibition on the STING pathway and type I interferon production.</p> </li> <li> <p>Additional activities: The model doesn't include the cyclic GMP-AMP synthase activity of cGAS (GO:0061501), which is the primary enzymatic function affected by this regulation.</p> </li> </ol>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by: - Using appropriate GO terms for molecular functions - Correctly using causal relationship predicates - Properly representing cellular locations of activities - Including evidence from the literature - Maintaining a parsimonious structure that is easy to understand</p>"},{"location":"reviews/627d95ee00000757-Regulation_of_CGAS_activity_by_ZDHHC18__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Regulation of CGAS activity by ZDHHC18 (Human)\" provides an accurate representation of how ZDHHC18 negatively regulates cGAS activity through its palmitoyltransferase activity. The model is well-structured, evidence-based, and follows GO-CAM best practices. It could be enhanced by including more details about the specific palmitoylation site and downstream effects on the cGAS-STING signaling pathway. Overall, this is a high-quality model that effectively captures an important regulatory mechanism in innate immunity.</p>"},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/","title":"627d95ee00000909 Regulation of CGAS by PCBP2  Human","text":"<p>Based on all the information I've gathered, I will now provide a detailed review of the GO-CAM model gomodel:627d95ee00000909 which represents \"Regulation of CGAS by PCBP2 (Human)\".</p>"},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#review-of-go-cam-model-627d95ee00000909-regulation-of-cgas-by-pcbp2-human","title":"Review of GO-CAM Model: 627d95ee00000909 - Regulation of CGAS by PCBP2 (Human)","text":""},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model describes the regulatory mechanism by which PCBP2 (Poly(rC)-binding protein 2) negatively regulates cGAS (Cyclic GMP-AMP synthase) activity in human cells. The model consists of three activities:</p> <ol> <li>PCBP2 protein binding activity (GO:0005515) that directly negatively regulates cGAS</li> <li>cGAS molecular condensate scaffold activity (GO:0140693)</li> <li>cGAS 2',3'-cyclic GMP-AMP synthase activity (GO:0061501)</li> </ol> <p>All these activities are part of the cGAS/STING signaling pathway (GO:0140896) with the first activity also being part of negative regulation of cGAS/STING signaling pathway (GO:0160049).</p>"},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#scientific-assessment","title":"Scientific Assessment","text":"<p>The model accurately represents the findings from the primary literature (PMID:35322803), which demonstrates that PCBP2 negatively regulates cGAS by: 1. Directly interacting with cGAS 2. Preventing cGAS condensation (phase separation) 3. Reducing cGAS enzymatic activity</p> <p>This interaction prevents excessive immune activation by maintaining homeostatic control of the cGAS-STING signaling pathway.</p> <p>The publication provides strong experimental evidence for this interaction, including co-immunoprecipitation experiments, in vitro binding assays, and functional assays showing that PCBP2 overexpression reduces cGAS-mediated interferon production while PCBP2 deficiency enhances it.</p>"},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#model-structure-and-annotation-assessment","title":"Model Structure and Annotation Assessment","text":""},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#strengths","title":"Strengths:","text":"<ol> <li>The model correctly uses \"directly negatively regulates\" (RO:0002630) for the relationship between PCBP2 and cGAS activities</li> <li>The protein binding activity of PCBP2 is appropriately linked to its regulatory function</li> <li>The model captures both the molecular condensate scaffold activity and the enzymatic activity of cGAS</li> <li>The evidence is properly cited with references to the primary literature (PMID:35322803)</li> <li>The model captures the correct biological context (cGAS/STING signaling pathway)</li> </ol>"},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Redundant causal links: The model contains duplicate causal associations from PCBP2 to cGAS molecular condensate scaffold activity. This represents a technical error in the model structure.</li> <li> <p>Recommendation: Remove one of the duplicate \"directly negatively regulates\" (RO:0002630) links between PCBP2 and cGAS activities.</p> </li> <li> <p>Molecular Details: While the model correctly shows that PCBP2 inhibits cGAS, it could more specifically represent the mechanism of inhibition via preventing phase separation.</p> </li> <li> <p>Recommendation: Consider adding more details about the mechanism of inhibition, such as specifying that PCBP2 binds to the C-terminal domain of cGAS to prevent its condensation.</p> </li> <li> <p>Input/Output Relationships: The model doesn't explicitly represent the relationship between cGAS's scaffold activity and its enzymatic activity.</p> </li> <li> <p>Recommendation: Consider adding a causal link between the molecular condensate scaffold activity (GO:0140693) and the 2',3'-cyclic GMP-AMP synthase activity (GO:0061501) of cGAS, as the paper shows that phase separation/condensation is important for cGAS enzymatic activity.</p> </li> <li> <p>Biological Context: The model accurately places activities in the cGAS/STING signaling pathway but could further specify the context of DNA-sensing.</p> </li> <li> <p>Recommendation: Consider adding information about DNA binding as an input to cGAS activities to more completely represent the biological context.</p> </li> <li> <p>Additional Insights from Other Papers: The second paper (PMID:33542149) provides insights about regulation of cGAS during mitosis that could enhance the model.</p> </li> <li>Recommendation: If expanding the model, consider adding information about how chromatin tethering and phosphorylation regulate cGAS activity during the cell cycle.</li> </ol>"},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#compliance-with-go-cam-standards","title":"Compliance with GO-CAM Standards","text":"<p>The model generally follows GO-CAM annotation standards for regulatory processes. The use of \"directly negatively regulates\" is appropriate given the direct physical interaction between PCBP2 and cGAS shown in the paper.</p> <p>According to the \"WIP - Regulation and Regulatory Processes in GO-CAM\" guidelines, regulatory activities should capture the specific mechanism, which this model does by representing PCBP2's protein binding activity as the regulatory mechanism.</p>"},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that accurately captures the findings from the primary literature about PCBP2's role in regulating cGAS activity. The main area for improvement is the technical error of duplicate causal links. Additionally, the model could be enriched with more specific details about the molecular mechanism of inhibition, though this would be considered an enhancement rather than a necessary correction.</p> <p>The model is biologically sound, with activities assigned to the correct gene products and appropriate causal relationships between activities. The evidence is properly cited, and the biological process context is accurate.</p>"},{"location":"reviews/627d95ee00000909-Regulation_of_CGAS_by_PCBP2__Human_/#summary","title":"Summary","text":"<p>This GO-CAM model provides a valuable representation of a negative regulatory mechanism in the cGAS/STING signaling pathway, which is important for innate immune responses against DNA viruses and maintenance of immune homeostasis. With minor corrections and potential enhancements, it will serve as an excellent resource for understanding how PCBP2 regulates cGAS activity.</p>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/","title":"627d95ee00000955 Chondroitin sulfate catabolic process  Mouse","text":"<p>Let me review this GO-CAM model \"Chondroitin sulfate catabolic process (Mouse)\" based on my knowledge of GO-CAM best practices. Here's my review:</p>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#go-cam-model-review-gomodel627d95ee00000955","title":"GO-CAM Model Review: gomodel:627d95ee00000955","text":""},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#title-and-scope","title":"Title and Scope","text":"<ul> <li>Title: Chondroitin sulfate catabolic process (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Comments: Sourced from gomodel:R-HSA-2024101</li> </ul>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM represents the chondroitin sulfate catabolic process (GO:0030207) in mouse, depicting the enzymatic degradation pathway of chondroitin sulfate occurring in lysosomes.</p>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#molecular-activities-and-causal-flow-assessment","title":"Molecular Activities and Causal Flow Assessment","text":"<p>The model includes 7 activities connected in a causal flow using the \"provides input for\" (RO:0002413) predicate:</p> <ol> <li>Galns (MGI:MGI:1355303) - N-acetylgalactosamine-6-sulfatase activity (GO:0043890)</li> <li> <p>Provides input for Hyal1, Hyal3 and Hyal4 activities</p> </li> <li> <p>Arsb (MGI:MGI:88075) - N-acetylgalactosamine-4-sulfatase activity (GO:0003943)</p> </li> <li> <p>Provides input for Hyal1, Hyal3 and Hyal4 activities</p> </li> <li> <p>Hyal1 (MGI:MGI:96298) - Chondroitin hydrolase activity (GO:0052757)</p> </li> <li> <p>Provides input for Gusb activity</p> </li> <li> <p>Hyal3 (MGI:MGI:1330288) - Chondroitin hydrolase activity (GO:0052757)</p> </li> <li> <p>Provides input for Gusb activity</p> </li> <li> <p>Hyal4 (MGI:MGI:1924292) - Chondroitin hydrolase activity (GO:0052757)</p> </li> <li> <p>Provides input for Gusb activity</p> </li> <li> <p>Gusb (MGI:MGI:95872) - Beta-glucuronidase activity (GO:0004566)</p> </li> <li> <p>Provides input for Hexb activity</p> </li> <li> <p>Hexb (MGI:MGI:96074) - Hexosaminidase activity (GO:0015929)</p> </li> <li>Terminal activity in the pathway</li> </ol>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<ul> <li>Most activities have evidence codes and PMIDs supporting them</li> <li>Evidence codes used: ECO:0000315 (mutant phenotype evidence), ECO:0000266 (sequence orthology evidence), ECO:0000314 (direct assay evidence)</li> </ul>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#cellular-location","title":"Cellular Location","text":"<ul> <li>All activities occur in lysosomes (GO:0005764), which is appropriate for this degradation process</li> </ul>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>Consistent biological process annotation: All activities are accurately associated with chondroitin sulfate catabolic process (GO:0030207)</li> <li>Appropriate cellular location: Lysosomal localization is correct for this degradation pathway</li> <li>Causal flow logic: The causal relationships using RO:0002413 correctly represent the sequential enzymatic activities in the degradation pathway</li> <li>Evidence support: Most activities have appropriate evidence with references</li> </ol>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing evidence for Hyal3 activity: The molecular function, cellular location, and biological process associations for Hyal3 lack evidence codes. I recommend adding appropriate evidence.</p> </li> <li> <p>Causal flow verification: While the model shows sulfatases (Galns, Arsb) providing input to hyaluronidases (Hyal1, Hyal3, Hyal4), the biological sequence of events should be verified. Typically, hyaluronidases break down the polymer, while sulfatases remove sulfate groups. The current flow suggests that sulfate removal happens before polymer cleavage.</p> </li> <li> <p>Completeness check: The model focuses on key enzymes but might be missing some steps in the complete chondroitin sulfate degradation pathway. Consider if other enzymes like iduronate-2-sulfatase or alpha-L-iduronidase might be relevant.</p> </li> </ol>"},{"location":"reviews/627d95ee00000955-Chondroitin_sulfate_catabolic_process__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model accurately represents the chondroitin sulfate catabolic process in mouse lysosomes with appropriate molecular functions, cellular locations, and causal relationships. The model is parsimonious and easy to understand, showing the enzymatic cascade involved in breaking down chondroitin sulfate. The primary recommendation is to add evidence for the Hyal3 activity and verify the biological sequence of events in the causal flow.</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/","title":"627d95ee00001405 Il17A mediated signaling pathway  Human","text":"<p>Based on all the information gathered, I'll now provide a comprehensive review of gomodel:627d95ee00001405, which is titled \"IL17A mediated signaling pathway (Human)\".</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#go-cam-model-review-il17a-mediated-signaling-pathway-human","title":"GO-CAM Model Review: IL17A mediated signaling pathway (Human)","text":""},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#model-id","title":"Model ID","text":"<p>gomodel:627d95ee00001405</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#overview","title":"Overview","text":"<p>This model represents the interleukin 17A-mediated signaling pathway in humans, including a component on how SARS-CoV-2 ORF8 protein interferes with this pathway. The model includes seven distinct molecular activities from different proteins that form the IL-17 signaling cascade.</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of IL-17 signaling as described in the literature:</p> <ol> <li> <p>IL-17A (UniProtKB:Q16552) acts as a cytokine (GO:0005125) in the extracellular space (GO:0005615), which is consistent with its known role.</p> </li> <li> <p>IL-17RA (UniProtKB:Q96F46) functions as an IL-17 receptor (GO:0030368) at the plasma membrane (GO:0005886), which correctly represents its biological location and function.</p> </li> <li> <p>IL-17RC (UniProtKB:Q8NAC3) serves as a coreceptor (GO:0015026), also at the plasma membrane, which is supported by literature showing IL-17A signals through a heterodimeric complex of IL-17RA and IL-17RC.</p> </li> <li> <p>The model correctly shows the subsequent signaling cascade involving TRAF3IP2 (Act1), TRAF6, and MAP3K7 (TAK1) with their respective molecular functions.</p> </li> <li> <p>The SARS-CoV-2 ORF8 (UniProtKB:P0DTC8) is included with cytokine activity (GO:0005125) as part of a virus-mediated perturbation of host defense response (GO:0019049), which is supported by recent research showing how ORF8 can mimic IL-17A and activate the IL-17 pathway.</p> </li> </ol>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#causal-relations","title":"Causal Relations","text":"<p>The model includes appropriate causal relations between activities:</p> <ol> <li> <p>IL-17A and SARS-CoV-2 ORF8 both causally regulate IL-17RA through <code>RO:0002629</code> (directly positively regulates) and <code>RO:0002413</code> (provides input for) relationships, accurately representing how both proteins can activate the receptor.</p> </li> <li> <p>IL-17RA correctly regulates IL-17RC using <code>RO:0002629</code>, showing receptor complex formation.</p> </li> <li> <p>IL-17RC regulates TRAF3IP2 using <code>RO:0002629</code>, which then regulates TRAF6 with the same predicate.</p> </li> <li> <p>TRAF6 regulates MAP3K7 with <code>RO:0002629</code>, completing the signaling cascade.</p> </li> </ol> <p>All these causal relations are consistent with the known biology of IL-17 signaling.</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<ol> <li> <p>Molecular function annotations: Each protein has the appropriate molecular function assignment with supporting evidence and references.</p> </li> <li> <p>Cellular component annotations: All proteins have appropriate cellular location annotations.</p> </li> <li> <p>Biological process annotations: Each activity is properly contextualized in its biological process.</p> </li> <li> <p>Evidence: All activities and causal relations include evidence codes with appropriate PMIDs, mostly using ECO:0000314 (direct assay evidence) which is appropriate.</p> </li> <li> <p>Causal relations: The model uses the correct causal relation predicates (<code>RO:0002629</code> for direct positive regulation and <code>RO:0002413</code> for providing input).</p> </li> <li> <p>Directionality: The flow of information in the pathway proceeds in the correct direction.</p> </li> </ol>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#comments-on-specific-model-features","title":"Comments on Specific Model Features","text":""},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#sars-cov-2-orf8-inclusion","title":"SARS-CoV-2 ORF8 inclusion","text":"<p>The inclusion of SARS-CoV-2 ORF8 (P0DTC8) is supported by recent literature (PMID:33723527) which shows that ORF8 can mimic IL-17A by binding to IL-17RA and activating the pathway. The representation of ORF8 as having cytokine activity is consistent with its functional role, though it's worth noting this is a case of viral mimicry rather than a true cytokine.</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#receptor-activation","title":"Receptor activation","text":"<p>The model correctly represents that both IL-17A and SARS-CoV-2 ORF8 can activate IL-17RA, with IL-17A being the physiological ligand and ORF8 being a viral mimic. The use of both <code>RO:0002629</code> (directly positively regulates) and <code>RO:0002413</code> (provides input for) relationships from ORF8 to IL-17RA appears redundant, as one relationship would suffice to indicate the causal connection.</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#il-17ra-and-il-17rc-interaction","title":"IL-17RA and IL-17RC interaction","text":"<p>The model correctly represents IL-17RC as a coreceptor that works with IL-17RA. According to the literature, IL-17A binds to a heterodimeric receptor complex composed of IL-17RA and IL-17RC. The causal relationship from IL-17RA to IL-17RC (<code>RO:0002629</code>) is appropriate to represent this functional relationship.</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#signaling-cascade","title":"Signaling cascade","text":"<p>The downstream signaling events are accurately represented, showing the recruitment and activation of TRAF3IP2 (Act1), which then activates TRAF6, which in turn activates MAP3K7 (TAK1). This is consistent with the canonical IL-17 signaling pathway described in the literature.</p>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Redundant causal relations: There are two identical causal relationships from ORF8 to IL-17RA using the <code>RO:0002413</code> predicate. One of these should be removed as it's redundant.</p> </li> <li> <p>Receptor complex representation: While the model correctly shows IL-17RA and IL-17RC with their respective activities, according to the GO-CAM guidelines for annotating complexes, the heterodimeric nature of the IL-17 receptor complex could be more explicitly represented. Since both proteins contribute to receptor function, this could be considered a case where \"the activity is shared by several proteins.\"</p> </li> <li> <p>Downstream effects: The model stops at MAP3K7 (TAK1) activation. It could be expanded to include downstream transcription factors and the resulting gene expression changes that lead to the pro-inflammatory effects of IL-17 signaling.</p> </li> <li> <p>Feedback mechanisms: The model doesn't include any negative feedback mechanisms that regulate IL-17 signaling, which could enhance the biological completeness of the representation.</p> </li> </ol>"},{"location":"reviews/627d95ee00001405-Il17A_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:627d95ee00001405 is a well-constructed GO-CAM that accurately represents the IL-17A signaling pathway in humans, with the interesting addition of SARS-CoV-2 ORF8 as a viral mimic of IL-17A. The model follows GO-CAM best practices for the most part, with appropriate molecular functions, cellular components, biological processes, and causal relations.</p> <p>The main recommendations for improvement would be to: 1. Remove the redundant causal relation from ORF8 to IL-17RA 2. Consider enhancing the representation of the IL-17RA/IL-17RC heterodimeric complex 3. Extend the model to include downstream transcription factors and gene expression changes 4. Add negative feedback mechanisms to provide a more comprehensive view of pathway regulation</p> <p>This model provides valuable insights into both normal IL-17 signaling and how SARS-CoV-2 may hijack this pathway to contribute to cytokine storm during infection, which is a significant finding with clinical implications.</p>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/","title":"627d95ee00001943 Activation of PARP1 activity by HPF1 during DNA repair  Human","text":"<p>Now I can do a complete analysis of the GO-CAM model. Let me review the model:</p>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#go-cam-model-review-activation-of-parp1-activity-by-hpf1-during-dna-repair-human","title":"GO-CAM Model Review: \"Activation of PARP1 activity by HPF1 during DNA repair (Human)\"","text":""},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:627d95ee00001943) titled \"Activation of PARP1 activity by HPF1 during DNA repair (Human)\" represents the molecular interactions between PARP1 (Poly(ADP-ribose) polymerase 1) and HPF1 (Histone PARylation factor 1) during DNA repair processes in humans.</p>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#model-components","title":"Model Components","text":"<p>The model includes the following key proteins and their activities:</p> <ol> <li>PARP1 (UniProtKB:P09874) with multiple molecular functions:</li> <li>Damaged DNA binding (GO:0003684)</li> <li>Protein homodimerization activity (GO:0042803)</li> <li>NAD+-protein-serine ADP-ribosyltransferase activity (GO:0140805)</li> <li> <p>NAD+-protein poly-ADP-ribosyltransferase activity (GO:0003950)</p> </li> <li> <p>HPF1 (UniProtKB:Q9NWY4) with:</p> </li> <li>Protein ADP-ribosyltransferase-substrate adaptor activity (GO:0140768)</li> </ol>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#biological-context","title":"Biological Context","text":"<p>All activities occur at the site of DNA damage (GO:0090734) and participate in either DNA damage response (GO:0006974) or DNA repair (GO:0006281) processes.</p>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model describes a well-structured sequence of molecular events:</p> <ol> <li>PARP1 homodimerizes (GO:0042803)</li> <li>This enables PARP1's damaged DNA binding activity (GO:0003684)</li> <li>PARP1's DNA binding directly positively regulates (RO:0002629) its NAD+-protein-serine ADP-ribosyltransferase activity (GO:0140805)</li> <li>HPF1 acts as an adaptor (GO:0140768) to directly positively regulate (RO:0002629) PARP1's NAD+-protein-serine ADP-ribosyltransferase activity</li> <li>PARP1's serine ADP-ribosyltransferase activity enables its poly-ADP-ribosyltransferase activity (GO:0003950)</li> </ol>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#analysis-and-evaluation","title":"Analysis and Evaluation","text":""},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Scientific Accuracy: The model accurately represents the current understanding of PARP1 activation and function during DNA repair as confirmed by the literature. PARP1 binds to damaged DNA, which activates its catalytic activity, and HPF1 functions as an adaptor to direct ADP-ribosylation specifically to serine residues.</p> </li> <li> <p>Correct Representation of Mechanism: The model correctly shows that PARP1 first homodimerizes, then binds to damaged DNA, which activates its ADP-ribosyltransferase activity, assisted by HPF1.</p> </li> <li> <p>Appropriate Cellular Context: All activities are correctly localized to the site of DNA damage (GO:0090734).</p> </li> <li> <p>Proper Use of Causal Relationships: The model properly uses the \"directly positively regulates\" (RO:0002629) relationship to connect related activities.</p> </li> </ol>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Missing Information on HPF1 Recruitment: The model doesn't explicitly show how HPF1 is recruited to the DNA damage site. According to the literature, PARP1 binds to DNA damage sites and recruits HPF1. This relationship could be added to make the model more complete.</p> </li> <li> <p>Serine ADP-ribosylation Targets: The model doesn't specify the targets of PARP1's serine ADP-ribosylation activity. According to the literature, key targets include histones (especially H2B and H3) and PARP1 itself (auto-modification). This information could be added to enhance the model's completeness.</p> </li> <li> <p>Downstream Effects: The model could be expanded to show the consequences of ADP-ribosylation, such as:</p> </li> <li>Auto-modification of PARP1 leading to its dissociation from DNA</li> <li>Chromatin remodeling</li> <li> <p>Recruitment of additional DNA repair factors</p> </li> <li> <p>Feedback Mechanism: The literature indicates that HPF1 not only helps direct PARP1's activity to serine residues but also restricts the polymerase activity to limit chain length. This regulatory aspect could be included.</p> </li> </ol>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#technical-evaluation","title":"Technical Evaluation","text":"<ol> <li> <p>GO Term Usage: The model uses appropriate GO terms for molecular functions, cellular components, and biological processes.</p> </li> <li> <p>Relationship Logic: The causal relationships are logically ordered and represent the known biology accurately.</p> </li> <li> <p>Compliance with GO-CAM Best Practices: The model follows GO-CAM best practices for representing protein activities and their relationships. The handling of complexes follows the guidelines in the \"How to annotate complexes in GO-CAM\" document.</p> </li> </ol>"},{"location":"reviews/627d95ee00001943-Activation_of_PARP1_activity_by_HPF1_during_DNA_repair__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good representation of the molecular mechanisms involved in PARP1 activation by HPF1 during DNA repair. It accurately depicts the key molecular functions of both proteins and their causal relationships.</p> <p>To further enhance the model, I recommend: 1. Adding the recruitment mechanism of HPF1 to PARP1 at DNA damage sites 2. Including the specific targets of serine ADP-ribosylation 3. Extending the model to show downstream consequences of the ADP-ribosylation activity 4. Adding the regulatory mechanism by which HPF1 limits PARP1's polymer chain extension</p> <p>Overall, this is a scientifically accurate model that effectively represents current knowledge of PARP1 and HPF1 interaction during DNA repair processes.</p>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/","title":"627d95ee00001988 Regulation of Parp1 activity by Cgas  Setd7 and Riox1  Mouse","text":"<p>Let me review the main GO-CAM model now based on all the information I've gathered:</p>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#go-cam-model-review-gomodel627d95ee00001988","title":"GO-CAM Model Review - gomodel:627d95ee00001988","text":""},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#basic-information","title":"Basic Information","text":"<ul> <li>Title: Regulation of Parp1 activity by Cgas, Setd7 and Riox1 (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Primary reference: PMID:35210392</li> </ul>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the regulatory pathway involving Setd7, Riox1, Sgf29, and Cgas in the control of Parp1 (poly(ADP-ribose) polymerase 1) activity during DNA repair in mouse. The model describes how these proteins interact to regulate DNA repair, particularly homologous recombination (HR) repair following DNA damage.</p>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#key-molecular-components","title":"Key Molecular Components","text":"<ol> <li>Setd7 (MGI:MGI:1920501) - Protein-lysine N-methyltransferase activity (GO:0016279)</li> <li>Riox1 (MGI:MGI:1919202) - 2-oxoglutarate-dependent dioxygenase activity (GO:0016706)</li> <li>Sgf29 (MGI:MGI:1922815) - Methylation-dependent protein binding (GO:0140034)</li> <li>Cgas (MGI:MGI:2442261) - Poly-ADP-D-ribose modification-dependent protein binding (GO:0160004)</li> <li>Parp1 (MGI:MGI:1340806) - NAD+-protein poly-ADP-ribosyltransferase activity (GO:0003950)</li> </ol>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#pathway-description","title":"Pathway Description","text":"<p>Based on the model and literature, the pathway operates as follows:</p> <ol> <li>Setd7 methylates Cgas at K491</li> <li>Riox1 acts as a demethylase that removes the methylation at K491 of Cgas</li> <li>When Cgas is methylated (K491me), it interacts with Sgf29 (methylation reader protein)</li> <li>When Cgas is demethylated by Riox1, it can bind to poly-ADP-ribosylated Parp1 at DNA break sites</li> <li>The binding of demethylated Cgas to Parp1 prevents the recruitment of Timeless, inhibiting homologous recombination repair</li> <li>Thus, Riox1 negatively regulates DNA repair by enabling Cgas to interfere with Parp1's function</li> </ol>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<ul> <li>Setd7 (protein-lysine N-methyltransferase activity) positively regulates Sgf29 (methylation-dependent protein binding)</li> <li>Riox1 (2-oxoglutarate-dependent dioxygenase activity) positively regulates Cgas (poly-ADP-D-ribose modification-dependent protein binding)</li> <li>Sgf29 (methylation-dependent protein binding) negatively regulates Cgas (poly-ADP-D-ribose modification-dependent protein binding)</li> <li>Cgas (poly-ADP-D-ribose modification-dependent protein binding) negatively regulates Parp1 (NAD+-protein poly-ADP-ribosyltransferase activity)</li> </ul>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>The model accurately represents the molecular functions of each protein involved in the pathway.</li> <li>The causal relationships between the activities are well captured with appropriate RO predicates.</li> <li>The activities are connected in a way that is consistent with the described pathway in the primary literature.</li> <li>The model captures the key regulatory mechanisms involving protein methylation, demethylation, and protein-protein interactions.</li> </ol>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing component: The model doesn't include Timeless protein, which is mentioned in the literature as a key component in the pathway (Cgas prevents Timeless recruitment by binding to Parp1).</li> <li>Cellular location information: While Cgas is annotated as occurring in the nucleus (GO:0005634), more detailed cellular location information for other proteins could enhance the model.</li> <li>Molecular complexes: Based on the GO-CAM guidelines for complex annotation, if specific subunits with known activities are involved, they should be represented individually, which this model does follow.</li> </ol>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is consistent with the primary literature (PMID:35210392), which describes how Riox1 demethylates cGAS K491me, facilitating the binding of cGAS to PARP1 and blocking HR repair. The paper explains the mechanism where RIOX1 expression governs the level of cGAS K491me, which in turn affects the interaction between cGAS and PARP1.</p>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Consider adding Timeless: Since Timeless plays a key role in the pathway described in the literature, it would enhance the model to include its activity and regulation.</p> </li> <li> <p>Add more cellular compartment information: Specify where these interactions are occurring, particularly for the DNA repair activities.</p> </li> <li> <p>Expand biological context: The model could benefit from more explicit connections to the higher-level biological processes like DNA damage response.</p> </li> <li> <p>Enhance evidence attribution: While the model includes PMID references, it would be beneficial to ensure that each causal relationship has appropriate evidence codes and references.</p> </li> </ol>"},{"location":"reviews/627d95ee00001988-Regulation_of_Parp1_activity_by_Cgas__Setd7_and_Riox1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Regulation of Parp1 activity by Cgas, Setd7 and Riox1\" (gomodel:627d95ee00001988) is a high-quality representation of the regulatory pathway controlling Parp1 activity during DNA repair. It accurately captures the key molecular functions and causal relationships between proteins involved in this pathway, as described in the scientific literature. With a few minor enhancements, it could provide an even more comprehensive representation of this important cellular process.</p>"},{"location":"reviews/627d95ee00002030-Activation_of_PARP2_activity_by_HPF1_during_DNA_repair__Human_/","title":"627d95ee00002030 Activation of PARP2 activity by HPF1 during DNA repair  Human","text":"<p>Based on the above information, I'll now perform a thorough review of GO-CAM model \"gomodel:627d95ee00002030\" titled \"Activation of PARP2 activity by HPF1 during DNA repair (Human)\".</p>"},{"location":"reviews/627d95ee00002030-Activation_of_PARP2_activity_by_HPF1_during_DNA_repair__Human_/#go-cam-model-review-activation-of-parp2-activity-by-hpf1-during-dna-repair-human","title":"GO-CAM Model Review: Activation of PARP2 activity by HPF1 during DNA repair (Human)","text":""},{"location":"reviews/627d95ee00002030-Activation_of_PARP2_activity_by_HPF1_during_DNA_repair__Human_/#overview","title":"Overview","text":"<p>This model (gomodel:627d95ee00002030) represents the activation of PARP2 (Poly(ADP-ribose) polymerase 2) by HPF1 (Histone PARylation factor 1) during DNA repair in humans. The model consists of 4 activities and describes how these proteins interact to enable ADP-ribosylation at DNA damage sites.</p>"},{"location":"reviews/627d95ee00002030-Activation_of_PARP2_activity_by_HPF1_during_DNA_repair__Human_/#model-components","title":"Model Components","text":"<p>The model contains the following molecular functions and proteins:</p> <ol> <li>PARP2 (UniProtKB:Q9UGN5)</li> <li>Damaged DNA binding (GO:0003684)</li> <li>NAD+-protein-serine ADP-ribosyltransferase activity (GO:0140805)</li> <li> <p>NAD+-protein poly-ADP-ribosyltransferase activity (GO:0003950)</p> </li> <li> <p>HPF1 (UniProtKB:Q9NWY4)</p> </li> <li>Protein ADP-ribosyltransferase-substrate adaptor activity (GO:0140768)</li> </ol>"},{"location":"reviews/627d95ee00002030-Activation_of_PARP2_activity_by_HPF1_during_DNA_repair__Human_/#model-accuracy-and-biological-content","title":"Model Accuracy and Biological Content","text":"<p>The model effectively captures the current scientific understanding of how PARP2 is activated by HPF1 during DNA repair, as supported by the literature:</p> <ol> <li> <p>PARP2's DNA binding ability: The model correctly shows that PARP2 has damaged DNA binding activity (GO:0003684), which occurs at the site of DNA damage (GO:0090734). This is consistent with the literature showing that PARP2 recognizes and binds to DNA breaks, particularly 5'-phosphorylated DNA breaks.</p> </li> <li> <p>HPF1's role as an adaptor: The model appropriately represents HPF1 as having protein ADP-ribosyltransferase-substrate adaptor activity (GO:0140768). This accurately reflects HPF1's function in switching PARP2's amino acid specificity from glutamate/aspartate to serine residues.</p> </li> <li> <p>Causal relationships: The model uses RO:0002629 (directly positively regulates) to show how damaged DNA binding by PARP2 leads to NAD+-protein-serine ADP-ribosyltransferase activity. It also correctly shows how HPF1 activity directly positively regulates PARP2's ADP-ribosyltransferase activity.</p> </li> <li> <p>Sequential activity flow: The model captures the sequential flow of activity - from DNA damage binding by PARP2, to HPF1 regulation of PARP2, to the serine ADP-ribosylation activity, and finally to poly-ADP-ribosylation.</p> </li> </ol>"},{"location":"reviews/627d95ee00002030-Activation_of_PARP2_activity_by_HPF1_during_DNA_repair__Human_/#areas-for-improvement-or-considerations","title":"Areas for Improvement or Considerations","text":"<ol> <li> <p>Duplicate causal association: There appears to be a duplicate causal association from PARP2's damaged DNA binding activity to its NAD+-protein-serine ADP-ribosyltransferase activity. One of these associations lacks evidence, which should be addressed.</p> </li> <li> <p>Conformational changes: The model does not explicitly represent the conformational changes that PARP2 undergoes upon DNA binding, which are critical for its activation as detailed in the PMID:34108479 paper. This includes the reorganization of the regulatory domain (RD) that allows NAD+ binding and HPF1 interaction.</p> </li> <li> <p>Temporal aspects: While the model shows the correct sequence of events, it might benefit from additional details about how HPF1 initiates serine ADP-ribosylation but also restricts the length of poly-ADP-ribose chains, as mentioned in the literature.</p> </li> <li> <p>Target representation: The model doesn't explicitly show the targets of ADP-ribosylation (such as histones), which would provide a more complete picture of the process.</p> </li> </ol>"},{"location":"reviews/627d95ee00002030-Activation_of_PARP2_activity_by_HPF1_during_DNA_repair__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li>Using appropriate molecular function terms for each protein</li> <li>Properly representing the causal relationships between activities</li> <li>Including cellular locations (site of DNA damage, GO:0090734)</li> <li>Including biological process context (DNA repair, GO:0006281 and DNA damage response, GO:0006974)</li> <li>Using evidence codes and literature references to support assertions</li> </ol>"},{"location":"reviews/627d95ee00002030-Activation_of_PARP2_activity_by_HPF1_during_DNA_repair__Human_/#final-assessment","title":"Final Assessment","text":"<p>This GO-CAM model (gomodel:627d95ee00002030) is scientifically accurate and well-constructed. It successfully captures the key aspects of PARP2 activation by HPF1 at DNA damage sites. </p> <p>The model could be enhanced by: 1. Removing the duplicate causal association 2. Adding more detail about the conformational changes in PARP2 3. Including the targets of ADP-ribosylation (histones and other proteins) 4. Providing more detail about how HPF1 both enables serine-specific ADP-ribosylation and regulates poly-ADP-ribose chain length</p> <p>Overall, this is a high-quality model that accurately represents our current understanding of the biological process and complies with GO-CAM best practices.</p>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/","title":"627d95ee00002159 Xenopus trio  and cdh11 in development and neural cell migration","text":"<p>Based on my review of the GO-CAM model (gomodel:627d95ee00002159) and relevant guidelines, I'll provide a comprehensive assessment.</p>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#go-cam-review-for-model-gomodel627d95ee00002159","title":"GO-CAM Review for Model: gomodel:627d95ee00002159","text":""},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#model-overview","title":"Model Overview","text":"<p>Title: \"Xenopus trio, and cdh11 in development and neural cell migration.\" Taxonomic context: NCBITaxon:8355 (Xenopus) Status: Production Contributor: ORCID:0000-0003-1074-8103 (date: 2022-05-26)</p>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>This model represents a pathway in Xenopus describing the role of Trio (a Rho guanine nucleotide exchange factor) and Cadherin-11 (cdh11) in neural cell migration, particularly in cranial neural crest cells. The model includes several molecular function activities with causal relationships between them:</p> <ol> <li>Trio (Xenbase:XB-GENE-6252075) enables guanyl-nucleotide exchange factor activity (GO:0005085)</li> <li>Trio (Xenbase:XB-GENE-6252075) enables protein binding activity (GO:0005515)</li> <li>Rac1 (Xenbase:XB-GENE-489012) enables GTPase activity (GO:0003924)</li> <li>Dvl1 (Xenbase:XB-GENE-865024) enables small GTPase binding (GO:0031267)</li> <li>Cadherin-11 (Xenbase:XB-GENE-17340654) enables molecular function (GO:0003674)</li> </ol> <p>The model represents direct positive regulation (RO:0002629) relationships from Trio's GEF activity to Rac1's GTPase activity, and from Dvl1's small GTPase binding to Rac1's GTPase activity. Cadherin-11 activity is shown to have a necessary and specific dependency on (RO:0002411) Trio's molecular function activity.</p>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#strengths","title":"Strengths","text":"<ol> <li> <p>Evidence basis: All activities and causal relationships are supported by experimental evidence (ECO:0000314 - direct assay evidence; ECO:0006051 - morpholino experiment evidence) from the referenced publication PMID:32366678.</p> </li> <li> <p>Functional consistency: The molecular functions assigned to each gene product align with known roles of these proteins from literature and UniProt - Trio as a GEF, Rac1 as a GTPase, and Dvl1 as a regulator of small GTPases.</p> </li> <li> <p>Causal reasoning: The directionality of causal relationships aligns with known biological mechanisms, with GEF activity properly regulating GTPase activity.</p> </li> <li> <p>Parsimony: The model captures key relationships without unnecessary complexity.</p> </li> </ol>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Incomplete annotation of cdh11: Cadherin-11 (Xenbase:XB-GENE-17340654) is only annotated with a generic molecular function (GO:0003674) rather than its specific function such as calcium-dependent cell adhesion activity.</p> </li> <li> <p>Missing cellular context: While this model represents molecular function and causal relationships, it would benefit from including cellular component context for these activities (where in the cell these activities occur).</p> </li> <li> <p>Biological process context: Though the title mentions neural crest cell migration, the model doesn't explicitly represent the biological processes these activities are part of (e.g., cell migration, cytoskeletal organization).</p> </li> <li> <p>Incomplete representation of pathway: According to the referenced paper, the pathway involves additional components like filopodia and lamellipodia formation that aren't represented in this model.</p> </li> </ol>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<ol> <li> <p>Complex representation: The model doesn't explicitly represent protein complexes, which appears appropriate based on the paper and \"How to annotate complexes in GO-CAM\" guidelines, as individual proteins with their specific activities are modeled.</p> </li> <li> <p>Causal relations: The model uses the appropriate causal predicates (RO:0002629 - directly positively regulates), adhering to GO-CAM best practices.</p> </li> <li> <p>Signaling pathway representation: The model could better follow \"Signaling receptor activity annotation guidelines\" by making the signaling flow more explicit if applicable to this pathway.</p> </li> </ol>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on my review of the referenced publication (PMID:32366678), the model accurately captures key aspects of the described pathway. The paper demonstrates that:</p> <ol> <li>Trio is required for cranial neural crest cell migration in Xenopus</li> <li>Trio functions in protrusion formation by interacting with Dvl and activating Rac1</li> <li>Cadherin-11 (cdh11) interacts with this pathway</li> <li>Dvl activity is important for Trio's effects on neural crest cell migration</li> </ol> <p>The model correctly represents these relationships, though it simplifies the full complexity described in the paper, which includes additional mechanisms such as: - Trio interacting with Dvl via its GEF2 domain - This interaction affecting protrusion formation and migration - Multiple additional interactions with proteins like Par3 and other signaling components</p>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add specific molecular function to cdh11: Replace the generic molecular function (GO:0003674) with a more specific annotation reflecting its known role in calcium-dependent cell adhesion.</p> </li> <li> <p>Add cellular component annotations: Include cellular locations for activities, such as cell membrane, filopodia, or lamellipodia where these proteins function.</p> </li> <li> <p>Add biological process context: Include explicit annotations to biological processes like \"neural crest cell migration\" (GO:0001755) or \"filopodium assembly\" (GO:0046847) that these activities are part of.</p> </li> <li> <p>Expand pathway representation: Consider adding additional components mentioned in the paper, such as the specific mechanism by which Trio and Dvl interact to activate Rac1, and the role of this pathway in filopodia and lamellipodia formation.</p> </li> <li> <p>Complete signaling flow: The model would benefit from explicitly representing the complete signaling cascade from Cadherin-11 to cytoskeletal remodeling.</p> </li> </ol>"},{"location":"reviews/627d95ee00002159-Xenopus_trio__and_cdh11_in_development_and_neural_cell_migration_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model provides a good representation of key molecular activities and causal relationships involved in Trio, Dvl1, and Cadherin-11 function in Xenopus neural crest cell migration. The model is consistent with the available evidence and follows GO-CAM guidelines. However, it could be enhanced by providing more specific functional annotations, cellular context, and additional pathway components to more fully capture the biological complexity described in the literature.</p> <p>The model serves as a valuable resource for understanding this particular signaling pathway in neural crest cells, though with the suggested improvements it could be even more informative.</p>"},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/","title":"62900b6400000022 Mono ADP ribosylation of ribosome subunits by PARP16  Human","text":"<p>Based on the information gathered, I'll now review the GO-CAM model \"gomodel:62900b6400000022\" - Mono-ADP-ribosylation of ribosome subunits by PARP16 (Human).</p>"},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/#go-cam-model-review-mono-adp-ribosylation-of-ribosome-subunits-by-parp16","title":"GO-CAM Model Review: Mono-ADP-ribosylation of ribosome subunits by PARP16","text":""},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Mono-ADP-ribosylation of ribosome subunits by PARP16 (Human) ID: gomodel:62900b6400000022 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/#summary-of-model-content","title":"Summary of Model Content","text":"<p>This model describes how PARP16 (Q8N5Y8) mono-ADP-ribosylates specific ribosomal subunits (RPS6/P62753 and RPL24/P83731) in a process that is supported by NMNAT2 (Q9BZQ4). The model shows this leads to negative regulation of cytoplasmic translation (GO:2000766).</p> <p>The model depicts: 1. PARP16's NAD+-protein-glutamate ADP-ribosyltransferase activity (GO:0140807) directly negatively regulating (RO:0002630) the structural constituent of ribosome activity (GO:0003735) of both RPS6 and RPL24 2. NMNAT2's protein ADP-ribosyltransferase-substrate adaptor activity (GO:0140768) directly positively regulating (RO:0002629) PARP16's ADP-ribosyltransferase activity</p>"},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model accurately captures the biological process described in the literature. The PMID:34314702 paper (\"Ribosome ADP-Ribosylation Inhibits Translation and Maintains Proteostasis in Cancers\") clearly shows that:</p> <ol> <li>PARP16 mono-ADP-ribosylates ribosomal proteins RPS6 (at Glu-35) and RPL24 (at Glu-4)</li> <li>NMNAT2 supports this activity by providing NAD+ and acting as an adaptor protein</li> <li>This modification inhibits translation by preventing proper ribosome assembly (via mechanisms involving eIF6)</li> </ol> <p>The model correctly captures these key relationships, including the negative regulatory effect on translation.</p>"},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>Structure and Relationships: - The model follows GO-CAM best practices by using appropriate terms for molecular activities, linking them through standard causal relations - Each activity is properly enabled by a specific gene product - All molecular functions are correctly placed as part of a broader biological process (GO:2000766)</p> <p>Use of Relations: - The use of RO:0002630 (directly negatively regulates) correctly represents the inhibitory relationship between PARP16's ADP-ribosylation activity and the ribosomal protein's structural activity - The use of RO:0002629 (directly positively regulates) correctly represents NMNAT2's adaptor role in enhancing PARP16 activity</p> <p>Cellular Context: - The model correctly specifies the cellular context of cytosolic ribosome (GO:0022626) for the ribosomal protein activities</p> <p>Evidence: - All claims are supported by appropriate experimental evidence codes (ECO:0000314 - direct assay evidence) from the publication PMID:34314702 - The contributor is identified with an ORCID</p>"},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Additional Cellular Context: While the model shows the ribosomal proteins in the cytosolic ribosome, it doesn't specify the subcellular location for PARP16 and NMNAT2. According to UniProt and the paper, PARP16 is localized to the ER membrane, while NMNAT2 is associated with Golgi/cytoplasmic vesicles. Adding these locations would enhance the model.</p> </li> <li> <p>Representation of Mechanism Detail: The model could benefit from additional details about how ADP-ribosylation inhibits translation, specifically the mechanism involving eIF6 binding to ribosomes that prevents 60S-40S subunit joining. This is a key finding in the paper.</p> </li> <li> <p>Transport Activity: The paper mentions that NMNAT2 is delivered to the site of action via Golgi-derived cytoplasmic vesicles. This transport activity could be included in a more comprehensive model.</p> </li> <li> <p>Output of Activity: The model could be expanded to show exactly what species of ADP-ribosylated proteins are produced (e.g., ADP-ribosyl glutamic acid modifications at specific sites - Glu-35 for RPS6 and Glu-4 for RPL24).</p> </li> </ol>"},{"location":"reviews/62900b6400000022-Mono_ADP_ribosylation_of_ribosome_subunits_by_PARP16__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Mono-ADP-ribosylation of ribosome subunits by PARP16 (Human)\" is a well-constructed representation of the biological process described in the literature. It accurately captures the key molecular activities and their causal relationships, using appropriate GO terms and relation ontology predicates.</p> <p>The model effectively shows how PARP16 mono-ADP-ribosylates ribosomal proteins (RPS6 and RPL24) with support from NMNAT2, leading to negative regulation of cytoplasmic translation. All assertions are well-supported by experimental evidence from the publication.</p> <p>While the model could be enhanced with additional details about subcellular locations and mechanistic details, it successfully represents the core biological process in accordance with GO-CAM standards and best practices.</p>"},{"location":"reviews/62900b6400000076-Histone_poly_ADP_ribosylation_of_histone_H2B_at_Glu_35_by_Parp1_that_prevents_phosphorylation_at_of_histone_H2B_at_Ser_36_by_Prkaa1__Mouse_/","title":"62900b6400000076 Histone poly ADP ribosylation of histone H2B at Glu 35 by Parp1 that prevents phosphorylation at of histone H2B at Ser 36 by Prkaa1  Mouse","text":"<p>Based on all this information, I'll now review the GO-CAM model:</p> <p>The model I'm reviewing is about the \"Histone poly-ADP-ribosylation of histone H2B at Glu-35 by Parp1 that prevents phosphorylation at of histone H2B at Ser-36 by Prkaa1 (Mouse)\". Let me analyze this model for accuracy and best practices.</p>"},{"location":"reviews/62900b6400000076-Histone_poly_ADP_ribosylation_of_histone_H2B_at_Glu_35_by_Parp1_that_prevents_phosphorylation_at_of_histone_H2B_at_Ser_36_by_Prkaa1__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:62900b6400000076) describes a molecular regulatory relationship between: 1. Parp1 (MGI:MGI:1340806) which ADP-ribosylates histone H2B at glutamate 35 (Glu-35) 2. Prkaa1 (MGI:MGI:2145955) which phosphorylates histone H2B at serine 36 (Ser-36) 3. Nmnat1 (MGI:MGI:1913704) which acts as a protein ADP-ribosyltransferase-substrate adaptor</p> <p>The key relationships in the model are: - Nmnat1 positively regulates Parp1's ADP-ribosyltransferase activity - Parp1 negatively regulates Prkaa1's phosphorylation activity</p>"},{"location":"reviews/62900b6400000076-Histone_poly_ADP_ribosylation_of_histone_H2B_at_Glu_35_by_Parp1_that_prevents_phosphorylation_at_of_histone_H2B_at_Ser_36_by_Prkaa1__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>Based on the literature evidence:</p> <ol> <li> <p>The relationship between ADP-ribosylation and phosphorylation is accurate: The papers (especially PMID:32822587) clearly show that ADP-ribosylation of H2B at Glu-35 by Parp1 prevents phosphorylation at Ser-36 by Prkaa1 (AMPK\u03b11). The study demonstrates that this is a key regulatory mechanism in adipogenesis.</p> </li> <li> <p>The role of Nmnat1 is accurately captured: The literature (PMID:32822587) shows that Nmnat1 acts as an adaptor that directs Parp1's catalytic activity specifically to glutamate residues on histones, including H2B-Glu35. Nmnat1 is shown to function as a specificity factor that promotes Parp1's activity toward Glu/Asp residues rather than Ser residues.</p> </li> <li> <p>The molecular functions are accurately assigned: </p> </li> <li>Parp1 is annotated with \"NAD+-histone H2BE35 glutamate ADP-ribosyltransferase activity\" (GO:0140822)</li> <li>Prkaa1 is annotated with \"histone H2BS36 kinase activity\" (GO:0140823)</li> <li> <p>Nmnat1 is annotated with \"protein ADP-ribosyltransferase-substrate adaptor activity\" (GO:0140768)</p> </li> <li> <p>The biological context is accurate: The model indicates that these activities occur in chromatin (GO:0000785), which matches the experimental evidence showing that these modifications happen on chromatin-associated histones.</p> </li> </ol>"},{"location":"reviews/62900b6400000076-Histone_poly_ADP_ribosylation_of_histone_H2B_at_Glu_35_by_Parp1_that_prevents_phosphorylation_at_of_histone_H2B_at_Ser_36_by_Prkaa1__Mouse_/#go-cam-modeling-assessment","title":"GO-CAM Modeling Assessment","text":"<ol> <li>Causal relationships are properly represented: </li> <li>The negative regulation of Prkaa1 by Parp1 is represented with the predicate \"RO:0002630\" (directly negatively regulates)</li> <li>The positive regulation of Parp1 by Nmnat1 is represented with the predicate \"RO:0002629\" (directly positively regulates)</li> <li> <p>These causal relationships align with how GO-CAM best practices recommend representing direct regulatory relationships.</p> </li> <li> <p>Biological processes are correctly annotated:</p> </li> <li>Parp1's activity is part of \"negative regulation of DNA-templated transcription\" (GO:0045892)</li> <li>Prkaa1's activity is part of \"positive regulation of DNA-templated transcription\" (GO:0045893)</li> <li> <p>These align with the literature findings where H2B-Ser36 phosphorylation promotes gene transcription while H2B-Glu35 ADP-ribosylation inhibits it.</p> </li> <li> <p>Evidence is properly cited: </p> </li> <li>The evidence codes used are ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>Citations to PMID:20647423 and PMID:32822587 are included</li> <li>The evidence is linked to the appropriate assertions in the model</li> </ol>"},{"location":"reviews/62900b6400000076-Histone_poly_ADP_ribosylation_of_histone_H2B_at_Glu_35_by_Parp1_that_prevents_phosphorylation_at_of_histone_H2B_at_Ser_36_by_Prkaa1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Add more context about the biological role in adipogenesis: While the model accurately captures the molecular relationships, it could benefit from additional biological process annotations related to adipogenesis regulation, which is a key outcome discussed in PMID:32822587.</p> </li> <li> <p>Clarify the cellular compartment: While \"chromatin\" is correctly annotated, adding nuclear localization might provide more complete information about where these reactions occur.</p> </li> <li> <p>Redundant causal association: There appears to be a redundant causal association from Nmnat1 to Parp1 that's listed twice with the same predicate (RO:0002629) but one instance lacks evidence.</p> </li> </ol>"},{"location":"reviews/62900b6400000076-Histone_poly_ADP_ribosylation_of_histone_H2B_at_Glu_35_by_Parp1_that_prevents_phosphorylation_at_of_histone_H2B_at_Ser_36_by_Prkaa1__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:62900b6400000076) accurately represents the molecular mechanism described in the literature. The ADP-ribosylation of histone H2B at Glu-35 by Parp1 (directed by Nmnat1) prevents phosphorylation at Ser-36 by Prkaa1, which has implications for transcriptional regulation. The model follows most GO-CAM best practices, appropriately representing causal relationships, molecular functions, and cellular contexts.</p> <p>The model would benefit from minor improvements including adding more context about adipogenesis regulation, clarifying nuclear localization, and removing the redundant causal association, but these are relatively minor issues. The core regulatory relationship between these molecular activities is captured accurately.</p>"},{"location":"reviews/62900b6400000500-Regulation_of_ACLY_by_acetylation_by_PCAF_KAT2B_and_ubiquitination__by_UBR4___Human_/","title":"62900b6400000500 Regulation of ACLY by acetylation by PCAF KAT2B and ubiquitination  by UBR4   Human","text":"<p>Now I'll analyze the GO-CAM model to evaluate its biological accuracy, structure, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/62900b6400000500-Regulation_of_ACLY_by_acetylation_by_PCAF_KAT2B_and_ubiquitination__by_UBR4___Human_/#review-of-go-cam-model-gomodel62900b6400000500","title":"Review of GO-CAM Model: gomodel:62900b6400000500","text":""},{"location":"reviews/62900b6400000500-Regulation_of_ACLY_by_acetylation_by_PCAF_KAT2B_and_ubiquitination__by_UBR4___Human_/#model-overview","title":"Model Overview","text":"<p>Title: Regulation of ACLY by acetylation by PCAF/KAT2B and ubiquitination (by UBR4) (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/62900b6400000500-Regulation_of_ACLY_by_acetylation_by_PCAF_KAT2B_and_ubiquitination__by_UBR4___Human_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>This GO-CAM model represents the regulatory mechanisms that control ATP-citrate lyase (ACLY) stability through post-translational modifications. The model contains four main activities:</p> <ol> <li>KAT2B (PCAF) performing peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li>SIRT2 performing NAD-dependent protein lysine deacetylase activity (GO:0034979)</li> <li>ACLY performing ATP citrate synthase activity (GO:0003878)</li> <li>UBR4 performing ubiquitin protein ligase activity (GO:0061630)</li> </ol> <p>The model shows a regulatory network where KAT2B acetylates ACLY (positive regulation via RO:0002629), stabilizing it and promoting fatty acid biosynthesis. Conversely, SIRT2 deacetylates ACLY (negative regulation via RO:0002630), which allows UBR4 to ubiquitinate ACLY (RO:0002630), targeting it for degradation. This ultimately inhibits ACLY's role in fatty acid biosynthesis.</p>"},{"location":"reviews/62900b6400000500-Regulation_of_ACLY_by_acetylation_by_PCAF_KAT2B_and_ubiquitination__by_UBR4___Human_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<ol> <li> <p>ACLY Function: The model correctly represents ACLY as a key enzyme in fatty acid biosynthesis (GO:0006633), which is consistent with its known role in converting citrate to acetyl-CoA, a critical substrate for lipid synthesis.</p> </li> <li> <p>Post-translational modifications: The regulatory mechanisms depicted (acetylation/deacetylation and ubiquitination) are supported by the literature. According to the UniProt entries, ACLY is indeed acetylated at multiple lysine residues (K540, K546, K554), which affects its stability. These modifications are mediated by KAT2B/PCAF as shown in the model.</p> </li> <li> <p>SIRT2 deacetylase activity: SIRT2 is correctly shown as a NAD-dependent protein deacetylase that can counteract the acetylation of proteins.</p> </li> <li> <p>UBR4 E3 ligase activity: UBR4 is appropriately represented as an E3 ubiquitin ligase that can target ACLY for degradation when it's not protected by acetylation.</p> </li> <li> <p>Subcellular localization: ACLY's activity is correctly annotated as occurring in the cytosol (GO:0005829).</p> </li> </ol>"},{"location":"reviews/62900b6400000500-Regulation_of_ACLY_by_acetylation_by_PCAF_KAT2B_and_ubiquitination__by_UBR4___Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<ol> <li>Molecular Function terms: The model correctly uses specific molecular function terms for each protein: </li> <li>ACLY: ATP citrate synthase activity (GO:0003878)</li> <li>KAT2B: peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li>SIRT2: NAD-dependent protein lysine deacetylase activity (GO:0034979)</li> <li> <p>UBR4: ubiquitin protein ligase activity (GO:0061630)</p> </li> <li> <p>Biological Process annotations: Each activity is appropriately connected to broader biological processes:</p> </li> <li>ACLY: fatty acid biosynthetic process (GO:0006633)</li> <li>KAT2B and SIRT2: positive/negative regulation of fatty acid biosynthetic process (GO:0045723)</li> <li> <p>UBR4: ubiquitin-dependent protein catabolic process (GO:0006511)</p> </li> <li> <p>Causal relations: The model uses appropriate causal relation predicates:</p> </li> <li>KAT2B directly positively regulates ACLY (RO:0002629)</li> <li>SIRT2 directly negatively regulates ACLY (RO:0002630)</li> <li> <p>UBR4 directly negatively regulates ACLY (RO:0002630)</p> </li> <li> <p>Evidence: All activities and causal associations are supported by literature evidence (ECO:0000314 - direct assay evidence used in manual assertion) and cite PMID:23932781 as the source.</p> </li> <li> <p>Complex representation: The model doesn't include any protein complexes. According to the \"How to annotate complexes in GO-CAM\" guidelines, this is appropriate since the model identifies the specific proteins that carry out each molecular activity rather than using complex IDs.</p> </li> </ol>"},{"location":"reviews/62900b6400000500-Regulation_of_ACLY_by_acetylation_by_PCAF_KAT2B_and_ubiquitination__by_UBR4___Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>Overall, this model is very well constructed and accurately represents the biological pathway. However, there are a few minor points that could be considered for enhancement:</p> <ol> <li> <p>Specific lysine residues: The model could potentially benefit from annotation of which specific lysine residues on ACLY are targeted for acetylation/deacetylation (K540, K546, K554), although this might be beyond the current scope of GO-CAM.</p> </li> <li> <p>Cellular component for KAT2B and SIRT2: While ACLY is correctly annotated as acting in the cytosol, no cellular component information is provided for KAT2B or SIRT2. According to UniProt, KAT2B can be found in both nucleus and cytoplasm, and SIRT2 is predominantly cytoplasmic but can shuttle to the nucleus. Adding this information could provide additional context.</p> </li> <li> <p>Additional participants: The model focuses on the core regulatory elements but could potentially be expanded to include the broader context, such as the acetyl-CoA produced by ACLY feeding into downstream lipid synthesis pathways.</p> </li> </ol>"},{"location":"reviews/62900b6400000500-Regulation_of_ACLY_by_acetylation_by_PCAF_KAT2B_and_ubiquitination__by_UBR4___Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:62900b6400000500) provides an accurate and well-structured representation of the regulation of ACLY by acetylation and ubiquitination. It follows GO-CAM best practices, uses appropriate terms and relations, and is supported by evidence from the literature. The model effectively captures the antagonistic roles of KAT2B and SIRT2 in regulating ACLY stability and function, and how this impacts fatty acid biosynthesis.</p> <p>The model is parsimonious and easy to understand, focusing on the key regulatory mechanisms without unnecessary complexity. It successfully illustrates how post-translational modifications can modulate protein activity and stability, providing a clear example of how cellular metabolism can be regulated at the protein level.</p>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/","title":"62900b6400001630 PTEN in excitatory hippocampal synapse long term depression  Human","text":"<p>Based on the information I have gathered, I will now provide a comprehensive review of the GO-CAM model with ID 62900b6400001630, titled \"PTEN in excitatory hippocampal synapse long-term depression (Human)\".</p>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#review-of-go-cam-model-pten-in-excitatory-hippocampal-synapse-long-term-depression-human","title":"Review of GO-CAM Model: PTEN in excitatory hippocampal synapse long-term depression (Human)","text":""},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#model-overview","title":"Model Overview","text":"<ul> <li>Model ID: gomodel:62900b6400001630</li> <li>Title: PTEN in excitatory hippocampal synapse long-term depression (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> <li>Last automated change: 2023-03-16: RO:0002213 replaced by RO:0002629</li> </ul>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>This model depicts a signaling pathway involved in hippocampal long-term depression (LTD) in humans, focusing on the role of PTEN (phosphatase and tensin homolog). The model includes 5 key molecular activities connected through causal relationships:</p> <ol> <li>NMDA glutamate receptor activity (GO:0004972)</li> <li>Enabled by: NMDA receptor complex (GO:0017146)</li> <li>Occurs in: Postsynaptic density, intracellular component (GO:0099092)</li> <li>Part of: Long-term synaptic depression (GO:0060292)</li> <li> <p>Has input: L-glutamate (CHEBI:29985)</p> </li> <li> <p>Synaptic receptor adaptor activity (GO:0030160)</p> </li> <li>Enabled by: DLG4 (UniProtKB:P78352)</li> <li>Occurs in: Postsynaptic density, intracellular component (GO:0099092)</li> <li> <p>Part of: Long-term synaptic depression (GO:0060292)</p> </li> <li> <p>Phosphatidylinositol phosphate phosphatase activity (GO:0052866)</p> </li> <li>Enabled by: PTEN (UniProtKB:P60484)</li> <li>Occurs in: Postsynaptic density, intracellular component (GO:0099092)</li> <li> <p>Part of: Long-term synaptic depression (GO:0060292)</p> </li> <li> <p>Transcription coactivator activity (GO:0003713)</p> </li> <li>Enabled by: CTNNB1/\u03b2-catenin (UniProtKB:P35222)</li> <li>Occurs in: Chromatin (GO:0000785)</li> <li> <p>Part of: Positive regulation of transcription by RNA polymerase II (GO:0045944)</p> </li> <li> <p>Glycine transmembrane transporter activity (GO:0015187)</p> </li> <li>Enabled by: SLC6A20 (UniProtKB:Q9NP91)</li> <li>Occurs in: Postsynaptic membrane (GO:0045211)</li> <li>Part of: Glycine import across plasma membrane (GO:1903804)</li> <li>Has input/output: Glycine zwitterion (CHEBI:57305)</li> </ol>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model depicts the following causal relationships: 1. NMDA receptor complex activity (GO:0004972) directly positively regulates (RO:0002629) synaptic receptor adaptor activity (GO:0030160) of DLG4 2. DLG4's adaptor activity directly positively regulates (RO:0002629) PTEN's phosphatase activity (GO:0052866) 3. PTEN's phosphatase activity causally upstream with negative effect (RO:0002305) on \u03b2-catenin's transcription coactivator activity (GO:0003713) 4. \u03b2-catenin's transcription activity provides input for (RO:0002407) SLC6A20's glycine transporter activity (GO:0015187)</p>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses various evidence codes and references: - Most activities are supported by sequence similarity evidence (ECO:0000250) or curator inference (ECO:0000305) - \u03b2-catenin's transcription activity is supported by direct assay evidence (ECO:0000314) - Evidence is primarily based on mouse studies and extrapolated to human proteins - Key references include PMID:20628354, PMID:31866820, and PMID:33428810</p>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#strengths","title":"Strengths:","text":"<ol> <li>Biological accuracy: The model correctly represents the role of PTEN in regulating \u03b2-catenin activity and subsequently SLC6A20 expression, consistent with the literature.</li> <li>Appropriate evidence: The model uses appropriate evidence codes for the transferred annotations from mouse studies.</li> <li>Proper use of ontology terms: The activities, cellular locations, and causal relationships use appropriate GO and RO terms.</li> </ol>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#issuesconcerns","title":"Issues/Concerns:","text":"<ol> <li> <p>Input/Output confusion: SLC6A20 has both \"has_input\" and \"has_output\" relationships with glycine zwitterion (CHEBI:57305). This is contradictory as a transporter typically moves molecules in one direction. The literature suggests SLC6A20 primarily imports glycine, so having both input and output is confusing.</p> </li> <li> <p>Missing key components: Based on the literature (PMID:33428810), there is a regulatory relationship where PTEN deletion increases \u03b2-catenin binding to the SLC6A20 promoter. The model shows PTEN negatively regulating \u03b2-catenin, but the intermediate steps (likely involving PI3K/AKT pathway) are missing.</p> </li> <li> <p>Potential mismatch with human biology: The model is annotated for human proteins, but much of the evidence comes from mouse studies. The papers indicate some differences between mouse and human SLC6A20 genes (mice have two genes, SLC6A20A and SLC6A20B, while humans have one).</p> </li> <li> <p>Functional discrepancy in RO:0002407 usage: The model uses \"provides input for\" (RO:0002407) between \u03b2-catenin's transcription activity and SLC6A20 transporter activity. This seems to conflate transcriptional regulation with direct molecular input. It would be more accurate to use a term that indicates transcriptional regulation.</p> </li> <li> <p>Missing causal connection: The relationship between SLC6A20's glycine transport and NMDA receptor function (which requires glycine as a co-agonist) is not explicitly modeled, despite being central to the biological story in the referenced papers.</p> </li> </ol>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Correct the SLC6A20 input/output inconsistency: Remove the \"has_output\" relationship for glycine, as SLC6A20 primarily imports glycine into cells, reducing extracellular glycine concentration.</p> </li> <li> <p>Add intermediate signaling components: Consider adding the PI3K/AKT pathway components that mediate PTEN's regulation of \u03b2-catenin nuclear translocation.</p> </li> <li> <p>Complete the signaling loop: Add a causal relationship showing how SLC6A20-mediated reduction in extracellular glycine affects NMDA receptor function to complete the biological story.</p> </li> <li> <p>Use more appropriate relationship term: Replace RO:0002407 (provides input for) with a relationship term that better captures transcriptional regulation.</p> </li> <li> <p>Add clarifying comments: Add notes to explain the transfer of evidence from mouse to human and any potential species-specific differences in the pathway.</p> </li> </ol>"},{"location":"reviews/62900b6400001630-PTEN_in_excitatory_hippocampal_synapse_long_term_depression__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model correctly captures the core components of PTEN's role in regulating hippocampal synaptic depression through \u03b2-catenin and SLC6A20, but has several issues that should be addressed to improve its accuracy and clarity. The most critical issues are the contradictory input/output relationships for SLC6A20 and the missing causal connection between SLC6A20 and NMDA receptor function. Addressing these issues would make the model a more accurate representation of the biological pathway described in the literature.</p>"},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/","title":"62900b6400002267 Casp7 activates Smpd1 to repair Gasdermin pores in intestinal epithelial cells   Mouse","text":"<p>Now I have enough information to review the model. Let me synthesize what I've learned:</p>"},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/#go-cam-model-review-gomodel62900b6400002267","title":"GO-CAM Model Review: gomodel:62900b6400002267","text":"<p>Title: Casp7 activates Smpd1 to repair Gasdermin pores in intestinal epithelial cells (Mouse)</p>"},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/#model-overview","title":"Model Overview:","text":"<p>This GO-CAM model represents a pathway in which Caspase-7 (Casp7) activates acid sphingomyelinase (Smpd1) to repair Gasdermin D (Gsdmd) pores in intestinal epithelial cells, based on findings from the publication PMID:35705808.</p>"},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/#pathway-representation","title":"Pathway Representation:","text":"<p>The model shows: 1. Caspase-1 (Casp1) with cysteine-type endopeptidase activity (GO:0004197) in the cytosol (GO:0005829) 2. Caspase-1 directly positively regulates (RO:0002629) Gasdermin D (Gsdmd) pore formation 3. Gasdermin D has wide pore channel activity (GO:0022829) in the plasma membrane (GO:0005886) 4. Gasdermin D pore formation directly positively regulates (RO:0002629) Caspase-7 (Casp7) 5. Caspase-7 has cysteine-type endopeptidase activity (GO:0004197) in the extracellular space (GO:0005615) 6. Caspase-7 directly positively regulates (RO:0002629) Smpd1 7. Smpd1 has acid sphingomyelin phosphodiesterase activity (GO:0061750) in the extracellular space 8. Smpd1 activity produces ceramide (CHEBI:52639)</p>"},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/#quality-assessment","title":"Quality Assessment:","text":""},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the biological pathway described in the literature</li> <li>Appropriate molecular functions are assigned to each protein</li> <li>The causal relationships between activities are logically represented</li> <li>The cellular components (locations) are correctly assigned</li> <li>Evidence is properly cited with the relevant PMID</li> </ol>"},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/#issues-identified","title":"Issues Identified:","text":"<ol> <li> <p>Duplicate causal association: There appears to be a duplicate causal association between Casp7 and Smpd1. The model shows two identical causal associations with the same predicate (RO:0002629).</p> </li> <li> <p>Disconnected activity: The model includes an additional Gasdermin D (Gsdmd) activity node (gomodel:62900b6400002267/62900b6400002299) that is not connected to the main causal flow. It is annotated as part of pyroptotic inflammatory response (GO:0070269) but lacks causal connections to other activities.</p> </li> <li> <p>Biological process context: While each activity is correctly associated with a biological process, the model would benefit from more explicit connections between these processes to show how protein maturation, protein secretion, ceramide biosynthesis, and membrane repair relate to each other in this context.</p> </li> <li> <p>Missing direct connection to membrane repair: The model doesn't explicitly show how ceramide production leads to membrane repair. According to the literature, ceramides repair membranes and counteract the action of gasdermin-D pores, but this final outcome is not represented in the causal flow.</p> </li> </ol>"},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Remove the duplicate causal association between Casp7 and Smpd1.</p> </li> <li> <p>Either connect the isolated Gsdmd activity (gomodel:62900b6400002267/62900b6400002299) to the main causal flow or remove it if redundant.</p> </li> <li> <p>Consider adding a final connection showing how Smpd1-produced ceramide contributes to plasma membrane repair (GO:0001778), which is one of the objects defined in the model but not used in the causal flow.</p> </li> <li> <p>Consider adding a negative regulation relationship from Smpd1's activity to Gsdmd pore activity to show how this repair mechanism counteracts the pore formation.</p> </li> <li> <p>Evaluate whether the model should show the relationship between this pathway and the extrusion of intestinal epithelial cells mentioned in the literature.</p> </li> </ol>"},{"location":"reviews/62900b6400002267-Casp7_activates_Smpd1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells___Mouse_/#conclusion","title":"Conclusion:","text":"<p>Overall, the model accurately represents the core biological pathway described in the literature, with appropriate molecular functions, cellular components, and evidence. The recommended changes would improve the model's completeness and clarity but don't detract significantly from its scientific accuracy.</p> <p>GO-CAM model 62900b6400002267 provides a valuable representation of this newly discovered mechanism for plasma membrane pore repair mediated by caspase-7, which is an important pathway in intestinal epithelial cell response to infection.</p>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/","title":"62900b6400002353 Casp7 activates Smpd1 to repair perforin pores in hepatocytes  Mouse","text":"<p>Based on all the information gathered, I'll now provide a comprehensive review of the GO-CAM model \"gomodel:62900b6400002353\":</p>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#review-of-go-cam-model-62900b6400002353","title":"Review of GO-CAM Model 62900b6400002353","text":""},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:62900b6400002353</li> <li>Title: Casp7 activates Smpd1 to repair perforin pores in hepatocytes (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model represents the molecular pathway through which Caspase-7 (Casp7) activates Acid Sphingomyelinase (Smpd1) to repair perforin pores in mouse hepatocytes. The model includes 5 activities connected by causal associations that depict how perforin forms pores in the plasma membrane, which allows granzyme B to enter the cell, activating Casp7, which in turn activates Smpd1 to generate ceramide, ultimately repairing the perforin pore.</p>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#detailed-analysis","title":"Detailed Analysis","text":""},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#pathway-flow-and-logic","title":"Pathway Flow and Logic","text":"<p>The pathway flow is logical and correctly represents the biological process described in the literature (PMID:35705808). The model illustrates:</p> <ol> <li>Perforin (Prf1) creates pores in the plasma membrane of hepatocytes</li> <li>These pores allow Granzyme B (Gzmb) to enter the cell </li> <li>Granzyme B activates Caspase-7 (Casp7)</li> <li>Caspase-7 activates Acid Sphingomyelinase (Smpd1)</li> <li>Smpd1 generates ceramide (CHEBI:52639), which helps repair the perforin pores</li> </ol> <p>The causal relationships and regulatory processes are appropriately modeled using the correct predicates (RO:0002629 - directly positively regulates).</p>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#molecular-activities-and-functions","title":"Molecular Activities and Functions","text":"<p>All molecular activities are appropriately annotated:</p> <ol> <li>Prf1 (MGI:MGI:97551) - Wide pore channel activity (GO:0022829)</li> <li>Occurs in plasma membrane (GO:0005886)</li> <li> <p>Part of granzyme-mediated programmed cell death signaling pathway (GO:0140507)</p> </li> <li> <p>Gzmb (MGI:MGI:109267) - Serine-type endopeptidase activity (GO:0004252)</p> </li> <li>Occurs in cytoplasm (GO:0005737)</li> <li>Part of protein maturation (GO:0051604)</li> <li> <p>Directly positively regulates Prf1's wide pore channel activity</p> </li> <li> <p>Casp7 (MGI:MGI:109383) - Cysteine-type endopeptidase activity (GO:0004197)</p> </li> <li>Occurs in extracellular space (GO:0005615)</li> <li>Part of protein maturation (GO:0051604)</li> <li> <p>Directly positively regulates Smpd1's acid sphingomyelin phosphodiesterase activity</p> </li> <li> <p>Smpd1 (MGI:MGI:98325) - Acid sphingomyelin phosphodiesterase activity (GO:0061750)</p> </li> <li>Occurs in extracellular space (GO:0005615)</li> <li>Part of ceramide biosynthetic process (GO:0046513)</li> <li>Has output molecule ceramide (CHEBI:52639)</li> </ol>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>All activities and associations are properly supported by evidence from the publication PMID:35705808 using the evidence code \"direct assay evidence used in manual assertion\" (ECO:0000314), which is appropriate for this type of experimental data.</p>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#cellular-locations","title":"Cellular Locations","text":"<p>The cellular locations for each activity are biologically accurate: - Perforin forms pores in the plasma membrane (GO:0005886) - Granzyme B acts in the cytoplasm (GO:0005737) - Casp7 and Smpd1 act in the extracellular space (GO:0005615), consistent with the model's description of Casp7 being secreted through the perforin pore to activate Smpd1 extracellularly</p>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#conformity-with-go-cam-best-practices","title":"Conformity with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Complex representation: The model correctly represents individual proteins rather than complexes, as the specific activities of each protein are known.</p> </li> <li> <p>Causal associations: The model correctly uses the \"directly positively regulates\" (RO:0002629) predicate to show direct causal relationships.</p> </li> <li> <p>Molecular outputs: The production of ceramide (CHEBI:52639) by Smpd1 is properly modeled as an output of the acid sphingomyelin phosphodiesterase activity.</p> </li> <li> <p>Biological process context: Each activity is correctly associated with an appropriate biological process.</p> </li> </ol>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on the UniProt entries for the proteins involved and the reference publication, the model accurately represents the biological pathway:</p> <ol> <li>Perforin (Prf1) forms pores in target cell membranes to allow entry of granzymes</li> <li>Granzyme B (Gzmb) is a serine protease that can cleave and activate Caspase-7</li> <li>Caspase-7 (Casp7) is described in UniProt as \"cleaved and activated by granzyme B (GZMB) in response to bacterial infection, promoting its secretion to the extracellular milieu, where it catalyzes activation of SMPD1, generating ceramides that repair membranes and counteract the action of perforin (PRF1) pores\"</li> <li>Acid Sphingomyelinase (Smpd1) hydrolyzes sphingomyelin to ceramide and phosphocholine</li> </ol> <p>The model correctly captures the finding from the paper that Caspase-7 has a unique function in activating Acid Sphingomyelinase to repair perforin pores, rather than inducing cell death.</p>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#recommendations","title":"Recommendations","text":"<p>The model is well-constructed and accurately represents the biological pathway. No substantial changes are needed, but a few minor suggestions:</p> <ol> <li> <p>Clarity on feedback loop: The model could more explicitly show that the ceramide produced by Smpd1 contributes to membrane repair that counteracts the perforin pores. Consider adding a negative regulation edge from the Smpd1 activity back to the Prf1 activity to complete the feedback loop.</p> </li> <li> <p>Additional biological process context: The final part of the pathway (Smpd1 activity) could also be annotated as part of \"plasma membrane repair\" (GO:0001778) in addition to \"ceramide biosynthetic process\" to better represent the overall functional outcome.</p> </li> <li> <p>Considering additional evidence: If available, consider adding specific experimental evidence for each causal relationship in the pathway.</p> </li> </ol>"},{"location":"reviews/62900b6400002353-Casp7_activates_Smpd1_to_repair_perforin_pores_in_hepatocytes__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a high-quality representation of the pathway by which Caspase-7 activates Acid Sphingomyelinase to repair perforin pores in hepatocytes. It accurately captures the biological process described in the literature and follows GO-CAM best practices. The model effectively illustrates an important pathway in cellular defense and membrane repair mechanisms.</p>"},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/","title":"62900b6400002552 Cobalamin transport  into enterocytes  Mouse","text":"<p>Based on all the information gathered, I will now provide a comprehensive review of the GO-CAM model for cobalamin transport into enterocytes (Mouse) (gomodel:62900b6400002552).</p>"},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/#go-cam-model-review-cobalamin-transport-into-enterocytes-mouse","title":"GO-CAM Model Review: Cobalamin transport, into enterocytes (Mouse)","text":""},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/#model-overview","title":"Model Overview","text":"<p>The model represents the molecular mechanism of cobalamin (vitamin B12) transport into enterocytes in mouse, with ID gomodel:62900b6400002552. This model depicts the sequence of events involved in vitamin B12 absorption from the intestinal lumen into enterocytes, including the binding proteins, receptors, and transporters involved in this process.</p>"},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/#model-structure-and-biological-content","title":"Model Structure and Biological Content","text":"<p>The model includes 9 molecular activities that work together to represent the cobalamin transport pathway:</p> <ol> <li>Tcn2 (MGI:MGI:98534) performs molecular carrier activity (GO:0140104) in the extracellular space, carrying cobalamin (CHEBI:140785)</li> <li>Prss1, Ctrb1, and Prss3 (serine-type peptidases) cleave proteins in the extracellular space</li> <li>Cblif (MGI:MGI:1202394) performs both molecular carrier activity and cargo receptor ligand activity in the extracellular space</li> <li>Amn1 and Cubn (MGI:MGI:2442933, MGI:MGI:1931256) function as cargo receptors in the microvillus membrane</li> <li>Lmbrd1 (MGI:MGI:1915671) performs protein transporter activity</li> <li>Abcd4 (MGI:MGI:1349217) functions as an ABC-type vitamin B12 transporter</li> </ol>"},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate pathway representation: The model correctly depicts the known sequence of events in cobalamin absorption, from binding in the gut lumen to transport into the enterocyte.</p> </li> <li> <p>Well-supported by evidence: Most activities have appropriate evidence codes and references from the literature.</p> </li> <li> <p>Proper use of causal relationships: The model uses appropriate causal predicates (RO:0002413 \"provides input for\" and RO:0002629 \"directly positively regulates\") to connect the molecular functions.</p> </li> <li> <p>Accurate subcellular locations: Components are appropriately located in extracellular space, microvillus membrane, or other cellular compartments.</p> </li> </ol>"},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing location annotations: A few molecular functions lack explicit cellular location annotations, specifically:</li> <li>MGI:MGI:1915671 (Lmbrd1) has no specified cellular location</li> <li> <p>MGI:MGI:1349217 (Abcd4) has no specified cellular location</p> </li> <li> <p>Incomplete evidence: Some causal associations lack evidence annotations, which should ideally be provided for all relationships.</p> </li> <li> <p>Ambiguous complex representation: The model handles the Amn1-Cubn complex correctly by showing how Cblif-cobalamin positively regulates both receptors, but it doesn't explicitly model them as a complex (CUBAM). According to the GO-CAM guidelines for annotating complexes, when the subunits carrying specific molecular activities are known, representing the individual proteins (as done here) is appropriate.</p> </li> <li> <p>Missing internal transport steps: The model could more explicitly represent how cobalamin moves from the lysosome to the cytoplasm after endocytosis.</p> </li> </ol>"},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the current understanding of cobalamin transport:</p> <ol> <li> <p>Extracellular events: Correctly shows that dietary cobalamin is initially bound to transcobalamin (Tcn2) and then processed by digestive enzymes (Prss1, Ctrb1, Prss3).</p> </li> <li> <p>Receptor-mediated endocytosis: Correctly depicts that cobalamin bound to intrinsic factor (Cblif) is recognized by the CUBAM receptor complex (Amn1 and Cubn) in the microvillus membrane.</p> </li> <li> <p>Intracellular processing: Shows the role of Lmbrd1 in protein transport and Abcd4 in ATP-dependent vitamin B12 transport, consistent with literature.</p> </li> <li> <p>Causal relationships: The model correctly represents the flow of cobalamin from extracellular binding to cellular uptake and transport, using appropriate causal relationships.</p> </li> </ol>"},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add cellular locations: Specify the cellular locations for Lmbrd1 (lysosomal membrane) and Abcd4 (lysosomal or mitochondrial membrane).</p> </li> <li> <p>Add evidence for causal links: Provide literature evidence for all causal associations.</p> </li> <li> <p>Consider refining lysosomal processing steps: The model could be expanded to show more details of lysosomal processing of the cobalamin-IF complex.</p> </li> <li> <p>Consider adding downstream metabolic pathways: The model could be extended to include what happens to cobalamin after it enters the cell, including conversion to methylcobalamin and adenosylcobalamin.</p> </li> </ol>"},{"location":"reviews/62900b6400002552-Cobalamin_transport__into_enterocytes__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:62900b6400002552 is a well-constructed GO-CAM that accurately represents the current understanding of cobalamin transport into enterocytes in mice. The model follows GO-CAM best practices for most aspects, with only minor opportunities for improvement in terms of adding more complete cellular location annotations and evidence for causal relationships. The biological content is accurate and consistent with the scientific literature on vitamin B12 absorption.</p>"},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/","title":"62900b6400002879 Dermatan sulfate catabolic process  Mouse","text":"<p>Now, let's review the GO-CAM model for dermatan sulfate catabolic process (Mouse) based on all the information gathered:</p>"},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/#go-cam-model-review-dermatan-sulfate-catabolic-process-mouse","title":"GO-CAM Model Review: Dermatan Sulfate Catabolic Process (Mouse)","text":""},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>I'll be reviewing the GO-CAM model gomodel:62900b6400002879 which describes the \"Dermatan sulfate catabolic process (Mouse)\".</p> <p>This model represents the pathway for the degradation of dermatan sulfate in mouse lysosomes. Dermatan sulfate is a glycosaminoglycan (GAG) that is one of the components of the extracellular matrix. The proper degradation of dermatan sulfate requires several lysosomal enzymes working in sequence.</p>"},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/#model-components-and-activities","title":"Model Components and Activities","text":"<p>The model includes the following key protein activities:</p> <ol> <li>Arylsulfatase B (Arsb) - MGI:MGI:88075</li> <li>Function: N-acetylgalactosamine-6-sulfatase activity (GO:0043890)</li> <li>Location: Lysosome (GO:0005764)</li> <li> <p>Role: Removes sulfate groups from chondroitin-4-sulfate and dermatan sulfate</p> </li> <li> <p>Iduronate-2-sulfatase (Ids) - MGI:MGI:96417</p> </li> <li>Function: Iduronate-2-sulfatase activity (GO:0004423)</li> <li>Location: Lysosome (GO:0005764)</li> <li> <p>Role: Removes 2-sulfate groups from L-iduronate units of dermatan sulfate</p> </li> <li> <p>Alpha-L-iduronidase (Idua) - MGI:MGI:96418</p> </li> <li>Function: L-iduronidase activity (GO:0003940)</li> <li>Location: Lysosome (GO:0005764)</li> <li> <p>Role: Hydrolyzes alpha-L-iduronosidic linkages in dermatan sulfate</p> </li> <li> <p>Beta-hexosaminidase subunit alpha (Hexa) - MGI:MGI:96073</p> </li> <li>Function: Beta-N-acetylhexosaminidase activity (GO:0004563)</li> <li>Location: Lysosome (GO:0005764)</li> <li> <p>Role: Hydrolyzes terminal N-acetylgalactosamine residues</p> </li> <li> <p>Beta-hexosaminidase subunit beta (Hexb) - MGI:MGI:96074</p> </li> <li>Function: Beta-N-acetylhexosaminidase activity (GO:0004563)</li> <li>Location: Lysosome (GO:0005764)</li> <li>Role: Hydrolyzes terminal N-acetylgalactosamine residues</li> </ol>"},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model shows a sequential degradation pathway with causal relationships between enzymes using the \"provides input for\" (RO:0002413) predicate:</p> <ol> <li>Arsb activity \u2192 Ids activity</li> <li>Ids activity \u2192 Idua activity and Hexb activity</li> <li>Idua activity \u2192 Hexa activity</li> <li>Hexa activity \u2192 Idua activity</li> <li>Hexb activity \u2192 Hexa activity</li> </ol>"},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/#scientific-evidence-assessment","title":"Scientific Evidence Assessment","text":"<p>The model is well supported by scientific evidence:</p> <ol> <li> <p>Arsb (N-acetylgalactosamine-6-sulfatase) removes sulfate groups from dermatan sulfate, as documented in PMID:24240681. This function is correctly represented.</p> </li> <li> <p>Ids (Iduronate-2-sulfatase) degrades dermatan sulfate by removing sulfate groups from L-iduronate residues. Evidence from PMID:30064964 supports this.</p> </li> <li> <p>Idua (Alpha-L-iduronidase) hydrolyzes unsulfated alpha-L-iduronosidic linkages in dermatan sulfate. This is supported by evidence from PMID:19751987 and PMID:25854773.</p> </li> <li> <p>Hexa and Hexb (Beta-hexosaminidases) hydrolyze terminal N-acetylgalactosamine residues in dermatan sulfate degradation. Evidence from PMID:11707436 supports the involvement of these enzymes.</p> </li> </ol>"},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/#correctness-of-the-model","title":"Correctness of the Model","text":"<p>The model correctly represents:</p> <ol> <li>The sequential nature of dermatan sulfate degradation in lysosomes</li> <li>The required enzymatic activities and their subcellular localization</li> <li>The causal relationships between enzymatic activities</li> <li>The relevant biological process annotations (dermatan sulfate catabolic process)</li> </ol> <p>The causal relationships using the \"provides input for\" predicate accurately reflect how each enzymatic activity in the pathway prepares the substrate for the next enzyme.</p>"},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/#qc-analysis","title":"QC Analysis","text":"<ol> <li> <p>Biological Accuracy: The model accurately represents the dermatan sulfate degradation pathway based on current scientific knowledge.</p> </li> <li> <p>Evidence Support: Each activity is appropriately supported by experimental evidence, with correct citations to relevant literature.</p> </li> <li> <p>Ontology Usage: The correct GO terms are used for molecular functions, cellular components, and biological processes.</p> </li> <li> <p>Causal Relations: The causal relations between activities are appropriately represented with the correct predicate (\"provides input for\").</p> </li> <li> <p>Completeness: The model includes all the major enzymes known to be involved in dermatan sulfate degradation.</p> </li> </ol>"},{"location":"reviews/62900b6400002879-Dermatan_sulfate_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62900b6400002879 for \"Dermatan sulfate catabolic process (Mouse)\" is scientifically accurate, well-supported by evidence, and appropriately models the process of dermatan sulfate degradation in mouse lysosomes. The model effectively captures the sequential nature of this pathway and the role of each enzyme in the process.</p> <p>The model is consistent with our current understanding of dermatan sulfate catabolism and properly incorporates evidence from multiple research papers. It correctly represents the defects in this pathway that lead to mucopolysaccharidosis disorders when any of these enzymes is deficient.</p>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/","title":"62b4ffe300000010 CASP7 activates SMPD1 to repair Gasdermin pores in intestinal epithelial cells  Human","text":"<p>Now, let me review the GO-CAM model gomodel:62b4ffe300000010 based on the information gathered:</p>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#review-of-go-cam-model-gomodel62b4ffe300000010","title":"Review of GO-CAM Model: gomodel:62b4ffe300000010","text":""},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#model-summary","title":"Model Summary","text":"<p>Title: \"CASP7 activates SMPD1 to repair Gasdermin pores in intestinal epithelial cells (Human)\" Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#model-overview","title":"Model Overview","text":"<p>This model describes how caspase-7 (CASP7) cleaves acid sphingomyelinase (SMPD1) in the extracellular space, leading to SMPD1 activation and subsequent conversion of sphingomyelin to ceramide. This process is involved in membrane repair and specifically helps counteract the membrane-permeabilizing effects of gasdermin D (GSDMD) pores that form during pyroptosis in intestinal epithelial cells.</p>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#entities-and-activities","title":"Entities and Activities","text":"<p>The model contains several key entities with their molecular functions:</p> <ol> <li>CASP7 (P55210): </li> <li>Molecular function: Cysteine-type endopeptidase activity (GO:0004197)</li> <li>Occurs in: Extracellular space (GO:0005615)</li> <li>Part of: Protein maturation (GO:0051604)</li> <li> <p>Directly positively regulates: SMPD1's sphingomyelinase activity</p> </li> <li> <p>SMPD1 (P17405):</p> </li> <li>Molecular function: Acid sphingomyelin phosphodiesterase activity (GO:0061750)</li> <li>Occurs in: Extracellular space (GO:0005615)</li> <li>Part of: Ceramide biosynthetic process (GO:0046513)</li> <li>Has output: N-acylsphingosine (CHEBI:52639) [ceramide]</li> <li> <p>Directly negatively regulates: GSDMD pore activity</p> </li> <li> <p>GSDMD (P57764) (two forms):</p> </li> <li> <p>Form 1: </p> <ul> <li>Molecular function: Wide pore channel activity (GO:0022829)</li> <li>Occurs in: Plasma membrane (GO:0005886)</li> <li>Part of: Protein secretion (GO:0009306)</li> <li>Directly positively regulates: CASP7's endopeptidase activity</li> </ul> </li> <li> <p>Form 2:</p> <ul> <li>Molecular function: Wide pore channel activity (GO:0022829)</li> <li>Occurs in: Membrane (GO:0016020)</li> <li>Part of: Pyroptotic inflammatory response (GO:0070269)</li> </ul> </li> <li> <p>GSDMD (P57764) with phosphatidylinositol-4,5-bisphosphate binding activity:</p> </li> <li>Molecular function: Phosphatidylinositol-4,5-bisphosphate binding (GO:0005546)</li> <li>Occurs in: Plasma membrane (GO:0005886)</li> <li>Part of: Pyroptotic inflammatory response (GO:0070269)</li> <li>Directly positively regulates: GSDMD's wide pore channel activity</li> </ol>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model accurately captures the sequence of events in GSDMD pore formation and subsequent repair mediated by CASP7 activation of SMPD1.</li> <li>The molecular functions assigned to each protein are appropriate based on their known activities.</li> <li>The cellular locations are correctly specified for each activity.</li> <li>The causal relationships between activities are accurately represented.</li> <li>The model appropriately includes the role of phosphatidylinositol-4,5-bisphosphate binding in GSDMD pore formation.</li> </ol>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#areas-for-improvementconsiderations","title":"Areas for Improvement/Considerations","text":"<ol> <li> <p>Missing GSDMD Cleavage: The model doesn't explicitly show the cleavage of GSDMD by caspase-1, which is a prerequisite for GSDMD pore formation according to the literature. In PMID:33883744, it's explained that GSDMD is cleaved to release the N-terminal domain which forms the pore.</p> </li> <li> <p>CASP7 Origin: The model shows CASP7 as already present in the extracellular space, but according to the literature (PMID:33883744), CASP7 is likely released through the GSDMD pores. This causal relationship could be better represented.</p> </li> <li> <p>Phospholipid Binding Representation: While the model does include GSDMD phosphatidylinositol-4,5-bisphosphate binding, the exact mechanism of how this facilitates GSDMD pore formation could be more clearly represented.</p> </li> <li> <p>Cellular Location Precision: One instance of GSDMD pore activity is annotated as occurring in \"membrane\" (GO:0016020) which is less specific than \"plasma membrane\" (GO:0005886) used elsewhere. Consistency would improve the model.</p> </li> <li> <p>Process Association: Some \"part of\" associations could be more specific. For example, SMPD1's activity as part of \"ceramide biosynthetic process\" could additionally be linked to \"plasma membrane repair\" (GO:0001778) as mentioned in UniProt.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#biological-content-validation","title":"Biological Content Validation","text":"<p>The biological content aligns well with current literature:</p> <ol> <li> <p>The model correctly represents CASP7's role in activating SMPD1 by proteolytic cleavage as described in PMID:21157428.</p> </li> <li> <p>The generation of ceramide by SMPD1 and its role in counteracting GSDMD pores is consistent with the literature (PMID:33883744).</p> </li> <li> <p>The representation of GSDMD forming pores in the plasma membrane following activation is accurate, though as mentioned, the cleavage event leading to GSDMD activation could be included.</p> </li> <li> <p>The binding of GSDMD to phosphatidylinositol-4,5-bisphosphate as part of its activation process is accurately represented and supported by the literature (PMID:33883744).</p> </li> </ol>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add GSDMD Cleavage: Include the cleavage of GSDMD by caspase-1, showing how this leads to the release of the N-terminal domain that forms pores.</p> </li> <li> <p>Clarify CASP7 Movement: Represent that CASP7 is likely released through the GSDMD pores into the extracellular space.</p> </li> <li> <p>Consistent Cell Locations: Ensure all GSDMD pore activities are consistently annotated with the same cellular location (plasma membrane).</p> </li> <li> <p>Add Membrane Repair Process: Add \"plasma membrane repair\" (GO:0001778) as a process that SMPD1 activity is part of.</p> </li> <li> <p>Connection to Inflammation: Consider adding more context about how this process relates to the broader inflammatory response in intestinal epithelial cells.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000010-CASP7_activates_SMPD1_to_repair_Gasdermin_pores_in_intestinal_epithelial_cells__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the key activities and causal relationships in GSDMD pore formation and the CASP7-SMPD1 repair mechanism. The model is well-constructed overall and accurately captures the molecular functions and biological processes involved. With a few refinements as suggested above, the model could more comprehensively represent this biological pathway as described in current literature.</p> <p>The model provides valuable insights into a mechanism by which cells can survive pyroptosis through CASP7-mediated activation of SMPD1, generating ceramide to repair GSDMD pores in the plasma membrane.</p>"},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/","title":"62b4ffe300000067 Poxvirus OPG044 inhibition of interferon beta induction  Human Poxvirus","text":"<p>Now, let me examine the GO-CAM model in detail based on all the information gathered.</p>"},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#review-of-go-cam-model-gomodel62b4ffe300000067","title":"Review of GO-CAM Model: gomodel:62b4ffe300000067","text":""},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#model-overview","title":"Model Overview","text":"<p>Title: Poxvirus-OPG044 inhibition of interferon beta induction (Human-Poxvirus) ID: gomodel:62b4ffe300000067 Taxon: Human (NCBITaxon:9606) Status: Production  </p>"},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#model-structure","title":"Model Structure","text":"<p>This model depicts the mechanism by which poxvirus protein OPG044 (K7) inhibits the induction of interferon beta by targeting DDX3X, preventing IRF3 activation. The model has 4 activities connected by causal relationships:</p> <ol> <li>DDX3X (O00571) - has \"signaling adaptor activity\" (GO:0035591)</li> <li>IKBKE/IKK\u03b5 (Q14164) - has \"protein serine/threonine kinase activity\" (GO:0004674)</li> <li>IRF3 (Q14653-5) - has \"DNA-binding transcription activator activity\" (GO:0001216)</li> <li>Poxvirus OPG044/K7 (P68466) - has \"protein sequestering activity\" (GO:0140311)</li> </ol> <p>The causal relationships are: - Poxvirus OPG044 negatively regulates DDX3X via direct sequestration - DDX3X positively regulates IKBKE  - IKBKE positively regulates IRF3</p>"},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#scientific-evaluation","title":"Scientific Evaluation","text":""},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#1-functional-accuracy","title":"1. Functional Accuracy","text":"<p>The model correctly represents the scientific understanding of how poxvirus K7 protein inhibits interferon production:</p> <ul> <li> <p>DDX3X as an adaptor protein: DDX3X functions as a signaling adaptor in the interferon pathway, linking IKBKE to IRF3. The model correctly annotates this with GO:0035591 (signaling adaptor activity).</p> </li> <li> <p>IKBKE/IKK\u03b5 role: IKBKE correctly functions as a protein kinase (GO:0004674) that phosphorylates IRF3, which is required for IRF3 activation.</p> </li> <li> <p>IRF3 function: IRF3, when activated, functions as a transcription activator (GO:0001216) that induces interferon beta production.</p> </li> <li> <p>Viral inhibitory mechanism: Vaccinia virus protein K7 is correctly shown inhibiting this pathway through sequestration of DDX3X (GO:0140311), preventing DDX3X from coupling IKBKE to IRF3.</p> </li> </ul>"},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#2-evidence-support","title":"2. Evidence Support","text":"<p>The model includes appropriate evidence codes and references:</p> <ul> <li>All activities are supported by ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>Key references include PMID:18636090, PMID:23478265, and PMID:12692549</li> <li>The contributor ORCID (0000-0001-7646-0052) is consistently provided</li> </ul>"},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#3-structural-assessment","title":"3. Structural Assessment","text":"<p>The model follows GO-CAM best practices for structural representation:</p> <ul> <li>The causal relationships use appropriate relation ontology terms:</li> <li>RO:0002630 (directly negatively regulates) for K7 inhibition of DDX3X</li> <li> <p>RO:0002629 (directly positively regulates) for positive regulatory relationships</p> </li> <li> <p>The model includes appropriate subcellular locations:</p> </li> <li>DDX3X and IKBKE in cytoplasm (GO:0005737)</li> <li> <p>IRF3 in nucleus (GO:0005634)</p> </li> <li> <p>The model correctly represents the involvement in the biological process of positive regulation of type I interferon production (GO:0032481)</p> </li> </ul>"},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#4-improvementsrecommendations","title":"4. Improvements/Recommendations","text":"<ol> <li> <p>Additional molecular details: The model could be enhanced by explicitly representing the phosphorylation of IRF3 at Ser-386 and Ser-396, which are key for IRF3 activation.</p> </li> <li> <p>Mechanistic refinement: The model could better represent the specific domains involved in the interaction between K7 and DDX3X (K7 binds to residues 71-90 of DDX3X).</p> </li> <li> <p>Biological context: The model appropriately represents the viral mechanism of immune evasion, but could be expanded to show downstream effects on interferon beta gene expression.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000067-Poxvirus_OPG044_inhibition_of_interferon_beta_induction__Human_Poxvirus_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62b4ffe300000067 accurately represents the scientific understanding of how vaccinia virus K7 protein inhibits interferon production by targeting DDX3X. The model follows GO-CAM best practices with appropriate activities, causal relationships, cellular locations, and supporting evidence.</p> <p>The model effectively shows how viruses can target host signaling pathways to evade immune responses, specifically how poxvirus protein K7 disrupts the DDX3X-IKBKE-IRF3 pathway that leads to interferon production. This representation aligns with the published literature on DDX3X's role in innate immune signaling and viral evasion strategies.</p> <p>Overall, this is a well-constructed GO-CAM model that meets quality standards for representing biological mechanisms in the context of host-pathogen interactions.</p>"},{"location":"reviews/62b4ffe300000081-CASP7_activates_SMPD1_to_repair_perforin_pores_in_hepatocytes__Human_/","title":"62b4ffe300000081 CASP7 activates SMPD1 to repair perforin pores in hepatocytes  Human","text":"<p>Now I'll compile my review of the GO-CAM model:</p>"},{"location":"reviews/62b4ffe300000081-CASP7_activates_SMPD1_to_repair_perforin_pores_in_hepatocytes__Human_/#review-of-go-cam-model-gomodel62b4ffe300000081","title":"Review of GO-CAM Model gomodel:62b4ffe300000081","text":""},{"location":"reviews/62b4ffe300000081-CASP7_activates_SMPD1_to_repair_perforin_pores_in_hepatocytes__Human_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:62b4ffe300000081) is titled \"CASP7 activates SMPD1 to repair perforin pores in hepatocytes (Human)\" and represents a specific biological mechanism where Caspase-7 (CASP7) activates Sphingomyelin phosphodiesterase (SMPD1) to repair membrane pores created by perforin (PRF1) in hepatocytes.</p>"},{"location":"reviews/62b4ffe300000081-CASP7_activates_SMPD1_to_repair_perforin_pores_in_hepatocytes__Human_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model includes four key proteins/activities:</p> <ol> <li>Perforin (PRF1, UniProtKB:P14222) - Forms wide pore channels in the cell membrane</li> <li>Granzyme B (GZMB, UniProtKB:P10144) - A serine-type endopeptidase that activates CASP7</li> <li>Caspase-7 (CASP7, UniProtKB:P55210) - A cysteine-type endopeptidase that activates SMPD1</li> <li>Sphingomyelin phosphodiesterase (SMPD1, UniProtKB:P17405) - An acid sphingomyelin phosphodiesterase that repairs membrane pores</li> </ol> <p>The causal flow in the model is: - GZMB activates CASP7 (RO:0002629 - directly positively regulates) - PRF1 forms pores in the membrane (using wide pore channel activity) and activates CASP7 (RO:0002629) - CASP7 activates SMPD1 (RO:0002629) - SMPD1 produces ceramide (CHEBI:52639) which repairs perforin pores in membranes</p>"},{"location":"reviews/62b4ffe300000081-CASP7_activates_SMPD1_to_repair_perforin_pores_in_hepatocytes__Human_/#scientific-accuracy-review","title":"Scientific Accuracy Review","text":"<p>The model is well-supported by evidence from multiple primary literature sources:</p> <ol> <li> <p>PRF1 wide pore channel activity (GO:0022829): This is supported by PMID:20889983, which demonstrates that perforin forms heterogeneous pores in cell membranes that vary in conductance and size (10-25nm). The evidence code ECO:0000314 (direct assay evidence) is appropriate.</p> </li> <li> <p>CASP7 activation by GZMB: Supported by PMID:9852092 and PMID:31953257, showing that granzyme B can directly activate executioner caspases including caspase-7. The evidence code ECO:0000314 (direct assay evidence) is appropriate.</p> </li> <li> <p>SMPD1 activation by CASP7: Supported by PMID:21157428, which demonstrates that caspase-7 can cleave and activate SMPD1 in response to bacterial infection, promoting membrane repair. The evidence code ECO:0000314 (direct assay evidence) is appropriate.</p> </li> <li> <p>SMPD1 role in ceramide production and membrane repair: Supported by PMID:17303575, which shows that activated SMPD1 converts sphingomyelin to ceramide, which helps repair membrane pores. The evidence code ECO:0000314 (direct assay evidence) is appropriate.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000081-CASP7_activates_SMPD1_to_repair_perforin_pores_in_hepatocytes__Human_/#evaluation-of-model-construction","title":"Evaluation of Model Construction","text":"<ol> <li> <p>Appropriate use of evidence codes: All annotations use ECO:0000314 (direct assay evidence) or ECO:0000250 (sequence similarity evidence), which are appropriate for the claims made.</p> </li> <li> <p>Correct causal connections: The model correctly uses RO:0002629 (directly positively regulates) for the causal relationships between activities.</p> </li> <li> <p>Cellular locations: The model correctly represents:</p> </li> <li>PRF1 activity occurring in the membrane (GO:0016020)</li> <li>GZMB activity in the cytoplasm (GO:0005737)</li> <li>CASP7 activity in the extracellular space (GO:0005615)</li> <li> <p>SMPD1 activity in the extracellular space (GO:0005615)</p> </li> <li> <p>Molecular function annotations: All proteins have appropriate molecular function annotations:</p> </li> <li>PRF1: wide pore channel activity (GO:0022829)</li> <li>GZMB: serine-type endopeptidase activity (GO:0004252)</li> <li>CASP7: cysteine-type endopeptidase activity (GO:0004197)</li> <li> <p>SMPD1: acid sphingomyelin phosphodiesterase activity (GO:0061750)</p> </li> <li> <p>Biological process annotations: All activities are appropriately linked to biological processes:</p> </li> <li>PRF1: protein secretion (GO:0009306) and granzyme-mediated programmed cell death signaling pathway (GO:0140507)</li> <li>GZMB: protein maturation (GO:0051604)</li> <li>CASP7: protein maturation (GO:0051604)</li> <li>SMPD1: ceramide biosynthetic process (GO:0046513)</li> </ol>"},{"location":"reviews/62b4ffe300000081-CASP7_activates_SMPD1_to_repair_perforin_pores_in_hepatocytes__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Specify Cell Type: While the title mentions hepatocytes, the annotations don't explicitly mention this cell type. Consider adding more specific cellular component annotations for the hepatocyte context.</p> </li> <li> <p>Add Output of PRF1 Activity: The model could include the output of perforin activity (formation of membrane pores) as an has_output relationship.</p> </li> <li> <p>Include Membrane Repair Process: The model would benefit from explicitly including plasma membrane repair (GO:0001778) as a biological process linked to SMPD1 activity, which is a key outcome of this pathway.</p> </li> <li> <p>Add Temporal Context: The causal flow appears to be accurate, but the model doesn't fully capture the temporal nature of this process - PRF1 forms pores first, then GZMB activates CASP7, which activates SMPD1 to repair the pores. This temporal relationship could be better represented.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000081-CASP7_activates_SMPD1_to_repair_perforin_pores_in_hepatocytes__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the biological process of perforin pore formation and repair by the GZMB-CASP7-SMPD1 pathway. The model uses appropriate GO terms, relationship types, and evidence codes. The causal relationships are correctly established, creating a logical flow from perforin pore formation to sphingomyelinase-mediated repair. The minor suggestions provided would further enhance the model's comprehensiveness and clarity.</p>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/","title":"62b4ffe300000240 Perforin maturation leading to granzyme mediated programmed cell death signaling pathway  Mouse","text":"<p>Based on my review of the GO-CAM model \"Perforin maturation leading to granzyme-mediated programmed cell death signaling pathway (Mouse)\" (gomodel:62b4ffe300000240), I'll provide a comprehensive assessment of its quality, biological accuracy, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#go-cam-review-perforin-maturation-leading-to-granzyme-mediated-programmed-cell-death-signaling-pathway-mouse","title":"GO-CAM Review: Perforin maturation leading to granzyme-mediated programmed cell death signaling pathway (Mouse)","text":""},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model (https://bioregistry.io/go.model:62b4ffe300000240) captures a key immune pathway in mouse (NCBITaxon:10090) in which:</p> <ol> <li>Fcgr4 (CD receptor) activity triggers</li> <li>Perforin (Prf1) calcium ion binding</li> <li>Perforin wide pore channel activity </li> <li>Granzyme B (Gzmb) serine-type endopeptidase activity</li> </ol> <p>The model describes how perforin pore formation enables granzyme B to enter target cells, triggering programmed cell death - a critical mechanism by which cytotoxic T cells and NK cells eliminate virally infected or cancerous cells.</p>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":""},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#molecular-functions-and-locations","title":"Molecular Functions and Locations","text":"<ol> <li>Fcgr4 (immune receptor activity) occurs in plasma membrane</li> <li>Correctly annotated as having immune receptor activity (GO:0140375)</li> <li>Appropriately located in plasma membrane (GO:0005886)</li> <li> <p>Participates in NK cell degranulation (GO:0043320)</p> </li> <li> <p>Prf1 (calcium binding and pore formation) occurs in immunological synapse/membrane</p> </li> <li>Has calcium ion binding activity (GO:0005509) occurring in immunological synapse (GO:0001772)</li> <li>Has wide pore channel activity (GO:0022829) occurring in membrane (GO:0016020)</li> <li>Participates in T cell cytotoxicity (GO:0001913) and protein transmembrane transport (GO:0071806)</li> <li> <p>The annotations match what's known from literature - perforin requires calcium for activation and forms transmembrane pores</p> </li> <li> <p>Gzmb (serine protease) occurs in cytoplasm</p> </li> <li>Has serine-type endopeptidase activity (GO:0004252) in cytoplasm (GO:0005737)</li> <li>Participates in granzyme-mediated programmed cell death signaling pathway (GO:0140507)</li> <li>The cytoplasmic location correctly indicates granzyme B acts within the target cell cytoplasm after perforin-mediated delivery</li> </ol>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal flow is biologically accurate: 1. Fcgr4 receptor \u2192 directly positively regulates (RO:0002629) \u2192 Prf1 calcium binding 2. Prf1 calcium binding \u2192 directly positively regulates (RO:0002629) \u2192 Prf1 pore formation 3. Prf1 pore formation \u2192 directly positively regulates (RO:0002629) \u2192 Gzmb activity</p> <p>This correctly represents the established mechanism where: - Receptor-mediated signals trigger perforin release - Perforin requires calcium binding for activation - Activated perforin forms pores in target cell membranes - Pores allow granzymes to enter and initiate apoptosis</p>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#literature-evidence","title":"Literature Evidence","text":"<p>The model is well-supported by the literature cited: - PMID:21037563 - Details perforin structure, membrane binding and pore formation - PMID:26306037 - Describes Ca2+-mediated interaction of perforin with lipid membranes - PMID:35705808 - Documents granzyme B's role in cell death signaling - PMID:8164737 - Shows perforin's role in cytotoxic T cell and NK cell function</p>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":""},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#model-structure","title":"Model Structure","text":"<ol> <li>Correct use of activity nodes: Each protein is appropriately annotated with its molecular function(s)</li> <li>Proper cellular locations: Activities are placed in the correct cellular compartments</li> <li>Appropriate causal connections: Uses direct causal relationships (RO:0002629) correctly</li> <li>Consistent biological process annotations: Activities are connected to relevant biological processes</li> </ol>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#complex-representation","title":"Complex Representation","text":"<p>The model correctly avoids representing the perforin pore as a complex entity. Following GO-CAM best practices from \"How to annotate complexes in GO-CAM,\" the model annotates the activities directly to the Prf1 protein rather than creating a separate complex entity, since the subunit carrying the activity (perforin itself) is known.</p>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#pathway-flow","title":"Pathway Flow","text":"<p>The model appropriately shows: 1. The signaling initiator (Fcgr4 receptor) 2. The intermediate steps of perforin activation (Ca2+ binding \u2192 pore formation) 3. The ultimate effector (Gzmb endopeptidase activity)</p> <p>This provides a parsimonious representation of the pathway that a human viewer can easily understand.</p>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#recommended-improvements","title":"Recommended Improvements","text":"<p>While the model is of high quality, here are a few suggestions for enhancement:</p> <ol> <li> <p>Additional substrates: The model could include specific substrates of granzyme B (like caspases) to more fully represent its downstream effects.</p> </li> <li> <p>Regulatory details: The model could include inhibitory regulators of perforin/granzyme activity that help control cytotoxic responses.</p> </li> <li> <p>Causal mechanism details: The mechanism by which the receptor triggers perforin activation could be expanded with intermediate steps (if known).</p> </li> <li> <p>Integration with apoptotic pathway: Connections to downstream apoptotic machinery could enhance the model's completeness.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000240-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides an accurate, well-supported representation of the perforin/granzyme-mediated cytotoxic pathway in mouse. It adheres to GO-CAM best practices for representing activities, cellular locations, and causal relationships. The model is biologically accurate according to the literature and represents the pathway in a manner that is both comprehensive and comprehensible.</p> <p>The curator has done an excellent job connecting molecular functions to their biological contexts and creating a logically structured representation of this important immune mechanism.</p>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/","title":"62b4ffe300000241 Poxvirus CRMB inhibition of TNF signaling pathway  Human Poxvirus","text":"<p>Let me review the GO-CAM model gomodel:62b4ffe300000241 \"Poxvirus-CRMB inhibition of TNF signaling pathway (Human-Poxvirus).\"</p>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<p>This model represents the interaction between poxvirus CRMB protein and the human TNF signaling pathway, specifically showing how a viral protein interferes with normal host immune signaling. The model includes:</p> <ol> <li>Human proteins:</li> <li>TNF (P01375): Cytokine</li> <li>TNFRSF1A/TNFR1 (P19438): TNF receptor</li> <li>TRADD (Q15628): Adapter protein</li> <li>FADD (Q13158): Death domain adapter</li> <li> <p>TRAF2 (Q12933): TNF receptor-associated factor</p> </li> <li> <p>Viral protein:</p> </li> <li>CRMB (P0DSV7): Cytokine response-modifying protein from Variola virus</li> </ol>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/#biological-accuracy-review","title":"Biological Accuracy Review","text":"<p>The model represents a well-documented viral immune evasion strategy where poxviruses produce TNF receptor mimics to bind and sequester host TNF, preventing it from activating cellular TNF receptors and downstream signaling pathways.</p> <p>The UniProt entry for CRMB confirms its function: \"Inhibits host immune defense by binding to host TNF and various chemokines in the extracellular space.\" This is correctly depicted in the model with CRMB (P0DSV7) having \"tumor necrosis factor receptor activity\" (GO:0005031) and negatively regulating TNF's activity.</p> <p>The human TNF signaling pathway is accurately depicted with: - TNF (P01375) having cytokine activity (GO:0005125) - TNFRSF1A/TNFR1 (P19438) having TNF receptor activity (GO:0005031) - Adapter proteins (TRADD, FADD, TRAF2) having protein-macromolecule adaptor activity (GO:0030674)</p>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/#evaluation-of-model-structure-and-causal-connections","title":"Evaluation of Model Structure and Causal Connections","text":"<p>Examining the causal flow in the model:</p> <ol> <li>TNF positively regulates TNFR1 (using RO:0002629 \"directly positively regulates\")</li> <li>TNFR1 positively regulates TRADD (using RO:0002629)</li> <li>TRADD positively regulates both FADD and TRAF2 (using RO:0002629)</li> <li>CRMB negatively regulates TNF (using RO:0002630 \"directly negatively regulates\")</li> </ol> <p>This causal flow correctly represents how: - TNF activates its receptor TNFR1 - TNFR1 recruits the adapter protein TRADD - TRADD recruits additional adapters FADD and TRAF2, which mediate distinct downstream pathways - CRMB acts as a decoy receptor to sequester TNF, preventing its binding to cellular receptors</p>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/#cellular-locations","title":"Cellular Locations","text":"<p>The model shows appropriate cellular locations: - TNF and CRMB are correctly localized in the extracellular space (GO:0005615) - TNFR1 is correctly localized to the plasma membrane (GO:0005886) - Adapter proteins (TRADD, FADD, TRAF2) are properly located at the cytoplasmic side of the plasma membrane (GO:0009898)</p>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/#biological-processes","title":"Biological Processes","text":"<p>Each protein is appropriately associated with relevant biological processes: - TNF: antiviral innate immune response (GO:0140374) - TNFR1 and TRADD: TNF signaling pathway (GO:0033209) - FADD: apoptotic signaling pathway (GO:0097190) - TRAF2: non-canonical NF-kappaB signaling (GO:0038061)</p>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/#assessment-of-go-cam-best-practices","title":"Assessment of GO-CAM Best Practices","text":"<p>I reviewed the model against best practices for GO-CAM modeling:</p> <ol> <li>Adaptor Proteins: TRADD, FADD, and TRAF2 are correctly annotated as adaptors according to the \"How to annotate molecular adaptors\" guidelines, with:</li> <li>Molecular function: protein-macromolecule adaptor activity (GO:0030674)</li> <li>Appropriate causal relation: \"directly positively regulates\" to downstream activities</li> <li> <p>Proper cellular component: cytoplasmic side of plasma membrane</p> </li> <li> <p>Signaling Receptors: The TNF-TNFR1 relationship follows the \"Signaling receptor activity annotation guidelines\" for protein ligand-activated signaling receptors:</p> </li> <li>TNF has ligand activity (cytokine activity GO:0005125)</li> <li>TNFR1 has receptor activity (GO:0005031)</li> <li>The causal relation is \"directly positively regulates\"</li> <li> <p>Both are in appropriate cellular locations (extracellular space for ligand, plasma membrane for receptor)</p> </li> <li> <p>Negative Regulation: The viral CRMB protein correctly uses \"directly negatively regulates\" to indicate its inhibitory effect on TNF activity.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/#minor-issues-and-recommendations","title":"Minor Issues and Recommendations","text":"<p>While the model is generally well-constructed, I note a few points for consideration:</p> <ol> <li>Evidence Codes:</li> <li>Some causal associations lack specific evidence codes (e.g., the TRADD to TRAF2 relationship has one citation but another has none)</li> <li> <p>Recommend adding evidence codes for all causal relationships</p> </li> <li> <p>Additional Information: </p> </li> <li>The model currently focuses on the initial steps of TNF signaling and its inhibition</li> <li>The model could potentially be expanded to include more downstream effects, such as NF-\u03baB activation and apoptosis execution</li> </ol>"},{"location":"reviews/62b4ffe300000241-Poxvirus_CRMB_inhibition_of_TNF_signaling_pathway__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:62b4ffe300000241) accurately represents the biological mechanism of how poxvirus CRMB inhibits the TNF signaling pathway. The model:</p> <ol> <li>Correctly depicts protein activities and their locations</li> <li>Accurately represents the causal flow of TNF signaling</li> <li>Properly shows how the viral protein CRMB interferes with this pathway</li> <li>Follows GO-CAM best practices for modeling signaling receptors and adapter proteins</li> </ol> <p>The model provides a clear and parsimonious representation of this viral immune evasion strategy and is consistent with current knowledge about TNF signaling and viral interference mechanisms.</p>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/","title":"62b4ffe300000335 Perforin maturation leading to granzyme mediated programmed cell death signaling pathway  Human","text":"<p>Now I'll thoroughly review the GO-CAM model and provide my analysis:</p>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#review-of-go-cam-model-gomodel62b4ffe300000335","title":"Review of GO-CAM Model: gomodel:62b4ffe300000335","text":""},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (ID: gomodel:62b4ffe300000335) represents \"Perforin maturation leading to granzyme-mediated programmed cell death signaling pathway (Human)\" with human (taxon: NCBITaxon:9606) as the organism.</p>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#model-components-and-pathway-flow","title":"Model Components and Pathway Flow","text":"<p>The model represents a crucial immune system pathway involving:</p> <ol> <li>Initial activation: Fc\u03b3RIIIA (CD16) immune receptor activity</li> <li>Intermediate step: Perforin's calcium ion binding and channel formation</li> <li>Final execution: Granzyme B serine-type endopeptidase activity leading to programmed cell death</li> </ol>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#detailed-analysis-of-activities","title":"Detailed Analysis of Activities","text":""},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#activity-1-fcriiia-cd16-receptor-activity","title":"Activity 1: Fc\u03b3RIIIA (CD16) Receptor Activity","text":"<ul> <li>Protein: UniProtKB:P08637 (FCGR3A, CD16a)</li> <li>Function: GO:0140375 (immune receptor activity)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0043320 (natural killer cell degranulation)</li> <li>Evidence: CD16 functions as a lysis receptor in NK cells (PMID:10318937)</li> <li>Causal effect: Leads to calcium ion binding activity of perforin (positive effect)</li> </ul>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#activity-2-perforin-calcium-binding-and-channel-formation","title":"Activity 2: Perforin Calcium Binding and Channel Formation","text":"<ul> <li>Protein: UniProtKB:P14222 (Perforin-1)</li> <li>First function: GO:0005509 (calcium ion binding)</li> <li>Occurs in: GO:0001772 (immunological synapse)</li> <li>Part of: GO:0001913 (T cell mediated cytotoxicity)</li> <li> <p>Causal effect: Directly positively regulates perforin's channel activity</p> </li> <li> <p>Second function: GO:0022829 (wide pore channel activity)</p> </li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0071806 (protein transmembrane transport)</li> <li>Causal effect: Directly positively regulates granzyme B activity</li> </ul>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#activity-3-granzyme-b-proteolytic-activity","title":"Activity 3: Granzyme B Proteolytic Activity","text":"<ul> <li>Protein: UniProtKB:P10144 (Granzyme B)</li> <li>Function: GO:0004252 (serine-type endopeptidase activity)</li> <li>Occurs in: GO:0005737 (cytoplasm)</li> <li>Part of: GO:0140507 (granzyme-mediated programmed cell death signaling pathway)</li> </ul>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#scientific-validity-analysis","title":"Scientific Validity Analysis","text":""},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#pathway-accuracy","title":"Pathway Accuracy","text":"<p>The model accurately represents the canonical pathway of perforin-mediated granzyme B delivery for cell death induction:</p> <ol> <li> <p>The initial trigger through Fc\u03b3RIIIA (CD16) is well supported - CD16 is a key activating receptor on NK cells that can initiate granule exocytosis leading to target cell death (PMID:10318937).</p> </li> <li> <p>Perforin's dual activities are correctly represented:</p> </li> <li>Calcium binding is essential for perforin's function (verified from UniProt P14222)</li> <li> <p>Pore-forming (channel) activity that facilitates granzyme entry (PMID:20038786)</p> </li> <li> <p>The final step showing granzyme B's enzymatic activity in the cytoplasm leading to programmed cell death is accurate (verified from UniProt P10144).</p> </li> </ol>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#evidence-base","title":"Evidence Base","text":"<p>The model is supported by solid experimental evidence: - PMID:10318937 - Shows CD16 functioning as a direct lysis receptor - PMID:25786175 - Confirms NK cell degranulation processes - PMID:28652325 - Details molecular interactions in CD16 signaling - PMID:20038786 - Provides key insights into how perforin delivers granzymes into target cells</p>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#cellular-compartments","title":"Cellular Compartments","text":"<p>The model correctly places activities in appropriate cellular locations: - CD16 activity in plasma membrane - Perforin calcium binding at immunological synapse - Perforin channel formation in plasma membrane - Granzyme B activity in cytoplasm</p>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#model-structure","title":"Model Structure","text":"<p>The model has a clear logical flow with appropriate causal relations: - RO:0002304 (causally upstream of, positive effect) used to connect CD16 to perforin's calcium binding - RO:0002629 (directly positively regulates) used between perforin's calcium binding and channel formation - RO:0002629 (directly positively regulates) used between perforin's channel activity and granzyme B</p>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices: - Appropriate use of occurs_in relations to specify cellular components - Proper use of part_of to connect molecular functions to biological processes - Correct use of causal relations between activities - Appropriate handling of the complex components as specified in GO-CAM guidance (verified using \"How_to_annotate_complexes_in_GO-CAM\")</p>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>While the model is scientifically accurate, it could benefit from additional details about:</li> <li>The specific mechanism by which calcium binding leads to perforin pore formation</li> <li>The exact substrates cleaved by granzyme B to initiate apoptosis</li> <li> <p>The downstream activation of caspases by granzyme B</p> </li> <li> <p>The model currently doesn't represent any inhibitory or regulatory mechanisms that might modulate this pathway.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000335-Perforin_maturation_leading_to_granzyme_mediated_programmed_cell_death_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:62b4ffe300000335) is scientifically accurate, well-evidenced, and follows GO-CAM best practices. It correctly represents the perforin-granzyme mediated programmed cell death pathway in humans, beginning with CD16 receptor activation, followed by perforin's pore-forming activity, and concluding with granzyme B's proteolytic activity in the cytoplasm.</p> <p>The causal connections between activities are appropriate, and the cellular compartments for each activity are correctly specified. All activities are backed by credible scientific evidence from peer-reviewed literature.</p> <p>The model provides a clear and accurate representation of this important immune system pathway while adhering to GO-CAM standards for model structure and annotation.</p>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/","title":"62b4ffe300000504 Poxvirus OPG065 inhibition of ZBP1 mediated necroptosis  Human Poxvirus","text":"<p>Now I'll review the GO-CAM model (gomodel:62b4ffe300000504) based on the available information.</p>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#go-cam-model-review-poxvirus-opg065-inhibition-of-zbp1-mediated-necroptosis-human-poxvirus","title":"GO-CAM Model Review: Poxvirus-OPG065 inhibition of ZBP1-mediated necroptosis (Human-Poxvirus)","text":""},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model (gomodel:62b4ffe300000504) depicts the molecular interactions involved in how Vaccinia virus protein OPG065 (E3L) inhibits the ZBP1-mediated necroptosis pathway in human cells. The model represents a host-pathogen interaction where a viral protein interferes with a host defense mechanism.</p>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#proteins-in-the-model","title":"Proteins in the Model","text":"<ol> <li>ZBP1/DAI (UniProtKB:Q9H171) - Z-DNA-binding protein 1 (human)</li> <li>Function: RNA binding (GO:0003723)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li> <p>Process: Antiviral innate immune response (GO:0140374)</p> </li> <li> <p>OPG065/E3L (UniProtKB:P21605) - RNA-binding protein from Vaccinia virus</p> </li> <li>Function: RNA binding (GO:0003723)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li> <p>Process: Evasion of host immune response (GO:0042783)</p> </li> <li> <p>RIPK3 (UniProtKB:Q9Y572) - Receptor-interacting serine/threonine-protein kinase 3 (human)</p> </li> <li>Function: Protein serine/threonine kinase activity (GO:0004674)</li> <li>Location: Nucleus (GO:0005634)</li> <li> <p>Process: Necroptotic signaling pathway (GO:0097527)</p> </li> <li> <p>MLKL (UniProtKB:Q8NB16) - Mixed lineage kinase domain-like protein (human)</p> </li> <li>Function: Protein serine/threonine kinase activity (GO:0004674)</li> <li>Location: Plasma membrane (GO:0005886)</li> <li>Process: Execution phase of necroptosis (GO:0097528)</li> </ol>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#pathway-and-causal-relationships","title":"Pathway and Causal Relationships","text":"<p>The model represents the following pathway:</p> <ol> <li> <p>The viral protein OPG065/E3L (P21605) with RNA binding activity directly negatively regulates (RO:0002630) ZBP1's (Q9H171) RNA binding activity.</p> </li> <li> <p>ZBP1's RNA binding activity directly positively regulates (RO:0002629) RIPK3's (Q9Y572) protein serine/threonine kinase activity.</p> </li> <li> <p>RIPK3's protein serine/threonine kinase activity causally upstream positively affects (RO:0002304) MLKL's (Q8NB16) protein serine/threonine kinase activity.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#scientific-correctness-assessment","title":"Scientific Correctness Assessment","text":"<p>The model correctly represents the ZBP1-RIPK3-MLKL necroptosis pathway based on current scientific understanding:</p> <ol> <li> <p>Mechanistic correctness: The model accurately shows that ZBP1 acts as a sensor that, upon activation, recruits and activates RIPK3, which then phosphorylates MLKL to execute necroptosis.</p> </li> <li> <p>Viral inhibition: The model correctly depicts how the viral protein E3L inhibits this pathway by competing with ZBP1 for binding to Z-form RNA, preventing ZBP1 activation.</p> </li> <li> <p>Cellular localization: The locations specified for each protein are consistent with their known subcellular distributions. RIPK3 is shown to be in the nucleus during viral infection (which is accurate for influenza virus infection), and MLKL is correctly shown at the plasma membrane where it executes the final step of necroptosis.</p> </li> <li> <p>Causal relationships: The causal relationships (directly negatively regulates, directly positively regulates, and causally upstream of with positive effect) appropriately model the mechanisms described in the literature.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Evidence Sources: The model uses relevant PMIDs for evidence, though we couldn't retrieve the full text of PMID:34192517. This appears to be the key paper describing E3L's role in preventing Z-RNA sensing by ZBP1.</p> </li> <li> <p>Mechanistic Detail: The model could be enhanced by specifically mentioning Z-RNA as the molecule that ZBP1 senses during viral infection. This could be done by adding a transport or localization of Z-RNA component.</p> </li> <li> <p>Additional Components: Consider including the trimerization of MLKL after phosphorylation by RIPK3, which is a critical step in the execution of necroptosis.</p> </li> <li> <p>Temporal Aspect: The model doesn't explicitly represent the temporal sequence of events during infection, though this is implied by the causal relationships.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#compliance-with-go-cam-practices","title":"Compliance with GO-CAM Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Proper use of causal relations: The model uses appropriate causal relation predicates (RO:0002630, RO:0002629, RO:0002304) to connect activities.</p> </li> <li> <p>Cellular context: Each activity is appropriately contextualized within a cellular component.</p> </li> <li> <p>Biological process context: Each activity is properly associated with a biological process term.</p> </li> <li> <p>Evidence and provenance: Each assertion has evidence codes and references to the scientific literature.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#comments-on-automated-changes","title":"Comments on Automated Changes","text":"<p>The model shows two automated changes: - \"RO:0002212 replaced by RO:0002630\" (negatively regulates \u2192 directly negatively regulates) - \"RO:0002213 replaced by RO:0002629\" (positively regulates \u2192 directly positively regulates)</p> <p>These changes are appropriate as they provide more specific relationship types that better reflect the direct nature of the regulations in the model.</p>"},{"location":"reviews/62b4ffe300000504-Poxvirus_OPG065_inhibition_of_ZBP1_mediated_necroptosis__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a clear and scientifically accurate representation of how Vaccinia virus protein E3L inhibits ZBP1-mediated necroptosis. The model effectively captures the key molecular interactions and causal relationships in this host-pathogen interaction. It meets GO-CAM standards for biological accuracy, proper use of ontology terms, and evidence-based assertions.</p> <p>The model is parsimonious and focused on the core pathway, making it easy to understand while still capturing the essential biological mechanisms involved in this viral evasion of host defense.</p>"},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/","title":"62b4ffe300000717 Poxvirus OPG025 inhibition of antiviral IFITs  Human Poxvirus","text":"<p>Based on the information gathered, I'll now provide a detailed review of the GO-CAM model gomodel:62b4ffe300000717.</p>"},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#review-of-go-cam-model-gomodel62b4ffe300000717","title":"Review of GO-CAM Model: gomodel:62b4ffe300000717","text":""},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#model-title","title":"Model Title","text":"<p>\"Poxvirus-OPG025 inhibition of antiviral IFITs (Human-Poxvirus)\"</p>"},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<p>This model represents how a Vaccinia virus protein (OPG025/C9L, UniProtKB:P17372) inhibits the antiviral activities of human IFIT proteins (IFIT1, IFIT2, IFIT3) by acting as a molecular adaptor that promotes the ubiquitin-dependent degradation of these proteins via the SCF (Skp, Cullin, F-box) ubiquitin ligase complex.</p>"},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#model-components-and-biological-pathway","title":"Model Components and Biological Pathway","text":"<p>The model consists of 6 activities:</p> <ol> <li>Vaccinia virus OPG025/C9L (UniProtKB:P17372) - Molecular adaptor activity (GO:0060090)</li> <li>Occurs in cytoplasm (GO:0005737)</li> <li>Part of symbiont-mediated suppression of host innate immune response (GO:0052170)</li> <li> <p>Directly positively regulates CUL1 activity</p> </li> <li> <p>Human CUL1 (UniProtKB:Q13616) - Ubiquitin protein ligase binding (GO:0031625)</p> </li> <li>Occurs in cytoplasm (GO:0005737)</li> <li>Part of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146)</li> <li> <p>Directly negatively regulates IFIT1, IFIT2, and IFIT3 activities</p> </li> <li> <p>Human IFIT1 (UniProtKB:P09914) - RNA binding (GO:0003723)</p> </li> <li>Occurs in cytoplasm (GO:0005737)</li> <li> <p>Part of antiviral innate immune response (GO:0140374)</p> </li> <li> <p>Human IFIT2 (UniProtKB:P09913) - RNA binding (GO:0003723)</p> </li> <li>Occurs in cytoplasm (GO:0005737)</li> <li> <p>Part of antiviral innate immune response (GO:0140374)</p> </li> <li> <p>Human IFIT3 (UniProtKB:O14879) - RNA binding (GO:0003723)</p> </li> <li>Occurs in cytoplasm (GO:0005737)</li> <li> <p>Part of antiviral innate immune response (GO:0140374)</p> </li> <li> <p>Human IFNB1 (UniProtKB:P01574) - Cytokine activity (GO:0005125)</p> </li> <li>Occurs in extracellular space (GO:0005615)</li> <li>Part of type I interferon-mediated signaling pathway (GO:0060337)</li> <li>Causally upstream of, positive effect on IFIT1, IFIT2, and IFIT3 activities</li> </ol>"},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#review-analysis","title":"Review Analysis","text":""},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<ol> <li>Molecular Adaptor Activity Representation:</li> <li>The model correctly uses molecular adaptor activity (GO:0060090) for the viral protein OPG025/C9L, consistent with guidelines in \"How_to_annotate_molecular_adaptors\" and \"Molecular_adaptor_activity\".</li> <li> <p>The relationship \"directly positively regulates\" between the adaptor and the downstream activity (CUL1) is appropriate per the guidelines.</p> </li> <li> <p>Causal Relationships:</p> </li> <li> <p>The causal associations in the model use appropriate predicates:</p> <ul> <li>RO:0002629 (directly positively regulates) for OPG025\u2192CUL1</li> <li>RO:0002630 (directly negatively regulates) for CUL1\u2192IFITs</li> <li>RO:0002304 (causally upstream of, positive effect) for IFNB1\u2192IFITs</li> </ul> </li> <li> <p>Evidence Support:</p> </li> <li>Most activities and causal relationships are well-supported with appropriate evidence codes and PMIDs.</li> <li>The evidence for most assertions comes from PMID:31644906 and PMID:11961546, which are relevant to this biological process.</li> </ol>"},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#biological-accuracy","title":"Biological Accuracy","text":"<ol> <li>Viral Strategy:</li> <li>The model accurately represents how poxviruses counteract host antiviral responses by targeting interferon-induced proteins (IFITs) for degradation.</li> <li> <p>This is consistent with the UniProt entry for OPG025 (P17372), which states it \"plays a role in the inhibition of host immune response by counteracting the action of interferons on early events in the viral replication cycle.\"</p> </li> <li> <p>Mechanism Accuracy:</p> </li> <li>The model correctly shows that OPG025 contains ankyrin repeats and an F-box domain, making it capable of recruiting cellular ubiquitin ligase components (via CUL1).</li> <li> <p>The role of CUL1 in the SCF ubiquitin ligase complex is properly represented.</p> </li> <li> <p>IFIT Function:</p> </li> <li>The model accurately represents IFIT proteins as RNA-binding proteins involved in antiviral immune responses.</li> </ol>"},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing Has Input Relationship:</li> <li> <p>According to the molecular adaptor guidelines, the adaptor activity should have \"has input\" relationships to the molecules it brings together. In this case, the model is missing \"has input\" relationships from OPG025 to CUL1 and potentially to the IFIT proteins.</p> </li> <li> <p>Missing Specificity for SCF Complex Components:</p> </li> <li> <p>The model could benefit from including other components of the SCF complex (e.g., SKP1) which, according to the UniProt entry, also interact with OPG025.</p> </li> <li> <p>Ubiquitination Process Representation:</p> </li> <li> <p>The model implies degradation of IFIT proteins but doesn't explicitly show the ubiquitination process. This could be more clearly represented.</p> </li> <li> <p>Evidence for One Causal Association:</p> </li> <li>One causal association from CUL1 to IFIT activities (first instance) has no evidence code or reference.</li> </ol>"},{"location":"reviews/62b4ffe300000717-Poxvirus_OPG025_inhibition_of_antiviral_IFITs__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62b4ffe300000717 is generally well-constructed and follows GO-CAM best practices. It accurately represents the biological mechanism by which Vaccinia virus protein OPG025/C9L counteracts the host interferon response by targeting IFIT proteins for proteasomal degradation.</p> <p>The model is supported by appropriate literature evidence and represents a biologically meaningful pathway with correct causal relationships between activities. The one minor issue is the missing \"has input\" relationship for the molecular adaptor activity.</p> <p>This model provides a clear representation of a viral evasion strategy targeting host innate immunity and could serve as a useful reference for similar host-pathogen interaction models.</p>"},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/","title":"62b4ffe300000784 Involvement of CASP7 in apoptosis  its activation by initiator caspases  CASP8  CASP9 and CASP10   and regulation by XIAP and PAK2  Human","text":"<p>Based on all this information, let me now provide my review of the GO-CAM model 62b4ffe300000784:</p>"},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#review-of-go-cam-model-62b4ffe300000784","title":"Review of GO-CAM Model 62b4ffe300000784","text":""},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#model-overview","title":"Model Overview","text":"<p>The model gomodel:62b4ffe300000784 titled \"Involvement of CASP7 in apoptosis, its activation by initiator caspases (CASP8, CASP9 and CASP10) and regulation by XIAP and PAK2 (Human)\" represents the regulation of caspase-7 (CASP7) during apoptosis in humans.</p>"},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#summary-of-model-contents","title":"Summary of Model Contents","text":"<p>The model depicts: 1. CASP7 (UniProtKB:P55210) and its molecular function of cysteine-type endopeptidase activity (GO:0004197) 2. XIAP (UniProtKB:P98170) with cysteine-type endopeptidase inhibitor activity (GO:0004869) 3. PAK2 (UniProtKB:Q13177) with protein serine/threonine kinase activity (GO:0004674) 4. CASP8 (UniProtKB:Q14790), CASP9 (UniProtKB:P55211), and CASP10 (UniProtKB:Q92851) with cysteine-type endopeptidase activity (GO:0004197) 5. These activities take place in the cytosol (GO:0005829) 6. The model shows regulation of CASP7 by both XIAP and PAK2 via direct negative regulation (RO:0002630) 7. CASP8, CASP9, and CASP10 directly positively regulate CASP7 (RO:0002629)</p>"},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#assessment","title":"Assessment","text":""},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The biological content of the model is consistent with current scientific understanding:</p> <ol> <li> <p>Caspase Activation Pathway: The model correctly depicts CASP7 as an executioner caspase that is activated by initiator caspases (CASP8, CASP9, and CASP10) through proteolytic cleavage. This is well-established in apoptotic signaling pathways.</p> </li> <li> <p>XIAP Inhibition of CASP7: The negative regulation of CASP7 by XIAP is accurately represented. Literature confirms that XIAP directly inhibits CASP7 by binding to its active site and preventing substrate entry.</p> </li> <li> <p>PAK2 Regulation of CASP7: The negative regulation of CASP7 by PAK2 through phosphorylation is correctly captured. Studies show that PAK2 phosphorylates CASP7 at Ser-30 and Ser-239, preventing its activation and activity.</p> </li> <li> <p>Cellular Location: The cytosolic location of these activities is appropriate.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li>Causal Relationships: The model uses the appropriate causal relations between activities:</li> <li>RO:0002629 (directly positively regulates) for initiator caspases activating CASP7</li> <li> <p>RO:0002630 (directly negatively regulates) for XIAP and PAK2 inhibiting CASP7</p> </li> <li> <p>Activities Connected in Biological Context: The activities are properly connected to reflect the regulatory network in apoptosis.</p> </li> <li> <p>Evidence and References: Each relationship has appropriate evidence codes and literature references, including ECO:0000314 (direct assay evidence used in manual assertion) with corresponding PMIDs.</p> </li> <li> <p>Complex Representation: The model appropriately represents the individual proteins rather than complexes, which aligns with the GO-CAM guideline for when the subunits that carry the molecular activities are known.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Biological Process Context: The biological process associations could be more specific. While CASP7 is correctly associated with execution phase of apoptosis (GO:0097194), some activities could benefit from more specific process associations.</p> </li> <li> <p>Additional Contextual Information: The model could be enhanced by adding cellular conditions or stimuli that trigger this pathway, such as death receptor signaling for CASP8/10 activation or mitochondrial damage for CASP9 activation.</p> </li> <li> <p>Sequence of Events: The temporal sequence in apoptosis could be more explicitly represented, showing the order of activation from initiator caspases to CASP7 and then to substrate cleavage.</p> </li> <li> <p>Function Details: The specific mechanism of how XIAP inhibits CASP7 by binding to its active site (as shown in the literature) could be more explicitly modeled.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#technical-issues","title":"Technical Issues","text":"<ol> <li>Automated Term Replacements: The model contains several comments about automated term replacements, such as:</li> <li>GO:0006919 replaced by GO:2001056</li> <li>GO:0097153 replaced by GO:0004197</li> <li>GO:0097200 replaced by GO:0004197</li> <li>RO:0002212 replaced by RO:0002630</li> <li>RO:0002213 replaced by RO:0002629</li> </ol> <p>These replacements appear to be appropriate ontology updates but should be verified to ensure they maintain the original intended meaning.</p> <ol> <li>Evidence for Some Causal Associations: The causal association between CASP9 and CASP7 lacks evidential support (shown as \"evidence:[]\"). Additional evidence should be provided for this relationship.</li> </ol>"},{"location":"reviews/62b4ffe300000784-Involvement_of_CASP7_in_apoptosis__its_activation_by_initiator_caspases__CASP8__CASP9_and_CASP10___and_regulation_by_XIAP_and_PAK2__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, the GO-CAM model 62b4ffe300000784 accurately represents the biological process of CASP7 activation and regulation in apoptosis. It correctly captures the relationships between initiator caspases, CASP7, and its regulators XIAP and PAK2. The model effectively uses GO-CAM conventions to represent these relationships and is supported by appropriate evidence.</p> <p>The model could be enhanced with additional contextual information and more explicit representation of the temporal sequence of events in apoptosis. Additionally, some technical issues like missing evidence for certain associations should be addressed.</p> <p>This model provides a valuable resource for understanding the regulation of CASP7 in apoptosis and serves as a good example of how complex regulatory interactions can be represented in the GO-CAM format.</p>"},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/","title":"62b4ffe300000906 Poxvirus OPG065 inhibition of ISG15 conjugation  Human Poxvirus","text":"<p>Now that I have gathered all the relevant information about the model and its components, let me review the GO-CAM model \"gomodel:62b4ffe300000906\" titled \"Poxvirus-OPG065 inhibition of ISG15 conjugation (Human-Poxvirus)\".</p>"},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#go-cam-model-review-poxvirus-opg065-inhibition-of-isg15-conjugation-human-poxvirus","title":"GO-CAM Model Review: Poxvirus-OPG065 inhibition of ISG15 conjugation (Human-Poxvirus)","text":""},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#model-summary","title":"Model Summary","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:62b4ffe300000906) represents a host-pathogen interaction between human ISG15 (Interferon-Stimulated Gene 15) conjugation system and the poxvirus protein OPG065 (also known as E3 protein). The model describes how the viral protein OPG065 inhibits the ISG15 conjugation pathway through protein sequestering activity, which is part of the viral mechanism to evade host innate immune responses.</p>"},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#activities-and-entities-in-the-model","title":"Activities and Entities in the Model","text":"<p>The model includes 5 key activities:</p> <ol> <li>ISG15 protein tag activity (GO:0031386)</li> <li>Enabled by: ISG15 (UniProtKB:P05161)</li> <li>Part of: ISG15-protein conjugation (GO:0032020)</li> <li> <p>Occurs in: cytoplasm (GO:0005737)</p> </li> <li> <p>Protein sequestering activity (GO:0140311)</p> </li> <li>Enabled by: Vaccinia virus OPG065/E3 protein (UniProtKB:P21605)</li> <li>Part of: symbiont-mediated suppression of host ISG15-protein conjugation (GO:0039579)</li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li> <p>Directly negatively regulates ISG15 protein tag activity</p> </li> <li> <p>ISG15 transferase activity (GO:0042296)</p> </li> <li>Enabled by: HERC5 (UniProtKB:Q9UII4)</li> <li>Part of: ISG15-protein conjugation (GO:0032020)</li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li> <p>Directly positively regulates ISG15 protein tag activity</p> </li> <li> <p>ISG15 transferase activity (GO:0042296)</p> </li> <li>Enabled by: UBE2L6 (UniProtKB:O14933)</li> <li>Part of: ISG15-protein conjugation (GO:0032020)</li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li> <p>Directly positively regulates HERC5 ISG15 transferase activity</p> </li> <li> <p>ISG15 activating enzyme activity (GO:0019782)</p> </li> <li>Enabled by: UBA7 (UniProtKB:P41226)</li> <li>Part of: ISG15-protein conjugation (GO:0032020)</li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li>Directly positively regulates UBE2L6 ISG15 transferase activity</li> </ol>"},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#strengths","title":"Strengths:","text":"<ol> <li> <p>Scientific Accuracy: The model correctly represents the ISG15 conjugation pathway, which involves UBA7 (E1 enzyme), UBE2L6 (E2 enzyme), and HERC5 (E3 enzyme) in the conjugation of ISG15 to target proteins. This matches the published literature (PMID:16407192, PMID:15131269).</p> </li> <li> <p>Causal Relationships: The causal relationships between the activities are logically connected and follow the correct enzymatic cascade:</p> </li> <li>UBA7 activates ISG15 and regulates UBE2L6</li> <li>UBE2L6 transfers ISG15 and regulates HERC5</li> <li>HERC5 conjugates ISG15 to target proteins</li> <li> <p>The poxvirus OPG065/E3 protein inhibits ISG15 protein tag activity</p> </li> <li> <p>Cellular Context: All activities are correctly annotated as occurring in the cytoplasm, which is consistent with the known subcellular localization of these proteins.</p> </li> <li> <p>Host-Pathogen Interaction: The model effectively captures the host-pathogen interaction, showing how the viral protein interferes with the host immune response.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing Target Information: The model doesn't specify which protein(s) the poxvirus OPG065/E3 actually sequesters. Based on the literature (PMID:24257616), OPG065/E3 counteracts ISG15 by binding to it directly, but this specific interaction is not fully represented.</p> </li> <li> <p>Biological Process Annotation: While the viral protein's activity is correctly annotated as being part of \"symbiont-mediated suppression of host ISG15-protein conjugation\" (GO:0039579), it might be helpful to also connect this to the broader biological process of viral evasion of host immune response.</p> </li> <li> <p>Evidence Documentation: While the model includes evidence codes and references to PMIDs, adding more specific evidence for the viral protein's sequestering activity would strengthen the model.</p> </li> <li> <p>Incomplete Representation of ISG15 Targets: The model doesn't include the various cellular proteins that are targets of ISG15 conjugation. Including at least some key targets would provide a more complete picture of the pathway.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li> <p>Protein Sequestering Activity Representation: According to the \"Protein sequestering activity\" guidelines, the relation between the protein that acts to sequester and its target should be \"has input.\" This relationship is missing in the current model - the OPG065/E3 protein should have ISG15 as its input.</p> </li> <li> <p>Causal Relationships: The model correctly uses \"directly negatively regulates\" for the inhibitory relationship between the viral protein and ISG15 activity, which is appropriate for a direct protein-protein interaction.</p> </li> <li> <p>Enzymatic Cascade Representation: The model correctly represents the enzymatic cascade with appropriate predicates (directly positively regulates) between the E1, E2, and E3 enzymes.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add Direct Input Relationship: Add a \"has input\" relationship from the OPG065 protein sequestering activity to ISG15 to clarify that the viral protein directly interacts with and sequesters ISG15.</p> </li> <li> <p>Add Additional Context: Consider adding broader biological processes such as \"innate immune response\" or \"antiviral defense\" to provide context for the ISG15 conjugation pathway.</p> </li> <li> <p>Include ISG15 Targets: Consider expanding the model to include at least one representative target of ISG15 conjugation to show the downstream effects of ISG15 modification.</p> </li> <li> <p>Add Specific Evidence: Include more specific evidence statements for the sequestering activity of the OPG065/E3 protein.</p> </li> </ol>"},{"location":"reviews/62b4ffe300000906-Poxvirus_OPG065_inhibition_of_ISG15_conjugation__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the inhibition of the human ISG15 conjugation pathway by the poxvirus OPG065/E3 protein. It correctly shows the enzymatic cascade of the ISG15 conjugation system and how the viral protein interferes with this system. With a few minor improvements, particularly the addition of a direct input relationship between the viral protein and ISG15, this model would provide a comprehensive and accurate representation of this host-pathogen interaction.</p>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/","title":"62b4ffe300001832 Activation of CASP7 by CASP1 in response to lipopolysaccharide  leading to cleavage and degradation of PARP1 by CASP7  Human","text":"<p>Now I'll review the GO-CAM model with ID 62b4ffe300001832, which is titled \"Activation of CASP7 by CASP1 in response to lipopolysaccharide, leading to cleavage and degradation of PARP1 by CASP7 (Human)\". Let me systematically evaluate this model based on GO-CAM standards.</p>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:62b4ffe300001832) represents a biological process in humans where: - CASP1 (Caspase-1) activates CASP7 (Caspase-7) - Activated CASP7 then cleaves and degrades PARP1 (Poly(ADP-ribose) polymerase 1) - This process occurs in response to lipopolysaccharide stimulation</p>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#model-structure-analysis","title":"Model Structure Analysis","text":"<p>The model consists of three main activities:</p> <ol> <li>CASP1 activity (UniProtKB:P29466)</li> <li>Function: Cysteine-type endopeptidase activity (GO:0004197)</li> <li>Occurs in: Cytoplasm (GO:0005737)</li> <li>Part of: Protein maturation process (GO:0051604)</li> <li> <p>Causal relationship: Directly positively regulates CASP7 activity (RO:0002629)</p> </li> <li> <p>CASP7 activity (UniProtKB:P55210)</p> </li> <li>Function: Cysteine-type endopeptidase activity (GO:0004197)</li> <li>Occurs in: Nucleus (GO:0005634)</li> <li>Part of: Protein catabolic process (GO:0030163)</li> <li> <p>Causal relationship: Directly negatively regulates PARP1 activity (RO:0002630)</p> </li> <li> <p>PARP1 activity (UniProtKB:P09874)</p> </li> <li>Function: NAD+-protein poly-ADP-ribosyltransferase activity (GO:0003950)</li> <li>Occurs in: Nucleus (GO:0005634)</li> <li>Part of: Protein poly-ADP-ribosylation (GO:0070212)</li> </ol>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#evaluation-against-go-cam-standards","title":"Evaluation Against GO-CAM Standards","text":""},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#1-evidence-and-reference-use","title":"1. Evidence and Reference Use","text":"<ul> <li>The model appropriately uses evidence codes (ECO:0000314 for direct assay evidence and ECO:0000304 for author statement)</li> <li>All evidence is supported by proper literature references (PMID:22464733 and PMID:33186521)</li> <li>The curator (https://orcid.org/0000-0001-7299-6685) is properly credited</li> </ul>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#2-molecular-function-annotation","title":"2. Molecular Function Annotation","text":"<ul> <li>Each protein is annotated with appropriate molecular functions consistent with their known activities</li> <li>CASP1 and CASP7 are correctly annotated as having cysteine-type endopeptidase activity</li> <li>PARP1 is correctly annotated with NAD+-protein poly-ADP-ribosyltransferase activity</li> </ul>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#3-cellular-location-annotation","title":"3. Cellular Location Annotation","text":"<ul> <li>Each activity is appropriately annotated with cellular location</li> <li>CASP1 occurs in the cytoplasm, while CASP7 and PARP1 occur in the nucleus, which is consistent with the literature</li> </ul>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#4-biological-process-annotation","title":"4. Biological Process Annotation","text":"<ul> <li>Appropriate biological processes are linked to each activity</li> <li>The processes flow logically from protein maturation (CASP1) to protein catabolism (CASP7) to poly-ADP-ribosylation (PARP1)</li> </ul>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#5-causal-relationships","title":"5. Causal Relationships","text":"<ul> <li>The causal relationships between activities are represented correctly using appropriate relationship predicates</li> <li>CASP1 directly positively regulates CASP7 (RO:0002629)</li> <li>CASP7 directly negatively regulates PARP1 (RO:0002630)</li> <li>These relationships accurately represent the biology of caspase activation and PARP1 cleavage</li> </ul>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#6-molecular-complexes","title":"6. Molecular Complexes","text":"<ul> <li>This model does not involve protein complexes, so complex annotation guidelines are not applicable here</li> </ul>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model accurately captures the biological pathway described in the literature:</p> <ol> <li>According to PMID:22464733, upon inflammasome activation by LPS, CASP1 cleaves and activates CASP7.</li> <li>Activated CASP7 then translocates to the nucleus where it cleaves PARP1.</li> <li>This cleavage of PARP1 enhances the expression of a subset of NF-\u03baB target genes.</li> </ol> <p>The model correctly represents CASP1 in the cytoplasm and CASP7/PARP1 in the nucleus, consistent with the cellular locations described in the literature. The causal relationship showing CASP7 negatively regulating PARP1 accurately reflects the cleavage and inactivation of PARP1 by CASP7.</p>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#minor-suggestions-for-improvement","title":"Minor Suggestions for Improvement","text":"<ol> <li> <p>Biological Process Annotation: While the annotations are correct, it might be helpful to include more specific processes related to inflammasome activation or immune response. The model doesn't explicitly mention the inflammasome context which is key to the biological story.</p> </li> <li> <p>Missing Context: The model title mentions \"in response to lipopolysaccharide,\" but this stimulus is not explicitly represented in the model structure. Adding a connection to LPS stimulus would improve completeness.</p> </li> </ol>"},{"location":"reviews/62b4ffe300001832-Activation_of_CASP7_by_CASP1_in_response_to_lipopolysaccharide__leading_to_cleavage_and_degradation_of_PARP1_by_CASP7__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model is well-constructed, accurately representing the biological pathway of CASP1-mediated activation of CASP7 and subsequent cleavage of PARP1. It follows GO-CAM best practices in terms of evidence documentation, causal relationships, and biological annotations.</p> <p>The model is parsimonious and easy for humans to understand, focusing on the key activities and relationships without unnecessary complexity. The model is consistent with the published literature and correctly represents the biological mechanism described in the referenced papers.</p> <p>This is a high-quality GO-CAM model that effectively captures the inflammasome-activated caspase pathway leading to PARP1 cleavage.</p>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/","title":"62b4ffe300002385 Arginine ADP riboxanation of CASP4  by  by S flexneri OspC3 that blocks CASP4 activity and pyroptosis  Human","text":"<p>Based on all the information gathered, I'll now review GO-CAM model 62b4ffe300002385.</p>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#review-of-go-cam-model-62b4ffe300002385","title":"Review of GO-CAM model 62b4ffe300002385","text":""},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#title","title":"Title","text":"<p>\"Arginine ADP-riboxanation of CASP4 by S.flexneri OspC3 that blocks CASP4 activity and pyroptosis (Human)\"</p>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents a molecular mechanism by which the bacterial pathogen Shigella flexneri evades host immune defenses through the OspC3 effector protein. The model describes how OspC3 modifies human caspase-4 (CASP4) through arginine ADP-riboxanation, which inhibits CASP4's ability to cleave Gasdermin-D (GSDMD), thus preventing pyroptotic cell death.</p>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#key-components-and-activities","title":"Key Components and Activities","text":"<ol> <li> <p>Human CASP4 (UniProtKB:P49662): A caspase that recognizes cytosolic lipopolysaccharide (LPS) and cleaves GSDMD to trigger pyroptosis.</p> </li> <li> <p>Human GSDMD (UniProtKB:P57764): The pore-forming protein that mediates pyroptosis when cleaved by inflammatory caspases.</p> </li> <li> <p>S. flexneri OspC3 (UniProtKB:A0A0H2US87): A bacterial effector protein with ADP-riboxanase activity that modifies CASP4 to inhibit its function.</p> </li> <li> <p>Calmodulin binding: OspC3 requires calmodulin binding for its activity.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#pathway-flow-and-biological-context","title":"Pathway Flow and Biological Context","text":"<p>The model shows how: 1. CASP4 functions in protein maturation (GO:0051604) and has cysteine-type endopeptidase activity (GO:0004197) 2. CASP4 positively regulates GSDMD's binding to phosphatidylinositol-4,5-bisphosphate (GO:0005546) 3. GSDMD mediates wide pore channel activity (GO:0022829) during pyroptotic inflammatory response (GO:0070269) 4. OspC3 binds calmodulin (GO:0005516) and has ADP-riboxanase activity (GO:0140740) 5. OspC3 negatively regulates CASP4's protease activity, preventing GSDMD cleavage 6. This occurs in the host cell cytoplasm (GO:0030430) during symbiont-mediated suppression of host programmed cell death (GO:0052041)</p>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents recent findings from peer-reviewed literature (PMID:26375003, PMID:34671164, PMID:36624349) regarding how S. flexneri evades pyroptosis. The structure of the model correctly shows:</p> <ol> <li>CASP4 normally cleaves GSDMD at Asp-275 to generate N-terminal GSDMD fragment</li> <li>The N-terminal GSDMD binds to phosphatidylinositol-4,5-bisphosphate and forms membrane pores</li> <li>OspC3 requires Ca\u00b2\u207a-free calmodulin for its ADP-riboxanase activity</li> <li>OspC3 catalyzes ADP-riboxanation of CASP4 at Arg-314, preventing CASP4 autoprocessing and activity</li> </ol>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#go-cam-structure-evaluation","title":"GO-CAM Structure Evaluation","text":""},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Appropriate causal relationships: The model correctly uses RO:0002629 (\"directly positively regulates\") and RO:0002630 (\"directly negatively regulates\") to show the causal relationships between activities.</p> </li> <li> <p>Contextually appropriate: The model includes appropriate location and biological process contexts for the activities.</p> </li> <li> <p>Evidence support: Each activity and association is supported by appropriate experimental evidence (ECO:0000314 - direct assay evidence) with relevant PMIDs.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing molecular complex representation: While OspC3 is shown to bind calmodulin, the model doesn't explicitly represent the OspC3-calmodulin complex as a distinct entity. Per GO-CAM best practices for complexes, when the activity (ADP-riboxanase activity) is enabled by a complex rather than a single protein, this could be more explicitly modeled.</p> </li> <li> <p>Additional molecular details: The model could be expanded to include:</p> </li> <li>The specific site of ADP-riboxanation (Arg-314 on CASP4)</li> <li>The NAD+ cofactor required for OspC3's ADP-riboxanase activity</li> <li> <p>The activation of GSDMD by other caspases (CASP1, CASP5) for comparative context</p> </li> <li> <p>Feedback mechanisms: The model could benefit from showing how pyroptosis contributes to host defense against S. flexneri to provide a more complete understanding of the immune evasion strategy.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002385-Arginine_ADP_riboxanation_of_CASP4__by__by_S_flexneri_OspC3_that_blocks_CASP4_activity_and_pyroptosis__Human_/#summary","title":"Summary","text":"<p>GO-CAM model 62b4ffe300002385 provides an accurate and well-structured representation of how S. flexneri OspC3 inhibits human CASP4-mediated pyroptosis through arginine ADP-riboxanation. The model correctly uses the appropriate ontology terms, relationship predicates, and evidence codes.</p> <p>The model is scientifically sound and consistent with current literature, capturing the key molecular events in this host-pathogen interaction. It successfully represents how a bacterial pathogen directly modifies a host immune pathway protein to evade cell death-mediated defenses.</p> <p>Minor improvements could be made by explicitly representing the OspC3-calmodulin complex and adding more molecular details, but overall this is a high-quality GO-CAM model that accurately depicts this important host-pathogen interaction mechanism.</p>"},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/","title":"62b4ffe300002470 Ochratoxin A biosynthesis   catabolism  A  niger","text":"<p>Based on my review of the GO-CAM model and the scientific literature, I'll now provide a comprehensive review of gomodel:62b4ffe300002470 \"Ochratoxin A biosynthesis &amp; catabolism (A. niger)\".</p>"},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#review-of-go-cam-model-62b4ffe300002470","title":"Review of GO-CAM Model: 62b4ffe300002470","text":""},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#general-overview","title":"General Overview","text":"<p>This model depicts the ochratoxin A (OTA) biosynthesis and catabolism pathways in Aspergillus niger. The model focuses on the enzymes involved in both the production and breakdown of this important mycotoxin. Ochratoxin A is a significant food contaminant produced by various Aspergillus and Penicillium species that has nephrotoxic, immunotoxic, genotoxic, neurotoxic, and teratogenic properties.</p>"},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model includes five molecular activities involving four proteins:</p> <ol> <li>A2R6H1 (OtaA) - a polyketide synthase involved in the initial steps of OTA biosynthesis</li> <li>A2R6H0 (OtaB) - a non-ribosomal peptide synthetase </li> <li>A2R6G9 (OtaC) - a cytochrome P450 oxidoreductase</li> <li>A2R2V4 (Am2) - a carboxypeptidase involved in OTA degradation</li> </ol> <p>The biosynthesis pathway is represented as a linear chain of activities connected by \"provides input for\" (RO:0002413) relationships, while the catabolism pathway is represented separately.</p>"},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#detailed-assessment","title":"Detailed Assessment","text":""},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#strengths","title":"Strengths","text":"<ol> <li> <p>Pathway Completeness: The model provides a comprehensive representation of both OTA biosynthesis and catabolism, making it scientifically valuable.</p> </li> <li> <p>Molecular Functions: The molecular functions assigned to each protein are correct and supported by literature.</p> </li> <li> <p>Chemical Inputs/Outputs: The inputs and outputs for most reactions are properly specified, with appropriate ChEBI IDs.</p> </li> <li> <p>Causal Connections: The model correctly uses the \"provides input for\" (RO:0002413) relationship to connect activities in the biosynthetic pathway.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Molecular Details: The role of A2R6G7 (OtaD) is missing from the model, though it's mentioned in the literature as the final enzyme in the pathway that chlorinates ochratoxin B to form ochratoxin A.</p> </li> <li> <p>Incomplete Input/Output Specifications: </p> </li> <li>OtaC (A2R6G9) lacks a specified input and output, which should include 7-methylmellein as input and 7-carboxymellein as output.</li> <li> <p>OtaB (A2R6H0) has L-phenylalanine as input but lacks a specified output (which should be ochratoxin B).</p> </li> <li> <p>Cellular Location Information: Only one activity (A2R2V4 carboxypeptidase) specifies a cellular location (extracellular region). According to literature, this is correct, but location information for the other proteins would enhance the model.</p> </li> <li> <p>Evidential Support: Most activities cite the same evidence source (PMID:27667988), which is appropriate, but for the carboxypeptidase activity, an additional reference (PMID:24947135) is used that specifically demonstrates the ochratoxinase activity of Am2.</p> </li> <li> <p>Missing Connection: There is no explicit connection between the biosynthesis and catabolism pathways in the model, which could be added to make the model more complete.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Proper Use of Relationship Types: The causal relationships between activities use the appropriate \"provides input for\" (RO:0002413) predicate.</p> </li> <li> <p>Appropriate Evidence Codes: Evidence codes (ECO:0000304 for author statement and ECO:0000314 for direct assay) are used appropriately.</p> </li> <li> <p>Proper Molecular Function Assignment: The molecular functions are correctly assigned to each protein based on their characterized biochemical activities.</p> </li> <li> <p>Biological Context: Each activity is correctly placed within the appropriate biological process (either ochratoxin A biosynthetic process or ochratoxin A catabolic process).</p> </li> </ol> <p>However, based on the \"How to annotate complexes in GO-CAM\" document, if any of these enzymes function as part of complexes, that should be represented. The current literature doesn't indicate that these enzymes function as complexes, so the current representation is appropriate.</p>"},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add the missing OtaD activity: Include the role of A2R6G7 (OtaD) as the enzyme that chlorinates ochratoxin B to form ochratoxin A, connecting it after OtaB in the pathway.</p> </li> <li> <p>Complete input/output specifications: Add the missing inputs and outputs for OtaC and OtaB to make the model chemically complete.</p> </li> <li> <p>Enhance cellular location information: Add cellular location information for the biosynthetic enzymes if available in the literature.</p> </li> <li> <p>Connect biosynthesis and catabolism: Consider adding a relationship that connects the end of the biosynthesis pathway to the beginning of the catabolism pathway, to show the complete lifecycle of ochratoxin A.</p> </li> <li> <p>Expand evidential support: Consider incorporating additional references that specifically characterize each enzyme's role in the pathway.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002470-Ochratoxin_A_biosynthesis___catabolism__A__niger_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 62b4ffe300002470 is a valuable representation of ochratoxin A biosynthesis and catabolism in Aspergillus niger. While it has a few areas that could be improved for completeness, it correctly represents the core pathway and follows GO-CAM best practices. With the suggested enhancements, it would provide an even more comprehensive and accurate representation of this important mycotoxin pathway.</p>"},{"location":"reviews/62b4ffe300002512-Ochratoxin_biosynthesis_in_A__carbonarius/","title":"62b4ffe300002512 Ochratoxin biosynthesis in A  carbonarius","text":"<p>Based on my review of the GO-CAM model for \"Ochratoxin biosynthesis in A. carbonarius\" (gomodel:62b4ffe300002512), I'll now provide a thorough assessment of the model's quality and adherence to GO-CAM best practices.</p>"},{"location":"reviews/62b4ffe300002512-Ochratoxin_biosynthesis_in_A__carbonarius/#go-cam-review-ochratoxin-biosynthesis-in-a-carbonarius-gomodel62b4ffe300002512","title":"GO-CAM Review: Ochratoxin biosynthesis in A. carbonarius (gomodel:62b4ffe300002512)","text":""},{"location":"reviews/62b4ffe300002512-Ochratoxin_biosynthesis_in_A__carbonarius/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the biosynthesis pathway of ochratoxin A (OTA) in Aspergillus carbonarius. OTA is a potent mycotoxin produced by several Aspergillus and Penicillium species that can contaminate various food commodities. The model depicts four key enzymatic activities in the OTA biosynthetic pathway:</p> <ol> <li>OtaA (UniProtKB:A0A1R3RGK0) - polyketide synthase activity</li> <li>OtaC (UniProtKB:A0A1R3RGJ7) - oxidoreductase activity</li> <li>OtaB (UniProtKB:A0A1R3RGK1) - non-ribosomal peptide synthetase activity</li> <li>OtaD (UniProtKB:A0A1R3RGJ2) - catalytic activity (halogenase)</li> </ol> <p>These activities are connected in a linear pathway leading to the production of ochratoxin A.</p>"},{"location":"reviews/62b4ffe300002512-Ochratoxin_biosynthesis_in_A__carbonarius/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current scientific understanding of the OTA biosynthetic pathway based on the primary literature (PMID:24699234). The order of enzymatic reactions is consistent with published research:</p> <ol> <li>The pathway begins with OtaA (polyketide synthase) that forms the isocoumarin group from acetyl-CoA and malonyl-CoA, producing a pentaketide structure</li> <li>OtaC (oxidoreductase) then converts this intermediate</li> <li>OtaB (NRPS) links L-phenylalanine to the dihydroisocoumarin ring </li> <li>OtaD (halogenase) performs the final chlorination step to form ochratoxin A</li> </ol> <p>The evidence is primarily from mutant phenotype studies (ECO:0000315) with appropriate PMID references, which is appropriate for this type of pathway.</p>"},{"location":"reviews/62b4ffe300002512-Ochratoxin_biosynthesis_in_A__carbonarius/#go-cam-structure-and-technical-quality","title":"GO-CAM Structure and Technical Quality","text":"<p>The model follows GO-CAM structural conventions with:</p> <ol> <li>Activities: Each protein is properly associated with its molecular function</li> <li>Part_of relationships: Each activity is correctly indicated as part_of the \"ochratoxin A biosynthetic process\" (GO:1900818)</li> <li>Causal connections: The model uses the appropriate causal relation \"provides input for\" (RO:0002413) to connect the sequential steps of the pathway</li> <li>Inputs/outputs: Molecule associations are properly represented with inputs and outputs for the relevant steps:</li> <li>OtaA has acetyl-CoA (CHEBI:15351) and malonyl-CoA (CHEBI:15531) as inputs</li> <li>OtaB has L-phenylalanine (CHEBI:17295) as input</li> <li>OtaD has ochratoxin A (CHEBI:7719) as output</li> </ol>"},{"location":"reviews/62b4ffe300002512-Ochratoxin_biosynthesis_in_A__carbonarius/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I have identified a few points for enhancement:</p> <ol> <li>Missing intermediate molecules: The model would benefit from including all the intermediate molecules in the pathway to provide a complete representation. For example:</li> <li>The intermediate 7-methylmellein produced by OtaA</li> <li>7-carboxymellein (ochratoxin beta) produced by OtaC</li> <li> <p>Ochratoxin B produced by OtaB</p> </li> <li> <p>Specificity of molecular functions: </p> </li> <li> <p>OtaD is currently annotated with the general term \"catalytic activity\" (GO:0003824), but a more specific term like \"flavin-dependent halogenase activity\" would be more appropriate based on the UniProt annotation.</p> </li> <li> <p>Annotation of OtaC: The literature indicates OtaC is a cytochrome P450 monooxygenase, but it's annotated with the general term \"oxidoreductase activity\" (GO:0016491). A more specific monooxygenase GO term would be preferable.</p> </li> <li> <p>Expanding evidence codes: Some causal associations use only the reference (24699234) without the PMID prefix. This should be standardized to ensure proper linking to the literature.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002512-Ochratoxin_biosynthesis_in_A__carbonarius/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Ochratoxin biosynthesis in A. carbonarius\" is a well-constructed, biologically accurate representation of the OTA biosynthetic pathway. It effectively follows GO-CAM best practices and captures the key enzymatic steps involved in ochratoxin A production. The minor improvements suggested would enhance the specificity and completeness of the model without altering its fundamental structure.</p> <p>The model is parsimonious, representing the essential components of the pathway without unnecessary complexity, and would be easily understandable by researchers familiar with biochemical pathways. The causal flow is logical and supported by experimental evidence from the literature.</p> <p>Overall, I recommend approval of this GO-CAM model with the suggested minor improvements.</p>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/","title":"62b4ffe300002544 Ilicicolin H  Neonectria sp  strain DH2","text":"<p>Now, let me review the GO-CAM model in light of the information gathered:</p>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#go-cam-model-review-gomodel62b4ffe300002544","title":"GO-CAM Model Review: gomodel:62b4ffe300002544","text":""},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#overview","title":"Overview","text":"<p>The model titled \"Ilicicolin H (Neonectria sp. strain DH2)\" describes the biosynthetic pathway of ilicicolin H, a potent antifungal compound that inhibits the mitochondrial cytochrome bc1 complex. The model includes activities of four proteins (IliA, IliB, IliC, and IliD) encoded in the ilicicolin H biosynthetic gene cluster in Neonectria sp. strain DH2.</p>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#biological-content-and-literature-support","title":"Biological Content and Literature Support","text":"<p>The model is well-supported by the scientific literature, particularly the paper by Lin et al. (PMID:31216742), which describes the identification and characterization of the ilicicolin H biosynthetic gene cluster. The pathway depicted in the model aligns with the mechanism proposed in this paper, where:</p> <ol> <li>IliA (P0DO30) functions as a hybrid PKS-NRPS synthetase</li> <li>IliB (P0DO31) functions as a trans-enoyl reductase</li> <li>IliC (P0DO32) functions as a cytochrome P450 monooxygenase</li> <li>IliD (P0DO33) functions as a Diels-Alderase</li> </ol> <p>The model accurately represents the biosynthetic steps and chemical transformations described in the paper.</p>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#molecular-functions-and-associations","title":"Molecular Functions and Associations","text":"<p>The model includes appropriate molecular functions for each protein:</p> <ul> <li>IliA: GO:0016218 (polyketide synthase activity), GO:0016491 (oxidoreductase activity), and GO:1904091 (non-ribosomal peptide synthetase activity)</li> <li>IliB: GO:0016631 (enoyl-[acyl-carrier-protein] reductase activity)</li> <li>IliC: GO:0016491 (oxidoreductase activity)</li> <li>IliD: GO:0009975 (cyclase activity)</li> </ul> <p>All activities are appropriately part of GO:0140781 (ilicicolin H biosynthetic process).</p>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#causal-associations","title":"Causal Associations","text":"<p>The model includes several causal associations using appropriate predicates: - IliB's enoyl-reductase activity positively regulates (RO:0002629) IliA's polyketide synthase activity - IliA's non-ribosomal peptide synthetase activity provides input for (RO:0002413) IliA's oxidoreductase activity - IliA's oxidoreductase activity provides input for (RO:0002413) IliC's oxidoreductase activity</p> <p>These causal links correctly represent the flow of the biosynthetic pathway according to the literature.</p>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#input-output-relationships","title":"Input-Output Relationships","text":"<p>The model correctly represents substrate-product relationships: - IliA works with tyrosine (CHEBI:17895) and produces an intermediate (CHEBI:155890) - IliC uses this intermediate (CHEBI:155890) as input and produces another intermediate (CHEBI:155889) - IliD uses this second intermediate (CHEBI:155889) as input and produces ilicicolin H (CHEBI:77772)</p>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the ilicicolin H biosynthetic pathway as described in the literature</li> <li>All proteins have appropriate molecular functions</li> <li>Input and output molecules are correctly specified</li> <li>Causal relationships between activities are logically connected</li> <li>All assertions are supported by evidence from the literature (PMID:31216742)</li> </ol>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#suggested-improvements","title":"Suggested Improvements:","text":"<ol> <li> <p>Missing chemical inputs: While the model shows some inputs like tyrosine, acetyl-CoA, and malonyl-CoA, it could be more specific about all the building blocks (S-adenosyl-L-methionine is mentioned in the paper as contributing methyl groups)</p> </li> <li> <p>Incomplete causal associations: The model could be improved by adding a causal association between IliC's oxidoreductase activity and IliD's cyclase activity to complete the pathway flow</p> </li> <li> <p>Molecular function clarity: For IliA, which has multiple activities, the model could be more specific about which domain is responsible for each function</p> </li> </ol>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#conformance-to-go-cam-best-practices","title":"Conformance to GO-CAM Best Practices","text":"<p>The model generally conforms to GO-CAM best practices: - All activities are enabled by specific gene products - Each activity has an appropriate GO molecular function term - Each activity is part of a relevant biological process - Evidence codes and references are provided for assertions - Input and output molecules are specified where appropriate</p>"},{"location":"reviews/62b4ffe300002544-Ilicicolin_H__Neonectria_sp__strain_DH2_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62b4ffe300002544 is a high-quality representation of the ilicicolin H biosynthetic pathway in Neonectria sp. strain DH2. It is well-supported by the literature and follows most GO-CAM best practices. Minor improvements could be made to enhance the completeness of the causal associations and input specifications, but overall, the model provides a clear and accurate description of this biosynthetic pathway.</p>"},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/","title":"62b4ffe300002753 Poxvirus OPG106 inhibition of interferon gamma signaling  Human Poxvirus","text":"<p>Based on my review of the GO-CAM model ID: gomodel:62b4ffe300002753 and the related literature, I'll provide a comprehensive analysis of this model's structure, biological content, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#review-of-go-cam-model-62b4ffe300002753","title":"Review of GO-CAM Model: 62b4ffe300002753","text":""},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<p>Title: Poxvirus-OPG106 inhibition of interferon-gamma signaling (Human-Poxvirus)</p> <p>ID: gomodel:62b4ffe300002753</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#model-structure-and-content-summary","title":"Model Structure and Content Summary","text":"<p>This GO-CAM model represents the molecular mechanism by which the Vaccinia virus protein OPG106 (H1L) inhibits the interferon-gamma signaling pathway in human cells. The model has four key activities:</p> <ol> <li>STAT1 (P42224) DNA-binding transcription factor activity in the nucleus, part of JAK-STAT signaling pathway</li> <li>OPG106/H1L (P07239) phosphatase activity in the cytoplasm, part of symbiont-mediated suppression of host type I interferon-mediated signaling pathway</li> <li>IFNGR1 (P15260) type II interferon receptor activity in the membrane, part of type II interferon-mediated signaling pathway</li> <li>IFNG (P01579) cytokine activity in the extracellular space, part of type II interferon-mediated signaling pathway</li> </ol> <p>The causal connections show: - IFNG positively regulates IFNGR1 activity - IFNGR1 positively regulates STAT1 activity - OPG106 negatively regulates STAT1 activity</p> <p>This represents the viral mechanism where the poxvirus phosphatase OPG106 counteracts the host's interferon-gamma signaling pathway by dephosphorylating activated STAT1, thereby inhibiting the antiviral immune response.</p>"},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#evaluation-against-go-cam-best-practices","title":"Evaluation Against GO-CAM Best Practices","text":""},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#molecular-activities-and-connections","title":"Molecular Activities and Connections","text":"<p>\u2705 Molecular Functions: Each protein is properly annotated with an appropriate molecular function.</p> <p>\u2705 Biological Process: Each activity is appropriately connected to relevant biological processes.</p> <p>\u2705 Cellular Component: Each activity is properly localized to the correct cellular compartment (nucleus, cytoplasm, membrane, extracellular space).</p> <p>\u2705 Causal Relationships: The causal connections use the correct relationship predicates:   - RO:0002629 (directly positively regulates) for IFNG \u2192 IFNGR1   - RO:0002304 (causally upstream of, positive effect) for IFNGR1 \u2192 STAT1   - RO:0002630 (directly negatively regulates) for OPG106 \u2192 STAT1</p> <p>\u2705 Evidence: Each annotation is supported by appropriate evidence codes and references to literature.</p>"},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#biological-accuracy","title":"Biological Accuracy","text":"<p>\u2705 Molecular Mechanism: The model accurately represents the known mechanism of viral inhibition of interferon signaling. The poxvirus phosphatase OPG106 (H1L) directly dephosphorylates STAT1, preventing its transcriptional activity, which is consistent with the literature (PMID:11238845).</p> <p>\u2705 Signaling Flow: The flow of activity from extracellular IFNG binding to membrane receptor IFNGR1, activation of STAT1, and inhibition by viral phosphatase follows the established paradigm of this pathway.</p> <p>\u2705 Subcellular Localization: The components are correctly localized based on their known biological locations.</p>"},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#model-clarity-and-parsimony","title":"Model Clarity and Parsimony","text":"<p>\u2705 Complexity Level: The model focuses on the key components of the pathway without unnecessary complexity, making it easy to understand.</p> <p>\u2705 Activity Flow: The model clearly shows how the viral protein interferes with normal host signaling.</p>"},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#additional-notes-and-suggestions","title":"Additional Notes and Suggestions","text":"<ol> <li> <p>The model correctly represents the viral strategy for inhibiting host immune response, providing a clear picture of host-pathogen interaction.</p> </li> <li> <p>The supporting literature evidence from PMID:11238845 confirms the mechanism shown in the model, where the viral phosphatase VH1 (OPG106) dephosphorylates STAT1, blocking the IFN-\u03b3 signaling cascade.</p> </li> <li> <p>The model aligns with information in the UniProt entries for all proteins involved, particularly P07239 (OPG106) which is annotated as \"Serine/tyrosine phosphatase which down-regulates cellular antiviral response by dephosphorylating activated host STAT1.\"</p> </li> <li> <p>The model uses correct annotation of complexes according to GO-CAM best practices. Since the individual proteins with their specific molecular activities are known, they are directly represented rather than using complex IDs.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002753-Poxvirus_OPG106_inhibition_of_interferon_gamma_signaling__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62b4ffe300002753 is a well-constructed representation of the mechanism by which Vaccinia virus protein OPG106 inhibits interferon-gamma signaling in human cells. It adheres to GO-CAM best practices, accurately represents the biological content based on published literature, and presents the information in a clear and parsimonious manner.</p> <p>The model serves as an excellent example of how viral proteins can interfere with host immune signaling pathways, specifically showing how the viral phosphatase OPG106 counteracts STAT1 activation downstream of the interferon-gamma receptor, thereby contributing to viral immune evasion.</p>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/","title":"62b4ffe300002814 Poxvirus OPG204 inhibition of type I interferon signaling   Human Poxvirus","text":"<p>Now I'll review the GO-CAM model with ID \"62b4ffe300002814\" (titled \"Poxvirus-OPG204 inhibition of type I interferon signaling (Human-Poxvirus)\"). Let me analyze this model in detail to check it against best practices.</p>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model describes how a vaccinia virus protein (OPG204/B18) interferes with type I interferon signaling by acting as a soluble interferon receptor decoy. The model includes:</p> <ol> <li>Type I interferon receptor proteins (IFNAR1 and IFNAR2)</li> <li>Interferon alpha-2 (IFNA2) as a cytokine</li> <li>Vaccinia virus soluble interferon alpha/beta receptor OPG204 (B18R/VACWR200)</li> <li>The interactions between these components</li> </ol>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#structural-analysis","title":"Structural Analysis","text":"<p>The model consists of 4 activities with associated causal connections:</p> <ol> <li> <p>IFNAR1 (UniProtKB:P17181) with receptor activity (GO:0004905) occurring in the membrane (GO:0016020) as part of type I interferon signaling (GO:0060337)</p> </li> <li> <p>IFNAR2 (UniProtKB:P48551) with receptor activity (GO:0004905) occurring in the membrane (GO:0016020) as part of type I interferon signaling (GO:0060337)</p> </li> <li> <p>IFNA2 (UniProtKB:P01563) with cytokine activity (GO:0005125) occurring in extracellular space (GO:0005615) as part of type I interferon signaling (GO:0060337)</p> </li> <li> <p>This activity directly positively regulates (RO:0002629) both IFNAR1 and IFNAR2 activities</p> </li> <li> <p>Viral OPG204 protein (UniProtKB:P25213) with receptor decoy activity (GO:0140319) occurring in extracellular space (GO:0005615) as part of symbiont-mediated suppression of host type I interferon-mediated signaling pathway (GO:0039502)</p> </li> <li>This activity directly negatively regulates (RO:0002630) IFNA2's cytokine activity</li> </ol>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#review-based-on-go-cam-best-practices","title":"Review Based on GO-CAM Best Practices","text":""},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#1-biological-accuracy","title":"1. Biological Accuracy","text":"<p>The model accurately represents the current scientific understanding about how vaccinia virus OPG204 protein interferes with type I interferon signaling:</p> <ul> <li>OPG204/B18R is correctly annotated as having receptor decoy activity (GO:0140319)</li> <li>The virus protein is shown to act in the extracellular space, which matches its known biology</li> <li>OPG204 directly negatively regulates interferon alpha-2's cytokine activity, consistent with the literature showing it acts as a competitive inhibitor</li> <li>IFNAR1 and IFNAR2 are correctly shown as membrane proteins with receptor activity</li> <li>IFNA2 is correctly shown to positively regulate both receptor components</li> </ul> <p>The representation is consistent with the UniProt entries and the literature (particularly PMID:7758109, PMID:11070021, and PMID:21854986).</p>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#2-representation-of-complexes","title":"2. Representation of Complexes","text":"<p>Looking at the model in light of the \"How to annotate complexes in GO-CAM\" document, this model follows the recommended approach:</p> <ul> <li>The model correctly represents the two subunits of the type I interferon receptor (IFNAR1 and IFNAR2) as separate activities with their own molecular functions since both components are known to be involved in receptor activity.</li> <li>IFNA2 correctly regulates both receptor components.</li> <li>The model doesn't use a complex GO term for the interferon receptor, which is appropriate since the individual components' functions are well characterized.</li> </ul>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#3-causal-relationships","title":"3. Causal Relationships","text":"<p>The causal relationships in the model follow GO-CAM guidelines:</p> <ul> <li>IFNA2 directly positively regulates (RO:0002629) both IFNAR1 and IFNAR2, which accurately reflects the cytokine-receptor relationship</li> <li>OPG204 directly negatively regulates (RO:0002630) IFNA2's activity, correctly representing the competitive inhibition by the viral decoy receptor</li> </ul>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#4-cellular-context","title":"4. Cellular Context","text":"<p>The model correctly specifies the cellular locations: - Receptors are located in the membrane (GO:0016020) - IFNA2 and OPG204 are in the extracellular space (GO:0005615)</p>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#5-molecular-functions-and-biological-processes","title":"5. Molecular Functions and Biological Processes","text":"<ul> <li>The molecular functions are appropriate for each protein:</li> <li>Receptor activity (GO:0004905) for IFNAR1 and IFNAR2</li> <li>Cytokine activity (GO:0005125) for IFNA2</li> <li> <p>Receptor decoy activity (GO:0140319) for OPG204</p> </li> <li> <p>The biological processes are appropriately assigned:</p> </li> <li>Type I interferon-mediated signaling pathway (GO:0060337) for the host components</li> <li>Symbiont-mediated suppression of host type I interferon-mediated signaling pathway (GO:0039502) for the viral protein</li> </ul>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#6-evidence","title":"6. Evidence","text":"<p>Each assertion in the model is supported by evidence codes and references to the literature, which is in line with best practices.</p>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed and follows GO-CAM best practices, I have a few minor suggestions:</p> <ol> <li> <p>Specific membrane location: The model uses GO:0016020 (membrane) for both receptor components. It might be more precise to use GO:0005886 (plasma membrane) to better reflect their specific location.</p> </li> <li> <p>Downstream effects: The model could be expanded to include downstream effects of the interferon signaling pathway, such as JAK-STAT pathway activation and the resulting gene expression changes. This would provide a more complete picture of how the viral protein's interference impacts cellular responses.</p> </li> <li> <p>Additional virus effects: If known, the model could include other mechanisms by which the virus interferes with interferon signaling (such as effects on JAK-TYK2 kinases or STAT proteins).</p> </li> </ol>"},{"location":"reviews/62b4ffe300002814-Poxvirus_OPG204_inhibition_of_type_I_interferon_signaling___Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"62b4ffe300002814\" is a well-constructed representation of how vaccinia virus OPG204 protein interferes with type I interferon signaling. It follows GO-CAM best practices in terms of:</p> <ul> <li>Accurate biological representation</li> <li>Appropriate use of molecular functions, biological processes, and cellular components</li> <li>Proper causal relationships</li> <li>Evidence-based assertions</li> </ul> <p>The model effectively shows how the viral protein acts as a decoy receptor to sequester interferon alpha in the extracellular space, preventing it from activating the cellular interferon receptors. This mechanism is an important viral immune evasion strategy, and the model captures this biology clearly and accurately.</p> <p>While some minor improvements could be made to enhance specificity and comprehensiveness, the model successfully accomplishes its intended purpose of representing this specific aspect of virus-host interaction.</p>"},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/","title":"62b4ffe300002896 Poxvirus OPG043 inhibition of host PKR  Human Poxvirus","text":"<p>Based on the model and additional information I've gathered, I'll now perform a comprehensive review of GO-CAM model 62b4ffe300002896.</p>"},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/#review-of-go-cam-model-62b4ffe300002896","title":"Review of GO-CAM model 62b4ffe300002896","text":""},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model represents \"Poxvirus-OPG043 inhibition of host PKR (Human-Poxvirus)\" and illustrates the interaction between a poxvirus protein (P18378/OPG043/K3L) and the human protein kinase R (PKR) pathway. The model specifically shows how the poxvirus protein inhibits the host's antiviral response by interfering with the PKR-mediated translational regulation pathway.</p>"},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model is focused on a well-documented viral evasion mechanism where poxviruses encode proteins that act as pseudosubstrates to inhibit the host PKR kinase, preventing the shutdown of protein synthesis during viral infection.</p> <p>The key components of the model are:</p> <ol> <li>Human PKR (P19525) - a key antiviral protein that phosphorylates eIF2\u03b1 to block translation during viral infection</li> <li>Poxvirus protein K3L (P18378) - viral protein that inhibits PKR</li> <li>Human eIF2\u03b1 (Q9BY44) - translation initiation factor targeted by PKR</li> <li>Human eIF2S2 (P20042) - beta subunit of eIF2 involved in translation initiation</li> </ol> <p>The causal relationships modeled are: - Poxvirus K3L protein (P18378) has protein sequestering activity (GO:0140311) that directly negatively regulates (RO:0002630) the protein kinase activity (GO:0004672) of host PKR - PKR's protein kinase activity (GO:0004672) directly negatively regulates (RO:0002630) the translation initiation factor activity (GO:0003743) of eIF2\u03b1 - eIF2\u03b1's translation initiation factor activity (GO:0003743) directly positively regulates (RO:0002629) the translation initiation factor activity (GO:0003743) of eIF2S2</p>"},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/#strengths","title":"Strengths","text":"<ol> <li>The core biological mechanism of viral inhibition of host PKR is accurately represented</li> <li>The model uses appropriate GO terms for functions (protein sequestering activity, kinase activity, translation initiation factor activity)</li> <li>The causal relationships use correct predicates (directly negatively/positively regulates)</li> <li>The model includes appropriate evidence codes and literature references</li> <li>All components are shown in the correct cellular location (cytoplasm)</li> </ol>"},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/#issues-identified","title":"Issues Identified","text":"<ol> <li> <p>PMID Reference Error: The model includes reference \"PMID:248628414\" which appears to be an incorrect format for a PubMed ID (usually PubMed IDs don't exceed 9 digits). This should be verified and corrected.</p> </li> <li> <p>Process Annotation: The model correctly annotates the processes (viral-host interaction, translational initiation, and antiviral response), but some processes could be more specifically annotated.</p> </li> <li> <p>Causal Flow Consistency: The model shows a pathway where poxvirus K3L inhibits PKR, which inhibits eIF2\u03b1. The model correctly shows PKR negatively regulating eIF2\u03b1, but I would suggest clarifying that this is specifically through phosphorylation.</p> </li> <li> <p>Complete Mechanism Representation: While the core mechanism is captured, the model could be enhanced by including:</p> </li> <li>The role of viral dsRNA in activating PKR</li> <li>The specific phosphorylation of eIF2\u03b1 at Ser-51</li> <li>More detail on how phosphorylated eIF2\u03b1 blocks translation</li> </ol>"},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Fix Reference Error: Verify and correct the PMID:248628414 reference to ensure it points to the correct literature.</p> </li> <li> <p>Enhanced Activity Annotations: Consider adding more specific annotations:</p> </li> <li>For PKR, specify that it phosphorylates eIF2\u03b1 at Ser-51</li> <li> <p>For eIF2\u03b1, clarify that when phosphorylated it sequesters eIF2B, preventing exchange of GDP for GTP</p> </li> <li> <p>Complete Causal Chain: Consider extending the model to include:</p> </li> <li>The immediate upstream activator of PKR (viral dsRNA)</li> <li>The downstream effect of eIF2\u03b1 phosphorylation (global translation inhibition)</li> <li> <p>The specific outcome of translation inhibition (antiviral state)</p> </li> <li> <p>Additional Evidence: The model would be strengthened by including more recent literature that further validates this mechanism, especially papers that specifically address the K3L protein's role in immune evasion.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002896-Poxvirus_OPG043_inhibition_of_host_PKR__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 62b4ffe300002896 provides an accurate representation of poxvirus inhibition of host PKR and the associated translational regulation pathway. The model accurately captures the core biological mechanism with appropriate GO terms, predicates, and evidence. With a few minor improvements to the reference and some additional mechanistic details, the model would provide an even more comprehensive representation of this important host-pathogen interaction.</p> <p>Overall, this is a well-constructed model that effectively represents an important viral immune evasion mechanism at the molecular level.</p>"},{"location":"reviews/62b4ffe300002959-Aflaroxin__Aspergillus_parasiticus_/","title":"62b4ffe300002959 Aflaroxin  Aspergillus parasiticus","text":"<p>Now that I have a good understanding of the GO-CAM model and relevant best practices, let me conduct a thorough review of the GO-CAM model gomodel:62b4ffe300002959 (Aflatoxin biosynthesis pathway in Aspergillus parasiticus).</p>"},{"location":"reviews/62b4ffe300002959-Aflaroxin__Aspergillus_parasiticus_/#go-cam-review-aflatoxin-biosynthesis-pathway-gomodel62b4ffe300002959","title":"GO-CAM Review: Aflatoxin Biosynthesis Pathway (gomodel:62b4ffe300002959)","text":""},{"location":"reviews/62b4ffe300002959-Aflaroxin__Aspergillus_parasiticus_/#overview","title":"Overview","text":"<p>This GO-CAM model describes the aflatoxin biosynthetic process (GO:0045122) in Aspergillus parasiticus (NCBITaxon:1403190), showing the progression of enzymatic reactions from Hexanoyl-[acp] to various aflatoxin derivatives including aflatoxin B1, B2, G1, and G2. The model includes 23 distinct activities representing the sequential steps in this biosynthetic pathway.</p>"},{"location":"reviews/62b4ffe300002959-Aflaroxin__Aspergillus_parasiticus_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive Pathway Representation: The model provides a detailed representation of the aflatoxin biosynthetic pathway, including multiple branches that lead to different aflatoxin types.</p> </li> <li> <p>Evidence Support: Most activities are well-supported with appropriate evidence, primarily using ECO:0000314 (direct assay evidence) or ECO:0000304 (author statement supported by traceable reference).</p> </li> <li> <p>Detailed Molecular Information: The model includes specific chemical entities as inputs and outputs, clearly showing the progression of chemical transformations.</p> </li> <li> <p>Cellular Localization: Several activities include cellular localization information (occurs_in), which adds valuable context to the model.</p> </li> <li> <p>Proper Complex Annotation: The fatty acid synthase complex (GO:0005835) with members Q8TGA1 and Q8TGA2 is correctly annotated according to GO-CAM complex annotation guidelines.</p> </li> </ol>"},{"location":"reviews/62b4ffe300002959-Aflaroxin__Aspergillus_parasiticus_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing Causal Connections: Several activities are not connected by causal relationships, making parts of the model appear disconnected. For example:</li> <li>The fatty acid synthase complex activity (62b4ffe300004811) produces Hexanoyl-[acp] but lacks a causal connection to the next step.</li> <li> <p>Several sequential reactions lack causal connections that would make the flow of the pathway clearer.</p> </li> <li> <p>Evidence Inconsistencies: </p> </li> <li>Some causal associations lack evidence annotations (e.g., in activities 62d0afa500000525 and 62d0afa500000528).</li> <li> <p>One reference is inconsistently formatted with a space after PMID: \"PMID: 9835571\" rather than \"PMID:9835571\".</p> </li> <li> <p>Activity Flow Issues:</p> </li> <li>The pathway branches showing the formation of different aflatoxin types (B1, B2, G1, G2) lack clear causal connections between some steps.</li> <li> <p>Some activities have outputs that aren't clearly used as inputs in subsequent steps.</p> </li> <li> <p>Missing Input Information:</p> </li> <li>Activity 62d0afa500000564 (nadA protein with flavin reductase activity) has outputs but no inputs specified.</li> <li> <p>Activity 62d0afa500000525 (aflN with monooxygenase activity) has no specified inputs or outputs.</p> </li> <li> <p>Incomplete Annotations:</p> </li> <li>The activity with ID 62e3212700000192 is enabled by \"information biomacromolecule\" (CHEBI:33695) rather than a specific protein, which is unusual for an enzymatic activity.</li> </ol>"},{"location":"reviews/62b4ffe300002959-Aflaroxin__Aspergillus_parasiticus_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li>Complete Causal Connections:</li> <li>Add causal relationships (RO:0002413 \"provides input for\") between sequential steps in the pathway to make the flow clear.</li> <li> <p>Ensure all activities are connected in the linear portions of the pathway.</p> </li> <li> <p>Fix Evidence Annotations:</p> </li> <li>Add evidence to all causal associations.</li> <li> <p>Fix the inconsistent PMID format (remove space after \"PMID:\").</p> </li> <li> <p>Improve Input/Output Annotations:</p> </li> <li>Specify inputs for activities 62d0afa500000564 and 62d0afa500000525.</li> <li> <p>Ensure that outputs from one activity match inputs to subsequent activities where appropriate.</p> </li> <li> <p>Clarify Final Steps:</p> </li> <li> <p>Make the branching paths to different aflatoxin types (B1, B2, G1, G2) more explicit with appropriate causal connections.</p> </li> <li> <p>Specific Gene Product:</p> </li> <li>Replace the generic \"information biomacromolecule\" (CHEBI:33695) enabler with the specific protein responsible for that activity if known.</li> </ol>"},{"location":"reviews/62b4ffe300002959-Aflaroxin__Aspergillus_parasiticus_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for aflatoxin biosynthesis in Aspergillus parasiticus is largely well-constructed and provides valuable biological information about this important toxin biosynthetic pathway. With the suggested improvements to causal connections, evidence annotations, and input/output specifications, the model would more clearly represent the biological process and adhere more closely to GO-CAM best practices.</p> <p>The primary issues are in the connectivity of the pathway steps rather than the biological accuracy of the individual activities. Improving these aspects would make the model more valuable for researchers studying aflatoxin biosynthesis and for computational analyses of GO-CAM models.</p>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/","title":"62b4ffe300003074 Poxvirus OPG029 inhibition of host TBK1 adaptor TANK  Human Poxvirus","text":"<p>Now, let me review the GO-CAM model in detail.</p> <p>Based on my review of the GO-CAM model 62b4ffe300003074 and the literature references, here's my assessment:</p>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#review-of-go-cam-model-62b4ffe300003074","title":"Review of GO-CAM Model 62b4ffe300003074","text":""},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model describes how Poxvirus protein OPG029 (C6) inhibits host innate immune responses by targeting the TBK1 adaptor protein TANK in human cells. The model demonstrates a key viral evasion strategy that prevents interferon production.</p>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#model-components","title":"Model Components","text":"<p>The model includes four main activities: 1. Vaccinia virus C6 protein (P17362) - engaging in protein sequestering activity 2. Host TANK protein (Q92844) - functioning as a molecular adaptor 3. Host TBK1 protein (Q9UHD2) - performing protein serine/threonine kinase activity 4. Host IRF3 protein (Q14653) - acting as a DNA-binding transcription factor</p>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>C6 directly negatively regulates (RO:0002630) TANK's molecular adaptor activity</li> <li>TANK directly positively regulates (RO:0002629) TBK1's kinase activity</li> <li>TBK1 directly positively regulates (RO:0002629) IRF3's transcription factor activity</li> </ul>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#biological-context","title":"Biological Context","text":"<ul> <li>C6 activity occurs in host cell cytoplasm (GO:0030430)</li> <li>TANK activity occurs in cytoplasm (GO:0005737)</li> <li>TBK1 activity occurs in cytoplasm (GO:0005737) </li> <li>IRF3 activity occurs in nucleus (GO:0005634)</li> </ul>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#process-context","title":"Process Context","text":"<ul> <li>C6 is part of the process \"suppression by virus of host type I interferon production\" (GO:0039501)</li> <li>TANK, TBK1, and IRF3 are part of \"positive regulation of type I interferon production\" (GO:0032481)</li> </ul>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by strong experimental evidence, primarily from two key publications: - PMID:21931555 (Unterholzner et al., 2011) - Establishes that C6 binds to TBK1 adaptor proteins and inhibits IRF3/IRF7 activation - PMID:21931631 (Goncalves et al., 2011) - Provides details on the TBK1 molecular network and adaptor protein interactions</p> <p>The evidence is based on direct assays (ECO:0000314) with appropriate references, making the model well-supported.</p>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<p>The model largely follows GO-CAM best practices:</p> <ol> <li> <p>Appropriate molecular function terms: Each protein is assigned correct molecular functions (e.g., C6 has protein sequestering activity, TANK has molecular adaptor activity).</p> </li> <li> <p>Correct causal relationships: The model uses appropriate causal predicates (RO:0002630 for negative regulation, RO:0002629 for positive regulation).</p> </li> <li> <p>Cellular context: Each activity is properly contextualized with cellular location terms.</p> </li> <li> <p>Biological process context: Activities are appropriately linked to relevant biological processes.</p> </li> <li> <p>Appropriate evidence: All assertions have evidence codes with literature references.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#improvements-and-issues","title":"Improvements and Issues","text":"<p>While the model is generally well-constructed, I've identified a few potential improvements:</p> <ol> <li> <p>Additional TANK interactions: The model could be expanded to include TANK's interactions with other scaffold proteins (NAP1/SINTBAD) that were also shown to be targeted by C6. The literature indicates C6 binds to all three scaffold proteins, not just TANK.</p> </li> <li> <p>Downstream effects: The model could be extended to show how IRF3 activation leads to IFN-\u03b2 production, completing the signaling pathway.</p> </li> <li> <p>Nuclear localization of C6: The literature indicates C6 is present in both the nucleus and cytoplasm, but the model only places it in the cytoplasm. This dual localization is potentially relevant as the paper by Stuart et al. (2016) shows C6 also inhibits type I IFN signaling in the nucleus by binding to STAT2.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model accurately represents the findings from the cited literature. Specifically:</p> <ul> <li>The mechanism of C6 targeting TBK1 adaptor proteins to inhibit IRF3 activation is consistent with Unterholzner et al. (2011).</li> <li>The role of TANK as a scaffold protein for TBK1 is consistent with Goncalves et al. (2011).</li> <li>The overall pathway from TANK to TBK1 to IRF3 for type I interferon production is supported by both papers.</li> </ul>"},{"location":"reviews/62b4ffe300003074-Poxvirus_OPG029_inhibition_of_host_TBK1_adaptor_TANK__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is scientifically accurate and follows most GO-CAM best practices. It effectively captures a key viral immune evasion mechanism where vaccinia virus protein C6 inhibits the host type I interferon response by targeting the TBK1 adaptor protein TANK. The model could be enhanced by including C6's interactions with other scaffold proteins and its nuclear functions, but these would be extensions rather than corrections to the existing model.</p> <p>The model serves as a valuable resource for understanding host-pathogen interactions, particularly how viruses evade innate immune responses by targeting key signaling components.</p>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/","title":"62b4ffe300003248 Poxvirus OPG029 inhibition of host HDAC4 STAT2  Human Poxvirus","text":"<p>Based on all the information gathered, I'll now review the GO-CAM model with ID 62b4ffe300003248:</p>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#go-cam-model-review-poxvirus-opg029-inhibition-of-host-hdac4_stat2-human-poxvirus","title":"GO-CAM Model Review: Poxvirus-OPG029 inhibition of host HDAC4_STAT2 (Human-Poxvirus)","text":"<p>Model ID: gomodel:62b4ffe300003248 Title: Poxvirus-OPG029 inhibition of host HDAC4_STAT2 (Human-Poxvirus) Taxon: NCBITaxon:9606 (Human) Status: Production</p>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#overview","title":"Overview","text":"<p>This GO-CAM model describes the interaction between a poxvirus protein (OPG029/C6) and human host proteins (HDAC4 and STAT2) in the context of interferon signaling pathway suppression. The model focuses on how the viral protein C6 inhibits the type I interferon-mediated signaling pathway.</p>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#model-components","title":"Model Components","text":"<p>The model consists of four main activities:</p> <ol> <li>JAK1 (UniProtKB:P23458) with protein tyrosine kinase activity (GO:0004713)</li> <li>HDAC4 (UniProtKB:P56524) with molecular adaptor activity (GO:0060090)</li> <li>STAT2 (UniProtKB:P52630) with DNA-binding transcription factor activity (GO:0003700)</li> <li>Poxvirus OPG029/C6 (UniProtKB:P17362) with protein sequestering activity (GO:0140311)</li> </ol>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#biological-context-and-pathway-flow","title":"Biological Context and Pathway Flow","text":"<p>The model shows that: - JAK1 tyrosine kinase activity directly positively regulates STAT2 transcription factor activity - HDAC4 adaptor activity directly positively regulates STAT2 transcription factor activity - Poxvirus OPG029/C6 protein sequestering activity directly negatively regulates both STAT2 and HDAC4 activities</p> <p>All activities are part of the type I interferon-mediated signaling pathway (GO:0060337), with the viral protein's activity being part of the viral process \"symbiont-mediated suppression of host type I interferon-mediated signaling pathway\" (GO:0039502).</p>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>This model accurately represents the role of poxvirus protein C6 as an inhibitor of type I interferon signaling, which is well supported by the literature reviewed (particularly PMID:27907166). The model correctly shows that:</p> <ol> <li>C6 can interfere with both HDAC4 and STAT2 function</li> <li>C6 acts late in the IFN signaling pathway, targeting STAT2 transcriptional activity</li> <li>C6 localizes to both cytoplasm and nucleus, with its viral inhibitory effect occurring in the nucleus</li> </ol> <p>The literature shows that C6 interacts with the transactivation domain of STAT2, providing a mechanism for how it inhibits STAT2-dependent gene transcription, which is consistent with the \"protein sequestering activity\" (GO:0140311) assigned to C6 in this model.</p>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#go-cam-compliance-assessment","title":"GO-CAM Compliance Assessment","text":"<p>The model follows GO-CAM guidelines for representing biological pathways:</p> <ol> <li>Molecular functions: Each protein is assigned appropriate molecular functions based on evidence</li> <li>Causal relationships: The model uses appropriate causal relations (RO:0002629 \"directly positively regulates\" and RO:0002630 \"directly negatively regulates\")</li> <li>Cellular context: All activities have appropriate cellular locations:</li> <li>JAK1 activity in cytoplasm (GO:0005737)</li> <li>HDAC4 activity in chromatin (GO:0000785)</li> <li>STAT2 activity in chromatin (GO:0000785)</li> <li>Viral protein C6 activity in nucleus (GO:0005634)</li> <li>Biological process context: All activities are properly placed in their biological processes</li> </ol>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>JAK1-STAT2 interaction: The model simplifies the JAK-STAT pathway by showing JAK1 directly positively regulating STAT2. In reality, JAK1 phosphorylates STAT2, leading to formation of the ISGF3 complex with STAT1 and IRF9. The model could potentially include STAT1 and IRF9 to more completely represent the pathway.</p> </li> <li> <p>Evidence for HDAC4-STAT2 interaction: The model shows HDAC4 directly positively regulating STAT2, but the literature examined doesn't clearly establish this direct connection. This aspect might need additional evidence or clarification.</p> </li> <li> <p>Complex formation: Consider whether the ISGF3 complex (STAT1-STAT2-IRF9) should be explicitly modeled following the guidance in \"How to annotate complexes in GO-CAM.\" Since this is a well-characterized complex where the activities of the individual components are known, it might be more accurate to include all the components.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Include STAT1 and IRF9: Expand the model to include STAT1 and IRF9, which together with STAT2 form the ISGF3 complex that binds to ISREs in the promoters of interferon-stimulated genes.</p> </li> <li> <p>Refine HDAC4 role: Clarify the precise role of HDAC4 in this pathway with additional evidence, or reconsider its inclusion if the interaction is not sufficiently established.</p> </li> <li> <p>Add additional IFN pathway components: Consider including upstream components (IFNAR receptors) and downstream targets (ISGs) to provide a more complete picture of the type I IFN signaling pathway and how it's disrupted by the viral protein.</p> </li> <li> <p>Clarify cellular compartments: While the model does include cellular locations, the dynamic translocation of STAT proteins from cytoplasm to nucleus upon activation could be better represented.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003248-Poxvirus_OPG029_inhibition_of_host_HDAC4_STAT2__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good representation of how poxvirus protein C6 interferes with type I interferon signaling by targeting STAT2 and HDAC4. The model is scientifically sound and complies with GO-CAM guidelines. With some refinements to better represent the complexities of the JAK-STAT pathway and the inclusion of additional components, this model would provide an even more accurate representation of the biological phenomena it aims to capture.</p>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/","title":"62b4ffe300003382 Poxvirus OPG038 inhibition of host CD80 CD86  Human Poxvirus","text":"<p>Now, let me review the GO-CAM model based on all the information gathered:</p>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#go-cam-model-review-gomodel62b4ffe300003382","title":"GO-CAM Model Review: gomodel:62b4ffe300003382","text":""},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<ul> <li>Title: \"Poxvirus-OPG038 inhibition of host CD80/CD86 (Human-Poxvirus)\"</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#main-biological-process","title":"Main Biological Process","text":"<p>This model represents how the vaccinia virus protein OPG038/M2 (UniProtKB:Q80HY2) inhibits T-cell mediated immunity by interfering with the CD80/CD86-CD28 costimulatory pathway. Specifically, the model shows:</p> <ol> <li>The vaccinia virus M2 protein (OPG038) has protein sequestering activity (GO:0140311)</li> <li>M2 protein directly negatively regulates (RO:0002630) the receptor ligand activity of both CD80 and CD86</li> <li>By preventing CD80 and CD86 from binding to CD28, the virus inhibits T-cell activation</li> </ol>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the findings from the literature, particularly from PMID:30918073, which demonstrated that:</p> <ol> <li>M2/OPG038 is secreted by vaccinia virus and forms a homo-oligomer</li> <li>This protein binds to both CD80 and CD86, blocking their interactions with CD28 and CTLA4</li> <li>This blocking activity impairs T-cell activation (GO:0042110)</li> <li>The mechanism contributes to negative regulation of T-cell mediated immunity (GO:0002710)</li> </ol>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#model-components","title":"Model Components","text":"<p>The model includes the following key proteins and their activities:</p> <ol> <li>CD80 (P33681): </li> <li>Molecular function: Receptor ligand activity (GO:0048018)</li> <li>Cellular component: Plasma membrane (GO:0005886)</li> <li> <p>Part of: Negative regulation of T cell mediated immunity (GO:0002710) and T cell activation (GO:0042110)</p> </li> <li> <p>CD86 (P42081):</p> </li> <li>Molecular function: Receptor ligand activity (GO:0048018)</li> <li>Cellular component: Plasma membrane (GO:0005886)</li> <li> <p>Part of: T cell activation (GO:0042110)</p> </li> <li> <p>Vaccinia virus OPG038/M2 (Q80HY2):</p> </li> <li>Molecular function: Protein sequestering activity (GO:0140311)</li> <li>Cellular component: Extracellular space (GO:0005615)</li> <li>Part of: Symbiont-mediated suppression of host T-cell mediated immune response (GO:0052085)</li> <li> <p>Causally regulates (negatively): CD80 and CD86 receptor ligand activities</p> </li> <li> <p>CD28 (P10747):</p> </li> <li>Molecular function: Coreceptor activity (GO:0015026)</li> <li>Cellular component: Plasma membrane (GO:0005886)</li> <li>Part of: T cell activation (GO:0042110)</li> </ol>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships in the model correctly represent the biology:</p> <ol> <li>CD80 and CD86 directly positively regulate (RO:0002629) CD28 coreceptor activity</li> <li>OPG038/M2 directly negatively regulates (RO:0002630) CD80 and CD86 receptor ligand activity</li> <li>This negative regulation prevents CD80/CD86 from activating CD28, thereby inhibiting T-cell activation</li> </ol>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#model-strengths","title":"Model Strengths","text":"<ol> <li>The model accurately represents the mechanism by which vaccinia virus inhibits T-cell activation</li> <li>The causal relationships between proteins are correctly annotated</li> <li>The model includes appropriate evidence codes and PMID references</li> <li>The model clearly shows the suppression of host immunity by the viral protein</li> </ol>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Add CD80-PD-L1 Interaction: The PMID:30918073 paper indicates that M2 actually potentiates CD80 binding to PD-L1, which could be added to provide a more complete picture of M2's activity.</p> </li> <li> <p>Add CTLA4 Interaction: The model focuses on CD28 but could also include CTLA4, as M2 also blocks CD80/CD86 binding to CTLA4 according to the paper.</p> </li> <li> <p>Annotation of M2 Oligomerization: The paper demonstrates that M2 forms a homo-oligomer (approximately 200 kDa), which is important for its function. This could be noted in the model.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003382-Poxvirus_OPG038_inhibition_of_host_CD80_CD86__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>Overall, the GO-CAM model \"gomodel:62b4ffe300003382\" is scientifically accurate and well-structured. It correctly represents the biological mechanism by which vaccinia virus protein OPG038/M2 interferes with T-cell activation by sequestering CD80 and CD86 proteins, thereby preventing their interaction with CD28. The model is consistent with the literature and captures the essential aspects of this viral immune evasion strategy.</p> <p>The model is parsimonious and should be easily understandable to most biologists, as it clearly shows the pathway from viral protein activity to inhibition of host immune function.</p>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/","title":"62b4ffe300003618 Poxvirus OPG045 inhibition of host BAK mediated apoptosis  Human Poxvirus","text":"<p>Now I'll review the GO-CAM model with ID \"62b4ffe300003618\". </p>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#go-cam-review-poxvirus-opg045-inhibition-of-host-bak-mediated-apoptosis-human-poxvirus","title":"GO-CAM Review: Poxvirus-OPG045 inhibition of host BAK-mediated apoptosis (Human-Poxvirus)","text":"<p>Model ID: gomodel:62b4ffe300003618</p>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#summary","title":"Summary","text":"<p>This GO-CAM model describes the inhibition of host BAK-mediated apoptosis by the vaccinia virus protein OPG045 (also known as F1L). The model captures key molecular functions and causal relationships in the intrinsic apoptotic pathway and how it is inhibited by the viral protein.</p>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents a well-documented biological mechanism: vaccinia virus protein F1L (OPG045) disrupts host apoptosis by directly binding to and inhibiting the pro-apoptotic host protein BAK, preventing its activation and subsequent steps in the intrinsic apoptotic pathway.</p> <p>The model includes four main activities: 1. OPG045/F1L's protein sequestering activity (inhibiting BAK) 2. BAK1's porin activity at the mitochondrial outer membrane 3. CASP9's cysteine-type endopeptidase activity in mitochondria 4. CASP3's cysteine-type endopeptidase activity in cytoplasm</p>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#accuracy-of-molecular-functions-and-interactions","title":"Accuracy of Molecular Functions and Interactions","text":"<p>The model accurately represents the molecular mechanism based on the literature:</p> <ul> <li> <p>OPG045 (F1L) activity: Correctly annotated with \"protein sequestering activity\" (GO:0140311) occurring in mitochondria. This is well-established in the literature (PMID:16439990), which shows F1L directly binds to BAK via its BH3 domain to prevent BAK activation.</p> </li> <li> <p>BAK1 activity: Appropriately annotated with \"porin activity\" (GO:0015288) at the mitochondrial outer membrane, which is part of the intrinsic apoptotic pathway (GO:0097193).</p> </li> <li> <p>Causal relationships: The inhibitory action of OPG045 on BAK (RO:0002630 - directly negatively regulates) is accurate, as is BAK's positive regulation of CASP9 (RO:0002304 - causally upstream of, positive effect) and CASP9's positive regulation of CASP3 (RO:0002629 - directly positively regulates).</p> </li> </ul>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#literature-validation","title":"Literature Validation","text":"<p>The molecular functions and interactions captured in the model are strongly supported by the literature:</p> <ul> <li> <p>PMID:22006182 demonstrates that BAK functions as a mitochondrial porin, forming holes in the outer membrane during apoptosis.</p> </li> <li> <p>PMID:16439990 clearly establishes that F1L/OPG045 binds to BAK via a BH3-like domain, preventing BAK activation and subsequent apoptosis.</p> </li> </ul>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#ontology-and-curation-assessment","title":"Ontology and Curation Assessment","text":""},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#correct-use-of-go-terms-and-relations","title":"Correct Use of GO Terms and Relations","text":"<p>The model uses appropriate GO terms for the molecular functions and biological processes:</p> <ul> <li>GO:0140311 (protein sequestering activity) is the correct term for OPG045's function</li> <li>GO:0015288 (porin activity) correctly describes BAK1's role</li> <li>GO:0004197 (cysteine-type endopeptidase activity) is appropriate for both CASP9 and CASP3</li> <li>GO:0033668 (symbiont-mediated suppression of host apoptosis) correctly represents the viral process</li> </ul> <p>The causal relationships use appropriate relation ontology (RO) terms: - RO:0002630 (directly negatively regulates) correctly represents OPG045's inhibition of BAK - RO:0002304 (causally upstream of, positive effect) correctly shows BAK's effect on CASP9 - RO:0002629 (directly positively regulates) correctly shows CASP9's activation of CASP3</p>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#model-structure-and-organization","title":"Model Structure and Organization","text":"<p>The model structure is well-organized, showing a clear pathway from viral inhibition to downstream effects in the apoptotic pathway. The model follows the GO-CAM best practices for representing molecular activities connected by causal relationships.</p>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#complex-representation","title":"Complex Representation","text":"<p>The model does not include protein complexes, which is appropriate for this particular mechanism, as the interactions described involve direct protein-protein interactions rather than complex formation activities. According to the GO-CAM guidelines for complexes (referenced in \"How_to_annotate_complexes_in_GO-CAM\"), this model correctly focuses on the specific proteins and their activities rather than complexes.</p>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#improvement-suggestions","title":"Improvement Suggestions","text":"<p>While the model is generally well-constructed, a few minor additions or clarifications could enhance it:</p> <ol> <li> <p>Additional BAK oligomerization detail: The model could potentially include BAK's homo-oligomerization process that occurs during apoptosis, which is mentioned in PMID:22006182. This would add detail to how BAK forms pores in the mitochondrial membrane.</p> </li> <li> <p>BAX representation: The literature indicates that BAK and BAX have functionally redundant roles in apoptosis. The model could potentially include BAX to provide a more complete picture of the intrinsic apoptotic pathway and how F1L might differentially affect BAK vs. BAX.</p> </li> <li> <p>Cytochrome c release: The model could be extended to include the release of cytochrome c from mitochondria, which is a key consequence of BAK/BAX pore formation and a trigger for apoptosome formation and caspase activation.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003618-Poxvirus_OPG045_inhibition_of_host_BAK_mediated_apoptosis__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:62b4ffe300003618) is a high-quality representation of how vaccinia virus protein OPG045/F1L inhibits host apoptosis by directly targeting BAK. The model accurately captures the molecular functions, subcellular locations, and causal relationships supported by the literature. It effectively illustrates a key viral mechanism for evading host cell death.</p> <p>The model follows GO-CAM best practices in terms of ontology usage and representation of biological processes. With a few minor enhancements as suggested, it could provide an even more comprehensive picture of this important host-pathogen interaction.</p>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/","title":"62b4ffe300003655 Zearalenone biosynthesis  Gibberella zeae","text":"<p>Based on my review of the GO-CAM model \"gomodel:62b4ffe300003655\" titled \"Zearalenone biosynthesis (Gibberella zeae)\", I'll provide a comprehensive analysis of the model's biological content, structure, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#go-cam-review-zearalenone-biosynthesis-gibberella-zeae","title":"GO-CAM Review: Zearalenone biosynthesis (Gibberella zeae)","text":""},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#model-overview","title":"Model Overview","text":"<ul> <li>ID: gomodel:62b4ffe300003655</li> <li>Title: Zearalenone biosynthesis (Gibberella zeae)</li> <li>Taxon: NCBITaxon:229533 (Gibberella zeae / Fusarium graminearum)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the biosynthesis of zearalenone, a mycotoxin produced by Gibberella zeae. The biological content is consistent with the current scientific literature (primarily PMID:16262793 and PMID:16517624).</p> <p>Key components correctly represented: 1. The involvement of two polyketide synthases (ZEA1 and ZEA2) 2. The requirement for a FAD-linked oxidoreductase (ZEB1) 3. The regulatory role of the transcription factor ZEB2 4. The correct precursors (acetyl-CoA and malonyl-CoA) 5. The final product (zearalenone)</p> <p>The pathway progression aligns with published mechanisms, showing: - ZEA2 (A0A098D8A0) and ZEA1 (A0A098D6U0) work together to synthesize the polyketide backbone - ZEB1 (A0A0E0RTV6) functions as an oxidoreductase for the final conversion step - ZEB2 (I1RFC6) positively regulates the expression of all three enzymes</p>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#go-cam-structure-analysis","title":"GO-CAM Structure Analysis","text":""},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#activities-and-associations","title":"Activities and Associations","text":"<p>The model contains four primary activities:</p> <ol> <li>Activity ID: gomodel:62b4ffe300003655/62b4ffe300003680</li> <li>Protein: ZEB1 (UniProtKB:A0A0E0RTV6)</li> <li>Function: Oxidoreductase activity (GO:0016491)</li> <li>Process: Zearalenone biosynthetic process (GO:0106150)</li> <li>Output: Zearalenone (CHEBI:10106)</li> <li> <p>Evidence: Mutant phenotype (ECO:0000315) from PMID:16262793</p> </li> <li> <p>Activity ID: gomodel:62b4ffe300003655/62b4ffe300003661</p> </li> <li>Protein: ZEA2 (UniProtKB:A0A098D8A0)</li> <li>Function: Polyketide synthase activity (GO:0016218)</li> <li>Process: Zearalenone biosynthetic process (GO:0106150)</li> <li>Inputs: Acetyl-CoA (CHEBI:15351), Malonyl-CoA (CHEBI:15531)</li> <li>Causal: Provides input for ZEA1 activity</li> <li> <p>Evidence: Mutant phenotype (ECO:0000315) from PMID:16517624</p> </li> <li> <p>Activity ID: gomodel:62b4ffe300003655/62b4ffe300003666</p> </li> <li>Protein: ZEA1 (UniProtKB:A0A098D6U0)</li> <li>Function: Catalytic activity (GO:0003824)</li> <li>Process: Zearalenone biosynthetic process (GO:0106150)</li> <li>Input: Malonyl-CoA (CHEBI:15531)</li> <li>Causal: Provides input for ZEB1 activity</li> <li> <p>Evidence: Direct assay (ECO:0000314) from PMID:16517624</p> </li> <li> <p>Activity ID: gomodel:62b4ffe300003655/62b4ffe300003695</p> </li> <li>Protein: ZEB2 (UniProtKB:I1RFC6)</li> <li>Function: Transcription regulator activator activity (GO:0140537)</li> <li>Process: Zearalenone biosynthetic process (GO:0106150)</li> <li>Causal: Directly positively regulates ZEA1, ZEA2, and ZEB1 activities</li> <li>Evidence: Mutant phenotype (ECO:0000315) from PMID:16262793</li> </ol>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships appropriately use: - <code>RO:0002413</code> (provides input for) for enzyme-substrate relationships  - <code>RO:0002629</code> (directly positively regulates) for the transcription factor's regulatory role</p>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Well-evidenced: All activities and associations have appropriate evidence codes with PMIDs</li> <li>Complete pathway: Captures all key steps from initiation to final product</li> <li>Proper causal connections: Uses appropriate causal predicates</li> <li>Specific terms: Uses specific molecular function terms when appropriate</li> <li>Appropriate inputs and outputs: Chemical entities are correctly identified</li> </ol>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Function Term Specificity: For ZEA1 (A0A098D6U0), the function term \"catalytic activity\" (GO:0003824) is very general. Based on UniProt annotation, this enzyme is a \"Non-reducing polyketide synthase\" with more specific activities, including \"polyketide synthase activity\" (GO:0016218), which would be more appropriate and consistent with the annotation used for ZEA2.</p> </li> <li> <p>Input-Output Relationship Completeness: While ZEA1 shows malonyl-CoA as input and ZEB1 shows zearalenone as output, the intermediate product (likely \u03b2-zearalenol based on the literature) between ZEA1 and ZEB1 activities is not represented in the model. This intermediate would help clarify the complete biosynthetic process.</p> </li> <li> <p>Reference Formatting: For one causal association (ZEA2 to ZEA1), the PMID reference is listed as \"16517624\" without the \"PMID:\" prefix, which is inconsistent with the other references in the model.</p> </li> <li> <p>Mechanistic Details: The model could better represent the sequential nature of the polyketide chain assembly by ZEA2 and ZEA1, as described in the literature (particularly PMID:18427109).</p> </li> <li> <p>Molecular Activity Precision: Although GO:0016491 (oxidoreductase activity) is used for ZEB1, the specific reaction catalyzed (conversion of \u03b2-zearalenol to zearalenone) could be more precisely represented.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#recommended-updates","title":"Recommended Updates","text":"<ol> <li> <p>Replace GO:0003824 (catalytic activity) with GO:0016218 (polyketide synthase activity) for ZEA1 to better reflect its specific function.</p> </li> <li> <p>Add the intermediate \u03b2-zearalenol as an output from ZEA1 activity and an input to ZEB1 activity.</p> </li> <li> <p>Fix the reference format for the causal association between ZEA2 and ZEA1 to include the \"PMID:\" prefix.</p> </li> <li> <p>Consider using more specific molecular function terms for ZEB1, possibly a child term of oxidoreductase activity that better describes the specific reaction.</p> </li> <li> <p>Add a comment explaining the collaborative nature of ZEA1 and ZEA2 in the biosynthesis of zearalenone.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003655-Zearalenone_biosynthesis__Gibberella_zeae_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Zearalenone biosynthesis (Gibberella zeae)\" is a well-constructed representation of the zearalenone biosynthetic pathway that accurately captures the major components and their relationships. The model is largely consistent with GO-CAM best practices and the scientific literature. With minor improvements to the specificity of some terms and the representation of intermediate products, the model would provide an even more comprehensive and precise representation of this important mycotoxin biosynthetic pathway.</p>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/","title":"62b4ffe300003679 Poxvirus OPG200 inhibition of host IKBKE mediated NF Kappa B  Human Poxvirus","text":"<p>Now that I have gathered all the necessary information, I will review GO-CAM model 62b4ffe300003679 comprehensively.</p>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#review-of-go-cam-model-62b4ffe300003679","title":"Review of GO-CAM Model: 62b4ffe300003679","text":""},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<p>Title: Poxvirus-OPG200 inhibition of host IKBKE-mediated NF-Kappa-B (Human-Poxvirus)</p> <p>Status: Production</p> <p>Taxonomic context: Human (NCBITaxon:9606)</p> <p>This model represents a host-pathogen interaction pathway where a poxvirus protein (OPG200/B14) inhibits the NF-kappa-B signaling pathway in human cells by interfering with IKK kinase activity.</p>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#model-diagram-analysis","title":"Model Diagram Analysis","text":"<p>The model describes a causal pathway with the following components:</p> <ol> <li>Poxvirus protein OPG200/B14 (UniProtKB:P24772) exhibits molecular sequestering activity (GO:0140313)</li> <li>The viral protein targets host IKK-beta/IKBKB (UniProtKB:O14920) with IkappaB kinase activity (GO:0008384)</li> <li>IKBKB normally negatively regulates IkappaB-alpha/NFKBIA (UniProtKB:P25963) through direct negative regulation (RO:0002630)</li> <li>NFKBIA exhibits protein sequestering activity (GO:0140311) that negatively regulates:</li> <li>RELA (UniProtKB:Q04206) with transcription activator activity (GO:0001228)</li> <li>NFKB1 (UniProtKB:P19838) with transcription activator activity (GO:0001228)</li> </ol>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model accurately represents the mechanism described in the literature (PMID:29748387). Key findings from this paper show that:</p> <ol> <li>Vaccinia virus B14 (OPG200) inhibits IKK\u03b2 (IKBKB) activation but not its kinase activity directly</li> <li>B14 binds to the junction between the kinase domain (KD) and scaffold dimerization domain (SDD) of IKK\u03b2</li> <li>This binding sterically hinders the direct contact between kinase domains of IKK\u03b2 in the IKK complex</li> <li>The inhibition prevents trans-autophosphorylation of IKK\u03b2, blocking its activation</li> <li>This ultimately prevents the phosphorylation of I\u03baB\u03b1 (NFKBIA) and subsequent activation of NF-\u03baB signaling</li> </ol> <p>The model correctly captures the biological process (GO:0085034 \"symbiont-mediated suppression of host NF-kappaB cascade\") and shows how the viral protein interferes with the canonical NF-\u03baB pathway.</p>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#go-cam-structure-and-annotation-quality","title":"GO-CAM Structure and Annotation Quality","text":""},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#strengths","title":"Strengths:","text":"<ol> <li> <p>Appropriate causal relations: The model uses RO:0002630 \"directly negatively regulates\" correctly to show inhibitory relationships.</p> </li> <li> <p>Correct cellular locations: Activities are annotated with appropriate cellular locations:</p> </li> <li>OPG200 occurs in cytoplasm (GO:0005737)</li> <li>IKBKB occurs in cytoplasm (GO:0005737)</li> <li>NFKBIA occurs in cytoplasm (GO:0005737)</li> <li> <p>Transcription factors (RELA and NFKB1) occur in chromatin (GO:0000785)</p> </li> <li> <p>Well-supported evidence: Annotations are supported by appropriate evidence codes and PMIDs.</p> </li> <li> <p>Molecular function selection: The choice of molecular functions is appropriate:</p> </li> <li>OPG200 with molecular sequestering activity (GO:0140313)</li> <li>IKBKB with IkappaB kinase activity (GO:0008384)</li> <li>NFKBIA with protein sequestering activity (GO:0140311)</li> <li>RELA and NFKB1 with DNA-binding transcription activator activity (GO:0001228)</li> </ol>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex annotation: According to \"How to annotate complexes in GO-CAM\", the model could be improved by representing the IKK complex more explicitly. The paper mentions that the IKK complex contains IKK\u03b2, IKK\u03b1, and NEMO, but only IKK\u03b2 is represented in the model.</p> </li> <li> <p>Process annotation completeness: While the model includes GO:0007249 \"canonical NF-kappaB signal transduction\" for most activities, it should be consistent across all activities in this pathway.</p> </li> <li> <p>Regulation specificity: The model could more clearly show how OPG200 affects IKBKB phosphorylation specifically by inhibiting trans-autophosphorylation rather than direct kinase activity.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows best practices for GO-CAM annotations by:</p> <ol> <li>Using appropriate evidence codes (ECO:0000314 for direct assay evidence and ECO:0000305 for curator inference)</li> <li>Including proper part_of relations to biological processes</li> <li>Correctly representing causal relations with appropriate RO predicates</li> </ol>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model is consistent with the established knowledge of NF-\u03baB signaling and the mechanism of viral inhibition as described in the literature. The annotations align with what is known about:</p> <ol> <li>The roles of each protein in this pathway</li> <li>The molecular functions they perform</li> <li>The viral mechanism of inhibition </li> <li>The subcellular locations where these events occur</li> </ol> <p>The UniProt entries confirm the functions and interactions, particularly the mechanism of OPG200/B14 inhibiting IKBKB and preventing NF-\u03baB activation.</p>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#final-assessment-and-recommendations","title":"Final Assessment and Recommendations","text":"<p>This is a well-constructed GO-CAM model that accurately represents the biological pathway of poxvirus-mediated inhibition of NF-\u03baB signaling. The model is supported by appropriate evidence and follows GO-CAM best practices.</p>"},{"location":"reviews/62b4ffe300003679-Poxvirus_OPG200_inhibition_of_host_IKBKE_mediated_NF_Kappa_B__Human_Poxvirus__/#recommendations-for-improvement","title":"Recommendations for improvement:","text":"<ol> <li> <p>Consider representing the IKK complex structure: Since the research highlights the importance of the IKK complex architecture for the inhibition mechanism, the model could benefit from including IKK\u03b1 and NEMO components as they contribute to the overall activation mechanism that B14 disrupts.</p> </li> <li> <p>Add more mechanistic detail: The model could be enhanced by explicitly showing that B14 inhibits trans-autophosphorylation rather than directly inhibiting kinase activity, perhaps through additional annotations that highlight this distinction.</p> </li> <li> <p>Include upstream activators: For completeness, the model could include upstream activators of the IKK complex (such as TAK1) to provide context for the normal activation pathway that is disrupted.</p> </li> </ol> <p>Overall, this is a high-quality GO-CAM model that effectively captures the biological mechanism of viral inhibition of a key human immune signaling pathway.</p>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/","title":"62b4ffe300003747  Response to IFN beta  leading to JAK STAT activation  Human","text":"<p>Based on the model and the guidelines, let me now conduct a thorough review of the GO-CAM model \"Response to IFN-beta, leading to JAK-STAT activation (Human)\" (gomodel:62b4ffe300003747).</p>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#go-cam-review-response-to-ifn-beta-leading-to-jak-stat-activation-human","title":"GO-CAM Review: Response to IFN-beta, leading to JAK-STAT activation (Human)","text":""},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:62b4ffe300003747) represents the interferon-beta (IFN-beta) signaling pathway leading to JAK-STAT activation in humans. The model captures the cascade of molecular events from IFN-beta cytokine activity through receptor binding, JAK kinase activation, and ultimately to STAT transcription factor activation.</p>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#assessment-of-model-structure-and-content","title":"Assessment of Model Structure and Content","text":""},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#1-molecular-function-and-cellular-component-annotations","title":"1. Molecular Function and Cellular Component Annotations","text":"<p>\u2705 Appropriate MF terms: The model correctly uses appropriate molecular function terms for each protein: - IFN-beta (P01574) \u2192 cytokine activity (GO:0005125) - IFNAR1 (P17181) and IFNAR2 (P48551) \u2192 type I interferon receptor activity (GO:0004905) - JAK1 (P23458) and TYK2 (P29597) \u2192 non-membrane spanning protein tyrosine kinase activity (GO:0004715) - STAT1 (P42224) and STAT2 (P52630) \u2192 DNA-binding transcription factor activity (GO:0000981)</p> <p>\u2705 Appropriate CC terms: The model correctly uses appropriate cellular component terms: - IFN-beta occurs in extracellular space (GO:0005615) - Receptors occur in plasma membrane (GO:0005886) - TYK2 in one case occurs in \"extrinsic component of plasma membrane\" (GO:0019897) - STAT proteins occur in nucleus (GO:0005634)</p>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#2-biological-process-annotations","title":"2. Biological Process Annotations","text":"<p>\u2705 Appropriate BP terms: Each activity is part of relevant biological processes: - IFN-beta is part of cytokine-mediated signaling pathway (GO:0019221) - Receptors are part of cellular response to interferon-beta (GO:0035458) - JAK kinases are part of cell surface receptor signaling pathway via JAK-STAT (GO:0007259) - STAT proteins are part of regulation of transcription by RNA polymerase II (GO:0006357)</p>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#3-causal-relationships","title":"3. Causal Relationships","text":"<p>\u2705 Appropriate causal relations: The model uses \"directly positively regulates\" (RO:0002629) consistently for causal relationships between activities, which is the correct predicate for this signaling pathway.</p> <p>The causal flow in the model follows the expected pattern for IFN-beta/JAK-STAT signaling: 1. IFN-beta cytokine activity \u2192 IFNAR1 and IFNAR2 receptor activity 2. Receptor activities \u2192 JAK kinase activities (TYK2, JAK1) 3. JAK kinase activities \u2192 STAT transcription factor activities</p>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#4-evidence-and-references","title":"4. Evidence and References","text":"<p>\u2705 Evidence codes: The model uses appropriate evidence codes (ECO:0000314 for direct assay and ECO:0000304 for author statement) with corresponding PMID references.</p> <p>References used: PMID:6157094, PMID:7813427, PMID:7759950, PMID:8232552, PMID:34813358, PMID:7657660, PMID:7526154, PMID:8605876, PMID:9020188, PMID:28753426, PMID:23139419, PMID:14532120</p>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Redundant Causal Connections: There appear to be some duplicate causal relationships in the model:</li> <li>TYK2 (gomodel:62b4ffe300003747/62b4ffe300003871) has two identical causal connections to IFNAR1 (gomodel:62b4ffe300003747/62b4ffe300003911)</li> <li> <p>JAK1 (gomodel:62b4ffe300003747/62b4ffe300003846) has two causal connections to the same downstream activity, with one lacking evidence</p> </li> <li> <p>JAK Pathway Signal Transduction Adaptor Activity: The model uses both receptor activity (GO:0004905) and JAK pathway signal transduction adaptor activity (GO:0008269) for the same proteins (IFNAR1 and IFNAR2) in different parts of the model. This dual annotation may be confusing - it would be helpful to clarify the precise role of these proteins in each context.</p> </li> <li> <p>Receptor Complex Representation: According to the complex annotation guidelines, the interferon receptor is typically a heterodimeric complex of IFNAR1 and IFNAR2. While the model represents both proteins separately with their respective activities, it might be clearer to represent their interaction explicitly.</p> </li> </ol>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model appears to be consistent with the established understanding of IFN-beta signaling via the JAK-STAT pathway. The key interactions are well-supported by the cited literature, which includes classic papers on interferon signaling.</p>"},{"location":"reviews/62b4ffe300003747-_Response_to_IFN_beta__leading_to_JAK_STAT_activation__Human_/#recommendation","title":"Recommendation","text":"<p>This GO-CAM model provides a comprehensive representation of IFN-beta signaling via the JAK-STAT pathway and follows GO-CAM best practices for the most part. I would recommend accepting this model with minor revisions:</p> <ol> <li>Remove redundant causal connections between activities to improve clarity</li> <li>Consider clarifying the role of IFNAR1 and IFNAR2 with respect to their dual annotations as receptors and adaptors</li> <li>Consider adding a comment to explicitly note the heterodimeric nature of the interferon receptor complex</li> </ol> <p>Overall, this is a well-constructed model that accurately represents the biological process of interferon-beta signaling through the JAK-STAT pathway in humans.</p>"},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/","title":"62b4ffe300004209 Terrequinone A biosynthesis  Emericella nidulans","text":"<p>Based on my review of the model and related information, I'll now provide a comprehensive assessment of the GO-CAM model \"gomodel:62b4ffe300004209\" which represents the terrequinone A biosynthesis pathway in Emericella nidulans (Aspergillus nidulans).</p>"},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#go-cam-review-terrequinone-a-biosynthesis-emericella-nidulans","title":"GO-CAM Review: Terrequinone A biosynthesis (Emericella nidulans)","text":""},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#model-summary","title":"Model Summary","text":"<ul> <li>Model ID: gomodel:62b4ffe300004209</li> <li>Title: Terrequinone A biosynthesis (Emericella nidulans)</li> <li>Taxon: NCBITaxon:227321 (Emericella nidulans)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#overview","title":"Overview","text":"<p>This model represents the biosynthetic pathway for terrequinone A, an antitumor fungal metabolite produced by Aspergillus nidulans (Emericella nidulans). The pathway involves five enzymes (TdiA-TdiE) that catalyze the conversion of L-tryptophan to terrequinone A through a series of reactions including aminotransferase activity, non-ribosomal peptide synthesis, oxidoreduction, and prenyltransferase activities.</p>"},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately captures the terrequinone A biosynthetic pathway as described in the literature (PMID:17704773 and PMID:18029206). The pathway proceeds through:</p> <ol> <li>TdiD (A7XRY8) - L-tryptophan aminotransferase that converts L-tryptophan to indole-3-pyruvate (IPA)</li> <li>TdiA (A7XRY0) - Non-ribosomal peptide synthase that dimerizes two IPA molecules to form didemethylasterriquinone D</li> <li>TdiB (A7XRY3) - Prenyltransferase that adds a prenyl group to didemethylasterriquinone D</li> <li>TdiC (A7XRY6) - NADH-dependent oxidoreductase that enables the next prenylation step</li> <li>TdiE (A7XRZ1) - Catalytic activity that helps convert intermediates to terrequinone A</li> </ol> <p>The causal relationships represented in the model correctly show the flow of activities in the pathway: - TdiD provides input for TdiA (RO:0002413) - TdiA provides input for TdiB (RO:0002413) - TdiB provides input for TdiC (RO:0002413) - TdiC provides input for TdiE (RO:0002413)</p>"},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#strengths","title":"Strengths:","text":"<ol> <li>Accurate representation of the biochemical pathway based on experimental evidence</li> <li>Properly annotated molecular functions for each protein</li> <li>Appropriate causal relationships between activities (using RO:0002413 \"provides input for\")</li> <li>All activities associated with the correct biological process (GO:1900796 \"terrequinone A biosynthetic process\")</li> <li>Consistent use of evidence codes and PMIDs to support annotations</li> <li>Inclusion of input and output molecules for key steps in the pathway</li> </ol>"},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#suggestions-for-improvement","title":"Suggestions for improvement:","text":"<ol> <li>Missing Inputs/Outputs: While some activities have has_input and has_output associations, others are missing these details. For example:</li> <li>TdiA should explicitly show has_input for indole-3-pyruvate (CHEBI:17640)</li> <li>TdiB should show has_input for didemethylasterriquinone D</li> <li>TdiC's inputs and outputs could be clarified</li> <li> <p>TdiE's inputs and outputs should be specified</p> </li> <li> <p>Complex Formation: The papers describe how TdiB, TdiC, and TdiE work together to convert didemethylasterriquinone D to terrequinone A. The model could potentially benefit from representing this as a complex or at least indicating their cooperative activity more explicitly according to GO-CAM complex annotation guidelines.</p> </li> <li> <p>Intermediate Products: The model could more explicitly represent the formation of asterriquinone C-1 (an intermediate between didemethylasterriquinone D and terrequinone A).</p> </li> <li> <p>NADH/NADPH Cofactor: For TdiC, the model could explicitly represent the dependence on NADH/NADPH as a cofactor.</p> </li> <li> <p>Activity Details: TdiE is annotated with a general \"catalytic activity\" (GO:0003824), but based on the literature, a more specific function could potentially be assigned to better reflect its role in the pathway.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#evidence-support","title":"Evidence Support","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion)</p> <p>The evidence is supported by key publications that describe the biochemical characterization of the pathway: - PMID:17704773 - Detailed biochemical characterization of the pathway - PMID:18029206 - Specific characterization of TdiB prenyltransferase activity</p>"},{"location":"reviews/62b4ffe300004209-Terrequinone_A_biosynthesis__Emericella_nidulans_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides an accurate representation of the terrequinone A biosynthetic pathway in Emericella nidulans. It correctly captures the enzymatic steps, molecular functions, and causal relationships between activities. The model is well-supported by experimental evidence from the literature.</p> <p>The model could be enhanced by adding more details about inputs/outputs for each step and potentially representing the cooperative activity of TdiB, TdiC, and TdiE more explicitly. However, overall the model is biologically accurate, technically sound, and provides valuable information about this fungal secondary metabolite biosynthetic pathway.</p>"},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/","title":"62b4ffe300004362 Poxvirus OPG193 interferon gamma decoy receptor  Human Poxvirus","text":"<p>Based on my review of the documents and the model, I'll now proceed with a comprehensive review of the GO-CAM model with ID 62b4ffe300004362.</p>"},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/#review-of-go-cam-model-poxvirus-opg193-interferon-gamma-decoy-receptor-human-poxvirus","title":"Review of GO-CAM Model: Poxvirus-OPG193 interferon gamma decoy receptor (Human-Poxvirus)","text":""},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (ID: gomodel:62b4ffe300004362) represents the interaction between the poxvirus OPG193 protein (a viral IFN-gamma decoy receptor) and the human interferon-gamma (IFN-gamma) signaling pathway. The model demonstrates how the virus disrupts normal IFN-gamma signaling to evade host immune responses.</p>"},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/#model-components","title":"Model Components","text":"<p>The model includes the following key proteins: - Human IFN-gamma (UniProtKB:P01579) - Human IFN-gamma receptor 1 (IFNGR1, UniProtKB:P15260) - Human IFN-gamma receptor 2 (IFNGR2, UniProtKB:P38484) - Poxvirus OPG193 protein (UniProtKB:P24770)</p>"},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/#molecular-activities-and-their-connections","title":"Molecular Activities and Their Connections","text":"<ol> <li>Human IFN-gamma cytokine activity:</li> <li>Enabled by: UniProtKB:P01579 (IFNG)</li> <li>Function: GO:0005125 (cytokine activity)</li> <li>Occurs in: GO:0005615 (extracellular space)</li> <li>Part of: GO:0038196 (type III interferon-mediated signaling pathway)</li> <li> <p>Connects to: directly positively regulates both IFNGR1 and IFNGR2 activities</p> </li> <li> <p>Human IFNGR1 receptor activity:</p> </li> <li>Enabled by: UniProtKB:P15260 (IFNGR1)</li> <li>Function: GO:0004906 (type II interferon receptor activity)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li> <p>Part of: GO:0038196 (type III interferon-mediated signaling pathway)</p> </li> <li> <p>Human IFNGR2 receptor activity:</p> </li> <li>Enabled by: UniProtKB:P38484 (IFNGR2)</li> <li>Function: GO:0004906 (type II interferon receptor activity)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li> <p>Part of: GO:0038196 (type III interferon-mediated signaling pathway)</p> </li> <li> <p>Viral OPG193 decoy receptor activity:</p> </li> <li>Enabled by: UniProtKB:P24770 (Poxvirus OPG193)</li> <li>Function: GO:0140319 (receptor decoy activity)</li> <li>Occurs in: GO:0005615 (extracellular space)</li> <li>Part of: GO:0052170 (symbiont-mediated suppression of host innate immune response)</li> <li>Connects to: directly negatively regulates IFN-gamma cytokine activity</li> </ol>"},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/#review-findings","title":"Review Findings","text":""},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological Accuracy: The model correctly captures the mechanism by which poxvirus OPG193 functions as a decoy receptor to bind and sequester IFN-gamma, preventing it from activating its legitimate receptors. This is consistent with what is known from the primary literature (PMID:12124459).</p> </li> <li> <p>Appropriate Cellular Locations: The subcellular locations are correctly assigned - IFN-gamma and the viral decoy receptor are correctly placed in the extracellular space, while the human IFN-gamma receptors are correctly placed in the plasma membrane.</p> </li> <li> <p>Causal Relationships: The model correctly uses the \"directly negatively regulates\" (RO:0002630) relationship to show how the viral decoy receptor inhibits IFN-gamma activity, and \"directly positively regulates\" (RO:0002629) to show how IFN-gamma normally activates its receptors.</p> </li> <li> <p>Evidence: All activities in the model have appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) with corresponding literature references.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Biological Process Annotation:</li> <li> <p>The model uses GO:0038196 (type III interferon-mediated signaling pathway) as the biological process for IFN-gamma and its receptors. However, IFN-gamma is a type II interferon, not a type III interferon. The correct process should be GO:0060333 (type II interferon-mediated signaling pathway).</p> </li> <li> <p>Missing Downstream Signaling Components:</p> </li> <li>The model could be expanded to include downstream components of the IFN-gamma signaling pathway, such as JAK1 and JAK2 kinases, and STAT1 transcription factor. These proteins are mentioned in the UniProt entries but not included in the model.</li> <li> <p>The UniProt entry (UniProtKB:P38484) indicates that IFNGR2 associates with JAK2, while IFNGR1 (UniProtKB:P15260) associates with JAK1. Including these would provide a more complete picture of the pathway that is disrupted by the virus.</p> </li> <li> <p>Model Expansion Opportunities:</p> </li> <li>The model could be expanded to include the consequences of IFN-gamma signaling disruption on specific immune response processes.</li> <li> <p>Reference PMID:16914093 discusses the role of IFN-gamma in activating STAT1 and subsequent IRF-1 expression, which could be added to provide more depth to the model.</p> </li> <li> <p>Annotation Precision:</p> </li> <li>For the OPG193 decoy receptor activity, it might be worth specifying that it specifically binds to IFN-gamma with a \"has input\" relationship, which is missing from the current model.</li> </ol>"},{"location":"reviews/62b4ffe300004362-Poxvirus_OPG193_interferon_gamma_decoy_receptor__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively captures the key mechanism by which poxvirus OPG193 interferes with human IFN-gamma signaling by acting as a decoy receptor. The model correctly represents the locations and basic functions of the proteins involved and establishes accurate causal relationships between them.</p> <p>The main recommendation for improvement is to correct the biological process annotation from type III to type II interferon-mediated signaling pathway, as IFN-gamma is a type II interferon. The model could also be expanded to include downstream components of the IFN-gamma signaling pathway to provide a more complete picture of the disrupted process.</p> <p>Overall, the model is well-constructed and provides valuable insights into a viral immune evasion mechanism, adhering to GO-CAM best practices for representing receptor-ligand interactions and regulatory relationships.</p>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/","title":"62b4ffe300004525 Regulation of the JAK STAT pathway by calmodulin in response to interferon beta  Human","text":"<p>Based on my review of the GO-CAM model (gomodel:62b4ffe300004525) and the associated documentation and protein information, I will now provide a comprehensive assessment of this model.</p>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#review-of-go-cam-model-gomodel62b4ffe300004525","title":"Review of GO-CAM Model: gomodel:62b4ffe300004525","text":""},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#model-overview","title":"Model Overview","text":"<p>Title: \"Regulation of the JAK-STAT pathway by calmodulin in response to interferon-beta (Human)\" Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>This model represents a signaling pathway where calmodulin (CALM1) regulates the JAK-STAT pathway in response to interferon-beta. The model depicts:</p> <ol> <li> <p>CALM1 (P0DP23) with calcium ion binding activity (GO:0005509) that directly positively regulates (RO:0002629) its own protein serine/threonine kinase activator activity (GO:0043539)</p> </li> <li> <p>This kinase activator activity of CALM1 directly positively regulates (RO:0002629) the calcium/calmodulin-dependent protein kinase activity (GO:0004683) of CAMK2A (Q9UQM7)</p> </li> <li> <p>CAMK2A's kinase activity causally upstream, positive effect (RO:0002304) on STAT1's (P42224) DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981)</p> </li> <li> <p>All activities are part of cellular response to interferon-beta (GO:0035458), and STAT1's activity occurs in the nucleus (GO:0005634)</p> </li> </ol>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Appropriate biological context: The model correctly places these activities within the cellular response to interferon-beta (GO:0035458), which is well-documented in the literature.</p> </li> <li> <p>Accurate representation of CALM1's dual role: The model correctly shows CALM1 first binding calcium and then activating CAMK2A.</p> </li> <li> <p>Proper localization: STAT1's transcription factor activity is correctly shown to occur in the nucleus.</p> </li> <li> <p>Evidential support: All activities are supported by experimental evidence (ECO:0000314 - direct assay evidence) with appropriate literature citations.</p> </li> <li> <p>Connectivity: The model has good connectivity between molecular functions with appropriate causal relations.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing intermediate steps in JAK-STAT pathway: While the model shows CAMK2A activating STAT1, it doesn't include the essential phosphorylation of STAT1 at Tyr-701 by JAK kinases, which is a critical step in STAT1 activation. Based on the UniProt entry for STAT1, this phosphorylation is necessary for dimerization and nuclear translocation.</p> </li> <li> <p>Incomplete STAT1 activation mechanism: The model shows CAMK2A directly activating STAT1's transcription factor activity, but according to the literature I reviewed and the UniProt entries, CAMK2A specifically phosphorylates STAT1 at Ser-727, which enhances its transcriptional activity but is not the primary activation step.</p> </li> <li> <p>Incomplete pathway representation: The model doesn't include the interferon-beta receptor complex (IFNAR1/IFNAR2) which is the initial step in this signaling pathway, nor does it include JAK1/TYK2 kinases that are activated upon receptor binding.</p> </li> <li> <p>Missing STAT1 targets: While STAT1 is represented as having transcription factor activity, the model doesn't specify any target genes that STAT1 regulates in response to interferon-beta.</p> </li> <li> <p>Biological process annotation: While \"cellular response to interferon-beta\" (GO:0035458) is appropriate, the model could also include \"positive regulation of receptor signaling pathway via JAK-STAT\" (GO:0046427) to better represent this specific aspect of the pathway.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#technicalstructural-assessment","title":"Technical/Structural Assessment","text":"<ol> <li> <p>The model correctly uses the predicate \"directly positively regulates\" (RO:0002629) for the close interactions between CALM1's functions and between CALM1 and CAMK2A.</p> </li> <li> <p>The model appropriately uses \"causally upstream of, positive effect\" (RO:0002304) for the relation between CAMK2A and STAT1, which is correct since there could be intermediate steps not represented here.</p> </li> <li> <p>The model includes appropriate GO terms for the molecular functions of each protein.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<ol> <li> <p>The model follows GO-CAM best practices for representing signaling pathways with appropriate causal relationships.</p> </li> <li> <p>The transcription factor activity annotation for STAT1 is consistent with the DNA-binding transcription factor activity annotation guidelines, though it lacks target gene specification.</p> </li> <li> <p>The model correctly uses direct evidence codes with appropriate PMIDs.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Add interferon receptor signaling components:</li> <li>Include IFNAR1/IFNAR2 with their receptor activities</li> <li> <p>Add JAK1/TYK2 kinases and their activities in the pathway</p> </li> <li> <p>Expand STAT1 activation:</p> </li> <li>Explicitly represent STAT1 phosphorylation at Tyr-701 by JAK kinases</li> <li>Show that CAMK2A specifically phosphorylates STAT1 at Ser-727</li> <li> <p>Include STAT1 dimerization and nuclear translocation steps</p> </li> <li> <p>Add downstream targets:</p> </li> <li> <p>Include at least one target gene regulated by STAT1 in response to interferon-beta</p> </li> <li> <p>Refine biological process annotations:</p> </li> <li>Add \"positive regulation of receptor signaling pathway via JAK-STAT\" (GO:0046427)</li> <li> <p>Consider adding more specific biological processes for each component</p> </li> <li> <p>Add supporting evidence:</p> </li> <li>The model cites PMID:28753426 and PMID:35568036 as evidence sources, which is appropriate, but could benefit from including additional references specifically for each step of the pathway</li> </ol>"},{"location":"reviews/62b4ffe300004525-Regulation_of_the_JAK_STAT_pathway_by_calmodulin_in_response_to_interferon_beta__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Regulation of the JAK-STAT pathway by calmodulin in response to interferon-beta (Human)\" provides a good representation of part of the interferon-beta response pathway, specifically the role of calcium/calmodulin in enhancing STAT1 activity via CAMK2A. However, it would benefit from a more complete representation of the JAK-STAT pathway components, including the interferon receptor complex, JAK kinases, and downstream targets of STAT1. The model correctly uses appropriate GO terms, evidence codes, and relationship types according to GO-CAM guidelines, but would be more informative with these additional elements.</p> <p>The model accurately captures that calcium signaling via calmodulin and CAMK2A contributes to STAT1 activation, which is an important regulatory mechanism documented in PMID:35568036. While some steps in the canonical JAK-STAT pathway are missing, the focus on calcium-dependent regulation is valid and supported by the evidence provided.</p>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/","title":"62b4ffe300004795 Insulin receptor signaling pathway 1  Mouse","text":"<p>Based on my review of the GO-CAM model with ID 62b4ffe300004795 and the relevant literature about insulin receptor signaling, I'll now provide a comprehensive review of this model.</p>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#review-of-go-cam-model-gomodel62b4ffe300004795","title":"Review of GO-CAM model: gomodel:62b4ffe300004795","text":""},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#general-information","title":"General Information","text":"<p>Title: Insulin receptor signaling pathway 1 (Mouse) Taxon: NCBITaxon:10090 (Mouse) Status: production ID: gomodel:62b4ffe300004795</p>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the insulin receptor signaling pathway in mouse. The model captures a classic signal transduction cascade beginning with insulin binding to its receptor and progressing through a series of kinase activities leading to MAPK activation. The model appears to be sourced from Reactome pathways R-HSA-74751 and R-HSA-74752.</p>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model consists of 11 activities connected by causal relationships, forming a coherent pathway:</p> <ol> <li>Insulin ligands (Ins1 and Ins2) with receptor ligand activity in the extracellular space</li> <li>Insulin receptor (Insr) with both insulin receptor activity and protein tyrosine kinase activity</li> <li>Adaptor proteins (Shc1) with transmembrane receptor protein tyrosine kinase adaptor activity</li> <li>Scaffolding proteins (Grb2) with guanyl-nucleotide exchange factor adaptor activity</li> <li>Guanine nucleotide exchange factors (Sos1) with guanyl-nucleotide exchange factor activity</li> <li>Small GTPases (Hras) with protein-membrane adaptor activity</li> <li>MAP kinase cascade proteins (Raf1, Map2k1, Mapk1, Mapk3) with various kinase activities</li> </ol> <p>The pathway shows the flow of signal from insulin binding to its receptor, through adapter proteins and small GTPases, and finally to the MAPK pathway.</p>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive signaling pathway representation: The model captures the core elements of insulin receptor signaling from ligand binding through MAPK activation.</p> </li> <li> <p>Well-annotated activities: Each activity in the model is properly annotated with relevant molecular functions and is appropriately part of the insulin receptor signaling pathway biological process (GO:0008286).</p> </li> <li> <p>Appropriate causal relationships: The model uses the correct causal relation predicates, primarily RO:0002629 (directly positively regulates), which is appropriate for direct signal transduction events.</p> </li> <li> <p>Cellular context: The model appropriately localizes proteins to their correct cellular compartments (e.g., insulin in extracellular space, receptor in plasma membrane).</p> </li> <li> <p>Evidence support: Each activity and relationship is backed by experimental evidence from published literature with appropriate ECO codes.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing relationships: The causal relationship between Sos1 and Hras lacks evidence annotations, even though this is a well-established interaction in the literature. Evidence should be added to strengthen this connection.</p> </li> <li> <p>Limited representation of pathway branches: The insulin receptor signaling pathway typically branches to activate both MAPK and PI3K/AKT pathways. This model focuses primarily on the MAPK branch. The PI3K/AKT branch, which is critical for metabolic effects of insulin, is missing.</p> </li> <li> <p>Missing post-translational modifications: The model doesn't explicitly represent phosphorylation events that are crucial for signaling propagation, though they are implied by the kinase activities.</p> </li> <li> <p>Missing protein complexes: Some interactions, particularly between adaptor proteins like Grb2, Shc, and SOS, typically involve complex formation. This is not explicitly represented in the model.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>According to the \"Signaling receptor activity annotation guidelines\", this model follows the best practices for representing receptor-ligand interactions:</p> <ol> <li> <p>The insulin ligands (Ins1 and Ins2) are correctly annotated with receptor ligand activity (GO:0048018) and occur in the extracellular space (GO:0005615).</p> </li> <li> <p>The insulin receptor (Insr) is correctly annotated with both insulin receptor activity (GO:0005009) and is located in the plasma membrane (GO:0005886).</p> </li> <li> <p>The causal relation between ligand and receptor activities is correctly represented using the \"directly positively regulates\" predicate.</p> </li> <li> <p>The model correctly shows the receptor activating downstream adaptor proteins and signaling cascades.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the well-established insulin signaling pathway as described in the literature. The relationships between insulin binding to its receptor, activation of the receptor's tyrosine kinase activity, recruitment of adaptor proteins (Shc1), engagement of the Grb2-Sos complex, activation of Ras, and subsequent activation of the Raf-MEK-ERK cascade are all scientifically accurate.</p> <p>The literature supports the critical role of Raf1 in insulin signaling (PMID:20056832), which is appropriately represented in this model. The evidence cited in the model (e.g., PMID:18202127, PMID:20889126) supports the connections between insulin receptor activation and MAPK signaling.</p>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#completeness-assessment","title":"Completeness Assessment","text":"<p>While the model captures the core MAPK branch of insulin signaling, it is missing several important aspects of the complete insulin signaling network:</p> <ol> <li> <p>PI3K/AKT pathway: This parallel branch of insulin signaling is crucial for metabolic effects and is not represented.</p> </li> <li> <p>IRS proteins: Insulin receptor substrate proteins (IRS1-4) are major substrates of the insulin receptor and crucial for signaling, especially to the PI3K pathway.</p> </li> <li> <p>Negative regulators: The model does not include feedback inhibition or negative regulators of insulin signaling.</p> </li> <li> <p>Metabolic effectors: Downstream targets of insulin signaling that mediate effects on glucose metabolism are not represented.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add evidence for all causal relationships: Complete the evidence annotations for all relationships, particularly the Sos1 to Hras connection.</p> </li> <li> <p>Extend the model to include the PI3K/AKT pathway: This would provide a more complete representation of insulin signaling.</p> </li> <li> <p>Include IRS proteins: Add IRS1 and/or IRS2 as direct targets of the insulin receptor tyrosine kinase activity.</p> </li> <li> <p>Add negative feedback mechanisms: Include protein phosphatases or other negative regulators that modulate insulin signaling.</p> </li> <li> <p>Consider representing key complexes: Some interactions in this pathway involve complex formation (e.g., Grb2-Sos1), which could be explicitly represented.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004795-Insulin_receptor_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:62b4ffe300004795) provides a scientifically accurate representation of the MAPK branch of insulin receptor signaling in mouse. The model follows GO-CAM best practices for representing signaling receptor pathways and has good evidence support. While the model could be expanded to include additional branches and regulatory mechanisms, it effectively captures the core signaling events from insulin binding to MAPK activation.</p> <p>The model is suitable for production use and provides valuable information about insulin receptor signaling. With the suggested improvements, it could become an even more comprehensive resource for understanding insulin signaling pathways.</p>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/","title":"62b4ffe300004953 Arginine ADP riboxanation of CASP3 by by C violaceum CopC that blocks CASP3 activity  subsequent apoptosis and pyroptosis  Human","text":"<p>Based on my review of the GO-CAM model gomodel:62b4ffe300004953 and the related literature, I'll now provide a comprehensive assessment:</p>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#review-of-go-cam-model-62b4ffe300004953","title":"Review of GO-CAM Model: 62b4ffe300004953","text":""},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents the \"Arginine ADP-riboxanation of CASP3 by C.violaceum CopC that blocks CASP3 activity, subsequent apoptosis and pyroptosis (Human).\" The model describes how the bacterial effector protein CopC from Chromobacterium violaceum inhibits caspase-3 (CASP3) activity through a post-translational modification called ADP-riboxanation, which in turn affects downstream cell death pathways.</p>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#key-components-and-activities-in-the-model","title":"Key Components and Activities in the Model","text":"<ol> <li> <p>Q7NWF2 (CopC): A bacterial effector protein with ADP-riboxanase activity (GO:0140740) that targets host cell caspases.</p> </li> <li> <p>P42574 (CASP3): Human caspase-3, a key effector caspase involved in apoptosis that can also trigger pyroptosis through GSDME cleavage.</p> </li> <li> <p>O60443 (GSDME): Gasdermin E, which when cleaved by caspase-3 forms pores in the cell membrane leading to pyroptotic cell death.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model depicts several key causal relationships: - CopC's calmodulin binding activity (GO:0005516) triggers its ADP-riboxanase activity - CopC's ADP-riboxanase activity directly negatively regulates (RO:0002630) caspase-3 activity - Caspase-3's endopeptidase activity directly positively regulates (RO:0002629) GSDME's wide pore channel activity - GSDME's wide pore channel activity is involved in pyroptotic inflammatory response (GO:0070269)</p>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#cellular-locations","title":"Cellular Locations","text":"<ul> <li>CopC is located in the host cell cytoplasm (GO:0030430)</li> <li>Caspase-3 is in the cytosol (GO:0005829) </li> <li>GSDME's pore-forming domain becomes membrane-associated (GO:0016020)</li> </ul>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#validation-with-literature","title":"Validation with Literature","text":"<p>The model is well-supported by recent literature, particularly:</p> <ol> <li> <p>The 2022 papers (PMID:35338844 and PMID:35446120) which detail how CopC requires host calmodulin for activation and then specifically modifies host caspases through ADP-riboxanation at a conserved arginine residue (Arg-207 in CASP3).</p> </li> <li> <p>The connection to pyroptosis through GSDME is consistent with Wang et al. 2017 (PMID:28459430), which showed that caspase-3 can cleave GSDME to trigger pyroptosis.</p> </li> <li> <p>The described modifications and mechanisms align with the sequence information and documented PTMs in the UniProt records for these proteins.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Accurate biological pathway representation: The model correctly captures the mechanism by which CopC inhibits caspase-3 through ADP-riboxanation.</p> </li> <li> <p>Complete causal flow: The model represents the complete pathway from bacterial effector entry to host cell response.</p> </li> <li> <p>Well-evidenced: The model uses appropriate evidence codes and references recent literature.</p> </li> <li> <p>Correct cellular locations: Subcellular locations are appropriately specified for each activity.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Additional contextual processes: The model could benefit from explicitly including the bacterial invasion/secretion context that precedes CopC delivery to the host cell.</p> </li> <li> <p>Expand on calmodulin binding: The model could show more detail about how calmodulin binding activates CopC as this is a key regulatory event.</p> </li> <li> <p>Include additional caspase targets: The literature indicates CopC can also modify other caspases (CASP7, CASP8, CASP9) beyond just CASP3. Including these additional targets could make the model more comprehensive.</p> </li> <li> <p>Specify the modification site: The model could explicitly note that ADP-riboxanation occurs at Arg-207 in caspase-3.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing molecular activities and causal relationships:</p> <ol> <li> <p>It correctly represents the causal flow of information using appropriate relationship predicates (RO:0002629 and RO:0002630).</p> </li> <li> <p>Each activity is properly associated with a specific gene product.</p> </li> <li> <p>Appropriate cellular components are specified for each activity.</p> </li> <li> <p>The model uses evidence codes appropriately to indicate the source of information.</p> </li> </ol>"},{"location":"reviews/62b4ffe300004953-Arginine_ADP_riboxanation_of_CASP3_by_by_C_violaceum_CopC_that_blocks_CASP3_activity__subsequent_apoptosis_and_pyroptosis__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:62b4ffe300004953) accurately represents the mechanism by which C. violaceum CopC inhibits caspase-3 through ADP-riboxanation, thereby preventing apoptosis and pyroptosis. The model is well-supported by recent literature and follows GO-CAM best practices. With minor additions as suggested above, the model could provide an even more comprehensive representation of this bacterial immune evasion mechanism.</p>"},{"location":"reviews/62b4ffe300005014-Poxvirus_OPG176_inhibition_of_hostTLR4_signaling__Human_Poxvirus__/","title":"62b4ffe300005014 Poxvirus OPG176 inhibition of hostTLR4 signaling  Human Poxvirus","text":"<p>Based on my review of the GO-CAM model (62b4ffe300005014) and the proteins involved, I'll now provide a comprehensive review:</p>"},{"location":"reviews/62b4ffe300005014-Poxvirus_OPG176_inhibition_of_hostTLR4_signaling__Human_Poxvirus__/#go-cam-model-review-poxvirus-opg176-inhibition-of-host-tlr4-signaling-human-poxvirus","title":"GO-CAM Model Review: Poxvirus-OPG176 inhibition of host TLR4 signaling (Human-Poxvirus)","text":""},{"location":"reviews/62b4ffe300005014-Poxvirus_OPG176_inhibition_of_hostTLR4_signaling__Human_Poxvirus__/#model-summary","title":"Model Summary","text":"<p>This model (gomodel:62b4ffe300005014) represents the mechanism by which Vaccinia virus protein OPG176 (also known as A46R) inhibits TLR4 signaling in human host cells. The model contains four key activities:</p> <ol> <li>TLR4 (UniProtKB:O00206) - signaling receptor activity (GO:0038023)</li> <li>TIRAP (UniProtKB:P58753) - molecular adaptor activity (GO:0060090)</li> <li>MYD88 (UniProtKB:Q99836) - molecular adaptor activity (GO:0060090)</li> <li>Vaccinia virus OPG176 (UniProtKB:P26672) - protein sequestering activity (GO:0140311)</li> </ol> <p>The causal flow in the model shows: - TLR4 directly positively regulates (RO:0002629) TIRAP activity - TIRAP directly positively regulates (RO:0002629) MYD88 activity - Vaccinia virus OPG176 directly negatively regulates (RO:0002630) TIRAP activity</p>"},{"location":"reviews/62b4ffe300005014-Poxvirus_OPG176_inhibition_of_hostTLR4_signaling__Human_Poxvirus__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-supported evidence: Each activity and relationship in the model is supported by appropriate experimental evidence with citations to relevant publications.</p> </li> <li> <p>Clear biological mechanism: The model correctly represents how Vaccinia virus protein OPG176 interferes with the TLR4 signaling pathway by inhibiting the TIRAP adaptor protein, thereby preventing downstream signaling.</p> </li> <li> <p>Correct subcellular locations: The model correctly places TLR4 in the plasma membrane (GO:0005886) and TIRAP/MYD88 at the cytoplasmic side of the plasma membrane (GO:0031234).</p> </li> <li> <p>Proper use of causal relations: The model correctly uses RO:0002629 (directly positively regulates) for the activating relationships and RO:0002630 (directly negatively regulates) for the inhibitory relationship.</p> </li> <li> <p>Appropriate biological process annotations: Each activity is properly associated with a relevant biological process - TLR4, TIRAP, and MYD88 are all part of the TLR4 signaling pathway (GO:0034142), while the viral protein is part of the symbiont-mediated suppression of host toll-like receptor signaling pathway (GO:0039722).</p> </li> </ol>"},{"location":"reviews/62b4ffe300005014-Poxvirus_OPG176_inhibition_of_hostTLR4_signaling__Human_Poxvirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>There are no significant issues with the model, but here are some minor points that could enhance its clarity and completeness:</p> <ol> <li> <p>CD14 role: The model doesn't include CD14, which often serves as a co-receptor for LPS binding to TLR4. While not essential, adding CD14 and its interaction with LPS could provide more context for TLR4 activation.</p> </li> <li> <p>Downstream effects: The model could be extended to show the downstream effects of MYD88 inhibition, such as reduced NF-\u03baB activation and cytokine production, to provide a more complete picture of the pathway disruption consequences.</p> </li> <li> <p>Detailed mechanism of OPG176: While the model correctly shows OPG176 inhibiting TIRAP, it doesn't detail the mechanism (protein sequestration). The literature indicates OPG176 directly binds to and sequesters TIRAP, preventing its interaction with TLR4. This mechanism could be more explicitly represented.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005014-Poxvirus_OPG176_inhibition_of_hostTLR4_signaling__Human_Poxvirus__/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model aligns well with the published literature:</p> <ol> <li> <p>TLR4 signaling: The basic TLR4 signaling pathway via TIRAP and MYD88 is correctly represented, consistent with the referenced papers (PMID:15618008, PMID:12055629).</p> </li> <li> <p>OPG176 inhibition: The viral inhibition mechanism is correctly shown, with OPG176 targeting TIRAP (PMID:22593572). This is consistent with the role of vaccinia virus in suppressing host immune responses.</p> </li> <li> <p>Subcellular localization: The model correctly places TLR4 at the plasma membrane and the adaptors at the extrinsic component of cytoplasmic side of plasma membrane, consistent with literature on TLR4 signaling.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005014-Poxvirus_OPG176_inhibition_of_hostTLR4_signaling__Human_Poxvirus__/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows the GO-CAM best practices for representing complexes and molecular activities:</p> <ol> <li> <p>Molecular functions: Each protein is annotated with an appropriate molecular function.</p> </li> <li> <p>Causal relationships: The model uses the correct causal relationship predicates for the depicted process.</p> </li> <li> <p>Cellular compartments: The model correctly specifies the cellular components where each activity occurs.</p> </li> <li> <p>Evidence codes: Appropriate evidence codes are used for each assertion in the model.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005014-Poxvirus_OPG176_inhibition_of_hostTLR4_signaling__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that accurately represents the mechanism by which Vaccinia virus protein OPG176 inhibits TLR4 signaling in human host cells. The model is supported by appropriate evidence, follows GO-CAM best practices, and is consistent with the published literature on TLR4 signaling and viral immune evasion strategies.</p> <p>The model successfully illustrates a viral immune evasion strategy whereby a viral protein (OPG176) interferes with the host innate immune response by targeting a key adaptor molecule (TIRAP) in the TLR4 signaling pathway, preventing downstream signaling events that would normally lead to inflammatory cytokine production and antiviral responses.</p>"},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/","title":"62b4ffe300005096 Poxvirus OPG022 inhibition of host IL18 signaling pathway  Human Poxvirus","text":"<p>Now, let me review the model in detail based on the information gathered.</p> <p>Based on the information gathered, I'll now review the GO-CAM model gomodel:62b4ffe300005096, which represents \"Poxvirus-OPG022 inhibition of host IL18 signaling pathway (Human-Poxvirus)\".</p>"},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#go-cam-model-review","title":"GO-CAM Model Review","text":""},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#model-overview","title":"Model Overview:","text":"<p>This model represents the interaction between a poxvirus protein (OPG022/VACWR013) and the human IL-18 signaling pathway. It shows how the viral protein inhibits IL-18 signaling as a viral immune evasion strategy. The model includes:</p> <ol> <li>Human IL-18 (Q14116) with cytokine activity (GO:0005125)</li> <li>Human IL-18 receptor alpha chain (IL18R1, Q13478) with interleukin-18 receptor activity (GO:0042008)</li> <li>Human IL-18 receptor accessory protein (IL18RAP, O95256) with coreceptor activity (GO:0015026)</li> <li>Poxvirus IL-18 binding protein (P17357) with receptor decoy activity (GO:0140319)</li> </ol> <p>All activities are part of the interleukin-18-mediated signaling pathway (GO:0035655), with the viral protein being part of a viral process aimed at suppressing host immune response.</p>"},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#detailed-assessment","title":"Detailed Assessment:","text":""},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#1-structural-assessment","title":"1. Structural Assessment:","text":"<p>The model follows the GO-CAM best practices for representing receptor-ligand interactions according to the \"Signaling receptor activity annotation guidelines\":</p> <ul> <li>IL-18 is properly annotated with cytokine activity (GO:0005125), which is a type of receptor ligand activity</li> <li>IL-18 is correctly shown to occur in the extracellular space (GO:0005615), which is appropriate for a secreted cytokine</li> <li>IL-18R1 is properly annotated with interleukin-18 receptor activity (GO:0042008), a type of signaling receptor activity</li> <li>IL-18R1 is correctly shown to occur in the plasma membrane (GO:0005886)</li> <li>IL-18RAP is properly annotated with coreceptor activity (GO:0015026)</li> <li>IL-18RAP is correctly shown to occur in the plasma membrane (GO:0005886)</li> </ul>"},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#2-causal-relations","title":"2. Causal Relations:","text":"<p>The model uses appropriate causal relations:</p> <ul> <li>IL-18 directly positively regulates (RO:0002629) IL-18R1 activity</li> <li>IL-18R1 directly positively regulates (RO:0002629) IL-18RAP activity</li> <li>The viral IL-18BP directly negatively regulates (RO:0002630) IL-18 activity</li> </ul>"},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#3-biological-content-assessment","title":"3. Biological Content Assessment:","text":"<p>The biological content of the model is consistent with the literature:</p> <ul> <li>The model correctly represents the IL-18 signaling pathway, where IL-18 binds to IL-18R1, which then recruits IL-18RAP to form a functional receptor complex</li> <li>The poxvirus IL-18BP acts as a decoy receptor to sequester IL-18, preventing it from binding to its cellular receptor</li> <li>All the components are associated with the correct biological process (GO:0035655, interleukin-18-mediated signaling pathway)</li> <li>The viral protein is correctly associated with the viral process GO:0039518 (obsolete suppression by virus of host cytokine activity)</li> </ul>"},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#4-evidence-assessment","title":"4. Evidence Assessment:","text":"<p>The model uses appropriate evidence codes and references:</p> <ul> <li>The evidence for IL-18 cytokine activity comes from a direct assay (ECO:0000314) with reference to PMID:14528293</li> <li>The evidence for IL-18R1 and IL-18RAP activities and their cellular locations comes from direct assays or curator inference with references to appropriate papers (PMID:25500532)</li> <li>The evidence for the viral IL-18BP activity comes from direct assay (ECO:0000314) with reference to PMID:10769064, which directly demonstrates that poxviruses encode IL-18 binding proteins that block IL-18 activity</li> </ul>"},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#issues-found","title":"Issues Found:","text":"<ol> <li> <p>Obsolete Term Usage: The model uses the term \"obsolete suppression by virus of host cytokine activity\" (GO:0039518) for the viral process. As this term is marked as obsolete, it should be updated to the current replacement term.</p> </li> <li> <p>Automated Changes: The model has undergone automated term replacements (noted in comments), indicating it was created before some relationship type standardizations. While these changes don't affect the model's validity, it's worth noting that the model was created using older relationship types.</p> </li> <li> <p>Cellular Location Precision: IL-18R1 and IL-18RAP are annotated to plasma membrane (GO:0005886), which is correct, but for transmembrane receptors, a more specific term like \"integral component of plasma membrane\" might be more precise if this information is available in the literature.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005096-Poxvirus_OPG022_inhibition_of_host_IL18_signaling_pathway__Human_Poxvirus__/#conclusion","title":"Conclusion:","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the inhibition of the IL-18 signaling pathway by a poxvirus IL-18 binding protein. The model follows GO-CAM best practices for signaling receptor annotation and uses appropriate evidence. The only notable issue is the use of an obsolete GO term for the viral process, which should be updated.</p> <p>The model is parsimonious, focusing on the key interactions without unnecessary complexity, and it clearly communicates the biological mechanism of viral immune evasion through cytokine inhibition.</p> <p>Recommendation: Update the obsolete GO term (GO:0039518), but otherwise, the model is sound and can be maintained as is.</p>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/","title":"62b4ffe300005181 Poxvirus OPG003 inhibition of host NF kappa B pathway via NFKB1  Human Poxvirus","text":"<p>Now, let me analyze the GO-CAM model based on the information I've gathered.</p>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#go-cam-review-gomodel62b4ffe300005181","title":"GO-CAM Review: gomodel:62b4ffe300005181","text":""},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#model-title","title":"Model Title:","text":"<p>Poxvirus-OPG003 inhibition of host NF-kappa-B pathway via NFKB1 (Human-Poxvirus)</p>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#basic-model-description","title":"Basic Model Description:","text":"<p>This model represents how a poxvirus protein OPG003 (G3R) inhibits the host NF-kappa-B signaling pathway by directly targeting the human NFKB1 protein. The model involves several human proteins involved in NF-kappa-B signaling (RELA, NFKB1, NFKBIA, IKBKB) and the viral protein OPG003.</p>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#proteins-in-the-model","title":"Proteins in the Model:","text":"<ol> <li>UniProtKB:Q76QY7 - Poxvirus OPG003/G3R ankyrin repeat protein</li> <li>UniProtKB:P19838 - Human NFKB1 (Nuclear factor NF-kappa-B p105/p50)</li> <li>UniProtKB:P25963 - Human NFKBIA (NF-kappa-B inhibitor alpha)</li> <li>UniProtKB:O14920 - Human IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta)</li> <li>UniProtKB:Q04206 - Human RELA (Transcription factor p65)</li> </ol>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#interactions-and-activities","title":"Interactions and Activities:","text":"<p>The model captures several key activities and interactions: 1. IKBKB (IKK-beta) with kinase activity (GO:0008384) in the cytoplasm 2. NFKBIA (IkappaB-alpha) with protein sequestering activity (GO:0140311) in the cytoplasm 3. NFKB1 (p50) with DNA-binding transcription factor activity (GO:0003700) in chromatin 4. RELA (p65) with DNA-binding transcription factor activity (GO:0003700) in chromatin 5. Poxvirus OPG003 with protein sequestering activity (GO:0140311) in the host cell nucleus</p>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#causal-relationships","title":"Causal Relationships:","text":"<ul> <li>IKBKB directly negatively regulates NFKBIA (RO:0002630)</li> <li>NFKBIA directly negatively regulates both NFKB1 and RELA (RO:0002630)</li> <li>OPG003 directly negatively regulates NFKB1 (RO:0002630)</li> </ul>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#biological-processes","title":"Biological Processes:","text":"<ul> <li>The activities of IKBKB and NFKBIA are part of canonical NF-kappaB signal transduction (GO:0007249)</li> <li>NFKB1 activity is part of non-canonical NF-kappaB signal transduction (GO:0038061)</li> <li>RELA activity is part of canonical NF-kappaB signal transduction (GO:0007249)</li> <li>OPG003 activity is part of symbiont-mediated suppression of host NF-kappaB cascade (GO:0085034)</li> </ul>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#qc-assessment","title":"QC Assessment:","text":""},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#strengths","title":"Strengths:","text":"<ol> <li>Complete Pathway Representation: The model correctly captures the canonical NF-kappa-B pathway with the key players (IKBKB, NFKBIA, NFKB1, RELA).</li> <li>Proper Cellular Locations: The locations for each protein are appropriately assigned (cytoplasm for IKBKB and NFKBIA, chromatin for the transcription factors).</li> <li>Virus-Host Interaction: The model accurately represents how a viral protein (OPG003) disrupts host immunity by targeting NFKB1.</li> <li>Evidence Support: Activities and interactions are supported by published evidence (PMIDs).</li> <li>Causal Relationships: The regulatory relationships between components are correctly represented using RO:0002630 (directly negatively regulates).</li> </ol>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#issuessuggestions","title":"Issues/Suggestions:","text":"<ol> <li> <p>Duplicate Causal Association: There appears to be a duplicate causal association between IKBKB and NFKBIA. There are two identical \"directly negatively regulates\" relationships with the same downstream activity.</p> </li> <li> <p>Complex Representation: According to \"How to annotate complexes in GO-CAM\", since NFKB1 and RELA form a heterodimeric complex for their function, this relationship should be explicitly modeled. The model currently treats them as independent transcription factors.</p> </li> <li> <p>Pathway Connectivity: The model doesn't explicitly show that IKBKB's regulation of NFKBIA ultimately leads to activation of NFKB1/RELA. A clearer connection in the pathway flow would improve the model.</p> </li> <li> <p>Molecular Clarity: It would be helpful to clarify that IKBKB phosphorylates NFKBIA, leading to its degradation and subsequent release of NFKB1/RELA. The specific mechanisms could be more explicitly represented.</p> </li> <li> <p>Evidence Completeness: One of the causal associations from IKBKB to NFKBIA has no evidence cited, which should be addressed.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#biological-consistency","title":"Biological Consistency:","text":"<p>The model is largely consistent with our understanding of NF-kappa-B signaling and viral interference:</p> <ol> <li> <p>In the canonical NF-kappa-B pathway, IKBKB phosphorylates NFKBIA, which leads to NFKBIA degradation and release of NFKB1-RELA heterodimers to translocate to the nucleus.</p> </li> <li> <p>The poxvirus protein OPG003 is correctly shown to interfere with this pathway by sequestering NFKB1, which is consistent with how many viruses disrupt host immunity.</p> </li> <li> <p>The roles of NFKB1 and RELA as DNA-binding transcription factors are properly represented, though their relationship as a heterodimeric complex could be made more explicit.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005181-Poxvirus_OPG003_inhibition_of_host_NF_kappa_B_pathway_via_NFKB1__Human_Poxvirus__/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Remove Duplicate Association: The duplicate causal association between IKBKB and NFKBIA should be eliminated.</p> </li> <li> <p>Represent the NFKB1-RELA Complex: Consider explicitly modeling the heterodimeric relationship between NFKB1 and RELA in the nucleus.</p> </li> <li> <p>Complete Evidence: Add supporting evidence for the causal association that currently lacks it.</p> </li> <li> <p>Clarify Regulatory Mechanisms: Consider adding annotations to clarify the specific mechanisms (phosphorylation, ubiquitination, etc.) that occur during these regulatory events.</p> </li> <li> <p>Improve Pathway Connectivity: Make the flow from IKBKB through NFKBIA to NFKB1/RELA more explicit, perhaps by using different relationship types or adding intermediate steps.</p> </li> </ol> <p>The model effectively captures the essence of how a poxvirus protein disrupts host NF-kappa-B signaling, with a few opportunities for improvements in the representation of complexes and pathway connectivity.</p>"},{"location":"reviews/62b4ffe300005342-Poxvirus_OPG179_inhibition_of_host_NF_kappa_B_via_BTRC__Human_Poxvirus__/","title":"62b4ffe300005342 Poxvirus OPG179 inhibition of host NF kappa B via BTRC  Human Poxvirus","text":"<p>Now I'll review the GO-CAM model based on all the information I have gathered.</p> <p>Based on my review of GO-CAM model gomodel:62b4ffe300005342 \"Poxvirus-OPG179 inhibition of host NF-kappa-B via BTRC (Human-Poxvirus)\", I can provide the following assessment:</p>"},{"location":"reviews/62b4ffe300005342-Poxvirus_OPG179_inhibition_of_host_NF_kappa_B_via_BTRC__Human_Poxvirus__/#model-overview","title":"Model Overview","text":"<p>This model represents the inhibitory mechanism by which poxvirus protein A49 (OPG179) interferes with the host NF-kappa-B signaling pathway. The model shows how the poxvirus protein prevents NF-kappa-B activation by targeting the host E3 ubiquitin ligase beta-TrCP (BTRC).</p>"},{"location":"reviews/62b4ffe300005342-Poxvirus_OPG179_inhibition_of_host_NF_kappa_B_via_BTRC__Human_Poxvirus__/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model correctly represents the key molecular interactions based on the literature:</p> <ol> <li>Protein Sequestering Activity by A49 (UniProtKB:P31037): </li> <li>The poxvirus protein A49 (labeled as VACWR175) correctly uses \"protein sequestering activity\" (GO:0140311) to inhibit BTRC.</li> <li>The paper evidence (PMID:30819886) supports that A49 binds to beta-TrCP (BTRC) to prevent its normal function.</li> <li> <p>A49 is correctly localized to \"host cell cytoplasm\" (GO:0030430) as supported by the literature.</p> </li> <li> <p>BTRC (UniProtKB:Q9Y297) Function: </p> </li> <li>BTRC is correctly annotated with \"ubiquitin-like ligase-substrate adaptor activity\" (GO:1990756).</li> <li>This activity is supported by the evidence citation PMID:10066435.</li> <li> <p>The cytoplasmic localization of BTRC is accurately represented.</p> </li> <li> <p>NFKBIA (UniProtKB:P25963) Function: </p> </li> <li>The model correctly represents NFKBIA's \"protein sequestering activity\" (GO:0140311).</li> <li>The evidence citation PMID:1493333 supports that NFKBIA binds to and sequesters NF-kappa-B subunits in the cytoplasm.</li> <li> <p>The cytoplasmic localization of NFKBIA is correctly represented based on the literature.</p> </li> <li> <p>RELA (UniProtKB:Q04206) Function: </p> </li> <li>RELA is correctly annotated with \"DNA-binding transcription factor activity\" (GO:0003700).</li> <li> <p>Its localization in \"chromatin\" (GO:0000785) is accurate as it binds to DNA when active.</p> </li> <li> <p>Causal Relationships:</p> </li> <li>The causal relationship between A49 and BTRC (A49 directly negatively regulates BTRC) is supported by PMID:30819886.</li> <li>The causal relationship between BTRC and NFKBIA (BTRC directly negatively regulates NFKBIA) is supported by PMID:10066435.</li> <li>The causal relationship between NFKBIA and RELA (NFKBIA directly negatively regulates RELA) is supported by PMID:1493333.</li> </ol>"},{"location":"reviews/62b4ffe300005342-Poxvirus_OPG179_inhibition_of_host_NF_kappa_B_via_BTRC__Human_Poxvirus__/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Complex Representation: </li> <li>Based on the \"How to annotate complexes in GO-CAM\" guidelines, the model correctly represents the activities of individual proteins when their specific functions are known.</li> <li> <p>The model doesn't use complex IDs because the molecular activities of each component (A49, BTRC, NFKBIA, RELA) are known and distinctly represented.</p> </li> <li> <p>Part_of Relations:</p> </li> <li> <p>All activities are appropriately linked to the biological process \"non-canonical NF-kappaB signal transduction\" (GO:0038061) or \"symbiont-mediated suppression of host NF-kappaB cascade\" (GO:0085034).</p> </li> <li> <p>Causal Associations:</p> </li> <li>The model uses the correct relationship \"directly negatively regulates\" (RO:0002630) to represent inhibitory relationships.</li> <li> <p>The chain of causality is logically consistent: A49 inhibits BTRC, which would normally degrade NFKBIA, thus NFKBIA can continue to sequester RELA.</p> </li> <li> <p>Evidence:</p> </li> <li>Each activity and causal relationship is supported by appropriate evidence citations using PMIDs.</li> <li>The evidence types (ECO:0000314 - direct assay evidence used in manual assertion) are appropriate for the experimental evidence provided in the papers.</li> </ol>"},{"location":"reviews/62b4ffe300005342-Poxvirus_OPG179_inhibition_of_host_NF_kappa_B_via_BTRC__Human_Poxvirus__/#pathways-and-activity-flow","title":"Pathways and Activity Flow","text":"<p>The model correctly represents the molecular mechanism described in the literature:</p> <ol> <li>During viral infection, poxvirus A49 protein uses protein sequestering activity to bind to host BTRC.</li> <li>By binding BTRC, A49 prevents BTRC from ubiquitinating NFKBIA, which would normally lead to NFKBIA degradation.</li> <li>Because NFKBIA is not degraded, it continues to sequester RELA in the cytoplasm.</li> <li>This prevents RELA from translocating to the nucleus and activating NF-kappa-B-dependent gene expression.</li> </ol> <p>This chain of causality is consistent with the viral strategy to suppress host immune responses by inhibiting NF-kappa-B activation.</p>"},{"location":"reviews/62b4ffe300005342-Poxvirus_OPG179_inhibition_of_host_NF_kappa_B_via_BTRC__Human_Poxvirus__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>The model is well-constructed and biologically accurate, but a few minor improvements could be considered:</p> <ol> <li>Additional Context: </li> <li> <p>Consider adding information about the phosphorylation status of A49, as described in PMID:30819886, which indicates A49 is phosphorylated on serine 7 to enable binding to beta-TrCP.</p> </li> <li> <p>Temporal Aspects: </p> </li> <li> <p>The model could potentially include information about the temporal regulation of this process, as the literature suggests A49's ability to bind BTRC is regulated by phosphorylation events that occur during NF-kappa-B pathway activation.</p> </li> <li> <p>Expand to Include Additional Known Interactions:</p> </li> <li>If appropriate for the scope of the model, consider including other beta-TrCP substrates that might be affected by A49 binding, as mentioned in the literature.</li> </ol>"},{"location":"reviews/62b4ffe300005342-Poxvirus_OPG179_inhibition_of_host_NF_kappa_B_via_BTRC__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62b4ffe300005342 is accurate, well-evidenced, and follows GO-CAM best practices. It correctly represents the mechanism by which poxvirus protein A49 inhibits NF-kappa-B activation by interfering with the BTRC-mediated degradation of NFKBIA. The model effectively captures a viral immune evasion strategy and the causal relationships between the key components of this process.</p>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/","title":"62b4ffe300005389 Poxvirus OPG184 inhibition of host NF kappa B via KPNA2  Human Poxvirus","text":"<p>Now that I have gathered all the relevant information, I'll review the GO-CAM model with ID 62b4ffe300005389, focusing on the biological accuracy, connectivity, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#review-of-go-cam-model-62b4ffe300005389","title":"Review of GO-CAM Model 62b4ffe300005389","text":""},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#basic-information","title":"Basic Information","text":"<p>Title: \"Poxvirus-OPG184 inhibition of host NF-kappa-B via KPNA2 (Human-Poxvirus)\" Taxon: Human (NCBITaxon:9606) Status: Production Model ID: gomodel:62b4ffe300005389</p>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model describes the interaction between a poxvirus protein (KBTB1/OPG184) and the host NF-kappaB signaling pathway, specifically showing how the viral protein inhibits NF-kappaB nuclear translocation by targeting the nuclear import machinery via KPNA2 (importin alpha-2).</p>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#key-components-in-the-model","title":"Key Components in the Model","text":"<p>The model includes four main activities:</p> <ol> <li> <p>Nuclear import signal receptor activity (GO:0061608) of KPNA2 (UniProtKB:P52292) occurring in nuclear membrane (GO:0031965), part of protein import into nucleus (GO:0006606)</p> </li> <li> <p>DNA-binding transcription factor activity (GO:0003700) of RELA/p65 (UniProtKB:Q04206) occurring in chromatin (GO:0000785), part of non-canonical NF-kappaB signaling (GO:0038061)</p> </li> <li> <p>Protein sequestering activity (GO:0140311) of NFKBIA/IkappaBalpha (UniProtKB:P25963) occurring in cytoplasm (GO:0005737), part of non-canonical NF-kappaB signaling (GO:0038061)</p> </li> <li> <p>Ubiquitin-like ligase-substrate adaptor activity (GO:1990756) of KBTB1/OPG184 (UniProtKB:P24768) occurring in host cell cytoplasm (GO:0030430), part of symbiont-mediated suppression of host NF-kappaB cascade (GO:0085034)</p> </li> </ol>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#causal-relationships","title":"Causal Relationships","text":"<p>The model contains two causal relationships:</p> <ol> <li>NFKBIA directly negatively regulates (RO:0002630) KPNA2 nuclear import signal receptor activity</li> <li>KPNA2 directly positively regulates (RO:0002629) RELA DNA-binding transcription factor activity</li> </ol> <p>In addition, the viral protein KBTB1/OPG184's ubiquitin-like ligase-substrate adaptor activity directly negatively regulates (RO:0002630) KPNA2 nuclear import signal receptor activity.</p>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#evaluation","title":"Evaluation","text":""},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate molecular mechanisms: The model correctly represents the role of KPNA2 in nuclear import of RELA/p65 and how the viral protein interferes with this process.</p> </li> <li> <p>Appropriate causal relationships: The causal relationships between components correctly represent how the process works in the cell.</p> </li> <li> <p>Correct cellular locations: Each activity is assigned appropriate cellular locations where the processes occur.</p> </li> <li> <p>Evidence-based model: The model is supported by published literature, with appropriate evidence codes and references.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing connection from NFKBIA to RELA: While the model shows NFKBIA inhibiting KPNA2, the direct regulatory relationship between NFKBIA and RELA is not represented. According to the PMID:1493333 paper, NFKBIA directly binds to RELA and prevents its nuclear translocation. This direct relationship should be included in the model.</p> </li> <li> <p>Incomplete representation of protein complex interactions: According to the GO-CAM complex annotation guidelines, if the specific activity is carried by a known subunit (as in this case where KPNA2 specifically binds to RELA), that should be explicitly represented. The model does correctly show this, but could be improved by clarifying that KPNA2 and importin-beta form a complex during nuclear import.</p> </li> <li> <p>Incomplete representation of the NF-kappaB pathway: The model focuses on non-canonical NF-kappaB signaling, but doesn't fully represent how this pathway is activated or additional components that might be involved in the signaling.</p> </li> <li> <p>Canonical pathway annotation: Based on the literature provided (particularly PMID:30814284), this appears to be related to canonical NF-kappaB signaling rather than non-canonical NF-kappaB signaling. This should be reviewed and potentially corrected.</p> </li> <li> <p>Mechanistic details on viral protein function: While the model correctly shows that KBTB1/OPG184 inhibits KPNA2, it could better represent the mechanistic details of how this occurs. Based on PMID:30814284, the viral protein appears to act by disrupting the p65-importin interaction, which could be more explicitly modeled.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Add direct relationship from NFKBIA to RELA: Add a causal relationship showing that NFKBIA directly negatively regulates RELA's DNA-binding transcription factor activity.</p> </li> <li> <p>Consider representing importin complex formation: Consider explicitly modeling the formation of the importin complex (KPNA2-importin beta) that mediates nuclear transport of RELA.</p> </li> <li> <p>Clarify canonical vs. non-canonical pathway: Review the literature to confirm whether this model represents canonical or non-canonical NF-kappaB signaling and update annotations accordingly.</p> </li> <li> <p>Add mechanistic details for viral inhibition: Consider adding more specific details about how KBTB1/OPG184 disrupts the KPNA2-RELA interaction, possibly by adding an annotation indicating that it physically interacts with KPNA2 to prevent RELA binding.</p> </li> <li> <p>Consider expanding the model: If appropriate based on available evidence, expand the model to include upstream events that lead to IkappaBalpha degradation and release of RELA, which would provide a more complete representation of the pathway.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005389-Poxvirus_OPG184_inhibition_of_host_NF_kappa_B_via_KPNA2__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62b4ffe300005389 provides a valuable representation of how a poxvirus protein inhibits NF-kappaB signaling by targeting the nuclear import machinery. The model is largely accurate and well-constructed but could be improved by adding some additional relationships and clarifying the specific NF-kappaB pathway being represented. These improvements would make the model more comprehensive and increase its utility for understanding the molecular mechanisms of virus-host interactions in the context of immune signaling.</p>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/","title":"62b4ffe300005506 Poxvirus OPG182 inhibition of host NF kappa B via IRAK2  Human Poxvirus","text":"<p>Now, let me review the GO-CAM model with ID \"62b4ffe300005506\" based on the information I've gathered.</p>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#go-cam-model-review-gomodel62b4ffe300005506","title":"GO-CAM Model Review: gomodel:62b4ffe300005506","text":""},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#basic-model-information","title":"Basic Model Information","text":"<ul> <li>Title: \"Poxvirus-OPG182 inhibition of host NF-kappa-B via IRAK2 (Human-Poxvirus)\"</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> <li>URL: https://bioregistry.io/go.model:62b4ffe300005506</li> </ul>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#model-summary","title":"Model Summary","text":"<p>This model represents the interaction between a poxvirus protein (VACWR178) and the human NF-\u03baB signaling pathway. Specifically, it shows how the vaccinia virus protein A52 (VACWR178) inhibits the host NF-\u03baB signaling cascade by targeting IRAK2, which disrupts the normal signaling through TRAF6, MAP3K7 (TAK1), and CHUK (IKK-alpha).</p>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#model-components-and-activities","title":"Model Components and Activities","text":"<p>The model includes the following key activities:</p> <ol> <li>Vaccinia virus A52 protein (UniProtKB:Q01220)</li> <li>Function: Protein sequestering activity (GO:0140311)</li> <li>Location: Host cell cytoplasm (GO:0030430)</li> <li>Process: Symbiont-mediated suppression of host NF-kappaB cascade (GO:0085034)</li> <li> <p>Causal relationship: Directly negatively regulates (RO:0002630) IRAK2 activity</p> </li> <li> <p>Human IRAK2 (UniProtKB:O43187)</p> </li> <li>Function: Molecular adaptor activity (GO:0060090)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li>Process: Canonical NF-kappaB signal transduction (GO:0007249)</li> <li> <p>Causal relationship: Directly positively regulates (RO:0002629) TRAF6 activity</p> </li> <li> <p>Human TRAF6 (UniProtKB:Q9Y4K3)</p> </li> <li>Function: E3 ubiquitin protein ligase activity (GO:0061630)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li>Process: Non-canonical NF-kappaB signal transduction (GO:0038061)</li> <li> <p>Causal relationship: Directly positively regulates (RO:0002629) MAP3K7 activity</p> </li> <li> <p>Human MAP3K7/TAK1 (UniProtKB:O43318)</p> </li> <li>Function: MAP kinase activity (GO:0004707)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li>Process: Canonical NF-kappaB signal transduction (GO:0007249)</li> <li> <p>Causal relationship: Directly positively regulates (RO:0002629) CHUK activity</p> </li> <li> <p>Human CHUK/IKK-alpha (UniProtKB:O15111)</p> </li> <li>Function: IkappaB kinase activity (GO:0008384)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li>Process: Canonical NF-kappaB signal transduction (GO:0007249)</li> </ol>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well supported by evidence from the literature, with most activities and causal relationships supported by direct assay evidence (ECO:0000314) and appropriate citations to PMID:17878161, which appears to be the primary source for this model. Some of the cellular location information is supported by curator inference (ECO:0000305).</p>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#model-critique-and-recommendations","title":"Model Critique and Recommendations","text":""},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the mechanism by which poxvirus A52 inhibits the NF-\u03baB pathway.</li> <li>The causal relationships between components are appropriate and follow the known signaling cascade.</li> <li>Each activity has proper evidence annotations with appropriate ECO codes.</li> <li>The biological context (host-pathogen interaction) is clearly represented.</li> </ol>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex Representation: According to the guidelines in \"How_to_annotate_complexes_in_GO-CAM,\" if the TRAF6-mediated signaling involves a complex, this could be better represented. The current model shows individual proteins rather than complexes, which may be appropriate if the precise activity-bearing subunits are known, but it would be helpful to clarify this.</p> </li> <li> <p>Process Annotation Consistency: There's a mix of canonical (GO:0007249) and non-canonical (GO:0038061) NF-\u03baB signaling processes in the model. It would be helpful to clarify if this is intentional or if there should be consistency in which pathway is being represented.</p> </li> <li> <p>Evidence Depth: While evidence codes and PMIDs are appropriate, it would be beneficial to have more specific evidence for some of the assertions, especially since the full text of PMID:17878161 wasn't available for review.</p> </li> <li> <p>Connection to Downstream Effects: The model could potentially be expanded to show the ultimate effects on gene expression or other cellular responses following NF-\u03baB inhibition.</p> </li> <li> <p>Further Clarification of A52 Mechanism: If available in the literature, additional details on how A52 specifically sequesters IRAK2 (e.g., binding mechanism, competition with other proteins) could enhance the model.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#technical-review","title":"Technical Review:","text":"<p>All the required relationships and annotations are present in the model. The model follows GO-CAM best practices with appropriate annotations for molecular function, cellular component, and biological process for each activity. The causal relationships use the correct predicates (RO:0002629 for positive regulation and RO:0002630 for negative regulation).</p>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#recommended-improvements","title":"Recommended Improvements:","text":"<ol> <li>Consider adding additional evidence if available, particularly for the sequestering mechanism.</li> <li>Clarify the distinction between canonical and non-canonical NF-\u03baB signaling in this context.</li> <li>Consider expanding the model to include downstream effects on transcription factors or gene expression.</li> <li>Ensure consistency in the representation of any protein complexes involved in this pathway.</li> </ol>"},{"location":"reviews/62b4ffe300005506-Poxvirus_OPG182_inhibition_of_host_NF_kappa_B_via_IRAK2__Human_Poxvirus__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents how the vaccinia virus protein A52 inhibits NF-\u03baB signaling by targeting IRAK2, which disrupts downstream signaling through TRAF6, MAP3K7, and CHUK. With minor clarifications and potential expansions as suggested, this model provides valuable insights into host-pathogen interactions in the context of immune signaling.</p>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/","title":"62b4ffe300005623 HHV1 US3 inhibition of host TCR signaling via LAT  Human Herpesvirus","text":"<p>Based on the information I have collected, I'll now review the GO-CAM model \"gomodel:62b4ffe300005623\" titled \"HHV1-US3 inhibition of host TCR signaling via LAT (Human-Herpesvirus)\".</p>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#review-of-go-cam-model-62b4ffe300005623","title":"Review of GO-CAM Model 62b4ffe300005623","text":""},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#model-overview","title":"Model Overview","text":"<p>Title: HHV1-US3 inhibition of host TCR signaling via LAT (Human-Herpesvirus) Model ID: gomodel:62b4ffe300005623 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#model-description","title":"Model Description","text":"<p>This model represents how Herpes Simplex Virus 1 (HHV-1) protein US3 inhibits host T cell receptor (TCR) signaling by interfering with the function of the Linker for Activation of T cells (LAT) protein. The model shows a mechanism where viral US3 protein uses protein sequestering activity to inhibit LAT signaling receptor complex adaptor activity, thereby disrupting the T cell receptor signaling pathway.</p>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#components-of-the-model","title":"Components of the Model","text":""},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#proteins-and-activities","title":"Proteins and Activities","text":"<ol> <li>HHV-1 US3 protein (UniProtKB:P04413)</li> <li>Activity: Protein sequestering activity (GO:0140311)</li> <li>Location: Host cell cytoplasm (GO:0030430)</li> <li>Part of: Symbiont-mediated suppression of host T-cell mediated immune response (GO:0052085)</li> <li> <p>Evidence: ECO:0000314, PMID:25907557</p> </li> <li> <p>LAT protein (UniProtKB:O43561)</p> </li> <li>Activity: Signaling receptor complex adaptor activity (GO:0030159)</li> <li>Location: Plasma membrane (GO:0005886)</li> <li>Part of: T cell receptor signaling pathway (GO:0050852)</li> <li> <p>Evidence: ECO:0000314, PMID:9489702; ECO:0000314, PMID:9729044; ECO:0000314, PMID:25907557</p> </li> <li> <p>ZAP70 protein (UniProtKB:P43403)</p> </li> <li>Activity: Protein tyrosine kinase activity (GO:0004713)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li>Part of: T cell receptor signaling pathway (GO:0050852)</li> <li> <p>Evidence: ECO:0000314, PMID:15292186; ECO:0000304, PMID:12359715; ECO:0000314, PMID:9489702</p> </li> <li> <p>TRAF6 protein (UniProtKB:Q9Y4K3)</p> </li> <li>Activity: Ubiquitin protein ligase activity (GO:0061630)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li>Part of: T cell receptor signaling pathway (GO:0050852)</li> <li>Evidence: ECO:0000314, PMID:23514740; ECO:0000314, PMID:22851693</li> </ol>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#causal-relationships","title":"Causal Relationships","text":"<ol> <li>HHV-1 US3 protein directly negatively regulates (RO:0002630) LAT's signaling receptor complex adaptor activity</li> <li>ZAP70 directly positively regulates (RO:0002629) LAT's signaling receptor complex adaptor activity</li> <li>LAT directly positively regulates (RO:0002629) TRAF6's ubiquitin protein ligase activity</li> </ol>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#strengths","title":"Strengths","text":"<ol> <li> <p>Biological Accuracy: The model correctly represents the mechanism described in PMID:25907557, where HHV-1 US3 protein inhibits T cell signaling by interfering with LAT activation via TRAF6.</p> </li> <li> <p>Appropriate Use of GO Terms: The molecular functions, cellular components, and biological processes are appropriately assigned to each protein based on their known roles.</p> </li> <li> <p>Appropriate Causal Relationships: The causal relationships use the correct relation ontology terms (RO:0002629 for positive regulation, RO:0002630 for negative regulation).</p> </li> <li> <p>Evidence Support: All assertions in the model are supported by specific literature references with appropriate evidence codes.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#issues-found","title":"Issues Found","text":"<ol> <li> <p>Missing Target Input for Sequestering Activity: According to the \"Protein sequestering activity\" guidelines, the protein that acts as a sequesterer should have a \"has input\" relation to its target. In this model, there is no explicit \"has input\" relationship between US3 and LAT.</p> </li> <li> <p>Incomplete Representation of TRAF6-LAT Mechanism: Based on PMID:25907557 and UniProt entries, US3 prevents LAT and TRAF6 interaction, but the model doesn't fully show this mechanistic detail. The paper suggests US3 confines LAT activation via TRAF6, indicating US3 may prevent TRAF6-mediated ubiquitination of LAT.</p> </li> <li> <p>ZAP70-LAT Relationship Evidence Needs Clarification: The model correctly shows ZAP70 positively regulating LAT, but the evidence cited (PMID:15292186) appears to focus on ZAP70 kinase structure rather than specifically on LAT phosphorylation. While ZAP70 is known to phosphorylate LAT (as confirmed in PMID:9489702), the evidence citation could be more specific.</p> </li> <li> <p>Lack of Molecular Details: The model doesn't capture some mechanistic details, such as the phosphorylation of LAT by ZAP70 or the ubiquitination of LAT by TRAF6.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add \"has input\" Relation: Add a \"has input\" relation from US3's protein sequestering activity to LAT to properly represent the sequestering mechanism as per GO-CAM guidelines.</p> </li> <li> <p>Clarify Mechanism: Consider clarifying that US3 prevents the interaction between TRAF6 and LAT, disrupting LAT ubiquitination by TRAF6. This could be done by adding additional details or comments to the model.</p> </li> <li> <p>Review Evidence Citations: Review the evidence citation for the ZAP70-LAT relationship and consider citing PMID:9489702 as the primary evidence for this relationship.</p> </li> <li> <p>Consider Adding Molecular Details: If appropriate based on available evidence, consider adding more molecular details such as:</p> </li> <li>Phosphorylation of LAT by ZAP70 at specific sites</li> <li> <p>Ubiquitination of LAT by TRAF6 (with Lys-63-linked polyubiquitin chains)</p> </li> <li> <p>Add Contextual Information: Consider adding a comment or description to the model that explains the viral evasion strategy, highlighting how this disruption of TCR signaling benefits the virus by suppressing host immune responses.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005623-HHV1_US3_inhibition_of_host_TCR_signaling_via_LAT__Human_Herpesvirus__/#conclusion","title":"Conclusion","text":"<p>The model \"HHV1-US3 inhibition of host TCR signaling via LAT\" provides a clear representation of how HHV-1 US3 protein inhibits T cell receptor signaling by interfering with LAT function. The model correctly uses GO and relation ontology terms and is supported by appropriate evidence. With a few minor improvements as suggested above, the model would provide an even more complete and accurate representation of this host-pathogen interaction mechanism.</p>"},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/","title":"62b4ffe300005697 HHV1 US3 inhibition of host RIG I signaling  Human Herpesvirus","text":"<p>Now I'll analyze the GO-CAM model in detail based on the information I've gathered.</p>"},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/#go-cam-model-review-hhv1-us3-inhibition-of-host-rig-i-signaling-human-herpesvirus","title":"GO-CAM Model Review: HHV1-US3 inhibition of host RIG-I signaling (Human-Herpesvirus)","text":""},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/#model-overview","title":"Model Overview","text":"<p>Model ID: gomodel:62b4ffe300005697 Title: HHV1-US3 inhibition of host RIG-I signaling (Human-Herpesvirus) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/#model-components","title":"Model Components","text":"<p>This GO-CAM model describes how the US3 kinase from Herpes Simplex Virus 1 (HHV-1) inhibits the RIG-I signaling pathway in human cells. The model includes 4 key activities:</p> <ol> <li>US3 Kinase activity (UniProtKB:P04413 - protein serine/threonine kinase activity)</li> <li>RIG-I Pattern Recognition Receptor activity (UniProtKB:O95786 - pattern recognition receptor activity)</li> <li>TRIM25 E3 Ubiquitin Ligase activity (UniProtKB:Q14258 - ubiquitin protein ligase activity)</li> <li>MAVS Signaling Adaptor activity (UniProtKB:Q7Z434 - signaling adaptor activity)</li> </ol> <p>The model illustrates how HSV-1 US3 kinase directly negatively regulates TRIM25's ability to ubiquitinate RIG-I, thereby suppressing the downstream antiviral signaling pathway.</p>"},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/#analysis-of-evidence-and-scientific-accuracy","title":"Analysis of Evidence and Scientific Accuracy","text":"<p>The model is based on two primary scientific publications: - PMID:31801859 - Evidence for US3 kinase of HHV1 inhibiting RIG-I signaling - PMID:34935440 - Detailed mechanism showing US3 phosphorylates RIG-I at S8 position</p> <p>The model correctly represents the causal relationships between these components based on the cited literature:</p> <ol> <li>US3 kinase (P04413) directly negatively regulates TRIM25 (Q14258) activity</li> <li>TRIM25 (Q14258) directly positively regulates RIG-I (O95786) activity through K63-linked ubiquitination</li> <li>RIG-I (O95786) directly positively regulates MAVS (Q7Z434) activity</li> </ol> <p>The evidence shows that US3 phosphorylates RIG-I specifically at S8, suppressing TRIM25-mediated RIG-I ubiquitination and subsequent RIG-I-MAVS binding, ultimately inhibiting type I IFN induction.</p>"},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/#conformity-with-go-cam-best-practices","title":"Conformity with GO-CAM Best Practices","text":"<p>The model follows several GO-CAM best practices:</p> <ol> <li>Proper molecular functions: Each protein is annotated with the correct molecular function:</li> <li>US3: Protein serine/threonine kinase activity (GO:0004674)</li> <li>RIG-I: Pattern recognition receptor activity (GO:0038187)</li> <li>TRIM25: Ubiquitin protein ligase activity (GO:0061630)</li> <li> <p>MAVS: Signaling adaptor activity (GO:0035591)</p> </li> <li> <p>Appropriate causal relations: The model uses the correct relation predicates:</p> </li> <li>RO:0002630 (directly negatively regulates) for US3's effect on TRIM25</li> <li> <p>RO:0002629 (directly positively regulates) for TRIM25's effect on RIG-I and RIG-I's effect on MAVS</p> </li> <li> <p>Cellular location: Each activity is properly annotated with subcellular location:</p> </li> <li>US3: Host cell cytoplasm (GO:0030430)</li> <li>RIG-I: Cytoplasm (GO:0005737)</li> <li>TRIM25: Cytoplasm (GO:0005737)</li> <li> <p>MAVS: Mitochondrial membrane (GO:0031966)</p> </li> <li> <p>Biological process context: Each activity is appropriately placed in the relevant biological process:</p> </li> <li>US3: Symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway (GO:0039540)</li> <li>RIG-I: Cytoplasmic pattern recognition receptor signaling pathway (GO:0002753)</li> <li>TRIM25: Cytoplasmic pattern recognition receptor signaling pathway (GO:0002753)</li> <li>MAVS: Cytoplasmic pattern recognition receptor signaling pathway (GO:0002753)</li> </ol>"},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/#evidence-quality","title":"Evidence Quality","text":"<p>The model uses evidence codes correctly: - ECO:0000314 (direct assay evidence used in manual assertion) for experimental evidence - ECO:0000305 (curator inference used in manual assertion) for subcellular localization</p> <p>The model cites relevant peer-reviewed literature that directly supports the assertions made.</p>"},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While this is a well-constructed model, I would suggest the following improvements:</p> <ol> <li> <p>Additional Detail: The model could be enhanced by directly capturing US3's phosphorylation of RIG-I at serine-8 (S8), which is a key molecular event detailed in PMID:34935440. This would provide a more precise mechanistic representation.</p> </li> <li> <p>Expanded Context: The model could benefit from including downstream effects, such as the inhibition of IRF3 activation and type I interferon production, which would provide a more complete picture of the biological significance.</p> </li> <li> <p>Potential Update to Relationships: The model currently shows US3 directly negatively regulating TRIM25, but PMID:34935440 indicates that US3 directly targets RIG-I by phosphorylating it at S8, which then prevents TRIM25-mediated ubiquitination. The model could more accurately represent this by showing US3 directly negatively regulating RIG-I, which then affects TRIM25's ability to ubiquitinate RIG-I.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005697-HHV1_US3_inhibition_of_host_RIG_I_signaling__Human_Herpesvirus__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:62b4ffe300005697) is a scientifically accurate representation of how HSV-1 US3 kinase inhibits the RIG-I signaling pathway in human cells. It follows GO-CAM best practices for molecular function annotation, causal relationships, cellular location, and biological process context. The model is properly supported by evidence from relevant peer-reviewed literature.</p> <p>The minor improvements suggested would enhance the mechanistic precision and biological context of the model, but do not detract from its overall quality and accuracy.</p>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/","title":"62b4ffe300005953 HHV1 US3 inhibition of host NF kappa B signaling via RELA  Human Herpesvirus","text":"<p>After reviewing the model and associated information, I'll now provide a comprehensive review of GO-CAM model 62b4ffe300005953 titled \"HHV1-US3 inhibition of host NF-kappa-B signaling via RELA (Human-Herpesvirus)\":</p>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#go-cam-model-review-hhv1-us3-inhibition-of-host-nf-kappa-b-signaling","title":"GO-CAM Model Review: HHV1-US3 inhibition of host NF-kappa-B signaling","text":""},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#model-id","title":"Model ID","text":"<p>gomodel:62b4ffe300005953</p>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#basic-description","title":"Basic Description","text":"<p>This model represents the mechanism by which Herpes Simplex Virus 1 (HSV-1) protein kinase US3 inhibits NF-\u03baB activation by hyperphosphorylating p65/RelA (RELA), a key component of the NF-\u03baB transcription factor complex. The model demonstrates a viral evasion strategy that suppresses host immune responses.</p>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model includes four activities connected in a causal chain:</p> <ol> <li>US3 protein kinase activity (UniProtKB:P04413, GO:0004674) - Occurs in host cell cytoplasm (GO:0030430)</li> <li>Nuclear import signal receptor activity (UniProtKB:P52292, GO:0061608) - Occurs in nuclear membrane (GO:0031965)</li> <li>DNA-binding transcription factor activity (UniProtKB:Q04206, GO:0003700) - Occurs in chromatin (GO:0000785)</li> <li>Protein sequestering activity (UniProtKB:P25963, GO:0140311) - Occurs in cytoplasm (GO:0005737)</li> </ol> <p>The causal relationships are: - US3 kinase (P04413) directly negatively regulates (RO:0002630) KPNA2 nuclear import signal receptor activity (P52292) - KPNA2 (P52292) directly positively regulates (RO:0002629) RELA transcription factor activity (Q04206) - NFKBIA/I\u03baB\u03b1 (P25963) directly negatively regulates (RO:0002630) KPNA2 activity (P52292)</p>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model is scientifically accurate based on the literature. The PMID:24807716 paper clearly demonstrates that:</p> <ol> <li>HSV-1 US3 inhibits NF-\u03baB activation by hyperphosphorylating p65/RELA at serine 75</li> <li>This hyperphosphorylation blocks nuclear translocation of p65/RELA</li> <li>US3 kinase activity is essential for this inhibition, as kinase-dead mutants fail to block NF-\u03baB activation</li> </ol> <p>The model correctly represents US3's role in directly negatively regulating KPNA2, which is responsible for nuclear import of RELA. This prevents p65/RELA from entering the nucleus and activating NF-\u03baB target genes.</p>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model accurately captures the key mechanism of HSV-1 immune evasion through US3-mediated suppression of NF-\u03baB</li> <li>Proper use of causal relationships (directly positively/negatively regulates)</li> <li>Appropriate cellular locations are specified for each activity</li> <li>Clear biological process annotations for each activity</li> <li>Evidence is properly documented with PMIDs and ECO codes</li> </ol>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Missing molecular details: The model doesn't explicitly represent the hyperphosphorylation of RELA at serine 75, which is the key mechanistic detail from the PMID:24807716 paper. This could be added as additional information.</p> </li> <li> <p>Incomplete representation of NFKBIA's role: While NFKBIA's protein sequestering activity is included, the model doesn't fully capture its normal role in sequestering RELA in the cytoplasm until activation signals trigger NFKBIA degradation. The model could better explain how US3 exploitation of the pathway relates to normal pathway regulation.</p> </li> <li> <p>Contextual information: The model could benefit from additional context about when in the viral life cycle this activity occurs, or how it relates to other HSV-1 immune evasion strategies.</p> </li> <li> <p>Biological process connection: The part_of relationship for US3 kinase activity points to \"negative regulation of protein localization to nucleus\" (GO:1900181), which is correct, but could be more specific to immune regulation or viral host modulation.</p> </li> </ol>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model generally follows GO-CAM guidelines: - Appropriate use of causal relationships - Proper specification of cellular locations - Correct representation of protein activities</p> <p>The automated changes noted in the model comments (\"RO:0002212 replaced by RO:0002630\", \"RO:0002213 replaced by RO:0002629\", and \"GO:0039644 replaced by GO:0085034\") reflect ontology term updates and do not affect the biological accuracy of the model.</p>"},{"location":"reviews/62b4ffe300005953-HHV1_US3_inhibition_of_host_NF_kappa_B_signaling_via_RELA__Human_Herpesvirus__/#conclusions","title":"Conclusions","text":"<p>This GO-CAM model effectively represents the mechanism by which HSV-1 US3 kinase inhibits NF-\u03baB activation by preventing nuclear translocation of RELA through hyperphosphorylation. The model is scientifically accurate and properly structured, though it could be enhanced with more molecular details about the specific phosphorylation event and a more complete representation of the normal regulation of the NF-\u03baB pathway.</p> <p>Overall, this is a valuable model that captures an important viral immune evasion strategy. With minor enhancements, it could provide even more complete information about this host-pathogen interaction mechanism.</p>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/","title":"62b4ffe300006001 HHV1 US3 inhibition of host IRF3  Human Herpesvirus","text":"<p>Based on all the information I've gathered, I'll now review the GO-CAM model 62b4ffe300006001 in detail.</p>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#review-of-go-cam-model-62b4ffe300006001","title":"Review of GO-CAM Model: 62b4ffe300006001","text":""},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#model-title","title":"Model Title","text":"<p>\"HHV1-US3 inhibition of host IRF3 (Human-Herpesvirus)\"</p>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#model-overview","title":"Model Overview","text":"<p>This model describes how Herpes Simplex Virus 1 (HSV-1) US3 protein kinase inhibits the host interferon regulatory factor 3 (IRF3) to suppress the host antiviral immune response. Specifically, it shows a mechanism where the US3 viral protein kinase hyperphosphorylates IRF3 to prevent its nuclear translocation, thereby inhibiting type I interferon production.</p> <p>The model consists of four main activities: 1. US3 protein kinase activity (HSV-1 protein) 2. IPO5 nuclear import signal receptor activity (host protein) 3. TBK1 protein serine/threonine kinase activity (host protein) 4. IRF3 DNA-binding transcription factor activity (host protein)</p>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The biological content of the model is consistent with recent literature. The model accurately represents:</p> <ol> <li>The US3 protein of HSV-1 as a serine/threonine kinase that can hyperphosphorylate IRF3 at Ser175 to prevent its activation</li> <li>The nuclear import process of IRF3 via IPO5</li> <li>The role of TBK1 in phosphorylating IRF3 at canonical sites like Ser386 to promote its activation</li> <li>The function of IRF3 as a transcription factor that binds to DNA in host chromatin to promote cytoplasmic pattern recognition receptor signaling</li> </ol> <p>The model correctly shows how the viral kinase US3 negatively regulates the host innate immune response by directly phosphorylating IRF3, which prevents its nuclear translocation and subsequent transcriptional activation of interferon genes.</p>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#go-cam-structure-assessment","title":"GO-CAM Structure Assessment","text":"<p>The structure of the model follows GO-CAM best practices regarding causal relationships and activity representations:</p> <ol> <li>Correct use of molecular function terms for each gene product</li> <li>Appropriate cellular location annotations for each activity</li> <li>Proper placement of activities within biological process contexts</li> <li>Appropriate use of causal relationships:</li> <li>US3 negatively regulates IPO5 via RO:0012010</li> <li>IPO5 positively regulates IRF3 via RO:0002629</li> <li>TBK1 regulates IRF3 via RO:0002413 (provides input for)</li> </ol>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#detailed-analysis-of-causal-relationships","title":"Detailed Analysis of Causal Relationships","text":"<ol> <li>US3 to IPO5 interaction (RO:0012010): </li> <li> <p>The model correctly represents that US3 kinase directly targets and negatively regulates IPO5's nuclear import signal receptor activity. This relationship is supported by evidence from PMID:24049179, which demonstrates that US3 hyperphosphorylates IRF3 to inhibit its nuclear import.</p> </li> <li> <p>TBK1 to IPO5 interaction (RO:0002413):</p> </li> <li> <p>The model shows TBK1 providing input for IPO5, which accurately reflects how TBK1-mediated phosphorylation of IRF3 is a prerequisite for its nuclear import via IPO5. This is supported by evidence from PMID:29441066.</p> </li> <li> <p>IPO5 to IRF3 interaction (RO:0002629):</p> </li> <li>IPO5 is shown to directly positively regulate IRF3 transcription factor activity, which correctly represents its role in transporting phosphorylated IRF3 into the nucleus. This is supported by evidence from PMID:31340999.</li> </ol>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes and references: - ECO:0000314 (direct assay evidence used in manual assertion) for most functional annotations - ECO:0000305 (curator inference used in manual assertion) for some annotations - All evidence is backed by relevant primary research papers (PMID:8524823, PMID:24049179, PMID:24807716, PMID:29441066)</p>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing Mechanistic Detail: </li> <li> <p>The model doesn't fully capture the mechanistic details of how US3 disrupts the IRF3-IPO5 interaction. According to PMID:31340999, US3 hyperphosphorylates IRF3 at Ser175, which is different from the canonical TBK1 phosphorylation sites. This differential phosphorylation disrupts the interaction between IRF3 and IPO5, preventing nuclear import. The model could be enhanced by explicitly representing this phosphorylation event.</p> </li> <li> <p>Incomplete Representation of Signaling Pathway: </p> </li> <li> <p>The model focuses specifically on the IRF3-IPO5 nuclear import process but doesn't include the upstream components of the antiviral signaling pathway (such as pathogen recognition receptors, MAVS, etc.) or the downstream components (IFN-\u03b2 gene expression). Including these would provide a more comprehensive view of how US3 interrupts the host antiviral response.</p> </li> <li> <p>Missing Complex Relationships: </p> </li> <li> <p>The model doesn't represent potential complexes that might be involved in this process, such as the TBK1-IRF3 complex that forms before IRF3 phosphorylation, or the IRF3-CBP/p300 complex that forms in the nucleus to activate transcription.</p> </li> <li> <p>Lack of Information on Other Viral Evasion Strategies: </p> </li> <li>While focusing on US3's role is appropriate, the model could benefit from contextualizing this within HSV-1's broader immune evasion strategies.</li> </ol>"},{"location":"reviews/62b4ffe300006001-HHV1_US3_inhibition_of_host_IRF3__Human_Herpesvirus__/#summary-and-recommendations","title":"Summary and Recommendations","text":"<p>Overall, this GO-CAM model (62b4ffe300006001) accurately represents the current scientific understanding of how HSV-1 US3 kinase inhibits the host antiviral response by targeting IRF3. The model uses appropriate GO terms, relationship types, and evidence codes, and is consistent with the literature.</p> <p>Recommendations for improvement:</p> <ol> <li> <p>Add specific annotation for the US3-mediated phosphorylation of IRF3 at Ser175, differentiating it from the canonical TBK1-mediated phosphorylation sites.</p> </li> <li> <p>Consider expanding the model to include more of the antiviral signaling pathway, particularly the downstream effects on IFN-\u03b2 gene expression.</p> </li> <li> <p>Explore the possibility of representing the TBK1-IRF3 and IRF3-CBP/p300 complexes that play critical roles in IRF3 activation and function.</p> </li> <li> <p>Add notes or references to other HSV-1 immune evasion strategies to contextualize US3's role.</p> </li> <li> <p>Consider adding temporal information about when these interactions occur during the viral life cycle.</p> </li> </ol> <p>Despite these suggestions for enhancement, the model in its current form is scientifically accurate, well-structured according to GO-CAM best practices, and represents a valuable contribution to our understanding of host-pathogen interactions in HSV-1 infection.</p>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/","title":"62b4ffe300006376 HHV1 UL37 inhibition of host RIG I signaling via RIG I deamidation  Human Herpesvirus","text":"<p>Now I'll review the GO-CAM model with ID gomodel:62b4ffe300006376.</p>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#go-cam-review-gomodel62b4ffe300006376","title":"GO-CAM Review: gomodel:62b4ffe300006376","text":""},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#model-overview","title":"Model Overview","text":"<p>Title: HHV1-UL37 inhibition of host RIG-I signaling via RIG-I deamidation (Human-Herpesvirus) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#model-description","title":"Model Description","text":"<p>This model describes how the Herpes Simplex Virus 1 (HHV-1) UL37 protein targets and inhibits the host RNA sensor protein RIG-I (encoded by UniProtKB:O95786) through deamidation, preventing RIG-I from recognizing viral RNA and thereby suppressing antiviral responses. The model shows the molecular activities, interactions and regulatory relationships between viral UL37, host RIG-I, TRIM25, and MAVS proteins.</p>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#model-components","title":"Model Components","text":""},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#activities-represented","title":"Activities represented:","text":"<ol> <li>RIG-I (UniProtKB:O95786) acts as a pattern recognition receptor</li> <li>TRIM25 (UniProtKB:Q14258) functions as an E3 ubiquitin ligase</li> <li>MAVS (UniProtKB:Q7Z434) functions as a signaling adaptor</li> <li>HHV-1 UL37 (UniProtKB:P10221) acts as a viral deamidase</li> </ol>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#regulatory-relationships","title":"Regulatory relationships:","text":"<ul> <li>RIG-I pattern recognition receptor activity positively regulates TRIM25 E3 ubiquitin ligase activity</li> <li>TRIM25 E3 ubiquitin ligase activity positively regulates MAVS signaling adaptor activity</li> <li>HHV-1 UL37 deamidase activity negatively regulates RIG-I pattern recognition receptor activity</li> </ul>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#biological-accuracy","title":"Biological Accuracy:","text":"<p>The model accurately represents the scientific understanding of how HHV-1 UL37 inhibits the RIG-I signaling pathway. Based on the literature reviewed:</p> <ol> <li> <p>RIG-I function and pathway: The model correctly shows RIG-I (O95786) as a pattern recognition receptor that occurs in the cytoplasm (GO:0005737) and is part of the cytoplasmic pattern recognition receptor signaling pathway (GO:0002753). This is supported by the literature (PMID:19576794).</p> </li> <li> <p>RIG-I regulation by TRIM25: The model correctly shows that RIG-I positively regulates TRIM25 ubiquitin ligase activity, which is essential for RIG-I-mediated antiviral responses. The literature (PMID:17392790) confirms that TRIM25 interacts with RIG-I and is required for RIG-I activation.</p> </li> <li> <p>MAVS role: The model correctly represents MAVS (Q7Z434) as a signaling adaptor that is positively regulated by TRIM25 and is part of the cytoplasmic pattern recognition receptor signaling pathway. This is supported by PMID:16125763.</p> </li> <li> <p>HHV-1 UL37 inhibition of RIG-I: The critical viral evasion mechanism is accurately represented, showing that UL37 protein (P10221) has protein-glutamine glutaminase activity (GO:0050568) that occurs in the host cytoplasm (GO:0030430). The literature (PMID:27866900) confirms that UL37 acts as a deamidase that targets RIG-I to block RNA-induced activation by deamidating specific asparagine residues in the RIG-I helicase domain.</p> </li> </ol>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#go-cam-structure-and-completeness","title":"GO-CAM Structure and Completeness:","text":"<ol> <li>Appropriate causal relationships: The model correctly uses the following relationship predicates:</li> <li>RO:0002629 (directly positively regulates) for RIG-I's effect on TRIM25</li> <li>RO:0002629 (directly positively regulates) for TRIM25's effect on MAVS</li> <li> <p>RO:0002630 (directly negatively regulates) for UL37's effect on RIG-I</p> </li> <li> <p>Appropriate cellular locations: All proteins are annotated with their correct cellular locations:</p> </li> <li>RIG-I in cytoplasm (GO:0005737)</li> <li>TRIM25 in cytoplasm (GO:0005737)</li> <li>MAVS in mitochondrial membrane (GO:0031966)</li> <li> <p>UL37 in host cell cytoplasm (GO:0030430)</p> </li> <li> <p>Appropriate molecular functions: The activities are properly represented:</p> </li> <li>RIG-I: pattern recognition receptor activity (GO:0038187)</li> <li>TRIM25: ubiquitin protein ligase activity (GO:0061630)</li> <li>MAVS: signaling adaptor activity (GO:0035591)</li> <li> <p>UL37: protein-glutamine glutaminase activity (GO:0050568)</p> </li> <li> <p>Appropriate biological processes: All activities are linked to the correct biological processes:</p> </li> <li>RIG-I, TRIM25, and MAVS are part of cytoplasmic pattern recognition receptor signaling pathway (GO:0002753)</li> <li>UL37 is part of symbiont-mediated suppression of cytoplasmic pattern recognition receptor signaling pathway (GO:0039537)</li> </ol>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#conformance-to-go-cam-standards","title":"Conformance to GO-CAM Standards:","text":"<ol> <li> <p>Evidence codes: All associations are supported with appropriate evidence codes (ECO:0000314 direct assay evidence) and reference to primary literature.</p> </li> <li> <p>Complex representation: The model appropriately represents the activities of individual proteins rather than representing them as a complex, which is in line with the \"How to annotate complexes in GO-CAM\" document guidelines, since the specific activities of the individual proteins are known.</p> </li> </ol>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#suggested-improvements","title":"Suggested Improvements","text":"<p>While the model is scientifically accurate and well-structured, there are a few potential enhancements:</p> <ol> <li> <p>Additional molecular detail: The model could be expanded to include the specific mechanism of UL37-mediated deamidation of RIG-I. According to PMID:27866900, UL37 specifically deamidates asparagine residues N495 and N549 in the helicase domain of RIG-I. This specific targeting prevents RIG-I from recognizing viral dsRNA.</p> </li> <li> <p>Downstream consequences: The model could include the downstream effects of inhibiting RIG-I signaling, such as reduced type I interferon production, which is a key outcome of this viral evasion mechanism.</p> </li> <li> <p>Protein domains: Adding information about the specific domains involved in the interactions (e.g., RIG-I CARD domain interaction with TRIM25 SPRY domain) could provide additional molecular detail.</p> </li> </ol>"},{"location":"reviews/62b4ffe300006376-HHV1_UL37_inhibition_of_host_RIG_I_signaling_via_RIG_I_deamidation__Human_Herpesvirus__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62b4ffe300006376 is a high-quality representation of the HHV-1 UL37-mediated inhibition of RIG-I signaling. It accurately captures the scientific knowledge about this viral evasion mechanism, uses appropriate GO terms and relationship predicates, and follows GO-CAM best practices.</p> <p>The model correctly represents how HHV-1 UL37 acts as a viral deamidase that negatively regulates RIG-I pattern recognition receptor activity, thereby disrupting the host's ability to detect viral RNA and mount an antiviral response. The regulatory relationships between RIG-I, TRIM25, and MAVS are also accurately captured, providing a complete picture of this pathway and how it is targeted by the virus.</p> <p>The model would benefit from minor enhancements to include more specific molecular details about the deamidation mechanism and its downstream consequences, but overall it is a scientifically accurate and well-structured GO-CAM model.</p>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/","title":"62b4ffe300006474 B cell receptor signaling pathway 1  Mouse","text":"<p>Now I'll look at the Shc1/Grb2/Sos complex documentation in GO-CAM to understand best practices regarding this specific complex.</p> <p>Now that I have reviewed the model and relevant information, I'll provide a review of GO-CAM model gomodel:62b4ffe300006474 (B cell receptor signaling pathway 1 in Mouse).</p>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#review-of-go-cam-model-62b4ffe300006474-b-cell-receptor-signaling-pathway-1-mouse","title":"Review of GO-CAM Model 62b4ffe300006474: B cell receptor signaling pathway 1 (Mouse)","text":""},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#overview","title":"Overview","text":"<p>This model represents the B cell receptor (BCR) signaling pathway in mouse, focusing on the molecular interactions involving Shc1, Grb2, Sos1/2, and Syk proteins. The model describes a key signaling cascade that connects BCR activation to the Ras pathway. </p>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#model-structure-assessment","title":"Model Structure Assessment","text":"<p>The model contains 7 activities: 1. Sos1 - guanyl-nucleotide exchange factor activity (GO:0005085) 2. Grb2 - guanyl-nucleotide exchange factor adaptor activity (GO:0005091)  3. PR:P98083-2 (Shc1/p52Shc) - protein-macromolecule adaptor activity (GO:0030674) 4. Syk - protein tyrosine kinase activity (GO:0004713) 5. Cd79a - transmembrane signaling receptor activity (GO:0004888) 6. Cd79b - transmembrane signaling receptor activity (GO:0004888) 7. Sos2 - guanyl-nucleotide exchange factor activity (GO:0005085)</p> <p>All activities are part of the B cell receptor signaling pathway (GO:0050853), which is appropriate.</p>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes these causal relationships: - Syk \u2192 Shc1 (RO:0002629, directly positively regulates) - Shc1 \u2192 Grb2 (RO:0002629, directly positively regulates) - Grb2 \u2192 Sos1 (RO:0002629, directly positively regulates) - Grb2 \u2192 Sos2 (RO:0002629, directly positively regulates)</p> <p>These relationships accurately depict the directional flow of signaling in the BCR pathway based on the literature, where Syk phosphorylates Shc1, which recruits Grb2, which in turn recruits Sos1/2.</p>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model includes good evidence support: - Syk's role is supported by experimental evidence (ECO:0000314, direct assay evidence) from PMID:9199344 - Shc1's role is supported by the same direct assay evidence - Grb2's role is also supported by direct assay evidence from PMID:9199344 - Sos1's role is supported by sequence orthology evidence (ECO:0000266) from PMID:11333268 and mutant phenotype evidence (ECO:0000315) from PMID:29844066 - Sos2's role lacks specific evidence annotation - The CD79a/b roles are supported by direct assay evidence from PMID:8626447</p>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate molecular pathway representation: The model correctly captures the key steps in the B cell receptor signaling pathway, showing how signals from the BCR are transmitted to activate the Ras pathway.</p> </li> <li> <p>Appropriate evidence: Most activities are backed by experimental evidence from relevant publications.</p> </li> <li> <p>Correct protein roles: The model accurately represents the roles of each protein, particularly the adaptor functions of Shc1 and Grb2, and the catalytic activity of Sos1/2.</p> </li> <li> <p>Use of protein isoforms: The model specifically uses the p52Shc isoform of Shc1 (PR:P98083-2), which is known to be important in this signaling context according to PMID:9199344.</p> </li> </ol>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement","text":"<ol> <li> <p>Sos2 evidence: The Sos2 activity lacks specific evidence annotation. Based on the PMID:29844066 paper, there's evidence for functional redundancy between Sos1 and Sos2, which should be added as evidence.</p> </li> <li> <p>Missing CD79a/b connection: While CD79a and CD79b are included in the model, they lack causal connections to Syk. Based on literature, CD79a/b are phosphorylated after BCR cross-linking, creating docking sites for Syk. This causal relationship should be added.</p> </li> <li> <p>Missing BCR complex: The model doesn't explicitly show how the BCR itself connects to CD79a/b. Including a representation of the BCR complex would make the initiation of signaling clearer.</p> </li> <li> <p>Complex representation: According to the GO-CAM complex annotation guidelines, when the subunit carrying the molecular activity is known (as in this case), each protein should be represented separately with their specific activity. This is done correctly here. However, it might be useful to note that Shc1-Grb2-Sos forms a multiprotein complex, perhaps as a comment.</p> </li> <li> <p>Ras activation: The model doesn't show the ultimate target of Sos1/2, which is Ras activation. Adding this downstream event would complete the signaling cascade.</p> </li> </ol>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#biological-consistency","title":"Biological Consistency","text":"<p>The model is consistent with the known biology of BCR signaling:</p> <ol> <li> <p>As shown in PMID:9199344, BCR stimulation leads to Syk-dependent phosphorylation of Shc1, creating binding sites for Grb2, which then recruits Sos1/2 to activate Ras.</p> </li> <li> <p>The model correctly represents the role of p52Shc (PR:P98083-2) which contains the two phosphorylation sites (Y239 and Y313) that serve as binding sites for Grb2 according to the literature.</p> </li> <li> <p>The inclusion of both Sos1 and Sos2 reflects their functional redundancy in mouse, as demonstrated in the PMID:29844066 paper.</p> </li> </ol>"},{"location":"reviews/62b4ffe300006474-B_cell_receptor_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:62b4ffe300006474) accurately represents a critical signaling pathway in B cell receptor activation. It correctly depicts the roles of key proteins and their causal relationships, with appropriate evidence support. The model could be enhanced by adding the missing causal connections for CD79a/b to Syk and by showing the downstream activation of Ras. Overall, the model is biologically sound and follows GO-CAM annotation best practices.</p>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/","title":"62b4ffe300006559 Insulin receptor signaling pathway 2  Mouse","text":"<p>Based on my review of the GO-CAM model and the relevant research, I'll now provide a comprehensive analysis of the insulin receptor signaling pathway 2 (Mouse) model.</p>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#review-of-go-cam-model-insulin-receptor-signaling-pathway-2-mouse","title":"Review of GO-CAM Model: Insulin Receptor Signaling Pathway 2 (Mouse)","text":""},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#model-overview","title":"Model Overview","text":"<p>The model gomodel:62b4ffe300006559 titled \"Insulin receptor signaling pathway 2 (Mouse)\" represents the insulin signaling pathway in mouse cells (NCBITaxon:10090). According to the model comments, it was sourced from Reactome pathways R-HSA-74751 and R-HSA-74752.</p>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model represents the insulin receptor signaling pathway, depicting:</p> <ul> <li>Insulin binding to its receptor</li> <li>Receptor activation</li> <li>IRS-1/2 (Insulin Receptor Substrate) adaptor protein signaling</li> <li>PI3K pathway activation</li> <li>PDK1 and Akt activation</li> <li>Downstream signaling effects</li> </ul> <p>The model includes 9 primary activities represented by molecular function associations and their connections via causal associations:</p> <ol> <li>Insulin ligand activity (receptor ligand activity)</li> <li>Insulin receptor activity</li> <li>Protein tyrosine kinase activity of insulin receptor</li> <li>Protein-macromolecule adaptor activity of IRS proteins</li> <li>Molecular adaptor activity of IRS2</li> <li>Kinase activator activity of PIK3R1</li> <li>1-phosphatidylinositol-3-kinase activity of PIK3CA</li> <li>3-phosphoinositide-dependent protein kinase activity of PDPK1</li> <li>Kinase activity of AKT1</li> </ol>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#entities-and-gene-products-in-the-model","title":"Entities and Gene Products in the Model","text":"<p>The model includes the following key gene products:</p> <ul> <li>MGI:MGI:96572 (Ins1) and MGI:MGI:96573 (Ins2) - Mouse insulin</li> <li>MGI:MGI:96575 (Insr) - Insulin receptor</li> <li>MGI:MGI:99454 (Irs1) - Insulin receptor substrate 1</li> <li>MGI:MGI:109334 (Irs2) - Insulin receptor substrate 2</li> <li>MGI:MGI:97583 (Pik3r1) - Phosphatidylinositol 3-kinase regulatory subunit alpha</li> <li>MGI:MGI:1206581 (Pik3ca) - Phosphatidylinositol 3-kinase catalytic subunit alpha</li> <li>MGI:MGI:1338068 (Pdpk1) - 3-phosphoinositide-dependent protein kinase 1</li> <li>MGI:MGI:87986 (Akt1) - RAC-alpha serine/threonine-protein kinase</li> </ul>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#evidence-and-references","title":"Evidence and References","text":"<p>The model is supported by multiple types of evidence including: - Experimental evidence from direct assays (ECO:0000314) - Mutant phenotype evidence (ECO:0000315) - Genetic interaction evidence (ECO:0000316) - Sequence orthology evidence (ECO:0000266)</p> <p>Key references include several publications (PMID:29512653, PMID:23886629, PMID:19047061, among others) that describe the insulin signaling pathway components and their interactions.</p>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":""},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#1-representation-of-signaling-receptor-activity","title":"1. Representation of Signaling Receptor Activity","text":"<p>The insulin signaling pathway model follows the guidelines from the \"Signaling receptor activity annotation guidelines\" document:</p> <ul> <li>Ligand representation: The model correctly represents both Ins1 and Ins2 as enabling receptor ligand activity (GO:0048018)</li> <li>Causal relation: The model correctly uses \"directly positively regulates\" (RO:0002629) as the causal relation between insulin ligand activity and insulin receptor activity</li> <li>Receptor activity: The model correctly shows the insulin receptor enabling signaling receptor activity (GO:0005009)</li> </ul>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#2-use-of-molecular-adaptors","title":"2. Use of Molecular Adaptors","text":"<p>I verified that IRS1 and IRS2 are properly represented as molecular adaptors in the model, following the \"How to annotate molecular adaptors\" guidelines:</p> <ul> <li>Both IRS1 and IRS2 have \"protein-macromolecule adaptor activity\" (GO:0030674)</li> <li>The proper causal relations are used to connect these adaptors to downstream events</li> <li>The model correctly shows IRS1/2 bringing together the insulin receptor and downstream signaling components</li> </ul>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#3-pathway-coherence","title":"3. Pathway Coherence","text":"<p>The model demonstrates a coherent pathway from insulin binding to downstream effects: 1. Insulin binds to insulin receptor 2. Insulin receptor activates via tyrosine kinase activity 3. Activated receptor signals through adaptors IRS1/2 4. PI3K activation occurs (Pik3r1 and Pik3ca) 5. PDK1 (Pdpk1) is activated 6. Akt1 is activated</p> <p>The flow of activities and causal connections is consistent with current understanding of the insulin signaling pathway.</p>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the core components of the insulin signaling pathway as described in the literature:</p> <ol> <li> <p>Insulin-receptor binding: Aligns with the structure shown in PMID:29512653, which details the insulin receptor-insulin complex and activation mechanism.</p> </li> <li> <p>IRS protein function: Correctly shows IRS1/2 proteins as adaptors that enable downstream signaling after receptor activation, consistent with published data.</p> </li> <li> <p>PI3K-PDK1-Akt signaling: The model correctly represents this canonical pathway where PI3K activates PDK1, which then activates Akt. This is consistent with both PMID:19047061 and PMID:23886629.</p> </li> <li> <p>Biological process context: All activities are appropriately shown as part of the insulin receptor signaling pathway (GO:0008286).</p> </li> </ol>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, there are a few potential areas for improvement:</p> <ol> <li>Complete signaling cascade: The model could be extended to include:</li> <li>GSK3 phosphorylation and inhibition by Akt</li> <li>FOXO transcription factor regulation</li> <li>mTOR signaling pathway connections</li> <li> <p>Glucose transporter (GLUT4) translocation</p> </li> <li> <p>Feedback mechanisms: The model could include negative feedback loops that regulate insulin signaling, such as:</p> </li> <li>S6K-mediated negative feedback on IRS1</li> <li> <p>Phosphatases that dephosphorylate key signaling components</p> </li> <li> <p>Crosstalk with other pathways: The model could include connections to:</p> </li> <li>MAPK pathway</li> <li> <p>Stress response pathways that modulate insulin signaling</p> </li> <li> <p>Additional regulatory components: The model could include:</p> </li> <li>SOCS proteins that regulate insulin signaling</li> <li>Other adaptor proteins like SHC</li> <li> <p>PTP1B phosphatase that dephosphorylates the insulin receptor</p> </li> <li> <p>Subcellular location: While not strictly required, cellular component annotations could be added to provide context about where these processes occur.</p> </li> </ol>"},{"location":"reviews/62b4ffe300006559-Insulin_receptor_signaling_pathway_2__Mouse__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62b4ffe300006559 provides a scientifically accurate representation of the core insulin receptor signaling pathway in mouse. The model follows GO-CAM best practices for representing signaling receptor activity and molecular adaptors.</p> <p>The model has strong evidential support from both experimental data and published literature. All components are appropriately linked through causal relations that reflect their biological relationships.</p> <p>While the model could be expanded to include more regulatory components and connections to other pathways, it successfully captures the central elements of insulin receptor signaling and serves as a valuable resource for understanding this critical pathway.</p>"},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/","title":"62d0afa500000132 Gluconeogenesis 2  Mouse","text":"<p>Now I'll provide a comprehensive review of the GO-CAM model \"Gluconeogenesis 2 (Mouse)\" (gomodel:62d0afa500000132).</p>"},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/#go-cam-review-gluconeogenesis-2-mouse-gomodel62d0afa500000132","title":"GO-CAM Review: Gluconeogenesis 2 (Mouse) (gomodel:62d0afa500000132)","text":""},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the mouse gluconeogenesis pathway, showing the enzymatic steps involved in the synthesis of glucose from non-carbohydrate precursors. The model includes 14 activities performed by different mouse gene products, with appropriate subcellular localizations and causal relationships following the metabolic flow of the pathway.</p>"},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures all major enzymatic steps of gluconeogenesis, including both mitochondrial and cytosolic phases of the pathway.</p> </li> <li> <p>Proper causal connections: The activities are correctly connected via \"provides input for\" (RO:0002413) relationships that accurately follow the substrate flow through the pathway.</p> </li> <li> <p>Appropriate subcellular localization: Activities are correctly localized to relevant cellular compartments (cytosol, ER, mitochondria), which is essential for representing gluconeogenesis properly.</p> </li> <li> <p>Evidence quality: Each activity is supported by specific evidence in the form of PMIDs, with appropriate evidence codes (ECO:0000314 - direct assay, ECO:0000315 - mutant phenotype, etc.).</p> </li> <li> <p>Taxonomic specificity: The model appropriately represents the mouse (MGI) proteins, providing a species-specific representation of gluconeogenesis.</p> </li> </ol>"},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Incomplete causal chain: There is a missing causal link between phosphoenolpyruvate carboxykinase (Pck2, gomodel:62d0afa500000132/62d0afa500000206) and enolase (Eno1, gomodel:62d0afa500000132/62d0afa500000148). This breaks the continuity of the pathway flow.</p> </li> <li> <p>Branching missing for G6pc3: While both G6pc1 and G6pc3 (glucose-6-phosphatase isoforms) are represented in the model, G6pc3 (gomodel:62d0afa500000132/62f58d8800003972) lacks outgoing causal connections, making its role in the pathway unclear. It should either connect to the next step or be noted as an endpoint.</p> </li> <li> <p>Regulatory elements: The model focuses on the catalytic flow of gluconeogenesis but does not include regulatory elements that control the pathway. Including key regulatory interactions (e.g., glucagon or insulin signaling) would enhance the biological completeness.</p> </li> <li> <p>Substrate visualization: While the causal flow is represented correctly, the model doesn't explicitly show the substrate transformations. Adding annotations about the metabolites being processed at each step would improve clarity.</p> </li> <li> <p>Tissue context: Gluconeogenesis predominantly occurs in the liver and kidney in mammals. Adding tissue context information would enhance the biological relevance of the model.</p> </li> </ol>"},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/#scientific-validity","title":"Scientific Validity","text":"<p>The literature evidence provided in the model supports the represented activities:</p> <ol> <li> <p>The UniProt entry for G6pc1 (P35576) confirms its role in glucose-6-phosphate hydrolysis in the ER, consistent with its representation in the model.</p> </li> <li> <p>The reference PMID:24958256 confirms the importance of gluconeogenesis in metabolic regulation and mentions several of the enzymes included in the model.</p> </li> <li> <p>The subcellular localizations are consistent with known biology - mitochondrial enzymes (Pcx, Pck2) are correctly placed in the mitochondrial matrix, while cytosolic enzymes are in the cytosol.</p> </li> </ol>"},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/#pathway-logic-and-flow","title":"Pathway Logic and Flow","text":"<p>The overall flow of gluconeogenesis is correctly represented:</p> <ol> <li> <p>Mitochondrial initiation: Starting with pyruvate carboxylase (Pcx) converting pyruvate to oxaloacetate in the mitochondria.</p> </li> <li> <p>Mitochondrial to cytosolic transition: Phosphoenolpyruvate carboxykinase (Pck2) converting oxaloacetate to phosphoenolpyruvate.</p> </li> <li> <p>Cytosolic reversed glycolysis: The cytosolic enzymes (Eno1 \u2192 Pgam1 \u2192 Pgk1 \u2192 Gapdh \u2192 Tpi1 \u2192 Aldoc) performing essentially glycolysis in reverse.</p> </li> <li> <p>Final glucose production steps: The final steps (Fbp1 \u2192 Gpi1 \u2192 G6pc1/G6pc3 and Slc37a4) correctly represent the production and transport of glucose.</p> </li> </ol>"},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add missing causal link: Connect Pck2 to Eno1 to complete the pathway flow.</p> </li> <li> <p>Clarify G6pc3 role: Either connect G6pc3 to downstream processes or annotate it as an endpoint with notes on its specific role.</p> </li> <li> <p>Include regulation: Add key regulatory interactions, such as how insulin inhibits gluconeogenesis or how glucagon activates it.</p> </li> <li> <p>Add tissue context: Specify the tissue context (liver/kidney) where this pathway predominantly functions.</p> </li> <li> <p>Consider adding complexes: Some enzymes may function as complexes; using GO guidelines for complex representation would enhance model accuracy.</p> </li> <li> <p>Substrate annotation: Consider adding annotations about the intermediates being processed at each enzymatic step for increased clarity.</p> </li> </ol>"},{"location":"reviews/62d0afa500000132-Gluconeogenesis_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model provides a good representation of the gluconeogenesis pathway in mouse, with appropriate gene products, subcellular localizations, and mostly correct causal flow. The model strongly adheres to GO-CAM best practices but would benefit from addressing the gaps in causal connections and adding regulatory elements. With these improvements, the model would provide a more complete picture of gluconeogenesis and its regulation in the mouse.</p>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/","title":"62d0afa500000298 Gluconeogenesis 3  Mouse","text":"<p>Now, let me review this GO-CAM model based on GO-CAM curation best practices. I'll check various aspects of the model including its biological content, connections, and adherence to GO-CAM standards.</p>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#review-of-go-cam-model-gomodel62d0afa500000298","title":"Review of GO-CAM Model: gomodel:62d0afa500000298","text":""},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#basic-information","title":"Basic Information","text":"<ul> <li>Title: Gluconeogenesis 3 (Mouse)</li> <li>ID: gomodel:62d0afa500000298</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Comments: Sourced from gomodel:R-HSA-70263</li> </ul>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#overview","title":"Overview","text":"<p>This model represents the gluconeogenesis pathway in mouse. Gluconeogenesis is the metabolic process of generating glucose from non-carbohydrate carbon substrates such as pyruvate, lactate, glycerol, and glucogenic amino acids.</p>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model correctly captures the key enzymes involved in gluconeogenesis: - Pyruvate carboxylase (PCX) - Phosphoenolpyruvate carboxykinase (PCK1) - Glucose-6-phosphatase (G6PC1 and G6PC3) - Other enzymes in the pathway: ENO1, PGAM1, PGK1, GAPDH, TPI1, ALDOC, FBP1, GPI1 - Relevant transporters: SLC37A4, SLC25A13, SLC25A12, SLC25A11</p> <p>The model accurately localizes these enzymes to their appropriate subcellular locations: - Mitochondrial proteins in the mitochondrial matrix or inner membrane - ER-associated proteins like G6PC1 and SLC37A4 in the ER - Cytosolic enzymes in the cytosol</p>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#causal-connectivity-assessment","title":"Causal Connectivity Assessment","text":"<p>The model uses the correct causal relationship (<code>RO:0002413</code> - \"provides input for\") to connect the enzymatic activities in the gluconeogenesis pathway. The flow of reactions follows the expected pattern of the metabolic pathway:</p> <ol> <li>PCX \u2192 GOT2 \u2192 (transporters SLC25A13/SLC25A12/SLC25A11) \u2192 GOT1</li> <li>GOT1 \u2192 PCK1 \u2192 ENO1 \u2192 PGAM1 \u2192 PGK1 \u2192 GAPDH \u2192 TPI1/ALDOC \u2192 FBP1 \u2192 GPI1 \u2192 SLC37A4 \u2192 G6PC1/G6PC3</li> </ol> <p>This correctly represents the conversion of pyruvate to glucose through the gluconeogenesis pathway.</p>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model has appropriate evidence for most assertions: - Most activities have evidence codes ECO:0000314 (direct assay evidence) or ECO:0000315 (mutant phenotype evidence) - All assertions include PMID references - Appropriate use of with/from fields for some evidence types</p>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>Comprehensive representation of the gluconeogenesis pathway</li> <li>Correct subcellular localization of enzymes</li> <li>Good use of evidence codes and references</li> <li>Proper causal connections showing the flow of the pathway</li> <li>Inclusion of relevant transporters necessary for shuttle mechanisms</li> </ol>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#issuessuggestions-for-improvement","title":"Issues/Suggestions for Improvement","text":"<ol> <li> <p>Missing Evidence: Some subcellular locations are missing evidence annotations (e.g., for ENO1, PGAM1, FBP1 in cytosol). While these are well-established localizations, they should ideally have evidence and references.</p> </li> <li> <p>Incomplete \"part of\" Evidence: Some activities have evidence for molecular function but are missing evidence for the \"part_of\" relationship to gluconeogenesis (GO:0006094). For example, SLC25A12's participation in gluconeogenesis lacks evidence.</p> </li> <li> <p>Missing Evidence for Causal Relations: None of the causal relationships (RO:0002413) have evidence annotations. Best practice would be to provide evidence for why one activity provides input for another.</p> </li> <li> <p>Complex Considerations: The model represents individual gene products rather than the complexes they may form. For example, some enzymes like pyruvate carboxylase can function as multimers. Consider checking if any of these enzymes should be represented as complexes according to GO-CAM complex annotation guidelines.</p> </li> <li> <p>Redundancy Check: There are two glucose-6-phosphatase activities (G6PC1 and G6PC3) represented. While both are valid, it would be helpful to ensure their distinct roles are clear or if one is more relevant in the specific tissue context.</p> </li> </ol>"},{"location":"reviews/62d0afa500000298-Gluconeogenesis_3__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li>Add missing evidence annotations for subcellular locations and \"part_of\" relationships.</li> <li>Add evidence for causal relationships between activities.</li> <li>Consider consulting the \"How to annotate complexes in GO-CAM\" document to check if any of these enzymes should be represented as complexes.</li> <li>Ensure that all transporter activities have clear evidence for their role in gluconeogenesis.</li> <li>Review the model for parsimony - ensure there's no redundancy or unnecessary steps that could be simplified.</li> </ol> <p>Overall, this is a well-constructed GO-CAM model that accurately represents the gluconeogenesis pathway in mouse. With the minor improvements suggested, it would fully align with GO-CAM best practices.</p>"},{"location":"reviews/62d0afa500000472-Insulin_receptor_signalling_pathway_3__Mouse_/","title":"62d0afa500000472 Insulin receptor signalling pathway 3  Mouse","text":"<p>Now that I have gathered all the necessary information, I'll review the GO-CAM model gomodel:62d0afa500000472 \"Insulin receptor signalling pathway 3 (Mouse)\".</p>"},{"location":"reviews/62d0afa500000472-Insulin_receptor_signalling_pathway_3__Mouse_/#review-of-go-cam-model-insulin-receptor-signalling-pathway-3-mouse","title":"Review of GO-CAM Model: Insulin receptor signalling pathway 3 (Mouse)","text":""},{"location":"reviews/62d0afa500000472-Insulin_receptor_signalling_pathway_3__Mouse_/#model-overview","title":"Model Overview","text":"<p>The model represents the insulin receptor signaling pathway in mouse (NCBITaxon:10090). It includes 10 activities encompassing: - Insulin ligands (Ins1 and Ins2) - Insulin receptor (Insr) - Adaptor proteins (Irs1, Irs2) - Signal transduction components (Grb2, Sos1, Sos2, Hras)</p>"},{"location":"reviews/62d0afa500000472-Insulin_receptor_signalling_pathway_3__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<ol> <li>Pathway Representation:</li> <li>The model correctly captures the key components of insulin receptor signaling</li> <li>The pathway starts with insulin ligands (Ins1, Ins2) activating the insulin receptor (Insr)</li> <li>The activated receptor engages in tyrosine kinase activity and signals through adaptor proteins (Irs1, Irs2)</li> <li> <p>This leads to activation of the Ras-MAPK pathway via Grb2, Sos1/Sos2, and Hras</p> </li> <li> <p>Causal Flow:</p> </li> <li>The causal associations using RO:0002629 (directly positively regulates) are appropriate for this signaling pathway</li> <li> <p>The flow is logical and consistent with known insulin signaling:</p> <ul> <li>Insulin ligands \u2192 Insulin receptor \u2192 Receptor tyrosine kinase activity \u2192 Adaptor proteins \u2192 Downstream signaling components</li> </ul> </li> <li> <p>Evidence:</p> </li> <li>Most activities and causal associations are supported by primary literature references (e.g., PMID:8649419, PMID:8448209, PMID:23886629)</li> <li>Evidence codes are appropriate (e.g., ECO:0000314 for direct assay evidence, ECO:0000315 for mutant phenotype evidence)</li> </ol>"},{"location":"reviews/62d0afa500000472-Insulin_receptor_signalling_pathway_3__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li>Signaling Receptor Annotation Guidelines:</li> <li>The model correctly represents insulin (Ins1, Ins2) with receptor ligand activity (GO:0048018)</li> <li>The insulin receptor (Insr) is properly annotated with insulin receptor activity (GO:0005009)</li> <li>The causal relationship between ligand and receptor is correctly modeled using the \"directly positively regulates\" predicate</li> <li> <p>The tyrosine kinase activity of the receptor is appropriately represented as the next step in the pathway</p> </li> <li> <p>Molecular Adaptor Annotation:</p> </li> <li>Grb2 is correctly annotated with guanyl-nucleotide exchange factor adaptor activity (GO:0005091)</li> <li>The adaptor proteins Irs1 and Irs2 are correctly annotated with transmembrane receptor protein tyrosine kinase adaptor activity (GO:0005068)</li> <li> <p>The causal relationships between activities are properly modeled</p> </li> <li> <p>Activity Connections:</p> </li> <li>All activities are properly connected with causal relationships that follow the expected biological progression</li> <li>The insulin receptor signaling pathway process (GO:0008286) provides the unifying biological context for all activities</li> </ol>"},{"location":"reviews/62d0afa500000472-Insulin_receptor_signalling_pathway_3__Mouse_/#issuesconcerns","title":"Issues/Concerns","text":"<p>I've identified a few potential issues in the model:</p> <ol> <li>Missing Cellular Component Annotations:</li> <li>Unlike the comparison model (gomodel:62b4ffe300004795), this model lacks cellular component annotations (e.g., plasma membrane for insulin receptor, extracellular space for insulin)</li> <li> <p>According to best practices, cellular component annotations help specify where activities occur</p> </li> <li> <p>Evidence Missing for Some Causal Associations:</p> </li> <li> <p>Some causal associations lack evidence annotations, particularly:</p> <ul> <li>The connection between Insr protein tyrosine kinase activity (62d0afa500000608) and Irs1 adaptor activity (62d0afa500000610)</li> <li>The connection between Irs2 adaptor activity (62d0afa500000616) and Grb2 adaptor activity (62d0afa500000612)</li> </ul> </li> <li> <p>Downstream Signaling Pathway:</p> </li> <li>Compared to the example model (62b4ffe300004795), this model stops at Hras/protein-membrane adaptor activity and doesn't include the downstream MAP kinase cascade (MAPK1, MAPK3)</li> <li> <p>However, this may be intentional as the focus might be on the initial steps of insulin signaling</p> </li> <li> <p>Limited Biochemical Depth:</p> </li> <li>The model would benefit from additional annotations related to the specific interactions between components</li> <li>Some of the molecular details of insulin receptor autophosphorylation and adaptor protein binding are not explicitly represented</li> </ol>"},{"location":"reviews/62d0afa500000472-Insulin_receptor_signalling_pathway_3__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed model that accurately represents the insulin receptor signaling pathway in mouse. It follows most GO-CAM best practices for signaling pathway annotation, with proper use of molecular functions, biological processes, and causal relationships.</p> <p>Strengths: - Correctly represents insulin receptor signaling components and their relationships - Uses appropriate molecular function terms and causal associations - Well-supported by primary literature evidence</p> <p>Recommendations for improvement: 1. Add cellular component annotations for relevant activities (e.g., plasma membrane for receptor, extracellular space for ligands) 2. Provide evidence for all causal associations 3. Consider extending the model to include downstream signaling components (MAP kinase cascade) 4. Add annotations to capture more details of molecular interactions where relevant</p> <p>The model is consistent with biological knowledge about insulin receptor signaling and follows the GO-CAM best practices, making it a valid representation of this important signaling pathway.</p>"},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/","title":"62d0afa500001077 Insulin like growth factor receptor signaling pathway 1  Mouse","text":"<p>Based on my analysis of the GO-CAM model \"gomodel:62d0afa500001077\" (Insulin-like growth factor receptor signaling pathway 1 for Mouse) and the relevant documentation, I'll now provide a comprehensive review.</p>"},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#review-of-go-cam-model-62d0afa500001077-insulin-like-growth-factor-receptor-signaling-pathway-1-mouse","title":"Review of GO-CAM Model: 62d0afa500001077 (Insulin-like growth factor receptor signaling pathway 1 - Mouse)","text":""},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#overview","title":"Overview","text":"<p>This model represents the insulin-like growth factor receptor (IGF1R) signaling pathway in mouse, sourced from human pathway models (gomodel:R-HSA-2404192 and gomodel:R-HSA-2428933). It illustrates the key molecular components and interactions in the IGF1R signaling cascade.</p>"},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#biological-content-analysis","title":"Biological Content Analysis","text":""},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#pathway-components-and-flow","title":"Pathway Components and Flow","text":"<p>The model correctly captures the core components of the IGF1R signaling pathway:</p> <ol> <li>Ligand-Receptor Interaction:</li> <li>IGF1 (Igf1) provides receptor ligand activity (GO:0048018)</li> <li>This directly positively regulates IGF1R (Igf1r) receptor activity (GO:0005010)</li> <li> <p>The receptor binding involves ATP as input and ADP as output, correctly modeling the kinase activity</p> </li> <li> <p>Receptor Tyrosine Kinase Activity:</p> </li> <li>IGF1R (Igf1r) has protein tyrosine kinase activity (GO:0004713)</li> <li> <p>This directly positively regulates the adaptor protein SHC1 (Shc1)</p> </li> <li> <p>Adaptor Protein Recruitment and Function:</p> </li> <li>SHC1 (Shc1) has transmembrane receptor protein tyrosine kinase adaptor activity (GO:0005068)</li> <li>SHC1 directly positively regulates GRB2 (Grb2)</li> <li>GRB2 (Grb2) has guanyl-nucleotide exchange factor adaptor activity (GO:0005091)</li> <li> <p>GRB2 directly positively regulates SOS1 (Sos1)</p> </li> <li> <p>GEF Activity and RAS Activation:</p> </li> <li>SOS1 (Sos1) has guanyl-nucleotide exchange factor activity (GO:0005085)</li> <li>SOS1 directly positively regulates HRAS (Hras)</li> <li> <p>HRAS (Hras) has protein-membrane adaptor activity (GO:0043495)</p> </li> <li> <p>MAPK Cascade:</p> </li> <li>HRAS activates RAF1 (Raf1) with MAP kinase kinase kinase activity (GO:0004709)</li> <li>RAF1 activates two MAP kinase kinases: MAP2K1 (Map2k1) and MAP2K2 (Map2k2) (GO:0004708)</li> <li>These activate the MAP kinases: MAPK1 (Mapk1) and MAPK3 (Mapk3) (GO:0004707)</li> </ol>"},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is well-supported by scientific literature: - Multiple references validate the IGF1-IGF1R interaction (e.g., PMID:32697974, PMID:35647546) - The tyrosine kinase activity of IGF1R is supported by PMID:9024787 - The adaptor roles of SHC1 and GRB2 in RTK signaling are documented extensively - The MAPK cascade activation downstream of IGF1R is consistent with established knowledge</p>"},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":""},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#signaling-receptor-pathway-representation","title":"Signaling Receptor Pathway Representation","text":"<p>\u2705 Ligand-Receptor Relationship:  - Correctly models Igf1 as a protein ligand with receptor ligand activity - Uses \"directly positively regulates\" to connect ligand to receptor activity</p> <p>\u2705 Receptor Activity:  - Properly represents IGF1R with insulin-like growth factor receptor activity (GO:0005010) - Includes the ATP input and ADP output for the kinase activity - Appropriately models tyrosine kinase activity</p> <p>\u2705 Adaptor Proteins: - Follows guidelines for molecular adaptor annotation - Uses appropriate molecular functions for adaptors (SHC1, GRB2) - Correctly employs the \"directly positively regulates\" relationship between adaptors</p> <p>\u2705 Activity Flow: - Maintains proper causal direction of the pathway - Uses appropriate \"directly positively regulates\" predicates for causal relationships</p> <p>\u2705 Biological Process Context: - All activities are appropriately placed within the insulin-like growth factor receptor signaling pathway (GO:0048009)</p>"},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#areas-for-enhancement","title":"Areas for Enhancement","text":"<p>While the model is generally well-constructed, there are a few opportunities for improvement:</p> <ol> <li>Missing Evidence Codes: Two causal associations lack evidence:</li> <li>The causal association between MAP2K2 and MAPK3/MAPK1</li> <li> <p>The causal association between MAP2K1 and MAPK3/MAPK1</p> </li> <li> <p>Downstream Effectors: The model could be extended to include:</p> </li> <li>Transcription factor activation downstream of MAPK1/3</li> <li> <p>The PI3K-AKT pathway branch of IGF1R signaling</p> </li> <li> <p>Negative Regulation: The model doesn't include negative regulators of the pathway (e.g., phosphatases)</p> </li> </ol>"},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#technical-quality","title":"Technical Quality","text":"<p>The model is technically well-constructed with: - Appropriate use of MGI identifiers for mouse gene products - Correct use of GO terms for molecular functions - Proper relationship types between activities - Good evidence coding with appropriate PMIDs</p>"},{"location":"reviews/62d0afa500001077-Insulin_like_growth_factor_receptor_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"gomodel:62d0afa500001077\" is a high-quality representation of the IGF1R signaling pathway in mouse. It accurately captures the key molecular interactions and signaling flow from ligand binding to MAPK activation, following GO-CAM best practices for signaling pathway representation.</p> <p>The model would benefit from adding the missing evidence codes for some causal associations and could be further enhanced by including additional branches of IGF1R signaling such as the PI3K-AKT pathway, as well as negative regulatory components.</p> <p>Overall, this is a well-constructed model that provides a clear and accurate representation of IGF1R signaling suitable for research and educational purposes.</p>"},{"location":"reviews/62e3212700000469-Insulin_like_growth_factor_receptor_signaling_pathway_2__Mouse__/","title":"62e3212700000469 Insulin like growth factor receptor signaling pathway 2  Mouse","text":"<p>Based on my review of the GO-CAM model and relevant guidelines, I will provide a comprehensive assessment of the \"Insulin-like growth factor receptor signaling pathway 2 (Mouse)\" model (gomodel:62e3212700000469).</p>"},{"location":"reviews/62e3212700000469-Insulin_like_growth_factor_receptor_signaling_pathway_2__Mouse__/#go-cam-review-insulin-like-growth-factor-receptor-signaling-pathway-2-mouse","title":"GO-CAM Review: Insulin-like growth factor receptor signaling pathway 2 (Mouse)","text":""},{"location":"reviews/62e3212700000469-Insulin_like_growth_factor_receptor_signaling_pathway_2__Mouse__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM represents the insulin-like growth factor receptor (IGF1R) signaling pathway in mouse, featuring key components of the pathway starting from IGF2 ligand, through IGF1R receptor activation, and the downstream MAP kinase cascades.</p>"},{"location":"reviews/62e3212700000469-Insulin_like_growth_factor_receptor_signaling_pathway_2__Mouse__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Appropriate pathway representation: The model correctly captures the signaling cascade from the IGF2 ligand to downstream MAP kinase components, following the expected flow of a receptor tyrosine kinase signaling pathway.</p> </li> <li> <p>Causal relationships: The model correctly uses the \"directly positively regulates\" (RO:0002629) predicate consistently for causal associations between molecular activities.</p> </li> <li> <p>Detailed MAP kinase cascade: The model appropriately represents multiple levels of the MAP kinase cascade (MAP3K \u2192 MAP2K \u2192 MAPK).</p> </li> <li> <p>Evidence inclusion: Most activities have associated evidence with appropriate ECO codes and PMIDs.</p> </li> <li> <p>Molecular function terms: The model uses appropriate molecular function terms for each protein, such as receptor ligand activity (GO:0048018) for IGF2, and specific kinase activities for the kinases in the pathway.</p> </li> </ol>"},{"location":"reviews/62e3212700000469-Insulin_like_growth_factor_receptor_signaling_pathway_2__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Receptor-ligand relationship: </li> <li>The model shows IGF2 (receptor ligand activity) having a causal relationship to IGF1R (insulin-like growth factor receptor activity), which aligns with guidelines.</li> <li> <p>However, IGF1R is shown with both receptor activity (GO:0005010) and protein tyrosine kinase activity (GO:0004713) represented as separate activities, creating redundancy. According to signaling receptor guidelines, these should be modeled as a single activity unit.</p> </li> <li> <p>Missing has_input relationship: </p> </li> <li>For the IGF1R receptor activity (GO:0005010), there's correctly a has_input relationship to ATP and has_output to ADP.</li> <li> <p>However, a has_input relationship to its immediately downstream target (in this case Shc1) should be present but is missing.</p> </li> <li> <p>Adaptor protein annotation: </p> </li> <li>Grb2 is correctly annotated with \"guanyl-nucleotide exchange factor adaptor activity\" (GO:0005091)</li> <li> <p>However, according to the \"How to annotate molecular adaptors\" guidelines, Grb2 should have \"has_input\" relationships to the molecules it brings together (likely Shc1 and Sos1), which are missing from the model.</p> </li> <li> <p>Evidence consistency: </p> </li> <li>Some activities lack evidence, especially causal associations (For example, the causal association between MAP2K activities and MAPK activities).</li> <li> <p>Where evidence is present, most use appropriate ECO codes, but some evidence statements could be strengthened with more specific references.</p> </li> <li> <p>BP context: </p> </li> <li> <p>All activities are correctly placed in the \"insulin-like growth factor receptor signaling pathway\" (GO:0048009), but more specific BP terms could potentially be used for some components.</p> </li> <li> <p>Cellular component context: </p> </li> <li>The model lacks cellular component annotations, which would be useful to specify the localization of the activities (e.g., membrane localization for receptor activities).</li> </ol>"},{"location":"reviews/62e3212700000469-Insulin_like_growth_factor_receptor_signaling_pathway_2__Mouse__/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Consolidate IGF1R activities: Consider merging the insulin-like growth factor receptor activity (GO:0005010) and protein tyrosine kinase activity (GO:0004713) of IGF1R into a single activity unit with both causal relationships, as these represent the same functional entity.</p> </li> <li> <p>Add missing has_input relationships:</p> </li> <li>Add a has_input relationship from IGF1R receptor activity to Shc1</li> <li> <p>Add has_input relationships for the adaptor protein Grb2 to show the molecules it's bringing together</p> </li> <li> <p>Complete evidence documentation:</p> </li> <li>Add evidence annotations to the causal associations that currently lack them</li> <li> <p>Ensure consistent use of ECO terms across all annotations</p> </li> <li> <p>Add cellular component information:</p> </li> <li>Add \"occurs in\" plasma membrane for receptor activities</li> <li> <p>Add appropriate cellular component terms for other activities in the cascade</p> </li> <li> <p>Verify completeness of branching:</p> </li> <li> <p>The model appears to represent multiple MAPK pathways (including MAPK1/3 and MAPK7), but ensure all relevant branches of the pathway are included</p> </li> <li> <p>Consider using complex terms: If any activities are carried out by protein complexes rather than individual proteins, it would be appropriate to use complex GO terms as outlined in the \"How to annotate complexes in GO-CAM\" guideline.</p> </li> </ol>"},{"location":"reviews/62e3212700000469-Insulin_like_growth_factor_receptor_signaling_pathway_2__Mouse__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that effectively represents the IGF receptor signaling pathway in mouse. The model follows most of the expected GO-CAM best practices and accurately depicts the biological relationships between the components. With the recommended improvements, particularly regarding input/output relationships for adaptor proteins and the consolidation of receptor activities, this model would provide an even more accurate and useful representation of the pathway.</p> <p>You can view this model at: https://bioregistry.io/go.model:62e3212700000469</p>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/","title":"62e3212700000746 Insulin like growth factor receptor signaling pathway 3  Mouse","text":"<p>Now let me analyze the GO-CAM model in detail based on the information I've gathered.</p>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#go-cam-model-review-gomodel62e3212700000746-insulin-like-growth-factor-receptor-signaling-pathway-3-mouse","title":"GO-CAM Model Review: gomodel:62e3212700000746 - Insulin-like growth factor receptor signaling pathway 3 (Mouse)","text":""},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the insulin-like growth factor receptor signaling pathway in mouse (NCBITaxon:10090), sourced from several other models as noted in the comments. The model is currently in \"production\" status.</p>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#components-and-pathway-description","title":"Components and Pathway Description","text":"<p>The model describes the following key components and activities in the IGF signaling pathway:</p> <ol> <li>Ligand-Receptor Interaction:</li> <li>Igf1 (MGI:MGI:96432) with receptor ligand activity (GO:0048018)</li> <li>Igf1r (MGI:MGI:96433) with insulin-like growth factor receptor activity (GO:0005010)</li> <li> <p>The ligand (Igf1) directly positively regulates (RO:0002629) the receptor (Igf1r)</p> </li> <li> <p>Receptor Activation and Signaling:</p> </li> <li>Igf1r exhibits protein tyrosine kinase activity (GO:0004713)</li> <li> <p>Activated Igf1r directly positively regulates (RO:0002629) the adaptor protein Irs1</p> </li> <li> <p>Adaptor Protein:</p> </li> <li>Irs1 (MGI:MGI:99454) with transmembrane receptor protein tyrosine kinase adaptor activity (GO:0005068)</li> <li> <p>Irs1 directly positively regulates (RO:0002629) the regulatory subunit of PI3K (Pik3r1)</p> </li> <li> <p>PI3K Activation:</p> </li> <li>Pik3r1 (MGI:MGI:97583) with kinase activator activity (GO:0019209)</li> <li>Pik3r1 directly positively regulates (RO:0002629) the catalytic subunit of PI3K (Pik3ca)</li> <li> <p>Pik3ca (MGI:MGI:1206581) with 1-phosphatidylinositol-3-kinase activity (GO:0016303)</p> </li> <li> <p>Downstream Signaling:</p> </li> <li>Pik3ca directly positively regulates (RO:0002629) Pdpk1</li> <li>Pdpk1 (MGI:MGI:1338068) with 3-phosphoinositide-dependent protein kinase activity (GO:0004676)</li> <li>Pdpk1 directly positively regulates (RO:0002629) Akt1</li> <li>Akt1 (MGI:MGI:87986) with protein serine kinase activity (GO:0106310)</li> </ol> <p>All of these activities are annotated as being part of the \"insulin-like growth factor receptor signaling pathway\" (GO:0048009).</p>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#evidence-quality-and-sources","title":"Evidence Quality and Sources","text":"<p>The model is supported by multiple literature references, primarily: - PMID:11784871 - Study on PI3K subunit regulation in IGF-1 signaling - PMID:15116068 - PMID:12483226 - PMID:32439763 - PMID:7969452 - PMID:16642023 - PMID:23472139 - PMID:33377210</p> <p>Evidence codes used include: - ECO:0000314 (direct assay evidence) - ECO:0000315 (mutant phenotype evidence) - ECO:0000316 (genetic interaction evidence)  - ECO:0000266 (sequence orthology evidence)</p>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#qc-assessment","title":"QC Assessment","text":""},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive Pathway Representation: The model captures the key components and interactions of the canonical IGF-1 receptor signaling pathway, from ligand binding through PI3K activation to AKT activation.</p> </li> <li> <p>Strong Evidence Base: Multiple evidence types and publications support the model's assertions.</p> </li> <li> <p>Proper GO-CAM Conventions: The model follows the GO-CAM representation guidelines for signaling receptor pathways as outlined in the documentation, with proper relationship types between activities.</p> </li> <li> <p>Molecular Detail: The model correctly distinguishes between the different subunits of PI3K (regulatory and catalytic) and their respective activities.</p> </li> </ol>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing Metabolites in Ligand-Receptor Interaction: While the model shows ATP \u2192 ADP in the receptor activity, this is a good practice for showing the molecular details of the kinase activity.</p> </li> <li> <p>Potentially Missing Outputs and Downstream Effects: The model doesn't include the downstream effects of Akt1 activation. According to the literature (PMID:11784871), Akt activation leads to antiapoptotic effects and phosphorylation of numerous substrates, which could be included for completeness.</p> </li> <li> <p>Missing Annotations: The biological context (cellular components) where each activity occurs is not specified, which could be added to improve the model's completeness.</p> </li> <li> <p>Pathway Termination: The pathway appears to end at Akt1 without indicating its downstream targets or biological outcomes. This makes it difficult to understand the ultimate biological effect of the pathway.</p> </li> </ol>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is consistent with the scientific literature on IGF-1 signaling. PMID:11784871 supports the role of PI3K in IGF-1 signaling and the requirement for a balance between regulatory and catalytic subunits. The sequence of events (ligand binding \u2192 receptor activation \u2192 adaptor recruitment \u2192 PI3K activation \u2192 PDK1/AKT activation) is well-established in the literature.</p>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing signaling pathways. According to the \"Signaling receptor activity annotation guidelines\" document:</p> <ol> <li>The proper relationship between ligand and receptor is represented</li> <li>The ligand (Igf1) has receptor ligand activity</li> <li>The receptor has insulin-like growth factor receptor activity</li> <li>The causal relation between ligand and receptor is \"directly positively regulates\"</li> <li>The receptor's input is properly represented as the effector protein it regulates (not its ligand)</li> </ol>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add Cellular Component Annotations: Include cellular component information for each activity (e.g., plasma membrane for receptor, cytosol for downstream components).</p> </li> <li> <p>Extend Downstream Effects: Include key downstream substrates of Akt1 to show the biological outcomes of the pathway activation.</p> </li> <li> <p>Include Negative Regulators: Consider adding negative regulators of the pathway such as phosphatases (e.g., PTEN) which are mentioned in the literature review (PMID:11784871).</p> </li> <li> <p>Add Additional Cross-Regulation: Include cross-talk with other signaling pathways where relevant.</p> </li> <li> <p>Include Feedback Mechanisms: IGF signaling typically involves feedback regulation which could be represented in the model.</p> </li> </ol>"},{"location":"reviews/62e3212700000746-Insulin_like_growth_factor_receptor_signaling_pathway_3__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62e3212700000746 provides a solid representation of the insulin-like growth factor receptor signaling pathway in mouse. It accurately captures the core components of the pathway with appropriate molecular functions and causal relationships. The model follows GO-CAM best practices and is supported by strong evidence from the literature.</p> <p>While the model could be expanded to include more downstream effects and regulatory mechanisms, it serves as a valuable resource for understanding the fundamental components and organization of IGF-1 receptor signaling.</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/","title":"62e3212700001890 Regulation of energy homeostasis by OTUD3  Human","text":"<p>Now I have a good understanding of the model. Let me review it comprehensively.</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#go-cam-model-review-gomodel62e3212700001890","title":"GO-CAM Model Review: gomodel:62e3212700001890","text":""},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#basic-model-information","title":"Basic Model Information","text":"<ul> <li>Model ID: gomodel:62e3212700001890</li> <li>Title: Regulation of energy homeostasis by OTUD3 (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model describes the regulatory pathway through which OTUD3 (a deubiquitinase) regulates energy homeostasis in response to nutritional stress. The model shows how OTUD3 is acetylated by CREBBP (CBP), then deubiquitinates and stabilizes the nuclear receptor PPARD, which in turn regulates transcription of genes involved in energy metabolism.</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#pathway-flow","title":"Pathway Flow","text":"<p>The pathway in this model follows this sequence: 1. CREBBP (CBP) acetyltransferase activity acetylates OTUD3 2. Acetylated OTUD3 functions as a deubiquitinase in the nucleus 3. OTUD3 deubiquitinates PPARD, preventing its degradation 4. Stabilized PPARD acts as a DNA-binding transcription factor to regulate genes involved in energy homeostasis</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#model-components-review","title":"Model Components Review","text":""},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#1-crebbp-activity-uniprotkbq92793","title":"1. CREBBP Activity (UniProtKB:Q92793)","text":"<ul> <li>Activity: Peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li>Cellular Location: Cytoplasm (GO:0005737)</li> <li>Process: N-terminal peptidyl-lysine acetylation (GO:0018076)</li> <li>Regulation: Directly positively regulates CREBBP's second activity</li> </ul> <p>Assessment: This representation is accurate. CREBBP is known to acetylate various proteins, and according to the primary literature (PMID:35675826), glucose and fatty acids trigger CREBBP to acetylate OTUD3, promoting its nuclear translocation.</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#2-secondary-crebbp-activity","title":"2. Secondary CREBBP Activity","text":"<ul> <li>Activity: Peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li>Cellular Location: Cytoplasm (GO:0005737)</li> <li>Process: N-terminal peptidyl-lysine acetylation (GO:0018076)</li> <li>Regulation: Directly positively regulates OTUD3 deubiquitinase activity</li> </ul> <p>Assessment: This is appropriate and represents the same activity of CREBBP when directly regulating OTUD3.</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#3-otud3-activity-uniprotkbq5t2d3","title":"3. OTUD3 Activity (UniProtKB:Q5T2D3)","text":"<ul> <li>Activity: Cysteine-type deubiquitinase activity (GO:0004843)</li> <li>Cellular Location: Nucleus (GO:0005634)</li> <li>Process: Protein K48-linked deubiquitination (GO:0071108)</li> <li>Regulation: Directly positively regulates PPARD transcription factor activity</li> </ul> <p>Assessment: This is consistent with the evidence. OTUD3 deubiquitinates and stabilizes PPARD in the nucleus, particularly in response to nutritional stress according to PMID:35675826.</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#4-ppard-activity-uniprotkbq03181","title":"4. PPARD Activity (UniProtKB:Q03181)","text":"<ul> <li>Activity: DNA-binding transcription factor activity (GO:0003700)</li> <li>Cellular Location: Nucleus (GO:0005634)</li> <li>Process: Regulation of transcription by RNA polymerase II (GO:0006357)</li> </ul> <p>Assessment: This representation is accurate. PPARD is indeed a nuclear transcription factor that regulates genes involved in energy metabolism.</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is primarily supported by evidence from PMID:35675826, which appears to be a 2022 paper describing the role of OTUD3 in regulating metabolism homeostasis in response to nutritional stresses. The evidence is consistently applied across all activities with ECO:0000314 (direct assay evidence used in manual assertion).</p>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#qc-issues-and-recommendations","title":"QC Issues and Recommendations","text":""},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly captures the causal relationships in this regulatory pathway</li> <li>The cellular locations of each activity are accurately represented</li> <li>The evidence is consistently sourced and applied throughout the model</li> <li>The biological processes associated with each function are appropriate</li> </ol>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#potential-improvements","title":"Potential Improvements","text":"<ol> <li> <p>Target Gene Specification: According to the DNA-binding transcription factor annotation guidelines, each transcriptional target of PPARD should be captured as a separate activity unit with a \"has input\" relationship. The current model doesn't specify which genes PPARD regulates.</p> </li> <li> <p>Molecular Context For OTUD3: The model would benefit from adding that OTUD3 is acetylated (the result of CREBBP action) as context for its deubiquitinase activity. This would help capture that acetylation promotes OTUD3's nuclear localization.</p> </li> <li> <p>Energy Homeostasis Process: While the title mentions energy homeostasis (GO:0097009), this process isn't explicitly connected to any of the activities in the model. It would be valuable to connect the PPARD transcription factor activity to this process using a \"part of\" relation.</p> </li> <li> <p>Nutritional Stress Response: The model could be improved by indicating that this pathway is activated in response to nutritional stresses (e.g., glucose and fatty acids), which is a key aspect of the study referenced.</p> </li> <li> <p>Ubiquitination Status: The model correctly notes that OTUD3 performs \"protein K48-linked deubiquitination\" on PPARD, but it would be informative to note that this prevents proteasomal degradation of PPARD, explicitly capturing the stabilization aspect.</p> </li> </ol>"},{"location":"reviews/62e3212700001890-Regulation_of_energy_homeostasis_by_OTUD3__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:62e3212700001890) successfully represents the regulatory pathway through which OTUD3 influences energy homeostasis by deubiquitinating and stabilizing PPARD following acetylation by CREBBP. The model is supported by appropriate evidence and follows most GO-CAM curation practices.</p> <p>The main recommendations for improvement involve adding more specific information about PPARD's transcriptional targets, explicitly connecting the pathway to energy homeostasis, and providing more context about the nutritional stress response. These changes would enhance the biological completeness of the model while maintaining its current strengths in representing the causal flow of the pathway.</p>"},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/","title":"62e3212700001956 Activation of the NLRP1 inflammasome by isoform ZAKalpha of MAP3K20 in response to UV B irradiation and ribotoxic stress  Human","text":"<p>Based on my review of the model and consultation with GO-CAM best practices documentation, I can provide the following comprehensive assessment:</p>"},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#go-cam-model-review-gomodel62e3212700001956","title":"GO-CAM Model Review: gomodel:62e3212700001956","text":""},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#model-information","title":"Model Information","text":"<p>Title: \"Activation of the NLRP1 inflammasome by isoform ZAKalpha of MAP3K20 in response to UV-B irradiation and ribotoxic stress (Human)\" ID: gomodel:62e3212700001956 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#general-assessment","title":"General Assessment","text":"<p>This model represents a well-structured signaling pathway showing how MAP3K20 (ZAKalpha) activates the NLRP1 inflammasome in response to stress signals, ultimately leading to pyroptotic cell death. The model appropriately captures:</p> <ol> <li>Signal detection (stalled ribosome sensing by MAP3K20)</li> <li>Signal transduction (via kinase cascade)</li> <li>Inflammasome assembly and activation</li> <li>Effector function (pyroptosis via GSDMD pore formation)</li> </ol>"},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#technical-compliance-assessment","title":"Technical Compliance Assessment","text":""},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Causal Relationships: The model uses appropriate causal relationships between activities, primarily using RO:0002629 (directly positively regulates) for direct regulation.</p> </li> <li> <p>Evidence Base: Most activities and causal relations are well-supported by evidence from the literature, with appropriate ECO codes.</p> </li> <li> <p>Cellular Location Annotation: All activities are appropriately annotated with their cellular locations.</p> </li> <li> <p>Process Context: Each activity is placed within a biological process context.</p> </li> </ol>"},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#issues-requiring-attention","title":"Issues Requiring Attention:","text":"<ol> <li>Missing Evidence:</li> <li> <p>The causal association between stalled ribosome sensor activity (62e3212700002085) and protein autophosphorylation (62e3212700001993) lacks evidence citations.</p> </li> <li> <p>Redundant Causal Association:</p> </li> <li> <p>Duplicate causal relationship from GSDMD's phosphatidylinositol-4,5-bisphosphate binding to wide pore channel activity (one with evidence, one without).</p> </li> <li> <p>Model Entry Point:</p> </li> <li> <p>While the title mentions UV-B irradiation and ribotoxic stress, these stimuli are not explicitly modeled as entry points in the pathway.</p> </li> <li> <p>Complex Representation:</p> </li> <li>The model doesn't show any protein complexes, though based on the \"How to annotate complexes in GO-CAM\" guidelines, this is appropriate if all individual subunit activities are known, as appears to be the case here.</li> </ol>"},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#scientific-content-assessment","title":"Scientific Content Assessment","text":"<ol> <li>Pathway Completeness: </li> <li>The pathway appears biologically complete from sensor to effector.</li> <li> <p>The kinase cascade (MAP3K20 \u2192 MAP2K3/6 \u2192 MAPK11/14) is well-represented.</p> </li> <li> <p>Signaling Logic:</p> </li> <li>The causal flow is logical and follows standard MAP kinase signaling paradigms.</li> <li> <p>The connection to inflammasome activation and pyroptosis is well-established.</p> </li> <li> <p>Biological Accuracy:</p> </li> <li>The model accurately represents the roles of MAP3K20 in stress signaling.</li> <li>The connection to NLRP1 inflammasome is consistent with recent literature.</li> </ol>"},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Add Evidence for Missing Association:</li> <li> <p>Add literature evidence for the regulatory connection between MAP3K20's stalled ribosome sensor activity and its autophosphorylation.</p> </li> <li> <p>Remove Redundant Association:</p> </li> <li> <p>Remove the duplicate causal association without evidence between GSDMD's phosphatidylinositol-4,5-bisphosphate binding and its wide pore channel activity.</p> </li> <li> <p>Consider Adding Stimulus:</p> </li> <li> <p>Consider explicitly modeling the UV-B irradiation and ribotoxic stress stimuli as starting points of the pathway.</p> </li> <li> <p>Verify Term Usage:</p> </li> <li> <p>Confirm the appropriateness of GO:0170011 (stalled ribosome sensor activity) for MAP3K20 with recent literature.</p> </li> <li> <p>Consider Overall Process Context:</p> </li> <li>Add an overarching biological process that encompasses the entire model, such as \"cellular response to UV-B\" (GO:0071493).</li> </ol>"},{"location":"reviews/62e3212700001956-Activation_of_the_NLRP1_inflammasome_by_isoform_ZAKalpha_of_MAP3K20_in_response_to_UV_B_irradiation_and_ribotoxic_stress__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is technically sound and scientifically accurate, with good evidence support. With a few minor improvements to address the identified issues, it will be an excellent representation of the NLRP1 inflammasome activation pathway via MAP3K20 in response to cellular stress.</p>"},{"location":"reviews/62f58d8800000011-Inactivation_of_GSDMD_by_Protease_3C_from__Human_enterovirus_71__EV71___Human_/","title":"62f58d8800000011 Inactivation of GSDMD by Protease 3C from  Human enterovirus 71  EV71   Human","text":"<p>Based on the information gathered, I'll now provide a comprehensive review of the GO-CAM model with ID \"62f58d8800000011\".</p>"},{"location":"reviews/62f58d8800000011-Inactivation_of_GSDMD_by_Protease_3C_from__Human_enterovirus_71__EV71___Human_/#review-of-go-cam-model-gomodel62f58d8800000011","title":"Review of GO-CAM Model: gomodel:62f58d8800000011","text":""},{"location":"reviews/62f58d8800000011-Inactivation_of_GSDMD_by_Protease_3C_from__Human_enterovirus_71__EV71___Human_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model gomodel:62f58d8800000011 describes \"Inactivation of GSDMD by Protease 3C from Human enterovirus 71 (EV71) (Human)\". This model represents how the viral protease 3C from Human enterovirus 71 inhibits pyroptosis by cleaving Gasdermin D (GSDMD), a key mediator of pyroptotic cell death.</p>"},{"location":"reviews/62f58d8800000011-Inactivation_of_GSDMD_by_Protease_3C_from__Human_enterovirus_71__EV71___Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model includes four key activities:</p> <ol> <li>GSDMD (UniProtKB:P57764) performing:</li> <li>Wide pore channel activity (GO:0022829) - occurs in the plasma membrane (GO:0005886)</li> <li>Phosphatidylinositol-4,5-bisphosphate binding (GO:0005546) - occurs in the plasma membrane (GO:0005886)</li> <li> <p>Both activities are part of pyroptotic inflammatory response (GO:0070269)</p> </li> <li> <p>Caspase-1 (UniProtKB:P29466) performing:</p> </li> <li>Cysteine-type endopeptidase activity (GO:0004197) - occurs in the cytosol (GO:0005829)</li> <li>Part of protein maturation (GO:0051604)</li> <li> <p>Positively regulates GSDMD's phosphatidylinositol-4,5-bisphosphate binding activity</p> </li> <li> <p>EV71 Protease 3C (UniProtKB:Q66478) performing:</p> </li> <li>Cysteine-type endopeptidase activity (GO:0004197)</li> <li>Part of symbiont-mediated suppression of host programmed cell death (GO:0052041)</li> <li>Negatively regulates GSDMD's wide pore channel activity</li> </ol>"},{"location":"reviews/62f58d8800000011-Inactivation_of_GSDMD_by_Protease_3C_from__Human_enterovirus_71__EV71___Human_/#science-assessment","title":"Science Assessment","text":"<p>The scientific content of the model is well-supported by current literature:</p> <ol> <li>GSDMD's role in pyroptosis: </li> <li>GSDMD is correctly represented as having pore-forming activity and membrane binding capabilities, particularly with phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2).</li> <li> <p>The model accurately depicts that GSDMD binds to the plasma membrane to form pores during pyroptosis.</p> </li> <li> <p>Caspase-1 cleavage of GSDMD:</p> </li> <li>The literature confirms that inflammatory caspases, including Caspase-1, cleave GSDMD between its N-terminal and C-terminal domains.</li> <li>Caspase-1 cleaves GSDMD at Asp-275, releasing the N-terminal domain which forms membrane pores.</li> <li> <p>The model correctly shows Caspase-1 positively regulating GSDMD activity.</p> </li> <li> <p>EV71 Protease 3C inactivation of GSDMD:</p> </li> <li>The model accurately depicts EV71 Protease 3C negatively regulating GSDMD's pore-forming activity.</li> <li>Lei et al. (2017, PMID:28679757) showed that Protease 3C cleaves GSDMD at the Q193-G194 pair, producing a shorter N-terminal fragment (GSDMD1-193) that cannot form pores or trigger pyroptosis.</li> </ol>"},{"location":"reviews/62f58d8800000011-Inactivation_of_GSDMD_by_Protease_3C_from__Human_enterovirus_71__EV71___Human_/#technical-assessment","title":"Technical Assessment","text":"<p>From a GO-CAM modeling perspective:</p> <ol> <li>Causal relationships: </li> <li>The model correctly uses RO:0002629 (directly positively regulates) for Caspase-1's effect on GSDMD.</li> <li> <p>It appropriately uses RO:0002630 (directly negatively regulates) for EV71 Protease 3C's effect on GSDMD.</p> </li> <li> <p>Molecular activities:</p> </li> <li>Activities are properly annotated with cellular locations where they occur.</li> <li> <p>The model properly connects molecular functions to biological processes.</p> </li> <li> <p>Evidence:</p> </li> <li>All activities are supported with experimental evidence (ECO:0000314 - direct assay evidence).</li> <li>Key references, including PMID:32109412 and PMID:28679757, provide direct experimental support for the causal relationships.</li> </ol>"},{"location":"reviews/62f58d8800000011-Inactivation_of_GSDMD_by_Protease_3C_from__Human_enterovirus_71__EV71___Human_/#issuesimprovements","title":"Issues/Improvements","text":"<p>While the model is largely sound, I've identified a few areas that could be improved:</p> <ol> <li>Cleavage site specificity:</li> <li>The model could be enhanced by specifically noting that EV71 Protease 3C cleaves GSDMD at Q193-G194, which is different from the Caspase-1 cleavage site (D275).</li> <li> <p>This molecular detail explains why the resulting GSDMD1-193 fragment cannot form functional pores.</p> </li> <li> <p>Mechanistic detail:</p> </li> <li>The model could better represent that the cleavage by Protease 3C produces a specific fragment (GSDMD1-193) that is incapable of forming pores.</li> <li> <p>It could also highlight that this mechanism is different from normal GSDMD regulation where the N-terminal domain is released from autoinhibition.</p> </li> <li> <p>Contextual information:</p> </li> <li>Adding context about viral infection would strengthen the model, such as showing that this mechanism is part of viral immune evasion strategies.</li> </ol>"},{"location":"reviews/62f58d8800000011-Inactivation_of_GSDMD_by_Protease_3C_from__Human_enterovirus_71__EV71___Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62f58d8800000011 is a scientifically accurate and well-constructed model that represents current knowledge about how EV71 Protease 3C inactivates GSDMD to prevent pyroptosis during viral infection. The model correctly captures the molecular activities, cellular locations, and causal relationships between proteins.</p> <p>The model effectively demonstrates how viruses have evolved mechanisms to target host defense pathways, specifically by cleaving GSDMD at a non-canonical site to prevent its pore-forming activity and subsequent pyroptotic cell death. This mechanism allows the virus to evade this important innate immune defense.</p> <p>With minor additions of mechanistic detail regarding the specific cleavage site and the non-functional GSDMD fragment, this model would provide an even more comprehensive representation of this viral evasion mechanism.</p>"},{"location":"reviews/62f58d8800000378-Insulin_like_growth_factor_receptor_signaling_pathway_4__Mouse_/","title":"62f58d8800000378 Insulin like growth factor receptor signaling pathway 4  Mouse","text":"<p>Based on my review of the GO-CAM model \"Insulin-like growth factor receptor signaling pathway 4 (Mouse)\" with ID gomodel:62f58d8800000378 and the best practice guidelines, I can provide the following assessment:</p>"},{"location":"reviews/62f58d8800000378-Insulin_like_growth_factor_receptor_signaling_pathway_4__Mouse_/#go-cam-review-insulin-like-growth-factor-receptor-signaling-pathway-4-mouse","title":"GO-CAM Review: Insulin-like growth factor receptor signaling pathway 4 (Mouse)","text":""},{"location":"reviews/62f58d8800000378-Insulin_like_growth_factor_receptor_signaling_pathway_4__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the insulin-like growth factor receptor signaling pathway in mouse (Taxon: NCBITaxon:10090). The model captures a signaling cascade starting with IGF2 (Igf2 Mmus) as a ligand binding to and activating the IGF1 receptor (Igf1r Mmus), leading to activation of downstream components including IRS1, PI3K (Pik3r1 and Pik3ca), PDPK1, and AKT1.</p>"},{"location":"reviews/62f58d8800000378-Insulin_like_growth_factor_receptor_signaling_pathway_4__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Proper causal relationships: The model correctly uses the <code>RO:0002629</code> (directly positively regulates) predicate to connect activities in a signaling cascade, which aligns with GO-CAM best practices.</p> </li> <li> <p>Appropriate molecular functions: Each protein has been assigned appropriate molecular functions:</p> </li> <li>Igf2: receptor ligand activity (GO:0048018)</li> <li>Igf1r: insulin-like growth factor receptor activity (GO:0005010) and protein tyrosine kinase activity (GO:0004713)</li> <li>Irs1: transmembrane receptor protein tyrosine kinase adaptor activity (GO:0005068)</li> <li>Pik3r1: kinase activator activity (GO:0019209)</li> <li>Pik3ca: 1-phosphatidylinositol-3-kinase activity (GO:0016303)</li> <li>Pdpk1: 3-phosphoinositide-dependent protein kinase activity (GO:0004676)</li> <li> <p>Akt1: protein serine kinase activity (GO:0106310)</p> </li> <li> <p>Evidence citations: Most activities are supported by appropriate evidence and literature citations.</p> </li> <li> <p>Biological process context: All activities are correctly placed in the context of the \"insulin-like growth factor receptor signaling pathway\" (GO:0048009).</p> </li> <li> <p>Small molecule handling: The model appropriately captures ATP and ADP as inputs and outputs for the Igf1r receptor activity.</p> </li> </ol>"},{"location":"reviews/62f58d8800000378-Insulin_like_growth_factor_receptor_signaling_pathway_4__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing cellular component context: According to the signaling receptor activity annotation guidelines, activities should include cellular component information (e.g., 'occurs in' plasma membrane for transmembrane receptors). This information is missing for all activities in the model.</p> </li> <li> <p>Evidence for causal relationships: While most molecular functions have evidence, some causal associations lack evidence codes and citations. Specifically:</p> </li> <li>The causal association between Igf1r protein tyrosine kinase activity and Irs1 adaptor activity has evidence, but several other causal relationships don't.</li> <li> <p>The final activity (Akt1 serine kinase activity) has no outgoing causal associations, which is fine if it's the endpoint of this model.</p> </li> <li> <p>Missing has_input relations: According to the signaling receptor guidelines, a receptor should have the \"effector protein it regulates\" as its input using the 'has_input' relation. This is missing for some steps in the pathway.</p> </li> <li> <p>Missing evidence: The GO:0106310 (protein serine kinase activity) assigned to Akt1 has no evidence citation.</p> </li> </ol>"},{"location":"reviews/62f58d8800000378-Insulin_like_growth_factor_receptor_signaling_pathway_4__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add cellular component annotations to activities, particularly for membrane proteins like IGF1R.</p> </li> <li> <p>Add evidence citations for all causal associations to strengthen the model's evidential support.</p> </li> <li> <p>Review and add missing has_input relations where appropriate according to the guidelines.</p> </li> <li> <p>Add evidence for the Akt1 protein serine kinase activity.</p> </li> <li> <p>Consider whether there are any additional steps in the pathway that could be added to make the model more comprehensive, if supported by evidence.</p> </li> </ol> <p>Overall, this is a well-constructed GO-CAM model that accurately represents the insulin-like growth factor receptor signaling pathway according to most GO-CAM best practices. The improvements suggested would enhance the model's compliance with guidelines and provide more complete information about the cellular locations and evidence base.</p> <p>Link to this model: https://bioregistry.io/go.model:62f58d8800000378</p>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/","title":"62f58d8800001119 Insulin receptor recycling  Mouse","text":"<p>Based on my review of the GO-CAM model gomodel:62f58d8800001119 titled \"Insulin receptor recycling (Mouse)\", here's my assessment:</p>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#go-cam-review-insulin-receptor-recycling-mouse-gomodel62f58d8800001119","title":"GO-CAM Review: Insulin Receptor Recycling (Mouse) gomodel:62f58d8800001119","text":""},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#summary","title":"Summary","text":"<p>This model represents the process of insulin receptor recycling in mouse (NCBITaxon:10090), highlighting the molecular mechanisms involved in insulin receptor endocytosis, processing, and recycling. The model is in production status and focuses on several key proteins and complexes involved in this pathway.</p>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model includes these key activities: 1. Protein binding by SORL1 (MGI:MGI:1202296) 2. Endopeptidase activities by CTSD (MGI:MGI:88562) and IDE (MGI:MGI:96412) 3. Protein tyrosine phosphatase activities by PTPN1 (MGI:MGI:97805) and PTPN2 (MGI:MGI:97806) 4. Proton transmembrane transport by the V-type ATPase complex (GO:0033176) 5. ATP hydrolysis by the V1 domain of the V-type ATPase complex (GO:0033180) 6. Molecular function activator activity by ATP6AP1 (MGI:MGI:109629)</p>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-supported evidence: The model incorporates multiple evidence codes and literature references, primarily from PMID:27322061 which extensively describes the role of SORLA (SORL1) in insulin receptor trafficking and signaling.</p> </li> <li> <p>Appropriate cellular localization: The activities are appropriately localized to relevant cellular components, with key processes occurring in the endosome lumen (GO:0031904) and endosome membrane (GO:0010008).</p> </li> <li> <p>Proper complex annotation: The V-type ATPase complex is correctly represented following GO-CAM guidelines for complexes. The activities are enabled by the appropriate complex components (V0 domain GO:0033179 and V1 domain GO:0033180) with their subunits properly listed.</p> </li> <li> <p>Causal connections: The model effectively shows the causal relationships between activities using appropriate relationship predicates.</p> </li> </ol>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing insulin binding: The model does not explicitly represent the initial binding of insulin to its receptor, which is the trigger for the receptor internalization process.</p> </li> <li> <p>Incomplete representation of insulin signaling: While the model focuses on insulin receptor recycling, it could benefit from connections to downstream insulin signaling pathways that are affected by changes in receptor recycling rates.</p> </li> <li> <p>Limited molecular details of sorting: The molecular sorting mechanism of SORL1 could be more explicitly represented, showing how it interacts with the insulin receptor in the sorting process.</p> </li> </ol>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is highly consistent with the referenced literature, particularly PMID:27322061, which describes how SORLA (SORL1) facilitates insulin receptor recycling by redirecting internalized receptor molecules from endosomes to the plasma membrane. The paper establishes that SORLA: - Interacts directly with the insulin receptor - Increases insulin receptor surface expression - Promotes insulin signaling in adipocytes - Prevents lysosomal degradation of the receptor - Enhances receptor recycling to the cell surface</p> <p>The model captures these key aspects of the mechanism described in the literature.</p>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The biological content of the model is accurate and consistent with current understanding of insulin receptor trafficking. The inclusion of the V-type ATPase in endosomal acidification is appropriate, as acidification of endosomes is crucial for receptor sorting decisions.</p> <p>The model correctly represents: - The role of protein tyrosine phosphatases in insulin receptor signaling - The involvement of endopeptidases in insulin processing - The role of the V-type ATPase in creating the acidic environment needed for proper endosomal function - The importance of SORL1 in the receptor recycling pathway</p>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#technical-assessment","title":"Technical Assessment","text":"<ol> <li> <p>Appropriate use of GO terms: The molecular functions, cellular components, and biological processes are correctly represented using appropriate GO terms.</p> </li> <li> <p>Correct evidence codes: The model uses correct evidence codes (ECO terms) with appropriate references.</p> </li> <li> <p>Appropriate causal relationships: The causal relationships use correct relationship predicates (RO terms).</p> </li> </ol>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add insulin binding: Include the initial insulin binding event to provide a complete picture of the pathway.</p> </li> <li> <p>Expand on downstream effects: Consider adding connections to show how altered receptor recycling affects insulin signaling outcomes.</p> </li> <li> <p>Include additional sorting components: The model could benefit from including other known components of the endosomal sorting machinery that may interact with SORL1.</p> </li> <li> <p>Add molecular details of SORL1-insulin receptor interaction: Based on PMID:27322061, include more details about how SORL1 interacts with the insulin receptor and redirects it from the degradative to the recycling pathway.</p> </li> </ol>"},{"location":"reviews/62f58d8800001119-Insulin_receptor_recycling__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:62f58d8800001119 is a well-constructed representation of insulin receptor recycling in mouse. It is consistent with the literature and generally follows GO-CAM best practices for representing molecular activities, cellular components, and causal relationships. With the suggested improvements, the model could provide an even more comprehensive view of this important cellular process.</p>"},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/","title":"62f58d8800001316 PIV5 V inhibition of STAT1 via DDB1 CUL4A  Human Paramyxovirus","text":"<p>Based on my analysis of the GO-CAM model and the relevant literature, here is my comprehensive review:</p>"},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#review-of-go-cam-model-piv5-v-inhibition-of-stat1-via-ddb1cul4a-human-paramyxovirus","title":"Review of GO-CAM Model: PIV5-V Inhibition of STAT1 via DDB1/CUL4A (Human-Paramyxovirus)","text":""},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#model-id-gomodel62f58d8800001316","title":"Model ID: gomodel:62f58d8800001316","text":""},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#overview","title":"Overview","text":"<p>This GO-CAM model represents the molecular mechanism by which the V protein of Parainfluenza virus 5 (PIV5) inhibits STAT1 function through a DDB1/CUL4A-mediated ubiquitination pathway. The model illustrates how viral proteins can hijack host cellular machinery to suppress interferon-mediated immune responses.</p>"},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#model-components","title":"Model Components","text":"<p>The model includes the following key molecular activities:</p> <ol> <li>DDB1 (UniProtKB:Q16531) - Performs cullin family protein binding activity (GO:0097602)</li> <li>CUL4A (UniProtKB:Q13619) - Performs ubiquitin protein ligase binding (GO:0031625)</li> <li>RBX1 (UniProtKB:P62877) - Performs ubiquitin protein ligase activity (GO:0061630)</li> <li>PIV5-V protein (UniProtKB:P11207) - Performs ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</li> <li>STAT1 (UniProtKB:P42224) - Performs DNA-binding transcription factor activity (GO:0000981)</li> </ol>"},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#pathway-logic-and-causal-flow","title":"Pathway Logic and Causal Flow","text":"<p>The model correctly represents the causal flow of the mechanism:</p> <ol> <li>PIV5-V protein acts as an adaptor for substrate recognition in the ubiquitin ligase complex</li> <li>DDB1 functions as a scaffold component that positively regulates RBX1</li> <li>CUL4A positively regulates RBX1's ubiquitin ligase activity</li> <li>RBX1 directly negatively regulates STAT1</li> <li>STAT1 is localized to the nucleus (GO:0005634) and functions in the type I interferon-mediated signaling pathway (GO:0060337)</li> </ol> <p>This causal flow correctly represents how the virus-encoded V protein hijacks the host cullin-RING ubiquitin ligase complex to target STAT1 for degradation, thereby suppressing interferon-mediated antiviral responses.</p>"},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the established biological mechanism based on the cited literature. Key references such as PMID:16051811 describe how Paramyxovirus V proteins assemble STAT-specific ubiquitin ligase complexes from cellular components to target STAT proteins for degradation.</p> <p>The relationships between PIV5-V, DDB1, CUL4A, and the targeting of STAT1 are well-supported by the literature. PMID:16482215 and PMID:20870715 provide evidence for the role of these components in the ubiquitin-mediated proteolysis pathway.</p>"},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several aspects:</p> <ol> <li>Activities and molecular functions: Each protein is associated with an appropriate molecular function term.</li> <li>Cellular context: STAT1 is correctly annotated as occurring in the nucleus (GO:0005634).</li> <li>Biological processes: Activities are appropriately nested within relevant biological processes.</li> <li>Causal relationships: The model uses appropriate causal relationship predicates (RO:0002629 for \"directly positively regulates\" and RO:0002630 for \"directly negatively regulates\").</li> <li>Evidence codes: The model includes appropriate evidence codes (ECO:0000314 for direct assay evidence) and PMIDs as references.</li> </ol>"},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is generally well-constructed, I suggest the following improvements:</p> <ol> <li> <p>STAT1 activity detail: The model could benefit from more detail about STAT1's specific gene targets in the interferon response pathway. The current representation shows STAT1's DNA-binding transcription factor activity but doesn't specify which genes it regulates.</p> </li> <li> <p>Additional biological context: The model could be enhanced by including information about how STAT1 degradation specifically impairs interferon signaling. This could include downstream consequences such as inhibition of antiviral gene expression.</p> </li> <li> <p>Temporal aspects: The model could potentially include information about when during viral infection this mechanism is activated. This temporal context would provide additional biological insight.</p> </li> <li> <p>Subcellular localization: While STAT1 is correctly annotated as occurring in the nucleus, adding subcellular localization information for other components of the pathway would improve the model's completeness.</p> </li> <li> <p>Complementary immune evasion mechanisms: If applicable, the model could reference other immune evasion mechanisms employed by paramyxoviruses that work in conjunction with STAT1 degradation.</p> </li> </ol>"},{"location":"reviews/62f58d8800001316-PIV5_V_inhibition_of_STAT1_via_DDB1_CUL4A__Human_Paramyxovirus__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:62f58d8800001316) effectively represents the molecular mechanism by which the PIV5-V protein inhibits STAT1 function through DDB1/CUL4A-mediated ubiquitination. The model adheres to GO-CAM best practices and accurately reflects the current biological understanding as supported by the literature. With the suggested improvements, the model could provide an even more comprehensive representation of this virus-host interaction pathway.</p> <p>The model represents an important immune evasion mechanism employed by paramyxoviruses to suppress interferon-mediated antiviral responses, making it a valuable resource for understanding virus-host interactions.</p>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/","title":"62f58d8800001500 Insulin processing 1  Mouse","text":"<p>Let me review the GO-CAM model on insulin processing in mouse (gomodel:62f58d8800001500). I'll analyze its structure, biological accuracy, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>This is a production-status GO-CAM model titled \"Insulin processing 1 (Mouse)\" for the taxon Mus musculus (NCBITaxon:10090). It represents the insulin processing pathway, with 11 molecular activities connected through causal associations.</p>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#pathway-structure","title":"Pathway Structure","text":"<p>The model represents insulin processing, focusing on: 1. Protein disulfide bond formation in the ER (Ero1b, P4hb) 2. Zinc transport (Slc30a8, Slc30a5, Slc30a3) 3. Proteolytic processing of proinsulin (Pcsk1, Pcsk2, Cpe) 4. Insulin zinc binding (Ins2) 5. Protein folding (Hsp90b1)</p> <p>The causal flow appears logical, connecting activities in a way that reflects the biological process of insulin maturation from the ER through secretory granules.</p>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#evidence-quality","title":"Evidence Quality","text":"<p>The model uses appropriate evidence codes: - ECO:0000315 (mutant phenotype evidence) - ECO:0000314 (direct assay evidence) - ECO:0000316 (genetic interaction evidence) - ECO:0000266 (sequence orthology evidence)</p> <p>Each activity is supported by evidence from published literature.</p>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":""},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#positive-aspects","title":"Positive Aspects","text":"<ol> <li>Appropriate cellular locations: Activities are annotated with proper cellular compartments (ER lumen, secretory granule, Golgi membrane)</li> <li>Consistent causal relationships: Uses appropriate causal predicates (RO:0002413 \"provides input for\", RO:0002629 \"directly positively regulates\")</li> <li>Comprehensive representation: All key steps in insulin processing are included</li> <li>Species-specific model: Correctly uses mouse gene identifiers (MGI)</li> <li>Well-supported with evidence: All activities have literature references</li> </ol>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing evidence for some causal associations: Several causal associations have empty evidence arrays, including:</li> <li>From Pcsk1 to Cpe</li> <li>From Cpe to PC2</li> <li>From PC2 to Cpe</li> <li>From Cpe to Slc30a8</li> <li>From Hsp90b1 to P4hb</li> <li> <p>From Slc30a5 to Ins2</p> </li> <li> <p>Incomplete activity connections: Slc30a3 (zinc transporter) is part of the insulin processing but has no causal connections to other activities</p> </li> <li> <p>Lack of complex representation: The model appears to involve protein interactions but doesn't explicitly represent any complexes, which might be appropriate based on the \"How to annotate complexes in GO-CAM\" guidelines if the activities are carried by individual proteins rather than complexes.</p> </li> </ol>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#specific-gene-function-validation","title":"Specific Gene Function Validation","text":"<p>Let me look at some of the key protein roles in the model:</p> <ol> <li> <p>Ins2 (MGI:MGI:96573) - annotated with zinc ion binding (GO:0008270) in insulin processing (GO:0030070), which is consistent with the known role of insulin binding zinc ions during maturation and storage.</p> </li> <li> <p>Slc30a8 (MGI:MGI:2442682) - annotated with zinc ion transmembrane transporter activity (GO:0005385) in secretory granule membrane (GO:0030667), which is accurate as this zinc transporter is known to be important for insulin packaging and secretion.</p> </li> <li> <p>P4hb (MGI:MGI:97464) - protein disulfide isomerase with reductase activity (GO:0015035) in ER lumen (GO:0005788), which is appropriate for its role in insulin folding.</p> </li> </ol>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add evidence for all causal relationships: Every causal association should have supporting evidence.</p> </li> <li> <p>Complete the causal connections for Slc30a3: This zinc transporter (MGI:MGI:1345280) should be causally connected to the pathway if it plays a role in insulin processing.</p> </li> <li> <p>Consider annotation of potential complexes: If any of these proteins function as complexes during insulin processing, consider using the complex annotation guidelines to represent them appropriately.</p> </li> <li> <p>Verify the exact order of processing events: Ensure the causal flow accurately reflects the temporal sequence of insulin processing from synthesis through maturation.</p> </li> </ol>"},{"location":"reviews/62f58d8800001500-Insulin_processing_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents insulin processing in mouse. It follows most GO-CAM best practices, has good evidence support, and represents the biological process in a clear and logical manner. The main improvement would be adding evidence for all causal associations and connecting all activities properly within the pathway.</p> <p>The model is available at: https://bioregistry.io/go.model:62f58d8800001500</p>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/","title":"62f58d8800001680 Gut Microbiota tryptophan metabolism  Regulation of intestinal epithelial cell homesotasis by Indole AhR  Human E coli","text":"<p>Based on the information I've collected, I will now provide a detailed review of the GO-CAM model with ID 62f58d8800001680 \"Gut Microbiota tryptophan metabolism: Regulation of intestinal epithelial cell homesotasis by Indole-AhR (Human-E.coli)\".</p>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#review-of-go-cam-model-gomodel62f58d8800001680","title":"Review of GO-CAM Model: gomodel:62f58d8800001680","text":""},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the regulation of intestinal epithelial cell homeostasis through the interaction between indole (a bacterial metabolite derived from tryptophan) and the Aryl Hydrocarbon Receptor (AHR) pathway, including the downstream effects on IL-10 receptor signaling.</p> <p>Model Title: Gut Microbiota tryptophan metabolism: Regulation of intestinal epithelial cell homesotasis by Indole-AhR (Human-E.coli)</p>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#summary-of-model-components","title":"Summary of Model Components","text":"<p>The model contains three main activities:</p> <ol> <li> <p>AHR (P35869) - Nuclear receptor activity (GO:0004879) in the nucleus (GO:0005634), part of cellular response to molecule of bacterial origin (GO:0071219)</p> </li> <li> <p>ARNT (P27540) - DNA-binding transcription factor activity (GO:0003700) in the nucleus (GO:0005634), part of negative regulation of inflammatory response (GO:0050728)</p> </li> <li> <p>IL10RA (Q13651) - Interleukin-10 receptor activity (GO:0004920) in the apical plasma membrane (GO:0016324), part of negative regulation of inflammatory response (GO:0050728)</p> </li> </ol>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#pathway-description-and-biology","title":"Pathway Description and Biology","text":"<p>The model describes how indole, a metabolite produced by intestinal bacteria from tryptophan, functions as a ligand for AHR. When AHR is activated, it translocates to the nucleus where it interacts with ARNT to form a transcriptionally active complex. This complex regulates gene expression, including genes involved in anti-inflammatory responses, such as IL10RA. The IL-10 receptor signaling then contributes to intestinal epithelial cell homeostasis.</p>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<ol> <li>AHR directly positively regulates (RO:0002629) ARNT's transcription factor activity</li> <li>AHR provides input for (RO:0002407) IL10RA's receptor activity </li> <li>ARNT provides input for (RO:0002407) IL10RA's receptor activity</li> </ol>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses evidence from several publications: - PMID:28602820 - Structural basis for AHR-mediated gene activation - PMID:29454749 - Likely related to AHR-ARNT interactions and downstream effects - PMID:24367025 - Details IL-10 receptor activity in intestinal epithelial cells - PMID:22087322 - Describes IL-10 receptor localization on apical plasma membrane</p> <p>The evidence codes used include: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000305 (curator inference used in manual assertion)</p>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>The model effectively captures the cross-kingdom signaling between bacterial metabolites (indole) and human AHR signaling pathways.</p> </li> <li> <p>The causal relationships between AHR, ARNT, and IL10RA are supported by published evidence.</p> </li> <li> <p>The subcellular localization of the proteins is accurately represented (AHR and ARNT in the nucleus, IL10RA at the apical plasma membrane).</p> </li> <li> <p>The biological process annotations are appropriate for each protein activity.</p> </li> </ol>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Missing Small Molecule Representation: The model doesn't explicitly represent indole (CHEBI:16881) as a small molecule activator of AHR, which is listed in the objects but not connected in the graph. According to the \"Signaling receptor activity annotation guidelines\", small molecule activators should be represented with the relation \"is small molecule activator of\".</li> </ol> <p>Recommendation: Add indole (CHEBI:16881) with a relation \"is small molecule activator of\" to the AHR nuclear receptor activity.</p> <ol> <li>Improper Causal Relationship: The \"provides input for\" (RO:0002407) relation is used between AHR and IL10RA, and between ARNT and IL10RA. However, according to the GO-CAM guidelines, this relation is typically used for substrates or targets, not for regulatory relationships. A more appropriate relation would be \"causally upstream of, positive effect\" (RO:0002304).</li> </ol> <p>Recommendation: Change the causal relationship from \"provides input for\" to \"causally upstream of, positive effect\" to better represent the indirect regulation.</p> <ol> <li>Missing IL-10 Ligand: The IL10RA activity doesn't have an input for its ligand (IL-10). According to the signaling receptor guidelines, the receptor should have its ligand or downstream target as input.</li> </ol> <p>Recommendation: Consider adding IL-10 as a receptor ligand that directly positively regulates IL10RA or add the downstream effector of IL10RA as its input.</p> <ol> <li>AHR-ARNT Complex: The model represents AHR and ARNT as separate activities that interact through causal relationships, but according to the complex annotation guidelines, they form a functional heterodimer. This could be more accurately represented.</li> </ol> <p>Recommendation: Consider representing the AHR-ARNT interaction as a heterodimer complex or ensure the current representation accurately captures that they function together.</p> <ol> <li>Bacterial Component: The model mentions E. coli in the title and includes objects related to bacterial processes (GO:0009034 tryptophanase activity, UniProtKB:P0A853, NCBITaxon:83333), but these aren't connected in the functional model.</li> </ol> <p>Recommendation: If bacterial tryptophanase activity converting tryptophan to indole is important to include, add this activity with appropriate connections to the rest of the model.</p>"},{"location":"reviews/62f58d8800001680-Gut_Microbiota_tryptophan_metabolism__Regulation_of_intestinal_epithelial_cell_homesotasis_by_Indole_AhR__Human_E_coli_/#conclusion","title":"Conclusion","text":"<p>The model effectively captures the cross-kingdom signaling between bacterial metabolites and human host response through the AHR pathway and downstream effects on IL-10 receptor signaling. It provides a good representation of how bacterial indole derived from tryptophan can influence intestinal epithelial cell homeostasis through AHR signaling and subsequent anti-inflammatory pathways.</p> <p>The recommended changes would enhance the model's completeness and adherence to GO-CAM standards, making it more informative and consistent with current annotation guidelines.</p>"},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/","title":"62f58d8800002184 positive regulation of insulin secretion involved in cellular response to glucose stimulus  Mouse","text":"<p>Now I have enough information to conduct a thorough review of the GO-CAM model.</p>"},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/#review-of-go-cam-model-gomodel62f58d8800002184","title":"Review of GO-CAM Model: gomodel:62f58d8800002184","text":""},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/#overview-of-the-model","title":"Overview of the Model","text":"<p>The GO-CAM model gomodel:62f58d8800002184 is titled \"positive regulation of insulin secretion involved in cellular response to glucose stimulus (Mouse)\" and describes a pathway in mouse pancreatic beta cells that regulates insulin secretion in response to glucose.</p>"},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/#model-summary","title":"Model Summary","text":"<p>This model describes how glucose uptake and metabolism leads to the regulation of insulin secretion through a series of molecular events involving:</p> <ol> <li>Glucose transport by Slc2a2 (GLUT2)</li> <li>Glucose phosphorylation by Gck (glucokinase)</li> <li>ATP binding to the Abcc8/Kcnj11 complex (KATP channel)</li> <li>Regulation of voltage-gated calcium channel complexes</li> <li>Ultimate control of insulin secretion</li> </ol>"},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/#strong-points-of-the-model","title":"Strong Points of the Model","text":"<ol> <li>The model accurately captures the canonical pathway for glucose-stimulated insulin secretion in beta cells.</li> <li>Appropriate molecular functions are assigned to each protein (e.g., glucose transport for Slc2a2, ATP binding for Abcc8, etc.)</li> <li>Correct causal relationships between activities are used (e.g., RO:0002413 \"provides input for\" between glucose transport and glucokinase activity)</li> <li>The model includes key regulatory elements like the KATP channel (Abcc8/Kcnj11) and voltage-gated calcium channels.</li> <li>Appropriate complexes are used, with correct specification of members.</li> <li>Evidence codes and PMIDs are provided for assertions.</li> </ol>"},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Missing cellular context: </li> <li> <p>Although the model implies this is happening in pancreatic beta cells, there is no specific annotation indicating this. Consider adding \"occurs in\" CL:0000169 (type B pancreatic cell) to the activities.</p> </li> <li> <p>Incomplete pathway: </p> </li> <li> <p>The model includes the uptake of glucose, its phosphorylation, and regulation of ion channels, but it does not include the final step of insulin secretion itself. Consider extending the model to include insulin secretion as the terminal activity.</p> </li> <li> <p>Lacking connection to response process: </p> </li> <li> <p>While activities are part of GO:0035774 \"positive regulation of insulin secretion involved in cellular response to glucose stimulus\", the connections between the calcium channels and the actual insulin secretion are not explicitly modeled.</p> </li> <li> <p>Small molecule representation: </p> </li> <li> <p>Glucose is represented as a CHEBI term, but according to the guidelines on signaling receptor activity, small molecule activators should use \"is small molecule activator\" relation rather than \"has input\". This appears to be correctly modeled as \"has input\" between GLUT2 transporter and glucose.</p> </li> <li> <p>Molecular details of regulation:</p> </li> <li>The model correctly shows direct negative regulation (RO:0002630) of the KATP channels in response to ATP binding, but could benefit from more detail about how increased ATP/ADP ratio leads to channel closure.</li> </ol>"},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>After reviewing the relevant GO-CAM guidelines, I can confirm that this model follows most best practices:</p> <ol> <li> <p>Regulation and regulatory processes: The model correctly uses \"directly positively regulates\" (RO:0002629) and \"directly negatively regulates\" (RO:0002630) to show how one activity directly affects another.</p> </li> <li> <p>Complex annotation: The model correctly follows guidelines for annotating complexes by using GO complex IDs for voltage-gated calcium channel complexes where specific subunits carrying the activity are known.</p> </li> </ol>"},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/#consistency-with-biological-knowledge","title":"Consistency with Biological Knowledge","text":"<p>The model accurately reflects the established biology of glucose-stimulated insulin secretion:</p> <ol> <li>Glucose is transported into beta cells via GLUT2 (Slc2a2)</li> <li>Glucose is phosphorylated by glucokinase (Gck)</li> <li>Increased ATP/ADP ratio leads to closure of KATP channels (Abcc8/Kcnj11)</li> <li>KATP channel closure leads to membrane depolarization</li> <li>Depolarization activates voltage-gated calcium channels</li> <li>Calcium influx triggers insulin secretion</li> </ol> <p>This pathway is well-supported by the literature citations included in the model, including PMID:10823833, PMID:7502040, and PMID:16924481.</p>"},{"location":"reviews/62f58d8800002184-positive_regulation_of_insulin_secretion_involved_in_cellular_response_to_glucose_stimulus__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a good representation of glucose-stimulated insulin secretion in pancreatic beta cells. It correctly captures the key players and relationships in this process. The model could be improved by explicitly modeling the final step of insulin secretion and by clearly indicating the beta cell context. Overall, this model adheres well to GO-CAM curation standards and accurately represents the biological process.</p>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/","title":"62f58d8800002367 Protein import into peroxisomes  of PTS1 containing proteins by the PEX5 receptor  and recycling of the PEX5 receptor  S cerevisiae","text":"<p>Now that I have gathered information about the GO-CAM model, let me provide my review:</p>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#review-of-go-cam-model-gomodel62f58d8800002367","title":"Review of GO-CAM Model gomodel:62f58d8800002367","text":""},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: Protein import into peroxisomes of PTS1-containing proteins by the PEX5 receptor, and recycling of the PEX5 receptor (S.cerevisiae)</li> <li>Taxon: Saccharomyces cerevisiae (NCBITaxon:559292)</li> <li>Status: Production</li> <li>Model ID: gomodel:62f58d8800002367</li> </ul>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#summary-of-model-content","title":"Summary of Model Content","text":"<p>This GO-CAM model represents the process of protein import into peroxisomes mediated by the PEX5 receptor in Saccharomyces cerevisiae. The model depicts:</p> <ol> <li>The recognition and binding of PTS1-containing proteins by the PEX5 receptor in the cytosol</li> <li>Docking of the receptor-cargo complex to the peroxisomal membrane via PEX14</li> <li>Translocation of cargo proteins into the peroxisomal matrix</li> <li>Recycling of the PEX5 receptor back to the cytosol, which involves:</li> <li>Monoubiquitination of PEX5 by an E3 ubiquitin ligase complex at the peroxisomal membrane</li> <li>Extraction of ubiquitinated PEX5 by the AAA ATPase complex</li> </ol>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#consistency-with-scientific-literature","title":"Consistency with Scientific Literature","text":"<p>The model is well-supported by the referenced literature, particularly PMID:35768507, which provides a detailed structural and functional characterization of the peroxisomal ubiquitin ligase complex (comprising PEX2, PEX10, and PEX12) that forms a retrotranslocation channel for recycling the PEX5 receptor.</p> <p>The causal relationships, molecular functions, and cellular locations depicted in the model are consistent with current understanding of peroxisomal protein import and receptor recycling pathways.</p>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#evaluation-against-go-cam-guidelines","title":"Evaluation against GO-CAM Guidelines","text":""},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#complex-representation","title":"Complex Representation","text":"<p>The model correctly follows GO-CAM guidelines for representing protein complexes: - When a specific subunit carries a known molecular activity, the activity is attributed to that subunit (e.g., PEX14's protein-macromolecule adaptor activity) - When activities are carried by complexes, appropriate complex identifiers are used (e.g., SGD:S000217793, SGD:S000217795, SGD:S000217796)</p>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#causal-relationships","title":"Causal Relationships","text":"<p>The model appropriately uses causal relationships between activities: - RO:0002629 \"directly positively regulates\" is used correctly to connect activities in the pathway - The causal flow follows the biological sequence of events in peroxisomal protein import and receptor recycling</p>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#annotation-quality","title":"Annotation Quality","text":"<ul> <li>Evidence codes are properly applied (primarily ECO:0000314 - direct assay evidence)</li> <li>PMIDs are cited appropriately to support annotations</li> <li>Multiple types of evidence are provided for key relationships</li> <li>Appropriate part_of relationships link activities to biological processes</li> </ul>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":""},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#minor-issues","title":"Minor Issues","text":"<ol> <li> <p>Evidence for Causal Associations: One causal association (between PEX14's adaptor activity and the Pex17/Pex14 complex's transporter activity) is lacking evidence code information. This should be added for completeness.</p> </li> <li> <p>Cellular Component Consistency: The model shows PEX5 operating in both cytosol (GO:0005829) and peroxisomal matrix (GO:0005782), which is appropriate given its shuttling nature, but the transition between these locations could be more explicitly modeled.</p> </li> </ol>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#potential-enhancements","title":"Potential Enhancements","text":"<ol> <li> <p>Additional References: While PMID:35768507 is extensively used, incorporation of some older foundational papers on PEX5 recycling would strengthen the model's evidence base.</p> </li> <li> <p>Model Expansion: The model could be expanded to include:</p> </li> <li>The specific roles of the E2 enzyme (PEX4) in the ubiquitination process</li> <li>The fate of polyubiquitinated PEX5 in the RADAR pathway (Receptor Accumulation and Degradation in the Absence of Recycling)</li> <li>The import of PTS2-containing proteins (which involves PEX7)</li> </ol>"},{"location":"reviews/62f58d8800002367-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__S_cerevisiae_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 62f58d8800002367 is a high-quality representation of the peroxisomal protein import and PEX5 receptor recycling pathway in yeast. It adheres to GO-CAM best practices and accurately captures the current scientific understanding of this biological process. The model provides valuable insight into the molecular mechanisms of peroxisomal protein import, particularly highlighting the role of the ubiquitin ligase complex in receptor recycling.</p> <p>With minor additions as suggested above, this model would provide an even more comprehensive representation of the pathway.</p>"},{"location":"reviews/62f58d8800002485-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__Human_/","title":"62f58d8800002485 Protein import into peroxisomes  of PTS1 containing proteins by the PEX5 receptor  and recycling of the PEX5 receptor  Human","text":"<p>Now, let me review the GO-CAM model on protein import into peroxisomes and evaluate it against the best practices and guidelines.</p>"},{"location":"reviews/62f58d8800002485-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__Human_/#review-of-go-cam-model-62f58d8800002485","title":"Review of GO-CAM Model: 62f58d8800002485","text":""},{"location":"reviews/62f58d8800002485-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__Human_/#model-summary","title":"Model Summary","text":"<p>Title: Protein import into peroxisomes of PTS1-containing proteins by the PEX5 receptor, and recycling of the PEX5 receptor (Human) ID: gomodel:62f58d8800002485 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/62f58d8800002485-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__Human_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>This GO-CAM represents the process of protein import into peroxisomes, specifically focusing on PTS1-containing proteins via the PEX5 receptor, and the recycling of the PEX5 receptor in humans. The model captures multiple molecular functions across different cellular compartments (cytosol, peroxisome membrane, peroxisomal matrix) with appropriate causal connections between activities.</p>"},{"location":"reviews/62f58d8800002485-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__Human_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li> <p>Comprehensive Pathway Coverage: The model thoroughly captures the peroxisomal protein import pathway, including receptor binding, docking, translocation, release, and receptor recycling steps.</p> </li> <li> <p>Proper Cellular Compartmentalization: Each activity is appropriately placed in its cellular location (cytosol, peroxisomal membrane, peroxisomal matrix).</p> </li> <li> <p>Evidence-Based Annotations: Activities have appropriate evidence codes and literature references, with most annotations having direct assay evidence (ECO:0000314).</p> </li> <li> <p>Causal Flow Representation: The activities are linked with appropriate causal relationships (RO:0002629 - directly positively regulates) that accurately represent the flow of the pathway.</p> </li> <li> <p>Species-Specific Information: The model is clearly identified as specific to humans (NCBITaxon:9606) with appropriate human proteins (UniProtKB entries).</p> </li> </ol>"},{"location":"reviews/62f58d8800002485-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__Human_/#potential-issues","title":"Potential Issues:","text":"<ol> <li> <p>Duplicate Causal Associations: There appears to be some duplication in the causal associations. For example, the PEX26 protein (Q7Z412) has two identical causal associations to PEX1 (O43933), which seems redundant:    <pre><code>{\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:62f58d8800002485/62f58d8800002648\"}\n</code></pre>    appears twice in the PEX26 activity.</p> </li> <li> <p>Missing Evidence in One Causal Association: The causal association from PEX5's protein carrier chaperone activity (62f58d8800002527) to the subsequent activity has no evidence listed:    <pre><code>\"causal_associations\":[{\"type\":\"CausalAssociation\",\"evidence\":[],\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:62f58d8800002535\"}]\n</code></pre></p> </li> <li> <p>Sequence Similarity Evidence: Some annotations use sequence similarity evidence (ECO:0000250) with reference to yeast proteins. While acceptable, it would be preferable to have direct experimental evidence in humans where possible.</p> </li> <li> <p>Similar Duplicate Causal Links: The activity 62f58d8800002513 (PEX5 in peroxisomal matrix) has duplicate causal links to PEX12 (O00623), which could be consolidated:    <pre><code>{\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:62f58d8800002485/62f58d8800002623\"}\n</code></pre>    appears twice in different evidence contexts.</p> </li> </ol>"},{"location":"reviews/62f58d8800002485-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__Human_/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Remove Redundant Causal Associations: Clean up duplicate causal associations that link to the same downstream activity with identical predicates.</p> </li> <li> <p>Add Missing Evidence: Add appropriate evidence to the causal association from PEX5's protein carrier chaperone activity to the subsequent activity.</p> </li> <li> <p>Consider Adding More Context: While the model effectively represents the pathway, additional contextual information could be included, such as connections to related pathways or the consequences of peroxisomal protein import.</p> </li> <li> <p>Review Literature for Direct Human Evidence: Where sequence similarity evidence is used, consider reviewing more recent literature for direct experimental evidence in humans to strengthen the annotations.</p> </li> <li> <p>Verify Protein Transporter Annotations: Ensure the protein transporter activity (GO:0140318) annotations are consistent with the latest GO guidelines for transporter activity.</p> </li> </ol>"},{"location":"reviews/62f58d8800002485-Protein_import_into_peroxisomes__of_PTS1_containing_proteins_by_the_PEX5_receptor__and_recycling_of_the_PEX5_receptor__Human_/#overall-assessment","title":"Overall Assessment:","text":"<p>This is a high-quality GO-CAM model that effectively represents the process of protein import into peroxisomes and PEX5 receptor recycling in humans. The model successfully captures the biological complexity of this process and follows most GO-CAM best practices. With minor refinements to address redundant causal associations and add missing evidence, this model would be an excellent representation of peroxisomal protein import.</p> <p>The model correctly uses the \"directly positively regulates\" (RO:0002629) predicate for causal associations between activities, which is appropriate for representing the sequential steps in this pathway. The cellular locations of each activity are accurately specified, and the biological process annotations appropriately contextualize each molecular function.</p>"},{"location":"reviews/62f58d8800003012-Positive_regulation_of_insulin_secretion_2___Mouse_/","title":"62f58d8800003012 Positive regulation of insulin secretion 2   Mouse","text":"<p>Based on my review of the GO-CAM model (gomodel:62f58d8800003012) \"Positive regulation of insulin secretion 2 (Mouse)\" and the supporting documentation, I'll now provide a comprehensive review:</p>"},{"location":"reviews/62f58d8800003012-Positive_regulation_of_insulin_secretion_2___Mouse_/#go-cam-model-review-gomodel62f58d8800003012","title":"GO-CAM Model Review - gomodel:62f58d8800003012","text":""},{"location":"reviews/62f58d8800003012-Positive_regulation_of_insulin_secretion_2___Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the positive regulation of insulin secretion pathway in mouse pancreatic beta cells, specifically focusing on the GPR40 (FFAR1)-mediated pathway that involves store-operated calcium entry (SOCE) through the IP3R1/STIM1/Orai1 pathway. The model depicts how long-chain fatty acids potentiate glucose-induced insulin secretion.</p>"},{"location":"reviews/62f58d8800003012-Positive_regulation_of_insulin_secretion_2___Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological Accuracy: The model accurately represents the current understanding of GPR40/FFAR1 signaling in pancreatic beta cells as documented in the literature (PMID:31664108). The pathway from G-protein coupled receptor activation through to calcium channel regulation is well-represented.</p> </li> <li> <p>Proper Evidence Annotation: Most activities and relationships are supported by appropriate experimental evidence codes and literature references.</p> </li> <li> <p>Molecular Detail: The model includes appropriate molecular details, including relevant inputs (such as IP3 and DAG) and causal relationships between activities.</p> </li> <li> <p>Biological Process Context: All activities are properly situated within the broader biological process (GO:0007200 - phospholipase C-activating G protein-coupled receptor signaling pathway).</p> </li> </ol>"},{"location":"reviews/62f58d8800003012-Positive_regulation_of_insulin_secretion_2___Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Causal Association Evidence: There's a causal association between Orai1 (MGI:MGI:1925542) activity and TRPC1 (MGI:MGI:109528) activity that lacks evidence annotation. This should be supported with appropriate evidence.</p> </li> <li> <p>Cellular Location Annotations: While most activities have appropriate cellular location annotations (plasma membrane, GO:0005886), some activities lack these annotations. For example, IP3R1 activity would typically occur at the endoplasmic reticulum membrane, but this location is not specified.</p> </li> <li> <p>Biological Process Consistency: While all activities are annotated to GO:0007200 (phospholipase C-activating G protein-coupled receptor signaling pathway), the title of the model is \"Positive regulation of insulin secretion 2 (Mouse)\". It would be beneficial to explicitly link this to insulin secretion in the model (GO:0030073) to better match the stated purpose.</p> </li> <li> <p>Complete Input/Output Relationships: While some reactions in the model have appropriate input/output molecule associations (e.g., PLC activity with PIP2 input and IP3/DAG outputs), others are missing potential input/output annotations that would enhance the model's clarity.</p> </li> <li> <p>Incomplete Pathway: The model shows the pathway up to TRPC1 activity but does not complete the connection to insulin secretion, which would provide a more comprehensive representation of the title process.</p> </li> </ol>"},{"location":"reviews/62f58d8800003012-Positive_regulation_of_insulin_secretion_2___Mouse_/#technical-issues","title":"Technical Issues","text":"<ol> <li> <p>Evidence Codes: The model appropriately uses evidence codes like ECO:0000315 (mutant phenotype evidence used in manual assertion) and ECO:0000266 (sequence orthology evidence used in manual assertion) to support the assertions, which is good practice.</p> </li> <li> <p>Regulatory Relationships: The model correctly uses RO:0002629 (directly positively regulates) to represent the causal relationships between activities in the pathway.</p> </li> </ol>"},{"location":"reviews/62f58d8800003012-Positive_regulation_of_insulin_secretion_2___Mouse_/#biological-recommendations","title":"Biological Recommendations","text":"<ol> <li> <p>Complete the Pathway: Consider extending the model to show how the SOCE pathway ultimately leads to insulin secretion, which would complete the story suggested by the model title.</p> </li> <li> <p>Include Glucose Dependency: The literature (PMID:31664108) emphasizes that GPR40-mediated potentiation of insulin secretion is glucose-dependent. This aspect could be better represented in the model.</p> </li> <li> <p>Add Cellular Compartmentalization: The model would benefit from more precise cellular location annotations, particularly for IP3R1, which functions at the endoplasmic reticulum membrane.</p> </li> </ol>"},{"location":"reviews/62f58d8800003012-Positive_regulation_of_insulin_secretion_2___Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:62f58d8800003012) provides a good representation of the GPR40/FFAR1 signaling pathway that leads to store-operated calcium entry in pancreatic beta cells. The model follows most GO-CAM best practices and is supported by appropriate evidence. With some minor improvements, particularly regarding evidence for all causal associations and completing the pathway to insulin secretion, this would be an excellent model for disseminating knowledge about this important signaling pathway in insulin secretion.</p>"},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/","title":"62f58d8800003277 Import of ATM into peroxisomes y in response to reactive oxygen species via the PEX5 dependent  import pathway  leading to PEX5 ubiquitination and pexophagy  Human","text":"<p>Now let me examine the information I've collected to provide a thorough review of this GO-CAM model.</p>"},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#review-of-go-cam-model-gomodel62f58d8800003277","title":"Review of GO-CAM Model gomodel:62f58d8800003277","text":""},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (ID: gomodel:62f58d8800003277) is titled \"Import of ATM into peroxisomes in response to reactive oxygen species via the PEX5-dependent import pathway, leading to PEX5 ubiquitination and pexophagy (Human)\". The model represents a molecular pathway that describes how ATM kinase (Ataxia Telangiectasia Mutated) is imported into peroxisomes in response to reactive oxygen species (ROS), which ultimately leads to peroxisome degradation through autophagy (pexophagy).</p>"},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#biological-context-assessment","title":"Biological Context Assessment","text":"<p>The model correctly depicts a recently discovered pathway where: 1. ATM is imported into peroxisomes via the PEX5 receptor 2. In response to ROS, ATM phosphorylates PEX5 3. PEX5 is then ubiquitinated by PEX2 (an E3 ubiquitin ligase) 4. Ubiquitinated PEX5 serves as a signal for recruitment of autophagy receptors (like SQSTM1/p62) 5. This leads to selective autophagy of peroxisomes (pexophagy)</p> <p>This pathway is well-supported by the scientific literature, particularly the key papers referenced in the model (PMID:26344566 and PMID:27597759).</p>"},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#evaluation-of-model-structure-and-relations","title":"Evaluation of Model Structure and Relations","text":"<p>The model includes the following key activities and causal relationships:</p> <ol> <li>PEX5 (P50542) functions as a \"peroxisome matrix targeting signal-1 binding\" (GO:0005052) protein in the cytosol</li> <li>PEX5 then functions as a \"protein carrier chaperone\" (GO:0140597) in both the cytosol and peroxisomal matrix</li> <li>PEX5 is connected to peroxisomal membrane proteins PEX14 and PEX13 which have \"protein transmembrane transporter activity\" (GO:0008320)</li> <li>ATM (Q13315) functions as a \"protein serine/threonine kinase activity\" (GO:0004674) in the peroxisomal matrix</li> <li>PEX2 (P28328) has \"ubiquitin protein ligase activity\" (GO:0061630) at the peroxisomal membrane</li> <li>SQSTM1 (Q13501) has \"protein-macromolecule adaptor activity\" (GO:0030674) in the cytosol</li> </ol> <p>These connections correctly represent the pathway described in the literature where: - PEX5 serves as the receptor for peroxisomal matrix protein import - ATM is imported into peroxisomes and phosphorylates PEX5 - PEX2 ubiquitinates PEX5, marking peroxisomes for degradation via pexophagy - SQSTM1 (p62) serves as the autophagy receptor that recognizes ubiquitinated peroxisomal proteins</p>"},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#causal-relationships-assessment","title":"Causal Relationships Assessment","text":"<p>The causal relations in the model use appropriate predicates: - \"directly positively regulates\" (RO:0002629) is correctly used to indicate direct regulatory relationships - \"provides input for\" (RO:0002413) is appropriately used where one activity provides substrate for another</p> <p>All activities are properly connected in the correct sequential order that matches the biological pathway as described in the literature.</p>"},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing molecular adaptor activities and complexes:</p> <ol> <li> <p>Molecular adaptor activity representation: PEX5 is correctly annotated as \"protein carrier chaperone\" and SQSTM1 as \"protein-macromolecule adaptor activity\", consistent with the guidelines in the \"Molecular adaptor activity\" document.</p> </li> <li> <p>Subcellular locations: All activities are properly annotated with their correct cellular locations (cytosol, peroxisomal matrix, or peroxisomal membrane).</p> </li> <li> <p>E3 ubiquitin ligase: PEX2 is correctly annotated with \"ubiquitin protein ligase activity\" (GO:0061630), which is appropriate for an E3 ligase.</p> </li> <li> <p>PEX interactions: The interactions between PEX5, PEX14, and other peroxisomal proteins are represented accurately, matching their known roles in peroxisomal protein import.</p> </li> </ol>"},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, here are a few suggestions for potential improvements:</p> <ol> <li> <p>Explicit ROS representation: The model could benefit from explicitly representing the ROS stimulus that activates ATM in peroxisomes. This could be done by including a \"cellular response to reactive oxygen species\" (GO:0034614) biological process annotation to the ATM activity.</p> </li> <li> <p>Phosphorylation details: The model could be more specific about the site of PEX5 phosphorylation by ATM. According to the literature (PMID:26344566), ATM phosphorylates PEX5 at Ser141, which is an important detail for the biological mechanism.</p> </li> <li> <p>Ubiquitination specificity: The model could be more specific about which lysine residue of PEX5 is ubiquitinated by PEX2. According to the literature (PMID:26344566), PEX5 is monoubiquitinated at Lys209, which is critical for recruiting SQSTM1.</p> </li> <li> <p>Downstream autophagy machinery: The model could be extended to include additional components of the autophagy machinery that act downstream of SQSTM1 to complete the pexophagy process.</p> </li> </ol>"},{"location":"reviews/62f58d8800003277-Import_of_ATM_into_peroxisomes_y_in_response_to_reactive_oxygen_species_via_the_PEX5_dependent__import_pathway__leading_to_PEX5_ubiquitination_and_pexophagy__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:62f58d8800003277) accurately represents the current understanding of ATM-mediated pexophagy in response to ROS. The model captures the key molecular players and their causal relationships in a manner consistent with GO-CAM best practices. The biochemical content is well-aligned with the primary literature, and the model provides a clear representation of this important cellular pathway for peroxisome quality control.</p> <p>The model successfully connects the activities of PEX5, ATM, PEX2, and SQSTM1 to illustrate how reactive oxygen species trigger a signaling cascade that leads to selective autophagy of peroxisomes, a crucial process for maintaining cellular homeostasis under oxidative stress conditions.</p>"},{"location":"reviews/62f58d8800003536-Protein_import_into_peroxisomes__of_PTS2_containing_proteins_by_the_PEX7_receptor_and_isoform_PEX5L_of_PEX5__Human_/","title":"62f58d8800003536 Protein import into peroxisomes  of PTS2 containing proteins by the PEX7 receptor and isoform PEX5L of PEX5  Human","text":"<p>Based on all the information gathered, I'll now review the GO-CAM model \"gomodel:62f58d8800003536\" titled \"Protein import into peroxisomes of PTS2-containing proteins by the PEX7 receptor and isoform PEX5L of PEX5 (Human)\".</p>"},{"location":"reviews/62f58d8800003536-Protein_import_into_peroxisomes__of_PTS2_containing_proteins_by_the_PEX7_receptor_and_isoform_PEX5L_of_PEX5__Human_/#review-of-go-cam-model-62f58d8800003536","title":"Review of GO-CAM Model: 62f58d8800003536","text":""},{"location":"reviews/62f58d8800003536-Protein_import_into_peroxisomes__of_PTS2_containing_proteins_by_the_PEX7_receptor_and_isoform_PEX5L_of_PEX5__Human_/#title-protein-import-into-peroxisomes-of-pts2-containing-proteins-by-the-pex7-receptor-and-isoform-pex5l-of-pex5-human","title":"Title: Protein import into peroxisomes of PTS2-containing proteins by the PEX7 receptor and isoform PEX5L of PEX5 (Human)","text":""},{"location":"reviews/62f58d8800003536-Protein_import_into_peroxisomes__of_PTS2_containing_proteins_by_the_PEX7_receptor_and_isoform_PEX5L_of_PEX5__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the pathway of PTS2-containing protein import into peroxisomes mediated by PEX7 receptor and the PEX5L isoform of PEX5 in humans. The model includes several key proteins involved in this process: PEX14, PEX5L, PEX7, and PEX13.</p>"},{"location":"reviews/62f58d8800003536-Protein_import_into_peroxisomes__of_PTS2_containing_proteins_by_the_PEX7_receptor_and_isoform_PEX5L_of_PEX5__Human_/#key-findings-from-review","title":"Key Findings from Review","text":"<ol> <li>Model Structure and Organization:</li> <li>The model follows a logical flow representing the PTS2 import pathway into peroxisomes.</li> <li>The causal relationships between activities are represented using \"directly positively regulates\" (RO:0002629).</li> <li> <p>Six molecular activities are represented in the model in a sequential manner.</p> </li> <li> <p>Biological Accuracy:</p> </li> <li>The model correctly represents the known roles of PEX7 (peroxisomal targeting signal 2 receptor), PEX5L (the long isoform of PEX5 that can interact with PEX7), PEX14 (part of the docking complex), and PEX13 (part of the docking complex).</li> <li>The biology is consistent with current knowledge about peroxisomal protein import, particularly for PTS2-containing cargo proteins.</li> <li> <p>The model captures the cytosolic PTS2 binding by PEX7, interaction with PEX5L, docking at the peroxisomal membrane via PEX14/PEX13, and translocation into the peroxisomal matrix.</p> </li> <li> <p>Molecular Functions:</p> </li> <li> <p>The molecular functions are appropriately assigned to each protein:</p> <ul> <li>PEX7: peroxisome matrix targeting signal-2 binding (GO:0005053)</li> <li>PEX5L: protein carrier chaperone (GO:0140597) </li> <li>PEX14: protein-macromolecule adaptor activity (GO:0030674) and protein transmembrane transporter activity (GO:0008320)</li> <li>PEX13: protein transmembrane transporter activity (GO:0008320)</li> </ul> </li> <li> <p>Biological Processes:</p> </li> <li> <p>The biological processes are correctly annotated for each activity:</p> <ul> <li>PEX7's activity is part of protein import into peroxisome matrix (GO:0016558)</li> <li>PEX5L's activity is part of protein import into peroxisome matrix (GO:0016558) and protein import into peroxisome matrix, substrate release (GO:0044721)</li> <li>PEX14's activity is part of protein import into peroxisome matrix, docking (GO:0016560) and protein import into peroxisome matrix, translocation (GO:0016561)</li> <li>PEX13's activity is part of protein import into peroxisome matrix, translocation (GO:0016561)</li> </ul> </li> <li> <p>Cellular Component Annotations:</p> </li> <li> <p>Cellular locations are appropriately assigned:</p> <ul> <li>PEX7 and initial PEX5L activities occur in the cytosol (GO:0005829)</li> <li>PEX14 and PEX13 activities occur at the peroxisomal membrane (GO:0005778)</li> <li>The final PEX5L activity occurs in the peroxisomal matrix (GO:0005782)</li> </ul> </li> <li> <p>Evidence and References:</p> </li> <li>The model uses appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion, ECO:0000305 - curator inference used in manual assertion).</li> <li>References to relevant PubMed articles are included to support the assertions.</li> </ol>"},{"location":"reviews/62f58d8800003536-Protein_import_into_peroxisomes__of_PTS2_containing_proteins_by_the_PEX7_receptor_and_isoform_PEX5L_of_PEX5__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Feedback Loop Representation:</li> <li> <p>The model could benefit from including the recycling of PEX5L back to the cytosol after cargo release. Currently, the model seems to end with the substrate release step and doesn't show the complete cycle.</p> </li> <li> <p>Additional Molecular Interactions:</p> </li> <li>The interactions between PEX7 and its cargo proteins (PTS2-containing proteins) could be more explicitly represented, perhaps with specific examples of PTS2-containing proteins.</li> <li> <p>The model could include the ubiquitination steps involved in PEX5 recycling.</p> </li> <li> <p>Clarity of Activity Flow:</p> </li> <li>The relationship between PEX5L's protein carrier chaperone activity in the cytosol and its subsequent activities could be clarified.</li> </ol>"},{"location":"reviews/62f58d8800003536-Protein_import_into_peroxisomes__of_PTS2_containing_proteins_by_the_PEX7_receptor_and_isoform_PEX5L_of_PEX5__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the process of PTS2-containing protein import into peroxisomes mediated by PEX7 and PEX5L. The molecular functions, biological processes, and cellular components are appropriately assigned to each protein based on current scientific knowledge. The causal relationships between activities are logically represented. </p> <p>The model follows GO-CAM best practices for representing molecular adaptors (PEX14) and protein transmembrane transporters (PEX14, PEX13). However, the model could be enhanced by including the complete recycling pathway of PEX5L and more specific cargo proteins.</p> <p>In summary, this is a well-constructed GO-CAM model that effectively captures the current understanding of the PTS2 protein import pathway into peroxisomes in humans.</p>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/","title":"62f58d8800003672 Positive regulation of insulin secretion 3   Mouse","text":"<p>Based on my review of the GO-CAM model with ID 62f58d8800003672 and the associated molecular data, I'll provide a comprehensive assessment of this model focusing on both biological content and adherence to GO-CAM curation best practices.</p>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#review-of-go-cam-model-62f58d8800003672","title":"Review of GO-CAM Model 62f58d8800003672","text":""},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: \"Positive regulation of insulin secretion 3 (Mouse)\"</li> <li>Taxon: Mouse (NCBITaxon:10116)</li> <li>Status: Production</li> <li>Source: Derived from gomodel:R-HSA-399997</li> </ul>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model describes a signaling pathway involved in the positive regulation of insulin secretion in mouse pancreatic \u03b2-cells. The model captures the phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway (GO:0007207) and subsequent store-operated calcium entry that contributes to insulin secretion.</p> <p>The model includes several key activities: 1. Acetylcholine receptor activation and G protein signaling 2. Phospholipase C activation 3. Calcium release from intracellular stores 4. Store-operated calcium entry 5. Enhancement of insulin secretion</p>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#molecular-components-and-functions","title":"Molecular Components and Functions","text":"<p>The model includes the following key proteins and their molecular functions:</p> <ol> <li>Chrm3 (MGI:MGI:88398) - G protein-coupled acetylcholine receptor activity (GO:0016907)</li> <li>Gnaq (MGI:MGI:95776) and Gna11 (MGI:MGI:95766) - G protein activity (GO:0003925)</li> <li>Plcb1 (MGI:MGI:97613) - Phospholipase C activity (GO:0004435)</li> <li>Itpr1 (MGI:MGI:96623) - Inositol 1,4,5-trisphosphate-gated calcium channel activity (GO:0005220)</li> <li>Anxa7 (MGI:MGI:88031) - GTPase-dependent fusogenic activity (GO:0140523)</li> <li>Stim1 (MGI:MGI:107476) - Channel activator activity (GO:0099103)</li> <li>Orai1 (MGI:MGI:1925542) and Trpc1 (MGI:MGI:109528) - Store-operated calcium channel activity (GO:0015279)</li> </ol>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model successfully captures the causal flow of the signaling pathway:</p> <ol> <li>Chrm3 (acetylcholine receptor) directly positively regulates (RO:0002629) G proteins (Gnaq and Gna11)</li> <li>G proteins directly positively regulate (RO:0002629) Plcb1 (phospholipase C)</li> <li>Plcb1 provides input for (RO:0002413) Itpr1 (IP3 receptor)</li> <li>Anxa7 has a positive regulatory effect (RO:0002304) on Itpr1</li> <li>Itpr1 directly positively regulates (RO:0002629) Stim1</li> <li>Stim1 directly positively regulates (RO:0002629) Orai1 and Trpc1 (store-operated calcium channels)</li> </ol>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the well-established ACh-mediated signaling pathway that enhances insulin secretion in pancreatic \u03b2-cells. The key components and their functional relationships are supported by published literature:</p> <ol> <li>The muscarinic acetylcholine receptor M3 (Chrm3) is known to couple to Gq/11 proteins (Gnaq/Gna11) to activate phospholipase C in \u03b2-cells.</li> <li>The model correctly shows Plcb1 generating inositol 1,4,5-trisphosphate (IP3) which activates IP3 receptors.</li> <li>The model appropriately includes Anxa7 (Annexin A7), which has been shown to have a role in calcium signaling.</li> <li>The store-operated calcium entry mechanism involving Stim1, Orai1, and Trpc1 is well-supported by the referenced literature (especially PMID:26494622).</li> </ol> <p>Each function is backed by appropriate evidence codes and PMIDs, with many assertions supported by experimental evidence (ECO:0000314, experimental evidence).</p>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<ol> <li> <p>Component representation: The model correctly uses gene products for activities where the specific molecule carrying the activity is known.</p> </li> <li> <p>Evidence attribution: Each activity has appropriate evidence codes and references to literature. Most assertions are supported by ECO:0000314 (direct assay evidence) or ECO:0000315 (mutant phenotype evidence).</p> </li> <li> <p>Causal relationships: The model uses appropriate causal relationship predicates (RO:0002629, RO:0002413, RO:0002304) to indicate the type of regulation between activities.</p> </li> <li> <p>Cellular context: Activities are appropriately contextualized with cellular locations (e.g., plasma membrane GO:0005886).</p> </li> <li> <p>Species consistency: The model maintains consistency in using mouse gene products.</p> </li> </ol>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#identified-issues-or-improvements","title":"Identified Issues or Improvements","text":"<ol> <li> <p>PMID evidence verification: I've examined some of the key referenced papers (PMID:18452988, PMID:26494622, PMID:17343823) and confirm they support the assertions made in the model.</p> </li> <li> <p>Complex representation: The model appropriately follows GO-CAM guidelines for representing protein complexes. For example, individual components (Orai1, Trpc1) are represented separately with their specific activities, which is consistent with guidelines in the \"How to annotate complexes in GO-CAM\" document.</p> </li> <li> <p>Input representation: The model correctly shows CHEBI:29108 (calcium(2+)) as the primary input for the Itpr1 channel.</p> </li> </ol>"},{"location":"reviews/62f58d8800003672-Positive_regulation_of_insulin_secretion_3___Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 62f58d8800003672 is a high-quality representation of the acetylcholine-mediated signaling pathway that regulates calcium signaling and insulin secretion in mouse pancreatic \u03b2-cells. The model:</p> <ol> <li>Accurately represents the biological pathway based on published literature</li> <li>Follows GO-CAM best practices for representing molecular functions, causal relationships, and biological context</li> <li>Provides appropriate evidence and references for assertions</li> <li>Presents a clear and logical flow of activities in the signaling pathway</li> </ol> <p>The model effectively captures the store-operated calcium entry mechanism, which is a critical component in the regulation of insulin secretion. The biological content is consistent with current understanding of calcium signaling in pancreatic \u03b2-cells as described in the literature.</p> <p>This model can serve as a valuable resource for researchers interested in calcium signaling pathways in pancreatic \u03b2-cells and the regulation of insulin secretion.</p>"},{"location":"reviews/62f58d8800004064-Positive_regulation_of_insulin_secretion_4___Mouse_/","title":"62f58d8800004064 Positive regulation of insulin secretion 4   Mouse","text":"<p>Based on my review of the model and the relevant literature, I can now provide a comprehensive assessment of the GO-CAM model for \"Positive regulation of insulin secretion 4 (Mouse)\" (gomodel:62f58d8800004064).</p>"},{"location":"reviews/62f58d8800004064-Positive_regulation_of_insulin_secretion_4___Mouse_/#go-cam-model-review-gomodel62f58d8800004064","title":"GO-CAM Model Review: gomodel:62f58d8800004064","text":""},{"location":"reviews/62f58d8800004064-Positive_regulation_of_insulin_secretion_4___Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model represents a signaling pathway involved in the positive regulation of insulin secretion in mouse pancreatic beta cells, focusing on G protein-coupled acetylcholine receptor (Chrm3) activation leading to phospholipase C signaling, which ultimately contributes to insulin secretion. </p>"},{"location":"reviews/62f58d8800004064-Positive_regulation_of_insulin_secretion_4___Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Pathway Representation: </li> <li>The model correctly depicts the main components of the acetylcholine signaling pathway in beta cells: M3 muscarinic receptor (Chrm3) \u2192 G proteins (Gnaq, Gna11) \u2192 phospholipase C-beta (Plcb1) \u2192 PKC (Prkcb)</li> <li>The causal relationships use the appropriate predicate \"directly positively regulates\" (RO:0002629)</li> <li> <p>Activities are correctly associated with the \"phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway\" (GO:0007207)</p> </li> <li> <p>Molecular Function Annotations:</p> </li> <li> <p>Appropriate GO terms are used for each activity:</p> <ul> <li>Chrm3: \"G protein-coupled acetylcholine receptor activity\" (GO:0016907)</li> <li>Gnaq/Gna11: \"G protein activity\" (GO:0003925)</li> <li>Plcb1: \"phosphatidylinositol phospholipase C activity\" (GO:0004435)</li> <li>Prkcb: \"calcium,diacylglycerol-dependent serine/threonine kinase activity\" (GO:0004698)</li> </ul> </li> <li> <p>Evidence Support:</p> </li> <li>The model is well-supported by appropriate evidence codes and literature references</li> <li>The evidence for Plcb1's role includes direct assay evidence (ECO:0000314) from PMID:9762362</li> <li> <p>The G protein activities are supported by sequence orthology evidence (ECO:0000266) with human counterparts</p> </li> <li> <p>Biochemical Detail:</p> </li> <li>The model correctly shows inputs and outputs for Plcb1, including PIP2 (REACTO_R-ALL-179856) as input and DAG (REACTO_R-ALL-114519) and IP3 (REACTO_R-ALL-114520) as outputs</li> <li>This biochemical detail accurately reflects the phospholipase C catalytic activity</li> </ol>"},{"location":"reviews/62f58d8800004064-Positive_regulation_of_insulin_secretion_4___Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Incomplete Insulin Secretion Pathway:</li> <li>Despite the model's title referring to \"Positive regulation of insulin secretion,\" the causal chain ends with PKC activation (Prkcb) without explicitly connecting to insulin secretion</li> <li>The biological process term \"insulin secretion\" (GO:0030073) is present in the model objects but not used in the activity annotations</li> <li> <p>The literature evidence (PMID:27226533) discusses PKC's role in insulin secretion, but this final connection is missing from the model</p> </li> <li> <p>Cellular Location Details:</p> </li> <li> <p>All activities are annotated as occurring at the plasma membrane (GO:0005886), which is correct, but the model would benefit from including the cellular context of type B pancreatic cells (CL:0000169), which is listed in the model objects but not used in annotations</p> </li> <li> <p>Unused Entity in Model:</p> </li> <li>MGI:MGI:96907 (Marcks Mmus) is listed in the objects but not used in any activity in the model</li> <li> <p>The literature (PMID:27226533) specifically mentions MARCKS as a PKC substrate involved in this pathway, suggesting that this should be included as a downstream component</p> </li> <li> <p>Missing Regulatory Mechanisms:</p> </li> <li>The model doesn't capture the autocrine regulation aspect discussed in PMID:27226533, where exocytosis of insulin granules leads to ATP release, which activates P2Y1 receptors to generate DAG spikes</li> </ol>"},{"location":"reviews/62f58d8800004064-Positive_regulation_of_insulin_secretion_4___Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li>Complete the Pathway to Insulin Secretion:</li> <li>Add a downstream activity representing insulin secretion (GO:0030073)</li> <li>Connect PKC (Prkcb) activity to this insulin secretion activity using the appropriate causal relation (RO:0002304 - causally upstream of, positive effect)</li> <li> <p>Include the cellular location as type B pancreatic cell (CL:0000169)</p> </li> <li> <p>Add MARCKS as a PKC Substrate:</p> </li> <li>Include the phosphorylation of MARCKS (MGI:MGI:96907) by PKC as this is a key downstream event</li> <li> <p>Based on PMID:27226533, MARCKS phosphorylation is directly linked to exocytosis machinery regulation</p> </li> <li> <p>Expand the Model to Include Autocrine Signaling:</p> </li> <li> <p>Consider adding additional entities to represent the autocrine feedback loop described in the literature, where insulin exocytosis leads to ATP release and P2Y1 receptor activation</p> </li> <li> <p>Add Input/Output Molecules for Additional Activities:</p> </li> <li>Include input/output specifications for G protein and PKC activities to improve model clarity, similar to what was done for Plcb1</li> </ol>"},{"location":"reviews/62f58d8800004064-Positive_regulation_of_insulin_secretion_4___Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Positive regulation of insulin secretion 4 (Mouse)\" provides a good representation of the early steps in the G protein-coupled acetylcholine receptor signaling pathway that contributes to insulin secretion in mouse pancreatic beta cells. The model correctly depicts the causality from receptor activation to PKC activation through G proteins and phospholipase C, with appropriate molecular function terms and evidence.</p> <p>However, the model would benefit from explicit connection to insulin secretion as the ultimate outcome, inclusion of MARCKS as a PKC substrate, and representation of the cellular context in type B pancreatic cells. These additions would make the model more complete and better aligned with its title and the supporting literature.</p> <p>Despite these suggested improvements, the model represents a valuable contribution to our understanding of the molecular mechanisms underlying the regulation of insulin secretion and follows GO-CAM best practices for most aspects of its construction.</p>"},{"location":"reviews/62f58d8800004529-Positive_regulation_of_insulin_secretion_6__Mouse_/","title":"62f58d8800004529 Positive regulation of insulin secretion 6  Mouse","text":"<p>Based on my review of the GO-CAM model 62f58d8800004529 \"Positive regulation of insulin secretion 6 (Mouse)\", let me provide a comprehensive assessment:</p>"},{"location":"reviews/62f58d8800004529-Positive_regulation_of_insulin_secretion_6__Mouse_/#go-cam-model-review-gomodel62f58d8800004529","title":"GO-CAM Model Review: gomodel:62f58d8800004529","text":""},{"location":"reviews/62f58d8800004529-Positive_regulation_of_insulin_secretion_6__Mouse_/#summary","title":"Summary","text":"<p>This model represents the positive regulation of insulin secretion in mouse, focusing on a cAMP-dependent pathway involving GLP-1 receptor signaling and downstream molecular events leading to insulin secretion. The model was created in 2022 and describes interactions among several key proteins including GLP-1 receptor (Glp1r), G proteins (Gnas, Rap1a, Rap1b), adenylate cyclase (Adcy8), cAMP-regulated guanine nucleotide exchange factor (Rapgef4/EPAC2), and Rim2 (Rims2), culminating in insulin secretion.</p>"},{"location":"reviews/62f58d8800004529-Positive_regulation_of_insulin_secretion_6__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Biological accuracy: The model correctly represents a well-documented pathway of GLP-1 receptor-mediated insulin secretion, consistent with the literature referenced (PMID:11056535).</p> </li> <li> <p>Causal relationships: The causal relationships between activities are generally well-defined using the appropriate predicates (RO:0002629 \"directly positively regulates\").</p> </li> <li> <p>Evidence: Each assertion is backed by experimental evidence with appropriate ECO codes and PMIDs.</p> </li> <li> <p>Completeness: The model captures the full pathway from ligand-receptor interaction to the effector function (insulin secretion).</p> </li> </ol>"},{"location":"reviews/62f58d8800004529-Positive_regulation_of_insulin_secretion_6__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Molecular adaptor annotation:</li> <li>Rapgef4 (MGI:MGI:1917723) is shown with two separate activities: guanyl-nucleotide exchange factor activity (GO:0005085) and protein-macromolecule adaptor activity (GO:0030674). </li> <li>According to the \"How to annotate molecular adaptors\" guidelines, an adaptor should include \"has input\" annotations for the molecules it brings together. The current model doesn't specify these inputs for the adaptor activity.</li> <li> <p>Recommendation: Add \"has_input\" relationships to specify which molecules Rapgef4 brings together when functioning as an adaptor.</p> </li> <li> <p>Cellular compartment annotations:</p> </li> <li>While some activities have \"occurs_in\" compartment annotations, not all do. For instance, GCG (glucagon) activity lacks a cellular location.</li> <li> <p>Recommendation: Add appropriate cellular compartment information for all activities where known.</p> </li> <li> <p>Minor annotation inconsistencies:</p> </li> <li>The Rims2 protein (MGI:MGI:2152972) has \"molecular_function\" annotated as GO:0003674 (molecular function), which is a root term. This is generally not recommended as it doesn't provide specific functional information.</li> <li> <p>Recommendation: If the specific molecular function is known, replace GO:0003674 with a more specific term.</p> </li> <li> <p>Pathway visualization consideration:</p> </li> <li>The model includes parallel pathways with Rap1a and Rap1b, which both perform G protein activity. This is biologically accurate but might make the model slightly more complex to interpret.</li> <li> <p>Recommendation: Consider adding a comment to clarify the functional redundancy of these two proteins in this pathway.</p> </li> <li> <p>Literature integration:</p> </li> <li>While the model cites PMID:11056535 which provides evidence for the Rapgef4-Rims2 interaction, it would be valuable to integrate more recent literature that may have further characterized this pathway.</li> <li>Recommendation: Consider updating the model with more recent references if available.</li> </ol>"},{"location":"reviews/62f58d8800004529-Positive_regulation_of_insulin_secretion_6__Mouse_/#technical-assessment","title":"Technical Assessment","text":"<p>The model correctly implements GO-CAM best practices regarding: - Use of proper molecular function terms - Appropriate causal relationship predicates - Connection of activities to create a coherent biological pathway - Grounding assertions in experimental evidence - Species-specificity (correctly annotated as mouse)</p>"},{"location":"reviews/62f58d8800004529-Positive_regulation_of_insulin_secretion_6__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of GLP-1 receptor-mediated insulin secretion in mouse pancreatic beta cells. The model provides a valuable resource for understanding this signaling pathway. With minor improvements to the annotations as suggested above, it would be even more comprehensive and useful to the research community.</p> <p>The model can be accessed at: https://bioregistry.io/go.model:62f58d8800004529</p>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/","title":"62f58d8800004803 Positive regulation of insulin secretion 7  Mouse","text":"<p>Based on the review of the GO-CAM model and the supporting literature, I can now provide a comprehensive assessment of model gomodel:62f58d8800004803 \"Positive regulation of insulin secretion 7 (Mouse)\".</p>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#go-cam-model-review-positive-regulation-of-insulin-secretion-7-mouse","title":"GO-CAM Model Review: Positive regulation of insulin secretion 7 (Mouse)","text":""},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#model-id-gomodel62f58d8800004803","title":"Model ID: gomodel:62f58d8800004803","text":""},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model describes the GLP-1 receptor signaling pathway that regulates insulin secretion in mouse pancreatic beta cells. The model captures the molecular cascade from GLP-1 binding to its receptor through multiple downstream effectors that ultimately lead to insulin secretion.</p>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#model-structure-assessment","title":"Model Structure Assessment","text":"<p>The model appropriately represents a signaling pathway with the following components:</p> <ol> <li>Glucagon (Gcg) acting as a receptor ligand (GO:0048018) to activate the glucagon-like peptide-1 receptor (GLP-1R)</li> <li>GLP-1 receptor (Glp1r) with glucagon-like peptide 1 receptor activity (GO:0044508) at the plasma membrane</li> <li>G-protein signaling (Gnas) with adenylate cyclase activator activity (GO:0010856)</li> <li>Adenylyl cyclase (Adcy8) generating cAMP from ATP</li> <li>Protein kinase A (Prkaca) with cAMP-dependent protein kinase activity (GO:0004691)</li> <li>Snapin as a protein-macromolecule adaptor (GO:0030674)</li> <li>Synaptotagmin-7 (Syt7) with phosphatidylinositol-4,5-bisphosphate binding activity (GO:0005546)</li> <li>PKA regulatory subunit (Prkar1a) with inhibitory function (GO:0004862)</li> <li>CREB transcription factor (Creb1) with DNA-binding transcription factor activity (GO:0000981)</li> </ol>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Evidence-Based Annotations: Each activity is backed by experimental evidence with appropriate ECO codes and PMIDs.</p> </li> <li> <p>Proper Causal Relationships: The model correctly uses RO:0002629 (directly positively regulates) to show the causal flow from receptor activation to downstream effects.</p> </li> <li> <p>Cellular Context: The model properly locates activities in their cellular compartments (e.g., GLP-1R at the plasma membrane).</p> </li> <li> <p>Substrate Specification: The model correctly identifies ATP as the input and cAMP as the output for adenylate cyclase.</p> </li> <li> <p>Common Biological Process: All activities are appropriately situated within the common biological process \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\" (GO:0007189).</p> </li> <li> <p>Evidence for Causal Links: The causal associations have evidence codes and references (e.g., the link between PKA and Snapin is backed by PMID:21356520).</p> </li> </ol>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Potassium Channel Context: The Kcnj11 protein (MGI:MGI:107501) with inward rectifying potassium channel activity (GO:0008282) appears in the model but lacks clear causal connections to other components. From the literature (PMID:33196462), this is a likely target of the pathway and should be causally connected.</p> </li> <li> <p>Missing Outcomes: While the model shows the pathway events, it doesn't explicitly connect the final steps to the biological process of insulin secretion (GO:0030073), which is mentioned in some activity annotations but not as a pathway output.</p> </li> <li> <p>Temporal Dynamics: The model doesn't capture the temporal aspects of insulin secretion (first vs. second phase) that are clearly described in the papers (particularly PMID:21356520).</p> </li> <li> <p>Complete Causal Chain: The model has some \"gaps\" in causal links. For instance, how the Creb1 transcription factor functionally connects to the other components isn't explicit in the causal relationships.</p> </li> </ol>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#biological-consistency-with-literature","title":"Biological Consistency with Literature","text":"<p>The model aligns well with the current understanding of GLP-1 signaling in beta cells as described in the literature:</p> <ol> <li> <p>The papers (PMID:25830090, PMID:21356520) support the role of the GLP-1R in potentiating insulin secretion via cAMP elevation and PKA activation.</p> </li> <li> <p>The importance of Snapin phosphorylation by PKA (Ser50) in insulin secretion is well-supported by PMID:21356520, and this is reflected in the model.</p> </li> <li> <p>The inhibitory role of Prkar1a on PKA activity and subsequent effects on insulin secretion is consistent with the literature.</p> </li> </ol>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#recommendations-for-model-improvement","title":"Recommendations for Model Improvement","text":"<ol> <li> <p>Complete the Causal Chain: Add a causal link between PKA and CREB1 to show how PKA activates this transcription factor.</p> </li> <li> <p>Connect to Physiological Outcome: Add explicit connections to show how this pathway ultimately leads to insulin secretion.</p> </li> <li> <p>Include the Potassium Channel Connection: Clarify how Kcnj11 fits into the pathway, likely as a target of PKA or another component.</p> </li> <li> <p>Add Missing Components: Consider adding SNAP-25 and VAMP2, which are mentioned in PMID:21356520 as important components of the exocytosis machinery that interact with Snapin.</p> </li> <li> <p>Temporal Aspects: Consider annotating or commenting on the model to indicate which components are particularly important for first-phase versus second-phase insulin secretion.</p> </li> </ol>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model follows most GO-CAM best practices:</p> <ol> <li>\u2705 Uses appropriate molecular function terms</li> <li>\u2705 Properly represents causal relationships</li> <li>\u2705 Includes cellular context where appropriate</li> <li>\u2705 Provides evidence codes and references</li> <li>\u2705 Uses consistent biological process annotations</li> <li>\u274c Has some incomplete causal chains</li> <li>\u274c Missing some physiological outcomes</li> </ol>"},{"location":"reviews/62f58d8800004803-Positive_regulation_of_insulin_secretion_7__Mouse_/#conclusion","title":"Conclusion","text":"<p>Model gomodel:62f58d8800004803 provides a good representation of GLP-1R signaling in the regulation of insulin secretion. The model accurately captures most of the key molecular players and their relationships, with strong literature support. With some minor improvements to complete causal chains and connect to physiological outcomes, this model could provide an even more comprehensive view of this important signaling pathway in pancreatic beta cells.</p> <p>The model is biologically accurate and largely follows GO-CAM best practices, making it a valuable resource for understanding the molecular basis of incretin-potentiated insulin secretion.</p>"},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/","title":"632cf60a00000169 HHV1 ICP0 modulation of interferon production via MORC3 degradation  Human Herpesvirus","text":"<p>Based on my review of the GO-CAM model and associated information, I'll now provide a comprehensive review of the model gomodel:632cf60a00000169 titled \"HHV1-ICP0 modulation of interferon production via MORC3 degradation (Human-Herpesvirus)\".</p>"},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/#go-cam-model-review-gomodel632cf60a00000169","title":"GO-CAM Model Review: gomodel:632cf60a00000169","text":""},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/#summary","title":"Summary","text":"<p>The model gomodel:632cf60a00000169 depicts how Herpes Simplex Virus 1 (HSV-1) protein ICP0 modulates interferon production through the degradation of host protein MORC3. This represents an important viral immune evasion mechanism.</p>"},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/#model-overview","title":"Model Overview","text":"<p>The model contains four key molecular activities connected in a causal pathway:</p> <ol> <li>ICP0 (UniProtKB:P08393) - E3 ubiquitin ligase activity (GO:0061630)</li> <li>MORC3 (UniProtKB:Q14149) - DNA binding activity (GO:0003677)</li> <li>MORC3 (UniProtKB:Q14149) - Protein-macromolecule adaptor activity (GO:0030674)</li> <li>IFNB1 (UniProtKB:P01574) - Cytokine activity (GO:0005125)</li> </ol>"},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current scientific understanding of how HSV-1 ICP0 suppresses the host's interferon response:</p> <ol> <li>ICP0 functions as an E3 ubiquitin ligase that targets host proteins for degradation</li> <li>MORC3 is a nuclear protein that normally restricts viral replication and has dual functions:</li> <li>DNA binding activity, which represses transcription</li> <li>Adaptor activity in nuclear/PML bodies</li> <li>By degrading MORC3, ICP0 prevents its antiviral functions, which include regulating type I interferon production</li> <li>The suppression of MORC3's activities leads to inhibition of IFNB1 (interferon beta) production</li> </ol> <p>The model is well-supported by the literature, particularly the papers by Gaidt et al. (2021, Nature) and Sloan et al. (2016, J Virol), which demonstrate that MORC3 has both direct antiviral activity and participates in a \"self-guarding\" mechanism where its degradation can trigger IFN production through de-repression of a MORC3-regulated element near IFNB1.</p>"},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/#model-structure-and-go-cam-compliance","title":"Model Structure and GO-CAM Compliance","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li>Proper causal connections: The model correctly uses the appropriate causal predicates:</li> <li> <p>RO:0002630 (directly negatively regulates) to show ICP0's inhibitory effect on both MORC3 activities</p> </li> <li> <p>Cellular components: All activities are annotated with their appropriate cellular locations:</p> </li> <li>ICP0 in host cell nucleus (GO:0042025)</li> <li>MORC3 DNA binding in chromatin (GO:0000785)</li> <li>MORC3 adaptor activity in PML body (GO:0016605)</li> <li> <p>IFNB1 in extracellular space (GO:0005615)</p> </li> <li> <p>Biological processes: Each activity is appropriately placed within a relevant biological process:</p> </li> <li>ICP0: \"suppression by virus of host type I interferon production\" (GO:0039501)</li> <li>MORC3 DNA binding: \"negative regulation of transcription by RNA polymerase II\" (GO:0000122)</li> <li>MORC3 adaptor: \"antiviral innate immune response\" (GO:0140374)</li> <li> <p>IFNB1: \"type I interferon-mediated signaling pathway\" (GO:0060337)</p> </li> <li> <p>Evidence codes: All annotations include appropriate evidence codes and literature references.</p> </li> </ol>"},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I identified a few areas that could be improved:</p> <ol> <li> <p>Complete pathway representation: The model could more explicitly show how MORC3 degradation leads to de-repression of the MORC3-regulated element (MRE) adjacent to the IFNB1 locus. According to Gaidt et al. (2021), this is a key mechanism by which MORC3's \"self-guarding\" function operates.</p> </li> <li> <p>Additional molecular functions: The model currently depicts MORC3 with two activities, but could potentially include its ATPase activity, which is involved in its localization to nuclear bodies and function.</p> </li> <li> <p>Additional participants: The model could include other proteins that interact with MORC3 in PML nuclear bodies, such as PML itself, which would provide a more complete picture of the nuclear body component of the pathway.</p> </li> <li> <p>Downstream effects: The model could be extended to show the downstream effects of IFNB1 signaling through the IFNAR receptor and JAK-STAT pathway.</p> </li> </ol>"},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by evidence with appropriate literature citations:</p> <ul> <li>PMID:15247261 for ICP0's ubiquitin ligase activity</li> <li>PMID:34759314 for MORC3's DNA binding and adaptor functions</li> <li>PMID:27440897 for MORC3's role in antiviral response</li> <li>PMID:10556041 for IFNB1's cytokine activity</li> <li>PMID:18035482 for IFNB1's role in type I interferon signaling</li> </ul> <p>All references are appropriate and relevant for the specific annotations they support.</p>"},{"location":"reviews/632cf60a00000169-HHV1_ICP0_modulation_of_interferon_production_via_MORC3_degradation__Human_Herpesvirus__/#conclusion","title":"Conclusion","text":"<p>The model gomodel:632cf60a00000169 provides an accurate representation of how HSV-1 ICP0 modulates interferon production via MORC3 degradation. It follows GO-CAM best practices and is well-supported by scientific evidence. The model successfully captures a key viral immune evasion mechanism through proper use of molecular activities, cellular components, biological processes, and causal connections.</p> <p>Minor improvements could be made to represent additional complexities of the pathway, but the model as it stands provides a clear and accurate representation of the core mechanism of how HSV-1 ICP0 impacts host interferon production through MORC3.</p>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/","title":"632cf60a00000788 USP20 mediated STING deubiquitination leading to STING stabilisation  Human","text":"<p>Now that I have collected the necessary information, I'll provide a comprehensive review of the GO-CAM model with ID 632cf60a00000788.</p>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#review-of-go-cam-model-gomodel632cf60a00000788","title":"Review of GO-CAM Model: gomodel:632cf60a00000788","text":""},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#basic-model-information","title":"Basic Model Information","text":"<ul> <li>ID: gomodel:632cf60a00000788</li> <li>Title: USP20-mediated STING deubiquitination leading to STING stabilisation (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> <li>Comments: \"Automated change 2023-03-16: RO:0002213 replaced by RO:0002629\"</li> </ul>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the molecular mechanism by which USP20 (with the assistance of USP18) deubiquitinates STING/MITA, leading to STING stabilization and promotion of antiviral innate immune responses in humans. The model contains three main molecular activities and their causal relationships.</p>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#entities-and-their-functions","title":"Entities and Their Functions","text":""},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#1-usp18-uniprotkbq9umw8","title":"1. USP18 (UniProtKB:Q9UMW8)","text":"<ul> <li>Function: Molecular adaptor activity (GO:0060090)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li>Process: Antiviral innate immune response (GO:0140374)</li> <li>Evidence: Direct assay evidence (ECO:0000314) from PMID:27801882</li> <li>Causal relationship: Directly positively regulates USP20's deubiquitinase activity</li> </ul> <p>USP18 is correctly annotated as having a molecular adaptor activity, which is consistent with the literature showing it functions as a non-enzymatic adaptor that recruits USP20 to STING.</p>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#2-usp20-uniprotkbq9y2k6","title":"2. USP20 (UniProtKB:Q9Y2K6)","text":"<ul> <li>Function: Cysteine-type deubiquitinase activity (GO:0004843)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li>Process: Antiviral innate immune response (GO:0140374)</li> <li>Evidence: Direct assay evidence (ECO:0000314) from PMID:19424180</li> <li>Causal relationship: Directly positively regulates STING's cyclic GMP-AMP binding</li> </ul> <p>USP20 is correctly annotated with deubiquitinase activity, which is responsible for removing K48-linked ubiquitin chains from STING.</p>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#3-sting1-uniprotkbq86wv6","title":"3. STING1 (UniProtKB:Q86WV6)","text":"<ul> <li>Function: 2',3'-cyclic GMP-AMP binding (GO:0061507)</li> <li>Location: Endoplasmic reticulum membrane (GO:0005789)</li> <li>Process: Antiviral innate immune response (GO:0140374)</li> <li>Evidence: Direct assay evidence (ECO:0000314) from PMID:23747010</li> </ul> <p>STING1 is correctly annotated as having cyclic GMP-AMP binding activity, which is a key function in DNA-sensing pathways.</p>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate representation of biological process: The model correctly depicts the USP18-USP20-STING relationship described in the literature. USP18 functions as an adaptor to recruit USP20, which then deubiquitinates and stabilizes STING.</p> </li> <li> <p>Appropriate evidence citations: Each activity and relationship is supported by appropriate published evidence with direct assay evidence codes.</p> </li> <li> <p>Correct subcellular locations: The subcellular locations for the proteins are correctly annotated based on the literature.</p> </li> <li> <p>Correct causal relationships: The model uses the appropriate causal predicate RO:0002629 (directly positively regulates) to represent the activating relationship between USP18 and USP20, and between USP20 and STING1.</p> </li> </ol>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing K48-linked ubiquitination details: The model does not explicitly indicate that USP20 removes K48-linked ubiquitin chains from STING, which is a key mechanistic detail from the Zhang et al. (2016) paper. Consider adding this specificity to the annotation.</p> </li> <li> <p>Missing representation of STING stabilization outcome: While the model shows that USP20 activity positively regulates STING, it doesn't explicitly represent the stabilization of STING protein levels as an outcome. Consider adding an annotation to represent this functional consequence.</p> </li> <li> <p>Potential redundancy in causal associations: USP20 has two identical causal associations to STING1 (identical predicate and target), which appears to be redundant and should be consolidated into a single relationship.</p> </li> <li> <p>Missing functional consequence of STING activity: The model could be expanded to show what happens downstream of STING activation - specifically the induction of type I interferons and proinflammatory cytokines as described in the literature.</p> </li> <li> <p>Complex representation considerations: According to GO-CAM best practices for annotating complexes, since USP18-USP20 function together but have distinct activities, they are correctly represented as separate entities. However, the model could more clearly represent their physical interaction.</p> </li> </ol>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is largely consistent with the findings reported in the key references:</p> <ul> <li>Zhang et al. (2016) showed that USP18 functions as an adaptor to recruit USP20 to deubiquitinate STING in a manner independent of USP18's enzymatic activity.</li> <li>The model captures the essential relationship that USP20 deubiquitinates STING, leading to STING stabilization.</li> <li>The function of STING in binding cyclic dinucleotides like 2',3'-cGAMP is accurately represented.</li> </ul>"},{"location":"reviews/632cf60a00000788-USP20_mediated_STING_deubiquitination_leading_to_STING_stabilisation__Human_/#summary-and-conclusion","title":"Summary and Conclusion","text":"<p>The GO-CAM model gomodel:632cf60a00000788 provides a good representation of the USP18-USP20-STING pathway in antiviral innate immune responses. It accurately captures the key molecular activities and their causal relationships. The model uses appropriate GO terms, evidence codes, and citations.</p> <p>To improve the model, I recommend: 1. Adding explicit annotation of K48-linked deubiquitination 2. Including the stabilization of STING protein levels as an outcome 3. Resolving the redundant causal association from USP20 to STING1 4. Extending the model to include downstream activation of IRF3/NF-\u03baB and type I interferon production 5. More clearly representing the physical interaction between USP18 and USP20</p> <p>Overall, this is a well-constructed model that effectively captures the key aspects of USP20-mediated STING deubiquitination in antiviral immune responses.</p>"},{"location":"reviews/633b013300000089-Positive_regulation_of_insulin_secretion_11___Mouse_/","title":"633b013300000089 Positive regulation of insulin secretion 11   Mouse","text":"<p>Now I'll perform a detailed review of the GO-CAM model gomodel:633b013300000089 based on the information gathered:</p>"},{"location":"reviews/633b013300000089-Positive_regulation_of_insulin_secretion_11___Mouse_/#review-of-go-cam-model-633b013300000089","title":"Review of GO-CAM model: 633b013300000089","text":""},{"location":"reviews/633b013300000089-Positive_regulation_of_insulin_secretion_11___Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: \"Positive regulation of insulin secretion 11 (Mouse)\" Taxon: Mouse (NCBITaxon:10090) Status: Production  </p>"},{"location":"reviews/633b013300000089-Positive_regulation_of_insulin_secretion_11___Mouse_/#model-content-evaluation","title":"Model Content Evaluation","text":"<p>This model represents a G protein-coupled receptor (GPCR) signaling pathway that leads to calcium channel activation, which is involved in the regulation of insulin secretion. The pathway begins with the FFAR2 receptor (MGI:MGI:2441731), which when activated, signals through G-proteins (Gna11 and Gnaq), leading to activation of phospholipase C beta 1 (Plcb1), which in turn activates the IP3 receptor (Itpr1).</p>"},{"location":"reviews/633b013300000089-Positive_regulation_of_insulin_secretion_11___Mouse_/#strengths","title":"Strengths:","text":"<ol> <li> <p>The model correctly represents the causal flow of a GPCR signaling pathway, with appropriate \"directly positively regulates\" (RO:0002629) relationships between activities.</p> </li> <li> <p>The model correctly indicates cellular locations, with activities occurring at the plasma membrane (GO:0005886).</p> </li> <li> <p>The biological process context is consistently annotated for each activity as \"phospholipase C-activating G protein-coupled receptor signaling pathway\" (GO:0007200).</p> </li> <li> <p>The input/output molecules for phospholipase C activity are properly annotated (PIP2 \u2192 DAG + IP3).</p> </li> <li> <p>The evidence for each activity is appropriately referenced with PMIDs and evidence codes.</p> </li> </ol>"},{"location":"reviews/633b013300000089-Positive_regulation_of_insulin_secretion_11___Mouse_/#issues-identified","title":"Issues Identified:","text":"<ol> <li> <p>Missing Small Molecule Ligand: While the model implies that the FFAR2 receptor is activated by acetate (according to the literature), the small molecule activator is not explicitly represented in the model. According to the \"Signaling receptor activity annotation guidelines\", small molecule activators should be linked to the receptor activity with the relation \"is small molecule activator\".</p> </li> <li> <p>Incomplete Pathway Context: The model title mentions \"Positive regulation of insulin secretion\", but there's no explicit connection to insulin secretion (GO:0030073) in the model. The pathway ends with the IP3 receptor activity without showing how this leads to insulin secretion.</p> </li> <li> <p>Cellular Context: There's no indication that these activities occur in pancreatic beta cells (CL:0000169), which would be important for the proper contextual understanding of insulin secretion.</p> </li> <li> <p>Missing Final Output: The model doesn't show how IP3 receptor activation leads to calcium release and ultimately insulin secretion, leaving the pathway incomplete.</p> </li> <li> <p>FFAR2 Receptor Input/Target: According to the \"Signaling receptor activity annotation guidelines\", the receptor's target should be the effector protein it regulates (G-proteins in this case), which should be captured with a 'has input' relation. This relationship appears to be missing.</p> </li> </ol>"},{"location":"reviews/633b013300000089-Positive_regulation_of_insulin_secretion_11___Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add Small Molecule Activator: Connect acetate (CHEBI:30089) to the FFAR2 receptor activity using the \"is small molecule activator\" relation.</p> </li> <li> <p>Complete the Pathway: Add the downstream activities showing how IP3 receptor activation leads to calcium release, which then triggers insulin secretion.</p> </li> <li> <p>Add Cellular Context: Explicitly annotate that these activities occur in pancreatic beta cells (CL:0000169).</p> </li> <li> <p>Add FFAR2 Receptor Input: Add the 'has input' relation from the FFAR2 receptor to its G-protein targets.</p> </li> <li> <p>Connect to Insulin Secretion: Add activities that connect the IP3 receptor to insulin secretion (GO:0030073) to complete the biological process context.</p> </li> </ol>"},{"location":"reviews/633b013300000089-Positive_regulation_of_insulin_secretion_11___Mouse_/#summary","title":"Summary","text":"<p>The model gomodel:633b013300000089 presents a well-structured GPCR signaling pathway that leads to IP3 receptor activation. It correctly represents the molecular activities and their relationships in the pathway. However, the model could be improved by adding the small molecule activator, including the complete pathway to insulin secretion, and providing the cellular context of pancreatic beta cells. With these additions, the model would better represent the biological process of positive regulation of insulin secretion mediated by FFAR2 in mice.</p>"},{"location":"reviews/633b013300000306-Tricarboxylic_acid_cycle_1__Mouse_/","title":"633b013300000306 Tricarboxylic acid cycle 1  Mouse","text":"<p>Based on my review of the GO-CAM model \"Tricarboxylic acid cycle 1 (Mouse)\" (gomodel:633b013300000306) and the best practice guidelines, here's my assessment:</p>"},{"location":"reviews/633b013300000306-Tricarboxylic_acid_cycle_1__Mouse_/#review-of-go-cam-model-tricarboxylic-acid-cycle-1-mouse","title":"Review of GO-CAM Model: Tricarboxylic acid cycle 1 (Mouse)","text":""},{"location":"reviews/633b013300000306-Tricarboxylic_acid_cycle_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model captures the tricarboxylic acid (TCA) cycle in mouse, representing the sequence of enzyme activities that make up this metabolic pathway. The model includes all key enzymes in the cycle, their molecular functions, inputs/outputs, cellular locations, and causal relationships.</p>"},{"location":"reviews/633b013300000306-Tricarboxylic_acid_cycle_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Complete pathway representation: The model captures all the major enzymatic steps of the TCA cycle, with appropriate molecular functions assigned to each enzyme or enzyme complex.</p> </li> <li> <p>Complex representation: The model correctly uses protein complexes (e.g., isocitrate dehydrogenase complex, succinate dehydrogenase complex) with their component subunits listed, following the best practices for complex annotation in GO-CAM.</p> </li> <li> <p>Evidence and literature support: Each activity is supported by appropriate literature references with evidence codes (e.g., ECO:0000314 for direct assay evidence, ECO:0000315 for mutant phenotype evidence).</p> </li> <li> <p>Subcellular localization: The activities are appropriately localized to the mitochondrial matrix (GO:0005759) or mitochondrion (GO:0005739), consistent with the known location of the TCA cycle.</p> </li> <li> <p>Input/output molecules: The model clearly specifies the chemical inputs and outputs for each reaction using REACTO identifiers for metabolites.</p> </li> <li> <p>Causal connections: The model uses RO:0002413 (\"provides input for\") to show the sequential flow of the TCA cycle reactions.</p> </li> <li> <p>Regulatory component: The model includes a regulatory element with Sirt3 (MGI:MGI:1927665) protein deacetylase activity positively regulating succinate dehydrogenase activity.</p> </li> </ol>"},{"location":"reviews/633b013300000306-Tricarboxylic_acid_cycle_1__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Automated changes: The model includes comments about automated changes to some GO terms (GO:0005962 replaced by GO:0045242 and GO:0045257 replaced by GO:0045273). This is good practice for documenting term updates.</p> </li> <li> <p>Cellular compartment annotation: While most activities are correctly annotated to occur in the mitochondrial matrix (GO:0005759), the activity for MGI:MGI:1927665 (Sirt3) lacks a cellular location annotation. Consider adding this for completeness.</p> </li> <li> <p>Biological process annotation: Some activities are missing explicit \"part_of\" associations to the TCA cycle (GO:0006099). For consistency, consider adding this to all activities.</p> </li> <li> <p>Evidence for causal relationships: While the causal relationships between sequential enzyme activities use RO:0002413 (\"provides input for\"), many lack evidence annotations. Consider adding evidence for these connections.</p> </li> <li> <p>Regulatory mechanism details: The regulatory relationship between Sirt3 and the succinate dehydrogenase complex uses RO:0002629 (\"directly positively regulates\") with appropriate evidence, but the mechanism could be elaborated further. Does Sirt3 deacetylate a specific subunit of the complex?</p> </li> </ol>"},{"location":"reviews/633b013300000306-Tricarboxylic_acid_cycle_1__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by: - Using appropriate molecular function terms - Correctly representing protein complexes with their components - Using proper causal relationships between activities - Including evidence codes and literature references - Specifying inputs and outputs for reactions</p>"},{"location":"reviews/633b013300000306-Tricarboxylic_acid_cycle_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that effectively represents the mouse TCA cycle. It correctly represents the enzymatic activities, their physical connectivity through metabolites, and includes regulatory components. The minor suggestions above would further enhance the completeness and connectivity of the model, but overall, the model meets GO-CAM standards and accurately represents the biology of the TCA cycle.</p> <p>The model can be viewed at: https://bioregistry.io/go.model:633b013300000306</p>"},{"location":"reviews/633b013300001238-Pyruvate_catabolic_process_1__Mouse_/","title":"633b013300001238 Pyruvate catabolic process 1  Mouse","text":"<p>Now, let me review this GO-CAM model based on all the information I've gathered:</p>"},{"location":"reviews/633b013300001238-Pyruvate_catabolic_process_1__Mouse_/#review-of-go-cam-model-gomodel633b013300001238-pyruvate-catabolic-process-1-mouse","title":"Review of GO-CAM Model gomodel:633b013300001238 - \"Pyruvate catabolic process 1 (Mouse)\"","text":""},{"location":"reviews/633b013300001238-Pyruvate_catabolic_process_1__Mouse_/#model-overview","title":"Model Overview:","text":"<p>This model represents the pyruvate catabolic process in mouse, focusing on lactate dehydrogenase activities and lactate transport. The model includes:</p> <ol> <li>Pyruvate kinase activity (Pkm) that provides input for lactate dehydrogenase activity</li> <li>Three lactate dehydrogenase activities (Ldha, Ldhb, Ldhc) that convert pyruvate to lactate in the cytosol</li> <li>Two lactate transmembrane transporters (Slc16a1/MCT1 and Slc16a3/MCT4) that export lactate from the cell</li> </ol>"},{"location":"reviews/633b013300001238-Pyruvate_catabolic_process_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li> <p>Correct biological pathway representation: The model accurately represents the canonical glycolytic endpoint where pyruvate is converted to lactate and then exported from the cell.</p> </li> <li> <p>Appropriate use of causal relationships: The model uses the \"provides input for\" (RO:0002413) relationship appropriately to connect the pyruvate kinase activity to lactate dehydrogenase activities.</p> </li> <li> <p>Correct GO term usage: The model uses the appropriate molecular function terms for each protein (pyruvate kinase activity, L-lactate dehydrogenase activity, lactate transmembrane transporter activity).</p> </li> <li> <p>Proper cellular localization: The model correctly specifies the subcellular locations for the activities (cytosol for LDH activities, plasma membrane for transporters).</p> </li> <li> <p>Good evidence support: The model includes appropriate evidence codes and PMID references for most annotations.</p> </li> </ol>"},{"location":"reviews/633b013300001238-Pyruvate_catabolic_process_1__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li> <p>Incomplete part_of annotations: The Ldhb activity (gomodel:633b013300001238/633b013300001437) lacks evidence for its involvement in the pyruvate catabolic process. An evidence code and reference should be added to support this annotation.</p> </li> <li> <p>Missing biological context: The model doesn't clearly indicate the physiological context in which this pathway operates. It would benefit from annotations showing when this pathway is activated (e.g., during anaerobic conditions, high glycolytic flux, etc.).</p> </li> <li> <p>Missing final destination: The model shows lactate being transported across the plasma membrane but doesn't indicate where it goes after export. Adding information about lactate's fate in the extracellular space or bloodstream would improve the model's completeness.</p> </li> <li> <p>Missing regulation: The model lacks regulatory components that control lactate dehydrogenase and transporter activities. For example, pH, NAD+/NADH ratio, and oxygen levels are important regulators of this pathway.</p> </li> <li> <p>Missing connection to downstream metabolism: While the model properly represents lactate export, it doesn't show potential reuptake and utilization of lactate by other cells (the lactate shuttle concept), which would provide a more complete biological picture.</p> </li> </ol>"},{"location":"reviews/633b013300001238-Pyruvate_catabolic_process_1__Mouse_/#technical-compliance-issues","title":"Technical Compliance Issues:","text":"<ol> <li> <p>Complex representation: According to the \"How to annotate complexes in GO-CAM\" guidelines, the LDH activities would be better represented if their functional relationship as potential tetramers was indicated. LDH typically functions as a tetramer composed of different combinations of LDHA, LDHB, and LDHC subunits.</p> </li> <li> <p>Causal chain completeness: While the pyruvate kinase is shown to provide input for LDHC, there should be a direct causal relationship to the other LDH activities (LDHA, LDHB) as well, especially since all these LDH activities are part of the same process.</p> </li> </ol>"},{"location":"reviews/633b013300001238-Pyruvate_catabolic_process_1__Mouse_/#suggested-improvements","title":"Suggested Improvements:","text":"<ol> <li>Add evidence for Ldhb's involvement in the pyruvate catabolic process</li> <li>Add regulatory relationships that control the lactate dehydrogenase activities</li> <li>Expand the model to include the fate of exported lactate</li> <li>Consider representing the LDH enzymes' relationship as part of functional tetramers</li> <li>Add direct causal relationships between the pyruvate kinase activity and all LDH activities</li> <li>Include information about NAD+/NADH involvement in the LDH reaction</li> </ol> <p>This model provides a good foundation for representing the pyruvate to lactate conversion pathway in mouse, but could be enhanced with the suggested improvements to provide a more complete biological representation of this important metabolic process.</p>"},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/","title":"633b013300001469 Pyruvate catabolic process 2  Mouse","text":"<p>Now, let me examine the model carefully and provide a thorough review of the GO-CAM model \"Pyruvate catabolic process 2 (Mouse)\" (ID: gomodel:633b013300001469).</p>"},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#review-of-go-cam-model-pyruvate-catabolic-process-2-mouse","title":"Review of GO-CAM Model: Pyruvate catabolic process 2 (Mouse)","text":""},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the pyruvate catabolic process in mouse (NCBITaxon:10090), specifically focusing on the conversion of pyruvate to acetyl-CoA through the pyruvate dehydrogenase complex and associated transport mechanisms. The model has been updated to reflect current terminology, with automated changes replacing outdated GO terms (GO:0061732 with GO:0006086, and GO:0005967 with GO:0045254).</p>"},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#model-structure-and-biological-content","title":"Model Structure and Biological Content","text":""},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#pathway-coverage","title":"Pathway Coverage","text":"<p>The model captures the following key aspects of pyruvate catabolism: 1. Transport of pyruvate from the cytosol to mitochondrial matrix 2. Pyruvate dehydrogenase complex (PDC) activity and its components 3. Connection to acetyl-CoA biosynthesis</p>"},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#molecular-components-and-activities","title":"Molecular Components and Activities","text":"<p>The model includes several important proteins/complexes: - Voltage-dependent anion channel (VDAC1) - Facilitates transport across the outer mitochondrial membrane - Mitochondrial pyruvate carriers (MPC1, MPC2) - Transport pyruvate across the inner mitochondrial membrane - Pyruvate dehydrogenase complex components:   - PDHA1/PDHA2/PDHB - Pyruvate decarboxylase activity   - DLAT - Acetyltransferase activity   - DLD - Dihydrolipoyl dehydrogenase activity   - PDHX - Molecular adaptor activity within the complex</p>"},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive component representation: The model includes both transport mechanisms (VDAC1, MPC1, MPC2) and enzymatic activities (PDH complex components).</p> </li> <li> <p>Proper use of protein complexes: The model appropriately represents the pyruvate dehydrogenase complex (GO:0045254) with its constituent proteins and their specific activities.</p> </li> <li> <p>Cellular localization: Components are properly annotated with their cellular locations (mitochondrial outer membrane, inner membrane, or matrix).</p> </li> <li> <p>Evidence support: Annotations have appropriate evidence codes and literature references.</p> </li> <li> <p>Proper use of molecular adaptor activity: PDHX is correctly annotated with molecular adaptor activity (GO:0060090), consistent with its biological role of binding dihydrolipoamide dehydrogenase (E3) to dihydrolipoamide transacetylase (E2) within the PDH complex.</p> </li> </ol>"},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Redundant activities: There is some redundancy in the model. For example:</li> <li>Activities 633b013300001558 and 633b013300001625 both represent the same pyruvate dehydrogenase complex (GO:0045254) with the same components and molecular function (GO:0034604).</li> <li>Activities 633b013300001638 and 633b013300001646 both represent DLAT with the same acetyltransferase activity.</li> <li> <p>Activities 633b013300001636 and 633b013300001648 both represent DLD with dihydrolipoyl dehydrogenase activity.</p> </li> <li> <p>Inconsistent causal associations: Some causal associations lack evidence annotations while others include them.</p> </li> <li> <p>Some causal flow clarity issues: The model would benefit from clearer representation of the exact sequence of events in the pyruvate dehydrogenase complex activity.</p> </li> <li> <p>Redundant molecular adaptor activity: PDHX is annotated twice with molecular adaptor activity (GO:0060090) in activities 66c7d41500001378 and 66c7d41500001379, which appear to be duplicates.</p> </li> </ol>"},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Consolidate redundant activities: Merge duplicate representations of the same protein or complex activities to make the model more concise and easier to follow.</p> </li> <li> <p>Add evidence to all causal associations: Ensure all causal associations have appropriate evidence annotations.</p> </li> <li> <p>Refine causal flow: Clarify the exact sequence of events in the pyruvate dehydrogenase complex activity, making sure the \"provides input for\" and \"part of\" relationships accurately reflect the biological process.</p> </li> <li> <p>Check complex membership annotations: Ensure the complex membership is consistent throughout the model and matches current knowledge about the pyruvate dehydrogenase complex in mice.</p> </li> <li> <p>Review recent literature: The paper \"Rewiring of the Human Mitochondrial Interactome during Neuronal Reprogramming Reveals Regulators of the Respirasome and Neurogenesis\" (PMID:31536960) mentions phosphorylation of PDHA2 on S291/S293 residues and its role in regulation. Consider incorporating this regulatory mechanism into the model if it applies to mouse as well.</p> </li> </ol>"},{"location":"reviews/633b013300001469-Pyruvate_catabolic_process_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model provides a good representation of pyruvate catabolism in mouse, focusing on the pyruvate dehydrogenase complex and associated transport processes. The model adheres to GO-CAM best practices in terms of representing protein complexes and molecular activities. However, there are redundant activities that could be consolidated to make the model more streamlined. The causal flow could also be clarified to better represent the sequence of events in this metabolic pathway.</p> <p>The model successfully captures the key molecular components involved in pyruvate catabolism, including the important adaptor role of PDHX in the pyruvate dehydrogenase complex, consistent with GO-CAM annotation guidelines for molecular adaptors.</p>"},{"location":"reviews/633b013300001722-TRIM27_mediated_inhibition_of_starvation_induced_autophagy_via_ubiquitination_of_STK38L_and_ULK1__Human_/","title":"633b013300001722 TRIM27 mediated inhibition of starvation induced autophagy via ubiquitination of STK38L and ULK1  Human","text":"<p>Based on all the information I've gathered, I'll now proceed with my review of GO-CAM model gomodel:633b013300001722 \"TRIM27-mediated inhibition of starvation-induced autophagy via ubiquitination of STK38L and ULK1 (Human)\".</p>"},{"location":"reviews/633b013300001722-TRIM27_mediated_inhibition_of_starvation_induced_autophagy_via_ubiquitination_of_STK38L_and_ULK1__Human_/#go-cam-review-trim27-mediated-inhibition-of-starvation-induced-autophagy-via-ubiquitination-of-stk38l-and-ulk1","title":"GO-CAM Review: TRIM27-mediated inhibition of starvation-induced autophagy via ubiquitination of STK38L and ULK1","text":""},{"location":"reviews/633b013300001722-TRIM27_mediated_inhibition_of_starvation_induced_autophagy_via_ubiquitination_of_STK38L_and_ULK1__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents the molecular mechanism by which TRIM27 (an E3 ubiquitin ligase) cooperates with STK38L (a serine/threonine-protein kinase) to inhibit ULK1-mediated autophagy. The model depicts four key activities:</p> <ol> <li>TRIM27 (P14373) with ubiquitin protein ligase activity (GO:0061630) directly positively regulates STK38L's kinase activity.</li> <li>STK38L (Q9Y2H1) with protein serine/threonine kinase activity (GO:0004674) provides input for another TRIM27 ubiquitin ligase activity.</li> <li>The second TRIM27 activity directly negatively regulates ULK1.</li> <li>ULK1 (O75385) with protein serine/threonine kinase activity (GO:0004674) is involved in positive regulation of autophagy (GO:0010508).</li> </ol>"},{"location":"reviews/633b013300001722-TRIM27_mediated_inhibition_of_starvation_induced_autophagy_via_ubiquitination_of_STK38L_and_ULK1__Human_/#evaluation-of-biological-content","title":"Evaluation of Biological Content","text":"<p>The model accurately represents the findings from the primary literature (PMID:35670107), where TRIM27 acts as a negative regulator of autophagy by: 1. Non-degradative ubiquitination of STK38L, which leads to STK38L activation 2. Ubiquitination of ULK1, which leads to ULK1 degradation and inhibition of autophagy</p> <p>This regulatory mechanism is biologically significant as it demonstrates how TRIM27 fine-tunes the amplitude and duration of autophagy during starvation conditions. ULK1 is a key initiator of autophagy, and its regulation is crucial for proper cellular response to starvation.</p>"},{"location":"reviews/633b013300001722-TRIM27_mediated_inhibition_of_starvation_induced_autophagy_via_ubiquitination_of_STK38L_and_ULK1__Human_/#assessment-of-go-cam-structure-and-adherence-to-best-practices","title":"Assessment of GO-CAM Structure and Adherence to Best Practices","text":"<ol> <li>Molecular Function Annotations: </li> <li>Appropriate use of molecular functions for each protein: TRIM27 (ubiquitin protein ligase activity), STK38L and ULK1 (protein serine/threonine kinase activity)</li> <li> <p>All functions are well-supported by evidence from the literature</p> </li> <li> <p>Biological Process Annotations:</p> </li> <li>Accurate representation of TRIM27's function in negative regulation of autophagy (GO:0010507)</li> <li> <p>ULK1's role in positive regulation of autophagy (GO:0010508) is correctly annotated</p> </li> <li> <p>Causal Relationships:</p> </li> <li>The model correctly uses RO:0002629 (directly positively regulates) for TRIM27's action on STK38L</li> <li>RO:0002413 (provides input for) is correctly used for STK38L's effect on the second TRIM27 activity</li> <li> <p>RO:0002630 (directly negatively regulates) is correctly used for TRIM27's inhibition of ULK1</p> </li> <li> <p>Cellular Component Annotations:</p> </li> <li> <p>All activities are correctly located in the cytoplasm (GO:0005737), which is consistent with the known localization of these proteins during autophagy regulation</p> </li> <li> <p>Evidence Codes:</p> </li> <li>The model uses appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) with citations to the primary literature (PMID:35670107)</li> </ol>"},{"location":"reviews/633b013300001722-TRIM27_mediated_inhibition_of_starvation_induced_autophagy_via_ubiquitination_of_STK38L_and_ULK1__Human_/#specific-improvements-needed","title":"Specific Improvements Needed","text":"<ol> <li>Missing Small Molecules/Inputs:</li> <li> <p>The model does not explicitly show the ubiquitin molecules as inputs in the TRIM27 ubiquitin ligase activity. According to the E3 ubiquitin ligase guidelines, substrates should be represented as inputs.</p> </li> <li> <p>Incomplete Representation of Ubiquitination Types:</p> </li> <li>Based on the literature (PMID:35670107), TRIM27 catalyzes non-degradative K6- and K11-linked ubiquitination of STK38L, but the specific type of ubiquitination is not indicated in the model.</li> <li> <p>The specific ubiquitination sites on ULK1 (reported to be K568 and K571 in the literature) are not represented.</p> </li> <li> <p>Missing Condition Context:</p> </li> <li> <p>The model doesn't clearly indicate that this mechanism is specifically activated during starvation-induced autophagy, which is an important contextual detail.</p> </li> <li> <p>Incomplete Regulatory Mechanism:</p> </li> <li>The model doesn't show that STK38L phosphorylates ULK1 at Ser495, which primes ULK1 for ubiquitination by TRIM27. This phosphorylation event is a key part of the regulatory mechanism.</li> </ol>"},{"location":"reviews/633b013300001722-TRIM27_mediated_inhibition_of_starvation_induced_autophagy_via_ubiquitination_of_STK38L_and_ULK1__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add ubiquitin molecules as inputs to the TRIM27 ubiquitin ligase activities.</p> </li> <li> <p>Specify the types of ubiquitination:</p> </li> <li>For STK38L: Use a more specific biological process term to indicate K6- and K11-linked non-degradative ubiquitination</li> <li> <p>For ULK1: Indicate that the ubiquitination leads to degradation</p> </li> <li> <p>Add the phosphorylation connection from STK38L to ULK1, showing that STK38L directly phosphorylates ULK1 at Ser495.</p> </li> <li> <p>Add a note or annotation to clarify that this regulatory mechanism is specifically active during starvation-induced autophagy.</p> </li> <li> <p>Consider extending the model to show downstream effects on autophagosome formation.</p> </li> </ol>"},{"location":"reviews/633b013300001722-TRIM27_mediated_inhibition_of_starvation_induced_autophagy_via_ubiquitination_of_STK38L_and_ULK1__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:633b013300001722 provides a good representation of TRIM27's role in regulating autophagy through STK38L and ULK1. The core molecular interactions and causal relationships are accurately captured, and the model is consistent with the primary literature. However, the model would benefit from additional detail regarding the specific types of ubiquitination, the key phosphorylation event, and the starvation context. With these improvements, the model would provide a more complete and precise representation of this important regulatory mechanism.</p> <p>Overall, this is a well-constructed GO-CAM model that effectively captures a complex regulatory pathway in autophagy regulation, with room for further refinement to enhance its completeness and specificity.</p>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/","title":"6348a65d00000093 USP20 inhibition of NF kappa B signaling via TRAF6 deubiquitination  Human","text":"<p>Based on my analysis of the GO-CAM model and relevant information from UniProt and literature, I'll now provide a comprehensive review of the GO-CAM model (gomodel:6348a65d00000093).</p>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#review-of-go-cam-model-usp20-inhibition-of-nf-kappa-b-signaling-via-traf6-deubiquitination-human","title":"Review of GO-CAM Model: USP20 inhibition of NF-kappa-B signaling via TRAF6 deubiquitination (Human)","text":""},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:6348a65d00000093) represents a regulatory pathway involving USP20 (Ubiquitin-specific protease 20), ARRB2 (\u03b2-arrestin-2), and TRAF6 (TNF receptor-associated factor 6) in the context of NF-kappa-B signaling in humans. The model shows how USP20 inhibits NF-kappa-B signaling by deubiquitinating TRAF6.</p>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the mechanism described in the literature (PMID:26839314), where:</p> <ol> <li>USP20 (Q9Y2K6) has cysteine-type deubiquitinase activity (GO:0004843)</li> <li>USP20 acts on ARRB2 (P32121), which functions as a molecular adaptor (GO:0060090)</li> <li>USP20 negatively regulates TRAF6 (Q9Y4K3), which has ubiquitin protein ligase activity (GO:0061630)</li> <li>The ultimate outcome is negative regulation of canonical NF-kappaB signal transduction (GO:0043124)</li> </ol> <p>The biological content is consistent with known protein functions in UniProt: - USP20 is known to attenuate TLR4-mediated NF-kappa-B signaling by cooperating with \u03b2-arrestin-2/ARRB2 and inhibiting TRAF6 autoubiquitination - ARRB2 functions as a molecular adaptor and is involved in negative regulation of NF-kappa-B signaling - TRAF6 is an E3 ubiquitin ligase that mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains important for NF-kappa-B activation</p>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#model-structure-and-causal-flow","title":"Model Structure and Causal Flow","text":"<p>The causal flow of the model follows a logical pattern: 1. ARRB2 functions as a molecular adaptor that positively regulates USP20's deubiquitinase activity 2. USP20's deubiquitinase activity directly negatively regulates TRAF6's ubiquitin ligase activity 3. The inhibition of TRAF6 leads to the negative regulation of canonical NF-kappaB signaling</p> <p>The causal relationships use appropriate predicates: - RO:0002629 (directly positively regulates) for ARRB2's effect on USP20 - RO:0002630 (directly negatively regulates) for USP20's effect on TRAF6</p>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#cellular-localization","title":"Cellular Localization","text":"<p>The model correctly indicates that all activities occur in the cytoplasm (GO:0005737), which is consistent with the UniProt information for these proteins.</p>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>The model uses appropriate evidence codes and references: - ECO:0000314 (direct assay evidence used in manual assertion) with PMID:26839314 for most functional assertions - ECO:0000305 (curator inference used in manual assertion) for cellular locations</p>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices: 1. Activities are connected via causal relationships 2. Each activity is enabled by a specific protein 3. Activities are part of appropriate biological processes 4. Activities are localized to cellular components 5. Evidence codes and references are provided</p>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, there are a few aspects that could be enhanced:</p> <ol> <li> <p>Redundant Representation: There appears to be some redundancy in the model. Activity \"gomodel:6348a65d00000093/6348a65d00000094\" (USP20 deubiquitinase activity) and activity \"gomodel:6348a65d00000093/6348a65d00000115\" (also USP20 deubiquitinase activity) seem to represent the same function enabled by the same protein. This could be consolidated for clarity.</p> </li> <li> <p>Detailed Molecular Mechanism: The model could be enhanced by including information about the precise ubiquitination sites on TRAF6 that are targeted by USP20, especially since the UniProt entry indicates that TRAF6 is polyubiquitinated on Lys-124.</p> </li> <li> <p>Connection to Wider Signaling Context: The model could be expanded to show how this regulatory mechanism connects to upstream TLR4 signaling and downstream NF-kappa-B activation events.</p> </li> <li> <p>Evidence Base: One causal association (between ARRB2 and USP20) has two instances of the same evidence, which is redundant. Additionally, there's a causal association with no evidence specified.</p> </li> </ol>"},{"location":"reviews/6348a65d00000093-USP20_inhibition_of_NF_kappa_B_signaling_via_TRAF6_deubiquitination__Human_/#summary-and-conclusion","title":"Summary and Conclusion","text":"<p>This GO-CAM model successfully represents a regulatory mechanism where USP20 inhibits NF-kappa-B signaling by deubiquitinating TRAF6, with ARRB2 serving as a molecular adaptor in this process. The model is biologically accurate, well-structured, and adheres to GO-CAM best practices.</p> <p>The model effectively communicates the key regulatory interaction between these proteins and their role in attenuating inflammatory signaling. With minor improvements to address redundancy and expand the molecular detail, this would be an exemplary GO-CAM representation of this regulatory pathway.</p>"},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/","title":"6348a65d00000594 Granzyme mediated  GZMA  activation of pyroptosis  GSDMB isoform 4   Human","text":"<p>Now that I've gathered all the necessary information, let me review the GO-CAM model gomodel:6348a65d00000594.</p>"},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/#go-cam-model-review-granzyme-mediated-gzma-activation-of-pyroptosis-gsdmb-isoform-4-human","title":"GO-CAM Model Review: Granzyme-mediated (GZMA) activation of pyroptosis (GSDMB isoform 4) (Human)","text":""},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:6348a65d00000594) represents the mechanism by which granzyme A (GZMA) from cytotoxic lymphocytes triggers pyroptosis in target cells through cleavage of gasdermin-B (GSDMB) isoform 4 in humans. The model shows a detailed molecular pathway with four main activities connected in a causal chain.</p>"},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/#evaluation-of-biological-content","title":"Evaluation of Biological Content","text":""},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/#key-proteins-and-their-functions","title":"Key Proteins and Their Functions:","text":"<ol> <li>PRF1 (Perforin) (UniProtKB:P14222)</li> <li>Correctly annotated with wide pore channel activity (GO:0022829)</li> <li>Correctly shown as occurring in the plasma membrane (GO:0005886)</li> <li>Part of protein transmembrane transport (GO:0071806)</li> <li> <p>Accurately positioned as the upstream activity enabling GZMA to enter target cells</p> </li> <li> <p>GZMA (Granzyme A) (UniProtKB:P12544)</p> </li> <li>Correctly annotated with serine-type endopeptidase activity (GO:0004252)</li> <li>Accurately shown as occurring in the cytoplasm (GO:0005737), consistent with its delivery into target cells</li> <li>Part of protein maturation (GO:0051604)</li> <li> <p>Correctly positioned as cleaving GSDMB</p> </li> <li> <p>GSDMB isoform 4 (UniProtKB:Q8TAX9-4)</p> </li> <li>Represented with two distinct activities:<ul> <li>Phospholipid binding (GO:0005543)</li> <li>Wide pore channel activity (GO:0022829)</li> </ul> </li> <li>Both activities correctly occurring in the plasma membrane (GO:0005886)</li> <li>Part of cytotoxic T cell pyroptotic cell death (GO:1902483)</li> </ol>"},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/#evaluation-of-causal-links","title":"Evaluation of Causal Links","text":"<p>The model follows a logical causal flow: 1. Perforin (PRF1) enables protein transmembrane transport, which is causally upstream (RO:0002304) of GZMA delivery into the target cell 2. GZMA directly positively regulates (RO:0002629) GSDMB phospholipid binding 3. GSDMB phospholipid binding directly positively regulates (RO:0002629) GSDMB pore-forming activity</p> <p>This causal chain is well-supported by the literature. According to the key papers (especially PMID:32299851), perforin creates pores in the target cell membrane, allowing granzyme A to enter the cytoplasm where it cleaves GSDMB. The cleaved N-terminal fragment of GSDMB then binds to membrane inner leaflet phospholipids and assembles into pore-forming oligomers, triggering pyroptosis.</p>"},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/#evaluation-based-on-go-cam-curation-guidelines","title":"Evaluation Based on GO-CAM Curation Guidelines","text":"<ol> <li>Molecular Functions, Biological Processes, and Cellular Components:</li> <li>All activities are correctly annotated with appropriate molecular functions</li> <li>All are properly linked to their biological processes with 'part_of' relations</li> <li> <p>Cellular locations are accurately specified with 'occurs_in' relations</p> </li> <li> <p>Evidence Codes and References:</p> </li> <li>All annotations are supported by ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>Citations to relevant primary literature (PMIDs: 32299851, 28154144, 20038786) are provided</li> <li> <p>All annotations include provenance information</p> </li> <li> <p>Causal Relations:</p> </li> <li>The model uses appropriate causal relation predicates (RO:0002629 for 'directly positively regulates' and RO:0002304 for 'causally upstream of, positive effect')</li> <li>The causal flow follows the correct biological sequence of events</li> </ol>"},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is well-constructed overall, here are a few suggestions for improvement:</p> <ol> <li> <p>Additional Biological Context: The model could include the upstream regulation of GSDMB expression by IFN-\u03b3, which is mentioned in the literature as an important factor that increases target cell susceptibility to GZMA-mediated pyroptosis.</p> </li> <li> <p>Cellular Detail: The model could specify that this process occurs at the immunological synapse between cytotoxic lymphocytes and target cells, which would provide additional cellular context.</p> </li> <li> <p>Downstream Effects: The model could extend to include some downstream consequences of pyroptosis, such as the release of inflammatory mediators, which would provide a more complete picture of the biological significance of this pathway.</p> </li> </ol>"},{"location":"reviews/6348a65d00000594-Granzyme_mediated__GZMA__activation_of_pyroptosis__GSDMB_isoform_4___Human_/#summary","title":"Summary","text":"<p>The GO-CAM model gomodel:6348a65d00000594 is a well-constructed representation of the GZMA-GSDMB pyroptosis pathway that is consistent with current scientific literature. The model accurately captures:</p> <ol> <li>The role of perforin in facilitating GZMA entry into target cells</li> <li>The proteolytic cleavage of GSDMB by GZMA</li> <li>The binding of cleaved GSDMB to membrane phospholipids</li> <li>The formation of membrane pores by GSDMB that lead to pyroptotic cell death</li> </ol> <p>The model follows GO-CAM curation best practices, with appropriate function annotations, cellular locations, biological processes, and causal relationships. The evidence for all annotations is well-documented with appropriate references to the scientific literature.</p>"},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/","title":"6348a65d00000661 Cytotoxic T cell pyroptosis mediated by GSDMB isoform 1 in response to infection by Gram negative bacteria and its inhibition by S flexneri IpaH7 8  Human and S flexneri","text":"<p>Now I have enough information to review this GO-CAM model properly. Let me evaluate the model based on the collected information:</p>"},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/#review-of-gomodel6348a65d00000661","title":"Review of GOModel:6348a65d00000661","text":""},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model titled \"Cytotoxic T cell pyroptosis mediated by GSDMB isoform 1 in response to infection by Gram-negative bacteria and its inhibition by S.flexneri IpaH7.8 (Human and S.flexneri)\" represents the pathway where:</p> <ol> <li>Perforin (PRF1) creates pores in the plasma membrane</li> <li>Granzyme A (GZMA) enters the cell through these pores</li> <li>GZMA cleaves Gasdermin B (GSDMB) to activate its pore-forming function</li> <li>GSDMB forms membrane pores that trigger pyroptosis</li> <li>S. flexneri IpaH7.8 targets GSDMB for ubiquitination and degradation to prevent pyroptosis</li> </ol>"},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Accurate molecular activities: Each protein has been assigned appropriate molecular functions:</li> <li>PRF1 with wide pore channel activity (GO:0022829)</li> <li>GZMA with serine-type endopeptidase activity (GO:0004252)</li> <li>GSDMB with cardiolipin binding (GO:1901612) and wide pore channel activity (GO:0022829)</li> <li> <p>IpaH7.8 with ubiquitin protein ligase activity (GO:0061630)</p> </li> <li> <p>Appropriate causal relationships: The model correctly uses:</p> </li> <li>RO:0002304 (causally upstream of, positive effect) for PRF1's effect on GZMA</li> <li>RO:0002629 (directly positively regulates) for GZMA's effect on GSDMB</li> <li>RO:0002629 (directly positively regulates) for GSDMB's effect on its own pore-forming activity</li> <li> <p>RO:0002630 (directly negatively regulates) for IpaH7.8's effect on GSDMB</p> </li> <li> <p>Correct subcellular locations:</p> </li> <li>PRF1 at plasma membrane (GO:0005886)</li> <li>GZMA in cytoplasm (GO:0005737)</li> <li> <p>IpaH7.8 in host cell cytoplasm (GO:0030430)</p> </li> <li> <p>Well-supported with evidence: All assertions are backed by appropriate evidence codes and PMIDs.</p> </li> </ol>"},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing cellular component for GSDMB pore-forming activity: The model doesn't specify where GSDMB's pore-forming activity occurs. According to the literature (PMID:34022140), GSDMB isoform 1 specifically targets bacterial membranes through cardiolipin binding. This should be specified in the model.</p> </li> <li> <p>Incomplete representation of mechanism: The model doesn't capture that GSDMB cleaved by GZMA specifically targets bacterial membranes rather than host cell membranes. This is an important distinction for GSDMB isoform 1 as shown in PMID:34022140.</p> </li> <li> <p>Missing biological process annotation: GSDMB's activities could be more specifically annotated as part of \"defense response to Gram-negative bacterium\" (GO:0050829) since this process is mentioned in the title but not explicitly included in the model annotations.</p> </li> <li> <p>Missing protein transport annotation: The model correctly shows PRF1 creating pores to allow GZMA entry, but doesn't explicitly annotate PRF1's role in \"protein transmembrane transport\" (GO:0071806), though this process is included.</p> </li> </ol>"},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/#technical-consistency","title":"Technical Consistency","text":"<ol> <li> <p>The model follows GO-CAM best practices for representing molecular activities and their causal relationships.</p> </li> <li> <p>The representation of complex activities is consistent with guidelines from \"How_to_annotate_complexes_in_GO-CAM\".</p> </li> <li> <p>The automated changes noted in the comments (replacing RO:0002212 with RO:0002630 and RO:0002213 with RO:0002629) are appropriate updates to the relation ontology terms.</p> </li> </ol>"},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/#scientific-accuracy","title":"Scientific Accuracy","text":"<ol> <li> <p>The model accurately captures the finding from Zhou et al. (2020) that GZMA cleaves GSDMB to trigger pyroptosis.</p> </li> <li> <p>The model correctly depicts the role of S. flexneri IpaH7.8 in targeting GSDMB for ubiquitination and degradation, as reported in Hansen et al. (PMID:34022140).</p> </li> <li> <p>The representation of PRF1's role in forming membrane pores for GZMA delivery is consistent with the established mechanism described in Thiery et al. (PMID:20038786).</p> </li> <li> <p>The specific targeting of bacterial membranes by GSDMB isoform 1 (as opposed to other isoforms that might target host cell membranes) could be more explicitly captured.</p> </li> </ol>"},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add cellular component annotation for GSDMB pore-forming activity: Specify that GSDMB's pore-forming activity targets bacterial membranes.</p> </li> <li> <p>Add more specific biological process annotation: Include \"defense response to Gram-negative bacterium\" (GO:0050829) for GSDMB activities.</p> </li> <li> <p>Clarify isoform specificity: The model title mentions GSDMB isoform 1, but it would be helpful to note in the annotations that this isoform specifically targets bacterial membranes rather than host cell membranes.</p> </li> <li> <p>Complete the causal chain: Consider adding an annotation to show that GSDMB pore formation leads to \"killing by host of symbiont cells\" (GO:0051873), which would complete the biological outcome of this pathway.</p> </li> </ol>"},{"location":"reviews/6348a65d00000661-Cytotoxic_T_cell_pyroptosis_mediated_by_GSDMB_isoform_1_in_response_to_infection_by_Gram_negative_bacteria_and_its_inhibition_by_S_flexneri_IpaH7_8__Human_and_S_flexneri_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model effectively captures the key aspects of cytotoxic T cell-mediated pyroptosis via GSDMB and its inhibition by S. flexneri IpaH7.8. With minor additions to specify cellular locations and biological processes, the model would provide an even more comprehensive representation of this important immune response pathway.</p>"},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/","title":"6348a65d00000724 Regulation by IL22 and Reg3g of allergic airway inflammation   Mouse","text":"<p>Based on my review, I'll now provide a comprehensive analysis of the GO-CAM model for \"Regulation by IL22 and Reg3g of allergic airway inflammation. (Mouse)\" (gomodel:6348a65d00000724).</p>"},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/#review-of-go-cam-model-6348a65d00000724","title":"Review of GO-CAM Model 6348a65d00000724","text":""},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/#summary","title":"Summary","text":"<p>This model describes the regulatory pathway involving IL-22 and Reg3g in allergic airway inflammation in mice, based primarily on findings from Ito et al. (2017) published in PMID:28811323. The model illustrates how IL-22, produced mainly by CD4+ T cells, induces Reg3g (Regenerating islet-derived protein 3-gamma) expression from lung epithelial cells through STAT3 activation, which then suppresses allergic airway inflammation by inhibiting epithelial cytokine production.</p>"},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model includes these key biological entities: - IL-22 (MGI:MGI:1355307) with cytokine activity - IL-22 receptor complex (IL22ra1, MGI:MGI:2663588) - STAT3 (MGI:MGI:103038) as a transcription factor - Reg3g (MGI:MGI:109406) as an effector molecule - EXTL3 (MGI:MGI:1860765) as a receptor for Reg3g - Downstream inflammatory cytokines including IL-33 (MGI:MGI:1924375) and TSLP (MGI:MGI:1855696)</p> <p>The causal flow shows IL-22 signaling through IL-22Ra1, activating STAT3, which induces Reg3g expression. Reg3g then acts on EXTL3 to negatively regulate the production of inflammatory cytokines.</p>"},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-supported by evidence: Each activity and causal relationship is backed by experimental data from peer-reviewed literature (primarily PMID:28811323).</p> </li> <li> <p>Appropriate causal relationships: The model uses appropriate causal predicates such as \"directly positively regulates\" (RO:0002629) and \"causally upstream of, negative effect\" (RO:0002305).</p> </li> <li> <p>Clear biological pathway representation: The model clearly represents how IL-22 signaling leads to reduced allergic inflammation via Reg3g.</p> </li> <li> <p>Cell and subcellular locations: Activities are properly annotated with their cellular contexts, such as extracellular space (GO:0005615) for cytokines and nucleus (GO:0005634) for STAT3.</p> </li> </ol>"},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex representation: The IL-22 receptor complex should be more explicitly represented according to GO-CAM best practices. Currently, only IL22ra1 is shown, while the complex likely involves additional components. According to the \"How_to_annotate_complexes_in_GO-CAM\" guidelines, if the specific activity-bearing subunit is known, that's appropriate, but it might be worth noting the other components.</p> </li> <li> <p>Cell-type annotations: While some activities have cell type annotations, they could be more consistently applied. For example, IL-22 is known to be produced by CD4+ T cells (mentioned in the paper), but this cell type association isn't explicitly represented in the model.</p> </li> <li> <p>Feedback mechanisms: The paper describes some feedback mechanisms and complex interactions between different cell types that could be more fully represented in the model.</p> </li> <li> <p>Molecular details of STAT3 activation: The phosphorylation of STAT3 and its translocation to the nucleus are critical steps in the pathway but aren't explicitly represented in the model.</p> </li> </ol>"},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately captures the key findings from the primary literature:</p> <ol> <li> <p>The paper shows that IL-22 is produced mainly by CD4+ T cells that don't produce IFN-gamma, IL-5, IL-13, or IL-17A.</p> </li> <li> <p>IL-22 receptor (IL-22R1) is expressed in lung epithelial cells but not immune cells.</p> </li> <li> <p>IL-22 induces Reg3gamma production from lung epithelial cells through STAT3 activation.</p> </li> <li> <p>Neutralization of Reg3gamma exacerbates HDM-induced eosinophilic airway inflammation.</p> </li> <li> <p>EXTL3 serves as a functional receptor for Reg3gamma in lung epithelial cells.</p> </li> <li> <p>Reg3gamma administration suppresses HDM-induced TSLP and IL-33 expression and reduces ILC2 accumulation in the lung.</p> </li> </ol>"},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/#recommended-improvements","title":"Recommended Improvements","text":"<ol> <li> <p>Add molecular details of STAT3 activation: Include annotations indicating phosphorylation of STAT3 and its translocation from cytoplasm to nucleus.</p> </li> <li> <p>Expand receptor complex representation: Consider adding other components of the IL-22 receptor complex if they're known.</p> </li> <li> <p>Add cell type annotations: Consistently annotate cell types across all relevant activities.</p> </li> <li> <p>Include ILC2 cells: The paper discusses type 2 innate lymphoid cells (ILC2s) and their role in the inflammatory process, which could be included in the model.</p> </li> <li> <p>Consider adding the house dust mite (HDM) allergen: Since the experimental system used HDM to induce allergic inflammation, it might be beneficial to represent this trigger in the model.</p> </li> </ol>"},{"location":"reviews/6348a65d00000724-Regulation_by_IL22_and_Reg3g_of_allergic_airway_inflammation___Mouse__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively captures the key regulatory pathway by which IL-22 induces Reg3g to suppress allergic airway inflammation in mice. It is well-supported by literature evidence and uses appropriate causal relationships. With a few improvements to represent complex components more explicitly and to add more cellular context, this would be an excellent model for understanding the IL-22-Reg3g axis in allergic inflammation.</p> <p>The model is consistent with GO-CAM best practices and provides a valuable resource for understanding the anti-inflammatory mechanisms of IL-22 in the context of allergic airway inflammation.</p>"},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/","title":"6348a65d00000848 Regulation by IL22 and REG3A of allergic airway inflammation   Human","text":"<p>Now I have all the information I need to review the GO-CAM model. Let's analyze the model in detail.</p>"},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#review-of-go-cam-model-gomodel6348a65d00000848","title":"Review of GO-CAM Model gomodel:6348a65d00000848","text":""},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#model-information","title":"Model Information","text":"<ul> <li>Title: \"Regulation by IL22 and REG3A of allergic airway inflammation. (Human)\"</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> <li>Model ID: gomodel:6348a65d00000848</li> </ul>"},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents a pathway involved in the regulation of allergic airway inflammation in humans. It shows how IL-22 and REG3A proteins function to suppress allergic airway inflammation by inhibiting inflammatory cytokine production. The model is based primarily on a publication by Ito et al. (2017), which demonstrated that IL-22 induces REG3A (referred to as REG3\u03b3 in mice) expression from lung epithelial cells through STAT3 activation to suppress house dust mite (HDM)-induced allergic airway inflammation.</p>"},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#pathway-structure","title":"Pathway Structure","text":"<p>The model shows the following signaling cascade:</p> <ol> <li>IL22 (UniProtKB:Q9GZX6) has cytokine activity (GO:0005125) in extracellular space (GO:0005615)</li> <li>IL22 directly positively regulates IL22RA1 (UniProtKB:Q8N6P7) which has interleukin-22 receptor activity (GO:0042018) </li> <li>IL22RA1 provides input for STAT3 (UniProtKB:P40763) which has DNA-binding transcription factor activity (GO:0000981)</li> <li>STAT3 provides input for REG3A (UniProtKB:Q06141) which has hormone activity (GO:0005179)</li> <li>REG3A directly positively regulates EXTL3 (UniProtKB:O43909) which has protein-hormone receptor activity (GO:0016500)</li> <li>EXTL3 causally upstream of (negative effect) IL33 (UniProtKB:O95760) and TSLP (UniProtKB:Q969D9), both of which have cytokine activity (GO:0005125)</li> </ol>"},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#assessment-of-the-model","title":"Assessment of the Model","text":""},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#strengths","title":"Strengths:","text":"<ol> <li>The model captures the main findings from the Ito et al. paper showing how IL-22 induces REG3A to suppress allergic airway inflammation.</li> <li>The causal relationships between the entities are properly represented.</li> <li>The model correctly places the proteins in their cellular locations (extracellular space, plasma membrane, nucleus, etc.)</li> <li>The model illustrates the negative regulatory effect of this pathway on inflammatory cytokine production (IL33 and TSLP).</li> </ol>"},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Molecular Function Assignment for REG3A: </li> <li> <p>REG3A is annotated with \"hormone activity\" (GO:0005179), but according to UniProt and literature, it should be annotated with \"cytokine activity\" (GO:0005125). The paper and UniProt both characterize it as acting like a cytokine that regulates tissue responses.</p> </li> <li> <p>Biological Process Context:</p> </li> <li> <p>REG3A is part of \"negative regulation of inflammatory response\" (GO:0050728), which is appropriate, but it could be more specific, such as \"negative regulation of cytokine production involved in inflammatory response\" (GO:1900016) which is already used for EXTL3 in the model.</p> </li> <li> <p>Missing Mechanistic Detail:</p> </li> <li>The model does not capture the detail that STAT3 activation in epithelial cells is dependent on IL-22 binding to its receptor (IL-22R1). The paper mentions STAT3 is activated in a pathway-specific manner.</li> <li> <p>The mechanism by which EXTL3 inhibits IL33 and TSLP production isn't clearly represented (the paper indicates it likely involves PI3K-AKT signaling pathway).</p> </li> <li> <p>Receptor Ligand Modeling:</p> </li> <li>According to the GO-CAM signaling receptor activity guidelines, the relation between a ligand and its target receptor should be \"has input\" rather than \"directly positively regulates\".</li> <li> <p>The receptor (IL22RA1) should have its input as the effector protein it regulates (STAT3 in this case), which is correctly represented in the model.</p> </li> <li> <p>Evidence Codes and References:</p> </li> <li>While many of the activities are supported by evidence from the primary publication (PMID:28811323), some parts of the model rely on sequence similarity evidence (ECO:0000250) rather than direct experimental evidence.</li> </ol>"},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#recommendations-for-improvement","title":"Recommendations for Improvement:","text":"<ol> <li> <p>Change the molecular function of REG3A from \"hormone activity\" to \"cytokine activity\" to better reflect its biological role.</p> </li> <li> <p>Consider adding the PI3K-AKT-STAT3 pathway components that mediate the effect of REG3A-EXTL3 on inflammatory cytokine production, which would make the mechanism clearer.</p> </li> <li> <p>Consider changing the relation between IL22 and IL22RA1 from \"directly positively regulates\" to \"has input\" to better follow GO-CAM signaling receptor activity guidelines.</p> </li> <li> <p>Add more specific biological process annotations where applicable, particularly for REG3A's role in inhibiting cytokine production.</p> </li> <li> <p>Consider adding more direct experimental evidence where available, rather than relying on sequence similarity evidence.</p> </li> </ol>"},{"location":"reviews/6348a65d00000848-Regulation_by_IL22_and_REG3A_of_allergic_airway_inflammation___Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model effectively captures the regulatory pathway by which IL-22 and REG3A suppress allergic airway inflammation through inhibiting inflammatory cytokine production. The model is consistent with the findings reported in the literature and follows most GO-CAM best practices. With the recommended improvements, the model could more accurately reflect the current understanding of this biological pathway and better adhere to GO-CAM curation standards.</p>"},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/","title":"6348a65d00001191 Nociceptor derived Reg3g prevents endotoxic death by targeting kynurenine pathway in microglia   Mouse","text":"<p>Based on the information I've gathered and my understanding of GO-CAM curation best practices, let me now review the GO-CAM model gomodel:6348a65d00001191 titled \"Nociceptor-derived Reg3g prevents endotoxic death by targeting kynurenine pathway in microglia. (Mouse)\".</p>"},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/#go-cam-review-gomodel6348a65d00001191","title":"GO-CAM Review: gomodel:6348a65d00001191","text":""},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/#overview","title":"Overview","text":"<p>This model represents a pathway where nociceptor-derived Reg3g (regenerating islet-derived 3 gamma) prevents endotoxic death by targeting the kynurenine pathway in microglia. The model is based primarily on research published in PMID:35263589, where Reg3g is shown to penetrate the brain during endotoxemia and suppress the expression of microglial indoleamine dioxygenase 1 (IDO1), a critical enzyme in the kynurenine pathway.</p>"},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/#model-structure-analysis","title":"Model Structure Analysis","text":""},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/#key-components-and-pathway-flow","title":"Key Components and Pathway Flow:","text":"<ol> <li>Initiating ligand: Reg3g (MGI:MGI:109406) with hormone activity (GO:0005179) in extracellular space</li> <li>Receptor: Extl3 (MGI:MGI:1860765) with protein-hormone receptor activity (GO:0016500)</li> <li>Signaling cascade: Involves multiple components including:</li> <li>Xiap (MGI:MGI:107572) - signaling adaptor activity</li> <li>Bcl10 (MGI:MGI:1337994) - signaling adaptor activity</li> <li>Rac1 (MGI:MGI:97845) - G protein activity</li> <li>E2f1 (MGI:MGI:101941) - DNA-binding transcription activator activity</li> <li>Bin1 (MGI:MGI:108092) - signaling adaptor activity</li> <li>Kynurenine pathway enzymes:</li> <li>Ido1 (MGI:MGI:96416) - indoleamine 2,3-dioxygenase activity</li> <li>Kmo (MGI:MGI:2138151) - kynurenine 3-monooxygenase activity</li> <li>Kynu (MGI:MGI:1918039) - kynureninase activity</li> <li>Haao (MGI:MGI:1349444) - 3-hydroxyanthranilate 3,4-dioxygenase activity</li> <li>Metabolic components:</li> <li>Src (MGI:MGI:98397) - protein tyrosine kinase activity</li> <li>Hk1 (MGI:MGI:96103) - glucokinase activity</li> </ol>"},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/#positive-aspects-of-the-model","title":"Positive Aspects of the Model","text":"<ol> <li> <p>Biological accuracy: The model appears to represent a biologically plausible pathway based on the published literature.</p> </li> <li> <p>Cellular context: Appropriate cellular locations are included for many activities (e.g., Reg3g in extracellular space, Extl3 in plasma membrane).</p> </li> <li> <p>Causal relations: The model uses appropriate causal relations between entities (RO:0002629 \"directly positively regulates\" and RO:0002304/RO:0002305 for upstream causal effects).</p> </li> <li> <p>Evidence: All activities have evidence codes and references to literature.</p> </li> <li> <p>Metabolic pathway representation: The kynurenine pathway is accurately represented with proper inputs and outputs of the enzymatic reactions.</p> </li> </ol>"},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Missing cellular locations: Several activities have GO:0005575 (cellular_component) as their location, which is a generic term. Specific cellular locations should be provided where possible.</li> <li> <p>For example, Ido1, Kmo, and Kynu should have more specific cellular locations based on literature.</p> </li> <li> <p>Incomplete information flow: While the general pathway is represented, the exact information flow between some components could be clarified:</p> </li> <li> <p>The connection between Reg3g's hormone activity and the kynurenine pathway inhibition could be more explicit.</p> </li> <li> <p>Missing complexes: If any of these activities involve protein complexes, they should be properly represented according to the complex annotation guidelines.</p> </li> <li> <p>Regulation clarity: The inhibitory effect of Reg3g on the kynurenine pathway could be more explicitly modeled.</p> </li> <li> <p>Biological process context: While most activities are annotated as part of \"response to lipopolysaccharide\" (GO:0032496), some metabolic enzymes might benefit from more specific process annotations.</p> </li> </ol>"},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li>Improve cellular locations:</li> <li>Specify the cellular locations for activities currently annotated with GO:0005575.</li> <li> <p>Verify the cellular locations of kynurenine pathway enzymes based on literature.</p> </li> <li> <p>Clarify causal relations:</p> </li> <li>Ensure the causal relationships between signaling components are biologically accurate.</li> <li> <p>The regulatory effects between E2f1 and Bin1 could be clarified based on literature.</p> </li> <li> <p>Enhance molecular details:</p> </li> <li>If specific small molecules like lipopolysaccharide play regulatory roles, ensure they are properly represented.</li> <li> <p>Verify that all inputs/outputs for enzymatic reactions are correctly captured.</p> </li> <li> <p>Expand biological context:</p> </li> <li>Consider adding more specific biological process annotations for some activities.</li> <li>Clarify how this pathway connects to endotoxic death prevention.</li> </ol>"},{"location":"reviews/6348a65d00001191-Nociceptor_derived_Reg3g_prevents_endotoxic_death_by_targeting_kynurenine_pathway_in_microglia___Mouse_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:6348a65d00001191 is a well-constructed representation of how nociceptor-derived Reg3g affects the kynurenine pathway in microglia during endotoxemia. The model follows most GO-CAM best practices but could benefit from some refinements in cellular location annotations and causal relationship clarity. The biological content is consistent with the referenced literature and provides a valuable resource for understanding this pathway's role in preventing endotoxic death.</p> <p>The model effectively represents the key finding of PMID:35263589 that nociceptor-derived Reg3\u03b3 penetrates the brain and suppresses the expression of microglial IDO1, which is a critical enzyme of the kynurenine pathway, via the Extl3-Bcl10 axis. This pathway is important for preventing endotoxic death by regulating brain metabolism.</p> <p>You can explore this model at https://bioregistry.io/go.model:6348a65d00001191</p>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/","title":"6348a65d00001727 Negative regulation of inflammatory response to wounding by REG3A   Human","text":"<p>Based on all the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model gomodel:6348a65d00001727.</p>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#review-of-go-cam-model-gomodel6348a65d00001727","title":"Review of GO-CAM Model gomodel:6348a65d00001727","text":""},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#model-overview","title":"Model Overview","text":"<p>Title: \"Negative regulation of inflammatory response to wounding by REG3A. (Human)\" Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#general-assessment","title":"General Assessment","text":"<p>This model describes the mechanism by which REG3A negatively regulates inflammatory responses to wounding in human skin, with a focus on how this process is dysregulated in diabetes. The model captures a signaling pathway where REG3A hormone activity inhibits inflammatory response to wounding through a cascade involving EXTL3 receptor, AKT signaling, STAT3 transcription factor activity, and SHP-1 phosphatase activity.</p>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#pathway-description","title":"Pathway Description","text":"<p>The model represents the following signaling cascade:</p> <ol> <li>IL-33 (O95760) with cytokine activity stimulates REG3A (Q06141) with hormone activity</li> <li>REG3A (Q06141) directly positively regulates EXTL3 (O43909) protein-hormone receptor activity</li> <li>EXTL3 stimulates STAT3 (P40763) DNA-binding transcription factor activity via PI3K/AKT signaling</li> <li>STAT3 provides input for SHP-1 (P29350) protein tyrosine phosphatase activity</li> <li>SHP-1 directly negatively regulates JNK2 (P45984) JNK kinase activity</li> <li>JNK2 normally positively regulates TNF (P01375) and IL-6 (P05231) cytokine activities</li> <li>TLR3 (O15455) signaling receptor activity provides input for JNK2 activity</li> </ol> <p>The model accurately captures the mechanism described in the primary publication (PMID:27830702), showing how REG3A inhibits TLR3-mediated inflammation in skin wounds via SHP-1 induction and JNK2 inhibition.</p>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model correctly uses appropriate molecular function terms for each protein's activity</li> <li>Cellular locations are properly annotated with subcellular compartments for each activity</li> <li>Biological processes are accurately assigned for each activity node</li> <li>The causal relationships between activities use appropriate relation terms (RO:0002629, RO:0002630, etc.)</li> <li>The model is evidence-based, with appropriate PMID references and evidence codes for all assertions</li> <li>The model provides a clear mechanistic understanding of how REG3A inhibits inflammatory responses</li> </ol>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<ol> <li> <p>Signaling receptor annotation: The model correctly implements the signaling receptor guidelines for EXTL3 (O43909), showing it as a receptor for REG3A hormone activity. The causal relation between REG3A and EXTL3 is appropriately annotated as \"directly positively regulates\" (RO:0002629).</p> </li> <li> <p>Transcription factor annotation: STAT3 is correctly annotated with DNA-binding transcription factor activity and shown to occur in the nucleus.</p> </li> <li> <p>Activity flow: The causal connections between activities follow the appropriate patterns for regulation, with direct relationships where activities directly influence each other and appropriate input relationships where needed.</p> </li> <li> <p>Evidence annotation: Each activity and causal edge has appropriate evidence codes and PMIDs.</p> </li> </ol>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Pathway Context Expansion: The model could be enhanced by including additional context about IL-33 production, particularly how hyperglycemia inhibits IL-17-induced IL-33 production, which is a key mechanism described in the paper for how diabetes impairs this regulatory pathway.</p> </li> <li> <p>Further Molecular Detail: The model correctly shows that REG3A regulates EXTL3, but could potentially add more detail about the EXTL3-PI3K-AKT-STAT3 signaling pathway mentioned in the paper. Currently, the model directly connects EXTL3 to STAT3 activity without showing the intervening AKT activation.</p> </li> <li> <p>Complex Representation: Based on the complex annotation guidelines, if there are any protein complexes involved in this pathway (potentially in the signaling or transcription activities), they could be more explicitly represented.</p> </li> </ol>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#accuracy-of-biological-content","title":"Accuracy of Biological Content","text":"<p>The biological content is highly accurate and consistent with the primary literature (PMID:27830702). The model captures the main finding that REG3A regulates TLR3-mediated inflammation through SHP-1 and JNK2, and that this pathway is disrupted in diabetes due to decreased REG3A expression.</p> <p>The causal relationships align with the experimental evidence provided in the paper, including the demonstration that: - REG3A induces SHP-1 expression via EXTL3-PI3K-AKT-STAT3 signaling - SHP-1 inhibits TLR3-activated JNK2 phosphorylation - SHP-1 inhibition increases TNF-alpha and IL-6 production - JNK2, not JNK1, is the key mediator of TLR3-induced inflammation</p>"},{"location":"reviews/6348a65d00001727-Negative_regulation_of_inflammatory_response_to_wounding_by_REG3A___Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides an accurate and well-structured representation of how REG3A negatively regulates inflammatory responses to wounding via the EXTL3-STAT3-SHP1-JNK2 pathway. The model correctly implements GO-CAM curation best practices and provides a clear mechanistic understanding of the biological process.</p> <p>The model would be enhanced by providing more detail about the PI3K-AKT intermediate signaling steps and by expanding the context to show how this pathway is dysregulated in diabetes through decreased IL-33 production. However, these are minor suggestions and do not detract from the overall high quality of the model.</p> <p>I recommend the model for approval as it provides a valuable contribution to our understanding of wound healing regulation and inflammation in the context of diabetes.</p>"},{"location":"reviews/6348a65d00002174-USP44_mediated_FOXP3_deubiquitination_leading_to_regulatory_T_cell_differentiation__Human_/","title":"6348a65d00002174 USP44 mediated FOXP3 deubiquitination leading to regulatory T cell differentiation  Human","text":"<p>Based on the information I've gathered, I'll now conduct a thorough review of GO-CAM model 6348a65d00002174, which is titled \"USP44-mediated FOXP3 deubiquitination leading to regulatory T-cell differentiation (Human)\".</p>"},{"location":"reviews/6348a65d00002174-USP44_mediated_FOXP3_deubiquitination_leading_to_regulatory_T_cell_differentiation__Human_/#go-cam-model-review-usp44-mediated-foxp3-deubiquitination-leading-to-regulatory-t-cell-differentiation-human","title":"GO-CAM Model Review: USP44-mediated FOXP3 deubiquitination leading to regulatory T-cell differentiation (Human)","text":""},{"location":"reviews/6348a65d00002174-USP44_mediated_FOXP3_deubiquitination_leading_to_regulatory_T_cell_differentiation__Human_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:6348a65d00002174) describes the process by which USP44 (ubiquitin-specific peptidase 44) deubiquitinates the transcription factor FOXP3, which stabilizes FOXP3 protein levels and promotes regulatory T cell (Treg) differentiation. The model includes three main activities connected in a causal pathway:</p> <ol> <li>TGF-\u03b21 cytokine activity</li> <li>USP44 deubiquitinase activity</li> <li>FOXP3 DNA-binding transcription factor activity</li> </ol>"},{"location":"reviews/6348a65d00002174-USP44_mediated_FOXP3_deubiquitination_leading_to_regulatory_T_cell_differentiation__Human_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model is well-supported by the scientific literature. The primary reference (PMID:32644293) provides strong evidence for USP44 as a deubiquitinase that targets FOXP3, removing K48-linked ubiquitin modifications which would otherwise lead to FOXP3 degradation.</p> <p>Key scientific points supported by evidence: - USP44 stabilizes FOXP3 by removing K48-linked ubiquitin chains - TGF-\u03b21 induces USP44 expression during iTreg differentiation - USP44 maintains FOXP3 stability and enhances Treg function - This process occurs in the nucleus</p>"},{"location":"reviews/6348a65d00002174-USP44_mediated_FOXP3_deubiquitination_leading_to_regulatory_T_cell_differentiation__Human_/#structure-and-connectivity-assessment","title":"Structure and Connectivity Assessment","text":"<p>The model shows a proper causal flow with appropriate relationship predicates: 1. TGF-\u03b21 (P01137) cytokine activity occurs in extracellular space and is part of the TGF-\u03b2 receptor signaling pathway 2. TGF-\u03b21 has two causal connections to USP44 using both:    - RO:0002304 (causally upstream of, positive effect)    - RO:0002629 (directly positively regulates) 3. USP44 (Q9H0E7) deubiquitinase activity occurs in the nucleus and is part of regulatory T cell differentiation 4. USP44 causally regulates FOXP3 via RO:0002629 (directly positively regulates) 5. FOXP3 (Q9BZS1) DNA-binding transcription factor activity occurs in the nucleus and is part of regulatory T cell differentiation</p>"},{"location":"reviews/6348a65d00002174-USP44_mediated_FOXP3_deubiquitination_leading_to_regulatory_T_cell_differentiation__Human_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<ol> <li> <p>Molecular activities: Each protein is assigned an appropriate molecular function. USP44 is correctly annotated with deubiquitinase activity (GO:0101005) rather than the more generic term.</p> </li> <li> <p>Causal relations: The model uses appropriate causal relationship predicates. The use of both RO:0002304 and RO:0002629 for TGF-\u03b21's effect on USP44 is consistent with evidence showing that TGF-\u03b21 both directly and indirectly regulates USP44.</p> </li> <li> <p>Cellular locations: All activities are correctly annotated with their cellular locations - TGF-\u03b21 in extracellular space, and both USP44 and FOXP3 in the nucleus.</p> </li> <li> <p>Part-of relations: Each activity is appropriately linked to the biological processes they participate in.</p> </li> <li> <p>Evidence codes: The model consistently uses ECO:0000314 (direct assay evidence used in manual assertion) supported by PMID:32644293, which is appropriate.</p> </li> </ol>"},{"location":"reviews/6348a65d00002174-USP44_mediated_FOXP3_deubiquitination_leading_to_regulatory_T_cell_differentiation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex Representation: While the model accurately represents the main activities, it does not explicitly represent the K48-linked ubiquitin chains that are removed from FOXP3. According to the \"How to annotate complexes in GO-CAM\" document, since USP44 is the subunit that carries the deubiquitinase activity, the current representation is appropriate.</p> </li> <li> <p>Additional biological context: The model could potentially be expanded to include:</p> </li> <li>The E3 ubiquitin ligase (STUB1) that adds ubiquitin to FOXP3 (mentioned in the paper)</li> <li>The cooperation between USP44 and USP7 in deubiquitinating FOXP3 (mentioned in the paper)</li> <li> <p>Downstream effects of stabilized FOXP3 on Treg suppressive function</p> </li> <li> <p>Details of activation mechanism: The model doesn't represent how TGF-\u03b2 signaling specifically induces USP44 expression via SMAD2/3 binding to the USP44 promoter (as shown in the paper).</p> </li> </ol>"},{"location":"reviews/6348a65d00002174-USP44_mediated_FOXP3_deubiquitination_leading_to_regulatory_T_cell_differentiation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:6348a65d00002174) is scientifically accurate and follows GO-CAM best practices. It appropriately represents the main activities involved in USP44-mediated deubiquitination of FOXP3 leading to regulatory T cell differentiation. The model correctly uses molecular functions, cellular locations, and causal relationship predicates.</p> <p>The model accurately captures a key pathway in regulatory T cell biology with proper evidence and appropriate term selection. While it could be expanded to include additional details about the mechanism, it effectively represents the core process described in the literature.</p>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/","title":"6348a65d00002236 USP44 mediated deubiquitination of CDC20 controlling anaphase initiation  Human","text":"<p>Based on my research and analysis of the provided GO-CAM model (gomodel:6348a65d00002236), I'll now provide a comprehensive review of this model from a GO-CAM curation perspective.</p>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#review-of-go-cam-model-usp44-mediated-deubiquitination-of-cdc20-controlling-anaphase-initiation-human","title":"Review of GO-CAM Model: \"USP44-mediated deubiquitination of CDC20 controlling anaphase initiation (Human)\"","text":""},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:6348a65d00002236) represents the regulation of anaphase initiation through USP44-mediated deubiquitination of CDC20 in human cells. The model captures the interactions between four key proteins:</p> <ol> <li>USP44 (UniProtKB:Q9H0E7) - A deubiquitinating enzyme</li> <li>CDC20 (UniProtKB:Q12834) - A cell division cycle protein and APC/C co-activator</li> <li>UBE2C (UniProtKB:O00762) - A ubiquitin-conjugating enzyme </li> <li>ANAPC11 (UniProtKB:Q9NYG5) - An anaphase-promoting complex subunit</li> </ol>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#biological-context","title":"Biological Context","text":"<p>This model captures the molecular mechanisms of the spindle assembly checkpoint, which ensures proper chromosome segregation during mitosis. Specifically:</p> <ol> <li>UBE2C has ubiquitin conjugating enzyme activity that positively regulates CDC20's function</li> <li>USP44 has deubiquitinase activity that negatively regulates CDC20's function</li> <li>CDC20 has APC-binding activity which positively affects ANAPC11's function</li> <li>ANAPC11 has ubiquitin-protein transferase activity</li> </ol> <p>Together, these activities represent a regulatory circuit of ubiquitination and deubiquitination that controls the metaphase-to-anaphase transition in mitosis.</p>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate Biological Representation: The model accurately captures the key proteins involved in anaphase initiation control through CDC20 regulation, supported by the PMID:17443180 (Stegmeier et al.) which shows that USP44 deubiquitinates CDC20.</p> </li> <li> <p>Appropriate Causal Relations: The model correctly uses RO:0002304 (causally upstream of, positive effect) and RO:0002630 (directly negatively regulates) to represent the relationships between activities.</p> </li> <li> <p>Clear Cellular Localization: All activities are appropriately annotated with cellular compartments (GO:0005680 for anaphase-promoting complex, GO:0072686 for mitotic spindle).</p> </li> <li> <p>Proper Evidence Codes: The model uses appropriate evidence codes like ECO:0000314 (direct assay evidence) with corresponding PMID references.</p> </li> </ol>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Redundant Causal Association: There appear to be two identical causal associations from USP44's deubiquitinase activity to CDC20's activity, both using the same predicate (RO:0002630). One of these lacks evidence while the other cites PMID:17443180. The redundant association without evidence should be removed.</p> </li> <li> <p>Missing Evidence for One Connection: The causal association between CDC20's APC binding activity (gomodel:6348a65d00002236/6348a65d00002247) and ANAPC11's ubiquitin-protein transferase activity lacks evidence (empty evidence array).</p> </li> <li> <p>Could Benefit from Additional Context: While the model accurately captures the core regulatory mechanism, it could be enhanced by including additional proteins involved in this pathway, such as MAD2L1, which is known to form a complex with CDC20 as described in the referenced paper.</p> </li> <li> <p>No Transport or Input Activities: The model doesn't include any chemical entities or transport activities that could provide additional contextual information about the process.</p> </li> </ol>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model is biologically accurate and supported by the literature. The Stegmeier et al. paper (PMID:17443180) clearly demonstrates:</p> <ol> <li>USP44 is a deubiquitinating enzyme critical for spindle checkpoint function</li> <li>USP44 prevents premature activation of APC/C by deubiquitinating CDC20 </li> <li>USP44 helps stabilize the inhibitory MAD2-CDC20 complex</li> <li>There's a dynamic balance between ubiquitination and deubiquitination in regulating anaphase entry</li> </ol> <p>The GO-CAM model accurately represents these findings, though it doesn't capture the full complexity of the MAD2-CDC20 interaction described in the paper.</p>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>Reviewing against GO-CAM best practices:</p> <ol> <li> <p>Complex Annotation: The model follows best practices by representing individual protein activities rather than annotating to complexes (as per \"How_to_annotate_complexes_in_GO-CAM\").</p> </li> <li> <p>Regulation Representation: The model correctly represents regulation by using appropriate causal relationships between activities, following the guidelines in \"Regulation and Regulatory Processes in GO-CAM\".</p> </li> <li> <p>Part_of Relations: Each molecular function is appropriately annotated as part_of a biological process (GO:0045841 and GO:0045842).</p> </li> <li> <p>Cellular Context: All activities include occurs_in annotations to provide cellular context.</p> </li> </ol>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Remove Redundant Causal Association: Delete the USP44's negative regulation of CDC20 that lacks evidence.</p> </li> <li> <p>Add Evidence for Missing Connection: Add evidence for the causal association between CDC20 and ANAPC11.</p> </li> <li> <p>Consider Expanding the Model: Include MAD2L1 and its interaction with CDC20 to better represent the full regulatory mechanism described in the paper.</p> </li> <li> <p>Add Chemical Entity: Consider adding ubiquitin as a chemical entity to provide more context to the ubiquitination/deubiquitination processes.</p> </li> <li> <p>Clarify UBE2C's Role: The evidence for UBE2C's role (PMID:12629039) could not be accessed, so verifying this relationship with alternative evidence might be beneficial.</p> </li> </ol>"},{"location":"reviews/6348a65d00002236-USP44_mediated_deubiquitination_of_CDC20_controlling_anaphase_initiation__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the key molecular mechanisms involved in USP44-mediated regulation of anaphase initiation through CDC20 deubiquitination. With a few minor improvements, it would be an excellent representation of this biological process.</p> <p>The model follows most GO-CAM best practices and is supported by high-quality experimental evidence from the literature. The main suggestion for improvement is to remove redundant relationships and potentially expand the model to include additional relevant proteins like MAD2L1 for a more comprehensive representation of the regulatory network.</p>"},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/","title":"6348a65d00002600 Negative regulation of white adipogenesis by OVOL2   Human","text":"<p>Based on my review of the GO-CAM model and all the available information, I will now provide a comprehensive evaluation of gomodel:6348a65d00002600:</p>"},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/#review-of-go-cam-model-gomodel6348a65d00002600","title":"Review of GO-CAM Model: gomodel:6348a65d00002600","text":""},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"Negative regulation of white adipogenesis by OVOL2. (Human)\" represents a biological pathway where OVOL2 (Ovo-like zinc finger 2) negatively regulates white adipogenesis. The model is based on human data and has a \"production\" status.</p>"},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/#model-components","title":"Model Components","text":"<p>The model consists of four main activities: 1. OVOL2 (Q9BRP0) - Transcription corepressor activity (GO:0003714) 2. CEBPA (P49715) - DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228) 3. SLC2A4/GLUT4 (P14672) - D-glucose transmembrane transporter activity (GO:0055056) 4. FABP4 (P15090) - Long-chain fatty acid transmembrane transporter activity (GO:0005324)</p> <p>The model describes how OVOL2 negatively regulates CEBPA, which in turn positively regulates both SLC2A4 and FABP4, leading to white fat cell proliferation.</p>"},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model contains three causal associations: 1. OVOL2 directly negatively regulates (RO:0002630) CEBPA 2. CEBPA provides input for (RO:0002407) SLC2A4 3. CEBPA provides input for (RO:0002407) FABP4</p>"},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by appropriate evidence, primarily from PMID:36228616, which describes OVOL2's role in suppressing white adipogenesis by blocking CEBPA binding to its transcriptional targets. The model also references PMID:12556481 and PMID:12077340 as supporting evidence for specific relationships.</p>"},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Biological accuracy: The model correctly represents OVOL2's role in inhibiting white adipogenesis as described in the primary literature (PMID:36228616).</li> <li>Proper protein-protein interaction representation: The interaction between OVOL2 and CEBPA is correctly modeled, with OVOL2 directly inhibiting CEBPA's transcriptional activity.</li> <li>Appropriate downstream targets: The model correctly identifies FABP4 and GLUT4 as downstream targets of CEBPA in the adipogenesis pathway.</li> <li>Correct causal relationships: The causal relationships (negative regulation of CEBPA by OVOL2 and positive regulation of FABP4/GLUT4 by CEBPA) align with the literature.</li> </ol>"},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Minor evidence issue: Evidence statements appear to be appropriate, but the annotation linking FABP4 to GO:0005324 (long-chain fatty acid transmembrane transporter activity) cites transfer from mouse ortholog (P04117) via ECO:0000250. While FABP4 does indeed bind and transport fatty acids, suggesting it acts as a fatty acid transporter, the evidence would be stronger with direct experimental evidence in human cells.</p> </li> <li> <p>Improvement opportunity: The model could be enhanced by including additional molecular details about how OVOL2 inhibits CEBPA, such as:</p> </li> <li>The physical interaction between OVOL2's zinc finger domains and CEBPA's bZIP domain</li> <li> <p>The mechanism by which this interaction prevents CEBPA binding to DNA targets</p> </li> <li> <p>Model completeness: The model could be expanded to include:</p> </li> <li>Additional downstream targets of CEBPA in the adipogenesis pathway</li> <li>The role of PPAR\u03b3, which is mentioned in the literature as an important player in adipogenesis</li> <li> <p>The thermogenic function of OVOL2 in brown/beige adipocytes, which is also described in PMID:36228616</p> </li> <li> <p>Cellular contextualization: The model would benefit from including cellular components for all activities, such as specifying that OVOL2 and CEBPA activities occur in the nucleus.</p> </li> </ol>"},{"location":"reviews/6348a65d00002600-Negative_regulation_of_white_adipogenesis_by_OVOL2___Human_/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:6348a65d00002600 is a high-quality GO-CAM model that accurately represents the negative regulation of white adipogenesis by OVOL2 through inhibition of CEBPA transcriptional activity. The model adheres to GO-CAM best practices for representing protein activities and causal relationships. It is supported by appropriate evidence from the literature, particularly PMID:36228616, which provides detailed molecular insights into OVOL2's dual role in promoting thermogenesis and limiting white adipogenesis.</p> <p>The model could be improved by providing more molecular detail about the OVOL2-CEBPA interaction, expanding the representation of the adipogenesis pathway, and adding cellular context information. However, these are suggestions for enhancement rather than corrections of errors, as the model is fundamentally accurate in its current form.</p>"},{"location":"reviews/6348a65d00002622-Ascorbic_acid_biosynthetic_process_1__Mouse_/","title":"6348a65d00002622 Ascorbic acid biosynthetic process 1  Mouse","text":"<p>Let me review the model based on what I've found so far:</p>"},{"location":"reviews/6348a65d00002622-Ascorbic_acid_biosynthetic_process_1__Mouse_/#review-of-go-cam-model-ascorbic-acid-biosynthetic-process-1-mouse","title":"Review of GO-CAM Model: Ascorbic acid biosynthetic process 1 (Mouse)","text":""},{"location":"reviews/6348a65d00002622-Ascorbic_acid_biosynthetic_process_1__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:6348a65d00002622) represents the ascorbic acid (vitamin C) biosynthetic pathway in mouse, which consists of a sequence of enzymatic activities:</p> <ol> <li>UTP-monosaccharide-1-phosphate uridylyltransferase (Ugp2)</li> <li>UDP-glucose 6-dehydrogenase (Ugdh)</li> <li>Alpha-glucuronidase (Ugt1a6a)</li> <li>L-glucuronate reductase (Akr1a1)</li> <li>Gluconolactonase (Rgn)</li> <li>L-gulonolactone oxidase (Gulo)</li> </ol>"},{"location":"reviews/6348a65d00002622-Ascorbic_acid_biosynthetic_process_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate Biological Pathway: The model correctly represents the known enzymatic steps in mouse ascorbic acid biosynthesis. This pathway is well-established in the literature.</p> </li> <li> <p>Correct Causal Flow: The model uses the RO:0002413 \"provides input for\" relation to connect the enzymes in the proper order of the biochemical pathway, showing a clear linear flow from Ugp2 to Gulo, culminating in the production of L-ascorbate.</p> </li> <li> <p>Proper Evidence Documentation: Each activity in the model is supported by appropriate evidence codes (ECO terms) and references to scientific literature. The model uses a combination of direct assay (ECO:0000314), mutant phenotype (ECO:0000315), genetic interaction (ECO:0000316), and sequence orthology (ECO:0000266) evidence.</p> </li> <li> <p>Taxonomic Specificity: The model is correctly specified as being for mouse (NCBITaxon:10090), which is appropriate since mice, unlike humans, can synthesize ascorbic acid.</p> </li> </ol>"},{"location":"reviews/6348a65d00002622-Ascorbic_acid_biosynthetic_process_1__Mouse_/#areas-for-improvement-or-verification","title":"Areas for Improvement or Verification","text":"<ol> <li> <p>Molecular Input/Output Specification: While L-ascorbate is specified as the output of the Gulo activity, intermediate metabolites between the other enzymatic steps are not explicitly represented as inputs/outputs. Adding these would enhance the clarity of the model.</p> </li> <li> <p>Part_of Relation Consistency: All activities are annotated as part_of GO:0009058 (biosynthetic process), which is correct but somewhat general. It would be more specific to annotate them as part_of \"ascorbic acid biosynthetic process\" (GO:0019853).</p> </li> <li> <p>Missing Subcellular Location: The model doesn't specify the subcellular locations of these activities. Based on the UniProt data, these enzymes function in different cellular compartments (e.g., cytoplasm, endoplasmic reticulum).</p> </li> <li> <p>Evidence Documentation: Although evidence is present, some activities rely on a single piece of evidence. Additional supporting evidence would strengthen the model.</p> </li> <li> <p>Missing Context: It would be useful to include information about tissue-specificity (liver is the primary site of ascorbic acid synthesis in mice).</p> </li> </ol>"},{"location":"reviews/6348a65d00002622-Ascorbic_acid_biosynthetic_process_1__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li>Add Intermediate Metabolites: Specify the chemical entities that serve as inputs and outputs for each enzymatic step:</li> <li> <p>Beta-D-glucose 1-phosphate \u2192 UDP-glucose \u2192 UDP-glucuronate \u2192 L-gluconate \u2192 L-gulonolactone \u2192 L-ascorbate</p> </li> <li> <p>Refine Part_of Relations: Consider changing the part_of relationship from the general \"biosynthetic process\" to the more specific \"ascorbic acid biosynthetic process\" (GO:0019853).</p> </li> <li> <p>Add Subcellular Locations: Add cellular component annotations for each activity, particularly for Gulo which is known to be localized to the endoplasmic reticulum.</p> </li> <li> <p>Context Enrichment: Consider adding information about the tissue context (liver) where this pathway primarily occurs.</p> </li> <li> <p>Activity Regulation: Based on the literature (like PMID:10606751), there's evidence that this pathway is regulated by the aromatic hydrocarbon receptor (AhR). This regulatory aspect could be incorporated into the model.</p> </li> </ol>"},{"location":"reviews/6348a65d00002622-Ascorbic_acid_biosynthetic_process_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model accurately represents the ascorbic acid biosynthetic pathway in mouse with appropriate causal connections between activities. The model follows GO-CAM best practices in terms of using appropriate evidence codes and references. With the suggested enhancements, the model could provide an even more comprehensive representation of this important biosynthetic pathway.</p>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/","title":"635b1e3e00000382 Xylulose 5 Phosphate biosynthetic process 1  Mouse","text":"<p>Based on my review of the GO-CAM model \"gomodel:635b1e3e00000382\" (Xylulose-5-Phosphate biosynthetic process 1 (Mouse)), I will provide a comprehensive assessment focusing on its biological accuracy, adherence to GO-CAM guidelines, and overall quality.</p>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#go-cam-model-review-xylulose-5-phosphate-biosynthetic-process-1-mouse","title":"GO-CAM Model Review: Xylulose-5-Phosphate biosynthetic process 1 (Mouse)","text":""},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:635b1e3e00000382) describes the xylulose 5-phosphate biosynthetic process in mouse, focusing on the interactions between four key enzymes involved in glycolysis and the pentose phosphate pathway:</p> <ol> <li>Transketolase (TKT) - MGI:MGI:105992 (UniProt: P40142)</li> <li>Transaldolase (TALDO1) - MGI:MGI:1274789 (UniProt: Q93092)</li> <li>Triose-phosphate isomerase (TPI1) - MGI:MGI:98797 (UniProt: P17751)</li> <li>Glucose-6-phosphate isomerase (GPI1) - MGI:MGI:95797 (UniProt: P06745)</li> </ol>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#pathway-accuracy","title":"Pathway Accuracy","text":"<p>The model accurately represents the enzymatic activities involved in the xylulose 5-phosphate biosynthetic pathway:</p> <ol> <li> <p>Transketolase (TKT) catalyzes the transfer of two-carbon units (ketol group) from a ketose donor to an aldose acceptor. In this pathway, it's correctly shown converting glyceraldehyde 3-phosphate and sedoheptulose 7-phosphate to D-xylulose 5-phosphate and ribose 5-phosphate.</p> </li> <li> <p>Transaldolase (TALDO1) is correctly represented as catalyzing the reversible conversion of sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate to erythrose 4-phosphate and fructose 6-phosphate.</p> </li> <li> <p>Triose-phosphate isomerase (TPI1) is appropriately shown converting glycerone phosphate (dihydroxyacetone phosphate) to D-glyceraldehyde 3-phosphate.</p> </li> <li> <p>Glucose-6-phosphate isomerase (GPI1) is correctly shown producing fructose 6-phosphate, which feeds into this pathway.</p> </li> </ol>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model uses the correct causal relation \"RO:0002413\" (provides input for) to connect the activities of these enzymes, showing how the product of one enzyme activity becomes the substrate for another:</p> <ul> <li>TPI1 \u2192 TKT (glyceraldehyde 3-phosphate as output of TPI1 is input for TKT)</li> <li>TPI1 \u2192 TALDO1 (glyceraldehyde 3-phosphate as output of TPI1 is input for TALDO1)</li> <li>GPI1 \u2192 TKT (outputs of GPI1 feed into subsequent reactions)</li> <li>TKT \u2192 TALDO1 (bidirectional relationship showing how these activities are interconnected)</li> <li>TALDO1 \u2192 TKT (bidirectional relationship showing how these activities are interconnected)</li> </ul>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#evidence-support","title":"Evidence Support","text":"<p>The model uses appropriate evidence codes:</p> <ul> <li>ECO:0000314 (direct assay evidence used in manual assertion) - Used for most connections</li> <li>ECO:0000315 (mutant phenotype evidence used in manual assertion) - Used for GPI1</li> <li>ECO:0000304 (author statement supported by traceable reference) - Used for biological process associations</li> <li>ECO:0000316 (genetic interaction evidence used in manual assertion) - Used for TPI1</li> </ul> <p>The literature cited (PMIDs 5360673, 27103217, 3443296, 30174313) is relevant to the pathway, although I couldn't fully retrieve the earliest reference (5360673).</p>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":""},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#molecular-function-representation","title":"Molecular Function Representation","text":"<p>The model correctly follows GO-CAM best practices for molecular function representation:</p> <ol> <li>Each enzyme is represented with its specific molecular function:</li> <li>Transketolase activity (GO:0004802)</li> <li>Transaldolase activity (GO:0004801)</li> <li>Triose-phosphate isomerase activity (GO:0004807)</li> <li> <p>Glucose-6-phosphate isomerase activity (GO:0004347)</p> </li> <li> <p>All activities have appropriate enabled_by associations to the correct gene products.</p> </li> </ol>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#cellular-component-representation","title":"Cellular Component Representation","text":"<p>The model appropriately represents the cellular location of activities: - All activities occur in the cytosol (GO:0005829), which is correct for these glycolytic/pentose phosphate pathway enzymes.</p>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#biological-process-association","title":"Biological Process Association","text":"<p>The model correctly associates the activities with appropriate biological processes: - Transketolase and transaldolase activities are part of the xylulose 5-phosphate biosynthetic process (GO:1901159) - Triose-phosphate isomerase and glucose-6-phosphate isomerase activities are part of canonical glycolysis (GO:0061621)</p> <p>This accurately represents the biological reality that these enzymes participate in interconnected metabolic networks.</p>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#substrateproduct-representation","title":"Substrate/Product Representation","text":"<p>The model accurately represents the molecular inputs and outputs for each enzymatic reaction: - Transketolase:   - Inputs: D-glyceraldehyde 3-phosphate (CHEBI:59776), sedoheptulose 7-phosphate (CHEBI:15721)   - Outputs: D-xylulose 5-phosphate (CHEBI:57737), D-erythrose 4-phosphate (CHEBI:16897)</p> <ul> <li>Transaldolase:</li> <li>Inputs: D-erythrose 4-phosphate (CHEBI:16897), fructose 6-phosphate (CHEBI:57634)</li> <li> <p>Outputs: D-glyceraldehyde 3-phosphate (CHEBI:59776), sedoheptulose 7-phosphate (CHEBI:15721)</p> </li> <li> <p>Triose-phosphate isomerase:</p> </li> <li>Inputs: Glycerone phosphate (CHEBI:57642)</li> <li> <p>Outputs: D-glyceraldehyde 3-phosphate (CHEBI:59776)</p> </li> <li> <p>Glucose-6-phosphate isomerase:</p> </li> <li>Outputs: Fructose 6-phosphate (CHEBI:57634)</li> </ul>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#causal-flow-and-readability","title":"Causal Flow and Readability","text":"<p>The model presents a clear causal flow showing how these enzymes work together in the pathway. The connections between activities logically follow the flow of metabolites through the pathway, which enhances readability and comprehension.</p>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is overall very good, I have a few minor suggestions for improvement:</p> <ol> <li> <p>Add Input for GPI1: The model doesn't specify the input for glucose-6-phosphate isomerase, which should be glucose 6-phosphate (CHEBI:58225). Adding this would make the reaction complete.</p> </li> <li> <p>Clarify Bidirectional Reactions: Some of these reactions are reversible in vivo. The use of RO:0002413 (provides input for) in both directions between TKT and TALDO1 implies this, but it might be clearer to explicitly note the reversibility of these reactions in annotations.</p> </li> <li> <p>Add More Contextual Information: Adding annotations about conditions that affect the directionality of these reactions (such as substrate availability or energy status of the cell) would enhance the biological context.</p> </li> <li> <p>Consider Adding Regulatory Components: If known, adding how these enzymes are regulated (e.g., by allosteric modulators or post-translational modifications) would provide a more comprehensive picture of the pathway.</p> </li> </ol>"},{"location":"reviews/635b1e3e00000382-Xylulose_5_Phosphate_biosynthetic_process_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:635b1e3e00000382) is a high-quality representation of the xylulose 5-phosphate biosynthetic pathway in mouse. It follows GO-CAM best practices, is biologically accurate, and is supported by appropriate evidence. The model correctly represents the enzymatic activities, their subcellular locations, and their relationships in the pathway. With the suggested minor improvements, it would provide an even more comprehensive representation of this important metabolic pathway.</p>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/","title":"635b1e3e00000433 Xylulose 5 Phosphate biosynthetic process 2  Mouse","text":"<p>Based on my analysis of the GO-CAM model ID 635b1e3e00000433 \"Xylulose-5-Phosphate biosynthetic process 2 (Mouse)\" and all the provided information, I will now provide a comprehensive review:</p>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#go-cam-model-review-gomodel635b1e3e00000433","title":"GO-CAM Model Review: gomodel:635b1e3e00000433","text":""},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#general-information","title":"General Information","text":"<ul> <li>Title: Xylulose-5-Phosphate biosynthetic process 2 (Mouse)</li> <li>ID: gomodel:635b1e3e00000433</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the xylulose-5-phosphate biosynthetic process in mouse, specifically focusing on the conversion pathways involving key enzymes in the non-oxidative branch of the pentose phosphate pathway. The model includes four enzymatic activities linked through causal relationships:</p> <ol> <li>Transketolase (TKT) - catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor</li> <li>Transaldolase (TALDO1) - catalyzes the transfer of a three-carbon dihydroxyacetone group between sugar phosphates</li> <li>Triose phosphate isomerase (TPI1) - catalyzes the interconversion between glyceraldehyde 3-phosphate and dihydroxyacetone phosphate</li> <li>Glucose phosphate isomerase (GPI1) - catalyzes the interconversion of glucose-6-phosphate and fructose-6-phosphate</li> </ol>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#model-structure-and-accuracy","title":"Model Structure and Accuracy","text":""},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#molecular-functions-and-causal-relationships","title":"Molecular Functions and Causal Relationships","text":"<p>The model correctly represents the following molecular activities with appropriate GO terms:</p> <ul> <li>GO:0004802 - transketolase activity (for Tkt)</li> <li>GO:0004801 - transaldolase activity (for Taldo1)</li> <li>GO:0004807 - triose phosphate isomerase activity (for Tpi1)</li> <li>GO:0004347 - glucose-6-phosphate isomerase activity (for Gpi1)</li> </ul> <p>The causal relationships between the activities are properly defined using the <code>RO:0002413</code> \"provides input for\" relation, establishing the correct flow of metabolites between these enzymes.</p>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#cellular-location","title":"Cellular Location","text":"<p>All activities are correctly annotated to occur in the cytosol (GO:0005829), which is the appropriate cellular compartment for these glycolytic/pentose phosphate pathway enzymes.</p>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#biological-process","title":"Biological Process","text":"<p>The activities are appropriately integrated into the biological process GO:1901159 (xylulose 5-phosphate biosynthetic process).</p>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model uses appropriate evidence codes and references: - ECO:0000314 (direct assay evidence used in manual assertion) with PMID:5360673 - ECO:0000315 (mutant phenotype evidence used in manual assertion) with PMID:27103217 - ECO:0000316 (genetic interaction evidence used in manual assertion) with PMID:30174313</p> <p>I verified these references and they appropriately support the annotations made in this model.</p>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#biochemical-accuracy","title":"Biochemical Accuracy","text":"<p>This model accurately represents the biochemical conversion of metabolites:</p> <ol> <li>Transaldolase (TALDO1) converts:</li> <li>Inputs: D-erythrose 4-phosphate (CHEBI:16897) and fructose-6-phosphate (CHEBI:57634)</li> <li> <p>Outputs: glyceraldehyde 3-phosphate (CHEBI:59776) and sedoheptulose 7-phosphate (CHEBI:15721)</p> </li> <li> <p>Transketolase (TKT) converts:</p> </li> <li>Inputs: glyceraldehyde 3-phosphate (CHEBI:59776) and sedoheptulose 7-phosphate (CHEBI:15721)</li> <li> <p>Outputs: D-ribose 5-phosphate (CHEBI:78346) and D-xylulose 5-phosphate (CHEBI:57737)</p> </li> <li> <p>Triose phosphate isomerase (TPI1) provides glyceraldehyde 3-phosphate (CHEBI:59776) as input to transketolase.</p> </li> <li> <p>Glucose phosphate isomerase (GPI1) produces fructose-6-phosphate (CHEBI:57634) which acts as an input for transaldolase.</p> </li> </ol> <p>The connectivity between these enzymes appropriately represents the metabolic flow in the non-oxidative branch of the pentose phosphate pathway.</p>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#improvements-and-suggestions","title":"Improvements and Suggestions","text":"<p>While the model is generally accurate and well-constructed, I have a few suggestions for improvement:</p> <ol> <li> <p>Additional Biological Context: The model could be enriched by connecting this pathway to related biological processes like the pentose phosphate pathway (GO:0006098) and the non-oxidative branch of the pentose phosphate pathway (GO:0009052).</p> </li> <li> <p>Regulation Representation: Consider adding regulatory aspects of these enzymes if relevant information is available from the literature.</p> </li> <li> <p>Connection to Oxidative Branch: It might be valuable to represent the connection to the oxidative branch of the pentose phosphate pathway in a future version of this model or in a linked model.</p> </li> <li> <p>Input/Output for GPI1: While the model correctly shows GPI1 providing input to TALDO1, it might be helpful to explicitly show the input glucose-6-phosphate for GPI1 to make the model more complete.</p> </li> </ol>"},{"location":"reviews/635b1e3e00000433-Xylulose_5_Phosphate_biosynthetic_process_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the xylulose-5-phosphate biosynthetic process in mouse through the non-oxidative branch of the pentose phosphate pathway. The model appropriately represents the molecular functions, biological process context, and causal relationships between the enzymatic activities involved. The evidence used to support the annotations is appropriate and current.</p> <p>The model successfully captures the metabolic flow from glucose-6-phosphate isomerase through transaldolase and transketolase activities to produce xylulose-5-phosphate, with triose phosphate isomerase playing a supporting role in providing a necessary substrate. This representation is consistent with our current understanding of this metabolic pathway as supported by the cited literature.</p>"},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/","title":"635b1e3e00001811 The NLRP3 inflammasome  Human","text":"<p>Based on all the information I've gathered, let me now provide a detailed review of the GO-CAM model \"gomodel:635b1e3e00001811\" titled \"The NLRP3 inflammasome (Human)\":</p>"},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/#review-of-go-cam-model-the-nlrp3-inflammasome-human","title":"Review of GO-CAM Model: The NLRP3 inflammasome (Human)","text":""},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/#summary","title":"Summary","text":"<p>This GO-CAM model (ID: gomodel:635b1e3e00001811) represents the NLRP3 inflammasome pathway in humans, depicting how this crucial innate immune complex assembles and functions to trigger pyroptosis and cytokine secretion. The model shows the activities of several key proteins including NLRP3, CASP1, GSDMD, and the resulting mature cytokines IL1B and IL18.</p>"},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model effectively captures the key components and activities in the NLRP3 inflammasome pathway, from sensor activation to cytokine secretion.</p> </li> <li> <p>Correct use of causal relationships: The model uses appropriate causal relationships (mostly RO:0002629 \"directly positively regulates\") between activities.</p> </li> <li> <p>Well-supported evidence: Each activity and relationship has appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) with supporting literature references.</p> </li> <li> <p>Appropriate molecular functions: The molecular functions assigned to each protein are appropriate based on their known roles (e.g., NLRP3 with sensing and adaptor activity, GSDMD with channel activity).</p> </li> <li> <p>Logical flow of activities: The model shows a clear progression from NLRP3 sensing to inflammasome assembly, caspase-1 activation, gasdermin D cleavage, and finally cytokine release.</p> </li> </ol>"},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Cellular component annotations: While most components have appropriate cellular locations, some refinements could be made:</li> <li> <p>NLRP3 (UniProtKB:Q96P20) is shown in multiple locations (GO:0005815 microtubule organizing center, GO:0016020 membrane). While this is consistent with the literature, indicating specific membrane compartments like \"Golgi apparatus membrane\" (based on UniProt data) would be more precise.</p> </li> <li> <p>Missing environmental triggers: The model doesn't explicitly represent the stimuli that activate NLRP3 (e.g., PAMPs, DAMPs, ATP, nigericin). Including these would provide a more complete picture of inflammasome activation.</p> </li> <li> <p>Complexes representation: According to the \"How to annotate complexes in GO-CAM\" guideline, when the subunit carrying an activity is known, individual proteins should be represented rather than using a complex ID. The model follows this correctly by showing individual components, but it could be useful to explicitly show the complex formation step.</p> </li> <li> <p>NEK7 regulation of NLRP3: The model includes NEK7's molecular function activator activity (GO:0140677) acting on NLRP3, which is accurate according to the literature. However, the mechanism by which NEK7 licenses NLRP3 activation could be more explicitly shown, as it's a critical regulatory step.</p> </li> <li> <p>PYCARD/ASC representation: While NLRP3 and CASP1 are represented, the adaptor protein PYCARD/ASC (which bridges NLRP3 and CASP1) is not explicitly included in the model. Adding PYCARD would make the model more complete.</p> </li> <li> <p>Upstream signaling events: The model could include the \"priming\" step of NLRP3 inflammasome activation, which involves NF-\u03baB-mediated transcriptional upregulation of NLRP3 and pro-IL1B.</p> </li> </ol>"},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/#specific-comments-on-activities-and-relationships","title":"Specific Comments on Activities and Relationships","text":"<ol> <li>NLRP3 activities (UniProtKB:Q96P20):</li> <li>Correctly shown with multiple molecular functions including molecular sensor activity (GO:0140299), signaling adaptor activity (GO:0035591), and phospholipid binding activities (GO:0070273).</li> <li>The model correctly represents the localization to microtubule organizing center and membrane.</li> <li> <p>The activities are appropriately connected to show the sequential activation of NLRP3.</p> </li> <li> <p>CASP1 activities (UniProtKB:P29466):</p> </li> <li>Appropriately shown with cysteine-type endopeptidase activity (GO:0004197).</li> <li> <p>The causal relationships showing CASP1 cleaving GSDMD and pro-cytokines are accurate.</p> </li> <li> <p>GSDMD activities (UniProtKB:P57764):</p> </li> <li>Correctly represented with phospholipid binding activities (GO:0070273, GO:0005546) and wide pore channel activity (GO:0022829).</li> <li> <p>The progression from binding phospholipids to forming pores that allow cytokine release is well-represented.</p> </li> <li> <p>Cytokine activities (IL1B and IL18):</p> </li> <li>Both are appropriately shown with cytokine activity (GO:0005125) in the extracellular space.</li> <li> <p>The model correctly shows these as the terminal outputs of the pathway.</p> </li> <li> <p>NEK7 regulation:</p> </li> <li>The molecular function activator activity (GO:0140677) of NEK7 directly regulating NLRP3 is well-supported by recent literature.</li> </ol>"},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is consistent with current understanding of NLRP3 inflammasome biology, including:</p> <ol> <li>The role of NLRP3 as a sensor for various stimuli</li> <li>The requirement for NEK7 as a licensing factor for NLRP3 activation</li> <li>The cleavage of GSDMD by CASP1 to form membrane pores</li> <li>The maturation and secretion of IL1B and IL18 through these pores</li> </ol> <p>The model reflects findings from recent publications (e.g., PMID:35254907, PMID:35114687, PMID:36227980) cited in the evidence.</p>"},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/#suggestions-for-enhancement","title":"Suggestions for Enhancement","text":"<ol> <li> <p>Add PYCARD/ASC: Include PYCARD (UniProtKB:Q9ULZ3) and its pyrin domain-mediated interactions with NLRP3, which is essential for inflammasome assembly.</p> </li> <li> <p>Represent oligomerization states: The model could explicitly show the oligomerization of NLRP3 and PYCARD/ASC, which is crucial for inflammasome function.</p> </li> <li> <p>Include priming step: Add the LPS/NF-\u03baB-mediated priming events that upregulate NLRP3 and pro-IL1B expression.</p> </li> <li> <p>Show post-translational modifications: Include key PTMs like phosphorylation, ubiquitination, and palmitoylation that regulate NLRP3 activity.</p> </li> <li> <p>Refine membrane locations: Specify the exact membrane compartments where NLRP3 and GSDMD operate (e.g., Golgi, plasma membrane).</p> </li> </ol>"},{"location":"reviews/635b1e3e00001811-The_NLRP3_inflammasome__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of NLRP3 inflammasome biology. The model effectively captures the key molecular activities and causal relationships in the pathway. With a few enhancements to include additional components and regulatory events, it could provide an even more comprehensive representation of this important innate immune pathway.</p>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/","title":"635b1e3e00002003 Inhibition of GSDMD mediated pyroptosis by M tuberculosis PtpB phosphatase that alters membrane phospholipid composition  Human and M tuberculosis","text":"<p>Now let me analyze the GO-CAM model in detail. Based on the information gathered, I'll provide a review of the model.</p>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#review-of-go-cam-model-gomodel635b1e3e00002003","title":"Review of GO-CAM Model: gomodel:635b1e3e00002003","text":""},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#model-summary","title":"Model Summary","text":"<p>Title: Inhibition of GSDMD-mediated pyroptosis by M.tuberculosis PtpB phosphatase that alters membrane phospholipid composition (Human and M.tuberculosis)</p> <p>Taxon: NCBITaxon:9606 (Human)</p>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#biological-context","title":"Biological Context","text":"<p>This model represents how Mycobacterium tuberculosis protein PtpB inhibits gasdermin D (GSDMD)-mediated pyroptosis in host cells. The molecular mechanism involves PtpB acting as a phospholipid phosphatase that dephosphorylates phosphatidylinositol-4-phosphate (PI4P) and phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) in the host cell membrane, thereby disrupting the membrane localization of cleaved GSDMD and inhibiting cytokine release and pyroptosis.</p>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#model-structure-and-activities","title":"Model Structure and Activities","text":"<p>The model includes six molecular activities:</p> <ol> <li>Ubiquitin binding activity of PtpB (I6WXK4)</li> <li>Phosphatidylinositol-4,5-bisphosphate phosphatase activity of PtpB (I6WXK4)</li> <li>Phosphatidylinositol-4-phosphate phosphatase activity of PtpB (I6WXK4)</li> <li>Phosphatidylinositol-4-phosphate binding activity of human GSDMD (P57764)</li> <li>Phosphatidylinositol-4,5-bisphosphate binding activity of human GSDMD (P57764)</li> <li>Wide pore channel activity of human GSDMD (P57764)</li> </ol>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#causal-relationships","title":"Causal Relationships","text":"<p>The model depicts the following causal relationships: - PtpB ubiquitin binding activity directly positively regulates its phosphatidylinositol-4,5-bisphosphate phosphatase activity - PtpB ubiquitin binding activity directly positively regulates its phosphatidylinositol-4-phosphate phosphatase activity - PtpB phosphatidylinositol-4,5-bisphosphate phosphatase activity directly negatively regulates GSDMD phosphatidylinositol-4,5-bisphosphate binding - PtpB phosphatidylinositol-4-phosphate phosphatase activity directly negatively regulates GSDMD phosphatidylinositol-4-phosphate binding - GSDMD phosphatidylinositol-4,5-bisphosphate binding directly positively regulates GSDMD wide pore channel activity - GSDMD phosphatidylinositol-4-phosphate binding directly positively regulates GSDMD wide pore channel activity</p>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#evidence","title":"Evidence","text":"<p>All activities and relationships are supported by experimental evidence, primarily from PMID:36227980, with appropriate ECO codes (ECO:0000314 - direct assay evidence used in manual assertion).</p>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#review-findings","title":"Review Findings","text":""},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li> <p>Accurate Representation of Mechanism: The model accurately captures the molecular mechanism described in the literature (PMID:36227980) about how M. tuberculosis PtpB inhibits GSDMD-mediated pyroptosis.</p> </li> <li> <p>Appropriate GO Terms: The model uses appropriate GO terms for molecular functions, biological processes, and cellular components.</p> </li> <li> <p>Well-supported Evidence: All activities and causal relationships are properly supported by evidence and references.</p> </li> <li> <p>Appropriate Causal Logic: The causal flow from PtpB's phosphatase activity to the inhibition of GSDMD membrane localization and pore formation is logically represented.</p> </li> </ol>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#issues-identified","title":"Issues Identified:","text":"<ol> <li> <p>Redundant Causal Association: There are duplicate causal associations between activities. Specifically, there are two identical causal associations from <code>gomodel:635b1e3e00002003/635b1e3e00002138</code> (PtpB ubiquitin binding) to <code>gomodel:635b1e3e00002003/635b1e3e00002129</code> (PtpB phosphatidylinositol-4,5-bisphosphate phosphatase activity). The second one lacks evidence annotations.</p> </li> <li> <p>Cellular Location Clarification: While the model correctly places PtpB activities in the host cell plasma membrane (GO:0020002), the specific relationship between the bacterial protein's translocation to the host cell and its activities could be more explicitly modeled.</p> </li> <li> <p>Missing Biological Process Context: While the model includes the biological process \"symbiont-mediated suppression of host defense-related programmed cell death\" (GO:0034054) for PtpB activities, it might also include \"symbiont-mediated suppression of host inflammatory response\" (GO:0052036) as mentioned in the UniProt entry for PtpB.</p> </li> </ol>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Remove Redundant Associations: Remove the duplicate causal association from PtpB ubiquitin binding to PtpB phosphatidylinositol-4,5-bisphosphate phosphatase activity.</p> </li> <li> <p>Add Additional Biological Processes: Consider adding \"symbiont-mediated suppression of host inflammatory response\" (GO:0052036) to better capture the broader biological impact of PtpB's activities.</p> </li> <li> <p>Consider Adding Host Response Context: The model could potentially benefit from including additional activities related to the host immune response that are suppressed by this mechanism.</p> </li> <li> <p>Clarify Protein Secretion Mechanism: While outside the immediate scope of this model, it might be valuable to note that the mechanism by which PtpB is secreted from M. tuberculosis and enters host cells is not fully characterized.</p> </li> </ol>"},{"location":"reviews/635b1e3e00002003-Inhibition_of_GSDMD_mediated_pyroptosis_by_M_tuberculosis_PtpB_phosphatase_that_alters_membrane_phospholipid_composition__Human_and_M_tuberculosis_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model effectively represents the inhibition of GSDMD-mediated pyroptosis by M. tuberculosis PtpB phosphatase. It captures the key molecular mechanisms and causal relationships between the bacterial phosphatase activities and the disruption of host GSDMD membrane localization and function. With minor adjustments, particularly removing the redundant causal association, the model provides a clear and scientifically accurate representation of this pathogen-host interaction mechanism.</p>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/","title":"635b1e3e00002004 Activation of the NLRP3 inflammasome by MAPK8 JNK1 and BRCC3  Human","text":"<p>Let me now provide a comprehensive review of the GO-CAM model \"gomodel:635b1e3e00002004\" - Activation of the NLRP3 inflammasome by MAPK8/JNK1 and BRCC3.</p>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#go-cam-model-review-activation-of-the-nlrp3-inflammasome-by-mapk8jnk1-and-brcc3","title":"GO-CAM Model Review - \"Activation of the NLRP3 inflammasome by MAPK8/JNK1 and BRCC3\"","text":""},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: Activation of the NLRP3 inflammasome by MAPK8/JNK1 and BRCC3 (Human)</li> <li>ID: gomodel:635b1e3e00002004</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> <li>Comment: \"Automated change 2023-03-16: RO:0002213 replaced by RO:0002629\"</li> </ul>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#model-structure-and-key-components","title":"Model Structure and Key Components","text":"<p>The model focuses on the activation pathway of the NLRP3 inflammasome, involving primarily three key proteins: 1. NLRP3 (UniProtKB:Q96P20) - The NACHT, LRR and PYD domains-containing protein 3 2. MAPK8/JNK1 (UniProtKB:P45983) - Mitogen-activated protein kinase 8 3. BRCC3 (UniProtKB:P46736) - Lys-63-specific deubiquitinase BRCC36</p>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#biological-representation-accuracy","title":"Biological Representation Accuracy","text":"<p>The model accurately represents the current understanding of NLRP3 inflammasome activation as supported by the literature:</p> <ol> <li>NLRP3 Signaling Adaptor Activity (GO:0035591): </li> <li>Correctly annotated in membrane (GO:0016020) and microtubule organizing center (GO:0005815)</li> <li>Supported by evidence from PMID:35254907 and PMID:35114687</li> <li> <p>This is consistent with findings from PMID:30487600 showing NLRP3 localizes to different subcellular compartments during activation</p> </li> <li> <p>MAPK8/JNK1 Phosphorylation of NLRP3:</p> </li> <li>Correctly represents protein serine/threonine kinase activity (GO:0004674)</li> <li>The causal association (RO:0002629 \"directly positively regulates\") of MAPK8 to BRCC3 deubiquitinase</li> <li> <p>Based on PMID:28943315 which identified that JNK1-mediated phosphorylation of NLRP3 is essential for inflammasome activation</p> </li> <li> <p>BRCC3 Deubiquitinase Activity (GO:0061578):</p> </li> <li>Appropriately shows K63-linked deubiquitinase activity</li> <li>Connected to NLRP3 activation via \"directly positively regulates\" relation (RO:0002629)</li> <li> <p>Supported by PMID:28943315 which demonstrated BRCC3 removes K63-linked ubiquitin from NLRP3</p> </li> <li> <p>NLRP3 Phosphatidylinositol-4-phosphate Binding (GO:0070273):</p> </li> <li>Correctly located in membrane (GO:0016020)</li> <li>Evidence from PMID:30487600 which showed that NLRP3 recruitment to dispersed trans-Golgi network (dTGN) through PI4P binding is essential for inflammasome activation</li> </ol>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#pathway-flow-accuracy","title":"Pathway Flow Accuracy","text":"<p>The causal relationships in the model accurately depict the sequential activation process:</p> <ol> <li>MAPK8/JNK1 phosphorylates NLRP3 (priming step)</li> <li>BRCC3 deubiquitinates NLRP3 (removal of K63-linked ubiquitin)</li> <li>NLRP3 membrane localization through phosphatidylinositol-4-phosphate binding</li> <li>NLRP3 signaling adaptor activity in NLRP3 inflammasome complex assembly</li> </ol> <p>This sequence aligns with the literature findings that NLRP3 activation involves a two-step process: priming (phosphorylation) and activation (deubiquitination), followed by membrane recruitment and complex formation.</p>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#evidence-standards","title":"Evidence Standards","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) for all annotations - Each evidence is backed by peer-reviewed publications (PMID:28943315, PMID:30487600, PMID:35114687, PMID:35254907)</p>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#annotation-of-complexes","title":"Annotation of Complexes","text":"<p>The model follows GO-CAM best practices for complex annotation as outlined in the \"How to annotate complexes in GO-CAM\" document:</p> <ul> <li>Individual proteins (NLRP3, MAPK8, BRCC3) are annotated with their specific molecular functions</li> <li>NLRP3 is correctly annotated as part of the NLRP3 inflammasome complex assembly (GO:0044546)</li> <li>The causal relationships between functions are appropriately represented</li> </ul>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<p>While the model is overall accurate and well-evidenced, there are a few areas that could be enhanced:</p> <ol> <li>Additional NLRP3 Regulatory Mechanisms: </li> <li> <p>The model focuses on phosphorylation and deubiquitination but could include other regulatory mechanisms like NEK7 interaction, which is mentioned in the literature (PMID:35254907)</p> </li> <li> <p>Downstream Effects:</p> </li> <li> <p>The model could be extended to include downstream effects of NLRP3 inflammasome activation, such as caspase-1 activation and IL-1\u03b2 processing</p> </li> <li> <p>Alternative Cellular Locations:</p> </li> <li>While the model correctly represents membrane and MTOC localization, it could also include ER and mitochondrial associations mentioned in some literature</li> </ol>"},{"location":"reviews/635b1e3e00002004-Activation_of_the_NLRP3_inflammasome_by_MAPK8_JNK1_and_BRCC3__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"gomodel:635b1e3e00002004\" accurately represents the NLRP3 inflammasome activation pathway mediated by MAPK8/JNK1 phosphorylation and BRCC3 deubiquitination. The model is well-supported by scientific evidence and follows GO-CAM best practices for annotation.</p> <p>The representation of protein functions, subcellular locations, and causal relationships accurately reflects our current understanding of NLRP3 inflammasome biology. The model effectively captures the key regulatory steps in NLRP3 activation, particularly the roles of phosphorylation and deubiquitination in promoting inflammasome assembly.</p> <p>This model provides a valuable resource for researchers studying inflammasome biology and could be further enhanced by adding additional regulatory mechanisms and downstream effects of NLRP3 activation.</p>"},{"location":"reviews/636d9ce800000147-Cellular_response_to_glucagon_stimulus__Mouse_/","title":"636d9ce800000147 Cellular response to glucagon stimulus  Mouse","text":"<p>Based on all the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model \"gomodel:636d9ce800000147 - Cellular response to glucagon stimulus (Mouse)\".</p>"},{"location":"reviews/636d9ce800000147-Cellular_response_to_glucagon_stimulus__Mouse_/#review-of-go-cam-model-cellular-response-to-glucagon-stimulus-mouse","title":"Review of GO-CAM Model: Cellular response to glucagon stimulus (Mouse)","text":"<p>Model ID: gomodel:636d9ce800000147 Title: Cellular response to glucagon stimulus (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production</p>"},{"location":"reviews/636d9ce800000147-Cellular_response_to_glucagon_stimulus__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This model represents the glucagon signaling pathway in mouse, focusing on the cellular response to glucagon stimulus. The model includes 6 molecular activities and their causal relationships, covering the typical pathway from glucagon binding to its receptor through G-protein signaling, adenylate cyclase activation, and protein kinase activity.</p>"},{"location":"reviews/636d9ce800000147-Cellular_response_to_glucagon_stimulus__Mouse_/#biological-content-analysis","title":"Biological Content Analysis","text":"<p>The model accurately represents the canonical glucagon signaling pathway where:</p> <ol> <li>Gcg (glucagon) binds to Gcgr (glucagon receptor)</li> <li>Gcgr activates G protein (Gnas)</li> <li>G protein activates adenylate cyclase (Adcy8)</li> <li>Adenylate cyclase inhibition affects protein kinase A regulatory subunit (Prkar1a)</li> <li>PKA regulatory subunit inhibits PKA catalytic subunit (Prkaca)</li> </ol> <p>This flow of activities correctly represents the mechanism of glucagon signaling according to the literature, particularly as described in PMID:30380405.</p>"},{"location":"reviews/636d9ce800000147-Cellular_response_to_glucagon_stimulus__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Proper molecular function assignments: Each protein is assigned appropriate molecular functions (e.g., glucagon receptor activity for Gcgr, G protein activity for Gnas, etc.)</p> </li> <li> <p>Correct cellular locations: Activities are placed in appropriate cellular locations (plasma membrane for receptor and G-protein activities, cytosol for downstream components)</p> </li> <li> <p>Well-evidenced: Most activities are supported by experimental evidence with appropriate references (ECO:0000314 - direct assay evidence, ECO:0000315 - mutant phenotype evidence)</p> </li> <li> <p>Correct causal relationships: The causal relationships between activities are biologically accurate:</p> </li> <li>Glucagon receptor activation by glucagon (RO:0002629 - directly positively regulates)</li> <li>G protein activation by receptor (RO:0002629 - directly positively regulates)</li> <li>Adenylate cyclase activation by G protein (RO:0002629 - directly positively regulates)</li> <li> <p>Protein kinase A regulation properly captured with negative regulation (RO:0002630)</p> </li> <li> <p>Appropriate biological process context: All activities are correctly placed within the \"cellular response to glucagon stimulus\" (GO:0071377) biological process</p> </li> </ol>"},{"location":"reviews/636d9ce800000147-Cellular_response_to_glucagon_stimulus__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Direct Evidence for Some Causal Relationships: Some causal links don't have specific evidence annotations (e.g., the causal association between Gcgr activity and Gnas activity). Evidence should ideally be provided for each causal relationship.</p> </li> <li> <p>Lack of Downstream Effectors: The model doesn't extend beyond PKA activation to show the downstream metabolic effects of glucagon signaling (e.g., glycogen breakdown, gluconeogenesis). These processes are mentioned in the referenced studies and are key outcomes of glucagon signaling.</p> </li> <li> <p>Missing Cell Type Annotation: While the model is annotated at the cellular component level, it doesn't specify the cell type (likely hepatocytes) where this signaling occurs. The model includes CL:0000182 (hepatocyte) in its objects but doesn't use it in the activity annotations.</p> </li> <li> <p>No cAMP Representation: The model doesn't explicitly represent cAMP as an intermediate signaling molecule between adenylate cyclase and PKA, which is a key component of this pathway.</p> </li> <li> <p>Incomplete PKA Mechanism: The inhibitory mechanism of PKA regulation could be more clearly represented. In the classical model, cAMP binding to regulatory subunits causes their dissociation from catalytic subunits, allowing the latter to phosphorylate target proteins.</p> </li> </ol>"},{"location":"reviews/636d9ce800000147-Cellular_response_to_glucagon_stimulus__Mouse_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model generally follows the GO-CAM guidelines for signaling receptor activity and pathway representation:</p> <ol> <li> <p>Ligand-receptor relationship: Correctly modeled with glucagon having \"receptor ligand activity\" and causing direct positive regulation of the glucagon receptor.</p> </li> <li> <p>Receptor annotation: Receptor is properly annotated with \"glucagon receptor activity\" and located in the plasma membrane.</p> </li> <li> <p>Downstream signaling: The downstream signaling components are connected with appropriate causal relationships.</p> </li> <li> <p>Complex representation: The model doesn't include protein complexes, but this appears appropriate for this pathway where individual proteins are well-characterized.</p> </li> </ol>"},{"location":"reviews/636d9ce800000147-Cellular_response_to_glucagon_stimulus__Mouse_/#recommendation","title":"Recommendation","text":"<p>This is a solid GO-CAM model that accurately represents the core glucagon signaling pathway. To enhance its completeness and utility, I recommend:</p> <ol> <li>Adding evidence annotations for all causal relationships</li> <li>Extending the model to include downstream metabolic effects of PKA activation</li> <li>Adding cell type context (hepatocyte) to the annotations</li> <li>Considering the addition of cAMP as a small molecule mediator between adenylate cyclase and PKA</li> <li>Clarifying the PKA regulatory mechanism</li> </ol> <p>Overall, this is a well-constructed model that provides valuable information about glucagon signaling. With the suggested improvements, it would provide a more comprehensive representation of the pathway.</p>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/","title":"636d9ce800001192 DCAF12 controls MOV10 during T cell activation   Human","text":"<p>Based on all the gathered information, I'll now conduct a comprehensive review of the GO-CAM model gomodel:636d9ce800001192.</p>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#review-of-go-cam-model-gomodel636d9ce800001192","title":"Review of GO-CAM Model: gomodel:636d9ce800001192","text":""},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: DCAF12 controls MOV10 during T cell activation. (Human)</li> <li>Model ID: gomodel:636d9ce800001192</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#model-summary","title":"Model Summary","text":"<p>This GO-CAM model represents the molecular pathway by which the CRL4-DCAF12 ubiquitin ligase complex controls the levels of MOV10 RNA helicase during T cell activation in humans. The model describes how DCAF12 (Q5T6F0) acts as a substrate receptor in a CUL4A-based E3 ubiquitin ligase complex, recognizing the C-terminal acidic degron (glutamic acid-leucine motif) of MOV10 RNA helicase (Q9HCE1) and targeting it for ubiquitin-dependent degradation via the proteasome.</p>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#model-components","title":"Model Components","text":"<p>The model consists of four main molecular activities:</p> <ol> <li>MOV10 RNA helicase activity (GO:0032574)</li> <li>Enabled by: MOV10 (UniProtKB:Q9HCE1)</li> <li> <p>Part of: miRNA-mediated gene silencing by mRNA destabilization (GO:0035279)</p> </li> <li> <p>RBX1 ubiquitin protein ligase activity (GO:0061630)</p> </li> <li>Enabled by: RBX1 (UniProtKB:P62877) </li> <li>Part of: ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li> <p>Causal connection: Directly negatively regulates (RO:0002630) MOV10 RNA helicase activity</p> </li> <li> <p>CUL4A ubiquitin ligase complex scaffold activity (GO:0160072)</p> </li> <li>Enabled by: CUL4A (UniProtKB:Q13619)</li> <li>Part of: ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</li> <li>Location: Cytoplasm (GO:0005737)</li> <li> <p>Causal connection: Directly positively regulates (RO:0002629) DCAF12 ubiquitin-like ligase-substrate adaptor activity</p> </li> <li> <p>DCAF12 ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</p> </li> <li>Enabled by: DCAF12 (UniProtKB:Q5T6F0)</li> <li>Part of: ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627)</li> <li>Location: Cell component (GO:0005575)</li> <li>Causal connection: Provides input for (RO:0002413) RBX1 ubiquitin protein ligase activity</li> </ol>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#pathway-flow","title":"Pathway Flow","text":"<p>The model's causal flow correctly represents the process by which the CRL4-DCAF12 complex regulates MOV10:</p> <ol> <li>CUL4A acts as a scaffold that positively regulates DCAF12 substrate adaptor activity</li> <li>DCAF12 acts as the substrate receptor that recognizes MOV10's C-terminal degron</li> <li>DCAF12 provides input for RBX1 ubiquitin ligase activity</li> <li>RBX1's ubiquitin ligase activity directly negatively regulates MOV10 RNA helicase activity</li> </ol>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#literature-support-and-evidence","title":"Literature Support and Evidence","text":"<p>The model is well-supported by the primary literature, particularly the paper PMID:34065512, which directly identifies MOV10 as a substrate of the CRL4-DCAF12 complex and demonstrates its role in T cell activation. The paper provides strong experimental evidence for each aspect of the model:</p> <ol> <li>DCAF12 directly recognizes the C-terminal -EL motif of MOV10</li> <li>This interaction leads to ubiquitination and proteasomal degradation of MOV10</li> <li>The process is particularly important during T cell activation</li> <li>The degradation of MOV10 is dependent on the CRL4 complex</li> </ol>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#strengths","title":"Strengths:","text":"<ol> <li>Accurate representation of the pathway: The model correctly represents the molecular functions and causal relationships described in the literature.</li> <li>Well-supported by evidence: Each activity and relationship is backed by experimental evidence from published literature.</li> <li>Appropriate GO terms: The molecular functions, cellular locations, and biological processes are represented with accurate GO terms.</li> <li>Proper relationship predicates: The causal connections use appropriate relationship predicates that accurately reflect the biology.</li> </ol>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#concerns","title":"Concerns:","text":"<ol> <li> <p>Cellular location annotation for MOV10: MOV10's activity is annotated as occurring in \"cellular_component\" (GO:0005575), which is a root term. According to the literature, MOV10 is primarily located in the cytoplasm (specifically in P-bodies) during T cell activation. A more specific location term would improve the model.</p> </li> <li> <p>Evidence for MOV10 function: The MOV10 activity is supported by ECO:0000250 (sequence similarity evidence) with UniProtKB:P23249 as reference. While this is acceptable, direct experimental evidence would be stronger.</p> </li> <li> <p>Biological context: While the model correctly represents T cell activation in the title and context, it could benefit from explicitly connecting to T cell activation processes in the causal chain.</p> </li> </ol>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Update MOV10 location: Replace the general GO:0005575 term with a more specific term such as GO:0000932 (P-body) or at minimum GO:0005737 (cytoplasm) to better reflect MOV10's subcellular location during T cell activation.</p> </li> <li> <p>Add additional supporting evidence: If available, include direct experimental evidence for MOV10's RNA helicase activity from human studies.</p> </li> <li> <p>Consider expanding the model: The paper mentions that this pathway is particularly important during T cell activation. Consider connecting this pathway to T cell activation processes (GO:0042110) more explicitly in the model.</p> </li> <li> <p>Possible expansion: Consider including the destabilization of the C-terminal degron motif (-EL) of MOV10 as part of the causal chain, as this is the specific recognition mechanism described in the paper.</p> </li> </ol>"},{"location":"reviews/636d9ce800001192-DCAF12_controls_MOV10_during_T_cell_activation___Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:636d9ce800001192 provides an accurate and well-supported representation of the molecular pathway by which the CRL4-DCAF12 complex regulates MOV10 during T cell activation. The model follows the GO-CAM best practices for representing protein complexes by individually modeling the activities of each complex component with their specific molecular functions. With minor improvements to the location annotation for MOV10, this model will serve as an excellent resource for understanding this important regulatory mechanism in T cell biology.</p>"},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/","title":"636d9ce800001222 DCAF12 controls MOV10 during spermatogeneis   Human","text":"<p>Now I have enough information to review the GO-CAM model. Let me provide a comprehensive review:</p>"},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/#review-of-go-cam-model-gomodel636d9ce800001222","title":"Review of GO-CAM Model: gomodel:636d9ce800001222","text":""},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/#model-overview","title":"Model Overview","text":"<p>Title: \"DCAF12 controls MOV10 during spermatogeneis. (Human)\" Model ID: gomodel:636d9ce800001222 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/#model-content-summary","title":"Model Content Summary","text":"<p>This GO-CAM model represents the mechanism by which DCAF12 (DDB1- and CUL4-associated factor 12) controls MOV10 RNA helicase during spermatogenesis in humans. The model describes a ubiquitin-dependent protein catabolic process in which:</p> <ol> <li>CUL4A provides scaffold activity for the CRL4-DCAF12 ubiquitin ligase complex</li> <li>DCAF12 acts as the substrate adaptor (recognizing the C-terminal -EL degron in MOV10)</li> <li>RBX1 provides ubiquitin protein ligase activity</li> <li>MOV10 functions as an RNA helicase that is targeted for degradation</li> </ol> <p>The causal chain involves CUL4A (scaffold) \u2192 DCAF12 (substrate adaptor) \u2192 RBX1 (ligase) \u2192 MOV10 (target protein).</p>"},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/#scientific-correctness-assessment","title":"Scientific Correctness Assessment","text":"<p>The model accurately reflects the biological mechanism described in the primary literature (PMID:34065512). The paper clearly demonstrates that:</p> <ol> <li>DCAF12 is part of a CRL4 E3 ubiquitin ligase complex with CUL4A and RBX1</li> <li>This complex specifically recognizes the C-terminal glutamate-leucine (Glu-Leu) degron of MOV10</li> <li>The complex mediates ubiquitination of MOV10, leading to its degradation</li> <li>This regulation is important during spermatogenesis and T cell activation</li> </ol> <p>The causal relationships and molecular activities in the model correctly represent this process.</p>"},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/#go-cam-structure-and-compliance-assessment","title":"GO-CAM Structure and Compliance Assessment","text":"<p>The model follows GO-CAM best practices for representing complexes. Since the functional roles of each component in the complex are known, each protein is individually represented with its specific molecular function:</p> <ol> <li>CUL4A (UniProtKB:Q13619): Ubiquitin ligase complex scaffold activity (GO:0160072)</li> <li>DCAF12 (UniProtKB:Q5T6F0): Ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</li> <li>RBX1 (UniProtKB:P62877): Ubiquitin protein ligase activity (GO:0061630)</li> <li>MOV10 (UniProtKB:Q9HCE1): 5'-3' RNA helicase activity (GO:0032574)</li> </ol> <p>The causal relationships (using RO terms) are appropriately modeled: - CUL4A directly positively regulates (RO:0002629) DCAF12 - DCAF12 provides input for (RO:0002413) RBX1 - RBX1 directly negatively regulates (RO:0002630) MOV10</p> <p>All activities are correctly situated in biological context: - CUL4A and DCAF12 activities occur in the cytoplasm (GO:0005737) - DCAF12 activity is more specifically localized in the cytosol (GO:0005829) - All activities are part of the ubiquitin-dependent protein catabolic process via the C-end degron rule pathway (GO:0140627) - MOV10 activity is part of miRNA-mediated gene silencing by mRNA destabilization (GO:0035279)</p>"},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/#evidence-quality","title":"Evidence Quality","text":"<p>The annotations are supported by appropriate evidence codes and literature: - Direct assay evidence (ECO:0000314) from PMID:34065512 for most relationships - Additional supporting references including PMID:29779948, PMID:31267705, and PMID:22405651 - Evidence for MOV10's RNA helicase activity comes from PMID:24726324</p> <p>All contributions have clear provenance with ORCID identifiers (mainly https://orcid.org/0000-0001-8769-177X) and dates.</p>"},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is generally well-constructed, here are a few suggestions for improvement:</p> <ol> <li> <p>Missing cellular component for MOV10: MOV10's activity is currently annotated to \"cellular_component\" (GO:0005575), which is a placeholder term. Based on the literature, MOV10 is primarily located in the cytoplasm, and more specifically in P-bodies or cytoplasmic ribonucleoprotein granules. Adding this location would improve the model.</p> </li> <li> <p>T cell activation aspect: The model title and content focus on spermatogenesis, but the paper demonstrates that DCAF12 also controls MOV10 during T cell activation. A complementary model or extension of this model to include the T cell context would provide a more complete representation of the biology described in the paper.</p> </li> <li> <p>Connection to downstream processes: The model could be expanded to show how MOV10 degradation affects miRNA-mediated gene silencing, which is briefly described in the paper as one of the consequences of this regulatory mechanism.</p> </li> </ol>"},{"location":"reviews/636d9ce800001222-DCAF12_controls_MOV10_during_spermatogeneis___Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:636d9ce800001222 is a scientifically accurate and structurally sound representation of how the CRL4-DCAF12 ubiquitin ligase complex controls MOV10 during spermatogenesis. It follows GO-CAM best practices for representing complexes by showing each component with its specific molecular function and connecting them with appropriate causal relationships. The model is well-supported by evidence from the primary literature.</p> <p>The few suggested improvements would enhance the completeness of the model but don't detract significantly from its current quality. This model successfully captures the core mechanism described in the literature.</p>"},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/","title":"636d9ce800002041 Positive regulation of gluconeogenesis 1  Mouse","text":"<p>Based on my research, I can now provide a comprehensive review of GO-CAM model gomodel:636d9ce800002041 titled \"Positive regulation of gluconeogenesis 1 (Mouse)\".</p>"},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/#go-cam-model-review-positive-regulation-of-gluconeogenesis-1-mouse","title":"GO-CAM Model Review: Positive regulation of gluconeogenesis 1 (Mouse)","text":""},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the positive regulation of gluconeogenesis in mouse. It includes several key enzymes involved in the gluconeogenesis pathway and illustrates the regulatory relationship between cAMP-dependent protein kinase activity and fructose-2,6-bisphosphate metabolism, which plays a critical role in regulating the balance between glycolysis and gluconeogenesis.</p>"},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/#biological-content-analysis","title":"Biological Content Analysis","text":"<p>The model accurately represents the following components of the gluconeogenesis pathway in mouse:</p> <ol> <li>Key enzymes in gluconeogenesis pathway:</li> <li>Glucose-6-phosphatase activity (G6pc1, MGI:MGI:95607)</li> <li>Glucose-6-phosphate isomerase activity (Gpi1, MGI:MGI:95797)</li> <li>Fructose 1,6-bisphosphate 1-phosphatase activity (Fbp1, MGI:MGI:95492)</li> <li> <p>Glucose 6-phosphate:phosphate antiporter activity (Slc37a4, MGI:MGI:1316650)</p> </li> <li> <p>Regulatory components:</p> </li> <li>cAMP-dependent protein kinase activity (Prkaca, MGI:MGI:97592)</li> <li>Fructose-2,6-bisphosphate 2-phosphatase activity (Pfkfb1, MGI:MGI:107816)</li> </ol>"},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The model appropriately captures several important causal relationships:</p> <ol> <li> <p>cAMP-dependent protein kinase (Prkaca) directly positively regulates (RO:0002629) the fructose-2,6-bisphosphate 2-phosphatase activity (Pfkfb1). This is consistent with literature showing that PKA can phosphorylate and activate the phosphatase activity of the bifunctional enzyme Pfkfb1.</p> </li> <li> <p>Fructose-2,6-bisphosphate 2-phosphatase (Pfkfb1) provides input for (RO:0002413) glucose-6-phosphate isomerase (Gpi1) and directly positively regulates (RO:0002629) fructose 1,6-bisphosphate 1-phosphatase (Fbp1).</p> </li> <li> <p>The model correctly shows how the glucose-6-phosphate isomerase (Gpi1) provides input for (RO:0002413) the glucose 6-phosphate:phosphate antiporter (Slc37a4).</p> </li> <li> <p>Both fructose 1,6-bisphosphate 1-phosphatase (Fbp1) and fructose-2,6-bisphosphate 2-phosphatase (Pfkfb1) provide input for (RO:0002413) glucose-6-phosphate isomerase (Gpi1).</p> </li> <li> <p>The glucose 6-phosphate:phosphate antiporter (Slc37a4) provides input for (RO:0002413) glucose-6-phosphatase (G6pc1), which is the final step in glucose production.</p> </li> </ol>"},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000316 (genetic interaction evidence used in manual assertion) - ECO:0000266 (sequence orthology evidence used in manual assertion)</p> <p>Each assertion is supported by appropriate PMIDs, though some causal associations lack specific evidence annotations.</p>"},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological accuracy: The model correctly represents the key enzymatic steps in gluconeogenesis and their regulatory relationships.</p> </li> <li> <p>Inclusion of regulatory components: The inclusion of cAMP-dependent protein kinase (PKA) and fructose-2,6-bisphosphate 2-phosphatase reflects the important regulatory mechanism where glucagon acts via PKA to promote gluconeogenesis.</p> </li> <li> <p>Consistent causal flow: The model maintains a logical flow of activities that matches the known pathway of gluconeogenesis.</p> </li> <li> <p>Input/output relationships: The model correctly includes CHEBI:28602 (beta-D-fructofuranose 2,6-bisphosphate) as an input for the fructose-2,6-bisphosphate 2-phosphatase activity.</p> </li> </ol>"},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing Evidence for Some Causal Relationships: Some causal associations lack specific evidence annotations. These should be added to strengthen the model.</p> </li> <li> <p>Additional Contextual Detail: The model doesn't explicitly show the hormonal context (e.g., glucagon) that triggers cAMP elevation and subsequent PKA activation. Adding this upstream component would enhance the model's completeness.</p> </li> <li> <p>Expanded Regulatory Mechanism: The model could benefit from explicitly showing how the reduction of fructose-2,6-bisphosphate levels by Pfkfb1 relieves the inhibition of Fbp1, which is a key regulatory mechanism in the switch from glycolysis to gluconeogenesis.</p> </li> <li> <p>Molecular Connection to Metabolic State: Adding information about how this pathway is connected to the fasting state or low blood glucose levels would provide important physiological context.</p> </li> </ol>"},{"location":"reviews/636d9ce800002041-Positive_regulation_of_gluconeogenesis_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:636d9ce800002041 provides an accurate representation of the positive regulation of gluconeogenesis in mouse. It correctly captures the key enzymes involved in the pathway and the regulatory role of cAMP-dependent protein kinase in promoting gluconeogenesis through the modulation of fructose-2,6-bisphosphate levels. With minor additions as suggested, it could provide an even more comprehensive representation of this essential metabolic pathway.</p>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/","title":"63894f2500000740 FIP200 ubiquitination by TRIM21 leading to autophagy inhibition  Human","text":"<p>After reviewing all the information, I'll now provide a detailed assessment of the GO-CAM model gomodel:63894f2500000740.</p>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#review-of-go-cam-model-gomodel63894f2500000740","title":"Review of GO-CAM Model: gomodel:63894f2500000740","text":""},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: FIP200 ubiquitination by TRIM21 leading to autophagy inhibition (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#model-content-analysis","title":"Model Content Analysis","text":"<p>This model depicts a molecular pathway where TRIM21 (P19474) ubiquitinates FIP200/RB1CC1 (Q8TDY2), which leads to the inhibition of autophagy. The model also includes involvement of SETD2 (Q9BYW2) methyltransferase.</p>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#key-activities-and-associations","title":"Key Activities and Associations","text":"<ol> <li>SETD2 Activity (Q9BYW2):</li> <li>Molecular function: Protein-lysine N-methyltransferase activity (GO:0016279)</li> <li>Part of: Positive regulation of autophagy (GO:0010508)</li> <li>Negatively regulates: TRIM21's ubiquitin protein ligase activity</li> <li> <p>Evidence: ECO:0000314 (direct assay evidence) from PMID:28753426</p> </li> <li> <p>TRIM21 Activity (P19474):</p> </li> <li>Molecular function: Ubiquitin protein ligase activity (GO:0061630)</li> <li>Occurs in: Cytoplasm (GO:0005737)</li> <li>Part of: Protein K48-linked ubiquitination (GO:0070936)</li> <li>Negatively regulates: FIP200/RB1CC1's protein kinase binding</li> <li> <p>Evidence: ECO:0000314 (direct assay evidence) from PMID:36359729</p> </li> <li> <p>FIP200/RB1CC1 Activity (Q8TDY2):</p> </li> <li>Molecular function: Protein kinase binding (GO:0019901)</li> <li>Occurs in: ATG1/ULK1 kinase complex (GO:1990316)</li> <li>Part of: Autophagosome assembly (GO:0000045)</li> <li>Target of TRIM21's negative regulation</li> </ol>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#strengths","title":"Strengths","text":"<ol> <li>Scientific Accuracy: </li> <li>The model accurately represents the molecular mechanism described in PMID:36359729, which shows that TRIM21 ubiquitinates FIP200 at K1133, leading to its degradation and inhibiting autophagy.</li> <li> <p>The representation of SETD2's role in methylating FIP200, which prevents TRIM21-mediated ubiquitination, is consistent with the literature.</p> </li> <li> <p>Logical Structure:</p> </li> <li>The causal connections using RO:0002630 (directly negatively regulates) are appropriate.</li> <li> <p>The directional flow from SETD2 inhibiting TRIM21 activity, and TRIM21 inhibiting FIP200 activity is logical.</p> </li> <li> <p>Proper Evidence:</p> </li> <li>Evidence codes are correctly used (ECO:0000314 for direct assay evidence).</li> <li>All assertions are backed by appropriate literature references.</li> </ol>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Complex Representation:</li> <li> <p>According to the \"How to annotate complexes in GO-CAM\" guidance, FIP200/RB1CC1 is part of the ATG1/ULK1 kinase complex. The model correctly notes this, but could be enhanced by including more detailed information about other complex members that might be affected.</p> </li> <li> <p>Molecular Detail:</p> </li> <li>The specific lysine residue (K1133) on FIP200 that gets methylated by SETD2 and ubiquitinated by TRIM21 is not explicitly mentioned in the model, though it's a key detail in the paper.</li> <li> <p>The model doesn't explicitly capture that ubiquitination leads to protein degradation via the proteasome pathway, which is the mechanism of inhibition.</p> </li> <li> <p>Duplicate Causal Association:</p> </li> <li> <p>There appears to be a duplicate causal association from SETD2 to TRIM21 (two instances of RO:0002630), with one of them lacking evidence, which should be removed or properly annotated.</p> </li> <li> <p>Biological Process Context:</p> </li> <li>While the model does include that FIP200 is part of autophagosome assembly (GO:0000045), it could more clearly represent that TRIM21-mediated degradation of FIP200 specifically affects autophagy initiation, as described in the paper.</li> </ol>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<ol> <li>Appropriate Use of Predicates:</li> <li> <p>The model correctly uses RO:0002630 (directly negatively regulates) to indicate inhibition.</p> </li> <li> <p>Cellular Compartment Annotation:</p> </li> <li> <p>The model correctly places TRIM21 in the cytoplasm and FIP200 in the ATG1/ULK1 kinase complex.</p> </li> <li> <p>Evidence and References:</p> </li> <li>All activities have appropriate evidence codes and references, which is in line with best practices.</li> </ol>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Remove Duplicate Causal Association:</li> <li> <p>There's a duplicate causal association from SETD2 to TRIM21 with no evidence, which should be removed.</p> </li> <li> <p>Add Detail about Mechanism:</p> </li> <li> <p>Consider adding annotations to explicitly indicate that TRIM21-mediated ubiquitination leads to proteasomal degradation of FIP200.</p> </li> <li> <p>Specify Modification Site:</p> </li> <li> <p>Consider adding a note about K1133 being the specific site of both methylation and ubiquitination, which is key to the competitive mechanism.</p> </li> <li> <p>Complete the Pathway Context:</p> </li> <li>The model could better represent that this mechanism regulates autophagy initiation rather than just general autophagy.</li> </ol>"},{"location":"reviews/63894f2500000740-FIP200_ubiquitination_by_TRIM21_leading_to_autophagy_inhibition__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:63894f2500000740) provides a good representation of the molecular interactions involved in TRIM21-mediated ubiquitination of FIP200 and its inhibition by SETD2-mediated methylation. The model accurately captures the key molecular functions and biological processes described in the literature.</p> <p>The model could be improved by removing the duplicate causal association, adding more details about the specific modification site and mechanism of inhibition, and more clearly representing the impact on autophagy initiation. These refinements would make the model more informative and precise for users seeking to understand this regulatory pathway.</p>"},{"location":"reviews/63894f2500000870-Liquid_liquid_phase_separation_of_FXR1_drives_translation_of_mRNAs_and_regulation_of_FXR1_by_ubiquitination_and_phosphorylation__Human_/","title":"63894f2500000870 Liquid liquid phase separation of FXR1 drives translation of mRNAs and regulation of FXR1 by ubiquitination and phosphorylation  Human","text":"<p>After analyzing the GO-CAM model and reviewing the relevant documentation and literature, I'm ready to review the GO-CAM model \"Liquid-liquid phase separation of FXR1 drives translation of mRNAs and regulation of FXR1 by ubiquitination and phosphorylation (Human)\" with the ID gomodel:63894f2500000870.</p>"},{"location":"reviews/63894f2500000870-Liquid_liquid_phase_separation_of_FXR1_drives_translation_of_mRNAs_and_regulation_of_FXR1_by_ubiquitination_and_phosphorylation__Human_/#go-cam-model-review-gomodel63894f2500000870","title":"GO-CAM Model Review: gomodel:63894f2500000870","text":""},{"location":"reviews/63894f2500000870-Liquid_liquid_phase_separation_of_FXR1_drives_translation_of_mRNAs_and_regulation_of_FXR1_by_ubiquitination_and_phosphorylation__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the molecular mechanisms by which FXR1 (Fragile X Related 1) protein functions in translation regulation via liquid-liquid phase separation (LLPS), and how FXR1 itself is regulated through phosphorylation and ubiquitination. The model includes activities from various proteins including FXR1, the E3 ubiquitin ligase FBXO4, GSK3\u03b2 kinase, and the translation initiation factor EIF4A1.</p>"},{"location":"reviews/63894f2500000870-Liquid_liquid_phase_separation_of_FXR1_drives_translation_of_mRNAs_and_regulation_of_FXR1_by_ubiquitination_and_phosphorylation__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate representation of molecular activities: The model appropriately captures FXR1's known function in molecular condensate scaffold activity (GO:0140693) and mRNA 3'-UTR binding (GO:0003730) based on recent literature.</p> </li> <li> <p>Properly connected causal relationships: The model correctly represents the relationship between FXR1's condensate scaffold activity leading to translation initiation factor activity of EIF4A1, which is supported by the literature (PMID:34731628).</p> </li> <li> <p>Accurate representation of regulation: The model correctly captures GSK3\u03b2's role in phosphorylating FBXO4, which then targets FXR1 for ubiquitination, as demonstrated in PMID:29142209.</p> </li> <li> <p>Appropriate evidence codes: The model uses appropriate evidence codes for the assertions made, including sequence similarity evidence (ECO:0000250) when citing research in mouse (MGI identifiers), and direct assay evidence (ECO:0000314) when citing direct experimental support.</p> </li> </ol>"},{"location":"reviews/63894f2500000870-Liquid_liquid_phase_separation_of_FXR1_drives_translation_of_mRNAs_and_regulation_of_FXR1_by_ubiquitination_and_phosphorylation__Human_/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement","text":"<ol> <li> <p>Missing molecular function for GSK3\u03b2: While GSK3\u03b2 (UniProtKB:P49841) is shown to have \"protein serine/threonine kinase activity\" (GO:0004674), the specific target of this phosphorylation in the model is not explicitly connected. The literature shows GSK3\u03b2 phosphorylates FBXO4, which primes it for ubiquitination of FXR1. The causal relationship is shown, but a more specific annotation of the target would improve the model.</p> </li> <li> <p>Consider including the entire SCF complex: From PMID:29142209, it's clear that FBXO4 functions as part of the SCF (Skp1-Cul1-F-box) E3 ligase complex. The model currently shows only FBXO4 with the ubiquitin-like ligase-substrate adaptor activity (GO:1990756), but following the annotation guidance for complexes, it could be improved by including the other components of the SCF complex with their respective activities.</p> </li> <li> <p>Feedback regulation could be represented: The literature (PMID:29142209) describes a feedback loop where FXR1 translational represses FBXO4 by binding to its mRNA 3'-UTR. This important regulatory mechanism is not captured in the current model and could be added to provide a more complete understanding of the biological process.</p> </li> <li> <p>Consider adding cellular locations for more activities: While some activities have cellular locations specified (such as FXR1's molecular condensate scaffold activity occurring in intracellular membraneless organelle), others don't have locations specified. Adding these locations would enhance the model's completeness.</p> </li> <li> <p>Include the role of phosphorylation in FXR1 function: The literature indicates that phosphorylation of FXR1 at specific sites regulates its function, but this isn't fully captured in the current model.</p> </li> </ol>"},{"location":"reviews/63894f2500000870-Liquid_liquid_phase_separation_of_FXR1_drives_translation_of_mRNAs_and_regulation_of_FXR1_by_ubiquitination_and_phosphorylation__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model is generally biologically accurate based on the current literature. The model correctly represents:</p> <ul> <li>FXR1's role in translation activation through its molecular condensate scaffold activity and mRNA binding</li> <li>The regulation of FXR1 by GSK3\u03b2-mediated phosphorylation and subsequent FBXO4-mediated ubiquitination</li> <li>The role of EIF4A1 in translation initiation following recruitment by FXR1</li> </ul> <p>The scientific evidence provided (from PMIDs 35951695, 34731628, 29142209, and 30704899) supports these assertions.</p>"},{"location":"reviews/63894f2500000870-Liquid_liquid_phase_separation_of_FXR1_drives_translation_of_mRNAs_and_regulation_of_FXR1_by_ubiquitination_and_phosphorylation__Human_/#go-cam-best-practices-conformity","title":"GO-CAM Best Practices Conformity","text":"<p>The model follows most GO-CAM best practices: - Uses appropriate molecular function terms - Properly connects activities with causal relationships - Includes appropriate cellular locations where activities occur - Utilizes proper evidence codes with relevant references</p> <p>However, the model could better conform to best practices by: - More explicitly modeling the SCF complex components (as described in the \"How to annotate complexes in GO-CAM\" guidance) - Adding more specific cellular locations for all activities where known - Including all relevant causal relationships described in the literature</p>"},{"location":"reviews/63894f2500000870-Liquid_liquid_phase_separation_of_FXR1_drives_translation_of_mRNAs_and_regulation_of_FXR1_by_ubiquitination_and_phosphorylation__Human_/#conclusion-and-recommendations","title":"Conclusion and Recommendations","text":"<p>This GO-CAM model provides a good representation of FXR1 function in translation regulation and its own regulation through the GSK3\u03b2-FBXO4 axis. The model is scientifically accurate based on current literature and follows most GO-CAM best practices.</p> <p>To improve the model, I recommend: 1. Adding the other components of the SCF E3 ligase complex 2. Including the feedback regulation where FXR1 inhibits FBXO4 translation 3. Adding more specific cellular locations for all activities 4. Potentially expanding the model to include additional functions of FXR1 in LLPS-dependent processes</p> <p>Overall, this is a well-constructed model that effectively captures a complex biological process and would be even stronger with these suggested additions.</p>"},{"location":"reviews/63894f2500001748-FRM1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Human_/","title":"63894f2500001748 FRM1 binds N6 methyladenosine  m6A  containing mRNAs and promotes their nuclear export  Human","text":"<p>Based on my review of the GO-CAM model and related literature, I'll now provide a comprehensive review of the model:</p>"},{"location":"reviews/63894f2500001748-FRM1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Human_/#review-of-go-cam-model-gomodel63894f2500001748","title":"Review of GO-CAM Model: gomodel:63894f2500001748","text":""},{"location":"reviews/63894f2500001748-FRM1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the process of \"FRM1 binds N6-methyladenosine (m6A)-containing mRNAs and promotes their nuclear export (Human)\" and includes four main activities centered around the modification and nuclear export of m6A-containing mRNAs.</p> <p>The model describes a functional pathway where: 1. METTL14 has mRNA binding activity 2. METTL3 has mRNA m(6)A methyltransferase activity 3. FMR1 has N6-methyladenosine-containing RNA reader activity 4. XPO1 functions as a nuclear export signal receptor</p>"},{"location":"reviews/63894f2500001748-FRM1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Human_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the current understanding of the m6A RNA modification and export pathway. Key literature supports that:</p> <ol> <li> <p>The METTL3-METTL14 complex forms an active methyltransferase that adds m6A modifications to RNA. METTL3 is the catalytic component while METTL14 functions mainly as an RNA-binding scaffold to stabilize the complex and enhance RNA substrate recognition.</p> </li> <li> <p>FMR1 (FMRP) can recognize and bind to m6A-modified RNAs through its N6-methyladenosine-containing RNA reader activity.</p> </li> <li> <p>XPO1 (Exportin-1/CRM1) functions as a nuclear export signal receptor for the export of these modified mRNAs from the nucleus to the cytoplasm.</p> </li> </ol> <p>The directionality of the pathway is correctly represented with METTL14's mRNA binding activity directly positively regulating METTL3's m6A methyltransferase activity, which in turn directly positively regulates FMR1's m6A reader activity, which then directly positively regulates XPO1's nuclear export receptor activity.</p>"},{"location":"reviews/63894f2500001748-FRM1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows best practices for GO-CAM modeling:</p> <ol> <li> <p>Appropriate relations between activities: The model correctly uses RO:0002629 (directly positively regulates) to connect activities in a causal chain.</p> </li> <li> <p>Protein annotation: Each activity is appropriately enabled by a specific protein (UniProtKB identifiers).</p> </li> <li> <p>Cellular localization: Activities are correctly annotated with cellular locations. The METTL3/METTL14 activities and FMR1 activity occur in the nucleus (GO:0005634), consistent with where m6A modification and initial recognition would take place.</p> </li> <li> <p>Process association: Each activity is associated with the appropriate biological process:</p> </li> <li>METTL14 and METTL3 activities are part of mRNA modification (GO:0016556)</li> <li> <p>FMR1 and XPO1 activities are part of mRNA export from nucleus (GO:0006406)</p> </li> <li> <p>Evidence annotation: All activities and relationships are supported by appropriate evidence codes and literature references, primarily using ECO:0000314 (direct assay evidence) with citations to relevant publications.</p> </li> </ol>"},{"location":"reviews/63894f2500001748-FRM1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is well constructed, I have a few suggestions for possible enhancements:</p> <ol> <li> <p>Detailed molecular mechanism: The model could potentially be expanded to include more detail about how FMR1 recognizes m6A-modified mRNAs. Literature suggests that FMR1 contains specific domains involved in this recognition.</p> </li> <li> <p>Additional regulators: The literature indicates that this pathway may involve additional regulators like YTHDC1, which also functions as an m6A reader protein in the nucleus. Including this could provide a more complete picture of the m6A-mediated export pathway.</p> </li> <li> <p>Temporal aspects: The model could potentially include information about when in the mRNA lifecycle these modifications and export events occur (e.g., during or after transcription, relation to splicing).</p> </li> <li> <p>Subcellular localization: While nuclear localization is included, more specific nuclear structures (like nuclear speckles) could be added if supported by evidence.</p> </li> </ol>"},{"location":"reviews/63894f2500001748-FRM1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:63894f2500001748) is a high-quality representation of the process by which FMR1 binds N6-methyladenosine (m6A)-containing mRNAs and promotes their nuclear export in humans. The model is biologically accurate, well-structured according to GO-CAM guidelines, and properly evidenced. It effectively captures the causal chain of molecular activities involved in this specific mRNA processing pathway.</p> <p>The model is parsimonious and focuses on the core components of the pathway, making it easily understandable while still capturing the essential biological mechanism.</p>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/","title":"63894f2500001789 Fmr1 binds N6 methyladenosine  m6A  containing mRNAs and promotes their nuclear export  Mouse","text":"<p>Based on my review of the GO-CAM model and related literature, I can now provide a comprehensive assessment of the model:</p>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#go-cam-model-review-gomodel63894f2500001789","title":"GO-CAM Model Review: gomodel:63894f2500001789","text":""},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model gomodel:63894f2500001789 titled \"Fmr1 binds N6-methyladenosine (m6A)-containing mRNAs and promotes their nuclear export (Mouse)\" represents a pathway for mRNA export from the nucleus facilitated by m6A modification and FMRP protein.</p>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the biological pathway described in the primary literature (PMID: 31340148), which demonstrates that FMRP functions as an m6A reader that promotes nuclear export of methylated mRNAs during neural differentiation.</p> <p>The model captures the following key aspects of the pathway:</p> <ol> <li>Mettl14 (MGI:MGI:2442926) binds mRNA in the nucleus</li> <li>This facilitates Mettl3 (MGI:MGI:1927165) to perform mRNA m6A methyltransferase activity</li> <li>Fmr1 (MGI:MGI:95564) acts as an m6A reader with N6-methyladenosine-containing RNA reader activity</li> <li>Fmr1 directly positively regulates Xpo1 (MGI:MGI:2144013), which has nuclear export signal receptor activity</li> <li>This cascade results in mRNA export from the nucleus</li> </ol>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model generally follows GO-CAM best practices:</p>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#causal-relations","title":"Causal Relations","text":"<p>The model correctly uses RO:0002629 (directly positively regulates) to show the causal flow from one activity to another, creating a logical pathway from mRNA binding through m6A modification, m6A reading, and finally nuclear export.</p>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>Each activity has appropriate evidence codes and literature references: - ECO:0000314 (direct assay evidence) for most activities - ECO:0000250 (sequence similarity evidence) for Mettl14's mRNA binding - ECO:0000315 (mutant phenotype evidence) for Mettl14's role in mRNA modification</p>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#cellular-components","title":"Cellular Components","text":"<p>The model correctly specifies that activities occur in the nucleus (GO:0005634), which is essential for understanding mRNA export.</p>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#molecular-functions","title":"Molecular Functions","text":"<p>The molecular functions are appropriate for each protein: - GO:0003729 (mRNA binding) for Mettl14 - GO:0001734 (mRNA m6A methyltransferase activity) for Mettl3 - GO:1990247 (N6-methyladenosine-containing RNA reader activity) for Fmr1 - GO:0005049 (nuclear export signal receptor activity) for Xpo1</p>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#improvement-opportunities","title":"Improvement Opportunities","text":"<p>While the model is generally sound, a few improvements could be considered:</p> <ol> <li> <p>Inclusion of the complex: According to the literature and the \"How to annotate complexes in GO-CAM\" guidelines, Mettl3 and Mettl14 form a heterodimeric complex where Mettl14 serves as the RNA-binding scaffold and Mettl3 is the catalytic component. The model could potentially represent this as a complex, especially since the precise activities of each component are known.</p> </li> <li> <p>Representation of CRM1/XPO1 mechanism: The model could add that Fmr1 interacts with CRM1 (Xpo1) via its nuclear export sequence (NES) to facilitate nuclear export, as detailed in the paper.</p> </li> <li> <p>Target specificity: The model could note that this pathway specifically affects m6A-modified mRNAs related to neural differentiation, such as components of the Notch and Hedgehog signaling pathways.</p> </li> <li> <p>Automated change note: The model contains a note about \"GO:0080009 replaced by GO:0016556\" (mRNA modification). This appears to be a valid ontology update.</p> </li> </ol>"},{"location":"reviews/63894f2500001789-Fmr1_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_nuclear_export__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:63894f2500001789 is a high-quality representation of the m6A-dependent mRNA nuclear export pathway facilitated by FMRP. It accurately captures the key molecular functions, causal relationships, and cellular components from the primary literature. The model is well-supported by evidence and provides a clear understanding of how FMRP reads m6A-modified mRNAs to promote their nuclear export during neural differentiation.</p> <p>The model's parsimony makes it accessible while still capturing the essential biological details. Minor enhancements as suggested could further improve the model's comprehensiveness, but even in its current state, it effectively represents this important pathway in RNA processing and nuclear export.</p>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/","title":"63894f2500001894 ARRDC4 mediated activation of MDA5 through K63 ubiquitination by TRIM65  Human","text":"<p>Based on my review of GO-CAM model 63894f2500001894 and the relevant literature, I will now provide a detailed review of this model.</p>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#review-of-go-cam-model-63894f2500001894","title":"Review of GO-CAM Model: 63894f2500001894","text":""},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#model-overview","title":"Model Overview","text":"<p>Title: ARRDC4-mediated activation of MDA5 through K63-ubiquitination by TRIM65 (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>The model depicts a molecular pathway involving ARRDC4, TRIM65, and MAVS in the regulation of antiviral innate immune response.</p>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model accurately represents the findings from the primary reference (PMID:28594402), which demonstrates that ARRDC4 acts as an adaptor protein that interacts with MDA5 and recruits TRIM65 to promote K63-linked ubiquitination of MDA5, enhancing downstream signaling through MAVS.</p> <p>Key molecular activities captured in the model include: 1. TRIM65's ubiquitin protein ligase activity (GO:0061630) 2. ARRDC4's ubiquitin-like ligase-substrate adaptor activity (GO:1990756) 3. MAVS's signaling adaptor activity (GO:0035591)</p> <p>The causal relationships are also correctly represented, where: - ARRDC4 directly positively regulates TRIM65 (RO:0002629) - TRIM65 directly positively regulates MAVS (RO:0002629)</p>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#cellular-location-appropriateness","title":"Cellular Location Appropriateness","text":"<p>The cellular locations are correctly annotated based on the literature: - TRIM65 activity occurs in the cytoplasm (GO:0005737), supported by PMID:34512673 - ARRDC4 activity is correctly placed in the cytoplasm (GO:0005737) - MAVS activity is correctly placed on the mitochondrial membrane (GO:0031966), supported by PMID:20451243</p>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#evidence-and-annotation-quality","title":"Evidence and Annotation Quality","text":"<p>The model uses appropriate evidence codes and references: - ECO:0000314 (direct assay evidence used in manual assertion) with PMID references - ECO:0000305 (curator inference used in manual assertion) for the ARRDC4 location</p>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#go-cam-modeling-best-practices","title":"GO-CAM Modeling Best Practices","text":"<p>Based on the GO-CAM modeling guidelines for complexes, this model follows the recommended approach where the specific proteins carrying the activities are known and represented individually rather than using a complex ID.</p> <p>The causal flow in the model appropriately represents how ARRDC4 acts as an adapter to recruit TRIM65, which then ubiquitinates MDA5, leading to MAVS activation.</p>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#identified-issues","title":"Identified Issues","text":"<p>I noted a minor issue in the model related to causal relationships. There appears to be a duplicate causal association:</p> <pre><code>{\n  \"type\": \"CausalAssociation\",\n  \"evidence\": [],\n  \"predicate\": \"RO:0002629\",\n  \"downstream_activity\": \"gomodel:63894f2500001894/63894f2500001898\"\n}\n</code></pre> <p>This is a redundant entry without evidence that duplicates another causal relationship between ARRDC4 and TRIM65.</p>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Remove Duplicate Causal Association: The empty evidence causal association between ARRDC4 and TRIM65 should be removed as it's redundant.</p> </li> <li> <p>Add More Molecular Detail: The model could potentially be enhanced by adding more detailed information about:</p> </li> <li>The specific lysine residue (K743) on MDA5 that is ubiquitinated by TRIM65, as mentioned in the paper</li> <li> <p>The specific protein-protein interaction domains involved (e.g., ARRDC4's arrestin-like N domain interacts with MDA5)</p> </li> <li> <p>Process Annotation: While the model correctly shows that both TRIM65 and ARRDC4 participate in \"protein K63-linked ubiquitination\" (GO:0070534), it might be valuable to add additional biological process annotations to MAVS, such as \"positive regulation of interferon-beta production\" (GO:0032728), as this is the downstream outcome of this pathway.</p> </li> </ol>"},{"location":"reviews/63894f2500001894-ARRDC4_mediated_activation_of_MDA5_through_K63_ubiquitination_by_TRIM65__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model accurately represents the biological pathway described in the primary literature. The model effectively captures the role of ARRDC4 as an adaptor protein that promotes TRIM65-mediated K63-linked ubiquitination of MDA5, leading to MAVS activation and subsequent innate immune response. The model follows GO-CAM best practices for representing molecular activities and their causal relationships.</p> <p>The model is scientifically sound, with appropriate evidence and references supporting each assertion. The minor issues identified can be easily addressed to improve the model's clarity and completeness.</p>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/","title":"63894f2500002043 Positive regulation of glycolytic process 1  Mouse","text":"<p>Based on my review of the GO-CAM model gomodel:63894f2500002043 and the supporting evidence, I'll now provide a comprehensive evaluation of this model.</p>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#go-cam-model-review-gomodel63894f2500002043","title":"GO-CAM Model Review: gomodel:63894f2500002043","text":""},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#basic-model-information","title":"Basic Model Information","text":"<ul> <li>Model ID: gomodel:63894f2500002043</li> <li>Title: Positive regulation of glycolytic process 1 (Mouse)</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the positive regulation of the glycolytic process in mouse, specifically focusing on the regulation of glycolysis through fructose-2,6-bisphosphate (F2,6BP). The model includes four key activities represented by four distinct proteins:</p> <ol> <li>Pfkfb1 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1) - MGI:MGI:107816</li> <li>Pfkl (ATP-dependent 6-phosphofructokinase, liver type) - MGI:MGI:97547</li> <li>Gpi1 (Glucose-6-phosphate isomerase) - MGI:MGI:95797</li> <li>Ppp2ca (Protein phosphatase 2A catalytic subunit alpha) - MGI:MGI:1321159</li> </ol> <p>The model illustrates how these proteins interact to positively regulate glycolysis through a sequence of activities that involves producing and responding to fructose-2,6-bisphosphate, a key regulator of glycolytic flux.</p>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#detailed-review","title":"Detailed Review","text":""},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#1-biological-accuracy","title":"1. Biological Accuracy","text":"<p>The model accurately represents the canonical understanding of fructose-2,6-bisphosphate-mediated regulation of glycolysis:</p> <ul> <li>Pfkfb1 catalyzes the synthesis of fructose-2,6-bisphosphate from fructose-6-phosphate, which is supported by evidence from PMID:12230553.</li> <li>Pfkl is positively regulated by fructose-2,6-bisphosphate, enhancing glycolytic flux, as evidenced in PMID:8172601 and PMID:35530161.</li> <li>Gpi1 provides input for the Pfkfb1 activity, consistent with its role in converting glucose-6-phosphate to fructose-6-phosphate (PMID:2344351).</li> <li>Ppp2ca (Protein phosphatase 2A) positively regulates Pfkfb1 activity, consistent with its known role in dephosphorylating and thus activating Pfkfb1, as supported by PMID:7592845.</li> </ul> <p>The molecular interactions and causal relationships depicted in the model align with the known biochemistry of glycolysis regulation.</p>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#2-model-structure-and-completeness","title":"2. Model Structure and Completeness","text":"<p>The model includes the core components necessary to understand the positive regulation of glycolysis through fructose-2,6-bisphosphate:</p> <ul> <li>All activities are appropriately enabled by specific gene products.</li> <li>Cellular locations are specified when known (e.g., Pfkfb1 and Gpi1 in cytosol).</li> <li>Molecular functions are correctly assigned (e.g., 6-phosphofructo-2-kinase activity for Pfkfb1).</li> <li>Biological processes are properly indicated (e.g., Pfkl's participation in glycolytic process through fructose-6-phosphate).</li> <li>Causal relationships are clearly defined using appropriate relationship predicates.</li> </ul>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#strengths","title":"Strengths:","text":"<ul> <li>The model includes the output molecule (beta-D-fructofuranose 2,6-bisphosphate) for Pfkfb1 activity.</li> <li>The model uses appropriate causal relationship predicates (RO:0002629 for direct positive regulation and RO:0002413 for provides input for).</li> <li>The model includes occurrences in cellular components where known.</li> </ul>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#potential-improvements","title":"Potential improvements:","text":"<ul> <li>The model could potentially include more detail on the phosphorylation state of Pfkfb1 that is regulated by Ppp2ca.</li> <li>Additional details about the inputs and outputs for Pfkl activity could enhance completeness.</li> </ul>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#3-evidence-and-references","title":"3. Evidence and References","text":"<p>The model has robust evidential support:</p> <ul> <li>Appropriate evidence codes are used throughout (ECO:0000266, ECO:0000314, ECO:0000315).</li> <li>All activities are backed by literature references (PMIDs).</li> <li>Where homology-based evidence is used, appropriate \"with\" references are included.</li> </ul>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#4-go-cam-best-practices","title":"4. GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ul> <li>Complex representation: The model appropriately represents individual proteins rather than complexes since the activities are carried out by specific subunits.</li> <li>Causal relationships: The model correctly uses the \"directly positively regulates\" predicate (RO:0002629) for the regulatory relationships and \"provides input for\" (RO:0002413) for metabolic input relationships.</li> <li>Activity flow: The activities are connected in a logical flow that represents the biological pathway.</li> <li>Parsimony: The model is concise while capturing the essential regulatory relationships.</li> </ul>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#5-validation-against-literature","title":"5. Validation Against Literature","text":"<p>The scientific literature supports the relationships depicted in the model:</p> <ul> <li>PMID:12230553 describes the role of Fru-2,6-P2 in regulating hepatic carbohydrate metabolism, supporting the positive regulatory role of Pfkfb1 on glycolysis.</li> <li>PMID:8172601 supports the role of Pfkl in the phosphorylation of fructose-6-phosphate, an essential step in glycolysis.</li> <li>PMID:2344351 validates the role of Gpi1 (glucose-6-phosphate isomerase) in the early steps of glycolysis.</li> <li>PMID:26080680 provides evidence for the cytosolic localization of Gpi1.</li> <li>PMID:35530161 supports the involvement of Pfkl in the glycolytic process through fructose-6-phosphate.</li> </ul>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#6-isoform-specificity-and-tissue-context","title":"6. Isoform Specificity and Tissue Context","text":"<p>The model appropriately represents:</p> <ul> <li>The specific mouse isoforms of the proteins involved (Pfkfb1, Pfkl, Gpi1, Ppp2ca).</li> <li>The tissue context is implied to be liver-specific based on the liver-type Pfkl and the evidence used.</li> </ul>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#recommendations","title":"Recommendations","text":"<p>Based on my review, this model is scientifically accurate and adheres to GO-CAM best practices. It provides a clear representation of the positive regulation of glycolysis through fructose-2,6-bisphosphate in mouse.</p>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#minor-suggestions-for-enhancement","title":"Minor Suggestions for Enhancement:","text":"<ol> <li> <p>Add metabolic inputs/outputs for Pfkl: While the model shows Pfkl participating in glycolysis, adding its specific substrate (fructose-6-phosphate) and product (fructose-1,6-bisphosphate) would enhance clarity.</p> </li> <li> <p>Include the phosphorylation state details: The model could specify that Ppp2ca regulates Pfkfb1 by dephosphorylating specific residues, shifting the kinase/phosphatase activity ratio.</p> </li> <li> <p>Consider expanding the model: The model could be expanded to include additional regulatory inputs to Pfkfb1 (e.g., hormone signaling) or to show downstream glycolytic steps affected by increased Pfkl activity.</p> </li> </ol>"},{"location":"reviews/63894f2500002043-Positive_regulation_of_glycolytic_process_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:63894f2500002043 is a high-quality representation of the positive regulation of glycolysis via fructose-2,6-bisphosphate in mouse. It is scientifically accurate, well-evidenced, and follows GO-CAM best practices. The model effectively captures the key molecular activities and causal relationships involved in this regulatory pathway, making it a valuable resource for understanding glycolytic regulation.</p>"},{"location":"reviews/639bc18f00000090-Isg12a_K6_ubiquitination_by_TRIM21_leading_to_pyroptosis__Human_/","title":"639bc18f00000090 Isg12a K6 ubiquitination by TRIM21 leading to pyroptosis  Human","text":"<p>Let me now review the GO-CAM model based on all the information I've gathered. I'll need to check if it follows the GO-CAM best practices and if the biological representation is accurate.</p>"},{"location":"reviews/639bc18f00000090-Isg12a_K6_ubiquitination_by_TRIM21_leading_to_pyroptosis__Human_/#go-cam-review-gomodel639bc18f00000090","title":"GO-CAM Review: gomodel:639bc18f00000090","text":""},{"location":"reviews/639bc18f00000090-Isg12a_K6_ubiquitination_by_TRIM21_leading_to_pyroptosis__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Isg12a K6-ubiquitination by TRIM21 leading to pyroptosis (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>This model represents a pathway showing how TRIM21 (an E3 ubiquitin ligase) regulates virus-induced cell pyroptosis through polyubiquitination of ISG12a/IFI27 (an interferon-stimulated gene), leading to caspase-3 activation and eventually gasdermin E (GSDME)-mediated pyroptosis.</p>"},{"location":"reviews/639bc18f00000090-Isg12a_K6_ubiquitination_by_TRIM21_leading_to_pyroptosis__Human_/#pathway-analysis","title":"Pathway Analysis","text":"<p>The model describes four main activities in the following causal pathway:</p> <ol> <li>TRIM21 (P19474) - Ubiquitin protein ligase activity (GO:0061630)</li> <li>Located in cytoplasm (GO:0005737)</li> <li>Part of protein K6-linked ubiquitination process (GO:0085020)</li> <li> <p>Directly positively regulates ISG12a/IFI27</p> </li> <li> <p>ISG12a/IFI27 (P40305) - Molecular adaptor activity (GO:0060090)</p> </li> <li>Located in mitochondrion (GO:0005739)</li> <li>Part of pyroptotic inflammatory response (GO:0070269)</li> <li> <p>Causally upstream of, positive effect on Caspase-3 </p> </li> <li> <p>Caspase-3 (P42574) - Cysteine-type endopeptidase activity (GO:0004197)</p> </li> <li>Located in cytoplasm (GO:0005737)</li> <li>Part of pyroptotic inflammatory response (GO:0070269)</li> <li> <p>Directly positively regulates Gasdermin E</p> </li> <li> <p>Gasdermin E (O60443) - Wide pore channel activity (GO:0022829)</p> </li> <li>Located in plasma membrane (GO:0005886)</li> <li>Part of pyroptotic inflammatory response (GO:0070269)</li> <li>Terminal step in the pathway</li> </ol>"},{"location":"reviews/639bc18f00000090-Isg12a_K6_ubiquitination_by_TRIM21_leading_to_pyroptosis__Human_/#model-accuracy-review","title":"Model Accuracy Review","text":"<p>After examining the literature and molecular function data, I find the GO-CAM model is well-constructed and accurately represents the current scientific understanding of this pathway:</p> <ol> <li> <p>Evidence Base: The model is well-supported by primary literature (PMID:36426955), which specifically describes the role of TRIM21 in regulating virus-induced cell pyroptosis through IFI27 (ISG12a) ubiquitination.</p> </li> <li> <p>Molecular Functions: The molecular functions assigned to each protein are accurate:</p> </li> <li>TRIM21 is correctly annotated as an E3 ubiquitin ligase that catalyzes K6-linked ubiquitination of ISG12a</li> <li>ISG12a/IFI27 is correctly shown with molecular adaptor activity, as it functions to recruit caspase-3 to the mitochondria</li> <li>Caspase-3 is correctly identified as the protease that cleaves Gasdermin E</li> <li> <p>Gasdermin E is correctly shown with its pore-forming activity</p> </li> <li> <p>Subcellular Locations: The subcellular locations are accurately represented:</p> </li> <li>TRIM21 in cytoplasm</li> <li>ISG12a/IFI27 in mitochondrion</li> <li>Caspase-3 in cytoplasm</li> <li> <p>Gasdermin E in plasma membrane</p> </li> <li> <p>Causal Relationships: The causal associations between activities follow the biological process accurately, with appropriate relationship predicates:</p> </li> <li>TRIM21 directly positively regulates (RO:0002629) ISG12a</li> <li>ISG12a causally upstream of, positive effect (RO:0002304) on Caspase-3</li> <li>Caspase-3 directly positively regulates (RO:0002629) Gasdermin E</li> </ol>"},{"location":"reviews/639bc18f00000090-Isg12a_K6_ubiquitination_by_TRIM21_leading_to_pyroptosis__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Molecular activities are properly assigned to specific gene products</li> <li>Causal relationships between activities use appropriate predicates</li> <li>Cellular locations are properly annotated for each activity</li> <li>Biological processes are properly assigned to activities</li> <li>Evidence is provided for each assertion with appropriate ECO codes and literature references</li> </ol>"},{"location":"reviews/639bc18f00000090-Isg12a_K6_ubiquitination_by_TRIM21_leading_to_pyroptosis__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The biological pathway represented in this model is consistent with current understanding:</p> <ol> <li> <p>TRIM21-mediated ISG12a ubiquitination: The literature (PMID:36426955) confirms that TRIM21 mediates K6-linked polyubiquitination of ISG12a at Lys-69, which facilitates its translocation to mitochondria.</p> </li> <li> <p>ISG12a's role in caspase-3 activation: The research confirms that ISG12a, after ubiquitination and mitochondrial translocation, causes caspase-3 activation.</p> </li> <li> <p>Caspase-3 cleavage of Gasdermin E: Literature (PMID:28459430) confirms that caspase-3 cleaves Gasdermin E at Asp-270, releasing its N-terminal domain.</p> </li> <li> <p>Gasdermin E pore formation: The cleaved Gasdermin E N-terminal domain has been confirmed to form pores in the plasma membrane, leading to pyroptosis.</p> </li> </ol>"},{"location":"reviews/639bc18f00000090-Isg12a_K6_ubiquitination_by_TRIM21_leading_to_pyroptosis__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:639bc18f00000090 is a high-quality representation of the TRIM21-ISG12a-Caspase3-GSDME pathway leading to pyroptosis. It accurately reflects the scientific literature, correctly applies molecular function terms, and properly represents the causal relationships between activities.</p> <p>Key strengths of this model: - Accurate molecular function annotations - Correct subcellular localization - Appropriate causal relationships - Strong evidence base with relevant literature citations</p> <p>No significant issues or inaccuracies were identified in this model. It provides a clear and accurate representation of the biological pathway by which TRIM21-mediated ubiquitination of ISG12a leads to pyroptosis through caspase-3 activation and Gasdermin E pore formation.</p>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/","title":"639bc18f00000430 Negative regulation of glycolytic process through fructose 6 phosphate 2  Mouse","text":"<p>Based on all the information I've gathered, I can now review the GO-CAM model (gomodel:639bc18f00000430) for accuracy and adherence to best practices.</p>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#review-of-go-cam-model-639bc18f00000430","title":"Review of GO-CAM Model 639bc18f00000430","text":""},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#model-title","title":"Model Title","text":"<p>\"Negative regulation of glycolytic process through fructose-6-phosphate 2 (Mouse)\"</p>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#overview","title":"Overview","text":"<p>This model describes a regulatory pathway in mouse that involves the negative regulation of glycolysis through a pathway that includes: 1. Glucose-6-phosphate isomerase (Gpi1) 2. Fructose-2,6-bisphosphate 2-phosphatase activity (Pfkfb1) 3. cAMP-dependent protein kinase activity (Prkaca) 4. 6-phosphofructokinase activity (Pfkl)</p> <p>The model shows the relationship between these activities and their role in the negative regulation of glycolysis through fructose-6-phosphate.</p>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#structure-and-accuracy-assessment","title":"Structure and Accuracy Assessment","text":""},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#molecular-functions-and-proteins","title":"Molecular Functions and Proteins:","text":"<ol> <li>Pfkl (MGI:MGI:97547) - 6-phosphofructokinase activity (GO:0003872)</li> <li>This is correctly annotated as participating in glycolytic process through fructose-6-phosphate (GO:0061615)</li> <li> <p>The UniProt information confirms this is appropriate, as Pfkl is a key enzyme that catalyzes the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate</p> </li> <li> <p>Prkaca (MGI:MGI:97592) - cAMP-dependent protein kinase activity (GO:0004691)</p> </li> <li>Correctly annotated as participating in negative regulation of glycolytic process (GO:0045820)</li> <li> <p>The literature (PMID:16155866) supports this function, showing that PKA activity from this catalytic subunit can lead to decreased glycolysis</p> </li> <li> <p>Pfkfb1 (MGI:MGI:107816) - fructose-2,6-bisphosphate 2-phosphatase activity (GO:0004331)</p> </li> <li>Correctly annotated as participating in negative regulation of glycolytic process (GO:0045820)</li> <li>Located in cytosol (GO:0005829)</li> <li>Has input of beta-D-fructose 2,6-bisphosphate(4-) (CHEBI:58579)</li> <li> <p>The UniProt entry confirms Pfkfb1 has both kinase and phosphatase activities, and phosphorylation by PKA shifts it toward phosphatase activity</p> </li> <li> <p>Gpi1 (MGI:MGI:95797) - glucose-6-phosphate isomerase activity (GO:0004347)</p> </li> <li>Correctly annotated as being located in the cytosol (GO:0005829)</li> </ol>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#causal-relationships","title":"Causal Relationships:","text":"<ol> <li>Causal relationship 1: Prkaca directly positively regulates (RO:0002629) Pfkfb1</li> <li>This is supported by the literature. PMID:16155866 shows that PKA phosphorylates Pfkfb1, which shifts its activity toward the phosphatase function.</li> <li> <p>The UniProt entry for Pfkfb1 confirms that \"phosphorylation at Ser-33 inhibits the kinase and activates the bisphosphatase\"</p> </li> <li> <p>Causal relationship 2: Pfkfb1 directly negatively regulates (RO:0002630) Pfkl</p> </li> <li>This is accurate as the phosphatase activity of Pfkfb1 degrades fructose-2,6-bisphosphate, which is an activator of Pfkl</li> <li> <p>The decrease in F-2,6-P2 levels leads to decreased activity of phosphofructokinase, inhibiting glycolysis</p> </li> <li> <p>Causal relationship 3: Gpi1 provides input for (RO:0002413) Pfkfb1</p> </li> <li>This is accurate as glucose-6-phosphate isomerase produces fructose-6-phosphate, which is a substrate for Pfkfb1</li> </ol>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The pathway described in this model is biologically accurate and consistent with current knowledge:</p> <ol> <li>PKA (Prkaca) phosphorylates and activates the phosphatase activity of Pfkfb1</li> <li>Activated phosphatase activity of Pfkfb1 decreases the levels of fructose-2,6-bisphosphate</li> <li>Decreased fructose-2,6-bisphosphate leads to decreased activity of phosphofructokinase (Pfkl)</li> <li>This ultimately leads to negative regulation of glycolysis</li> </ol> <p>This is consistent with the literature, including PMID:16155866, which demonstrates that constitutively active PKA leads to decreased levels of fructose-2,6-bisphosphate and inhibition of glycolysis.</p>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<ol> <li> <p>Representation of molecule activities: The model correctly represents the molecular functions of each protein and their roles in biological processes.</p> </li> <li> <p>Causal relationships: The model uses appropriate causal relationship predicates:</p> </li> <li>RO:0002413 (provides input for) for enzymatic reactions where one enzyme produces a substrate for another</li> <li>RO:0002629 (directly positively regulates) for positive regulation </li> <li> <p>RO:0002630 (directly negatively regulates) for negative regulation</p> </li> <li> <p>Cellular components: The model includes appropriate cellular locations (cytosol for Pfkfb1 and Gpi1).</p> </li> <li> <p>Evidence: Each annotation has appropriate evidence codes and references to literature.</p> </li> <li> <p>Use of complexes: This model does not involve complexes, so the complex annotation guidelines do not apply here.</p> </li> </ol>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is accurate and well-constructed, a few potential improvements could be considered:</p> <ol> <li> <p>Additional molecular details: The model could potentially include the fact that Prkaca phosphorylates Pfkfb1 at Ser-33, which is a specific mechanism that shifts the activity of Pfkfb1.</p> </li> <li> <p>Additional biochemical context: The model could include ATP as an input for both Prkaca and Pfkl activities, as both are kinases that use ATP.</p> </li> <li> <p>Expanded pathway context: The model could be expanded to include how this regulation fits into the broader context of metabolic regulation, possibly including:</p> </li> <li>The role of glucagon in activating PKA</li> <li>The connection to gluconeogenesis, which is often upregulated when glycolysis is downregulated</li> </ol>"},{"location":"reviews/639bc18f00000430-Negative_regulation_of_glycolytic_process_through_fructose_6_phosphate_2__Mouse_/#summary","title":"Summary","text":"<p>This is a well-constructed GO-CAM model that accurately represents the negative regulation of glycolysis through the PKA-Pfkfb1-Pfkl axis. It adheres to the GO-CAM best practices for representing molecular activities and their causal relationships. The model is supported by appropriate evidence from the literature and provides a clear representation of the pathway in mouse. No significant errors or issues were found in the model.</p>"},{"location":"reviews/63a86a8600000221-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_1__Mouse_/","title":"63a86a8600000221 positive regulation of transcription from RNA polymerase II promoter by glucose 1  Mouse","text":"<p>After reviewing all the information, I'll now provide a comprehensive review of the GO-CAM model gomodel:63a86a8600000221.</p>"},{"location":"reviews/63a86a8600000221-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_1__Mouse_/#go-cam-model-review-gomodel63a86a8600000221","title":"GO-CAM Model Review: gomodel:63a86a8600000221","text":""},{"location":"reviews/63a86a8600000221-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"positive regulation of transcription from RNA polymerase II promoter by glucose 1 (Mouse)\" describes the molecular pathway of glucose-responsive transcriptional regulation in mouse hepatocytes, focusing on the role of ChREBP (Mlxipl) in activating genes involved in glycolysis and lipid synthesis.</p>"},{"location":"reviews/63a86a8600000221-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_1__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model includes 5 key activities:</p> <ol> <li>Kat2b activity: Peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li>Enabled by: Kat2b (MGI:MGI:1343094)</li> <li>Occurs in: nucleus (GO:0005634)</li> <li>Part of: positive regulation of transcription from RNA polymerase II promoter by glucose (GO:0000432)</li> <li> <p>Causally regulates: Mlxipl activity</p> </li> <li> <p>Mlxipl activity: DNA-binding transcription activator activity (GO:0001228)</p> </li> <li>Enabled by: Mlxipl/ChREBP (MGI:MGI:1927999)</li> <li>Occurs in: nucleus (GO:0005634) </li> <li>Part of: positive regulation of transcription from RNA polymerase II promoter by glucose (GO:0000432)</li> <li> <p>Causally regulates: Pklr activity</p> </li> <li> <p>Mlx activity: RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629)</p> </li> <li>Enabled by: Mlx (MGI:MGI:108398)</li> <li>Occurs in: nucleus (GO:0005634)</li> <li>Part of: positive regulation of transcription from RNA polymerase II promoter by glucose (GO:0000432)</li> <li> <p>Causally regulates: Mlxipl activity</p> </li> <li> <p>Pklr activity: Pyruvate kinase activity (GO:0004743)</p> </li> <li>Enabled by: Pklr (MGI:MGI:97604)</li> <li>Occurs in: cytosol (GO:0005829)</li> <li> <p>Part of: glycolytic process (GO:0006096)</p> </li> <li> <p>Sik2 activity: Protein serine kinase activity (GO:0106310)</p> </li> <li>Enabled by: Sik2 (MGI:MGI:2445031)</li> <li>Part of: negative regulation of transcription from RNA polymerase II promoter by glucose (GO:0061987)</li> <li>Causally regulates (negatively): Kat2b activity and Pklr activity</li> </ol>"},{"location":"reviews/63a86a8600000221-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_1__Mouse_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Comprehensive pathway representation: The model effectively captures the glucose-responsive transcriptional regulatory pathway, showing how glucose regulates transcription through ChREBP (Mlxipl) and its cofactors.</p> </li> <li> <p>Appropriate causal relationships: The causal relationships between activities are well represented, using appropriate relationship predicates (RO:0002629 for direct positive regulation, RO:0002630 for direct negative regulation, and RO:0002407 for positive regulation).</p> </li> <li> <p>Cellular context: The model correctly annotates the subcellular locations of the activities (nucleus for transcription factors, cytosol for metabolic enzymes).</p> </li> <li> <p>Biological process context: Each activity is appropriately placed in its relevant biological process context.</p> </li> <li> <p>Evidence base: The model is supported by experimental evidence from relevant publications.</p> </li> </ol>"},{"location":"reviews/63a86a8600000221-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_1__Mouse_/#model-issues-and-recommendations","title":"Model Issues and Recommendations","text":"<ol> <li>Missing activity context: Sik2 activity lacks a specified cellular compartment annotation. Based on its function in regulating transcription factors, I recommend adding:</li> <li> <p>Occurs in: cytosol or nucleus (depending on specific localization data)</p> </li> <li> <p>Regulatory mechanism clarification: The model indicates that Sik2 directly negatively regulates both Kat2b and Pklr activities. Based on the literature reviewed (PMID:21084751), Sik2 regulates p300 phosphorylation which affects ChREBP acetylation. The direct negative regulation of Pklr by Sik2 may need reconsideration, as it's more likely an indirect effect through the transcriptional cascade.</p> </li> <li> <p>Recommendation: Consider revising the causal relationship from Sik2 to Pklr to an indirect negative regulation relationship or remove this direct connection.</p> </li> <li> <p>Missing molecular context: The model doesn't include O-GlcNAcylation of ChREBP, which is an important post-translational modification affecting ChREBP stability and activity as described in PMID:21471514.</p> </li> <li> <p>Recommendation: Consider adding O-GlcNAc transferase (Ogt) activity and its regulation of ChREBP if this aspect is relevant to the specific focus of the model.</p> </li> <li> <p>Complex formation: According to the literature, Mlx and Mlxipl (ChREBP) function as a heterodimer. Following GO-CAM guidelines on \"How to annotate complexes in GO-CAM\", since both proteins have defined activities, they should be represented individually as done in this model, but their interaction could be more clearly represented.</p> </li> <li> <p>Recommendation: Consider adding a note or annotation clarifying the heterodimeric nature of the functional Mlx-ChREBP complex.</p> </li> <li> <p>Additional supporting literature: The model could benefit from adding references to recent literature on ChREBP regulation through acetylation and O-GlcNAcylation (e.g., PMID:21471514), especially to support the role of Kat2b in ChREBP acetylation.</p> </li> </ol>"},{"location":"reviews/63a86a8600000221-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:63a86a8600000221 provides an accurate representation of glucose-responsive transcriptional regulation in mouse hepatocytes, focusing on the key role of ChREBP (Mlxipl) in this pathway. The model effectively captures the transcriptional activation of metabolic genes through the coordinated actions of transcription factors and their regulators.</p> <p>The model adheres to GO-CAM best practices for representing transcription factor activities and their causal relationships, as outlined in the DNA-binding transcription factor activity annotation guidelines. Minor improvements as suggested would enhance the clarity and completeness of the biological mechanism represented.</p> <p>This model is an informative resource for understanding the molecular basis of glucose-responsive gene expression in the liver, which is relevant to carbohydrate and lipid metabolism research.</p>"},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/","title":"63a86a8600000288 positive regulation of transcription from RNA polymerase II promoter by glucose 2  Mouse","text":"<p>Now I'll put together my review of the GO-CAM model based on the information I've gathered:</p>"},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/#review-of-go-cam-model-gomodel63a86a8600000288","title":"Review of GO-CAM Model: gomodel:63a86a8600000288","text":""},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:63a86a8600000288) is titled \"positive regulation of transcription from RNA polymerase II promoter by glucose 2 (Mouse)\" and represents a pathway in Mus musculus (mouse) involving glucose-mediated regulation of lipid biosynthesis through ChREBP and related transcription factors.</p>"},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/#model-structure-analysis","title":"Model Structure Analysis","text":"<p>The model describes a regulatory pathway with several key molecular activities:</p> <ol> <li>Central Transcription Factor Activity:</li> <li>Mlxipl (ChREBP) functions as a DNA-binding transcription activator (GO:0001228) in the nucleus</li> <li>Mlx functions as an RNA polymerase II-specific DNA-binding transcription factor binding protein (GO:0061629) in the nucleus</li> <li> <p>Kat2b (p/CAF) functions as a peptide-lysine-N-acetyltransferase (GO:0061733) in the nucleus</p> </li> <li> <p>Metabolic Enzyme Activities:</p> </li> <li>Acaca enables acetyl-CoA carboxylase activity (GO:0003989) in the cytosol</li> <li> <p>Fasn enables fatty acid synthase activity (GO:0004312) in the cytosol</p> </li> <li> <p>Regulatory Kinase Activity:</p> </li> <li> <p>Sik2 enables protein serine kinase activity (GO:0106310)</p> </li> <li> <p>Causal Relationships:</p> </li> <li>Mlx directly positively regulates Mlxipl</li> <li>Kat2b directly positively regulates Mlxipl</li> <li>Mlxipl directly positively regulates both Acaca and Fasn</li> <li>Sik2 directly negatively regulates Kat2b, Acaca, and Fasn</li> </ol>"},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model accurately represents the glucose-responsive transcriptional regulation pathway involving ChREBP (Mlxipl) and its partner Mlx in the regulation of lipogenic gene expression, which is well-supported by the literature:</p> <ol> <li> <p>ChREBP-Mlx Interaction: The model correctly represents ChREBP (Mlxipl) and Mlx forming a functional heterodimer to regulate lipogenic gene expression. The heterodimer binds to carbohydrate response elements (ChoREs) in target gene promoters.</p> </li> <li> <p>Acetyltransferase Regulation: The inclusion of Kat2b (p/CAF) as a positive regulator of ChREBP activity through acetylation is supported by the literature, though p300 (not explicitly represented in this model) is also a key acetyltransferase for ChREBP.</p> </li> <li> <p>SIK2 Negative Regulation: The model correctly represents SIK2 as a negative regulator of the pathway. According to Bricambert et al. (2010), SIK2 inhibits ChREBP activity by phosphorylating p300, reducing its HAT activity, which in turn reduces ChREBP acetylation and DNA binding.</p> </li> <li> <p>Target Genes: The model correctly includes the key lipogenic enzymes Acaca (acetyl-CoA carboxylase) and Fasn (fatty acid synthase) as targets of ChREBP regulation.</p> </li> </ol>"},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/#go-cam-best-practice-compliance","title":"GO-CAM Best Practice Compliance","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Molecular Function Annotation: Each gene product is appropriately annotated with specific molecular functions.</p> </li> <li> <p>Cellular Component: The nuclear location of transcription factors and cytosolic location of metabolic enzymes are appropriately annotated.</p> </li> <li> <p>Biological Process: The activities are correctly linked to relevant biological processes (lipid biosynthesis and transcriptional regulation).</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal relationship predicates:</p> </li> <li>RO:0002629 (directly positively regulates) for direct positive regulatory relationships</li> <li>RO:0002630 (directly negatively regulates) for direct negative regulatory relationships</li> <li>RO:0002407 (directly positively regulates active state of) for transcriptional activation</li> </ol>"},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing p300 Coactivator: The model includes Kat2b (p/CAF) but not p300 (Ep300), which according to Bricambert et al. (2010) is a critical HAT for ChREBP acetylation at Lys672. This acetylation is crucial for ChREBP DNA binding and transcriptional activity. Adding p300 would provide a more complete representation of the pathway.</p> </li> <li> <p>Mechanism of SIK2 Regulation: The model shows SIK2 directly negatively regulating Kat2b, Acaca, and Fasn, but the literature suggests SIK2 primarily acts by phosphorylating p300 at Ser89, inhibiting its HAT activity. This mechanistic detail could be better represented.</p> </li> <li> <p>Glucose Sensing Mechanism: While the model title mentions \"positive regulation by glucose,\" the actual glucose sensing mechanisms (e.g., glucose metabolism to xylulose-5-phosphate, ChREBP nuclear translocation) are not explicitly represented.</p> </li> <li> <p>Expanded Target Gene Set: The model could be enhanced by including additional ChREBP target genes involved in glycolysis and lipogenesis (e.g., L-PK, ACL).</p> </li> </ol>"},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes:</p> <ol> <li>Direct Assay Evidence (ECO:0000314): Used for most protein interactions and molecular functions</li> <li>Genetic Interaction Evidence (ECO:0000316): Used for Acaca's acetyl-CoA carboxylase activity</li> <li>Mutant Phenotype Evidence (ECO:0000315): Used for Mlxipl's DNA-binding transcription activator activity</li> <li>Sequence Orthology Evidence (ECO:0000266): Used for Fasn's subcellular location</li> </ol> <p>The model cites relevant primary literature sources (PMID:17210641, PMID:21084751, PMID:15496471, etc.) that support the represented activities and relationships.</p>"},{"location":"reviews/63a86a8600000288-positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_2__Mouse_/#summary-and-recommendations","title":"Summary and Recommendations","text":"<p>This GO-CAM model accurately represents the core components of glucose-mediated regulation of lipogenic gene expression through ChREBP/Mlx transcription factors. The model follows GO-CAM best practices and is supported by appropriate evidence.</p> <p>Recommendations for improvement:</p> <ol> <li>Include p300 (Ep300) as a key acetyltransferase for ChREBP, with its regulation by SIK2 via Ser89 phosphorylation</li> <li>Clarify the mechanistic details of SIK2 regulation in the pathway</li> <li>Consider representing the glucose sensing mechanisms that activate ChREBP</li> <li>Expand the set of target genes to provide a more comprehensive view of the pathway</li> </ol> <p>Overall, this is a sound model that captures an important regulatory pathway linking glucose sensing to lipid metabolism, with potential relevance to metabolic disorders like fatty liver disease.</p>"},{"location":"reviews/63a86a8600000489-TRIM22_NT5C2_regulation_of_RIGI_via_ubiquitination__Human_/","title":"63a86a8600000489 TRIM22 NT5C2 regulation of RIGI via ubiquitination  Human","text":"<p>Now I have enough information to review the model. Let me provide a comprehensive review of GO-CAM model: gomodel:63a86a8600000489 \"TRIM22-NT5C2 regulation of RIGI via ubiquitination (Human)\".</p>"},{"location":"reviews/63a86a8600000489-TRIM22_NT5C2_regulation_of_RIGI_via_ubiquitination__Human_/#review-of-go-cam-model-trim22-nt5c2-regulation-of-rigi-via-ubiquitination-human","title":"Review of GO-CAM Model \"TRIM22-NT5C2 regulation of RIGI via ubiquitination (Human)\"","text":"<p>This model (gomodel:63a86a8600000489) represents the molecular mechanisms by which TRIM22 and NT5C2 regulate RIG-I (also known as DDX58) through different forms of ubiquitination in human cells, as part of the antiviral innate immune response.</p>"},{"location":"reviews/63a86a8600000489-TRIM22_NT5C2_regulation_of_RIGI_via_ubiquitination__Human_/#model-overview","title":"Model Overview","text":"<p>The model includes four activities, representing: 1. NT5C2 (P49902) with ubiquitin protein ligase activity 2. TRIM22 (Q8IYM9) with ubiquitin protein ligase activity 3. RIG-I (O95786) with pattern recognition receptor activity 4. MAVS (Q7Z434) with signaling adaptor activity</p> <p>The model captures how TRIM22 and NT5C2 differentially regulate RIG-I through distinct types of ubiquitination (K63-linked and K48-linked), affecting the downstream antiviral immune response pathway through MAVS.</p>"},{"location":"reviews/63a86a8600000489-TRIM22_NT5C2_regulation_of_RIGI_via_ubiquitination__Human_/#evidence-evaluation","title":"Evidence Evaluation","text":"<p>The model is primarily based on the paper by Fei et al. (2022) [PMID:36159777], which provides evidence for the interaction between TRIM22, NT5C2, and RIG-I. The paper demonstrates that TRIM22 promotes K63-linked ubiquitination of RIG-I, while NT5C2 is responsible for K48-linked ubiquitination. This dual regulation affects the RIG-I/NF-\u03baB signaling pathway.</p> <p>All activities in the model are appropriately supported by ECO evidence codes with proper references, primarily relying on direct assay evidence (ECO:0000314) from the cited publication.</p>"},{"location":"reviews/63a86a8600000489-TRIM22_NT5C2_regulation_of_RIGI_via_ubiquitination__Human_/#accuracy-assessment","title":"Accuracy Assessment","text":"<p>The model accurately represents the biological mechanism described in the primary paper:</p> <ol> <li> <p>TRIM22 (Q8IYM9) is correctly annotated with ubiquitin protein ligase activity (GO:0061630) and is associated with protein K63-linked ubiquitination (GO:0070534), which activates RIG-I signaling.</p> </li> <li> <p>NT5C2 (P49902) is correctly annotated with ubiquitin protein ligase activity (GO:0061630) and associated with protein K48-linked ubiquitination (GO:0070936), which negatively regulates RIG-I.</p> </li> <li> <p>The causal relationships are appropriately captured:</p> </li> <li>NT5C2 directly negatively regulates RIG-I (RO:0002630)</li> <li>TRIM22 directly positively regulates RIG-I (RO:0002629)</li> <li> <p>RIG-I directly positively regulates MAVS (RO:0002629)</p> </li> <li> <p>RIG-I (O95786) is correctly placed as a pattern recognition receptor (GO:0038187), part of the antiviral innate immune response (GO:0140374).</p> </li> <li> <p>MAVS (Q7Z434) is appropriately represented with signaling adaptor activity (GO:0035591).</p> </li> </ol>"},{"location":"reviews/63a86a8600000489-TRIM22_NT5C2_regulation_of_RIGI_via_ubiquitination__Human_/#potential-issues-and-recommendations","title":"Potential Issues and Recommendations","text":"<p>While the model is generally well-constructed, I identified a few issues that should be addressed:</p> <ol> <li> <p>Redundant causal connection: There are two identical causal connections from TRIM22 to RIG-I (both using RO:0002629). This appears to be a duplication that should be removed.</p> </li> <li> <p>Missing contextual information: Although the model describes the ubiquitination events well, it would benefit from additional information about the cellular location where this process takes place. Both proteins involved in ubiquitination should have \"occurs_in\" associations with the cytoplasm (GO:0005737), as correctly indicated for TRIM22 and RIG-I but not explicitly shown for NT5C2.</p> </li> <li> <p>Biological process annotation: The model could be enhanced by including additional biological process annotations that connect this pathway to interferon production and antiviral defense signaling.</p> </li> <li> <p>Improved representation of complex: While the model shows separate activities for TRIM22 and NT5C2, the paper suggests they function as a complex. According to the GO-CAM documentation for annotating complexes, when the subunits carrying the molecular activities are known (as in this case), representing the individual proteins as separate activities is appropriate, which this model does correctly.</p> </li> </ol>"},{"location":"reviews/63a86a8600000489-TRIM22_NT5C2_regulation_of_RIGI_via_ubiquitination__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows several GO-CAM best practices: - Each protein is annotated with appropriate molecular functions - Each activity has appropriate \"part_of\" biological process annotations - Causal relationships between activities use correct predicates - Evidence codes with appropriate reference citations are provided</p> <p>Specifically for E3 ligase representation, the model follows the guidelines by: - Using \"ubiquitin protein ligase activity\" (GO:0061630) for both E3 ligases - Specifying the type of ubiquitination (K48-linked vs K63-linked) in the biological process annotation - Using the appropriate causal relations to indicate positive or negative regulation</p>"},{"location":"reviews/63a86a8600000489-TRIM22_NT5C2_regulation_of_RIGI_via_ubiquitination__Human_/#summary-and-final-assessment","title":"Summary and Final Assessment","text":"<p>This GO-CAM model accurately represents the dual regulation of RIG-I by TRIM22 and NT5C2 through different types of ubiquitination, as described in the literature. The model is well-structured, uses appropriate GO terms and relationships, and follows the GO-CAM best practices for representing E3 ubiquitin ligase activities.</p> <p>The minor issues noted above (particularly the redundant causal connection) should be addressed, but they don't significantly impact the overall quality or accuracy of the model. This model effectively captures an important regulatory mechanism in the antiviral innate immune response pathway.</p>"},{"location":"reviews/63a86a8600000805-Positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_3__Mouse_/","title":"63a86a8600000805 Positive regulation of transcription from RNA polymerase II promoter by glucose 3  Mouse","text":"<p>Based on the information gathered, I'll now conduct a review of the GO-CAM model \"gomodel:63a86a8600000805\" titled \"Positive regulation of transcription from RNA polymerase II promoter by glucose 3 (Mouse)\".</p>"},{"location":"reviews/63a86a8600000805-Positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_3__Mouse_/#review-of-go-cam-model-gomodel63a86a8600000805","title":"Review of GO-CAM Model: gomodel:63a86a8600000805","text":""},{"location":"reviews/63a86a8600000805-Positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_3__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents a pathway depicting how glucose regulates transcription from RNA polymerase II promoters in mouse cells, focusing on lipid biosynthetic processes. The model includes 5 activities involving 4 proteins:</p> <ol> <li>Mlxipl (ChREBP) - DNA-binding transcription activator activity</li> <li>Mlx - RNA polymerase II-specific DNA-binding transcription factor binding</li> <li>Acaca - acetyl-CoA carboxylase activity</li> <li>Fasn - fatty acid synthase activity</li> <li>Ogt - protein O-acetylglucosaminyltransferase activity</li> </ol>"},{"location":"reviews/63a86a8600000805-Positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_3__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Correct molecular functions: The model uses appropriate molecular function terms for each protein. Notably, Mlxipl/ChREBP is correctly annotated with DNA-binding transcription activator activity (GO:0001228).</p> </li> <li> <p>Well-documented evidence: The model is supported by high-quality literature evidence, primarily from PMID:21471514, which details the role of O-GlcNAcylation in increasing ChREBP protein content and transcriptional activity in liver cells.</p> </li> <li> <p>Appropriate causal relationships: The causal relationships show how ChREBP activates downstream targets (Acaca and Fasn) in the lipid biosynthetic pathway, consistent with the literature. The model uses RO:0002407 (\"contributes to\") to connect the ChREBP transcription factor activity to its downstream targets.</p> </li> <li> <p>Subcellular localization: The model correctly places activities in their appropriate cellular compartments: transcription factors in the nucleus (GO:0005634) and metabolic enzymes in the cytosol (GO:0005829).</p> </li> <li> <p>Integration of regulatory mechanisms: The model shows how Ogt regulates ChREBP activity through O-GlcNAcylation, consistent with the findings in PMID:21471514.</p> </li> </ol>"},{"location":"reviews/63a86a8600000805-Positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_3__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Mlx regulation of ChREBP: The model shows Mlx (GO:0061629) directly positively regulating (RO:0002629) ChREBP (GO:0001228), but does not clearly represent the heterodimer formation. According to \"How to annotate complexes in GO-CAM\" guidelines, when the activity is shared by several proteins (as in a heterodimeric transcription factor), this should be explicitly represented. Evidence in PMID:21471514 suggests ChREBP partners with Mlx to form a functional transcription factor.</p> </li> <li> <p>Predicate usage: The model uses RO:0002407 (\"contributes to\") to link ChREBP to its downstream targets, rather than the more specific \"indirectly positively regulates\" (RO:0002304) recommended in the DNA-binding transcription factor activity annotation guidelines for the relationship between a transcription factor and its target gene activities.</p> </li> <li> <p>Representation of O-GlcNAcylation: While the model correctly shows Ogt regulating ChREBP activity, the mechanism of this regulation (O-GlcNAcylation stabilizing ChREBP protein and increasing its transcriptional activity) could be represented more explicitly.</p> </li> <li> <p>Glucose sensing mechanism: The model represents the biological process \"positive regulation of transcription from RNA polymerase II promoter by glucose\" (GO:0000432), but could more clearly show how glucose levels are sensed and how this signal is transmitted to activate ChREBP.</p> </li> <li> <p>Target gene specificity: The model shows ChREBP regulating both Acaca and Fasn, but could benefit from including additional documented target genes to provide a more comprehensive view of the lipogenic program activated by ChREBP.</p> </li> </ol>"},{"location":"reviews/63a86a8600000805-Positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_3__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the core elements of glucose-stimulated transcriptional regulation of lipogenic genes based on the literature evidence:</p> <ol> <li> <p>O-GlcNAcylation of ChREBP: PMID:21471514 demonstrates that ChREBP interacts with OGT and is O-GlcNAcylated, which stabilizes the protein and increases its transcriptional activity toward glycolytic and lipogenic genes (Acaca, Fasn) when combined with an active glucose flux.</p> </li> <li> <p>Metabolic pathway representation: The downstream activities (acetyl-CoA carboxylase and fatty acid synthase) correctly represent the lipid biosynthetic pathway controlled by ChREBP.</p> </li> <li> <p>Cellular localization: The localization of activities is consistent with known biology - ChREBP translocates to the nucleus upon activation to regulate transcription, while the lipogenic enzymes function in the cytosol.</p> </li> </ol>"},{"location":"reviews/63a86a8600000805-Positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_3__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Refine relationship between ChREBP and Mlx: Consider representing the Mlx-ChREBP interaction as a heterodimeric complex formation, which is required for DNA binding and transcriptional activation.</p> </li> <li> <p>Update causal relationships: Replace RO:0002407 with RO:0002304 (\"causally upstream of, positive effect\") to better reflect the indirect positive regulation between the transcription factor and its target genes.</p> </li> <li> <p>Expand representation of glucose sensing: Consider adding components showing how glucose flux leads to ChREBP activation, possibly including the hexosamine biosynthetic pathway that leads to UDP-GlcNAc production and subsequent O-GlcNAcylation.</p> </li> <li> <p>Include additional regulatory mechanisms: The model could be enhanced by including phosphorylation state changes of ChREBP that affect its nuclear translocation, as described in PMID:21471514.</p> </li> <li> <p>Add more comprehensive target gene representation: If supported by evidence, include additional documented ChREBP target genes involved in glycolysis and lipogenesis.</p> </li> </ol>"},{"location":"reviews/63a86a8600000805-Positive_regulation_of_transcription_from_RNA_polymerase_II_promoter_by_glucose_3__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"gomodel:63a86a8600000805\" is a scientifically accurate representation of glucose-regulated transcription of lipogenic genes in mouse liver cells. It effectively captures the role of O-GlcNAcylation in enhancing ChREBP activity and the downstream activation of lipogenic enzymes. The model follows most GO-CAM best practices but could be improved with minor adjustments to relationship types and a more detailed representation of the Mlx-ChREBP heterodimer. Overall, this is a high-quality model that successfully communicates the biological pathway of glucose-stimulated lipogenesis through ChREBP-mediated transcriptional activation.</p>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/","title":"63a86a8600001202 DHX16 mediated viral RNA recognition and activation of RIGI  Human","text":"<p>Now that I have a good understanding of the model and the relevant proteins, let me review the GO-CAM model gomodel:63a86a8600001202 in detail.</p>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#review-of-go-cam-model-63a86a8600001202","title":"Review of GO-CAM Model 63a86a8600001202","text":""},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:63a86a8600001202</li> <li>Title: DHX16-mediated viral RNA recognition and activation of RIGI (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the pathway by which DHX16 (a DEAH-box RNA helicase) recognizes viral RNA and cooperates with RIGI (RIG-I, an innate immune receptor) to trigger antiviral immunity responses. The model depicts a signaling cascade with specific molecular functions and causal relationships.</p>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#molecular-activities-and-connections","title":"Molecular Activities and Connections","text":"<p>The model includes 5 primary molecular activities across 3 proteins:</p> <ol> <li>DHX16 (UniProtKB:O60231) has three activities:</li> <li>Pattern recognition receptor activity (GO:0038187)</li> <li>Ubiquitin binding (GO:0043130)</li> <li> <p>Molecular adaptor activity (GO:0060090)</p> </li> <li> <p>RIGI (UniProtKB:O95786) has one activity:</p> </li> <li> <p>Pattern recognition receptor activity (GO:0038187)</p> </li> <li> <p>TRIM6 (UniProtKB:Q9C030) has one activity:</p> </li> <li>Ubiquitin protein ligase activity (GO:0061630)</li> </ol> <p>The causal connections in the model form a pathway where: - DHX16's pattern recognition receptor activity positively regulates its ubiquitin binding - DHX16's ubiquitin binding positively regulates its molecular adaptor activity - DHX16's molecular adaptor activity positively regulates RIGI's pattern recognition receptor activity - TRIM6's ubiquitin protein ligase activity positively regulates DHX16's ubiquitin binding</p>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#cellular-context","title":"Cellular Context","text":"<p>All activities in the model occur in the cytoplasm (GO:0005737) and are part of the antiviral innate immune response (GO:0140374).</p>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>All the molecular functions and causal connections are supported by evidence from PMID:35263596, which is a well-conducted study published in Cell Reports in 2022. The annotations have proper evidence codes (ECO:0000314 - direct assay evidence used in manual assertion).</p>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately captures the findings from the primary research paper:</p> <ol> <li>DHX16 acts as a pattern recognition receptor by detecting specific viral RNA patterns</li> <li>TRIM6 creates unanchored K48-linked polyubiquitin chains</li> <li>DHX16 binds these unanchored polyubiquitin chains</li> <li>The ubiquitin-bound DHX16 acts as a molecular adaptor to enhance RIG-I-dependent innate immune signaling</li> <li>This cascade leads to an effective antiviral innate immune response</li> </ol> <p>The paper demonstrated that DHX16's RNA helicase motif III is critical for direct interaction with specific viral RNAs, particularly those containing splicing signals from Influenza virus and SARS-CoV-2.</p>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<ol> <li>Molecular Function Representation: </li> <li>The model correctly uses enabling verbs (\"enabled by\") to connect gene products to molecular functions</li> <li> <p>The model accurately represents roles of each protein based on evidence</p> </li> <li> <p>Causal Relationships:</p> </li> <li>The model uses appropriate causal predicates (\"directly positively regulates\") to connect activities</li> <li> <p>The directional flow is logical and matches the biology</p> </li> <li> <p>Contexts:</p> </li> <li> <p>Cellular context (cytoplasm) and biological process (antiviral innate immune response) are appropriately assigned</p> </li> <li> <p>Molecular Adaptor Representation:</p> </li> <li>The model appropriately annotates DHX16 with molecular adaptor activity (GO:0060090)</li> <li> <p>This follows the guidelines from the \"Molecular adaptor activity\" document</p> </li> <li> <p>Complex Representation:</p> </li> <li>The model doesn't explicitly represent complexes but instead focuses on the causal cascade</li> <li>This is appropriate as the molecular activities are assigned to individual proteins</li> </ol>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model accurately captures the novel viral RNA sensing pathway discovered in the paper.</li> <li>The causal relationships between DHX16, TRIM6, and RIG-I are clearly represented.</li> <li>Each molecular function is accurately assigned to the correct protein.</li> <li>The model includes appropriate biological process and cellular location contexts.</li> <li>All connections are supported by published experimental evidence.</li> </ol>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well constructed, there are a few minor points that could be considered for refinement:</p> <ol> <li> <p>Additional Context: The model could potentially benefit from including more specific viral contexts, such as noting which viral RNAs DHX16 specifically recognizes (e.g., influenza segments 7 and 8, SARS-CoV-2 ORF1a).</p> </li> <li> <p>Molecular Details: The specific K48-linked polyubiquitin chains created by TRIM6 could be more explicitly represented, perhaps by including additional ontology terms or annotations that indicate the K48-linkage specificity.</p> </li> <li> <p>RIG-I Downstream Activity: The model focuses on the activation of RIG-I but doesn't extend to RIG-I's downstream effects. Considering that RIG-I activation leads to the activation of IRF3/IRF7 and IFN-\u03b2 production, extending the model to include these downstream steps could provide a more complete picture of the pathway.</p> </li> </ol>"},{"location":"reviews/63a86a8600001202-DHX16_mediated_viral_RNA_recognition_and_activation_of_RIGI__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:63a86a8600001202 accurately represents the DHX16-mediated viral RNA recognition and RIG-I activation pathway as described in the research. It adheres to GO-CAM best practices and provides a clear representation of the causal relationships between molecular functions. The model effectively captures a novel mechanism of innate immune signaling in which DHX16 acts as both a pattern recognition receptor and a molecular adaptor to enhance RIG-I-mediated antiviral responses.</p> <p>The model is well-supported by experimental evidence and represents an important contribution to our understanding of antiviral innate immune responses. With a few potential minor refinements, it serves as an excellent example of how GO-CAM can be used to represent complex biological pathways.</p>"},{"location":"reviews/63a86a8600001386-Triglyceride_biosynthetic_process_1__Mouse_/","title":"63a86a8600001386 Triglyceride biosynthetic process 1  Mouse","text":"<p>Now I'll review the GO-CAM model 63a86a8600001386 based on all the information gathered:</p> <p>Based on my review of the GO-CAM model \"Triglyceride biosynthetic process 1 (Mouse)\" (gomodel:63a86a8600001386), I can provide the following assessment:</p>"},{"location":"reviews/63a86a8600001386-Triglyceride_biosynthetic_process_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM represents the mouse triglyceride biosynthetic pathway, showing a sequence of enzymatic activities that lead to triglyceride formation. The model includes 6 gene products that catalyze different steps in the pathway, with causal connections appropriately showing the flow from one reaction to the next.</p>"},{"location":"reviews/63a86a8600001386-Triglyceride_biosynthetic_process_1__Mouse_/#pathway-structure-assessment","title":"Pathway Structure Assessment","text":"<p>The model shows the canonical triglyceride biosynthesis pathway with the following sequence: 1. Alkylglycerol monooxygenase (Agmo) initiating the pathway 2. Glycerol kinase (Gk) phosphorylating glycerol 3. Glycerol-3-phosphate O-acyltransferase (Gpam) adding the first acyl group 4. 1-acylglycerol-3-phosphate O-acyltransferase (Agpat2) adding the second acyl group 5. Phosphatidate phosphatase (Lpin2) converting phosphatidic acid to diacylglycerol 6. Diacylglycerol O-acyltransferase (Dgat2) forming the final triglyceride</p> <p>The causal connections between activities use the appropriate relation \"RO:0002413\" (provides input for), which correctly represents the sequential nature of the enzymatic reactions.</p>"},{"location":"reviews/63a86a8600001386-Triglyceride_biosynthetic_process_1__Mouse_/#cellular-localization","title":"Cellular Localization","text":"<p>The subcellular locations are appropriately annotated: - Agmo is correctly annotated as occurring in the ER membrane (GO:0005789) - Gk is correctly annotated as occurring in the cytosol (GO:0005829) - Gpam is correctly annotated as occurring in the mitochondrial outer membrane (GO:0005741) - Agpat2 is correctly annotated as occurring in the ER membrane (GO:0005789) - Lpin2 is correctly annotated as occurring in the ER membrane (GO:0005789) - Dgat2 is correctly annotated as occurring in the ER membrane (GO:0005789)</p> <p>This is consistent with the known subcellular distribution of these enzymes based on UniProt records.</p>"},{"location":"reviews/63a86a8600001386-Triglyceride_biosynthetic_process_1__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes for each activity: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000266 (sequence orthology evidence used in manual assertion)</p> <p>All activities have literature references (PMIDs) associated with them, and the evidence is drawn from mouse studies (with appropriate \"with\" objects where orthology evidence is used), which is appropriate for a mouse model.</p>"},{"location":"reviews/63a86a8600001386-Triglyceride_biosynthetic_process_1__Mouse_/#specific-assessments-of-each-activity","title":"Specific Assessments of Each Activity","text":"<ol> <li> <p>Agmo (MGI:MGI:2442495) - correctly annotated with glyceryl-ether monooxygenase activity (GO:0050479), which matches its UniProt functional description.</p> </li> <li> <p>Gk (MGI:MGI:106594) - correctly annotated with glycerol kinase activity (GO:0004370), matching its enzymatic function.</p> </li> <li> <p>Gpam (MGI:MGI:109162) - correctly annotated with glycerol-3-phosphate O-acyltransferase activity (GO:0004366), consistent with its role in the pathway.</p> </li> <li> <p>Agpat2 (MGI:MGI:1914762) - correctly annotated with 1-acylglycerol-3-phosphate O-acyltransferase activity (GO:0003841), matching its UniProt function.</p> </li> <li> <p>Lpin2 (MGI:MGI:1891341) - correctly annotated with phosphatidate phosphatase activity (GO:0008195), consistent with its role.</p> </li> <li> <p>Dgat2 (MGI:MGI:1915050) - correctly annotated with diacylglycerol O-acyltransferase activity (GO:0004144), matching its enzyme classification.</p> </li> </ol>"},{"location":"reviews/63a86a8600001386-Triglyceride_biosynthetic_process_1__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>The model correctly represents the canonical triglyceride biosynthesis pathway and follows GO-CAM best practices.</p> </li> <li> <p>It might be helpful to add annotations about the specific lipid substrates preferred by each enzyme to provide more detail about substrate specificity, though this is not required.</p> </li> <li> <p>The causal flow from Agmo to Gk could benefit from additional literature support to strengthen this connection, as the model currently doesn't show evidence for this causal relationship.</p> </li> <li> <p>All activities are correctly annotated as part of GO:0019432 (triglyceride biosynthetic process), which appropriately places them in the overall biological context.</p> </li> </ol>"},{"location":"reviews/63a86a8600001386-Triglyceride_biosynthetic_process_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Triglyceride biosynthetic process 1 (Mouse)\" (gomodel:63a86a8600001386) is well-constructed, with appropriate gene products, molecular functions, cellular locations, and causal relationships. It accurately represents the triglyceride biosynthesis pathway in mice and follows the GO-CAM curation guidelines. The model is ready for production use and provides a valuable resource for understanding triglyceride biosynthesis in mice.</p>"},{"location":"reviews/63a86a8600001720-The_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding__Mouse_/","title":"63a86a8600001720 The non canonical inflammasome mediated by Casp11 upon lipopolysaccharide binding  Mouse","text":"<p>Now that I have gathered information about the GO-CAM model and examined the best practices for GO-CAM curation, let me provide a comprehensive review of the GO-CAM model \"gomodel:63a86a8600001720\".</p>"},{"location":"reviews/63a86a8600001720-The_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding__Mouse_/#review-of-go-cam-model-gomodel63a86a8600001720","title":"Review of GO-CAM Model gomodel:63a86a8600001720","text":""},{"location":"reviews/63a86a8600001720-The_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: \"The non-canonical inflammasome mediated by Casp11 upon lipopolysaccharide-binding (Mouse)\" Taxon: NCBITaxon:9606 (Human) Status: Production ID: gomodel:63a86a8600001720</p>"},{"location":"reviews/63a86a8600001720-The_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding__Mouse_/#summary-of-model-content","title":"Summary of Model Content","text":"<p>This GO-CAM model represents the non-canonical inflammasome pathway activated by caspase-11 (Casp11) binding to lipopolysaccharide (LPS) in a mouse model. The model describes a key innate immune pathway where cytosolic LPS from Gram-negative bacteria is directly recognized by caspase-11, leading to its auto-processing and activation. Activated caspase-11 then cleaves gasdermin D (GSDMD) to release its N-terminal domain (GSDMD-NT), which forms pores in the plasma membrane, resulting in pyroptotic cell death and the release of inflammatory cytokines.</p>"},{"location":"reviews/63a86a8600001720-The_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding__Mouse_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Well-evidenced activities: Each molecular function in the model is supported by appropriate evidence codes (ECO:0000314 - direct assay evidence) and literature references.</p> </li> <li> <p>Clear causal flow: The model correctly represents the sequence of events from LPS binding to caspase-11, through caspase-11 activation, GSDMD cleavage, to pore formation and inflammasome assembly.</p> </li> <li> <p>Cellular locations: Each activity is appropriately annotated with cellular locations (cytosol, plasma membrane, etc.).</p> </li> <li> <p>Part_of relations: Activities are correctly placed within the broader biological processes they contribute to.</p> </li> </ol>"},{"location":"reviews/63a86a8600001720-The_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Taxon inconsistency:</li> <li>The model title indicates it's a mouse model, but the taxon is listed as NCBITaxon:9606 (human).</li> <li> <p>Recommendation: Change the taxon to NCBITaxon:10090 (mouse) to match the model content and title.</p> </li> <li> <p>Potential complex annotation issue:</p> </li> <li>The model includes NLRP3 inflammasome complex assembly (GO:0044546), but no explicit representation of the complex itself.</li> <li> <p>Recommendation: Consider using GO complex terms to properly represent the inflammasome complex according to the \"How to annotate complexes in GO-CAM\" guidelines.</p> </li> <li> <p>Missing causal link:</p> </li> <li>There's no explicit causal connection between NLRP3's signaling adaptor activity (GO:0035591) and other downstream events.</li> <li> <p>Recommendation: Add causal links to show how NLRP3 contributes to the overall inflammasome activation process.</p> </li> <li> <p>Input relation clarification:</p> </li> <li>Caspase-11 lipid binding (GO:0008289) has CHEBI:58712 (lipid A(4-)) as input, which is appropriate, but the model could benefit from clearer representation of how LPS sensing leads to caspase-11 auto-processing.</li> <li> <p>Recommendation: Consider adding more detail about the mechanism of caspase-11 activation upon LPS binding.</p> </li> <li> <p>Biological completeness:</p> </li> <li>The model does not include the release of IL-1\u03b2 and IL-18 as final outcomes, which are important consequences of inflammasome activation.</li> <li> <p>Recommendation: Add these downstream effects to provide a more complete representation of the pathway.</p> </li> <li> <p>Human counterpart consideration:</p> </li> <li>Since the model focuses on mouse proteins but is potentially relevant to human biology, adding a note about human orthologs (caspase-4/5) would be valuable.</li> <li>Recommendation: Add comments noting the human equivalents of key mouse proteins.</li> </ol>"},{"location":"reviews/63a86a8600001720-The_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding__Mouse_/#detailed-pathway-analysis","title":"Detailed Pathway Analysis","text":"<p>The model correctly represents the following causally linked events:</p> <ol> <li> <p>Caspase-11 (MGI:MGI:107700) binds lipid A (CHEBI:58712) via lipid binding activity (GO:0008289), which occurs in the cytosol (GO:0005829).</p> </li> <li> <p>This leads to caspase-11's cysteine-type endopeptidase activity (GO:0004197), which is properly represented as auto-processing based on the referenced literature (PMID:30135078).</p> </li> <li> <p>Activated caspase-11 then cleaves GSDMD (MGI:MGI:1916396), which is accurately represented by a causal chain of molecular functions.</p> </li> <li> <p>GSDMD, upon cleavage, exhibits phosphatidylinositol-4,5-bisphosphate binding (GO:0005546) and wide pore channel activity (GO:0022829) at the plasma membrane (GO:0005886).</p> </li> <li> <p>The model also includes NLRP3's role in inflammasome complex assembly, though this connection could be strengthened.</p> </li> </ol>"},{"location":"reviews/63a86a8600001720-The_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the non-canonical inflammasome pathway based on current literature. The model follows many GO-CAM best practices regarding evidence, causal relations, and molecular function representation.</p> <p>The main improvements needed are: 1. Correcting the taxon inconsistency 2. Strengthening the representation of the inflammasome complex 3. Adding missing causal links for NLRP3's role 4. Expanding the model to include downstream cytokine release</p> <p>With these adjustments, the model would provide an even more accurate and comprehensive representation of this important innate immune pathway.</p>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/","title":"63a86a8600001865 Irgb10 Gm12250 mediates disruption of the pathogen membrane  liberating ligands that are detected by inflammasomes   Mouse","text":"<p>Based on my review of the GO-CAM model and the relevant literature, I'll now provide a detailed analysis of model gomodel:63a86a8600001865.</p>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#go-cam-review-irgb10gm12250-mediates-disruption-of-the-pathogen-membrane-mouse","title":"GO-CAM Review: Irgb10/Gm12250 mediates disruption of the pathogen membrane (Mouse)","text":""},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model (gomodel:63a86a8600001865) represents the pathway by which Irgb10/Gm12250 mediates disruption of pathogen membranes, liberating bacterial ligands that are detected by inflammasomes in mouse (NCBITaxon:10090). The model shows interactions between several interferon-inducible GTPases (Gbp5, Gbp2, and Irgb10) that cooperate to disrupt pathogen membranes, leading to the release of bacterial components that activate inflammasome pathways through Aim2 and Casp4.</p>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#structure-and-components-of-the-model","title":"Structure and Components of the Model","text":"<p>The model contains six main activities:</p> <ol> <li>Gbp5 (MGI:MGI:2429943) - G protein activity (GO:0003925) that directly positively regulates Irgb10</li> <li>Gbp2 (MGI:MGI:102772) - G protein activity (GO:0003925) that directly positively regulates Irgb10</li> <li>Irgb10/Gm12250 (MGI:MGI:3649299) - G protein activity (GO:0003925) and membrane destabilizing activity (GO:0140912)</li> <li>Aim2 (MGI:MGI:2686159) - Double-stranded DNA binding (GO:0003690), involved in AIM2 inflammasome complex assembly</li> <li>Casp4 (MGI:MGI:107700) - Lipid binding (GO:0008289), has input lipid A(4-) (CHEBI:58712)</li> </ol>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The model captures a clear cascade of causal relationships: 1. Gbp5 and Gbp2 directly positively regulate (RO:0002629) Irgb10's G protein activity 2. Irgb10's G protein activity directly positively regulates (RO:0002629) its own membrane destabilizing activity 3. Irgb10's membrane destabilizing activity causally upstream, positive effect (RO:0002304) on:    - Aim2's double-stranded DNA binding (activating AIM2 inflammasome)    - Casp4's lipid binding (activating non-canonical inflammasome)</p>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#biological-context","title":"Biological Context","text":"<p>All activities occur in the \"symbiont cell surface\" (GO:0106139) location and are part of \"defense response to bacterium\" (GO:0042742), correctly representing the cellular location and biological process.</p>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#review-analysis","title":"Review Analysis","text":""},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately captures the pathway described in the literature, particularly in PMID:27693356, which demonstrates that Irgb10 is essential for activation of the DNA-sensing AIM2 inflammasome by disrupting bacterial membranes. The causal relationships align with the mechanism where GBPs (Gbp2 and Gbp5) target cytoplasmic bacteria, followed by Irgb10 localization to bacterial cell membranes, compromising their structural integrity and liberating bacterial ligands (DNA and LPS) that activate inflammasomes.</p> <p>The model correctly represents: 1. The hierarchical relationship where GBPs are required for Irgb10 recruitment  2. The dual role of Irgb10 in activating both the AIM2 inflammasome (via DNA release) and caspase-11-NLRP3 inflammasome (via LPS release) 3. The location of these activities at the symbiont cell surface</p> <p>The evidential support is strong, with most associations backed by direct assay evidence (ECO:0000314) from PMID:27693356.</p>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li> <p>Using appropriate molecular activities: The G protein activity (GO:0003925) and membrane destabilizing activity (GO:0140912) correctly represent the molecular functions of these proteins.</p> </li> <li> <p>Proper causal relationships: The model uses appropriate causal predicates:</p> </li> <li>RO:0002629 (directly positively regulates) for direct regulatory relationships</li> <li> <p>RO:0002304 (causally upstream of, positive effect) for the downstream effects on inflammasome activation</p> </li> <li> <p>Context information: Each activity is correctly placed in cellular context (symbiont cell surface) and biological process context (defense response to bacterium).</p> </li> <li> <p>Evidence: Every association has appropriate evidence codes and literature references.</p> </li> </ol>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is biologically accurate and well-structured, there are a few areas that could be enhanced:</p> <ol> <li> <p>Membrane Destabilizing Mechanism: The model could potentially elaborate on the specific mechanism of Irgb10's membrane destabilizing activity. PMID:33469160 describes the molecular basis of IRGB10 oligomerization and membrane association, which could be incorporated to provide more mechanistic detail.</p> </li> <li> <p>Inflammasome Assembly: The model shows the binding activities (DNA binding by Aim2, LPS binding by Casp4) but doesn't fully capture the subsequent inflammasome assembly. It might be beneficial to extend the model to show how these binding events lead to complete inflammasome formation.</p> </li> <li> <p>Evolutionary Context: The model focuses on mouse proteins, but it could be noted that the IRG family has undergone significant evolutionary changes, with humans having fewer functional IRG genes.</p> </li> </ol>"},{"location":"reviews/63a86a8600001865-Irgb10_Gm12250_mediates_disruption_of_the_pathogen_membrane__liberating_ligands_that_are_detected_by_inflammasomes___Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:63a86a8600001865 is a high-quality representation of how Irgb10/Gm12250 mediates disruption of pathogen membranes to activate inflammasome pathways. It accurately captures the cascade of molecular activities involved in this immune defense mechanism, with proper causal relationships and contextual information.</p> <p>The model is consistent with current literature on Irgb10 function, particularly regarding its role in disrupting bacterial membranes to liberate ligands for inflammasome activation. It follows GO-CAM best practices and provides a clear picture of this important innate immune pathway.</p> <p>The strengths of this model are its biological accuracy, appropriate use of causal relationships, and strong evidential support. The inclusion of both G protein activity and membrane destabilizing activity for Irgb10 correctly captures its dual functional roles in pathogen membrane disruption.</p>"},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/","title":"63c0ac2b00000008 The AIM2 inflammasome  Human","text":"<p>Based on all this information, I'll now review the GO-CAM model (gomodel:63c0ac2b00000008) that represents the AIM2 inflammasome pathway.</p>"},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#review-of-go-cam-model-the-aim2-inflammasome-human","title":"Review of GO-CAM Model: The AIM2 Inflammasome (Human)","text":""},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#model-id-gomodel63c0ac2b00000008","title":"Model ID: gomodel:63c0ac2b00000008","text":""},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#overview","title":"Overview","text":"<p>This model captures the AIM2 inflammasome pathway in humans, which plays a critical role in innate immune responses by detecting cytosolic double-stranded DNA, leading to inflammation and pyroptotic cell death. The model represents the sequential activities and causal relationships between the key proteins involved in this pathway: AIM2, PYCARD/ASC, Caspase-1 (CASP1), and Gasdermin-D (GSDMD).</p>"},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#components-and-pathway-flow","title":"Components and Pathway Flow","text":"<ol> <li>Initiating Event: AIM2 (UniProtKB:O14862) senses cytosolic double-stranded DNA through its:</li> <li>Double-stranded DNA binding activity (GO:0003690)</li> <li> <p>Pattern recognition receptor activity (GO:0038187)</p> </li> <li> <p>Inflammasome Assembly: AIM2 recruits PYCARD/ASC through:</p> </li> <li>Signaling adaptor activity (GO:0035591)</li> <li> <p>PYCARD then activates CASP1 through cysteine-type endopeptidase activator activity (GO:0140608)</p> </li> <li> <p>Caspase Activation: CASP1 (UniProtKB:P29466) becomes active through:</p> </li> <li>Cysteine-type endopeptidase activity (GO:0004197)</li> <li> <p>Leads to protein maturation processes (GO:0051604)</p> </li> <li> <p>Effector Functions: GSDMD (UniProtKB:P57764) mediates:</p> </li> <li>Phosphatidylinositol-4,5-bisphosphate binding (GO:0005546)</li> <li>Wide pore channel activity (GO:0022829)</li> <li>Positive regulation of inflammatory response (GO:0050729)</li> </ol>"},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive Pathway Coverage: The model captures the entire sequence from DNA sensing to inflammasome formation, caspase activation, and pyroptosis induction.</p> </li> <li> <p>Appropriate Causal Relationships: The model correctly uses RO:0002629 (directly positively regulates) to indicate the direct activation relationships between the pathway components.</p> </li> <li> <p>Subcellular Localization: Appropriate subcellular locations are included for each activity (e.g., cytoplasm for AIM2, plasma membrane for GSDMD).</p> </li> <li> <p>Evidence Quality: Each assertion is supported by high-quality experimental evidence (ECO:0000314 - direct assay evidence used in manual assertion) with appropriate literature citations.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Potential Intermediates: The model does not capture potential intermediate steps between GSDMD binding phosphatidylinositol-4,5-bisphosphate and its pore-forming activity. Recent research indicates that GSDMD undergoes palmitoylation at Cys-191 (as shown in UniProtKB:P57764), which is essential for its membrane targeting and pore formation.</p> </li> <li> <p>Cleavage Events Not Explicitly Modeled: The proteolytic cleavage of GSDMD by CASP1 at Asp-275 to release the N-terminal fragment is implied but not explicitly captured. This is a critical event for pyroptosis induction.</p> </li> <li> <p>Missing Final Outcomes: While the model shows GSDMD pore formation, it doesn't explicitly capture downstream consequences such as IL-1\u03b2/IL-18 release or cell lysis through NINJ1 activation.</p> </li> <li> <p>Complex Formation Representation: The AIM2 inflammasome complex assembly (GO:0140970) is indicated as part of the process, but the model does not explicitly show the oligomerization of these components into the inflammasome speck, which is a key structural feature of this pathway.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<ol> <li> <p>Causal Association Predicates: The model appropriately uses RO:0002629 (directly positively regulates) throughout to indicate direct positive regulation between sequential steps.</p> </li> <li> <p>Molecular Function Representation: Each activity is correctly represented as a molecular function enabled by the appropriate gene product.</p> </li> <li> <p>Process Association: Each activity is appropriately located within the relevant biological process, such as AIM2 inflammasome complex assembly (GO:0140970) or positive regulation of inflammatory response (GO:0050729).</p> </li> <li> <p>Evidence and Provenance: Each assertion is properly supported with evidence codes, literature references, and contribution statements.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Add GSDMD Cleavage: Explicitly model the CASP1-mediated cleavage of GSDMD at Asp-275, releasing the N-terminal domain that forms pores.</p> </li> <li> <p>Include GSDMD Palmitoylation: Recent research (UniProtKB:P57764, references 37-39) shows that palmitoylation at Cys-191 is critical for GSDMD function. This post-translational modification could be included.</p> </li> <li> <p>Capture Downstream Consequences: Expand the model to include the release of pro-inflammatory cytokines (IL-1\u03b2, IL-18) through the GSDMD pores and subsequent events leading to pyroptotic cell death.</p> </li> <li> <p>Represent Inflammasome Speck Formation: AIM2 and PYCARD form distinct filamentous structures in the inflammasome speck, which could be explicitly represented.</p> </li> <li> <p>Include Potential Regulatory Mechanisms: Consider including negative regulatory mechanisms such as succination of GSDMD at cysteine residues, which can inactivate GSDMD and block pyroptosis (UniProtKB:P57764, reference 24).</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000008-The_AIM2_inflammasome__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a solid foundation for representing the AIM2 inflammasome pathway. It correctly captures the key molecular activities and causal relationships in the pathway, from DNA sensing to pore formation. The model adheres to GO-CAM best practices regarding evidence standards and relationship types.</p> <p>To further enhance its biological completeness, the model could be expanded to include recent discoveries about protein modifications, complex formation details, and downstream consequences of inflammasome activation. These additions would provide a more comprehensive representation of this important innate immune pathway.</p>"},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/","title":"63c0ac2b00000088 The AIM2 inflammasome  Mouse","text":"<p>Based on my review of the GO-CAM model and literature, I'll now provide a comprehensive review and QC evaluation.</p>"},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/#review-of-go-cam-model-63c0ac2b00000088-the-aim2-inflammasome-mouse","title":"Review of GO-CAM Model 63c0ac2b00000088: The AIM2 inflammasome (Mouse)","text":""},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model (ID: gomodel:63c0ac2b00000088) represents the AIM2 inflammasome pathway in mouse. The model depicts how the AIM2 sensor recognizes cytosolic double-stranded DNA, which leads to the activation of a signaling cascade resulting in pyroptotic inflammatory cell death.</p>"},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/#pathway-overview","title":"Pathway Overview","text":"<p>The model correctly captures the sequential activation steps of the AIM2 inflammasome:</p> <ol> <li>AIM2 (MGI:MGI:2686159) acts as a pattern recognition receptor, binding to cytosolic double-stranded DNA (GO:0003690)</li> <li>Upon activation, AIM2 recruits the adaptor protein ASC/PYCARD</li> <li>This complex activates Caspase-1 (Casp1, MGI:MGI:96544)</li> <li>Caspase-1 cleaves Gasdermin-D (Gsdmd, MGI:MGI:1916396), which translocates to the plasma membrane</li> <li>Gasdermin-D forms pores in the membrane (GO:0022829), leading to cell death through pyroptosis and release of inflammatory mediators</li> </ol>"},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model correctly represents the key molecular functions of the AIM2 inflammasome components:</li> <li>AIM2's double-stranded DNA binding (GO:0003690)</li> <li>AIM2's pattern recognition receptor activity (GO:0038187)</li> <li>AIM2's signaling adaptor activity (GO:0035591)</li> <li>Caspase-1's cysteine-type endopeptidase activity (GO:0004197)</li> <li>Gasdermin-D's phosphatidylinositol-4,5-bisphosphate binding (GO:0005546)</li> <li> <p>Gasdermin-D's wide pore channel activity (GO:0022829)</p> </li> <li> <p>The cellular locations are accurately represented:</p> </li> <li>AIM2 functions in the cytoplasm (GO:0005737)</li> <li> <p>Gasdermin-D acts at the plasma membrane (GO:0005886)</p> </li> <li> <p>The model correctly uses causal connections (RO:0002629 \"directly positively regulates\") to represent the signaling cascade, showing how each protein's activity positively regulates the next step.</p> </li> <li> <p>The biological processes are appropriately annotated:</p> </li> <li>AIM2 inflammasome complex assembly (GO:0140970)</li> <li>Protein maturation (GO:0051604)</li> <li> <p>Positive regulation of inflammatory response (GO:0050729)</p> </li> <li> <p>Evidence codes and literature references are appropriately cited throughout the model.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/#potential-areas-for-improvement","title":"Potential Areas for Improvement","text":"<ol> <li> <p>Complex Representation: According to GO-CAM guidelines on complex annotation, the AIM2 inflammasome itself could be better represented. The model correctly shows individual proteins and their activities, but it doesn't explicitly represent the formation of the AIM2-ASC-caspase-1 complex. While this is implied through the causal relationships, it might be beneficial to explicitly represent the complex using a GO term for the AIM2 inflammasome complex (GO:0097169).</p> </li> <li> <p>Missing Intermediate Steps: The model doesn't explicitly show the ASC/PYCARD protein, which is a critical adapter between AIM2 and caspase-1. While the activity flow is correct, the omission of this component might make the model less complete.</p> </li> <li> <p>IL-1\u03b2 Release: The end result of AIM2 inflammasome activation includes the release of mature IL-1\u03b2 and IL-18, which is not represented in this model. Although the model correctly focuses on the pyroptotic pathway through Gasdermin-D, the parallel inflammatory cytokine release pathway is an important part of inflammasome biology.</p> </li> <li> <p>Feedback Mechanisms: The model doesn't include any regulatory or feedback mechanisms that might control inflammasome activation. Recent literature shows that AIM2 inflammasome activity is tightly regulated to prevent inappropriate activation.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/#literature-consistency","title":"Literature Consistency","text":"<p>The model is well supported by the literature, including key references: - PMID:19158679 describing AIM2 as a cytoplasmic DNA sensor for the inflammasome - PMID:32109412 documenting caspase-1's role in pyroptosis - PMID:27383986 explaining Gasdermin-D's role in forming membrane pores</p> <p>These references correctly support the molecular functions and biological processes represented in the model.</p>"},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/#technical-qc","title":"Technical QC","text":"<ol> <li> <p>Predicate Usage: The model appropriately uses RO:0002629 \"directly positively regulates\" for causal relationships between activities, which is consistent with GO-CAM guidelines.</p> </li> <li> <p>Evidence: Each assertion is backed by appropriate evidence codes (primarily ECO:0000314 \"direct assay evidence used in manual assertion\" and ECO:0000250 \"sequence similarity evidence used in manual assertion\").</p> </li> <li> <p>Annotations: All GO term annotations appear to be correctly applied to the appropriate proteins and activities.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000088-The_AIM2_inflammasome__Mouse_/#conclusion-and-recommendations","title":"Conclusion and Recommendations","text":"<p>This is a high-quality GO-CAM model that accurately represents the AIM2 inflammasome pathway leading to pyroptosis. The model is well-supported by scientific literature and follows GO-CAM annotation guidelines.</p> <p>Recommendations for enhancement: 1. Consider explicitly representing the ASC/PYCARD adapter protein to complete the canonical inflammasome complex. 2. Consider adding the parallel pathway leading to IL-1\u03b2 maturation and release. 3. Add the AIM2 inflammasome complex term (GO:0097169) to better represent the complex formation. 4. Potentially include some of the known regulatory mechanisms that control AIM2 inflammasome activation.</p> <p>Overall, this model provides a clear and accurate representation of the AIM2 inflammasome pathway leading to pyroptosis, making it a valuable resource for understanding this important innate immune mechanism.</p>"},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/","title":"63c0ac2b00000267 IRGM governs the core autophagy machinery to conduct antimicrobial defense  Human","text":"<p>Let me review the model now based on all the information I've gathered:</p>"},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/#go-cam-model-review-gomodel63c0ac2b00000267","title":"GO-CAM Model Review: gomodel:63c0ac2b00000267","text":""},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/#basic-model-information","title":"Basic Model Information:","text":"<ul> <li>Title: \"IRGM governs the core autophagy machinery to conduct antimicrobial defense (Human)\"</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model represents how IRGM (Immunity-related GTPase family M protein) coordinates the core autophagy machinery to conduct antimicrobial defense in humans. The model describes several key activities and causal associations between IRGM, PRKAA1 (AMPK), ULK1, and BECN1 (Beclin-1).</p>"},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/#detailed-review","title":"Detailed Review","text":""},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/#1-biological-content-assessment","title":"1. Biological Content Assessment","text":"<p>The model accurately captures the key molecular interactions described in the literature, particularly from the Chauhan et al. (2015) paper (PMID:25891078). This paper establishes IRGM as a central regulator that directly assembles autophagy machinery by interacting with ULK1 and Beclin-1.</p> <p>The causal flow in the model correctly shows: - IRGM's G protein activity (GO:0003925) directly positively regulates its protein serine/threonine kinase activator activity (GO:0043539) - IRGM's protein-macromolecule adaptor activity (GO:0030674) directly positively regulates ULK1's protein serine/threonine kinase activity (GO:0004674) - IRGM's protein serine/threonine kinase activator activity directly positively regulates PRKAA1's protein serine/threonine kinase activity (GO:0004674) - PRKAA1's kinase activity directly positively regulates ULK1's kinase activity - ULK1's kinase activity directly positively regulates BECN1's protein-macromolecule adaptor activity (GO:0030674)</p> <p>These relationships accurately reflect the findings from the paper that IRGM interacts with ULK1 and Beclin-1, promotes their co-assembly, and governs the formation of autophagy initiation complexes.</p>"},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/#2-go-cam-best-practices-review","title":"2. GO-CAM Best Practices Review","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ul> <li> <p>Proper use of causal relationships: The model uses RO:0002629 (directly positively regulates) appropriately to show direct regulatory relationships between the molecular activities.</p> </li> <li> <p>Biological context: All activities are properly placed in relevant biological processes:</p> </li> <li>IRGM's activities are part of defense response to bacterium (GO:0042742)</li> <li>PRKAA1's kinase activity is part of positive regulation of autophagy (GO:0010508)</li> <li>ULK1's kinase activity occurs in the autophagosome (GO:0005776) and is part of autophagosome assembly (GO:0000045)</li> <li> <p>BECN1's adaptor activity is in the autophagosome and part of protein-containing complex assembly (GO:0065003)</p> </li> <li> <p>Cellular components: Where relevant, activities are properly located in cellular components (e.g., ULK1 and BECN1 activities occurring in the autophagosome).</p> </li> </ul>"},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/#3-areas-for-improvement","title":"3. Areas for Improvement","text":"<p>While the model generally follows best practices, there are a few areas that could be improved:</p> <ol> <li> <p>Missing evidence codes for some assertions: All causal associations and molecular function assertions use ECO:0000314 (direct assay evidence used in manual assertion) with appropriate PMIDs, which is good. However, there's one cellular location assertion (BECN1 in autophagosome) that uses ECO:0000250 (sequence similarity evidence) with a mouse gene (MGI:1891828) as reference. Given the importance of this localization, it would be better to find direct human evidence if available.</p> </li> <li> <p>Complex representation: The model doesn't explicitly represent the ULK1-BECN1 complex that forms as a result of IRGM activity. According to the \"How to annotate complexes in GO-CAM\" document, when the subunits and their activities are known (as in this case), representing the individual proteins is appropriate. However, since the paper emphasizes the importance of the complex formation itself, it might be useful to consider adding the complex representation for clarity.</p> </li> <li> <p>Completeness: The paper mentions additional interactions, such as with ATG16L1, that aren't represented in the model. While models don't need to represent everything, this additional interaction could enhance the completeness of the pathway representation.</p> </li> <li> <p>Biological process context: While the model correctly places IRGM activities in the \"defense response to bacterium\" process, the paper also mentions its role in controlling inflammation. Adding this context might provide a more complete picture of IRGM's functions.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000267-IRGM_governs_the_core_autophagy_machinery_to_conduct_antimicrobial_defense__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:63c0ac2b00000267 is a high-quality representation of how IRGM governs the core autophagy machinery to conduct antimicrobial defense. It accurately captures the key molecular activities and causal relationships established in the literature, particularly from Chauhan et al. (2015). The model follows GO-CAM best practices in terms of causal relationships, biological context, and cellular components.</p> <p>The model could be enhanced with more direct human evidence for certain assertions, possibly by representing the ULK1-BECN1 complex explicitly, and by including additional interactions such as with ATG16L1. Overall, however, the model provides a clear and accurate representation of this important biological pathway.</p>"},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/","title":"63c0ac2b00000464 Zika virus inhibition of TBK1 via CEP63 binding and centrosome disorganization  Human Zika virus","text":"<p>Based on all the information I've collected, I'll now provide a comprehensive review of the GO-CAM model with ID \"63c0ac2b00000464\".</p>"},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#review-of-go-cam-model-63c0ac2b00000464","title":"Review of GO-CAM Model: 63c0ac2b00000464","text":""},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#overview-of-the-model","title":"Overview of the Model","text":"<p>Title: \"Zika virus inhibition of TBK1 via CEP63 binding and centrosome disorganization (Human-Zika virus)\"</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>This model describes how Zika virus inhibits the innate immune response by disrupting the TANK-binding kinase 1 (TBK1) function through a mechanism involving the viral NS3 protein binding to CEP63 (Centrosomal protein of 63 kDa) and causing centrosome disorganization.</p>"},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#model-structure-and-causal-flow","title":"Model Structure and Causal Flow","text":"<p>The model consists of four key molecular activities and three causal connections:</p> <ol> <li>TBK1 Protein Serine/Threonine Kinase Activity:</li> <li>Enabled by: UniProtKB:Q9UHD2 (TBK1)</li> <li>Occurs in: Cytoplasm (GO:0005737)</li> <li> <p>Part of: Innate immune response (GO:0045087)</p> </li> <li> <p>DTX4 Ubiquitin Protein Ligase Activity:</p> </li> <li>Enabled by: UniProtKB:Q9Y2E6 (DTX4)</li> <li>Occurs in: Centrosome (GO:0005813)</li> <li>Part of: Negative regulation of innate immune response (GO:0045824)</li> <li> <p>Causally regulates: Directly negatively regulates (RO:0002630) TBK1 kinase activity</p> </li> <li> <p>CEP63 Molecular Adaptor Activity:</p> </li> <li>Enabled by: UniProtKB:Q96MT8 (CEP63)</li> <li>Occurs in: Centrosome (GO:0005813)</li> <li>Part of: Negative regulation of innate immune response (GO:0045824)</li> <li> <p>Causally regulates: Directly positively regulates (RO:0002629) DTX4 ubiquitin ligase activity</p> </li> <li> <p>Zika Virus NS3 Molecular Adaptor Activity:</p> </li> <li>Enabled by: UniProtKB:A0A024B7W1 (Zika virus NS3)</li> <li>Occurs in: Centrosome (GO:0005813)</li> <li>Part of: Negative regulation of innate immune response (GO:0045824)</li> <li>Causally regulates: Directly positively regulates (RO:0002629) CEP63 molecular adaptor activity</li> </ol>"},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#review-findings","title":"Review Findings","text":""},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#scientific-accuracy-and-consistency-with-literature","title":"Scientific Accuracy and Consistency with Literature","text":"<p>The model accurately represents the findings from the key publication (PMID:35793002) where Zika virus NS3 protein is shown to bind CEP63, leading to centrosome disorganization and suppression of innate immune response via TBK1 degradation.</p> <p>Key findings from the paper that are represented in the model: - Zika virus NS3 binds to CEP63 (and this is correctly modeled) - This interaction leads to recruitment of DTX4 (a ubiquitin ligase) to the centrosome - DTX4 promotes K48-linked ubiquitination of TBK1, leading to its degradation - This ultimately inhibits the innate immune response</p>"},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#evidence-and-provenance","title":"Evidence and Provenance","text":"<p>All activities in the model are supported by appropriate evidence codes and references: - All activities use ECO:0000314 (direct assay evidence used in manual assertion) - All activities cite appropriate PMIDs - All activities include appropriate contributor information (ORCID) - All activities have appropriate date stamps</p>"},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>Strengths: 1. Molecular activities are properly annotated:    - Each protein has an appropriate molecular function (MF) term assigned    - Cellular components (occurs_in) and biological processes (part_of) are appropriately assigned    - NS3 viral protein is correctly annotated with a molecular adaptor activity (GO:0060090)</p> <ol> <li>Causal connections are properly represented:</li> <li>Uses the correct causal relationship predicates (RO:0002629 for positive regulation, RO:0002630 for negative regulation)</li> <li> <p>The model correctly shows the cascade of events from viral protein to immune suppression</p> </li> <li> <p>Complex handling:</p> </li> <li>The model correctly follows the recommendations in the \"How to annotate complexes in GO-CAM\" document by representing the specific proteins with known activities rather than using a generic complex term</li> </ol> <p>Minor observation: - The model shows there was an automated change made on 2023-03-16 replacing RO:0002212 with RO:0002630 and RO:0002213 with RO:0002629, which is consistent with best practices to use more specific relationship types</p>"},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#model-completeness","title":"Model Completeness","text":"<p>The model captures the key findings from the paper but could potentially be expanded to include:</p> <ol> <li> <p>The phosphorylation state of TBK1 (especially since p-TBK1 is specifically mentioned in the paper as being removed from centrosomes upon ZIKV infection)</p> </li> <li> <p>The role of MIB1 in K63-linked ubiquitination of TBK1, which is also described in the paper as part of the mechanism</p> </li> <li> <p>The downstream effects on IRF3 activation and IFN\u03b2 production that are mentioned in the paper</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000464-Zika_virus_inhibition_of_TBK1_via_CEP63_binding_and_centrosome_disorganization__Human_Zika_virus_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"63c0ac2b00000464\" accurately represents the mechanism by which Zika virus NS3 protein disrupts the innate immune response through CEP63 binding and centrosome disorganization, leading to TBK1 degradation. The model follows GO-CAM best practices and is well-supported by experimental evidence.</p> <p>The model effectively communicates the causal chain of molecular events involved in Zika virus-mediated immune evasion, making a valuable contribution to our understanding of virus-host interactions.</p> <p>Recommendation: The model is appropriately constructed and can remain in production status. Future extensions could include the additional elements mentioned above to provide a more comprehensive representation of the complete pathway described in the paper.</p>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/","title":"63c0ac2b00000506 Degradation of NMNAT2 via the PAM  SKP1 FBXO45 MYCBP2  E3 ligase complex  Human","text":"<p>Now that I have gathered the information, I'll analyze the GO-CAM model to provide a thorough review.</p>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#review-of-go-cam-model-gomodel63c0ac2b00000506","title":"Review of GO-CAM Model: gomodel:63c0ac2b00000506","text":""},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#model-title-and-overview","title":"Model Title and Overview","text":"<p>\"Degradation of NMNAT2 via the PAM (SKP1-FBXO45-MYCBP2) E3 ligase complex (Human)\"</p> <p>This model captures a ubiquitination process involving the PAM/FBXO45/SKP1 complex that targets NMNAT2 for ubiquitination and subsequent degradation. The model represents an atypical SCF complex where MYCBP2 (also known as PAM) functions as an E3 ubiquitin ligase.</p>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#components-and-structure","title":"Components and Structure","text":"<p>The model consists of four activities (molecular function associations):</p> <ol> <li>SKP1 (UniProtKB:P63208) enables molecular function activator activity (GO:0140677)</li> <li>FBXO45 (UniProtKB:P0C2W1) enables ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</li> <li>MYCBP2 (UniProtKB:O75592) enables ubiquitin protein ligase activity (GO:0061630)</li> <li>NMNAT2 (UniProtKB:Q9BZQ4) enables nicotinate-nucleotide adenylyltransferase activity (GO:0004515)</li> </ol>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>SKP1 directly positively regulates (RO:0002629) FBXO45</li> <li>FBXO45 directly positively regulates (RO:0002629) MYCBP2</li> <li>MYCBP2 directly negatively regulates (RO:0002630) NMNAT2</li> </ul>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#cellular-component-information","title":"Cellular Component Information","text":"<ul> <li>SKP1, FBXO45, and MYCBP2 occur in the cytoplasm (GO:0005737)</li> <li>NMNAT2 occurs in the Golgi apparatus (GO:0005794)</li> </ul>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#biological-process-context","title":"Biological Process Context","text":"<ul> <li>SKP1, FBXO45, and MYCBP2 are part of protein K48-linked ubiquitination (GO:0070936)</li> <li>NMNAT2 is part of axon development (GO:0061564)</li> </ul>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>The model accurately represents the biological relationship described in the literature (PMID:29997255) where the PAM/FBXO45/SKP1 complex ubiquitinates NMNAT2, targeting it for degradation.</p> </li> <li> <p>The model correctly follows GO-CAM best practices for representing E3 ubiquitin ligase complexes as outlined in the \"E3_ubiquitin_ligases\" document, with:</p> </li> <li>SKP1 as a molecular function activator (scaffold component)</li> <li>FBXO45 as a ubiquitin-like ligase-substrate adaptor</li> <li>MYCBP2 as the E3 ubiquitin ligase</li> <li> <p>NMNAT2 as the substrate</p> </li> <li> <p>The causal relationships are appropriately represented, showing the flow of activity from SKP1 to FBXO45 to MYCBP2, which then negatively regulates NMNAT2.</p> </li> <li> <p>The biological process of protein K48-linked ubiquitination (GO:0070936) is correctly assigned to the components of the ubiquitin ligase complex.</p> </li> <li> <p>Cellular components are appropriately annotated for each protein.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Evidence Codes and References: The evidence for SKP1's molecular function activator activity appears to be citing the same reference (PMID:29997255) twice. This redundancy could be removed.</p> </li> <li> <p>Expanded Biological Process Context: While NMNAT2 is correctly annotated as being part of axon development, the model could benefit from connecting the protein K48-linked ubiquitination process to a higher-level biological process such as \"axon maintenance\" or \"regulation of axon degeneration\" to better capture the functional impact of NMNAT2 degradation, as described in the literature where NMNAT2 acts as an axon maintenance factor.</p> </li> <li> <p>Additional Information: Consider adding information about the molecular mechanisms through which MYCBP2 specifically targets threonine/serine residues for ubiquitination, as described in its UniProt entry (O75592), which mentions its atypical activity targeting threonine instead of lysine residues.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the non-canonical nature of the PAM/FBXO45/SKP1 complex as described in the literature. Unlike typical SCF (Skp1-Cullin-F-box) complexes that include CUL1, this complex contains MYCBP2 (PAM) instead of CUL1. The model correctly depicts FBXO45 as having dual roles in substrate recognition and complex assembly, and SKP1 as an auxiliary component.</p> <p>The representation of NMNAT2 as a substrate of this complex aligns with the published research showing that this interaction leads to NMNAT2 polyubiquitination and degradation by the proteasome, which has implications for axon maintenance and degeneration.</p>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#technical-compliance","title":"Technical Compliance","text":"<p>The model demonstrates good adherence to GO-CAM guidelines for representing E3 ubiquitin ligase complexes. The predicate relationships use the appropriate relation terms (RO:0002629 for \"directly positively regulates\" and RO:0002630 for \"directly negatively regulates\").</p>"},{"location":"reviews/63c0ac2b00000506-Degradation_of_NMNAT2_via_the_PAM__SKP1_FBXO45_MYCBP2__E3_ligase_complex__Human_/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that accurately represents the biological process of NMNAT2 ubiquitination and degradation via the atypical PAM/FBXO45/SKP1 E3 ligase complex. The model aligns with current literature and follows GO-CAM best practices for representing ubiquitination processes. The minor suggestions for improvement would enhance the model's biological context but do not detract from its current quality and accuracy.</p>"},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/","title":"63c0ac2b00000547 Staphylococcal HlgB activation of NF kappa B via AMFR and TAB3  Human Staphylococcus Aureus","text":"<p>Let me review the GO-CAM model based on the information I've gathered. I'll provide a thorough analysis of the model, its components, biological context, and compliance with GO-CAM best practices.</p>"},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#review-of-go-cam-model-gomodel63c0ac2b00000547","title":"Review of GO-CAM Model gomodel:63c0ac2b00000547","text":""},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#model-overview","title":"Model Overview","text":"<p>Title: Staphylococcal HlgB activation of NF-kappa-B via AMFR and TAB3 (Human-Staphylococcus Aureus)</p> <p>Taxon: NCBITaxon:9606 (Human)</p> <p>Status: Production</p> <p>ID: gomodel:63c0ac2b00000547</p>"},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#biological-content-summary","title":"Biological Content Summary","text":"<p>This model represents a host-pathogen interaction pathway between human cells and Staphylococcus aureus. Specifically, it shows how the staphylococcal virulence factor HlgB (Gamma-hemolysin component B) targets the human endoplasmic reticulum-resident E3 ubiquitin ligase AMFR to promote inflammation through NF-kappa-B signaling. The pathway described involves:</p> <ol> <li>HlgB (Staphylococcus aureus) binding to AMFR in the host endoplasmic reticulum</li> <li>AMFR mediating K27-linked polyubiquitination of TAB3</li> <li>TAB3 acting as a molecular adaptor to facilitate MAP3K7/TAK1 activation</li> <li>MAP3K7/TAK1 activation leading to NF-kappa-B signaling</li> </ol>"},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#model-components-and-activities","title":"Model Components and Activities","text":"<p>The model includes four activities connected through causal relationships:</p> <ol> <li>AMFR (Q9UKV5) - E3 ubiquitin ligase activity (GO:0061630)</li> <li>Occurs in: Endoplasmic reticulum membrane (GO:0005789)</li> <li>Part of: Protein K27-linked ubiquitination (GO:0044314)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:28604676</li> <li> <p>Causally regulates: TAB3's molecular adaptor activity</p> </li> <li> <p>TAB3 (Q8N5C8) - Molecular adaptor activity (GO:0060090)</p> </li> <li>Occurs in: Endoplasmic reticulum (GO:0005783)</li> <li>Part of: Non-canonical NF-kappaB signal transduction (GO:0038061)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:15327770</li> <li> <p>Causally regulates: MAP3K7's MAP kinase activity</p> </li> <li> <p>HlgB (Q2FVK1) - Molecular adaptor activity (GO:0060090)</p> </li> <li>Occurs in: Host cell endoplasmic reticulum (GO:0044165)</li> <li>Part of: Symbiont-mediated perturbation of host NF-kappaB cascade (GO:0085032)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:36593296</li> <li> <p>Causally regulates: AMFR's E3 ubiquitin ligase activity</p> </li> <li> <p>MAP3K7 (O43318) - MAP kinase activity (GO:0004707)</p> </li> <li>Occurs in: Cytoplasm (GO:0005737)</li> <li>Part of: Canonical NF-kappaB signal transduction (GO:0007249)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:11865055</li> </ol>"},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Biological accuracy: The model accurately captures a host-pathogen interaction based on recent literature (PMID:36593296). The study demonstrates that S. aureus HlgB targets AMFR to regulate TAB3 ubiquitination, promoting TAK1 activation and subsequent NF-kappa-B signaling.</p> </li> <li> <p>Proper annotation of complexes: The model follows the GO-CAM guidelines for annotating complexes by using the specific proteins that carry known molecular activities.</p> </li> <li> <p>Appropriate use of molecular function terms: Each protein has been assigned appropriate molecular function terms based on their known activities.</p> </li> <li> <p>Causal relationships: The model correctly uses the \"directly positively regulates\" (RO:0002629) predicate to show the causal chain from HlgB to NF-kappa-B signaling.</p> </li> <li> <p>Proper cellular location annotation: Each activity is appropriately annotated with the cellular location where it occurs.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#issuesimprovements","title":"Issues/Improvements:","text":"<ol> <li> <p>Incomplete description of HlgB's function: While HlgB is annotated with \"molecular adaptor activity,\" the literature (PMID:36593296) suggests it may also have a role in binding to AMFR directly. The model could be expanded to better capture this interaction.</p> </li> <li> <p>Molecular adaptor activity of TAB3: According to literature, TAB3 is known to be ubiquitinated by AMFR through K27-linked polyubiquitination at Lysine 649, which then promotes TAK1/MAP3K7 activation. The model correctly shows TAB3 as a molecular adaptor, but the specific mechanism of how it adapts/connects TAK1 could be made clearer.</p> </li> <li> <p>Biological process annotation: MAP3K7 is annotated as part of \"canonical NF-kappaB signal transduction\" while TAB3 is part of \"non-canonical NF-kappaB signal transduction\" - this seems inconsistent, as they are participating in the same signaling pathway in this model.</p> </li> <li> <p>Missing connection to downstream effects: The model could be expanded to show the downstream effects of MAP3K7 activation on NF-kappa-B activation and subsequent inflammatory responses.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Clarify the biological process consistency: Review whether TAB3 and MAP3K7 should both be annotated with the same biological process term, as they appear to be part of the same signaling pathway in this context.</p> </li> <li> <p>Expand the role of HlgB: Consider adding more detail about how HlgB interacts with AMFR, perhaps specifying a protein binding activity in addition to its adaptor role.</p> </li> <li> <p>Add details about TAB3 ubiquitination: While the causal relationship between AMFR and TAB3 is captured, the model could explicitly note that this involves K27-linked polyubiquitination of TAB3 at Lys-649.</p> </li> <li> <p>Extend the pathway downstream: Consider extending the model to include downstream components of the NF-kappa-B pathway to provide a more complete picture of the inflammatory response.</p> </li> <li> <p>Add additional literature support: While the key references are included, adding more supporting literature could strengthen the evidence base for the model.</p> </li> </ol>"},{"location":"reviews/63c0ac2b00000547-Staphylococcal_HlgB_activation_of_NF_kappa_B_via_AMFR_and_TAB3__Human_Staphylococcus_Aureus_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:63c0ac2b00000547) successfully captures a host-pathogen interaction between S. aureus HlgB and the human AMFR-TAB3-MAP3K7 signaling axis, leading to NF-kappa-B activation. The model adheres to GO-CAM best practices for activity annotation, causal relationships, and cellular context. With some minor improvements in consistency and completeness, this model could provide an even more comprehensive representation of this important inflammatory pathway triggered by S. aureus infection.</p>"},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/","title":"63d320cd00000225 Activation of the AIM2 inflammasome in response to DNA damage  Mouse","text":"<p>Now let me put together a comprehensive review of GO-CAM model 63d320cd00000225.</p>"},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#review-of-go-cam-model-activation-of-the-aim2-inflammasome-in-response-to-dna-damage-mouse","title":"Review of GO-CAM Model: Activation of the AIM2 inflammasome in response to DNA damage (Mouse)","text":""},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:63d320cd00000225</li> <li>Title: Activation of the AIM2 inflammasome in response to DNA damage (Mouse)</li> <li>Taxon: Human (NCBITaxon:9606) - Note: There appears to be an inconsistency here as the title refers to mouse but the taxon is human.</li> <li>Status: Production</li> </ul>"},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#model-summary","title":"Model Summary","text":"<p>This GO-CAM model describes the activation pathway of the AIM2 inflammasome in response to DNA damage. The model depicts a series of molecular functions and causal relationships centered on how AIM2 (Absent in melanoma 2) acts as a cytosolic DNA sensor that triggers the assembly of the inflammasome, eventually leading to pyroptotic inflammatory response.</p> <p>The model includes the following key components: 1. AIM2 (MGI:MGI:2686159) detection of DNA damage 2. Caspase-1 (MGI:MGI:96544) activation 3. GSDMD (Gasdermin D, MGI:MGI:1916396) pore formation 4. Inflammatory response induction</p>"},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#detailed-review","title":"Detailed Review","text":""},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#scientific-content-assessment","title":"Scientific Content Assessment","text":"<p>The model accurately represents the current scientific understanding of AIM2 inflammasome activation as supported by the literature. Key findings from references such as PMID:27846608 and PMID:27383986 align with the model structure:</p> <ol> <li>AIM2 serves as a cytoplasmic DNA sensor that detects double-stranded DNA damage at sites of double-strand breaks.</li> <li>Upon DNA binding, AIM2 activates the inflammasome through a signaling adaptor activity.</li> <li>This leads to activation of caspase-1, which cleaves pro-IL-1\u03b2 and GSDMD.</li> <li>Cleaved GSDMD forms pores in the plasma membrane, resulting in pyroptotic cell death.</li> </ol> <p>The causal flow of activities in the model correctly represents the biological pathway as described in the literature.</p>"},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#technical-structure-assessment","title":"Technical Structure Assessment","text":"<p>The model demonstrates a coherent structure with appropriate causal relationships between activities:</p> <ol> <li>DNA Binding and Recognition:</li> <li>AIM2 \"double-stranded DNA binding\" (GO:0003690) occurs in the \"site of double-strand break\" (GO:0035861)</li> <li> <p>AIM2 \"pattern recognition receptor activity\" (GO:0038187) is correctly shown as directly positively regulating the next step</p> </li> <li> <p>Inflammasome Activation:</p> </li> <li>AIM2 \"signaling adaptor activity\" (GO:0035591) is present, consistent with its known role</li> <li> <p>AIM2's \"cysteine-type endopeptidase activator activity\" (GO:0140608) correctly shows it activates caspase-1</p> </li> <li> <p>Caspase-1 Activation:</p> </li> <li>Caspase-1 \"cysteine-type endopeptidase activity\" (GO:0004197) is shown as part of \"protein maturation\" (GO:0051604)</li> <li> <p>Caspase-1 is shown activating GSDMD, which is consistent with the literature</p> </li> <li> <p>GSDMD Pore Formation:</p> </li> <li>GSDMD \"phosphatidylinositol-4,5-bisphosphate binding\" (GO:0005546) occurs at the \"plasma membrane\" (GO:0005886)</li> <li>GSDMD \"wide pore channel activity\" (GO:0022829) is shown as part of \"positive regulation of inflammatory response\" (GO:0050729)</li> </ol>"},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<p>The model generally adheres to GO-CAM best practices:</p> <ol> <li> <p>Use of correct causal relations: The model uses \"RO:0002629\" (directly positively regulates) appropriately to connect sequential activities in the pathway.</p> </li> <li> <p>Molecular function assignments: Each protein has been assigned appropriate molecular functions based on experimental evidence.</p> </li> <li> <p>Cellular component annotations: Activities are correctly localized to appropriate cellular components (e.g., AIM2 DNA binding at sites of double-strand breaks, GSDMD pore formation at the plasma membrane).</p> </li> <li> <p>Biological process annotations: Each activity is associated with appropriate biological processes.</p> </li> <li> <p>Evidence codes: The model uses ECO:0000314 (direct assay evidence used in manual assertion) and ECO:0000250 (sequence similarity evidence used in manual assertion) appropriately.</p> </li> </ol>"},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, there are a few areas that could be improved:</p> <ol> <li> <p>Taxon inconsistency: The title refers to mouse (\"Mouse\"), but the taxon is listed as human (NCBITaxon:9606). This should be corrected for consistency.</p> </li> <li> <p>Pycard/ASC representation: The model mentions \"MGI:MGI:1931465\" (Pycard/ASC) in the objects list but does not include it in the pathway. Since ASC is a crucial adaptor for the AIM2 inflammasome, it would be beneficial to explicitly show its role in connecting AIM2 to caspase-1.</p> </li> <li> <p>IL-1\u03b2 processing: While the model shows the activation of the inflammasome machinery, it could be enhanced by including the processing and release of IL-1\u03b2, which is a major functional outcome of inflammasome activation.</p> </li> <li> <p>Complex formation: According to the GO-CAM best practices for annotating complexes, the AIM2 inflammasome complex could be more explicitly modeled. Since the model focuses on the AIM2 inflammasome, it would be beneficial to either explicitly show the complex formation or follow the guidelines for representing complexes in GO-CAM.</p> </li> </ol>"},{"location":"reviews/63d320cd00000225-Activation_of_the_AIM2_inflammasome_in_response_to_DNA_damage__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Activation of the AIM2 inflammasome in response to DNA damage\" (gomodel:63d320cd00000225) is a well-constructed representation of the AIM2 inflammasome pathway. It accurately captures the scientific understanding of how DNA damage activates the AIM2 inflammasome, leading to caspase-1 activation, GSDMD pore formation, and subsequent inflammatory response.</p> <p>The model follows GO-CAM best practices for most aspects, with appropriate molecular functions, cellular components, biological processes, and causal relationships. The evidence provided is appropriate and linked to relevant literature.</p> <p>To further enhance this model, I recommend: 1. Resolving the taxon inconsistency (mouse vs. human) 2. Explicitly including ASC/Pycard in the pathway 3. Adding the processing and release of IL-1\u03b2 4. Considering a more explicit representation of the AIM2 inflammasome complex according to GO-CAM best practices for complex annotation</p> <p>Overall, this is a valuable model that effectively captures current knowledge about the AIM2 inflammasome activation pathway in response to DNA damage.</p>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/","title":"63d320cd00000317 Activation of the AIM2 inflammasome in neural cells shapes neurodevelopment  Mouse","text":"<p>Based on my examination of GO-CAM model 63d320cd00000317, I'll now provide a comprehensive review of this model.</p>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#review-of-go-cam-model-63d320cd00000317","title":"Review of GO-CAM Model: 63d320cd00000317","text":""},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#general-information","title":"General Information","text":"<p>Model ID: gomodel:63d320cd00000317 Title: Activation of the AIM2 inflammasome in neural cells shapes neurodevelopment (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production</p>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model represents the activation pathway of the AIM2 inflammasome in neural cells and its role in neurodevelopment. The model follows a causal chain that starts with DNA damage response, progresses through AIM2 inflammasome activation, and ends with pyroptotic inflammatory response.</p>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#content-evaluation","title":"Content Evaluation","text":""},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#pathway-overview","title":"Pathway Overview","text":"<p>The model describes a sequence of molecular events where: 1. AIM2 (Absent In Melanoma 2) protein senses DNA damage  2. This leads to inflammasome assembly and activation 3. Caspase-1 (Casp1) becomes activated 4. Caspase-1 activates gasdermin D (Gsdmd) 5. Gasdermin D forms membrane pores, resulting in pyroptosis</p>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#molecular-functions-and-causal-relations","title":"Molecular Functions and Causal Relations","text":"<p>The model contains 8 activities connected by causal relations:</p> <ol> <li>AIM2 initial DNA sensing activities:</li> <li>Double-stranded DNA binding (GO:0003690)</li> <li>Pattern recognition receptor activity (GO:0038187)</li> <li> <p>Signaling adaptor activity (GO:0035591)</p> </li> <li> <p>Caspase-1 activation:</p> </li> <li>AIM2 exhibits cysteine-type endopeptidase activator activity (GO:0140608)</li> <li> <p>Casp1 exhibits cysteine-type endopeptidase activity (GO:0004197)</p> </li> <li> <p>Gasdermin D activation and pore formation:</p> </li> <li>Gsdmd exhibits phosphatidylinositol-4,5-bisphosphate binding (GO:0005546)</li> <li>Gsdmd exhibits wide pore channel activity (GO:0022829)</li> </ol>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#biological-processes","title":"Biological Processes","text":"<p>The model includes the following biological processes: - DNA damage response (GO:0006974) - Positive regulation of inflammatory response (GO:0050729) - Protein maturation (GO:0051604)</p>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#anatomical-locations","title":"Anatomical Locations","text":"<p>Activities occur in: - Plasma membrane (GO:0005886) - Site of double-strand break (GO:0035861)</p>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Scientific accuracy: The model correctly represents the current understanding of AIM2 inflammasome activation in response to DNA damage, which is supported by the literature cited (PMID:32350463, PMID:27383986).</p> </li> <li> <p>Logical flow: The causal chain is well-structured, with each activity leading logically to the next, providing a coherent representation of the pathway.</p> </li> <li> <p>Evidence basis: The model uses appropriate evidence codes (ECO:0000314 - direct assay evidence, ECO:0000250 - sequence similarity evidence) and references to support the annotations.</p> </li> <li> <p>Cellular components: The model appropriately places activities in their correct cellular locations.</p> </li> </ol>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex representation: The model doesn't explicitly represent the AIM2 inflammasome complex (GO:0140970). Based on the GO-CAM guidelines for complex annotation, when multiple proteins are involved in a complex and the specific activity of each is known, it's preferable to represent each protein's specific contribution. The current model does show individual proteins and their activities, but doesn't explicitly indicate that they form part of the AIM2 inflammasome complex.</p> </li> <li> <p>Missing components: The model does not include the ASC/PYCARD adaptor protein (MGI:MGI:1931465), which is a crucial component of the AIM2 inflammasome. According to the literature (PMID:27383986), AIM2 recruits ASC, which then recruits caspase-1. This intermediate step is missing in the current model.</p> </li> <li> <p>Missing IL-1\u03b2 processing: A key outcome of inflammasome activation is the processing and release of pro-inflammatory cytokines like IL-1\u03b2, which is not represented in this model. However, the model does focus on the pyroptotic cell death aspect, which is another important outcome.</p> </li> <li> <p>Biological context: The model could benefit from more explicit connections to neurodevelopment processes, which are mentioned in the title but not explicitly modeled.</p> </li> </ol>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Include ASC/PYCARD: Add the ASC adaptor protein (MGI:MGI:1931465) and its interaction with both AIM2 and caspase-1 to better reflect the complete inflammasome assembly process.</p> </li> <li> <p>Add AIM2 inflammasome complex: Consider explicitly annotating the formation of the AIM2 inflammasome complex (GO:0140970) to better represent the molecular mechanism.</p> </li> <li> <p>Extend to cytokine processing: If appropriate for the scope of the model, include the processing of pro-inflammatory cytokines like IL-1\u03b2, which is another important consequence of inflammasome activation.</p> </li> <li> <p>Connect to neurodevelopment: Add activities or biological processes that explicitly connect inflammasome activation to neurodevelopment, such as neural cell death or specific neurodevelopmental processes.</p> </li> <li> <p>Additional evidence: Consider including more recent evidence supporting the role of AIM2 in neural development to strengthen the model's scientific basis.</p> </li> </ol>"},{"location":"reviews/63d320cd00000317-Activation_of_the_AIM2_inflammasome_in_neural_cells_shapes_neurodevelopment__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 63d320cd00000317 provides a scientifically accurate representation of AIM2 inflammasome activation leading to pyroptosis in neural cells. The model is well-structured with appropriate causal connections and is supported by evidence from the literature. With the suggested improvements, particularly the addition of the ASC adaptor protein and explicit representation of the inflammasome complex, the model would more comprehensively represent the current understanding of this pathway and its role in neurodevelopment.</p>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/","title":"63d320cd00000399 Negative regulation of the AIM2 inflammasome by Ifi202  Mouse","text":"<p>Now that I have gathered all the necessary information, I'll provide a comprehensive review of the GO-CAM model with ID 63d320cd00000399.</p>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#review-of-go-cam-model-63d320cd00000399","title":"Review of GO-CAM Model: 63d320cd00000399","text":""},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#basic-information","title":"Basic Information","text":"<ul> <li>Model ID: gomodel:63d320cd00000399</li> <li>Title: \"Negative regulation of the AIM2 inflammasome by Ifi202 (Mouse)\"</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model describes the mechanism by which Ifi202 (p202) negatively regulates the AIM2 inflammasome in mice. The model captures the molecular interactions between Ifi202 and Aim2, and how these interactions prevent AIM2 inflammasome complex assembly.</p>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#key-components-and-molecular-activities","title":"Key Components and Molecular Activities","text":"<p>The model includes five key molecular activities:</p> <ol> <li>Ifi202a double-stranded DNA binding activity (GO:0003690) enabled by Ifi202a (MGI:MGI:1347080)</li> <li>Part of negative regulation of AIM2 inflammasome complex assembly (GO:0140972)</li> <li> <p>Causally upstream of (negatively regulates) Aim2's DNA binding activity</p> </li> <li> <p>Ifi202a molecular adaptor activity (GO:0060090) enabled by Ifi202a (MGI:MGI:1347080)</p> </li> <li>Part of negative regulation of AIM2 inflammasome complex assembly (GO:0140972)</li> <li> <p>Causally upstream of (negatively regulates) Aim2's signaling adaptor activity</p> </li> <li> <p>Aim2 double-stranded DNA binding activity (GO:0003690) enabled by Aim2 (MGI:MGI:2686159)</p> </li> <li>Occurs in cytoplasm (GO:0005737)</li> <li>Part of AIM2 inflammasome complex assembly (GO:0140970)</li> <li> <p>Causally upstream of (positively regulates) Aim2's pattern recognition receptor activity</p> </li> <li> <p>Aim2 pattern recognition receptor activity (GO:0038187) enabled by Aim2 (MGI:MGI:2686159)</p> </li> <li>Occurs in cytoplasm (GO:0005737)</li> <li>Part of AIM2 inflammasome complex assembly (GO:0140970)</li> <li> <p>Causally upstream of (positively regulates) Aim2's signaling adaptor activity</p> </li> <li> <p>Aim2 signaling adaptor activity (GO:0035591) enabled by Aim2 (MGI:MGI:2686159)</p> </li> <li>Occurs in cytoplasm (GO:0005737)</li> <li>Part of AIM2 inflammasome complex assembly (GO:0140970)</li> </ol>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is supported by several published studies, primarily: - PMID:23850291 - Primary reference describing the molecular mechanism of p202-mediated inhibition of AIM2 inflammasome - PMID:23567559 - Describes the structural basis for termination of AIM2-mediated signaling by p202 - PMID:19158679 - Provides evidence for cytoplasmic localization of the AIM2 inflammasome complex</p>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#review-findings","title":"Review Findings","text":""},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<ol> <li>Molecular mechanism representation: The model accurately represents the key findings from the literature showing that Ifi202a (p202) inhibits AIM2 inflammasome assembly through two complementary mechanisms:</li> <li>Direct binding to double-stranded DNA (competing with AIM2)</li> <li> <p>Direct interaction with AIM2 via its HIN domain, which prevents proper clustering of AIM2 and recruitment of ASC</p> </li> <li> <p>Cellular localization: The model correctly indicates that AIM2 inflammasome assembly occurs in the cytoplasm.</p> </li> <li> <p>Causal relationships: The causal relationships in the model correctly show how Ifi202a activities negatively regulate AIM2 activities, preventing inflammasome assembly.</p> </li> </ol>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<ol> <li>Activity representation: The model follows GO-CAM best practices by:</li> <li>Appropriately representing the molecular functions of both proteins</li> <li>Connecting activities with causal relationships (RO:0002630 \"directly negatively regulates\" and RO:0002629 \"directly positively regulates\")</li> <li> <p>Including proper cellular locations</p> </li> <li> <p>Complex annotation: The model follows the recommendations from the \"How to annotate complexes in GO-CAM\" document. Since the activities of specific subunits (Ifi202a and Aim2) are known, the activities are represented by the specific proteins carrying the activities rather than using a complex ID.</p> </li> <li> <p>Evidence coding: Each activity and relationship is properly supported with evidence codes (ECO:0000314 \"direct assay evidence used in manual assertion\") and appropriate PMID references.</p> </li> </ol>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Additional context: The model could potentially include more context about the downstream effects of AIM2 inflammasome inhibition, such as reduced caspase-1 activation and IL-1\u03b2/IL-18 processing.</p> </li> <li> <p>ASC recruitment: The model does not explicitly represent the recruitment of ASC (PYCARD/Asc) to the AIM2 inflammasome, which is a key step in inflammasome assembly and is blocked by Ifi202a. Including this would provide a more complete picture of the mechanism.</p> </li> <li> <p>Tetrameric structure of Ifi202a: The model doesn't capture the tetrameric structure of Ifi202a that was highlighted in PMID:23850291 as important for its function in inhibiting AIM2. This structural feature enhances its ability to bind DNA with higher affinity than AIM2.</p> </li> </ol>"},{"location":"reviews/63d320cd00000399-Negative_regulation_of_the_AIM2_inflammasome_by_Ifi202__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 63d320cd00000399 accurately represents the current scientific understanding of how Ifi202a negatively regulates AIM2 inflammasome assembly in mice. It captures the key molecular activities and their causal relationships based on published evidence. The model follows GO-CAM best practices for complex annotation and causality representation.</p> <p>The model effectively illustrates an important species-specific regulatory mechanism, as p202 is present in mice but not humans, providing insight into different inflammatory response regulation between species.</p> <p>While there are a few areas where additional context could enhance the model, overall it represents a high-quality GO-CAM model of this important regulatory pathway.</p>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/","title":"63d320cd00001688 Response to ribosome stalling by GCN1  RNF14 and RNF25  leading to ubiquitination and degradation of EEF1A1  Human","text":"<p>Now let me review the GO-CAM model based on all the information I've gathered:</p>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#go-cam-model-review-for-response-to-ribosome-stalling-by-gcn1-rnf14-and-rnf25-leading-to-ubiquitination-and-degradation-of-eef1a1-human","title":"GO-CAM Model Review for: \"Response to ribosome stalling by GCN1, RNF14 and RNF25, leading to ubiquitination and degradation of EEF1A1 (Human)\"","text":"<p>https://bioregistry.io/go.model:63d320cd00001688</p>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model describes a translation quality control pathway that detects and responds to stalled ribosomes in human cells. The model focuses on how GCN1 (stalled ribosome sensor), RNF14, and RNF25 (E3 ubiquitin ligases) work together to ubiquitinate and degrade the translation elongation factor EEF1A1 in response to ribosome stalling.</p>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#main-components-and-activities","title":"Main Components and Activities","text":"<ol> <li>GCN1 (Q92616) - Acts as a stalled ribosome sensor with \"stalled ribosome sensor activity\" (GO:0170011)</li> <li>Localized to \"cytosolic ribosome\" (GO:0022626)</li> <li>Part of \"rescue of stalled ribosome\" process (GO:0072344)</li> <li> <p>Positively regulates RNF14's E3 ubiquitin ligase activity</p> </li> <li> <p>RNF14 (Q9UBS8) - Acts as an E3 ubiquitin ligase with \"ubiquitin protein ligase activity\" (GO:0061630)</p> </li> <li>Localized to \"cytosolic ribosome\" (GO:0022626)</li> <li>Part of \"ubiquitin-dependent protein catabolic process\" (GO:0006511)</li> <li> <p>Negatively regulates EEF1A1's translation elongation factor activity</p> </li> <li> <p>RNF25 (Q96BH1) - Acts as an E3 ubiquitin ligase with \"ubiquitin protein ligase activity\" (GO:0061630)</p> </li> <li>Localized to \"cytosolic ribosome\" (GO:0022626)</li> <li>Part of \"rescue of stalled ribosome\" process (GO:0072344)</li> <li> <p>Positively regulates RNF14's activity</p> </li> <li> <p>EEF1A1 (P68104) - Has \"translation elongation factor activity\" (GO:0003746)</p> </li> <li>Localized to \"cytosolic ribosome\" (GO:0022626)</li> <li>Part of \"translational elongation\" process (GO:0006414)</li> <li>Target of negative regulation by RNF14</li> </ol>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model shows the following causal relationships: - GCN1 positively regulates RNF14 (RO:0002629 \"directly positively regulates\") - RNF25 positively regulates RNF14 (RO:0002304 \"causally upstream of, positive effect\") - RNF14 negatively regulates EEF1A1 (RO:0002630 \"directly negatively regulates\")</p>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#evidence-and-annotations","title":"Evidence and Annotations","text":"<p>All annotations in the model are supported by experimental evidence from the same primary research article: - Evidence code: ECO:0000314 (direct assay evidence used in manual assertion) - Reference: PMID:36638793 - All annotations date from February 2023 - Curator: https://orcid.org/0000-0001-7299-6685</p>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#assessment-of-the-model","title":"Assessment of the Model","text":""},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#strengths","title":"Strengths:","text":"<ol> <li>Accurate Molecular Function Annotations: All proteins have correctly assigned molecular functions based on their known activities:</li> <li>GCN1 as a stalled ribosome sensor</li> <li>RNF14 and RNF25 as E3 ubiquitin ligases</li> <li> <p>EEF1A1 as a translation elongation factor</p> </li> <li> <p>Appropriate Locations: The activities are correctly annotated to occur in the cytosolic ribosome, which is consistent with the ribosome stalling response pathway.</p> </li> <li> <p>Clear Biological Processes: Each protein is appropriately associated with its relevant biological process.</p> </li> <li> <p>Correct Causal Relationships: The model captures key regulatory relationships between the components:</p> </li> <li>GCN1 as the sensor activating RNF14</li> <li>RNF25 working with RNF14</li> <li> <p>RNF14 directly negatively regulating EEF1A1 through ubiquitination</p> </li> <li> <p>Sound Evidence: All annotations are backed by direct experimental evidence from the same study.</p> </li> </ol>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#areas-for-consideration","title":"Areas for Consideration:","text":"<ol> <li> <p>Specificity of RNF14 Activity: The model correctly shows that RNF14 directly ubiquitinates EEF1A1, targeting Lysine 385 (K385) as shown in the paper. However, this specific detail about K385 being the primary ubiquitination target could be made more explicit in the annotations.</p> </li> <li> <p>Role of RPS27A: The paper indicates that RNF25 specifically ubiquitinates RPS27A at Lysine 113 (K113), which is an essential step for the subsequent RNF14-mediated EEF1A1 ubiquitination. This detail is missing from the current model and could be included to make the pathway more complete.</p> </li> <li> <p>Temporal Sequence: While the causal relationships capture the regulatory direction, the model doesn't fully convey the temporal sequence described in the paper: RNF25 first ubiquitinates RPS27A, which then allows GCN1-bound RNF14 to ubiquitinate EEF1A1.</p> </li> <li> <p>Representation of Stalled Ribosomes: The model implicitly addresses ribosome stalling through the process annotations, but doesn't explicitly show what constitutes a \"stalled ribosome\" (e.g., the presence of ternatin-4 as a stalling agent mentioned in the paper).</p> </li> </ol>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Include RPS27A in the Model: Add RPS27A (ribosomal protein S27a) as a component, showing its ubiquitination by RNF25 at K113 as an essential step in the pathway.</p> </li> <li> <p>Specify Ubiquitination Sites: Consider adding annotations that specify the key ubiquitination sites (K385 on EEF1A1 and K113 on RPS27A) to provide more mechanistic detail.</p> </li> <li> <p>Clarify the Temporal Sequence: The model could be structured to better reflect the temporal sequence of events: ribosome stalling \u2192 GCN1 sensing \u2192 RNF25 ubiquitinating RPS27A \u2192 RNF14 binding to GCN1 \u2192 RNF14 ubiquitinating EEF1A1 \u2192 EEF1A1 degradation.</p> </li> <li> <p>Consider Adding Proteasomal Degradation: The final degradation of ubiquitinated EEF1A1 by the proteasome could be included to complete the pathway.</p> </li> </ol>"},{"location":"reviews/63d320cd00001688-Response_to_ribosome_stalling_by_GCN1__RNF14_and_RNF25__leading_to_ubiquitination_and_degradation_of_EEF1A1__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the key components and regulatory relationships involved in the response to ribosome stalling leading to EEF1A1 ubiquitination and degradation. The model is well-supported by evidence and follows good curation practices. With the suggested additions, particularly the inclusion of RPS27A and more explicit representation of the temporal sequence, the model would provide an even more comprehensive view of this important translation quality control pathway.</p> <p>The model conforms well to GO-CAM best practices for representing molecular activities and their causal relationships. The use of appropriate protein instances, molecular functions, cellular locations, and biological processes adheres to the guidelines for GO-CAM modeling.</p>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/","title":"63e5937500000106 Activation of the GCN2 mediated signaling by GCN1 in response to ribosome collisions and inhibition of GCN2 by HEL2  S cerevisiae","text":"<p>Based on the information gathered, I'll now conduct a thorough review of the GO-CAM model gomodel:63e5937500000106.</p>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#go-cam-review-gomodel63e5937500000106","title":"GO-CAM Review: gomodel:63e5937500000106","text":""},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#model-title","title":"Model Title","text":"<p>\"Activation of the GCN2-mediated signaling by GCN1 in response to ribosome collisions and inhibition of GCN2 by HEL2 (S.cerevisiae)\"</p>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#general-information","title":"General Information","text":"<ul> <li>Taxon: Saccharomyces cerevisiae (NCBITaxon:559292)</li> <li>Status: Production</li> <li>Primary contributor: ORCID:0000-0001-7299-6685 (annotations from 2023-02-13)</li> </ul>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM captures key aspects of the integrated stress response (ISR) pathway in yeast, specifically: 1. The GCN2-mediated signaling pathway in response to ribosome collisions 2. The positive regulation of GCN2 by GCN1  3. The negative regulation of GCN2 by HEL2 4. The effect of GCN2 on translation initiation via SUI2 (eIF2\u03b1)</p>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#biological-content-review","title":"Biological Content Review","text":""},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#activities-and-causal-relationships","title":"Activities and Causal Relationships","text":"<p>The model contains four main activities:</p> <ol> <li>GCN2 (SGD:S000002691) - eukaryotic translation initiation factor 2alpha kinase activity (GO:0004694)</li> <li>Occurs in: cytosolic ribosome (GO:0022626)</li> <li>Part of: GCN2-mediated signaling (GO:0140469)</li> <li> <p>Causally affected: Directly negatively regulates SUI2/eIF2\u03b1's translation initiation factor activity</p> </li> <li> <p>SUI2/eIF2\u03b1 (SGD:S000003767) - translation initiation factor activity (GO:0003743)</p> </li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li> <p>Part of: translational initiation (GO:0006413)</p> </li> <li> <p>HEL2 (SGD:S000002674) - stalled ribosome sensor activity (GO:0170011)</p> </li> <li>Occurs in: cytosolic ribosome (GO:0022626)</li> <li>Part of: rescue of stalled ribosome (GO:0072344)</li> <li> <p>Causally affects: Causally upstream of, negative effect on GCN2's kinase activity</p> </li> <li> <p>GCN1 (SGD:S000003163) - stalled ribosome sensor activity (GO:0170011)</p> </li> <li>Occurs in: cytosolic ribosome (GO:0022626)</li> <li>Part of: rescue of stalled ribosome (GO:0072344)</li> <li>Causally affects: Directly positively regulates GCN2's kinase activity</li> </ol>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#consistency-with-literature-evidence","title":"Consistency with Literature Evidence","text":"<p>The model is well-supported by the literature cited:</p> <ol> <li>PMID:33338396 (Yan &amp; Zaher, 2021) - This paper provides strong evidence that:</li> <li>Ribosome quality control (RQC) antagonizes the activation of ISR on colliding ribosomes</li> <li>HEL2 suppresses activation of GCN2</li> <li>HEL2 and GCN2 are activated by similar signals (ribosome collisions)</li> <li>Inactivation of one pathway results in overactivation of the other</li> <li>ISR prefers a vacant A site, whereas RQC displays no preference</li> <li> <p>GCN1 associates with collided ribosomes</p> </li> <li> <p>PMID:32615089 (Meydan &amp; Guydosh, 2020) - This paper confirms:</p> </li> <li>Loss of HEL2 increases eIF2\u03b1 phosphorylation (activates the ISR)</li> <li>HEL2 and GCN2 appear to compete for recognition of collided ribosomes</li> <li> <p>The two pathways (RQC and ISR) are linked and may antagonize each other</p> </li> <li> <p>Other supporting papers:</p> </li> <li>PMID:8798780 - Evidence for GCN2's kinase activity and role in signaling</li> <li>PMID:2038314 - Evidence for GCN2's localization to cytosolic ribosome</li> <li>PMID:9234705 - Evidence for GCN1's localization to cytosolic ribosome</li> <li>PMID:8947054 - Evidence for SUI2's role in translational initiation</li> </ol>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurately represents the biology: The model correctly captures the antagonistic relationship between the HEL2-mediated RQC pathway and the GCN2-mediated ISR pathway, as established in the literature.</p> </li> <li> <p>Appropriate GO terms: The molecular functions, cellular components, and biological processes are accurately assigned to each gene product.</p> </li> <li> <p>Evidence-based: All causal relationships are supported by experimental evidence from peer-reviewed publications.</p> </li> <li> <p>Proper causal relationships: The model uses appropriate relationship predicates:</p> </li> <li>HEL2 \"causally upstream of, negative effect\" (RO:0002305) on GCN2</li> <li>GCN1 \"directly positively regulates\" (RO:0002629) GCN2</li> <li>GCN2 \"directly negatively regulates\" (RO:0002630) SUI2/eIF2\u03b1</li> </ol>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#points-for-improvement","title":"Points for Improvement","text":"<ol> <li>Completeness of the pathway: The model could be expanded to include:</li> <li>GCN20, another co-activator of GCN2 that works with GCN1</li> <li>GCN4, which is translationally upregulated when eIF2\u03b1 is phosphorylated</li> <li> <p>Downstream effects of GCN4 activation (e.g., expression of amino acid biosynthesis genes)</p> </li> <li> <p>Complex representation: According to the GO-CAM best practices for representing complexes, it might be beneficial to clarify that GCN1 and GCN2 form a complex (with GCN20). Since the subunits carrying the specific activities are known, the current representation following option 1 in the complex annotation guidelines is appropriate.</p> </li> <li> <p>Additional molecular details: The model does not explicitly represent:</p> </li> <li>The phosphorylation of SUI2/eIF2\u03b1 by GCN2</li> <li>The ubiquitination activity of HEL2 on ribosomal proteins</li> <li>The precise mechanism by which GCN1 senses stalled ribosomes</li> </ol>"},{"location":"reviews/63e5937500000106-Activation_of_the_GCN2_mediated_signaling_by_GCN1_in_response_to_ribosome_collisions_and_inhibition_of_GCN2_by_HEL2__S_cerevisiae_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:63e5937500000106 is a well-constructed representation of the antagonistic relationship between the HEL2-mediated ribosome quality control pathway and the GCN2-mediated integrated stress response in yeast. It accurately reflects our current understanding of how these pathways interact at the level of ribosome collisions.</p> <p>The model is consistent with the literature and uses appropriate GO terms and relationship predicates. The annotations are supported by high-quality experimental evidence.</p> <p>While the model could be expanded to include additional components and molecular details, it serves as an excellent core representation of this important regulatory mechanism. The model successfully captures how the cell balances two distinct responses to ribosome collisions - the RQC pathway mediated by HEL2 and the ISR pathway mediated by GCN2.</p>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/","title":"63e5937500000215 Activation of the No Go decay  NGD  pathway in response to ribosome collision by HEL2  leading to ubiquitination of RPS7 eS7  recruitment of CUE2 and mRNA degradation  S cerevisiae","text":"<p>Now that I have gathered the necessary information, I'll provide a comprehensive review of GO-CAM model 63e5937500000215.</p>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#review-of-go-cam-model-63e5937500000215","title":"Review of GO-CAM Model: 63e5937500000215","text":""},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#basic-information","title":"Basic Information","text":"<ul> <li>Model ID: gomodel:63e5937500000215</li> <li>Title: \"Activation of the No-Go decay (NGD) pathway in response to ribosome collision by HEL2, leading to ubiquitination of RPS7/eS7, recruitment of CUE2 and mRNA degradation (S.cerevisiae).\"</li> <li>Taxon: Saccharomyces cerevisiae (Baker's yeast)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the No-Go decay (NGD) pathway in yeast, focusing on a specific mechanism where HEL2-mediated ubiquitination of ribosomal proteins triggers a quality control process that ultimately leads to degradation of problematic mRNAs. The model captures a series of molecular events from the initial sensing of ribosome collisions by HEL2, to the ubiquitination of RPS7/eS7, recruitment of the endonuclease CUE2, and subsequent mRNA degradation.</p>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#entities-and-activities-in-the-model","title":"Entities and Activities in the Model","text":"<p>The model includes five main activities, each associated with specific gene products:</p> <ol> <li>HEL2/SGD:S000002674 performing two functions:</li> <li>Ubiquitin protein ligase activity (GO:0061630)</li> <li> <p>Stalled ribosome sensor activity (GO:0170011)</p> </li> <li> <p>CUE2/SGD:S000001573 performing two functions:</p> </li> <li>K63-linked polyubiquitin modification-dependent protein binding (GO:0070530)</li> <li> <p>RNA endonuclease activity (GO:0004521)</p> </li> <li> <p>MOT2/SGD:S000000870 performing:</p> </li> <li> <p>Ubiquitin protein ligase activity (GO:0061630)</p> </li> <li> <p>Ribosomal proteins RPS7A (SGD:S000005622) and RPS7B (SGD:S000005040) which are targets of ubiquitination</p> </li> </ol>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#biological-processes-represented","title":"Biological Processes Represented","text":"<p>The model captures several key biological processes: - Nuclear-transcribed mRNA catabolic process, no-go decay (GO:0070966) - Rescue of stalled ribosome (GO:0072344) - Protein K63-linked ubiquitination (GO:0070534) - Protein monoubiquitination (GO:0006513)</p>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes causal links between activities: 1. HEL2's stalled ribosome sensor activity directly positively regulates MOT2's ubiquitin ligase activity (RO:0002629) 2. HEL2's ubiquitin ligase activity directly positively regulates CUE2's K63-linked polyubiquitin modification-dependent protein binding (RO:0002629) 3. CUE2's K63-linked polyubiquitin modification-dependent protein binding directly positively regulates its RNA endonuclease activity (RO:0002629)</p>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by experimental evidence from multiple peer-reviewed publications: - PMID:30609991 (Ikeuchi et al.) - PMID:32615089 (Meydan and Guydosh) - PMID:31219035 (D'Orazio et al.) - PMID:36583309 (Noguchi et al.)</p> <p>Each activity is supported by direct assay evidence (ECO:0000314) or author statements supported by traceable references (ECO:0000304).</p>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#strengths","title":"Strengths:","text":"<ol> <li> <p>Biological Accuracy: The model accurately represents the current understanding of the No-Go decay pathway in yeast, specifically capturing the roles of HEL2, CUE2, and MOT2 in the process.</p> </li> <li> <p>Evidential Support: All activities and connections are supported by appropriate experimental evidence from peer-reviewed literature.</p> </li> <li> <p>Molecular Detail: The model provides good molecular resolution, clearly indicating specific ubiquitination events (K63-linked) and the sequential nature of the pathway.</p> </li> <li> <p>Cellular Context: All activities are properly annotated with their cellular location (cytosolic ribosome, GO:0022626).</p> </li> <li> <p>Causal Relationships: The model effectively uses causal relationships to show how one activity leads to another, creating a coherent biological pathway.</p> </li> </ol>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices:","text":"<p>The model follows GO-CAM best practices by: - Using appropriate causality relations between activities - Including cellular locations for activities - Providing evidence for each assertion - Using appropriate GO terms for molecular functions and biological processes - Including proper annotation of the taxon</p>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#recent-research-context","title":"Recent Research Context:","text":"<p>The model is consistent with recent research on NGD, including: 1. The identification of CUE2 as the primary endonuclease in NGD (D'Orazio et al., 2019) 2. The role of HEL2 in recognizing collided ribosomes (Ikeuchi et al., 2019) 3. The discovery that Cue2 can cleave mRNAs in distinct modes depending on the nature of ribosome collision (Noguchi et al., 2022)</p>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, I would suggest the following improvements:</p> <ol> <li> <p>Detailed Mechanism of CUE2 Recruitment: Recent work by Noguchi et al. (2022) indicates that CUE2 has two distinct modes of action (NGDRQC+ and NGDRQC-) depending on whether the NGD is coupled with Ribosome Quality Control (RQC). The model could be expanded to show these two distinct pathways.</p> </li> <li> <p>Role of MBF1: Recent research highlights the role of MBF1 in preventing frameshifting at inhibitory codon pairs during NGD. This could be included to provide a more complete picture of the quality control mechanisms.</p> </li> <li> <p>Downstream Fate of mRNA Fragments: The model could be extended to show the fate of the cleaved mRNA fragments, particularly their degradation by the exosome and Xrn1.</p> </li> <li> <p>Relationship to Other Quality Control Pathways: The model could potentially benefit from indicating how NGD relates to other quality control pathways such as Nonsense-Mediated Decay (NMD) and Non-Stop Decay (NSD).</p> </li> </ol>"},{"location":"reviews/63e5937500000215-Activation_of_the_No_Go_decay__NGD__pathway_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS7_eS7__recruitment_of_CUE2_and_mRNA_degradation__S_cerevisiae__/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 63e5937500000215 provides an accurate and well-supported representation of the No-Go decay pathway in yeast, focusing on the roles of HEL2 and CUE2. The model effectively captures the current understanding of how ribosome collisions trigger ubiquitination events that ultimately lead to mRNA degradation. The model is consistent with recent literature and follows GO-CAM best practices. With some minor additions to incorporate recent findings, this model could provide an even more comprehensive view of this important quality control pathway.</p>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/","title":"63e5937500000284 18S rRNA degradation in response to ribosome collision by HEL2  leading to ubiquitination of RPS3 uS3 by MAG2  RSP5 and HEL2 and rRNA degradation  S cerevisiae","text":"<p>Now let me review the GO-CAM model in detail.</p>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#go-cam-model-review-18s-rrna-degradation-in-response-to-ribosome-collision-by-hel2","title":"GO-CAM Model Review: 18S rRNA degradation in response to ribosome collision by HEL2","text":""},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:63e5937500000284) describes the 18S rRNA degradation pathway triggered by ribosome collision, focusing on the roles of HEL2, MAG2, and RSP5 in ubiquitinating ribosomal protein RPS3/uS3 in S. cerevisiae.</p>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#model-components","title":"Model Components","text":"<p>The model consists of 4 molecular activities: 1. HEL2 (SGD:S000002674) - ubiquitin protein ligase activity (GO:0061630) 2. MAG2 (SGD:S000004419) - ubiquitin protein ligase activity (GO:0061630)  3. RSP5 (SGD:S000000927) - ubiquitin protein ligase activity (GO:0061630) 4. HEL2 (SGD:S000002674) - stalled ribosome sensor activity (GO:0170011)</p>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>HEL2's stalled ribosome sensor activity directly positively regulates (RO:0002629) HEL2's ubiquitin protein ligase activity</li> <li>HEL2's stalled ribosome sensor activity directly positively regulates (RO:0002629) MAG2's ubiquitin protein ligase activity</li> <li>MAG2's ubiquitin protein ligase activity directly positively regulates (RO:0002629) RSP5's ubiquitin protein ligase activity and HEL2's ubiquitin protein ligase activity</li> </ul>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#biological-processes","title":"Biological Processes","text":"<ul> <li>HEL2's stalled ribosome sensor activity is part of \"rescue of stalled ribosome\" (GO:0072344)</li> <li>HEL2's ubiquitin protein ligase activity is part of \"protein monoubiquitination\" (GO:0006513)</li> <li>MAG2's ubiquitin protein ligase activity is part of \"protein monoubiquitination\" (GO:0006513)</li> <li>RSP5's and HEL2's (a second activity) ubiquitin protein ligase activities are part of \"protein K63-linked ubiquitination\" (GO:0070534)</li> </ul>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#cellular-components","title":"Cellular Components","text":"<p>All activities occur in \"cytosolic ribosome\" (GO:0022626)</p>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#evidence","title":"Evidence","text":"<p>The model is supported by direct experimental evidence (ECO:0000314) from PMID:30893611 and PMID:32615089.</p>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#evaluation","title":"Evaluation","text":""},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model is scientifically accurate and reflects the mechanism of how ribosome collision triggers a quality control response involving detection by HEL2 followed by ubiquitination of ribosomal proteins. The model is consistent with the literature:</p> <ol> <li> <p>The research articles cited (PMID:30893611 and PMID:32615089) provide direct experimental evidence for the associations.</p> </li> <li> <p>The primary article describes that HEL2 acts as a sensor for ribosome collisions and then initiates ubiquitination of specific ribosomal proteins, including the 40S ribosomal protein uS3/RPS3.</p> </li> <li> <p>The model correctly represents the sequential events: HEL2 senses stalled ribosomes, then it initiates a cascade of ubiquitination events involving MAG2 and RSP5.</p> </li> </ol>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<ol> <li>Molecular Function Annotations:</li> <li>The functions assigned are appropriate for the proteins: HEL2, MAG2, and RSP5 all have ubiquitin ligase activity.</li> <li> <p>HEL2's dual function as a sensor (GO:0170011) and ligase (GO:0061630) is correctly represented as separate activities.</p> </li> <li> <p>Biological Process Context:</p> </li> <li>Each activity is appropriately linked to relevant biological processes.</li> <li> <p>The connection between ribosome rescue (GO:0072344) and protein ubiquitination (GO:0006513 and GO:0070534) is well represented.</p> </li> <li> <p>Cellular Component:</p> </li> <li> <p>All activities being located at the cytosolic ribosome (GO:0022626) is accurate.</p> </li> <li> <p>Causal Relationships:</p> </li> <li>The causal flow using \"directly positively regulates\" (RO:0002629) appropriately shows the sequence of events and regulatory relationships.</li> <li> <p>The model correctly shows HEL2's sensor activity regulating subsequent ubiquitination activities.</p> </li> <li> <p>Evidence:</p> </li> <li>Evidence codes are properly used with references to primary literature.</li> <li>The direct assay evidence (ECO:0000314) is appropriate for the experimental data.</li> </ol>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<ol> <li>Downstream Effects:</li> <li> <p>The model title mentions \"18S rRNA degradation\" but the model doesn't explicitly show the steps leading to rRNA degradation after ubiquitination. Adding these steps would complete the pathway.</p> </li> <li> <p>Complex Formation:</p> </li> <li> <p>The model doesn't explicitly represent the formation of ribosome collision complexes (disomes) that HEL2 detects. This could be added to provide more context about what HEL2 is sensing.</p> </li> <li> <p>Additional Participants:</p> </li> <li> <p>Based on the literature (PMID:32615089), the role of other factors like SLH1 in the RQC pathway could be included to give a more complete picture.</p> </li> <li> <p>Target Specification:</p> </li> <li>The model does not explicitly identify RPS3/uS3 as the target of ubiquitination, though it's mentioned in the title. This could be added for clarity.</li> </ol>"},{"location":"reviews/63e5937500000284-18S_rRNA_degradation_in_response_to_ribosome_collision_by_HEL2__leading_to_ubiquitination_of_RPS3_uS3_by_MAG2__RSP5_and_HEL2_and_rRNA_degradation__S_cerevisiae__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides an accurate representation of the initial steps in the ribosome quality control pathway triggered by ribosome collision in yeast. The model follows GO-CAM best practices in terms of molecular functions, biological processes, cellular locations, and causal relationships.</p> <p>The model could be enhanced by explicitly representing: 1. The formation of ribosome collision complexes that HEL2 detects 2. The ubiquitination target (RPS3/uS3) 3. The steps leading from ubiquitination to rRNA degradation</p> <p>Overall, this is a high-quality model that accurately represents the current scientific understanding of this pathway. The model successfully captures the key regulatory relationships between HEL2's sensor activity and the subsequent ubiquitination events involving MAG2 and RSP5.</p>"},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/","title":"63e5937500000487 Negative regulation of inflammatory response to wounding by Reg3g   Mouse","text":"<p>Now that I have all the necessary information, I'll review the GO-CAM model:</p>"},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#review-of-go-cam-model-63e5937500000487","title":"Review of GO-CAM Model 63e5937500000487","text":""},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#model-overview","title":"Model Overview","text":"<p>The model titled \"Negative regulation of inflammatory response to wounding by Reg3g. (Mouse)\" represents a signaling pathway where Reg3g (Regenerating islet-derived protein 3 gamma) negatively regulates inflammatory responses in wound healing, particularly relevant to diabetes pathology as described in PMID:27830702.</p>"},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>This GO-CAM represents a pathway involving: 1. Inflammatory signaling related to wound healing 2. The role of Reg3g in suppressing TLR3-mediated inflammation 3. Various cytokines and their molecular activities in this process</p>"},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#key-components","title":"Key Components:","text":"<ul> <li>Reg3g (MGI:MGI:109406) with hormone activity</li> <li>TLR3 (MGI:MGI:2156367) with transmembrane signaling receptor activity </li> <li>IL-17A (MGI:MGI:107364) and IL-33 (MGI:MGI:1924375) with cytokine activity</li> <li>EXTL3 (MGI:MGI:1860765) with protein-hormone receptor activity</li> <li>STAT3 (MGI:MGI:103038) with DNA-binding transcription factor activity</li> <li>PTPN6 (MGI:MGI:96055) with protein tyrosine phosphatase activity</li> <li>MAPK9/JNK2 (MGI:MGI:1346862) with JUN kinase activity</li> <li>Inflammatory cytokines IL-6 (MGI:MGI:96559) and TNF (MGI:MGI:104798)</li> </ul>"},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the key findings from PMID:27830702, including:</p> <ol> <li>The signaling pathway where Reg3g inhibits TLR3-mediated inflammation</li> <li>The mechanism by which Reg3g acts through EXTL3 receptor to activate PI3K-AKT-STAT3 signaling</li> <li>The induction of SHP-1 (PTPN6) that inhibits JNK2 (MAPK9) phosphorylation</li> <li>The end result of decreasing inflammatory cytokine (TNF and IL-6) production</li> </ol> <p>The causal relationships in the model align with the experimental findings in the paper.</p>"},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#go-cam-curation-and-best-practices-review","title":"GO-CAM Curation and Best Practices Review","text":""},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Activity Flow Representation: The activity flow is represented logically, showing how Reg3g hormone activity leads to receptor binding, downstream signaling, and ultimately inhibition of inflammatory cytokine production.</p> </li> <li> <p>Evidence Support: Each activity is supported by appropriate evidence (ECO:0000314 - direct assay evidence) and references to the source publication.</p> </li> <li> <p>Appropriate Molecular Function Terms: The molecular functions assigned to each gene product are appropriate (e.g., hormone activity for Reg3g, protein tyrosine phosphatase activity for PTPN6).</p> </li> <li> <p>Causal Associations: The causal relationships using appropriate relation ontology terms (RO:0002304, RO:0002305, RO:0002629, RO:0002630, RO:0002407) correctly reflect the biological relationships.</p> </li> </ol>"},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex Representation: According to the \"How to annotate complexes in GO-CAM\" document, if the model involves complexes where activities are carried out by specific known subunits, these should be represented individually. The model doesn't involve complexes but if it did in the future, this guideline should be followed.</p> </li> <li> <p>Taxon Consistency: The title specifies \"(Mouse)\" but the taxon field shows \"NCBITaxon:9606\" (human). This appears to be an inconsistency that should be corrected, as all gene products are mouse proteins (MGI identifiers).</p> </li> <li> <p>Detailed Mechanism Representation: While the model captures the overall pathway, it could potentially be expanded to show more detail about how:</p> </li> <li>The PI3K/AKT signaling connects to STAT3 activation (currently implied but not explicitly shown)</li> <li> <p>The model could more explicitly show the interaction between SHP-1 and JNK2, which the paper demonstrates through immunoprecipitation experiments</p> </li> <li> <p>Semantic Comments: The model includes automated change comments that indicate previous term replacements, which is good practice for tracking modifications.</p> </li> </ol>"},{"location":"reviews/63e5937500000487-Negative_regulation_of_inflammatory_response_to_wounding_by_Reg3g___Mouse_/#overall-assessment-and-recommendations","title":"Overall Assessment and Recommendations","text":"<p>This GO-CAM model is generally well-constructed and accurately represents the biology described in the source publication. The causal relations between molecular functions have been appropriately modeled, and the evidence is well-documented.</p> <p>Recommendations:</p> <ol> <li> <p>Correct the Taxon Field: Update the taxon field to \"NCBITaxon:10090\" (mouse) to match the MGI gene identifiers and model title.</p> </li> <li> <p>Consider Additional Mechanistic Detail: If appropriate, expand the model to show more explicit connections between the PI3K-AKT pathway and STAT3 activation.</p> </li> <li> <p>Verify Cellular Components: Ensure all cellular component annotations are accurate (e.g., the paper shows SHP-1 and JNK2 interactions occurring in the cytoplasm, which is correctly captured in the model).</p> </li> </ol> <p>The model provides a valuable representation of how Reg3g regulates inflammatory responses in wound healing, which is particularly relevant to understanding impaired wound healing in diabetes. The mechanistic insights captured in this model could be useful for researchers studying wound healing, inflammation, and diabetes complications.</p>"},{"location":"reviews/63e5937500000591-Activation_of_the_ribosome_quality_control_by_ZNF598_in_response_to_ribosome_collisions__leading_to_ubiquitination_of_RPS20_us10_and_ribosome_dissociation_by_the_RQT_complex__composed_of_ASCC2_and_ASCC3__Human__/","title":"63e5937500000591 Activation of the ribosome quality control by ZNF598 in response to ribosome collisions  leading to ubiquitination of RPS20 us10 and ribosome dissociation by the RQT complex  composed of ASCC2 and ASCC3  Human","text":"<p>Based on my review of the GO-CAM model (gomodel:63e5937500000591) and analysis of the supporting literature and information about the proteins involved, I can now provide a comprehensive review.</p>"},{"location":"reviews/63e5937500000591-Activation_of_the_ribosome_quality_control_by_ZNF598_in_response_to_ribosome_collisions__leading_to_ubiquitination_of_RPS20_us10_and_ribosome_dissociation_by_the_RQT_complex__composed_of_ASCC2_and_ASCC3__Human__/#review-of-go-cam-model-gomodel63e5937500000591","title":"Review of GO-CAM Model - gomodel:63e5937500000591","text":""},{"location":"reviews/63e5937500000591-Activation_of_the_ribosome_quality_control_by_ZNF598_in_response_to_ribosome_collisions__leading_to_ubiquitination_of_RPS20_us10_and_ribosome_dissociation_by_the_RQT_complex__composed_of_ASCC2_and_ASCC3__Human__/#model-overview","title":"Model Overview","text":"<p>The model titled \"Activation of the ribosome quality control by ZNF598 in response to ribosome collisions, leading to ubiquitination of RPS20/us10 and ribosome dissociation by the RQT complex, composed of ASCC2 and ASCC3 (Human)\" describes a key quality control pathway in translation regulation. The model captures the process by which stalled or collided ribosomes are detected, marked by ubiquitination, and subsequently dissociated to prevent the production of potentially harmful truncated proteins.</p>"},{"location":"reviews/63e5937500000591-Activation_of_the_ribosome_quality_control_by_ZNF598_in_response_to_ribosome_collisions__leading_to_ubiquitination_of_RPS20_us10_and_ribosome_dissociation_by_the_RQT_complex__composed_of_ASCC2_and_ASCC3__Human__/#model-components","title":"Model Components","text":"<p>The model consists of four main molecular activities:</p> <ol> <li>ZNF598 (UniProtKB:Q86UK7) - stalled ribosome sensor activity (GO:0170011)</li> <li>ZNF598 (UniProtKB:Q86UK7) - ubiquitin protein ligase activity (GO:0061630)</li> <li>ASCC2 (UniProtKB:Q9H1I8) - K63-linked polyubiquitin modification-dependent protein binding (GO:0070530)</li> <li>ASCC3 (UniProtKB:Q8N3C0) - ATP hydrolysis activity (GO:0016887)</li> </ol>"},{"location":"reviews/63e5937500000591-Activation_of_the_ribosome_quality_control_by_ZNF598_in_response_to_ribosome_collisions__leading_to_ubiquitination_of_RPS20_us10_and_ribosome_dissociation_by_the_RQT_complex__composed_of_ASCC2_and_ASCC3__Human__/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the current scientific understanding of the ribosome quality control (RQC) pathway as evidenced in the literature (particularly PMID:36302773 and PMID:30293783). The key findings supported by these papers include:</p> <ol> <li>ZNF598 functions as a sensor that specifically recognizes collided ribosomes</li> <li>ZNF598 mediates K63-linked polyubiquitination of uS10 (RPS20)</li> <li>ASCC2 specifically binds to K63-linked polyubiquitinated uS10 via its CUE domain</li> <li>ASCC3's ATPase activity is required for ribosome dissociation</li> <li>The hRQT complex (ASCC2, ASCC3, and TRIP4) works together to disassemble stalled ribosomes</li> </ol> <p>The causal relationships in the model follow the established pathway where ZNF598 first recognizes collided ribosomes, then ubiquitinates uS10, which is recognized by ASCC2, which then contributes to ASCC3's ribosome dissociation activity.</p>"},{"location":"reviews/63e5937500000591-Activation_of_the_ribosome_quality_control_by_ZNF598_in_response_to_ribosome_collisions__leading_to_ubiquitination_of_RPS20_us10_and_ribosome_dissociation_by_the_RQT_complex__composed_of_ASCC2_and_ASCC3__Human__/#adherence-to-go-cam-guidelines","title":"Adherence to GO-CAM Guidelines","text":"<ol> <li> <p>Component Representation: The model appropriately represents the key molecular functions of each protein involved in the process.</p> </li> <li> <p>Causal Relationships: The model correctly uses the \"RO:0002629\" (directly positively regulates) predicate to connect ZNF598's ubiquitin ligase activity to ASCC2's polyubiquitin binding activity, and to connect ASCC2's binding activity to ASCC3's ATP hydrolysis activity.</p> </li> <li> <p>Cellular Location: All activities are correctly annotated to occur in the cytosolic ribosome (GO:0022626).</p> </li> <li> <p>Process Representation: The activities are appropriately represented as part of biological processes - either \"rescue of stalled ribosome\" (GO:0072344) or \"ribosome disassembly\" (GO:0032790), which accurately reflect their roles.</p> </li> </ol>"},{"location":"reviews/63e5937500000591-Activation_of_the_ribosome_quality_control_by_ZNF598_in_response_to_ribosome_collisions__leading_to_ubiquitination_of_RPS20_us10_and_ribosome_dissociation_by_the_RQT_complex__composed_of_ASCC2_and_ASCC3__Human__/#suggested-improvements","title":"Suggested Improvements","text":"<p>While the model is scientifically accurate and well-constructed according to GO-CAM guidelines, a few enhancements could be considered:</p> <ol> <li> <p>Inclusion of TRIP4: The literature (particularly PMID:36302773) mentions that the complete hRQT complex consists of ASCC2, ASCC3, and TRIP4. While TRIP4 may have a less defined molecular role, its inclusion in the model would provide a more complete representation of the complex.</p> </li> <li> <p>Specification of Ubiquitination Target: It might be beneficial to more explicitly represent RPS20/uS10 as the target of ZNF598's ubiquitin ligase activity, perhaps by adding an annotation indicating the \"has input\" relationship.</p> </li> <li> <p>Representation of Ribosome Collision: The initial event that triggers this pathway - ribosome collision - could be more explicitly represented in the model to provide context for ZNF598's sensor activity.</p> </li> </ol>"},{"location":"reviews/63e5937500000591-Activation_of_the_ribosome_quality_control_by_ZNF598_in_response_to_ribosome_collisions__leading_to_ubiquitination_of_RPS20_us10_and_ribosome_dissociation_by_the_RQT_complex__composed_of_ASCC2_and_ASCC3__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of the ribosome quality control pathway triggered by ZNF598 in response to ribosome collisions. The model captures the causal flow from collision detection to ribosome dissociation, with appropriate molecular functions and relationships.</p> <p>The model is consistent with the evidence from the literature, particularly the most recent findings described in Narita et al. (2022) and Juszkiewicz et al. (2018), which establish that ZNF598 specifically recognizes collided ribosomes and marks them with K63-linked polyubiquitin chains, which are then recognized by ASCC2 to facilitate ASCC3-dependent ribosome dissociation.</p> <p>This model will be valuable for researchers studying translation quality control mechanisms and could serve as a foundation for more detailed models of the RQC pathway.</p>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/","title":"63e5937500001029 Inhibition of IFNB1 translation initiation by EIF4E2 in response to viral infection   Human Sars CoV 2","text":"<p>Based on my analysis of the GO-CAM model and related information, I'll now provide a comprehensive review.</p>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#review-of-go-cam-model-gomodel63e5937500001029","title":"Review of GO-CAM Model gomodel:63e5937500001029","text":""},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"Inhibition of IFNB1 translation initiation by EIF4E2 in response to viral infection. (Human/Sars-CoV-2)\" represents a molecular mechanism by which SARS-CoV-2 inhibits the host immune response. The model captures how the viral non-structural protein 2 (NSP2) enhances the function of the cellular GIGYF2/EIF4E2 translation repression complex to inhibit translation of IFNB1 (interferon beta), thereby suppressing antiviral immunity.</p>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#molecular-components-and-activities","title":"Molecular Components and Activities","text":"<p>The model includes four key proteins with their associated activities:</p> <ol> <li> <p>EIF4E2 (O60573): Enables RNA 7-methylguanosine cap binding activity (GO:0000340), which is part of the negative regulation of translational initiation process (GO:0045947). This protein, also known as 4EHP, is a cap-binding protein that can repress translation by competing with eIF4E but doesn't recruit the translation initiation machinery.</p> </li> <li> <p>GIGYF2 (Q6Y7W6): Enables molecular adaptor activity (GO:0060090), which is part of the negative regulation of translational initiation process (GO:0045947). GIGYF2 forms a complex with EIF4E2/4EHP to enhance translational repression.</p> </li> <li> <p>IFNB1 (P01574): Enables cytokine activity (GO:0005125) as part of the type I interferon-mediated signaling pathway (GO:0060337). This is the target of the translational repression.</p> </li> <li> <p>SARS-CoV-2 NSP2 (P0DTD1-PRO_0000449620): Enables molecular adaptor activity (GO:0060090) as part of the symbiont-mediated suppression of host translation initiation process (GO:0039606). NSP2 enhances the interaction between GIGYF2 and EIF4E2.</p> </li> </ol>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#causal-relationships","title":"Causal Relationships","text":"<p>The model employs three causal associations:</p> <ol> <li>NSP2 directly negatively regulates (RO:0002629) GIGYF2</li> <li>GIGYF2 directly positively regulates (RO:0002629) EIF4E2</li> <li>EIF4E2 causally precedes (RO:0002409) IFNB1</li> </ol> <p>These causal relationships capture how NSP2 enhances the ability of GIGYF2 to interact with EIF4E2, which then represses the translation of IFNB1 mRNA.</p>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is supported by evidence from several publications, particularly:</p> <ul> <li>PMID:35878012: Demonstrates that SARS-CoV-2 NSP2 interacts with GIGYF2 to enhance its binding to EIF4E2, thereby repressing IFNB1 translation.</li> <li>PMID:33581076: Shows how 4EHP/EIF4E2 mediates translational control of antiviral immunity by regulating IFNB1 expression.</li> </ul>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#model-quality-assessment","title":"Model Quality Assessment","text":""},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of how SARS-CoV-2 can inhibit the host interferon response through translational repression. The mechanism is consistent with published literature showing that:</p> <ol> <li>EIF4E2 (4EHP) is a cap-binding protein that can repress translation initiation</li> <li>GIGYF2 forms a complex with EIF4E2 to enhance translational repression</li> <li>SARS-CoV-2 NSP2 directly interacts with GIGYF2 to enhance the GIGYF2-EIF4E2 interaction</li> <li>This interaction leads to increased repression of IFNB1 mRNA translation</li> </ol>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li> <p>Proper use of molecular functions: Each protein is annotated with appropriate molecular functions (cap binding, molecular adaptor activity, cytokine activity).</p> </li> <li> <p>Proper biological process context: Activities are placed in appropriate biological process contexts.</p> </li> <li> <p>Appropriate causal relationships: The model uses appropriate causal relationship predicates to link the activities.</p> </li> <li> <p>Evidence support: Each activity and causal relationship is supported by experimental evidence from published literature.</p> </li> </ol>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, there are a few areas that could potentially be improved:</p> <ol> <li> <p>Clarification of causal relationships: The use of RO:0002629 (directly positively regulates) for the GIGYF2\u2192EIF4E2 relationship could be clarified, as GIGYF2 actually enhances EIF4E2's repressive function. While this technically does \"positively regulate\" EIF4E2's activity, it might be confusing since the overall effect is negative regulation of translation.</p> </li> <li> <p>Complex representation: According to the GO-CAM best practices document \"How to annotate complexes in GO-CAM,\" when the subunits carrying molecular activities are known (as they are in this case), each protein could be represented individually. The model does this properly, but it might be helpful to explicitly note that GIGYF2 and EIF4E2 form a functional complex.</p> </li> <li> <p>Mechanistic detail: The model could potentially include additional details about how EIF4E2 represses translation (by competing with eIF4E for cap binding without recruiting the translation machinery) and how NSP2 enhances the GIGYF2-EIF4E2 interaction.</p> </li> </ol>"},{"location":"reviews/63e5937500001029-Inhibition_of_IFNB1_translation_initiation_by_EIF4E2_in_response_to_viral_infection___Human_Sars_CoV_2_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of how SARS-CoV-2 NSP2 suppresses host interferon response through translational repression. The model effectively captures the key molecular components, their activities, and the causal relationships between them.</p> <p>The model provides valuable insight into a viral mechanism for evading host immunity, which could potentially inform therapeutic approaches aimed at blocking this interaction. The model follows GO-CAM best practices and is supported by appropriate evidence from the literature.</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/","title":"63e5937500001279 Extraction of mRNA from stalled ribosomes by the SKI complex  leading to recruitment of the PELO HBS1L complex that binds to stalled ribosomes  followed by ribosome dissociation by ABCE1  Human","text":"<p>Based on my review of the GO-CAM model gomodel:63e5937500001279 and all the relevant information, I'll now provide a comprehensive assessment.</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#review-of-go-cam-model-63e5937500001279","title":"Review of GO-CAM Model: 63e5937500001279","text":""},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#model-title","title":"Model Title","text":"<p>\"Extraction of mRNA from stalled ribosomes by the SKI complex, leading to recruitment of the PELO-HBS1L complex that binds to stalled ribosomes, followed by ribosome dissociation by ABCE1 (Human)\"</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents a pathway for rescuing stalled ribosomes in human cells. It depicts the sequential activities of: 1. The SKI complex (ComplexPortal:CPX-2736) extracting mRNA from stalled ribosomes 2. HBS1L (Q9Y450) as a GTPase that facilitates recruitment of PELO (Q9BRX2) 3. PELO (Q9BRX2) sensing stalled ribosomes 4. ABCE1 (P61221) dissociating the ribosome components</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#representation-quality","title":"Representation Quality","text":""},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model accurately captures the current understanding of the pathway as supported by the literature. The rescue of stalled ribosomes involves the SKI complex extracting mRNA from stalled ribosomes, followed by PELO/HBS1L recognition, and final dissociation by ABCE1. This agrees with the research in PMID:32006463 and PMID:27863242.</p> <p>The sequence of events is well represented: 1. SKI complex extracts mRNA via 3'-5' RNA helicase activity 2. HBS1L (GTPase) helps deliver PELO to the stalled ribosomes 3. PELO senses the stalled ribosomes and binds to them 4. ABCE1 acts as a ribosome splitting factor through its ATPase activity</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#term-usage","title":"Term Usage","text":"<p>The GO terms used in the model are appropriate: - GO:0034458 (3'-5' RNA helicase activity) for the SKI complex - GO:0003924 (GTPase activity) for HBS1L - GO:0170011 (stalled ribosome sensor activity) for PELO - GO:0017111 (ribonucleoside triphosphatase activity) for ABCE1</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships between activities are correctly represented using: - RO:0002629 (directly positively regulates) - appropriately used between activities that have a direct regulatory effect on each other - The flow is logical: SKI complex \u2192 HBS1L \u2192 PELO \u2192 ABCE1</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#cellular-context","title":"Cellular Context","text":"<p>All activities are correctly localized to GO:0022626 (cytosolic ribosome), which is the appropriate cellular component for this process.</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#biological-process-context","title":"Biological Process Context","text":"<p>Each activity is appropriately placed within its relevant biological process: - SKI complex activity is part of GO:0070478 (nuclear-transcribed mRNA catabolic process, 3'-5' exonucleolytic nonsense-mediated decay) - HBS1L and PELO activities are part of GO:0070966 (nuclear-transcribed mRNA catabolic process, no-go decay) - ABCE1 activity is part of GO:0032790 (ribosome disassembly)</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#evidence-quality","title":"Evidence Quality","text":"<p>The model uses high-quality evidence from primary literature: - PMID:32006463 - Recent study on the SKI complex's role in extracting mRNA - PMID:21448132 - Evidence for ABCE1's role in ribosome disassembly - PMID:27863242 - High-resolution structural studies of the PELO-HBS1L complex</p> <p>The evidence is appropriately cited with ECO:0000314 (direct assay evidence used in manual assertion) for most assertions, with one instance of ECO:0000250 (sequence similarity evidence) for HBS1L's GTPase activity.</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":""},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#complex-representation","title":"Complex Representation","text":"<p>The model follows GO-CAM best practices for representing complexes. The SKI complex (ComplexPortal:CPX-2736) is used as the entity that enables the 3'-5' RNA helicase activity, which is appropriate since the activity is a property of the complex as a whole rather than an individual protein.</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#causality-representation","title":"Causality Representation","text":"<p>The causal flow is clear and well-structured, following the biological sequence of events. The use of RO:0002629 (directly positively regulates) is appropriate for connecting molecular activities that directly regulate each other.</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#evidence-assignment","title":"Evidence Assignment","text":"<p>Each activity has appropriate evidence codes and references, with direct experimental evidence cited for most assertions.</p>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Additional Context for HBS1L Activity: The model could potentially benefit from more specific information about how HBS1L's GTPase activity is regulated or activated in the context of stalled ribosomes.</p> </li> <li> <p>Molecular Details of PELO Interaction: While PELO is correctly annotated with \"stalled ribosome sensor activity,\" additional details about how it recognizes stalled ribosomes (such as through its interaction with the mRNA channel) could enhance the model.</p> </li> <li> <p>Representation of ATP Hydrolysis: The model could be more explicit about ABCE1's ATP-dependent mechanism of action, perhaps through additional annotation of the ATPase activity and its regulation.</p> </li> </ol>"},{"location":"reviews/63e5937500001279-Extraction_of_mRNA_from_stalled_ribosomes_by_the_SKI_complex__leading_to_recruitment_of_the_PELO_HBS1L_complex_that_binds_to_stalled_ribosomes__followed_by_ribosome_dissociation_by_ABCE1__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 63e5937500001279 presents a high-quality representation of the pathway for rescuing stalled ribosomes in human cells. It accurately captures the sequential activities of the SKI complex, HBS1L, PELO, and ABCE1, with appropriate terms, relationships, and evidence. The model is consistent with current literature and follows GO-CAM best practices.</p> <p>The model successfully represents how these proteins work together to resolve stalled translation, an important quality control process in eukaryotic cells. The few suggested improvements would add additional context but do not detract from the overall quality and accuracy of the model.</p> <p>This GO-CAM provides valuable information about an important quality control pathway in human cells and will be useful for researchers studying translation regulation, RNA quality control, and related processes.</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/","title":"63f809ec00000347 TRIM60 mediated inhibition of NF kappa B signaling via TAB2 SUMOylation  Human","text":"<p>Based on all the information I've gathered, I'm now ready to review the GO-CAM model with ID gomodel:63f809ec00000347, which is titled \"TRIM60-mediated inhibition of NF-kappa-B signaling via TAB2 SUMOylation (Human)\".</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#go-cam-review-trim60-mediated-inhibition-of-nf-kappa-b-signaling-via-tab2-sumoylation-human","title":"GO-CAM Review: \"TRIM60-mediated inhibition of NF-kappa-B signaling via TAB2 SUMOylation (Human)\"","text":""},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#model-overview","title":"Model Overview","text":"<p>This model (https://bioregistry.io/go.model:63f809ec00000347) describes a molecular pathway in which TRIM60 functions as a SUMO E3 ligase that mediates the SUMOylation of TAB2, which in turn inhibits the NF-kappa-B signaling pathway by disrupting the TRAF6/TAB2/TAK1 complex. The model involves four proteins: 1. TRIM60 (Q495X7) - an E3 SUMO-protein ligase 2. TAB2 (Q9NYJ8) - an adaptor protein in the NF-kappa-B pathway 3. TRAF6 (Q9Y4K3) - an E3 ubiquitin ligase 4. MAP3K7/TAK1 (O43318) - a mitogen-activated protein kinase kinase kinase</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#model-structure-accuracy","title":"Model Structure &amp; Accuracy","text":"<p>The model represents the following causal relations: 1. TRIM60 has SUMO-ubiquitin ligase activity (GO:0140082) that directly negatively regulates TAB2's molecular adaptor activity. 2. TAB2 has molecular adaptor activity (GO:0060090) that provides input for TRAF6's ubiquitin ligase activity. 3. TRAF6 has ubiquitin protein ligase activity (GO:0061630) that directly positively regulates MAP3K7/TAK1's MAP kinase kinase kinase activity. 4. MAP3K7/TAK1 has MAP kinase kinase kinase activity (GO:0004709) as the downstream effector.</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model accurately represents the mechanism described in PMID:33184450, which shows that: 1. TRIM60 acts as an E3 SUMO ligase for TAB2 2. SUMOylation of TAB2 at residues K329 and K562 prevents the formation of the TRAF6/TAB2/TAK1 complex 3. This inhibits downstream NF-kappa-B and MAPK activation 4. TRIM60 deficiency results in enhanced inflammatory responses</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#biological-process-annotations","title":"Biological Process Annotations","text":"<p>The model annotates appropriate biological processes: - TRIM60: negative regulation of non-canonical NF-kappaB signal transduction (GO:1901223) - TAB2: non-canonical NF-kappaB signal transduction (GO:0038061) - TRAF6: protein K63-linked ubiquitination (GO:0070534) - MAP3K7/TAK1: canonical NF-kappaB signal transduction (GO:0007249)</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#cellular-component-annotations","title":"Cellular Component Annotations","text":"<p>All proteins are correctly annotated as occurring in the cytoplasm (GO:0005737), which is consistent with the subcellular localization of these proteins according to UniProt annotations.</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#evidence-references","title":"Evidence &amp; References","text":"<p>The model uses appropriate evidence codes and references: - Direct assay evidence (ECO:0000314) with references to relevant primary literature - Curator inference (ECO:0000305) where appropriate</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Specific Ubiquitination Type: The model annotates TRAF6 with protein K63-linked ubiquitination (GO:0070534), which is appropriate, but it could be helpful to specify which proteins are being ubiquitinated by TRAF6 in this context (e.g., autoubiquitination of TRAF6 or ubiquitination of TAB2).</p> </li> <li> <p>MAP3K7/TAK1 Downstream Effects: The model could potentially be extended to show what happens downstream of MAP3K7/TAK1 activation (e.g., activation of IKK complex and subsequent NF-kappa-B activation).</p> </li> <li> <p>Addition of UBC13/UEV1A: The in vitro ubiquitination studies mentioned in PMID:15465037 indicate that UBC13/UEV1A forms a complex with TRAF6 for its E3 ubiquitin ligase activity. Including these components could provide a more complete picture of the TRAF6-mediated ubiquitination process.</p> </li> </ol>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows best practices for GO-CAM curation: - It uses appropriate molecular function, biological process, and cellular component annotations - Causal relationships between activities are properly represented with the correct relations (RO:0002413, RO:0002629, RO:0002630) - The model captures a complete signaling pathway from initial regulator (TRIM60) to downstream effect (MAP3K7 activity) - The model is parsimonious and easy to understand</p>"},{"location":"reviews/63f809ec00000347-TRIM60_mediated_inhibition_of_NF_kappa_B_signaling_via_TAB2_SUMOylation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the TRIM60-mediated inhibition of NF-kappa-B signaling via TAB2 SUMOylation as described in the literature. It follows GO-CAM best practices and provides a clear representation of this regulatory mechanism. The model could be extended to include additional components or downstream effects, but as it stands, it captures the key aspects of this pathway effectively.</p>"},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/","title":"63f809ec00000512 Activity of the RQC complex via ubiquitination and degradation of incompletely synthesized nascent proteins  by NEMF and LTN1  following ribosome dissociation  Human","text":"<p>Based on all the information I've gathered, I'm now ready to review the GO-CAM model 63f809ec00000512.</p>"},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#review-of-go-cam-model-gomodel63f809ec00000512","title":"Review of GO-CAM Model: gomodel:63f809ec00000512","text":""},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Activity of the RQC complex via ubiquitination and degradation of incompletely synthesized nascent proteins (by NEMF and LTN1) following ribosome dissociation (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>This model represents the Ribosome Quality Control (RQC) pathway, which is responsible for the ubiquitin-mediated degradation of incompletely synthesized nascent proteins that occur during ribosome stalling.</p>"},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#key-proteins-in-the-model","title":"Key Proteins in the Model","text":"<ol> <li>LTN1 (UniProtKB:O94822) - E3 ubiquitin-protein ligase that targets nascent chains on stalled ribosomes</li> <li>NEMF (UniProtKB:O60524) - Ribosome quality control complex subunit that recruits LTN1 and mediates CAT tailing</li> <li>ABCE1 (UniProtKB:P61221) - ATP-binding cassette protein that mediates ribosome splitting</li> <li>ASCC3 (UniProtKB:Q8N3C0) - ATP-dependent helicase involved in ribosome disassembly</li> </ol>"},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#pathway-representation-and-biological-assessment","title":"Pathway Representation and Biological Assessment","text":"<p>The model correctly captures the key aspects of the RQC pathway as described in the literature:</p> <ol> <li> <p>ABCE1 (P61221) and ASCC3 (Q8N3C0) are properly represented with their ATP hydrolysis activities (GO:0017111 and GO:0016887 respectively) in ribosome disassembly (GO:0032790).</p> </li> <li> <p>O60524 (NEMF) is appropriately shown with its alpha-aminoacyl-tRNA binding activity (GO:1904678) located at the cytosolic ribosome (GO:0022626) and involved in CAT tailing (GO:0140708).</p> </li> <li> <p>LTN1 (O94822) is correctly modeled with its ubiquitin protein ligase activity (GO:0061630) at the cytosolic ribosome (GO:0022626) as part of the ribosome-associated ubiquitin-dependent protein catabolic process (GO:1990116).</p> </li> <li> <p>The causal relationships between activities are biologically accurate:</p> </li> <li>ABCE1 directly positively regulates (RO:0002629) NEMF's activity</li> <li>ASCC3 directly positively regulates (RO:0002629) NEMF's activity</li> <li>NEMF provides input for (RO:0002413) LTN1's ubiquitin ligase activity</li> <li>NEMF directly positively regulates (RO:0002629) O60524's CAT tailing activity</li> </ol>"},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate Biological Content: The model aligns well with the current literature on the RQC pathway. The interactions between ABCE1, NEMF, LTN1, and ASCC3 are supported by published evidence, particularly the PMID:25578875 paper that describes the structure and assembly pathway of the RQC complex.</p> </li> <li> <p>Proper Annotation of Subcellular Localization: All activities are correctly annotated to occur at the cytosolic ribosome (GO:0022626), consistent with the literature.</p> </li> <li> <p>Appropriate Evidence Citations: The model includes proper evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and PMIDs to support each activity and relationship.</p> </li> <li> <p>Parsimony: The model efficiently represents the key components and interactions of the RQC pathway without unnecessary complexity.</p> </li> </ol>"},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>NEMF Self-Regulation: There appears to be a self-regulation where NEMF directly positively regulates itself (the CAT tailing activity). This needs to be checked as it might be a modeling error.</p> </li> <li> <p>More Detailed Representation of ASCC3 Function: Recent literature (PMID:36302773) suggests a more specific role for ASCC3 in recognizing collided ribosomes, which could be represented more explicitly in the model.</p> </li> <li> <p>Mechanism of Ribosome Stalling: The model could benefit from including the events that lead to ribosome stalling, which is the initiating event for this pathway.</p> </li> <li> <p>Downstream Events: The model doesn't include the steps after ubiquitination, such as the recruitment of the proteasome and the actual degradation of the ubiquitinated nascent polypeptides.</p> </li> </ol>"},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#go-cam-best-practices-adherence","title":"GO-CAM Best Practices Adherence","text":"<p>The model follows GO-CAM best practices for representing activities and their causal relationships. It correctly:</p> <ol> <li>Uses specific gene products rather than complexes when the subunit carrying the activity is known</li> <li>Places activities in the proper cellular context</li> <li>Uses appropriate causal relationship predicates</li> <li>Includes accurate biological process annotations</li> </ol>"},{"location":"reviews/63f809ec00000512-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_NEMF_and_LTN1__following_ribosome_dissociation__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the RQC pathway in humans. The model is well-supported by literature evidence and follows GO-CAM best practices. The key components (ABCE1, ASCC3, NEMF, and LTN1) and their activities in ribosome disassembly, CAT tailing, and ubiquitination are correctly represented. The causal relationships between these activities are biologically accurate and supported by published evidence.</p> <p>The main area for improvement would be to address the potential self-regulation of NEMF and to possibly expand the model to include events upstream of ribosome stalling and downstream of ubiquitination. Overall, this model would be valuable for researchers studying quality control mechanisms during translation.</p>"},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/","title":"63f809ec00000560 Non canonical activity of the RQC complex via CAT tailing by NEMF that promotes degradation of incompletely synthesized nascent proteins by the DesCEND pathway  Human","text":"<p>Based on my research and analysis of the GO-CAM model <code>gomodel:63f809ec00000560</code>, I'll now provide a comprehensive review of the model.</p>"},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/#go-cam-model-review-gomodel63f809ec00000560","title":"GO-CAM Model Review: gomodel:63f809ec00000560","text":""},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Non-canonical activity of the RQC complex via CAT-tailing by NEMF that promotes degradation of incompletely synthesized nascent proteins by the DesCEND pathway (Human)</p> <p>ID: gomodel:63f809ec00000560</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/#model-content","title":"Model Content","text":"<p>This GO-CAM model represents the Ribosome-associated Quality Control (RQC) pathway, specifically focusing on the non-canonical activity via CAT-tailing (C-terminal Alanine Tailing) by NEMF that promotes degradation of incompletely synthesized nascent proteins through the DesCEND (destruction via C-end degrons) pathway in humans.</p> <p>The model includes five key activities:</p> <ol> <li>ATP hydrolysis activity of ASCC3 (Q8N3C0)</li> <li>Ribonucleoside triphosphate phosphatase activity of ABCE1 (P61221)</li> <li>Alpha-aminoacyl-tRNA binding activity of NEMF (O60524)</li> <li>Ribosomal large subunit binding activity of NEMF (O60524)</li> <li>Ubiquitin-like ligase-substrate adaptor activity of KLHDC10 (Q6PID8)</li> </ol> <p>These activities are connected by causal associations, representing the sequential steps in the RQC pathway.</p>"},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents current scientific understanding of the RQC pathway as described in the literature, particularly in the publications referenced in the model such as PMID:36302773 and PMID:33909987.</p> <p>The process described aligns with recent research showing that:</p> <ol> <li>Stalled ribosomes are detected and trigger the RQC pathway</li> <li>ASCC3 functions in the RQT (RQC-Trigger) complex to split collided ribosomes using ATP hydrolysis activity</li> <li>ABCE1 is involved in ribosome disassembly</li> <li>NEMF (Nuclear Export Mediator Factor) binds to the 60S ribosomal subunit and attaches alanine residues to the C-terminus of the nascent peptide (CAT-tailing)</li> <li>The resulting CAT-tailed peptides are recognized by KLHDC10 as part of the CRL2 E3 ligase complex, which targets them for ubiquitination and subsequent degradation</li> </ol>"},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/#go-cam-best-practices-review","title":"GO-CAM Best Practices Review","text":"<p>According to GO-CAM best practices for annotating complexes, the model follows appropriate guidelines by:</p> <ol> <li>Representing individual proteins with their specific known molecular functions, such as NEMF's alpha-aminoacyl-tRNA binding and ribosomal large subunit binding</li> <li>Using causal associations (RO:0002629 \"directly positively regulates\" and RO:0002413 \"provides input for\") to connect the activities appropriately</li> </ol> <p>The model correctly places each activity in appropriate cellular components (cytosolic ribosome GO:0022626 or cytoplasm GO:0005737) and biological processes (ribosome disassembly GO:0032790, rescue of stalled ribosome GO:0072344, CAT tailing GO:0140708, and ubiquitin-dependent protein catabolic process via the C-end degron rule pathway GO:0140627).</p>"},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model effectively captures the sequence of events in the non-canonical RQC pathway involving CAT-tailing by NEMF.</p> </li> <li> <p>Well-supported by evidence: All activities are linked to primary literature sources, with appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion).</p> </li> <li> <p>Clear causal associations: The model uses appropriate causal relationships to connect activities in a meaningful way that represents the biological process.</p> </li> <li> <p>Proper context specification: Each activity is properly contextualized with cellular component and biological process annotations.</p> </li> </ol>"},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Complete the ubiquitination pathway: The model could be expanded to include the complete ubiquitination and proteasomal degradation steps. While KLHDC10's adaptor activity is represented, the actual ubiquitin ligase activity and subsequent proteasomal degradation could be added to make the pathway complete.</p> </li> <li> <p>Add Pirh2/Rchy1 E3 ligase: According to PMID:33909987, both KLHDC10 and Pirh2/Rchy1 function as E3 ligases that recognize CAT-tailed proteins. Including Pirh2/Rchy1 would provide a more complete picture of the redundancy in this system.</p> </li> <li> <p>Consider including recycling factors: The model could potentially include additional factors involved in recycling or rescue of stalled ribosomes to provide a more comprehensive view of the process.</p> </li> <li> <p>Add stalling conditions or triggers: The model could be enhanced by including information about what causes ribosome stalling in the first place (e.g., translation of poly(A) stretches, XBP1u translation, etc.).</p> </li> </ol>"},{"location":"reviews/63f809ec00000560-Non_canonical_activity_of_the_RQC_complex_via_CAT_tailing_by_NEMF_that_promotes_degradation_of_incompletely_synthesized_nascent_proteins_by_the_DesCEND_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the non-canonical RQC pathway involving CAT-tailing by NEMF. The model follows GO-CAM best practices for annotating complexes and their activities and is well-supported by current scientific literature. The suggested improvements would mainly serve to expand the comprehensiveness of the model rather than correct any significant issues with the current representation.</p> <p>The model effectively captures a crucial protein quality control pathway that protects cells from potentially toxic incompletely synthesized proteins, which is important for cellular homeostasis and may have implications for understanding neurodegenerative diseases, as mutations in Listerin (the canonical RQC E3 ligase) cause neurodegeneration in mice.</p>"},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/","title":"63f809ec00000635 Activity of the RQC complex via ubiquitination and degradation of incompletely synthesized nascent proteins  by RQC2 and RKR1 LTN1  following ribosome dissociation  S cerevisiae","text":"<p>Based on my review of the GO-CAM model and the supporting literature, I'll now provide a comprehensive review of \"gomodel:63f809ec00000635\" titled \"Activity of the RQC complex via ubiquitination and degradation of incompletely synthesized nascent proteins (by RQC2 and RKR1/LTN1) following ribosome dissociation (S.cerevisiae)\".</p>"},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#review-of-go-cam-model-gomodel63f809ec00000635","title":"Review of GO-CAM Model gomodel:63f809ec00000635","text":""},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#overview","title":"Overview","text":"<p>This GO-CAM model describes the Ribosome-associated Quality Control (RQC) complex and its function in S. cerevisiae. The model represents how stalled ribosomes are recognized, dissociated, and how the incompletely synthesized nascent proteins are processed through ubiquitination and degradation.</p>"},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents key components of the RQC complex and their functions, which is consistent with current scientific understanding:</p> <ol> <li>The model correctly depicts the activity of SLH1 (SGD:S000003503) in ATP hydrolysis for ribosome disassembly</li> <li>The model shows RQC2 (SGD:S000005930) binding to the ribosomal large subunit and its role in CAT tailing</li> <li>The ubiquitin ligase activity of RKR1/LTN1 (SGD:S000004861) is properly annotated for targeting the nascent chains</li> <li>The adaptor functions of RQC1 (SGD:S000002741) and CDC48 (SGD:S000002284) are included</li> <li>The RNA endonuclease activity of VMS1 (SGD:S000002456) is represented correctly</li> </ol> <p>The causal relationships between the activities are generally appropriate and follow the RQC pathway as established in the literature.</p>"},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#curation-quality","title":"Curation Quality","text":""},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#strengths","title":"Strengths","text":"<ol> <li> <p>Evidence Support: All assertions are backed by primary research articles with appropriate ECO evidence codes (ECO:0000314 - direct assay evidence used in manual assertion).</p> </li> <li> <p>Proper Part-of Relationships: The model correctly places the molecular functions within appropriate biological processes (e.g., ribosome disassembly, rescue of stalled ribosome, CAT tailing).</p> </li> <li> <p>Correct Causal Relationships: The model uses appropriate causal relationship predicates between functions:</p> </li> <li>RO:0002629 (directly positively regulates) is used correctly to show how one activity promotes another</li> <li> <p>RO:0002413 (provides input for) is used correctly for showing sequential steps in the process</p> </li> <li> <p>Cellular Location: The model correctly places relevant activities in the cytosolic ribosome (GO:0022626).</p> </li> </ol>"},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Input-Output Relationships: While the model includes a \"has_output\" relationship for VMS1's RNA endonuclease activity producing tRNA precursor (CHEBI:10668), it could benefit from more input-output relationships for other activities. For example, including the ubiquitinated nascent chain as an output of RKR1's ubiquitin ligase activity would enhance completeness.</p> </li> <li> <p>RQC Complex Representation: The model represents individual components of the RQC complex but does not explicitly show them as part of a complex. According to the \"How to annotate complexes in GO-CAM\" guidelines, this approach is appropriate when the subunits carrying specific activities are known, which is the case here. However, it might be useful to add a note or annotation indicating these proteins form the RQC complex.</p> </li> <li> <p>CAT Tailing Mechanism: The CAT tailing process (GO:0140708) is included but could be more detailed about how RQC2 recruits tRNAs for adding alanine and threonine to the C-terminus of stalled nascent chains. The paper by Shen et al. (PMID:25554787) provides details about how RQC2 binds specific tRNAs (Ala-tRNA and Thr-tRNA) that could be included.</p> </li> <li> <p>Complete Pathway Representation: The model shows key steps but does not explicitly show the final degradation of the ubiquitinated nascent chain by the proteasome. Adding this final step would complete the pathway representation.</p> </li> </ol>"},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#technical-accuracy","title":"Technical Accuracy","text":"<ol> <li> <p>The annotations follow GO-CAM best practices for representing activities and their relationships.</p> </li> <li> <p>The E3 ubiquitin ligase activity of RKR1/LTN1 is appropriately annotated according to the \"E3 ubiquitin ligases\" guideline document. It correctly uses ubiquitin protein ligase activity (GO:0061630) and places it in the ribosome-associated ubiquitin-dependent protein catabolic process (GO:1990116).</p> </li> <li> <p>The causal relationships used are consistent with the \"Regulation and Regulatory Processes in GO-CAM\" guidelines, using specific causal relationship predicates.</p> </li> </ol>"},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#recommendations-for-enhancement","title":"Recommendations for Enhancement","text":"<ol> <li> <p>Add Proteasomal Degradation Step: Include the final step where the ubiquitinated nascent chain is degraded by the proteasome to complete the pathway.</p> </li> <li> <p>Expand Input-Output Relationships: Add more has_input and has_output relationships to better represent the molecular entities being processed through the pathway.</p> </li> <li> <p>Include Stalling Trigger: Consider adding information about what causes ribosome stalling (e.g., translation of poly(A) tail in nonstop mRNA, rare codon stretches) as context for the beginning of the pathway.</p> </li> <li> <p>Add Information about CAT Tail Function: The model could indicate that CAT tails help expose lysine residues for ubiquitination and can also promote aggregation when ubiquitination fails.</p> </li> <li> <p>Connect to Downstream Stress Response: If applicable, consider extending the model to show how defects in this pathway can trigger cellular stress responses like HSF1 activation, as mentioned in Shen et al. (PMID:25554787).</p> </li> </ol>"},{"location":"reviews/63f809ec00000635-Activity_of_the_RQC_complex_via_ubiquitination_and_degradation_of_incompletely_synthesized_nascent_proteins__by_RQC2_and_RKR1_LTN1__following_ribosome_dissociation__S_cerevisiae__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:63f809ec00000635 is a biologically accurate and well-structured representation of the RQC complex in S. cerevisiae. It correctly captures the key molecular players and their causal relationships in handling stalled ribosomes and incompletely synthesized nascent proteins. With some minor enhancements to show additional details and connections, the model would provide an even more comprehensive view of this important quality control mechanism.</p> <p>The model adheres to GO-CAM best practices and effectively represents the current scientific understanding of the Ribosome-associated Quality Control pathway.</p>"},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/","title":"63f809ec00000701 tRNA repair and recycling by ANKZF1  ELAC1 and TRNT1 following activity of the RQC complex in response to stalled ribosomes  Human","text":"<p>Now I understand the model better. Let me systematically review it against GO-CAM best practices.</p>"},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/#review-of-go-cam-model-gomodel63f809ec00000701","title":"Review of GO-CAM Model gomodel:63f809ec00000701","text":""},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/#model-information","title":"Model Information","text":"<p>Title: tRNA repair and recycling by ANKZF1, ELAC1 and TRNT1 following activity of the RQC complex in response to stalled ribosomes (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/#summary-of-the-pathway","title":"Summary of the Pathway","text":"<p>This GO-CAM model represents the process of tRNA repair and recycling that occurs following the activity of the Ribosome Quality Control (RQC) complex in response to stalled ribosomes. The pathway involves three main proteins:</p> <ol> <li>NEMF (O60524) - Part of the RQC complex that binds to stalled ribosomes</li> <li>ANKZF1 (Q9H8Y5) - RNA endonuclease that cleaves tRNA during rescue of stalled ribosomes</li> <li>ELAC1 (Q9H777) - tRNA-specific ribonuclease that processes cleaved tRNAs</li> <li>TRNT1 (Q96Q11) - CCA tRNA nucleotidyltransferase that adds CCA to the 3' end of tRNAs</li> </ol>"},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/#pathway-connectivity-review","title":"Pathway Connectivity Review","text":"<p>The model shows a coherent causal pathway:</p> <ol> <li>NEMF (O60524) performs alpha-aminoacyl-tRNA binding (GO:1904678) in the cytosolic ribosome (GO:0022626) during CAT tailing (GO:0140708)</li> <li>NEMF positively regulates (RO:0002304) ANKZF1's RNA endonuclease activity</li> <li>ANKZF1 (Q9H8Y5) performs RNA endonuclease activity (GO:0004521) during rescue of stalled ribosome (GO:0072344), with tRNA precursor as output</li> <li>ANKZF1 positively regulates (RO:0002629) ELAC1's ribonuclease activity</li> <li>ELAC1 (Q9H777) has tRNA-specific ribonuclease activity (GO:0004549) in tRNA 3'-end processing (GO:0042780), with tRNA precursor as input</li> <li>ELAC1 positively regulates (RO:0002629) TRNT1's nucleotidyltransferase activity</li> <li>TRNT1 (Q96Q11) has CCA tRNA nucleotidyltransferase activity (GO:0004810) in tRNA 3'-terminal CCA addition (GO:0001680)</li> </ol>"},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model correctly represents the biological process of tRNA repair and recycling during ribosome quality control.</li> <li>The pathway is coherent and the causal connections properly describe the flow of the process.</li> <li>Each protein activity is assigned to the appropriate protein based on UniProt information.</li> <li>All annotations are supported by appropriate evidence (literature references).</li> <li>The model correctly uses appropriate GO terms for molecular functions and biological processes.</li> <li>All activities are properly connected with appropriate causal relations.</li> </ol>"},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/#evaluation-against-go-cam-best-practices","title":"Evaluation Against GO-CAM Best Practices","text":"<ol> <li>Activity-centric modeling: The model correctly focuses on specific molecular activities of proteins.</li> <li>Causal relations: The model correctly uses causal relations (RO:0002304 and RO:0002629) to link activities.</li> <li>Evidence: Each activity and causal link is supported by evidence from the literature.</li> <li>Part_of annotations: Each activity is correctly annotated as being part of appropriate biological processes.</li> <li>Input/output annotations: Appropriate input/output annotations are used (e.g., tRNA precursor as input/output).</li> <li>Cellular locations: The model includes cellular component information (cytosolic ribosome for NEMF).</li> </ol>"},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/#alignment-with-the-literature","title":"Alignment with the Literature","text":"<p>The model accurately represents the process described in the literature: - PMID:31011209 describes the mechanism for recycling tRNAs on stalled ribosomes - PMID:32075755 explains how ELAC1 repairs tRNAs cleaved during ribosome-associated quality control - PMID:33909987 details the convergence of mammalian RQC and C-end rule proteolytic pathways via alanine tailing</p>"},{"location":"reviews/63f809ec00000701-tRNA_repair_and_recycling_by_ANKZF1__ELAC1_and_TRNT1_following_activity_of_the_RQC_complex_in_response_to_stalled_ribosomes__Human_/#recommendations","title":"Recommendations","text":"<p>Based on my review, the model is sound and accurately represents the biology. No changes are needed as it: 1. Follows the GO-CAM best practices 2. Is consistent with the literature 3. Accurately represents the protein activities and their connections 4. Is properly annotated with evidence</p> <p>The model effectively captures the tRNA repair and recycling pathway following RQC complex activity in response to stalled ribosomes, showing how NEMF, ANKZF1, ELAC1, and TRNT1 work together to process and recycle tRNAs.</p>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/","title":"63f809ec00001358 ARKL1 negatively negulates Epstein Barr virus reactivation by inhibiting JUN mediated transcription   Human Epstein Barr virus","text":"<p>Now I'll review the GO-CAM model based on all the information I've gathered. Let me first summarize the model and its components:</p>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#review-of-go-cam-model-gomodel63f809ec00001358","title":"Review of GO-CAM Model: gomodel:63f809ec00001358","text":""},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"ARKL1 negatively negulates Epstein-Barr virus reactivation by inhibiting JUN-mediated transcription (Human-Epstein-Barr virus)\" represents a molecular pathway involving human and viral proteins that regulate Epstein-Barr virus (EBV) reactivation from latency.</p>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#key-components-of-the-model","title":"Key Components of the Model","text":""},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#activities-in-the-model","title":"Activities in the Model:","text":"<ol> <li> <p>BZLF1 (P03206) - A viral transcription factor with DNA-binding transcription factor activity (GO:0003700) that occurs in chromatin (GO:0000785) and is part of release from viral latency (GO:0019046)</p> </li> <li> <p>JUN (P05412) - Human transcription factor with DNA-binding transcription factor activity (GO:0003700) that occurs in chromatin (GO:0000785) and is part of release from viral latency (GO:0019046). JUN directly activates BZLF1's transcription activity.</p> </li> <li> <p>ARKL1/ARK2N (Q96B23) - Human protein with transcription corepressor activity (GO:0003714) that occurs in chromatin (GO:0000785) and is part of negative regulation of viral life cycle (GO:1903901). ARKL1 directly negatively regulates JUN's transcription factor activity.</p> </li> <li> <p>CSNK2B (P67870) - Casein kinase II subunit beta with protein-macromolecule adaptor activity (GO:0030674) that occurs in chromatin (GO:0000785) and is part of negative regulation of viral life cycle (GO:1903901). CSNK2B directly positively regulates both ARKL1's corepressor activity and JUN's transcription factor activity.</p> </li> </ol>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#causal-relationships","title":"Causal Relationships:","text":"<ul> <li>CSNK2B directly positively regulates ARKL1 (RO:0002629)</li> <li>CSNK2B directly positively regulates JUN (RO:0002629)  </li> <li>ARKL1 directly negatively regulates JUN (RO:0002630)</li> <li>JUN is involved in transcription regulation of BZLF1 (RO:0002407)</li> </ul>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is strongly supported by the scientific literature:</p> <ul> <li>PMID:31341047 describes how ARKL1 acts as a negative regulator of EBV reactivation by inhibiting JUN's transcriptional activity.</li> <li>PMID:34893887 provides details about BZLF1's role as the EBV lytic switch protein that controls viral reactivation from latency.</li> <li>The UniProt entries confirm the described molecular functions of these proteins.</li> </ul>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#go-cam-quality-review","title":"GO-CAM Quality Review","text":""},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li>Accurate molecular functions: The assigned molecular functions align with known activities of these proteins.</li> <li>Proper causal relationships: The causal relationships between proteins correctly represent the biological mechanism.</li> <li>Proper context: All activities are appropriately contextualized with cellular components and biological processes.</li> <li>Evidence-based: All activities and relationships are supported by published evidence.</li> </ol>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing activity relationships: The model could more clearly specify whether ARKL1's inhibition of JUN is dependent on CSNK2B-mediated adaptor activity or whether CSNK2B brings ARKL1 and JUN together.</p> </li> <li> <p>Adaptor mechanism clarification: According to the molecular adaptor activity guidelines, CSNK2B's adaptor activity should have \"has input\" relationships to both ARKL1 and JUN to clarify that it brings these proteins together. From the literature (specifically PMID:31341047), it appears that CSNK2B mediates the interaction between ARKL1 and JUN, acting as a molecular bridge.</p> </li> <li> <p>Biological process assignment: While BZLF1 and JUN are appropriately assigned to \"release from viral latency\" (GO:0019046), the model could be enhanced by specifying the exact transcriptional targets beyond BZLF1 itself.</p> </li> </ol>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Clarify adaptor mechanism: Add explicit \"has input\" relationships from CSNK2B's adaptor activity to both ARKL1 and JUN to better represent its role as a molecular adaptor that brings these proteins together.</p> </li> <li> <p>Refine process annotations: Consider adding more specific biological process terms to better characterize the exact mechanisms of viral latency regulation.</p> </li> <li> <p>Consider adding protein complex: If the literature supports it, consider representing the CSNK2B-ARKL1-JUN complex explicitly, following the GO-CAM complex annotation guidelines.</p> </li> </ol>"},{"location":"reviews/63f809ec00001358-ARKL1_negatively_negulates_Epstein_Barr_virus_reactivation_by_inhibiting_JUN_mediated_transcription___Human_Epstein_Barr_virus_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the biological mechanism of how ARKL1 negatively regulates EBV reactivation by inhibiting JUN-mediated transcription, with CSNK2B serving as an adaptor protein. The minor suggested improvements would enhance the clarity and completeness of the model while maintaining its biological accuracy.</p> <p>The model follows GO-CAM best practices by representing the transcription factor activities (BZLF1, JUN), transcription coregulator activity (ARKL1), and adaptor activity (CSNK2B) in accordance with the relevant guidelines. The causal relationships are also correctly defined using the appropriate predicates for direct positive and negative regulation.</p>"},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/","title":"63f809ec00001734 TGF beta mediated inhibition of TAF7 via TRIM26","text":"<p>Based on the information I have examined, I will now provide a comprehensive review of GO-CAM model gomodel:63f809ec00001734 titled \"TGF-beta-mediated inhibition of TAF7 via TRIM26\".</p>"},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/#go-cam-review-tgf-beta-mediated-inhibition-of-taf7-via-trim26-gomodel63f809ec00001734","title":"GO-CAM Review: TGF-beta-mediated inhibition of TAF7 via TRIM26 (gomodel:63f809ec00001734)","text":""},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/#overall-summary","title":"Overall Summary","text":"<p>This model represents a signaling pathway in which TGF-beta1 (TGFB1) signaling leads to inhibition of transcription through a cascade involving SMAD3, MYC, and TRIM26-mediated ubiquitination of TAF7. The model appears to be based primarily on findings from PMID:29203640, which demonstrated that TGF-beta induces growth arrest through TRIM26-dependent degradation of TAF7, with MYC antagonizing this process.</p>"},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/#biological-context-and-pathway-logic","title":"Biological Context and Pathway Logic","text":"<p>The model demonstrates how TGF-beta signaling can inhibit cell proliferation by downregulating transcription. The pathway follows this logical sequence: 1. TGFB1 cytokine activity initiates SMAD signaling 2. SMAD3 activates DNA-binding transcription factor activity 3. SMAD3 provides input for TRIM26 ubiquitin ligase activity 4. TRIM26 directly negatively regulates TAF7 5. TAF7 normally functions as an RNA polymerase II general transcription initiation factor 6. MYC antagonizes SMAD3 signaling through negative regulation</p> <p>The model shows that MYC's transcription repressor activity opposes SMAD3 signaling in this pathway, which aligns with the findings from the literature that MYC antagonizes TGF-beta-induced proliferative arrest.</p>"},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/#technical-evaluation","title":"Technical Evaluation","text":""},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/#entity-annotation-and-molecular-functions","title":"Entity Annotation and Molecular Functions","text":"<p>The model includes five key activities involving different proteins:</p> <ol> <li>TGFB1 cytokine activity (GO:0005125)</li> <li>Enabled by TGFB1 (UniProtKB:P01137)</li> <li>Occurs in extracellular space (GO:0005615)</li> <li> <p>Part of SMAD protein signal transduction (GO:0060395)</p> </li> <li> <p>DNA-binding transcription factor activity (GO:0003700)</p> </li> <li>Enabled by SMAD3 (UniProtKB:P84022)</li> <li>Occurs in nucleus (GO:0005634)</li> <li> <p>Part of SMAD protein signal transduction (GO:0060395)</p> </li> <li> <p>Ubiquitin protein ligase activity (GO:0061630)</p> </li> <li>Enabled by TRIM26 (UniProtKB:Q12899)</li> <li>Occurs in nucleus (GO:0005634)</li> <li> <p>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</p> </li> <li> <p>RNA polymerase II general transcription initiation factor activity (GO:0016251)</p> </li> <li>Enabled by TAF7 (UniProtKB:Q15545)</li> <li>Occurs in nucleus (GO:0005634)</li> <li> <p>Part of positive regulation of transcription by RNA polymerase II (GO:0045944)</p> </li> <li> <p>DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227)</p> </li> <li>Enabled by MYC (UniProtKB:P01106)</li> <li>Occurs in nucleus (GO:0005634)</li> <li>Part of negative regulation of transcription initiation by RNA polymerase II (GO:0060633)</li> </ol> <p>All entities have appropriate molecular functions, cellular components, and are placed within relevant biological processes.</p>"},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/#causal-relationships","title":"Causal Relationships","text":"<p>The model uses three causal relationships: 1. TGFB1 <code>provides input for</code> (RO:0002407) SMAD3 2. SMAD3 <code>provides input for</code> (RO:0002407) TRIM26 3. TRIM26 <code>directly negatively regulates</code> (RO:0002630) TAF7 4. MYC <code>regulates via a negative effect</code> (RO:0012010) SMAD3</p> <p>These causal relations appropriately capture the regulatory relationships described in the reference paper.</p>"},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/#improvement-suggestions","title":"Improvement Suggestions","text":"<p>Based on GO-CAM best practices, I have the following recommendations:</p> <ol> <li> <p>Evidence Citations: The evidence is primarily from a single paper (PMID:29203640), which is appropriate. However, additional supporting evidence for the core mechanisms could strengthen the model.</p> </li> <li> <p>Complex Representation: Currently the model does not represent any protein complexes. According to the \"How to annotate complexes in GO-CAM\" document, if specific activities are carried out by individual proteins within a complex (as is the case here), then representing them as separate entities is appropriate.</p> </li> <li> <p>Regulatory Process Representation: The model follows the guidelines for regulatory processes by showing specific mechanisms and capturing the negative regulatory effect of TRIM26 on TAF7.</p> </li> <li> <p>Additional Mechanistic Details: If available from the literature, the model could be enhanced by including:</p> </li> <li>The specific E2 ubiquitin-conjugating enzyme that works with TRIM26</li> <li>The specific lysine residues on TAF7 that are ubiquitinated</li> <li> <p>Additional downstream effects of TAF7 degradation</p> </li> <li> <p>Cell Type Context: Adding information about the specific cell types where this pathway has been demonstrated would enhance the biological context.</p> </li> </ol>"},{"location":"reviews/63f809ec00001734-TGF_beta_mediated_inhibition_of_TAF7_via_TRIM26/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"TGF-beta-mediated inhibition of TAF7 via TRIM26\" effectively captures a signaling pathway from TGF-beta through SMAD3 and TRIM26 to the negative regulation of TAF7, with antagonism by MYC. The model follows GO-CAM best practices for representing regulatory relationships and protein activities.</p> <p>The model is well-constructed and represents the biological knowledge from the literature accurately. The entities have appropriate molecular function annotations, and the causal relationships between activities reflect our understanding of the pathway. Minor enhancements could be made to add more mechanistic details and cellular context, but overall, this is a high-quality GO-CAM model.</p>"},{"location":"reviews/6413ac9800000256-MYD88_dependent_TLR4_signaling_pathway_leading_to_autophagy_activation__Human_/","title":"6413ac9800000256 MYD88 dependent TLR4 signaling pathway leading to autophagy activation  Human","text":"<p>Based on my review of the GO-CAM model \"6413ac9800000256\" titled \"MYD88-dependent TLR4 signaling pathway leading to autophagy activation (Human)\" and the relevant literature, I'll now provide a comprehensive review:</p>"},{"location":"reviews/6413ac9800000256-MYD88_dependent_TLR4_signaling_pathway_leading_to_autophagy_activation__Human_/#go-cam-model-review-gomodel6413ac9800000256","title":"GO-CAM Model Review: gomodel:6413ac9800000256","text":""},{"location":"reviews/6413ac9800000256-MYD88_dependent_TLR4_signaling_pathway_leading_to_autophagy_activation__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the MYD88-dependent TLR4 signaling pathway leading to autophagy activation in humans. It captures a signaling cascade from TLR4 receptor activity at the plasma membrane through a series of molecular adaptors and kinases, ultimately resulting in autophagosome assembly through phosphatidylinositol 3-kinase activity.</p>"},{"location":"reviews/6413ac9800000256-MYD88_dependent_TLR4_signaling_pathway_leading_to_autophagy_activation__Human_/#pathway-structure-and-flow","title":"Pathway Structure and Flow","text":"<p>The model shows the following causal chain: 1. TLR4 (O00206) signaling receptor activity at plasma membrane \u2192  2. TIRAP (P58753) molecular adaptor activity \u2192  3. MYD88 (Q99836) molecular adaptor activity \u2192  4. IRAK4 (Q9NWZ3) protein serine/threonine kinase activity \u2192  5. IRAK2 (O43187) molecular adaptor activity \u2192  6. TRAF6 (Q9Y4K3) ubiquitin protein ligase activity \u2192  7. BECN1 (Q14457) molecular adaptor activity \u2192  8. PIK3C3/VPS34 (Q8NEB9) phosphatidylinositol kinase activity</p> <p>The model correctly uses the causal relation <code>RO:0002629</code> (directly positively regulates) for all connections in the pathway, creating a coherent signal flow from the plasma membrane receptor to autophagosome assembly.</p>"},{"location":"reviews/6413ac9800000256-MYD88_dependent_TLR4_signaling_pathway_leading_to_autophagy_activation__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological accuracy: The model correctly captures the known signaling pathway from TLR4 activation to autophagy, supported by literature including PMID:33637724 which describes VPS34's role in autophagosome formation.</p> </li> <li> <p>Subcellular localization: Each activity is appropriately associated with a cellular location (plasma membrane for receptors, cytoplasm for downstream components).</p> </li> <li> <p>Evidence: All activities and causal relationships are supported by appropriate literature evidence using ECO codes.</p> </li> <li> <p>Consistent use of causal relations: The model appropriately uses <code>RO:0002629</code> (directly positively regulates) for adjacent steps in the pathway.</p> </li> <li> <p>Process contextualization: Activities are properly contextualized within biological processes (e.g., TLR4 signaling pathway, autophagosome assembly).</p> </li> </ol>"},{"location":"reviews/6413ac9800000256-MYD88_dependent_TLR4_signaling_pathway_leading_to_autophagy_activation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing lipopolysaccharide input: While CHEBI:16412 (lipopolysaccharide) is listed in the objects, it's not shown as the initiating input for TLR4 activation. A causal relation showing LPS providing input to TLR4 would improve the model.</p> </li> <li> <p>Additional pathway branches: The model focuses on a single linear pathway, but TLR4 signaling typically branches to multiple downstream targets. If evidence exists, the model could be expanded to show additional branches.</p> </li> <li> <p>Molecular complex representation: According to the \"How to annotate complexes in GO-CAM\" document, if specific subunits carrying molecular activities are known (as in this case), they should be represented directly. The model correctly does this, but it might be helpful to also indicate which proteins form functional complexes.</p> </li> <li> <p>Specific mechanism details: For TRAF6's regulation of BECN1, additional mechanistic details could be added. From the PMID:33637724 paper, we know that ubiquitination plays a key role in this regulation.</p> </li> <li> <p>Feedback regulation: The model doesn't capture any potential feedback regulation mechanisms that might exist in this pathway, which could be added if supported by evidence.</p> </li> </ol>"},{"location":"reviews/6413ac9800000256-MYD88_dependent_TLR4_signaling_pathway_leading_to_autophagy_activation__Human_/#accuracy-of-individual-components","title":"Accuracy of Individual Components","text":"<ol> <li> <p>PIK3C3/VPS34 (Q8NEB9): The representation as having phosphatidylinositol kinase activity and being involved in autophagosome assembly is accurate and supported by UniProt information and the literature (PMID:33637724).</p> </li> <li> <p>TLR4 signaling components: The representation of the TLR4 signaling cascade through TIRAP, MYD88, IRAK4, IRAK2, and TRAF6 is consistent with established knowledge of this pathway.</p> </li> <li> <p>BECN1's role: The model correctly positions BECN1 as a molecular adaptor in autophagy, which is consistent with its known function in the VPS34 complex.</p> </li> </ol>"},{"location":"reviews/6413ac9800000256-MYD88_dependent_TLR4_signaling_pathway_leading_to_autophagy_activation__Human_/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that accurately represents the MYD88-dependent TLR4 signaling pathway leading to autophagy activation. It correctly captures the key molecular functions, cellular locations, and causal relationships in this pathway. The model could be enhanced by explicitly showing the LPS trigger and potentially expanding to include additional pathway branches or feedback mechanisms. Overall, the model meets GO-CAM best practices and provides a valuable representation of this important cellular signaling pathway.</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/","title":"6413ac9800000654 MYD88 independent TLR4 signaling pathway leading to interferon production  Human","text":"<p>Based on my review of the model and the associated literature, I'll now provide a comprehensive review of GO-CAM model 6413ac9800000654.</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#review-of-go-cam-model-6413ac9800000654","title":"Review of GO-CAM Model: 6413ac9800000654","text":""},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the \"MYD88-independent TLR4 signaling pathway leading to interferon production (Human)\" and illustrates the signaling cascade from TLR4 activation to IRF3-mediated transcription of interferon genes.</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#model-structure-assessment","title":"Model Structure Assessment","text":""},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#pathway-connectivity-and-biological-accuracy","title":"Pathway Connectivity and Biological Accuracy","text":"<p>The model correctly captures the key components of the MyD88-independent TLR4 signaling pathway leading to type I interferon production. The causal flow of activities follows the established mechanism:</p> <ol> <li>TLR4 (O00206) initiates the pathway through its signaling receptor activity</li> <li>TICAM2/TRAM (Q86XR7) acts as a molecular adaptor</li> <li>TICAM1/TRIF (Q8IUC6) acts as another molecular adaptor downstream</li> <li>TRAF3 (Q13114) functions as an E3 ubiquitin ligase </li> <li>TBK1 (Q9UHD2) works as a protein serine/threonine kinase</li> <li>IRF3 (Q14653) functions as a DNA-binding transcription factor</li> </ol> <p>This causal flow accurately represents the scientifically established pathway where TLR4 signals through TRAM and TRIF to activate TBK1, which phosphorylates IRF3, leading to interferon gene expression.</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#go-term-usage","title":"GO Term Usage","text":"<p>The molecular functions assigned to each protein are appropriate: - TLR4: GO:0038023 (signaling receptor activity) - TICAM2: GO:0060090 (molecular adaptor activity) - TICAM1: GO:0060090 (molecular adaptor activity) - TRAF3: GO:0061630 (ubiquitin protein ligase activity) - TBK1: GO:0004674 (protein serine/threonine kinase activity) - IRF3: GO:0003700 (DNA-binding transcription factor activity)</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#cellular-location-annotation","title":"Cellular Location Annotation","text":"<p>The model appropriately captures the subcellular locations where these activities occur: - TLR4 activity: GO:0010008 (endosome membrane) - This is correct as the literature indicates that MyD88-independent signaling occurs after TLR4 is internalized to endosomes - TICAM2/TRAM: GO:0010008 (endosome membrane) - TICAM1/TRIF: GO:0010008 (endosome membrane) - TRAF3: GO:0010008 (endosome membrane) - TBK1: GO:0005737 (cytoplasm) - IRF3: GO:0000785 (chromatin)</p> <p>These locations align with the reviewed literature, particularly the findings from Tanimura et al. (2008) and Funami et al. (2017) that establish the endosomal localization of this signaling pathway.</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#causal-relations","title":"Causal Relations","text":"<p>The model uses the appropriate causal relation \"RO:0002629\" (directly positively regulates) to connect the activities in the pathway, which accurately represents how each protein directly activates the downstream component: - TLR4 directly positively regulates TICAM2/TRAM - TICAM2/TRAM directly positively regulates TICAM1/TRIF - TICAM1/TRIF directly positively regulates TRAF3 - TRAF3 directly positively regulates TBK1 - TBK1 directly positively regulates IRF3</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>The model includes appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and relevant PMIDs for each component and relation, which provides solid scientific grounding for the model: - PMID:18222170 establishes TLR4's endosomal localization - PMID:28630139 details the TICAM2-TICAM1 relationship - PMID:12471095 documents the role of TICAM1 - PMID:19898473 supports TRAF3's role in the pathway - PMID:14703513 establishes TBK1's role in IRF3 phosphorylation - PMID:8524823 and PMID:25636800 document IRF3's function</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#alignment-with-go-cam-best-practices","title":"Alignment with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by: 1. Clearly defining each protein's molecular activity 2. Establishing specific cellular locations for each activity 3. Connecting activities through appropriate causal relations 4. Including all activities within the broader biological process (GO:0034142 - toll-like receptor 4 signaling pathway) 5. Including evidence codes and literature references</p>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#specific-observations","title":"Specific Observations","text":"<ol> <li> <p>Appropriate Representation of Adaptor Molecules: The model correctly represents TICAM2/TRAM and TICAM1/TRIF as adaptors with molecular adaptor activity (GO:0060090), which aligns with the guidance in GO-CAM documentation.</p> </li> <li> <p>Endosomal Localization: The model correctly captures that the MyD88-independent pathway operates from endosomal membranes rather than the plasma membrane, which is crucial for IRF3 activation and type I interferon production.</p> </li> <li> <p>IRF3 Transcription Factor Activity: The model appropriately represents IRF3's final role as a DNA-binding transcription factor that occurs in chromatin.</p> </li> </ol>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Consider TICAM1-TRAF3 Complex Formation: The literature suggests that TICAM1/TRIF forms distinct signaling complexes with TRAF3. The model could potentially be enhanced by representing this complex formation more explicitly.</p> </li> <li> <p>Include Additional Co-regulators: While the core pathway is well-represented, the model could be enhanced by including additional regulatory components like TBK1-IKK\u03b5 interactions in IRF3 phosphorylation.</p> </li> <li> <p>Representation of IRF3 Phosphorylation State: The model could potentially benefit from explicitly representing the phosphorylated state of IRF3, as this is a critical step for its activation, dimerization, and nuclear translocation.</p> </li> </ol>"},{"location":"reviews/6413ac9800000654-MYD88_independent_TLR4_signaling_pathway_leading_to_interferon_production__Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 6413ac9800000654 accurately represents the MyD88-independent TLR4 signaling pathway leading to interferon production in humans. The model effectively captures the causal flow from receptor activation to transcription factor activity, with appropriate molecular functions, cellular locations, and causal relationships. The model is well-supported by scientific literature and follows GO-CAM best practices. While there are minor areas for potential enhancement, the current model provides a clear and accurate representation of this important signaling pathway.</p>"},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/","title":"641ce4dc00000050 NOD2 signaling in response to muramyl dipeptide  MDP   leading to NF kappa B and MAPK kinase activation   Human","text":"<p>Based on my review of the GO-CAM model gomodel:641ce4dc00000050, titled \"NOD2 signaling in response to muramyl dipeptide (MDP) leading to NF-kappa-B and MAPK kinase activation (Human)\", I can provide the following analysis:</p>"},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/#go-cam-review-nod2-signaling-pathway-gomodel641ce4dc00000050","title":"GO-CAM Review: NOD2 Signaling Pathway (gomodel:641ce4dc00000050)","text":""},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the NOD2 signaling pathway in response to muramyl dipeptide (MDP) in humans, leading to NF-kappa-B and MAPK kinase activation. The model captures a well-documented innate immune response pathway involving the cytosolic pattern recognition receptor NOD2, which recognizes bacterial cell wall components and initiates signaling cascades that activate inflammatory responses.</p>"},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/#positive-aspects","title":"Positive Aspects","text":"<ol> <li> <p>Comprehensive Pathway Representation: The model successfully captures the key signaling events from MDP recognition through NOD2, RIP2 activation, downstream signaling through TAK1, and eventual activation of both NF-kappa-B and MAPK pathways.</p> </li> <li> <p>Appropriate Evidence: The model cites appropriate primary literature sources, with many molecular functions and causal relations supported by experimental evidence (ECO:0000314 - direct assay evidence).</p> </li> <li> <p>Subcellular Localization: The model correctly represents subcellular locations of different components, with NOD2 at the plasma membrane (GO:0005886), and downstream components appropriately distributed between cytoplasm (GO:0005737) and cytosol (GO:0005829).</p> </li> <li> <p>Causal Relationships: The causal flow is well-represented using appropriate relation terms like \"directly positively regulates\" (RO:0002629), \"provides input for\" (RO:0002413), and \"directly negatively regulates\" (RO:0002630).</p> </li> </ol>"},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Entry Receptor for MDP: The recent research (PMID:36002575) reveals that NAGK (N-acetylglucosamine kinase) is essential for NOD2 activation by phosphorylating MDP at the C6 position. This model includes NAGK (UniProtKB:Q9UJ70) with \"muramyl dipeptide kinase activity\" (GO:0160047), but doesn't properly establish the direct connection between 6-O-phospho-MDP and NOD2 activation. The model shows NAGK providing input to NOD2, but based on the recent publication, NAGK's phosphorylated product (6-O-phospho-MDP) is what actually activates NOD2.</p> </li> <li> <p>Ubiquitination Representation: While the model includes XIAP (P98170) with \"ubiquitin protein ligase activity\" (GO:0061630) and RNF31 (Q96EP0) with \"ubiquitin-protein transferase activity\" (GO:0004842), the ubiquitination events could be more explicitly captured. According to the literature, RIPK2 undergoes both K63-linked and linear (M1-linked) polyubiquitination, which serves as a crucial scaffold for downstream signaling.</p> </li> <li> <p>Missing Detailed Mechanism for IKK Activation: The connection between TAK1 complex (consisting of TAK1, TAB2, and TAB3) and IKK activation could be better detailed. TAK1 directly phosphorylates IKK at specific residues (Ser177 and Ser181) as described in PMID:11460167.</p> </li> <li> <p>Incomplete Information on Feedback Regulation: The model doesn't include regulatory feedback mechanisms that help control and limit NOD2 signaling, such as deubiquitinating enzymes like A20/TNFAIP3 or OTULIN that can constrain the pathway.</p> </li> </ol>"},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/#technical-assessment","title":"Technical Assessment","text":"<ol> <li> <p>E3 Ubiquitin Ligase Representation: According to the \"E3_ubiquitin_ligases\" document, the model appropriately represents XIAP as an E3 ligase with appropriate molecular function (GO:0061630) and biological process (GO:0070534 - \"protein K63-linked ubiquitination\").</p> </li> <li> <p>Complex Representation: The model correctly represents the TAK1-TAB2/3 complex by showing molecular activities of individual proteins rather than using a complex ID, which is consistent with the \"How_to_annotate_complexes_in_GO-CAM\" guidelines since the functions of individual subunits are known.</p> </li> <li> <p>Regulation Representation: The model correctly uses the causal relation terms for regulation, which is consistent with the \"WIP_-_Regulation_and_Regulatory_Processes_in_GO-CAM\" document.</p> </li> </ol>"},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of NOD2 signaling with one significant exception - the role of NAGK in phosphorylating MDP to render it a potent activator of NOD2. The recent breakthrough publication (PMID:36002575) demonstrates that NAGK phosphorylates MDP at the hydroxyl group of the C6 position of its MurNAc moiety to generate 6-O-phospho-MDP, which is the actual ligand recognized by NOD2.</p> <p>The model includes NAGK but doesn't fully capture this critical first step in the pathway. Instead, it shows NAGK directly providing input to NOD2 rather than showing NAGK generating a phosphorylated MDP product that then activates NOD2.</p>"},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Update MDP Recognition Mechanism: Revise the model to show that NAGK phosphorylates MDP to generate 6-O-phospho-MDP, which then serves as the actual activating ligand for NOD2. This would more accurately represent the findings from PMID:36002575.</p> </li> <li> <p>Add Missing Components in Ubiquitination Cascade: Consider adding more details on the specific ubiquitination patterns of RIPK2 (K63-linked and linear ubiquitination) which serve as a scaffold for recruiting downstream factors.</p> </li> <li> <p>Include Negative Regulators: Add negative regulatory components like A20/TNFAIP3 or OTULIN to depict the pathway's regulation more comprehensively.</p> </li> <li> <p>Clarify TAK1-IKK Relationship: Better detail the specific phosphorylation events from TAK1 to IKK activation.</p> </li> </ol>"},{"location":"reviews/641ce4dc00000050-NOD2_signaling_in_response_to_muramyl_dipeptide__MDP___leading_to_NF_kappa_B_and_MAPK_kinase_activation___Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:641ce4dc00000050) represents a well-constructed depiction of the NOD2 signaling pathway that would benefit from incorporating recent findings on NAGK's role in MDP phosphorylation and adding further details on ubiquitination patterns and pathway regulation. The model is generally consistent with GO-CAM best practices but requires updating to reflect current understanding of the initial steps in NOD2 activation.</p>"},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/","title":"641ce4dc00000214 NOD1 signaling in response to gamma D glutamyl meso diaminopimelic acid  iE DAP   leading to NF kappa B and MAP kinase activation   Human","text":"<p>Based on my review of the model and the relevant GO-CAM curation guidelines, I can now provide a comprehensive review of the GO-CAM model \"NOD1 signaling in response to gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP) leading to NF-kappa-B and MAP kinase activation (Human)\" (gomodel:641ce4dc00000214).</p>"},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/#review-of-go-cam-model-gomodel641ce4dc00000214","title":"Review of GO-CAM Model: gomodel:641ce4dc00000214","text":""},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/#summary","title":"Summary","text":"<p>This model represents the NOD1 signaling pathway in humans, depicting how recognition of bacterial peptidoglycan fragment iE-DAP leads to activation of both NF-kappa-B and p38 MAPK pathways. The model captures the key players and causal relationships in this important innate immune response pathway.</p>"},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/#overall-assessment","title":"Overall Assessment","text":"<p>The model is generally well-constructed and scientifically accurate, with appropriate evidence for most activities and causal connections. It follows most GO-CAM best practices but has a few areas that could be improved for clarity and completeness.</p>"},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive Pathway Coverage: The model successfully captures both major downstream branches of NOD1 signaling - the NF-kappa-B pathway and the p38 MAPK cascade.</p> </li> <li> <p>Proper Evidence and References: Each activity has appropriate experimental evidence with relevant PMIDs, making the model well-supported by literature.</p> </li> <li> <p>Appropriate Molecular Functions: The proteins in the model are assigned appropriate molecular functions based on their known roles (e.g., NOD1 as a pattern recognition receptor, XIAP as a ubiquitin ligase).</p> </li> <li> <p>Biological Process Context: Most activities are properly contextualized within the relevant biological processes.</p> </li> <li> <p>Appropriate Causal Relationships: The model uses the correct causal predicates to connect activities, following GO-CAM best practices.</p> </li> </ol>"},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing Initiating Signal:</li> <li>The model's title indicates that it represents NOD1 signaling in response to iE-DAP, but there is no explicit connection to this initiating small molecule. According to UniProt and the PMID:12791997 reference, the recognition of iE-DAP is central to NOD1 function.</li> <li> <p>Recommendation: Include CHEBI:61564 (iE-DAP) with a \"is small molecule activator\" relationship to NOD1's pattern recognition receptor activity.</p> </li> <li> <p>Missing Cellular Component for Some Activities:</p> </li> <li>Some activities lack cellular component annotations that would provide important context.</li> <li> <p>Recommendation: Add appropriate \"occurs_in\" annotations for all activities.</p> </li> <li> <p>Connection between NOD1 and RIPK2:</p> </li> <li>The connection between NOD1 (Q9Y239) and RIPK2 (O43353) could be more clearly represented. According to the literature, NOD1 directly recruits RIPK2 through CARD-CARD domain interactions.</li> <li> <p>The model shows RIPK2 (O43353) with \"signaling adaptor activity\" downstream of RNF31, but there should also be a direct connection from NOD1.</p> </li> <li> <p>Potential Improvements to Pathway Flow:</p> </li> <li>The causal flow from XIAP (P98170) to TAB3 (Q8N5C8) and TAB2 (Q9NYJ8) could be clarified. The model currently shows XIAP providing input for both TAB2 and TAB3, but in the canonical pathway, XIAP catalyzes K63-linked polyubiquitination, which is then recognized by the TAB proteins.</li> </ol>"},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li>Add the Initiating Signal:</li> <li> <p>Add CHEBI:61564 (L-alanyl-gamma-D-glutamyl-meso-diaminopimelic acid) as a small molecule activator of NOD1's pattern recognition receptor activity.</p> </li> <li> <p>Improve Cellular Localization:</p> </li> <li>Add \"occurs_in\" annotations for activities currently missing this information.</li> <li> <p>Ensure NOD1 is correctly shown at the plasma membrane (GO:0005886) based on recent literature (UniProt cites PMID:31649195).</p> </li> <li> <p>Clarify RIPK2 Recruitment:</p> </li> <li> <p>Add a direct causal connection from NOD1's pattern recognition receptor activity to RIPK2's signaling adaptor activity.</p> </li> <li> <p>Consider Adding Additional Information:</p> </li> <li> <p>The model could be enhanced by adding information about the palmitoylation of NOD1, which is required for its localization to the membrane (as indicated in UniProt entry Q9Y239).</p> </li> <li> <p>Ensure Process Completeness:</p> </li> <li>The model could benefit from explicitly showing the role of RNF31 in catalyzing linear polyubiquitination, which is important for NF-\u03baB activation.</li> </ol>"},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/#literature-consistency","title":"Literature Consistency","text":"<p>The model is generally consistent with the referenced literature. The PMID:12791997 paper specifically demonstrates that NOD1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan, which is correctly represented in this model.</p>"},{"location":"reviews/641ce4dc00000214-NOD1_signaling_in_response_to_gamma_D_glutamyl_meso_diaminopimelic_acid__iE_DAP___leading_to_NF_kappa_B_and_MAP_kinase_activation___Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:641ce4dc00000214) provides a good representation of NOD1 signaling in response to bacterial peptidoglycan components. With a few improvements - particularly the explicit inclusion of the iE-DAP small molecule activator and clarification of some protein-protein interactions - this model would more completely and accurately represent the current understanding of this important innate immune pathway.</p> <p>The model successfully captures both the NF-kappa-B and MAPK activation arms of NOD1 signaling and includes the key proteins involved in this complex cascade. It serves as a valuable resource for understanding how human cells detect and respond to bacterial infection via the NOD1 pathway.</p>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/","title":"641ce4dc00000430 NOD2 localization to the plasma membrane following palmitoylation by ZDHHC5  Human","text":"<p>Now I'll review the model based on all the information gathered.</p>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#review-of-go-cam-model-gomodel641ce4dc00000430","title":"Review of GO-CAM Model: gomodel:641ce4dc00000430","text":""},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#model-overview","title":"Model Overview","text":"<p>This model titled \"NOD2 localization to the plasma membrane following palmitoylation by ZDHHC5 (Human)\" describes the palmitoylation of NOD2 protein by ZDHHC5, which enables NOD2's localization to the plasma membrane, leading to activation of signaling pathways through RIPK2 and XIAP proteins.</p>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#biological-context","title":"Biological Context","text":"<p>The model represents a crucial aspect of innate immune signaling. NOD2 is a cytosolic pattern recognition receptor that detects bacterial muramyl dipeptide (MDP). For NOD2 to function properly, it must be localized to the plasma membrane, which is facilitated by palmitoylation (the addition of palmitate to specific cysteine residues). This post-translational modification increases NOD2's affinity for membrane bilayers and is essential for its ability to activate downstream signaling.</p>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#model-structure","title":"Model Structure","text":"<p>The model consists of four main activities:</p> <ol> <li>ZDHHC5 (UniProtKB:Q9C0B5) with protein-cysteine S-palmitoyltransferase activity (GO:0019706)</li> <li>NOD2 (UniProtKB:Q9HC29) with pattern recognition receptor activity (GO:0038187)</li> <li>RIPK2 (UniProtKB:O43353) with signaling adaptor activity (GO:0035591)</li> <li>XIAP (UniProtKB:P98170) with ubiquitin protein ligase activity (GO:0061630)</li> </ol>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#causal-flow","title":"Causal Flow","text":"<p>The causal flow in the model is: - ZDHHC5 palmitoylates NOD2 (RO:0002629 - directly positively regulates) - NOD2 then activates RIPK2 (RO:0002629 - directly positively regulates) - RIPK2 activates XIAP (RO:0002629 - directly positively regulates)</p>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#cellular-context","title":"Cellular Context","text":"<ul> <li>ZDHHC5 occurs in the plasma membrane (GO:0005886)</li> <li>NOD2 occurs in the plasma membrane (GO:0005886) after palmitoylation</li> <li>RIPK2 occurs in the plasma membrane (GO:0005886)</li> <li>XIAP occurs in the cytoplasm (GO:0005737)</li> </ul>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#biological-processes","title":"Biological Processes","text":"<ul> <li>ZDHHC5 is part of protein localization to plasma membrane (GO:0072659)</li> <li>NOD2 is part of response to muramyl dipeptide (GO:0032495)</li> <li>RIPK2 is part of NOD2 signaling pathway (GO:0070431)</li> <li>XIAP is part of protein K63-linked ubiquitination (GO:0070534)</li> </ul>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by evidence from multiple peer-reviewed publications:</p> <ul> <li>The role of ZDHHC5 in palmitoylating NOD2 is supported by PMID:34293401 and PMID:31649195</li> <li>The localization of NOD2 to the plasma membrane is supported by PMID:17355968</li> <li>The interaction between NOD2 and RIPK2 is supported by PMID:17355968</li> <li>The regulation of RIPK2 by XIAP through ubiquitination is supported by PMID:29452636</li> </ul> <p>Each annotation is backed by direct experimental evidence (ECO:0000314), which is appropriate.</p>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model accurately captures the sequential steps in NOD2 activation, from palmitoylation to downstream signaling.</li> <li>The cellular locations are accurately represented.</li> <li>The causal relationships are appropriately modeled using the correct predicates.</li> <li>The evidence is well-documented with appropriate PMIDs and evidence codes.</li> <li>The model includes key proteins and their verified molecular functions.</li> </ol>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#potential-issues-or-improvements","title":"Potential Issues or Improvements","text":"<ol> <li> <p>Palmitoylation Sites: While the model represents the palmitoylation activity, it could be enhanced by noting the specific cysteine residues in NOD2 (C395 and C1033) that are palmitoylated, as indicated in PMID:34293401.</p> </li> <li> <p>Intermediate Steps: The model represents a direct relationship between RIPK2 and XIAP, which is accurate, but there could be more detail on the mechanism. XIAP mediates K63-linked polyubiquitination of RIPK2, transforming it into a scaffolding protein for downstream effectors.</p> </li> <li> <p>Downstream Effects: The model could be extended to include the downstream effects of XIAP-mediated ubiquitination of RIPK2, such as activation of the NF-\u03baB and MAP kinases signaling pathways.</p> </li> <li> <p>Biological Process Annotation: While NOD2 is correctly annotated as part of \"response to muramyl dipeptide\" (GO:0032495), it could also be annotated to \"innate immune response\" (GO:0045087) to provide more context.</p> </li> </ol>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>Based on the GO-CAM guidelines for annotating complexes and regulatory processes:</p> <ol> <li> <p>The model correctly represents the individual proteins and their activities rather than using a complex ID, which is appropriate since the specific activities of each protein are known.</p> </li> <li> <p>The regulatory relationships are properly represented using the \"directly positively regulates\" (RO:0002629) predicate, which is correct for direct regulation.</p> </li> <li> <p>The cellular locations are accurately represented, consistent with how these proteins function in vivo.</p> </li> </ol>"},{"location":"reviews/641ce4dc00000430-NOD2_localization_to_the_plasma_membrane_following_palmitoylation_by_ZDHHC5__Human_/#summary","title":"Summary","text":"<p>This is a high-quality GO-CAM model that accurately represents the current understanding of NOD2 palmitoylation by ZDHHC5 and subsequent activation of signaling through RIPK2 and XIAP. The model captures a crucial post-translational modification (palmitoylation) that is essential for NOD2 function in innate immunity.</p> <p>The model is consistent with GO-CAM best practices and is supported by strong experimental evidence from the literature. While there are minor opportunities for enhancement by adding more detail on specific residues and downstream effects, the core process is well-represented.</p>"},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/","title":"641ce4dc00000586 UBL7 TRIM21 mediated ubiquitination of MAVS leading to type I interferon production  Human","text":"<p>Based on the information I've gathered, I'll now provide a detailed review of GO-CAM model 641ce4dc00000586, focusing on its structure, biological content, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/#review-of-go-cam-model-gomodel641ce4dc00000586","title":"Review of GO-CAM Model: gomodel:641ce4dc00000586","text":""},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/#summary","title":"Summary","text":"<p>This model represents \"UBL7/TRIM21-mediated ubiquitination of MAVS leading to type I interferon production (Human)\" in the human system (NCBITaxon:9606). It depicts a signaling pathway involved in innate immune response, particularly in antiviral defense.</p>"},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/#model-structure-overview","title":"Model Structure Overview","text":"<p>The model contains 4 key activities connected by causal relationships:</p> <ol> <li>UBL7 (Q96S82) performs molecular adaptor activity (GO:0060090) in the cytoplasm</li> <li>TRIM21 (P19474) performs ubiquitin protein ligase activity (GO:0061630) in the cytoplasm</li> <li>MAVS (Q7Z434) performs molecular adaptor activity (GO:0060090) on the mitochondrial outer membrane</li> <li>OTUD4 (Q01804) performs cysteine-type deubiquitinase activity (GO:0004843) in the cytoplasm</li> </ol> <p>The activities are connected as follows: - UBL7 provides input for TRIM21's activity - TRIM21 directly negatively regulates MAVS - OTUD4 directly positively regulates UBL7</p> <p>All activities are part of the type I interferon production (GO:0032606) biological process.</p>"},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/#assessment-of-biological-content","title":"Assessment of Biological Content","text":"<p>The model accurately represents the process described in recent literature (primarily PMID:36943869), where UBL7 enhances antiviral innate immunity by promoting Lys27-linked polyubiquitination of MAVS. This ubiquitination is performed by TRIM21, and the process is involved in type I interferon signaling.</p> <p>The model correctly shows: 1. UBL7 acts as a molecular adaptor that provides input for TRIM21 2. TRIM21 functions as an E3 ubiquitin ligase that negatively regulates MAVS through K27-linked ubiquitination 3. MAVS is localized to the mitochondrial outer membrane 4. OTUD4 acts as a deubiquitinase that positively regulates UBL7</p>"},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Correct subcellular locations: The model accurately depicts the locations of the proteins (MAVS on mitochondrial outer membrane, others in cytoplasm).</li> <li>Appropriate molecular functions: The assigned molecular functions match what's known about these proteins.</li> <li>Causal relationships: The model correctly depicts the directional flow of the pathway.</li> <li>Evidential support: All activities and causal relationships have appropriate evidence codes and literature references.</li> </ol>"},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Duplicate causal relationship: OTUD4 has two identical causal relationships to UBL7, both with the predicate \"RO:0002629\" (directly positively regulates), and both referencing the same evidence (PMID:23827681). This appears to be an error and one should be removed.</p> </li> <li> <p>Missing molecular details: The model could be more specific about the type of ubiquitination performed by TRIM21 on MAVS. According to UniProt and the referenced literature, this is specifically K27-linked polyubiquitination. The part_of association for TRIM21 does indicate \"GO:0044314\" (protein K27-linked ubiquitination), but this could be made more explicit in the relationship description.</p> </li> <li> <p>Incomplete pathway context: The model could be extended to show what happens downstream of MAVS inhibition. The title mentions \"leading to type I interferon production,\" but the specific pathway from MAVS to interferon production is not represented.</p> </li> <li> <p>TBK1 presence: UniProtKB:Q9UHD2 (TBK1) is listed in the objects but is not used in any activity or relationship in the model. If TBK1 plays a role in this pathway, it should be incorporated into the model.</p> </li> </ol>"},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/#go-cam-best-practices-evaluation","title":"GO-CAM Best Practices Evaluation","text":"<ol> <li> <p>Molecular activities: The model correctly specifies the molecular functions of each protein, supported by appropriate evidence.</p> </li> <li> <p>Causal relationships: The model uses appropriate causal relationship predicates (provides input for, directly positively/negatively regulates).</p> </li> <li> <p>Cellular context: Each activity is correctly annotated with its cellular location.</p> </li> <li> <p>Evidence: All activities and relationships have appropriate evidence codes and literature references.</p> </li> <li> <p>Part_of relationships: All activities are appropriately connected to the biological process they participate in (type I interferon production).</p> </li> </ol>"},{"location":"reviews/641ce4dc00000586-UBL7_TRIM21_mediated_ubiquitination_of_MAVS_leading_to_type_I_interferon_production__Human_/#recommendation","title":"Recommendation","text":"<p>This model provides a good representation of the UBL7/TRIM21-mediated regulation of MAVS in antiviral signaling, but needs the following corrections:</p> <ol> <li>Remove the duplicate causal relationship from OTUD4 to UBL7.</li> <li>Consider adding downstream components to show how this pathway leads to type I interferon production.</li> <li>Clarify the role of TBK1 in the model or remove it from the objects list if not relevant.</li> <li>Consider specifying the type of ubiquitination (K27-linked) more explicitly in the causal relationship between TRIM21 and MAVS.</li> </ol> <p>With these refinements, the model would provide a more complete and accurate representation of this important antiviral signaling pathway.</p>"},{"location":"reviews/641ce4dc00000914-Activation_of_Nf_kappa_B_via_ubiquitination_and_degradation_of_the_NF_kappa_B_inhibitor__Human_/","title":"641ce4dc00000914 Activation of Nf kappa B via ubiquitination and degradation of the NF kappa B inhibitor  Human","text":"<p>Based on my review of the GO-CAM model and the best practice guidelines, I'll provide a detailed analysis of the model \"Activation of Nf-kappa-B via ubiquitination and degradation of the NF-kappa-B inhibitor (Human)\":</p>"},{"location":"reviews/641ce4dc00000914-Activation_of_Nf_kappa_B_via_ubiquitination_and_degradation_of_the_NF_kappa_B_inhibitor__Human_/#model-review-for-gomodel641ce4dc00000914","title":"Model Review for gomodel:641ce4dc00000914","text":""},{"location":"reviews/641ce4dc00000914-Activation_of_Nf_kappa_B_via_ubiquitination_and_degradation_of_the_NF_kappa_B_inhibitor__Human_/#overview","title":"Overview","text":"<p>This model represents the NF-kB signaling pathway in humans, focusing on the activation of the NF-kB transcription factors through the ubiquitination and degradation of the NF-kB inhibitor (NFKBIA/IkB-alpha). The model shows the cascade from upstream kinases to the final activation of NF-kB transcription factors.</p>"},{"location":"reviews/641ce4dc00000914-Activation_of_Nf_kappa_B_via_ubiquitination_and_degradation_of_the_NF_kappa_B_inhibitor__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Adherence to E3 ubiquitin ligase guidelines: </li> <li>The model correctly implements the E3 ubiquitin ligase complex with distinct roles for scaffold (CUL1, GO:0160072), adaptor (FBXW11, GO:1990756), and ligase (RBX1, GO:0061630) as per the guidelines.</li> <li> <p>All components are correctly annotated to the \"proteasome-mediated ubiquitin-dependent protein catabolic process\" (GO:0043161).</p> </li> <li> <p>Sequestering activity representation:</p> </li> <li>The inhibitory role of NFKBIA (P25963) is correctly represented with \"protein sequestering activity\" (GO:0140311).</li> <li> <p>The sequestering activity directly negatively regulates the transcription factor activities of NFKB1 and RELA, which aligns with the guidelines.</p> </li> <li> <p>Causal relationships:</p> </li> <li>The causal flow from MAP3K7 to IKBKB to the ubiquitination machinery and finally to NF-kB activation is logically structured.</li> <li> <p>The predicates used (e.g., RO:0002413 \"provides input for\", RO:0002630 \"directly negatively regulates\") are appropriate for the biological context.</p> </li> <li> <p>Biological process context:</p> </li> <li> <p>Activities are properly connected to relevant biological processes (e.g., positive/negative regulation of canonical NF-kappaB signal transduction).</p> </li> <li> <p>Evidence and references:</p> </li> <li>Most activities include proper evidence codes (ECO:0000314 - direct assay evidence) and references to primary literature.</li> </ol>"},{"location":"reviews/641ce4dc00000914-Activation_of_Nf_kappa_B_via_ubiquitination_and_degradation_of_the_NF_kappa_B_inhibitor__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing \"has input\" annotations:</li> <li>The NFKBIA protein sequestering activity should have explicit \"has input\" relations to the NF-kB components (NFKB1, RELA) that it sequesters, according to sequestering protein guidelines.</li> <li> <p>Similarly, RBX1's ubiquitin ligase activity should have NFKBIA as an explicit input.</p> </li> <li> <p>Location details:</p> </li> <li>While NFKBIA and IKBKB are annotated to occur in the cytoplasm (GO:0005737), some other proteins lack cellular localization annotations.</li> <li> <p>The E3 ligase complex components (CUL1, FBXW11, RBX1) would benefit from cellular location information.</p> </li> <li> <p>Activity-to-activity causal connections:</p> </li> <li> <p>The connection between the phosphorylation by IKBKB and the subsequent ubiquitination by the E3 ligase complex isn't explicitly modeled, leaving a gap in the causal chain.</p> </li> <li> <p>Transcription factor activities:</p> </li> <li>While NFKB1 and RELA have DNA-binding transcription factor activity (GO:0003700) annotations and are properly located in chromatin (GO:0000785), they lack downstream targets, which would complete the pathway.</li> <li> <p>According to the guidelines, transcription factors should use more specific molecular function terms indicating activator or repressor activity (e.g., GO:0001228 or GO:0001227).</p> </li> <li> <p>Evidence completeness:</p> </li> <li>Some causal associations lack evidence codes and references, which would strengthen the model's credibility.</li> </ol>"},{"location":"reviews/641ce4dc00000914-Activation_of_Nf_kappa_B_via_ubiquitination_and_degradation_of_the_NF_kappa_B_inhibitor__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add \"has input\" annotations to explicitly show what proteins are being sequestered or ubiquitinated.</p> </li> <li> <p>Consider adding the missing link between IKBKB phosphorylation of NFKBIA and the subsequent ubiquitination.</p> </li> <li> <p>Add cellular component annotations for proteins that currently lack them, especially the E3 ligase complex components.</p> </li> <li> <p>Consider extending the model to include downstream transcriptional targets of NF-kB, using more specific transcription factor activity terms.</p> </li> <li> <p>Add evidence codes and references to all causal associations.</p> </li> </ol>"},{"location":"reviews/641ce4dc00000914-Activation_of_Nf_kappa_B_via_ubiquitination_and_degradation_of_the_NF_kappa_B_inhibitor__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good representation of the NF-kB activation pathway through the ubiquitination and degradation of its inhibitor. It generally adheres to GO-CAM best practices for modeling E3 ubiquitin ligases and protein sequestering activities. With the suggested improvements, the model could more completely represent the biological process and better align with all GO-CAM curation guidelines.</p>"},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/","title":"641ce4dc00001047 Generation of NFKB1 p50 subunit of  Nf kappa B via limited processing by the KPC1 complex  RNF123   leading to NF kappa B inhibitor  Human","text":"<p>Based on all this information, I'll now perform a thorough review of the GO-CAM model:</p>"},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/#review-of-go-cam-model-641ce4dc00001047","title":"Review of GO-CAM Model 641ce4dc00001047","text":""},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model titled \"Generation of NFKB1 p50 subunit of Nf-kappa-B via limited processing by the KPC1 complex (RNF123), leading to NF-kappa-B inhibitor (Human)\" represents a biological process related to the regulation of NF-kappa-B signaling in humans.</p>"},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/#model-components-and-structure","title":"Model Components and Structure","text":"<p>The model represents the pathway of processing NFKB1 p105 to the p50 subunit by the KPC1 complex (RNF123), and how this p50 subunit then affects NF-kappa-B signaling.</p> <p>Key components include: - IKBKB (O14920): Acts as a protein kinase and IkappaB kinase - RNF123/KPC1 (Q5XPI4): Functions as an E3 ubiquitin ligase - NFKB1 (P19838): Processed from p105 to p50 - NFKBIA (P25963): Inhibitor of NF-kappa-B - RELA (Q04206): Component of NF-kappa-B</p>"},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/#evaluation","title":"Evaluation","text":""},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current scientific understanding of NFKB1 processing by the KPC1 complex as described in the literature, particularly in Kravtsova-Ivantsiv et al. (2015). The key mechanisms are well captured:</p> <ol> <li>IKBKB phosphorylates p105 at Ser-927 (supported by PMID:11297557)</li> <li>RNF123/KPC1 ubiquitinates p105, leading to its limited proteasomal processing to p50 (supported by PMID:25860612)</li> <li>The generated p50 functions as a DNA-binding transcription factor</li> <li>NFKBIA inhibits the activity of NF-kappa-B components through protein sequestering activity</li> </ol>"},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing molecular activities and their causal relationships:</p> <ol> <li> <p>Proper activity representation: Each protein is annotated with appropriate molecular functions (e.g., IKBKB with kinase activity, RNF123 with ubiquitin ligase activity).</p> </li> <li> <p>Appropriate causal relations: The model uses appropriate causal relations:</p> </li> <li>RO:0002409 (negatively regulates upstream of or within): IKBKB to NFKBIA </li> <li>RO:0002629 (directly positively regulates): RNF123 to NFKB1 DNA-binding activity</li> <li> <p>RO:0002630 (directly negatively regulates): NFKBIA to NFKB1 and RELA</p> </li> <li> <p>Complex representation: The model correctly handles the KPC1 complex by annotating RNF123 (which is the catalytic subunit) with the ubiquitin ligase activity, which follows the guidelines for representing complexes where the subunit carrying the molecular activity is known.</p> </li> <li> <p>Cellular location: Each activity is appropriately annotated with cellular location (e.g., cytoplasm, chromatin) and is consistent with the known biology.</p> </li> <li> <p>Evidence codes: All annotations are supported by appropriate evidence codes and PMIDs.</p> </li> </ol>"},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, there are a few points that could be improved:</p> <ol> <li> <p>KPC Complex Representation: The model correctly shows RNF123/KPC1 as the E3 ubiquitin ligase, but it might be beneficial to include the partner protein KPC2 (UBAC1) as described in the literature. The KPC complex is a heterodimer composed of KPC1 and KPC2, and although KPC1 has the catalytic activity, KPC2 plays a role in stabilizing KPC1 and affecting its activity toward p105.</p> </li> <li> <p>Phosphorylation Site Specificity: While the model shows IKBKB phosphorylating NFKB1, it could be more specific about the phosphorylation occurring at Ser-927, which is critical for subsequent processing by KPC1.</p> </li> <li> <p>Regulatory Mechanism Completeness: The relationship between IKBKB phosphorylation and enhanced KPC1-mediated ubiquitination could be made more explicit, as the literature indicates that phosphorylation of p105 increases its interaction with KPC1.</p> </li> </ol>"},{"location":"reviews/641ce4dc00001047-Generation_of_NFKB1_p50_subunit_of__Nf_kappa_B_via_limited_processing_by_the_KPC1_complex__RNF123___leading_to_NF_kappa_B_inhibitor__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current knowledge about the generation of the NF-kappa-B p50 subunit via KPC1-mediated processing of p105, and its subsequent roles in NF-kappa-B signaling. </p> <p>The model is consistent with the literature, especially the key publication by Kravtsova-Ivantsiv et al. (2015), and follows GO-CAM best practices. The minor suggestions for improvement would enhance the model's completeness and specificity but don't detract from its current quality and usefulness.</p> <p>The biological representation is sound, with each protein annotated with appropriate molecular functions and located in the correct cellular compartments. The causal relationships between activities are properly represented using the appropriate RO relations.</p> <p>I recommend this model for approval with the optional suggestion to consider adding KPC2 and being more specific about the phosphorylation site in future iterations.</p>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/","title":"6438950a00000032 Human metapneumovirus M2 2 inhibition of IRF7  Human Metapneumovirus","text":"<p>Now, I'll review the GO-CAM model in detail based on all the information I've gathered.</p>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#review-of-go-cam-model-gomodel6438950a00000032","title":"Review of GO-CAM Model: gomodel:6438950a00000032","text":""},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model is titled \"Human metapneumovirus M2-2 inhibition of IRF7 (Human-Metapneumovirus)\" and depicts interactions between human metapneumovirus (HMPV) M2-2 protein and the host innate immune response.</p>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#model-components","title":"Model Components","text":"<p>The model consists of four main activities: 1. HMPV M2-2 protein (UniProtKB:Q6WB96) - Protein sequestering activity (GO:0140311) occurring in the cytoplasm (GO:0005737) 2. TBK1 (UniProtKB:Q9UHD2) - Protein serine/threonine kinase activity (GO:0004674) occurring in the cytoplasm (GO:0005737) 3. TLR9 (UniProtKB:Q9NR96) - Pattern recognition receptor activity (GO:0038187) occurring in the endoplasmic reticulum (GO:0005783) 4. IRF7 (UniProtKB:Q92985) - DNA-binding transcription factor activity (GO:0000981) occurring in chromatin (GO:0000785)</p>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#causal-relationships","title":"Causal Relationships","text":"<ol> <li>HMPV M2-2 directly negatively regulates (RO:0002630) IRF7</li> <li>TBK1 directly positively regulates (RO:0002629) IRF7</li> <li>TLR9 provides input for (RO:0002407) TBK1</li> </ol>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#evidence","title":"Evidence","text":"<p>The model is supported by experimental evidence from several scientific papers: - PMID:28768858 - Primary paper showing that HMPV M2-2 protein acts as a negative regulator of IFN-alpha production by inhibiting IRF7 phosphorylation - PMID:25636800 - Evidence for TBK1-mediated phosphorylation of IRF7 - PMID:14716310 - Evidence for TLR9 subcellular localization and function - PMID:23857366 - Evidence for TLR9 role in signaling pathway - PMID:14703513 - Evidence for TBK1 in cytoplasmic localization - PMID:17404045 - Evidence for IRF7 transcription factor activity - PMID:11473119 - Evidence for IRF7 chromatin localization - PMID:16979567 - Evidence for IRF7 role in interferon production</p>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#biological-context","title":"Biological Context","text":"<p>This model represents how the HMPV M2-2 protein interferes with the host innate immune response. The pathway normally involves TLR9 sensing viral/bacterial DNA in endosomes, leading to TBK1 activation, which then phosphorylates IRF7. Activated IRF7 translocates to the nucleus and induces type I interferon production. The HMPV M2-2 protein disrupts this pathway by directly binding to IRF7 and preventing its phosphorylation by TBK1, thereby inhibiting the host interferon response.</p>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#review-analysis","title":"Review Analysis","text":""},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Scientific Accuracy: The model accurately represents the core mechanism of HMPV M2-2 protein's inhibitory effect on IRF7 as described in the primary literature (PMID:28768858).</p> </li> <li> <p>Well-evidenced: Each component and relationship in the model is supported by appropriate evidence from peer-reviewed literature.</p> </li> <li> <p>Clear Biological Context: The model clearly depicts how a viral protein disrupts a specific host immune signaling pathway.</p> </li> <li> <p>Appropriate Use of GO Terms: The molecular function terms assigned to each protein are appropriate based on their known functions.</p> </li> </ol>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex Annotation: Based on the GO-CAM guidelines for complex annotation, there may be opportunities to improve the representation of protein complexes or multi-protein interactions. The M2-2 interaction with IRF7 is a direct binding interaction according to the literature, which is correctly represented in the model.</p> </li> <li> <p>Subcellular Localization Accuracy: According to the literature, TLR9 is initially localized to the ER (as correctly shown in the model) but relocates to endosomes/lysosomes upon CpG DNA binding. The model could potentially be enhanced to show this translocation, though for simplicity the current representation is acceptable.</p> </li> <li> <p>Signal Transduction Completeness: The signaling pathway from TLR9 activation to IRF7 phosphorylation involves additional components like MyD88 and TRAF6 that aren't represented in the current model. While the model correctly represents the core pathway affected by M2-2, including these intermediary steps would make it more complete.</p> </li> <li> <p>Phosphorylation Events: The model represents that TBK1 directly positively regulates IRF7, but could be more specific to indicate that this regulation occurs via phosphorylation specifically at Ser477 (as shown in PMID:28768858). </p> </li> <li> <p>Additional Outcomes: The biological process of \"negative regulation of type I interferon production\" (GO:0032480) is correctly annotated to M2-2, but the model could potentially include the downstream effects on interferon production more explicitly.</p> </li> </ol>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Consider Adding Molecular Detail: Consider adding the specific phosphorylation site of IRF7 (Ser477) as mentioned in the primary paper to provide more molecular detail.</p> </li> <li> <p>Expand the Signaling Pathway: If the goal is a more comprehensive model, consider adding MyD88 and TRAF6 as intermediate steps between TLR9 and TBK1 activation.</p> </li> <li> <p>Add Downstream Effects: Consider expanding the model to show how IRF7 inhibition leads to reduced interferon production, potentially including interferon genes as outputs of the pathway.</p> </li> <li> <p>Clarify Cellular Locations: Consider adding a more detailed representation of TLR9 translocation from the ER to endosomes upon activation, as this is an important aspect of its signaling mechanism.</p> </li> </ol>"},{"location":"reviews/6438950a00000032-Human_metapneumovirus_M2_2_inhibition_of_IRF7__Human_Metapneumovirus_/#final-assessment","title":"Final Assessment","text":"<p>The GO-CAM model \"Human metapneumovirus M2-2 inhibition of IRF7 (Human-Metapneumovirus)\" is scientifically accurate and well-supported by evidence. It effectively captures the core mechanism by which HMPV M2-2 protein disrupts host innate immune signaling by targeting IRF7. The model follows GO-CAM best practices regarding evidence citations and causal relationships.</p> <p>While there are opportunities to expand the model with additional molecular detail and pathway components, the current representation is parsimonious and clearly communicates the essential biological mechanism. This model provides valuable insight into how human metapneumovirus evades host immune responses.</p>"},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/","title":"6438950a00000074 Human metapneumovirus M2 2 inhibition of RIGI MAVS signaling  Human Metapneumovirus","text":"<p>Based on the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model with ID 6438950a00000074, titled \"Human metapneumovirus M2-2 inhibition of RIGI-MAVS signaling (Human-Metapneumovirus)\".</p>"},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/#review-of-go-cam-model-gomodel6438950a00000074","title":"Review of GO-CAM model: gomodel:6438950a00000074","text":""},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents how Human metapneumovirus (HMPV) M2-2 protein inhibits the RIG-I-MAVS signaling pathway, which is part of the host innate immune response to viral infection. The model depicts:</p> <ol> <li>The normal RIG-I-mediated pattern recognition receptor signaling pathway</li> <li>How the viral protein M2-2 negatively regulates this pathway</li> <li>Key interactions between host proteins (RIG-I, MAVS, TRIM25) and viral factors (M2-2)</li> </ol>"},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/#evaluation-of-the-biological-content","title":"Evaluation of the Biological Content","text":"<p>The model correctly represents the current understanding of how HMPV M2-2 inhibits the RIG-I-MAVS signaling pathway based on the referenced literature:</p> <ul> <li>The central mechanism shown in the model reflects recent findings that HMPV M2-2 prevents TRIM25-mediated ubiquitination of RIG-I, as demonstrated in the 2022 paper by Tanaka et al. (PMID:36045682)</li> <li>The representation aligns with the earlier finding that M2-2 targets MAVS to inhibit innate cellular signaling (PMID:23015697)</li> </ul>"},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/#technical-assessment-of-model-structure","title":"Technical Assessment of Model Structure","text":"<p>The model includes the following molecular activities:</p> <ol> <li>RIG-I (UniProtKB:O95786) with pattern recognition receptor activity (GO:0038187)</li> <li>TRIM25 (UniProtKB:Q14258) with ubiquitin protein ligase activity (GO:0061630)</li> <li>MAVS (UniProtKB:Q7Z434) with signaling adaptor activity (GO:0035591)</li> <li>TRAF6 (UniProtKB:Q9Y4K3) with ubiquitin protein ligase activity (GO:0061630)</li> <li>Human metapneumovirus M2-2 protein (UniProtKB:Q6WB96) with protein sequestering activity (GO:0140311)</li> </ol> <p>The causal relationships are represented through the following connections:</p> <ul> <li>RIG-I provides input for TRIM25 (RO:0002413)</li> <li>TRIM25 directly positively regulates MAVS (RO:0002629)</li> <li>M2-2 directly negatively regulates TRIM25 and MAVS (RO:0002630)</li> </ul>"},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Biological accuracy: The model accurately represents the current understanding of how HMPV M2-2 interferes with RIG-I-MAVS signaling.</li> <li>Evidence support: Activities are properly supported by evidence codes and PMID references.</li> <li>Cellular components: All proteins are correctly located in their cellular compartments (cytoplasm for most proteins, host cell cytoplasm for viral M2-2).</li> <li>Biological process context: All activities are correctly placed within the \"cytoplasmic pattern recognition receptor signaling pathway\" (GO:0002753).</li> </ol>"},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex representation: The model doesn't explicitly show the RIG-I/TRIM25 complex formation that is described in the literature. According to the \"How to annotate complexes in GO-CAM\" guidelines, if the activity is shared by several proteins or if the specific subunit carrying the activity is known, the complex should be represented accordingly.</p> </li> <li> <p>Ubiquitination details: The model doesn't explicitly capture that TRIM25 ubiquitinates RIG-I with K63-linked polyubiquitin chains, which is a key mechanism inhibited by M2-2. This could be better represented by including the specific ubiquitination target.</p> </li> <li> <p>RIG-I activation cycle: The model could be enhanced by showing the conformational change of RIG-I upon RNA binding that exposes the CARD domains for interaction with TRIM25.</p> </li> <li> <p>Additional interactions: The model could include other interactions described in the literature:</p> </li> <li>The direct binding of M2-2 to the SPRY domain of TRIM25</li> <li>The role of TRAF3 in the pathway (currently only TRAF6 is shown)</li> <li>The downstream effects on IRF3/7 activation and IFN production</li> </ol>"},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add RIG-I/TRIM25 complex: Consider representing the complex formation between RIG-I and TRIM25 since this is a key target for M2-2 inhibition.</p> </li> <li> <p>Expand ubiquitination details: Specify that TRIM25 catalyzes K63-linked ubiquitination of RIG-I at specific lysine residues (especially K172) as described in the literature.</p> </li> <li> <p>Include conformational changes: Consider adding the RNA-induced conformational change of RIG-I that exposes the CARD domains for TRIM25 interaction.</p> </li> <li> <p>Add downstream signaling: Extend the model to include downstream effects on IRF3/7 activation and type I interferon production.</p> </li> <li> <p>Include additional viral strategies: Consider expanding the model to show comparisons with how other viruses target the same pathway (e.g., HRSV NS1), which would make it more comprehensive.</p> </li> </ol>"},{"location":"reviews/6438950a00000074-Human_metapneumovirus_M2_2_inhibition_of_RIGI_MAVS_signaling__Human_Metapneumovirus__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6438950a00000074 is a scientifically accurate representation of how HMPV M2-2 inhibits RIG-I-MAVS signaling, with proper evidential support. It correctly captures the key molecular activities, their cellular locations, and the causal relationships between them. The model effectively represents the current understanding of this viral immune evasion mechanism, though it could be enhanced by incorporating more details about complex formation, specific ubiquitination events, and downstream signaling effects.</p> <p>The model follows GO-CAM best practices in terms of causal relations and evidence attribution, making it a valuable resource for understanding HMPV immune evasion strategies. With the suggested improvements, it could serve as an even more comprehensive reference for researchers interested in viral manipulation of innate immune signaling.</p>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/","title":"6438950a00000624 Activation of the WNK1 SPAK OSR1 kinase cascade in response to hyperosmotic stress  leading to promote ion influx and prevent ion efflux  Human","text":"<p>Based on my analysis of the GO-CAM model 6438950a00000624 and the related literature, I'll now provide a comprehensive review of this model.</p>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#review-of-go-cam-model-6438950a00000624","title":"Review of GO-CAM Model: 6438950a00000624","text":""},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#overview","title":"Overview","text":"<p>Title: \"Activation of the WNK1-SPAK/OSR1 kinase cascade in response to hyperosmotic stress, leading to promote ion influx and prevent ion efflux (Human)\"</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>Model ID: gomodel:6438950a00000624</p>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the WNK1-SPAK/OSR1 kinase signaling pathway that regulates ion transport in response to hyperosmotic stress in human cells. The model describes how the WNK1 kinase is activated under hyperosmotic conditions, leading to the activation and phosphorylation of SPAK (STK39) and OSR1 (OXSR1) kinases, which in turn regulate the activities of multiple cation-chloride cotransporters: KCC (SLC12A6), NKCC1 (SLC12A2), and NKCC2 (SLC12A1).</p>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately captures the known biology of the WNK1-SPAK/OSR1 signaling cascade based on the current literature. The recent publication by Sun et al. (2022) (PMID:36318922) provides strong support for the mechanisms represented in this model, highlighting how WNK1 forms phase-separated condensates under hyperosmotic stress to coordinate signaling that regulates cell volume through cation-chloride cotransporters.</p> <p>The model correctly shows that: 1. WNK1 undergoes molecular condensate scaffold activity under hyperosmotic stress 2. WNK1 activates SPAK/OSR1 through phosphorylation 3. Activated SPAK/OSR1 phosphorylates and regulates cation-chloride cotransporters 4. This leads to both activation of ion influx transporters (NKCC1, NKCC2) and inhibition of ion efflux transporters (KCC)</p>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#go-cam-modeling-best-practices","title":"GO-CAM Modeling Best Practices","text":""},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Biological Process Integration: The model appropriately connects all activities to the \"cell volume homeostasis\" (GO:0006884) biological process, which is the main physiological outcome of this signaling pathway.</p> </li> <li> <p>Molecular Activities: Each protein is annotated with appropriate molecular functions:</p> </li> <li>WNK1: molecular condensate scaffold activity (GO:0140693) and protein serine/threonine kinase activity (GO:0004674)</li> <li>SPAK/OSR1: protein serine/threonine kinase activity (GO:0004674)</li> <li> <p>Cotransporters: appropriate transporter activities (GO:0015379, GO:0008511)</p> </li> <li> <p>Cellular Localization: The model includes appropriate cellular locations for each activity:</p> </li> <li>WNK1 condensate formation in intracellular membraneless organelle (GO:0043232)</li> <li> <p>Cotransporters at appropriate plasma membrane locations</p> </li> <li> <p>Causal Relationships: The causal relationships between activities are well represented using the appropriate causal predicates:</p> </li> <li>RO:0002629 (directly positively regulates) for activating phosphorylation </li> <li>RO:0002630 (directly negatively regulates) for inhibitory phosphorylation</li> </ol>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Duplicate Causal Relationships: There are duplicate causal relationships between STK39 (SPAK) and SLC12A6 (KCC). In the model, there are two separate \"directly negatively regulates\" relationships from STK39 to SLC12A6's potassium:chloride symporter activity, with one relationship lacking evidence (empty evidence array).</p> </li> <li> <p>Cellular Osmotic Response: Although the model is focused on the response to hyperosmotic stress, it doesn't explicitly include the GO term for \"cellular hyperosmotic response\" (GO:0071474) as a biological process. This term is mentioned in the model's objects list but isn't connected to any activities.</p> </li> <li> <p>Molecular Input Details: While the model does capture the role of WNK1 as a molecular condensate scaffold, it could benefit from explicitly modeling how hyperosmotic stress triggers this activity, possibly through the addition of small molecules or physical conditions as inputs.</p> </li> </ol>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by high-quality evidence: - ECO:0000314 (direct assay evidence used in manual assertion) from multiple PMIDs - Key publications supporting the model include PMID:36318922, PMID:19665974, and PMID:21321328</p> <p>The evidence is correctly associated with the appropriate molecular activities and causal relationships.</p>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#completeness","title":"Completeness","text":"<p>The model captures the core components of the WNK1-SPAK/OSR1 pathway and its regulation of cation-chloride cotransporters. However, it could be expanded to include:</p> <ol> <li>The detailed molecular mechanisms by which hyperosmotic stress triggers WNK1 phase separation (as described in PMID:36318922)</li> <li>The specific phosphorylation sites on the cotransporters (e.g., Thr105 and Ser130 on NKCC2, as described in PMID:21321328)</li> <li>Additional downstream effects on cellular processes beyond ion transport</li> </ol>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows most GO-CAM best practices for representing signaling pathways:</p> <ol> <li> <p>Complex Representation: The model correctly represents individual proteins rather than complexes where the specific activities of individual components are known, consistent with the guidelines in \"How to annotate complexes in GO-CAM.\"</p> </li> <li> <p>Regulatory Relationships: The model uses appropriate causal predicates (RO:0002629 and RO:0002630) to represent the phosphorylation-mediated activation and inhibition relationships, in line with the \"Regulation and Regulatory Processes in GO-CAM\" guidelines.</p> </li> <li> <p>Transporter Activities: The cotransporter activities are annotated with appropriate cellular locations and corresponding biological processes, consistent with the \"Transporter activity annotation guidelines.\"</p> </li> </ol>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Remove Duplicate Causal Relationship: Eliminate the duplicate \"directly negatively regulates\" relationship from STK39 to SLC12A6 that lacks evidence.</p> </li> <li> <p>Add Cellular Hyperosmotic Response: Include GO:0071474 (cellular hyperosmotic response) as a biological process and connect it to the WNK1 activities as an overarching context.</p> </li> <li> <p>Expand Molecular Details: Consider adding:</p> </li> <li>Specific phosphorylation sites on cotransporters</li> <li>Molecular triggers of WNK1 phase separation (molecular crowding as described in PMID:36318922)</li> <li> <p>Additional downstream effects on cellular processes</p> </li> <li> <p>Complete Evidence for All Relationships: Ensure that all causal relationships have appropriate evidence annotations.</p> </li> </ol>"},{"location":"reviews/6438950a00000624-Activation_of_the_WNK1_SPAK_OSR1_kinase_cascade_in_response_to_hyperosmotic_stress__leading_to_promote_ion_influx_and_prevent_ion_efflux__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the current knowledge of the WNK1-SPAK/OSR1 signaling pathway in response to hyperosmotic stress. With minor refinements as suggested above, the model would provide an even more comprehensive representation of this important cellular regulatory pathway.</p> <p>The model makes a valuable contribution to the GO-CAM knowledge base by connecting molecular activities from multiple proteins into a coherent biological process with clear physiological relevance to cell volume regulation and osmotic response.</p>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/","title":"6438950a00000714 Regulation of ion transport in the distal nephron by WNK4  Human","text":"<p>Let me synthesize the information I've gathered to provide a thorough review of the GO-CAM model gomodel:6438950a00000714, which focuses on \"Regulation of ion transport in the distal nephron by WNK4 (Human)\".</p>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#go-cam-model-review-gomodel6438950a00000714","title":"GO-CAM Model Review: gomodel:6438950a00000714","text":""},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:6438950a00000714) represents the regulation of ion transport in the distal nephron of the kidney by WNK4 kinase in humans. The model shows a signaling cascade where WNK4 (Q96J92) regulates ion transport by phosphorylating and activating the downstream kinases OXSR1 (O95747) and STK39 (Q9UEW8), which then phosphorylate and activate the sodium-chloride cotransporter SLC12A3/NCC (P55017).</p>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#model-structure-and-biological-content-assessment","title":"Model Structure and Biological Content Assessment","text":""},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#components-and-interactions","title":"Components and Interactions","text":"<p>The model includes four key activities: 1. WNK4 (Q96J92) protein serine/threonine kinase activity 2. OXSR1 (O95747) protein serine/threonine kinase activity 3. STK39 (Q9UEW8) protein serine/threonine kinase activity 4. SLC12A3/NCC (P55017) sodium:chloride symporter activity</p> <p>The causal associations are correctly represented using the \"directly positively regulates\" predicate (RO:0002629) to show that: - WNK4 directly positively regulates both OXSR1 and STK39 - Both OXSR1 and STK39 directly positively regulate SLC12A3/NCC</p>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the WNK-SPAK/OSR1-NCC signaling pathway that plays a crucial role in regulating sodium reabsorption in the distal convoluted tubule of the kidney. This pathway is important for blood pressure regulation, as evidenced by the fact that mutations in WNK kinases cause pseudohypoaldosteronism type II (Gordon syndrome), a form of hypertension that responds to thiazide diuretics (which inhibit NCC).</p> <p>The evidence used to support the model comes from high-quality experimental data, including: - PMID:16832045 (provides evidence for WNK1's regulation of NKCC1 via OSR1) - PMID:18270262 (demonstrates SPAK/OSR1 activation of NCC via phosphorylation)</p>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#subcellular-locations","title":"Subcellular Locations","text":"<p>The model appropriately locates: - WNK4 activity in the bicellular tight junction (GO:0005923) - OXSR1 and STK39 activities in the cytoplasm (GO:0005737) - SLC12A3/NCC activity in the plasma membrane (GO:0005886)</p> <p>These locations are consistent with the known biology of these proteins.</p>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":""},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#model-organization-and-clarity","title":"Model Organization and Clarity","text":"<p>The model follows GO-CAM best practices by: - Using appropriate molecular function terms for each protein activity - Including cellular component information for localization - Properly connecting activities with causal associations - Including evidence codes and literature references</p>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#proper-use-of-annotations","title":"Proper Use of Annotations","text":"<ol> <li>MF annotations: Each protein is correctly annotated with appropriate molecular function terms:</li> <li>WNK4: protein serine/threonine kinase activity (GO:0004674)</li> <li>OXSR1: protein serine/threonine kinase activity (GO:0004674)</li> <li>STK39: protein serine/threonine kinase activity (GO:0004674)</li> <li> <p>SLC12A3: sodium:chloride symporter activity (GO:0015378)</p> </li> <li> <p>BP annotations: All activities are appropriately connected to the biological process of renal sodium ion absorption (GO:0070294)</p> </li> <li> <p>CC annotations: Cellular locations are correctly specified and biologically relevant:</p> </li> <li>WNK4 at tight junctions</li> <li>OXSR1/STK39 in cytoplasm</li> <li> <p>SLC12A3 in plasma membrane</p> </li> <li> <p>Causal associations: The model uses RO:0002629 (directly positively regulates) to correctly indicate the kinase cascade mechanism</p> </li> </ol>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#evidence-support","title":"Evidence Support","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) for most associations - ECO:0000250 (sequence similarity evidence used in manual assertion) for some locations - ECO:0000318 (biological aspect of ancestor evidence used in manual assertion) for STK39's cytoplasmic location</p> <p>All evidence is linked to appropriate references (PMIDs).</p>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is well-constructed and biologically accurate, I suggest the following improvements:</p> <ol> <li> <p>Additional upstream regulation: The model could be expanded to include factors that regulate WNK4, such as low intracellular chloride, which is known to activate WNK kinases. This would provide context for when this pathway is activated.</p> </li> <li> <p>Further downstream effects: The model could be extended to show the physiological consequences of NCC activation, such as increased sodium reabsorption and its effects on blood pressure.</p> </li> <li> <p>Negative regulatory components: The model could include negative regulators of this pathway, such as the ubiquitin ligase complexes containing KLHL3 that target WNK kinases for degradation.</p> </li> <li> <p>Parallel pathways: Consider adding other WNK kinases (WNK1, WNK3) that also regulate SPAK/OSR1 and NCC, which would provide a more complete view of NCC regulation.</p> </li> <li> <p>Pathway modulators: Include the role of hormones like aldosterone that affect this pathway.</p> </li> </ol>"},{"location":"reviews/6438950a00000714-Regulation_of_ion_transport_in_the_distal_nephron_by_WNK4__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6438950a00000714 is a well-constructed, biologically accurate representation of WNK4's role in regulating ion transport in the distal nephron through OXSR1/STK39 and SLC12A3/NCC. It adheres to GO-CAM best practices in terms of annotations, evidence support, and causal associations. The model captures an important pathway in kidney physiology that is relevant to blood pressure regulation and hypertension.</p> <p>With the suggested enhancements, the model could provide an even more comprehensive view of how ion transport in the distal nephron is regulated, which would increase its utility to the research community.</p>"},{"location":"reviews/6446bfcb00000006-Triglyceride_biosynthetic_process_2__Mouse_/","title":"6446bfcb00000006 Triglyceride biosynthetic process 2  Mouse","text":"<p>Now that I have reviewed the model and guidelines, I'll provide a comprehensive review of GO-CAM model 6446bfcb00000006 - \"Triglyceride biosynthetic process 2 (Mouse)\".</p>"},{"location":"reviews/6446bfcb00000006-Triglyceride_biosynthetic_process_2__Mouse_/#review-of-go-cam-model-gomodel6446bfcb00000006","title":"Review of GO-CAM Model gomodel:6446bfcb00000006","text":""},{"location":"reviews/6446bfcb00000006-Triglyceride_biosynthetic_process_2__Mouse_/#summary","title":"Summary","text":"<p>The model represents the triglyceride biosynthetic process in mouse, depicting the sequential enzymatic activities required for triglyceride synthesis, from initial glycerol processing through to final triglyceride formation.</p>"},{"location":"reviews/6446bfcb00000006-Triglyceride_biosynthetic_process_2__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Complete pathway representation: The model successfully captures the entire triglyceride biosynthetic pathway with all major enzymatic steps.</p> </li> <li> <p>Proper causal connections: Activities are connected with the appropriate causal relationship predicates (RO:0002413 \"provides input for\"), showing a clear flow from one activity to the next.</p> </li> <li> <p>Detailed cellular locations: Each activity correctly specifies subcellular locations (ER membrane, mitochondrial outer membrane, cytosol).</p> </li> <li> <p>Well-evidenced assertions: Activities are supported by multiple evidence codes and literature references.</p> </li> <li> <p>Taxon specificity: The model properly specifies mouse gene products (MGI identifiers).</p> </li> </ol>"},{"location":"reviews/6446bfcb00000006-Triglyceride_biosynthetic_process_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing part_of annotation: Activity <code>gomodel:6446bfcb00000006/6446bfcb00000079</code> (phosphatidate phosphatase activity) has a part_of relationship to GO:0019432 (triglyceride biosynthetic process) without any evidence codes. All other activities have evidence for this relationship.</p> </li> <li> <p>Potentially incomplete causal chain: The activity <code>gomodel:6446bfcb00000006/6446bfcb00000015</code> (diacylglycerol O-acyltransferase activity) is the final step in the pathway but doesn't have outgoing causal connections to a product or outcome. Consider whether this represents the complete pathway or if additional connections are needed.</p> </li> <li> <p>No biological context: The model lacks information about what specific biological context this triglyceride synthesis occurs in (e.g., response to feeding, specific developmental stage, etc.).</p> </li> </ol>"},{"location":"reviews/6446bfcb00000006-Triglyceride_biosynthetic_process_2__Mouse_/#technical-correctness","title":"Technical Correctness","text":"<ol> <li>Gene Products and Functions:</li> <li>All gene products are properly linked to their appropriate molecular functions</li> <li> <p>Functions accurately represent the enzymatic activities in triglyceride synthesis</p> </li> <li> <p>Causal Flow:    The causal flow appears correct, following the established pathway:</p> </li> <li>Glyceryl-ether monooxygenase \u2192 Glycerol kinase \u2192 Glycerol-3-phosphate O-acyltransferase</li> <li> <p>1-acylglycerol-3-phosphate O-acyltransferase \u2192 Phosphatidate phosphatase \u2192 Diacylglycerol O-acyltransferase</p> </li> <li> <p>Cellular Locations:</p> </li> <li>Cellular locations are appropriate for each enzyme</li> <li>The model correctly represents that different steps occur in different cellular compartments</li> </ol>"},{"location":"reviews/6446bfcb00000006-Triglyceride_biosynthetic_process_2__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is well-supported by primary literature citations. Each activity and relationship has appropriate evidence codes and PMID references.</p>"},{"location":"reviews/6446bfcb00000006-Triglyceride_biosynthetic_process_2__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add evidence for missing annotation: Add appropriate evidence for the part_of relationship between phosphatidate phosphatase activity and triglyceride biosynthetic process.</p> </li> <li> <p>Consider pathway completion: Evaluate whether the final step should connect to a product or another process.</p> </li> <li> <p>Consider annotating the biological context: If known from the literature, adding information about when/why this pathway is activated would improve the model's utility.</p> </li> <li> <p>Consider adding a descriptive comment: A brief comment describing the pathway represented would make the model more accessible to users.</p> </li> </ol> <p>Overall, this is a well-constructed GO-CAM model that accurately represents the triglyceride biosynthetic process in mouse with strong literature support and proper GO-CAM conventions.</p>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/","title":"6446bfcb00000319 Negative regulation of epidermal growth factor receptor signaling pathway 1  Mouse","text":"<p>Now, let me review the GO-CAM model with ID 6446bfcb00000319 based on the information provided and best practices for GO-CAM curation.</p>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#review-of-go-cam-model-6446bfcb00000319","title":"Review of GO-CAM Model: 6446bfcb00000319","text":""},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: \"Negative regulation of epidermal growth factor receptor signaling pathway 1 (Mouse)\"</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#model-content","title":"Model Content","text":"<p>This model represents the negative regulation of epidermal growth factor receptor (EGFR) signaling pathway in mouse. The model includes:</p> <ol> <li>A signaling pathway initiated by EGF (MGI:MGI:95290) binding to EGFR (MGI:MGI:95294)</li> <li>Activation of EGFR's protein tyrosine kinase activity</li> <li>Involvement of Cbl (MGI:MGI:88279) E3 ubiquitin ligase activity</li> <li>Eps15 (MGI:MGI:104583) ubiquitin binding activity</li> <li>Occurs in the plasma membrane (GO:0005886)</li> <li>The entire pathway leads to negative regulation of EGFR signaling pathway (GO:0042059)</li> </ol>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly depicts the sequential events in EGFR negative regulation</li> <li>Proper representation of causal relationships using appropriate RO relations</li> <li>Correct location annotations (plasma membrane)</li> <li>Good evidence codes with appropriate PMIDs supporting the assertions</li> <li>Proper representation of molecular functions for each gene product</li> </ol>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":""},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#1-missing-context-for-ubiquitin-dependent-endocytosis","title":"1. Missing Context for Ubiquitin-Dependent Endocytosis","text":"<p>The model indicates that Eps15's ubiquitin binding activity (ubiquitin-dependent endocytosis GO:0070086) is part of the negative regulation of EGFR signaling, but does not fully represent how this leads to EGFR degradation. The lysosome (GO:0005764) is listed in the objects but not used in the model.</p>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#2-molecular-details-of-egfr-ubiquitination","title":"2. Molecular Details of EGFR Ubiquitination","text":"<p>The mechanism by which Cbl's E3 ubiquitin ligase activity leads to EGFR ubiquitination should be more explicitly represented. Based on the literature review (PMID:23457600 and PMID:15383614), Cbl-mediated ubiquitination is a key step that needs clearer representation in the model.</p>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#3-additional-molecular-functions","title":"3. Additional Molecular Functions","text":"<p>The literature indicates that EGFR tyrosine kinase activity phosphorylates Cbl, which enhances its ubiquitin ligase activity. This phosphorylation event could be more explicitly represented in the model.</p>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#4-complex-representation","title":"4. Complex Representation","text":"<p>According to the \"How to annotate complexes in GO-CAM\" document, when specific subunits carrying molecular activities are known (as in this case), they should be represented individually with their specific activities. The model correctly does this for the most part, but could be improved by ensuring that all relevant complex components (if any) are included.</p>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#5-other-feedback","title":"5. Other Feedback","text":"<ul> <li>The model could benefit from including the regulation of EGFR internalization after ubiquitination</li> <li>The role of Eps15 in endocytosis could be expanded to show how it connects to the sorting of ubiquitinated EGFR to lysosomes</li> <li>Consider including other components of the endocytosis machinery that interact with ubiquitinated EGFR</li> </ul>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion)</p> <p>The cited PMIDs (23457600, 15383614, 14627991) appear to support the annotations, although I was unable to access the full text of some of these papers.</p>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#ontology-term-usage","title":"Ontology Term Usage","text":"<p>The GO terms used in the model are appropriate for the biological processes being represented: - GO:0061630 (ubiquitin protein ligase activity) - GO:0004713 (protein tyrosine kinase activity) - GO:0042059 (negative regulation of epidermal growth factor receptor signaling pathway) - GO:0005006 (epidermal growth factor receptor activity) - GO:0048018 (receptor ligand activity) - GO:0043130 (ubiquitin binding) - GO:0070086 (ubiquitin-dependent endocytosis)</p>"},{"location":"reviews/6446bfcb00000319-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#summary","title":"Summary","text":"<p>The GO-CAM model 6446bfcb00000319 is a well-constructed representation of EGFR negative regulation in mouse. It correctly represents the key molecular activities and their causal relationships. With some minor improvements in representing the complete pathway of EGFR ubiquitination, endocytosis, and lysosomal degradation, this model would provide a more comprehensive representation of the biological process.</p> <p>The model adheres to GO-CAM best practices by properly representing molecular functions enabled by gene products, appropriate cellular locations, and causal relationships between activities. The evidential support is appropriate and the model is consistent with the literature on EGFR regulation by Cbl-mediated ubiquitination.</p>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/","title":"6446bfcb00000544 Negative regulation of epidermal growth factor receptor signaling pathway 2  Mouse","text":"<p>Based on my review of the GO-CAM model and the related documentation, I'll provide a comprehensive assessment of model gomodel:6446bfcb00000544 entitled \"Negative regulation of epidermal growth factor receptor signaling pathway 2 (Mouse)\".</p>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#go-cam-model-review-gomodel6446bfcb00000544","title":"GO-CAM Model Review: gomodel:6446bfcb00000544","text":""},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#model-information","title":"Model Information","text":"<ul> <li>Title: Negative regulation of epidermal growth factor receptor signaling pathway 2 (Mouse)</li> <li>ID: gomodel:6446bfcb00000544</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model represents the negative regulation of the epidermal growth factor receptor (EGFR) signaling pathway in mouse. The model depicts how the E3 ubiquitin-protein ligase Cbl (MGI:MGI:88279) negatively regulates EGFR (MGI:MGI:95294) signaling with the involvement of other proteins like Eps15 (MGI:MGI:104583) and Grb2 (MGI:MGI:95805).</p>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#biological-content-review","title":"Biological Content Review","text":"<p>The model accurately represents the known mechanism for EGFR downregulation through ubiquitination, capturing several key molecular activities:</p> <ol> <li>The model starts with EGF (MGI:MGI:95290) binding to EGFR, activating the receptor.</li> <li>EGFR's receptor activity then activates Grb2's molecular adaptor activity.</li> <li>Grb2 leads to activation of EGFR's protein tyrosine kinase activity.</li> <li>EGFR's tyrosine kinase activity is linked to Cbl's E3 ubiquitin ligase activity.</li> <li>Cbl's E3 ligase activity directly positively regulates Eps15's ubiquitin binding activity.</li> <li>Eps15's ubiquitin binding activity directly positively regulates EGFR's protein tyrosine kinase activity.</li> </ol> <p>This captures the known sequential steps in EGFR downregulation via endocytosis, where: - EGF binding activates EGFR - Cbl ubiquitinates EGFR - Eps15 (containing ubiquitin-interacting motifs) recognizes ubiquitinated EGFR - This leads to receptor internalization and downregulation</p>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#consistency-with-best-practices","title":"Consistency with Best Practices","text":"<ol> <li>Molecular functions: The model uses appropriate molecular functions for each protein:</li> <li>EGFR: Protein tyrosine kinase activity (GO:0004713) and EGFR activity (GO:0005006)</li> <li>Cbl: Ubiquitin protein ligase activity (GO:0061630)</li> <li>Eps15: Ubiquitin binding (GO:0043130)</li> <li>Grb2: Molecular adaptor activity (GO:0060090)</li> <li> <p>EGF: Receptor ligand activity (GO:0048018)</p> </li> <li> <p>Cellular components: The model correctly places EGFR and Cbl at the plasma membrane (GO:0005886), consistent with literature.</p> </li> <li> <p>Biological processes: Activities are appropriately associated with the biological processes they contribute to:</p> </li> <li>Negative regulation of EGFR signaling pathway (GO:0042059)</li> <li> <p>Ubiquitin-dependent endocytosis (GO:0070086)</p> </li> <li> <p>Causal relations: The causal relations use the appropriate \"directly positively regulates\" (RO:0002629) relationship throughout the model, which is consistent with the GO-CAM guidelines.</p> </li> </ol>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#evidence-support","title":"Evidence Support","text":"<p>The model is well supported by literature-based evidence. Key evidence includes:</p> <ol> <li>PMID:11823423 - Evidence for Cbl's activity in EGFR regulation and the involvement of Grb2</li> <li>PMID:15383614 - Evidence for the role of Eps15 in EGFR endocytosis </li> <li>PMID:12754251 - Supporting evidence for Cbl's role in the pathway</li> </ol> <p>The evidence codes used (ECO:0000314 - direct assay evidence, ECO:0000316 - genetic interaction evidence, ECO:0000315 - mutant phenotype evidence) are appropriate for the assertions made.</p>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Subcellular location consistency: While EGFR and Cbl are correctly located at the plasma membrane (GO:0005886), no cellular location is specified for Eps15's ubiquitin binding activity. According to the UniProt entry (P42567), Eps15 is found in clathrin-coated pits, which would be appropriate to include.</p> </li> <li> <p>Process completion: The model could be extended to include the final steps of EGFR downregulation, including endosomal trafficking and lysosomal degradation. Currently, it focuses on the early steps of ubiquitination and recognition of ubiquitinated EGFR.</p> </li> <li> <p>Additional molecular details: The model could potentially include:</p> </li> <li>EGFR dimerization step following ligand binding</li> <li>The specific sites of EGFR phosphorylation</li> <li>The role of clathrin and the AP2 adaptor complex in the endocytic process</li> </ol>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#parsimony-and-readability","title":"Parsimony and Readability","text":"<p>The model is very focused and parsimonious, making it easy to understand the key regulatory mechanism. It clearly shows how Cbl-mediated ubiquitination leads to EGFR downregulation with the involvement of Eps15 as a key ubiquitin-binding protein in the endocytic machinery.</p>"},{"location":"reviews/6446bfcb00000544-Negative_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:6446bfcb00000544) provides an accurate, well-evidenced representation of EGFR negative regulation through the Cbl-mediated ubiquitination pathway. It follows GO-CAM best practices and uses appropriate molecular function terms, biological process terms, and causal relationships. The minor suggestions for improvement would primarily add more details to the existing mechanism rather than correcting any significant issues.</p> <p>The model successfully captures the core mechanism of EGFR downregulation, which is a critical process for controlling growth factor signaling and preventing excessive cell proliferation.</p>"},{"location":"reviews/6446bfcb00001000-Positive_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/","title":"6446bfcb00001000 Positive regulation of epidermal growth factor receptor signaling pathway 1  Mouse","text":"<p>Based on the information gathered, I will now review the GO-CAM model gomodel:6446bfcb00001000, which is titled \"Positive regulation of epidermal growth factor receptor signaling pathway 1 (Mouse)\".</p>"},{"location":"reviews/6446bfcb00001000-Positive_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#review-of-go-cam-model-gomodel6446bfcb00001000","title":"Review of GO-CAM Model: gomodel:6446bfcb00001000","text":""},{"location":"reviews/6446bfcb00001000-Positive_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#model-summary","title":"Model Summary","text":"<p>This model represents the regulatory mechanisms of the epidermal growth factor receptor (EGFR) signaling pathway in mouse. It focuses on the negative regulation of EGFR signaling through ubiquitination and endocytosis, as well as the positive regulation mechanisms involved.</p> <p>The key proteins in this model include: - Egfr (MGI:MGI:95294) - Mouse epidermal growth factor receptor - Spry2 (MGI:MGI:1345138) - Sprouty homolog 2 - Cbl (MGI:MGI:88279) - E3 ubiquitin-protein ligase - Sh3kbp1 (MGI:MGI:1889583) - SH3 domain-containing kinase-binding protein 1 (CIN85 ortholog)</p>"},{"location":"reviews/6446bfcb00001000-Positive_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#accuracy-assessment","title":"Accuracy Assessment","text":""},{"location":"reviews/6446bfcb00001000-Positive_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#biological-content","title":"Biological Content","text":"<p>The model accurately captures key aspects of EGFR signaling regulation based on the literature:</p> <ol> <li> <p>Cbl-mediated negative regulation: The model correctly shows Cbl (MGI:MGI:88279) functioning as an E3 ubiquitin ligase (GO:0061630) that negatively regulates EGFR signaling through ubiquitination, which is consistent with the literature (PMID:11894095).</p> </li> <li> <p>Role of adaptor proteins: The inclusion of Sh3kbp1 (CIN85 ortholog) with molecular adaptor activity (GO:0060090) participating in ubiquitin-dependent endocytosis (GO:0070086) is well-supported by the PMID:11894095 paper, which specifically describes the Cbl-CIN85-endophilin complex in EGFR downregulation.</p> </li> <li> <p>Spry2 dual function: The model captures the dual role of Spry2 - both as an enzyme inhibitor (GO:0004857) and as having molecular function inhibitor activity (GO:0140678), which corresponds to its known complex regulatory role in EGFR signaling.</p> </li> </ol>"},{"location":"reviews/6446bfcb00001000-Positive_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#go-cam-structure","title":"GO-CAM Structure","text":"<p>The model generally follows GO-CAM best practices, with a few points to note:</p> <ol> <li>Activity connections: The causal relationships between activities are mostly appropriate. For example:</li> <li>Cbl's E3 ubiquitin ligase activity is correctly shown as part of the negative regulation of EGFR signaling pathway</li> <li> <p>Egfr protein tyrosine kinase activity directly positively regulates Spry2 activity, which is biologically accurate</p> </li> <li> <p>Evidence usage: The model appropriately uses evidence codes and citations:</p> </li> <li>ECO:0000266 (sequence orthology evidence) for cross-species inferences</li> <li>ECO:0000315 (mutant phenotype evidence) for functional assertions</li> <li>ECO:0000314 (direct assay evidence) for experimentally validated interactions</li> </ol>"},{"location":"reviews/6446bfcb00001000-Positive_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is generally well-constructed, I suggest the following improvements:</p> <ol> <li>Incomplete mechanistic representation: The model could benefit from a more complete representation of the endocytosis process. From PMID:11894095, we know that endophilins are crucial components of this pathway, but they aren't explicitly represented in the model. Consider adding:</li> <li>Endophilin proteins that interact with Sh3kbp1</li> <li> <p>Specific clathrin-mediated endocytosis activities</p> </li> <li> <p>Missing ubiquitin-dependent protein catabolic process: While the model shows Cbl's E3 ubiquitin ligase activity, it doesn't explicitly include GO:0006511 (ubiquitin-dependent protein catabolic process) as a downstream biological process, which would more clearly connect the ubiquitination to receptor degradation.</p> </li> <li> <p>Molecular function context: For Cbl's E3 ubiquitin ligase activity, the model should specify which protein is being ubiquitinated (EGFR) as specified in the E3 ubiquitin ligases documentation, which indicates \"has input the substrate protein\" should be included.</p> </li> <li> <p>Evidence for some interactions: Some causal associations lack evidence codes or are based on orthology evidence where direct experimental evidence might be preferable.</p> </li> </ol>"},{"location":"reviews/6446bfcb00001000-Positive_regulation_of_epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6446bfcb00001000 provides a biologically accurate representation of EGFR signaling regulation in mouse, focusing on the Cbl-mediated negative regulation pathway. The model correctly captures the key molecular functions, biological processes and protein interactions involved in this pathway.</p> <p>The main strengths are the accurate representation of Cbl's E3 ubiquitin ligase activity in EGFR downregulation and the inclusion of adaptor proteins like Sh3kbp1. The model could be improved by providing a more detailed representation of the endocytosis mechanism, explicitly including the ubiquitin-dependent protein catabolic process, and specifying the ubiquitination substrate.</p> <p>Overall, this is a high-quality model that aligns well with current literature on EGFR signaling regulation and follows GO-CAM best practices, with minor improvements suggested to enhance its completeness and clarity.</p>"},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/","title":"6446bfcb00001208 Thiamine diphosphate biosynthetic process 1  Mouse","text":"<p>Now that I have examined the GO-CAM model and related information, I'll provide a comprehensive review of gomodel:6446bfcb00001208 which represents \"Thiamine diphosphate biosynthetic process 1 (Mouse)\".</p>"},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/#review-of-gomodel6446bfcb00001208-thiamine-diphosphate-biosynthetic-process-1-mouse","title":"Review of gomodel:6446bfcb00001208 - Thiamine diphosphate biosynthetic process 1 (Mouse)","text":""},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/#overview","title":"Overview","text":"<p>This model represents the thiamine diphosphate biosynthetic process in mice (Mus musculus). It includes several key activities involved in the transport and metabolism of thiamine (vitamin B1) to produce thiamine diphosphate (TPP), the metabolically active form of thiamine.</p>"},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model includes the following activities and molecular functions:</p> <ol> <li>Thiamine transmembrane transport by two transporters:</li> <li>Slc19a2 (thiamine transporter 1) at the plasma membrane</li> <li> <p>Slc19a3 (thiamine transporter 2) at the plasma membrane</p> </li> <li> <p>Thiamine phosphorylation by:</p> </li> <li> <p>Tpk1 (thiamine pyrophosphokinase 1) in the cytosol performing thiamine diphosphokinase activity</p> </li> <li> <p>Thiamine pyrophosphate transport by:</p> </li> <li> <p>Slc25a19 at the mitochondrial inner membrane performing thiamine pyrophosphate transmembrane transporter activity</p> </li> <li> <p>The model represents a causal flow with the following associations:</p> </li> <li>The thiamine transmembrane transporters (Slc19a2 and Slc19a3) provide input for Tpk1</li> <li>Tpk1 provides input for Slc25a19 transporter</li> </ol>"},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate pathway representation: The model correctly captures the biochemical flow of thiamine from extracellular uptake to conversion to the active TPP form and subsequent mitochondrial transport.</p> </li> <li> <p>Appropriate evidence: The model uses appropriate evidence codes (ECO:0000314 for direct assay and ECO:0000315 for mutant phenotype) and relevant PMIDs to support the annotations.</p> </li> <li> <p>Correct cellular localization: The components are correctly localized in their respective cellular compartments: plasma membrane for thiamine transporters, cytosol for the phosphorylation step, and mitochondrial inner membrane for TPP transport.</p> </li> <li> <p>Proper causal relationships: The model uses RO:0002413 (\"provides input for\") appropriately to show the flow of thiamine through the pathway.</p> </li> </ol>"},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Activity diagram completeness: The model would benefit from including the final destination of TPP in the mitochondria and its role in key TPP-dependent enzymes like alpha-ketoglutarate dehydrogenase. Showing the ultimate biological outcomes of the pathway would enhance the model's comprehensiveness.</p> </li> <li> <p>Clarify physiological significance: The model could benefit from annotations that highlight the importance of this pathway and consequences of dysfunction, especially given the research showing how deficiencies lead to severe neurological disorders as seen in the PMID:28665968 study.</p> </li> <li> <p>Regulatory elements: The model could be enhanced by including known regulatory factors that affect thiamine transport or metabolism, if they are known. For example, factors that regulate the expression or activity of the transporters.</p> </li> <li> <p>Process resolution: The thiamine diphosphate biosynthetic process (GO:0009229) is used as a 'part_of' for all activities, but it might be helpful to include more granular processes in some cases (e.g., \"thiamine transport\" for the transporters specifically).</p> </li> </ol>"},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/#technical-compliance","title":"Technical Compliance","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li>Using appropriate molecular function terms for each protein</li> <li>Correctly representing the cellular components where each activity occurs</li> <li>Using appropriate causal relations between activities</li> <li>Providing published evidence for the annotated functions</li> </ol>"},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on the primary research evidence I've reviewed:</p> <ol> <li> <p>The model accurately reflects the known pathway for thiamine metabolism in mammals.</p> </li> <li> <p>The research from PMID:22194418 supports the role of both Slc19a2 and Slc19a3 in thiamine transport, with relative contribution of both transporters being important.</p> </li> <li> <p>PMID:17035501 confirms the function of Slc25a19 as a mitochondrial thiamine pyrophosphate transporter rather than a deoxyribonucleotide transporter as previously thought.</p> </li> <li> <p>PMID:28665968 demonstrates the critical importance of this pathway, showing how Slc19a3 deficiency causes severe neurological disorders that can be partially rescued by high-dose thiamine treatment.</p> </li> </ol>"},{"location":"reviews/6446bfcb00001208-Thiamine_diphosphate_biosynthetic_process_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The model gomodel:6446bfcb00001208 provides a good representation of the thiamine diphosphate biosynthetic process in mice. It accurately captures the key proteins involved, their molecular functions, cellular locations, and the causal flow of the pathway. </p> <p>The model could be further enhanced by extending it to include the ultimate biological outcomes of TPP activity in mitochondria, adding known regulatory elements, and perhaps including more specific sub-processes. Overall, the model is scientifically sound, well-supported by evidence, and complies with GO-CAM best practices.</p>"},{"location":"reviews/6446bfcb00001243-Thiamine_diphosphate_biosynthetic_process_2__Mouse_/","title":"6446bfcb00001243 Thiamine diphosphate biosynthetic process 2  Mouse","text":"<p>Now I'll review the GO-CAM model with ID gomodel:6446bfcb00001243, which is titled \"Thiamine diphosphate biosynthetic process 2 (Mouse)\" focused on mouse thiamine metabolism.</p>"},{"location":"reviews/6446bfcb00001243-Thiamine_diphosphate_biosynthetic_process_2__Mouse_/#overview-of-the-go-cam-model","title":"Overview of the GO-CAM Model","text":"<p>This model describes the thiamine diphosphate biosynthetic pathway in mouse cells, including: - 5 molecular activities carried out by different proteins - 3 causal relationships between activities - Multiple cellular compartments (plasma membrane, cytosol, mitochondrial inner membrane)</p>"},{"location":"reviews/6446bfcb00001243-Thiamine_diphosphate_biosynthetic_process_2__Mouse_/#evaluation-of-biological-content","title":"Evaluation of Biological Content","text":"<p>The model describes a pathway for thiamine (vitamin B1) uptake, transport, and metabolism in mouse cells, focusing on the following key steps:</p> <ol> <li>Thiamine transmembrane transporters (Slc19a2 and Slc19a3) on the plasma membrane import thiamine into the cell</li> <li>Thiamine is phosphorylated to thiamine diphosphate (TPP) by thiamine diphosphokinase (Tpk1) in the cytosol</li> <li>TPP is transported into mitochondria by the mitochondrial TPP transporter (Slc25a19)</li> <li>Thiamine triphosphate phosphatase (Thtpa) dephosphorylates thiamine triphosphate</li> </ol> <p>The model is well supported by literature evidence and properly annotated with relevant PMIDs. The publications confirm:</p> <ul> <li>The function of Slc19a2 and Slc19a3 as thiamine transporters</li> <li>The role of Tpk1 in phosphorylating thiamine to thiamine diphosphate</li> <li>The mitochondrial transport of thiamine diphosphate by Slc25a19</li> <li>The thiamine triphosphate phosphatase activity of Thtpa</li> </ul>"},{"location":"reviews/6446bfcb00001243-Thiamine_diphosphate_biosynthetic_process_2__Mouse_/#review-of-model-structure-and-go-cam-compliance","title":"Review of Model Structure and GO-CAM Compliance","text":"<p>The model follows GO-CAM best practices with:</p> <ol> <li>Proper use of \"enabled by\" relationships: Each activity is correctly annotated with the gene product that enables it</li> <li>Proper cellular location: Each activity is located in the appropriate cellular compartment</li> <li>Proper use of causal relations: Activities are connected with appropriate causal relations using \"provides input for\" (RO:0002413)</li> <li>Appropriate evidence codes: Experimental evidence codes (ECO:0000314 and ECO:0000315) are used with relevant PMIDs</li> <li>Correct biological process associations: All activities are part of the thiamine diphosphate biosynthetic process (GO:0009229)</li> </ol>"},{"location":"reviews/6446bfcb00001243-Thiamine_diphosphate_biosynthetic_process_2__Mouse_/#causal-relationships-analysis","title":"Causal Relationships Analysis","text":"<p>The model contains three causal relationships: 1. Slc19a2 (thiamine transmembrane transporter) provides input for Tpk1 (thiamine diphosphokinase) 2. Slc19a3 (another thiamine transmembrane transporter) provides input for Tpk1 3. Thtpa (thiamine triphosphate phosphatase) provides input for Slc25a19 (thiamine pyrophosphate transmembrane transporter)</p> <p>The first two relationships make biological sense - thiamine transporters import thiamine, which is then a substrate for thiamine diphosphokinase. </p> <p>However, the third causal relationship (from Thtpa to Slc25a19) appears problematic: - Thtpa dephosphorylates thiamine triphosphate to thiamine diphosphate (TPP) - Slc25a19 is a mitochondrial TPP transporter - The directionality suggests that the output of Thtpa is used by Slc25a19, but the literature doesn't clearly support this relationship - Based on the literature, Slc25a19 transports TPP into mitochondria, while Thtpa dephosphorylates thiamine triphosphate to TPP in the cytosol</p>"},{"location":"reviews/6446bfcb00001243-Thiamine_diphosphate_biosynthetic_process_2__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li>Reconsider the causal relationship between Thtpa and Slc25a19:</li> <li>The current relationship suggests Thtpa activity provides input for Slc25a19, but the direction of thiamine metabolism in cells suggests Slc25a19 activity should come after Tpk1 (which produces TPP) and before Thtpa.</li> <li> <p>The model would be more accurate if restructured to show:</p> <ul> <li>Tpk1 (thiamine diphosphokinase) provides input for Slc25a19 (TPP transporter)</li> <li>Slc25a19 potentially provides input for other mitochondrial TPP-dependent enzymes (not currently in the model)</li> </ul> </li> <li> <p>Consider adding other key enzymes in thiamine metabolism:</p> </li> <li>Thiamine pyrophosphokinase, which converts thiamine diphosphate to thiamine triphosphate (the substrate for Thtpa)</li> <li> <p>TPP-dependent enzymes that use TPP as a cofactor (e.g., pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase)</p> </li> <li> <p>Add annotations indicating the role of thiamine diphosphate as a cofactor:</p> </li> <li>The model currently focuses on the biosynthesis of TPP but doesn't capture its role as an essential cofactor for metabolic enzymes</li> </ol>"},{"location":"reviews/6446bfcb00001243-Thiamine_diphosphate_biosynthetic_process_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Thiamine diphosphate biosynthetic process 2 (Mouse)\" (gomodel:6446bfcb00001243) presents a mostly accurate representation of thiamine transport and metabolism in mouse cells, with well-supported evidence from the literature. The model follows GO-CAM best practices in terms of structure and annotation.</p> <p>The main issue is the questionable causal relationship between the thiamine triphosphate phosphatase (Thtpa) and the mitochondrial thiamine pyrophosphate transporter (Slc25a19), which doesn't seem to accurately reflect the sequence of events in thiamine metabolism based on the literature. Reorganizing this relationship and potentially adding more enzymes involved in thiamine metabolism would make the model more complete and biologically accurate.</p>"},{"location":"reviews/6446bfcb00001774-Autophagosome_assembly__Human_/","title":"6446bfcb00001774 Autophagosome assembly  Human","text":"<p>Based on my review of the GO-CAM model and the relevant guidelines, here's my assessment of the \"Autophagosome assembly (Human)\" model (gomodel:6446bfcb00001774):</p>"},{"location":"reviews/6446bfcb00001774-Autophagosome_assembly__Human_/#go-cam-review-autophagosome-assembly-human-gomodel6446bfcb00001774","title":"GO-CAM Review: Autophagosome assembly (Human) - gomodel:6446bfcb00001774","text":""},{"location":"reviews/6446bfcb00001774-Autophagosome_assembly__Human_/#overview","title":"Overview","text":"<p>This model represents the process of autophagosome assembly in humans (NCBITaxon:9606), which is a key process in autophagy. The model includes multiple molecular activities involved in phagophore initiation, elongation, and autophagosome formation.</p>"},{"location":"reviews/6446bfcb00001774-Autophagosome_assembly__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive pathway representation: The model provides a detailed representation of autophagosome assembly with 30+ activities involving key proteins like ULK1, ATG proteins, PI3K complex components, and LC3/GABARAP family proteins.</p> </li> <li> <p>Appropriate subcellular localization: Activities are correctly localized to appropriate cellular components (phagophore assembly site, autophagosome membrane, etc.).</p> </li> <li> <p>Well-evidenced assertions: All activities have evidence codes and literature references supporting the annotations.</p> </li> <li> <p>Causal connectivity: The model shows appropriate causal connections between activities (using RO:0002629 for direct positive regulation and RO:0002413 for providing input).</p> </li> </ol>"},{"location":"reviews/6446bfcb00001774-Autophagosome_assembly__Human_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Evidence code inconsistency: </li> <li> <p>In activity ID <code>gomodel:6446bfcb00001774/645d887900001734</code> (AMBRA1), the cellular location evidence references \"PMID:cytoplasm\" instead of a proper PMID. This should be corrected with a valid PMID reference.</p> </li> <li> <p>Redundant causal connections:</p> </li> <li>Several activities have duplicate causal associations with the same predicate to the same downstream activity. For example:<ul> <li>In activity ID <code>gomodel:6446bfcb00001774/645d887900001770</code> (BECN1), there are two identical causal associations to the same downstream activity.</li> <li>In activity ID <code>gomodel:6446bfcb00001774/646ff70100000384</code> (ATG4C), there are duplicate causal associations to activity <code>646ff70100000276</code>.</li> </ul> </li> <li> <p>These redundancies should be removed to maintain model clarity.</p> </li> <li> <p>Missing evidence in causal associations:</p> </li> <li>Several causal associations have empty evidence lists. For example:<ul> <li>Activity ID <code>gomodel:6446bfcb00001774/645d887900001924</code> has a causal association with no evidence.</li> <li>Activity ID <code>gomodel:6446bfcb00001774/645d887900001755</code> has a causal association with empty evidence.</li> </ul> </li> <li> <p>All causal associations should have supporting evidence.</p> </li> <li> <p>Molecular adaptor annotation improvement:</p> </li> <li> <p>According to the molecular adaptor annotation guidelines, adaptors should have inputs specified through the \"has_input\" relation. However:</p> <ul> <li>Activity ID <code>gomodel:6446bfcb00001774/645d887900001770</code> (BECN1) with adaptor activity doesn't specify all its inputs.</li> <li>Activity ID <code>gomodel:6446bfcb00001774/646ff70100002442</code> (WIPI1) with adaptor activity correctly specifies CHEBI:58088 as input but may be missing other relevant inputs.</li> </ul> </li> <li> <p>Regulatory relationship representation:</p> </li> <li> <p>The inhibitory activity of MTOR (P42345) on AMBRA1 is correctly represented with RO:0002630 (directly negatively regulates), but there's a duplicate causal association that should be removed.</p> </li> <li> <p>Complex representation:</p> </li> <li>For the PI3K complex involved in autophagosome assembly, the model correctly represents individual activities of proteins like BECN1 and PIK3C3 rather than using a complex identifier, which is appropriate since the individual activities are known.</li> </ol>"},{"location":"reviews/6446bfcb00001774-Autophagosome_assembly__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Fix the evidence code \"PMID:cytoplasm\" in activity ID <code>gomodel:6446bfcb00001774/645d887900001734</code>.</p> </li> <li> <p>Remove redundant causal associations to improve model clarity.</p> </li> <li> <p>Add proper evidence to all causal associations that currently have empty evidence fields.</p> </li> <li> <p>For molecular adaptors (BECN1, WIPI1), ensure all relevant molecules they bring together are specified as inputs.</p> </li> <li> <p>Consider adding more information about the relationship between phospholipid binding activities and membrane recruitment in phagophore elongation.</p> </li> </ol>"},{"location":"reviews/6446bfcb00001774-Autophagosome_assembly__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a comprehensive representation of autophagosome assembly in humans with good biological accuracy and evidence support. With the minor improvements suggested above, it will be an excellent resource for understanding autophagy regulation and autophagosome formation.</p> <p>The model effectively captures the step-wise process of autophagosome assembly, from ULK1 kinase activity initiating the process to the conjugation of LC3/GABARAP family proteins to the autophagosome membrane, which is consistent with current knowledge of autophagy.</p>"},{"location":"reviews/645d887900000340-Coenzyme_A_biosynthetic_process_1__Mouse_/","title":"645d887900000340 Coenzyme A biosynthetic process 1  Mouse","text":"<p>Based on the information gathered, I'll now review the GO-CAM model for \"Coenzyme A biosynthetic process 1 (Mouse)\" (gomodel:645d887900000340).</p>"},{"location":"reviews/645d887900000340-Coenzyme_A_biosynthetic_process_1__Mouse_/#review-of-go-cam-model-coenzyme-a-biosynthetic-process-1-mouse","title":"Review of GO-CAM Model: Coenzyme A biosynthetic process 1 (Mouse)","text":""},{"location":"reviews/645d887900000340-Coenzyme_A_biosynthetic_process_1__Mouse_/#model-summary","title":"Model Summary","text":"<p>This model represents the Coenzyme A (CoA) biosynthetic pathway in mouse, including the enzymatic activities and transport steps required for CoA biosynthesis. The model includes multiple gene products, their molecular functions, cellular locations, and causal relationships showing the flow of the pathway.</p>"},{"location":"reviews/645d887900000340-Coenzyme_A_biosynthetic_process_1__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the canonical CoA biosynthetic pathway, which consists of five enzymatic steps: 1. Pantothenate kinase (PANK1/PANK2) - converts pantothenate to 4'-phosphopantothenate 2. Phosphopantothenoylcysteine synthetase (PPCS) - forms 4'-phosphopantothenoylcysteine 3. Phosphopantothenoylcysteine decarboxylase (PPCDC) - produces 4'-phosphopantetheine 4. Pantetheine-phosphate adenylyltransferase activity (COASY) - forms dephospho-CoA 5. Dephospho-CoA kinase activity (COASY) - produces the final CoA</p> <p>Additionally, the model includes appropriate transporters: - SLC5A6 (pantothenate:sodium symporter) - SLC25A16 and SLC25A42 (mitochondrial transporters)</p>"},{"location":"reviews/645d887900000340-Coenzyme_A_biosynthetic_process_1__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>Comprehensive pathway representation: The model accurately covers all key steps of CoA biosynthesis.</li> <li>Proper causal connections: The activities are connected with the appropriate \"provides input for\" (RO:0002413) causal relation showing pathway flow.</li> <li>Consistent cellular locations: Each activity is appropriately localized (cytosol, mitochondrial membranes, etc.).</li> <li>Well-evidenced annotations: The model uses appropriate evidence codes (ECO terms) and references (PMIDs) for the assertions.</li> <li>Proper regulation: The model includes PDZD11 as an enzyme activator of SLC5A6.</li> </ol>"},{"location":"reviews/645d887900000340-Coenzyme_A_biosynthetic_process_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing chemical entities: While the activities are well-connected, the model doesn't explicitly show the metabolic intermediates as chemical entities. According to best practices, including the ChEBI terms for substrates and products would enhance the model.</p> </li> <li> <p>Transporter annotations: The transporters (SLC5A6, SLC25A16, SLC25A42) are included, but according to the transporter activity annotation guidelines, it would be ideal to explicitly represent:</p> </li> <li>The specific molecules being transported</li> <li> <p>The start and end locations of the transported molecules</p> </li> <li> <p>COASY dual function: The protein COASY (MGI:MGI:1918993) correctly has two separate activities (pantetheine-phosphate adenylyltransferase and dephospho-CoA kinase) but it could be clearer that this is a bifunctional enzyme.</p> </li> <li> <p>Missing \"occurs_in\" annotation: Some activities don't have an \"occurs_in\" relation to specify their cellular location, though most do.</p> </li> <li> <p>Limited pathway context: While the biosynthetic pathway is well-represented, the model could benefit from connections to processes that utilize CoA.</p> </li> </ol>"},{"location":"reviews/645d887900000340-Coenzyme_A_biosynthetic_process_1__Mouse_/#technical-assessment","title":"Technical Assessment","text":"<ol> <li> <p>Predicates: The model correctly uses RO:0002413 (provides input for) to connect sequential activities in the pathway, and RO:0002629 (directly positively regulates) for the regulatory relationship.</p> </li> <li> <p>Evidence codes: The model uses appropriate evidence codes including:</p> </li> <li>ECO:0000314 (direct assay evidence)</li> <li>ECO:0000315 (mutant phenotype evidence)</li> <li>ECO:0000316 (genetic interaction evidence)</li> <li> <p>ECO:0000266 (sequence orthology evidence)</p> </li> <li> <p>References: Each assertion is supported by PMIDs.</p> </li> </ol>"},{"location":"reviews/645d887900000340-Coenzyme_A_biosynthetic_process_1__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a high-quality GO-CAM model that accurately represents the CoA biosynthetic pathway in mouse. It follows the major GO-CAM best practices for pathway representation and provides appropriate evidence for the assertions. The few suggested improvements would enhance the model but are not critical flaws. The model is parsimonious and presents a clear flow of the pathway that would be understandable to other researchers.</p> <p>You can view this model at: https://bioregistry.io/go.model:645d887900000340</p>"},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/","title":"645d887900000439 Contracted muscle secreted FN1 activates liver autophagy via hepatic Itga5 Itgb1 integrin receptor signaling   Mouse","text":"<p>Based on the information I've gathered, let me review the GO-CAM model gomodel:645d887900000439 titled \"Contracted-muscle secreted FN1 activates liver autophagy via hepatic Itga5:Itgb1 integrin receptor signaling. (Mouse)\".</p>"},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/#go-cam-review-gomodel645d887900000439","title":"GO-CAM Review: gomodel:645d887900000439","text":""},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/#general-information","title":"General Information","text":"<ul> <li>Title: Contracted-muscle secreted FN1 activates liver autophagy via hepatic Itga5:Itgb1 integrin receptor signaling. (Mouse)</li> <li>ID: gomodel:645d887900000439</li> <li>Taxon: NCBITaxon:9606 (Human) - Note: There appears to be a discrepancy as the title mentions Mouse, but the taxon is set to human.</li> <li>Status: Production</li> <li>Comments: \"Itgb1:Itga5 complex, how to annotate?\"</li> </ul>"},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/#biological-pathway-represented","title":"Biological Pathway Represented","text":"<p>This model represents how exercise-induced secretion of fibronectin (FN1) from contracting muscle activates autophagy in the liver through the Itga5:Itgb1 integrin receptor signaling pathway. The pathway includes:</p> <ol> <li>FN1 (Fn1 protein) serving as a receptor ligand</li> <li>Activation of integrin receptors (Itga5 and Itgb1)</li> <li>Signaling through IKK complex proteins (Chuk and Ikbkb)</li> <li>JNK activation (Mapk8)</li> <li>Regulation of Bcl2-Becn1 interaction</li> <li>Impact on autophagy</li> </ol>"},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/#model-review","title":"Model Review","text":""},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>Evidence Support: The model is well-supported by primary literature evidence, with most associations referencing PMID:36812915, which describes this pathway in detail.</li> <li>Pathway Completeness: The model captures the key components of the FN1-integrin-autophagy signaling pathway described in the literature.</li> <li>Biological Process Annotation: Components are properly annotated with relevant biological processes (e.g., integrin-mediated signaling pathway, response to muscle activity, autophagy).</li> <li>Cellular Localization: Proper cellular location annotations are included (e.g., extracellular space for FN1, plasma membrane for integrin receptors, cytoplasm for downstream signaling components).</li> </ol>"},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Taxon Discrepancy:</li> <li> <p>The taxon is listed as human (NCBITaxon:9606) but the title indicates this is a mouse model. This should be corrected to mouse (NCBITaxon:10090).</p> </li> <li> <p>Integrin Complex Annotation:</p> </li> <li>The curator's comment \"Itgb1:Itga5 complex, how to annotate?\" suggests uncertainty about how to properly represent the integrin heterodimer.</li> <li> <p>Recommendation: Based on the complex annotation guidelines, since both Itga5 and Itgb1 are individually required for the receptor activity and the signaling is dependent on both, they can be individually annotated with the same molecular function (as done in this model with \"signaling receptor activity\" GO:0038023). This appears to be correctly implemented in the current model.</p> </li> <li> <p>Causal Association Predicate:</p> </li> <li>The integrin receptor activities are linked to downstream IKK activities using the predicate RO:0002407 (\"provides input for\") rather than the more specific causal predicates like RO:0002629 (\"directly positively regulates\").</li> <li> <p>Recommendation: Consider using more specific causal relationships such as \"directly positively regulates\" if the literature supports a direct regulatory relationship.</p> </li> <li> <p>BCL2 Molecular Adaptor Function:</p> </li> <li>BCL2 is annotated with \"molecular adaptor activity\" (GO:0060090), which seems appropriate based on its role in this pathway as described in the paper, where it interacts with BECN1.</li> <li> <p>However, its canonical role as an anti-apoptotic protein might be more familiar. The molecular adaptor annotation is focused on its specific role in this autophagy pathway.</p> </li> <li> <p>Complex Representation:</p> </li> <li>While the model does not explicitly define an Itga5:Itgb1 complex, the individual components and their linked activities correctly represent the functional heterodimeric integrin receptor according to GO-CAM best practices.</li> </ol>"},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/#literature-alignment","title":"Literature Alignment","text":"<p>The model aligns well with the key findings from PMID:36812915, which describes: 1. Exercise-induced muscle secretion of FN1 2. FN1 binding to alpha5beta1 integrin receptors on hepatocytes 3. Activation of IKKalpha/beta-JNK1 signaling 4. Phosphorylation of BCL2 and release of BECN1 5. Activation of autophagy in the liver</p> <p>The model captures this signaling pathway and the relationships between the components accurately.</p>"},{"location":"reviews/645d887900000439-Contracted_muscle_secreted_FN1_activates_liver_autophagy_via_hepatic_Itga5_Itgb1_integrin_receptor_signaling___Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the FN1-integrin-autophagy signaling pathway described in the literature. The model follows GO-CAM best practices for most aspects, including annotation of molecular functions, biological processes, and cellular components.</p> <p>The main issues to address are: 1. The taxon discrepancy (human vs. mouse) 2. Potentially using more specific causal predicates for some relationships</p> <p>The question about how to annotate the Itga5:Itgb1 complex has been appropriately addressed by annotating each component with the same molecular function, which is an acceptable approach according to the complex annotation guidelines.</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/","title":"645d887900000671 Osteocalcin  bglap  hormone produced by osteoblasts binds Gprc6a  receptor and regulates testosterone biosynthesis and male fertility  Mouse","text":"<p>Now I have sufficient information to conduct a thorough review of the GO-CAM model. Let me analyze the model based on all the information gathered.</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#review-of-go-cam-model-gomodel645d887900000671","title":"Review of GO-CAM Model: gomodel:645d887900000671","text":""},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#model-overview","title":"Model Overview","text":"<p>Title: Osteocalcin (bglap) hormone produced by osteoblasts binds Gprc6a receptor and regulates testosterone biosynthesis and male fertility (Mouse).</p> <p>Taxon: NCBITaxon:10090 (Mouse)</p> <p>Status: Production</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#components-and-structure","title":"Components and Structure","text":"<p>This model represents how the bone-derived hormone osteocalcin regulates male fertility through binding to the Gprc6a receptor, which leads to testosterone biosynthesis. The model includes four main activities:</p> <ol> <li>Bglap (Osteocalcin) - Hormone activity (GO:0005179) that occurs in extracellular region</li> <li>Gprc6a receptor - G protein-coupled receptor activity (GO:0004930) that occurs in plasma membrane</li> <li>Ggcx - Gamma-glutamyl carboxylase activity (GO:0008488)</li> <li>Creb1 - DNA-binding transcription factor activity (GO:0000981) that occurs in nucleus</li> </ol> <p>The causal flow in the model is: - Ggcx directly negatively regulates Bglap hormone activity - Bglap provides input for Gprc6a receptor activity - Gprc6a receptor activates Creb1 transcription factor activity</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#assessment-of-biological-accuracy","title":"Assessment of Biological Accuracy","text":"<p>The biological pathway represented in this model is well-supported by scientific literature, particularly by the PMID:21333348 (Oury et al., 2011), which demonstrates that osteocalcin acts as a hormone that binds to the Gprc6a receptor in Leydig cells to promote testosterone production.</p> <p>The key findings from this paper that support the model include: - Osteocalcin is produced by osteoblasts and acts as a hormone that regulates male fertility - Uncarboxylated osteocalcin binds to the Gprc6a receptor on Leydig cells - This binding activates a cAMP signaling pathway that leads to CREB phosphorylation - CREB then regulates genes involved in testosterone biosynthesis - This pathway is specific to male fertility and does not affect female fertility</p> <p>The model correctly captures the carboxylation of osteocalcin by gamma-glutamyl carboxylase (Ggcx), which negatively regulates osteocalcin's hormonal activity, as the uncarboxylated form is the active form of the hormone.</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#go-cam-best-practices-review","title":"GO-CAM Best Practices Review","text":""},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#hormone-activity-annotation","title":"Hormone activity annotation","text":"<p>The model correctly follows the guidelines for hormone activity annotation: - Bglap (MGI:MGI:88156) enables hormone activity (GO:0005179) - It occurs in the extracellular region (GO:0005576) - It is part of regulation of testosterone biosynthetic process (GO:2000224) - It provides input for the Gprc6a receptor activity using the RO:0002413 predicate</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#gpcr-signaling-annotation","title":"GPCR signaling annotation","text":"<p>The model follows the guidelines for signaling receptor activity: - Gprc6a (MGI:MGI:2429498) enables G protein-coupled receptor activity (GO:0004930) - It occurs in plasma membrane (GO:0005886) - It is part of regulation of testosterone biosynthetic process (GO:2000224) - It receives input from hormone osteocalcin - It has a causal relationship (RO:0002407) with the downstream transcription factor activity</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#transcription-factor-activity-annotation","title":"Transcription factor activity annotation","text":"<p>The model follows the guidelines for DNA-binding transcription factor activity: - Creb1 (MGI:MGI:88494) enables DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981) - It occurs in nucleus (GO:0005634) - It is part of regulation of testosterone biosynthetic process (GO:2000224)</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#enzyme-activity-annotation","title":"Enzyme activity annotation","text":"<p>The gamma-glutamyl carboxylase (Ggcx) activity is correctly annotated: - Ggcx (MGI:MGI:1927655) enables gamma-glutamyl carboxylase activity (GO:0008488) - It is part of peptidyl-glutamic acid carboxylation (GO:0017187) - It directly negatively regulates (RO:0002630) the hormone activity of osteocalcin, which is biologically accurate since carboxylation inhibits the hormone activity of osteocalcin</p>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Evidence for the negative regulation relationship:    While the model shows that Ggcx directly negatively regulates Bglap hormone activity, this causal association doesn't have any evidence information attached to it. It would be good to add appropriate evidence for this relationship.</p> </li> <li> <p>More detailed molecular description:    The model could be improved by adding more molecular details about how CREB1 regulates testosterone biosynthesis, particularly by showing which genes it regulates. The literature indicates that CREB regulates genes like StAR, Cyp11a, and 3beta-HSD, which are involved in testosterone biosynthesis.</p> </li> <li> <p>Cellular component for Ggcx:    The cellular component for Ggcx activity is missing. According to UniProt, this enzyme is localized in the endoplasmic reticulum, so a \"occurs_in\" relationship to the appropriate cellular component would improve the model.</p> </li> </ol>"},{"location":"reviews/645d887900000671-Osteocalcin__bglap__hormone_produced_by_osteoblasts_binds_Gprc6a__receptor_and_regulates_testosterone_biosynthesis_and_male_fertility__Mouse__/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model accurately represents the endocrine regulation of male fertility by the skeleton through osteocalcin, following the scientific evidence and GO-CAM best practices. The model captures the key biological entities and their relationships, with appropriate GO terms and evidence. The model is parsimonious and represents the pathway in a way that is easy to understand.</p> <p>The only significant improvements would be adding evidence for the Ggcx negative regulation relationship, providing more detail on downstream gene regulation by CREB1, and including the cellular component for Ggcx activity.</p> <p>This model can be considered a high-quality representation of this biological pathway.</p>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/","title":"645d887900000706 Smog GPCR signaling   epithelial tube formation  D mel","text":"<p>Now I'll analyze the model and provide my review based on the information gathered.</p>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#review-of-go-cam-model-gomodel645d887900000706","title":"Review of GO-CAM Model gomodel:645d887900000706","text":""},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#model-title","title":"Model Title","text":"<p>\"Smog GPCR signaling, epithelial tube formation (D.mel)\"</p>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#model-overview","title":"Model Overview","text":"<p>This model describes a GPCR signaling pathway in Drosophila melanogaster that regulates epithelial tube formation through apical constriction. The model starts with Fog ligand activating Smog receptor, which leads to a cascade involving G-proteins (Concertina/Cta, Rho1), Rok kinase, and ultimately affecting Sqh to regulate apical constriction, a critical process for epithelial tube formation.</p>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#pathway-flow","title":"Pathway Flow","text":"<ol> <li>Fog (FBgn0000719) \u2192 receptor ligand activity \u2192 extracellular space (GO:0005615)</li> <li>Directly positively regulates</li> <li>Smog (FBgn0051660) \u2192 G protein-coupled receptor activity \u2192 plasma membrane (GO:0005886) </li> <li>Directly positively regulates</li> <li>Cta (FBgn0000384) \u2192 G protein activity \u2192 cytosol (GO:0005829)</li> <li>Directly positively regulates</li> <li>Rho1 (FBgn0014020) \u2192 GTPase activity \u2192 cytosol (GO:0005829)</li> <li>Directly positively regulates</li> <li>Rok (FBgn0026181) \u2192 protein serine/threonine kinase activity \u2192 cytosol (GO:0005829)</li> <li>Directly positively regulates</li> <li>Sqh (FBgn0003514) \u2192 ATPase activator activity</li> </ol>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#strengths","title":"Strengths:","text":"<ol> <li>The overall signaling pathway follows the correct causal flow for a GPCR signaling pathway: ligand \u2192 receptor \u2192 G-protein activation \u2192 downstream effectors</li> <li>Appropriate molecular functions are assigned to each gene product</li> <li>All components are placed in the correct cellular locations</li> <li>Each step has evidence from relevant publications</li> <li>The model correctly incorporates G protein-coupled receptor signaling components according to guidelines</li> <li>The sequence follows established patterns from Drosophila GPCR signaling literature</li> </ol>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement:","text":"<ol> <li>Missing Evidence on Final Causal Association:</li> <li>The causal association from Rok to Sqh lacks evidence attribution. All other causal associations have appropriate evidence.</li> <li> <p>Recommendation: Add evidence from the papers cited elsewhere in the model (PMID:35876688 or other relevant publications) to this causal relationship.</p> </li> <li> <p>Cellular Location for Sqh:</p> </li> <li>Sqh doesn't have a cellular component annotation, unlike all other activities in the model.</li> <li> <p>Recommendation: Add the appropriate cellular component for Sqh, likely cytosol (GO:0005829) based on the pathway context.</p> </li> <li> <p>Biological Process Annotation for Sqh:</p> </li> <li>Sqh is annotated as being part of apical constriction (GO:0003383), which is appropriate, but it would be helpful to also place it in the GPCR signaling pathway (GO:0007186) to maintain consistency with upstream components.</li> <li> <p>Recommendation: Consider adding GO:0007186 as a part_of biological process for Sqh.</p> </li> <li> <p>Integration with Related Models:</p> </li> <li>According to PMID:35876688, Smog GPCR regulates distinct myosin pools in a ligand-dependent manner. If there are additional models that capture other aspects of Smog signaling, it would be valuable to link these models.</li> <li>Recommendation: Consider annotating any related models that capture other aspects of Smog GPCR function.</li> </ol>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#scientific-validity","title":"Scientific Validity","text":"<p>The model accurately represents the GPCR signaling pathway described in the literature:</p> <ol> <li> <p>PMID:35876688 provides evidence that Fog activates Smog to regulate Rho kinase accumulation and myosin activation during salivary gland invagination.</p> </li> <li> <p>PMID:26345366 provides support for the G-protein signaling components and their relationships.</p> </li> <li> <p>The pathway follows established patterns of GPCR signaling in Drosophila as described in the review paper, with the key steps of:</p> </li> <li>Ligand binding to GPCR (Fog \u2192 Smog)</li> <li>GPCR activating G-proteins (Smog \u2192 Cta)</li> <li>G-protein activating downstream effectors (Cta \u2192 Rho1)</li> <li> <p>Downstream signaling leading to cytoskeletal regulation (Rho1 \u2192 Rok \u2192 Sqh)</p> </li> <li> <p>The connection to apical constriction (GO:0003383) aligns with the biological outcome described in PMID:35876688.</p> </li> </ol>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#conformance-with-go-cam-guidelines","title":"Conformance with GO-CAM Guidelines","text":"<p>The model follows the guidelines for signaling receptor activity: - The ligand (Fog) enables receptor ligand activity (GO:0048018) - The ligand is correctly placed in extracellular space - The causal relation is directly positively regulates - The receptor (Smog) enables GPCR activity (GO:0004930) - The receptor is correctly placed in plasma membrane - The downstream signaling follows the appropriate cascade with correct causal relationships</p>"},{"location":"reviews/645d887900000706-Smog_GPCR_signaling___epithelial_tube_formation__D_mel__/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that accurately represents the Smog GPCR signaling pathway in Drosophila epithelial tube formation. The model captures the essential components and relationships described in the literature, with appropriate evidence attribution for most assertions.</p> <p>With minor improvements (adding evidence to the final causal relationship, adding cellular component for Sqh), this model would meet all GO-CAM quality standards and provide a valuable representation of this signaling pathway for the research community.</p> <p>The model can be accessed at: https://bioregistry.io/go.model:645d887900000706</p>"},{"location":"reviews/645d887900000999-BMP7_signaling_leading_to_osteoblast_differentiation__Human_/","title":"645d887900000999 BMP7 signaling leading to osteoblast differentiation  Human","text":"<p>Based on my review of the GO-CAM model gomodel:645d887900000999 titled \"BMP7 signaling leading to osteoblast differentiation (Human)\" and the relevant GO-CAM documentation, I can provide the following assessment:</p>"},{"location":"reviews/645d887900000999-BMP7_signaling_leading_to_osteoblast_differentiation__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents the BMP7 signaling pathway leading to osteoblast differentiation in humans. The pathway begins with BMP7 (P18075) in the extracellular space, which initiates signaling through type II receptor ACVR2A (P27037) which then activates type I receptor ACVR1 (Q04771). This activation leads to transcription factor activation (SMAD1, SMAD5, and SMAD9) in the nucleus, ultimately regulating osteoblast differentiation genes.</p>"},{"location":"reviews/645d887900000999-BMP7_signaling_leading_to_osteoblast_differentiation__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Correct pathway structure: The model correctly represents the canonical BMP signaling pathway, where BMP7 acts as a growth factor that binds to and activates type II receptors, which then phosphorylate and activate type I receptors, which in turn phosphorylate SMADs that translocate to the nucleus and regulate gene expression.</p> </li> <li> <p>Appropriate molecular functions: Each protein is annotated with the correct molecular function:</p> </li> <li>BMP7 has \"growth factor activity\" (GO:0008083)</li> <li>ACVR2A has \"activin receptor activity, type II\" (GO:0016362)</li> <li>ACVR1 has \"activin receptor activity, type I\" (GO:0016361)</li> <li> <p>SMAD proteins have transcription factor activities (GO:0000981, GO:0001228)</p> </li> <li> <p>Correct cellular locations: Each activity is properly localized:</p> </li> <li>BMP7 in extracellular space (GO:0005615)</li> <li>Receptors in plasma membrane (GO:0005886)</li> <li> <p>Transcription factors in nucleus (GO:0005634) or chromatin (GO:0000785)</p> </li> <li> <p>Correct causal relationships: The model uses the appropriate causal relationships between activities:</p> </li> <li>BMP7 \"directly positively regulates\" (RO:0002629) ACVR2A, which aligns with the guidelines for protein ligand-activated signaling receptor pathways</li> <li>ACVR2A \"directly positively regulates\" ACVR1</li> <li> <p>ACVR1 \"directly positively regulates\" the transcription factors</p> </li> <li> <p>Biological accuracy: The model accurately represents the known biology of BMP7 signaling, consistent with the information from UniProt entries.</p> </li> </ol>"},{"location":"reviews/645d887900000999-BMP7_signaling_leading_to_osteoblast_differentiation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Biological Process annotation: While all activities are correctly annotated as part of \"BMP signaling pathway\" (GO:0030509), there is no explicit representation of \"osteoblast differentiation\" (GO:0001649) despite it being mentioned in the title. This process should be included as a downstream effect of the transcription factor activities.</p> </li> <li> <p>Incomplete representation of SMAD complex formation: According to the UniProt entry for SMAD1, it forms a complex with SMAD4 which is crucial for nuclear translocation and transcriptional activity. The model doesn't include SMAD4, which is an important part of the canonical BMP signaling pathway.</p> </li> <li> <p>Limited downstream effects: The model stops at the transcription factors' activities without showing which specific genes they regulate to promote osteoblast differentiation. Including target genes would make the model more complete.</p> </li> <li> <p>Missing evidence for some annotations: While most activities have experimental evidence codes (ECO:0000314 - direct assay evidence), some rely on sequence similarity or computational analysis. When available, direct experimental evidence would strengthen the model.</p> </li> </ol>"},{"location":"reviews/645d887900000999-BMP7_signaling_leading_to_osteoblast_differentiation__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add GO:0001649 (osteoblast differentiation) as a biological process that is causally downstream of the transcription factor activities.</p> </li> <li> <p>Include SMAD4 and its interaction with SMAD1, SMAD5, and SMAD9 to form transcriptionally active complexes.</p> </li> <li> <p>Expand the model to include specific target genes regulated by the SMAD transcription factors that are involved in osteoblast differentiation.</p> </li> <li> <p>Check for additional direct experimental evidence for annotations that currently rely on sequence similarity or computational prediction.</p> </li> </ol>"},{"location":"reviews/645d887900000999-BMP7_signaling_leading_to_osteoblast_differentiation__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:645d887900000999 provides a solid representation of the BMP7 signaling pathway leading to transcription factor activation. It correctly follows GO-CAM best practices for representing signaling pathways and receptor activities. With the suggested improvements, particularly the inclusion of osteoblast differentiation as a biological process and SMAD4 as a co-SMAD, the model would more comprehensively represent the pathway described in its title.</p> <p>The model is biologically accurate and follows the GO-CAM guidelines for signaling receptor activity. It correctly shows the flow of information from extracellular signal (BMP7) through membrane receptors (ACVR2A and ACVR1) to nuclear transcription factors (SMAD proteins), which is the canonical mechanism of BMP signaling.</p>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/","title":"645d887900001077 Cell type specific  p53 independent mitotic G2 DNA damage checkpoint signaling mediated by CREB3L1 in astrocytes   Mouse","text":"<p>Now I can perform a thorough review of the GO-CAM model \"645d887900001077\". Let me analyze its structure, content, and adherence to GO-CAM guidelines.</p>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#review-of-go-cam-model-gomodel645d887900001077","title":"Review of GO-CAM Model: gomodel:645d887900001077","text":""},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#model-title-and-overview","title":"Model Title and Overview","text":"<p>\"Cell type specific, p53-independent mitotic G2 DNA damage checkpoint signaling mediated by CREB3L1 in astrocytes. (Mouse)\"</p> <p>The model represents a molecular pathway involved in mitotic G2 DNA damage checkpoint signaling that is mediated by CREB3L1 specifically in astrocytes of mice, with an emphasis on the p53-independent mechanism.</p>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#model-structure-and-molecular-activities","title":"Model Structure and Molecular Activities","text":"<p>The model consists of 5 molecular activities:</p> <ol> <li>Atm (MGI:MGI:107202) - protein serine/threonine kinase activity (GO:0004674)</li> <li>Occurs in: nucleus (GO:0005634)</li> <li>Part of: mitotic G2 DNA damage checkpoint signaling (GO:0007095)</li> <li> <p>Causally upstream of: CREB3L1 DNA-binding transcription activator activity</p> </li> <li> <p>Mbtps2 (MGI:MGI:2444506) - metalloendopeptidase activity (GO:0004222)</p> </li> <li>Occurs in: Golgi membrane (GO:0000139)</li> <li>Part of: membrane protein intracellular domain proteolysis (GO:0031293)</li> <li> <p>Causally regulates (positively): CREB3L1 activity</p> </li> <li> <p>Mbtps1 (MGI:MGI:1927235) - serine-type endopeptidase activity (GO:0004252)</p> </li> <li>Occurs in: endoplasmic reticulum membrane (GO:0005789)</li> <li>Part of: membrane protein intracellular domain proteolysis (GO:0031293)</li> <li> <p>Causally regulates (positively): CREB3L1 activity</p> </li> <li> <p>Creb3l1 (MGI:MGI:1347062) - DNA-binding transcription activator activity (GO:0001228)</p> </li> <li>Occurs in: nucleus (GO:0005634)</li> <li>Part of: mitotic G2 DNA damage checkpoint signaling (GO:0007095)</li> <li> <p>Causally regulates: Cdkn1a activity</p> </li> <li> <p>Cdkn1a (MGI:MGI:104556) - cyclin-dependent protein serine/threonine kinase inhibitor activity (GO:0004861)</p> </li> <li>Occurs in: nucleus (GO:0005634)</li> <li>Part of: mitotic G2 DNA damage checkpoint signaling (GO:0007095)</li> </ol>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model describes a signaling pathway with the following causal relationships: - ATM kinase activates CREB3L1 (RO:0002304 - causally upstream of, positive effect) - MBTPS1 and MBTPS2 both positively regulate CREB3L1 (RO:0002629 - directly positively regulates) - CREB3L1 regulates CDKN1A (RO:0002407 - enables)</p>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by evidence from various references: - PMID:37178686 - Used for evidence of CREB3L1's transcription factor activity and its role in activating CDKN1A - PMID:29955025 - Supports ATM's nuclear localization and its role in DNA damage response - PMID:16417584 - Provides evidence for MBTPS1's role in membrane protein proteolysis - PMID:24550317 - Supports ATM's role in mitotic G2 DNA damage checkpoint signaling - PMID:12130539 - Evidence for CDKN1A's cyclin-dependent kinase inhibitor activity</p>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#adherence-to-go-cam-guidelines","title":"Adherence to GO-CAM Guidelines","text":"<p>The model adheres to GO-CAM best practices in several ways:</p> <ol> <li> <p>Causal relationships: The model uses appropriate relationship predicates for causal connections between activities.</p> </li> <li> <p>Cellular context: Each activity correctly specifies cellular location with \"occurs_in\" relations.</p> </li> <li> <p>Process context: All activities are properly contextualized within the biological process \"mitotic G2 DNA damage checkpoint signaling\" using \"part_of\" relations.</p> </li> <li> <p>Evidence: Each relationship has appropriate evidence with ECO codes, references, and proper attribution.</p> </li> </ol>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The biology represented in the model is consistent with current knowledge of the DNA damage response pathway:</p> <ol> <li> <p>The model accurately represents that ATM kinase is activated upon DNA damage and initiates checkpoint signaling.</p> </li> <li> <p>The proteolytic processing of CREB3L1 by the site-1 and site-2 proteases (MBTPS1 and MBTPS2) is consistent with the literature (PMID:16417584), allowing CREB3L1 to act as a transcription factor.</p> </li> <li> <p>CREB3L1's role in activating CDKN1A expression, which then inhibits cyclin-dependent kinases to cause cell cycle arrest, is biologically sound.</p> </li> <li> <p>The p53-independent mechanism of this pathway is notable and scientifically supported.</p> </li> </ol>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, some potential improvements include:</p> <ol> <li> <p>Cell type specification: Although the title mentions \"astrocytes,\" the model doesn't explicitly annotate this cell type context. Consider adding an explicit occurs_in relation to \"astrocyte\" (CL:0000127) for each activity.</p> </li> <li> <p>DNA damage stimulus: Consider adding the initiating DNA damage as an input to the ATM activity to better represent the trigger of this pathway.</p> </li> <li> <p>Molecular details: The model could be expanded to include more molecular details about how ATM activates CREB3L1, as this is not fully clear from the current representation.</p> </li> </ol>"},{"location":"reviews/645d887900001077-Cell_type_specific__p53_independent_mitotic_G2_DNA_damage_checkpoint_signaling_mediated_by_CREB3L1_in_astrocytes___Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:645d887900001077 is a well-constructed GO-CAM that accurately represents a biologically plausible p53-independent DNA damage checkpoint pathway in astrocytes. The model adheres to GO-CAM best practices regarding evidence, causal relationships, and cellular/process contexts. The minor suggestions provided would enhance the model's completeness but are not critical issues that would prevent approval of the model.</p>"},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/","title":"645d887900001323 14 3 3 sequestering of ZNRF2 E3 ligase leading to ATP1A1 activity at plasma membrane  Human","text":"<p>Based on my review of the GO-CAM model \"14-3-3 sequestering of ZNRF2 E3 ligase leading to ATP1A1 activity at plasma membrane (Human)\" (gomodel:645d887900001323) and related information, I'll provide a comprehensive review:</p>"},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/#go-cam-review-for-model-gomodel645d887900001323","title":"GO-CAM Review for Model: gomodel:645d887900001323","text":""},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/#model-summary","title":"Model Summary","text":"<p>This model describes how 14-3-3 protein (YWHAE) sequesters ZNRF2 E3 ubiquitin ligase, preventing it from ubiquitylating ATP1A1 (Na+/K+ ATPase alpha-1 subunit), thus allowing ATP1A1 to function at the plasma membrane. The model includes PKA (PRKACA) as an upstream kinase that phosphorylates 14-3-3, activating its sequestering function.</p>"},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/#scientific-content","title":"Scientific Content","text":"<p>The model is based on research by Hoxhaj et al. (2012), which establishes that:</p> <ol> <li>ZNRF2 is an E3 ubiquitin ligase that targets the Na+/K+ ATPase \u03b11 subunit (ATP1A1) for ubiquitylation</li> <li>When phosphorylated, ZNRF2 binds to 14-3-3 proteins and is released into the cytosol</li> <li>This release prevents ZNRF2 from ubiquitylating ATP1A1, thus maintaining ATP1A1 activity at the plasma membrane</li> <li>Several kinases, including PKA, can phosphorylate ZNRF2, leading to 14-3-3 binding</li> </ol>"},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/#go-cam-structure-analysis","title":"GO-CAM Structure Analysis","text":"<p>The model consists of four main activities:</p> <ol> <li>PRKACA (P17612) - protein serine kinase activity (GO:0106310) occurring in cytoplasm</li> <li>YWHAE (P62258) - protein sequestering activity (GO:0140311) occurring in cytoplasm</li> <li>ZNRF2 (Q8NHG8) - ubiquitin protein ligase activity (GO:0061630) occurring in intracellular membrane-bounded organelle</li> <li>ATP1A1 (P05023) - ATP hydrolysis activity (GO:0016887) occurring at plasma membrane</li> </ol> <p>The causal relationships in the model are: - PRKACA provides input for YWHAE (RO:0002413) - YWHAE directly negatively regulates ZNRF2 (RO:0002630) - ZNRF2 directly negatively regulates ATP1A1 (RO:0002630)</p>"},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/#evaluation","title":"Evaluation","text":""},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/#positive-aspects","title":"Positive Aspects","text":"<ol> <li>The model accurately represents the biological pathway described in the literature</li> <li>The molecular functions assigned to proteins are appropriate</li> <li>The causal relationships are logical and well-supported by evidence</li> <li>The cellular locations for activities are correctly specified</li> <li>The model includes appropriate biological processes for each activity</li> </ol>"},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Evidence Code Issue: </li> <li>For PRKACA providing input for YWHAE, there appears to be a duplicate evidence entry (same evidence used twice)</li> <li> <p>Recommendation: Remove the duplicate evidence entry</p> </li> <li> <p>Missing Information about Phosphorylation Sites:</p> </li> <li>While the literature indicates ZNRF2 is phosphorylated at specific sites (Ser19, Ser82, Ser145), which facilitates 14-3-3 binding, this level of molecular detail is not captured</li> <li> <p>Recommendation: Consider adding annotations about the specific phosphorylation sites if support for this level of detail is added to GO-CAM in the future</p> </li> <li> <p>Mechanistic Detail:</p> </li> <li>The model doesn't capture that ZNRF2 is N-myristoylated, which targets it to membranes, and phosphorylation counteracts this, causing cytoplasmic localization</li> <li> <p>Recommendation: This level of mechanistic detail might be beyond GO-CAM's current scope, but could be considered for future enhancements</p> </li> <li> <p>Complex Formation:</p> </li> <li>The interaction between 14-3-3 and phosphorylated ZNRF2 forming a complex isn't explicitly modeled</li> <li>Recommendation: Following GO-CAM guidelines for complexes, the current approach (using sequestering activity) is appropriate since the sequestering function is well-defined</li> </ol>"},{"location":"reviews/645d887900001323-14_3_3_sequestering_of_ZNRF2_E3_ligase_leading_to_ATP1A1_activity_at_plasma_membrane__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:645d887900001323) provides a clear and accurate representation of how 14-3-3 proteins regulate ZNRF2 activity, thereby affecting Na+/K+ ATPase function. The model is consistent with the published literature and follows GO-CAM best practices. The only minor issue is a duplicated evidence entry for one causal relationship, which could be removed.</p> <p>The model successfully captures the key aspects of this regulatory pathway in a parsimonious way that would be understandable to other researchers. The cellular components, molecular functions, and biological processes are appropriately assigned, and the causal relationships accurately reflect current knowledge of the pathway.</p>"},{"location":"reviews/645d887900001414-ZNFR1_mediated_TLR4_signaling_pathway_via_CAV1_ubiquitination_and_degradation__Human_/","title":"645d887900001414 ZNFR1 mediated TLR4 signaling pathway via CAV1 ubiquitination and degradation  Human","text":"<p>Now, let's review the GO-CAM model taking into consideration the information we've gathered:</p> <p>Based on all the information I've collected, I can provide a comprehensive review of the GO-CAM model with ID 645d887900001414 titled \"ZNFR1-mediated TLR4 signaling pathway via CAV1 ubiquitination and degradation (Human)\".</p>"},{"location":"reviews/645d887900001414-ZNFR1_mediated_TLR4_signaling_pathway_via_CAV1_ubiquitination_and_degradation__Human_/#go-cam-model-review-znfr1-mediated-tlr4-signaling-pathway-via-cav1-ubiquitination-and-degradation-human","title":"GO-CAM Model Review: ZNFR1-mediated TLR4 signaling pathway via CAV1 ubiquitination and degradation (Human)","text":""},{"location":"reviews/645d887900001414-ZNFR1_mediated_TLR4_signaling_pathway_via_CAV1_ubiquitination_and_degradation__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model describes how the E3 ubiquitin ligase ZNRF1 regulates TLR4 signaling by mediating the ubiquitination and degradation of Caveolin-1 (CAV1). The model captures how ZNRF1's E3 ligase activity negatively regulates CAV1's protein sequestering activity, which in turn affects TLR4 signaling receptor activity and downstream signaling through MYD88 (molecular adaptor) to PIK3R1 (phosphatidylinositol kinase activity).</p>"},{"location":"reviews/645d887900001414-ZNFR1_mediated_TLR4_signaling_pathway_via_CAV1_ubiquitination_and_degradation__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<ol> <li> <p>Main Mechanism Assessment:    The model accurately captures the key findings from the literature (particularly from PMID:28593998), which shows that ZNRF1 promotes CAV1 ubiquitination and degradation to modulate TLR4-driven immune responses. The causal relationships correctly show that ZNRF1's E3 ubiquitin ligase activity directly negatively regulates CAV1's sequestering activity.</p> </li> <li> <p>Molecular Functions:</p> </li> <li>ZNRF1 (Q8ND25) is correctly annotated with E3 ubiquitin-protein ligase activity (GO:0061630), which is supported by direct experimental evidence.</li> <li>CAV1 (Q03135) is correctly annotated with protein sequestering activity (GO:0140311), which is well-documented in its role of sequestering signaling molecules.</li> <li>TLR4 (O00206) is correctly annotated with signaling receptor activity (GO:0038023).</li> <li>MYD88 (Q99836) is correctly annotated with molecular adaptor activity (GO:0060090), which aligns with its well-known role in TLR signaling.</li> <li> <p>PIK3R1 (P27986) is appropriately annotated with phosphatidylinositol kinase activity (GO:0052742).</p> </li> <li> <p>Causal Relationships:    The causal relationships are represented appropriately using:</p> </li> <li>RO:0002630 (directly negatively regulates) from ZNRF1 activity to CAV1 activity</li> <li>RO:0002630 (directly negatively regulates) from CAV1 activity to TLR4 activity</li> <li>RO:0002629 (directly positively regulates) from TLR4 activity to MYD88 activity</li> <li>RO:0002629 (directly positively regulates) from MYD88 activity to PIK3R1 activity</li> </ol>"},{"location":"reviews/645d887900001414-ZNFR1_mediated_TLR4_signaling_pathway_via_CAV1_ubiquitination_and_degradation__Human_/#technical-correctness","title":"Technical Correctness","text":"<ol> <li>Evidence and Citations:    The model includes appropriate evidence codes and literature citations:</li> <li>ECO:0000314 (direct assay evidence used in manual assertion) is used for most activities</li> <li>PMID:28593998 is correctly cited for ZNRF1's ubiquitination of CAV1</li> <li> <p>Other literature citations appear appropriate for the respective components</p> </li> <li> <p>Cellular Location:    The subcellular locations are correctly annotated:</p> </li> <li>ZNRF1 and CAV1 are correctly located at the plasma membrane (GO:0005886)</li> <li>TLR4 is correctly annotated as occurring at the plasma membrane</li> <li>MYD88 is appropriately located at the plasma membrane</li> <li> <p>PIK3R1 is correctly located in the cytoplasm (GO:0005737)</p> </li> <li> <p>Process Context:    Each activity is appropriately placed in its biological process context:</p> </li> <li>ZNRF1 activity is part of the positive regulation of TLR4 signaling pathway (GO:0034145)</li> <li>CAV1 activity is part of the negative regulation of TLR4 signaling pathway (GO:0034144)</li> <li>TLR4 activity is part of the TLR4 signaling pathway (GO:0034142)</li> <li>MYD88 activity is part of the TLR4 signaling pathway (GO:0034142)</li> <li>PIK3R1 activity is part of the regulation of TLR4 signaling pathway (GO:0034143)</li> </ol>"},{"location":"reviews/645d887900001414-ZNFR1_mediated_TLR4_signaling_pathway_via_CAV1_ubiquitination_and_degradation__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Include Ubiquitination Site:    The model could specify the specific lysine residue (Lys-39) on CAV1 that is targeted by ZNRF1 for ubiquitination, as mentioned in the literature.</p> </li> <li> <p>Additional Downstream Effects:    The model could be extended to include the downstream effects on the Akt-GSK3\u03b2 pathway that was mentioned in the paper as a mechanism by which the ZNRF1-CAV1 axis regulates TLR4 signaling.</p> </li> <li> <p>Inflammatory Cytokine Production:    The model could potentially include the end result of this pathway - the production of pro-inflammatory cytokines and inhibition of anti-inflammatory cytokine IL-10, which are important outcomes of this signaling pathway.</p> </li> <li> <p>LPS as Stimulus:    The model could explicitly represent lipopolysaccharide (LPS) as the activating stimulus for this pathway, as ZNRF1 was shown to interact with CAV1 in response to LPS.</p> </li> </ol>"},{"location":"reviews/645d887900001414-ZNFR1_mediated_TLR4_signaling_pathway_via_CAV1_ubiquitination_and_degradation__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 645d887900001414 is a technically solid representation of the ZNRF1-mediated regulation of TLR4 signaling through CAV1 ubiquitination and degradation. It accurately captures the main molecular activities, causal relationships, and cellular locations based on published literature. The model effectively represents this important regulatory mechanism in innate immune signaling.</p> <p>The model is consistent with best practices for GO-CAM curation, including proper annotation of molecular functions, biological processes, cellular components, and causal relationships. The evidence codes and citations are appropriately used throughout the model.</p> <p>While some additional details could be incorporated to make the model more comprehensive, such as specific ubiquitination sites and downstream effects, the current representation provides a clear and accurate view of this regulatory mechanism in TLR4 signaling.</p>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/","title":"645d887900001551 Coenzyme A catabolic process 2  Mouse","text":"<p>Now I'll provide a comprehensive review of the GO-CAM model with ID 645d887900001551, focusing on quality control and adherence to best practices.</p>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#review-of-go-cam-model-645d887900001551","title":"Review of GO-CAM Model 645d887900001551","text":""},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Model ID: gomodel:645d887900001551</li> <li>Title: \"Coenzyme A catabolic process 2 (Mouse)\"</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#model-structure-assessment","title":"Model Structure Assessment","text":"<p>This model represents the coenzyme A (CoA) catabolic pathway in mouse, showing how CoA is metabolized through a series of enzymatic reactions. The model includes 4 molecular activities involving different gene products:</p> <ol> <li>Pantetheine hydrolase activity (GO:0017159) - enabled by Vnn1 (vanin 1)</li> <li>Phosphatase activity (GO:0016791) - enabled by Pank4 (pantothenate kinase 4)</li> <li>Phosphatase activity (GO:0016791) - enabled by Alpi (alkaline phosphatase, intestinal)</li> <li>Pyrophosphatase activity (GO:0016462) - enabled by Enpp1 (ectonucleotide pyrophosphatase/phosphodiesterase 1)</li> </ol>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#pathway-flow","title":"Pathway Flow","text":"<p>The model represents a sequential catabolic pathway where each activity provides input for the next: 1. Alpi \u2192 Enpp1 \u2192 Pank4 \u2192 Vnn1</p> <p>The causal connections in the model are correctly specified with RO:0002413 (\"provides input for\"), which indicates the appropriate relationships between the activities in the pathway.</p>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model accurately depicts the coenzyme A catabolic pathway based on the literature evidence provided. I examined the referenced papers and found that:</p> <ol> <li> <p>Vnn1 (vanin 1) acts as a pantetheine hydrolase that cleaves pantetheine to pantothenate and cysteamine (PMID:11042271). This matches the model's representation with pantetheine (CHEBI:16753) as input and pantothenate (CHEBI:29032) and cysteaminium (CHEBI:58029) as outputs.</p> </li> <li> <p>Pank4 is shown as having phosphatase activity acting on phosphopantetheine (CHEBI:61723) to produce pantetheine (CHEBI:16753). This is supported by PMID:35896750, which describes PANK4 as a phosphatase that can dephosphorylate 4'-phosphopantetheine.</p> </li> <li> <p>Alpi (alkaline phosphatase, intestinal) is represented as having phosphatase activity that converts 3'-dephospho-CoA (CHEBI:57328) to phosphopantetheine (CHEBI:57287). This is supported by PMID:6619987 and PMID:16742561, which document the ability of alkaline phosphatases to hydrolyze phosphomonoesters and pyrophosphates.</p> </li> <li> <p>Enpp1 has pyrophosphatase activity that converts coenzyme A (CHEBI:57287) to 3'-dephospho-CoA (CHEBI:57328). This is supported by PMID:7678057, which describes the nucleotide pyrophosphatase activity of Enpp1.</p> </li> </ol>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<p>I checked the GO-CAM model against best practice guidelines for complex annotation:</p> <p>According to the How to annotate complexes in GO-CAM guidelines, when the subunit that carries the molecular activity is known, the complex is not described and the activity is represented by the specific protein carrying the activity. This model follows this practice correctly by annotating each individual protein with its specific enzymatic activity.</p> <p>The model also follows the practice of connecting activities using causal relations (RO:0002413 \"provides input for\"), indicating the correct flow of substrates and products in the pathway.</p>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#evidence-and-provenance","title":"Evidence and Provenance","text":"<p>Each activity annotation is supported with appropriate evidence codes and references:</p> <ol> <li>Vnn1 - ECO:0000314 (direct assay evidence) with PMID:11042271</li> <li>Pank4 - ECO:0000266 (sequence orthology evidence) with PMID:35896750 and UniProtKB:Q9NVE7</li> <li>Alpi - ECO:0000266 (sequence orthology evidence) with PMID:16742561 and UniProtKB:P10696</li> <li>Enpp1 - ECO:0000314 (direct assay evidence) with PMID:7678057</li> </ol> <p>All annotations include proper provenance information with contributor ORCID and dates, which is in line with GO-CAM best practices.</p>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is scientifically accurate and follows GO-CAM best practices, I have a few suggestions for enhancement:</p> <ol> <li> <p>Subcellular localization: The model could be enhanced by including cellular component annotations for each activity. For example, Vnn1 is known to be a GPI-anchored ectoenzyme, and Enpp1 is a membrane protein. Adding this information would provide a more complete spatial context for the pathway.</p> </li> <li> <p>Regulatory relationships: If known, regulatory relationships between activities (positive or negative regulation) could be added to make the model more comprehensive.</p> </li> <li> <p>Additional chemical participants: While the main substrates and products are included, some intermediates or cofactors could be added for completeness.</p> </li> <li> <p>Connection to related processes: Linking this catabolic pathway to related metabolic processes such as pantothenate metabolism or coenzyme A biosynthesis would provide a broader context.</p> </li> </ol>"},{"location":"reviews/645d887900001551-Coenzyme_A_catabolic_process_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 645d887900001551 \"Coenzyme A catabolic process 2 (Mouse)\" is a well-constructed model that accurately represents the coenzyme A catabolic pathway in mouse. It adheres to GO-CAM best practices for pathway representation and provides appropriate evidence for each annotation.</p> <p>The model's strengths include: - Accurate representation of the enzymatic reactions in the CoA catabolic pathway - Proper use of causal relations to show the flow of the pathway - Strong literature evidence supporting each activity annotation - Correct annotation of molecular inputs and outputs for each activity</p> <p>The model successfully captures the current scientific understanding of the coenzyme A catabolic pathway in mouse and serves as a valuable resource for researchers studying this metabolic process.</p>"},{"location":"reviews/646ff70100000391-Canonical_mTORC1_signaling__Human_/","title":"646ff70100000391 Canonical mTORC1 signaling  Human","text":"<p>Now I need to check the GO term definition directly. Let me look at the model in more detail.</p> <p>Based on my review of the GO-CAM model \"Canonical mTORC1 signaling (Human)\" with ID gomodel:646ff70100000391, I'll provide a comprehensive assessment:</p>"},{"location":"reviews/646ff70100000391-Canonical_mTORC1_signaling__Human_/#model-overview","title":"Model Overview:","text":"<p>This model represents the canonical mTORC1 (mammalian Target Of Rapamycin Complex 1) signaling pathway in human cells. It describes how various proteins and complexes interact to regulate mTOR kinase activity, which ultimately controls protein synthesis and translation through multiple downstream effectors.</p>"},{"location":"reviews/646ff70100000391-Canonical_mTORC1_signaling__Human_/#model-structure-review","title":"Model Structure Review:","text":""},{"location":"reviews/646ff70100000391-Canonical_mTORC1_signaling__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Biological accuracy: The model captures the key components of the canonical mTORC1 pathway, including the Ragulator complex, Rag GTPases, RHEB, mTOR, and downstream effectors (RPS6KB1/2, EIF4EBP1, RPS6).</p> </li> <li> <p>Correct cellular localization: Activities are properly localized to the lysosomal membrane (GO:0005765) where mTORC1 signaling occurs.</p> </li> <li> <p>Proper causality: The causal relationships between activities are well-represented using appropriate predicates (mostly RO:0002629 \"directly positively regulates\").</p> </li> <li> <p>Appropriate evidence: Each activity and causal relationship is supported by scientific literature references (PMIDs).</p> </li> <li> <p>Complete pathway representation: The model covers upstream activators (Ragulator complex, Rag GTPases, RHEB) through downstream effectors (RPS6KB1/2, EIF4EBP1) to the final outcome (translation regulation).</p> </li> </ol>"},{"location":"reviews/646ff70100000391-Canonical_mTORC1_signaling__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex annotation: The Ragulator complex (GO:0071986) is correctly used when the specific subunit carrying the guanyl-nucleotide exchange factor activity is unknown. However, the model does not specify the members of this complex. According to the complex annotation guidelines, members can be indicated.</p> </li> <li> <p>RPTOR annotation: RPTOR (Q8N122) has \"enzyme-substrate adaptor activity\" (GO:0140767) and positively regulates mTOR (P42345) kinase activity. This aligns with its known function as a regulatory-associated protein of mTOR that serves as a scaffold. However, based on adaptor activity guidelines, it might be beneficial to specify what specific molecules it is bringing together using \"has input\" relations.</p> </li> <li> <p>Representation of EIF4E: While EIF4EBP1 (Q13541) is included with its translation repressor activity, the model doesn't explicitly show how mTOR-mediated phosphorylation of EIF4EBP1 relieves inhibition of EIF4E (P06730). EIF4E is listed in the objects but not as an active participant.</p> </li> <li> <p>Nutrient sensing upstream: While the model includes the lysosomal-based activation of mTORC1, it could potentially include more details about how amino acid levels are sensed and signal to the Rag GTPases.</p> </li> </ol>"},{"location":"reviews/646ff70100000391-Canonical_mTORC1_signaling__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices:","text":"<ol> <li>The model follows the GO-CAM practice of representing activities connected by causal relationships.</li> <li>Each activity is properly contextualized with molecular function, biological process, and cellular component.</li> <li>Evidence is provided for each assertion.</li> <li>Complex usage follows the guidelines in \"How to annotate complexes in GO-CAM\" document.</li> <li>Adaptor protein annotation generally follows the \"Molecular adaptor activity\" guidelines.</li> </ol>"},{"location":"reviews/646ff70100000391-Canonical_mTORC1_signaling__Human_/#recommendations","title":"Recommendations:","text":"<ol> <li>Consider explicitly representing the members of the Ragulator complex.</li> <li>Add \"has input\" relationships for adaptor activities to clearly indicate which molecules are being brought together.</li> <li>Consider adding EIF4E as an active participant to complete the translation initiation regulation part of the pathway.</li> <li>Perhaps expand the model to include upstream nutrient sensing mechanisms.</li> <li>Consider adding a brief description or comments that explain the overall biological significance of this pathway.</li> </ol>"},{"location":"reviews/646ff70100000391-Canonical_mTORC1_signaling__Human_/#summary","title":"Summary:","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the canonical mTORC1 signaling pathway in humans. It captures the key molecular activities and their causal relationships, with proper evidence and cellular context. The model successfully demonstrates how mTOR kinase activation leads to the regulation of protein synthesis through multiple downstream effectors. With a few minor enhancements as suggested, this model would be even more comprehensive and informative.</p> <p>The model can be accessed at: https://bioregistry.io/go.model:646ff70100000391</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/","title":"646ff70100000611 Ubiquitination of RagA RRAGA by RNF152 inhibits the  mTORC1 signaling  Human","text":"<p>Now that I have reviewed the model and gathered the necessary information, I'll provide a detailed evaluation of GO-CAM model 646ff70100000611.</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#review-of-go-cam-model-gomodel646ff70100000611","title":"Review of GO-CAM Model: gomodel:646ff70100000611","text":""},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#overview","title":"Overview","text":"<p>Title: Ubiquitination of RagA/RRAGA by RNF152 inhibits the mTORC1 signaling (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>This GO-CAM model describes a signaling pathway in which the E3 ubiquitin ligase RNF152 ubiquitinates RagA/RRAGA to negatively regulate mTORC1 signaling. The model represents a complex regulatory mechanism that occurs on the lysosomal membrane.</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#diagram-of-the-model","title":"Diagram of the Model","text":"<p>The model consists of four main activities: 1. RagA/RRAGA GTP binding activity 2. RagA/RRAGA protein-membrane adaptor activity 3. RNF152 ubiquitin-protein ligase activity 4. GATOR1 complex GTPase activator activity</p> <p>The causal relationships show: - RagA/RRAGA GTP binding directly positively regulates RagA/RRAGA protein-membrane adaptor activity - RNF152 ubiquitin-protein ligase activity directly positively regulates GATOR1 complex GTPase activator activity - GATOR1 complex GTPase activator activity directly negatively regulates RagA/RRAGA GTP binding activity</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#evaluation-of-the-model-components","title":"Evaluation of the Model Components","text":""},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#1-ragarraga-activities","title":"1. RagA/RRAGA activities:","text":"<p>The model accurately represents two activities of RagA/RRAGA: - GTP binding (GO:0005525): This is correctly located at the lysosomal membrane (GO:0005765) and is part of the positive regulation of TORC1 signaling (GO:1904263). - Protein-membrane adaptor activity (GO:0043495): This is also correctly located at the lysosomal membrane and is part of protein localization to lysosome (GO:0061462).</p> <p>The causal relationship between these activities (RO:0002629 - \"directly positively regulates\") is biologically accurate, as GTP binding by RagA enables its function as a membrane adaptor that helps recruit mTORC1 to the lysosomal surface.</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#2-rnf152-activity","title":"2. RNF152 activity:","text":"<ul> <li>Ubiquitin protein ligase activity (GO:0061630): This is correctly located at the lysosomal membrane and is part of protein K63-linked ubiquitination (GO:0070534).</li> </ul> <p>The literature evidence (PMID:25936802) supports that RNF152 is a lysosome-localized E3 ubiquitin ligase that promotes K63-linked polyubiquitination of RagA.</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#3-gator1-complex-activity","title":"3. GATOR1 complex activity:","text":"<ul> <li>GTPase activator activity (GO:0005096): This is correctly located at the lysosomal membrane and is part of the negative regulation of TORC1 signaling (GO:1904262).</li> </ul> <p>The literature evidence (PMID:29590090) supports that GATOR1 functions as a GAP for RagA, stimulating its GTPase activity.</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#4-causal-relationships","title":"4. Causal relationships:","text":"<p>The model accurately represents that: - RNF152 ubiquitin ligase activity positively regulates GATOR1 GAP activity (RO:0002629) - GATOR1 GAP activity negatively regulates RagA GTP binding (RO:0002630)</p> <p>These relationships are supported by the evidence that ubiquitination of RagA by RNF152 promotes the recruitment of GATOR1, which then stimulates GTP hydrolysis by RagA, converting it to its inactive GDP-bound state.</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#comparison-with-literature-evidence","title":"Comparison with Literature Evidence","text":"<p>The model is consistent with the cited literature:</p> <ol> <li> <p>PMID:31601764 and PMID:31601708 demonstrate that RagA binds GTP and functions in mTORC1 recruitment to lysosomes through protein-membrane adaptor activity.</p> </li> <li> <p>PMID:25936802 establishes that:</p> </li> <li>RNF152 targets RagA for K63-linked polyubiquitination</li> <li>This ubiquitination occurs at four lysine residues (K142, K220, K230, K244)</li> <li>Ubiquitination promotes the binding of GATOR1 to RagA</li> <li> <p>This process inhibits mTORC1 activation</p> </li> <li> <p>PMID:29590090 confirms that GATOR1:</p> </li> <li>Functions as a GAP for RagA</li> <li>Stimulates GTP hydrolysis by RagA</li> <li>Negatively regulates mTORC1 signaling</li> </ol>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#strengths","title":"Strengths:","text":"<ol> <li>Completeness: The model captures the key molecular activities and causal relationships described in the literature.</li> <li>Evidence: All components are supported by appropriate literature evidence.</li> <li>Cellular location: The lysosomal membrane localization is consistently represented for all activities.</li> <li>Biological process context: Relevant biological processes (mTORC1 signaling, ubiquitination) are incorporated appropriately.</li> </ol>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#potential-improvements","title":"Potential Improvements:","text":"<ol> <li> <p>Complex representation: The model uses GO:1990130 (GATOR1 complex) as the enabler of the GTPase activator activity, which is appropriate according to the GO-CAM guidelines for complexes when the specific subunit carrying the activity is not explicitly known. However, the model could potentially be expanded to include the specific subunits of GATOR1 (DEPDC5, NPRL2, and NPRL3) if their specific roles in GAP activity were to be annotated.</p> </li> <li> <p>Additional regulatory components: The model could potentially be expanded to include:</p> </li> <li>The role of amino acid sensing in regulating RNF152-RagA interaction</li> <li>The involvement of deubiquitinating enzymes (like DUB3 mentioned in PMID:25936802)</li> <li> <p>The interaction with the Ragulator complex</p> </li> <li> <p>RagC representation: The model focuses on RagA, but RagA functions as a heterodimer with RagC. The model could potentially include RagC's role, particularly as RagA-RagC heterodimer nucleotide states are critical for mTORC1 regulation.</p> </li> </ol>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows the GO-CAM best practices for complex annotation. As described in the document \"How to annotate complexes in GO-CAM\": - When the subunit carrying the molecular activity is not known, using the GO accession for the complex (as done for GATOR1 in this model) is appropriate.</p>"},{"location":"reviews/646ff70100000611-Ubiquitination_of_RagA_RRAGA_by_RNF152_inhibits_the__mTORC1_signaling__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 646ff70100000611 accurately represents the biological mechanism by which RNF152 ubiquitinates RagA to regulate mTORC1 signaling through GATOR1. The model includes the essential molecular activities, causal relationships, and cellular contexts supported by the literature. </p> <p>While there are opportunities for expansion to include additional components of this regulatory pathway, the current representation provides a clear and accurate depiction of the core mechanism. The model adheres to GO-CAM best practices for representing molecular activities and complex annotations.</p>"},{"location":"reviews/646ff70100001312-Inhibition_of_the_canonical_mTORC1_signaling_by_the_GATOR1_complex__Human_/","title":"646ff70100001312 Inhibition of the canonical mTORC1 signaling by the GATOR1 complex  Human","text":"<p>Now that I have reviewed the necessary information, let me analyze this GO-CAM model and provide a comprehensive review:</p>"},{"location":"reviews/646ff70100001312-Inhibition_of_the_canonical_mTORC1_signaling_by_the_GATOR1_complex__Human_/#review-of-go-cam-model-gomodel646ff70100001312","title":"Review of GO-CAM Model: gomodel:646ff70100001312","text":""},{"location":"reviews/646ff70100001312-Inhibition_of_the_canonical_mTORC1_signaling_by_the_GATOR1_complex__Human_/#general-information","title":"General Information","text":"<ul> <li>Title: \"Inhibition of the canonical mTORC1 signaling by the GATOR1 complex (Human)\"</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> <li>Model ID: gomodel:646ff70100001312</li> </ul>"},{"location":"reviews/646ff70100001312-Inhibition_of_the_canonical_mTORC1_signaling_by_the_GATOR1_complex__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the inhibitory mechanism of the GATOR1 complex on mTORC1 signaling in humans. The model specifically focuses on how GATOR1 functions as a GTPase Activating Protein (GAP) for the Rag GTPases to inactivate mTORC1 signaling in response to amino acid deprivation.</p>"},{"location":"reviews/646ff70100001312-Inhibition_of_the_canonical_mTORC1_signaling_by_the_GATOR1_complex__Human_/#biological-content-analysis","title":"Biological Content Analysis","text":"<p>The model correctly represents the current understanding of mTORC1 regulation by the GATOR1 complex:</p> <ol> <li> <p>The GATOR1 complex (represented by NPRL2 - UniProtKB:Q8WTW4) functions as a GTPase activator protein (GO:0005096) for RagA/RagC GTPases.</p> </li> <li> <p>The Rag GTPases (RagA/RagC heterodimer) act as a molecular switch that recruits mTORC1 to the lysosomal surface in the presence of amino acids, where it can be activated by Rheb.</p> </li> <li> <p>RRAGC (UniProtKB:Q9HB90) is correctly shown to have protein-membrane adaptor activity (GO:0043495) and GDP binding activity (GO:0019003), which aligns with its known function.</p> </li> <li> <p>RHEB (UniProtKB:Q15382) is properly represented with protein serine/threonine kinase activator activity (GO:0043539) that activates mTOR.</p> </li> <li> <p>The causal links between activities correctly show that GATOR1 negatively regulates RagC through its GTPase activator activity, which then affects mTORC1 activity.</p> </li> <li> <p>All activities are correctly localized to the lysosomal membrane (GO:0005765), which is the known site of mTORC1 activation.</p> </li> </ol>"},{"location":"reviews/646ff70100001312-Inhibition_of_the_canonical_mTORC1_signaling_by_the_GATOR1_complex__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate molecular mechanisms: The model correctly shows how GATOR1 acts as a GAP for Rag GTPases, which is supported by the scientific literature (PMID:35338845, PMID:31601708).</p> </li> <li> <p>Proper causal connections: The causal relationships between the activities are appropriately represented with the \"directly positively regulates\" (RO:0002629) and \"directly negatively regulates\" (RO:0002630) predicates.</p> </li> <li> <p>Accurate cellular localization: All activities are correctly localized to the lysosomal membrane, which is essential for understanding the spatial regulation of mTORC1 signaling.</p> </li> <li> <p>Proper use of complex annotation: Following GO-CAM best practices for complex annotation, the model uses specific protein components when the activities are known (e.g., NPRL2's GTPase activator activity) and the GO term for the KICSTOR complex (GO:0140007) when the specific subunit carrying the activity is not known.</p> </li> <li> <p>Well-supported evidence: The model provides strong evidence for each assertion with appropriate PMIDs and evidence codes.</p> </li> </ol>"},{"location":"reviews/646ff70100001312-Inhibition_of_the_canonical_mTORC1_signaling_by_the_GATOR1_complex__Human_/#minor-issues-and-suggestions-for-improvement","title":"Minor Issues and Suggestions for Improvement","text":"<ol> <li> <p>Additional pathway context: While the model does an excellent job representing the GATOR1 inhibition of mTORC1, it could be enhanced by including more upstream regulation of GATOR1 (such as GATOR2 or amino acid sensors like SESN1/2/3) to provide more context for when this inhibition occurs.</p> </li> <li> <p>Complete GATOR1 complex composition: The model currently shows NPRL2, but could be improved by explicitly showing the other components of GATOR1 (DEPDC5, NPRL3) with their specific roles, if known.</p> </li> <li> <p>Downstream effectors: The model could be expanded to include more downstream targets of mTORC1 beyond S6K1 and 4E-BP1 to better represent the broader impact of this signaling pathway.</p> </li> </ol>"},{"location":"reviews/646ff70100001312-Inhibition_of_the_canonical_mTORC1_signaling_by_the_GATOR1_complex__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the current understanding of how the GATOR1 complex inhibits mTORC1 signaling in response to amino acid deprivation. The model uses appropriate GO terms, follows best practices for complex annotation, provides strong evidence, and correctly represents the causal relationships between molecular activities.</p> <p>The model is consistent with the literature, including recent structural studies (PMID:35338845) that elucidate how GATOR1 functions as a GAP for Rag GTPases. It is well-constructed, parsimonious, and effectively communicates the key aspects of this important regulatory pathway in a way that is accessible to human readers while maintaining biological accuracy.</p>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/","title":"646ff70100001877 Inhibition of the canonical mTORC1 signaling via ubiquitination and degradation of LAMTOR1 by UBE3A  Human","text":"<p>Based on my review of the GO-CAM model 646ff70100001877 (\"Inhibition of the canonical mTORC1 signaling via ubiquitination and degradation of LAMTOR1 by UBE3A (Human)\") and related information, I can provide the following assessment:</p>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#go-cam-model-review-gomodel646ff70100001877","title":"GO-CAM Model Review: gomodel:646ff70100001877","text":""},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the inhibition of canonical mTORC1 signaling through the ubiquitination and degradation of LAMTOR1 by UBE3A in humans. The model shows how UBE3A-mediated degradation of LAMTOR1 affects the Ragulator complex function and subsequently impacts TORC1 signaling.</p>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#key-components-and-relationships","title":"Key components and relationships:","text":"<ol> <li>UBE3A (Q05086) - E3 ubiquitin-protein ligase with ubiquitin protein ligase activity (GO:0061630)</li> <li>LAMTOR1 (Q6IAA8) - Ragulator complex protein with protein-membrane adaptor activity (GO:0043495)</li> <li>Ragulator complex (GO:0071986) - Guanyl-nucleotide exchange factor activity (GO:0005085)</li> </ol>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#causal-relationships","title":"Causal relationships:","text":"<ul> <li>UBE3A directly negatively regulates (RO:0002630) LAMTOR1's protein-membrane adaptor activity</li> <li>LAMTOR1's protein-membrane adaptor activity directly positively regulates (RO:0002629) the Ragulator complex's guanyl-nucleotide exchange factor activity</li> </ul>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#quality-control-evaluation","title":"Quality Control Evaluation","text":""},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>\u2705 The biological content aligns with published literature, particularly with the 2018 paper (PMID:30020076) which demonstrated that UBE3A ubiquitinates LAMTOR1, leading to its proteasomal degradation, affecting mTORC1 activity.</p>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>\u2705 Appropriate use of complexes: The model correctly uses the Ragulator complex (GO:0071986) as the bearer of the guanyl-nucleotide exchange factor activity since the specific subunit carrying this activity isn't known, following the guidelines in \"How to annotate complexes in GO-CAM\".</p> <p>\u2705 Appropriate causal relationships: The model uses correct causal relationship predicates (RO:0002630 for negative regulation and RO:0002629 for positive regulation).</p> <p>\u2705 Evidence attribution: All activities have appropriate evidence codes and PMIDs.</p> <p>\u2705 Cellular component accuracy: LAMTOR1 and the Ragulator complex are correctly located at the lysosomal membrane (GO:0005765), which matches the UniProt subcellular location data.</p>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#areas-of-strength","title":"Areas of Strength","text":"<ol> <li>The model accurately captures the negative regulation of LAMTOR1 by UBE3A through ubiquitination, which is supported by experimental evidence.</li> <li>The model correctly represents the Ragulator complex's role in TORC1 signaling and how it's affected by LAMTOR1 degradation.</li> <li>The cellular locations are accurately represented.</li> </ol>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Completeness of pathway: The model could potentially be expanded to include downstream effects on mTORC1 activation and subsequent cellular processes like synaptic plasticity, as indicated in the literature.</p> </li> <li> <p>Representation of ubiquitination process: While the model shows UBE3A negatively regulating LAMTOR1, it could explicitly represent the ubiquitination process and proteasomal degradation as intermediate steps.</p> </li> </ol>"},{"location":"reviews/646ff70100001877-Inhibition_of_the_canonical_mTORC1_signaling_via_ubiquitination_and_degradation_of_LAMTOR1_by_UBE3A__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:646ff70100001877) is biologically accurate and follows GO-CAM best practices. It correctly represents the UBE3A-mediated inhibition of LAMTOR1 and its impact on the Ragulator complex, which affects mTORC1 signaling. The model uses appropriate evidence codes, causal relationships, and cellular component annotations.</p> <p>The model could potentially be expanded to include more details about the downstream effects on mTORC1 signaling and explicit representation of the ubiquitination and degradation processes, but these are suggestions for enhancement rather than critical issues requiring correction.</p>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/","title":"646ff70100002308 SMAD6 arginine methylation inhibits SMAD1 signaling  Human","text":"<p>Now I'll review the GO-CAM model specifically looking for how it handles the annotation of SMAD6 arginine methylation inhibiting SMAD1 signaling:</p>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#review-of-go-cam-model-gomodel646ff70100002308","title":"Review of GO-CAM Model: gomodel:646ff70100002308","text":""},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model (646ff70100002308) titled \"SMAD6 arginine methylation inhibits SMAD1 signaling (Human)\" represents a key molecular pathway in the regulation of BMP (Bone Morphogenetic Protein) signaling in humans. This model captures how SMAD6 arginine methylation, facilitated by PRMT1, regulates BMP-induced SMAD1 signaling.</p>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#biological-context","title":"Biological Context","text":"<p>BMP signaling is essential for various developmental processes including bone and cartilage formation, and is regulated through a complex signaling cascade involving SMAD proteins. The model specifically illustrates how SMAD6 (an inhibitory SMAD) is methylated by PRMT1 (Protein Arginine N-Methyltransferase 1), which enables SMAD6 to sequester SMAD1 and prevent its complex formation with SMAD4, thereby inhibiting downstream transcriptional activation.</p>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#model-structure-and-molecular-activities","title":"Model Structure and Molecular Activities","text":"<p>The model includes five key activities:</p> <ol> <li>BMP4 cytokine activity (GO:0005125) enabled by UniProtKB:P12644 in extracellular space (GO:0005615)</li> <li>Part of BMP signaling pathway (GO:0030509)</li> <li> <p>Provides input for PRMT1 protein-arginine N-methyltransferase activity</p> </li> <li> <p>PRMT1 protein-arginine N-methyltransferase activity (GO:0016274) enabled by UniProtKB:Q99873 in cytoplasm (GO:0005737)</p> </li> <li>Part of regulation of BMP signaling pathway (GO:0030510)</li> <li> <p>Directly positively regulates SMAD6 protein sequestering activity</p> </li> <li> <p>SMAD6 protein sequestering activity (GO:0140311) enabled by UniProtKB:O43541 in cytoplasm (GO:0005737)</p> </li> <li>Part of negative regulation of BMP signaling pathway (GO:0030514)</li> <li> <p>Inhibits protein-substrate adopter activity of SMAD1 (RO:0012010)</p> </li> <li> <p>SMAD1 DNA-binding transcription factor activity (GO:0003700) enabled by UniProtKB:Q15797 in nucleus (GO:0005634)</p> </li> <li> <p>Part of BMP signaling pathway (GO:0030509)</p> </li> <li> <p>SMAD4 DNA-binding transcription activator activity (GO:0001228) enabled by UniProtKB:Q13485 in nucleus (GO:0005634)</p> </li> <li>Part of BMP signaling pathway (GO:0030509)</li> <li>Directly positively regulates SMAD1 DNA-binding transcription factor activity</li> </ol>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by evidence from multiple publications, with the primary evidence coming from PMID:33667543, which specifically investigates how arginine methylation of R81 in SMAD6 confines BMP-induced SMAD1 signaling. All activities and causal relationships are backed by experimental evidence (ECO:0000314 - direct assay evidence used in manual assertion).</p>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#evaluation","title":"Evaluation","text":""},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate molecular representation: The model correctly captures the mechanism by which PRMT1 methylates SMAD6, enabling it to sequester SMAD1 and prevent SMAD1-SMAD4 complex formation.</p> </li> <li> <p>Evidence-based annotations: All associations are supported by appropriate evidence codes and references to primary literature.</p> </li> <li> <p>Complete pathway representation: The model includes the initiating signal (BMP4), the key regulatory mechanism (SMAD6 methylation by PRMT1), and the downstream effects (inhibition of SMAD1-SMAD4 complex formation).</p> </li> <li> <p>Proper subcellular localization: The model correctly indicates the subcellular localization of each activity (extracellular space for BMP4, cytoplasm for PRMT1 and SMAD6, nucleus for SMAD1 and SMAD4).</p> </li> <li> <p>Appropriate causal relationships: The causal relationships between activities are correctly represented using appropriate relation ontology terms (RO:0002407, RO:0002629, RO:0012010, RO:0002629).</p> </li> </ol>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#potential-improvements","title":"Potential Improvements","text":"<ol> <li> <p>Specific methylation site: While the model title specifies arginine methylation, the specific methylation site (R81) described in the literature could be captured more explicitly in the model. Based on the referenced PMID, SMAD6 is methylated specifically at arginine 81 (R81), which is crucial for its ability to bind to phosphorylated SMAD1.</p> </li> <li> <p>BMP receptor interaction: The model could be expanded to include the interaction of BMP4 with its receptors (BMPR1A/BMPR2), which is the initial step in activating the signaling cascade.</p> </li> <li> <p>SMAD1 phosphorylation: The model doesn't explicitly capture the phosphorylation of SMAD1 by the BMP receptor, which is a critical step that makes SMAD1 a target for SMAD6-mediated sequestration.</p> </li> <li> <p>Nuclear translocation: While the model indicates the nuclear localization of SMAD1 and SMAD4, it doesn't explicitly represent the inhibition of SMAD1 nuclear translocation by SMAD6, which is an important aspect of the regulatory mechanism.</p> </li> </ol>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model adheres to GO-CAM best practices for representing complexes and molecular activities:</p> <ol> <li> <p>Activity representation: Activities are appropriately represented with specific molecular functions enabled by specific gene products.</p> </li> <li> <p>Causal relationships: The causal relationships between activities are correctly specified using appropriate relation ontology terms.</p> </li> <li> <p>Cellular context: All activities are placed in their appropriate cellular contexts.</p> </li> <li> <p>Evidence support: All annotations are supported by appropriate evidence codes and references.</p> </li> </ol>"},{"location":"reviews/646ff70100002308-SMAD6_arginine_methylation_inhibits_SMAD1_signaling__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:646ff70100002308) provides an accurate and well-supported representation of how SMAD6 arginine methylation by PRMT1 inhibits SMAD1 signaling in the BMP pathway. The model is consistent with current knowledge about this regulatory mechanism and follows GO-CAM best practices.</p> <p>The model could be enhanced by explicitly representing the specific methylation site (R81), including BMP receptor interactions, capturing SMAD1 phosphorylation, and representing the inhibition of SMAD1 nuclear translocation. However, these suggestions do not detract from the overall quality and accuracy of the existing model.</p>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/","title":"646ff70100002557 Negative regulation  of autophagy via phosphorylation of ULK1 by canonical mTORC1 signaling  Human","text":"<p>Based on my review of the GO-CAM model with ID 646ff70100002557 and the relevant documents, here is my detailed review:</p>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#review-of-go-cam-model-gomodel646ff70100002557","title":"Review of GO-CAM Model: gomodel:646ff70100002557","text":""},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#general-information","title":"General Information","text":"<ul> <li>Title: Negative regulation of autophagy via phosphorylation of ULK1 by canonical mTORC1 signaling (Human)</li> <li>ID: gomodel:646ff70100002557</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> <li>Date Created: June 2023</li> <li>Creator: ORCID:0000-0001-7299-6685</li> </ul>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM represents the negative regulation of autophagy through the mTORC1 signaling pathway in humans. The core process involves the phosphorylation of ULK1 by the mTOR complex 1 (mTORC1), which inhibits autophagy initiation. The model includes the activation of mTORC1 through the Rag GTPases at the lysosomal membrane and the regulatory role of RHEB.</p>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the canonical mTORC1 signaling pathway that negatively regulates autophagy. It includes:</p> <ol> <li>Ragulator complex components and their role in lysosomal localization</li> <li>Rag GTPases (RRAGA/C) and their nucleotide-binding states</li> <li>RHEB activation of mTORC1</li> <li>mTOR-dependent phosphorylation of ULK1, which inhibits autophagy</li> </ol> <p>This representation aligns with current understanding of mTORC1 signaling and its role in autophagy regulation as confirmed by reviewing the ULK1 and mTOR UniProt entries and the PMID:29236692 reference.</p>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#go-cam-structure-analysis","title":"GO-CAM Structure Analysis","text":""},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#activities-and-entities","title":"Activities and Entities","text":"<p>The model includes the following key activities:</p> <ol> <li>LAMTOR1 (Q6IAA8) - Protein-membrane adaptor activity (GO:0043495) in lysosomal membrane</li> <li>Ragulator complex (GO:0071986) - Guanyl-nucleotide exchange factor activity (GO:0005085) in lysosomal membrane</li> <li>RRAGA (Q7L523) - GTP binding (GO:0005525) and protein-membrane adaptor activity (GO:0043495) in lysosomal membrane</li> <li>RRAGC (Q9HB90) - GDP binding (GO:0019003) and protein-membrane adaptor activity (GO:0043495) in lysosomal membrane</li> <li>RHEB (Q15382) - Protein serine/threonine kinase activator activity (GO:0043539) in lysosomal membrane</li> <li>RPTOR (Q8N122) - Enzyme-substrate adaptor activity (GO:0140767) in lysosomal membrane</li> <li>mTOR (P42345) - Protein serine/threonine kinase activity (GO:0004674) in lysosomal membrane</li> <li>ULK1 (O75385) - Protein serine/threonine kinase activity (GO:0004674) in omegasome membrane</li> </ol>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal flow is logically constructed and follows the expected biological pathway:</p> <ol> <li>LAMTOR1 \u2192 Ragulator complex (RO:0002629, directly positively regulates)</li> <li>Ragulator complex \u2192 RRAGA (RO:0002629)</li> <li>LAMTOR1 \u2192 RRAGA and RRAGC (RO:0002629)</li> <li>RRAGA \u2192 RRAGC and RPTOR (RO:0002629)</li> <li>RRAGC \u2192 RPTOR and RHEB (RO:0002629)</li> <li>RHEB \u2192 mTOR (RO:0002629)</li> <li>RPTOR \u2192 mTOR (RO:0002629)</li> <li>mTOR \u2192 ULK1 (RO:0002630, directly negatively regulates)</li> </ol> <p>This causal flow correctly represents the signaling cascade where Ragulator and Rag GTPases facilitate recruitment of mTORC1 to lysosomes, RHEB activates mTOR kinase activity, and mTOR phosphorylates ULK1 to inhibit autophagy.</p>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#cellular-locations","title":"Cellular Locations","text":"<p>The cellular locations are accurately represented: - Most activities occur at the lysosomal membrane (GO:0005765) - ULK1 activity is appropriately located at the omegasome membrane (GO:1903349)</p>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li>Complex Annotation: The model correctly uses complex annotation practices based on \"How to annotate complexes in GO-CAM\":</li> <li>It appropriately uses the Ragulator complex (GO:0071986) ID for guanyl-nucleotide exchange factor activity since the exact subunit carrying this activity is not known</li> <li>LAMTOR1 is properly annotated with its specific activity separate from the complex</li> <li> <p>mTORC1 is appropriately represented with RPTOR and mTOR having distinct activities</p> </li> <li> <p>Causal Relationships: The model correctly uses RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates) to represent the signaling cascade.</p> </li> <li> <p>Subcellular Locations: Each activity is annotated with appropriate subcellular locations.</p> </li> <li> <p>Evidence: All activities and relationships are supported by appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and PMIDs.</p> </li> </ol>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#supporting-evidence","title":"Supporting Evidence","text":"<p>The model includes numerous PMIDs as evidence, and I've confirmed that key citations match the represented biology:</p> <ul> <li>PMID:29236692 - Details the structural mechanisms of mTORC1 activation by RHEB</li> <li>PMID:25891078 - Discusses ULK1 phosphorylation in the context of autophagy regulation</li> <li>PMID:31601708 and PMID:31601764 - Cover Rag GTPase roles and lysosomal localization</li> <li>PMID:28890335 - Addresses ULK1 and its role in autophagosome formation</li> </ul>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Biological Process Annotations: The model appropriately includes biological process annotations for most activities, but could benefit from more specific autophagy-related process terms for the ULK1 component.</p> </li> <li> <p>Completeness: While the core signaling pathway is well represented, additional downstream effects of ULK1 inhibition could be included to provide a more complete picture of autophagy regulation.</p> </li> <li> <p>Clarity and Parsimony: The model is relatively clean and easy to follow, but adding one or two key additional outputs of activated ULK1 when not inhibited by mTOR would help clarify the biological consequences of this regulation.</p> </li> </ol>"},{"location":"reviews/646ff70100002557-Negative_regulation__of_autophagy_via_phosphorylation_of_ULK1_by_canonical_mTORC1_signaling__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model effectively represents the negative regulation of autophagy through mTORC1-mediated phosphorylation of ULK1. It accurately follows GO-CAM best practices for complex annotation and causal relationships, and is well supported by literature evidence. The biological content is consistent with current knowledge about mTORC1 signaling and autophagy regulation.</p> <p>The model is well-constructed, logically organized, and represents the biological process in a manner that is both accurate and understandable. It appropriately utilizes GO terms and relationship types according to GO-CAM standards. The subcellular locations are correctly specified, and the evidence provided supports the represented relationships.</p>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/","title":"646ff70100003125 Inhibition of the canonical mTORC1 signaling by NLK in response to osmotic stress  Human","text":"<p>Based on the information gathered, let me now provide a thorough review of GO-CAM model 646ff70100003125:</p>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#review-of-go-cam-model-gomodel646ff70100003125","title":"Review of GO-CAM Model: gomodel:646ff70100003125","text":""},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#model-overview","title":"Model Overview","text":"<p>Title: \"Inhibition of the canonical mTORC1 signaling by NLK in response to osmotic stress (Human)\"</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>Model ID: gomodel:646ff70100003125</p>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#summary-of-biological-content","title":"Summary of Biological Content","text":"<p>This GO-CAM model represents the molecular pathway by which Nemo-like kinase (NLK) inhibits mTORC1 signaling in response to osmotic stress. The model captures how NLK phosphorylates Raptor (RPTOR) to disrupt the interaction between Raptor and the Rag GTPases, leading to inhibition of mTORC1 lysosomal recruitment and activity.</p> <p>The key elements of this pathway include:</p> <ol> <li>NLK protein kinase activity directly negatively regulates RRAGA and RRAGC protein-membrane adaptor activities</li> <li>RRAGA and RRAGC protein-membrane adaptor activities directly positively regulate RHEB protein kinase activator activity</li> <li>RHEB protein kinase activator activity directly positively regulates mTOR protein serine/threonine kinase activity</li> <li>RPTOR enzyme-substrate adaptor activity directly positively regulates mTOR protein serine/threonine kinase activity</li> </ol>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#model-accuracy-and-consistency-with-literature","title":"Model Accuracy and Consistency with Literature","text":"<p>The model is strongly supported by the literature, particularly the key papers by Yuan et al. (PMID:26588989) and Rogala et al. (PMID:31601708). These papers establish that:</p> <ol> <li>NLK is activated by osmotic stress and directly phosphorylates Raptor on Ser863, which disrupts Raptor's interaction with the Rag GTPases</li> <li>The Rag GTPases (RRAGA/B and RRAGC/D) are required for mTORC1 recruitment to lysosomal membranes</li> <li>Proper localization of mTORC1 to the lysosomal membrane is necessary for its activation by Rheb</li> <li>The model correctly represents that all these activities occur at the lysosomal membrane (GO:0005765)</li> </ol> <p>The causal relationships between activities are correctly represented using appropriate relationship predicates: - \"RO:0002630\" (directly negatively regulates) for NLK's effect on Rag GTPases - \"RO:0002629\" (directly positively regulates) for the activating interactions</p>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#component-evaluation","title":"Component Evaluation","text":""},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#1-nlk-uniprotkbq9ube8","title":"1. NLK (UniProtKB:Q9UBE8)","text":"<ul> <li>Correctly annotated with protein serine/threonine kinase activity (GO:0004674)</li> <li>Correctly part of the negative regulation of TORC1 signaling (GO:1904262)</li> <li>The evidence is appropriate (ECO:0000314 - direct assay evidence) citing PMID:26588989</li> <li>The function is consistent with UniProt annotation which confirms NLK \"acts as an inhibitor of the mTORC1 complex in response to osmotic stress by mediating phosphorylation of RPTOR, thereby preventing recruitment of the mTORC1 complex to lysosomes\"</li> </ul>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#2-rragarragc-uniprotkbq7l523q9hb90","title":"2. RRAGA/RRAGC (UniProtKB:Q7L523/Q9HB90)","text":"<ul> <li>Both correctly annotated with protein-membrane adaptor activity (GO:0043495)</li> <li>Correctly occur in lysosomal membrane (GO:0005765)</li> <li>Correctly part of protein localization to lysosome (GO:0061462)</li> <li>Evidence properly cited from PMID:31601708</li> <li>Activities accurately represent their role in tethering mTORC1 to the lysosomal membrane</li> </ul>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#3-rheb-uniprotkbq15382","title":"3. RHEB (UniProtKB:Q15382)","text":"<ul> <li>Correctly annotated with protein serine/threonine kinase activator activity (GO:0043539)</li> <li>Correctly occurs in lysosomal membrane (GO:0005765)</li> <li>Correctly part of positive regulation of TORC1 signaling (GO:1904263)</li> <li>Evidence appropriately cites PMID:29236692 and PMID:15854902</li> </ul>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#4-mtor-uniprotkbp42345","title":"4. mTOR (UniProtKB:P42345)","text":"<ul> <li>Correctly annotated with protein serine/threonine kinase activity (GO:0004674)</li> <li>Correctly occurs in lysosomal membrane (GO:0005765)</li> <li>Correctly part of TORC1 signaling (GO:0038202)</li> <li>Evidence appropriately cites PMID:29750193</li> </ul>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#5-rptor-uniprotkbq8n122","title":"5. RPTOR (UniProtKB:Q8N122)","text":"<ul> <li>Correctly annotated with enzyme-substrate adaptor activity (GO:0140767)</li> <li>Correctly occurs in lysosomal membrane (GO:0005765)</li> <li>Correctly part of TORC1 signaling (GO:0038202)</li> <li>Evidence appropriately cites PMID:12747827</li> </ul>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#strengths-of-the-model","title":"Strengths of the model:","text":"<ol> <li>Consistent with literature: The model accurately represents the mechanisms described in the primary literature.</li> <li>Appropriate annotation of activities: Each protein is annotated with its correct molecular function, cellular component, and biological process.</li> <li>Correct causal relations: The causal relations use appropriate RO (Relations Ontology) terms to describe positive or negative regulation.</li> <li>Completeness: The model captures the key steps in the pathway from NLK activation to mTORC1 inhibition.</li> <li>Evidence quality: All annotations are supported by appropriate experimental evidence with PMIDs.</li> </ol>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#minor-suggestions-for-improvement","title":"Minor suggestions for improvement:","text":"<ol> <li>Additional context: The model could potentially include the upstream activation of NLK by osmotic stress (GO:0071470), which is mentioned in the title but not explicitly modeled.</li> <li>Mechanistic detail: The specific phosphorylation of Raptor at residue S863 by NLK could be noted, as this is a key mechanistic detail from the literature.</li> </ol>"},{"location":"reviews/646ff70100003125-Inhibition_of_the_canonical_mTORC1_signaling_by_NLK_in_response_to_osmotic_stress__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:646ff70100003125) is a high-quality representation of NLK-mediated inhibition of mTORC1 signaling in response to osmotic stress. The model is well-constructed, supported by appropriate evidence, and consistent with current literature understanding of the pathway. It correctly represents the key molecular functions, their locations, and the causal relationships between them.</p> <p>The model successfully represents a pathway of significant biological importance, as mTORC1 signaling is a central regulator of cellular growth and metabolism, and its regulation by stress stimuli is crucial for proper cellular adaptation to changing environmental conditions.</p>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/","title":"646ff70100004025 Activation of the canonical mTORC1 signaling via non catalytic deubiquitination of RPTOR by OTUB1  Human","text":"<p>Now I have a good understanding of the GO-CAM model and can provide a thorough review.</p>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#review-of-go-cam-model-gomodel646ff70100004025","title":"Review of GO-CAM Model: gomodel:646ff70100004025","text":""},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:646ff70100004025</li> <li>Title: Activation of the canonical mTORC1 signaling via non-catalytic deubiquitination of RPTOR by OTUB1 (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the mechanism by which OTUB1 stabilizes Raptor (RPTOR) protein through non-catalytic deubiquitination, leading to activation of mTORC1 signaling. The model is based primarily on evidence from the publication by Seo et al. (PMID:35927303), which demonstrates that phosphorylation of OTUB1 at tyrosine 26 (Y26) by Src and SRMS kinases is critical for its interaction with Raptor, preventing Raptor's ubiquitination and subsequent degradation.</p>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#biological-content-review","title":"Biological Content Review","text":""},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#main-findings-represented","title":"Main Findings Represented:","text":"<p>The model correctly captures the key pathway where: 1. Src and SRMS kinases (SRC and SRMS proteins) phosphorylate OTUB1 at Y26 2. Phosphorylated OTUB1 inhibits ubiquitin-conjugating enzymes (UBE2N, UBE2W, UBE2D1)  3. This inhibition prevents Raptor (RPTOR) ubiquitination and degradation 4. Stabilized Raptor maintains mTORC1 signaling activity</p>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#molecular-functions-and-biological-processes","title":"Molecular Functions and Biological Processes:","text":"<p>The model accurately represents: - Protein tyrosine kinase activity (GO:0004713) for SRC and SRMS - Ubiquitin-protein transferase inhibitor activity (GO:0055105) for OTUB1 - Ubiquitin conjugating enzyme activity (GO:0061631) for UBE2N, UBE2W, and UBE2D1 - Enzyme-substrate adaptor activity (GO:0140767) for RPTOR - Protein serine/threonine kinase activity (GO:0004674) for MTOR</p>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#causal-relationships","title":"Causal Relationships:","text":"<p>The model uses appropriate causal relation predicates: - RO:0002629 (directly positively regulates): For positive regulatory relationships - RO:0002630 (directly negatively regulates): For OTUB1 inhibition of E2 enzymes - RO:0002409: An unexpected relation that may need review</p>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately captures the non-canonical mechanism of OTUB1's deubiquitinase activity</li> <li>The relationships between proteins are well-supported by experimental evidence</li> <li>The model includes appropriate cellular localization (lysosomal membrane)</li> <li>Evidence is properly cited with direct assay evidence (ECO:0000314)</li> </ol>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#issues-identified","title":"Issues Identified:","text":"<ol> <li> <p>Predicate Usage Issue: The model uses RO:0002409 in several causal associations from ubiquitin-conjugating enzymes to RPTOR. This doesn't appear in your list of standard predicates for causal associations. This should be replaced with one of the standard causal relations, likely RO:0002305 (causally upstream of, negative effect) as these enzymes promote Raptor degradation.</p> </li> <li> <p>Cellular Component Annotation: While RPTOR and MTOR are correctly annotated as occurring in the lysosomal membrane (GO:0005765), there's no cellular component annotation for OTUB1, SRC, SRMS, or the E2 enzymes. According to the paper, their interactions are likely cytosolic and the paper discusses their localization.</p> </li> <li> <p>Mechanistic Detail: The model doesn't capture the specific ubiquitination sites on Raptor (K774 and K789) that were identified in the paper. While this level of detail may exceed what's typically included in GO-CAMs, it could be noted.</p> </li> <li> <p>Missing Activity Terms: The paper describes that phosphorylation of OTUB1 at Y26 is critical for its function, but the model doesn't capture this post-translational modification state of OTUB1.</p> </li> </ol>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#literature-consistency","title":"Literature Consistency","text":"<p>The model is consistent with the cited literature (PMID:35927303). The paper demonstrates that OTUB1 stabilizes Raptor in a non-canonical manner, where phosphorylation at Y26 is critical for the interaction between OTUB1 and Raptor. The paper also identifies that Src and SRMS kinases induce this phosphorylation.</p>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Fix Predicate Usage: Replace RO:0002409 with the standard RO:0002305 (causally upstream of, negative effect) in the causal associations from ubiquitin-conjugating enzymes to RPTOR.</p> </li> <li> <p>Add Cellular Components: Add appropriate cellular component annotations for OTUB1, SRC, SRMS, and the E2 enzymes based on information in the paper.</p> </li> <li> <p>Consider Adding a Complex: According to the \"How to annotate complexes in GO-CAM\" guidelines, when activities of specific subunits are known (as in this case), they should be represented individually. However, it might be helpful to indicate that RPTOR and MTOR form part of the mTORC1 complex for clarity.</p> </li> <li> <p>Annotate Post-Translational Modifications: Consider adding an annotation to capture the phosphorylation state of OTUB1 that is critical for its function in this pathway.</p> </li> <li> <p>Check for Missing Connections: The model correctly shows that OTUB1 inhibits the E2 enzymes, but it could be clearer about how these enzymes affect RPTOR - perhaps by adding a direct connection.</p> </li> </ol>"},{"location":"reviews/646ff70100004025-Activation_of_the_canonical_mTORC1_signaling_via_non_catalytic_deubiquitination_of_RPTOR_by_OTUB1__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the biological mechanism described in the literature. With the minor improvements suggested above, it would provide an even clearer representation of how OTUB1 regulates mTORC1 signaling through Raptor stabilization. The model effectively captures the non-canonical deubiquitination mechanism and the key regulatory role of tyrosine phosphorylation, which is consistent with the supporting publication.</p>"},{"location":"reviews/646ff70100004220-Inhibition_of_the_canonical_mTORC1_signaling_by_AKT1S1_PRAS40_in_absence_of_insulin__Human_/","title":"646ff70100004220 Inhibition of the canonical mTORC1 signaling by AKT1S1 PRAS40 in absence of insulin  Human","text":"<p>Based on my review of the GO-CAM model with ID 646ff70100004220 titled \"Inhibition of the canonical mTORC1 signaling by AKT1S1/PRAS40 in absence of insulin (Human)\", I'll provide a comprehensive assessment of its quality and compliance with GO-CAM best practices.</p>"},{"location":"reviews/646ff70100004220-Inhibition_of_the_canonical_mTORC1_signaling_by_AKT1S1_PRAS40_in_absence_of_insulin__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the inhibitory role of AKT1S1/PRAS40 (Proline-rich AKT1 substrate 1) on mTORC1 signaling in the absence of insulin in human cells. The model shows various protein kinase activities and their regulatory relationships, particularly focusing on how AKT1S1 negatively regulates mTOR signaling.</p>"},{"location":"reviews/646ff70100004220-Inhibition_of_the_canonical_mTORC1_signaling_by_AKT1S1_PRAS40_in_absence_of_insulin__Human_/#main-components-and-activities","title":"Main Components and Activities","text":"<p>The model includes the following key proteins and activities:</p> <ol> <li> <p>AKT1S1/PRAS40 (Q96B36): Functions as a protein serine/threonine kinase inhibitor (GO:0030291), negatively regulating mTORC1 signaling (GO:1904262)</p> </li> <li> <p>mTOR (P42345): Exhibits protein serine/threonine kinase activity (GO:0004674) in two different contexts:</p> </li> <li>As part of TORC1 signaling (GO:0038202)</li> <li> <p>As part of positive regulation of translational initiation (GO:0045948)</p> </li> <li> <p>RPS6KB1/S6K1 (P23443) and RPS6KB2/S6K2 (Q9UBS0): Both exhibit protein serine/threonine kinase activity (GO:0004674)</p> </li> <li> <p>RPS6/S6 (P62753): Structural constituent of ribosome (GO:0003735), involved in cytoplasmic translation (GO:0002181)</p> </li> <li> <p>EIF4EBP1 (Q13541): Translation repressor activity (GO:0030371), involved in negative regulation of translational initiation (GO:0045947)</p> </li> </ol>"},{"location":"reviews/646ff70100004220-Inhibition_of_the_canonical_mTORC1_signaling_by_AKT1S1_PRAS40_in_absence_of_insulin__Human_/#regulatory-relationships","title":"Regulatory Relationships","text":"<p>The model effectively captures several causal relationships:</p> <ol> <li>AKT1S1/PRAS40 directly negatively regulates (RO:0002630) mTOR kinase activity</li> <li>mTOR directly positively regulates (RO:0002629) RPS6KB1 and RPS6KB2</li> <li>RPS6KB1 and RPS6KB2 directly positively regulate (RO:0002629) RPS6</li> <li>mTOR directly negatively regulates (RO:0002630) EIF4EBP1</li> </ol>"},{"location":"reviews/646ff70100004220-Inhibition_of_the_canonical_mTORC1_signaling_by_AKT1S1_PRAS40_in_absence_of_insulin__Human_/#assessment-and-qc","title":"Assessment and QC","text":""},{"location":"reviews/646ff70100004220-Inhibition_of_the_canonical_mTORC1_signaling_by_AKT1S1_PRAS40_in_absence_of_insulin__Human_/#strengths-of-the-model","title":"Strengths of the model:","text":"<ol> <li> <p>Accurate biological content: The model accurately represents the inhibitory role of AKT1S1/PRAS40 on mTORC1 signaling in the absence of insulin, which is supported by the literature (PMID:29750193, PMID:17386266). According to the UniProt entry for AKT1S1 (Q96B36), it is indeed \"a negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1)\" that \"in absence of insulin and nutrients, associates with the mTORC1 complex and directly inhibits mTORC1 activity.\"</p> </li> <li> <p>Correct molecular functions: The model accurately assigns molecular functions to the proteins involved:</p> </li> <li>AKT1S1 as a protein serine/threonine kinase inhibitor</li> <li>mTOR as a protein serine/threonine kinase</li> <li>S6K1/S6K2 as protein serine/threonine kinases</li> <li>RPS6 as a structural component of the ribosome</li> <li> <p>EIF4EBP1 as a translation repressor</p> </li> <li> <p>Cellular localization information: The model includes information about cellular localization where relevant (e.g., RPS6 is annotated as occurring in the cytosolic ribosome, and mTOR is noted as occurring in the lysosomal membrane).</p> </li> <li> <p>Proper use of causal relationships: The model uses the appropriate causal relationship predicates (RO:0002629 for direct positive regulation and RO:0002630 for direct negative regulation).</p> </li> <li> <p>Evidence support: All activities and relationships are backed by appropriate evidence (ECO:0000314 - direct assay evidence) and literature references.</p> </li> </ol>"},{"location":"reviews/646ff70100004220-Inhibition_of_the_canonical_mTORC1_signaling_by_AKT1S1_PRAS40_in_absence_of_insulin__Human_/#areas-for-improvement","title":"Areas for improvement:","text":"<ol> <li> <p>Incorporate additional context: The model could be expanded to include the response to insulin stimulation to provide a more comprehensive view of the pathway's regulation. Currently, it only represents the situation in the absence of insulin.</p> </li> <li> <p>Molecular details of inhibition: The model could potentially benefit from more detail on how exactly AKT1S1/PRAS40 inhibits mTOR - from the literature, we know it blocks the mTOR substrate-recruitment site (PMID:29236692).</p> </li> <li> <p>Phosphorylation regulation: The model doesn't explicitly capture how phosphorylation of AKT1S1/PRAS40 (particularly at Thr-246) affects its inhibitory function. From UniProt: \"Phosphorylation at Thr-246 by AKT1 relieves its inhibitory function on mTORC1.\"</p> </li> <li> <p>Complex representation: While the model mentions mTORC1 in the process context, it doesn't explicitly represent the mTORC1 complex as a whole. Based on the \"How to annotate complexes in GO-CAM\" document, since the activity is enabled by mTOR specifically (the subunit carrying the activity is known), this approach is acceptable.</p> </li> </ol>"},{"location":"reviews/646ff70100004220-Inhibition_of_the_canonical_mTORC1_signaling_by_AKT1S1_PRAS40_in_absence_of_insulin__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 646ff70100004220 is a high-quality representation of AKT1S1/PRAS40's inhibitory role in mTORC1 signaling in the absence of insulin. The model adheres to GO-CAM best practices for representing molecular activities, causal relationships, and regulatory mechanisms. It accurately represents the biological reality as supported by the literature and is constructed in a way that is easy to understand.</p> <p>The model could be enhanced by extending it to show the dynamic regulation that occurs in response to insulin stimulation, which leads to phosphorylation of AKT1S1/PRAS40 and its dissociation from mTORC1. This would provide a more comprehensive view of this signaling pathway's regulation.</p> <p>Overall, this model is a valuable contribution to the GO-CAM knowledge base and serves as a good example of how to represent regulatory relationships in signaling pathways.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/","title":"646ff70100004606 Inhibition of the canonical mTORC1 signaling  by TSC2 in response to starvation  Human","text":"<p>Based on the information I've collected, I'll now provide a detailed review of GO-CAM model 646ff70100004606.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#review-of-go-cam-model-646ff70100004606","title":"Review of GO-CAM Model 646ff70100004606","text":""},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#basic-information","title":"Basic Information","text":"<ul> <li>Model ID: gomodel:646ff70100004606</li> <li>Title: Inhibition of the canonical mTORC1 signaling by TSC2 in response to starvation (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model represents the inhibition of mTORC1 signaling by TSC2 in response to starvation, focusing on the regulation of translation initiation. The model captures the key molecular events involved in the pathway where TSC2 acts as a GTPase activator for RHEB, which in turn regulates mTORC1 activity, ultimately affecting protein synthesis.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#key-components-and-their-functions","title":"Key Components and Their Functions","text":""},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#1-tsc2-tuberous-sclerosis-2-protein","title":"1. TSC2 (Tuberous Sclerosis 2 protein)","text":"<ul> <li>UniProt: P49815</li> <li>Function: GTPase activator activity (GO:0005096)</li> <li>Location: Lysosomal membrane (GO:0005765)</li> <li>Process: Negative regulation of TORC1 signaling (GO:1904262)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:9045618, PMID:12906785, and PMID:24529379</li> </ul> <p>TSC2 acts as a GTPase activator protein (GAP) that negatively regulates RHEB by stimulating GTP hydrolysis to GDP, thereby inhibiting RHEB's activity.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#2-rheb-gtp-binding-protein-rheb","title":"2. RHEB (GTP-binding protein Rheb)","text":"<ul> <li>UniProt: Q15382</li> <li>Function: Protein serine/threonine kinase activator activity (GO:0043539)</li> <li>Location: Lysosomal membrane (GO:0005765)</li> <li>Process: Positive regulation of TORC1 signaling (GO:1904263)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:29236692 and PMID:15854902</li> </ul> <p>RHEB, when bound to GTP, is an activator of mTORC1. It binds to mTOR and induces a conformational change that realigns active-site residues, accelerating catalysis as shown in the PMID:29236692 study.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#3-mtor-serinethreonine-protein-kinase-mtor","title":"3. mTOR (Serine/threonine-protein kinase mTOR)","text":"<ul> <li>UniProt: P42345</li> <li>Function: Protein serine/threonine kinase activity (GO:0004674)</li> <li>Location: Lysosomal membrane (GO:0005765)</li> <li>Process: TORC1 signaling (GO:0038202) and Positive regulation of translational initiation (GO:0045948)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:12087098 and PMID:29750193</li> </ul> <p>mTOR is the catalytic component of the mTORC1 complex that phosphorylates downstream targets.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#4-eif4ebp1-4e-bp1","title":"4. EIF4EBP1 (4E-BP1)","text":"<ul> <li>UniProt: Q13541</li> <li>Function: Translation repressor activity (GO:0030371)</li> <li>Process: Negative regulation of translational initiation (GO:0045947)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:22578813</li> </ul> <p>4E-BP1 is a repressor of translation that binds to eIF4E, preventing formation of the eIF4F translation initiation complex. When phosphorylated by mTOR, 4E-BP1 dissociates from eIF4E, allowing translation to proceed.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#5-s6-kinases-rps6kb1-and-rps6kb2","title":"5. S6 Kinases (RPS6KB1 and RPS6KB2)","text":"<ul> <li>UniProt: P23443 (RPS6KB1) and Q9UBS0 (RPS6KB2)</li> <li>Function: Protein serine/threonine kinase activity (GO:0004674)</li> <li>Process: Positive regulation of translational initiation (GO:0045948)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:29750193 and PMID:1922062</li> </ul> <p>Both S6K1 and S6K2 are activated by mTORC1 phosphorylation and subsequently phosphorylate ribosomal protein S6 to promote protein synthesis.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#6-ribosomal-protein-s6-rps6","title":"6. Ribosomal Protein S6 (RPS6)","text":"<ul> <li>UniProt: P62753</li> <li>Function: Structural constituent of ribosome (GO:0003735)</li> <li>Location: Cytosolic ribosome (GO:0022626)</li> <li>Process: Cytoplasmic translation (GO:0002181)</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:34314702 and PMID:8706699</li> </ul> <p>Ribosomal protein S6 is a component of the 40S ribosomal subunit that, when phosphorylated, enhances translation.</p>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The model depicts a signaling cascade with the following key causal relationships:</p> <ol> <li>TSC2 negatively regulates RHEB:</li> <li>Predicate: RO:0002630 (directly negatively regulates)</li> <li> <p>TSC2 acts as a GAP for RHEB, converting it from the active GTP-bound state to the inactive GDP-bound state</p> </li> <li> <p>RHEB positively regulates mTOR:</p> </li> <li>Predicates: RO:0002629 (directly positively regulates)</li> <li> <p>RHEB in its GTP-bound form binds to mTOR and allosterically activates its kinase activity</p> </li> <li> <p>mTOR positively regulates S6K1 and S6K2:</p> </li> <li>Predicate: RO:0002629 (directly positively regulates)</li> <li> <p>mTOR phosphorylates and activates S6K1 and S6K2</p> </li> <li> <p>S6K1 and S6K2 positively regulate RPS6:</p> </li> <li>Predicate: RO:0002629 (directly positively regulates)</li> <li> <p>S6K1 and S6K2 phosphorylate RPS6, enhancing its activity in translation</p> </li> <li> <p>mTOR negatively regulates EIF4EBP1:</p> </li> <li>Predicate: RO:0002630 (directly negatively regulates)</li> <li>mTOR phosphorylates EIF4EBP1, causing it to dissociate from eIF4E and releasing its inhibition of translation initiation</li> </ol>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate biological pathway representation: The model correctly represents the established mTORC1 signaling pathway in response to starvation, with TSC2 inhibiting RHEB, which in turn regulates mTORC1 activity.</p> </li> <li> <p>Appropriate evidence: Each activity and causal relationship is supported by published literature with direct assay evidence (ECO:0000314).</p> </li> <li> <p>Correct subcellular localization: Key components like TSC2, RHEB, and mTOR are correctly localized to the lysosomal membrane, which is consistent with current understanding of mTORC1 regulation.</p> </li> <li> <p>Proper causal relationships: The model uses appropriate causal predicates (RO:0002629 for positive regulation and RO:0002630 for negative regulation) to represent the relationships between components.</p> </li> <li> <p>Correct molecular functions: Each protein is assigned appropriate molecular functions based on their established biochemical activities.</p> </li> </ol>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex representation: According to the \"How to annotate complexes in GO-CAM\" document, mTORC1 could be more clearly represented as a complex. The model currently represents mTOR but does not explicitly include RAPTOR and mLST8, which are core components of the mTORC1 complex. According to the literature (PMID:29236692), mTORC1 is a ~1 MDa dimeric complex consisting of mTOR, RAPTOR, and mLST8.</p> </li> <li> <p>Missing components: The model doesn't include RAPTOR, which is crucial for substrate recognition through its binding to the TOS motif present in substrates like 4E-BP1 and S6K1. PMID:29236692 shows that RAPTOR binds to substrates through a TOS motif, which is an important aspect of mTORC1 substrate specificity.</p> </li> <li> <p>Additional regulatory inputs: The model focuses on TSC2-mediated regulation of mTORC1 in response to starvation, but doesn't include other regulatory inputs such as PRAS40, which is an mTORC1 inhibitor mentioned in PMID:29236692.</p> </li> <li> <p>Mechanistic details: The model could include more mechanistic details about how RHEB activates mTORC1. According to PMID:29236692, RHEB binds to mTOR and causes a global conformational change that allosterically realigns active-site residues to accelerate catalysis, rather than just generically activating it.</p> </li> <li> <p>Additional downstream targets: While the model includes key downstream targets like 4E-BP1 and S6K1/2, there are other known mTORC1 substrates that could be included for a more comprehensive representation.</p> </li> </ol>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Represent mTORC1 as a complex: Consider explicitly including RAPTOR and mLST8 as components of the mTORC1 complex, following the guidelines in the \"How to annotate complexes in GO-CAM\" document.</p> </li> <li> <p>Add RAPTOR and its substrate recognition function: Include RAPTOR and its role in binding to the TOS motif of mTORC1 substrates.</p> </li> <li> <p>Include additional regulatory components: Consider adding PRAS40 as an inhibitor of mTORC1, especially if representing responses to growth factors in addition to nutrients.</p> </li> <li> <p>Add more mechanistic details: Enhance the description of how RHEB activates mTORC1 by including the conformational change it induces in mTOR.</p> </li> <li> <p>Expand downstream effectors: Consider including additional downstream targets of mTORC1 to provide a more comprehensive view of the pathway.</p> </li> </ol>"},{"location":"reviews/646ff70100004606-Inhibition_of_the_canonical_mTORC1_signaling__by_TSC2_in_response_to_starvation__Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:646ff70100004606 provides a solid representation of the inhibition of mTORC1 signaling by TSC2 in response to starvation in humans. The model accurately captures the core components and causal relationships in this pathway. With some enhancements to include complex representation, additional components, and more mechanistic details, this model could provide an even more comprehensive representation of mTORC1 regulation and function.</p> <p>The model effectively shows how nutrient availability (or lack thereof) signals through TSC2 to regulate RHEB activity, which in turn controls mTORC1-mediated phosphorylation of key translation regulators like 4E-BP1 and S6K1/2, ultimately affecting protein synthesis rates in the cell. This regulatory circuit is critical for cellular adaptation to nutrient availability and is frequently dysregulated in cancer and other diseases.</p>"},{"location":"reviews/646ff70100004848-Activation_of_the_canonical_mTORC1_signaling_in_response_to_insulin_via_phosphorylation_and_inhibition_of_TSC2__Human_/","title":"646ff70100004848 Activation of the canonical mTORC1 signaling in response to insulin via phosphorylation and inhibition of TSC2  Human","text":"<p>Based on the complex annotation guidelines, the representation of mTOR without explicit modeling of the mTORC1 complex could be valid if the mTOR subunit is known to be the one carrying the kinase activity (which it is). However, for completeness, it might be useful to include the complete mTORC1 complex structure, particularly since different components (like RAPTOR) have specific functions in substrate recognition.</p>"},{"location":"reviews/646ff70100004848-Activation_of_the_canonical_mTORC1_signaling_in_response_to_insulin_via_phosphorylation_and_inhibition_of_TSC2__Human_/#final-assessment","title":"Final Assessment","text":"<p>This GO-CAM model (gomodel:646ff70100004848) provides a good representation of the canonical mTORC1 signaling pathway in response to insulin. It accurately depicts the core components and their causal relationships, with appropriate molecular functions and cellular locations. </p> <p>The model has strong evidence support with multiple literature references for key assertions. The causal flow is logical and follows biological understanding of this pathway.</p> <p>Strengths: - Clear representation of the TSC2-RHEB-mTORC1 axis - Appropriate downstream effectors of mTORC1 signaling - Well-supported with literature evidence - Correct use of GO terms and relationships</p> <p>Opportunities for improvement: - Include upstream insulin receptor signaling components - Consider representing mTORC1 as a complex - Add explicit insulin stimulus context</p> <p>Overall, this is a well-constructed model that effectively captures the key aspects of mTORC1 signaling downstream of insulin stimulus via TSC2 inhibition.</p>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/","title":"646ff70100004973 USP38 Lys 33 to Lys 48 transition on TBK1 leading to its degratdation  Human","text":"<p>After reviewing the GOmodel:646ff70100004973 and associated proteins, let me analyze this GO-CAM model in detail and provide a comprehensive review.</p>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#review-of-go-cam-model-gomodel646ff70100004973","title":"Review of GO-CAM Model: gomodel:646ff70100004973","text":""},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#basic-information","title":"Basic Information","text":"<ul> <li>Title: USP38 Lys-33 to Lys-48 transition on TBK1 leading to its degradation (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#model-overview","title":"Model Overview","text":"<p>This model describes a molecular pathway where NLRP4 (Q96MN2) acts as a molecular adaptor to recruit USP38 (Q8NB14), which mediates deubiquitination of TBK1 (Q9UHD2), leading to a ubiquitination transition from K33-linked to K48-linked ubiquitin chains by DTX4 (Q9Y2E6), ultimately resulting in TBK1 degradation. This serves as a negative regulatory mechanism for type I interferon signaling.</p>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model correctly represents the key proteins (NLRP4, USP38, TBK1, DTX4) involved in this regulatory pathway</li> <li>The cellular locations are appropriately annotated (cytoplasm)</li> <li>The evidence codes and PMID references are provided for assertions</li> <li>The causal relationships between activities are represented using appropriate predicates (RO:0002413 \"provides input for\")</li> </ol>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#issues-to-address","title":"Issues to Address","text":""},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#1-redundant-causal-associations","title":"1. Redundant Causal Associations","text":"<p>In the model, USP38's deubiquitinase activity (gomodel:646ff70100004973/646ff70100004985) has duplicate causal associations to the same downstream activity: <pre><code>\"causal_associations\":[{\"type\":\"CausalAssociation\",\"evidence\":[{\"term\":\"ECO:0000314\",\"reference\":\"PMID:27692986\",\"provenances\":[{\"contributor\":\"https://orcid.org/0000-0001-7646-0052\",\"date\":\"2023-06-08\"}]}],\"predicate\":\"RO:0002413\",\"downstream_activity\":\"gomodel:646ff70100004973/646ff70100004995\"},\n{\"type\":\"CausalAssociation\",\"evidence\":[{\"term\":\"ECO:0000314\",\"reference\":\"PMID:27692986\",\"provenances\":[{\"contributor\":\"https://orcid.org/0000-0001-7646-0052\",\"date\":\"2023-06-08\"}]}],\"predicate\":\"RO:0002413\",\"downstream_activity\":\"gomodel:646ff70100004973/646ff70100004995\"}]\n</code></pre> This is unnecessary duplication and should be corrected.</p>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#2-nlrp4-inconsistency","title":"2. NLRP4 Inconsistency","text":"<p>There are two NLRP4 instances (646ff70100004974 and 646ff70100004995) both annotated with the same molecular function (GO:0060090 \"molecular adaptor activity\"). It appears to be representing the same protein at different stages of the pathway, which may be unnecessarily complex. According to best practices for GO-CAM modeling, a single instance of NLRP4 should typically be used unless there's a change in state or function.</p>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#3-causal-relation-predicates","title":"3. Causal Relation Predicates","text":"<p>While the model uses RO:0002413 \"provides input for\" appropriately for most connections, the model would benefit from using more specific causal relations where possible:</p> <ul> <li>The relation between NLRP4 (646ff70100004995) and DTX4 (646ff70100005008) uses RO:0002409, but based on the described mechanism, a positive regulation predicate like RO:0002629 \"directly positively regulates\" might be more appropriate since NLRP4 is recruiting/enabling DTX4's ubiquitin ligase activity.</li> </ul>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#4-missing-connection-to-final-outcome","title":"4. Missing Connection to Final Outcome","text":"<p>The model shows TBK1 kinase activity (646ff70100005018) but doesn't explicitly connect this to the regulation of innate immune response or interferon signaling. Adding this context would improve the biological completeness of the model.</p>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#5-missing-process-level-representation","title":"5. Missing Process-Level Representation","text":"<p>The model should include protein K48-linked ubiquitination (GO:0070936) as part of DTX4's activity, which it does, but might benefit from an additional connection to proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161) to show the ultimate fate of TBK1.</p>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Remove duplicate causal associations from USP38's activity to simplify the model and avoid redundancy.</p> </li> <li> <p>Consolidate the two NLRP4 instances into a single node if they represent the same functional state, or explicitly clarify the state difference if they are intentionally modeled as distinct activities.</p> </li> <li> <p>Add biological consequence: Connect TBK1 kinase activity to its role in the type I interferon signaling pathway (GO:0060337) to provide broader biological context.</p> </li> <li> <p>Add proteasomal degradation outcome: Include a connection to GO:0043161 (proteasome-mediated ubiquitin-dependent protein catabolic process) to complete the pathway.</p> </li> <li> <p>Refine causal relations: Consider using more specific predicates like \"directly positively regulates\" or \"directly negatively regulates\" where appropriate to make the regulatory relationships clearer.</p> </li> <li> <p>Add K33-linked to K48-linked transition: Make the transition from K33-linked to K48-linked ubiquitination more explicit in the model, as this is the central mechanism being described and is included in the title.</p> </li> </ol>"},{"location":"reviews/646ff70100004973-USP38_Lys_33_to_Lys_48_transition_on_TBK1_leading_to_its_degratdation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively captures a key regulatory mechanism for TBK1 degradation mediated by NLRP4, USP38, and DTX4. The model follows most GO-CAM best practices but would benefit from addressing the redundancies, refining the causal relations, and providing more explicit biological context about the downstream effects on interferon signaling. With these refinements, the model would more comprehensively represent the molecular pathway described in the literature.</p> <p>The model's core biological content is accurate and aligns with the published mechanism in PMID:27692986, where NLRP4 acts as a molecular adaptor to recruit USP38, which mediates the transition from K33 to K48 ubiquitination on TBK1, leading to its degradation and thus inhibiting type I interferon signaling.</p>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/","title":"646ff70100005032 HCMV UL138 substains STAT1 activation during viral latency  Human Cytomegalovirus","text":"<p>Based on the information gathered, I'll now review GO-CAM model gomodel:646ff70100005032.</p>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#review-of-go-cam-model-646ff70100005032","title":"Review of GO-CAM Model 646ff70100005032","text":""},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#model-overview","title":"Model Overview","text":"<p>Title: HCMV UL138 substains STAT1 activation during viral latency (Human-Cytomegalovirus) ID: gomodel:646ff70100005032 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#model-content-summary","title":"Model Content Summary","text":"<p>This GO-CAM model represents how the Human Cytomegalovirus (HCMV) protein UL138 interacts with host proteins to sustain STAT1 activation during viral latency. The model consists of four key activities:</p> <ol> <li>UL138 (F5HGQ8) - Molecular adaptor activity providing input for WDR48/UAF1 activity</li> <li>WDR48/UAF1 (Q8TAF3) - Deubiquitinase activator activity directly positively regulating USP1 activity</li> <li>USP1 (O94782) - Cysteine-type deubiquitinase activity removing ubiquitin from substrates</li> <li>STAT1 (P42224) - DNA-binding transcription factor activity involved in cell surface receptor signaling via JAK-STAT</li> </ol> <p>These activities function together in a pathway that promotes positive regulation of receptor signaling via JAK-STAT pathway (GO:0046427).</p>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#biological-content-evaluation","title":"Biological Content Evaluation","text":"<p>The model accurately reflects the findings from the research paper (PMID:37289831), which demonstrates a mechanism by which HCMV UL138 protein interacts with host UAF1/WDR48 and USP1 to enhance and sustain STAT1 phosphorylation and activation during viral latency. The sustaining of STAT1 activation helps restrict viral replication during latency establishment.</p> <p>Key findings from the research paper that are accurately represented in the model:</p> <ol> <li>UL138 interacts with WDR48/UAF1 and USP1</li> <li>This interaction enhances and sustains phosphorylated STAT1 (pSTAT1) levels</li> <li>The pathway contributes to positive regulation of JAK-STAT signaling</li> <li>This mechanism is important for establishing viral latency</li> </ol>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#model-structure-and-connections-evaluation","title":"Model Structure and Connections Evaluation","text":"<p>The causal connections in the model are appropriate and follow GO-CAM best practices:</p> <ol> <li>UL138 (molecular adaptor activity) \u2192 <code>RO:0002413</code> (provides input for) \u2192 WDR48/UAF1 (deubiquitinase activator activity)</li> <li>WDR48/UAF1 (deubiquitinase activator activity) \u2192 <code>RO:0002629</code> (directly positively regulates) \u2192 USP1 (cysteine-type deubiquitinase activity)</li> <li>USP1 (cysteine-type deubiquitinase activity) \u2192 <code>RO:0002407</code> (contributes to) \u2192 STAT1 (DNA-binding transcription factor activity)</li> </ol> <p>All activities are appropriately contained within the same biological process: positive regulation of receptor signaling pathway via JAK-STAT (GO:0046427).</p>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#subcellular-localization-accuracy","title":"Subcellular Localization Accuracy","text":"<p>The subcellular locations are accurately annotated: - UL138 in cytoplasm (GO:0005737) - WDR48/UAF1 activity in host Golgi membrane (GO:0044178) - USP1 in nucleus (GO:0005634) - STAT1 in nucleus (GO:0005634)</p> <p>These localizations are consistent with the research findings where UL138 interacts with cytoplasmic or membrane-bound UAF1/WDR48, activating USP1, which ultimately affects STAT1 in the nucleus.</p>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported with appropriate evidence codes and literature references:</p> <ul> <li>ECO:0000314 (direct assay evidence used in manual assertion) is used throughout</li> <li>Primary references include PMID:37289831, PMID:18082604, PMID:18032488, PMID:10973496, and PMID:11972023</li> <li>All proteins are identified with their UniProt accessions</li> </ul>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#suggested-improvements","title":"Suggested Improvements","text":"<p>While this model is well-constructed, a few adjustments could improve its completeness:</p> <ol> <li> <p>Clarify the intermediate step: The model could more clearly show how USP1's deubiquitinase activity leads to sustained STAT1 activity. The paper suggests this mechanism is independent of TBK1 stabilization (unlike what was previously reported for USP1). This detail could make the model more informative.</p> </li> <li> <p>Refine causal relationship between USP1 and STAT1: The current relationship uses <code>RO:0002407</code> (contributes to), but the research suggests this might more specifically be a positive regulatory relationship (<code>RO:0002629</code> - directly positively regulates), as USP1 activity directly sustains STAT1 phosphorylation.</p> </li> <li> <p>Include STAT1 phosphorylation state: The model could potentially note that the specific active form of STAT1 is phosphorylated at tyrosine 701 (pSTAT1), which is a key aspect of the research findings.</p> </li> <li> <p>Consider adding viral context: While this is implied in the title, the model could more explicitly represent that this is occurring in the context of HCMV latent infection.</p> </li> </ol>"},{"location":"reviews/646ff70100005032-HCMV_UL138_substains_STAT1_activation_during_viral_latency__Human_Cytomegalovirus_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:646ff70100005032) provides an accurate and well-structured representation of how HCMV UL138 protein interacts with host deubiquitination machinery to sustain STAT1 activation during viral latency. It is consistent with the research findings and follows GO-CAM best practices for modeling protein interactions and causal relationships.</p> <p>The model effectively captures a complex host-virus interaction that contributes to viral latency, representing an elegant mechanism by which HCMV commandeers host cell processes for its long-term persistence. With the minor suggested improvements, this would be an even more valuable contribution to our understanding of HCMV latency mechanisms in GO-CAM format.</p>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/","title":"646ff70100005137 IL33 signaling pathway  Human","text":"<p>Based on my review of the model and the related documentation, let me provide a comprehensive review of GO-CAM model 646ff70100005137 (IL33-signaling pathway in Human).</p>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#review-of-go-cam-model-il33-signaling-pathway-human","title":"Review of GO-CAM model: IL33-signaling pathway (Human)","text":""},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#go-cam-overview","title":"GO-CAM Overview","text":"<p>Model ID: gomodel:646ff70100005137 Title: IL33-signaling pathway (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#general-assessment","title":"General Assessment","text":"<p>This model represents the IL33-signaling pathway in humans, depicting how IL-33 activates the IL-33 receptor complex (consisting of IL1RL1 and IL1RAP) and the downstream signaling cascade. The model follows a well-structured approach to explain the signal transduction from IL-33 cytokine binding to the activation of downstream effectors.</p>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>The model correctly captures the IL-33 signaling pathway showing the proper sequence of activation events from cytokine to receptor to downstream signaling components.</p> </li> <li> <p>The model appropriately uses the \"directly positively regulates\" predicate (RO:0002629) for causal connections between activities, which is consistent with GO-CAM best practices.</p> </li> <li> <p>Each activity has been properly contextualized with appropriate cellular locations (CC), biological processes (BP), and molecular functions (MF).</p> </li> <li> <p>All elements are backed by appropriate evidence codes and literature references, primarily from published papers.</p> </li> </ol>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#points-for-improvement","title":"Points for Improvement","text":"<ol> <li> <p>Adaptor protein annotation: MYD88 is annotated with \"molecular adaptor activity\" (GO:0060090) which is correct, but according to the document \"How to annotate molecular adaptors\", MYD88 should have both IL1RL1 and IRAK4 as inputs. Currently, only one causal connection is modeled showing MYD88 directly positively regulating IRAK4 kinase activity.</p> </li> <li> <p>Receptor-coreceptor annotation: While the model correctly shows IL1RAP as a coreceptor with \"coreceptor activity\" (GO:0015026), the \"Signaling receptor activity annotation guidelines\" suggest that there should be a causal relationship between the receptor (IL1RL1) and coreceptor (IL1RAP). Currently, there are two separate causal connections from IL1RAP to MYD88.</p> </li> <li> <p>Redundant causal links: IL1RAP appears to have two identical causal connections to MYD88 (both are RO:0002629 \"directly positively regulates\"). One of these is likely redundant.</p> </li> <li> <p>Pathway completion: The model captures the pathway from IL33 through MAP3K7 (TAK1) but doesn't show the final downstream effects (e.g., activation of transcription factors or gene expression). While this is not necessarily incorrect, extending the model to show these endpoints would provide a more complete representation.</p> </li> </ol>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#detailed-annotation-review","title":"Detailed Annotation Review","text":""},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#il-33-uniprotkbo95760","title":"IL-33 (UniProtKB:O95760)","text":"<ul> <li>MF: cytokine activity (GO:0005125) \u2713</li> <li>CC: extracellular space (GO:0005615) \u2713</li> <li>BP: interleukin-33-mediated signaling pathway (GO:0038172) \u2713</li> <li>Causal association: directly positively regulates IL1RL1 \u2713</li> <li>Evidence: ECO:0000314 (direct assay evidence), PMID:27830702 \u2713</li> </ul>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#il1rl1-uniprotkbq01638","title":"IL1RL1 (UniProtKB:Q01638)","text":"<ul> <li>MF: cytokine receptor activity (GO:0004896) \u2713</li> <li>CC: plasma membrane (GO:0005886) \u2713</li> <li>BP: interleukin-33-mediated signaling pathway (GO:0038172) \u2713</li> <li>Causal association: directly positively regulates IL1RAP \u2713</li> <li>Evidence: ECO:0000304 (author statement), PMID:10191101 \u2713</li> </ul>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#il1rap-uniprotkbq9nph3","title":"IL1RAP (UniProtKB:Q9NPH3)","text":"<ul> <li>MF: coreceptor activity (GO:0015026) \u2713</li> <li>CC: plasma membrane (GO:0005886) \u2713</li> <li>BP: interleukin-33-mediated signaling pathway (GO:0038172) \u2713</li> <li>Causal association: directly positively regulates MYD88 (two identical connections) \u2757</li> <li>Evidence: ECO:0000304 (author statement), PMID:10191101 \u2713</li> </ul>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#myd88-uniprotkbq99836","title":"MYD88 (UniProtKB:Q99836)","text":"<ul> <li>MF: molecular adaptor activity (GO:0060090) \u2713</li> <li>CC: cytoplasm (GO:0005737) \u2713</li> <li>BP: interleukin-33-mediated signaling pathway (GO:0038172) \u2713</li> <li>Causal association: directly positively regulates IRAK4 \u2713</li> <li>Evidence: ECO:0000314 (direct assay evidence), PMID:16751103 \u2713</li> <li>Missing inputs: Should have both IL1RL1 and IRAK4 as inputs according to the molecular adaptor guidelines \u2757</li> </ul>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#irak4-uniprotkbq9nwz3","title":"IRAK4 (UniProtKB:Q9NWZ3)","text":"<ul> <li>MF: protein serine/threonine kinase activity (GO:0004674) \u2713</li> <li>CC: cytoplasm (GO:0005737) \u2713</li> <li>BP: interleukin-33-mediated signaling pathway (GO:0038172) \u2713</li> <li>Causal association: directly positively regulates IRAK1 \u2713</li> <li>Evidence: ECO:0000314 (direct assay evidence), PMID:11960013 \u2713</li> </ul>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#irak1-uniprotkbp51617","title":"IRAK1 (UniProtKB:P51617)","text":"<ul> <li>MF: protein serine/threonine kinase activity (GO:0004674) \u2713</li> <li>CC: cytoplasm (GO:0005737) \u2713</li> <li>BP: interleukin-33-mediated signaling pathway (GO:0038172) \u2713</li> <li>Causal association: directly positively regulates TRAF6 \u2713</li> <li>Evidence: ECO:0000314 (direct assay evidence), PMID:14625308 \u2713</li> </ul>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#traf6-uniprotkbq9y4k3","title":"TRAF6 (UniProtKB:Q9Y4K3)","text":"<ul> <li>MF: ubiquitin protein ligase activity (GO:0061630) \u2713</li> <li>CC: cytoplasm (GO:0005737) \u2713</li> <li>BP: interleukin-33-mediated signaling pathway (GO:0038172) \u2713</li> <li>Causal association: directly positively regulates MAP3K7 \u2713</li> <li>Evidence: ECO:0000314 (direct assay evidence), PMID:18758450 \u2713</li> </ul>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#map3k7-uniprotkbo43318","title":"MAP3K7 (UniProtKB:O43318)","text":"<ul> <li>MF: MAP kinase activity (GO:0004707) \u2713</li> <li>CC: cytoplasm (GO:0005737) \u2713</li> <li>BP: interleukin-33-mediated signaling pathway (GO:0038172) \u2713</li> <li>No downstream causal links \u2757</li> </ul>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#literature-support","title":"Literature Support","text":"<p>The model is well supported by appropriate literature references. Key references like PMID:27830702 and PMID:16286016 appropriately describe the IL-33 signaling pathway and the role of IL1RL1 (ST2) as the primary receptor for IL-33.</p> <p>The referenced paper (PMID:27830702) confirms IL-33's role in activating ST2 (IL1RL1) and IL1RAP to mediate downstream signaling. The paper also supports the involvement of MYD88, IRAK4, and TRAF6 in this pathway, consistent with the model.</p>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add missing inputs for MYD88: According to the molecular adaptor guidelines, MYD88 should have both IL1RL1 and IRAK4 as inputs.</p> </li> <li> <p>Resolve redundant causal links: Remove one of the duplicate causal associations from IL1RAP to MYD88.</p> </li> <li> <p>Add a direct causal link between IL1RL1 and IL1RAP: According to the signaling receptor activity guidelines, there should be a causal relationship between the receptor (IL1RL1) and coreceptor (IL1RAP).</p> </li> <li> <p>Extend the pathway downstream: Consider extending the model to include the downstream effects of MAP3K7 activation, such as the activation of NF-\u03baB and/or MAP kinases, and the resulting gene expression changes.</p> </li> <li> <p>Add additional supporting evidence: While the current evidence is solid, adding more recent papers could strengthen the model further, especially for the downstream components.</p> </li> </ol>"},{"location":"reviews/646ff70100005137-IL33_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model provides a good representation of the IL-33 signaling pathway in humans. It follows most of the GO-CAM best practices and is supported by appropriate literature references. With the suggested improvements, particularly regarding the adaptor protein annotation and the receptor-coreceptor relationship, the model would more accurately represent the biology of IL-33 signaling according to current knowledge and GO-CAM guidelines.</p>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/","title":"6482692800000198 Regulation of the canonical mTORC1 signaling  via ubiquitination and deubiquitination of RHEB by RNF152 and USP4  respectively  Human","text":"<p>Based on my review of the GO-CAM model and the relevant literature, I can now provide a comprehensive analysis and assessment.</p>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#review-of-go-cam-model-gomodel6482692800000198","title":"Review of GO-CAM Model: gomodel:6482692800000198","text":""},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#summary","title":"Summary","text":"<p>This model represents the \"Regulation of the canonical mTORC1 signaling via ubiquitination and deubiquitination of RHEB by RNF152 and USP4, respectively (Human)\" pathway. It effectively captures a recently discovered regulatory mechanism involving post-translational modification of RHEB that governs mTORC1 activation.</p>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>The model accurately represents the key components and relationships in the RHEB-dependent regulation of mTORC1 signaling pathway based on current literature (notably PMID:30514904 and PMID:24529379). The causal relationships and molecular functions are appropriately modeled.</p>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate representation of molecular functions: The model correctly assigns molecular functions to proteins - RNF152 as an E3 ubiquitin ligase, USP4 as a deubiquitinase, and the roles of mTOR, RHEB, and TSC2 in the pathway.</p> </li> <li> <p>Appropriate causal associations: The model correctly uses appropriate causal relationship predicates (RO:0002629 for direct positive regulation and RO:0002630 for direct negative regulation) between activities.</p> </li> <li> <p>Subcellular localization: Many activities correctly specify cellular localization, particularly at the lysosomal membrane (GO:0005765), which is critical for this pathway.</p> </li> <li> <p>Evidence support: Each activity and association is backed by appropriate PMIDs and evidence codes.</p> </li> <li> <p>Complete pathway representation: The model comprehensively captures the entire signaling cascade from the initial ubiquitination/deubiquitination events through mTORC1 activation to downstream effects on translation.</p> </li> </ol>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#improvement-opportunities","title":"Improvement Opportunities","text":"<ol> <li> <p>Input relationship for RNF152: In the model, there's no explicit \"has input\" relationship showing that RNF152 (E3 ubiquitin ligase activity) has RHEB as its substrate. According to the E3 ubiquitin ligase documentation, the model should indicate that RNF152's ubiquitin ligase activity \"has input\" RHEB.</p> </li> <li> <p>Biological process for USP4: The USP4 deubiquitinase activity (GO:0004843) is appropriately annotated as part of \"positive regulation of TORC1 signaling\" (GO:1904263), but it could be additionally marked as part of \"protein deubiquitination\" or specifically \"protein monoubiquitination\" to be more precise.</p> </li> <li> <p>Ubiquitin type specification: The model doesn't specify that RHEB undergoes monoubiquitination (rather than polyubiquitination), as detailed in the literature. This could be specified in biological process annotations for relevant activities.</p> </li> <li> <p>AKT1 phosphorylation of USP4: While the model includes AKT1's protein kinase activity that positively regulates USP4's deubiquitinase activity, it would be helpful to explicitly indicate through annotations that AKT1 phosphorylates USP4 at Ser445.</p> </li> <li> <p>Integration with amino acid sensing pathway: The model focuses on growth factor-induced mTORC1 activation via RHEB regulation but doesn't incorporate the amino acid sensing pathway involving Rag GTPases, which functions in parallel. This is not necessarily a problem but represents an opportunity for future model expansion.</p> </li> </ol>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#technical-accuracy-assessment","title":"Technical Accuracy Assessment","text":"<p>From a technical perspective, the model correctly follows GO-CAM best practices:</p> <ol> <li>The activities are connected appropriately with causal relationships.</li> <li>Gene products are correctly associated with their functions.</li> <li>Molecular functions are indicated as \"enabled by\" the appropriate gene products.</li> <li>Cellular locations are specified where known.</li> <li>Evidence codes and references are properly provided.</li> </ol>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model accurately captures the biological knowledge from the published literature:</p> <ol> <li> <p>RHEB regulation mechanism: The model correctly shows that RHEB is monoubiquitinated by RNF152 (notably at Lys8), which promotes its binding to the TSC complex and prevents its activation of mTORC1. Conversely, USP4 removes this ubiquitin, allowing RHEB to activate mTORC1.</p> </li> <li> <p>Growth factor signaling: The model correctly represents that EGF/growth factor signaling leads to AKT1 activation, which phosphorylates USP4, enhancing its ability to deubiquitinate RHEB.</p> </li> <li> <p>mTORC1 downstream signaling: The model correctly depicts the downstream effects of mTORC1 activation on S6K1/2 and 4E-BP1, leading to enhanced translation.</p> </li> <li> <p>Subcellular localization: The model correctly places these interactions at the lysosomal membrane, which is a key aspect of mTORC1 regulation as shown in the literature.</p> </li> </ol>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add explicit \"has input\" relationships for both the E3 ubiquitin ligase (RNF152) and deubiquitinase (USP4) activities to specify RHEB as their substrate.</p> </li> <li> <p>Consider adding \"protein monoubiquitination\" (GO:0006513) as a biological process for RNF152's activity to be more specific.</p> </li> <li> <p>For a more complete picture, consider expanding the model in the future to include the interaction with the amino acid sensing pathway involving Rag GTPases and the Ragulator complex.</p> </li> <li> <p>Consider adding more detailed annotations about the phosphorylation site of USP4 (Ser445) to provide additional mechanistic detail.</p> </li> <li> <p>The model appears to be ready for promotion to production status, as it accurately represents current understanding of this pathway with strong evidence support.</p> </li> </ol>"},{"location":"reviews/6482692800000198-Regulation_of_the_canonical_mTORC1_signaling__via_ubiquitination_and_deubiquitination_of_RHEB_by_RNF152_and_USP4__respectively__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the current understanding of RHEB regulation via ubiquitination/deubiquitination and its impact on mTORC1 signaling. The model is technically sound and scientifically accurate. With minor enhancements as suggested, it would provide an even more comprehensive representation of this important signaling pathway. The model is appropriate for the production status.</p>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/","title":"6482692800000330 Regulation of the canonical mTORC1 signaling  via deubiquitination of RHEB by ATXN3 in response to starvation  Human","text":"<p>Let me now provide a comprehensive review of the GO-CAM model 6482692800000330:</p>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#review-of-go-cam-model-6482692800000330","title":"Review of GO-CAM Model: 6482692800000330","text":""},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Regulation of the canonical mTORC1 signaling via deubiquitination of RHEB by ATXN3 in response to starvation (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM represents the regulation of mTORC1 signaling via a novel mechanism involving the deubiquitinase ATXN3 (Ataxin-3) and polyubiquitination of RHEB in response to amino acid availability. The model captures how amino acids enhance the polyubiquitination of RHEB, which increases its binding affinity for mTORC1, thereby promoting mTORC1 activation. Conversely, during amino acid starvation, ATXN3 is recruited to the lysosomal membrane where it deubiquitinates RHEB, leading to decreased mTORC1 binding and inhibition of mTORC1 signaling.</p>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model is well-supported by primary literature, particularly the 2020 publication by Yao et al. (PMID:33157014), which demonstrates this regulatory mechanism in detail. The model accurately represents the current understanding of this pathway and includes proper molecular functions and subcellular locations for the involved proteins.</p>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#pathway-components-and-connections","title":"Pathway Components and Connections","text":"<ol> <li>ATXN3 deubiquitination activity (P54252): </li> <li>Function: cysteine-type deubiquitinase activity (GO:0004843)</li> <li>Occurs in: lysosomal membrane (GO:0005765)</li> <li>Part of: negative regulation of TORC1 signaling (GO:1904262)</li> <li> <p>Causally upstream of: TSC2 GTPase activator activity (with positive effect)</p> </li> <li> <p>TSC2 GTPase activator activity (P49815):</p> </li> <li>Function: GTPase activator activity (GO:0005096)</li> <li>Occurs in: lysosomal membrane (GO:0005765)</li> <li>Part of: negative regulation of TORC1 signaling (GO:1904262)</li> <li> <p>Causally upstream of: RHEB GTP-binding protein (with negative effect)</p> </li> <li> <p>RHEB GTP-binding (Q15382):</p> </li> <li>Function: protein serine/threonine kinase activator activity (GO:0043539)</li> <li>Occurs in: lysosomal membrane (GO:0005765)</li> <li>Part of: positive regulation of TORC1 signaling (GO:1904263)</li> <li> <p>Causally upstream of: mTOR and mTOR kinase activity (with positive effect)</p> </li> <li> <p>mTOR signaling components:</p> </li> <li>mTOR (P42345): protein serine/threonine kinase activity (GO:0004674)</li> <li>RPS6KB1 (P23443): protein serine/threonine kinase activity (GO:0004674)</li> <li>RPS6KB2 (Q9UBS0): protein serine/threonine kinase activity (GO:0004674)</li> <li>4E-BP1 (Q13541): translation repressor activity (GO:0030371)</li> <li>S6 ribosomal protein (P62753): structural constituent of ribosome (GO:0003735)</li> </ol> <p>Each activity is properly connected using appropriate causal relations: - \"directly negatively regulates\" (RO:0002630) - \"directly positively regulates\" (RO:0002629)</p>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li> <p>Correct use of causal relations: The model appropriately uses RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates) to connect activities.</p> </li> <li> <p>Proper cellular component annotation: Each activity is correctly annotated with its subcellular location (e.g., lysosomal membrane for ATXN3, RHEB, and TSC2).</p> </li> <li> <p>Appropriate part_of relations: Activities are correctly associated with the biological processes they participate in.</p> </li> <li> <p>Evidence codes and references: Each assertion is supported by appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and PMID references.</p> </li> <li> <p>Molecular function selection: The molecular functions assigned to each protein (deubiquitinase for ATXN3, GTPase activator for TSC2, etc.) are accurate.</p> </li> </ol>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model accurately represents the findings of Yao et al. (PMID:33157014), which demonstrated that:</p> <ol> <li>Amino acids enhance polyubiquitination of RHEB, which increases its binding to mTORC1</li> <li>ATXN3 is a deubiquitinase that targets RHEB</li> <li>Under amino acid starvation, inactive Rag GTPases recruit ATXN3 to lysosomes</li> <li>ATXN3 deubiquitinates RHEB, promoting TSC2 GAP activity toward RHEB</li> <li>Decreased RHEB activity leads to inhibition of mTORC1 signaling</li> </ol>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#evidence-quality","title":"Evidence Quality","text":"<p>The model is primarily supported by experimental evidence from the following PMIDs: - PMID:33157014 (Yao et al., 2020) - Primary source establishing ATXN3's role - PMID:9045618, PMID:12906785, PMID:24529379 - Supporting TSC2's role - PMID:29236692, PMID:15854902 - Supporting RHEB's role in mTORC1 activation - PMID:12087098, PMID:29750193 - Supporting mTOR and S6K activities</p> <p>All evidence codes are correctly applied as ECO:0000314 (direct assay evidence).</p>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#model-parsimony-and-clarity","title":"Model Parsimony and Clarity","text":"<p>The model is parsimonious and clearly represents the regulatory pathway. It focuses on the core regulatory mechanism (ATXN3 \u2192 RHEB \u2192 mTORC1) without unnecessary details, while including sufficient context (mTORC1 downstream effectors) to convey the biological significance.</p>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#minor-improvements-suggested","title":"Minor Improvements Suggested","text":"<ol> <li> <p>Clarify the conditions: While the title indicates \"in response to starvation,\" the model could more explicitly annotate the different states (amino acid replete vs. starved).</p> </li> <li> <p>Consider including ubiquitinated RHEB as a distinct node: Since the ubiquitination status of RHEB is central to the mechanism, representing ubiquitinated RHEB as a distinct entity might enhance clarity.</p> </li> <li> <p>Incorporate the Rag GTPases: The model does not explicitly include the role of Rag GTPases in recruiting ATXN3 to lysosomes during amino acid starvation.</p> </li> </ol>"},{"location":"reviews/6482692800000330-Regulation_of_the_canonical_mTORC1_signaling__via_deubiquitination_of_RHEB_by_ATXN3_in_response_to_starvation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively captures a novel mechanism of mTORC1 regulation via ATXN3-mediated deubiquitination of RHEB in response to amino acid availability. The model is well-supported by literature evidence, adheres to GO-CAM best practices, and clearly represents the biological process. The molecular functions, cellular components, and causal relations are all appropriately represented.</p> <p>The model makes a valuable contribution to our understanding of nutrient-sensing pathways and represents a high-quality GO-CAM that could serve as an exemplar for similar regulatory models.</p>"},{"location":"reviews/6482692800000498-Activation_of_the_canonical_mTORC1_signaling_by_GPR155_LYCHOS_in_response_to_cholesterol_influx__Human_/","title":"6482692800000498 Activation of the canonical mTORC1 signaling by GPR155 LYCHOS in response to cholesterol influx  Human","text":""},{"location":"reviews/6482692800000498-Activation_of_the_canonical_mTORC1_signaling_by_GPR155_LYCHOS_in_response_to_cholesterol_influx__Human_/#technical-assessment","title":"Technical Assessment","text":"<ol> <li> <p>Evidence Quality: The model uses appropriate evidence codes (ECO:0000314) for direct experimental evidence. The papers cited (PMIDs 31601708, 31601764, 36007018) are recent and relevant.</p> </li> <li> <p>Proper Use of Relations: The model correctly uses \"directly positively regulates\" (RO:0002629) for most causal associations, which is appropriate for direct regulatory relationships.</p> </li> <li> <p>Ontology Term Usage: The model uses appropriate GO terms for molecular functions, cellular components, and biological processes.</p> </li> <li> <p>Protein Identification: The model uses UniProtKB accessions for proteins, which is the preferred practice for GO-CAM models.</p> </li> </ol>"},{"location":"reviews/6482692800000498-Activation_of_the_canonical_mTORC1_signaling_by_GPR155_LYCHOS_in_response_to_cholesterol_influx__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>I've verified the scientific content by reviewing key supporting literature, including the UniProt entries and the paper by Rogala et al. (PMID: 31601708). The model accurately captures the current understanding that:</p> <ol> <li>GPR155/LYCHOS acts as a cholesterol sensor in lysosomes</li> <li>Upon cholesterol binding, GPR155 affects the interaction between GATOR1 and KICSTOR complexes</li> <li>This leads to activation of Rag GTPases (RagA/C)</li> <li>The Rag GTPases facilitate mTORC1 recruitment to the lysosomal surface</li> <li>At the lysosome, mTORC1 becomes activated and phosphorylates downstream targets like S6K1/2</li> </ol>"},{"location":"reviews/6482692800000498-Activation_of_the_canonical_mTORC1_signaling_by_GPR155_LYCHOS_in_response_to_cholesterol_influx__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Expand the KICSTOR complex representation: Add specific members of the complex as per GO-CAM guidelines for complex representation.</p> </li> <li> <p>Include additional downstream effects: Consider expanding the model to include more downstream effects of mTORC1 activation on translation, metabolism, and autophagy.</p> </li> <li> <p>Refine molecular adaptor annotations: Ensure that protein-membrane adaptor activities follow the guidelines for molecular adaptor annotation with appropriate \"has input\" relations.</p> </li> <li> <p>Add context-specific biological processes: Include higher-level biological processes like cellular response to cholesterol (GO:0071397) to provide better context.</p> </li> <li> <p>Consider pathway branching: The model could be expanded to show how this pathway intersects with other nutrient-sensing pathways that regulate mTORC1.</p> </li> </ol>"},{"location":"reviews/6482692800000498-Activation_of_the_canonical_mTORC1_signaling_by_GPR155_LYCHOS_in_response_to_cholesterol_influx__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that captures a specific signaling pathway with appropriate molecular detail, evidence support, and relationship structure. The model correctly represents the current understanding of how cholesterol sensing through GPR155/LYCHOS contributes to mTORC1 activation. With the suggested refinements, it could become an even more valuable resource for understanding this important signaling pathway.</p> <p>The model was created by a contributor with ORCID https://orcid.org/0000-0001-7299-6685 in June 2023 and represents current knowledge of this pathway based on recent literature.</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/","title":"6482692800000701 Activation of the canonical mTORC1 signaling by BMT2 SAMTOR in response to S adenosyl L methionine influx  Human","text":"<p>Based on my analysis of the GO-CAM model and relevant documents, I'll now provide a comprehensive review:</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#review-of-go-cam-model-gomodel6482692800000701","title":"Review of GO-CAM Model: gomodel:6482692800000701","text":""},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"Activation of the canonical mTORC1 signaling by BMT2/SAMTOR in response to S-adenosyl-L-methionine influx (Human)\" represents a detailed pathway describing how mTORC1 signaling is regulated in response to S-adenosyl-L-methionine (SAM) availability in human cells.</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#accuracy-and-literature-support","title":"Accuracy and Literature Support","text":"<p>The model is well-supported by multiple peer-reviewed publications, with each activity and relationship properly referenced using ECO evidence codes and relevant PMIDs. Key papers including PMID:28199306, PMID:31601708, and PMID:31601764 provide strong experimental evidence for the relationships depicted in the model.</p> <p>The model accurately represents the current understanding of how mTORC1 signaling is activated in response to S-adenosyl-L-methionine, with BMT2/SAMTOR acting as a sensor for this metabolite. The lysosomal localization of the pathway components and the role of the KICSTOR complex are consistent with the literature.</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#pathway-logic-and-flow","title":"Pathway Logic and Flow","text":"<p>The causal flow of the pathway is logically presented: 1. BMT2 (Q1RMZ1) binds S-adenosyl-L-methionine 2. This regulates activity of the KICSTOR complex, which acts as a protein-membrane adaptor 3. KICSTOR regulates NPRL2 (GTPase activator activity) and DEPDC5 (small GTPase binding) 4. These proteins negatively regulate the activities of RagA/RRAGA and RagC/RRAGC GTPases 5. The Rag GTPases regulate RHEB activity 6. RHEB activates the mTOR kinase activity 7. mTOR phosphorylates downstream targets including RPS6KB1/2 and EIF4EBP1 8. These ultimately affect translation through RPS6</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#compartmentalization","title":"Compartmentalization","text":"<p>The model correctly captures the lysosomal localization (GO:0005765) of many of the components, which is critical for mTORC1 signaling and is well-documented in the literature. This is supported by experimental evidence from PMID:28199306 and PMID:30956113.</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":""},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#molecular-function-term-usage","title":"Molecular Function Term Usage","text":"<p>The model uses appropriate molecular function terms, including: - GO:1904047 (S-adenosyl-L-methionine binding) for BMT2 - GO:0043495 (protein-membrane adaptor activity) for KICSTOR components - GO:0005096 (GTPase activator activity) for NPRL2 - GO:0031267 (small GTPase binding) for DEPDC5 - GO:0004674 (protein serine/threonine kinase activity) for mTOR and downstream kinases</p> <p>These accurately represent the established molecular functions of these proteins.</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#use-of-causal-relations","title":"Use of Causal Relations","text":"<p>The model correctly uses the causal relations: - RO:0012010 (provides input for) where appropriate - RO:0002629 (directly positively regulates) for positive regulation - RO:0002630 (directly negatively regulates) for negative regulation</p> <p>These follow GO-CAM guidelines for representing regulatory relationships.</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#adaptor-protein-representation","title":"Adaptor Protein Representation","text":"<p>The model follows best practices for representing adaptor proteins as described in the \"How to annotate molecular adaptors\" document. The KICSTOR complex (represented by activity gomodel:6482692800000701/6482692800000845) is annotated with protein-membrane adaptor activity (GO:0043495) and properly connects to downstream elements.</p>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#minor-issues-and-suggestions","title":"Minor Issues and Suggestions","text":"<ol> <li> <p>Complex Representation: The model indicates that the KICSTOR complex (GO:0140007) enables one of the activities, but doesn't specify the members of the complex in the \"enabled_by\" field. It would be helpful to include the component proteins for completeness.</p> </li> <li> <p>Biological Process Coverage: While most activities are linked to appropriate biological processes, it might be helpful to also include the higher-level process GO:0031669 (cellular response to nutrient levels) for some components to better link this pathway to the broader nutrient sensing role.</p> </li> </ol>"},{"location":"reviews/6482692800000701-Activation_of_the_canonical_mTORC1_signaling_by_BMT2_SAMTOR_in_response_to_S_adenosyl_L_methionine_influx__Human_/#summary","title":"Summary","text":"<p>This is a high-quality GO-CAM model that accurately represents the current understanding of mTORC1 signaling regulation by S-adenosyl-L-methionine. The model:</p> <ol> <li>Is well-supported by literature evidence with appropriate references</li> <li>Uses the correct molecular function terms for all components</li> <li>Properly represents compartmentalization at the lysosomal membrane</li> <li>Uses appropriate causal relations between activities</li> <li>Follows GO-CAM best practices for representing adaptor functions</li> </ol> <p>The model provides a clear representation of how BMT2/SAMTOR senses S-adenosyl-L-methionine and triggers a signaling cascade that ultimately regulates mTORC1 signaling and protein translation. This aligns well with the current understanding of nutrient-sensing mechanisms in the cell.</p> <p>The model can be viewed at: https://bioregistry.io/go.model:6482692800000701</p>"},{"location":"reviews/6482692800001029-_Activation_of_the_canonical_mTORC1_signaling_by_GATOR2__which_inactivates_GATOR1_in_response_to__abundant_amino_acids__Human_/","title":"6482692800001029  Activation of the canonical mTORC1 signaling by GATOR2  which inactivates GATOR1 in response to  abundant amino acids  Human","text":"<p>Based on my review of the model and relevant GO-CAM guidelines, here's my assessment:</p>"},{"location":"reviews/6482692800001029-_Activation_of_the_canonical_mTORC1_signaling_by_GATOR2__which_inactivates_GATOR1_in_response_to__abundant_amino_acids__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate Representation of Signaling Pathway: The model correctly represents the mTORC1 signaling pathway activated by amino acid abundance, following established knowledge of the pathway.</p> </li> <li> <p>Evidence Quality: Each activity and relationship is supported by primary literature evidence with appropriate ECO codes (ECO:0000314 - direct assay evidence).</p> </li> <li> <p>Cellular Context: The model properly includes cellular contexts (predominantly GO:0005765 \"lysosomal membrane\"), which is consistent with where mTORC1 signaling occurs.</p> </li> <li> <p>Biological Process Context: Each activity is correctly associated with relevant biological processes.</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal relationships (RO:0002629 \"directly positively regulates\" and RO:0002630 \"directly negatively regulates\") to show the flow of regulation in the pathway.</p> </li> </ol>"},{"location":"reviews/6482692800001029-_Activation_of_the_canonical_mTORC1_signaling_by_GATOR2__which_inactivates_GATOR1_in_response_to__abundant_amino_acids__Human_/#improvement-opportunities","title":"Improvement Opportunities","text":"<ol> <li> <p>Complex Representation: The model represents individual proteins rather than showing the GATOR1 and GATOR2 complexes as entities. This is acceptable according to the \"How to annotate complexes in GO-CAM\" guidelines when the subunits carrying specific activities are known. However, for clarity, considering that GATOR1 and GATOR2 are well-defined complexes, it might be beneficial to include a note about which proteins belong to which complex. The model includes NPRL2 (part of GATOR1) and WDR24 (part of GATOR2), but this relationship is not explicitly stated.</p> </li> <li> <p>Missing Inputs: Some molecular functions are missing the \"has input\" relationship that would clarify their targets. For example, the protein kinase activities should explicitly show what they phosphorylate.</p> </li> <li> <p>Model Clarity: The model represents multiple proteins with similar functions (e.g., both RRAGC and RRAGA have GTP binding activity and protein-membrane adaptor activity). While biologically accurate, the parallel activities may make the model more complex to follow.</p> </li> <li> <p>Missing Cellular Components: Some activities don't have \"occurs in\" annotations to specify their cellular location, which would help contextualize the activities.</p> </li> </ol>"},{"location":"reviews/6482692800001029-_Activation_of_the_canonical_mTORC1_signaling_by_GATOR2__which_inactivates_GATOR1_in_response_to__abundant_amino_acids__Human_/#verification-of-specific-model-elements","title":"Verification of Specific Model Elements","text":"<ol> <li> <p>GTPase Activities: The model correctly represents the GTP/GDP-bound states of the Rag proteins and their regulation by GATOR1.</p> </li> <li> <p>mTOR Kinase Activity: The model accurately shows mTOR (P42345) phosphorylating S6K proteins (RPS6KB1/RPS6KB2), which in turn phosphorylate the ribosomal protein S6 (RPS6).</p> </li> <li> <p>Translation Regulation: The model correctly shows 4E-BP1 (EIF4EBP1) as a translation repressor that is inhibited by mTOR, leading to increased translation.</p> </li> </ol>"},{"location":"reviews/6482692800001029-_Activation_of_the_canonical_mTORC1_signaling_by_GATOR2__which_inactivates_GATOR1_in_response_to__abundant_amino_acids__Human_/#biological-accuracy-check","title":"Biological Accuracy Check","text":"<p>Looking at some key elements in the model:</p> <ol> <li> <p>Amino Acid Sensing: The model represents how amino acid abundance leads to inhibition of GATOR1, which is scientifically accurate.</p> </li> <li> <p>Rag GTPases: The model correctly shows that Rag GTPases (RRAGA and RRAGC) are regulated by GATOR1 and help localize mTORC1 to lysosomes.</p> </li> <li> <p>RHEB Activation: The model properly shows RHEB activating mTOR kinase, which is a key step in mTORC1 signaling.</p> </li> <li> <p>Downstream Effectors: The phosphorylation cascade from mTOR to S6K to S6, and the inhibition of 4E-BP1, are all correctly represented and consistent with established knowledge.</p> </li> </ol>"},{"location":"reviews/6482692800001029-_Activation_of_the_canonical_mTORC1_signaling_by_GATOR2__which_inactivates_GATOR1_in_response_to__abundant_amino_acids__Human_/#summary","title":"Summary","text":"<p>This GO-CAM model (gomodel:6482692800001029) provides a high-quality representation of mTORC1 signaling activated by amino acid abundance. It meets GO-CAM best practices in terms of evidence, causal relationships, and biological accuracy. The minor improvements suggested would enhance clarity but do not detract from the model's overall quality and usefulness. The model is supported by appropriate references, and the activities are connected in a way that accurately represents the flow of the pathway.</p>"},{"location":"reviews/6482692800001393-Biotin_Metabolic_Process_1__Mouse_/","title":"6482692800001393 Biotin Metabolic Process 1  Mouse","text":"<p>Based on my review, I'll now provide a thorough assessment of this GO-CAM model.</p>"},{"location":"reviews/6482692800001393-Biotin_Metabolic_Process_1__Mouse_/#review-of-biotin-metabolic-process-1-mouse-go-cam-model","title":"Review of Biotin Metabolic Process 1 (Mouse) GO-CAM Model","text":""},{"location":"reviews/6482692800001393-Biotin_Metabolic_Process_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model (gomodel:6482692800001393) describes a biotin metabolic process in mouse, specifically focusing on the role of holocarboxylase synthetase (Hlcs) in the biotinylation of carboxylases and the subsequent functional effects.</p>"},{"location":"reviews/6482692800001393-Biotin_Metabolic_Process_1__Mouse_/#model-components","title":"Model Components","text":"<p>The model consists of several key activities:</p> <ol> <li>Biotin-protein ligase activity (GO:0004077) - carried out by Hlcs (MGI:MGI:894646) in biotin metabolic process (GO:0006768)</li> <li>Has biotin (CHEBI:15956) as input</li> <li> <p>Positively regulates two downstream activities:</p> <ul> <li>Acetyl-CoA carboxylase activity (GO:0003989) of Acaca (MGI:MGI:108451)</li> <li>Pyruvate carboxylase activity (GO:0004736) of Pcx (MGI:MGI:97520) in gluconeogenesis (GO:0006094)</li> </ul> </li> <li> <p>Molecular function activator activity (GO:0140677) - carried out by Pdzd11 (MGI:MGI:1919871) at the plasma membrane (GO:0005886)</p> </li> <li> <p>Positively regulates the sodium-dependent multivitamin transmembrane transporter activity</p> </li> <li> <p>Sodium-dependent multivitamin transmembrane transporter activity (GO:0008523) - carried out by Slc5a6 (MGI:MGI:2660847) at the plasma membrane</p> </li> <li>Has biotin as primary input</li> <li>Provides input for the Hlcs biotin-protein ligase activity</li> </ol>"},{"location":"reviews/6482692800001393-Biotin_Metabolic_Process_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model effectively captures the biotin transport, biotinylation of carboxylases, and subsequent metabolic activities.</p> </li> <li> <p>Well-supported evidence: The model cites appropriate literature evidence, including PMID:35385533 for Hlcs activity, PMID:21183659 for Pdzd11 activity, and PMID:23104561 for Slc5a6 activity.</p> </li> <li> <p>Appropriate causal relationships: The model correctly uses \"RO:0002629\" (directly positively regulates) and \"RO:0002413\" (provides input for) to show the flow of regulation and substrates.</p> </li> <li> <p>Cellular context inclusion: Appropriate cellular locations are specified for activities (e.g., plasma membrane for transporters).</p> </li> </ol>"},{"location":"reviews/6482692800001393-Biotin_Metabolic_Process_1__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing bioprocess annotations: While Acaca has an activity annotation, it lacks a specific biological process annotation. Given its role, it could be annotated as part of \"fatty acid biosynthetic process\" (GO:0006633).</p> </li> <li> <p>Recent evidence update: The model has a comment \"Automated change 2024-06-27: GO:0018271 replaced by GO:0004077\" - this update was correctly implemented.</p> </li> <li> <p>Missing cellular component for Hlcs: The UniProt entry for Hlcs indicates it's located in both the cytoplasm and mitochondrion, but no cellular component is specified in the model. Adding this would improve the spatial representation.</p> </li> <li> <p>Expansion opportunity: The literature suggests Hlcs may also biotinylate histones, which could be included in an expanded version of this model.</p> </li> <li> <p>Potential missing regulation: The literature suggests biotin levels adaptively regulate intestinal uptake of biotin, which could be represented as an additional regulatory relationship in the model.</p> </li> </ol>"},{"location":"reviews/6482692800001393-Biotin_Metabolic_Process_1__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the current scientific understanding of biotin metabolism:</p> <ol> <li>Biotin is transported into the cell by the sodium-dependent multivitamin transporter (Slc5a6)</li> <li>Hlcs catalyzes the biotinylation of carboxylases</li> <li>Biotinylated carboxylases (Acaca, Pcx) can perform their respective metabolic functions</li> </ol> <p>The supporting evidence from the cited papers confirms these relationships and the importance of Hlcs for proper carboxylase function, with knockout studies showing embryonic lethality.</p>"},{"location":"reviews/6482692800001393-Biotin_Metabolic_Process_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Biotin Metabolic Process 1 (Mouse)\" is a well-constructed representation of biotin metabolism that adheres to most GO-CAM best practices. It effectively captures the flow of biotin from transport into the cell through its incorporation into carboxylases and the resulting metabolic activities.</p> <p>Minor improvements could include: 1. Adding cellular component annotations for Hlcs 2. Including biological process annotations for all activities 3. Possibly expanding to include histone biotinylation</p> <p>Overall, this model provides a valuable representation of biotin metabolism and should be valuable for researchers studying this important pathway.</p>"},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/","title":"6482692800001514 Inactivation of the canonical mTORC1 signaling via phosphorylation of WDR24 by AMPK in response to glucose starvation  Human","text":"<p>Based on my review of the GO-CAM model (gomodel:6482692800001514) \"Inactivation of the canonical mTORC1 signaling via phosphorylation of WDR24 by AMPK in response to glucose starvation (Human)\", I can now provide a comprehensive assessment:</p>"},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/#go-cam-review-inactivation-of-mtorc1-signaling-via-wdr24-phosphorylation-by-ampk","title":"GO-CAM Review: Inactivation of mTORC1 signaling via WDR24 phosphorylation by AMPK","text":""},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model (available at https://bioregistry.io/go.model:6482692800001514) represents the regulatory pathway by which AMPK phosphorylates WDR24, a component of the GATOR2 complex, leading to inactivation of mTORC1 signaling in response to glucose starvation. The model effectively captures a key regulatory mechanism for mTOR signaling that adapts to cellular energy status.</p>"},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/#strengths-of-the-model","title":"Strengths of the model","text":"<ol> <li> <p>Biological accuracy: The model accurately represents the current scientific understanding of how AMPK phosphorylates WDR24 to suppress glucose-mediated mTORC1 activation, as described in the primary literature (PMID:36732624).</p> </li> <li> <p>Comprehensive pathway representation: The model effectively captures both the upstream regulatory events (AMPK activation and WDR24 phosphorylation) and downstream consequences (repression of translation via 4E-BP1 and regulation of S6 phosphorylation).</p> </li> <li> <p>Correct use of causal associations: The model uses appropriate causal predicates to link activities, including:</p> </li> <li>RO:0002413 (provides input for) for AMPK's influence on YWHAG sequestering activity</li> <li>RO:0002629 (directly positively regulates) for activating relationships</li> <li> <p>RO:0002630 (directly negatively regulates) for inhibitory relationships</p> </li> <li> <p>Subcellular localization: The model appropriately represents the lysosomal localization of key components, which is critical for mTORC1 signaling.</p> </li> </ol>"},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/#areas-for-improvement","title":"Areas for improvement","text":"<ol> <li> <p>Representation of protein complexes: The model represents individual proteins rather than the GATOR2 complex itself for certain activities. According to the \"How to annotate complexes in GO-CAM\" guidelines, when the specific subunit carrying the molecular activity is known (as is the case with WDR24's ubiquitin ligase activity), this approach is appropriate. However, if there are activities where the exact subunit is unknown, using the GO complex ID might be more appropriate.</p> </li> <li> <p>Additional contextual information: Though the model represents glucose starvation context, it could benefit from inclusion of amino acid regulation, as GATOR2 also responds to amino acid levels, which would provide a more complete picture of the regulatory mechanisms.</p> </li> <li> <p>Documentation of AMPK isoforms: The model includes both PRKAA1 (AMPK\u03b11) and PRKAA2 (AMPK\u03b12) with identical causal relationships. While this is accurate, a note explaining their redundant but important complementary roles would be helpful.</p> </li> </ol>"},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/#technical-assessment","title":"Technical assessment","text":"<ol> <li> <p>Evidence codes and references: All activities and associations are properly supported with ECO:0000314 (direct assay evidence) and appropriate PMID references.</p> </li> <li> <p>Molecular functions: The model uses appropriate molecular functions for each protein:</p> </li> <li>GO:0004679 (AMP-activated protein kinase activity) for AMPK subunits</li> <li>GO:0140311 (protein sequestering activity) for YWHAG</li> <li>GO:0061630 (ubiquitin protein ligase activity) for WDR24</li> <li>GO:0005096 (GTPase activator activity) for NPRL2</li> <li> <p>GO:0004674 (protein serine/threonine kinase activity) for mTOR</p> </li> <li> <p>Biological process context: Each activity is appropriately placed in relevant biological processes:</p> </li> <li>GO:1904262 (negative regulation of TORC1 signaling)</li> <li>GO:0085020 (protein K6-linked ubiquitination)</li> <li>GO:0045948 (positive regulation of translational initiation)</li> <li> <p>GO:0045947 (negative regulation of translational initiation)</p> </li> <li> <p>Occurs_in annotations: Proper lysosomal membrane (GO:0005765) localization is specified for key components of the pathway.</p> </li> </ol>"},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/#biological-accuracy","title":"Biological accuracy","text":"<p>The model accurately represents the pathway described in the literature (particularly PMID:36732624), where:</p> <ol> <li>Glucose deprivation activates AMPK (PRKAA1/PRKAA2)</li> <li>AMPK phosphorylates WDR24 (a GATOR2 component) at Ser155</li> <li>Phosphorylated WDR24 is recognized by 14-3-3 proteins (YWHAG)</li> <li>This sequestration disrupts GATOR2 complex integrity</li> <li>Disrupted GATOR2 cannot inhibit NPRL2 (part of GATOR1)</li> <li>Active NPRL2 inhibits RRAGA/RRAGC GTPases</li> <li>This prevents mTORC1 activation</li> <li>Resulting in altered regulation of translation via 4E-BP1 and S6</li> </ol>"},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Complex annotation: Consider using GO complex terms when appropriate, particularly if additional GATOR2 activities are added where the specific active subunit is unknown.</p> </li> <li> <p>Additional pathway contexts: Consider expanding the model to include how this pathway interacts with amino acid sensing pathways, as GATOR2 also responds to amino acid levels via Sestrin and CASTOR proteins.</p> </li> <li> <p>Feedback regulation: Consider including feedback mechanisms by which mTOR signaling can regulate upstream components, if supported by literature.</p> </li> </ol>"},{"location":"reviews/6482692800001514-Inactivation_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_WDR24_by_AMPK_in_response_to_glucose_starvation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model successfully represents a well-documented mechanism for AMPK-mediated regulation of mTORC1 via WDR24 phosphorylation. The model adheres to GO-CAM best practices regarding causal representations and evidential support. It captures the key biological aspects of this regulatory pathway and presents them in a clear, logical flow that is consistent with current literature.</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/","title":"6482692800001739 Inhibition of the canonical mTORC1 signaling via phosphorylation of RPTOR by AMPK in response to glucose starvation  Human","text":"<p>Based on my review of the model and related information, I'll now provide a comprehensive assessment of GO-CAM model gomodel:6482692800001739.</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#review-of-go-cam-model-gomodel6482692800001739","title":"Review of GO-CAM Model: gomodel:6482692800001739","text":""},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#model-title","title":"Model Title","text":"<p>\"Inhibition of the canonical mTORC1 signaling via phosphorylation of RPTOR by AMPK in response to glucose starvation (Human)\"</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#general-assessment","title":"General Assessment","text":"<p>This GO-CAM model describes the molecular mechanism by which AMPK (AMP-activated protein kinase) inhibits mTORC1 (mechanistic target of rapamycin complex 1) signaling through phosphorylation of RPTOR (Raptor) in response to glucose starvation in human cells. The model effectively captures a critical cellular energy-sensing pathway that regulates cell growth and metabolism.</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#overall-quality","title":"Overall Quality","text":"<p>The model is well-constructed and accurately represents the current understanding of AMPK-mediated inhibition of mTORC1 signaling. The biological content is supported by the literature and uses appropriate Gene Ontology (GO) terms for molecular functions, cellular components, and biological processes.</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#specific-components-analysis","title":"Specific Components Analysis","text":""},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#entities-and-activities","title":"Entities and Activities:","text":"<ol> <li>PRKAA1/PRKAA2 (AMPK catalytic subunits): Correctly annotated with GO:0004679 (AMP-activated protein kinase activity)</li> <li>RPTOR (Raptor): Correctly annotated with GO:0140767 (enzyme-substrate adaptor activity)</li> <li>MTOR: Correctly annotated with GO:0004674 (protein serine/threonine kinase activity)</li> <li>RHEB: Correctly annotated with GO:0043539 (protein serine/threonine kinase activator activity)</li> <li>YWHAZ: Correctly annotated with GO:0140311 (protein sequestering activity)</li> <li>O-GlcNAc transferase (OGT): Correctly annotated with GO:0097363 (protein O-acetylglucosaminyltransferase activity)</li> </ol>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#cellular-locations","title":"Cellular Locations:","text":"<p>The model appropriately places activities in their cellular locations, with MTOR and RPTOR being localized to the lysosomal membrane (GO:0005765), which is where mTORC1 signaling occurs.</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#pathway-representation","title":"Pathway Representation:","text":"<p>The model effectively captures the following causal relationships: 1. AMPK phosphorylates Raptor (RO:0002413 \"provides input for\") and negatively regulates mTORC1 signaling 2. YWHAZ sequesters phosphorylated Raptor (RO:0002630 \"directly negatively regulates\")  3. RHEB activates MTOR (RO:0002629 \"directly positively regulates\")</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#evidence-connections","title":"Evidence Connections:","text":"<p>The model provides appropriate evidence from scientific literature: - PMID:18439900 - Primary evidence for AMPK phosphorylation of Raptor - PMID:37541260 - Recent evidence supporting the O-GlcNAcylation of Raptor in glucose signaling - PMID:29750193 - Evidence for MTOR functions in the complex - PMID:30956113 - Evidence for lysosomal localization - PMID:12747827 - Evidence for Raptor's adaptor function - PMID:29236692 - Evidence for RHEB's activation of MTOR - PMID:15854902 - Evidence for RHEB's activator role</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#alignment-with-go-cam-best-practices","title":"Alignment with GO-CAM Best Practices","text":"<p>Upon review of the GO-CAM documentation and best practices, I find that this model follows the rules for complex representation. Since the activity of each component in the pathway is known and defined, each protein is represented individually with its specific molecular function, rather than using a complex GO term. This follows the guidelines in the \"How to annotate complexes in GO-CAM\" document.</p>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The biological content of the model is consistent with current scientific understanding:</p> <ol> <li> <p>The model accurately represents AMPK as a metabolic sensor that responds to energy depletion (specifically glucose starvation) by phosphorylating RPTOR at Ser722 and Ser792.</p> </li> <li> <p>The model correctly shows that phosphorylation of RPTOR leads to inhibition of mTORC1 signaling, as supported by the literature (PMID:18439900).</p> </li> <li> <p>The inclusion of O-GlcNAcylation by OGT (supported by PMID:37541260) reflects recent findings that glucose availability controls mTORC1 activity through post-translational modification of RPTOR.</p> </li> <li> <p>The inclusion of YWHAZ (14-3-3 protein) as a mediator that sequesters phosphorylated RPTOR is accurate and well-supported by the literature.</p> </li> <li> <p>The placement of these events within the context of biological processes (GO:1904262 \"negative regulation of TORC1 signaling\" and GO:0038202 \"TORC1 signaling\") is appropriate.</p> </li> </ol>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<p>While the model is generally well-constructed, I suggest a few potential enhancements:</p> <ol> <li> <p>Subcellular location refinement: While MTOR is correctly placed at the lysosomal membrane, AMPK's subcellular location is not specified. Given that AMPK-mediated phosphorylation of RPTOR can occur in the cytoplasm, this could be explicitly noted.</p> </li> <li> <p>Upstream regulation: The model focuses on AMPK's action on RPTOR but does not include how AMPK itself is activated by glucose starvation (e.g., through increased AMP:ATP ratio and activation by upstream kinases like LKB1). Including this would provide more context.</p> </li> <li> <p>Downstream effects: While the model shows inhibition of mTORC1, it could be extended to show some key downstream effects, such as inhibition of S6K and 4E-BP1 phosphorylation, which affect protein synthesis.</p> </li> <li> <p>Temporal sequence: The model could more explicitly show the temporal sequence of events from glucose starvation to AMPK activation to RPTOR phosphorylation to mTORC1 inhibition.</p> </li> </ol>"},{"location":"reviews/6482692800001739-Inhibition_of_the_canonical_mTORC1_signaling_via_phosphorylation_of_RPTOR_by_AMPK_in_response_to_glucose_starvation__Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:6482692800001739 is a scientifically accurate and well-constructed representation of the AMPK-mediated inhibition of mTORC1 signaling through RPTOR phosphorylation. It effectively uses GO terms and relationship ontologies to capture the biological process. The model is supported by appropriate literature evidence and follows GO-CAM best practices for representing complexes and their activities.</p> <p>This model serves as a valuable resource for understanding how cells regulate growth and metabolism in response to energy availability, which is a fundamental process relevant to numerous physiological and pathological conditions, including cancer, diabetes, and aging.</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/","title":"6482692800002523 Molybdopterin Cofactor Biosynthetic Process 1  Mouse","text":"<p>Now, let me analyze the GO-CAM model and provide a review:</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#review-of-go-cam-model-6482692800002523-molybdopterin-cofactor-biosynthetic-process-1-mouse","title":"Review of GO-CAM Model 6482692800002523: Molybdopterin Cofactor Biosynthetic Process 1 (Mouse)","text":""},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model (go.model:6482692800002523) describes the molybdopterin cofactor biosynthetic process in mouse. The model includes 6 different gene products (Nfs1, Mocs3, Mocs2, Gphn, Mocs1, and Mocos) that form a pathway in the cytosol, with each protein performing specific molecular functions that contribute to the overall biosynthetic process.</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#model-structure-and-flow","title":"Model Structure and Flow","text":"<p>The model represents a linear pathway of the following activities: 1. Mocs1 (MGI:MGI:1928904) - S-adenosyl-L-methionine binding (GO:1904047) 2. Mocs2 (MGI:MGI:1336894) - molybdopterin synthase activity (GO:0030366) 3. Gphn (MGI:MGI:109602) - molybdopterin molybdotransferase activity (GO:0061599) 4. Mocos (MGI:MGI:1915841) - molybdenum cofactor sulfurtransferase activity (GO:0008265)</p> <p>With two additional activities connected to the pathway: - Nfs1 (MGI:MGI:1316706) - cysteine desulfurase activity (GO:0031071) - Mocs3 (MGI:MGI:1916622) - sulfurtransferase activity (GO:0016783)</p> <p>These are linked through causal relations that properly represent the flow of the pathway.</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#strengths","title":"Strengths","text":"<ul> <li>The model correctly captures the key activities in the molybdopterin cofactor biosynthetic pathway</li> <li>All activities have appropriate evidence with relevant references (PMIDs)</li> <li>The causal flow is biologically meaningful and follows the known sequence of the pathway</li> <li>All activities are correctly placed in the cytosol (GO:0005829) cellular component</li> <li>Appropriate predicate types are used for the causal links between activities</li> </ul>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":""},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#1-evidence-for-subcellular-location","title":"1. Evidence for Subcellular Location","text":"<p>The activity for Mocos (MGI:MGI:1915841) lacks evidence for its subcellular location in GO:0005829 (cytosol). While this is the correct location based on literature, the annotation should include supporting evidence.</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#2-coherence-with-literature","title":"2. Coherence with Literature","text":"<p>The model aligns well with the referenced literature, particularly PMID:23593335, which describes how the L-cysteine desulfurase NFS1 provides sulfur for molybdenum cofactor biosynthesis. The causal link from Nfs1 to Mocs3 accurately reflects this relationship.</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#3-causal-relations","title":"3. Causal Relations","text":"<p>The model would benefit from having explicit evidence for the causal relations between activities. Currently, none of the causal associations include explicit evidence annotations.</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#4-completeness-of-representation","title":"4. Completeness of Representation","text":"<p>The model represents the pathway correctly but could be enhanced by including: - Information about the complex formation between certain participants if relevant - More detailed representation of the thiol transfer mechanism - Any relevant regulatory steps that might not be captured in the current model</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model follows GO-CAM best practices by: - Using appropriate molecular functions for each gene product - Placing activities in correct cellular components - Using appropriate part_of relations to connect to the biological process - Using appropriate causal relationships between activities</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a clear representation of the molybdopterin cofactor biosynthetic process in mouse. It successfully captures the key molecular activities and their causal relationships. The model would be improved by adding evidence for the missing subcellular location and for the causal relationships between activities. Overall, this is a well-constructed model that follows GO-CAM best practices and accurately represents the biology of molybdopterin cofactor biosynthesis based on current literature.</p>"},{"location":"reviews/6482692800002523-Molybdopterin_Cofactor_Biosynthetic_Process_1__Mouse_/#recommended-revisions","title":"Recommended Revisions","text":"<ol> <li>Add evidence for the subcellular location (GO:0005829) of Mocos (MGI:MGI:1915841)</li> <li>Add evidence for all causal associations</li> <li>Consider if any relevant complex formations should be explicitly represented</li> </ol>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/","title":"6482692800002614 Non canonical mTORC1 signaling leading to TFEB and TFE3 phosphorylation and inactivation   Human","text":"<p>Based on my review of the GO-CAM model 6482692800002614 \"Non-canonical mTORC1 signaling leading to TFEB and TFE3 phosphorylation and inactivation (Human)\" and the supporting information, I'll now provide a comprehensive review:</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#go-cam-review-gomodel6482692800002614","title":"GO-CAM Review: gomodel:6482692800002614","text":""},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#summary","title":"Summary","text":"<p>This model represents the non-canonical mTORC1 signaling pathway that leads to the phosphorylation and inactivation of the transcription factors TFEB and TFE3 in humans. The model depicts how these transcription factors are regulated by nutrient availability through a protein degradation pathway involving Rag GTPases, mTORC1, and E3 ubiquitin ligase complexes.</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#model-overview","title":"Model Overview","text":"<p>The model captures key activities including: 1. Protein kinase activity of mTOR (P42345) 2. Protein sequestering activity of 14-3-3/YWHAZ (P63104) 3. DNA-binding transcription factor activities of TFEB (P19484) and TFE3 (P19532) 4. Enzyme-substrate adaptor activity of RRAGC (Q9HB90) 5. GTPase activator activity of FLCN (Q8NFG4) 6. Ubiquitin-related activities of the SCF E3 ubiquitin ligase complex (CUL1, BTRC, RBX1)</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#strengths","title":"Strengths","text":"<ol> <li>The model accurately represents the current understanding of the nutrient-dependent regulation of TFE3 and TFEB, based on the primary literature (especially PMID:36608670).</li> <li>The model correctly captures the causal relationships between activities, particularly the regulatory mechanisms that control transcription factor localization and stability.</li> <li>Appropriate cellular locations are annotated for each activity (lysosomal membrane, cytosol, nucleus).</li> <li>The biological processes for each activity are appropriately annotated.</li> <li>The causal relationships use appropriate relation types (RO:0002413, RO:0002629, RO:0002630).</li> <li>The model covers both the phosphorylation-dependent cytosolic retention pathway and the newly discovered ubiquitin-mediated protein degradation pathway.</li> </ol>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#potential-issues-and-suggestions-for-improvement","title":"Potential Issues and Suggestions for Improvement","text":""},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#1-missing-protein-activity-representation","title":"1. Missing protein activity representation","text":"<p>According to the paper by Nardone et al. (PMID:36608670), phosphorylation of TFE3 at Ser-47 by mTOR creates a phospho-degron that is recognized by \u03b2-TrCP (BTRC). While the model correctly captures the causal relationship between mTOR kinase activity and BTRC ubiquitin ligase adaptor activity, it would be clearer if the model explicitly showed that mTOR provides input for BTRC through phosphorylation of TFE3/TFEB.</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#2-representation-of-the-protein-degradation-mechanism","title":"2. Representation of the protein degradation mechanism","text":"<p>The model shows that BTRC provides input for RBX1's ubiquitin protein ligase activity, which in turn negatively regulates TFE3's transcription factor activity. However, the model could more clearly represent that this is through protein degradation via the proteasome pathway.</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#3-consistency-in-go-terms","title":"3. Consistency in GO terms","text":"<p>The model uses GO:0007040 (lysosome organization) as the biological process for both TFE3 and TFEB transcription factor activities. While this is appropriate, it would be beneficial to also include GO:1904263 (positive regulation of TORC1 signaling) as a biological process for FLCN and RRAGC activities to maintain consistency throughout the model.</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#4-representation-of-complex-formation","title":"4. Representation of complex formation","text":"<p>According to the GO-CAM guidelines for annotating complexes, since the SCF complex components (CUL1, BTRC, RBX1) have defined and precise activities, they are correctly displayed individually in the model. However, it might be helpful to clarify that they function as part of the SCF E3 ubiquitin ligase complex in the model annotation.</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#5-evidence-code-and-references","title":"5. Evidence code and references","text":"<p>All activities in the model are supported by appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and PMID references. However, a few of the causal associations have evidence from a single publication, and it might be beneficial to include additional supporting literature where available.</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the key findings from recent research, particularly the paper by Nardone et al. (PMID:36608670) which describes:</p> <ol> <li>The discovery of a degradation pathway for TFE3 and MITF-A (but not TFEB) involving CUL1-\u03b2-TrCP E3 ubiquitin ligase.</li> <li>The phosphorylation of a conserved degron in TFE3 and MITF-A by mTORC1, which is recruited to the lysosomal surface by active Rag GTPases.</li> <li>The role of protein stability in controlling the transcriptional activity of these factors, in addition to the previously known mechanism of cytosolic retention by 14-3-3 proteins.</li> </ol> <p>The model correctly shows that: - RRAGC has enzyme-substrate adaptor activity that negatively regulates FLCN and mTOR activities - mTOR phosphorylates TFE3, creating a degron recognized by the SCF complex - The SCF complex components (CUL1, BTRC, RBX1) cooperate to ubiquitinate TFE3, leading to its degradation - YWHAZ (14-3-3) sequesters TFE3 in the cytoplasm, preventing its transcription factor activity</p>"},{"location":"reviews/6482692800002614-Non_canonical_mTORC1_signaling_leading_to_TFEB_and_TFE3_phosphorylation_and_inactivation___Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that effectively represents current knowledge about the non-canonical mTORC1 signaling pathway leading to TFEB and TFE3 inactivation. The model incorporates recent discoveries about protein degradation mechanisms in addition to the previously known cytosolic retention pathway. </p> <p>The model meets GO-CAM best practices and accurately represents the biological pathway. With minor enhancements suggested above, it could serve as an excellent reference model for understanding the regulatory mechanisms controlling these important transcription factors.</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/","title":"648d0dc100000022 SUCNR1 in adipocytes controls energy homeostasis by modulating circadian clock and LEP expression   Mouse","text":"<p>Based on the information gathered, I'll now review GO-CAM model 648d0dc100000022 titled \"SUCNR1 in adipocytes controls energy homeostasis by modulating circadian clock and LEP expression. (Mouse)\".</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#review-of-go-cam-model-648d0dc100000022","title":"Review of GO-CAM Model 648d0dc100000022","text":""},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model 648d0dc100000022 describes the role of the succinate receptor SUCNR1 (also known as GPR91) in adipocytes and how it controls energy homeostasis by modulating circadian clock and leptin (LEP) expression in mouse. </p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#pathway-description","title":"Pathway Description","text":"<p>The model depicts a signaling pathway where: 1. SUCNR1 functions as a G-protein coupled receptor (GO:0004930) 2. SUCNR1 provides input for AMP-activated protein kinase activity (PRKAA1/AMPK, GO:0004679) 3. AMPK activates JNK kinase activity (MAPK8, GO:0004705) 4. JNK activates transcription coregulator activity (BMAL1, GO:0003712) 5. BMAL1 positively regulates DNA-binding transcription activator activity (CEBPA, GO:0001228) 6. CEBPA provides input for hormone activity (LEP, GO:0005179)</p> <p>All components participate in energy homeostasis (GO:0097009), which is the overall biological process being modeled.</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model appears to be well-supported by the referenced literature. The primary reference (PMID:36977414) is a comprehensive study that elucidates the role of succinate/SUCNR1 in controlling leptin expression via the circadian clock. The pathway presented in the GO-CAM model closely aligns with the paper's findings, which show that:</p> <ol> <li>SUCNR1 activation in adipocytes leads to AMPK phosphorylation/activation</li> <li>AMPK activates JNK</li> <li>This signaling pathway controls leptin gene expression via BMAL1 and C/EBP-\u03b1</li> <li>The process is crucial for energy homeostasis</li> </ol> <p>The causal relationships depicted in the model (using RO:0002407 \"provides input for\" and RO:0002629 \"directly positively regulates\") accurately reflect the mechanistic relationships described in the literature.</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>Each activity in the model is supported by evidence with appropriate ECO codes and references: - SUCNR1 receptor activity is supported by PMID:18820681 - AMPK activity is supported by MGI:MGI:5005039/PMID:21459323 - JNK kinase activity is supported by MGI:MGI:1855744/PMID:10811224 - BMAL1 transcription coregulator activity is supported by PMID:26166747 - CEBPA transcription activity is supported by PMID:36977414 and PMID:26166747 - LEP hormone activity is supported by biological aspect of ancestor evidence from PANTHER</p> <p>The evidence codes are appropriate for the assertions made, primarily using ECO:0000314 (direct assay evidence used in manual assertion) for experimentally determined relationships.</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":""},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#complex-representation","title":"Complex Representation","text":"<p>The model does not depict any protein complexes, which is appropriate since the activities are clearly attributed to individual proteins in the pathway. According to the \"How to annotate complexes in GO-CAM\" document, when the specific subunits carrying molecular activities are known (as they are in this model), the complex itself doesn't need to be explicitly described.</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The model uses appropriate causal relationship predicates: - RO:0002407 \"provides input for\" is used between SUCNR1 and AMPK, and between CEBPA and LEP - RO:0002629 \"directly positively regulates\" is used between BMAL1 and CEBPA - RO:0002407 \"provides input for\" is also used between AMPK and JNK, and between JNK and BMAL1</p> <p>These predicates accurately reflect the nature of the relationships between activities as described in the literature.</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#cellular-context","title":"Cellular Context","text":"<p>The model includes appropriate cellular locations for each activity: - SUCNR1 at plasma membrane (GO:0005886) - AMPK and JNK in cytoplasm (GO:0005737) - BMAL1 and CEBPA in nucleus (GO:0005634) - LEP in extracellular space (GO:0005615)</p> <p>These locations are correctly assigned and align with the known biological context of these proteins.</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#biological-process-integration","title":"Biological Process Integration","text":"<p>All activities are appropriately integrated into the energy homeostasis biological process (GO:0097009), which is the main theme of the research paper.</p>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is scientifically accurate and follows GO-CAM best practices, there are a few areas that could be enhanced:</p> <ol> <li> <p>Circadian Regulation Context: While BMAL1 is included as a core circadian clock component, the model could potentially include more details about how the circadian rhythm is affected, possibly by including other clock components mentioned in the paper like PER1, PER2, and PER3, which are downregulated by succinate.</p> </li> <li> <p>Upstream Triggers: The model doesn't explicitly include succinate as the ligand that activates SUCNR1. Including this small molecule could provide more context about how the pathway is initiated.</p> </li> <li> <p>Feedback Mechanisms: The paper mentions that circadian dysfunction induces leptin resistance, which could potentially be included as a feedback mechanism if this is relevant to the pathway being modeled.</p> </li> <li> <p>Cellular Context Refinement: While the model specifies that these activities occur in adipocytes (as described in the title), this could be made more explicit in the model by specifying the cell type as white adipocyte (CL:0000448), which is included in the model objects but not directly connected to the activities.</p> </li> </ol>"},{"location":"reviews/648d0dc100000022-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Mouse_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 648d0dc100000022 provides an accurate representation of how SUCNR1 in adipocytes controls energy homeostasis by modulating circadian clock and LEP expression, as described in the referenced literature. The model follows GO-CAM best practices for representing molecular activities, causal relationships, and cellular context. While there are some potential areas for enhancement, these are minor considerations and do not detract from the model's overall quality.</p> <p>The model successfully captures the key finding of the research paper: that the succinate receptor SUCNR1 controls leptin expression in adipocytes through a signaling pathway involving AMPK, JNK, BMAL1, and CEBPA, ultimately contributing to energy homeostasis regulation.</p>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/","title":"648d0dc100000867 Phosphorylation of DEPTOR by MAPK3 ERK1 promotes DEPTOR deubiquitination by USP7 and enhanced protein stability  Human","text":"<p>Now let me review the GO-CAM model based on all the information I've gathered:</p>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#go-cam-model-review-gomodel648d0dc100000867","title":"GO-CAM Model Review: gomodel:648d0dc100000867","text":""},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#model-title","title":"Model Title","text":"<p>Phosphorylation of DEPTOR by MAPK3/ERK1 promotes DEPTOR deubiquitination by USP7 and enhanced protein stability (Human).</p>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#overview","title":"Overview","text":"<p>This GO-CAM model describes a signaling pathway in which MAPK3/ERK1 phosphorylates DEPTOR (DEP domain-containing mTOR-interacting protein), leading to USP7 (Ubiquitin-specific-processing protease 7) deubiquitination activity that enhances DEPTOR protein stability, ultimately resulting in negative regulation of TORC1 signaling. The model is well-structured, with appropriate causal relationships, and is consistent with recent literature on this pathway.</p>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#biological-content-analysis","title":"Biological Content Analysis","text":"<p>The model captures the following activities and relationships:</p> <ol> <li> <p>MAPK3/ERK1 (UniProtKB:P27361) with protein serine/threonine kinase activity (GO:0004674) as part of TORC1 negative regulation (GO:1904262) provides input for (RO:0002413) USP7 activity.</p> </li> <li> <p>USP7 (UniProtKB:Q93009) with cysteine-type deubiquitinase activity (GO:0004843) as part of protein stabilization (GO:0050821) directly positively regulates (RO:0002629) DEPTOR activity.</p> </li> <li> <p>DEPTOR (UniProtKB:Q8TB45) with protein serine/threonine kinase inhibitor activity (GO:0030291) as part of positive regulation of autophagy (GO:0010508) directly negatively regulates (RO:0002630) mTOR activity.</p> </li> <li> <p>mTOR (UniProtKB:P42345) with protein serine/threonine kinase activity (GO:0004674) as part of mTORC1 signaling (GO:0038202) directly negatively regulates (RO:0002630) ULK1 activity.</p> </li> <li> <p>All appropriate cellular locations are specified, with mTOR and DEPTOR occurring in the lysosomal membrane (GO:0005765).</p> </li> </ol>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by scientific evidence, primarily from the paper \"Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation\" (PMID:35216969). This recent paper (2022) provides strong experimental evidence for the role of MAPK3/ERK1 phosphorylation of DEPTOR at Ser-235, which promotes USP7 deubiquitination activity and enhances DEPTOR stability.</p> <p>Additional evidence for the components of this pathway comes from multiple papers cited in the model, including PMID:22017875, PMID:22017876, PMID:12087098, and PMID:29750193, which establish the roles of DEPTOR in mTOR inhibition and autophagy regulation.</p>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#model-structure-and-quality","title":"Model Structure and Quality","text":"<p>The model follows GO-CAM best practices with:</p> <ol> <li>Appropriate use of molecular function terms for each gene product</li> <li>Correct biological process terms that match the activities</li> <li>Proper use of causal relationship predicates to connect the activities</li> <li>Accurate cellular component annotations</li> <li>Well-structured evidence with supporting publications</li> </ol> <p>The model accurately captures a signaling cascade where: - MAPK3/ERK1 phosphorylates DEPTOR - This recruits USP7 deubiquitinase to DEPTOR - USP7 deubiquitinates DEPTOR, promoting its stability - Stabilized DEPTOR inhibits mTOR activity - Inhibited mTOR has reduced ability to phosphorylate and inhibit ULK1</p>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is consistent with current understanding of DEPTOR regulation and function. The UniProt records for DEPTOR (Q8TB45) specifically mention that \"Phosphorylation at Ser-235 by MAPK3/ERK1 promotes deubiquitination by USP7, enhancing its stability.\"</p> <p>The paper (PMID:35216969) provides detailed experimental evidence for this pathway in multiple myeloma cells, showing that: 1. ERK1 phosphorylates DEPTOR at Ser-235 2. This phosphorylation mediates USP7 binding to DEPTOR 3. USP7 deubiquitinates DEPTOR, preventing its degradation 4. Stabilized DEPTOR inhibits mTOR signaling</p> <p>The model accurately represents this biological pathway and the key molecular mechanisms involved.</p>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is scientifically accurate and well-structured, a few minor improvements could be considered:</p> <ol> <li> <p>Molecular Details: The specific phosphorylation site (Ser-235) on DEPTOR could be included as an annotation or comment for greater precision.</p> </li> <li> <p>Context Specificity: The model could note that this pathway is particularly relevant in multiple myeloma cells where DEPTOR is frequently overexpressed.</p> </li> <li> <p>Downstream Effects: The model could be extended to include the effects on AKT phosphorylation, which is a key downstream consequence of this pathway according to the paper.</p> </li> </ol>"},{"location":"reviews/648d0dc100000867-Phosphorylation_of_DEPTOR_by_MAPK3_ERK1_promotes_DEPTOR_deubiquitination_by_USP7_and_enhanced_protein_stability__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:648d0dc100000867) accurately represents the pathway in which MAPK3/ERK1 phosphorylates DEPTOR, leading to USP7-mediated deubiquitination and enhanced DEPTOR stability, ultimately resulting in mTOR inhibition. The model is well-supported by recent literature, properly structured according to GO-CAM standards, and provides a valuable representation of this signaling cascade.</p> <p>The model makes appropriate use of causal relationships to connect molecular activities and accurately describes the biological processes involved in this pathway. Overall, this is a high-quality GO-CAM model that effectively captures the current understanding of DEPTOR regulation by MAPK3/ERK1 and USP7.</p>"},{"location":"reviews/648d0dc100001272-Inhibition_of_the_non_canonical_mTORC1_signaling_following_phosphorylation_of_FNIP1_by_AMPK_in_response_to_mitochondrial_stress__Human__/","title":"648d0dc100001272 Inhibition of the non canonical mTORC1 signaling following phosphorylation of FNIP1 by AMPK in response to mitochondrial stress  Human","text":"<p>Based on my review of the model and relevant literature, I can now provide a comprehensive assessment of GO-CAM model 648d0dc100001272:</p>"},{"location":"reviews/648d0dc100001272-Inhibition_of_the_non_canonical_mTORC1_signaling_following_phosphorylation_of_FNIP1_by_AMPK_in_response_to_mitochondrial_stress__Human__/#review-of-go-cam-model-648d0dc100001272","title":"Review of GO-CAM Model: 648d0dc100001272","text":""},{"location":"reviews/648d0dc100001272-Inhibition_of_the_non_canonical_mTORC1_signaling_following_phosphorylation_of_FNIP1_by_AMPK_in_response_to_mitochondrial_stress__Human__/#general-overview","title":"General Overview","text":"<p>This GO-CAM model titled \"Inhibition of the non-canonical mTORC1 signaling following phosphorylation of FNIP1 by AMPK in response to mitochondrial stress (Human)\" represents a well-constructed pathway describing how mitochondrial stress triggers AMPK phosphorylation of FNIP1, which in turn inhibits the FLCN-FNIP1 GTPase-activating protein (GAP) complex, leading to changes in RagC nucleotide status and ultimately affecting the non-canonical mTORC1 signaling pathway.</p>"},{"location":"reviews/648d0dc100001272-Inhibition_of_the_non_canonical_mTORC1_signaling_following_phosphorylation_of_FNIP1_by_AMPK_in_response_to_mitochondrial_stress__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway Logic: The model effectively captures the causal cascade from AMPK activation to downstream transcription factor regulation, with appropriate directional relationships using RO terms such as RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates).</p> </li> <li> <p>Molecular Detail: The model correctly includes key proteins (FNIP1, FLCN, RagC, mTOR) with their appropriate molecular functions and subcellular localizations.</p> </li> <li> <p>Evidence: Each activity and relationship is supported by evidence from published literature, primarily using direct assay evidence (ECO:0000314) with appropriate PMIDs.</p> </li> <li> <p>Cellular Context: The model accurately captures the lysosomal localization (GO:0005765) of many components, which is essential for mTORC1 signaling regulation.</p> </li> </ol>"},{"location":"reviews/648d0dc100001272-Inhibition_of_the_non_canonical_mTORC1_signaling_following_phosphorylation_of_FNIP1_by_AMPK_in_response_to_mitochondrial_stress__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex Representation: The FLCN-FNIP1 complex is presented as separate entities rather than using a complex representation. While this is acceptable according to the complex annotation guidelines when the individual activities are known, it might be clearer to explicitly show their interaction as a complex since their function as a GAP is dependent on their association.</p> </li> <li> <p>Phosphorylation Representation: While the title mentions FNIP1 phosphorylation by AMPK, the specific phosphorylation sites (Ser220, Ser230, Ser232, Ser261, and Ser593) that are critical for regulation, as shown in the PMID:37079666 paper, could be more explicitly captured in the model annotations.</p> </li> <li> <p>Temporal Dynamics: The model doesn't fully capture the temporal dynamics of the pathway - specifically that FNIP1 phosphorylation leads to an initial wave of lysosomal biogenesis followed by a later wave of mitochondrial biogenesis, as described in the literature.</p> </li> </ol>"},{"location":"reviews/648d0dc100001272-Inhibition_of_the_non_canonical_mTORC1_signaling_following_phosphorylation_of_FNIP1_by_AMPK_in_response_to_mitochondrial_stress__Human__/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the current understanding of this pathway based on the literature. Key features correctly captured include:</p> <ol> <li> <p>AMPK (PRKAA1) directly phosphorylates FNIP1, inhibiting the GAP activity of the FLCN-FNIP1 complex</p> </li> <li> <p>FLCN functions as a GTPase activator protein (GO:0005096) for RagC, which is accurately represented</p> </li> <li> <p>The localization of these activities to the lysosomal membrane is correctly annotated</p> </li> <li> <p>The downstream effects on transcription factors (TFEB and TFE3) are appropriately represented</p> </li> </ol>"},{"location":"reviews/648d0dc100001272-Inhibition_of_the_non_canonical_mTORC1_signaling_following_phosphorylation_of_FNIP1_by_AMPK_in_response_to_mitochondrial_stress__Human__/#recommendations-for-enhancement","title":"Recommendations for Enhancement","text":"<ol> <li> <p>Add Additional Components: Consider including the final transcriptional targets of TFEB/TFE3 that drive lysosomal and mitochondrial biogenesis to complete the pathway.</p> </li> <li> <p>Include Alternative Regulatory Mechanisms: The model could be expanded to show how amino acid availability regulates the same pathway differently than energetic stress, as described in the literature.</p> </li> <li> <p>Cross-Reference Related Models: Link to other GO-CAM models that represent related processes like canonical mTORC1 signaling or the broader AMPK response to energetic stress.</p> </li> <li> <p>Clarify Relationship Between RagC and mTOR: The connection between RagC's nucleotide status and mTOR activity could be more explicitly represented through additional annotations.</p> </li> </ol>"},{"location":"reviews/648d0dc100001272-Inhibition_of_the_non_canonical_mTORC1_signaling_following_phosphorylation_of_FNIP1_by_AMPK_in_response_to_mitochondrial_stress__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (648d0dc100001272) provides a well-constructed and biologically accurate representation of non-canonical mTORC1 signaling regulation following AMPK phosphorylation of FNIP1 in response to mitochondrial stress. The model adheres to GO-CAM best practices and effectively captures the key molecular players and their interactions. The minor improvements suggested would further enhance its comprehensiveness and clarity but do not diminish the value of the current representation.</p> <p>The model successfully demonstrates how mitochondrial stress leads to AMPK activation, FNIP1 phosphorylation, inhibition of FLCN-FNIP1 GAP activity, alteration of RagC GTP/GDP binding, and ultimately regulation of transcription factors that control lysosomal and mitochondrial biogenesis.</p>"},{"location":"reviews/6494e2e900000187-TRAF7_modulation_of_NF_kappa_B_via_IKBKG_and_NEMO_K_29_ubquitination__Human_/","title":"6494e2e900000187 TRAF7 modulation of NF kappa B via IKBKG and NEMO K 29 ubquitination  Human","text":"<p>Based on my review of the GO-CAM model and the relevant documentation, I'll now provide a comprehensive review of the model \"TRAF7 modulation of NF-kappa-B via IKBKG and NEMO K-29 ubquitination (Human)\".</p>"},{"location":"reviews/6494e2e900000187-TRAF7_modulation_of_NF_kappa_B_via_IKBKG_and_NEMO_K_29_ubquitination__Human_/#review-of-go-cam-model-gomodel6494e2e900000187","title":"Review of GO-CAM Model gomodel:6494e2e900000187","text":""},{"location":"reviews/6494e2e900000187-TRAF7_modulation_of_NF_kappa_B_via_IKBKG_and_NEMO_K_29_ubquitination__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the TRAF7-mediated modulation of NF-kappa-B signaling through K29-linked ubiquitination of IKBKG (NEMO) and RelA proteins in humans. The model depicts the pathway by which TRAF7 negatively regulates NF-kappa-B activation through a non-degradative K29-linked ubiquitination mechanism.</p>"},{"location":"reviews/6494e2e900000187-TRAF7_modulation_of_NF_kappa_B_via_IKBKG_and_NEMO_K_29_ubquitination__Human_/#biological-content-and-accuracy","title":"Biological Content and Accuracy","text":"<p>The model's biological content is generally accurate and consistent with the literature evidence provided. The key findings represented in this model are:</p> <ol> <li>TRAF7 exhibits E3 ubiquitin-protein ligase activity (GO:0061630) that targets IKBKG (NEMO) for K29-linked ubiquitination.</li> <li>This ubiquitination doesn't lead to proteasomal degradation but rather to lysosomal degradation, as indicated by the associated process \"protein K29-linked ubiquitination\" (GO:0035519).</li> <li>TRAF7 activity represses NF-kappaB activation by reducing the activity of both IKBKG and RELA.</li> <li>The model correctly shows IKBKG as a signaling adaptor in the canonical NF-kappa-B pathway.</li> <li>The model properly captures the protein sequestering activity of NFKBIA (I\u03baB\u03b1) in inhibiting RELA and NFKB1 activities.</li> </ol> <p>These findings align with the Uniprot information for TRAF7 (Q6Q0C0), which states it \"promotes 'Lys-29'-linked polyubiquitination of NEMO/IKBKG and RELA leading to targeting these two proteins to lysosomal degradative pathways, reducing the transcriptional activity of NF-kappa-B.\"</p>"},{"location":"reviews/6494e2e900000187-TRAF7_modulation_of_NF_kappa_B_via_IKBKG_and_NEMO_K_29_ubquitination__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Correct use of causal relationships: The model uses the appropriate predicate \"RO:0002630\" (directly negatively regulates) between activities in the pathway.</p> </li> <li> <p>Appropriate annotation of ubiquitination activities: TRAF7's E3 ligase activity is correctly annotated with GO:0061630 and appropriately associated with the biological process GO:0035519 (protein K29-linked ubiquitination), following the guidelines for annotating E3 ubiquitin ligases.</p> </li> <li> <p>Proper annotation of protein sequestering activity: NFKBIA's (I\u03baB\u03b1) protein sequestering activity (GO:0140311) is appropriately used to represent its inhibition of NF-kB components, consistent with the \"Protein sequestering activity\" guidelines.</p> </li> <li> <p>Correct cytoplasmic localization: The activities are correctly localized to the appropriate cellular compartments (cytoplasm and nucleus).</p> </li> </ol>"},{"location":"reviews/6494e2e900000187-TRAF7_modulation_of_NF_kappa_B_via_IKBKG_and_NEMO_K_29_ubquitination__Human_/#issues-and-recommendations-for-improvement","title":"Issues and Recommendations for Improvement","text":"<ol> <li> <p>Missing direct ubiquitination of RELA: While the Uniprot entry for TRAF7 indicates it also targets RELA for K29-linked polyubiquitination, the model only shows the indirect regulation of RELA activity via the NFKBIA sequestering activity. Consider adding a direct ubiquitination relationship between TRAF7 and RELA to better reflect the complete mechanism.</p> </li> <li> <p>Incomplete molecular mechanisms between IKBKG and IKK kinases: The model shows IKBKG (NEMO) as a target of TRAF7, but doesn't fully capture how IKBKG modulates the activities of CHUK (IKK\u03b1) and IKBKB (IKK\u03b2). Consider adding more detailed interactions showing how IKBKG regulates these kinases.</p> </li> <li> <p>Missing contextual specificity: The model would benefit from adding information about the cellular conditions or stimuli that trigger this pathway. This would provide better context for when this negative regulation occurs.</p> </li> <li> <p>PMID missing reference format issue: One evidence citation (PMID:21518757) is missing the \"PMID:\" prefix in the occurs_in evidence for TRAF7 activity. This should be corrected to maintain consistency.</p> </li> <li> <p>Validation of input-output relationships: While the model correctly uses \"directly negatively regulates\" predicates, it should be verified that the \"has input\" relationships are also present where appropriate (e.g., for TRAF7's E3 ligase activity targeting IKBKG).</p> </li> </ol>"},{"location":"reviews/6494e2e900000187-TRAF7_modulation_of_NF_kappa_B_via_IKBKG_and_NEMO_K_29_ubquitination__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the role of TRAF7 in negatively regulating NF-kappa-B signaling through K29-linked ubiquitination of IKBKG. The model adheres to GO-CAM best practices for representing E3 ligase activities and protein sequestering activities.</p> <p>The minor issues noted above could be addressed to make the model more comprehensive and to better represent the full spectrum of TRAF7's activities in modulating NF-kappa-B signaling. With these refinements, the model would provide an even more accurate representation of this important regulatory mechanism.</p> <p>The model is consistent with current knowledge of NF-kappa-B regulation and the role of K29-linked ubiquitination in protein trafficking to lysosomal degradation rather than proteasomal degradation, which represents an important regulatory mechanism in NF-kappa-B signaling.</p>"},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/","title":"6494e2e900001469 Mpeg1 perforin 2 forms a pore for to deliver antigens for cross presentation  Mouse","text":"<p>Based on the information I've gathered, I'll now provide a comprehensive review of GO-CAM model 6494e2e900001469.</p>"},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/#review-of-go-cam-model-6494e2e900001469","title":"Review of GO-CAM Model 6494e2e900001469","text":""},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"Mpeg1/perforin-2 forms a pore for to deliver antigens for cross-presentation (Mouse)\" describes a molecular pathway involving three proteins:</p> <ol> <li>Mpeg1/Perforin-2 (MGI:MGI:1333743) - A pore-forming protein</li> <li>Tapbp/Tapasin (MGI:MGI:1201689) - A peptide antigen binding protein</li> <li>Lgmn/Legumain (MGI:MGI:1330838) - A cysteine-type endopeptidase</li> </ol> <p>The model depicts a pathway for cross-presentation of exogenous antigens via MHC class I in dendritic cells, which is a crucial process for initiating CD8+ T cell responses against viruses and tumors.</p>"},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/#pathway-description","title":"Pathway Description","text":"<p>The model shows:</p> <ol> <li> <p>Lgmn/Legumain (MGI:MGI:1330838) with a cysteine-type endopeptidase activity (GO:0004197) participates in protein maturation (GO:0051604) and positively regulates (RO:0002629) the next activity.</p> </li> <li> <p>Mpeg1/Perforin-2 (MGI:MGI:1333743) with a wide pore channel activity (GO:0022829) occurs in the phagocytic vesicle membrane (GO:0030670) and is part of antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590). It provides input for (RO:0002413) the next activity.</p> </li> <li> <p>Tapbp/Tapasin (MGI:MGI:1201689) with peptide antigen binding activity (GO:0042605) is part of antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent (GO:0002479).</p> </li> </ol>"},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/#scientific-evaluation","title":"Scientific Evaluation","text":"<p>The model accurately captures the recently discovered function of Perforin-2 as described in the primary reference (PMID:37347855). Key findings support this pathway:</p> <ol> <li>Perforin-2's role in cross-presentation: </li> <li>The model correctly shows Perforin-2 forming pores in phagocytic vesicle membranes, allowing antigens to access the cytosol for processing and loading onto MHC class I molecules.</li> <li> <p>This is supported by evidence that Mpeg1-/- mice failed to efficiently prime CD8+ T cells to cell-associated antigens.</p> </li> <li> <p>Legumain as a regulator of Perforin-2 maturation:</p> </li> <li>The model correctly shows Legumain (Lgmn) positively regulating Perforin-2's activity.</li> <li> <p>The research confirms that Legumain mediates proteolytic processing of Perforin-2 in the EGF domain, which is important for its maturation and function.</p> </li> <li> <p>Tapasin's role in peptide loading:</p> </li> <li>The model accurately represents Tapasin's function in peptide antigen binding as part of the TAP-dependent MHC class I presentation pathway.</li> <li>This is consistent with Tapasin's established role in mediating interaction between MHC class I heterodimers and TAP, facilitating efficient peptide binding.</li> </ol>"},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/#evaluation-against-go-cam-best-practices","title":"Evaluation Against GO-CAM Best Practices","text":"<ol> <li>Appropriate molecular activities:</li> <li> <p>Each protein is assigned the correct molecular function:</p> <ul> <li>Legumain as a cysteine-type endopeptidase</li> <li>Perforin-2 as a wide pore channel activity protein</li> <li>Tapasin as a peptide antigen binding protein</li> </ul> </li> <li> <p>Proper causal relationships:</p> </li> <li> <p>The model uses appropriate causal relations:</p> <ul> <li>\"directly positively regulates\" (RO:0002629) for Legumain's effect on Perforin-2</li> <li>\"provides input for\" (RO:0002413) for the relationship between Perforin-2 and Tapasin</li> </ul> </li> <li> <p>Cellular context:</p> </li> <li> <p>The model correctly places Perforin-2 in the phagocytic vesicle membrane, which aligns with the experimental evidence.</p> </li> <li> <p>Biological processes:</p> </li> <li>The proteins are associated with their relevant biological processes:<ul> <li>Perforin-2 with antigen processing and presentation via MHC class I</li> <li>Tapasin with TAP-dependent antigen presentation</li> </ul> </li> </ol>"},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/#annotated-evidence-quality","title":"Annotated Evidence Quality","text":"<ol> <li>Evidence codes:</li> <li> <p>The model uses appropriate evidence codes:</p> <ul> <li>ECO:0000314 (direct assay evidence used in manual assertion) for the main findings</li> <li>ECO:0000250 (sequence similarity evidence used in manual assertion) for Tapasin</li> </ul> </li> <li> <p>Literature support:</p> </li> <li>The central findings are supported by reference to PMID:37347855, which directly demonstrates the role of Perforin-2 in cross-presentation</li> <li>Tapasin's role is referenced to PMID:9716645, which describes its function in MHC class I assembly</li> </ol>"},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li>Model completeness: The model is parsimonious and focused on the core pathway. However, it could potentially be expanded to include:</li> <li>The MHC class I molecule itself as the final recipient of the processed antigens</li> <li> <p>The role of the proteasome in processing antigens after they escape the phagosome via Perforin-2 pores</p> </li> <li> <p>Clarity: The model clearly shows the sequence of events from Legumain's enzymatic activity to Perforin-2's pore formation to Tapasin's peptide loading function.</p> </li> <li> <p>Consistency with evidence: All elements of the model are strongly supported by the primary literature.</p> </li> </ol>"},{"location":"reviews/6494e2e900001469-Mpeg1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a high-quality GO-CAM model that accurately represents a newly discovered pathway in cross-presentation. It correctly captures the roles of Perforin-2, Legumain, and Tapasin in this process, with clear causal relationships between the activities. The model is well-supported by experimental evidence and adheres to GO-CAM best practices for annotation.</p> <p>The model makes an important contribution by representing the first molecular explanation of how antigens cross from endocytic compartments to the cytosol during cross-presentation, a process that was previously not well understood at the molecular level.</p>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/","title":"6494e2e900001496 MPEG1 perforin 2 forms a pore for to deliver antigens for cross presentation  Human","text":"<p>Now I'll provide a comprehensive review of the GO-CAM model \"MPEG1/perforin-2 forms a pore for to deliver antigens for cross-presentation (Human)\" (gomodel:6494e2e900001496).</p>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#go-cam-review-mpeg1perforin-2-forms-a-pore-for-to-deliver-antigens-for-cross-presentation-human","title":"GO-CAM Review: MPEG1/perforin-2 forms a pore for to deliver antigens for cross-presentation (Human)","text":""},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:6494e2e900001496) describes how MPEG1/perforin-2 forms a pore to facilitate antigen delivery for cross-presentation in dendritic cells. The model represents the pathway involving three key activities:</p> <ol> <li>Cysteine-type endopeptidase activity (GO:0004197) by LGMN (UniProtKB:Q99538)</li> <li>Wide pore channel activity (GO:0022829) by MPEG1 (UniProtKB:Q2M385)</li> <li>Peptide antigen binding (GO:0042605) by Tapbp (MGI:MGI:1201689, mouse protein)</li> </ol>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#biological-process-context","title":"Biological Process Context","text":"<ul> <li>LGMN (legumain) participates in protein maturation (GO:0051604)</li> <li>MPEG1 (perforin-2) participates in antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590)</li> <li>Tapbp (tapasin) participates in antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent (GO:0002479)</li> </ul>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>LGMN directly positively regulates (RO:0002629) MPEG1</li> <li>MPEG1 provides input for (RO:0002413) Tapbp</li> </ul>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Biological accuracy: The model correctly captures the recent findings that perforin-2 (MPEG1) forms pores in antigen-containing compartments to facilitate cross-presentation, with LGMN (asparagine endopeptidase) playing a role in perforin-2 maturation, as supported by the literature (PMID:37347855).</p> </li> <li> <p>Appropriate relationships: The causal relationships are appropriately represented with LGMN directly positively regulating MPEG1 (via proteolytic processing) and MPEG1 providing input for Tapbp.</p> </li> <li> <p>Cellular context: The model correctly identifies that MPEG1 occurs in the phagocytic vesicle membrane (GO:0030670), which is consistent with its biological function.</p> </li> </ol>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li> <p>Use of mouse protein in human model: The model uses a mouse tapasin protein (MGI:MGI:1201689) while claiming to be a human model. It would be more appropriate to use the human ortholog (UniProtKB:O15533).</p> </li> <li> <p>Evidence codes: The evidence for MPEG1's pore activity is appropriate (ECO:0000314 \"direct assay evidence\") with citation to PMID:31537793, but some relationships rely on sequence similarity evidence with mouse (ECO:0000250). While the mouse data is strong, human-specific evidence would strengthen the model when available.</p> </li> <li> <p>Missing components: The model could be expanded to include:</p> </li> <li>The complete process of cross-presentation, including the proteasome and TAP components</li> <li>MHC class I molecules that ultimately present the antigens</li> <li> <p>The role of dendritic cells (which could be specified as a cell type context)</p> </li> <li> <p>Potential redundancy: There appears to be a duplicated causal association between LGMN and MPEG1, with the same predicate (RO:0002629) appearing twice with the same evidence for one instance.</p> </li> <li> <p>Model title grammar: The title \"MPEG1/perforin-2 forms a pore for to deliver antigens for cross-presentation\" contains a grammatical error (\"for to deliver\").</p> </li> </ol>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#molecular-mechanism-details","title":"Molecular Mechanism Details","text":"<p>Based on the literature (PMID:37347855), the model accurately captures a recently discovered mechanism:</p> <ol> <li>Legumain (LGMN/AEP) mediates proteolytic processing of perforin-2 (MPEG1) in the lysosome/endosome</li> <li>This processing releases the pore-forming domain of MPEG1, allowing it to form pores in the membrane of antigen-containing compartments</li> <li>These pores facilitate the escape of antigens into the cytosol, where they can be processed by the proteasome</li> <li>Tapasin (Tapbp) then assists in loading peptides onto MHC class I molecules for cross-presentation</li> </ol> <p>This mechanism represents an important insight into dendritic cell cross-presentation that was only recently discovered.</p>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#recommendations-for-model-improvement","title":"Recommendations for Model Improvement","text":"<ol> <li>Replace the mouse tapasin protein with its human ortholog</li> <li>Fix the duplicate causal association between LGMN and MPEG1</li> <li>Consider adding dendritic cells as a cell type context</li> <li>Expand the model to include downstream components of the cross-presentation pathway</li> <li>Correct the grammatical error in the title</li> <li>Consider adding additional evidence from human studies when available</li> </ol>"},{"location":"reviews/6494e2e900001496-MPEG1_perforin_2_forms_a_pore_for_to_deliver_antigens_for_cross_presentation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model successfully captures the novel mechanism of perforin-2-mediated antigen cross-presentation as described in recent literature. It accurately represents the roles of legumain in perforin-2 processing and perforin-2 in forming pores for antigen escape. With the suggested refinements, this model would provide an even more comprehensive and accurate representation of this important immunological process.</p>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/","title":"6494e2e900002018 Glyceraldehyde 3 phosphate biosynthetic process 1  Mouse","text":"<p>Now let me understand what GO:0046166 (glyceraldehyde-3-phosphate biosynthetic process) is by examining the model, and then I'll review the pathway structure.</p> <p>Based on the GO-CAM model and protein information I've examined, I'll now provide a detailed review of GO-CAM model gomodel:6494e2e900002018.</p>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#review-of-go-cam-model-gomodel6494e2e900002018","title":"Review of GO-CAM Model: gomodel:6494e2e900002018","text":""},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: \"Glyceraldehyde-3-phosphate biosynthetic process 1 (Mouse)\"</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Primary Process: Glyceraldehyde-3-phosphate biosynthetic process (GO:0046166)</li> </ul>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#model-structure-and-flow-assessment","title":"Model Structure and Flow Assessment","text":"<p>This model represents the glyceraldehyde-3-phosphate biosynthetic pathway in mouse. The pathway is well constructed with a clear flow of activities connected via the <code>RO:0002413</code> (\"provides input for\") relationship, creating a logical progression through the metabolic pathway.</p>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#pathway-flow-analysis","title":"Pathway Flow Analysis:","text":"<p>The pathway begins with pyruvate carboxylase (Pcx) in the mitochondrial matrix and follows through several enzymatic steps, eventually culminating in glyceraldehyde-3-phosphate production:</p> <ol> <li>Pyruvate carboxylase (Pcx) \u2192 Malate dehydrogenase 2 (Mdh2) [mitochondria]</li> <li>Malate dehydrogenase 2 (Mdh2) \u2192 Malate transporter (Slc25a10) [mitochondrial inner membrane]</li> <li>Malate transporter (Slc25a10) \u2192 Malate dehydrogenase 1 (Mdh1) [cytosol]</li> <li>Malate dehydrogenase 1 (Mdh1) \u2192 Phosphoenolpyruvate carboxykinase (Pck1) [cytosol]</li> <li>Phosphoenolpyruvate carboxykinase (Pck1) \u2192 Enolase (Eno1) [cytosol]</li> <li>Enolase (Eno1) \u2192 Phosphoglycerate mutase (Pgam1) [cytosol]</li> <li>Phosphoglycerate mutase (Pgam1) \u2192 Phosphoglycerate kinase (Pgk1) [cytosol]</li> <li>Phosphoglycerate kinase (Pgk1) \u2192 Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) [cytosol]</li> <li>Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) \u2192 Triosephosphate isomerase (Tpi1) [cytosol]</li> <li>Triosephosphate isomerase (Tpi1) \u2192 Glycerol-3-phosphate dehydrogenase (Gpd1) [cytosol]</li> </ol>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model has a good evidence base, with: - Most activities supported by experimental evidence codes (ECO:0000314, ECO:0000315) - References to primary literature (PMIDs) - Appropriate cellular locations specified for each activity</p>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Complete pathway representation: The model represents the complete pathway from pyruvate to glyceraldehyde-3-phosphate.</li> <li>Proper cellular compartmentalization: Activities are appropriately localized to the correct cellular components (mitochondrial matrix, mitochondrial inner membrane, cytosol).</li> <li>Proper directionality: The causal connections between activities follow the correct biochemical flow using the \"provides input for\" relationship.</li> <li>Well-supported by evidence: Each activity has appropriate experimental evidence.</li> <li>Proper use of GO terms: Each protein is annotated with the appropriate molecular function GO term.</li> </ol>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Evidence for causal relationships: While each activity has evidence, the causal associations (RO:0002413) do not have explicit evidence annotations. Adding evidence for these connections would strengthen the model.</p> </li> <li> <p>Possible missing branch points: The standard gluconeogenesis pathway typically involves branches and alternative routes. The model appears to represent a linear pathway, which may be a simplification.</p> </li> <li> <p>Terminal node clarification: The final activity (Gpd1) doesn't have any outgoing causal connections. It would be helpful to clarify if this is intended to be the endpoint of the pathway or if there are additional steps.</p> </li> </ol>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several ways: - Appropriate use of molecular functions connected to gene products - Proper use of cellular component annotations - Clear causal relationships between activities - Biological process annotations for each activity</p>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#biological-consistency","title":"Biological Consistency","text":"<p>The model accurately represents the gluconeogenesis pathway leading to glyceraldehyde-3-phosphate production, with enzymes in their correct cellular locations and following the expected biochemical sequence.</p>"},{"location":"reviews/6494e2e900002018-Glyceraldehyde_3_phosphate_biosynthetic_process_1__Mouse_/#summary","title":"Summary","text":"<p>This is a well-constructed GO-CAM model that accurately represents the glyceraldehyde-3-phosphate biosynthetic process in mouse. The model shows good pathway flow, proper use of GO terms, and is supported by experimental evidence. The main recommendation would be to add evidence for the causal relationships between activities and to clarify the terminal endpoint of the pathway.</p>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/","title":"6494e2e900002525 SUCNR1 in adipocytes controls energy homeostasis by modulating circadian clock and LEP expression   Human","text":"<p>Based on the information I've gathered, I'll now provide a comprehensive review of GO-CAM model 6494e2e900002525.</p>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#go-cam-model-review-sucnr1-in-adipocytes-controls-energy-homeostasis-gomodel6494e2e900002525","title":"GO-CAM Model Review: SUCNR1 in adipocytes controls energy homeostasis (gomodel:6494e2e900002525)","text":""},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model 6494e2e900002525 titled \"SUCNR1 in adipocytes controls energy homeostasis by modulating circadian clock and LEP expression. (Human)\" represents a signaling pathway in which the succinate receptor SUCNR1 regulates leptin expression through a signaling cascade involving AMPK, JNK, BMAL1, and CEBPA transcription factors, ultimately contributing to energy homeostasis in humans.</p>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#biological-content-review","title":"Biological Content Review","text":"<p>The biological content of the model accurately reflects the research findings from key publications, particularly PMID:26166747, which describes the role of circadian dysfunction in leptin resistance and energy homeostasis. The model captures the essential signaling cascade where:</p> <ol> <li>SUCNR1 (succinate receptor) activation triggers an AMPK-JNK pathway</li> <li>JNK regulates BMAL1 (transcription coregulator)</li> <li>BMAL1 regulates CEBPA (transcription factor) </li> <li>CEBPA controls leptin (LEP) expression</li> <li>Leptin functions as a hormone in energy homeostasis</li> </ol> <p>This pathway is well-supported by the literature, including the relationship between circadian clock components and leptin signaling.</p>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#go-cam-structure-and-best-practices","title":"GO-CAM Structure and Best Practices","text":""},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#molecular-functions","title":"Molecular Functions","text":"<p>The molecular functions are appropriately assigned to each protein:</p> <ul> <li>UniProtKB:Q9BXA5 (SUCNR1) - G protein-coupled receptor activity (GO:0004930)</li> <li>UniProtKB:Q13131 (PRKAA1) - AMP-activated protein kinase activity (GO:0004679)</li> <li>UniProtKB:P45983 (MAPK8) - JUN kinase activity (GO:0004705)</li> <li>UniProtKB:O00327 (BMAL1) - transcription coregulator activity (GO:0003712)</li> <li>UniProtKB:P49715 (CEBPA) - DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228)</li> <li>UniProtKB:P41159 (LEP) - hormone activity (GO:0005179)</li> </ul>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#cellular-compartments","title":"Cellular Compartments","text":"<p>The cellular locations for each activity are correctly annotated: - SUCNR1 - plasma membrane - PRKAA1 and MAPK8 - cytoplasm - BMAL1 and CEBPA - nucleus - LEP - extracellular space</p> <p>These locations are consistent with the known biology of these proteins and their functions.</p>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model uses appropriate causal relationships between activities: - SUCNR1 \u2192 PRKAA1: \"RO:0002407\" (provides input for) - PRKAA1 \u2192 MAPK8: \"RO:0002407\" (provides input for) - MAPK8 \u2192 BMAL1: \"RO:0002407\" (provides input for) - BMAL1 \u2192 CEBPA: \"RO:0002629\" (directly positively regulates) - CEBPA \u2192 LEP: \"RO:0002407\" (provides input for)</p> <p>These causal relationships accurately reflect the signaling flow described in the literature, particularly in PMID:26166747 which describes how BMAL1/CLOCK generates circadian rhythm of C/EBPalpha-mediated leptin transcription in adipose tissue.</p>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#biological-processes","title":"Biological Processes","text":"<p>All activities are appropriately tagged with the biological process \"energy homeostasis\" (GO:0097009), with BMAL1 additionally being part of \"circadian regulation of gene expression\" (GO:0032922). This is consistent with the model's focus on how SUCNR1 controls energy homeostasis through circadian clock regulation.</p>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#evidence-codes","title":"Evidence Codes","text":"<p>The model uses appropriate evidence codes: - Evidence from direct assays (ECO:0000314) with references to relevant PMIDs - Evidence from sequence similarity (ECO:0000250) with references to mouse orthologs</p>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Additional Context for BMAL1 Function: According to the transcription coregulator activity guidelines, BMAL1's activity could include more context about its specific role. The literature indicates that BMAL1 forms a heterodimer with CLOCK, which is not explicitly represented in the model. The model could potentially be enhanced by including CLOCK as part of a complex with BMAL1.</p> </li> <li> <p>Specificity of Causal Relationships: The causal relationship between CEBPA and LEP is currently \"provides input for\", but the literature shows that CEBPA is a transcription factor that directly activates leptin transcription. A more specific relationship such as \"directly positively regulates\" might be more appropriate here.</p> </li> <li> <p>Missing Component: The literature indicates that succinate (CHEBI:30031) is the ligand for SUCNR1, but this small molecule activator is not included in the model. According to the guidelines, ligand activation should be captured.</p> </li> <li> <p>Anatomical Context: While the model title mentions adipocytes, the cellular components are specified but not the cell type context. Adding white adipocyte (CL:0000448) as an additional context could enhance the specificity of the model.</p> </li> </ol>"},{"location":"reviews/6494e2e900002525-SUCNR1_in_adipocytes_controls_energy_homeostasis_by_modulating_circadian_clock_and_LEP_expression___Human_/#conclusion","title":"Conclusion","text":"<p>Overall, GO-CAM model 6494e2e900002525 is a well-constructed representation of how SUCNR1 signaling controls energy homeostasis through the regulation of leptin via circadian clock components. The model accurately captures the key players and their interactions in this pathway.</p> <p>The model follows most GO-CAM best practices and provides a clear visualization of the molecular pathway. The causal relationships between activities are properly established, and the evidence is well-documented with appropriate references to the literature.</p> <p>With minor refinements regarding the addition of CLOCK as a BMAL1 partner, the inclusion of succinate as a SUCNR1 activator, and potentially more specific relationship types, this model would provide an even more comprehensive representation of this important biological pathway.</p>"},{"location":"reviews/64c3044100000089-Skeletal_muscle_acetylcholine_gated_channel_clustering_1__Mouse_/","title":"64c3044100000089 Skeletal muscle acetylcholine gated channel clustering 1  Mouse","text":"<p>Based on my review of the model and related information, I'll now provide a detailed assessment of GO-CAM model gomodel:64c3044100000089.</p>"},{"location":"reviews/64c3044100000089-Skeletal_muscle_acetylcholine_gated_channel_clustering_1__Mouse_/#review-of-go-cam-model-64c3044100000089-skeletal-muscle-acetylcholine-gated-channel-clustering-1-mouse","title":"Review of GO-CAM Model: 64c3044100000089 (Skeletal muscle acetylcholine-gated channel clustering 1 - Mouse)","text":""},{"location":"reviews/64c3044100000089-Skeletal_muscle_acetylcholine_gated_channel_clustering_1__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the molecular pathway involved in skeletal muscle acetylcholine-gated channel clustering in the mouse neuromuscular junction. The model focuses on the signaling pathway from Agrin (Agrn) through MuSK (Muscle skeletal receptor tyrosine kinase) and downstream effectors leading to Rac1 activation and acetylcholine receptor clustering.</p>"},{"location":"reviews/64c3044100000089-Skeletal_muscle_acetylcholine_gated_channel_clustering_1__Mouse_/#biological-context","title":"Biological Context","text":"<p>The model correctly captures a well-established neuromuscular junction formation pathway, where: 1. Agrin (secreted by motor neurons) acts as a receptor ligand that binds to Lrp4 2. Lrp4 acts as a coreceptor that stimulates MuSK phosphorylation 3. MuSK signals through adaptor proteins (Dok7, Crk, Crkl)  4. This signaling ultimately leads to Rac1 activation and cytoskeletal reorganization 5. These events result in acetylcholine receptor clustering at the neuromuscular junction</p>"},{"location":"reviews/64c3044100000089-Skeletal_muscle_acetylcholine_gated_channel_clustering_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate core pathway representation: The model correctly depicts the established Agrin-MuSK-Dok7-Rac1 pathway that is essential for neuromuscular junction formation.</p> </li> <li> <p>Appropriate causal associations: The model uses the correct causal connections between activities, utilizing \"directly positively regulates\" (RO:0002629) relationships where appropriate to show the signaling flow.</p> </li> <li> <p>Comprehensive molecular functions: The model includes the essential molecular functions like receptor ligand activity (Agrin), protein tyrosine kinase activity (MuSK), coreceptor activity (Lrp4), signaling adaptor activity (Dok7, Crk, Crkl), and G protein activity (Rac1).</p> </li> <li> <p>Proper cellular localization: The model correctly places components in their appropriate cellular compartments (e.g., extracellular space for Agrin, postsynaptic membrane for MuSK).</p> </li> <li> <p>Well-supported with evidence: Each assertion in the model is supported by experimental evidence, mostly from direct assays (ECO:0000314) and genetic interaction experiments (ECO:0000316), with appropriate citations to the primary literature.</p> </li> </ol>"},{"location":"reviews/64c3044100000089-Skeletal_muscle_acetylcholine_gated_channel_clustering_1__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Rapsn role clarity: The model includes Rapsn (receptor-associated protein of the synapse), which is known to be a critical adapter protein for acetylcholine receptor clustering, but does not connect it to the rest of the pathway via causal associations. Rapsn plays a critical role as a molecular adaptor in neuromuscular junction formation and should be causally connected.</p> </li> <li> <p>Farp1 connection details: The model includes Farp1 (FERM, ARH/RhoGEF and pleckstrin domain protein 1) as a guanyl-nucleotide exchange factor, but its connection to Rac1 could be more explicitly detailed with additional evidence, as it appears to be an important regulatory step in the pathway.</p> </li> <li> <p>Missing PTMs: The model could include more post-translational modifications known to be important in this pathway, particularly the tyrosine phosphorylation of Dok7 (on Y396 and Y406) which is described in the primary literature as being essential for recruiting Crk and Crkl.</p> </li> <li> <p>Additional biological processes: The model focuses on positive regulation of Rac protein signal transduction (GO:0035022) and skeletal muscle acetylcholine-gated channel clustering (GO:0071340), but could also include related processes such as neuromuscular junction development (GO:0007528) to provide a more comprehensive picture.</p> </li> </ol>"},{"location":"reviews/64c3044100000089-Skeletal_muscle_acetylcholine_gated_channel_clustering_1__Mouse_/#suggestions-for-model-enhancement","title":"Suggestions for Model Enhancement","text":"<ol> <li> <p>Add causal connection between Rapsn and downstream components: Include a causal relationship between Rapsn's protein-macromolecule adaptor activity and the appropriate downstream activity, as Rapsn is essential for clustering acetylcholine receptors.</p> </li> <li> <p>Expand Farp1 role: Clarify the role of Farp1 as a guanyl-nucleotide exchange factor for Rac1, perhaps with additional evidence from the literature.</p> </li> <li> <p>Add tyrosine phosphorylation annotations: Include annotations for the key tyrosine phosphorylation events, particularly for Dok7, which are crucial for recruiting Crk and Crkl.</p> </li> <li> <p>Include neuromuscular junction development: Add GO:0007528 (neuromuscular junction development) as an additional biological process to provide a more complete functional context.</p> </li> </ol>"},{"location":"reviews/64c3044100000089-Skeletal_muscle_acetylcholine_gated_channel_clustering_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of skeletal muscle acetylcholine-gated channel clustering. The model captures the essential components and relationships of the pathway with appropriate evidence. The suggested improvements would further enhance the model's comprehensiveness and connectivity.</p> <p>The model is consistent with GO-CAM best practices and accurately represents the biology of neuromuscular junction formation according to current literature. It provides a valuable resource for understanding the molecular mechanisms of skeletal muscle acetylcholine receptor clustering.</p>"},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/","title":"64c3044100000125 Positive regulation of acetylcholine receptor transcription  Mouse","text":"<p>Based on my review of the GO-CAM model and the supporting literature, I'll now provide a comprehensive review of the model.</p>"},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/#review-of-go-cam-model-64c3044100000125","title":"Review of GO-CAM Model: 64c3044100000125","text":""},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/#model-overview","title":"Model Overview","text":"<p>The model titled \"Positive regulation of acetylcholine receptor transcription (Mouse)\" (https://bioregistry.io/go.model:64c3044100000125) describes a signaling pathway in mouse muscle cells where Neuregulin-1 (NRG1) stimulates the transcription of acetylcholine receptor (AChR) genes through a MAP kinase cascade, ultimately leading to GABPA-mediated transcriptional activation. This pathway is important for neuromuscular junction development and synaptic function.</p>"},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Strong Evidential Support: The model is well-supported by multiple research papers (e.g., PMID:11318655, PMID:8702681) that provide experimental evidence for the pathway connections. The citations are used appropriately for each connection in the model.</p> </li> <li> <p>Correct Use of Molecular Functions: The molecular functions assigned to each gene product (e.g., receptor ligand activity for NRG1, protein tyrosine kinase activity for ErbB2/3, etc.) are appropriate based on the scientific literature.</p> </li> <li> <p>Clear Pathway Flow: The model presents a coherent signaling cascade from NRG1 binding to receptors through MAP kinase activation to transcriptional activation of AChR genes, which aligns with established literature.</p> </li> <li> <p>Appropriate Causal Connections: The model correctly uses the RO:0002629 (\"directly positively regulates\") predicate for causal relationships between activities in the pathway.</p> </li> </ol>"},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Evidence for Some Causal Associations: Some causal connections (between RAF1 and MAP2K1/MAP2K4) lack explicit evidence annotations. All causal associations should include supporting evidence.</p> </li> <li> <p>Cellular Component Annotations: While some activities in the model have appropriate cellular component annotations (e.g., postsynaptic membrane for receptor activities), some intermediate steps in the pathway would benefit from more specific cellular localization.</p> </li> <li> <p>Model Completeness: The model could potentially benefit from including:</p> </li> <li>The downstream effects of CHRNE (acetylcholine receptor subunit epsilon) activation</li> <li>A more explicit representation of how JNK cascade activation leads to MAPK8 activity</li> </ol>"},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the current scientific understanding of NRG1-induced AChR transcription as described in the primary literature. Key highlights of the pathway include:</p> <ol> <li> <p>NRG1 Signaling Initiation: The model correctly shows NRG1 (Mmus) activating neuregulin receptor activity of ErbB3, which occurs in the extracellular space.</p> </li> <li> <p>Receptor Tyrosine Kinase Activation: The model shows ErbB2 tyrosine kinase activation downstream of ErbB3, which is consistent with the literature showing ErbB2/ErbB3 heterodimerization.</p> </li> <li> <p>MAPK Cascade: The model accurately depicts the three-tier kinase cascade (RAF1 \u2192 MAP2K1/MAP2K4 \u2192 MAPK8) that is activated following receptor stimulation.</p> </li> <li> <p>Transcription Factor Activation: The model correctly shows MAPK8-mediated activation of GABPA, which then activates transcription of the acetylcholine receptor gene (CHRNE), as supported by PMID:11318655, which demonstrated that NRG1-induced phosphorylation of GABPA at threonine 280 contributes to AChR gene transcription.</p> </li> </ol>"},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<p>The model generally follows GO-CAM best practices, particularly:</p> <ol> <li> <p>Activity Connections: Activities are connected using appropriate predicates that reflect the biological relationships.</p> </li> <li> <p>Evidence Documentation: Most activities and connections are supported by appropriate evidence codes and literature references.</p> </li> <li> <p>Complex Representation: The model appropriately represents protein complexes by focusing on the specific activities of individual subunits rather than using complex terms, which is consistent with GO-CAM best practices.</p> </li> </ol>"},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Add evidence annotations to the causal associations between RAF1 (MGI:97847) and MAP2K1/MAP2K4, preferably from the cited literature.</p> </li> <li> <p>Consider adding cellular component annotations for the MAP kinase cascade components to better represent their subcellular localization.</p> </li> <li> <p>Consider adding information about the biological outcome of acetylcholine receptor activity in the context of neuromuscular junction function.</p> </li> </ol>"},{"location":"reviews/64c3044100000125-Positive_regulation_of_acetylcholine_receptor_transcription__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model presents a scientifically accurate representation of the NRG1-induced signaling pathway leading to acetylcholine receptor transcription in mouse muscle cells. The model is well-supported by experimental evidence and follows GO-CAM best practices. With minor enhancements as suggested above, the model would provide an even more comprehensive representation of this important signaling pathway.</p>"},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/","title":"64c3044100001787 Inhibition of cGAS STING signaling in the nucleus by BANF1  Human","text":"<p>Based on the information retrieved, I'll now conduct a thorough review of the GO-CAM model with ID \"64c3044100001787\" titled \"Inhibition of cGAS-STING signaling in the nucleus by BANF1 (Human)\".</p>"},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#go-cam-model-review-inhibition-of-cgas-sting-signaling-in-the-nucleus-by-banf1-human","title":"GO-CAM Model Review: \"Inhibition of cGAS-STING signaling in the nucleus by BANF1 (Human)\"","text":""},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#model-id-gomodel64c3044100001787","title":"Model ID: gomodel:64c3044100001787","text":""},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model describes the inhibition of cGAS-STING signaling in the nucleus by the BANF1 protein in humans. The model focuses on a molecular mechanism where BANF1 restricts cGAS activity on nuclear DNA to prevent inappropriate innate immune activation, which could lead to autoimmunity. The pathway involves several key proteins:</p> <ul> <li>BANF1 (Barrier-to-autointegration factor)</li> <li>CGAS (Cyclic GMP-AMP synthase)</li> <li>STING1 (Stimulator of interferon genes protein)</li> </ul>"},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#key-activities-and-connections-in-the-model","title":"Key Activities and Connections in the Model","text":"<p>The model consists of several molecular activities connected by causal relationships:</p> <ol> <li>BANF1 (O75531) binds double-stranded DNA in the nucleus</li> <li>BANF1 directly positively regulates CGAS (Q8N884) inhibition</li> <li>CGAS binds double-stranded DNA in the nucleus and produces cGAMP</li> <li>CGAS provides input for condensate formation which contributes to STING1 activation</li> <li>STING1 (Q86WV6) binds cGAMP and transduces signals leading to interferon production</li> </ol>"},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#biological-context","title":"Biological Context","text":"<p>This model describes an important regulatory mechanism for innate immunity. The cGAS-STING pathway is a key sensor of cytosolic DNA that can trigger type I interferon responses. When nuclear DNA is exposed (e.g., during nuclear envelope breakdown), BANF1 prevents inappropriate activation of this pathway by outcompeting cGAS for binding to nuclear DNA.</p>"},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<ol> <li>Complex Annotation: </li> <li>The model correctly represents the individual activities of each protein rather than using complex IDs, since the specific activities of each protein are known.</li> <li> <p>This approach aligns with the complex annotation guidelines from \"How to annotate complexes in GO-CAM\".</p> </li> <li> <p>Regulatory Processes:</p> </li> <li>The model correctly uses the \"directly positively regulates\" relation (RO:0002629) to connect BANF1's DNA binding activity to CGAS inhibition.</li> <li> <p>This follows the guidelines in \"Regulation and Regulatory Processes in GO-CAM\" where the regulatory mechanism is known and has a specific effect.</p> </li> <li> <p>Location Specification:</p> </li> <li> <p>Each activity appropriately includes location information (nucleus, ER membrane) which is critical for understanding the spatial organization of this pathway.</p> </li> <li> <p>Evidence Attribution:</p> </li> <li>All activities are supported by appropriate experimental evidence from peer-reviewed literature.</li> </ol>"},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<ol> <li>BANF1 Function:</li> <li>The model correctly captures BANF1's role in binding to DNA (GO:0003690) in the nucleus and its inhibitory effect on cGAS.</li> <li> <p>This is consistent with the literature that describes BANF1 as outcompeting cGAS for DNA binding.</p> </li> <li> <p>cGAS Activities:</p> </li> <li>The model includes both cGAS's enzymatic activity (GO:0061501, 2',3'-cyclic GMP-AMP synthase activity) and its ability to form molecular condensates (GO:0140693).</li> <li> <p>These activities are accurately represented as occurring in the nucleus.</p> </li> <li> <p>STING1 Activities:</p> </li> <li>The model correctly depicts STING1's binding to cGAMP (GO:0061507) and signaling adaptor activity (GO:0035591) in the ER membrane.</li> <li> <p>The causal relationships between STING1 activities are biologically accurate.</p> </li> <li> <p>Causal Flow:</p> </li> <li>The flow of causal relationships in the model accurately represents the biological process:<ul> <li>BANF1 inhibits cGAS activity on nuclear DNA</li> <li>cGAS produces cGAMP and forms condensates</li> <li>STING1 binds cGAMP and activates downstream signaling</li> </ul> </li> </ol>"},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Temporal Aspects:</li> <li> <p>The model could potentially benefit from additional information about when this inhibition is most critical (e.g., during mitosis or in response to certain cellular stresses).</p> </li> <li> <p>Downstream Effects:</p> </li> <li> <p>While the model focuses on the core regulatory mechanism, it could be expanded to include downstream effects of STING1 activation, such as TBK1 and IRF3 activation leading to interferon production.</p> </li> <li> <p>Cross-talk with Other Pathways:</p> </li> <li>The model could be enhanced by including connections to other regulatory pathways that might influence this process.</li> </ol>"},{"location":"reviews/64c3044100001787-Inhibition_of_cGAS_STING_signaling_in_the_nucleus_by_BANF1__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Inhibition of cGAS-STING signaling in the nucleus by BANF1 (Human)\" is a well-constructed representation of this important regulatory mechanism. It adheres to GO-CAM best practices and accurately represents the biological process based on current scientific literature.</p> <p>The model highlights a critical regulatory mechanism that prevents inappropriate activation of innate immune responses by self-DNA, which is essential for maintaining immune homeostasis. The specific activities of BANF1, cGAS, and STING1 are represented with appropriate molecular functions, locations, and causal relationships.</p> <p>This model provides a valuable resource for understanding how cells distinguish between self and non-self DNA to properly regulate innate immune responses.</p>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/","title":"64d5781900000111 Activation of cGAS STING signaling following acetylation by KAT5  Human","text":"<p>Based on the information gathered, I can now provide a comprehensive review of the GO-CAM model gomodel:64d5781900000111.</p>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#review-of-go-cam-model-gomodel64d5781900000111","title":"Review of GO-CAM Model: gomodel:64d5781900000111","text":""},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#model-overview","title":"Model Overview","text":"<p>Model ID: 64d5781900000111 Title: Activation of cGAS-STING signaling following acetylation by KAT5 (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#summary-of-the-model-content","title":"Summary of the Model Content","text":"<p>This model represents the activation pathway of the cGAS-STING signaling cascade in humans, specifically focusing on how KAT5-mediated acetylation of cGAS enhances the innate immune response to DNA viruses. The model includes three main proteins:</p> <ol> <li>cGAS (UniProtKB:Q8N884) - Cyclic GMP-AMP synthase, the cytosolic DNA sensor</li> <li>KAT5 (UniProtKB:Q92993-4) - Histone acetyltransferase, which acetylates cGAS</li> <li>CGAS-STING pathway (GO:0140896)</li> </ol> <p>The model includes the following molecular activities and causal relationships: - KAT5 has peptide-lysine-N-acetyltransferase activity (GO:0061733) - KAT5 acetylates cGAS, which directly positively regulates cGAS DNA binding - cGAS has double-stranded DNA binding activity (GO:0003690) - cGAS DNA binding directly positively regulates cGAS's molecular condensate scaffold activity (GO:0140693) - cGAS has 2',3'-cyclic GMP-AMP synthase activity (GO:0061501)</p>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#review-findings","title":"Review Findings","text":""},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#structural-accuracy","title":"Structural Accuracy","text":"<p>The model correctly captures the key sequential elements of the cGAS activation pathway: 1. KAT5 acetylates cGAS 2. Acetylated cGAS binds to double-stranded DNA 3. DNA binding enhances cGAS's ability to act as a molecular condensate scaffold 4. cGAS produces 2',3'-cyclic GMP-AMP, activating the STING pathway</p>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by scientific evidence, with all activities backed by experimental evidence: - All assertions are supported by experimental evidence (ECO:0000314 - direct assay evidence used in manual assertion) - The model cites multiple peer-reviewed publications: PMID:32911482, PMID:32912999, PMID:31544964, PMID:32817552, PMID:30842659, PMID:30842662, and PMID:17360565 - The evidence aligns with current understanding of cGAS activation</p>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model is consistent with the current scientific understanding of cGAS activation as described in the cited literature. The cited papers provide strong evidence for:</p> <ol> <li>The acetylation of cGAS by KAT5 (PMID:32817552)</li> <li>The importance of DNA binding for cGAS activation (PMID:32911482, PMID:32912999)</li> <li>The formation of molecular condensates by cGAS upon DNA binding (PMID:32911482)</li> <li>The connection between these activities and the cGAS-STING signaling pathway (PMID:31544964)</li> </ol>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Causal relationships: The model properly uses RO:0002629 (directly positively regulates) to connect the activities in the causal chain.</p> </li> <li> <p>Cellular location: All activities correctly specify their cellular locations (nucleus - GO:0005634).</p> </li> <li> <p>Molecular activities: The model appropriately assigns molecular functions to each protein - peptide-lysine-N-acetyltransferase activity to KAT5, and double-stranded DNA binding, molecular condensate scaffold activity, and 2',3'-cyclic GMP-AMP synthase activity to cGAS.</p> </li> <li> <p>Part-of relations: Activities are correctly connected to the biological process \"cGAS/STING signaling pathway\" (GO:0140896) using part_of relations.</p> </li> </ol>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<p>While the model is accurate and well-constructed, there are a few areas that could be enhanced:</p> <ol> <li> <p>Specific acetylation sites: The model could be more specific about which lysine residues of cGAS are acetylated by KAT5. According to PMID:32817552, KAT5 acetylates specific lysine residues in the N-terminus of cGAS (K47, K56, K62, and K83). Adding this information would increase the model's precision.</p> </li> <li> <p>Molecular mechanism details: The model could potentially include additional details about how acetylation enhances DNA binding, such as by explaining that acetylation of N-terminal lysines increases the DNA binding affinity of cGAS.</p> </li> <li> <p>Downstream effects: While the model shows the activation of cGAS's 2',3'-cyclic GMP-AMP synthase activity, it doesn't show the production of cGAMP and its effects on STING. Including these downstream steps would make the model more complete.</p> </li> <li> <p>Nuclear localization vs. cytosolic activity: Recent literature suggests that cGAS can be found in both the nucleus (bound to nucleosomes, which inhibits its activity) and the cytosol (where it's activated by foreign DNA). The model shows all activities occurring in the nucleus, but it might be more accurate to indicate that while cGAS is found in the nucleus, its actual DNA-sensing activity against viral DNA typically occurs in the cytosol.</p> </li> </ol>"},{"location":"reviews/64d5781900000111-Activation_of_cGAS_STING_signaling_following_acetylation_by_KAT5__Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 64d5781900000111 is a scientifically accurate and well-constructed representation of the KAT5-mediated activation of cGAS in the cGAS-STING signaling pathway. The model appropriately uses GO terms and relations to capture the causal relationships between molecular activities, and is well-supported by experimental evidence from peer-reviewed publications.</p> <p>The model correctly captures how KAT5 acetylates cGAS, which enhances cGAS's ability to bind double-stranded DNA, form molecular condensates, and synthesize 2',3'-cyclic GMP-AMP to activate the STING pathway. This pathway is crucial for innate immune responses to DNA viruses and cytosolic self-DNA.</p> <p>With a few minor enhancements to include more specific details about acetylation sites and subcellular location of activities, this model would provide an even more comprehensive representation of this important signaling pathway.</p>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/","title":"64d5781900000443 Inhibition of cGAS STING signaling in the cytosol by TREX1  Human","text":"<p>Now I'll analyze the GO-CAM model and provide my review.</p>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#review-of-go-cam-model-gomodel64d5781900000443","title":"Review of GO-CAM Model: gomodel:64d5781900000443","text":""},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Inhibition of cGAS-STING signaling in the cytosol by TREX1 (Human) Taxon: Human (NCBITaxon:9606) Status: Production Model ID: gomodel:64d5781900000443</p>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#model-summary","title":"Model Summary","text":"<p>This GO-CAM model represents the inhibition of cGAS-STING signaling in the cytosol by TREX1 in humans. The model focuses on how TREX1 (three-prime repair exonuclease 1) acts as a negative regulator of cGAS (cyclic GMP-AMP synthase) activity, preventing inappropriate activation of the innate immune response by self-DNA.</p>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#model-components","title":"Model Components","text":"<p>The model includes the following key proteins: 1. cGAS (UniProtKB:Q8N884) - A cytosolic DNA sensor that produces cGAMP upon detecting DNA 2. TREX1 (UniProtKB:Q9NSU2) - A 3'-5' DNA exonuclease that degrades cytosolic DNA</p>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#model-activities-and-processes","title":"Model Activities and Processes","text":"<p>The model captures the following activities and biological processes:</p> <ol> <li>cGAS molecular condensate scaffold activity (GO:0140693)</li> <li>Enabled by cGAS (UniProtKB:Q8N884)</li> <li>Occurs in the cytosol (GO:0005829)</li> <li>Part of cGAS/STING signaling pathway (GO:0140896)</li> <li> <p>Evidence: Direct assay evidence (ECO:0000314) from PMID:32912999 and PMID:32911482</p> </li> <li> <p>cGAS double-stranded DNA binding (GO:0003690)</p> </li> <li>Enabled by cGAS (UniProtKB:Q8N884)</li> <li>Occurs in the cytosol (GO:0005829)</li> <li>Part of cGAS/STING signaling pathway (GO:0140896)</li> <li> <p>Evidence: Direct assay evidence (ECO:0000314) from PMID:32911482 and PMID:32912999</p> </li> <li> <p>cGAS 2',3'-cyclic GMP-AMP synthase activity (GO:0061501)</p> </li> <li>Enabled by cGAS (UniProtKB:Q8N884)</li> <li>Occurs in the cytosol (GO:0005829)</li> <li>Part of cGAS/STING signaling pathway (GO:0140896)</li> <li> <p>Evidence: Direct assay evidence (ECO:0000314) from PMID:32911482 and PMID:32912999</p> </li> <li> <p>TREX1 double-stranded DNA 3'-5' DNA exonuclease activity (GO:0008311)</p> </li> <li>Enabled by TREX1 (UniProtKB:Q9NSU2)</li> <li>Occurs in the endoplasmic reticulum membrane (GO:0005789)</li> <li>Part of negative regulation of cGAS/STING signaling pathway (GO:0160049)</li> <li>Evidence: Direct assay evidence (ECO:0000314) from PMID:33476576</li> </ol>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes the following causal relationships:</p> <ol> <li>TREX1 double-stranded DNA 3'-5' DNA exonuclease activity (RO:0012010) \u2192 cGAS double-stranded DNA binding</li> <li> <p>Evidence: Direct assay evidence (ECO:0000314) from PMID:33476576</p> </li> <li> <p>cGAS molecular condensate scaffold activity (RO:0002629) \u2192 cGAS 2',3'-cyclic GMP-AMP synthase activity</p> </li> <li> <p>Evidence: Direct assay evidence (ECO:0000314) from PMID:30842659 and PMID:30842662</p> </li> <li> <p>cGAS double-stranded DNA binding (RO:0002629) \u2192 cGAS molecular condensate scaffold activity</p> </li> <li>Evidence: Direct assay evidence (ECO:0000314) from PMID:32911482 and PMID:32912999</li> </ol>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#scientific-evaluation","title":"Scientific Evaluation","text":""},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of cGAS activation and its inhibition by TREX1:</p> <ol> <li> <p>cGAS Activation Mechanism: The model correctly shows that double-stranded DNA binding by cGAS leads to its molecular condensate scaffold activity, which then enables its enzymatic function to produce cGAMP. This is consistent with recent literature showing that cGAS undergoes phase separation upon DNA binding, which is crucial for its activation.</p> </li> <li> <p>TREX1 Inhibitory Role: The model correctly represents TREX1's role in degrading cytosolic DNA, which prevents cGAS from binding to DNA and becoming activated. This is consistent with research showing that TREX1 prevents inappropriate activation of the cGAS-STING pathway by self-DNA.</p> </li> <li> <p>Subcellular Locations: The model accurately represents the subcellular locations - cGAS activities in the cytosol and TREX1 activity at the endoplasmic reticulum membrane.</p> </li> </ol>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li> <p>Molecular Activities: Each protein is appropriately annotated with its specific molecular function.</p> </li> <li> <p>Causal Connections: The causal relationships between molecular activities are represented using appropriate relationship types (RO:0002629 for 'directly positively regulates' and RO:0012010 for causal relationship from TREX1 to cGAS).</p> </li> <li> <p>Evidence: All annotations are supported by appropriate evidence codes and literature references.</p> </li> </ol>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well constructed, I've identified a few potential areas for improvement:</p> <ol> <li> <p>TREX1 Mechanism Clarification: The connection between TREX1 and cGAS DNA binding uses RO:0012010, which isn't one of the standard causal relationship predicates mentioned in your guidelines (RO:0002413, RO:0002629, RO:0002630, RO:0002304, RO:0002305). A more standard predicate like RO:0002630 (directly negatively regulates) might be more appropriate to represent TREX1's inhibitory effect on cGAS DNA binding.</p> </li> <li> <p>Molecular Complexes: The model represents individual proteins rather than complexes. This is appropriate in this case since each protein's distinct activity is known, but it might be worth clarifying if TREX1 functions as a dimer or if other components are involved in its regulation of cGAS.</p> </li> <li> <p>Biological Context: The model could potentially be expanded to include additional context, such as the downstream consequences of cGAMP production (activation of STING) and the resulting immune response.</p> </li> <li> <p>Feedback Regulation: The model could potentially be enhanced by including any known feedback mechanisms regulating either cGAS or TREX1 activity.</p> </li> </ol>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#literature-support","title":"Literature Support","text":"<p>The model is well-supported by recent literature:</p> <ol> <li> <p>The papers cited (PMID:32911482, PMID:32912999) provide strong structural evidence for how cGAS binds to DNA and how this binding is regulated.</p> </li> <li> <p>The references support the key biological assertions made in the model about the relationships between DNA binding, phase separation (molecular condensate scaffold activity), and enzymatic function of cGAS.</p> </li> <li> <p>The inhibitory role of TREX1 is supported by the cited literature, though I couldn't access the full text of PMID:33476576 to verify all details.</p> </li> </ol>"},{"location":"reviews/64d5781900000443-Inhibition_of_cGAS_STING_signaling_in_the_cytosol_by_TREX1__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:64d5781900000443) provides an accurate and well-structured representation of the inhibition of cGAS-STING signaling by TREX1 in human cells. The model effectively captures the key molecular activities and causal relationships in this pathway, with strong supporting evidence from the literature.</p> <p>The model could be slightly improved by clarifying the causal relationship predicate used for TREX1's effect on cGAS, and potentially expanded to include additional context about downstream signaling and feedback regulation. However, these are minor suggestions for an already well-constructed model that adheres to GO-CAM best practices and accurately represents current scientific knowledge.</p>"},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/","title":"64d5781900000615 Activation of canonical mTORC1 following glycosylation of RPTOR by OGT in response to glucose sufficiency  Human","text":"<p>Based on my review of the GO-CAM model and the supporting information, I'll now provide a comprehensive review of model gomodel:64d5781900000615, focused on its quality, biological accuracy, and adherence to GO-CAM standards.</p>"},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/#review-of-go-cam-model-64d5781900000615","title":"Review of GO-CAM model: 64d5781900000615","text":""},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/#httpsbioregistryiogomodel64d5781900000615","title":"https://bioregistry.io/go.model:64d5781900000615","text":""},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/#title-and-overall-description","title":"Title and Overall Description","text":"<p>The model titled \"Activation of canonical mTORC1 following glycosylation of RPTOR by OGT in response to glucose sufficiency (Human)\" represents a molecular mechanism of mTORC1 (mammalian Target of Rapamycin Complex 1) activation through glycosylation of the RPTOR component by OGT (O-GlcNAc transferase) in response to glucose. This signaling pathway is important for cellular growth, metabolism regulation, and protein synthesis in humans.</p>"},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/#model-accuracy-and-biological-content","title":"Model Accuracy and Biological Content","text":"<p>Overall, this GO-CAM model has been constructed with detailed and accurate biological information. It correctly represents:</p> <ol> <li> <p>The central role of RPTOR (Raptor) glycosylation in mTORC1 activation - The model correctly captures how O-GlcNAcylation of RPTOR by OGT at Thr-700 (as shown in PMID:37541260) facilitates interaction with Rag GTPases and promotes translocation to lysosomes.</p> </li> <li> <p>The Rag GTPase involvement - The model accurately represents RRAGA (RagA) and RRAGC (RagC) roles in regulating mTORC1 localization to lysosomes following glucose signaling.</p> </li> <li> <p>The activation of MTOR kinase activity - Following proper localization, the model correctly shows how RHEB activates MTOR's protein serine/threonine kinase activity (GO:0004674), which then phosphorylates downstream targets.</p> </li> <li> <p>Downstream effectors - The model includes the key mTORC1 substrates including EIF4EBP1 and ribosomal protein S6 kinases (RPS6KB1 and RPS6KB2), linking mTORC1 to translational control.</p> </li> </ol>"},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<p>The model generally follows GO-CAM best practices with a few points to note:</p> <ol> <li> <p>Causal relationships - The model appropriately uses causal predicates (particularly RO:0002629 \"directly positively regulates\") to connect activities in a biologically meaningful way.</p> </li> <li> <p>Subcellular locations - Correct use of cellular component terms for the lysosomal membrane (GO:0005765) and cytosol (GO:0005829) reflecting the importance of mTORC1 translocation from cytosol to lysosome for activation.</p> </li> <li> <p>Complex representation - The model follows the guidelines in \"How to annotate complexes in GO-CAM\" by correctly representing individual protein components of mTORC1 with their specific activities rather than using a complex term, as the activities of specific subunits (e.g., RPTOR and MTOR) are known.</p> </li> <li> <p>Evidence codes and references - Each activity and causal relationship is properly supported with evidence codes (ECO:0000314 - direct assay evidence) and PMID citations, which I've verified contain the relevant information.</p> </li> </ol>"},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/#positive-aspects","title":"Positive Aspects","text":"<ol> <li> <p>The model accurately represents the recent finding that OGT-mediated O-GlcNAcylation of RPTOR at Thr-700 is a key mechanism for translating glucose signals to mTORC1 (PMID:37541260).</p> </li> <li> <p>It includes not just the core pathway but also the downstream effects on translational machinery, providing a more complete biological story.</p> </li> <li> <p>Evidence codes are consistently and appropriately applied throughout the model.</p> </li> <li> <p>The model properly represents the subcellular localization changes that are crucial for mTORC1 activation.</p> </li> </ol>"},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/#minor-issuessuggestions-for-improvement","title":"Minor Issues/Suggestions for Improvement","text":"<ol> <li> <p>Glucose sensing mechanism - While the model shows OGT responding to glucose stimulus (GO:0071333), it might be valuable to include more detail on how glucose levels are sensed upstream of OGT.</p> </li> <li> <p>AMPK regulation - The model doesn't include the counteracting role of AMPK, which phosphorylates RPTOR at Ser-722 and Ser-792 to inhibit O-GlcNAcylation during glucose starvation (as mentioned in PMID:37541260). Including this would provide a more complete picture of the bidirectional regulation.</p> </li> <li> <p>mTORC1 dimerization - Recent structural studies (PMID:29236692) indicate that mTORC1 functions as a dimer, and RHEB binding appears to be cooperative. This aspect of mTORC1 regulation could be represented in the model.</p> </li> </ol>"},{"location":"reviews/64d5781900000615-Activation_of_canonical_mTORC1_following_glycosylation_of_RPTOR_by_OGT_in_response_to_glucose_sufficiency__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a high-quality representation of current knowledge about mTORC1 activation via RPTOR glycosylation by OGT in response to glucose. It accurately captures the molecular mechanisms described in the literature, particularly the recent findings from PMID:37541260, and follows GO-CAM curation best practices.</p> <p>The model successfully connects glucose sensing to translational regulation through a well-documented series of causal events, making it useful for researchers interested in nutrient sensing, mTOR signaling, and translational control. The minor suggestions noted above could further enhance what is already a comprehensive and accurate model.</p>"},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/","title":"64d5781900002033 Insulin mediated activation of the ARF6 RAC1 axis in neurite outgrowth  Human","text":"<p>Based on the information gathered from the model and the various protein entries, let me review the GO-CAM model.</p>"},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#go-cam-model-review-insulin-mediated-activation-of-the-arf6-rac1-axis-in-neurite-outgrowth-human","title":"GO-CAM Model Review: Insulin-mediated activation of the ARF6-RAC1 axis in neurite outgrowth (Human)","text":""},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#model-id-gomodel64d5781900002033","title":"Model ID: gomodel:64d5781900002033","text":""},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#overview","title":"Overview","text":"<p>This model represents the pathway by which insulin stimulates neurite outgrowth through the activation of ARF6-RAC1 signaling, mediated by the neuronal adapter protein FE65 (APBB1) and atypical protein kinase C iota (PRKCI). The model consists of a chain of molecular activities that forms a signaling cascade from insulin hormone activity in the extracellular space to G protein activity in the cytosol, ultimately contributing to positive regulation of neuron projection development.</p>"},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#components","title":"Components","text":"<p>The model includes the following key proteins: 1. Insulin (INS) - UniProtKB:P01308 2. Protein kinase C iota (PRKCI) - UniProtKB:P41743 3. Amyloid beta precursor protein binding family B member 1 (APBB1/FE65) - UniProtKB:O00213 4. ADP-ribosylation factor 6 (ARF6) - UniProtKB:P62330</p>"},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#molecular-function-activities-and-causal-relationships","title":"Molecular Function Activities and Causal Relationships","text":"<ol> <li> <p>Insulin (INS) performs hormone activity (GO:0005179) in the extracellular space (GO:0005615), which activates (RO:0002407) the protein serine/threonine kinase activity of PRKCI.</p> </li> <li> <p>Protein kinase C iota (PRKCI) performs protein serine/threonine kinase activity (GO:0004674) in the cytosol (GO:0005829), which directly positively regulates (RO:0002629) the molecular adaptor activity of APBB1.</p> </li> <li> <p>APBB1/FE65 performs molecular adaptor activity (GO:0060090) in the cytoplasm (GO:0005737), which directly positively regulates (RO:0002629) the G protein activity of ARF6.</p> </li> <li> <p>ARF6 performs G protein activity (GO:0003925) in the cytosol (GO:0005829).</p> </li> </ol> <p>All activities are part of the biological process of positive regulation of neuron projection development (GO:0010976).</p>"},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#review","title":"Review","text":""},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#strength-and-accuracy","title":"Strength and Accuracy","text":"<ol> <li> <p>Biological accuracy: The model aligns well with the latest research on insulin's role in neurite outgrowth. The key paper (PMID:36250347) describes how insulin stimulates atypical protein kinase C (PRKCI)-mediated phosphorylation of the neuronal adaptor FE65 to potentiate neurite outgrowth by activating ARF6-Rac1 signaling, which is accurately captured in this model.</p> </li> <li> <p>Evidence support: Each component and relationship is supported by experimental evidence from appropriate publications (e.g., PMID:36250347, PMID:14986111, PMID:8226978, PMID:18468999).</p> </li> <li> <p>Annotation quality: The molecular functions are appropriately assigned to each protein based on their documented activities.</p> </li> </ol>"},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing component: The model omits RAC1, which is mentioned in the title and is a critical downstream component in this pathway. According to PMID:36250347, ARF6 activates RAC1, which then contributes to neurite outgrowth. I recommend adding RAC1 and its GTPase activity as a downstream element activated by ARF6.</p> </li> <li> <p>Causal relationship redundancy: There appears to be a redundant causal association between PRKCI and APBB1. The model shows two identical RO:0002629 (directly positively regulates) relationships from PRKCI to APBB1, one of which lacks evidence. This duplicate should be removed.</p> </li> <li> <p>Cellular component precision: While ARF6 is annotated to the cytosol (GO:0005829), the literature (PMID:14978216, PMID:32103017) indicates its activity also occurs at the plasma membrane and in cell projections when involved in neurite outgrowth. Consider adding more specific cellular locations for ARF6 activity.</p> </li> <li> <p>Molecular mechanism details: The specific phosphorylation of APBB1 at Serine 459 by PRKCI is an important mechanistic detail from PMID:36250347 that could be more clearly represented in the model.</p> </li> <li> <p>Pathway completeness: The model could benefit from including the activation of PRKCI by insulin signaling intermediates, as this is not a direct interaction. Consider adding the insulin receptor and relevant signaling components between insulin and PRKCI.</p> </li> </ol>"},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li> <p>The model follows the GO-CAM guidelines for representing a causal chain of molecular activities.</p> </li> <li> <p>The use of \"part_of\" to connect all activities to the biological process (GO:0010976) is appropriate.</p> </li> <li> <p>The \"occurs_in\" relationships correctly specify cellular components for each activity.</p> </li> <li> <p>The causal relationships use appropriate relation ontology terms (RO:0002407 and RO:0002629).</p> </li> <li> <p>The representation of complexes is not applicable in this model since no complexes are involved in the pathway as currently modeled.</p> </li> </ol>"},{"location":"reviews/64d5781900002033-Insulin_mediated_activation_of_the_ARF6_RAC1_axis_in_neurite_outgrowth__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good representation of insulin-mediated activation of ARF6 in neurite outgrowth. It captures the core signaling cascade from insulin to ARF6 through PRKCI and APBB1, with appropriate molecular functions, cellular locations, and causal relationships. To improve the model's completeness and accuracy, I recommend adding RAC1 as a downstream component, removing the redundant causal relationship, specifying the phosphorylation of APBB1 at Ser459, and considering more precise cellular locations for ARF6. These changes would make the model more informative and better aligned with the current understanding of this signaling pathway.</p>"},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/","title":"64e7eefa00000854 Tumor necrosis factor mediated signaling pathway 1  Mouse","text":"<p>Now that I've reviewed the model and guidelines, I'll provide a comprehensive review of the GO-CAM model gomodel:64e7eefa00000854 - \"Tumor necrosis factor-mediated signaling pathway 1 (Mouse)\".</p>"},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/#go-cam-model-review-tumor-necrosis-factor-mediated-signaling-pathway-1-mouse","title":"GO-CAM Model Review: Tumor necrosis factor-mediated signaling pathway 1 (Mouse)","text":""},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/#model-summary","title":"Model Summary:","text":"<p>This GO-CAM model (ID: gomodel:64e7eefa00000854) represents the tumor necrosis factor (TNF) signaling pathway in mouse. The model accurately portrays TNF-mediated signaling, starting with TNF ligand binding to its receptor, followed by recruitment of adaptor proteins, and culminating in the activation of the NF-\u03baB pathway. The model includes both the positive regulatory aspects of the pathway and negative regulation elements.</p>"},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Pathway Completeness: The model provides a comprehensive view of the TNF signaling pathway from receptor binding through downstream effectors.</p> </li> <li> <p>Evidential Support: Almost all interactions are backed by appropriate experimental evidence, primarily from research papers, with proper ECO codes for the type of evidence.</p> </li> <li> <p>Molecular Functions: The molecular functions assigned to proteins are appropriate (e.g., TNF has receptor ligand activity, TNFR1 has signaling receptor activity, TRADD has signaling adaptor activity).</p> </li> <li> <p>Appropriate Causal Relations: The model uses appropriate causal relation predicates between activities (e.g., \"directly positively regulates\", \"provides input for\").</p> </li> <li> <p>Proper Biological Context: Activities are correctly placed in the appropriate biological processes (GO:0043123 - positive regulation of canonical NF-kappaB signal transduction).</p> </li> </ol>"},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Missing Evidence: There's one causal association missing evidence:</li> <li> <p>The causal relation between Rnf31 (MGI:MGI:1934704) E3 ubiquitin ligase activity and Ripk1 (MGI:MGI:108212) signaling adaptor activity lacks evidence. Evidence should be added to support this interaction.</p> </li> <li> <p>Complexity Annotation:</p> </li> <li> <p>The NF-kappaB p50/p65 complex (GO:0035525) is appropriately represented as enabling DNA-binding transcription activator activity, consistent with the guidelines for complex annotation.</p> </li> <li> <p>E3 Ubiquitin Ligase Representation:</p> </li> <li>The LUBAC complex components are represented individually rather than as a complex, which is appropriate according to guidelines when the individual activities of each component are known.</li> <li> <p>Rbck1 (MGI:MGI:1344372) with ubiquitin ligase activator activity, Sharpin (MGI:MGI:1913331) with protein-macromolecule adaptor activity, and Rnf31 (MGI:MGI:1934704) with E3 ubiquitin ligase activity are all correctly annotated according to the E3 ubiquitin ligase guidelines.</p> </li> <li> <p>BP Context Consistency: </p> </li> <li>Most activities are part of \"positive regulation of canonical NF-kappaB signal transduction\" (GO:0043123), which is appropriate.</li> <li>However, some ubiquitination-related activities are correctly placed in \"protein polyubiquitination\" (GO:0000209), providing appropriate context for these activities.</li> <li> <p>Nfkbia (MGI:MGI:104741) is correctly placed in \"negative regulation of canonical NF-kappaB signal transduction\" (GO:0043124).</p> </li> <li> <p>Receptor Activity Annotation:</p> </li> <li>The TNF receptor (Tnfrsf1a) and ligand (Tnf) interactions follow the guidelines for protein ligand-activated signaling receptor annotation.</li> <li> <p>The relationship between ligand and receptor activity uses \"directly positively regulates\" as recommended.</p> </li> <li> <p>Signaling Adaptors Representation:</p> </li> <li>The model includes multiple signaling adaptors (TRADD, TRAF2, RIP1) which are correctly annotated with \"signaling adaptor activity\" (GO:0035591).</li> <li>The causal relationships between these adaptors follow appropriate chain of activation as described in literature.</li> </ol>"},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/#technical-review","title":"Technical Review:","text":"<p>According to GO-CAM guidelines: 1. Complex annotation: Correctly implemented for the NF-\u03baB complex. 2. Molecular adaptors: Properly annotated with appropriate inputs and causal relations. 3. E3 ubiquitin ligases: Correctly represented with proper functions and relations. 4. Signaling receptor activity: TNF and TNFR1 interaction follows prescribed guidelines. 5. Causal relations: Uses appropriate causal relations for regulatory relationships.</p>"},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/#biological-content-consistency","title":"Biological Content Consistency:","text":"<p>The model accurately represents the TNF signaling pathway as described in the literature. The referenced articles (especially PMID:18641653) support the role of TRADD as a critical adaptor in TNF signaling that orchestrates the formation of TNFR1 signaling complexes, which is reflected in the model.</p> <p>The inclusion of negative regulation by Nfkbia (I\u03baB\u03b1) provides appropriate regulatory balance to the pathway.</p>"},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement:","text":"<ol> <li> <p>Add evidence for the missing causal relation between Rnf31 and Ripk1.</p> </li> <li> <p>Consider adding more detailed information about the NF-\u03baB-mediated transcriptional response, which could extend the model beyond signaling activation.</p> </li> <li> <p>The current model focuses on the canonical NF-\u03baB activation pathway. Consider adding elements of the non-canonical pathway if relevant.</p> </li> </ol>"},{"location":"reviews/64e7eefa00000854-Tumor_necrosis_factor_mediated_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion:","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the TNF signaling pathway leading to NF-\u03baB activation in mouse. It follows GO-CAM best practices for annotation of complexes, signaling receptors, E3 ubiquitin ligases, and adaptors. The model is parsimonious and provides a clear representation of the pathway that would be understandable to researchers familiar with signaling pathways.</p> <p>The model is suitable for release with only minor updates recommended, primarily adding the missing evidence for one causal relation.</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/","title":"64e7eefa00001233 Extrinsic apoptotic signaling pathway via death domain receptors 1 Mouse","text":"<p>Based on my review, I'll now provide a detailed assessment of GO-CAM model gomodel:64e7eefa00001233, which represents \"Extrinsic apoptotic signaling pathway via death domain receptors 1 (Mouse)\".</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#review-of-go-cam-model-gomodel64e7eefa00001233","title":"Review of GO-CAM Model: gomodel:64e7eefa00001233","text":""},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the extrinsic apoptotic signaling pathway via death domain receptors in mouse, focusing on the TNF (Tumor Necrosis Factor) pathway leading to apoptosis. The model captures the causal chain from TNF ligand binding to its receptor through adapter proteins to caspase activation.</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Appropriate pathway representation: The model correctly captures the key components of the TNF-mediated extrinsic apoptotic pathway, from ligand-receptor binding to downstream signaling events.</p> </li> <li> <p>Cellular locations: The model appropriately assigns cellular locations to the molecular functions, with TNF and its receptor at the plasma membrane (GO:0005886) and the adaptor proteins and caspases in the cytosol (GO:0005829).</p> </li> <li> <p>Proper causal relationships: The model uses appropriate causal relationships (RO:0002413 \"provides input for\" and RO:0002629 \"directly positively regulates\") to connect the activities in the pathway.</p> </li> <li> <p>Evidence support: Most activities and causal links are supported by experimental evidence with appropriate ECO codes and PMIDs.</p> </li> </ol>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":""},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#1-tnf-receptor-activity-annotation","title":"1. TNF Receptor Activity Annotation","text":"<p>Issue: The TNF receptor (Tnfrsf1a) is correctly annotated with \"tumor necrosis factor receptor activity\" (GO:0005031) and is shown as regulated by TNF through the \"directly positively regulates\" relationship. However, the molecular function has no input specified.</p> <p>Recommendation: According to the signaling receptor activity guidelines, the receptor should have its downstream effector (TRADD in this case) as input. Modify the model to add \"has input\" relationship between the receptor activity and TRADD.</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#2-missing-biological-process-for-tnf","title":"2. Missing Biological Process for TNF","text":"<p>Issue: While TNF is annotated as part of \"positive regulation of execution phase of apoptosis\" (GO:1900119), it would be more accurate to also associate it with a more specific term related to TNF signaling.</p> <p>Recommendation: Consider annotating TNF to \"tumor necrosis factor-mediated signaling pathway\" (GO:0033209) or a more specific child term to better reflect its primary role in the pathway.</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#3-tradd-and-fadd-annotations","title":"3. TRADD and FADD Annotations","text":"<p>Issue: Both TRADD and FADD are annotated with the generic \"signaling adaptor activity\" (GO:0035591), which is correct but could be more specific.</p> <p>Recommendation: Consider using a more specific child term like \"death domain binding\" (GO:0070513) for both proteins to better reflect their specific role in death receptor signaling. This would enhance the specificity of the model.</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#4-ripk1-protein-kinase-activity","title":"4. RIPK1 Protein Kinase Activity","text":"<p>Issue: RIPK1 is correctly annotated with \"protein kinase activity\" (GO:0004672), but this is a broad term that doesn't capture its specific role.</p> <p>Recommendation: Consider using the more specific term \"protein serine/threonine kinase activity\" (GO:0004674) or even \"death domain containing receptor interacting serine/threonine kinase activity\" (GO:0097110) if appropriate.</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#5-pathway-context","title":"5. Pathway Context","text":"<p>Issue: The overall biological process for most activities is annotated as \"positive regulation of execution phase of apoptosis\" (GO:1900119), but the model actually represents the extrinsic apoptotic signaling pathway.</p> <p>Recommendation: Consider annotating the activities to \"extrinsic apoptotic signaling pathway\" (GO:0097191) or, more specifically, \"extrinsic apoptotic signaling pathway via death domain receptors\" (GO:0008625), which would better reflect the primary biological process being modeled.</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#6-complex-annotation-issue","title":"6. Complex Annotation Issue","text":"<p>Issue: According to the \"How to annotate complexes in GO-CAM\" guidelines, when the subunit carrying the molecular activity is known (as in this case), the complex is not described and the activity is represented by the specific protein carrying it. The model follows this guideline correctly, but it doesn't capture that TRADD, FADD, RIPK1, and Caspase-8 can form a complex called the death-inducing signaling complex (DISC).</p> <p>Recommendation: While the current representation is valid, consider adding a note or comment indicating that these proteins form the DISC complex in this context. This would provide additional valuable information without changing the model structure.</p>"},{"location":"reviews/64e7eefa00001233-Extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors_1_Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, model gomodel:64e7eefa00001233 is a well-structured representation of the TNF-mediated extrinsic apoptotic pathway in mouse. It correctly captures the key molecular functions, their cellular locations, and the causal relationships between them. The issues identified are mostly related to the specificity of the GO terms used and the context of the pathway, rather than fundamental errors in the model structure. </p> <p>The model effectively shows how TNF binding to its receptor initiates a signaling cascade through TRADD, RIPK1, and FADD to activate Caspase-8, ultimately leading to the execution phase of apoptosis. With the suggested improvements, the model would provide an even more precise and informative representation of this important biological pathway.</p>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/","title":"64e7eefa00001258 Inhibition of ALKBH5 RNA demethylase activity by sumoylation in response to reactive oxygen species  Human","text":"<p>Now I have sufficient information to review the GO-CAM model. Let me analyze the model in detail based on the information provided.</p>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#review-of-go-cam-model-gomodel64e7eefa00001258","title":"Review of GO-CAM Model: gomodel:64e7eefa00001258","text":""},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#model-title","title":"Model Title","text":"<p>Inhibition of ALKBH5 RNA demethylase activity by sumoylation in response to reactive oxygen species (Human)</p>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#overview","title":"Overview","text":"<p>This model represents a molecular pathway showing how reactive oxygen species (ROS) lead to the inhibition of ALKBH5 RNA demethylase activity through a SUMOylation mechanism, which impacts RNA metabolism.</p>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#model-components","title":"Model Components","text":"<p>The model consists of five molecular activities: 1. MAPK8/JNK1 protein serine/threonine kinase activity (GO:0004674) 2. MAPK9/JNK2 protein serine/threonine kinase activity (GO:0004674) 3. PIAS4 SUMO ligase activity (GO:0061665) 4. SENP1 SUMO-specific endopeptidase activity (GO:0070139) 5. ALKBH5 mRNA N6-methyladenosine dioxygenase activity (GO:1990931)</p>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>MAPK8/JNK1 and MAPK9/JNK2 kinases both provide input for (RO:0002413) PIAS4 SUMO ligase activity</li> <li>PIAS4 SUMO ligase activity directly negatively regulates (RO:0002630) ALKBH5 mRNA N6-methyladenosine dioxygenase activity</li> <li>SENP1 SUMO-specific endopeptidase activity directly positively regulates (RO:0002629) ALKBH5 mRNA N6-methyladenosine dioxygenase activity</li> </ul>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#biological-context","title":"Biological Context","text":"<ul> <li>The MAPK8/JNK1 and MAPK9/JNK2 activities are part of cellular response to reactive oxygen species (GO:0034614)</li> <li>PIAS4 and SENP1 activities are part of regulation of mRNA stability (GO:0043488)</li> <li>ALKBH5 activity is part of mRNA destabilization (GO:0061157)</li> <li>ALKBH5 activity occurs in nuclear speck (GO:0016607)</li> </ul>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#scientific-support","title":"Scientific Support","text":"<p>The model is based primarily on evidence from PMID:34048572, which demonstrates that: 1. ROS activates MAPK8/JNK1 and MAPK9/JNK2 kinases 2. These kinases phosphorylate ALKBH5 at serine residues S87 and S325 3. Phosphorylation facilitates ALKBH5 SUMOylation by PIAS4 at lysine residues K86 and K321 4. SUMOylation inhibits ALKBH5's RNA demethylase activity by blocking its substrate accessibility 5. SENP1 can desumoylate ALKBH5, restoring its RNA demethylase activity</p> <p>There's also evidence from PMID:23177736 about ALKBH5's localization to nuclear speck.</p>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model accurately represents the key molecular players and their activities in the ROS-induced SUMOylation of ALKBH5.</li> <li>The causal relationships between activities are supported by experimental evidence.</li> <li>The biological processes and cellular component annotations are appropriate.</li> <li>The model correctly uses the \"provides input for\" and \"directly regulates\" relationships.</li> </ol>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#issues-to-address","title":"Issues to Address","text":"<ol> <li>Missing Components: The model doesn't include ERK signaling, which according to PMID:34048572 is upstream of JNK and essential for the phosphorylation of ALKBH5.</li> <li>Molecular Detail: The specific phosphorylation sites (S87 and S325) and SUMOylation sites (K86 and K321) on ALKBH5 are not represented in the model.</li> <li>Downstream Effects: The model doesn't include the consequences of ALKBH5 inhibition on m6A levels and subsequent effects on DNA damage repair genes (FAAP20, ATRX, and RFC2).</li> <li>Directness of Relationships: The relationship between the JNK kinases and PIAS4 might be more accurately represented as indirect, since JNK phosphorylates ALKBH5, not PIAS4 directly.</li> <li>Evidence Depth: The evidence for SENP1's role could be strengthened, as its interaction with ALKBH5 is mentioned but less extensively characterized in the paper compared to PIAS4.</li> </ol>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Add the ERK kinase activity upstream of JNK kinases to complete the signaling pathway.</li> <li>Consider adding UBC9 (SUMO E2 conjugation enzyme) as a mediator between JNK and PIAS4, as the paper shows that phosphorylation enhances ALKBH5's interaction with UBC9.</li> <li>Add the downstream effects of ALKBH5 inhibition on m6A levels and DNA damage repair genes as this is a significant biological outcome of the pathway.</li> <li>Adjust the relationship between JNK kinases and PIAS4 to more accurately reflect the indirect nature of the interaction.</li> <li>Consider annotating the specific sites of phosphorylation and SUMOylation using annotations or notes.</li> </ol>"},{"location":"reviews/64e7eefa00001258-Inhibition_of_ALKBH5_RNA_demethylase_activity_by_sumoylation_in_response_to_reactive_oxygen_species__Human_/#summary","title":"Summary","text":"<p>The GO-CAM model gomodel:64e7eefa00001258 provides a good representation of the inhibition of ALKBH5 RNA demethylase activity by SUMOylation in response to reactive oxygen species. The model accurately depicts the key molecular players and their causal relationships. However, it could be improved by adding upstream ERK signaling, more molecular details about the phosphorylation and SUMOylation sites, downstream effects on m6A levels and DNA repair genes, and by refining the directness of some relationships. Overall, the model is scientifically sound and supported by experimental evidence.</p>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/","title":"64e7eefa00001299 RBM33 binds N6 methyladenosine  m6A  containing mRNAs and promotes their demethylation by ALKBH5 RNA demethylase  Human","text":"<p>Based on the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model gomodel:64e7eefa00001299.</p>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#review-of-go-cam-model-gomodel64e7eefa00001299","title":"Review of GO-CAM Model: gomodel:64e7eefa00001299","text":""},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#model-summary","title":"Model Summary","text":"<p>Title: RBM33 binds N6-methyladenosine (m6A)-containing mRNAs and promotes their demethylation by ALKBH5 RNA demethylase (Human) Model ID: gomodel:64e7eefa00001299 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#overview-of-biological-process","title":"Overview of Biological Process","text":"<p>This model describes the mechanism by which RBM33 functions as an m6A reader protein that recruits ALKBH5 to N6-methyladenosine (m6A)-modified mRNAs and promotes their demethylation, affecting mRNA stability. The model also indicates that SENP1, a SUMO-specific protease, participates in this process by removing SUMO modifications from ALKBH5, which enhances its demethylase activity.</p>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#molecular-components-and-their-functions","title":"Molecular Components and Their Functions","text":"<ol> <li>RBM33 (UniProtKB:Q96EV2):</li> <li>Function: N6-methyladenosine-containing RNA reader activity (GO:1990247)</li> <li>Process: Regulation of mRNA stability (GO:0043488)</li> <li> <p>Role: Binds to m6A-modified mRNAs and recruits ALKBH5 to these targets</p> </li> <li> <p>ALKBH5 (UniProtKB:Q6P6C2):</p> </li> <li>Function: mRNA N6-methyladenosine dioxygenase activity (GO:1990931)</li> <li>Process: mRNA destabilization (GO:0061157)</li> <li>Location: Nuclear speck (GO:0016607)</li> <li> <p>Role: Enzymatically removes m6A modifications from mRNAs</p> </li> <li> <p>SENP1 (UniProtKB:Q9P0U3):</p> </li> <li>Function: SUMO-specific endopeptidase activity (GO:0070139)</li> <li>Process: Regulation of mRNA stability (GO:0043488)</li> <li>Role: Removes SUMO modifications from ALKBH5, enhancing its activity</li> </ol>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#causal-relations-in-the-model","title":"Causal Relations in the Model","text":"<p>The model describes two key causal relationships:</p> <ol> <li>RBM33 directly positively regulates (RO:0002629) ALKBH5's m6A demethylase activity</li> <li>RBM33 provides input for (RO:0002413) SENP1's desumoylase activity</li> <li>SENP1 directly positively regulates (RO:0002629) ALKBH5's m6A demethylase activity</li> </ol>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#evidence-sources","title":"Evidence Sources","text":"<p>The model is supported by evidence from the following primary research publications: - PMID:37257451 - Evidence for RBM33's role as an m6A reader and its regulation of ALKBH5 - PMID:34048572 - Evidence for ALKBH5 regulation by sumoylation and SENP1's role - PMID:23177736 - Evidence for ALKBH5's localization in nuclear speck</p>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#assessment-of-model-quality","title":"Assessment of Model Quality","text":""},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#strengths","title":"Strengths","text":"<ol> <li>Completeness: The model captures the essential components of the described pathway, including the key proteins (RBM33, ALKBH5, SENP1) and their functions.</li> <li>Evidence Support: All assertions are backed by published experimental evidence with appropriate citations and evidence codes.</li> <li>Connectivity: The causal connections between components are clearly defined using appropriate relationship predicates.</li> <li>Biological Accuracy: The model accurately represents the current understanding of m6A-mediated post-transcriptional regulation and is consistent with the literature.</li> </ol>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Cellular Context: While ALKBH5 is correctly annotated as occurring in nuclear speck (GO:0016607), the model could benefit from specifying the cellular locations of RBM33 and SENP1.</li> <li>Downstream Effects: The model could be expanded to show the downstream effects of m6A demethylation on specific target mRNAs and their biological consequences.</li> <li>Regulatory Context: The model does not capture potential upstream regulators of RBM33 function, which might provide additional context about when this pathway is activated.</li> </ol>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#comparison-with-related-models","title":"Comparison with Related Models","text":"<p>I reviewed a related model (gomodel:64e7eefa00001258 - \"Inhibition of ALKBH5 RNA demethylase activity by sumoylation in response to reactive oxygen species\") which provides complementary information about ALKBH5 regulation. That model shows:</p> <ol> <li>A parallel regulatory pathway where reactive oxygen species (ROS) activate MAPK8/9 kinases</li> <li>MAPK8/9 activate PIAS4, which then negatively regulates ALKBH5 through SUMOylation</li> <li>This results in decreased ALKBH5 activity</li> </ol> <p>The current model (gomodel:64e7eefa00001299) shows the reverse process, where SENP1 removes those SUMO modifications, enhancing ALKBH5 activity, and RBM33 serves as a reader that guides ALKBH5 to its target mRNAs.</p>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by: 1. Using appropriate relationship predicates for causal connections 2. Including cellular components for relevant activities 3. Annotating activities with the correct molecular function terms 4. Using proper evidence codes and references 5. Using cellular context and biological process annotations</p>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#biological-significance","title":"Biological Significance","text":"<p>This model represents an important post-transcriptional regulatory mechanism. N6-methyladenosine (m6A) is the most abundant internal modification in eukaryotic mRNAs and affects various aspects of RNA metabolism including stability, splicing, and translation. The model explains how RBM33 functions as a reader protein that recognizes m6A-modified RNAs and recruits ALKBH5 to remove these modifications, thereby affecting mRNA stability and potentially gene expression.</p> <p>The interaction between RBM33, SENP1, and ALKBH5 provides a nuanced mechanism for the selective demethylation of m6A-marked transcripts, which could be relevant in various biological contexts including cancer biology as suggested by the evidence papers.</p>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#suggestions-for-enhancement","title":"Suggestions for Enhancement","text":"<ol> <li>Consider including specific target mRNAs that are regulated by this pathway, if known.</li> <li>Add cellular localization information for RBM33 and SENP1 activities.</li> <li>Potentially expand the model to show the upstream regulators of RBM33 or factors that influence its expression or activity.</li> <li>If applicable, include information about how this pathway is dysregulated in specific disease contexts.</li> </ol>"},{"location":"reviews/64e7eefa00001299-RBM33_binds_N6_methyladenosine__m6A__containing_mRNAs_and_promotes_their_demethylation_by_ALKBH5_RNA_demethylase__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model effectively represents the molecular mechanism by which RBM33 binds m6A-containing mRNAs and promotes their demethylation by ALKBH5. The model is well-constructed, evidence-based, and consistent with GO-CAM best practices. It provides valuable insights into the regulation of m6A demethylation, an important mechanism for post-transcriptional gene regulation.</p>"},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/","title":"64e7eefa00001978 ALKBH5 is involved in paraspeckle assembly and is regulated by acetylation and deacetylation by KAT8 and HDAC7  respectively  Human","text":"<p>Now that I have all the necessary information, I'll review the GO-CAM model gomodel:64e7eefa00001978.</p>"},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#review-of-go-cam-model-gomodel64e7eefa00001978","title":"Review of GO-CAM Model: gomodel:64e7eefa00001978","text":""},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>Title: ALKBH5 is involved in paraspeckle assembly and is regulated by acetylation and deacetylation by KAT8 and HDAC7, respectively (Human).</p> <p>Taxon: NCBITaxon:9606 (Human)</p> <p>Status: Production</p> <p>This model represents how ALKBH5 (RNA demethylase) is involved in paraspeckle assembly through its phase separation properties, and how its activity is regulated through acetylation (by KAT8) and deacetylation (by HDAC7).</p>"},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#overall-assessment","title":"Overall Assessment","text":"<p>Overall, this is a well-constructed model that captures the key molecular interactions between ALKBH5, PSPC1, KAT8, and HDAC7 in the context of paraspeckle assembly. The model accurately represents recent scientific findings regarding ALKBH5's role in RNA m6A demethylation and how this activity is regulated by post-translational modifications (specifically acetylation at K235).</p>"},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#biological-content-evaluation","title":"Biological Content Evaluation","text":""},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#key-components-and-their-activities","title":"Key Components and Their Activities:","text":"<ol> <li>ALKBH5 (UniProtKB:Q6P6C2)</li> <li>Represented with molecular condensate scaffold activity (GO:0140693)</li> <li>RNA N6-methyladenosine dioxygenase activity (GO:1990931)</li> <li>Located in paraspeckles (GO:0042382)</li> <li> <p>Part of membraneless organelle assembly (GO:0140694)</p> </li> <li> <p>KAT8 (UniProtKB:Q9H7Z6)</p> </li> <li>Peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li>Part of regulation of mRNA processing (GO:0050684)</li> <li> <p>Positively regulates ALKBH5's activity</p> </li> <li> <p>HDAC7 (UniProtKB:Q8WUI4)</p> </li> <li>Protein lysine deacetylase activity (GO:0033558)</li> <li>Part of regulation of mRNA processing (GO:0050684)</li> <li> <p>Negatively regulates ALKBH5's activity</p> </li> <li> <p>PSPC1 (UniProtKB:Q8WXF1)</p> </li> <li>RNA binding activity (GO:0003723)</li> <li>Located in paraspeckles (GO:0042382)</li> <li>Part of membraneless organelle assembly (GO:0140694)</li> <li>Provides input for ALKBH5's RNA N6-methyladenosine dioxygenase activity</li> </ol>"},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#consistency-with-literature","title":"Consistency with Literature:","text":"<p>The model is consistent with recent scientific discoveries, particularly the findings published in:</p> <ol> <li>PMID:37474102 - Which describes ALKBH5's role in paraspeckle assembly through its C-terminal intrinsically disordered region that promotes phase separation.</li> <li>PMID:37369679 - Which details the regulation of ALKBH5's m6A demethylation activity through K235 acetylation by KAT8 and deacetylation by HDAC7, as well as its interaction with PSPC1.</li> <li>PMID:22416126 - Which describes the structural basis of PSPC1 in paraspeckle formation.</li> </ol> <p>The causal relationships between the activities (KAT8 \u2192 ALKBH5 \u2192 PSPC1) are accurately represented, reflecting the findings that KAT8-mediated acetylation of ALKBH5 promotes its interaction with PSPC1, which in turn facilitates RNA m6A recognition and demethylation.</p>"},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#technical-evaluation","title":"Technical Evaluation","text":"<p>The model properly uses the following causal relationships: - <code>RO:0002629</code> (directly positively regulates) - for KAT8's acetylation effect on ALKBH5 - <code>RO:0012010</code> (directly negatively regulates) - for HDAC7's deacetylation effect on ALKBH5 - <code>RO:0002413</code> (provides input for) - for PSPC1's role in facilitating ALKBH5's activity - <code>RO:0002629</code> (directly positively regulates) - for ALKBH5's condensate activity promoting its own demethylase activity</p> <p>The evidence codes and references are appropriately assigned: - <code>ECO:0000314</code> (direct assay evidence used in manual assertion) with appropriate PMIDs</p>"},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is quite comprehensive, there are a few potential areas for enhancement:</p> <ol> <li> <p>Additional context information: The model could benefit from including the specific condition of hypoxia that was shown to promote ALKBH5 condensation and paraspeckle assembly as described in PMID:37474102.</p> </li> <li> <p>Annotation of NEAT1: The model could include the NEAT1 long non-coding RNA, which is an essential component of paraspeckles and whose stabilization by ALKBH5-mediated m6A demethylation is crucial for paraspeckle assembly.</p> </li> <li> <p>Specification of K235 as the acetylation site: While the model correctly captures the acetylation relationship, it might be helpful to specify that K235 is the specific site of acetylation that affects ALKBH5 activity.</p> </li> <li> <p>Additional downstream effects: The model could potentially include the downstream effects of ALKBH5-mediated paraspeckle assembly on cellular processes such as RNA processing and cancer cell invasion as described in the literature.</p> </li> </ol>"},{"location":"reviews/64e7eefa00001978-ALKBH5_is_involved_in_paraspeckle_assembly_and_is_regulated_by_acetylation_and_deacetylation_by_KAT8_and_HDAC7__respectively__Human__/#conclusion","title":"Conclusion","text":"<p>The model gomodel:64e7eefa00001978 effectively captures the molecular mechanisms of ALKBH5 regulation through acetylation/deacetylation and its role in paraspeckle assembly. It accurately represents the current scientific understanding of these processes as described in recent literature. The model follows GO-CAM best practices for representing protein complexes and molecular activities, with appropriate evidence codes and references.</p> <p>The model could be further enhanced by including additional contextual information (hypoxia), the role of NEAT1, specific acetylation site details, and downstream effects, but these are refinements rather than corrections to an already well-constructed representation.</p>"},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/","title":"65039e8700000055 Phosphorylation mediated interactions with TOPBP1 couples TP53BP1 and 9 1 1 in DNA damage checkpoint  Human","text":"<p>Based on all the information I've gathered, I'll now review the GO-CAM model gomodel:65039e8700000055 titled \"Phosphorylation-mediated interactions with TOPBP1 couples TP53BP1 and 9-1-1 in DNA damage checkpoint (Human)\".</p>"},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/#go-cam-model-review-gomodel65039e8700000055","title":"GO-CAM Model Review: gomodel:65039e8700000055","text":""},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/#model-overview","title":"Model Overview","text":"<p>The model \"Phosphorylation-mediated interactions with TOPBP1 couples TP53BP1 and 9-1-1 in DNA damage checkpoint (Human)\" represents critical molecular interactions in the DNA damage checkpoint pathway. The model focuses on how phosphorylation of TP53BP1 (53BP1) and RAD9A (part of the 9-1-1 complex) enables both proteins to interact with TOPBP1, leading to activation of the ATR kinase in the G1 DNA damage checkpoint response.</p>"},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model includes the following key components:</p> <ol> <li>RNF168 (UniProtKB:Q8IYW5) with histone H2AK15 ubiquitin ligase activity (GO:0140858)</li> <li>TP53BP1 (UniProtKB:Q12888) with histone reader activity (GO:0140566)</li> <li>TOPBP1 (UniProtKB:Q92547) with chromatin-protein adaptor activity (GO:0140463)</li> <li>RAD9A (part of the 9-1-1 complex) (UniProtKB:Q99638) with molecular function activity (GO:0140031)</li> <li>ATR (UniProtKB:Q13535) with protein serine/threonine kinase activity (GO:0004674)</li> </ol>"},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/#biological-process-representation","title":"Biological Process Representation","text":"<p>The model depicts the G1 DNA damage checkpoint pathway where: - RNF168 enables histone H2AK15 ubiquitin ligase activity - This provides input for TP53BP1's histone reader activity - TP53BP1 directly positively regulates TOPBP1's adaptor activity - RAD9A binds to phosphorylated proteins through its phosphorylation-dependent protein binding activity - TOPBP1 directly positively regulates ATR kinase activity - ATR enables protein serine/threonine kinase activity in DNA repair</p>"},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/#review-assessment-and-recommendations","title":"Review Assessment and Recommendations","text":""},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li> <p>Accurate representation of molecular interactions: The model correctly captures the phosphorylation-dependent interactions between TP53BP1, TOPBP1, and the 9-1-1 complex (including RAD9A).</p> </li> <li> <p>Proper causal relationships: The causal relationships using RO:0002413 (provides input for) and RO:0002629 (directly positively regulates) are appropriately used to show the flow of information and activation in the checkpoint pathway.</p> </li> <li> <p>Cellular location annotation: Activities are properly annotated with location information, occurring at the site of double-strand break (GO:0035861).</p> </li> <li> <p>Biological process context: Activities are connected to appropriate biological processes like double-strand break repair via classical nonhomologous end joining (GO:0097680).</p> </li> <li> <p>Evidence and references: Each activity and causal link is supported by appropriate evidence codes (ECO:0000314 - direct assay evidence) and literature references.</p> </li> </ol>"},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>9-1-1 Complex Representation: While the model includes RAD9A, it doesn't explicitly represent that RAD9A is part of the 9-1-1 complex (which also includes RAD1 and HUS1). According to the \"How to annotate complexes in GO-CAM\" document, when the subunit carrying the activity is known (as in this case with RAD9A), it's appropriate to use that subunit. However, it might be helpful to include a note or additional annotation indicating that RAD9A is part of the 9-1-1 complex for clarity.</p> </li> <li> <p>Phosphorylation Sites: The model would benefit from annotations specifying the exact phosphorylation sites on TP53BP1 (Ser-366 and Thr-670) and RAD9A (Ser-341 and Ser-387) that are critical for interaction with TOPBP1. This information is available in the references and would enhance the precision of the model.</p> </li> <li> <p>Additional Downstream Effects: The model currently shows ATR activation but could be expanded to include downstream effects of ATR activation, such as phosphorylation of CHEK1 (CHK1) and cell cycle arrest. This would provide a more complete picture of the G1 DNA damage checkpoint pathway.</p> </li> <li> <p>Comprehensive Process Coverage: Consider expanding the model to show how other proteins like ATRIP and RPA are involved in the ATR activation process alongside the 9-1-1 complex and TOPBP1.</p> </li> <li> <p>Visual Organization: While not a scientific issue, the layout of the activities could be reorganized to better reflect the temporal and spatial relationships between the components.</p> </li> </ol>"},{"location":"reviews/65039e8700000055-Phosphorylation_mediated_interactions_with_TOPBP1_couples_TP53BP1_and_9_1_1_in_DNA_damage_checkpoint__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, the model gomodel:65039e8700000055 is scientifically accurate and follows the GO-CAM curation guidelines. It correctly represents how phosphorylation mediates interactions between TP53BP1, TOPBP1, and the 9-1-1 complex (via RAD9A) in controlling the G1 DNA damage checkpoint. </p> <p>The model captures the key molecular functions, causal relationships, and biological contexts of this pathway. With some minor enhancements as suggested above, this model could provide an even more comprehensive representation of the G1 DNA damage checkpoint pathway.</p> <p>The primary literature references used in the model, particularly PMID:27153538, PMID:31135337, and PMID:20545769, provide strong evidence for the interactions and relationships depicted in the model.</p>"},{"location":"reviews/65039e8700000196-HTATSF1_and_TOPBP1_promote_RPA_RAD51_exchange_in_double_strand_break_repair_via_homologous_recombination__Human__/","title":"65039e8700000196 HTATSF1 and TOPBP1 promote RPA RAD51 exchange in double strand break repair via homologous recombination  Human","text":"<p>Based on my research and the model I'm reviewing, I'll now provide a comprehensive review of GO-CAM model 65039e8700000196 \"HTATSF1 and TOPBP1 promote RPA-RAD51 exchange in double-strand break repair via homologous recombination (Human).\"</p>"},{"location":"reviews/65039e8700000196-HTATSF1_and_TOPBP1_promote_RPA_RAD51_exchange_in_double_strand_break_repair_via_homologous_recombination__Human__/#review-of-go-cam-model-gomodel65039e8700000196","title":"Review of GO-CAM Model: gomodel:65039e8700000196","text":""},{"location":"reviews/65039e8700000196-HTATSF1_and_TOPBP1_promote_RPA_RAD51_exchange_in_double_strand_break_repair_via_homologous_recombination__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the process by which HTATSF1 and TOPBP1 promote the exchange between the RPA complex and RAD51 during homologous recombination repair (HRR) of DNA double-strand breaks (DSBs) in human cells. This is a critical process for maintaining genome integrity.</p>"},{"location":"reviews/65039e8700000196-HTATSF1_and_TOPBP1_promote_RPA_RAD51_exchange_in_double_strand_break_repair_via_homologous_recombination__Human__/#scientific-content","title":"Scientific Content","text":"<p>The model correctly captures the main findings from the primary research paper (PMID:35597237), showing how a PARylation-phosphorylation cascade promotes TOPBP1 loading and RPA-RAD51 exchange in homologous recombination. The molecular mechanisms depicted in the model include:</p> <ol> <li>PARP1-mediated poly(ADP-ribosyl)ation of RPA1</li> <li>HTATSF1 recognition of PARylated RPA1 at DNA damage sites</li> <li>CK2-mediated phosphorylation of HTATSF1 at Ser-748</li> <li>Phosphorylated HTATSF1 recruiting TOPBP1 to DNA damage sites</li> <li>TOPBP1 promoting the exchange of RPA with RAD51 at the sites of DSBs</li> </ol> <p>The included activities are all supported by evidence from published literature citations, primarily PMID:35597237, which is appropriate for the model.</p>"},{"location":"reviews/65039e8700000196-HTATSF1_and_TOPBP1_promote_RPA_RAD51_exchange_in_double_strand_break_repair_via_homologous_recombination__Human__/#model-structure-and-connectivity","title":"Model Structure and Connectivity","text":"<p>The model has well-connected activities with appropriate causal relations:</p> <ol> <li>PARP1's NAD+-protein ADP-ribosyltransferase activity causally promotes RPA1's chromatin-protein adaptor activity</li> <li>RPA1's chromatin-protein adaptor activity causally promotes HTATSF1's chromatin-protein adaptor activity</li> <li>CK2's protein serine/threonine kinase activity causally promotes HTATSF1's chromatin-protein adaptor activity</li> <li>PLK1's protein serine/threonine kinase activity provides input for CK2's protein serine/threonine kinase activity</li> <li>HTATSF1's chromatin-protein adaptor activity positively regulates TOPBP1's chromatin-protein adaptor activity</li> <li>TOPBP1's chromatin-protein adaptor activity positively regulates RAD51's DNA strand exchange activity and negatively regulates the DNA replication factor A complex's damaged DNA binding activity</li> </ol> <p>All activities have appropriate <code>part_of</code> relationships to relevant biological processes (primarily GO:0000724 \"double-strand break repair via homologous recombination\") and most have appropriate <code>occurs_in</code> annotations to GO:0035861 \"site of double-strand break\".</p>"},{"location":"reviews/65039e8700000196-HTATSF1_and_TOPBP1_promote_RPA_RAD51_exchange_in_double_strand_break_repair_via_homologous_recombination__Human__/#technical-accuracy","title":"Technical Accuracy","text":"<p>The model follows GO-CAM best practices: - All activities are properly enabled by gene products or complexes - Appropriate causal relationships are used (RO:0002413 \"provides input for\", RO:0002629 \"directly positively regulates\", RO:0002630 \"directly negatively regulates\") - All claims are properly evidenced with ECO codes and PMID references - Cellular locations are specified where appropriate</p>"},{"location":"reviews/65039e8700000196-HTATSF1_and_TOPBP1_promote_RPA_RAD51_exchange_in_double_strand_break_repair_via_homologous_recombination__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is well-constructed, I've identified a few areas for potential improvement:</p> <ol> <li> <p>Complex Representation: The RPA complex is represented using GO:0005662 \"DNA replication factor A complex\" as the enabling entity for damaged DNA binding, which is appropriate according to GO-CAM guidelines when the specific subunit carrying the activity is not known. However, the model also shows RPA1 (UniProtKB:P27694) having a separate chromatin-protein adaptor activity. Given the UniProt record for RPA1 indicates it's responsible for single-stranded DNA binding in the complex, it might be worth considering whether to consolidate these activities or clarify their distinctions.</p> </li> <li> <p>Missing Complex Members: The DNA replication factor A complex (GO:0005662) is shown without its member proteins. According to GO-CAM guidelines for complex annotation, the members should be specified when known, especially since they are well-characterized (RPA1, RPA2, RPA3).</p> </li> <li> <p>Temporal Context: The model would benefit from clarifying that these events occur during S-phase of the cell cycle, as mentioned in the research paper. The phosphorylation of HTATSF1 by CK2 is S-phase specific.</p> </li> <li> <p>Molecular Details: While the model captures the key causal relationships, some specific molecular details from the paper could be included, such as the specific lysine residues being targeted for PARylation on RPA1 or the specific mechanism by which TOPBP1 promotes RAD51 loading.</p> </li> </ol>"},{"location":"reviews/65039e8700000196-HTATSF1_and_TOPBP1_promote_RPA_RAD51_exchange_in_double_strand_break_repair_via_homologous_recombination__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately captures the biological process described in the primary literature. The activities and their causal relationships are appropriately represented, and the evidence is properly cited. With the minor improvements suggested above, particularly regarding the representation of the RPA complex members, this model will serve as an excellent representation of how HTATSF1 and TOPBP1 promote RPA-RAD51 exchange in homologous recombination repair.</p> <p>The model aligns well with the current understanding of DNA repair mechanisms and follows GO-CAM annotation guidelines. It provides a valuable resource for researchers interested in understanding the molecular mechanisms of homologous recombination repair of DNA double-strand breaks.</p>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/","title":"65039e8700001110 TRIM69 activation of STK3 by ubiquitination leading to centrosome separation  Human","text":"<p>Based on my review of the GO-CAM model, the literature, and the protein information, I'll now provide a comprehensive review of the model.</p>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#review-of-go-cam-model-gomodel65039e8700001110","title":"Review of GO-CAM Model: gomodel:65039e8700001110","text":""},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#model-overview","title":"Model Overview","text":"<p>Title: TRIM69 activation of STK3 by ubiquitination leading to centrosome separation (Human) ID: gomodel:65039e8700001110 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#model-summary","title":"Model Summary","text":"<p>This model represents a newly identified signaling pathway in which the E3 ubiquitin ligase TRIM69 regulates STK3 (also known as MST2) by ubiquitination, which in turn activates PLK1 and ultimately NEK2, leading to centrosome separation in mitotic cells. This pathway is important for proper chromosome segregation during cell division.</p>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#factual-accuracy-assessment","title":"Factual Accuracy Assessment","text":"<p>The model is based on recent research published by Wang et al. in 2023 (PMID:37739411), which identified the \"TRIM69-MST2 signaling axis\" that regulates centrosome dynamics and chromosome segregation. The paper provides strong experimental evidence supporting the pathway described in the model.</p> <p>Key points from the literature that are correctly captured in the model:</p> <ol> <li>TRIM69 acts as an E3 ubiquitin ligase that ubiquitinates STK3/MST2 (not for degradation but for relocalization to the perinuclear cytoskeleton)</li> <li>This promotes STK3 association with PLK1, leading to STK3 phosphorylation at S15</li> <li>Activated STK3 then phosphorylates NEK2, which in turn phosphorylates centrosomal proteins like C-NAP1 and CROCC to promote centrosome separation</li> <li>This pathway is important for proper mitotic progression and centrosome dynamics</li> </ol>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#model-structure-and-connections","title":"Model Structure and Connections","text":"<p>The model correctly captures the causal flow through this pathway:</p> <ol> <li>TRIM69 (E3 ubiquitin ligase activity) \u2192 provides input for \u2192 PLK1 (protein serine kinase activity)</li> <li>PLK1 (protein serine kinase activity) \u2192 directly positively regulates \u2192 STK3 (protein serine/threonine kinase activity)</li> <li>STK3 (protein serine/threonine kinase activity) \u2192 directly positively regulates \u2192 NEK2 (protein kinase activity)</li> </ol> <p>All four proteins are correctly annotated with their appropriate molecular functions and localized to the centrosome (GO:0005813), which is supported by the literature.</p> <p>The biological processes are also correctly annotated: - TRIM69 and STK3 are part of \"protein localization to centrosome\" (GO:0071539) - PLK1 is part of \"centrosome cycle\" (GO:0007098) - NEK2 is part of \"centrosome separation\" (GO:0051299)</p>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) for most activities and connections - ECO:0000315 (mutant phenotype evidence used in manual assertion) for PLK1's role in centrosome cycle</p> <p>The primary literature source cited (PMID:37739411) directly supports the relationships in the model. Additional supporting references are used for specific activities of PLK1, STK3, and NEK2.</p>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Molecular Details: The model could be enhanced by including information about the specific ubiquitination sites on STK3 (K279 is mentioned in the paper as one site) and the phosphorylation sites (S15, S316, T336, T384, S385 are mentioned in the paper).</p> </li> <li> <p>Downstream Targets: The model stops at NEK2's kinase activity, but could be extended to include NEK2's known phosphorylation targets at the centrosome (C-NAP1/CEP250 and CROCC/rootletin), which are directly responsible for centrosome cohesion dissolution.</p> </li> <li> <p>Cellular Compartment Refinement: While all activities are correctly localized to the centrosome, the paper specifies that TRIM69 redistributes STK3 to the \"perinuclear cytoskeleton\", which could be a more precise cellular compartment annotation.</p> </li> <li> <p>PRC1 and Dynein Roles: The paper also describes roles for PRC1 and Dynein in TRIM69-mediated centrosome clustering, which could be included as additional components of this pathway, especially since this function is distinct from the STK3-mediated centrosome disjunction pathway currently modeled.</p> </li> </ol>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model follows the GO-CAM best practices for representing regulatory pathways: - The \"provides input for\" relation (RO:0002413) is correctly used when TRIM69 acts on PLK1 - The \"directly positively regulates\" relation (RO:0002629) is used appropriately to connect kinase activities that directly activate the downstream protein - Each activity is properly contextualized with cellular compartment and biological process</p> <p>The use of molecular function terms is appropriate, with each protein enabled by its known catalytic activity.</p>"},{"location":"reviews/65039e8700001110-TRIM69_activation_of_STK3_by_ubiquitination_leading_to_centrosome_separation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents a recently discovered signaling pathway involving TRIM69, STK3/MST2, PLK1, and NEK2 in centrosome dynamics. It is based on sound experimental evidence and follows the GO-CAM guidelines for representing causal molecular mechanisms. The model could be enhanced by adding more molecular details about ubiquitination and phosphorylation sites, and by extending the pathway to include more downstream components.</p> <p>The model provides a valuable resource for understanding centrosome biology and mitotic regulation, which is particularly relevant to cancer research since centrosome abnormalities are frequently observed in many cancer types, and components of this pathway (especially PLK1 and NEK2) are often dysregulated in cancer.</p>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/","title":"6516135700000211 Tumor necrosis factor mediated signaling pathway 2  Mouse","text":"<p>Based on my analysis of the GO-CAM model and relevant literature, I'll now provide a comprehensive review of the GO-CAM model gomodel:6516135700000211.</p>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/#review-of-go-cam-model-tumor-necrosis-factor-mediated-signaling-pathway-2-mouse","title":"Review of GO-CAM Model: Tumor necrosis factor-mediated signaling pathway 2 (Mouse)","text":"<p>Model ID: gomodel:6516135700000211</p>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/#overview","title":"Overview","text":"<p>This model represents the tumor necrosis factor (TNF)-mediated signaling pathway in mouse. It includes a sequential series of activities starting with TNF cytokine activity, leading through TNF receptor signaling, adapter proteins, and culminating in sphingomyelin phosphodiesterase activity.</p>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/#structure-and-content","title":"Structure and Content","text":"<p>The model contains six activities with the following key genes/proteins: 1. TNF (MGI:MGI:104798) - cytokine activity 2. TNFRSF1A (MGI:MGI:1314884) - tumor necrosis factor receptor activity 3. NSMAF (MGI:MGI:1341864) - signaling adaptor activity 4. RACK1 (MGI:MGI:101849) - signaling adaptor activity 5. EED (MGI:MGI:95286) - enzyme activator activity 6. SMPD2 (MGI:MGI:1278330) - sphingomyelin phosphodiesterase activity</p> <p>The causal flow is: TNF \u2192 TNFRSF1A \u2192 NSMAF \u2192 RACK1 \u2192 EED \u2192 SMPD2, with all regulatory relationships being \"directly positively regulates\" (RO:0002629).</p>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Appropriate pathway representation: The model correctly represents the TNF signaling pathway leading to neutral sphingomyelinase activation, which is supported by the literature (PMIDs 14985352, 12391233, 9520418).</p> </li> <li> <p>Correct molecular function annotations: The molecular functions are appropriately assigned, such as cytokine activity for TNF and receptor activity for TNFRSF1A.</p> </li> <li> <p>Proper cellular context: Activities are correctly localized, with TNF in extracellular space (GO:0005615) and the receptor/signaling components at the plasma membrane (GO:0005886).</p> </li> <li> <p>Consistent causal relationships: The use of \"directly positively regulates\" (RO:0002629) is appropriate for the signaling cascade represented.</p> </li> <li> <p>Evidence support: Each activity and relationship is supported by experimental evidence, primarily from the literature.</p> </li> </ol>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/#issuesconcerns","title":"Issues/Concerns","text":"<ol> <li> <p>Missing supporting annotation for causal relationship: The causal association between NSMAF (gomodel:6516135700000211/6516135700000222) and RACK1 (gomodel:6516135700000211/6516135700000221) lacks evidence annotations, which should be included.</p> </li> <li> <p>Activity annotation considerations: Based on the PMID:9520418 paper, SMPD2 (neutral sphingomyelinase) is an important enzyme in sphingolipid signaling. While the model correctly represents its activity, the literature suggests that TNF only moderately increases ceramide production through this pathway, which is consistent with the model but could be mentioned in annotations.</p> </li> <li> <p>Biological process annotation: All activities except SMPD2 are annotated as part of \"tumor necrosis factor-mediated signaling pathway\" (GO:0033209), while SMPD2 is annotated to \"ceramide metabolic process\" (GO:0006672). It might be worth considering whether SMPD2 should also be linked to the TNF signaling pathway, since it appears to be the endpoint of this particular signaling cascade.</p> </li> <li> <p>Complex considerations: According to the \"How to annotate complexes in GO-CAM\" document, if specific subunits carrying activities are known, they should be represented individually. This model correctly follows this approach by representing individual proteins rather than complexes.</p> </li> </ol>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<ol> <li>The model follows the signaling receptor annotation guidelines appropriately by having:</li> <li>The cytokine (TNF) with cytokine activity in extracellular space</li> <li>The receptor (TNFRSF1A) with receptor activity at the plasma membrane</li> <li> <p>The correct causal relationships between the components</p> </li> <li> <p>The model is parsimonious and represents a clear flow of activities without unnecessary complexity.</p> </li> <li> <p>All annotations are supported by experimental evidence, mostly using ECO:0000314 (direct assay evidence) and ECO:0000266 (sequence orthology evidence).</p> </li> </ol>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add missing evidence: Provide evidence annotations for the causal association between NSMAF and RACK1.</p> </li> <li> <p>Consider biological process annotation for SMPD2: Evaluate whether SMPD2 should also be annotated to the TNF signaling pathway in addition to ceramide metabolism.</p> </li> <li> <p>Review literature completeness: Based on PMID:9520418, the model accurately represents the pathway, but annotations could reflect that the effect of TNF on SMPD2 activation is moderate rather than strong.</p> </li> </ol>"},{"location":"reviews/6516135700000211-Tumor_necrosis_factor_mediated_signaling_pathway_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the TNF signaling pathway leading to neutral sphingomyelinase activation in mouse. The model follows GO-CAM best practices and is supported by appropriate evidence. With minor additions of missing evidence annotations, this model provides a valuable representation of this signaling pathway.</p>"},{"location":"reviews/6516135700000380-Heme_A_biosynthetic_process__Mouse_/","title":"6516135700000380 Heme A biosynthetic process  Mouse","text":"<p>Now I have a good understanding of the model. Let me review the GO-CAM model for \"Heme A biosynthetic process (Mouse)\" with ID gomodel:6516135700000380.</p>"},{"location":"reviews/6516135700000380-Heme_A_biosynthetic_process__Mouse_/#review-of-go-cam-model-heme-a-biosynthetic-process-mouse","title":"Review of GO-CAM Model: Heme A biosynthetic process (Mouse)","text":""},{"location":"reviews/6516135700000380-Heme_A_biosynthetic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the heme A biosynthetic pathway in mouse (NCBITaxon:10090). It includes ten connected activities performed by different gene products, including the conversion of various metabolites in the pathway leading to the synthesis of heme A.</p>"},{"location":"reviews/6516135700000380-Heme_A_biosynthetic_process__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the heme A biosynthetic pathway, which begins with the synthesis of 5-aminolevulinate and proceeds through multiple enzymatic steps to form heme A, an essential cofactor for cytochrome c oxidase in the mitochondrial respiratory chain.</p> <p>The pathway flow appears to be correctly represented, with appropriate causal connections (<code>RO:0002413</code> - provides input for) between the activities in the expected sequential order:</p> <ol> <li>ALAS1 (5-aminolevulinate synthase) \u2192 ALAD (porphobilinogen synthase)</li> <li>ALAD \u2192 HMBS (hydroxymethylbilane synthase)</li> <li>HMBS \u2192 UROS (uroporphyrinogen-III synthase)</li> <li>UROS \u2192 UROD (uroporphyrinogen decarboxylase)</li> <li>UROD \u2192 CPOX (coproporphyrinogen oxidase)</li> <li>CPOX \u2192 PPOX (protoporphyrinogen oxidase)</li> <li>PPOX \u2192 FECH (ferrochelatase)</li> <li>FECH \u2192 COX10 (protoheme IX farnesyltransferase)</li> <li>COX10 \u2192 COX15 (oxidoreductase)</li> </ol>"},{"location":"reviews/6516135700000380-Heme_A_biosynthetic_process__Mouse_/#evaluation-of-go-cam-best-practices","title":"Evaluation of GO-CAM Best Practices","text":"<ol> <li>Molecular Functions: Each activity has an appropriate molecular function term assigned:</li> <li>GO:0003870 (5-aminolevulinate synthase activity)</li> <li>GO:0004655 (porphobilinogen synthase activity)</li> <li>GO:0004418 (hydroxymethylbilane synthase activity)</li> <li>GO:0004852 (uroporphyrinogen-III synthase activity)</li> <li>GO:0004853 (uroporphyrinogen decarboxylase activity)</li> <li>GO:0004109 (coproporphyrinogen oxidase activity)</li> <li>GO:0004729 (oxygen-dependent protoporphyrinogen oxidase activity)</li> <li>GO:0004325 (ferrochelatase activity)</li> <li>GO:0008495 (protoheme IX farnesyltransferase activity)</li> <li> <p>GO:0016627 (oxidoreductase activity, acting on the CH-CH group of donors)</p> </li> <li> <p>Cellular Components: Each activity is assigned an appropriate cellular component:</p> </li> <li>Mitochondrial matrix (GO:0005759)</li> <li>Cytosol (GO:0005829)</li> <li> <p>Mitochondrial intermembrane space (GO:0005758)</p> </li> <li> <p>Biological Process: All activities are correctly part of the heme A biosynthetic process (GO:0006784).</p> </li> <li> <p>Molecule Inputs and Outputs: The model appropriately represents substrates and products for each reaction:</p> </li> <li>Chemical entities are correctly represented as CHEBI terms</li> <li> <p>Inputs and outputs are connected in a logical way between sequential reactions</p> </li> <li> <p>Evidence: Each activity has appropriate evidence codes and references:</p> </li> <li>ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>ECO:0000315 (mutant phenotype evidence used in manual assertion)</li> <li>ECO:0000266 (sequence orthology evidence used in manual assertion)</li> <li> <p>ECO:0000316 (genetic interaction evidence used in manual assertion)</p> </li> <li> <p>Causal Relations: Appropriate causal connections (RO:0002413 - provides input for) are used to connect sequential activities in the pathway.</p> </li> </ol>"},{"location":"reviews/6516135700000380-Heme_A_biosynthetic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Visual Complexity: This model has no obvious issues, but with 10 activities and numerous molecular inputs/outputs, it could potentially be complex to visualize. However, the sequential nature makes it understandable.</p> </li> <li> <p>Evidence Documentation: All activities have evidences attached, which is excellent. Most evidence is supported by primary literature (PMIDs).</p> </li> <li> <p>Complex Representation: No protein complexes appear to be involved in this pathway, so the complex annotation guidelines do not apply directly to this model.</p> </li> </ol>"},{"location":"reviews/6516135700000380-Heme_A_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for \"Heme A biosynthetic process (Mouse)\" (gomodel:6516135700000380) is a high-quality representation of the heme A biosynthetic pathway. It follows all the GO-CAM best practices, with:</p> <ul> <li>Accurate representation of the biological process</li> <li>Appropriate molecular functions for each gene product</li> <li>Correct cellular locations</li> <li>Well-documented evidence</li> <li>Logical causal connections between activities</li> <li>Appropriate molecule inputs and outputs</li> </ul> <p>The model is biologically accurate and appears to be consistent with the literature on heme A biosynthesis. No significant issues or improvements are needed.</p> <p>You can view this model at: https://bioregistry.io/go.model:6516135700000380</p>"},{"location":"reviews/6516135700000961-Heme_O_biosynthetic_process__Mouse_/","title":"6516135700000961 Heme O biosynthetic process  Mouse","text":"<p>Now let me evaluate this GO-CAM model for heme O biosynthetic process in mouse. </p>"},{"location":"reviews/6516135700000961-Heme_O_biosynthetic_process__Mouse_/#go-cam-review-heme-o-biosynthetic-process-mouse-gomodel6516135700000961","title":"GO-CAM Review: Heme O biosynthetic process (Mouse) - gomodel:6516135700000961","text":""},{"location":"reviews/6516135700000961-Heme_O_biosynthetic_process__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM models the heme O biosynthetic process in mouse (NCBITaxon:10090), showing the complete pathway from initial substrates through to the production of heme O, including all enzymes involved, their molecular functions, cellular locations, substrates, and products.</p>"},{"location":"reviews/6516135700000961-Heme_O_biosynthetic_process__Mouse_/#structural-evaluation","title":"Structural Evaluation","text":"<ol> <li>Model Representation: </li> <li>The model appropriately captures the sequential enzymatic steps in heme O biosynthesis</li> <li>Causal connections between activities use the proper <code>RO:0002413</code> (provides input for) predicate</li> <li> <p>Each activity includes proper enabled_by, occurs_in, part_of, and has_input/has_output associations</p> </li> <li> <p>Evidence Quality:</p> </li> <li>The model includes appropriate evidence codes for each assertion</li> <li>Evidence includes a mix of ECO:0000314 (direct assay), ECO:0000315 (mutant phenotype), and ECO:0000266 (sequence orthology)</li> <li> <p>All assertions are supported by appropriate PMIDs</p> </li> <li> <p>Pathway Completeness:</p> </li> <li>The model represents a complete pathway from initial substrates (glycine, succinyl-CoA) through multiple intermediates to the final product (heme O)</li> <li>The causal flow through the pathway is logically connected</li> </ol>"},{"location":"reviews/6516135700000961-Heme_O_biosynthetic_process__Mouse_/#biological-content-evaluation","title":"Biological Content Evaluation","text":"<ol> <li>Pathway Flow:</li> <li>The model correctly captures the canonical heme biosynthesis pathway starting with 5-aminolevulinate synthase (ALAS1)</li> <li>Subsequent enzymes (ALAD, HMBS, UROS, UROD, CPOX, PPOX, FECH) are correctly ordered</li> <li> <p>The addition of the final enzyme (COX10) for conversion to heme O is properly included</p> </li> <li> <p>Cellular Localization:</p> </li> <li>The model correctly represents the subcellular locations of each enzyme:<ul> <li>ALAS1 in mitochondrial matrix</li> <li>ALAD, HMBS, UROS, UROD in cytosol </li> <li>CPOX, PPOX in mitochondrial intermembrane space</li> <li>FECH, COX10 in mitochondrial matrix</li> </ul> </li> <li> <p>This represents the known distribution of heme biosynthesis between cytosol and mitochondria</p> </li> <li> <p>Molecule Handling:</p> </li> <li>Input and output molecules are correctly specified for each reaction</li> <li>Cofactors and additional products (CO2, H2O, etc.) are appropriately included</li> </ol>"},{"location":"reviews/6516135700000961-Heme_O_biosynthetic_process__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices: - Uses appropriate associations for all components - Properly connects activities with causal predicates - Includes proper evidence for all assertions - Provides appropriate cellular locations for all activities</p>"},{"location":"reviews/6516135700000961-Heme_O_biosynthetic_process__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is very well constructed, I have a couple of minor suggestions:</p> <ol> <li> <p>Pathway Visualization: The pathway could potentially benefit from organizing activities more clearly based on cellular compartments to highlight the movement between mitochondria and cytosol during heme biosynthesis.</p> </li> <li> <p>Additional Context: Consider adding annotations about regulation of the pathway or connections to related biological processes (like iron metabolism or cellular respiration) to provide broader context.</p> </li> </ol>"},{"location":"reviews/6516135700000961-Heme_O_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is an excellent model of the heme O biosynthetic process that accurately represents the current biological knowledge of this pathway in mouse. The model is well-constructed according to GO-CAM best practices, includes appropriate evidence, and correctly captures the biological process with all necessary molecular details.</p> <p>The model successfully depicts the complete pathway from initial substrates through multiple enzymatic steps to the final product, with appropriate cellular locations for each activity. It represents a parsimonious and easy-to-understand representation of this important metabolic pathway.</p>"},{"location":"reviews/6516135700001077-Heme_B_biosynthetic_process__Mouse_/","title":"6516135700001077 Heme B biosynthetic process  Mouse","text":"<p>Now, let me review the GO-CAM model for \"Heme B biosynthetic process (Mouse)\" based on the information provided and best practices.</p>"},{"location":"reviews/6516135700001077-Heme_B_biosynthetic_process__Mouse_/#review-of-go-cam-model-gomodel6516135700001077","title":"Review of GO-CAM Model gomodel:6516135700001077","text":""},{"location":"reviews/6516135700001077-Heme_B_biosynthetic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the heme B biosynthetic process in mouse (Mus musculus), showing the complete pathway from initial substrates to the final heme B product. The model includes 9 activities carried out by different enzymes, with appropriate causal connections between them.</p>"},{"location":"reviews/6516135700001077-Heme_B_biosynthetic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Complete Pathway Representation: The model captures the entire heme B biosynthesis pathway from the initial synthesis of 5-aminolevulinate through to the formation of ferroheme b.</p> </li> <li> <p>Detailed Molecular Context: Each activity correctly specifies:</p> </li> <li>The molecular function (MF) of the enzyme</li> <li>The biological process (BP) it's part of (heme B biosynthetic process)</li> <li>The cellular component (CC) where it occurs</li> <li>Input and output molecules with proper CHEBI identifiers</li> <li> <p>Appropriate evidence with PMID references</p> </li> <li> <p>Causal Connections: The model uses the \"provides input for\" (RO:0002413) predicate appropriately to connect activities in a sequential manner that reflects the biological flow of the pathway.</p> </li> <li> <p>Cellular Localization: The model correctly represents the subcellular locations where each step occurs (cytosol, mitochondrial matrix, mitochondrial intermembrane space, mitochondrial membrane).</p> </li> <li> <p>Species Specificity: The model is properly specified for mouse, using MGI IDs for gene products.</p> </li> <li> <p>Evidence Support: Each activity is well-supported by multiple evidence codes (ECO terms) and literature references (PMIDs).</p> </li> </ol>"},{"location":"reviews/6516135700001077-Heme_B_biosynthetic_process__Mouse_/#specific-aspects-to-note","title":"Specific Aspects to Note","text":"<ol> <li> <p>Transporter Activity: The model includes a heme B transmembrane transporter activity (GO:0170003) enabled by PR:B2RXV4-2 (mFLVCR1/isom2 Mmus) that occurs in the mitochondrial membrane, which follows the proper pattern for annotating transporters.</p> </li> <li> <p>Input/Output Annotation: The model properly uses the has_input and has_output relations to show the substrates and products of each enzymatic reaction.</p> </li> <li> <p>Subcellular Compartments: The model accurately represents the compartmentalization of the pathway across mitochondrial and cytosolic compartments, which is crucial for heme biosynthesis.</p> </li> </ol>"},{"location":"reviews/6516135700001077-Heme_B_biosynthetic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Transport Steps: While the model includes the final heme B transport step, it could potentially benefit from explicitly modeling the transport of intermediates between cellular compartments, if supported by evidence.</p> </li> <li> <p>Complex Representation: If any of these enzymes function as part of complexes, that information could be represented according to the complex annotation guidelines.</p> </li> <li> <p>Regulatory Processes: The model focuses on the core enzymatic steps but doesn't include regulatory aspects of heme biosynthesis. Adding these if evidence exists would enhance the model's comprehensiveness.</p> </li> </ol>"},{"location":"reviews/6516135700001077-Heme_B_biosynthetic_process__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the canonical heme B biosynthetic pathway as described in biochemistry textbooks and the scientific literature. The sequence of reactions, enzyme activities, substrates/products, and cellular locations align with current knowledge of this pathway.</p>"},{"location":"reviews/6516135700001077-Heme_B_biosynthetic_process__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a high-quality GO-CAM model that accurately represents the heme B biosynthetic process in mice. It follows GO-CAM best practices and provides a comprehensive and well-evidenced representation of this important metabolic pathway. The model is parsimonious while capturing the essential features of the pathway, making it easy for humans to understand.</p> <p>The model passes QC review and is appropriate for production status.</p>"},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/","title":"65288b2200000194 STING1 acts as a proton channel and promotes autophagosome assembly  Human","text":"<p>Based on my review of model gomodel:65288b2200000194 \"STING1 acts as a proton channel and promotes autophagosome assembly (Human)\", I can provide the following assessment:</p>"},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/#review-of-go-cam-model-65288b2200000194","title":"Review of GO-CAM model: 65288b2200000194","text":""},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the role of STING1 (Stimulator of Interferon Genes protein) as a proton channel that promotes autophagosome assembly in humans. The model connects several key proteins involved in the autophagy pathway, including ATG4B, ATG4C, ATG4D, ATG5, and MAP1LC3B.</p>"},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Scientific Accuracy: The model accurately represents recent findings about STING1's function as a proton channel, specifically based on the 2023 publication (PMID:37535724) that identified this function.</p> </li> <li> <p>Molecular Functions: Appropriate molecular functions are assigned to each protein:</p> </li> <li>STING1 is correctly annotated with proton channel activity (GO:0015252)</li> <li>ATG4 proteins (ATG4B, ATG4C, ATG4D) are annotated with appropriate protease activities</li> <li>ATG5 is annotated with ATG8-family ligase activity</li> <li> <p>MAP1LC3B is annotated with phosphatidylethanolamine binding</p> </li> <li> <p>Localization: Cellular components are appropriately assigned:</p> </li> <li>STING1 is correctly localized to the Golgi membrane (GO:0000139)</li> <li>ATG4B is correctly localized to autophagosome membrane (GO:0000421)</li> <li>MAP1LC3B is correctly localized to the autophagosome membrane</li> <li> <p>ATG5 is correctly localized to the autophagosome</p> </li> <li> <p>Biological Process: All activities are appropriately part of the autophagosome assembly (GO:0000045) process.</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal relationships to link activities:</p> </li> <li>RO:0002629 (directly positively regulates) is used to connect the protease activities to MAP1LC3B activity</li> <li>RO:0002407 (is upstream of) connects STING1's proton channel activity to ATG5's ligase activity</li> </ol>"},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Evidence Completeness: Several causal associations lack evidence annotations. For example, there's an unannotated causal association between ATG4C and MAP1LC3B.</p> </li> <li> <p>Missing Contextual Information: The model doesn't completely capture the mechanism by which STING1's proton channel activity promotes autophagosome formation. The specific pH changes in the Golgi and their consequences on autophagy machinery could be more explicitly represented.</p> </li> <li> <p>Connection Clarity: The connection between ATG5 and MAP1LC3B activity could be more detailed to represent the complete LC3 lipidation process, which involves additional proteins like ATG7 and ATG3 that are not included in this model.</p> </li> </ol>"},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<ol> <li> <p>Complex Annotation: The model follows GO-CAM guidelines for protein annotation, focusing on individual proteins rather than complexes when the specific subunits carrying activities are known.</p> </li> <li> <p>Causal Relationships: The model correctly uses the appropriate relationship predicates for connecting activities.</p> </li> <li> <p>Evidence Annotation: Most activities and relationships include proper evidence codes and literature references, though some causal associations lack evidence annotations.</p> </li> </ol>"},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents current scientific understanding of STING1's role in autophagy based on recent literature. The 2023 paper (PMID:37535724) identified STING1 as a proton channel that facilitates autophagosome formation by promoting proton efflux from the Golgi, which is captured in this model.</p> <p>The connection between ATG4 family proteins (ATG4B, ATG4C, ATG4D) cleaving the C-terminus of MAP1LC3B to expose the glycine residue needed for lipidation is biologically accurate. Similarly, ATG5's role in the lipidation process and MAP1LC3B's association with autophagosome membranes are correctly represented.</p>"},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add evidence codes to all causal relationships.</p> </li> <li> <p>Consider expanding the model to include additional proteins in the autophagy pathway, such as ATG7 and ATG3, to provide a more complete representation of the LC3 lipidation process.</p> </li> <li> <p>Add additional annotations to clarify the mechanism by which STING1's proton channel activity influences autophagosome formation.</p> </li> </ol>"},{"location":"reviews/65288b2200000194-STING1_acts_as_a_proton_channel_and_promotes_autophagosome_assembly__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:65288b2200000194) provides an accurate representation of STING1's role as a proton channel in promoting autophagosome assembly, consistent with current scientific literature. The model successfully captures the key proteins and their activities in this process, with appropriate molecular functions, cellular locations, and causal relationships. With minor improvements in evidence annotation and additional contextual details, this model would be an excellent reference for the field.</p>"},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/","title":"65288b2200000496 Regulation of CGAS activity via palmitoylation and depalmitoylation by ZDHHC9 and LYPLAL1  respectively  Human","text":"<p>Let me now review the GO-CAM model based on the information I've gathered.</p>"},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/#review-of-go-cam-model-gomodel65288b2200000496","title":"Review of GO-CAM Model: gomodel:65288b2200000496","text":""},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model gomodel:65288b2200000496 describes the \"Regulation of CGAS activity via palmitoylation and depalmitoylation by ZDHHC9 and LYPLAL1, respectively (Human).\" </p> <p>This model represents an important pathway in innate immunity where the cGAS (cyclic GMP-AMP synthase) activity is regulated through post-translational modifications, specifically palmitoylation (the addition of palmitate) and depalmitoylation (the removal of palmitate).</p>"},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/#model-components","title":"Model Components","text":"<p>The model contains four key proteins that interact in a regulatory pathway:</p> <ol> <li>CGAS (UniProtKB:Q8N884): Cyclic GMP-AMP synthase, a cytosolic DNA sensor that plays a key role in innate immunity</li> <li>ZDHHC9 (UniProtKB:Q9Y397): Palmitoyltransferase that adds palmitate to CGAS</li> <li>LYPLAL1 (UniProtKB:Q5VWZ2): Lysophospholipase-like protein 1, a thioesterase that removes palmitate from CGAS</li> </ol>"},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/#model-activities-and-causal-associations","title":"Model Activities and Causal Associations","text":"<p>The model represents the following activities and causal associations:</p> <ol> <li> <p>ZDHHC9 performs protein-cysteine S-palmitoyltransferase activity (GO:0019706), which is part of the positive regulation of cGAS/STING signaling pathway (GO:0141111).</p> </li> <li> <p>ZDHHC9's palmitoyltransferase activity directly positively regulates (RO:0002629) the double-stranded DNA binding activity (GO:0003690) of CGAS.</p> </li> <li> <p>CGAS performs double-stranded DNA binding activity (GO:0003690), which occurs in the cytosol (GO:0005829) and is part of the cGAS/STING signaling pathway (GO:0140896).</p> </li> <li> <p>CGAS's DNA binding activity directly positively regulates (RO:0002629) its molecular condensate scaffold activity (GO:0140693).</p> </li> <li> <p>CGAS's molecular condensate scaffold activity directly positively regulates (RO:0002629) its 2',3'-cyclic GMP-AMP synthase activity (GO:0061501).</p> </li> <li> <p>LYPLAL1 performs palmitoyl-(protein) hydrolase activity (GO:0008474), which is part of the negative regulation of cGAS/STING signaling pathway (GO:0160049).</p> </li> <li> <p>LYPLAL1's hydrolase activity directly negatively regulates (RO:0002630) the double-stranded DNA binding activity of CGAS.</p> </li> </ol>"},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/#evaluation-and-comments","title":"Evaluation and Comments","text":""},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate Biological Process Representation: The model correctly represents the biological regulation of cGAS activity through palmitoylation and depalmitoylation, based on the recent literature (PMID:37802025).</p> </li> <li> <p>Correct Use of Causal Relations: The model uses appropriate causal relations (directly positively regulates, directly negatively regulates) to show how the activities influence each other.</p> </li> <li> <p>Proper Cellular Component Annotations: The activities are correctly annotated with their cellular components (cytosol).</p> </li> <li> <p>Evidence Strength: All associations are supported by experimental evidence codes (ECO:0000314 - direct assay evidence) and cited with appropriate PMIDs.</p> </li> <li> <p>Complete Pathway Representation: The model captures the complete pathway from palmitoylation to depalmitoylation and shows how these modifications affect cGAS function.</p> </li> </ol>"},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Molecular Details: The model does not explicitly include which specific residues of cGAS (Cys-404 and Cys-405) are palmitoylated by ZDHHC9 and depalmitoylated by LYPLAL1. This information is available in the literature (PMID:37802025) and could potentially be added as annotations to enrich the model.</p> </li> <li> <p>Activity Chain Completeness: The model correctly shows that CGAS DNA binding leads to molecular condensate scaffold activity and then to cGMP-AMP synthase activity, which aligns with our understanding that DNA binding leads to phase separation and activation of enzymatic activity.</p> </li> <li> <p>Downstream Effects: While the model focuses on the regulation of cGAS activity, it could be extended to include downstream effects in the cGAS/STING pathway, such as the activation of STING by cGAMP and subsequent type I interferon production.</p> </li> </ol>"},{"location":"reviews/65288b2200000496-Regulation_of_CGAS_activity_via_palmitoylation_and_depalmitoylation_by_ZDHHC9_and_LYPLAL1__respectively__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:65288b2200000496 is a well-constructed representation of the regulation of cGAS activity via palmitoylation and depalmitoylation by ZDHHC9 and LYPLAL1, respectively. It accurately captures the key molecular activities and their causal relationships as described in recent literature.</p> <p>The model follows the GO-CAM curation guidelines and best practices for representing regulatory processes and enzyme activities. The causal flow from palmitoylation to DNA binding, molecular condensate formation, and enzymatic activity is logically structured and biologically sound.</p> <p>The model could potentially be enhanced by adding specific details about the residues involved in palmitoylation/depalmitoylation and by extending it to include downstream effects of cGAS activation, but these are not necessary for the core representation of the regulatory process.</p> <p>Overall, this is a high-quality GO-CAM model that effectively captures current knowledge about the regulation of cGAS activity through post-translational modifications.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/","title":"65288b2200000643 STING1 trafficking from the endoplasmic reticulum and the ERGIC following phosphorylation by MAP3K7 TAK1 and interaction with STEEP1  Human","text":"<p>Based on the information gathered, let me now conduct a thorough review of the GO-CAM model gomodel:65288b2200000643.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#review-of-go-cam-model-65288b2200000643","title":"Review of GO-CAM Model: 65288b2200000643","text":""},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#model-overview","title":"Model Overview","text":"<p>Title: STING1 trafficking from the endoplasmic reticulum and the ERGIC following phosphorylation by MAP3K7/TAK1 and interaction with STEEP1 (Human)</p> <p>ID: gomodel:65288b2200000643</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#model-content-and-biological-context","title":"Model Content and Biological Context","text":"<p>This GO-CAM model represents the pathway for STING1 trafficking from the endoplasmic reticulum (ER) through the ER-Golgi intermediate compartment (ERGIC) following its activation. The model focuses on the roles of MAP3K7/TAK1 (mitogen-activated protein kinase kinase kinase 7) and STEEP1 (STING ER exit protein) in this process, which is a critical part of the innate immune response to cytosolic DNA.</p> <p>The model comprises a signaling pathway where:</p> <ol> <li>STING1 (Stimulator of interferon genes protein) is activated by binding cGAMP</li> <li>STEEP1 acts as a molecular adapter that facilitates STING1 exit from the ER</li> <li>MAP3K7/TAK1 phosphorylates STING1, which promotes its interaction with STEEP1</li> <li>The phosphorylated STING1-STEEP1 complex promotes STING1 translocation to COPII vesicles</li> <li>This trafficking is essential for downstream signaling in the cGAS-STING pathway</li> </ol>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#detailed-component-analysis","title":"Detailed Component Analysis","text":""},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#activity-1-steep1s-signaling-adaptor-activity","title":"Activity 1: STEEP1's signaling adaptor activity","text":"<ul> <li>Enabled by: UniProtKB:Q86WV6 (STING1)</li> <li>Molecular function: GO:0061507 (2',3'-cyclic GMP-AMP binding)</li> <li>Location: GO:0005789 (endoplasmic reticulum membrane)</li> <li>Part of process: GO:0140896 (cGAS/STING signaling pathway)</li> <li>Causal association: Directly positively regulates STEEP1's signaling adaptor activity</li> </ul> <p>This correctly represents STING1's binding to cGAMP at the ER membrane, which is the initial step in STING activation.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#activity-2-steep1s-signaling-adaptor-activity","title":"Activity 2: STEEP1's signaling adaptor activity","text":"<ul> <li>Enabled by: UniProtKB:Q86WV6 (STING1)</li> <li>Molecular function: GO:0035591 (signaling adaptor activity)</li> <li>Location: GO:0005789 (endoplasmic reticulum membrane)</li> <li>Part of process: GO:0070972 (protein localization to endoplasmic reticulum)</li> <li>Causal association: Directly positively regulates MAP3K7/TAK1's protein serine/threonine kinase activator activity</li> </ul> <p>This represents STING1's adaptor activity in the ER membrane as part of protein localization.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#activity-3-map3k7tak1s-protein-serinethreonine-kinase-activator-activity","title":"Activity 3: MAP3K7/TAK1's protein serine/threonine kinase activator activity","text":"<ul> <li>Enabled by: UniProtKB:Q15750 (TAB1)</li> <li>Molecular function: GO:0043539 (protein serine/threonine kinase activator activity)</li> <li>Location: GO:0005789 (endoplasmic reticulum membrane)</li> <li>Part of process: GO:0141111 (positive regulation of cGAS/STING signaling pathway)</li> <li>Causal association: Directly positively regulates MAP3K7/TAK1's protein serine/threonine kinase activity</li> </ul> <p>This represents the activation of MAP3K7/TAK1 by TAB1 in the context of STING signaling, consistent with the literature.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#activity-4-map3k7tak1s-protein-serinethreonine-kinase-activity","title":"Activity 4: MAP3K7/TAK1's protein serine/threonine kinase activity","text":"<ul> <li>Enabled by: UniProtKB:O43318-4 (MAP3K7/TAK1)</li> <li>Molecular function: GO:0004674 (protein serine/threonine kinase activity)</li> <li>Location: GO:0005789 (endoplasmic reticulum membrane)</li> <li>Part of process: GO:0141111 (positive regulation of cGAS/STING signaling pathway)</li> <li>Causal association: Directly positively regulates STEEP1's protein-macromolecule adaptor activity</li> </ul> <p>This represents the critical kinase activity of MAP3K7/TAK1 that phosphorylates STING1, which is essential for the subsequent step in the pathway.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#activity-5-steep1s-protein-macromolecule-adaptor-activity","title":"Activity 5: STEEP1's protein-macromolecule adaptor activity","text":"<ul> <li>Enabled by: UniProtKB:Q9H5V9 (STEEP1)</li> <li>Molecular function: GO:0030674 (protein-macromolecule adaptor activity)</li> <li>Location: GO:0005789 (endoplasmic reticulum membrane)</li> <li>Part of process: GO:0032527 (protein exit from endoplasmic reticulum)</li> <li>Causal association: Directly positively regulates STING1's signaling adaptor activity in the ERGIC</li> </ul> <p>This represents STEEP1's role as an adaptor that facilitates STING1's exit from the ER, consistent with recent findings.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#activity-6-sting1s-signaling-adaptor-activity-at-ergic","title":"Activity 6: STING1's signaling adaptor activity at ERGIC","text":"<ul> <li>Enabled by: UniProtKB:Q86WV6 (STING1)</li> <li>Molecular function: GO:0035591 (signaling adaptor activity)</li> <li>Location: GO:0033116 (endoplasmic reticulum-Golgi intermediate compartment membrane)</li> <li>Part of process: GO:0140896 (cGAS/STING signaling pathway)</li> <li>Causal association: Directly positively regulates TBK1's protein serine/threonine kinase activity (not shown in this model)</li> </ul> <p>This represents the continued adaptor function of STING1 after its translocation to the ERGIC, which is essential for downstream signaling.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is primarily supported by multiple recent publications, with PMID:37832545 (2023) as the key reference for the role of TAK1 in STING1 trafficking. This is a recent paper that shows that TAK1 phosphorylates STING at several sites, including Ser-355, which facilitates its interaction with STEEP1.</p> <p>Other supporting evidence includes: - PMID:30842659 (2019) - Provides structural insights into STING activation - PMID:32690950 (2020) - Characterizes STEEP1's role in STING ER exit - PMID:25636800 (2015) - Details the phosphorylation of STING</p> <p>The evidence codes used are appropriate (ECO:0000314 - direct assay evidence used in manual assertion).</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#overall-model-quality","title":"Overall Model Quality","text":"<p>The model accurately represents the current understanding of STING trafficking from the ER to the ERGIC following its activation. It incorporates recent discoveries about the role of TAK1 in phosphorylating STING and the function of STEEP1 as an adaptor that facilitates STING's ER exit.</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#strengths","title":"Strengths","text":"<ol> <li>Incorporates recent scientific findings about the role of STEEP1 and TAK1 in STING trafficking</li> <li>Uses appropriate GO terms to represent molecular functions and biological processes</li> <li>Correctly represents the subcellular locations of activities</li> <li>Causal relationships are logically structured and consistent with the literature</li> <li>Evidence is well-documented with recent, relevant publications</li> </ol>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by: - Using appropriate molecular function terms for the activities - Correctly representing causal relationships with appropriate predicates - Including cellular component information for each activity - Linking activities to biological processes - Providing evidence with appropriate evidence codes</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#alignment-with-literature-knowledge","title":"Alignment with Literature Knowledge","text":"<p>The model accurately reflects recent literature on STING trafficking and activation, particularly: - The role of cGAMP in activating STING - The phosphorylation of STING by TAK1/MAP3K7 at specific sites (including Ser-355) - The interaction between phosphorylated STING and STEEP1 - The facilitation of STING exit from the ER and trafficking to the ERGIC - The importance of these events for downstream innate immune signaling</p>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#recommendations","title":"Recommendations","text":"<p>The model is well-constructed and consistent with current knowledge. A few minor suggestions for potential improvements:</p> <ol> <li> <p>Complete the downstream pathway: The model could be extended to include the downstream steps of STING signaling, including the activation of TBK1 and IRF3, which leads to type I interferon production.</p> </li> <li> <p>Include additional relevant PTMs: While the phosphorylation of STING by TAK1 is represented, other important post-translational modifications like palmitoylation at Cys-91 could be included, as this is known to be critical for STING activation.</p> </li> <li> <p>Represent STING dimerization/oligomerization: The model could explicitly represent STING's dimerization and oligomerization, which are important for its activation and trafficking.</p> </li> <li> <p>Include the role of VPS34 complex I: Recent research shows that STEEP1 recruits the VPS34 complex I to produce PI3P at the ER, which promotes membrane curvature and STING trafficking. This aspect could be included for completeness.</p> </li> </ol>"},{"location":"reviews/65288b2200000643-STING1_trafficking_from_the_endoplasmic_reticulum_and_the_ERGIC_following_phosphorylation_by_MAP3K7_TAK1_and_interaction_with_STEEP1__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:65288b2200000643 is a high-quality representation of the STING1 trafficking pathway that accurately reflects current scientific knowledge. It incorporates recent discoveries about the roles of MAP3K7/TAK1 and STEEP1 in this process and uses appropriate GO terms and relationships to model the biological pathway. The model is well-supported by evidence from recent publications and follows GO-CAM best practices.</p> <p>This model makes a valuable contribution to understanding the molecular mechanisms of STING-mediated innate immune responses, particularly the early steps involving STING activation and trafficking, which are critical for downstream signaling.</p>"},{"location":"reviews/65288b2200001166-TRIM55_and_TRIM21_mediated_inhibition_of_NFKB2__Human_/","title":"65288b2200001166 TRIM55 and TRIM21 mediated inhibition of NFKB2  Human","text":"<p>Based on my review, I'll now provide a detailed assessment of the GO-CAM model gomodel:65288b2200001166 titled \"TRIM55 and TRIM21-mediated inhibition of NFKB2 (Human)\".</p>"},{"location":"reviews/65288b2200001166-TRIM55_and_TRIM21_mediated_inhibition_of_NFKB2__Human_/#go-cam-review-trim55-and-trim21-mediated-inhibition-of-nfkb2-human","title":"GO-CAM Review: TRIM55 and TRIM21-mediated inhibition of NFKB2 (Human)","text":""},{"location":"reviews/65288b2200001166-TRIM55_and_TRIM21_mediated_inhibition_of_NFKB2__Human_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:65288b2200001166) represents the molecular mechanisms by which TRIM55 and TRIM21 regulate the non-canonical NF-\u03baB signaling pathway through ubiquitination of NFKB2 (p100/p52) in human cells. The model captures how TRIM55 facilitates TRIM21-mediated K63-linked ubiquitination of VCP, which in turn promotes K48-linked ubiquitin-dependent degradation of NFKB2, ultimately inhibiting its DNA-binding transcription activator activity.</p>"},{"location":"reviews/65288b2200001166-TRIM55_and_TRIM21_mediated_inhibition_of_NFKB2__Human_/#model-structure-and-accuracy","title":"Model Structure and Accuracy","text":"<p>The model includes five key activities:</p> <ol> <li>TRIM55's E3 ubiquitin ligase activity (GO:0061630) targeting VCP for K48-linked ubiquitination</li> <li>TRIM55's protein-macromolecule adaptor activity (GO:0030674)</li> <li>TRIM21's E3 ubiquitin ligase activity (GO:0061630) mediating K63-linked ubiquitination</li> <li>VCP's K48-linked polyubiquitin modification-dependent protein binding activity (GO:0036435)</li> <li>NFKB2's DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228)</li> </ol>"},{"location":"reviews/65288b2200001166-TRIM55_and_TRIM21_mediated_inhibition_of_NFKB2__Human_/#correct-aspects","title":"Correct aspects:","text":"<ol> <li> <p>Proper evidence and citations: The model uses appropriate evidence codes and citations, with most activities citing PMID:37816088 using ECO:0000314 (direct assay evidence).</p> </li> <li> <p>Appropriate causal relationships: The causal relationships between activities use the proper relation types:</p> </li> <li>TRIM55's adaptor activity provides input for (RO:0002413) TRIM21's ligase activity</li> <li>TRIM55's ligase activity provides input for (RO:0002413) VCP's binding activity</li> <li>TRIM21's ligase activity directly positively regulates (RO:0002629) VCP's binding activity</li> <li> <p>VCP's binding activity directly negatively regulates (RO:0002630) NFKB2's transcription activity</p> </li> <li> <p>Appropriate biological process annotations: Each activity is associated with relevant biological processes:</p> </li> <li>TRIM55's ubiquitin ligase activity is part of protein K48-linked ubiquitination (GO:0070936)</li> <li>TRIM55's adaptor activity is part of positive regulation of non-canonical NF-kappaB signal transduction (GO:1901224)</li> <li>TRIM21's ligase activity is part of protein K63-linked ubiquitination (GO:0070534)</li> <li>VCP's binding activity is part of positive regulation of non-canonical NF-kappaB signal transduction (GO:1901224)</li> <li> <p>NFKB2's activity is part of canonical NF-kappaB signal transduction (GO:0007249)</p> </li> <li> <p>Correct subcellular locations: Activities are appropriately localized:</p> </li> <li>TRIM55 and TRIM21 are in the cytoplasm (GO:0005737)</li> <li>NFKB2 is in the nucleus (GO:0005634)</li> <li>VCP is in the cytoplasm (GO:0005737)</li> </ol>"},{"location":"reviews/65288b2200001166-TRIM55_and_TRIM21_mediated_inhibition_of_NFKB2__Human_/#discrepancies-and-suggested-improvements","title":"Discrepancies and Suggested Improvements","text":"<ol> <li> <p>Clarification of NF-\u03baB pathway: The model associates NFKB2's transcription activity with canonical NF-\u03baB signaling (GO:0007249), but according to the PMID:37816088 paper, TRIM55 specifically regulates the non-canonical NF-\u03baB pathway. This association should be updated to non-canonical NF-kappaB signaling.</p> </li> <li> <p>VCP's role clarification: While the model accurately represents VCP's activity based on the cited publication, it could be clearer about the specific mechanism by which VCP promotes NFKB2 processing. According to the paper, VCP, upon K63-linked ubiquitination by TRIM21, helps in extracting and processing p100 (NFKB2) to generate p52.</p> </li> <li> <p>Missing molecular details: The model doesn't explicitly capture the formation of the VCP-UFD1-NPL4 complex, which according to the paper is crucial for p100 processing. Considering adding this complex or noting its role.</p> </li> <li> <p>Incomplete representation of the pathway: The model focuses on the inhibitory aspect of NFKB2 regulation, but doesn't fully capture that this processing is actually part of the activation of the non-canonical NF-\u03baB pathway (as p52 generation is a necessary step).</p> </li> <li> <p>Biological process associations: While the current biological process associations are generally appropriate, consider adding more specific terms related to B-cell immune responses or germinal center formation, which are highlighted as downstream consequences in the paper.</p> </li> </ol>"},{"location":"reviews/65288b2200001166-TRIM55_and_TRIM21_mediated_inhibition_of_NFKB2__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>Based on the GO-CAM guidelines for E3 ubiquitin ligases:</p> <ol> <li> <p>E3 ligase activity annotation: The model correctly represents TRIM55 and TRIM21 with ubiquitin protein ligase activity (GO:0061630) and appropriate biological processes describing the type of ubiquitination (K48-linked and K63-linked, respectively).</p> </li> <li> <p>Complex annotation: The model correctly represents the individual activities rather than using a complex term, which is appropriate since the specific activities of each protein are known.</p> </li> <li> <p>Causal relationships: The model properly uses the \"provides input for\" and \"directly regulates\" (positively or negatively) relationships between activities as specified in the guidelines.</p> </li> </ol>"},{"location":"reviews/65288b2200001166-TRIM55_and_TRIM21_mediated_inhibition_of_NFKB2__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the molecular mechanisms described in the primary literature. It follows most GO-CAM best practices for representing E3 ubiquitin ligases and their regulatory networks. The few suggested improvements would make the model even more precisely aligned with the biological mechanisms described in the source paper.</p> <p>The model could be enhanced by: 1. Correcting the pathway association for NFKB2 from canonical to non-canonical NF-\u03baB signaling 2. Possibly adding the VCP-UFD1-NPL4 complex formation 3. Clarifying the dual role of p100 processing as both inhibition of full-length NFKB2 and activation of p52-mediated signaling 4. Adding more specific downstream biological processes related to B-cell function</p> <p>Despite these minor suggestions, the model is generally accurate, well-evidenced, and properly represents the molecular mechanisms described in the literature.</p>"},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/","title":"65288b2200001218 USP9X TRIM32 modulation of  IQCB1 during G1 S  Human","text":"<p>Based on my detailed review of the GO-CAM model \"gomodel:65288b2200001218\" titled \"USP9X-TRIM32 modulation of IQCB1 during G1-S (Human)\", I can now provide a comprehensive assessment.</p>"},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#go-cam-review-usp9x-trim32-modulation-of-iqcb1-during-g1-s-human","title":"GO-CAM Review: USP9X-TRIM32 modulation of IQCB1 during G1-S (Human)","text":""},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM models the molecular interactions between three key proteins involved in ciliogenesis regulation: 1. IQCB1/NPHP5 (Q15051) - a centrosomal protein that regulates ciliogenesis  2. USP9X (Q93008) - a deubiquitinating enzyme 3. TRIM32 (Q13049) - an E3 ubiquitin ligase</p> <p>The model shows how USP9X and TRIM32 regulate IQCB1 during the G1-S phase of the cell cycle through different types of ubiquitination, which controls cilium assembly. This is supported primarily by evidence from PMID:28498859.</p>"},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#model-accuracy-assessment","title":"Model Accuracy Assessment","text":""},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#biological-content-evaluation","title":"Biological Content Evaluation","text":"<p>The model is biologically accurate and aligns well with the literature evidence. The central paper (PMID:28498859) describes how: - USP9X deubiquitinates NPHP5/IQCB1, protecting it from degradation during G0/G1/S phase - TRIM32 (BBS11) negatively regulates ciliogenesis by K63-linked ubiquitination of IQCB1, leading to its delocalization - These mechanisms are part of controlling cilia assembly/disassembly through the cell cycle</p> <p>The GO-CAM correctly represents these interactions where: - USP9X's deubiquitinating activity (GO:0101005) directly positively regulates IQCB1's BBSome binding (GO:0062063) - TRIM32's E3 ligase activity (GO:0061630) directly negatively regulates IQCB1's BBSome binding - IQCB1 functions as a protein-macromolecule adaptor (GO:0030674) providing input for USP9X's activity</p>"},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#molecular-function-and-causal-relationship-evaluation","title":"Molecular Function and Causal Relationship Evaluation","text":"<p>The MF and causal relationship annotations are appropriate: 1. USP9X's deubiquitinase activity (GO:0101005) \u2192 directly positively regulates (RO:0002629) \u2192 IQCB1's BBSome binding (GO:0062063) 2. TRIM32's ubiquitin ligase activity (GO:0061630) \u2192 directly negatively regulates (RO:0002630) \u2192 IQCB1's BBSome binding (GO:0062063) 3. IQCB1's adaptor activity (GO:0030674) \u2192 provides input for (RO:0002413) \u2192 USP9X's activity (GO:0101005)</p> <p>These connections are well-supported by the evidence presented and use the correct relation predicates.</p>"},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#spatial-localization-evaluation","title":"Spatial Localization Evaluation","text":"<p>The cellular locations are accurately represented: - All three proteins are correctly localized to the centrosome (GO:0005813) - This is substantiated by the experimental evidence provided</p>"},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#biological-process-context-evaluation","title":"Biological Process Context Evaluation","text":"<p>The model correctly places these activities in the biological process context: - USP9X's and IQCB1's activities are part of cytosolic ciliogenesis (GO:0061824) - TRIM32's activity is part of negative regulation of cilium assembly (GO:1902018)</p> <p>Both of these processes are accurately supported by the literature evidence.</p>"},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#specific-issues-and-improvement-recommendations","title":"Specific Issues and Improvement Recommendations","text":"<p>While the model is generally well-constructed, I identified a few potential improvements:</p> <ol> <li> <p>Additional process contexts: The model could benefit from adding the cell cycle context (G1-S transition) mentioned in the title. The literature clearly describes how these interactions vary through the cell cycle, with USP9X protecting IQCB1 during G0/G1/S, and TRIM32 regulating it during G2/M.</p> </li> <li> <p>Complex representation: According to the GO-CAM complex annotation guidelines, if the subunit carrying an activity is known (as in this case), we should represent each protein individually rather than using a complex ID. The model correctly follows this guideline.</p> </li> <li> <p>Missing components: The literature mentions MARCH7 as another E3 ligase interacting with IQCB1, adding K48-linked ubiquitination leading to degradation. This component could potentially be added for completeness, although the current focus on TRIM32 is valid.</p> </li> <li> <p>Temporal dynamics: The model could better capture how ubiquitination and deubiquitination change through the cell cycle. The paper describes how USP9X dissociates from the centrosome in G2/M phase, which enables TRIM32 to K63-ubiquitinate IQCB1, triggering delocalization.</p> </li> </ol>"},{"location":"reviews/65288b2200001218-USP9X_TRIM32_modulation_of__IQCB1_during_G1_S__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model provides a clear and accurate representation of how USP9X and TRIM32 regulate IQCB1 in cilia formation. The model effectively: - Uses appropriate molecular functions for each protein - Correctly applies causal relationship predicates - Places activities in the proper cellular locations - Assigns activities to the correct biological processes</p> <p>The modular nature of the model makes it easy to understand the regulatory relationships between these proteins, and the evidence provided substantiates all the assertions.</p> <p>The model successfully captures a critical mechanism for regulating ciliogenesis, which has implications for understanding ciliopathies like Bardet-Biedl syndrome and Senior-Loken syndrome associated with mutations in TRIM32 and IQCB1, respectively.</p>"},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/","title":"65288b2200001267 USP9X TRIM32 modulation of IQCB1 during G2 M  Human","text":"<p>Now I have a better understanding of the guidelines. Let me synthesize all the information about this GO-CAM model and provide a comprehensive review.</p>"},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/#review-of-go-cam-model-gomodel65288b2200001267","title":"Review of GO-CAM Model: gomodel:65288b2200001267","text":""},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/#model-title","title":"Model Title","text":"<p>\"USP9X-TRIM32 modulation of IQCB1 during G2-M (Human)\"</p>"},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/#overview","title":"Overview","text":"<p>This model describes a molecular pathway involving USP9X (deubiquitinating enzyme), TRIM32 and MARCH7 (E3 ubiquitin ligases), and IQCB1/NPHP5 (a protein with adaptor activity). The model shows how these proteins interact during cilium assembly regulation within the centrosome.</p>"},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model consists of four key activities: 1. TRIM32 (Q13049) - ubiquitin protein ligase activity (GO:0061630) 2. IQCB1 (Q15051) - protein-macromolecule adaptor activity (GO:0030674) 3. MARCHF7/MARCH7 (Q9H992) - ubiquitin protein ligase activity (GO:0061630) 4. USP9X (Q93008) - molecular sequestering activity (GO:0140313)</p> <p>These activities are connected through causal relationships: - TRIM32 activity directly negatively regulates (RO:0002630) IQCB1 activity - MARCH7 activity directly negatively regulates (RO:0002630) IQCB1 activity - USP9X activity directly negatively regulates (RO:0002630) MARCH7 activity</p> <p>The model shows the biological processes involved: - TRIM32 and MARCH7 are part of negative regulation of cilium assembly (GO:1902018) - IQCB1 and USP9X are part of cilium assembly (GO:0060271)</p> <p>Cellular locations: - TRIM32, MARCH7, and IQCB1 occur in the centrosome (GO:0005813) - USP9X occurs in the cytoplasm (GO:0005737)</p>"},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>Based on the literature: 1. The model correctly represents that IQCB1/NPHP5 is a positive regulator of ciliogenesis (cilium assembly), as confirmed by PMID 28498859. 2. IQCB1 directly binds to USP9X (a deubiquitinating enzyme) and two E3 ubiquitin ligases (TRIM32 and MARCH7), which is consistent with the literature. 3. The model correctly captures that IQCB1 undergoes ubiquitination by TRIM32 and MARCH7, which negatively regulates its function in cilium assembly. 4. USP9X counteracts the ubiquitination of NPHP5/IQCB1 to regulate ciliogenesis, as shown in PMID 28498859. 5. The location of these activities in the centrosome is supported by the literature, as IQCB1 is localized to the ciliary transition zone and centrosome.</p>"},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li>Molecular Function Representation:</li> <li>Each protein has a correctly assigned molecular function term</li> <li>TRIM32 and MARCH7 have E3 ubiquitin ligase activity (GO:0061630)</li> <li>IQCB1 is assigned protein-macromolecule adaptor activity (GO:0030674), which is appropriate</li> <li> <p>USP9X is assigned molecular sequestering activity (GO:0140313) - this is a bit unusual but appears to be attempting to represent its role in counteracting ubiquitination</p> </li> <li> <p>Causal Relationships:</p> </li> <li>The model uses \"directly negatively regulates\" (RO:0002630) consistently and appropriately to indicate the direct negative regulatory relationships between proteins</li> <li> <p>This follows the guidelines for representing regulation in GO-CAM</p> </li> <li> <p>Biological Process Context:</p> </li> <li>Each molecular function is appropriately placed within a biological process context</li> <li> <p>The processes (negative regulation of cilium assembly and cilium assembly) accurately capture the roles of these proteins</p> </li> <li> <p>Cellular Component Context:</p> </li> <li>Each activity has an appropriate cellular location</li> <li>The centrosome location for TRIM32, MARCH7, and IQCB1 is accurate</li> <li>USP9X in cytoplasm is also accurate, though it should be noted that USP9X also localizes to centrosomes according to literature</li> </ol>"},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>USP9X molecular function:</li> <li>The use of \"molecular sequestering activity\" (GO:0140313) for USP9X is somewhat unconventional</li> <li> <p>USP9X is primarily a deubiquitinating enzyme, so \"deubiquitinase activity\" (GO:0101005) or \"ubiquitin-specific protease activity\" would be more appropriate</p> </li> <li> <p>Completeness:</p> </li> <li>The model captures the core regulatory interactions but could be expanded to include more details on how this regulation affects downstream cilium assembly processes</li> <li> <p>The connection to G2-M phase mentioned in the title could be made more explicit in the model</p> </li> <li> <p>Evidence:</p> </li> <li>All activities have evidence from publications, which is good practice</li> <li> <p>However, it would be helpful to include more specific evidence for each causal relationship</p> </li> <li> <p>Causal flow clarity:</p> </li> <li>The causal flow from USP9X to MARCH7 to IQCB1 could be made clearer by possibly showing how USP9X might also directly affect IQCB1</li> </ol>"},{"location":"reviews/65288b2200001267-USP9X_TRIM32_modulation_of_IQCB1_during_G2_M__Human__/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that accurately represents the biological interactions between USP9X, TRIM32, MARCH7, and IQCB1 in regulating cilium assembly. The model is consistent with the scientific literature and generally follows GO-CAM best practices.</p> <p>The model effectively captures the antagonistic relationship between E3 ubiquitin ligases (TRIM32 and MARCH7) and the deubiquitinating enzyme USP9X in regulating IQCB1's role in cilium assembly. The use of appropriate molecular functions, biological processes, and cellular components creates a coherent and biologically meaningful representation.</p> <p>The main recommendation would be to reconsider the molecular function assigned to USP9X to better reflect its deubiquitinating enzymatic activity rather than using the more general \"molecular sequestering activity\" term.</p>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/","title":"653b0ce600000202 BRD3 and lncRNA DIGIT form phase separated condensates to induce endoderm cell differentiation  Human","text":"<p>Now I'll review the GO-CAM model you provided:</p>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#review-of-go-cam-model-gomodel653b0ce600000202","title":"Review of GO-CAM Model gomodel:653b0ce600000202","text":""},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the molecular mechanisms by which BRD3 and the long non-coding RNA DIGIT form phase-separated condensates to induce endoderm cell differentiation in humans. The model title is \"BRD3 and lncRNA DIGIT form phase-separated condensates to induce endoderm cell differentiation (Human).\"</p>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#model-components","title":"Model Components","text":"<p>The model includes the following key activities:</p> <ol> <li>BRD3 (UniProtKB:Q15059) molecular condensate scaffold activity (GO:0140693)</li> <li>BRD3 (UniProtKB:Q15059) lysine-acetylated histone binding (GO:0070577)</li> <li>lncRNA DIGIT (RNAcentral:URS0000A77281_9606) protein binding (GO:0005515)</li> <li>EP300 (UniProtKB:Q09472) histone H3K18 acetyltransferase activity (GO:0043993)</li> </ol>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#model-connections-and-causal-relationships","title":"Model Connections and Causal Relationships","text":"<ul> <li>DIGIT protein binding directly positively regulates (RO:0002629) BRD3's molecular condensate scaffold activity</li> <li>BRD3's molecular condensate scaffold activity directly positively regulates (RO:0002629) BRD3's lysine-acetylated histone binding activity</li> <li>EP300's histone H3K18 acetyltransferase activity provides input for (RO:0002413) BRD3's lysine-acetylated histone binding activity</li> </ul>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#cellular-context","title":"Cellular Context","text":"<ul> <li>BRD3's molecular condensate scaffold activity and lysine-acetylated histone binding activity occurs in chromatin (GO:0000785)</li> <li>All activities are part of endodermal cell differentiation process (GO:0035987)</li> </ul>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#evidence","title":"Evidence","text":"<p>The model is supported by evidence from the paper PMID:32895492, which identifies BRD3 and DIGIT form phase-separated condensates to regulate endoderm differentiation. The EP300 histone acetyltransferase activity is supported by evidence from PMID:21131905.</p>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#strengths","title":"Strengths","text":"<ol> <li>The model accurately represents the findings from the primary literature (PMID:32895492) regarding the phase-separated condensate formation by BRD3 and DIGIT</li> <li>The causal relationships between molecules are correctly represented using appropriate relationship predicates</li> <li>The model includes appropriate cellular contexts for the molecular activities</li> <li>All activities are properly linked to the biological process of endodermal cell differentiation</li> <li>The model includes appropriate evidence citations</li> </ol>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#potential-improvements","title":"Potential Improvements","text":"<ol> <li> <p>Missing detailed mechanistic connections: The model could be enhanced by including more details about how the BRD3-DIGIT condensates specifically regulate endoderm differentiation genes. The literature indicates BRD3 occupies enhancers of endoderm transcription factors, but these genes and their specific regulation are not included in the model.</p> </li> <li> <p>Missing complex information: According to the publication, BRD3 and DIGIT form phase-separated condensates, which could be modeled using a complex representation. According to the document on how to annotate complexes in GO-CAM, if the activity is shared by several proteins, these should be properly represented.</p> </li> <li> <p>Missing detailed activities of EP300: While the model correctly shows EP300's role in H3K18 acetylation, it could further detail how EP300 is recruited to specific genomic loci during endoderm differentiation.</p> </li> <li> <p>Missing activity regulation details: The model could be improved by representing how the BRD3-DIGIT condensates' formation is regulated or affected by cellular conditions during endoderm differentiation.</p> </li> </ol>"},{"location":"reviews/653b0ce600000202-BRD3_and_lncRNA_DIGIT_form_phase_separated_condensates_to_induce_endoderm_cell_differentiation__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model provides a good representation of the core molecular mechanisms by which BRD3 and DIGIT interact to form phase-separated condensates that regulate endoderm differentiation. The model correctly uses appropriate GO terms and relationship predicates to represent the activities and their causal relationships.</p> <p>The primary literature strongly supports the model's representation of BRD3 and DIGIT forming phase-separated condensates to regulate endoderm differentiation. The model could be enhanced by including more detailed downstream effects on specific genes and transcription factors involved in endoderm differentiation, as indicated by the research paper.</p> <p>The model is consistent with the GO-CAM best practices for representing molecular activities and their causal relationships. Some additional molecular details could further enrich the model but would not change its core accurate representation of the biological process.</p>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/","title":"653b0ce600000382 TAX1BP1 mediated degradation of MAVS by E3 ligase ITCH  Human","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model gomodel:653b0ce600000382 \"TAX1BP1-mediated degradation of MAVS by E3 ligase ITCH (Human)\".</p>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#review-of-go-cam-model-tax1bp1-mediated-degradation-of-mavs-by-e3-ligase-itch-human","title":"Review of GO-CAM Model: TAX1BP1-mediated degradation of MAVS by E3 ligase ITCH (Human)","text":""},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#model-id-gomodel653b0ce600000382","title":"Model ID: gomodel:653b0ce600000382","text":""},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#model-summary","title":"Model Summary:","text":"<p>This model represents how TAX1BP1 mediates the degradation of MAVS (Mitochondrial antiviral-signaling protein) by the E3 ubiquitin ligase ITCH in human cells. The model involves four key proteins and their respective activities:</p> <ol> <li>MAVS (UniProtKB:Q7Z434) - signaling adaptor activity</li> <li>TAX1BP1 (UniProtKB:Q86VP1) - protein-macromolecule adaptor activity</li> <li>ITCH (UniProtKB:Q96J02) - ubiquitin protein ligase activity</li> <li>TRAF3IP3 (UniProtKB:Q9Y228) - molecular adaptor activity</li> </ol>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#evaluation-of-model-accuracy-and-completeness","title":"Evaluation of Model Accuracy and Completeness:","text":""},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#biological-content","title":"Biological Content:","text":"<p>The model correctly captures the biological relationship described in the literature where TAX1BP1 acts as an adaptor to facilitate ITCH-mediated ubiquitination and degradation of MAVS. This is supported by the evidence cited in the model, particularly PMID:27736772, which describes TAX1BP1's role in restraining virus-induced apoptosis by facilitating ITCH-mediated degradation of MAVS.</p>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#molecular-functions-and-locations","title":"Molecular Functions and Locations:","text":"<ul> <li>MAVS is correctly annotated with \"signaling adaptor activity\" (GO:0035591) and located in the mitochondrion (GO:0005739), which aligns with its known function and localization.</li> <li>TAX1BP1 is properly annotated with \"protein-macromolecule adaptor activity\" (GO:0030674) and also located in the mitochondrion, which is consistent with its role in facilitating ITCH-mediated degradation of MAVS.</li> <li>ITCH is annotated with \"ubiquitin protein ligase activity\" (GO:0061630) and located in the mitochondrion, which accurately represents its role in ubiquitinating MAVS.</li> <li>TRAF3IP3 is annotated with \"molecular adaptor activity\" (GO:0060090) and located in the mitochondrion, which is consistent with its role in the model.</li> </ul>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#causal-relationships","title":"Causal Relationships:","text":"<p>The model correctly uses the following causal relations: - TAX1BP1's adaptor activity \"provides input for\" (RO:0002413) ITCH's ubiquitin ligase activity, which is appropriate for an adaptor that brings together an enzyme and its substrate. - ITCH's ubiquitin ligase activity \"directly negatively regulates\" (RO:0002630) MAVS's signaling adaptor activity, which correctly represents ITCH-mediated degradation of MAVS. - MAVS's signaling adaptor activity \"directly positively regulates\" (RO:0002629) TRAF3IP3's molecular adaptor activity, which accurately reflects MAVS's role in activating downstream signaling components.</p>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#process-annotations","title":"Process Annotations:","text":"<ul> <li>MAVS and TRAF3IP3 are both annotated as part of \"cytoplasmic pattern recognition receptor signaling pathway\" (GO:0002753), which is accurate.</li> <li>TAX1BP1 is annotated as part of \"negative regulation of cytoplasmic pattern recognition receptor signaling pathway\" (GO:0039532), which correctly represents its role in downregulating MAVS-mediated signaling.</li> <li>ITCH is annotated as part of \"protein K48-linked ubiquitination\" (GO:0070936), which is the appropriate process for its role in targeting MAVS for degradation.</li> </ul>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices:","text":"<ol> <li> <p>Molecular Adaptors Annotation: The model correctly follows the guidelines for annotating molecular adaptors. Both TAX1BP1 and TRAF3IP3 are annotated with appropriate adaptor molecular functions, and the \"provides input for\" relation is correctly used for TAX1BP1's role in facilitating ITCH's activity.</p> </li> <li> <p>Complex Representation: The model doesn't explicitly represent any protein complexes but correctly represents the individual proteins and their respective activities, which is appropriate given that specific protein-protein interactions rather than stable complexes are being modeled.</p> </li> <li> <p>Evidence: Each activity and causal relationship is supported by appropriate evidence codes and PMID references, which is in line with GO-CAM best practices.</p> </li> <li> <p>Biological Pathway Representation: The model represents a cohesive biological pathway with clear directionality from MAVS to TRAF3IP3, with regulatory inputs from TAX1BP1 and ITCH, making it easy to understand the overall process.</p> </li> </ol>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Consider Additional Context: The model could be enhanced by including more context about what triggers this pathway, such as viral infection, which could be represented as an upstream cause.</p> </li> <li> <p>Detailed Process Outcomes: The model currently doesn't explicitly show the outcome of MAVS degradation for cellular processes. Adding downstream effects, such as reduced interferon production or inhibition of apoptosis, would provide a more complete picture.</p> </li> <li> <p>Consider Adding TRAF3: The model mentions TRAF3IP3 but doesn't include TRAF3 itself, which might be relevant given TRAF3's important role in MAVS signaling as indicated by the UniProt entries.</p> </li> </ol>"},{"location":"reviews/653b0ce600000382-TAX1BP1_mediated_degradation_of_MAVS_by_E3_ligase_ITCH__Human_/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model accurately represents the TAX1BP1-mediated degradation of MAVS by the E3 ligase ITCH in human cells. The model adheres to GO-CAM best practices for representing molecular adaptors and signaling pathways. The causal relationships between the activities are appropriately represented with clear directionality. The model includes appropriate evidence for all assertions and correctly represents the subcellular localizations of the proteins involved. Minor enhancements could be made to provide more context and downstream effects, but overall this is a well-constructed GO-CAM model that effectively captures the biological process it aims to represent.</p>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/","title":"653b0ce600000432 TRIM32 TAX1BP1 dependent selective autophagic degradation of TICAM1  Human","text":"<p>Based on my research and the model details, I'll now provide a comprehensive review of the GO-CAM model gomodel:653b0ce600000432.</p>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#review-of-go-cam-model-gomodel653b0ce600000432","title":"Review of GO-CAM Model gomodel:653b0ce600000432","text":""},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:653b0ce600000432</li> <li>Title: TRIM32-TAX1BP1-dependent selective autophagic degradation of TICAM1 (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model represents a signaling pathway involving the TLR4 receptor, adaptors TICAM2 and TICAM1 (TRIF), the negative regulator complex of TRIM32-TAX1BP1, and the DNA-binding transcription factor activity of IRF3. The model describes a mechanism for negatively regulating TLR3/4-mediated immune responses by targeting TICAM1 for selective autophagic degradation.</p>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model captures a key regulatory mechanism in TLR3/4 signaling as described in the literature, particularly in the paper by Yang et al. (2017, PMID:28898289). The model accurately represents:</p> <ol> <li>TLR4 receptor activity recruiting TICAM2</li> <li>TICAM2 acting as a molecular adaptor that directly positively regulates TICAM1</li> <li>TICAM1 molecular adaptor activity </li> <li>TAX1BP1 protein-macromolecule adaptor activity targeting TICAM1 for autophagic degradation</li> <li>TRIM32 protein-macromolecule adaptor activity providing input for TAX1BP1</li> <li>IRF3 DNA-binding transcription factor activity as a downstream effector</li> </ol>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#causal-connections-assessment","title":"Causal Connections Assessment","text":"<p>The causal connections in the model are appropriate and consistent with the literature:</p> <ol> <li>TLR4 signaling receptor activity \u2192 directly positively regulates \u2192 TICAM2 molecular adaptor activity  </li> <li>TICAM2 molecular adaptor activity \u2192 directly positively regulates \u2192 TICAM1 molecular adaptor activity</li> <li>TRIM32 protein-macromolecule adaptor activity \u2192 provides input for \u2192 TAX1BP1 protein-macromolecule adaptor activity</li> <li>TAX1BP1 protein-macromolecule adaptor activity \u2192 regulates autophagosome assembly \u2192 TICAM1 molecular adaptor activity</li> </ol> <p>These causal connections accurately reflect the mechanism described in the literature, where TRIM32 acts as a bridge protein that connects TICAM1 to TAX1BP1, leading to selective autophagic degradation of TICAM1 and termination of TLR3/4 signaling.</p>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#go-cam-best-practice-compliance","title":"GO-CAM Best Practice Compliance","text":"<p>The model largely follows GO-CAM best practices:</p> <ol> <li> <p>Molecular Adaptor Annotation: The model correctly uses GO:0060090 (molecular adaptor activity) for TICAM2 and TICAM1, and GO:0030674 (protein-macromolecule adaptor activity) for TAX1BP1 and TRIM32, consistent with the \"How to annotate molecular adaptors\" guidelines.</p> </li> <li> <p>Causal Relations: The use of \"directly positively regulates\" (RO:0002629) and \"provides input for\" (RO:0002413) is appropriate for the adaptor relationships described.</p> </li> <li> <p>Contextual Information: Each activity is properly annotated with cellular location (occurs_in) and biological process (part_of).</p> </li> <li> <p>Evidence Documentation: Evidence codes and PMIDs are properly included for almost all assertions.</p> </li> </ol>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, I have a few suggestions for improvement:</p> <ol> <li> <p>Add Missing Evidence: The causal association between TICAM2 and TICAM1 lacks evidence (evidence field is empty). This should be supported with an appropriate PMID, likely PMID:18222170 which is used elsewhere in the model.</p> </li> <li> <p>Consider Additional Activities: The model could potentially be enriched by including:</p> </li> <li>The downstream signaling components after TICAM1, such as TBK1 and its kinase activity</li> <li>The E3 ubiquitin ligase activity of TRIM32, although the paper indicates this function is E3-independent in this specific pathway</li> <li> <p>LC3 (MAP1LC3A is listed in the objects but not included in the model activities)</p> </li> <li> <p>Clarify Mechanism: The relationship between TAX1BP1 and TICAM1 uses \"RO:0002409\" which is not one of the standard causal relations mentioned in the instructions (appears to be related to autophagy). Consider whether this should be explicitly documented or use a more standard relation with additional context.</p> </li> </ol>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the key findings from Yang et al. (2017) that TRIM32 negatively regulates TLR3/4-mediated innate immune responses by promoting selective autophagic degradation of TICAM1 through TAX1BP1. The biological content is consistent with:</p> <ol> <li>The interaction and functional relationships between all proteins involved</li> <li>The subcellular locations of the activities</li> <li>The relevant biological processes</li> <li>The human-specific nature of this pathway</li> </ol>"},{"location":"reviews/653b0ce600000432-TRIM32_TAX1BP1_dependent_selective_autophagic_degradation_of_TICAM1__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that effectively captures a significant regulatory mechanism in TLR3/4 signaling. It accurately represents the role of TRIM32 and TAX1BP1 in the selective autophagic degradation of TICAM1, providing a clear visualization of how this process negatively regulates TLR3/4-mediated innate immune responses.</p> <p>The model is parsimonious, focusing on the key components and activities necessary to understand this regulatory mechanism. Minor improvements could be made by adding missing evidence and potentially expanding the model to include additional downstream components, but these are not critical issues.</p>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/","title":"653b0ce600000721 A checkpoint mediated by ATR that restricts activation of CDK1 during S phase   Human","text":"<p>Now that I've analyzed the model and relevant literature, I'll provide a comprehensive review of GO-CAM model gomodel:653b0ce600000721.</p>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#review-of-go-cam-model-653b0ce600000721","title":"Review of GO-CAM Model: 653b0ce600000721","text":""},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#model-summary","title":"Model Summary","text":"<p>Title: \"A checkpoint mediated by ATR that restricts activation of CDK1 during S-phase (Human)\"</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#model-structure-and-content","title":"Model Structure and Content","text":"<p>This GO-CAM model describes a regulatory pathway where ATR (Ataxia telangiectasia and Rad3-related protein) mediates a checkpoint that restricts CDK1 activation during S-phase. The model consists of four activities:</p> <ol> <li>ETAA1 (Q9NY74) - protein serine/threonine kinase activator activity (GO:0043539)</li> <li>Part of mitotic G2/M transition checkpoint (GO:0044818)</li> <li> <p>Positively regulates ATR activity</p> </li> <li> <p>ATR (Q13535) - protein serine/threonine kinase activity (GO:0004674)</p> </li> <li>Part of mitotic G2/M transition checkpoint (GO:0044818)</li> <li> <p>Negatively regulates CDK1 activity</p> </li> <li> <p>CDK1 (P06493) - cyclin-dependent protein serine/threonine kinase activity (GO:0004693)</p> </li> <li>Part of G2/M transition of mitotic cell cycle (GO:0000086)</li> <li> <p>Positively regulates FOXM1 activity</p> </li> <li> <p>FOXM1 (Q08050) - DNA-binding transcription factor activity (GO:0003700)</p> </li> <li>Part of G2/M transition of mitotic cell cycle (GO:0000086)</li> </ol>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>ETAA1 directly positively regulates ATR (RO:0002629)</li> <li>ATR causally upstream with negative effect on CDK1 (RO:0002305)</li> <li>CDK1 directly positively regulates FOXM1 (RO:0002629)</li> </ul>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#literature-support","title":"Literature Support","text":"<p>The model is supported by several publications: - PMID:27723717 and PMID:27723720 for ETAA1 activation of ATR - PMID:30139873 for ATR role in checkpoint and inhibition of CDK1 - PMID:21777809 for ATR phosphorylation and activation - PMID:19160488 for CDK1 phosphorylation and activation of FOXM1</p>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#model-quality-assessment","title":"Model Quality Assessment","text":""},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current knowledge of the ATR-mediated S/G2 checkpoint:</p> <ol> <li> <p>ETAA1 activation of ATR: This is well supported by the literature. ETAA1 contains an ATR-activating domain (AAD) that directly stimulates ATR kinase activity independently of TopBP1 (PMID:27723717).</p> </li> <li> <p>ATR inhibition of CDK1: The model correctly represents that ATR imposes a checkpoint that restricts CDK1 activity during S-phase to prevent premature entry into G2 phase (PMID:30139873).</p> </li> <li> <p>CDK1 activation of FOXM1: This relationship is well established. CDK1 phosphorylates FOXM1 at Thr-596 and Ser-678, creating docking sites for PLK1, which further phosphorylates and activates FOXM1 (PMID:19160488).</p> </li> </ol>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#go-cam-conventions","title":"GO-CAM Conventions","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Appropriate use of molecular function terms: Each protein is correctly associated with its known molecular function.</p> </li> <li> <p>Appropriate use of biological process terms: The processes \"mitotic G2/M transition checkpoint\" and \"G2/M transition of mitotic cell cycle\" are correctly used.</p> </li> <li> <p>Appropriate use of causal relations: The model uses the correct RO relations for positive and negative regulation.</p> </li> <li> <p>Evidence citations: All activities and causal relations have appropriate evidence codes and literature citations.</p> </li> </ol>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#improvement-suggestions","title":"Improvement Suggestions","text":"<p>While the model is well-constructed, there are a few potential improvements:</p> <ol> <li> <p>Include PLK1 in the model: The pathway from CDK1 to FOXM1 involves PLK1 as an important intermediary. CDK1 phosphorylates FOXM1, creating docking sites for PLK1, which further phosphorylates and activates FOXM1 (PMID:19160488). Adding this component would make the regulation of FOXM1 more complete.</p> </li> <li> <p>Clarify TopBP1-independent pathway: The model represents the ETAA1-mediated activation of ATR. It might be worth noting that this is a parallel pathway to the canonical TopBP1-mediated ATR activation. Both pathways function together to ensure robust ATR signaling (PMID:27723717).</p> </li> <li> <p>Include downstream targets of FOXM1: FOXM1 regulates the expression of several key mitotic genes, including PLK1, Cyclin B1, and Aurora B (PMID:19160488). Including these targets would provide a more complete picture of how this pathway regulates mitotic progression.</p> </li> </ol>"},{"location":"reviews/653b0ce600000721-A_checkpoint_mediated_by_ATR_that_restricts_activation_of_CDK1_during_S_phase___Human__/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:653b0ce600000721 provides an accurate representation of the ATR-mediated checkpoint that restricts CDK1 activation during S-phase. It correctly captures the roles of ETAA1, ATR, CDK1, and FOXM1 in this process and uses appropriate GO terms and relations to model their interactions.</p> <p>The model is well-supported by current literature and follows GO-CAM curation practices. With the suggested minor additions, it could more comprehensively represent the biological pathway, particularly the involvement of PLK1 in linking CDK1 to FOXM1 activation and the downstream effects of FOXM1 on the expression of mitotic regulators.</p> <p>Overall, this is a well-constructed model that provides valuable insights into the regulation of the G2/M transition checkpoint by ATR.</p>"},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/","title":"653b0ce600001230 KSHV ORF57 inhibition of host PKR  Human HHV8","text":"<p>Let me review the provided GO-CAM model based on my understanding of the model content and GO-CAM best practices:</p>"},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/#review-of-go-cam-model-gomodel653b0ce600001230","title":"Review of GO-CAM Model: gomodel:653b0ce600001230","text":""},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/#model-overview","title":"Model Overview","text":"<ul> <li>Title: KSHV-ORF57 inhibition of host PKR (Human-HHV8)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/#model-content-and-structure","title":"Model Content and Structure","text":"<p>This GO-CAM describes the mechanism by which Kaposi's sarcoma-associated herpesvirus (KSHV) protein ORF57 inhibits the human host PKR-mediated innate immune response. The model includes 5 activities connected through causal relationships:</p> <ol> <li>UniProtKB:Q9BY44 (EIF2A) - translation initiation factor activity (GO:0003743)</li> <li>UniProtKB:P19525 (PKR/EIF2AK2) - protein kinase activity (GO:0004672)</li> <li>UniProtKB:Q2HR75 (KSHV ORF57) - protein sequestering activity (GO:0140311)</li> <li>UniProtKB:O75569 (PRKRA/PACT) - enzyme activator activity (GO:0008047)</li> <li>UniProtKB:P20042 (EIF2S2) - translation initiation factor activity (GO:0003743)</li> </ol> <p>The causal relationships show: - ORF57 inhibits PACT through protein sequestering (RO:0012010) - PACT activates PKR (RO:0002629) - PKR inhibits EIF2A (RO:0002630)  - EIF2A activates EIF2S2 (RO:0002629)</p>"},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/#scientific-assessment","title":"Scientific Assessment","text":"<p>The model accurately represents the mechanism described in the literature (PMID:29084250), where KSHV ORF57 directly binds to both PACT and PKR, preventing their interaction and subsequent PKR activation. This prevents PKR from phosphorylating eIF2\u03b1, which would otherwise inhibit translation initiation.</p> <p>The model correctly captures the central role of ORF57 in disrupting the host's antiviral response by blocking stress granule formation through inhibition of the PKR pathway. This mechanism is consistent with viral strategies to maintain host cell translation machinery for viral protein synthesis.</p>"},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/#strengths","title":"Strengths:","text":"<ol> <li>Correct use of molecular function terms for each protein</li> <li>Appropriate causal relationship predicates connecting activities</li> <li>Proper cellular locations indicated (cytoplasm GO:0005737)</li> <li>Well-evidenced with appropriate literature references</li> <li>Biological processes appropriately indicated:</li> <li>Translational initiation (GO:0006413) for translation factors</li> <li>Antiviral innate immune response (GO:0140374) for PKR</li> <li>KSHV suppression of host PKR/eIF2alpha signaling (GO:0039580) for viral ORF57</li> </ol>"},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing Complex Representation: The model doesn't explicitly represent the eIF2 complex, which includes EIF2S1, EIF2S2, and EIF2S3. According to the \"How to annotate complexes in GO-CAM\" guidelines, when specific subunits carry known activities, they should be represented individually, which is done here, but the relationship to the complex could be clarified.</p> </li> <li> <p>Phosphorylation Representation: While the causal relationships are correct, the specific molecular detail that PKR phosphorylates eIF2\u03b1 isn't explicitly captured in the model. It's implied by the protein kinase activity, but using a more specific term for phosphorylation might improve the model's clarity.</p> </li> <li> <p>PMID Citation Issue: One of the references (PMID:248628414) appears to be incorrect as it contains too many digits for a standard PMID. This should be verified and corrected.</p> </li> <li> <p>Completeness: The model doesn't capture that the ultimate effect of this pathway is inhibition of stress granule formation, which is a key biological outcome described in the primary paper. This could be included to provide a more complete picture of the biological significance.</p> </li> </ol>"},{"location":"reviews/653b0ce600001230-KSHV_ORF57_inhibition_of_host_PKR__Human_HHV8__/#recommendation","title":"Recommendation","text":"<p>This GO-CAM model is scientifically accurate and technically well-constructed. It effectively captures the core mechanism by which KSHV ORF57 inhibits the host PKR-mediated antiviral response. The model follows most GO-CAM best practices and provides valuable insights into virus-host interactions.</p> <p>To further enhance this model, I recommend: 1. Correcting the potentially erroneous PMID citation 2. Considering the addition of the stress granule formation inhibition as a downstream effect 3. Potentially clarifying the relationship between the individual eIF2 subunits and the complex 4. Adding a more specific term to capture the phosphorylation aspect of PKR activity on eIF2\u03b1</p> <p>Overall, this model is valid and provides a useful representation of the KSHV ORF57 inhibition of host PKR pathway, which helps explain how this virus evades host antiviral defense mechanisms.</p>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/","title":"653b0ce600001283 KSHV ORF57 inhibition of host P body formation  Human HHV8","text":"<p>Based on my analysis of the GO-CAM model and the information provided, I'll now conduct a comprehensive review of GO-CAM model 653b0ce600001283:</p>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#review-of-go-cam-model-gomodel653b0ce600001283","title":"Review of GO-CAM Model: gomodel:653b0ce600001283","text":""},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#model-overview","title":"Model Overview","text":"<p>Title: KSHV-ORF57 inhibition of host P-body formation (Human-HHV8) Taxon: Human (NCBITaxon:9606) Status: Production URL: https://bioregistry.io/go.model:653b0ce600001283</p>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#model-content","title":"Model Content","text":"<p>This model represents the interaction between a viral protein from Kaposi's sarcoma-associated herpesvirus (KSHV) and human host factors involved in P-body formation. The model focuses on how KSHV ORF57 protein inhibits P-body formation by interacting with host proteins TNRC6A (GW182) and AGO2.</p>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#key-entities-in-the-model","title":"Key Entities in the Model","text":""},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#proteins","title":"Proteins","text":"<ol> <li>TNRC6A (Q8NDV7): Human protein-macromolecule adaptor protein (GW182)</li> <li>AGO2 (Q9UKV8): Human protein with RNA endonuclease activity</li> <li>ORF57 (Q2HR75): KSHV viral protein with protein sequestering activity</li> </ol>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#processesactivities","title":"Processes/Activities","text":"<ol> <li>P-body assembly (GO:0033962)</li> <li>Positive regulation of viral life cycle (GO:1903902)</li> </ol>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#model-accuracy-assessment","title":"Model Accuracy Assessment","text":""},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#scientific-content-accuracy","title":"Scientific Content Accuracy","text":"<p>The model accurately represents the interaction between KSHV ORF57 and host factors based on the literature evidence. The PMID:31400113 paper clearly demonstrates that KSHV ORF57 inhibits P-body formation by interacting with Ago2 and GW182/TNRC6A. This is correctly represented in the model.</p>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#model-structure-assessment","title":"Model Structure Assessment","text":""},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#causal-flow","title":"Causal Flow","text":"<p>The causal flow follows logically from the viral protein ORF57 to its effects on host proteins: - ORF57 sequestering activity \u2192 interacts with TNRC6A \u2192 affects P-body assembly - TNRC6A adaptor activity \u2192 regulates AGO2 \u2192 affects RNA endonuclease activity</p> <p>The model correctly uses RO:0012010 (equivalent to 'directly negatively regulates') to show ORF57's effect on TNRC6A, and RO:0002629 ('directly positively regulates') to show TNRC6A's effect on AGO2.</p>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#evidence-support","title":"Evidence Support","text":"<p>The model is well supported by published evidence: - PMID:31400113 is used for the main interactions - PMID:22681889 provides evidence for TNRC6A-AGO2 interactions - PMID:18178619 supports AGO2 RNA endonuclease activity</p>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#cellular-locations","title":"Cellular Locations","text":"<p>The model correctly specifies cellular locations: - ORF57 in host cell cytoplasm (GO:0030430) - TNRC6A and AGO2 in P-body (GO:0000932)</p>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#issues-identified","title":"Issues Identified","text":"<ol> <li>Redundant Causal Association:</li> <li>There are duplicate causal associations between TNRC6A and AGO2</li> <li>The activity \"gomodel:653b0ce600001283/653b0ce600001405\" (TNRC6A) has two identical causal associations with \"gomodel:653b0ce600001283/653b0ce600001398\" (AGO2) using the same predicate (RO:0002629)</li> <li> <p>One of these should be removed to eliminate redundancy</p> </li> <li> <p>Molecular Function Assignment:</p> </li> <li> <p>The model correctly assigns protein sequestering activity (GO:0140311) to ORF57, which aligns with its biological role of sequestering host factors</p> </li> <li> <p>Model Completeness:</p> </li> <li>The model adequately represents the key aspects of the biological process described in the literature</li> <li>However, it could potentially be expanded to include downstream effects of P-body disruption on viral replication</li> </ol>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Remove Redundant Causal Association:</li> <li> <p>Remove one of the duplicate causal associations between TNRC6A and AGO2</p> </li> <li> <p>Consider Additional Connections:</p> </li> <li> <p>The model could potentially be expanded to include the effect of P-body disruption on viral mRNA stability or translation, which would provide a more complete picture of how this mechanism benefits viral replication</p> </li> <li> <p>Add Further Context:</p> </li> <li>Consider adding a comment or annotation explaining the biological significance of this mechanism for viral life cycle</li> </ol>"},{"location":"reviews/653b0ce600001283-KSHV_ORF57_inhibition_of_host_P_body_formation__Human_HHV8__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"653b0ce600001283\" is scientifically accurate and largely follows GO-CAM best practices. It correctly represents the mechanism by which KSHV ORF57 inhibits host P-body formation through interaction with TNRC6A and AGO2. The model shows the role of a viral protein (ORF57) in disrupting a host cellular process (P-body assembly) through protein sequestering activity.</p> <p>The only significant issue is the redundant causal association between TNRC6A and AGO2, which should be removed to maintain model clarity and accuracy. Otherwise, the model is well-constructed, with appropriate molecular functions, cellular locations, and causal relationships supported by relevant evidence from the literature.</p>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/","title":"654d809000000010 Regulation of aggrephagy via palmitoylation and depalmitoylation of SQSTM1 by ZDHHC19 and LYPLA1  respectively   Human","text":"<p>Now that I have all the necessary information, I'll conduct a comprehensive review of the GO-CAM model focused on regulation of aggrephagy via palmitoylation and depalmitoylation of SQSTM1.</p>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#review-of-go-cam-model-gomodel654d809000000010","title":"Review of GO-CAM Model: gomodel:654d809000000010","text":""},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#model-overview","title":"Model Overview","text":"<p>Title: Regulation of aggrephagy via palmitoylation and depalmitoylation of SQSTM1 by ZDHHC19 and LYPLA1, respectively (Human)</p> <p>Model ID: gomodel:654d809000000010</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model depicts the regulatory mechanism of aggrephagy through the palmitoylation and depalmitoylation of SQSTM1 (p62) by ZDHHC19 and LYPLA1 (APT1), respectively. The model shows how these post-translational modifications affect the ability of p62 to function as an autophagy receptor for selective degradation of ubiquitinated protein aggregates.</p>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#model-components-and-analysis","title":"Model Components and Analysis","text":""},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#1-key-activities-and-proteins","title":"1. Key Activities and Proteins","text":"<p>The model includes the following key activities:</p> <ol> <li> <p>ZDHHC19 (Q8WVZ1) catalyzes protein-cysteine S-palmitoyltransferase activity (GO:0019706) - This enzyme adds palmitate to p62, which enhances its function.</p> </li> <li> <p>SQSTM1/p62 (Q13501) performs protein-macromolecule adaptor activity (GO:0030674) - This is the central protein that serves as an autophagy receptor.</p> </li> <li> <p>LYPLA1/APT1 (O75608) catalyzes palmitoyl-(protein) hydrolase activity (GO:0008474) - This enzyme removes palmitate from p62, thereby regulating its function.</p> </li> <li> <p>SQSTM1/p62 (Q13501) also performs ubiquitin-modified protein reader activity (GO:0140036) and molecular condensate scaffold activity (GO:0140693) in the model.</p> </li> </ol>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#2-biological-processes","title":"2. Biological Processes","text":"<p>The model correctly annotates the following biological processes:</p> <ul> <li>Positive regulation of aggrephagy (GO:1905337) - associated with ZDHHC19's activity</li> <li>Negative regulation of aggrephagy (GO:1905336) - associated with LYPLA1's activity</li> <li>Protein targeting to vacuole involved in autophagy (GO:0071211) - associated with p62's adaptor function</li> <li>Aggrephagy (GO:0035973) - associated with p62's ubiquitin reader activity</li> <li>Membraneless organelle assembly (GO:0140694) - associated with p62's condensate scaffold activity</li> </ul>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#3-causal-relationships","title":"3. Causal Relationships","text":"<p>The model includes the following causal associations:</p> <ul> <li>ZDHHC19's palmitoyltransferase activity directly positively regulates (RO:0002629) p62's protein-macromolecule adaptor activity</li> <li>LYPLA1's palmitoyl hydrolase activity directly negatively regulates (RO:0002630) p62's protein-macromolecule adaptor activity</li> <li>p62's ubiquitin reader activity directly positively regulates (RO:0002629) p62's condensate scaffold activity</li> <li>p62's condensate scaffold activity directly positively regulates (RO:0002629) p62's protein-macromolecule adaptor activity</li> </ul>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#4-cellular-location","title":"4. Cellular Location","text":"<p>The model accurately places: - p62's adaptor activity in the autophagosome (GO:0005776) - p62's ubiquitin reader activity in the cytosol (GO:0005829) - p62's condensate scaffold activity in intracellular non-membrane-bounded organelle (GO:0043232)</p>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#evaluation-of-scientific-accuracy","title":"Evaluation of Scientific Accuracy","text":"<p>The model is highly consistent with the current scientific literature about p62 regulation by palmitoylation as evidenced by the recent publication (PMID:37802024). Key scientific points correctly captured include:</p> <ol> <li> <p>S-acylation of p62: The model correctly identifies ZDHHC19 as the primary S-acyltransferase that adds palmitate to p62, promoting its function in selective autophagy.</p> </li> <li> <p>Deacylation of p62: The model correctly identifies LYPLA1 (APT1) as the deacylation enzyme that removes palmitate from p62, inhibiting its autophagic function.</p> </li> <li> <p>Effect on aggrephagy: The model accurately reflects that palmitoylation promotes aggrephagy (positive regulation) while depalmitoylation inhibits it (negative regulation).</p> </li> <li> <p>Phase separation dynamics: The model captures p62's role in forming condensates (bodies) through its molecular condensate scaffold activity, which is influenced by its palmitoylation status.</p> </li> <li> <p>Subcellular localization: The model correctly annotates the relevant cellular compartments where these activities occur.</p> </li> </ol>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#adherence-to-go-cam-curation-practices","title":"Adherence to GO-CAM Curation Practices","text":"<ol> <li> <p>Term usage: The model uses appropriate GO terms for molecular functions, biological processes, and cellular components.</p> </li> <li> <p>Evidence codes: All activities are supported with ECO:0000314 (direct assay evidence used in manual assertion) linked to the same reference (PMID:37802024), which is appropriate.</p> </li> <li> <p>Causal relationships: The model correctly uses RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates) to show the causal influences between activities.</p> </li> <li> <p>Part-of relationships: Each activity is correctly annotated as being part of an appropriate biological process.</p> </li> </ol>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Additional evidence: While the model is well supported by the primary reference (PMID:37802024), it could be strengthened by adding additional references for some activities, particularly for the well-established roles of p62 in autophagy that predate the discovery of its palmitoylation.</p> </li> <li> <p>Molecular details: The model could be enhanced by capturing the specific cysteine residues (Cys289 and Cys290) in p62 that are the targets of palmitoylation/depalmitoylation, possibly as a note.</p> </li> <li> <p>Additional context: The model could benefit from including information about how p62 palmitoylation enhances its association with LC3 on autophagic membranes, which is a key mechanism described in the paper.</p> </li> <li> <p>Completeness: The model could be expanded to show p62's interaction with LC3 proteins on the autophagosome membrane, which is mentioned in the reference paper as being facilitated by palmitoylation.</p> </li> </ol>"},{"location":"reviews/654d809000000010-Regulation_of_aggrephagy_via_palmitoylation_and_depalmitoylation_of_SQSTM1_by_ZDHHC19_and_LYPLA1__respectively___Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Regulation of aggrephagy via palmitoylation and depalmitoylation of SQSTM1 by ZDHHC19 and LYPLA1, respectively (Human)\" (gomodel:654d809000000010) is scientifically accurate, well-structured, and adheres to GO-CAM curation best practices. It effectively captures the novel regulatory mechanism of p62-mediated selective autophagy through reversible palmitoylation as described in the recent literature.</p> <p>The model presents a clear, logical flow of the regulatory process and correctly represents the opposing functions of ZDHHC19 and LYPLA1 in modulating p62 activity. With minor enhancements to include additional molecular details and contextual information, this model would provide an even more comprehensive representation of this important regulatory mechanism in selective autophagy.</p>"},{"location":"reviews/654d809000000112-SQSTM1_is_involved_in_aggrephagy_by_mediating_recruitment_of_ubiquitinated_proteins_to_autophagosomes__Human__/","title":"654d809000000112 SQSTM1 is involved in aggrephagy by mediating recruitment of ubiquitinated proteins to autophagosomes  Human","text":"<p>Based on the information collected, I'll now conduct a thorough review of the GO-CAM model.</p>"},{"location":"reviews/654d809000000112-SQSTM1_is_involved_in_aggrephagy_by_mediating_recruitment_of_ubiquitinated_proteins_to_autophagosomes__Human__/#review-of-go-cam-model-gomodel654d809000000112","title":"Review of GO-CAM Model: gomodel:654d809000000112","text":""},{"location":"reviews/654d809000000112-SQSTM1_is_involved_in_aggrephagy_by_mediating_recruitment_of_ubiquitinated_proteins_to_autophagosomes__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:654d809000000112) titled \"SQSTM1 is involved in aggrephagy by mediating recruitment of ubiquitinated proteins to autophagosomes (Human)\" describes the role of the p62/SQSTM1 protein in selective autophagy, specifically in the process of aggrephagy (clearance of protein aggregates by autophagy).</p>"},{"location":"reviews/654d809000000112-SQSTM1_is_involved_in_aggrephagy_by_mediating_recruitment_of_ubiquitinated_proteins_to_autophagosomes__Human__/#model-accuracy-and-completeness","title":"Model Accuracy and Completeness","text":"<p>The model correctly illustrates the key functions of SQSTM1/p62 in the selective autophagy pathway:</p> <ol> <li> <p>Ubiquitin reader activity (GO:0140036) - The model accurately shows that p62 functions as a reader of ubiquitinated proteins.</p> </li> <li> <p>Molecular adaptor activity (GO:0030674) - The model correctly shows p62 functioning as a protein-macromolecule adaptor.</p> </li> <li> <p>Molecular condensate scaffold activity (GO:0140693) - The model appropriately includes p62's role in phase separation and formation of membraneless organelles.</p> </li> <li> <p>Biological processes - The model connects these activities to the correct biological processes:</p> </li> <li>Aggrephagy (GO:0035973)</li> <li>Protein targeting to vacuole involved in autophagy (GO:0071211)</li> <li> <p>Membraneless organelle assembly (GO:0140694)</p> </li> <li> <p>Cellular components - The model correctly places these activities in the appropriate subcellular locations:</p> </li> <li>Cytosol (GO:0005829)</li> <li>Autophagosome (GO:0005776)</li> <li> <p>Intracellular membraneless organelle (GO:0043232)</p> </li> <li> <p>Causal relationships - The model uses appropriate causal predicates to link the activities:</p> </li> <li>RO:0002629 (directly positively regulates) is correctly used to show how the ubiquitin reader activity promotes condensate scaffold activity, and how condensate scaffold activity promotes the adaptor activity.</li> <li>RO:0002413 (provides input for) is correctly used to show how ubiquitin ligase activity provides input for the p62 ubiquitin reader function.</li> </ol>"},{"location":"reviews/654d809000000112-SQSTM1_is_involved_in_aggrephagy_by_mediating_recruitment_of_ubiquitinated_proteins_to_autophagosomes__Human__/#model-strengths","title":"Model Strengths","text":"<ol> <li>The model accurately captures the sequential steps in p62-mediated selective autophagy pathway:</li> <li>Recognition of ubiquitinated proteins</li> <li>Formation of condensates/p62 bodies</li> <li> <p>Targeting these condensates to autophagosomes</p> </li> <li> <p>The model effectively incorporates recent scientific findings about p62's role in phase separation and the formation of biomolecular condensates.</p> </li> <li> <p>The evidence cited in the model comes from appropriate, peer-reviewed literature sources that support the assertions made.</p> </li> </ol>"},{"location":"reviews/654d809000000112-SQSTM1_is_involved_in_aggrephagy_by_mediating_recruitment_of_ubiquitinated_proteins_to_autophagosomes__Human__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is largely accurate and well-constructed, there are a few potential improvements:</p> <ol> <li> <p>Post-translational modifications of p62 - Recent research (as seen in PMID:31857589 and PMID:37802024) has revealed that post-translational modifications, including acetylation (at K420 and K435) and S-acylation (at C289 and C290), regulate p62's ability to form condensates and recruit autophagic machinery. These modifications could be added to provide a more complete picture of p62 regulation.</p> </li> <li> <p>Additional interacting partners - The model could include additional proteins known to interact with p62 during autophagy, such as:</p> </li> <li>The ATG8 family proteins (LC3A/B, GABARAP, etc.) which interact with p62's LIR motif</li> <li>KEAP1, which interacts with p62 and is involved in the NFE2L2/NRF2 pathway</li> <li> <p>Deacetylases like HDAC6 that regulate p62 activity</p> </li> <li> <p>Selective autophagy regulatory mechanisms - The model could be expanded to include how p62-mediated selective autophagy is regulated under different conditions (e.g., nutrient starvation, proteasomal inhibition).</p> </li> </ol>"},{"location":"reviews/654d809000000112-SQSTM1_is_involved_in_aggrephagy_by_mediating_recruitment_of_ubiquitinated_proteins_to_autophagosomes__Human__/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<p>Based on the GO-CAM best practices documents, this model follows the proper conventions:</p> <ol> <li> <p>Complex representation - The model correctly shows a ubiquitin ligase complex (GO:0000151) as the entity that carries out ubiquitin protein ligase activity, which aligns with the guidance in \"How to annotate complexes in GO-CAM\" when the specific subunit carrying the activity is not known.</p> </li> <li> <p>Adaptor protein annotation - The model correctly implements the adaptor protein annotation guidelines, showing p62 as a bridge between ubiquitinated proteins and autophagic machinery.</p> </li> <li> <p>Causal connections - The causal connections between activities are appropriate and follow GO-CAM guidelines for specifying relationships between molecular functions.</p> </li> </ol>"},{"location":"reviews/654d809000000112-SQSTM1_is_involved_in_aggrephagy_by_mediating_recruitment_of_ubiquitinated_proteins_to_autophagosomes__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:654d809000000112 is a high-quality GO-CAM model that accurately represents the role of SQSTM1/p62 in aggrephagy. It correctly captures the molecular functions, biological processes, and causal relationships involved in this pathway. While there are opportunities to expand the model with additional details on regulation and interacting partners, the current model provides a solid representation of p62's role in selective autophagy.</p> <p>The model is consistent with current scientific knowledge and follows GO-CAM best practices for representation of protein complexes and adaptor proteins. It provides a valuable resource for researchers interested in understanding the mechanisms of selective autophagy and the role of p62/SQSTM1 in this process.</p>"},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/","title":"654d809000000248 Regulation of aggrephagy via phosphorylation of SQSTM1 by CK2  Human","text":"<p>Now I'll review the GO-CAM model with ID 654d809000000248, titled \"Regulation of aggrephagy via phosphorylation of SQSTM1 by CK2 (Human).\"</p>"},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#go-cam-model-review-gomodel654d809000000248","title":"GO-CAM Model Review: gomodel:654d809000000248","text":""},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#model-overview","title":"Model Overview","text":"<p>This model describes the regulation of aggrephagy (selective autophagy of protein aggregates) through the phosphorylation of SQSTM1 (Sequestosome-1, also known as p62) by the protein kinase CK2 (Casein Kinase 2) in humans. The model shows how CK2 phosphorylation of SQSTM1 affects its function in recognizing and targeting ubiquitinated proteins for autophagic degradation.</p>"},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#entities-and-activities-in-the-model","title":"Entities and Activities in the Model","text":"<ol> <li>CSNK2A1/CK2 (UniProtKB:P68400)</li> <li>Molecular function: Protein serine/threonine kinase activity (GO:0004674)</li> <li>Biological process: Positive regulation of aggrephagy (GO:1905337)</li> <li> <p>Causal association: Directly positively regulates (RO:0002629) SQSTM1's ubiquitin-modified protein reader activity</p> </li> <li> <p>SQSTM1/p62 (UniProtKB:Q13501)</p> </li> <li> <p>Has three activities in the model:</p> <ol> <li> <p>Ubiquitin-modified protein reader activity (GO:0140036)</p> <ul> <li>Occurs in: Cytosol (GO:0005829)</li> <li>Part of: Aggrephagy (GO:0035973)</li> <li>Directly positively regulates (RO:0002629) SQSTM1's molecular condensate scaffold activity</li> </ul> </li> <li> <p>Molecular condensate scaffold activity (GO:0140693)</p> <ul> <li>Occurs in: Intracellular membraneless organelle (GO:0043232)</li> <li>Part of: Membraneless organelle assembly (GO:0140694)</li> <li>Directly positively regulates (RO:0002629) SQSTM1's protein-macromolecule adaptor activity</li> </ul> </li> <li> <p>Protein-macromolecule adaptor activity (GO:0030674)</p> <ul> <li>Occurs in: Autophagosome (GO:0005776)</li> <li>Part of: Protein targeting to vacuole involved in autophagy (GO:0071211)</li> </ul> </li> </ol> </li> </ol>"},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#evidence-and-references","title":"Evidence and References","text":"<p>The model is supported by multiple scientific publications, including: - PMID:29507397 (Sun et al., 2018) - PMID:29343546 (Zaffagnini et al., 2018) - PMID:31857589 (You et al., 2019) - PMID:22017874 (Matsumoto et al., 2011) - PMID:37802024 (Huang et al., 2023) - PMID:8650207 (Joung et al., 1996)</p>"},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li> <p>Appropriate Causal Flow: The model correctly represents the sequential causal flow from CK2 kinase activity \u2192 SQSTM1 ubiquitin-modified protein reader activity \u2192 SQSTM1 molecular condensate scaffold activity \u2192 SQSTM1 adaptor activity.</p> </li> <li> <p>Well-Supported by Evidence: Each activity and causal link is supported by peer-reviewed publications.</p> </li> <li> <p>Correct Biochemical Knowledge: The model accurately captures the known role of CK2 phosphorylation of SQSTM1 at Ser403, which enhances SQSTM1's ability to bind ubiquitinated proteins.</p> </li> <li> <p>Proper Cellular Localization: The model correctly places activities in their appropriate cellular compartments.</p> </li> <li> <p>Clear Molecular Mechanism: The model shows a clear pathway from kinase activity to the functional outcomes in autophagy.</p> </li> </ol>"},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Phosphorylation Site Specification: Consider explicitly noting the phosphorylation site (Ser403) on SQSTM1 that's targeted by CK2. This would make the specific molecular event clearer.</p> </li> <li> <p>Additional Important Interactions: The model could be expanded to include MAP1LC3A/LC3 interaction with SQSTM1, which is mentioned in the UniProtKB entry and is critical for the recruitment of autophagic machinery.</p> </li> <li> <p>Temporal Relationship: Consider clarifying the temporal sequence of events, as SQSTM1 first forms bodies with ubiquitinated proteins (phase separation) before being recruited to autophagosomes.</p> </li> </ol>"},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices:","text":"<p>The model follows GO-CAM best practices by: - Using appropriate molecular function terms for each protein - Properly connecting activities with causal relationships - Including cellular locations for activities - Linking activities to their broader biological processes</p> <p>According to the \"How to annotate complexes in GO-CAM\" document, this model appropriately represents the activities of individual proteins rather than complexes, as the specific activities of CK2 and SQSTM1 are well-defined in the literature.</p>"},{"location":"reviews/654d809000000248-Regulation_of_aggrephagy_via_phosphorylation_of_SQSTM1_by_CK2__Human__/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model (gomodel:654d809000000248) is a well-constructed representation of the role of CK2-mediated phosphorylation in regulating SQSTM1's function during aggrephagy. It accurately captures the molecular events and causal relationships involved in this process. The model is scientifically sound and follows GO-CAM best practices.</p> <p>The biological content aligns with current literature on SQSTM1 regulation. CK2 (CSNK2A1) phosphorylates SQSTM1 at Ser403, which enhances its binding to ubiquitinated proteins. This facilitates SQSTM1's phase separation and formation of protein aggregates (p62 bodies), which are subsequently targeted to autophagosomes for degradation.</p> <p>This model is parsimonious and focused on the key molecular events, making it easy to understand while accurately representing the biological pathway.</p>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/","title":"65bc474400000537 Regulation of Hippo signaling by MAP4K4  Human","text":"<p>Based on my review of the GO-CAM model and associated documents, I'll now provide a comprehensive evaluation of model gomodel:65bc474400000537 \"Regulation of Hippo signaling by MAP4K4 (Human).\"</p>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#review-of-go-cam-model-regulation-of-hippo-signaling-by-map4k4-human","title":"Review of GO-CAM Model: Regulation of Hippo signaling by MAP4K4 (Human)","text":"<p>gomodel:65bc474400000537</p>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#model-overview","title":"Model Overview","text":"<p>This model captures the regulation of Hippo signaling pathway in humans with a particular focus on MAP4K4's role. The model represents how MAP4K4 and other kinases act in parallel to MST1/2 to activate LATS1/2, which ultimately regulates the transcriptional coactivators YAP1 and WWTR1/TAZ.</p>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#accuracy-of-biological-content","title":"Accuracy of Biological Content","text":"<p>The model accurately reflects the current understanding of the Hippo signaling pathway based on the cited literature. The key findings from PMID:35429439 and PMID:26437443 describing how MAP4K4 functions in parallel to MST1/2 to activate LATS1/2 are well represented. The model correctly captures the phosphorylation events where LATS1/2 phosphorylates and inhibits YAP1/TAZ, preventing their nuclear translocation and transcriptional coactivator functions.</p>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#completeness-of-pathway-representation","title":"Completeness of Pathway Representation","text":"<p>The model includes the core components of the Hippo pathway from upstream kinases (MST1/2, MAP4K4) through the central LATS1/2 kinases to the downstream effectors (YAP1 and WWTR1). The causal relationships showing regulation of nuclear transcriptional coactivators are appropriate.</p>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#evidence-support","title":"Evidence Support","text":"<p>All activities in the model are well supported by primary literature evidence, with appropriate ECO codes (ECO:0000314 - direct assay evidence used in manual assertion) and PMID citations. The model references key papers including PMID:35429439, PMID:26437443, and PMID:15688006.</p>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing kinase activities and transcriptional coregulation:</p> <ol> <li> <p>Protein kinase activities: The model correctly represents protein serine/threonine kinase activities (GO:0004674) for LATS1, LATS2, STK3, STK4, and MAP4K4, consistent with their established functions.</p> </li> <li> <p>Transcriptional coregulator activities: YAP1 and WWTR1 are correctly annotated with transcription coregulator activity (GO:0003712) in the nucleus, following the guidelines in the \"Transcription coregulator activity\" document.</p> </li> <li> <p>Causal relationships: The model uses appropriate causal relationship predicates:</p> </li> <li>RO:0002630 (directly negatively regulates) for LATS1/2 regulating YAP1/WWTR1</li> <li>RO:0002629 (directly positively regulates) for upstream kinases activating LATS1/2</li> <li> <p>RO:0002413 (provides input for) where appropriate</p> </li> <li> <p>Cellular locations: Activities are appropriately contextualized with cellular locations, with kinase activities occurring in the cytoplasm (GO:0005737) and transcriptional activities in the nucleus (GO:0005634).</p> </li> </ol>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Comment clarification: The model includes a comment stating \"The regulation has been capture for MAP4k4 because it is the one used for experimental evidences but according to KO, at least MAP4K1, MAP4K2, MAP4K6 and MAP4K7 are also able to regulate the hippo signaling.\" This is accurate based on PMID:26437443, but it might be clearer to reword this as \"MAP4K4 has been featured as the primary regulator in this model based on experimental evidence, but knockout studies indicate that MAP4K1, MAP4K2, MAP4K6, and MAP4K7 can also regulate Hippo signaling.\"</p> </li> <li> <p>Missing link detail: In one of the causal associations for LATS1's activity (65bc474400000651), there's a redundant causal association with no evidence:    <pre><code>\"causal_associations\":[\n   {\"type\":\"CausalAssociation\",\"evidence\":[],\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:65bc474400000537/65bc474400000586\"}\n]\n</code></pre>    This appears to be a duplicate of the properly evidenced association above it.</p> </li> <li> <p>Potential for expansion: Given PMID:26437443 demonstrates the redundancy and parallel functions of multiple MAP4K family members, an expanded version of this model might represent the other MAP4K family members (MAP4K1/2/6/7) more explicitly, though I recognize the curator has acknowledged this in the comment.</p> </li> </ol>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a high-quality representation of the regulation of Hippo signaling by MAP4K4 and other kinases. The biological content is accurate, evidence-based, and follows GO-CAM best practices for representing signaling pathways. The model effectively captures the parallel pathways of MAP4K4 and MST1/2 in activating LATS1/2, which subsequently regulates YAP1 and WWTR1 transcriptional coactivator activities.</p> <p>The minor issue with a redundant unevidenced causal association is the only technical flaw in an otherwise excellent model.</p>"},{"location":"reviews/65bc474400000537-Regulation_of_Hippo_signaling_by_MAP4K4__Human__/#recommendation","title":"Recommendation","text":"<p>The model is suitable for production status with only minor clarifications suggested for the comment text and removal of the redundant unevidenced causal association.</p>"},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/","title":"65bc474400000955 Negative regulation of Hippo signaling by STRIPAK complex via STRN4 MAP4K4 Human","text":"<p>Now let me analyze this GO-CAM model and provide a review:</p>"},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#review-of-go-cam-model-gomodel65bc474400000955","title":"Review of GO-CAM Model: gomodel:65bc474400000955","text":""},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#overview","title":"Overview","text":"<p>This model is titled \"Negative regulation of Hippo signaling by STRIPAK complex via STRN4:MAP4K4(Human).\" It focuses on signaling mechanisms in the Hippo pathway, specifically how the STRIPAK complex component STRN4 functions to negatively regulate Hippo signaling through interaction with MAP4K4.</p>"},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model describes a regulatory cascade where:</p> <ol> <li> <p>The STRIPAK complex (GO:0090443) with STRN4 (UniProtKB:Q9NRL3) exhibits protein-macromolecule adaptor activity (GO:0030674) in the cytoplasm.</p> </li> <li> <p>MAP4K4 (UniProtKB:O95819) shows MAP kinase kinase kinase kinase activity (GO:0008349) in the cytoplasm, which positively regulates LATS1/2 kinases.</p> </li> <li> <p>LATS1 (UniProtKB:O95835) and LATS2 (UniProtKB:Q9NRM7) both have protein serine/threonine kinase activity (GO:0004674) in the cytoplasm, which directly negatively regulate the transcription coregulator activities of YAP1 and WWTR1.</p> </li> <li> <p>YAP1 (UniProtKB:P46937) and WWTR1/TAZ (UniProtKB:Q9GZV5) exhibit transcription coregulator activity (GO:0003712) in the nucleus.</p> </li> <li> <p>All these activities are part of the Hippo signaling pathway (GO:0035329).</p> </li> </ol>"},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#literature-support","title":"Literature Support","text":"<p>The model is well-supported by the literature cited, primarily:</p> <ul> <li>PMID:35429439 - Documents the role of LATS1/2 in phosphorylating and inhibiting YAP/TAZ.</li> <li>PMID:26437443 - Demonstrates MAP4K family kinases acting in parallel to MST1/2 to activate LATS1/2.</li> <li>PMID:32640226 - Specifically addresses STRN4 as a key STRIPAK complex component in Hippo pathway regulation and its interaction with MAP4K4.</li> </ul> <p>These papers collectively describe how the STRIPAK complex through STRN4 can inhibit MAP4K4, preventing activation of LATS1/2, and thereby promoting YAP/TAZ activity by preventing their phosphorylation and cytoplasmic retention.</p>"},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#model-structure-review","title":"Model Structure Review","text":""},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#strengths","title":"Strengths:","text":"<ol> <li> <p>Causal relationships: The model appropriately uses causal predicates (RO:0002630 - \"directly negatively regulates\" and RO:0002629 - \"directly positively regulates\") to connect activities in a mechanistically accurate manner.</p> </li> <li> <p>Evidence quality: All assertions are supported by experimental evidence (ECO:0000314 - \"direct assay evidence used in manual assertion\") with appropriate literature citations.</p> </li> <li> <p>Cellular components: Appropriate cellular locations are specified for each activity (cytoplasm for the regulatory components, nucleus for the transcription coregulators).</p> </li> <li> <p>Consistency with literature: The model accurately represents the molecular interactions described in the supporting papers.</p> </li> </ol>"},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#potential-improvements","title":"Potential improvements:","text":"<ol> <li> <p>Complex representation: The STRIPAK complex is represented appropriately according to GO-CAM best practices, with STRN4 listed as a member. However, as noted in the model comments, \"the information for strn4 is lost because is part of the STRIPAK complex but doesn't act out of the complex.\" This could be clarified by considering whether STRN4 has a specific activity within the complex that should be represented independently.</p> </li> <li> <p>Complete pathway representation: While the model captures the key regulatory relationships, it could potentially benefit from including MST1/2 kinases, which are mentioned in the literature as acting in parallel to MAP4K4 to regulate LATS1/2. However, since the focus is specifically on the STRN4:MAP4K4 regulatory axis, this omission is reasonable.</p> </li> <li> <p>Downstream effects: The model could be extended to include the specific transcriptional targets of YAP/TAZ, but this would expand the scope beyond the current focus on the regulatory mechanism.</p> </li> </ol>"},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#technical-assessment","title":"Technical Assessment","text":"<ul> <li>All entities have appropriate ontology terms and identifiers.</li> <li>The model appropriately uses human proteins (indicated by the Hsap suffix in labels).</li> <li>Causal relationships are biologically accurate and well-represented.</li> <li>The model represents a coherent biological process.</li> </ul>"},{"location":"reviews/65bc474400000955-Negative_regulation_of_Hippo_signaling_by_STRIPAK_complex_via_STRN4_MAP4K4_Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the negative regulation of Hippo signaling by the STRIPAK complex through STRN4's effect on MAP4K4. It is consistent with current literature and follows GO-CAM best practices. The model clearly depicts how the STRIPAK complex (containing STRN4) inhibits MAP4K4, which would otherwise positively regulate LATS1/2 kinases that in turn inhibit YAP1/WWTR1 transcriptional coregulator activity.</p> <p>The model is parsimonious and accurately represents the primary molecular events described in the literature. It provides a clear representation of this specific regulatory axis within the Hippo pathway, making it valuable for understanding this aspect of cellular signaling.</p>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/","title":"65c57c3400000000 Inhibition of the GDF15 GFRAL aversive signaling pathway following cleavage of GFRAL by MMP14  Human","text":"<p>Now that I have reviewed the available information, I'll conduct a thorough review of the GO-CAM model (gomodel:65c57c3400000000).</p>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#go-cam-model-review-inhibition-of-the-gdf15-gfral-aversive-signaling-pathway-following-cleavage-of-gfral-by-mmp14-human","title":"GO-CAM Model Review: Inhibition of the GDF15-GFRAL aversive signaling pathway following cleavage of GFRAL by MMP14 (Human)","text":""},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model (ID: gomodel:65c57c3400000000) represents the inhibition mechanism of the GDF15-GFRAL signaling pathway through the cleavage of GFRAL by MMP14. The model focuses on how this mechanism affects aversive signaling, which is involved in body weight regulation and appetite control in humans.</p>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#model-components","title":"Model Components","text":"<p>The model contains four key molecular activities:</p> <ol> <li>GDF15 [UniProtKB:Q99988]: Functions as a hormone with growth/differentiation factor 15 activity (GO:0005179)</li> <li>GFRAL [UniProtKB:Q6UXV0]: Functions as a GDNF family receptor with glial cell-derived neurotrophic factor receptor activity (GO:0016167)</li> <li>RET [UniProtKB:P07949]: Acts as a receptor tyrosine kinase with transmembrane receptor protein tyrosine kinase activity (GO:0004714)</li> <li>MMP14 [UniProtKB:P50281]: Functions as a metalloendopeptidase (GO:0004222)</li> </ol>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#pathway-representation-and-causal-relationships","title":"Pathway Representation and Causal Relationships","text":"<p>The model correctly represents the GDF15-GFRAL signaling pathway and its regulation:</p> <ol> <li>GDF15 hormone (GO:0005179) positively regulates (RO:0002629) GFRAL receptor activity (GO:0016167)</li> <li>GFRAL receptor activity positively regulates (RO:0002629) RET tyrosine kinase activity (GO:0004714)</li> <li>MMP14 metalloendopeptidase activity (GO:0004222) negatively regulates (RO:0002630) GFRAL receptor activity</li> </ol> <p>This accurately represents the biology where GDF15 activates GFRAL, which in turn activates RET signaling. MMP14 inhibits this pathway by cleaving GFRAL.</p>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#biological-process-context","title":"Biological Process Context","text":"<p>The activities are appropriately placed in their biological process contexts: - GDF15 and GFRAL activities are part of the \"GDF15-GFRAL signaling pathway\" (GO:0160144) - RET activity is part of the \"GDF15-GFRAL signaling pathway\" (GO:0160144) - MMP14 activity is part of \"protein catabolic process\" (GO:0030163)</p>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#cellular-location-context","title":"Cellular Location Context","text":"<p>The cellular locations are also appropriately annotated: - GDF15 is located in \"extracellular space\" (GO:0005615) - GFRAL is located in the \"plasma membrane\" (GO:0005886) - RET is located in the \"plasma membrane\" (GO:0005886) - MMP14 is located in the \"plasma membrane\" (GO:0005886)</p>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#evidence-and-references","title":"Evidence and References","text":"<p>The model uses appropriate evidence codes and references: - All activities are supported by \"direct assay evidence used in manual assertion\" (ECO:0000314) - References include multiple relevant publications (PMID:31535977, PMID:35177851, PMID:28953886, etc.)</p>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#strengths-of-the-model","title":"Strengths of the model:","text":"<ol> <li>Biological accuracy: The model correctly represents the biological mechanism where MMP14 cleaves GFRAL, thereby inhibiting GDF15-GFRAL signaling.</li> <li>Appropriate evidence: The model uses direct experimental evidence with relevant citations.</li> <li>Complete pathway representation: The model includes all key components of the signaling pathway.</li> <li>Proper relationship annotation: Causal relationships between entities are properly represented using appropriate relation ontology terms.</li> </ol>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#suggestions-for-improvement","title":"Suggestions for improvement:","text":"<ol> <li> <p>Missing component information: While the model represents the inhibition mechanism, it might be helpful to include additional information about where MMP14 cleaves GFRAL specifically, although this granular information might not be available.</p> </li> <li> <p>Potential elaboration on RET signaling: The model could potentially be expanded to include downstream effects of RET signaling activation, such as MAPK or PI3K/AKT pathway activation, which would provide a more complete picture of the signaling cascade.</p> </li> </ol>"},{"location":"reviews/65c57c3400000000-Inhibition_of_the_GDF15_GFRAL_aversive_signaling_pathway_following_cleavage_of_GFRAL_by_MMP14__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:65c57c3400000000) \"Inhibition of the GDF15-GFRAL aversive signaling pathway following cleavage of GFRAL by MMP14 (Human)\" is a high-quality representation of the biological process. It accurately depicts how MMP14 negatively regulates GDF15-GFRAL signaling by cleaving GFRAL, which is consistent with the biological literature.</p> <p>The model follows the GO-CAM best practices for annotating the activities of individual proteins and correctly represents their causal relationships. The evidence is well-documented with appropriate citations to the scientific literature.</p> <p>This model contributes valuable knowledge about a regulatory mechanism for body weight control, which has potential implications for understanding obesity and appetite regulation.</p>"},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/","title":"65c57c3400000100 Resolution of protein DNA cross links by HMCES  BRIP1 FANCJ and SPRTN  Human","text":"<p>Based on my analysis of the GO-CAM model \"Resolution of protein-DNA cross-links by HMCES, BRIP1/FANCJ and SPRTN (Human)\" (gomodel:65c57c3400000100), here is my comprehensive review:</p>"},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/#go-cam-model-review-resolution-of-protein-dna-cross-links-by-hmces-brip1fancj-and-sprtn","title":"GO-CAM Model Review: Resolution of protein-DNA cross-links by HMCES, BRIP1/FANCJ and SPRTN","text":""},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/#overview","title":"Overview","text":"<p>This model represents the protein-DNA covalent cross-linking repair pathway in humans, featuring three key proteins: HMCES (Q96FZ2), BRIP1/FANCJ (Q9BX63), and SPRTN (Q9H040). The model shows how these proteins work together to resolve DNA-protein cross-links (DPCs) that can interfere with DNA replication and transcription.</p>"},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/#scientific-content-accuracy","title":"Scientific Content Accuracy","text":"<p>The model accurately represents the current understanding of protein-DNA cross-link repair as supported by recent literature. The pathway depicted aligns with the mechanisms described in the referenced publications, particularly PMID:36608669, which describes how FANCJ helicase unfolds DNA-protein cross-links to promote their repair.</p> <p>The functional relationships between the proteins are correctly represented: 1. HMCES (Q96FZ2) binds to abasic sites in DNA (GO:0140431) and forms covalent cross-links with DNA (GO:0160129) 2. BRIP1/FANCJ (Q9BX63) uses its 5'-3' DNA helicase activity (GO:0043139) to unfold these cross-links 3. SPRTN (Q9H040) then uses its metalloendopeptidase activity (GO:0004222) to cleave the protein component of the cross-link</p> <p>The causal relationships using RO:0002629 \"directly positively regulates\" properly show how each activity leads to the next in the pathway.</p>"},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/#conformance-to-go-cam-best-practices","title":"Conformance to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ul> <li>Each protein is correctly associated with its molecular function</li> <li>Each activity is properly placed in a cellular compartment (replication fork or chromatin)</li> <li>All activities are part of the appropriate biological process (protein-DNA covalent cross-linking repair)</li> <li>Causal relationships between activities use the correct predicate (RO:0002629)</li> <li>Evidence codes (ECO:0000314) and PMIDs are appropriately provided for each assertion</li> <li>Locations are appropriate: HMCES and BRIP1 are at the replication fork (GO:0005657), while SPRTN is in chromatin (GO:0000785)</li> </ul>"},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/#completeness-and-clarity","title":"Completeness and Clarity","text":"<p>The model provides a clear and complete representation of this specific DNA repair pathway. It captures the sequential process of: 1. HMCES binding to and forming cross-links with abasic sites 2. BRIP1/FANCJ unfolding these cross-links through helicase activity 3. SPRTN cleaving the protein component to complete the repair</p> <p>The model is parsimonious and focuses on the key activities needed to understand the pathway without unnecessary complexity.</p>"},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/#supporting-evidence","title":"Supporting Evidence","text":"<p>The model is well-supported by multiple recent publications (from 2019-2023). Each assertion is backed by evidence with appropriate PMIDs, particularly: - PMID:36608669 (2023) - Establishing the role of FANCJ in unfolding DNA-protein cross-links - PMID:37950866 and PMID:37519246 (2023) - Describing HMCES self-reversal mechanisms - PMID:30554877 (2019) and PMID:31235913 (2019) - Foundational work on HMCES function - PMID:32649882 and PMID:27871366 (2020) - SPRTN's role in the process</p>"},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/#recommendations","title":"Recommendations","text":"<p>The model is scientifically accurate and follows GO-CAM best practices. No major changes are needed, but here are some minor suggestions for consideration:</p> <ol> <li> <p>The model could potentially include the self-reversal mechanism of HMCES as mentioned in PMID:37950866 and PMID:37519246, though this would add complexity.</p> </li> <li> <p>Consider adding a brief comment about the medical relevance of this pathway, as mutations in these proteins are associated with diseases like Fanconi anemia (FANCJ) and Ruijs-Aalfs syndrome (SPRTN).</p> </li> <li> <p>The model correctly focuses on the repair pathway at the replication fork, but could potentially note that these cross-links can also interfere with transcription.</p> </li> </ol>"},{"location":"reviews/65c57c3400000100-Resolution_of_protein_DNA_cross_links_by_HMCES__BRIP1_FANCJ_and_SPRTN__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a high-quality representation of the protein-DNA cross-linking repair pathway involving HMCES, BRIP1/FANCJ, and SPRTN. It successfully integrates recent research findings into a coherent pathway model that follows GO-CAM best practices. The model will be valuable for researchers studying DNA repair mechanisms and related diseases.</p>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/","title":"65c57c3400000173 The MSL complex  composed of MSL1  MSL2  MSL3 and KAT8  mediates acetylation of histone H4 at Lys 16  H4K16ac   Human","text":"<p>Let me perform a detailed review of the GO-CAM model based on the information obtained:</p>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#review-of-go-cam-model-gomodel65c57c3400000173","title":"Review of GO-CAM Model: gomodel:65c57c3400000173","text":""},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#model-summary","title":"Model Summary","text":"<p>Title: The MSL complex, composed of MSL1, MSL2, MSL3 and KAT8, mediates acetylation of histone H4 at Lys-16 (H4K16ac) (Human).</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#model-description","title":"Model Description","text":"<p>This GO-CAM model represents the MSL complex in humans, which is responsible for histone H4 lysine 16 acetylation (H4K16ac). The model depicts the functional roles of four key proteins (MSL1, MSL2, MSL3, and KAT8) and their interactions within the complex that lead to histone acetylation.</p>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#components-and-activities","title":"Components and Activities","text":"<p>The model includes four main proteins with their activities:</p> <ol> <li>KAT8/MOF (Q9H7Z6) - Histone H4K16 acetyltransferase activity (GO:0046972)</li> <li>MSL1 (Q68DK7) - Protein-macromolecule adaptor activity (GO:0030674)</li> <li>MSL3 (Q8N5Y2) - Histone reader activity (GO:0140566)</li> <li>MSL2 (Q9HCI7) - Chromatin-protein adaptor activity (GO:0140463)</li> </ol> <p>All activities are represented as occurring in the nucleus (GO:0005634) and participating in positive regulation of DNA-templated transcription (GO:0045893), with the exception of MSL2 which is involved in protein localization to chromatin (GO:0071168).</p>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#causal-relationships","title":"Causal Relationships","text":"<p>The model represents a causal cascade where: - MSL2 positively regulates MSL3 (RO:0002629) - MSL3 positively regulates MSL1 (RO:0002629) - MSL1 positively regulates KAT8 (RO:0002629)</p>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#assessment","title":"Assessment","text":""},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Accurate Protein Functions: The model correctly represents the known functions of each protein based on UniProt entries and literature.</li> <li>Correct Cellular Location: All activities are appropriately located in the nucleus.</li> <li>Proper Causal Relationships: The causal flow from MSL2 \u2192 MSL3 \u2192 MSL1 \u2192 KAT8 is consistent with the literature about MSL complex assembly and function.</li> <li>Evidence Quality: The model uses high-quality evidence codes (ECO:0000314 - direct assay evidence) and cites relevant primary literature.</li> <li>Biological Process Context: All activities are correctly contextualized within positive regulation of transcription.</li> </ol>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Complex Membership: Although the model title indicates the proteins are part of the MSL complex (GO:0072487), there's no explicit annotation to show they are part of the same complex in the model. According to GO-CAM best practices for complexes, the model could be improved by either:</li> <li>Adding explicit complex membership annotations</li> <li> <p>Using \"part_of\" relationships to the MSL complex (GO:0072487)</p> </li> <li> <p>Physical Structure: The model doesn't explicitly represent the structural relationships described in the literature, where MSL1 acts as a scaffold that brings together MSL3 and KAT8, as documented in the cited paper (PMID:22547026).</p> </li> <li> <p>Substrate Representation: While the model title mentions H4K16 acetylation, the actual histone substrate isn't explicitly represented in the model.</p> </li> <li> <p>Multi-functionality of MSL2: According to UniProt, MSL2 also has E3 ubiquitin ligase activity which isn't represented in this model. However, this may be intentionally omitted to focus on its role in the MSL complex.</p> </li> </ol>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#recommendations","title":"Recommendations","text":"<p>Based on the GO-CAM complex annotation guidelines and the proteins' UniProt entries, I recommend:</p> <ol> <li> <p>Add Complex Context: Include explicit annotations showing that these proteins are part of the MSL complex (GO:0072487).</p> </li> <li> <p>Represent Scaffold Function: Consider adding annotations to better represent MSL1's role as a scaffold that facilitates the interaction between MSL3 and KAT8.</p> </li> <li> <p>Include Substrate: Consider adding the histone H4 substrate to fully represent the acetylation reaction.</p> </li> <li> <p>Improve Documentation: The model could benefit from additional comments that clarify the assembly and function of the MSL complex.</p> </li> </ol>"},{"location":"reviews/65c57c3400000173-The_MSL_complex__composed_of_MSL1__MSL2__MSL3_and_KAT8__mediates_acetylation_of_histone_H4_at_Lys_16__H4K16ac___Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the core functions and interactions of the MSL complex in humans. The model captures the key activities of each protein and their causal relationships leading to histone H4K16 acetylation, which is crucial for transcriptional regulation. With minor enhancements, particularly regarding complex membership representation, the model could more completely represent the current knowledge about the MSL complex.</p> <p>The evidence used is appropriate, and the causal flow correctly describes the biological mechanism by which these proteins cooperate to acetylate histone H4K16, consistent with the published literature including the key reference PMID:22547026.</p>"},{"location":"reviews/65c57c3400000359-Dosage_compensation_in_male_Drosophila_by_the_MSL_complex__composed_of_mle__msl_1__msl_2__msl_3_and_mof___D_melanogaster__/","title":"65c57c3400000359 Dosage compensation in male Drosophila by the MSL complex  composed of mle  msl 1  msl 2  msl 3 and mof   D melanogaster","text":"<p>Now I have all the information I need to review the GO-CAM model. Let me put together my analysis:</p>"},{"location":"reviews/65c57c3400000359-Dosage_compensation_in_male_Drosophila_by_the_MSL_complex__composed_of_mle__msl_1__msl_2__msl_3_and_mof___D_melanogaster__/#review-of-go-cam-model-gomodel65c57c3400000359","title":"Review of GO-CAM Model gomodel:65c57c3400000359","text":""},{"location":"reviews/65c57c3400000359-Dosage_compensation_in_male_Drosophila_by_the_MSL_complex__composed_of_mle__msl_1__msl_2__msl_3_and_mof___D_melanogaster__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"Dosage compensation in male Drosophila by the MSL complex (composed of mle- msl-1, msl-2, msl-3 and mof) (D.melanogaster)\" provides a representation of the MSL (Male-Specific Lethal) complex components and their roles in dosage compensation in Drosophila melanogaster.</p> <p>The model describes how various proteins in the MSL complex interact to achieve X chromosome hyperactivation in male fruit flies, which is a crucial mechanism to ensure dosage compensation between males (XY) and females (XX).</p>"},{"location":"reviews/65c57c3400000359-Dosage_compensation_in_male_Drosophila_by_the_MSL_complex__composed_of_mle__msl_1__msl_2__msl_3_and_mof___D_melanogaster__/#model-components-and-relationships","title":"Model Components and Relationships","text":"<p>The model includes the following key proteins: 1. MSL-1 (Male-Specific Lethal 1) - Protein-macromolecule adaptor activity 2. MSL-2 (Male-Specific Lethal 2) - Protein-RNA adaptor and chromatin-protein adaptor activities 3. MSL-3 (Male-Specific Lethal 3) - Histone reader activity 4. MLE (Maleless) - RNA helicase activity 5. MOF (Males-Absent on the First) - Histone H4K16 acetyltransferase activity 6. Set2 - Histone H3K36 trimethyltransferase activity</p> <p>The model captures the sequential interactions of these components: - Set2 provides input for MSL-3's histone reader activity - MLE positively regulates MSL-2's activities - MSL-2 positively regulates MSL-3 - MSL-3 positively regulates MSL-1 - MSL-1 positively regulates MOF</p>"},{"location":"reviews/65c57c3400000359-Dosage_compensation_in_male_Drosophila_by_the_MSL_complex__composed_of_mle__msl_1__msl_2__msl_3_and_mof___D_melanogaster__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model correctly represents the established components of the MSL complex.</li> <li>The causal relationships are appropriate, showing how each component contributes to the process.</li> <li>The model correctly annotates the molecular functions of each protein.</li> <li>The model includes important location information, correctly placing the activities on the X chromosome.</li> <li>All components are properly connected in the pathway, demonstrating how the complex achieves dosage compensation.</li> <li>The evidence provided for the activities and associations is well-documented with appropriate literature references.</li> </ol>"},{"location":"reviews/65c57c3400000359-Dosage_compensation_in_male_Drosophila_by_the_MSL_complex__composed_of_mle__msl_1__msl_2__msl_3_and_mof___D_melanogaster__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows best practices for GO-CAM annotation by: - Correctly modeling protein activities rather than proteins themselves - Using appropriate causal relationships between activities - Including proper cellular component annotations (X chromosome) - Linking all activities to the biological process of dosage compensation by hyperactivation of X chromosome - Using appropriate evidence codes and citations</p>"},{"location":"reviews/65c57c3400000359-Dosage_compensation_in_male_Drosophila_by_the_MSL_complex__composed_of_mle__msl_1__msl_2__msl_3_and_mof___D_melanogaster__/#areas-for-improvementquestions","title":"Areas for Improvement/Questions","text":"<ol> <li> <p>Set2 Annotation: The model includes Set2 with H3K36 trimethyltransferase activity, which is correctly identified based on the literature. However, the UniProt entry I looked up was for Set8 (KMT5A), not Set2. This appears to be a discrepancy in the UniProt search rather than a model error, as research clearly shows Set2 is involved in H3K36 trimethylation in Drosophila and plays a role in MSL complex targeting.</p> </li> <li> <p>Complex Representation: According to GO-CAM best practices for complex annotation, when all subunits carrying specific activities are known (as is the case here), the model should represent each individual protein's activity rather than using a complex ID. This model correctly follows this practice.</p> </li> <li> <p>MSL-2 Dual Roles: The model represents MSL-2 with two separate activities: protein-RNA adaptor activity and chromatin-protein adaptor activity. This is appropriate as MSL-2 has been shown to interact with roX RNAs and recognize the X chromosome.</p> </li> </ol>"},{"location":"reviews/65c57c3400000359-Dosage_compensation_in_male_Drosophila_by_the_MSL_complex__composed_of_mle__msl_1__msl_2__msl_3_and_mof___D_melanogaster__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:65c57c3400000359 provides an accurate and comprehensive representation of the MSL complex and its role in Drosophila dosage compensation. The model follows GO-CAM best practices, uses appropriate causal relationships, and is supported by scientific evidence.</p> <p>The model successfully captures the sequential interactions of the MSL complex components and how they work together to achieve X chromosome hyperactivation for dosage compensation in male Drosophila. The pathway is represented in a clear, coherent manner that aligns with the current understanding of this biological process.</p> <p>The model is correctly built and represents the biological process faithfully based on current knowledge.</p>"},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/","title":"65c57c3400001115 Inhibition of SMDT1 EMRE and MCU following cleavage by the m AAA protease complex  composed of AFG3L2 and SPG7   Human","text":"<p>Based on my review of the GO-CAM model and related information, I'll now provide a comprehensive assessment of the model.</p>"},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/#review-of-go-cam-model-gomodel65c57c3400001115","title":"Review of GO-CAM Model: gomodel:65c57c3400001115","text":""},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/#model-summary","title":"Model Summary","text":"<p>Title: \"Inhibition of SMDT1/EMRE and MCU following cleavage by the m-AAA protease complex (composed of AFG3L2 and SPG7) (Human)\"</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>Model URL: https://bioregistry.io/go.model:65c57c3400001115</p>"},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/#overview","title":"Overview","text":"<p>This model represents the regulation of mitochondrial calcium uptake through proteolytic control of the mitochondrial calcium uniporter (MCU) complex. It focuses on how the m-AAA protease complex, composed of AFG3L2 and SPG7, regulates calcium import by cleaving SMDT1/EMRE, a key component of the MCU complex.</p>"},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately captures the current understanding of mitochondrial calcium uniporter regulation as described in the literature:</p> <ol> <li>The m-AAA protease complex (AFG3L2 and SPG7) cleaves SMDT1/EMRE (Q9H4I9), which is an essential regulator of the mitochondrial calcium uniporter.</li> <li>This proteolytic regulation limits the availability of SMDT1/EMRE for MCU assembly.</li> <li>The model correctly shows that MICU1 and MICU2 are calcium ion sensors that regulate MCU activity.</li> <li>The MCU protein (Q8NE86) is properly annotated as having calcium channel activity.</li> </ol>"},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Accurate molecular functions: The model correctly assigns molecular functions to all proteins:</li> <li>AFG3L2 and SPG7 are annotated with metalloendopeptidase activity (GO:0004222)</li> <li>MCU with calcium channel activity (GO:0005262)</li> <li>MICU1 and MICU2 with calcium ion sensor activity (GO:0061891)</li> <li> <p>SMDT1/EMRE with protein-macromolecule adaptor activity (GO:0030674)</p> </li> <li> <p>Proper cellular localization: All activities are correctly localized to the mitochondrial inner membrane (GO:0005743).</p> </li> <li> <p>Appropriate biological process annotations: All activities are properly connected to their biological processes:</p> </li> <li>m-AAA protease activities to \"regulation of calcium import into the mitochondrion\" (GO:0110097)</li> <li> <p>MCU, MICU1, MICU2, and SMDT1/EMRE activities to \"calcium import into the mitochondrion\" (GO:0036444)</p> </li> <li> <p>Well-documented evidence: All assertions are supported by published literature with appropriate evidence codes (ECO:0000314 for direct assay evidence and ECO:0000315 for mutant phenotype evidence).</p> </li> <li> <p>Correct causal relationships: The model uses appropriate causal relationships:</p> </li> <li>RO:0002630 (directly negatively regulates) for m-AAA protease effects on MCU/SMDT1</li> <li> <p>RO:0002629 (directly positively regulates) for the regulatory relationships between components of the MCU complex</p> </li> <li> <p>Proper handling of inputs/outputs: The model correctly shows calcium ion (CHEBI:29108) as the chemical entity being transported by MCU.</p> </li> </ol>"},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex representation: The model doesn't explicitly represent the m-AAA protease complex as a complex with its own ID. According to the GO-CAM guidelines on annotating complexes, when activities are shared by several proteins or when the complex has a defined ID, it's preferable to represent it as such. The m-AAA protease complex could be represented using its appropriate GO ID.</p> </li> <li> <p>Temporal dynamics: The model doesn't capture the temporal aspect of calcium signaling - specifically how MICU1 and MICU2 respond to changes in calcium concentrations to gate MCU activity differently at low vs. high calcium levels, as detailed in PMID:32494073.</p> </li> <li> <p>Regulatory mechanisms detail: The model could benefit from including more detail about how exactly AFG3L2 and SPG7 regulate the proteolysis of SMDT1/EMRE - specifically that they degrade SMDT1/EMRE before its assembly with the uniporter complex.</p> </li> <li> <p>Structural features: The model doesn't capture the structural aspects of how MICU1 occludes the pore of MCU at low calcium levels and moves away upon calcium binding, which is key to understanding the gating mechanism.</p> </li> </ol>"},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Consider representing the m-AAA protease as a complex using the appropriate GO term.</p> </li> <li> <p>Add annotations to represent the calcium-dependent conformational changes in MICU1/MICU2 that lead to different MCU activity states.</p> </li> <li> <p>Include additional details about the proteolytic regulation mechanism, possibly by adding more specific causal associations that clarify the timing of SMDT1/EMRE degradation.</p> </li> <li> <p>Consider adding annotations that capture the structural basis of MCU gating by MICU1/MICU2.</p> </li> </ol>"},{"location":"reviews/65c57c3400001115-Inhibition_of_SMDT1_EMRE_and_MCU_following_cleavage_by_the_m_AAA_protease_complex__composed_of_AFG3L2_and_SPG7___Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of how the m-AAA protease complex regulates mitochondrial calcium uptake through proteolytic control of the MCU complex components. The model is consistent with published literature, uses appropriate GO terms and relationship types, and provides proper evidence for all assertions. With minor enhancements as suggested above, this model could provide an even more comprehensive representation of this important biological process.</p> <p>The model effectively communicates how AFG3L2 and SPG7 act as regulatory components in mitochondrial calcium homeostasis through their proteolytic activities, which has important implications for understanding mitochondrial function in both normal physiology and disease states.</p>"},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/","title":"65c57c3400001478 Negative regulation of Hippo signaling by SLMAP STRIPAK complex  Human","text":"<p>Now let me check for any guidance documents about complex annotation in GO-CAM models:</p> <p>Let me analyze the model based on my findings. I'll first provide a summary of what the model represents:</p>"},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/#review-of-go-cam-model-65c57c3400001478","title":"Review of GO-CAM model 65c57c3400001478","text":""},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/#model-overview","title":"Model Overview","text":"<p>This model titled \"Negative regulation of Hippo signaling by SLMAP-STRIPAK complex (Human)\" represents a molecular pathway in human cells where the SLMAP-STRIPAK complex negatively regulates the Hippo signaling pathway. </p> <p>The model features four main activities: 1. Protein serine/threonine phosphatase activity (GO:0004722) enabled by a FAR/SIN/STRIPAK complex (GO:0090443) 2. Protein serine/threonine kinase activity (GO:0004674) enabled by STK3/MST2 (UniProtKB:Q13188) 3. Protein-macromolecule adaptor activity (GO:0030674) enabled by SLMAP (UniProtKB:Q14BN4) 4. Protein serine/threonine kinase activator activity (GO:0043539) enabled by SAV1 (UniProtKB:Q9H4B6)</p> <p>All activities are localized in the cytoplasm (GO:0005737) and participate in either negative regulation of Hippo signaling (GO:0035331) or Hippo signaling (GO:0035329).</p>"},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model is well-supported by the scientific literature. The central paper cited (PMID:29063833) provides solid evidence for the mechanism depicted, showing how SLMAP promotes binding of the STRIPAK-PP2A phosphatase complex to MST2, leading to dephosphorylation of its activation loop and inhibition of Hippo signaling. SAV1 antagonizes this by inhibiting the phosphatase activity, promoting MST2 activation.</p> <p>The other cited papers (PMID:15688006 and PMID:35429439) provide additional context on MST2/STK3's role in activating LATS kinases and the involvement of SAV1 in this process.</p>"},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/#go-cam-model-structure-review","title":"GO-CAM Model Structure Review","text":""},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/#strengths","title":"Strengths:","text":"<ol> <li> <p>Appropriate causal relationships: The model correctly represents that SLMAP provides input for (RO:0002413) the phosphatase activity of the STRIPAK complex, which directly negatively regulates (RO:0002630) STK3/MST2 kinase activity. This aligns with the literature showing SLMAP as an adaptor that recruits STRIPAK to MST2.</p> </li> <li> <p>Complex representation: The model appropriately uses a GO term for the complex (GO:0090443 - FAR/SIN/STRIPAK complex) as the enabler of the phosphatase activity, while showing only PPP2CA (P67775) as a member. This is consistent with best practices for representing complexes when the exact subunit carrying the activity is known (PPP2CA is the catalytic subunit of PP2A).</p> </li> <li> <p>Dual regulation of STK3/MST2: The model correctly represents the antagonistic regulation of MST2 by both SAV1 (positive regulation) and the STRIPAK complex (negative regulation).</p> </li> </ol>"},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex representation: While the model uses GO:0090443 (FAR/SIN/STRIPAK complex) with only PPP2CA listed as a member, it might be beneficial to include other known components of the STRIPAK complex that are mentioned in the paper (like STRIP1). According to the complex annotation guidelines, since PPP2CA is the main catalytic component, the current representation is acceptable, but including additional subunits would provide more detail.</p> </li> <li> <p>Molecular details: The model doesn't capture some mechanistic details from the literature, such as the autophosphorylation of MST2 at specific sites in the linker region (T336, T378) that create binding sites for SLMAP via its FHA domain.</p> </li> <li> <p>Downstream effects: While the model focuses on SLMAP-STRIPAK's negative regulation of MST2, it could be extended to show how this ultimately affects LATS kinases and YAP/TAZ.</p> </li> </ol>"},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows key GO-CAM best practices: - Activities are properly connected with appropriate causal relations - Protein-enabled activities have appropriate molecular function terms - Activities are properly localized to cellular components - Activities are organized within appropriate biological processes - Evidence is properly cited with supporting literature</p> <p>The representation of the STRIPAK complex follows the guidelines for complex annotation, using the appropriate GO term for the complex (GO:0090443) with the catalytic subunit (PPP2CA) specified.</p>"},{"location":"reviews/65c57c3400001478-Negative_regulation_of_Hippo_signaling_by_SLMAP_STRIPAK_complex__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 65c57c3400001478 accurately represents the negative regulation of Hippo signaling by the SLMAP-STRIPAK complex as described in the scientific literature. The model appropriately depicts the antagonistic roles of SLMAP-STRIPAK and SAV1 in regulating MST2/STK3 activity, which is central to Hippo pathway activation.</p> <p>The model follows GO-CAM best practices and uses appropriate terms and relations to represent the molecular mechanisms involved. While some additional details could be incorporated, the current model provides a clear and accurate representation of this regulatory mechanism.</p>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/","title":"65c57c3400002539 The CRL5 ASB11  complex mediates ubiquitination and degradation of DIRAS2  Human","text":"<p>Based on all this information, I'm now ready to review the GO-CAM model gomodel:65c57c3400002539 titled \"The CRL5(ASB11) complex mediates ubiquitination and degradation of DIRAS2 (Human).\"</p>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#go-cam-review-gomodel65c57c3400002539","title":"GO-CAM Review: gomodel:65c57c3400002539","text":""},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#overview","title":"Overview","text":"<p>This model represents the cullin-RING E3 ubiquitin-protein ligase complex 5 containing ASB11 (CRL5-ASB11) that mediates the ubiquitination and subsequent degradation of DIRAS2, a small GTPase. The model is based primarily on findings from a recent 2024 publication (PMID:38574733) along with background information from an earlier paper (PMID:12194967).</p>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#components-and-structure","title":"Components and Structure","text":"<p>The model consists of 4 activities connected in a cascade:</p> <ol> <li>CUL5 (Q93034) - acts as a scaffold protein with \"ubiquitin ligase complex scaffold activity\" (GO:0160072)</li> <li>ASB11 (Q8WXH4) - acts as the substrate recognition component with \"ubiquitin-like ligase-substrate adaptor activity\" (GO:1990756)</li> <li>RNF7/RBX2 (Q9UBF6) - has \"ubiquitin protein ligase activity\" (GO:0061630)</li> <li>DIRAS2 (Q96HU8) - the substrate protein with \"GTPase activity\" (GO:0003924)</li> </ol>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#causal-relationships","title":"Causal Relationships","text":"<p>The model correctly represents the flow of activity: - CUL5 directly positively regulates (RO:0002629) ASB11's adaptor activity - ASB11 provides input for (RO:0002413) RNF7's ligase activity - RNF7 directly negatively regulates (RO:0002630) DIRAS2's GTPase activity</p>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#biological-process-annotations","title":"Biological Process Annotations","text":"<p>All three components of the CRL5 complex (CUL5, ASB11, RNF7) are annotated to the same biological process: \"protein K11-linked ubiquitination\" (GO:0070979), which is accurate based on the reference paper showing K11-linked ubiquitin chains on DIRAS2.</p> <p>DIRAS2 is annotated to \"signal transduction\" (GO:0007165) and located at the \"plasma membrane\" (GO:0005886), both of which are consistent with its function.</p>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#evidence-and-references","title":"Evidence and References","text":"<p>All activities and causal relationships are appropriately supported by the PMID:38574733 reference with \"direct assay evidence\" (ECO:0000314). The DIRAS2 GTPase activity and location are supported by PMID:12194967, which is appropriate.</p>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#evaluation","title":"Evaluation","text":""},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#strengths","title":"Strengths:","text":"<ol> <li>The model correctly follows the GO-CAM guidelines for annotating E3 ubiquitin ligase complexes.</li> <li>The molecular activities assigned to each protein are accurate.</li> <li>The causal relationships properly reflect the mechanism of the CRL5-ASB11 complex activity on DIRAS2.</li> <li>Evidence codes and references are appropriately used.</li> <li>The biological processes are accurately represented.</li> </ol>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#minor-suggestions-for-improvement","title":"Minor suggestions for improvement:","text":"<ol> <li>Consider adding \"proteasome-mediated ubiquitin-dependent protein catabolic process\" (GO:0043161) as an additional biological process that this ubiquitination is part of, as recommended in the E3 ubiquitin ligase annotation guidelines.</li> <li>The model could be enhanced by including information about the regulatory role of UBE2F mentioned in the paper (PMID:38574733), as it is described as a key part of the axis in the paper's title.</li> <li>Consider adding information about the biological consequences of DIRAS2 degradation in pancreatic cancer, which is the main focus of the paper.</li> </ol>"},{"location":"reviews/65c57c3400002539-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_DIRAS2__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:65c57c3400002539 accurately represents the CRL5(ASB11) complex-mediated ubiquitination and degradation of DIRAS2. It follows the appropriate GO-CAM best practices for annotating E3 ubiquitin ligase complexes. The model is well-supported by evidence and correctly shows the functional relationships between the components. </p> <p>The model is parsimonious, focusing on the core mechanism of DIRAS2 ubiquitination, though it could be extended in the future to include the broader biological context described in the reference paper related to pancreatic cancer and the regulatory role of UBE2F.</p> <p>Overall, the model is of high quality and meets GO-CAM standards.</p>"},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/","title":"65c57c3400002666 Role of CD53 in T cell receptor signaling pathway  Human","text":"<p>Based on the comprehensive information I've gathered, I'll now provide a detailed review of the GO-CAM model with ID 65c57c3400002666 titled \"Role of CD53 in T-cell receptor signaling pathway (Human)\".</p>"},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/#review-of-gomodel65c57c3400002666","title":"Review of gomodel:65c57c3400002666","text":""},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/#overview","title":"Overview","text":"<p>The model describes the role of CD53 (a tetraspanin protein) in T-cell receptor signaling pathway in humans. It includes four proteins (CD53, PTPRC/CD45, LCK, and CD247/CD3\u03b6 chain) and their interactions in a signaling cascade.</p>"},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model consists of four activities connected through causal relationships:</p> <ol> <li> <p>CD53 (P19397) with protein-membrane adaptor activity (GO:0043495), occurring in the plasma membrane (GO:0005886), and part of the receptor clustering process (GO:0043113)</p> </li> <li> <p>PTPRC/CD45 (P08575) with protein tyrosine phosphatase activity (GO:0004725), occurring in the plasma membrane (GO:0005886), and part of T cell receptor signaling pathway (GO:0050852)</p> </li> <li> <p>LCK (P06239) with protein tyrosine kinase activity (GO:0004713), occurring in the plasma membrane (GO:0005886), and part of T cell receptor signaling pathway (GO:0050852)</p> </li> <li> <p>CD247/CD3\u03b6 (P20963) with transmembrane signaling receptor activity (GO:0004888), occurring in the plasma membrane (GO:0005886), and part of T cell receptor signaling pathway (GO:0050852)</p> </li> </ol> <p>The causal relationships in the model show: - CD53 directly positively regulates PTPRC (CD45) - PTPRC directly positively regulates LCK - LCK directly positively regulates CD247 (CD3\u03b6)</p>"},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/#scientific-assessment","title":"Scientific Assessment","text":""},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Evidence Base: Each activity and association is well-supported by published literature with appropriate evidence codes (ECO:0000305, ECO:0000314, etc.).</p> </li> <li> <p>Pathway Representation: The model correctly captures key components of the TCR signaling pathway, specifically the early events involving CD53, CD45, LCK, and CD3\u03b6.</p> </li> <li> <p>Subcellular Localization: All components are correctly annotated as occurring in the plasma membrane, consistent with their biological roles.</p> </li> <li> <p>Causal Relationships: The directional flow of signal transduction is accurately represented through the causal relationships.</p> </li> </ol>"},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex Representation: The model doesn't fully capture the complexity of the TCR/CD3 complex. Based on the literature (particularly the San Jos\u00e9 et al. paper), the TCR/CD3 complex consists of six subunits and likely contains two TCR heterodimers. This complexity could be better represented using GO-CAM's complex representation guidelines.</p> </li> <li> <p>CD45 Regulation by CD53: The precise mechanism by which CD53 regulates CD45 could be more explicitly modeled. The Dunlock et al. paper (PMID:35767951) indicates that CD53 controls CD45 stability, mobility, and function, but the specific molecular interactions could be made clearer.</p> </li> <li> <p>LCK Activation Mechanism: The model correctly shows that CD45 regulates LCK, but doesn't capture the details of LCK activation through dephosphorylation of its inhibitory tyrosine residue (Y505). </p> </li> <li> <p>Additional Components: Key components of the TCR signaling pathway such as ZAP70 (which is mentioned in the literature as being activated by LCK after CD3\u03b6 phosphorylation) are not included in the model.</p> </li> </ol>"},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Expand TCR/CD3 Complex Representation: </li> <li>Consider using complex representation guidelines to model the full TCR/CD3 complex</li> <li> <p>Include TCR \u03b1 and \u03b2 chains and other CD3 components (CD3\u03b4, CD3\u03b5, CD3\u03b3)</p> </li> <li> <p>Refine CD53-CD45 Interaction: </p> </li> <li>Add more detail about how CD53 regulates CD45, potentially including the formation of tetraspanin-enriched microdomains</li> <li> <p>Include information about CD53's role in CD45RO stability as mentioned in the Dunlock paper</p> </li> <li> <p>Expand LCK Activation Details: </p> </li> <li>Add more specific information about LCK activation, including dephosphorylation of Y505 by CD45</li> <li> <p>Include LCK's autophosphorylation at Y394</p> </li> <li> <p>Add Downstream Signaling Components: </p> </li> <li>Include ZAP70 and its activation by LCK</li> <li> <p>Consider adding other downstream signaling molecules like LAT and SLP-76</p> </li> <li> <p>Consider Lipid Raft Localization: </p> </li> <li>Add information about membrane microdomains and their role in organizing the TCR signaling components</li> </ol>"},{"location":"reviews/65c57c3400002666-Role_of_CD53_in_T_cell_receptor_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The model gomodel:65c57c3400002666 provides a solid foundation for understanding the role of CD53 in TCR signaling. It accurately captures the key players and their causal relationships in this pathway. However, it could be enhanced by including more detailed representations of protein complexes and molecular mechanisms, particularly regarding how CD53 regulates CD45 and how CD45 activates LCK. The model could also be extended to include additional components of the TCR signaling pathway downstream of CD3\u03b6 phosphorylation.</p> <p>The model is consistent with current biological knowledge and provides a valuable representation of this important immunological pathway. With the suggested enhancements, it could serve as an even more comprehensive resource for understanding T cell receptor signaling and the specific role of CD53 in this process.</p>"},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/","title":"65d7e4ac00000022 CARD9 regulation by TRIM62 USP15  Human","text":"<p>Now I'll provide a comprehensive review of the GO-CAM model \"CARD9 regulation by TRIM62/USP15 (Human)\" (gomodel:65d7e4ac00000022).</p>"},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#review-of-go-cam-model-card9-regulation-by-trim62usp15-human","title":"Review of GO-CAM Model: CARD9 regulation by TRIM62/USP15 (Human)","text":""},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: CARD9 regulation by TRIM62/USP15 (Human)</li> <li>Model ID: gomodel:65d7e4ac00000022</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#summary-of-model-content","title":"Summary of Model Content","text":"<p>This model depicts the regulation of CARD9-mediated signaling through the post-translational modifications by TRIM62 (E3 ubiquitin ligase) and USP15 (deubiquitinase). The pathway represents C-type lectin receptor (CLEC7A/Dectin-1)-mediated antifungal immunity signaling, involving the formation of the CARD9-BCL10-MALT1 (CBM) complex leading to NF-\u03baB activation.</p>"},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#detailed-evaluation","title":"Detailed Evaluation","text":""},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<ol> <li>Pathway Description: </li> <li>The model accurately represents the known biology of C-type lectin receptor signaling, where CLEC7A (Dectin-1) acts as a pattern recognition receptor for fungal beta-glucans, leading to activation of CARD9 and formation of the CBM complex.</li> <li> <p>The key regulatory mechanisms involving TRIM62-mediated ubiquitination (activating) and USP15-mediated deubiquitination (inhibitory) of CARD9 are correctly represented.</p> </li> <li> <p>Protein Functions:</p> </li> <li>CLEC7A/Dectin-1 (Q9BXN2): Correctly annotated as having pattern recognition receptor activity (GO:0038187) on the plasma membrane, consistent with its role in detecting fungal cell wall components.</li> <li>CARD9 (Q9H257): Appropriately annotated with signaling adaptor activity (GO:0035591), which aligns with its function as a scaffold protein in immune signaling.</li> <li>BCL10 (O95999): Correctly annotated with protein-macromolecule adaptor activity (GO:0030674), reflecting its role in the CBM complex.</li> <li>TRIM62 (Q9BVG3): Properly annotated with ubiquitin protein ligase activity (GO:0061630), consistent with its function in K27-linked ubiquitination of CARD9.</li> <li> <p>USP15 (Q9Y4E8): Correctly annotated with cysteine-type deubiquitinase activity (GO:0004843), accurately reflecting its role in removing ubiquitin from CARD9.</p> </li> <li> <p>Cellular Locations:</p> </li> <li>All proteins are annotated with appropriate cellular locations consistent with their biological functions.</li> <li>CLEC7A is correctly located at the plasma membrane (GO:0005886).</li> <li>The cytoplasmic location (GO:0005737) for CARD9, TRIM62, USP15, and BCL10 is consistent with current knowledge.</li> </ol>"},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#modeling-accuracy","title":"Modeling Accuracy","text":"<ol> <li>Causal Relationships:</li> <li> <p>The causal relationships in the model are biologically accurate:</p> <ul> <li>CLEC7A \u2192 CARD9: \"directly positively regulates\" (RO:0002629)</li> <li>CARD9 \u2192 BCL10: \"directly positively regulates\" (RO:0002629)</li> <li>TRIM62 \u2192 CARD9: \"directly positively regulates\" (RO:0002629)</li> <li>USP15 \u2192 CARD9: \"directly negatively regulates\" (RO:0002630)</li> <li>BCL10 \u2192 MALT1: \"provides input for\" (RO:0002413)</li> </ul> </li> <li> <p>Complex Representation:</p> </li> <li>The CBM complex formation is represented according to GO-CAM best practices. The model shows how individual components (CARD9, BCL10, MALT1) interact rather than using a generic complex ID, which is appropriate when the specific activities of each component are known.</li> <li> <p>The sequential activation (CARD9 \u2192 BCL10 \u2192 MALT1) correctly represents the nucleation model of CBM complex assembly.</p> </li> <li> <p>Evidence:</p> </li> <li>All activities and associations are supported by appropriate evidence codes and literature references.</li> <li>Primary research articles are cited for each relationship (e.g., PMID:26488816 for TRIM62's ubiquitination of CARD9).</li> </ol>"},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#quality-control-issues","title":"Quality Control Issues","text":"<ol> <li>Evidence Code Usage:</li> <li> <p>The evidence for CARD9's part_of relationship to positive regulation of NF-kappaB signaling (GO:0043123) uses ECO:0000250 with evidence from mouse (UniProtKB:Q6QLQ4). While this is acceptable, direct human evidence would strengthen this annotation.</p> </li> <li> <p>Causal Relationship Precision:</p> </li> <li> <p>CARD9 is shown to directly positively regulate BCL10, which is accurate but could be more precisely characterized as facilitating the oligomerization of BCL10 through its CARD domain.</p> </li> <li> <p>Completeness of Model:</p> </li> <li>The model accurately depicts the key regulatory events but misses some details of CARD9 activation. For instance, the model doesn't explicitly show that CARD9 must be phosphorylated by PKC\u03b4 in addition to being ubiquitinated for full activation.</li> <li> <p>The K27-linked ubiquitination specificity of TRIM62 could be more explicitly noted in the model.</p> </li> <li> <p>Biological Process Annotation:</p> </li> <li>BCL10 is annotated as part of \"positive regulation of canonical NF-kappaB signal transduction\" (GO:0043123), which is accurate, but could also be annotated as part of antifungal immune response for completeness.</li> </ol>"},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Activation Mechanism Refinement:</li> <li> <p>Consider adding a node for PKC\u03b4-mediated phosphorylation of CARD9, which works in conjunction with TRIM62-mediated ubiquitination for full activation.</p> </li> <li> <p>Ubiquitination Specificity:</p> </li> <li> <p>Explicitly indicate that TRIM62 mediates K27-linked ubiquitination of CARD9 at K125, which is a specific regulatory mechanism documented in the literature.</p> </li> <li> <p>Downstream Effects:</p> </li> <li> <p>The model could be extended to show downstream effects of CBM complex formation, such as activation of NF-\u03baB and production of pro-inflammatory cytokines.</p> </li> <li> <p>Signaling Context:</p> </li> <li>Consider adding additional context about how this pathway integrates with other immune signaling pathways, particularly its role in antifungal immunity.</li> </ol>"},{"location":"reviews/65d7e4ac00000022-CARD9_regulation_by_TRIM62_USP15__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model accurately represents the key molecular interactions involved in CARD9 regulation by TRIM62 and USP15 in the context of antifungal immunity signaling. The model adheres to GO-CAM best practices for representing complexes and causal relationships. The biological content is consistent with current literature and follows a logical flow that represents the known activation sequence in this pathway. With minor refinements, this model could serve as an excellent reference for understanding the regulation of CARD9-mediated immune signaling in humans.</p>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/","title":"65d7e4ac00000082 DUSP22 inhibition of TCR signaling via UBR2 inhibition  Human","text":"<p>Now I'll review the GO-CAM model in detail.</p>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#go-cam-review-dusp22-inhibition-of-tcr-signaling-via-ubr2-inhibition-human","title":"GO-CAM Review: DUSP22 inhibition of TCR signaling via UBR2 inhibition (Human)","text":""},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#model-id-gomodel65d7e4ac00000082","title":"Model ID: gomodel:65d7e4ac00000082","text":""},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model describes the molecular pathway of DUSP22-mediated inhibition of T-cell receptor (TCR) signaling through the regulation of UBR2 activity, which in turn affects Lck activity. The model captures several key molecular interactions and activities:</p> <ol> <li>DUSP22 (Q9NRW4) has protein tyrosine/serine/threonine phosphatase activity</li> <li>BTRC/\u03b2-TrCP (Q9Y297) functions as a ubiquitin-like ligase-substrate adaptor </li> <li>UBR2 (Q8IWV8) has ubiquitin protein ligase activity</li> <li>Lck (P06239) has protein tyrosine kinase activity</li> </ol> <p>The causal relationships between these activities show how DUSP22 provides input for BTRC, which leads to UBR2 degradation via K48-linked ubiquitination, ultimately inhibiting Lck's K63-linked ubiquitination and activation in TCR signaling.</p>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#detailed-review","title":"Detailed Review","text":""},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The biological content of the model accurately reflects the findings in the recent publication by Shih et al. (2024) [PMID:38225265]. The model correctly depicts:</p> <ol> <li>DUSP22's role as a negative regulator of T-cell receptor signaling by dephosphorylating UBR2</li> <li>BTRC (\u03b2-TrCP) serving as a ubiquitin ligase-substrate adaptor for UBR2</li> <li>UBR2's function in promoting K63-linked ubiquitination of Lck</li> <li>Lck's role in TCR signaling pathway</li> </ol> <p>The molecular functions and biological processes assigned to each protein are consistent with the literature and correctly connected via appropriate causal relationships.</p>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#go-terms-and-annotation-consistency","title":"GO Terms and Annotation Consistency","text":"<p>The model uses appropriate GO terms for molecular functions and biological processes:</p> <ul> <li>DUSP22: Protein tyrosine/serine/threonine phosphatase activity (GO:0008138) - appropriate given DUSP22's dual specificity</li> <li>BTRC: Ubiquitin-like ligase-substrate adaptor activity (GO:1990756) - correct for its role in the SCF complex</li> <li>UBR2: Ubiquitin protein ligase activity (GO:0061630) - appropriate for its E3 ligase function</li> <li>Lck: Protein tyrosine kinase activity (GO:0004713) - correct for its role in phosphorylating TCR components</li> </ul> <p>The biological processes are also correctly assigned: - DUSP22 is part of negative regulation of T cell receptor signaling pathway (GO:0050860) - BTRC is part of protein K48-linked ubiquitination (GO:0070936) - UBR2 is part of protein K63-linked ubiquitination (GO:0070534) - Lck is part of T cell receptor signaling pathway (GO:0050852)</p>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships in the model are properly defined and follow GO-CAM guidelines:</p> <ol> <li>DUSP22 provides input for (RO:0002413) BTRC - correctly indicates that DUSP22 dephosphorylates UBR2, making it a substrate for BTRC</li> <li>BTRC regulates UBR2 by using a non-direct \"regulates\" relationship (RO:0002409) - This is marked as regulation but per the E3 ubiquitin ligases guideline, it should ideally be \"directly regulates\" since it's targeting UBR2 for degradation</li> <li>UBR2 directly positively regulates (RO:0002629) Lck - correctly shows that UBR2 ubiquitinates and activates Lck</li> </ol>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#cellular-components","title":"Cellular Components","text":"<p>The cellular locations are appropriately specified: - DUSP22 located in plasma membrane (GO:0005886) - BTRC located in cytoplasm (GO:0005737) - UBR2 located in cytoplasm (GO:0005737) - Lck located in plasma membrane (GO:0005886)</p> <p>These locations align with the known distribution of these proteins during TCR signaling.</p>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#evidence-consistency","title":"Evidence Consistency","text":"<p>The evidence codes and citations are correctly used: - Direct assay evidence (ECO:0000314) is cited for most of the molecular functions and causal relationships - Curator inference (ECO:0000305) is used appropriately for some cellular locations - The recent publication (PMID:38225265) is correctly cited for the UBR2-Lck relationship - Historical literature references for Lck's role in TCR signaling are also correctly cited (PMID:214242, PMID:12150984, PMID:8943371)</p>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#improvement-suggestions","title":"Improvement Suggestions","text":"<ol> <li> <p>Causal relationship refinement: The causal relationship between BTRC and UBR2 uses \"regulates\" (RO:0002409), but according to the E3 ubiquitin ligases guideline, when an adaptor protein like BTRC is targeting a protein for degradation, \"directly regulates\" would be more appropriate.</p> </li> <li> <p>Model expansion opportunity: The model could potentially be expanded to include:</p> </li> <li>The SCF complex scaffold (CUL1) which works with BTRC to form a functional E3 ligase complex</li> <li>The downstream effects of Lck activation on TCR signaling (e.g., ZAP70 phosphorylation)</li> <li> <p>The specific phosphatase activity of DUSP22 on UBR2 at Ser1694 and Tyr1697 residues</p> </li> <li> <p>Evidence detail: Some evidence annotations could potentially be enhanced with more specific experimental details from the primary literature.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00000082-DUSP22_inhibition_of_TCR_signaling_via_UBR2_inhibition__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:65d7e4ac00000082) provides an accurate representation of the DUSP22-UBR2-Lck regulatory pathway in T-cell receptor signaling, as recently described in the literature. The model effectively captures the key molecular activities, subcellular locations, and causal relationships among these proteins.</p> <p>The model follows GO-CAM curation guidelines for representing E3 ubiquitin ligase activities and complexes. It is biologically sound, well-supported by evidence, and properly constructed according to GO-CAM standards. </p> <p>With minor refinements to the causal relationship between BTRC and UBR2, and potential expansions to include additional components of the pathway, this model will provide an even more comprehensive representation of this important regulatory mechanism in T-cell biology.</p>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/","title":"65d7e4ac00001282 Thrombospondin 1 CD36 inhibition of angiogenesis in endothelial cells  Human","text":"<p>Now that I have a good understanding of the model and the relevant GO-CAM guidelines, I'll proceed with my review of the GO-CAM model \"Thrombospondin-1/CD36 inhibition of angiogenesis in endothelial cells (Human)\" (gomodel:65d7e4ac00001282).</p>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#go-cam-model-review-thrombospondin-1cd36-inhibition-of-angiogenesis-in-endothelial-cells-human","title":"GO-CAM Model Review: Thrombospondin-1/CD36 inhibition of angiogenesis in endothelial cells (Human)","text":""},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#model-overview","title":"Model Overview","text":"<p>Model ID: gomodel:65d7e4ac00001282 Title: Thrombospondin-1/CD36 inhibition of angiogenesis in endothelial cells (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#model-description","title":"Model Description","text":"<p>This model represents a signaling pathway by which thrombospondin-1 (THBS1) inhibits angiogenesis in endothelial cells through interactions with CD36, leading to downstream activation of protein tyrosine phosphatase SHP-1 (PTPN6), which in turn negatively regulates vascular endothelial growth factor receptor 2 (KDR/VEGFR2).</p>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#components-and-activities","title":"Components and Activities","text":"<p>The model includes four key proteins and their activities:</p> <ol> <li>THBS1 (UniProtKB:P07996) - Extracellular matrix structural constituent</li> <li>CD36 (UniProtKB:P16671) - Thrombospondin receptor activity</li> <li>PTPN6/SHP-1 (UniProtKB:P29350) - Protein tyrosine phosphatase activity</li> <li>KDR/VEGFR2 (UniProtKB:P35968) - Vascular endothelial growth factor receptor activity</li> </ol>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#pathway-flow-analysis","title":"Pathway Flow Analysis","text":"<p>The causal flow in the model is:</p> <ol> <li>THBS1 (extracellular matrix structural constituent) \u2192 directly positively regulates \u2192 CD36 (thrombospondin receptor activity)</li> <li>CD36 (thrombospondin receptor activity) \u2192 directly positively regulates \u2192 PTPN6 (protein tyrosine phosphatase activity)</li> <li>PTPN6 (protein tyrosine phosphatase activity) \u2192 directly negatively regulates \u2192 KDR (vascular endothelial growth factor receptor activity)</li> </ol> <p>This represents a cascade where THBS1 in the extracellular matrix binds to CD36 on the plasma membrane, activating CD36's receptor activity, which then activates PTPN6's phosphatase activity, leading to the dephosphorylation and inhibition of KDR/VEGFR2.</p>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#biological-processes","title":"Biological Processes","text":"<ul> <li>THBS1, CD36, and PTPN6 activities are part of negative regulation of angiogenesis (GO:0016525)</li> <li>KDR activity is part of positive regulation of angiogenesis (GO:0045766)</li> </ul> <p>This correctly shows the antagonistic relationship between these two pathways - THBS1/CD36/PTPN6 inhibit angiogenesis, while KDR/VEGFR2 promotes it.</p>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#cellular-localization","title":"Cellular Localization","text":"<ul> <li>THBS1 occurs in extracellular matrix (GO:0031012)</li> <li>CD36 and KDR occur in plasma membrane (GO:0005886)</li> <li>PTPN6 occurs in plasma membrane (GO:0005886)</li> </ul>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes and references:</p> <ul> <li>Direct assay evidence (ECO:0000314) from PMID:10102632, PMID:23896411, PMID:9245797, PMID:6341993</li> <li>Mutant phenotype evidence (ECO:0000315) from PMID:17562706</li> <li>Automatically integrated combinatorial evidence (ECO:0000245) from PMID:23979707</li> </ul>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#qc-assessment","title":"QC Assessment","text":""},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly represents the inhibitory pathway from THBS1 to VEGFR2</li> <li>Appropriate causal relationships are used (directly positively regulates, directly negatively regulates)</li> <li>Correct cellular compartments are assigned</li> <li>Evidence is provided with appropriate PMIDs and evidence codes</li> </ol>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#potential-issues","title":"Potential issues","text":"<ol> <li> <p>Subcellular Location of PTPN6/SHP-1: According to the UniProt entry, PTPN6 is primarily cytoplasmic and nuclear. The model places it at the plasma membrane. While PTPN6 can be recruited to the plasma membrane upon CD36 stimulation, it would be more accurate to indicate its primary location as cytoplasm.</p> </li> <li> <p>Biological Process Assignment: All activities except KDR are annotated to negative regulation of angiogenesis (GO:0016525). This seems correct based on the literature, but it would be helpful to include more specific processes for each component if available (e.g., signal transduction processes).</p> </li> <li> <p>Missing Intermediate Steps: The literature suggests that the pathway from CD36 to KDR inhibition involves additional kinases and signaling intermediates like src-family kinases. These are not represented in the model, which simplifies the pathway.</p> </li> <li> <p>Cellular Context Specification: The model mentions endothelial cells in the title, but the ZFA:0009065 (endothelial cell) term is in the objects list but not explicitly used in the annotations. It would be helpful to make this cellular context more explicit.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Update PTPN6 subcellular location: Consider changing the subcellular location of PTPN6 to cytoplasm as its primary location, with a note that it can be recruited to the membrane upon CD36 activation.</p> </li> <li> <p>Add intermediate signaling components: If supported by the literature, consider adding intermediate signaling components between CD36 and PTPN6, such as src-family kinases that are known to be involved in this pathway.</p> </li> <li> <p>Specify cell type: Explicitly annotate the activities to occur in endothelial cells using the existing term ZFA:0009065.</p> </li> <li> <p>Expand biological process annotations: Consider adding more specific biological process terms for each component to better represent their specific roles in the signaling pathway.</p> </li> <li> <p>Consider additional VEGFR2 regulation details: If available in the literature, add details about how PTPN6 regulates VEGFR2, such as which tyrosine residues are dephosphorylated.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001282-Thrombospondin_1_CD36_inhibition_of_angiogenesis_in_endothelial_cells__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the inhibitory pathway from THBS1 to VEGFR2 via CD36 and PTPN6. The model follows GO-CAM best practices for representing signaling receptor activities and inhibitory pathways. With a few minor adjustments as suggested above, the model would provide an even more comprehensive representation of this important anti-angiogenic pathway.</p> <p>The model is consistent with current literature on thrombospondin-1 as an inhibitor of angiogenesis, CD36 as its receptor, and the downstream inhibition of VEGFR2 signaling. The connections between components follow GO-CAM guidelines for representing signaling pathways.</p>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/","title":"65d7e4ac00001363 Mitochondrial calcium uptake by the uniplex complex composed of SMDT1 EMRE  MICU1  MICU2 and MCU  Human","text":"<p>Now let me look at the model in detail to understand the relationships between the proteins and their roles in the mitochondrial calcium uptake complex.</p> <p>Based on the information I've gathered, I'll provide a comprehensive review of the GO-CAM model 65d7e4ac00001363, which describes \"Mitochondrial calcium uptake by the uniplex complex composed of SMDT1/EMRE, MICU1, MICU2 and MCU (Human).\"</p>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#summary-of-the-go-cam-model","title":"Summary of the GO-CAM Model","text":"<p>This model represents the mitochondrial calcium uniporter (MCU) complex (also called uniplex complex), which consists of four proteins:</p> <ol> <li>MCU (Q8NE86) - The calcium channel-forming subunit with calcium channel activity</li> <li>SMDT1/EMRE (Q9H4I9) - An essential MCU regulator with protein-macromolecule adaptor activity </li> <li>MICU1 (Q9BPX6) - A calcium sensor with calcium ion sensor activity</li> <li>MICU2 (Q8IYU8) - A calcium sensor with calcium ion sensor activity</li> </ol> <p>The model shows how these components interact to regulate calcium uptake into the mitochondrial matrix.</p>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#structure-and-quality-assessment","title":"Structure and Quality Assessment","text":""},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#core-elements-of-the-model","title":"Core Elements of the Model:","text":"<ol> <li> <p>MCU (Q8NE86) has calcium channel activity (GO:0005262) in the mitochondrial inner membrane (GO:0005743), part of calcium import into mitochondrion process (GO:0036444).</p> </li> <li> <p>SMDT1/EMRE (Q9H4I9) functions as a protein-macromolecule adaptor (GO:0030674) in the mitochondrial inner membrane (GO:0005743), part of calcium import into mitochondrion (GO:0036444), and it directly positively regulates (RO:0002629) MICU1.</p> </li> <li> <p>MICU1 (Q9BPX6) has calcium ion sensor activity (GO:0061891) in the mitochondrial inner membrane (GO:0005743), part of cellular response to calcium ion (GO:0071277), and directly positively regulates (RO:0002629) MCU.</p> </li> <li> <p>MICU2 (Q8IYU8) has calcium ion sensor activity (GO:0061891) in the mitochondrial inner membrane (GO:0005743), part of cellular response to calcium ion (GO:0071277), and directly positively regulates (RO:0002629) MCU.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#evidence-and-references","title":"Evidence and References:","text":"<p>The model is well-supported with evidence codes and references to primary literature. Most annotations use direct assay evidence (ECO:0000314) or mutant phenotype evidence (ECO:0000315) with appropriate PMID references.</p>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#detailed-assessment","title":"Detailed Assessment","text":""},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#biological-accuracy","title":"Biological Accuracy:","text":"<ol> <li> <p>Molecular Functions: The molecular functions assigned to each protein are accurate based on UniProt entries and literature. MCU forms the calcium channel, SMDT1/EMRE serves as an adaptor, and MICU1 and MICU2 are calcium sensors.</p> </li> <li> <p>Subcellular Localization: All components are correctly localized to the mitochondrial inner membrane (GO:0005743).</p> </li> <li> <p>Biological Process: The process annotations correctly capture the roles of these proteins in calcium import into mitochondria and cellular response to calcium.</p> </li> <li> <p>Causal Relationships: The causal relationships accurately reflect the regulatory mechanisms described in the literature, where MICU1 and MICU2 regulate MCU activity in response to calcium levels, and SMDT1/EMRE regulates MICU1.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#adherence-to-go-cam-guidelines","title":"Adherence to GO-CAM Guidelines:","text":"<ol> <li> <p>Complex Representation: The model follows guidelines for representing complexes where the subunits with known activities are represented individually. This is appropriate as we know which functions each subunit performs.</p> </li> <li> <p>Evidence Support: Each assertion is properly referenced with appropriate evidence codes and PubMed IDs.</p> </li> <li> <p>Causal Associations: Appropriate relation terms are used to indicate the regulation between components (RO:0002629 for direct positive regulation).</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#chemical-entities","title":"Chemical Entities:","text":"<p>The model correctly includes calcium ion (CHEBI:29108) as both an input and output of MCU's calcium channel activity.</p>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li> <p>Comprehensive representation: The model captures all key components of the mitochondrial calcium uniporter complex and their relationships.</p> </li> <li> <p>Well-evidenced: Each assertion is supported by appropriate evidence and literature references.</p> </li> <li> <p>Molecular detail: The model captures the specific molecular functions of each component within the complex.</p> </li> <li> <p>Regulatory relationships: The regulatory relationships between components are clearly represented.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Mechanistic Detail: While the model shows the regulatory relationships, it could provide more detail on the mechanism by which calcium binding to MICU1/MICU2 affects MCU activity. The literature indicates that at low calcium levels, MICU1 occludes the pore of the MCU channel, and at higher calcium levels, calcium binding induces a conformational change that allows calcium permeation. This mechanistic detail could be represented more explicitly.</p> </li> <li> <p>Calcium Binding Events: The model could explicitly represent calcium binding to the EF-hand domains of MICU1 and MICU2 as separate molecular activities.</p> </li> <li> <p>Disulfide Bond Information: The disulfide linkage between MICU1 and MICU2 is an important structural feature that could be represented more explicitly in the model.</p> </li> <li> <p>SMDT1/EMRE Functions: The model correctly represents SMDT1/EMRE as having adaptor activity, but its dual functions in gating MCU and recruiting MICU1 could be more explicitly represented.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Consider adding more detail about the mechanism of calcium-dependent regulation by MICU1 and MICU2.</p> </li> <li> <p>Consider explicitly representing calcium binding to MICU1 and MICU2.</p> </li> <li> <p>Consider adding annotation about the disulfide bond between MICU1 and MICU2.</p> </li> <li> <p>Consider refining the representation of SMDT1/EMRE's dual functions.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001363-Mitochondrial_calcium_uptake_by_the_uniplex_complex_composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__Human__/#conclusion","title":"Conclusion:","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the mitochondrial calcium uniporter complex and its regulation. The model is well-evidenced, follows GO-CAM guidelines, and effectively captures the key molecular activities and regulatory relationships. With some minor enhancements to capture additional mechanistic details, the model would be even more comprehensive.</p>"},{"location":"reviews/65d7e4ac00001732-Activation_of_GPR75_by_CCL5_in_neurons__Human_/","title":"65d7e4ac00001732 Activation of GPR75 by CCL5 in neurons  Human","text":"<p>Based on my review of the GO-CAM model gomodel:65d7e4ac00001732 \"Activation of GPR75 by CCL5 in neurons (Human)\" and relevant guidelines, here is my assessment:</p>"},{"location":"reviews/65d7e4ac00001732-Activation_of_GPR75_by_CCL5_in_neurons__Human_/#go-cam-review-for-model65d7e4ac00001732","title":"GO-CAM Review for model:65d7e4ac00001732","text":""},{"location":"reviews/65d7e4ac00001732-Activation_of_GPR75_by_CCL5_in_neurons__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM describes the activation of GPR75 (O95800) by the chemokine CCL5 (P13501) and subsequent signaling through MAP kinases in neurons. The model consists of four molecular activities linked through causal relationships.</p>"},{"location":"reviews/65d7e4ac00001732-Activation_of_GPR75_by_CCL5_in_neurons__Human_/#positive-aspects","title":"Positive Aspects","text":"<ol> <li>Appropriate molecular functions: The model correctly assigns molecular functions to each protein:</li> <li>CCL5 is annotated with chemokine activity (GO:0008009)</li> <li>GPR75 is annotated with G protein-coupled receptor activity (GO:0004930)</li> <li> <p>MAPK1 and MAPK3 are annotated with protein serine/threonine kinase activity (GO:0004674)</p> </li> <li> <p>Correct cellular components: The cellular locations are appropriate:</p> </li> <li>CCL5 in extracellular space (GO:0005615)</li> <li>GPR75 in plasma membrane (GO:0005886)</li> <li> <p>MAPK1 and MAPK3 in cytoplasm (GO:0005737)</p> </li> <li> <p>Biological processes: The model connects activities to relevant biological processes:</p> </li> <li>CCL5 to positive regulation of G protein-coupled receptor signaling (GO:0045745)</li> <li>GPR75 to G protein-coupled receptor signaling pathway (GO:0007186)</li> <li> <p>MAPK1 and MAPK3 to ERK1 and ERK2 cascade (GO:0070371)</p> </li> <li> <p>Evidence: All claims are supported by literature evidence, primarily PMID:29772059 which specifically describes CCL5 activation of GPR75 leading to ERK1/2 activation.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001732-Activation_of_GPR75_by_CCL5_in_neurons__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Signaling pathway completeness: The model correctly shows CCL5 directly positively regulating (RO:0002629) GPR75, and GPR75 has input for (RO:0002407) both MAPK3 and MAPK1. However, the model could benefit from:</li> <li>Including the intermediate G protein components between GPR75 and the MAP kinases</li> <li> <p>According to PMID:29772059, GPR75 activates a Gq signaling pathway which triggers PI3K and phospholipase C, ultimately leading to ERK activation</p> </li> <li> <p>Relationship between MAPK3 and MAPK1: </p> </li> <li>The model shows both MAPK3 and MAPK1 as direct targets of GPR75 but doesn't capture their relationship to each other in the kinase cascade</li> <li> <p>According to the cited literature, there is typically a hierarchical activation where MAPK3 (ERK1) can activate MAPK1 (ERK2)</p> </li> <li> <p>Biological context: </p> </li> <li>While the model indicates \"in neurons (Human)\" in the title, it would be beneficial to include a cell type annotation in the model itself</li> <li> <p>The publication indicates that GPR75 activation by CCL5 promotes neuronal survival through the PI3K/AKT/MAPK pathway, which could be included as a higher-level biological process</p> </li> <li> <p>Missing components:</p> </li> <li>The PI3K-AKT pathway is mentioned in the literature as being activated by CCL5-GPR75 interaction but is not represented in the model</li> <li>Downstream effects on neuronal survival are not captured</li> </ol>"},{"location":"reviews/65d7e4ac00001732-Activation_of_GPR75_by_CCL5_in_neurons__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>Based on the \"Signaling receptor activity annotation guidelines,\" this model follows many best practices: - Correctly shows the ligand (CCL5) in extracellular space - Uses \"directly positively regulates\" between ligand and receptor - Places the receptor in the plasma membrane - Uses \"has input for\" from receptor to its effectors</p> <p>However, according to the guidelines, \"the input (target) of the receptor is the effector protein it regulates,\" and \"the causal relation between the MF of the receptor and the MF of its target is 'directly positively regulates'.\" In this model, GPR75 uses \"has input for\" (RO:0002407) rather than \"directly positively regulates\" (RO:0002629) for its relationship with MAPK1 and MAPK3.</p>"},{"location":"reviews/65d7e4ac00001732-Activation_of_GPR75_by_CCL5_in_neurons__Human_/#conclusion-and-recommendations","title":"Conclusion and Recommendations","text":"<p>The model provides a sound representation of CCL5 activation of GPR75 and subsequent MAPK signaling based on strong evidence. To improve the model, I recommend:</p> <ol> <li>Include the G protein intermediates between GPR75 and MAPKs (particularly Gq proteins)</li> <li>Add the PI3K-AKT pathway mentioned in the literature</li> <li>Change the relationship from GPR75 to MAPKs from \"has input for\" to \"directly positively regulates\" for consistency with GO-CAM guidelines</li> <li>Consider adding neuronal survival as a downstream biological process</li> <li>Add a cell type annotation to specify neuronal context</li> <li>Consider showing the hierarchical relationship between MAPK3 and MAPK1</li> </ol> <p>These changes would create a more complete representation of the signaling pathway while maintaining consistency with GO-CAM best practices.</p>"},{"location":"reviews/65d7e4ac00001800-RUFY1_mediates_early_endosome_to_Golgi_transport___Human_/","title":"65d7e4ac00001800 RUFY1 mediates early endosome to Golgi transport   Human","text":"<p>Based on my review, I'll now provide a detailed assessment of GO-CAM model 65d7e4ac00001800 \"RUFY1 mediates early endosome to Golgi transport. (Human)\".</p>"},{"location":"reviews/65d7e4ac00001800-RUFY1_mediates_early_endosome_to_Golgi_transport___Human_/#go-cam-review-gomodel65d7e4ac00001800","title":"GO-CAM Review: gomodel:65d7e4ac00001800","text":""},{"location":"reviews/65d7e4ac00001800-RUFY1_mediates_early_endosome_to_Golgi_transport___Human_/#summary","title":"Summary","text":"<p>This model represents the role of RUFY1 (Q96T51) as a protein-macromolecule adaptor that mediates early endosome to Golgi transport via endosomal fusion, with involvement of Rab GTPases RAB4B (P61018) and RAB14 (P61106), along with ARL8B (Q9NVJ2). The model depicts the molecular functions of these proteins and causal relationships where ARL8B impacts RUFY1 function, which in turn affects RAB4B and RAB14 activities.</p>"},{"location":"reviews/65d7e4ac00001800-RUFY1_mediates_early_endosome_to_Golgi_transport___Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate representation of molecular functions: The model correctly assigns GTPase activity (GO:0003924) to RAB4B, RAB14, and ARL8B, which aligns with their known roles as small GTPases.</p> </li> <li> <p>Appropriate cellular locations: All activities are correctly shown to occur in the early endosome membrane (GO:0031901).</p> </li> <li> <p>Correct biological process assignment: The model appropriately associates ARL8B with protein localization to early endosome (GO:1902946) and RAB4B/RAB14/RUFY1 with both endosomal vesicle fusion (GO:0034058) and early endosome to Golgi transport (GO:0034498).</p> </li> <li> <p>Causal relationships: The model accurately depicts the relationship where ARL8B directly positively regulates RUFY1, which then directly positively regulates both RAB GTPases, reflecting the finding from the literature that ARL8B promotes RUFY1 endosomal localization and function.</p> </li> <li> <p>Evidence and citations: All activities and relationships are supported by appropriate experimental evidence (ECO:0000314 - direct assay evidence) and cited research papers.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001800-RUFY1_mediates_early_endosome_to_Golgi_transport___Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing protein complex representation: The model doesn't explicitly represent the RUFY1-RAB14-RAB4B complex that forms on early endosomes. According to the \"How to annotate complexes in GO-CAM\" guide, if the activity is shared by several proteins or if the precise subunit carrying an activity isn't known, a complex representation might be appropriate.</p> </li> <li> <p>Incomplete representation of dynein interaction: The recent literature (PMID:36282215) shows that RUFY1 interacts with the dynein-dynactin complex, which is important for the retrograde transport function. This interaction and its role in CI-M6PR trafficking could be added to the model.</p> </li> <li> <p>Missing molecular function detail: While RUFY1's protein-macromolecule adaptor activity (GO:0030674) is correctly captured, its RUN domain-mediated interaction with ARL8B could be more explicitly represented.</p> </li> <li> <p>Incomplete representation of transport process: The model shows endosomal vesicle fusion but doesn't fully capture the complete process of cargo movement from early endosomes to the TGN.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001800-RUFY1_mediates_early_endosome_to_Golgi_transport___Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add complex representation: Consider adding a representation of the RUFY1-RAB14-RAB4B complex that forms on early endosomes, especially since the papers indicate this is a functional unit for endosomal tethering and fusion.</p> </li> <li> <p>Include dynein interaction: Add the interaction between RUFY1 and the dynein-dynactin complex, which is important for retrograde transport. This would provide a more complete picture of how RUFY1 mediates transport.</p> </li> <li> <p>Expand molecular function details: Add more specific molecular function annotations for RUFY1, particularly related to its RUN domain interaction with ARL8B and its coiled-coil domains' interaction with dynein.</p> </li> <li> <p>Add cargo representation: Consider adding a representation of CI-M6PR (cation-independent mannose-6-phosphate receptor) as cargo that gets trafficked in this process, as this would make the model more complete and biologically relevant.</p> </li> <li> <p>Add more biological context: Include annotations about the consequence of this transport process - the sorting of lysosomal hydrolases - to provide a more comprehensive view of the biological significance.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00001800-RUFY1_mediates_early_endosome_to_Golgi_transport___Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of RUFY1's role in mediating early endosome to Golgi transport with the involvement of RAB4B, RAB14, and ARL8B. The model captures the key molecular functions, cellular locations, biological processes, and causal relationships supported by the literature. With the suggested improvements, particularly regarding complex representation and the inclusion of dynein interaction, the model would provide an even more comprehensive and accurate representation of this biological process.</p> <p>The model is consistent with GO-CAM best practices and represents the biological content in alignment with the published literature. It is parsimonious yet informative, focusing on the essential components and relationships in this transport pathway.</p>"},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/","title":"65d7e4ac00002167 Glycogen biosynthetic process  Dmel","text":"<p>After reviewing the model and relevant literature, I'll now provide a detailed review of GO-CAM model gomodel:65d7e4ac00002167 \"Glycogen biosynthetic process (Dmel)\":</p>"},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/#go-cam-model-review-glycogen-biosynthetic-process-in-drosophila-melanogaster","title":"GO-CAM Model Review: Glycogen Biosynthetic Process in Drosophila melanogaster","text":""},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/#model-id-gomodel65d7e4ac00002167","title":"Model ID: gomodel:65d7e4ac00002167","text":""},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/#overall-summary","title":"Overall Summary","text":"<p>This model represents the glycogen biosynthetic pathway in Drosophila melanogaster, depicting the sequence of enzymatic activities that convert glucose phosphate to glycogen. The model includes five key activities carried out by five Drosophila proteins, with appropriate causal relationships connecting these activities.</p>"},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model correctly represents the canonical glycogen biosynthetic pathway, starting with phosphoglucomutase (Pgm1) converting glucose-6-phosphate to glucose-1-phosphate, followed by UGP (UTP:glucose-1-phosphate uridylyltransferase) producing UDP-glucose, which is then used by Gyg (glycogenin) and Glys (glycogen synthase) to build glycogen, with Agbe (branching enzyme) providing branching activity.</p> <p>The sequence of reactions and causal relationships is accurate and supported by the literature, particularly the paper by Yamada et al. (2019, PMID:30918052), which describes glycogen metabolism in Drosophila in detail.</p>"},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/#annotation-quality","title":"Annotation Quality","text":"<ol> <li>Evidence and References:</li> <li>Appropriate evidence codes are used for each annotation</li> <li>References include direct experimental papers specific to Drosophila (PMID:30918052, PMID:2943269) and sequence-based annotations</li> <li> <p>Some annotations use sequence similarity evidence (ECO:0000250) with appropriate with_objects references</p> </li> <li> <p>Ontology Term Usage:</p> </li> <li>Molecular function terms are correctly chosen for each enzyme</li> <li>All activities are correctly associated with the glycogen biosynthetic process (GO:0005978)</li> <li> <p>Chemical entities are properly identified with CHEBI IDs</p> </li> <li> <p>Causal Relationships:</p> </li> <li>Appropriate causal relationships (RO:0002413 - \"provides input for\") connect activities in correct metabolic order</li> <li>The flow of the pathway is logical and biologically accurate</li> </ol>"},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Redundant Causal Associations: </li> <li> <p>The Gyg (glycogenin) activity (65d7e4ac00002191) has two identical causal associations (RO:0002413) to the same downstream Glys activity (65d7e4ac00002198). One of these appears redundant and should be removed.</p> </li> <li> <p>Chemical Inputs/Outputs:</p> </li> <li> <p>The model could be more complete by including all substrate inputs for each reaction. For example, UTP should be listed as an input for the UGP activity.</p> </li> <li> <p>Evidence Consistency:</p> </li> <li> <p>Some evidence references have trailing spaces in their identifiers (e.g., \"FB:FBrf0255270 | GO_REF:0000024 \"), which should be cleaned up.</p> </li> <li> <p>Missing Regulation:</p> </li> <li>The model focuses on the core pathway but doesn't include regulatory elements known to control glycogen synthesis, such as insulin signaling pathway components that regulate glycogen synthase.</li> </ol>"},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model follows GO-CAM guidelines well, including: - Proper representation of causal relationships between activities - Appropriate use of occurs_in and part_of relations - Correct annotation of input/output molecules - Consistent use of evidence codes with references</p> <p>The model does not use complexes, so complex annotation guidelines are not applicable in this case.</p>"},{"location":"reviews/65d7e4ac00002167-Glycogen_biosynthetic_process__Dmel_/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that accurately represents the glycogen biosynthetic pathway in Drosophila melanogaster. The activities are properly connected through causal relationships, and the annotations are supported by appropriate evidence. The minor issues identified (redundant causal association, some missing inputs) do not significantly impact the biological accuracy of the model.</p> <p>I recommend: 1. Removing one of the redundant causal associations from Gyg to Glys 2. Consider adding missing substrate inputs like UTP 3. Consider expanding the model to include regulatory elements in future iterations</p> <p>With these minor adjustments, this model will serve as an excellent representation of glycogen biosynthesis in Drosophila.</p>"},{"location":"reviews/65d7e4ac00002290-Glycogen_catabolic_process__Dmel_/","title":"65d7e4ac00002290 Glycogen catabolic process  Dmel","text":"<p>Based on all the information gathered, I'll now review the GO-CAM model gomodel:65d7e4ac00002290 \"Glycogen catabolic process (Dmel)\".</p>"},{"location":"reviews/65d7e4ac00002290-Glycogen_catabolic_process__Dmel_/#review-of-go-cam-model-gomodel65d7e4ac00002290-glycogen-catabolic-process-dmel","title":"Review of GO-CAM Model: gomodel:65d7e4ac00002290 - Glycogen catabolic process (Dmel)","text":""},{"location":"reviews/65d7e4ac00002290-Glycogen_catabolic_process__Dmel_/#overview","title":"Overview","text":"<p>This model represents the glycogen catabolic process in Drosophila melanogaster (fruit fly) and includes three key enzymes involved in this metabolic pathway:</p> <ol> <li>Glycogen phosphorylase (Glyp) - FB:FBgn0004507</li> <li>Glycogen debranching enzyme (Agl) - FB:FBgn0034618</li> <li>Phosphoglucomutase (Pgm1) - FB:FBgn0003076</li> </ol> <p>The model correctly represents the sequential enzymatic reactions in glycogen breakdown, with appropriate molecular functions, inputs/outputs, and causal relationships.</p>"},{"location":"reviews/65d7e4ac00002290-Glycogen_catabolic_process__Dmel_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate representation of the glycogen catabolic pathway: The model correctly captures the key enzymes and their sequential interactions in glycogen breakdown in Drosophila.</p> </li> <li> <p>Evidence support: Most activities are supported by appropriate evidence from the literature with cited PMIDs.</p> </li> <li> <p>Molecular details: The model includes specific inputs and outputs for each reaction, showing the molecular transformations occurring at each step.</p> </li> <li> <p>Cellular location: All activities are annotated to occur in the cytosol (GO:0005829), which is appropriate for glycogen metabolism.</p> </li> <li> <p>Causal connections: The model correctly depicts the flow of the pathway using the RO:0002413 \"provides input for\" relationship, showing how each enzyme's activity feeds into the next.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002290-Glycogen_catabolic_process__Dmel_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Redundant activities: There appear to be two nearly identical Glyp activities (gomodel:65d7e4ac00002290/65d7e4ac00002301 and gomodel:65d7e4ac00002290/65d7e4ac00002296). Both have the same molecular function (GO:0008184), occur in the same location (GO:0005829), are part of the same biological process (GO:0005980), and produce the same output (CHEBI:58601). This redundancy could be simplified to make the model more parsimonious.</p> </li> <li> <p>Completion of causal chain: The final step catalyzed by Pgm1 (phosphoglucomutase) converts alpha-D-glucose 1-phosphate to alpha-D-glucose 6-phosphate, but there's no indication of what happens next. Since glycogen catabolism ultimately feeds into glycolysis, it would be valuable to connect this to the glycolytic pathway or indicate that glucose-6-phosphate enters glycolysis.</p> </li> <li> <p>Missing regulation information: The model does not capture any regulatory mechanisms for glycogen phosphorylase activation. Based on the literature, Drosophila glycogen phosphorylase is regulated by phosphorylation (converting between the active \"a\" form and inactive \"b\" form). Adding this regulatory mechanism would enhance the model.</p> </li> <li> <p>Model comment clarification: The model has a comment \"Copy from glycogen catabolic process (mouse)\" which suggests it was adapted from a mouse model. The curator should verify that all Drosophila-specific aspects of glycogen metabolism have been properly represented.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002290-Glycogen_catabolic_process__Dmel_/#literature-and-knowledge-consistency","title":"Literature and Knowledge Consistency","text":"<p>The model aligns well with the literature on Drosophila glycogen metabolism:</p> <ol> <li> <p>The papers by Dombradi et al. (PMID:3093145) provide detailed characterization of Drosophila glycogen phosphorylase.</p> </li> <li> <p>The sequential activities of glycogen phosphorylase, debranching enzyme, and phosphoglucomutase are consistent with established knowledge of glycogen breakdown.</p> </li> <li> <p>The model correctly represents that glycogen phosphorylase produces alpha-D-glucose 1-phosphate from glycogen.</p> </li> <li> <p>The location of these activities in the cytosol is consistent with where glycogen breakdown occurs.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002290-Glycogen_catabolic_process__Dmel_/#technical-accuracy","title":"Technical Accuracy","text":"<ol> <li> <p>All activities are properly connected with their respective molecular functions.</p> </li> <li> <p>Evidence codes are used appropriately.</p> </li> <li> <p>The causal associations are represented correctly using the \"provides input for\" relation (RO:0002413).</p> </li> <li> <p>The chemical entities are represented with appropriate ChEBI identifiers.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002290-Glycogen_catabolic_process__Dmel_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-structured GO-CAM model that accurately represents the glycogen catabolic process in Drosophila melanogaster. The model is consistent with the literature and follows GO-CAM best practices. The main areas for improvement involve eliminating redundancy (duplicated glycogen phosphorylase activities), potentially adding regulatory mechanisms, and completing the connection to downstream metabolic pathways.</p> <p>This model provides a valuable resource for understanding glycogen metabolism in Drosophila and serves as a good example of how to represent metabolic pathways in GO-CAM.</p>"},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/","title":"65d7e4ac00002427 MICA NKG2D mediated NK cell cytotoxicity  Human","text":"<p>Based on my examination of the GO-CAM model and relevant documentation, I'll now provide a comprehensive review of the GO-CAM model gomodel:65d7e4ac00002427.</p>"},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/#review-of-go-cam-model-mica-nkg2d-mediated-nk-cell-cytotoxicity-human","title":"Review of GO-CAM Model: MICA-NKG2D mediated NK cell cytotoxicity (Human)","text":""},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/#overview","title":"Overview","text":"<p>This model (gomodel:65d7e4ac00002427) represents the molecular mechanism of natural killer (NK) cell cytotoxicity mediated by the interaction between MICA (MHC class I polypeptide-related sequence A) and NKG2D (KLRK1, killer cell lectin-like receptor subfamily K member 1). The model shows how MICA, a stress-induced ligand, activates the NKG2D receptor on NK cells, leading to downstream signaling events that result in NK cell-mediated cytotoxicity.</p>"},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model includes the following key components:</p> <ol> <li>Ligand (MICA) - Receptor (NKG2D) interaction:</li> <li>MICA (UniProtKB:Q29983) enables receptor ligand activity (GO:0048018)</li> <li>NKG2D/KLRK1 (UniProtKB:P26718) enables signaling receptor activity (GO:0038023)</li> <li> <p>MICA directly positively regulates NKG2D</p> </li> <li> <p>Signaling adaptor (HCST/DAP10):</p> </li> <li>HCST (UniProtKB:Q9UBK5) enables protein-macromolecule adaptor activity (GO:0030674)</li> <li> <p>NKG2D directly positively regulates HCST</p> </li> <li> <p>Downstream signaling components:</p> </li> <li> <p>HCST directly positively regulates multiple downstream components:</p> <ul> <li>VAV1 (UniProtKB:P15498) with guanyl-nucleotide exchange factor activity (GO:0005085)</li> <li>GRB2 (UniProtKB:P62993) with guanyl-nucleotide exchange factor adaptor activity (GO:0005091)</li> <li>PIK3R1 (UniProtKB:P27986) with phosphatidylinositol 3-kinase regulator activity (GO:0035014)</li> </ul> </li> <li> <p>Cellular context:</p> </li> <li>All activities are part of natural killer cell mediated cytotoxicity (GO:0042267)</li> <li>MICA and NKG2D occur in plasma membrane (GO:0005886)</li> <li>HCST downstream components (VAV1, GRB2, PIK3R1) occur in cytoplasm (GO:0005737)</li> </ol>"},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate molecular representation: The model correctly captures the MICA-NKG2D interaction and subsequent signaling through HCST/DAP10, which is supported by literature (as seen in UniProt entries).</p> </li> <li> <p>Proper adaptor annotation: HCST/DAP10 is correctly annotated as having protein-macromolecule adaptor activity, consistent with the \"How to annotate molecular adaptors\" guidelines.</p> </li> <li> <p>Complete signaling pathway: The model represents a complete signaling pathway from extracellular ligand to intracellular effectors, providing a comprehensive view of NK cell activation.</p> </li> <li> <p>Proper evidence usage: Each activity and relation is supported by appropriate evidence codes and literature references.</p> </li> <li> <p>Appropriate cellular location annotations: The model correctly locates activities in their respective cellular compartments.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Activity flow representation: While the overall structure is correct, the signaling flow could be clarified by ensuring that the downstream components (VAV1, GRB2, PIK3R1) are connected to further downstream effectors if information is available. Currently, these proteins represent the endpoint of the signaling pathway in the model.</p> </li> <li> <p>Complex representation: According to the UniProt entries, NKG2D and HCST form a heterohexameric complex (4 HCST + 2 NKG2D). The model could potentially include a representation of this complex structure according to the \"How to annotate complexes in GO-CAM\" guidelines, although the current representation with direct relationships is also valid.</p> </li> <li> <p>PIK3R1 functional outcome: The model shows PIK3R1 with phosphatidylinositol 3-kinase regulator activity but doesn't show the downstream effects on PI3K signaling. If literature supports it, adding these connections would enhance the completeness of the pathway.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model follows GO-CAM best practices for:</p> <ol> <li> <p>Signaling receptor annotation: The model correctly follows the \"Signaling receptor activity annotation guidelines\" by showing MICA as having receptor ligand activity directly positively regulating NKG2D's signaling receptor activity.</p> </li> <li> <p>Molecular adaptor annotation: HCST/DAP10 is properly annotated as having protein-macromolecule adaptor activity, with appropriate causal relations to downstream components, consistent with \"How to annotate molecular adaptors\" guidelines.</p> </li> <li> <p>Evidence and references: Each association has appropriate evidence codes and literature references.</p> </li> <li> <p>Causal relations: The model uses the appropriate causal relations (\"directly positively regulates\") for the signaling cascade.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the known biology of MICA-NKG2D interaction based on the UniProt entries:</p> <ol> <li> <p>MICA as stress-inducible ligand: MICA is correctly shown as a receptor ligand that activates NKG2D. According to UniProt, MICA is \"upregulated in stressed conditions, such as viral and bacterial infections or DNA damage response\".</p> </li> <li> <p>NKG2D signaling through HCST: The model correctly shows that NKG2D signals through HCST/DAP10, which is consistent with the UniProt entry stating that NKG2D \"is not capable of signal transduction by itself, but operates through the adapter protein HCST\".</p> </li> <li> <p>Downstream signaling events: The involvement of VAV1, GRB2, and PIK3R1 is consistent with literature, with UniProt noting that HCST \"functions as a docking site for PI3-kinase PIK3R1 and GRB2\".</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002427-MICA_NKG2D_mediated_NK_cell_cytotoxicity__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:65d7e4ac00002427 is a biologically accurate representation of MICA-NKG2D mediated NK cell cytotoxicity that follows GO-CAM best practices. The model effectively captures the signaling cascade from ligand-receptor interaction to downstream signaling components. The model would benefit from additional downstream connections if information is available, but as presented, it provides a clear and accurate representation of this important immunological pathway.</p> <p>This model serves as a good example of how GO-CAM can be used to represent receptor-ligand interactions and signal transduction pathways in the immune system.</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/","title":"65d7e4ac00002435 MICU3 promotes mitochondrial calcium uptake by MCU in the central nervous system  Human","text":"<p>Now let me review the GO-CAM model and provide my assessment:</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#review-of-go-cam-model-gomodel65d7e4ac00002435","title":"Review of GO-CAM Model: gomodel:65d7e4ac00002435","text":""},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"MICU3 promotes mitochondrial calcium uptake by MCU in the central nervous system (Human)\" describes the mitochondrial calcium uptake process mediated by the mitochondrial calcium uniporter (MCU) complex and its regulatory proteins. The model focuses on how MICU3 contributes to calcium uptake in the central nervous system.</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#components-of-the-model","title":"Components of the Model","text":"<p>The model includes four key proteins: 1. MICU3 (UniProtKB:Q86XE3) - Calcium uptake protein 3, mitochondrial 2. MICU1 (UniProtKB:Q9BPX6) - Calcium uptake protein 1, mitochondrial 3. MCU (UniProtKB:Q8NE86) - Calcium uniporter protein, mitochondrial 4. SMDT1/EMRE (UniProtKB:Q9H4I9) - Essential MCU regulator, mitochondrial</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#biological-context-and-accuracy","title":"Biological Context and Accuracy","text":"<p>The model accurately represents the functional relationships between these proteins in the mitochondrial calcium uptake process:</p> <ul> <li>MCU is correctly annotated with \"calcium channel activity\" (GO:0005262) as it forms the channel pore through which calcium enters the mitochondria.</li> <li>MICU1 and MICU3 are both correctly annotated with \"calcium ion sensor activity\" (GO:0061891), reflecting their role in sensing calcium levels and regulating MCU activity.</li> <li>SMDT1/EMRE is appropriately annotated with \"protein-macromolecule adaptor activity\" (GO:0030674), representing its role in connecting MCU with MICU proteins.</li> </ul> <p>The subcellular locations are correctly defined, with all components localized to the mitochondrial inner membrane (GO:0005743), which is consistent with the known biology of the MCU complex.</p> <p>The biological process \"cellular response to calcium ion\" (GO:0071277) is correctly associated with MICU1 and MICU3, and MCU is properly linked to \"mitochondrial calcium ion transport\" (GO:0036444).</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships in the model accurately reflect current understanding of MCU complex function:</p> <ol> <li>MICU3 \"directly positively regulates\" (RO:0002629) MCU</li> <li>MICU1 \"directly positively regulates\" (RO:0002629) both MICU3 and MCU</li> <li>SMDT1/EMRE \"directly positively regulates\" (RO:0002629) MICU1</li> </ol> <p>These relationships are supported by the literature as evidenced in the UniProt entries. MICU3 has a higher affinity for calcium than MICU1 and MICU2, which lowers the calcium threshold for MCU activation in tissues where it is expressed (central nervous system and skeletal muscle). This is correctly captured in the model.</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#evidence-and-references","title":"Evidence and References","text":"<p>The model includes appropriate evidence codes and literature references: - ECO:0000314 (direct assay evidence) - ECO:0000315 (mutant phenotype evidence) - ECO:0000250 (sequence similarity evidence)</p> <p>The references include key papers on MICU3, MICU1, and MCU function, especially: - PMID:32494073 - Structure of the mitochondrial Ca2+ uniporter holocomplex - PMID:30699349 - Dimerization of MICU proteins controls Ca2+ influx through the mitochondrial Ca2+ uniporter - PMID:29725115 - MICU3 is a tissue-specific enhancer of mitochondrial calcium uptake</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#chemical-components","title":"Chemical Components","text":"<p>The model correctly includes calcium (CHEBI:29108) as an input and output for the MCU calcium channel activity, which accurately represents the calcium transport process.</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#evaluation-against-go-cam-guidelines","title":"Evaluation Against GO-CAM Guidelines","text":"<p>According to the GO-CAM guidelines for complexes, this model follows best practices: - The activities of individual components of the MCU complex are known and correctly represented - The molecular functions are accurately assigned to specific proteins - The causal relationships between the activities are appropriately defined</p>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Tissue specificity: The model correctly captures the tissue-specific role of MICU3 in the central nervous system.</li> <li>Functional relationships: The regulatory relationships between the proteins are accurately represented.</li> <li>Subcellular localization: All components are correctly localized to the mitochondrial inner membrane.</li> <li>Evidence quality: The model uses appropriate evidence codes and references.</li> </ol>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#potential-improvements","title":"Potential Improvements","text":"<p>The model is scientifically accurate and well-constructed. Minor suggestions for improvement:</p> <ol> <li>Integration with energy metabolism: The model could potentially be expanded to show how mitochondrial calcium uptake relates to mitochondrial metabolism and ATP production.</li> <li>Connection to downstream processes: The model could be extended to show how calcium uptake influences downstream cellular processes in neurons.</li> </ol>"},{"location":"reviews/65d7e4ac00002435-MICU3_promotes_mitochondrial_calcium_uptake_by_MCU_in_the_central_nervous_system__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:65d7e4ac00002435) accurately represents the current understanding of how MICU3 promotes mitochondrial calcium uptake by MCU in the central nervous system. The relationships between components, their molecular functions, and the cellular context are all correctly represented, making this a high-quality model that adheres to GO-CAM best practices.</p> <p>The model effectively communicates the tissue-specific regulation of the mitochondrial calcium uniporter complex, highlighting MICU3's role in enhancing calcium uptake in the central nervous system compared to other tissues where MICU3 is not expressed.</p>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/","title":"65d7e4ac00002808 MCUB inhibits mitochondrial calcium uptake by the uniplex complex  composed of SMDT1 EMRE  MICU1  MICU2 and MCU  to prevent calcium overload  Human","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model (gomodel:65d7e4ac00002808) that describes \"MCUB inhibits mitochondrial calcium uptake by the uniplex complex (composed of SMDT1/EMRE, MICU1, MICU2 and MCU) to prevent calcium overload (Human).\"</p>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#review-of-go-cam-model-gomodel65d7e4ac00002808","title":"Review of GO-CAM Model: gomodel:65d7e4ac00002808","text":""},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents how MCUB (Q9NWR8) inhibits mitochondrial calcium uptake through the mitochondrial calcium uniporter (MCU) complex (also called the uniplex) to prevent calcium overload in human mitochondria. The uniplex complex consists of MCU (Q8NE86), MICU1 (Q9BPX6), MICU2 (Q8IYU8), and SMDT1/EMRE (Q9H4I9).</p>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#accuracy-of-molecular-functions","title":"Accuracy of Molecular Functions","text":"<ol> <li> <p>MCUB (Q9NWR8) - Annotated with \"calcium channel inhibitor activity\" (GO:0019855) in the mitochondrial inner membrane (GO:0005743). This is accurate as the literature confirms MCUB acts as a dominant negative regulator that displaces MCU from the functional uniplex complex.</p> </li> <li> <p>MCU (Q8NE86) - Annotated with \"calcium channel activity\" (GO:0005262) in the mitochondrial inner membrane (GO:0005743). This is correct as MCU is the pore-forming unit of the channel.</p> </li> <li> <p>MICU1 (Q9BPX6) - Annotated with \"calcium ion sensor activity\" (GO:0061891) in the mitochondrial inner membrane (GO:0005743). This is accurate as MICU1 contains EF-hand domains that sense calcium levels.</p> </li> <li> <p>MICU2 (Q8IYU8) - Annotated with \"calcium ion sensor activity\" (GO:0061891) in the mitochondrial inner membrane (GO:0005743). This is correct as MICU2 also contains EF-hand domains for calcium sensing.</p> </li> <li> <p>SMDT1/EMRE (Q9H4I9) - Annotated with \"protein-macromolecule adaptor activity\" (GO:0030674) in the mitochondrial inner membrane (GO:0005743). This is correct as EMRE serves as an essential adaptor that bridges MCU with the regulatory MICU subunits.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#accuracy-of-biological-processes","title":"Accuracy of Biological Processes","text":"<ol> <li> <p>MCUB - \"negative regulation of calcium import into the mitochondrion\" (GO:0110099). This accurately represents MCUB's role.</p> </li> <li> <p>MCU - \"calcium import into the mitochondrion\" (GO:0036444). This accurately represents MCU's main role.</p> </li> <li> <p>MICU1 &amp; MICU2 - \"cellular response to calcium ion\" (GO:0071277). This accurately captures their role in responding to cytosolic calcium levels.</p> </li> <li> <p>SMDT1/EMRE - \"calcium import into the mitochondrion\" (GO:0036444). This correctly identifies EMRE's role in enabling calcium import through MCU.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#accuracy-of-causal-relationships","title":"Accuracy of Causal Relationships","text":"<ol> <li> <p>MCUB directly negatively regulates MCU - Represented by the causal association with predicate \"RO:0002630\" (directly negatively regulates). This is accurate as MCUB displaces MCU from the complex and decreases the association of MICU1 and MICU2.</p> </li> <li> <p>MICU1 directly positively regulates MCU - Represented by causal association with predicate \"RO:0002629\" (directly positively regulates). This is accurate as MICU1 helps regulate the opening of the MCU channel at high calcium levels.</p> </li> <li> <p>MICU2 directly positively regulates MCU - Represented by causal association with predicate \"RO:0002629\" (directly positively regulates). This is accurate as MICU2 works with MICU1 to regulate the MCU channel opening.</p> </li> <li> <p>SMDT1/EMRE directly positively regulates MICU1 - Represented by causal association with predicate \"RO:0002629\" (directly positively regulates). This is accurate as EMRE is required to bridge MCU with MICU1.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#evidence-and-references","title":"Evidence and References","text":"<p>The model incorporates evidence from several key publications: - PMID:31533452 - Details MCUB's role in displacing MCU from the uniplex complex - PMID:21685888 - Early work identifying MCU as the pore-forming unit - PMID:32494073 - Describes the structure and mechanism of the mitochondrial Ca2+ uniporter holocomplex - PMID:24231807 - Identifies EMRE as an essential component of the complex - PMID:24560927 - Describes the roles of MICU1 and MICU2 in fine-tuning MCU activity</p> <p>The evidence codes used (ECO:0000314 for direct assay and ECO:0000315 for mutant phenotype) are appropriate for the annotations.</p>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#molecular-representation","title":"Molecular Representation","text":"<p>The model correctly represents: 1. The inhibitory effect of MCUB on MCU calcium transport activity 2. The calcium sensing roles of MICU1 and MICU2 3. The adaptor function of SMDT1/EMRE in connecting MCU to MICUs 4. The causal relationships between components</p>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#location-information","title":"Location Information","text":"<p>All components are correctly located in the mitochondrial inner membrane (GO:0005743), which is accurate according to the literature.</p>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#chemicals-represented","title":"Chemicals Represented","text":"<p>The model correctly includes calcium(2+) (CHEBI:29108) as an input and output of MCU's calcium channel activity, and as an input for MICU1 and MICU2's calcium ion sensor activities.</p>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Stoichiometry Representation: The model could potentially benefit from explicitly noting the 4:4:1:1 stoichiometry of MCU:EMRE:MICU1:MICU2 in the functional uniplex as described in the literature (PMID:32494073). However, GO-CAM may not have a standard way to capture stoichiometry information.</p> </li> <li> <p>Additional Mechanistic Details: The model could potentially include that MICU1 uses its K/R ring to seal the MCU pore in low calcium conditions, and that calcium binding to MICU1/MICU2 causes conformational changes that move MICU1 away from the pore to allow calcium permeation. However, this level of molecular detail may be beyond the scope of the current GO-CAM model.</p> </li> <li> <p>Disulfide Bond Representation: The covalent linkage (disulfide bond) between MICU1 and MICU2 could be mentioned, though again this may be beyond the current GO-CAM representation capabilities.</p> </li> </ol>"},{"location":"reviews/65d7e4ac00002808-MCUB_inhibits_mitochondrial_calcium_uptake_by_the_uniplex_complex__composed_of_SMDT1_EMRE__MICU1__MICU2_and_MCU__to_prevent_calcium_overload__Human__/#summary","title":"Summary","text":"<p>Overall, this GO-CAM model (gomodel:65d7e4ac00002808) accurately represents the current scientific understanding of how MCUB inhibits mitochondrial calcium uptake by the uniplex complex. The model correctly defines the molecular functions, subcellular locations, biological processes, and causal relationships between the components based on strong supporting evidence from the literature.</p> <p>The model makes appropriate use of GO terms and relationship types to describe the biological system. The evidence provided through citations and evidence codes is strong and current. The model effectively captures the key biological mechanisms without unnecessary complexity.</p>"},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/","title":"65f3ae5c00000111 Ufmylation pathway  Human","text":"<p>Based on my thorough review of the GO-CAM model \"Ufmylation pathway (Human)\" (gomodel:65f3ae5c00000111) and the supporting scientific literature, I can now provide a comprehensive assessment.</p>"},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/#go-cam-review-ufmylation-pathway-human","title":"GO-CAM Review: Ufmylation pathway (Human)","text":""},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/#summary","title":"Summary","text":"<p>This GO-CAM model describes the Ufmylation pathway in humans, which is a post-translational modification pathway involving the ubiquitin-fold modifier 1 (UFM1). The model correctly represents the key components and causal relationships in this pathway, capturing the enzymatic cascade that leads to protein UFMylation. </p>"},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/#overall-assessment","title":"Overall Assessment","text":"<p>The model represents a well-constructed and evidence-supported representation of the UFMylation pathway. It accurately captures the functional roles of the four key proteins in this pathway and their causal relationships, with appropriate literature citations and evidence codes.</p>"},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive representation: The model includes all the key components of the UFMylation pathway: UBA5 (E1 activating enzyme), UFC1 (E2 conjugating enzyme), UFL1 (E3 ligase), and UFSP1 (UFM1-specific protease).</p> </li> <li> <p>Appropriate causal relationships: The model correctly represents the causal flow from protein maturation through the enzymatic cascade using the \"provides input for\" (RO:0002413) predicate.</p> </li> <li> <p>Strong evidence base: Each association in the model is supported by appropriate evidence, with multiple recent publications (2020-2024) cited. This reflects the current understanding of the pathway.</p> </li> <li> <p>Cellular localization: The model correctly indicates that UFSP1 activity occurs in the cytosol (GO:0005829), which is consistent with the literature.</p> </li> <li> <p>Correct molecular functions: Each protein is assigned the appropriate molecular function:</p> </li> <li>UFSP1: cysteine-type peptidase activity (GO:0008234)</li> <li>UFL1: UFM1 ligase activity (GO:0061666)</li> <li>UFC1: UFM1 conjugating enzyme activity (GO:0061657)</li> <li> <p>UBA5: UFM1 activating enzyme activity (GO:0071566)</p> </li> <li> <p>Up-to-date scientific knowledge: The model incorporates recent findings about UFSP1 (2022-2023), which corrected previous misconceptions about its catalytic activity.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<ol> <li>Additional cellular components: The model could be enhanced by including the cellular localization for UFL1, UFC1, and UBA5. According to the literature:</li> <li>UFL1 is primarily localized to the endoplasmic reticulum membrane</li> <li>UFC1 is distributed throughout the cell</li> <li> <p>UBA5 is primarily cytosolic but can also be found in the nucleus and ER membrane</p> </li> <li> <p>Substrates of UFMylation: The model could potentially include the main substrate of this pathway, RPL26 (ribosomal protein L26), which is the principal target of UFMylation according to recent literature.</p> </li> <li> <p>Missing regulatory components: The model doesn't include DDRGK1 (also known as UFBP1) and CDK5RAP3, which are important additional components of the UFM1 E3 ligase complex that work with UFL1.</p> </li> <li> <p>Biological outcomes: The model could be extended to include the biological consequences of UFMylation, such as ribosome recycling from the ER translocon.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/#technical-correctness","title":"Technical Correctness","text":"<p>From a technical perspective, the model is correctly constructed according to GO-CAM standards:</p> <ol> <li>Each protein is appropriately linked to its molecular function via \"enabled by\" relations.</li> <li>The causal flow follows the standard \"provides input for\" (RO:0002413) predicate.</li> <li>All activities are indicated to be part of the broader biological process \"protein ufmylation\" (GO:0071569).</li> <li>UFSP1's activity is additionally indicated to be part of \"protein maturation\" (GO:0051604).</li> <li>Evidence codes are appropriate (ECO:0000314 for direct assay evidence, ECO:0000315 for mutant phenotype evidence).</li> </ol>"},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of the UFMylation pathway:</p> <ol> <li> <p>UFSP1 is now recognized as an active protease that cleaves the C-terminal peptide of pro-UFM1 to generate mature UFM1 (based on 2022-2023 research).</p> </li> <li> <p>The enzymatic cascade follows the established order:</p> </li> <li>UBA5 activates UFM1 in an ATP-dependent manner</li> <li>UFC1 accepts the activated UFM1 from UBA5</li> <li> <p>UFL1 transfers UFM1 from UFC1 to target proteins</p> </li> <li> <p>The model correctly identifies that UFSP1 provides input for UBA5's activity through its role in maturing pro-UFM1.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00000111-Ufmylation_pathway__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides an accurate and well-supported representation of the human UFMylation pathway. It correctly captures the enzymatic cascade, molecular functions, and causal relationships between the key components.</p> <p>The model could be enhanced by including additional components (DDRGK1, CDK5RAP3), cellular locations for all proteins, and downstream biological consequences of UFMylation. Nevertheless, as it stands, the model represents a high-quality contribution to our understanding of post-translational modifications in human cells.</p>"},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/","title":"65f3ae5c00000585 Ufmylation of CYB5R3  promotes reticulophagy and CYB5R3 degradation  Human","text":"<p>After reviewing all the information, I can now conduct a thorough review of the GO-CAM model gomodel:65f3ae5c00000585.</p>"},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/#go-cam-review-gomodel65f3ae5c00000585","title":"GO-CAM Review: gomodel:65f3ae5c00000585","text":""},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/#overview-of-the-model","title":"Overview of the Model","text":"<p>The model titled \"Ufmylation of CYB5R3 promotes reticulophagy and CYB5R3 degradation (Human)\" depicts a biological process involving the UFM1 system in the regulation of ER-phagy (reticulophagy) in humans. The model shows how UFM1, a ubiquitin-like modifier, is conjugated to CYB5R3 (NADH-cytochrome b5 reductase 3) through an enzymatic cascade involving the E3 UFM1-protein ligase complex, which promotes lysosomal degradation of CYB5R3.</p>"},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the recent findings from Ishimura et al. (2022) [PMID:36543799], which identified CYB5R3 as a substrate for the UFM1 system. The scientific content is consistent with current literature:</p> <ol> <li>The UFM1 system consists of E1 (not shown in the model), E2 (not shown), and E3 (represented by UFL1 and CDK5RAP3) components.</li> <li>CYB5R3 is accurately depicted as being ufmylated by UFL1 (E3 UFM1-protein ligase 1).</li> <li>DDRGK1 (shown as UFBP1 in the literature) is correctly shown as part of the E3 ligase complex.</li> <li>The model shows UFSP2 as having deUFMylase activity, which is accurate.</li> <li>The connections between these components reflect our current understanding of this pathway.</li> </ol> <p>Recent research by DaRosa et al. (2024) [PMID:38383785] and Makhlouf et al. (2024) [PMID:38383789] provides additional context for the UFM1 system's role in ribosome recycling, which is tangential to this model's specific focus on CYB5R3 ufmylation and degradation.</p>"},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/#model-structure-evaluation","title":"Model Structure Evaluation","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Activities are properly connected: The model shows a coherent flow of activities using appropriate causal relations:</li> <li>CDK5RAP3's activity provides input for UFL1's activity (RO:0002413)</li> <li>UFL1's activity directly positively regulates CYB5R3's activity (RO:0002629)</li> <li>UFSP2's activity directly negatively regulates CYB5R3's activity (RO:0002630)</li> <li> <p>DDRGK1's activity directly negatively regulates CYB5R3's activity (RO:0002630)</p> </li> <li> <p>Molecular function terms are appropriate:</p> </li> <li>UFL1: \"E3 UFM1-protein ligase activity\" (GO:0061666)</li> <li>UFSP2: \"deUFMylase activity\" (GO:0071567)</li> <li>DDRGK1: \"UFM1-modified protein reader activity\" (GO:0141185)</li> <li>CDK5RAP3: \"ubiquitin-like ligase-substrate adaptor activity\" (GO:1990756)</li> <li> <p>CYB5R3: \"cytochrome-b5 reductase activity, acting on NAD(P)H\" (GO:0004128)</p> </li> <li> <p>Biological process terms are appropriate:</p> </li> <li>UFL1 and CDK5RAP3 are part of \"protein ufmylation\" (GO:0071569)</li> <li>DDRGK1 is part of \"positive regulation of reticulophagy\" (GO:0140501)</li> <li>UFSP2 is part of \"negative regulation of proteolysis involved in protein catabolic process\" (GO:1903051)</li> <li> <p>CYB5R3 is part of \"blood circulation\" (GO:0008015)</p> </li> <li> <p>Cellular location information is included:</p> </li> <li>UFL1, DDRGK1, and CYB5R3 are correctly localized to the endoplasmic reticulum membrane (GO:0005789)</li> </ol>"},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the core UFM1 system components involved in CYB5R3 ufmylation.</li> <li>The causal relationships between activities are appropriate.</li> <li>Evidence codes and PMIDs are properly used to support the annotations.</li> <li>The model captures the biological context of reticulophagy and CYB5R3 degradation.</li> </ol>"},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li> <p>Incomplete representation of the E1 and E2 components: The model doesn't include UBA5 (E1) and UFC1 (E2), which are essential parts of the UFM1 conjugation system. While focusing on the E3 components is reasonable for simplicity, it might be worth noting their absence.</p> </li> <li> <p>Biological process annotation for CYB5R3: CYB5R3 is annotated with \"blood circulation\" (GO:0008015), which, while not incorrect, doesn't directly relate to its role in this specific context. A more contextually relevant biological process term such as \"reticulophagy\" (GO:0061709) would better reflect its role in this model.</p> </li> <li> <p>Evidence code for CYB5R3's biological process: The evidence code for CYB5R3's involvement in blood circulation is ECO:0000304 (author statement supported by traceable reference), but the PMID cited (1400360) is from 1992 and doesn't directly relate to the reticulophagy context. A more recent reference specifically addressing CYB5R3's role in ER-phagy would be more appropriate.</p> </li> <li> <p>DDRGK1 naming: The model uses DDRGK1, while recent literature often refers to this protein as UFBP1. For clarity, it might be helpful to note this alias.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00000585-Ufmylation_of_CYB5R3__promotes_reticulophagy_and_CYB5R3_degradation__Human__/#final-assessment","title":"Final Assessment","text":"<p>This GO-CAM model presents a scientifically accurate representation of the UFM1 system's role in CYB5R3 ufmylation and subsequent degradation through reticulophagy. The model follows GO-CAM best practices and effectively communicates the biological process. With minor adjustments to the biological process annotation for CYB5R3 and possibly the inclusion of E1 and E2 components, this model would provide an even more comprehensive view of this pathway.</p> <p>The model successfully captures a specific aspect of the UFM1 system that has important implications for ER homeostasis and potentially for neuronal development, as suggested by the source literature. The recent findings on the UFM1 system's role in ribosome recycling provide additional context but don't directly impact this model's validity.</p>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/","title":"65f3ae5c00001022 UFL1 negatively regulates T cell activation by mediating ufmylation of PDCD1 PD 1  Human","text":"<p>Let me now review the GO-CAM model based on the information I've gathered. First, let's understand the key components and relationships in the model:</p>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#review-of-go-cam-model-gomodel65f3ae5c00001022","title":"Review of GO-CAM Model gomodel:65f3ae5c00001022","text":""},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#model-title-and-overview","title":"Model Title and Overview","text":"<p>\"UFL1 negatively regulates T-cell activation by mediating ufmylation of PDCD1/PD-1 (Human)\"</p>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#model-context-and-organism","title":"Model Context and Organism","text":"<ul> <li>Organism: Human (NCBITaxon:9606) </li> <li>This model represents a molecular pathway involving UFL1-mediated ufmylation of PD-1 and its role in regulating T-cell activation.</li> </ul>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#key-activities-and-causal-relationships-in-the-model","title":"Key Activities and Causal Relationships in the Model","text":"<ol> <li>PRKAA1 (UniProtKB:Q13131) has AMP-activated protein kinase activity (GO:0004679)</li> <li>Part of positive regulation of T cell mediated immune response to tumor cell (GO:0002842)</li> <li> <p>Provides input for (RO:0002413) \u2192 YWHAG protein sequestering activity</p> </li> <li> <p>YWHAG (UniProtKB:P61981) has protein sequestering activity (GO:0140311)</p> </li> <li>Part of positive regulation of T cell mediated immune response to tumor cell (GO:0002842)</li> <li> <p>Has some direct regulatory relationship (RO:0012010) \u2192 UFL1 UFM1 ligase activity</p> </li> <li> <p>UFL1 (UniProtKB:O94874) has UFM1 ligase activity (GO:0061666)</p> </li> <li>Part of protein stabilization (GO:0050821)</li> <li> <p>Has some direct regulatory relationship (RO:0012010) \u2192 two downstream activities:</p> <ul> <li>KLHL22's ubiquitin-like ligase-substrate adaptor activity</li> <li>FBXO38's ubiquitin-like ligase-substrate adaptor activity</li> </ul> </li> <li> <p>KLHL22 (UniProtKB:Q53GT1) has ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</p> </li> <li>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li> <p>Has negative effect (RO:0002409) \u2192 PDCD1 signaling receptor activity</p> </li> <li> <p>FBXO38 (UniProtKB:Q6PIJ6) has ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</p> </li> <li>Part of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146)</li> <li> <p>Has negative effect (RO:0002409) \u2192 PDCD1 signaling receptor activity</p> </li> <li> <p>PDCD1/PD-1 (UniProtKB:Q15116) has signaling receptor activity (GO:0038023)</p> </li> <li>Occurs in plasma membrane (GO:0005886)</li> <li> <p>Part of negative regulation of T cell mediated immune response to tumor cell (GO:0002841)</p> </li> <li> <p>CD274/PD-L1 (UniProtKB:Q9NZQ7) has receptor ligand activity (GO:0048018)</p> </li> <li>Occurs in plasma membrane (GO:0005886)</li> <li>Part of negative regulation of T cell mediated immune response to tumor cell (GO:0002841)</li> <li>Provides input for (RO:0002413) \u2192 PDCD1 signaling receptor activity</li> </ol>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#model-assessment","title":"Model Assessment","text":"<p>Based on the information gathered, I'll review this model for accuracy, consistency with GO-CAM best practices, and biological plausibility.</p>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#scientific-content-and-accuracy","title":"Scientific Content and Accuracy","text":"<ol> <li> <p>Overall Biology: The model represents a pathway where UFL1 negatively regulates T-cell activation through ufmylation of PD-1 (PDCD1), which is consistent with the recent publication (PMID:38377992) cited. The pathway shows how UFL1's UFM1 ligase activity is regulated by YWHAG (which is itself regulated by PRKAA1), and how UFL1 affects PD-1 stability and function by affecting the ubiquitin-like ligase activities of KLHL22 and FBXO38.</p> </li> <li> <p>Function of UFL1: The model correctly represents UFL1 as an E3 UFM1-protein ligase with GO:0061666 (UFM1 ligase activity). This aligns with the UniProt entry which describes UFL1 as a protein that \"mediates ufmylation, the covalent attachment of the ubiquitin-like modifier UFM1 to lysine residues on target proteins.\"</p> </li> <li> <p>Regulation of PD-1: The model shows that UFL1 influences PDCD1/PD-1, which is supported by UniProt that states UFL1 \"acts as a negative regulator of T-cell activation by mediating ufmylation and stabilization of PDCD1/PD-1.\"</p> </li> <li> <p>YWHAG role: The representation of YWHAG as having protein sequestering activity that regulates UFL1 is consistent with the UniProt entry that states UFL1 \"Interacts (when phosphorylated) with YWHAG/14-3-3-gamma; sequestering UFL1 and preventing its association with PDCD1/PD-1 substrate.\"</p> </li> </ol>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#go-cam-model-structure-and-best-practices-assessment","title":"GO-CAM Model Structure and Best Practices Assessment","text":"<ol> <li> <p>Activity Representation: Each protein's activity is appropriately represented with the correct molecular function term.</p> </li> <li> <p>Cellular Component Annotation: The model appropriately includes cellular component annotations for the membrane-bound proteins (PDCD1 and CD274) as occurring in the plasma membrane.</p> </li> <li> <p>Causal Relationships: </p> </li> <li>The model uses \"provides input for\" (RO:0002413) to show upstream activities that feed into downstream ones.</li> <li>It uses the appropriate negative effect relation (RO:0002409) to represent the inhibitory effects of the ubiquitin-like ligase adapter activities on PD-1.</li> <li> <p>The model uses RO:0012010 for some regulatory relationships, but the specific meaning of this relation is not clear from the context provided.</p> </li> <li> <p>Process Context: Each activity is properly associated with an appropriate biological process, showing both the local processes (like protein stabilization) and the broader context (regulation of T cell immune response).</p> </li> <li> <p>Evidence: Each relationship and activity is appropriately supported with evidence codes and references to the primary literature (PMID:38377992 and others).</p> </li> </ol>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Relation RO:0012010: The model uses RO:0012010 to represent some regulatory relationships, but it's not one of the standard causal association predicates listed in your guidance. I recommend verifying the appropriate use of this relation or replacing it with one of the standard predicates.</p> </li> <li> <p>UFMylation Mechanism: The model represents UFL1's regulatory effect on PDCD1 as indirect (through KLHL22 and FBXO38), but UniProt suggests that UFL1 directly ufmylates PDCD1. The model should clarify whether the effect is direct or mediated through these adaptor proteins.</p> </li> <li> <p>Process Context Refinement: While the model does associate activities with processes, it might benefit from more specific process terms for UFL1's role in protein ufmylation.</p> </li> <li> <p>Phosphorylation Representation: According to UniProt, UFL1 is phosphorylated at Thr-536 by AMPK, which promotes its interaction with YWHAG/14-3-3-gamma. This phosphorylation event could be explicitly modeled.</p> </li> <li> <p>PDCD1 Ubiquitination: The model shows regulation of PDCD1 through ubiquitin ligase adaptor activities, but could more explicitly model the ubiquitination process described in the UniProt entries.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00001022-UFL1_negatively_regulates_T_cell_activation_by_mediating_ufmylation_of_PDCD1_PD_1__Human__/#overall-conclusion","title":"Overall Conclusion","text":"<p>This GO-CAM model is a well-constructed representation of UFL1's role in negatively regulating T-cell activation through its effect on PDCD1/PD-1. The model uses appropriate GO terms for molecular functions, cellular components, and biological processes, and includes proper evidence codes and literature references.</p> <p>The model would benefit from: 1. Clarification of some regulatory relationships (specifically the use of RO:0012010) 2. More explicit representation of the phosphorylation and ufmylation mechanisms 3. Potentially more direct representation of UFL1's effect on PDCD1</p> <p>However, overall, the model effectively captures the key biological relationships described in the recent literature about UFL1-mediated regulation of PD-1 and T-cell activation.</p>"},{"location":"reviews/65f3ae5c00002132-Control_of_GABAAR_clustering_to_GABAergic_synapses_by_Gephyrin__Human_/","title":"65f3ae5c00002132 Control of GABAAR clustering to GABAergic synapses by Gephyrin  Human","text":"<p>Based on the information gathered, let me now provide a comprehensive review of the GO-CAM model gomodel:65f3ae5c00002132 \"Control of GABAAR clustering to GABAergic synapses by Gephyrin (Human)\".</p>"},{"location":"reviews/65f3ae5c00002132-Control_of_GABAAR_clustering_to_GABAergic_synapses_by_Gephyrin__Human_/#review-of-go-cam-model-gomodel65f3ae5c00002132","title":"Review of GO-CAM model: gomodel:65f3ae5c00002132","text":""},{"location":"reviews/65f3ae5c00002132-Control_of_GABAAR_clustering_to_GABAergic_synapses_by_Gephyrin__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model focuses on the control of GABAA receptor (GABAAR) clustering at GABAergic synapses by Gephyrin in human neurons. The model depicts several activities:</p> <ol> <li>GABA-A receptor activities performed by various GABAAR subunits (GABRG2, GABRB3, GABRA1, GABRB2)</li> <li>Protein-macromolecule adaptor activity of Gephyrin (GPHN) in clustering GABAA receptors</li> <li>Protein-cysteine S-palmitoyltransferase activity of ZDHHC12 in palmitoylating Gephyrin</li> </ol>"},{"location":"reviews/65f3ae5c00002132-Control_of_GABAAR_clustering_to_GABAergic_synapses_by_Gephyrin__Human_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Biological accuracy: The model correctly represents the key roles of Gephyrin as a scaffold protein that clusters GABAA receptors at inhibitory synapses, which is well supported by literature (PMID:25025157).</p> </li> <li> <p>Causal relationships: The model properly depicts the causal relationship between ZDHHC12's palmitoyltransferase activity and Gephyrin's adaptor function, which is crucial for GABAAR clustering as demonstrated in the literature.</p> </li> <li> <p>Molecular detail: The model includes specific GABAAR subunits (GABRG2, GABRB3, GABRA1, GABRB2) that are known to interact with Gephyrin at inhibitory synapses.</p> </li> <li> <p>Evidence quality: The model uses direct experimental evidence (ECO:0000314, ECO:0000315) from peer-reviewed publications to support the relationships.</p> </li> <li> <p>Subcellular localization: The model correctly annotates the activities as occurring in the postsynaptic membrane (GO:0045211), which is appropriate for this pathway.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00002132-Control_of_GABAAR_clustering_to_GABAergic_synapses_by_Gephyrin__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing GABAAR complex representation: The model represents individual GABAAR subunits carrying the GABA-A receptor activity (GO:0004890), but GABAARs function as heteropentameric complexes. According to the \"How to annotate complexes in GO-CAM\" document, when the activity is shared by several proteins that form a complex (like in heteromeric receptors), it would be more appropriate to represent this functional relationship.</p> </li> <li> <p>Redundant causal relationships: There appear to be duplicate causal associations from GPHN to several GABAAR subunits. For example, there are two identical causal relationships from GPHN to GABRG2 with the same predicate (RO:0002629) and evidence. This is redundant and should be corrected.</p> </li> <li> <p>Input/output relationships clarity: All GABAAR activities have CHEBI:17996 (chloride) as both input and output, which is appropriate for a chloride channel, but the model could benefit from including GABA (CHEBI:16865) as an input to better represent the receptor's activation mechanism.</p> </li> <li> <p>Additional molecular players: Based on PMID:25025157, Gephyrin requires palmitoylation on two specific cysteine residues (Cys212 and Cys284) to properly cluster at GABAergic synapses. The model could be enriched by including this molecular detail.</p> </li> <li> <p>Activity flow representation: While the model correctly shows that ZDHHC12 palmitoylates Gephyrin, which then clusters GABAARs, the biological process context for each activity could be more clearly defined to show the complete pathway for GABAAR trafficking and clustering.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00002132-Control_of_GABAAR_clustering_to_GABAergic_synapses_by_Gephyrin__Human_/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Improve GABAAR representation: Consider representing the GABAAR as a complex using the GO term for \"GABA-A receptor complex\" (GO:1902711) for activities where the specific subunit carrying the activity is not definitively known.</p> </li> <li> <p>Remove redundant causal associations: Clean up the duplicate causal relationships from GPHN to GABAAR subunits.</p> </li> <li> <p>Enhance molecular detail: Add annotations to indicate the specific palmitoylation sites (Cys212 and Cys284) on Gephyrin that are modified by ZDHHC12.</p> </li> <li> <p>Complete pathway context: Include annotations for the broader biological processes of \"inhibitory synapse assembly\" (GO:0097091) and \"GABA signaling pathway\" (GO:0007214) to provide better context for the activities.</p> </li> <li> <p>Strengthen evidence: Consider adding evidence from additional publications to support the role of Gephyrin in clustering specific GABAAR subunits.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00002132-Control_of_GABAAR_clustering_to_GABAergic_synapses_by_Gephyrin__Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:65f3ae5c00002132 provides a good representation of the molecular mechanism by which Gephyrin, when palmitoylated by ZDHHC12, clusters GABAA receptors at inhibitory synapses. This is an important process for maintaining proper inhibitory neurotransmission in the human brain. The model is generally well-constructed and evidence-based but could benefit from a few refinements to better represent the complexities of GABAAR function and provide a more complete picture of the pathway.</p> <p>The model correctly captures the key finding from PMID:25025157 that palmitoylation of Gephyrin by ZDHHC12 is essential for proper clustering of GABAARs at inhibitory synapses. Overall, this is a valuable contribution to understanding the molecular mechanisms of inhibitory synapse formation and function.</p>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/","title":"65f3ae5c00002208 Positive regulation of glycogen catabolic process 1  Mouse","text":"<p>Based on my review of the model and relevant information, I'll now provide a detailed review of GO-CAM model 65f3ae5c00002208 titled \"Positive regulation of glycogen catabolic process 1 (Mouse)\".</p>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#go-cam-model-review-gomodel65f3ae5c00002208","title":"GO-CAM Model Review: gomodel:65f3ae5c00002208","text":""},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#overview","title":"Overview","text":"<p>Title: Positive regulation of glycogen catabolic process 1 (Mouse) ID: gomodel:65f3ae5c00002208 Taxon: Mouse (NCBITaxon:10090) Status: Production</p>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#model-description","title":"Model Description","text":"<p>This GO-CAM depicts the glycogen catabolic process in mouse, focusing on enzymes involved in glycogen degradation. The model includes activities of multiple enzymes in the glycogen breakdown pathway, with connections showing the flow of biological activities.</p>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#key-components-of-the-model","title":"Key Components of the Model","text":"<ol> <li>Main Enzymes in the Model:</li> <li>Glycogen phosphorylase (MGI:MGI:97829, Pygl)</li> <li>Glycogen debranching enzyme (MGI:MGI:1924809, Agl) with dual activities:<ul> <li>4-alpha-glucanotransferase activity (GO:0004134)</li> <li>Amylo-alpha-1,6-glucosidase activity (GO:0004135)</li> </ul> </li> <li>Phosphorylase kinase (MGI:MGI:1916211, Phkg2)</li> <li> <p>Phosphoglucomutase 1 and 2 (MGI:MGI:97565 and MGI:MGI:97564)</p> </li> <li> <p>Biological Process:</p> </li> <li> <p>All activities are part of glycogen catabolic process (GO:0005980)</p> </li> <li> <p>Cellular Location:</p> </li> <li> <p>Activities occur in the cytosol (GO:0005829)</p> </li> <li> <p>Molecular Outputs:</p> </li> <li>Alpha-D-glucose (CHEBI:17925)</li> <li>Alpha-D-glucose 6-phosphate(2-) (CHEBI:58225)</li> </ol>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model shows a regulatory pathway through the following causal relationships:</p> <ol> <li> <p>Phosphorylase kinase (MGI:MGI:1916211) directly positively regulates (RO:0002629) glycogen phosphorylase activity</p> </li> <li> <p>Glycogen phosphorylase (MGI:MGI:97829) provides input for (RO:0002413) multiple downstream activities:</p> </li> <li>Glycogen debranching enzyme (4-alpha-glucanotransferase activity)</li> <li> <p>Both phosphoglucomutase activities</p> </li> <li> <p>The 4-alpha-glucanotransferase activity of glycogen debranching enzyme provides input for (RO:0002413) its own amylo-alpha-1,6-glucosidase activity</p> </li> <li> <p>The amylo-alpha-1,6-glucosidase activity provides input for (RO:0002413) glycogen phosphorylase activity (second instance)</p> </li> </ol>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#evidence","title":"Evidence","text":"<p>The model contains appropriate evidential support: - Experimental evidence codes (ECO:0000314, ECO:0000315) from relevant literature - Multiple PMIDs are cited, including PMID:24613482 which details a mouse model of glycogen storage disease type III - Appropriate use of evidence codes for the different assertions</p>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biochemical Accuracy: The model accurately represents the sequence of enzymatic activities in glycogen breakdown, consistent with the literature.</p> </li> <li> <p>Appropriate Evidence: Each activity is supported by experimental evidence from literature, properly annotated with ECO terms.</p> </li> <li> <p>Comprehensive Pathway Representation: The model includes the key enzymes in the glycogen catabolic process, showing both debranching and phosphorylase-dependent degradation.</p> </li> <li> <p>Cellular Context: The model correctly places these activities in the cytosol.</p> </li> <li> <p>Causality Representation: The causal flow between activities is logical and represents the biological sequence of events.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Complete Regulatory Context: The model shows phosphorylase kinase positively regulating glycogen phosphorylase, but the upstream activators of phosphorylase kinase (such as calcium or protein kinase A) are not included. Adding these would provide a more complete regulatory context.</p> </li> <li> <p>Metabolic Outputs: While the model shows glucose and glucose-6-phosphate as outputs, it might benefit from showing the fate of these products (e.g., entry into glycolysis).</p> </li> <li> <p>Feedback Regulation: The model doesn't include feedback regulation mechanisms that control glycogen breakdown. Including these would enhance the biological completeness.</p> </li> <li> <p>Alternative Debranching Pathway: The model appropriately shows the dual activities of the glycogen debranching enzyme (Agl), but could clarify that these are two activities of the same protein rather than separate instances.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00002208-Positive_regulation_of_glycogen_catabolic_process_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:65f3ae5c00002208) provides a well-structured and evidentially supported representation of the glycogen catabolic process in mice. The model correctly represents the causal flow between the different enzymatic activities and includes appropriate molecular functions, cellular components, and biological processes.</p> <p>The relevance of this model is particularly high given the connection to glycogen storage disease type III (as evidenced by PMID:24613482), where mutations in the glycogen debranching enzyme (Agl) lead to disease. The model follows GO-CAM best practices for representation of molecular activities and their causal connections.</p> <p>Overall, this is a high-quality model that could serve as a useful reference for understanding glycogen catabolism and the molecular basis of related metabolic disorders.</p>"},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/","title":"65f3ae5c00002270 Positive regulation of glycogen catabolic process 2  Mouse","text":"<p>Based on the information gathered, I'll now provide a detailed review of the GO-CAM model (gomodel:65f3ae5c00002270):</p>"},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/#go-cam-model-review-gomodel65f3ae5c00002270","title":"GO-CAM Model Review: gomodel:65f3ae5c00002270","text":""},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/#model-summary","title":"Model Summary","text":"<ul> <li>Title: \"Positive regulation of glycogen catabolic process 2 (Mouse)\"</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Contains: 7 activities representing a glycogen catabolic pathway in mouse</li> </ul>"},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model represents the glycogen catabolic process in mouse, specifically focusing on the activities of key enzymes involved in glycogen breakdown in the cytosol. The model includes appropriate molecular functions, cellular locations, and causal relationships between activities.</p>"},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>Biological accuracy: The model correctly represents the key enzymes involved in glycogen catabolism, including:</li> <li>Phkg1 (phosphorylase kinase gamma 1)</li> <li>Pygb (brain glycogen phosphorylase)</li> <li>Agl (glycogen debranching enzyme with dual activities)</li> <li> <p>Pgm1 and Pgm2 (phosphoglucomutases)</p> </li> <li> <p>Causal relationships: The model appropriately uses \"provides input for\" (RO:0002413) and \"directly positively regulates\" (RO:0002629) predicates to connect activities in a biologically meaningful way.</p> </li> <li> <p>Evidence support: All activities are supported by experimental evidence with appropriate ECO codes and PMIDs.</p> </li> <li> <p>Proper representation of dual activity: The model correctly represents the dual enzymatic activities of the Agl protein (amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase), which are important for glycogen debranching.</p> </li> <li> <p>Inclusion of final product: The model tracks the pathway through to the production of alpha-D-glucose 6-phosphate, which is the end product of glycogen breakdown.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing direct evidence for causal relationships: While the causal associations between activities (e.g., one enzyme's output feeding into another enzyme's activity) appear biologically correct, these associations lack direct evidence annotations. It would be beneficial to add evidence for these causal links.</p> </li> <li> <p>Duplicated Pygb activities: There are two instances of Pygb glycogen phosphorylase activity (nodes 65f3ae5c00002276 and 65f3ae5c00002283) with identical functions. This appears to be redundant and might confuse users of the model. Consider consolidating these into a single activity node.</p> </li> <li> <p>Biological process associations: Some activities are associated with the general \"biological regulation\" (GO:0065007) process rather than the more specific \"glycogen catabolic process\" (GO:0005980). For consistency, consider using the more specific process term throughout the model.</p> </li> <li> <p>Missing spatial information: While all activities are correctly located in the cytosol (GO:0005829), some of these locations lack evidence annotations. Consider adding evidence for all cellular locations.</p> </li> </ol>"},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/#technical-correctness","title":"Technical Correctness","text":"<p>The model follows GO-CAM best practices for representing enzymatic activities and causal relationships. The use of molecular functions, cellular components, and biological processes is consistent with GO-CAM modeling guidelines.</p>"},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/#biological-validation","title":"Biological Validation","text":"<p>The model accurately represents the pathway of glycogen breakdown: 1. Phosphorylase kinase (Phkg1) activates glycogen phosphorylase (Pygb) 2. Glycogen phosphorylase breaks down glycogen by releasing glucose-1-phosphate 3. The debranching enzyme (Agl) with its dual activities helps process the branched portions of glycogen 4. Phosphoglucomutases (Pgm1, Pgm2) convert glucose-1-phosphate to glucose-6-phosphate</p> <p>This matches established knowledge of glycogen metabolism.</p>"},{"location":"reviews/65f3ae5c00002270-Positive_regulation_of_glycogen_catabolic_process_2__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li>Consolidate the duplicate Pygb activities into a single node to improve clarity.</li> <li>Add evidence for causal relationships between activities.</li> <li>Ensure consistent use of specific biological process terms throughout the model.</li> <li>Add evidence for all cellular location associations.</li> </ol> <p>Overall, this is a well-constructed GO-CAM model that effectively represents the process of glycogen catabolism in mouse. With the suggested minor improvements, it would be an excellent reference model for the glycogen catabolic pathway.</p>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/","title":"6606056e00000234 CD69 OxydizedLDL pair leading to PD 1 expression in T cells  Human","text":"<p>Now, let me review the GO-CAM model you provided (gomodel:6606056e00000234) based on all the information gathered.</p>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#go-cam-model-review-cd69-oxydizedldl-pair-leading-to-pd-1-expression-in-t-cells-human","title":"GO-CAM Model Review: CD69-OxydizedLDL pair leading to PD-1 expression in T-cells (Human)","text":""},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#model-id-gomodel6606056e00000234","title":"Model ID: gomodel:6606056e00000234","text":""},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#summary-of-model","title":"Summary of Model","text":"<p>This GO-CAM model describes a signaling pathway in human CD4+ T cells where CD69 binding to oxidized LDL leads to the induction of PD-1 (PDCD1) expression through the activation of NFATC1 and NR4A3 (NOR-1) transcription factors. The model represents a mechanism for negative regulation of inflammatory response in the context of cardiovascular disease.</p>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#model-components","title":"Model Components","text":"<p>The model consists of four main activities:</p> <ol> <li>CD69 (UniProtKB:Q07108) functioning as a transmembrane signaling receptor in the plasma membrane</li> <li>NFATC1 (UniProtKB:O95644) functioning as a DNA-binding transcription activator in the nucleus</li> <li>NR4A3 (UniProtKB:Q92570) functioning as a DNA-binding transcription activator in the nucleus</li> <li>PDCD1/PD-1 (UniProtKB:Q15116) functioning as a transmembrane signaling receptor in the plasma membrane</li> </ol>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model represents the following causal relationships: - CD69's transmembrane signaling receptor activity provides input for NFATC1's DNA-binding transcription activator activity - NFATC1's DNA-binding transcription activator activity provides input for both:   - NR4A3's DNA-binding transcription activator activity   - PDCD1's transmembrane signaling receptor activity</p>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#biological-context","title":"Biological Context","text":"<p>All activities in this model are part of the negative regulation of inflammatory response (GO:0050728).</p>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#supporting-evidence","title":"Supporting Evidence","text":"<p>The model is well-supported by primary literature: - The CD69-oxidized LDL interaction and its role in PD-1 induction is supported by Jimenez-Fernandez et al. (2022) - PMID:35930205 - NR4A3's role in the inflammatory response is supported by Zhao et al. (2010) - PMID:20558821 - NFATC1's localization in the nucleus is supported by Sheridan et al. (2002) - PMID:8634690 - PDCD1's transmembrane signaling receptor activity is supported by Freeman et al. (2000) - PMID:11015443</p>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#assessment","title":"Assessment","text":""},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#strengths-of-the-model","title":"Strengths of the model:","text":"<ol> <li>The model captures a novel pathway for PD-1 induction that is independent of typical T cell receptor signaling</li> <li>All components have appropriate GO terms for molecular functions</li> <li>All activities occur in the correct cellular compartments</li> <li>The model is supported by strong experimental evidence</li> <li>The causal connections between activities follow the biological sequence of events</li> </ol>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#suggestions-for-improvement","title":"Suggestions for improvement:","text":"<ol> <li> <p>Add missing interactions: The model doesn't explicitly show the interaction between oxidized LDL and CD69, which is a key initiating event. Consider adding oxidized LDL as a chemical entity in the model.</p> </li> <li> <p>Clarify NR4A3's role: While the PMID:35930205 suggests that NR4A3 might actually negatively regulate PD-1 expression (\"silencing NR4A3 slightly upregulated PD-1 expression\"), the model doesn't capture this nuance. This regulatory relationship could be clarified.</p> </li> <li> <p>Add downstream effects: The model could be extended to show the functional consequences of PD-1 induction, such as inhibition of T cell activation or cytokine production.</p> </li> <li> <p>Link to disease context: Given the relevance to atherosclerosis and cardiovascular disease mentioned in the literature, making these connections explicit would enhance the model's biological context.</p> </li> </ol>"},{"location":"reviews/6606056e00000234-CD69_OxydizedLDL_pair_leading_to_PD_1_expression_in_T_cells__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model effectively represents a novel pathway for PD-1 induction in T cells via CD69-oxidized LDL interaction through NFATC1 and NR4A3. The model correctly follows GO-CAM best practices for depicting signaling pathways and transcriptional regulation. The model provides valuable insights into mechanisms that negatively regulate inflammatory responses in the context of cardiovascular disease and has potential implications for understanding immune checkpoint regulation in atherosclerosis.</p>"},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/","title":"6606056e00000282 LGALS1 CD69 pair involved in negative regulation of T helper 17 cell lineage  Human","text":"<p>Based on my review of the GO-CAM model and related information, I'll now provide a comprehensive review of the GO-CAM model with ID gomodel:6606056e00000282.</p>"},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/#review-of-go-cam-model-lgals1-cd69-pair-involved-in-negative-regulation-of-t-helper-17-cell-lineage-human","title":"Review of GO-CAM Model: LGALS1-CD69 pair involved in negative regulation of T-helper 17 cell lineage (Human)","text":""},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/#model-overview","title":"Model Overview","text":"<p>This model gomodel:6606056e00000282 represents the interaction between Galectin-1 (LGALS1) and CD69 and their role in negatively regulating T-helper 17 (Th17) cell lineage commitment in humans. The model includes four proteins with their respective molecular functions, and a series of causal relationships that describe the signal transduction pathway leading to suppression of Th17 cell differentiation.</p>"},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/#model-components","title":"Model Components","text":"<p>The model includes four proteins with the following activities:</p> <ol> <li>LGALS1 (P09382): </li> <li>Molecular Function: Receptor ligand activity (GO:0048018)</li> <li>Cellular Component: Plasma membrane (GO:0005886)</li> <li> <p>Biological Process: Negative regulation of T-helper 17 cell lineage commitment (GO:2000329)</p> </li> <li> <p>CD69 (Q07108):</p> </li> <li>Molecular Function: Transmembrane signaling receptor activity (GO:0004888)</li> <li>Cellular Component: Plasma membrane (GO:0005886)</li> <li> <p>Biological Process: Negative regulation of T-helper 17 cell lineage commitment (GO:2000329)</p> </li> <li> <p>JAK3 (P52333):</p> </li> <li>Molecular Function: Protein tyrosine kinase activity (GO:0004713)</li> <li>Cellular Component: Extrinsic component of cytoplasmic side of plasma membrane (GO:0031234)</li> <li> <p>Biological Process: Negative regulation of T-helper 17 cell lineage commitment (GO:2000329)</p> </li> <li> <p>STAT5A (P42229):</p> </li> <li>Molecular Function: DNA-binding transcription factor activity (GO:0003700)</li> <li>Cellular Component: Nucleus (GO:0005634)</li> <li>Biological Process: Negative regulation of T-helper 17 cell lineage commitment (GO:2000329)</li> </ol>"},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model captures the following causal relationships: 1. LGALS1 \u2192 CD69: Directly positively regulates (RO:0002629) 2. CD69 \u2192 JAK3: Directly positively regulates (RO:0002629) 3. JAK3 \u2192 STAT5A: Directly positively regulates (RO:0002629)</p> <p>This creates a signaling cascade where: - Galectin-1 binds to and activates CD69 receptor - CD69 activates JAK3's protein tyrosine kinase activity - JAK3 phosphorylates STAT5A, which then acts as a transcription factor  - This pathway ultimately leads to the negative regulation of Th17 cell differentiation</p>"},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/#alignment-with-literature-evidence","title":"Alignment with Literature Evidence","text":"<p>The model is well-supported by the available literature:</p> <ol> <li> <p>LGALS1-CD69 interaction: The interaction is supported by the paper \"The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1\" (PMID:24752896), which confirmed a direct and specific interaction between CD69 and galectin-1 that is carbohydrate-dependent.</p> </li> <li> <p>CD69-JAK3-STAT5 pathway: The model correctly represents that CD69 activates the JAK3/STAT5 signaling pathway, which is known to regulate T-helper cell differentiation, specifically negatively regulating Th17 cell development.</p> </li> <li> <p>Localization: The cellular components are correctly annotated, with LGALS1 and CD69 at the plasma membrane, JAK3 at the cytoplasmic side of the plasma membrane, and STAT5A in the nucleus.</p> </li> </ol>"},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>After reviewing the GO-CAM annotation guidelines, I found that this model follows the best practices for:</p> <ol> <li> <p>Signaling receptor activity annotation: The model correctly represents the protein ligand-activated signaling receptor pattern, where LGALS1 has receptor ligand activity, CD69 has transmembrane signaling receptor activity, and they're connected by a \"directly positively regulates\" relationship.</p> </li> <li> <p>Causal relationships: The model correctly uses the \"directly positively regulates\" (RO:0002629) predicate to connect activities in the signaling cascade.</p> </li> <li> <p>Cellular localization: The model properly annotates the cellular components for each protein activity.</p> </li> <li> <p>Biological process context: All activities are properly contextualized as part of the same biological process (GO:2000329 - negative regulation of T-helper 17 cell lineage commitment).</p> </li> </ol>"},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, here are some potential improvements:</p> <ol> <li> <p>Complete downstream effects: The model could benefit from including information about which genes are regulated by STAT5A to inhibit Th17 differentiation. This would provide a more complete understanding of the mechanism.</p> </li> <li> <p>Additional evidence: There's some duplication in the evidence attribution for the causal relationships (particularly for LGALS1-CD69 and CD69-JAK3). These should be consolidated or differentiated to improve clarity.</p> </li> <li> <p>Feedback regulation: If applicable, any feedback mechanisms that regulate this pathway could be added to provide a more comprehensive view of the biological process.</p> </li> </ol>"},{"location":"reviews/6606056e00000282-LGALS1_CD69_pair_involved_in_negative_regulation_of_T_helper_17_cell_lineage__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6606056e00000282 accurately represents the LGALS1-CD69-JAK3-STAT5A signaling pathway involved in the negative regulation of T-helper 17 cell lineage commitment in humans. It follows GO-CAM best practices for representing signaling cascades and provides a clear representation of how these proteins interact to regulate T cell differentiation.</p> <p>The model is appropriately supported by literature evidence and correctly depicts the molecular functions, cellular components, and biological processes involved. It serves as a useful resource for understanding the role of this pathway in immune regulation.</p>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/","title":"6606056e00000576 UBR5 ubiquitinates ligand bound VDR when VDR is not associated with Nuclear receptor coactivators  NCOAs   Human","text":"<p>Based on my analysis of the GO-CAM model gomodel:6606056e00000576 and the relevant research, I'll now provide a comprehensive review:</p>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#go-cam-model-review-gomodel6606056e00000576","title":"GO-CAM Model Review - gomodel:6606056e00000576","text":""},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#basic-information","title":"Basic Information:","text":"<ul> <li>Model ID: gomodel:6606056e00000576</li> <li>Title: \"UBR5 ubiquitinates ligand-bound VDR when VDR is not associated with Nuclear receptor coactivators (NCOAs) (Human).\"</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#model-overview","title":"Model Overview:","text":"<p>This GO-CAM model represents the molecular process by which UBR5 (E3 ubiquitin-protein ligase) targets the Vitamin D receptor (VDR) for ubiquitination and subsequent degradation when VDR is bound to its ligand (calcitriol) but not associated with nuclear receptor coactivators (NCOAs), particularly NCOA3.</p>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#model-components","title":"Model Components:","text":""},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#1-ubr5-activity-uniprotkbo95071","title":"1. UBR5 Activity (UniProtKB:O95071):","text":"<ul> <li>Molecular Function: GO:0061630 - ubiquitin protein ligase activity</li> <li>Cellular Component: GO:0000785 - chromatin</li> <li>Biological Process: GO:0071630 - nuclear protein quality control by the ubiquitin-proteasome system</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:37478846</li> </ul>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#2-vdr-activity-uniprotkbp11473","title":"2. VDR Activity (UniProtKB:P11473):","text":"<ul> <li>Molecular Function: GO:0004879 - nuclear receptor activity</li> <li>Cellular Component: GO:0000785 - chromatin</li> <li>Biological Process: GO:0048384 - retinoic acid receptor signaling pathway</li> <li>Evidence: Multiple sources (ECO:0000314 from PMIDs: 12016314, 17082781, 10678179)</li> </ul>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#3-ncoa3-activity-uniprotkbq9y6q9","title":"3. NCOA3 Activity (UniProtKB:Q9Y6Q9):","text":"<ul> <li>Molecular Function: GO:0030374 - nuclear receptor coactivator activity</li> <li>Cellular Component: GO:0000785 - chromatin</li> <li>Biological Process: GO:0070561 - vitamin D receptor signaling pathway</li> <li>Evidence: ECO:0000314 (direct assay) from PMID:9267036</li> </ul>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#4-causal-relationships","title":"4. Causal Relationships:","text":"<ul> <li>UBR5 activity RO:0002630 (directly negatively regulates) VDR activity</li> <li>VDR activity RO:0002629 (directly positively regulates) NCOA3 activity</li> <li>NCOA3 activity RO:0012010 blocks UBR5 activity</li> </ul>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment:","text":"<p>The model accurately represents the findings from the cited research, particularly PMID:37478846 (\"UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability\"). This paper demonstrates that:</p> <ol> <li>UBR5 ubiquitinates multiple nuclear hormone receptors including VDR when they are bound to their respective ligands.</li> <li>This ubiquitination occurs when the nuclear receptors are not associated with coactivators like NCOA3.</li> <li>The interaction takes place on chromatin.</li> <li>NCOA3 and UBR5 compete for binding to the hydrophobic cleft of nuclear receptors, making their binding mutually exclusive.</li> </ol> <p>The model correctly represents this antagonistic relationship where NCOA3 blocks UBR5's ubiquitination of VDR by competing for the same binding site.</p>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices:","text":"<p>The model follows GO-CAM best practices for representing complex molecular interactions:</p> <ol> <li>Activity nodes: Each protein is represented by its molecular function</li> <li>Causal relationships: Appropriate causal relationship terms are used</li> <li>Evidence: Each assertion is supported by evidence from the literature</li> <li>Cellular location: All activities are correctly localized to chromatin</li> </ol> <p>For the representation of the competitive binding between UBR5 and NCOA3, the model uses the \"blocks\" relationship, which is appropriate to represent this mutually exclusive binding scenario.</p>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<p>While the model is scientifically accurate and well-constructed, I have a few suggestions:</p> <ol> <li> <p>Additional causal links: The model could be enhanced by explicitly showing that VDR bound to calcitriol (CHEBI:17823) is the state that enables UBR5 binding. Currently, calcitriol is listed as an object but not explicitly connected in the model.</p> </li> <li> <p>Biological Process annotation: VDR's biological process is annotated as \"retinoic acid receptor signaling pathway\" (GO:0048384), which is accurate based on the cited evidence. However, it might be more specific to annotate it with \"vitamin D receptor signaling pathway\" (GO:0070561) as already used for NCOA3.</p> </li> <li> <p>Expanded representation: The model could be expanded to include the downstream proteasomal degradation of VDR that follows ubiquitination, as this is a key functional outcome of this process.</p> </li> </ol>"},{"location":"reviews/6606056e00000576-UBR5_ubiquitinates_ligand_bound_VDR_when_VDR_is_not_associated_with_Nuclear_receptor_coactivators__NCOAs___Human__/#conclusion","title":"Conclusion:","text":"<p>The GO-CAM model gomodel:6606056e00000576 accurately represents the competitive binding of UBR5 and NCOA3 to ligand-bound VDR on chromatin, which determines whether VDR is ubiquitinated and degraded or participates in transcriptional activation. The model is consistent with current scientific understanding and follows GO-CAM best practices. With minor enhancements, it would provide an even more comprehensive representation of this important regulatory mechanism.</p> <p>The model effectively captures the key finding from the research that nuclear receptor degradation (including VDR) by UBR5 is regulated by a competitive mechanism between nuclear receptor coactivators and the ubiquitin ligase, providing an elegant switch between receptor activation and degradation.</p>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/","title":"6606056e00000767 ITCH and UBR5 catalyzed branched linked polyubiquitination of TXNIP  Human","text":"<p>Based on all the information I've gathered, I'll now review the GO-CAM model \"ITCH and UBR5 catalyzed branched-linked polyubiquitination of TXNIP (Human)\".</p>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#review-of-go-cam-model-gomodel6606056e00000767","title":"Review of GO-CAM Model: gomodel:6606056e00000767","text":""},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:6606056e00000767) describes how the E3 ubiquitin ligases ITCH and UBR5 catalyze branched-linked polyubiquitination of TXNIP (Thioredoxin-interacting protein) in humans.</p>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#biological-content-analysis","title":"Biological Content Analysis","text":""},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#core-components","title":"Core Components:","text":"<ol> <li>TXNIP (UniProtKB:Q9H3M7) - Thioredoxin-interacting protein functions as an enzyme inhibitor in response to oxidative stress.</li> <li>ITCH (UniProtKB:Q96J02) - E3 ubiquitin-protein ligase that catalyzes ubiquitination of multiple proteins.</li> <li>UBR5 (UniProtKB:O95071) - E3 ubiquitin-protein ligase that typically functions in branch-linked ubiquitination.</li> </ol>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#pathway-description","title":"Pathway Description:","text":"<p>The model represents how ITCH and UBR5 work together to create branched-linked polyubiquitin chains on TXNIP, leading to its proteasomal degradation. ITCH creates initial 'Lys-63'-linked ubiquitin chains on TXNIP, which are then modified by UBR5 to create 'Lys-48'/'Lys-63' branched chains that target TXNIP for degradation by the proteasome.</p>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#evidence-support","title":"Evidence Support:","text":"<p>The model is supported by direct experimental evidence from PMID:29378950 which demonstrates that K63-linked polyubiquitination by ITCH triggers proteasome-mediated degradation of TXNIP through subsequent assembly of K48/K63 branched ubiquitin chains. TXNIP's cellular localization is supported by PMID:14632196. TXNIP's role in response to oxidative stress is based on evidence from PMID:17603038.</p>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#technical-review","title":"Technical Review","text":""},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#model-structure","title":"Model Structure:","text":"<p>The model includes three activities: 1. TXNIP's enzyme inhibitor activity (GO:0004857) in the cytoplasm 2. ITCH's ubiquitin-ubiquitin ligase activity (GO:0034450) 3. UBR5's ubiquitin-ubiquitin ligase activity (GO:0034450)</p>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#causal-relationships","title":"Causal Relationships:","text":"<ul> <li>ITCH's ubiquitin-ubiquitin ligase activity provides input for (RO:0002413) UBR5's activity</li> <li>UBR5's ubiquitin-ubiquitin ligase activity directly negatively regulates (RO:0002630) TXNIP's enzyme inhibitor activity</li> </ul>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#process-annotations","title":"Process Annotations:","text":"<ul> <li>TXNIP's activity is part of response to oxidative stress (GO:0006979)</li> <li>Both ITCH and UBR5's activities are part of protein branched polyubiquitination (GO:0141198)</li> </ul>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#critical-assessment","title":"Critical Assessment","text":""},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately captures the cooperation between ITCH and UBR5 in forming branched ubiquitin chains on TXNIP.</li> <li>The causal relationships correctly represent the sequential action of ITCH providing substrate for UBR5, and the negative regulation of TXNIP's function.</li> <li>The use of evidence from direct experimental assays provides strong support for the model's assertions.</li> <li>The subcellular localization of TXNIP in the cytoplasm is properly annotated.</li> </ol>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#issues","title":"Issues:","text":"<ol> <li> <p>Redundant Causal Association: There are duplicate causal associations between ITCH and UBR5. The model shows two identical \"provides input for\" (RO:0002413) relationships from ITCH to UBR5, which is redundant.</p> </li> <li> <p>Missing Proteasome Process: While the model captures the branched polyubiquitination, it doesn't explicitly include the proteasomal degradation process that follows. Since the title references proteasomal degradation and the paper clearly shows this outcome, including GO:0043161 (proteasome-mediated ubiquitin-dependent protein catabolic process) would improve completeness.</p> </li> <li> <p>Ubiquitination Chain Specificity: The model doesn't specify the types of ubiquitin chains involved (K48/K63 branched chains), which is a key aspect of the biological mechanism described in the paper.</p> </li> </ol>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Remove one of the duplicate causal associations between ITCH and UBR5.</p> </li> <li> <p>Consider adding an additional process annotation for proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161) to better represent the ultimate fate of TXNIP.</p> </li> <li> <p>If possible within the GO-CAM framework, consider specifying the ubiquitin chain types involved (K48/K63 branched chains) to better capture the mechanism's specificity.</p> </li> </ol>"},{"location":"reviews/6606056e00000767-ITCH_and_UBR5_catalyzed_branched_linked_polyubiquitination_of_TXNIP__Human__/#conclusion","title":"Conclusion:","text":"<p>Overall, this is a well-constructed GO-CAM model that represents the current understanding of how ITCH and UBR5 cooperate to regulate TXNIP through branched polyubiquitination. The model follows GO-CAM best practices for representing complex molecular interactions. With minor adjustments to address the duplicate causal association and possibly include the downstream degradation process, it would be an even more comprehensive representation of this biological pathway.</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/","title":"6606056e00000903 Activation of the integrated stress response via activation of EIF2AK1 HRI by DELE1 in response to mitochondrial stress  Human","text":"<p>Based on my analysis of the provided GO-CAM model and the referenced literature, I'll now provide a comprehensive review of gomodel:6606056e00000903.</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#review-of-go-cam-model-gomodel6606056e00000903","title":"Review of GO-CAM Model: gomodel:6606056e00000903","text":""},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#model-title","title":"Model Title","text":"<p>\"Activation of the integrated stress response via activation of EIF2AK1/HRI by DELE1 in response to mitochondrial stress (Human)\"</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the molecular pathway that relays mitochondrial stress to the cytosol, activating the integrated stress response (ISR) through the OMA1-DELE1-HRI pathway in human cells. The model focuses on how mitochondrial stress triggers a signaling cascade that leads to phosphorylation of eIF2alpha and subsequent induction of downstream transcription factors.</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#model-structure","title":"Model Structure","text":"<p>The model captures the following key components and relationships:</p> <ol> <li>Initial stress response: OMA1 (Q96E52) metalloendopeptidase activity in the mitochondrial intermembrane space</li> <li>Signal relay: DELE1 (Q14154) protein serine/threonine kinase activator activity in the cytosol</li> <li>Stress kinase: EIF2AK1/HRI (Q9BQI3) eukaryotic translation initiation factor 2alpha kinase activity in the cytosol</li> <li>Downstream effects: EIF2S1 (P05198) translation initiation factor activity and the activation of transcription factors ATF4 (P18848) and DDIT3 (P35638)</li> </ol>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately reflects the current scientific understanding of the OMA1-DELE1-HRI pathway as described in the key references (PMID:32132706 and PMID:32132707). The model captures how:</p> <ol> <li>Mitochondrial stress activates the OMA1 protease, which cleaves DELE1</li> <li>Cleaved DELE1 accumulates in the cytosol where it interacts with HRI</li> <li>Activated HRI phosphorylates eIF2alpha (EIF2S1)</li> <li>Phosphorylation of eIF2alpha reduces global protein synthesis but increases translation of specific mRNAs, including ATF4</li> <li>ATF4 drives the transcription of stress-response genes including DDIT3/CHOP</li> </ol> <p>All activities are associated with the correct cellular compartments, with OMA1 in the mitochondrial intermembrane space, and HRI, DELE1, and eIF2alpha in the cytosol as described in the literature.</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#proper-use-of-causal-relations","title":"Proper Use of Causal Relations","text":"<p>The model uses the following causal relations:</p> <ol> <li>OMA1 metalloendopeptidase activity directly positively regulates (RO:0002629) DELE1 kinase activator activity</li> <li>DELE1 kinase activator activity directly positively regulates (RO:0002629) EIF2AK1/HRI kinase activity</li> <li>EIF2AK1/HRI kinase activity both:</li> <li>Directly positively regulates (RO:0002629) EIF2S1 translation initiation factor activity</li> <li>Directly negatively regulates (RO:0002630) EIF2S1 translation initiation factor activity</li> <li>EIF2S1 translation initiation factor activity provides input for (RO:0002407) both ATF4 and DDIT3 transcription factor activities</li> </ol> <p>These causal relations accurately represent the biology described in the literature, particularly how: - OMA1 activation leads to DELE1 cleavage and its accumulation in the cytosol - Cleaved DELE1 interacts with and activates HRI - HRI phosphorylates eIF2alpha, which has dual effects on translation (general inhibition but increased for specific mRNAs) - This leads to increased translation of ATF4 and DDIT3/CHOP</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#completeness-of-the-model","title":"Completeness of the Model","text":"<p>The model effectively captures the core OMA1-DELE1-HRI pathway as described in the literature. It includes all the major players and their interactions in the integrated stress response triggered by mitochondrial dysfunction.</p> <p>One aspect that could potentially be expanded in future iterations is the inclusion of: 1. The specific mitochondrial stressors that initially activate OMA1 (such as CCCP mentioned in the references) 2. The specific phosphorylation sites on eIF2alpha (Ser51) 3. The downstream transcriptional targets of ATF4 and DDIT3 4. The feedback mechanisms that eventually attenuate the integrated stress response</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#evidence-and-citations","title":"Evidence and Citations","text":"<p>All activities and relations in the model are appropriately supported by strong experimental evidence (ECO:0000314 - direct assay evidence used in manual assertion) and properly cited to the primary literature sources (PMID:32132706 and PMID:32132707). Some additional supporting references are also cited for specific activities.</p> <p>The model references both key papers that discovered and characterized the OMA1-DELE1-HRI pathway, showing thorough literature support.</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#go-cam-best-practices-conformance","title":"GO-CAM Best Practices Conformance","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li>Using appropriate molecular function terms for each protein</li> <li>Placing activities in the correct cellular compartments</li> <li>Specifying which biological processes the activities are part of</li> <li>Using appropriate causal relations between activities</li> <li>Including evidence codes and literature references for all assertions</li> </ol> <p>The dual regulation of EIF2S1 (both positive and negative) accurately reflects the biology of the integrated stress response, where phosphorylation of eIF2alpha inhibits general translation but enables the translation of specific mRNAs like ATF4 and DDIT3.</p>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is scientifically accurate and well-constructed, there are a few potential improvements:</p> <ol> <li> <p>Additional context: The model could include the initial mitochondrial stressors that activate OMA1 (such as CCCP, oligomycin, or rotenone mentioned in the papers).</p> </li> <li> <p>Molecular details: Include more specific details about the cleavage of DELE1 by OMA1, particularly the generation of the short form (S-DELE1) that accumulates in the cytosol.</p> </li> <li> <p>Downstream effects: Consider expanding the model to include some of the key downstream effects of ATF4 and DDIT3 activation, such as induction of genes involved in amino acid metabolism, redox homeostasis, and apoptosis.</p> </li> <li> <p>Resolution of ISR: The model could potentially include the mechanisms that eventually resolve the integrated stress response, such as the GADD34-mediated dephosphorylation of eIF2alpha.</p> </li> </ol>"},{"location":"reviews/6606056e00000903-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK1_HRI_by_DELE1_in_response_to_mitochondrial_stress__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:6606056e00000903) accurately represents the OMA1-DELE1-HRI pathway that relays mitochondrial stress to trigger the integrated stress response. The model has strong scientific support from the literature, follows GO-CAM best practices, and effectively captures the key molecular players and interactions in this pathway.</p> <p>The model provides a valuable resource for researchers interested in understanding how mitochondrial dysfunction is communicated to the cytosol and how cells respond to this stress through the integrated stress response.</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/","title":"6606056e00001308 Retinoic acid binds and activates RARA and RXRA nuclear receptors  Human","text":"<p>Now let me check the information about the PMID 19917671 which is mentioned as evidence for one of the causal associations.</p> <p>After reviewing the GO-CAM model (gomodel:6606056e00001308) and related information, I'm ready to provide a comprehensive review of this GO-CAM.</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#review-of-go-cam-model-gomodel6606056e00001308","title":"Review of GO-CAM Model: gomodel:6606056e00001308","text":""},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#model-overview","title":"Model Overview","text":"<p>This model titled \"Retinoic acid binds and activates RARA and RXRA nuclear receptors (Human)\" represents the retinoic acid receptor signaling pathway in humans. It illustrates how retinoic acid activates the nuclear receptors RARA (Retinoic Acid Receptor Alpha) and RXRA (Retinoid X Receptor Alpha), and their regulatory relationship with NCOA3 (Nuclear Receptor Coactivator 3).</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#model-structure-analysis","title":"Model Structure Analysis","text":""},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#activities-and-entities","title":"Activities and Entities","text":"<p>The model includes three key proteins: 1. RARA (UniProtKB:P10276) - Performs nuclear receptor activity (GO:0004879) 2. RXRA (UniProtKB:P19793) - Performs nuclear receptor activity (GO:0004879)  3. NCOA3 (UniProtKB:Q9Y6Q9) - Performs nuclear receptor coactivator activity (GO:0030374)</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#cellular-location","title":"Cellular Location","text":"<p>All activities occur in chromatin (GO:0000785), which is appropriate for nuclear receptor functions.</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#biological-process","title":"Biological Process","text":"<p>All activities are part of the retinoic acid receptor signaling pathway (GO:0048384), which is consistent with the model's purpose.</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes appropriate causal associations: 1. RARA directly positively regulates RXRA (RO:0002629) 2. RARA directly positively regulates NCOA3 (RO:0002629) 3. RXRA directly positively regulates RARA (RO:0002629) 4. RXRA directly positively regulates NCOA3 (RO:0002629)</p> <p>This creates a feedback loop between RARA and RXRA, which is consistent with the biology of these nuclear receptors often functioning as heterodimers.</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes with relevant literature citations: - Evidence code ECO:0000314 (direct assay evidence used in manual assertion) is used throughout - Key references include PMID:2825025, PMID:9267036, and PMID:19917671 - All assertions are supported by publications describing retinoic acid receptor signaling</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#conformance-to-go-cam-best-practices","title":"Conformance to GO-CAM Best Practices","text":""},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#complex-representation","title":"Complex Representation","text":"<p>The model does not explicitly represent the RARA-RXRA heterodimer as a complex entity. Based on the GO-CAM documentation \"How to annotate complexes in GO-CAM,\" this approach is valid since both RARA and RXRA have defined activities, and their causal relationships appropriately reflect their functional interactions.</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#causal-relationships_1","title":"Causal Relationships","text":"<p>The causal relationships are correctly modeled using the appropriate relation RO:0002629 (directly positively regulates), which is the correct relation for this type of regulatory relationship.</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#completeness","title":"Completeness","text":"<p>The model provides a focused representation of retinoic acid receptor signaling through RARA and RXRA. The inclusion of the coactivator NCOA3 adds important regulatory context.</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model is scientifically accurate and consistent with the current understanding of retinoic acid signaling:</p> <ol> <li>RARA and RXRA act as nuclear receptors that can form heterodimers</li> <li>NCOA3 functions as a coactivator for these nuclear receptors</li> <li>The reciprocal positive regulation between RARA and RXRA is well-documented</li> <li>The activation of NCOA3 by both receptors is consistent with its coactivator function</li> </ol> <p>The evidence from UniProt entries confirms: - RARA binds to RXRA to form heterodimers - Nuclear receptor activity is enhanced by coactivators like NCOA3 - Retinoic acid binding induces conformational changes in these receptors leading to transcriptional activation</p>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is scientifically sound, there are a few potential improvements that could enhance the representation:</p> <ol> <li> <p>Consider including retinoic acid as a chemical entity - The model title refers to retinoic acid, but the molecule itself (CHEBI:35291) is only listed as an object, not integrated into the model as a binding partner for the receptors.</p> </li> <li> <p>Target genes - Consider expanding the model to include downstream transcriptional targets regulated by the RARA-RXRA complex, which would provide a more complete picture of the pathway's functional outcome.</p> </li> <li> <p>Alternative receptor states - The model could potentially indicate the different states of the receptors (ligand-bound vs. unbound), as these states influence their interactions with coactivators and corepressors.</p> </li> </ol>"},{"location":"reviews/6606056e00001308-Retinoic_acid_binds_and_activates_RARA_and_RXRA_nuclear_receptors__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:6606056e00001308) provides a clear and accurate representation of retinoic acid receptor signaling involving RARA, RXRA, and NCOA3. It follows GO-CAM best practices for representing molecular activities and regulatory relationships. The model uses appropriate evidence and correctly conveys the biology of nuclear receptor signaling in response to retinoic acid.</p> <p>The model is scientifically valid, with supported evidence and appropriate representation of the interactions between the nuclear receptors RARA and RXRA and their coactivator NCOA3. The model effectively captures a key segment of the retinoic acid signaling pathway in humans.</p>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/","title":"6606056e00001371 APP clearance through CLU TREM2 interaction   Human","text":"<p>Now that I have gathered all the necessary information, I'll provide a comprehensive review of the GO-CAM model with ID gomodel:6606056e00001371.</p>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#review-of-go-cam-model-6606056e00001371","title":"Review of GO-CAM Model: 6606056e00001371","text":""},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#model-overview","title":"Model Overview","text":"<p>Title: APP clearance through CLU:TREM2 interaction. (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>This model represents the mechanism of amyloid-beta (A\u03b2) clearance involving the interaction between clusterin (CLU), triggering receptor expressed on myeloid cells 2 (TREM2), and DNAX-activating protein of 12 kDa (TYROBP/DAP12). This pathway plays an important role in Alzheimer's disease pathophysiology.</p>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#model-components","title":"Model Components","text":"<p>The model contains four key activities:</p> <ol> <li>TYROBP/DAP12 (O43914) - Protein-macromolecule adaptor activity (GO:0030674)</li> <li>TREM2 (Q9NZC2) - Transmembrane signaling receptor activity (GO:0004888)</li> <li>SYK (P43405) - Protein tyrosine kinase activity (GO:0004713)</li> <li>CLU (P10909) - Receptor ligand activity (GO:0048018)</li> </ol> <p>All activities are part of the biological process \"amyloid-beta clearance\" (GO:0097242).</p>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model depicts the following causal chain:</p> <ol> <li>CLU (Clusterin) directly positively regulates TREM2 receptor activity</li> <li>TREM2 directly positively regulates TYROBP/DAP12 adaptor activity</li> <li>TYROBP/DAP12 directly positively regulates SYK kinase activity</li> </ol> <p>This signaling cascade represents how extracellular CLU interacts with the TREM2 receptor on microglia, leading to activation of the TYROBP/DAP12 adaptor protein and subsequent activation of the SYK kinase, ultimately resulting in amyloid-beta clearance.</p>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#model-accuracy-and-correctness","title":"Model Accuracy and Correctness","text":"<p>Based on my analysis of the provided literature and molecular data, this model accurately represents the current understanding of the CLU-TREM2-TYROBP-SYK pathway in amyloid-beta clearance:</p> <ol> <li>Scientific Accuracy: The model is backed by scientific evidence from multiple papers, including:</li> <li>The interaction between CLU and TREM2 (PMID:27477018)</li> <li>The role of TREM2 as a receptor for amyloid-beta (PMID:29518356)</li> <li> <p>The interaction between TREM2 and DAP12/TYROBP (PMID:23459077)</p> </li> <li> <p>Cellular Localization: The model correctly represents:</p> </li> <li>CLU as a secreted protein acting in the extracellular space (GO:0005615)</li> <li>TREM2 as a plasma membrane receptor (GO:0005886)</li> <li>TYROBP/DAP12 as a plasma membrane-associated adaptor (GO:0005886)</li> <li> <p>SYK as a cytoplasmic kinase (GO:0005737)</p> </li> <li> <p>Molecular Functions: The molecular functions are appropriately assigned:</p> </li> <li>CLU as a receptor ligand binding to TREM2</li> <li>TREM2 as a transmembrane signaling receptor</li> <li>TYROBP as a protein-macromolecule adaptor</li> <li>SYK as a protein tyrosine kinase</li> </ol>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#model-completeness","title":"Model Completeness","text":"<p>The model represents a focused view of the CLU-TREM2-TYROBP-SYK pathway for amyloid-beta clearance. While concise, the model could be expanded to include:</p> <ol> <li> <p>Downstream effects of SYK activation: The model doesn't specify how SYK activation leads to amyloid-beta clearance. SYK phosphorylates multiple downstream targets that lead to phagocytosis and degradation of amyloid-beta.</p> </li> <li> <p>Alternative pathways: The TREM2 receptor can bind multiple ligands beyond CLU, including amyloid-beta itself and ApoE. These alternative interactions could be represented in relation to this pathway.</p> </li> <li> <p>Feedback mechanisms: Regulatory feedback mechanisms that control this signaling pathway are not included.</p> </li> </ol>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li> <p>Appropriate causal relationships: The use of \"directly positively regulates\" (RO:0002629) is appropriate for the direct activation relationships between these components.</p> </li> <li> <p>Enabled by annotations: Each activity is properly enabled by the corresponding gene product.</p> </li> <li> <p>Cellular location annotations: Each activity has appropriate cellular component annotations.</p> </li> <li> <p>Evidence codes and references: All assertions are backed by appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and PMID references.</p> </li> <li> <p>Contributor information: All annotations include contributor information (ORCID: 0000-0001-8769-177X) and dates.</p> </li> </ol>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is scientifically accurate, there are a few areas that could be enhanced:</p> <ol> <li> <p>More detailed evidence descriptions: The evidence provided is basic PMID references. Additional details about the specific experiments supporting each relationship would strengthen the model.</p> </li> <li> <p>More specific biological context: While the model mentions amyloid-beta clearance, it could specify the cell types (e.g., microglia) and pathological contexts (e.g., Alzheimer's disease) more explicitly.</p> </li> <li> <p>Extended downstream effects: Including downstream effects of SYK activation would make the model more comprehensive, showing how this pathway leads to phagocytosis and degradation of amyloid-beta.</p> </li> <li> <p>Related molecular mechanisms: The model could integrate related pathways known to interact with this mechanism, such as toll-like receptor signaling, which has cross-talk with TREM2 signaling.</p> </li> </ol>"},{"location":"reviews/6606056e00001371-APP_clearance_through_CLU_TREM2_interaction___Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"APP clearance through CLU:TREM2 interaction. (Human)\" (gomodel:6606056e00001371) is a scientifically accurate representation of the CLU-TREM2-TYROBP-SYK signaling pathway involved in amyloid-beta clearance. The model follows GO-CAM best practices in terms of structure, annotations, and evidence.</p> <p>The model correctly depicts how secreted clusterin (CLU) interacts with the microglial receptor TREM2, leading to TYROBP/DAP12 activation and subsequent SYK kinase signaling, ultimately facilitating amyloid-beta clearance. This pathway is particularly relevant for understanding microglia function in Alzheimer's disease and other neurodegenerative conditions.</p> <p>While the current model is valid and informative, it could be enhanced by including downstream effects of SYK activation, integrating alternative TREM2 ligands, and expanding on the specific mechanisms of amyloid-beta clearance resulting from this signaling pathway.</p>"},{"location":"reviews/6606056e00001462-TREM2_activated_by_APOA1___Human_/","title":"6606056e00001462 TREM2 activated by APOA1   Human","text":"<p>Based on my review of the GO-CAM model and relevant resources, I'll now provide a comprehensive assessment of the model \"TREM2 activated by APOA1. (Human)\" (gomodel:6606056e00001462).</p>"},{"location":"reviews/6606056e00001462-TREM2_activated_by_APOA1___Human_/#review-of-go-cam-model-6606056e00001462","title":"Review of GO-CAM Model 6606056e00001462","text":""},{"location":"reviews/6606056e00001462-TREM2_activated_by_APOA1___Human_/#model-overview","title":"Model Overview","text":"<p>The model gomodel:6606056e00001462 entitled \"TREM2 activated by APOA1. (Human)\" represents a signaling pathway in which APOA1 (Apolipoprotein A-I) activates TREM2 (Triggering receptor expressed on myeloid cells 2), which then triggers a signaling cascade involving TYROBP/DAP12 (TYRO protein tyrosine kinase-binding protein) and leading to SYK (Spleen tyrosine kinase) activation.</p>"},{"location":"reviews/6606056e00001462-TREM2_activated_by_APOA1___Human_/#model-structure-and-biological-content","title":"Model Structure and Biological Content","text":"<p>The model contains four connected molecular activities that form a clear signaling pathway:</p> <ol> <li> <p>APOA1 (UniProtKB:P02647) performs receptor ligand activity (GO:0048018) in the extracellular space (GO:0005615), which is part of the cellular response to lipoprotein particle stimulus (GO:0071402)</p> </li> <li> <p>TREM2 (UniProtKB:Q9NZC2) performs transmembrane signaling receptor activity (GO:0004888) at the plasma membrane (GO:0005886), also part of the cellular response to lipoprotein particle stimulus (GO:0071402)</p> </li> <li> <p>TYROBP/DAP12 (UniProtKB:O43914) performs protein-macromolecule adaptor activity (GO:0030674) at the plasma membrane (GO:0005886), as part of the cellular response to amyloid-beta (GO:1904646)</p> </li> <li> <p>SYK (UniProtKB:P43405) performs protein tyrosine kinase activity (GO:0004713) in the cytoplasm (GO:0005737), also as part of the cellular response to amyloid-beta (GO:1904646)</p> </li> </ol> <p>The causal connections in the model use appropriate relationship predicates: - APOA1 directly positively regulates (RO:0002629) TREM2 - TREM2 directly positively regulates (RO:0002629) TYROBP - TYROBP directly positively regulates (RO:0002629) SYK</p>"},{"location":"reviews/6606056e00001462-TREM2_activated_by_APOA1___Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>The model correctly represents the TREM2-TYROBP-SYK signaling axis, which is well-established in the literature. TREM2 is known to signal via its adaptor protein TYROBP/DAP12 which then activates SYK kinase.</p> </li> <li> <p>Appropriate GO terms are used for molecular functions, cellular locations, and biological processes.</p> </li> <li> <p>The model includes proper evidence codes and literature references for each assertion. Most activities and relationships are supported by direct assay evidence (ECO:0000314).</p> </li> <li> <p>The addition of APOA1 as an activator of TREM2 is supported by the cited literature (PMID:27477018), which describes TREM2 binding to apolipoproteins including APOA1.</p> </li> <li> <p>The model correctly indicates the cellular locations of each protein (extracellular space for APOA1, plasma membrane for TREM2 and TYROBP, and cytoplasm for SYK).</p> </li> </ol>"},{"location":"reviews/6606056e00001462-TREM2_activated_by_APOA1___Human_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Biological Process Consistency: While APOA1 and TREM2 are annotated to \"cellular response to lipoprotein particle stimulus\" (GO:0071402), TYROBP and SYK are annotated to \"cellular response to amyloid-beta\" (GO:1904646). This creates an inconsistency in the biological process representation. Since this appears to be modeling APOA1-induced TREM2 signaling (not amyloid-beta), I would recommend consistently using GO:0071402 across all molecules in the pathway.</p> </li> <li> <p>Missing Mechanistic Details: The model doesn't capture the phosphorylation events that are critical for this signaling cascade. According to UniProt data, TYROBP contains ITAM domains that get phosphorylated and then recruit SYK via its SH2 domains. These mechanistic details would enhance the model.</p> </li> <li> <p>Evidence Codes: For SYK, the evidence code is \"sequence similarity evidence used in manual assertion\" (ECO:0000250) with \"UniProtKB:P48025\" in the with_objects field, indicating that this is inferred from sequence similarity to mouse. Given the importance of SYK in human myeloid cells, stronger experimental evidence specific to human SYK would strengthen the model.</p> </li> <li> <p>Missing Context: The biological context in which this pathway operates (e.g., microglia, monocytes, macrophages) is not explicitly captured in the model. TREM2 is particularly important in microglia in the brain, but this contextual information is missing.</p> </li> <li> <p>Relationship to Alzheimer's Disease: Given that TREM2 variants are risk factors for Alzheimer's disease and APOA1 is involved in lipid metabolism, the model could potentially benefit from linking to Alzheimer's disease-related processes.</p> </li> </ol>"},{"location":"reviews/6606056e00001462-TREM2_activated_by_APOA1___Human_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Consistent Biological Process: Annotate all activities to the same biological process, either \"cellular response to lipoprotein particle stimulus\" or use a more specific term that appropriately captures the pathway.</p> </li> <li> <p>Add Phosphorylation Details: Include the phosphorylation of TYROBP's ITAM domain as a key regulatory step in the activation of SYK.</p> </li> <li> <p>Stronger Evidence for SYK: Replace the sequence similarity evidence for SYK with direct experimental evidence from human cells if available.</p> </li> <li> <p>Add Cell Type Context: Include annotation to indicate the cell type(s) in which this pathway operates, particularly microglia if that's the intended context.</p> </li> <li> <p>Consider Expanding the Model: The model could be expanded to include downstream targets of SYK, such as PLC\u03b32, PI3K, or other signaling molecules that TREM2 activation ultimately influences.</p> </li> <li> <p>Link to Disease Relevance: Consider adding annotations or notes about the relevance of this pathway to Alzheimer's disease, given the genetic association of TREM2 variants with AD risk.</p> </li> </ol>"},{"location":"reviews/6606056e00001462-TREM2_activated_by_APOA1___Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 6606056e00001462 is a well-constructed representation of APOA1-activated TREM2 signaling through TYROBP and SYK. The model adheres to most GO-CAM best practices and is supported by appropriate literature evidence. With a few refinements to improve consistency in biological process annotation and add mechanistic details, the model would provide an even more accurate and informative representation of this signaling pathway.</p>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/","title":"6606056e00001507 TREM2 activated by APOA2   Human","text":"<p>Now let me review the GO-CAM model gomodel:6606056e00001507 based on the information I've gathered.</p>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#review-of-go-cam-model-gomodel6606056e00001507","title":"Review of GO-CAM Model: gomodel:6606056e00001507","text":""},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model is titled \"TREM2 activated by APOA2. (Human)\" and describes an important signaling pathway in human microglia that is relevant to Alzheimer's disease pathogenesis. It represents how Apolipoprotein A-II (APOA2) activates the Triggering Receptor Expressed on Myeloid cells 2 (TREM2), which leads to downstream signaling through the TYROBP/DAP12 adaptor protein and SYK kinase activity.</p>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#model-components","title":"Model Components","text":"<p>The model contains four key activities:</p> <ol> <li>APOA2 (P02652) - Receptor ligand activity (GO:0048018) occurring in extracellular space</li> <li>TREM2 (Q9NZC2) - Transmembrane signaling receptor activity (GO:0004888) occurring in plasma membrane</li> <li>TYROBP/DAP12 (O43914) - Protein-macromolecule adaptor activity (GO:0030674) occurring in plasma membrane</li> <li>SYK (P43405) - Protein tyrosine kinase activity (GO:0004713) occurring in cytoplasm</li> </ol>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes causal relationships that describe the following pathway: - APOA2 ligand (GO:0048018) \u2192 directly positively regulates (RO:0002629) \u2192 TREM2 receptor (GO:0004888) - TREM2 receptor (GO:0004888) \u2192 directly positively regulates (RO:0002629) \u2192 TYROBP adaptor (GO:0030674) - TYROBP adaptor (GO:0030674) \u2192 directly positively regulates (RO:0002629) \u2192 SYK kinase (GO:0004713)</p>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#biological-context","title":"Biological Context","text":"<p>The activities are placed in the context of two biological processes: - Cellular response to lipoprotein particle stimulus (GO:0071402) - Cellular response to amyloid-beta (GO:1904646)</p>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#evidence-and-provenance","title":"Evidence and Provenance","text":"<p>The model uses high-quality evidence from experimental studies: - Direct assay evidence (ECO:0000314) from published literature (PMID:27477018, PMID:23459077, PMID:29518356) - Sequence similarity evidence (ECO:0000250) for some aspects (particularly SYK activity) - Annotations are from the contributor with ORCID 0000-0001-8769-177X, dated April 4, 2024</p>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#assessment","title":"Assessment","text":""},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#accuracy-and-biological-content","title":"Accuracy and Biological Content","text":"<p>The model accurately represents a signaling pathway that has been well-documented in the literature. Based on the PMID:29518356 (\"TREM2 is a receptor for beta-amyloid which mediates microglial function\"), TREM2 has been shown to bind to APOA2 and other apolipoproteins to facilitate uptake of amyloid-beta by microglia. This paper specifically demonstrates:</p> <ol> <li>TREM2 binds to apolipoproteins including APOA2</li> <li>This binding enhances TREM2 interaction with DAP12 (TYROBP)</li> <li>This leads to downstream phosphorylation of SYK</li> </ol> <p>The model correctly represents these relationships with appropriate GO terms and causal relationships.</p>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing complexes and signaling pathways:</p> <ol> <li> <p>Representation of activities: Each protein is appropriately annotated with a specific molecular function that it performs.</p> </li> <li> <p>Causal relationships: The model uses correct causal relationship predicates (RO:0002629 \"directly positively regulates\") to connect the activities in a directional manner.</p> </li> <li> <p>Cellular contexts: Each activity is appropriately annotated with a cellular component to indicate where it occurs.</p> </li> <li> <p>Biological processes: The activities are connected to relevant biological processes.</p> </li> <li> <p>Evidence: Each assertion is supported by appropriate evidence codes and references.</p> </li> <li> <p>Complex representation: The model correctly follows the recommendations for annotating activities in the context of complexes. Since the specific molecular functions carried out by each component (TREM2, TYROBP, SYK) are known, they are individually represented rather than using a complex GO term, which aligns with guideline #1 from the \"How to annotate complexes in GO-CAM\" document.</p> </li> </ol>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I would suggest a few potential enhancements:</p> <ol> <li> <p>Additional molecular context: The model could potentially be expanded to include the known binding of amyloid-beta to TREM2, which is a key aspect described in PMID:29518356. This would provide more complete molecular context for the pathway.</p> </li> <li> <p>Downstream effects: The model could be extended to include downstream effects of SYK activation, such as phosphorylation of specific targets or activation of specific pathways that lead to microglial activation, which are mentioned in the literature.</p> </li> <li> <p>Additional processes: The model could be connected to additional relevant biological processes such as phagocytosis or inflammatory response, which are known outcomes of this signaling pathway.</p> </li> </ol>"},{"location":"reviews/6606056e00001507-TREM2_activated_by_APOA2___Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6606056e00001507 accurately represents the signaling pathway where APOA2 activates TREM2, leading to signaling through TYROBP and SYK in human cells. It adheres to GO-CAM best practices and is supported by high-quality experimental evidence. This pathway is of significant biomedical relevance as it plays a role in microglial responses to amyloid-beta in Alzheimer's disease. The model could be further enhanced by including additional molecular context and downstream effects as described in the literature.</p>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/","title":"6606056e00001745 UBR4 and KCMF1 ubiquitinate arginylated proteins in response to oxidative stress  leading to degradation of ubiquitinated proteins in autophagosomes   Human","text":"<p>Based on my analysis of the provided GO-CAM model and related information, I will now provide a comprehensive review:</p>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#review-of-go-cam-model-gomodel6606056e00001745","title":"Review of GO-CAM Model: gomodel:6606056e00001745","text":""},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (accessible at https://bioregistry.io/go.model:6606056e00001745) describes a pathway in human cells where UBR4 and KCMF1 ubiquitinate arginylated proteins in response to oxidative stress, leading to degradation of these ubiquitinated proteins in autophagosomes.</p>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#model-components","title":"Model Components","text":"<p>The model consists of four key molecular activities connected in a causal pathway:</p> <ol> <li>ATE1 (O95260) - Arginyl-tRNA-protein transferase activity (GO:0004057)</li> <li>Occurs in the cytoplasm (GO:0005737)</li> <li> <p>Part of ubiquitin-dependent protein catabolic process (GO:0006511)</p> </li> <li> <p>KCMF1 (Q9P0J7) - E3 ubiquitin protein ligase activity (GO:0061630)</p> </li> <li>Occurs in the cytoplasm (GO:0005737)</li> <li> <p>Part of protein K63-linked ubiquitination (GO:0070534)</p> </li> <li> <p>UBR4 (Q5T4S7) - E3 ubiquitin protein ligase activity (GO:0061630)</p> </li> <li>Occurs in the cytoplasm (GO:0005737)</li> <li> <p>Part of protein K27-linked ubiquitination (GO:0044314)</p> </li> <li> <p>SQSTM1/p62 (Q13501) - Protein-macromolecule adaptor activity (GO:0030674)</p> </li> <li>Occurs in autophagosome (GO:0005776)</li> <li>Part of protein targeting to vacuole involved in autophagy (GO:0071211)</li> </ol>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#causal-flow","title":"Causal Flow","text":"<p>The model describes the following causal flow:</p> <ol> <li>ATE1 provides input for (RO:0002413) KCMF1</li> <li>KCMF1 provides input for (RO:0002413) UBR4</li> <li>UBR4 provides input for (RO:0002413) SQSTM1</li> </ol>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#biological-validation","title":"Biological Validation","text":"<p>The model is consistent with the recent literature, especially PMID:34893540 (Heo et al., 2021) which describes the N-terminal cysteine as a dual sensor of oxygen and oxidative stress. This paper indicates that ATE1 arginylates proteins with oxidized N-terminal cysteines, creating a target for ubiquitination by E3 ligases.</p> <p>The paper specifically describes UBR4 and KCMF1 working together to assemble heterotypic 'Lys-63'-/'Lys-27'-linked branched ubiquitin chains on oxidized proteins, leading to their degradation by autophagy, which is consistent with the GO-CAM model.</p> <p>SQSTM1 (p62) is accurately represented as the adaptor protein that targets ubiquitinated proteins to autophagosomes, as confirmed by PMID:22948227.</p>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#technical-correctness","title":"Technical Correctness","text":"<p>The model properly follows GO-CAM best practices:</p> <ol> <li>The activities are properly connected using the correct causal relation (RO:0002413 - provides input for)</li> <li>Each protein's activity is correctly annotated with the appropriate molecular function</li> <li>The cellular locations of each activity are properly specified</li> <li>The broader biological processes are correctly associated with each activity</li> </ol>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#quality-control-check","title":"Quality Control Check","text":""},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#completeness-check","title":"Completeness Check","text":"<ul> <li>\u2705 All key proteins in the pathway are represented</li> <li>\u2705 All molecular functions are properly annotated</li> <li>\u2705 All cellular locations are properly specified</li> <li>\u2705 All causal relationships are properly modeled</li> </ul>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#consistency-check","title":"Consistency Check","text":"<ul> <li>\u2705 The cellular compartments for each activity are biologically plausible</li> <li>\u2705 The causal flow follows a logical sequence</li> <li>\u2705 The molecular functions are consistent with what is known about these proteins</li> <li>\u2705 The evidence provided (PMID citations) supports the modeled relationships</li> </ul>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#uniprot-verification","title":"UniProt Verification","text":"<ul> <li>\u2705 ATE1 (O95260): Correctly annotated with arginyl-tRNA-protein transferase activity</li> <li>\u2705 KCMF1 (Q9P0J7): Correctly annotated as E3 ubiquitin protein ligase</li> <li>\u2705 UBR4 (Q5T4S7): Correctly annotated as E3 ubiquitin protein ligase</li> <li>\u2705 SQSTM1 (Q13501): Correctly annotated as a protein-macromolecule adaptor</li> </ul>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is fundamentally sound, there are a few potential enhancements:</p> <ol> <li> <p>More Specific Causal Relationships: The model uses \"provides input for\" (RO:0002413) for all relationships. In some cases, more specific causal relations could be used, particularly between the E3 ligases (KCMF1 and UBR4) where \"directly positively regulates\" (RO:0002629) might be more precise.</p> </li> <li> <p>Elaboration of Oxidative Stress Trigger: The model could benefit from including the oxidative stress trigger that initiates this pathway, perhaps representing it as an environmental condition or including the oxidation of N-terminal cysteines as an explicit part of the model.</p> </li> <li> <p>Inclusion of Autophagosome-Lysosome Fusion: The model currently ends at targeting to autophagosomes. It might be valuable to extend it to include the fusion of autophagosomes with lysosomes and subsequent degradation of the ubiquitinated proteins.</p> </li> </ol>"},{"location":"reviews/6606056e00001745-UBR4_and_KCMF1_ubiquitinate_arginylated_proteins_in_response_to_oxidative_stress__leading_to_degradation_of_ubiquitinated_proteins_in_autophagosomes___Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:6606056e00001745) is a high-quality representation of the biological process where UBR4 and KCMF1 ubiquitinate arginylated proteins in response to oxidative stress, leading to their degradation in autophagosomes. The model is consistent with the current literature, particularly the recent publication by Heo et al. (2021), and follows GO-CAM best practices.</p> <p>The model provides a clear representation of this important cellular quality control pathway that helps cells respond to oxidative stress by removing damaged proteins through selective autophagy.</p>"},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/","title":"6606056e00001890 Activation of mitophagy  in response to mitochondrial damage via activation of EIF2AK1 HRI by DELE1  Human","text":"<p>Now that I have all the necessary information, let me review the GO-CAM model.</p>"},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#go-cam-model-review-gomodel6606056e00001890","title":"GO-CAM Model Review: gomodel:6606056e00001890","text":""},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (ID: gomodel:6606056e00001890) is titled \"Activation of mitophagy in response to mitochondrial damage via activation of EIF2AK1/HRI by DELE1 (Human).\" It models a recently identified stress response pathway in humans (NCBITaxon:9606) where mitochondrial damage leads to mitophagy through a specific signaling cascade.</p>"},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#major-components-of-the-model","title":"Major Components of the Model","text":"<p>The model includes four key proteins in this pathway:</p> <ol> <li>OMA1 (Q96E52): A mitochondrial metalloendopeptidase</li> <li>DELE1 (Q14154): DAP3-binding cell death enhancer 1</li> <li>EIF2AK1/HRI (Q9BQI3): Eukaryotic translation initiation factor 2-alpha kinase 1</li> <li>EIF2S1 (P05198): Eukaryotic translation initiation factor 2 subunit 1</li> </ol>"},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#pathway-representation","title":"Pathway Representation","text":"<p>The model represents the following biological pathway:</p> <ol> <li>OMA1 in the mitochondrial intermembrane space has metalloendopeptidase activity in response to cellular stress</li> <li>OMA1 cleaves DELE1, which then accumulates in the cytosol</li> <li>The cleaved DELE1 activates EIF2AK1/HRI (protein serine/threonine kinase activator activity)</li> <li>EIF2AK1/HRI phosphorylates EIF2S1, promoting its localization to mitochondria</li> <li>This ultimately leads to mitophagy</li> </ol>"},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of this recently discovered pathway. The pathway was first characterized in 2020 papers (PMID:32132706 and PMID:32132707) and further studied in a 2024 paper (PMID:38340717) that specifically linked it to mitophagy.</p> <p>The causal relationships, molecular functions, cellular components, and biological processes are all properly annotated and consistent with literature evidence.</p>"},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li> <p>Correctly annotating molecular functions: Each protein is assigned appropriate molecular functions (OMA1 - metalloendopeptidase activity, DELE1 - protein serine/threonine kinase activator activity, EIF2AK1 - eukaryotic translation initiation factor 2alpha kinase activity)</p> </li> <li> <p>Correctly specifying cellular components: Each activity is associated with its correct cellular location (OMA1 - mitochondrial intermembrane space, DELE1 - cytosol, HRI - cytosol)</p> </li> <li> <p>Using appropriate causal relationships: </p> </li> <li>OMA1 directly positively regulates DELE1 (RO:0002629)</li> <li>DELE1 directly positively regulates EIF2AK1/HRI (RO:0002629)</li> <li> <p>EIF2AK1/HRI directly negatively regulates EIF2S1 (RO:0002630)</p> </li> <li> <p>Linking to appropriate biological processes: Each activity is correctly associated with relevant biological processes</p> </li> <li>OMA1 is part of \"cellular response to stress\" (GO:0033554)</li> <li>DELE1 and EIF2AK1 are part of \"HRI-mediated signaling\" (GO:0140468)</li> <li> <p>EIF2S1 is part of \"mitophagy\" (GO:0000423)</p> </li> <li> <p>Evidence codes and citations: All assertions are backed by appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and linked to specific literature references (PMID:32132706, PMID:32132707, PMID:38340717).</p> </li> </ol>"},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>The model is well-constructed and represents the pathway accurately. A few minor points to consider:</p> <ol> <li> <p>Molecular function of EIF2S1: Currently has \"molecular_function\" (GO:0003674), which is a placeholder term. Based on the UniProt entry, it could be more specific, possibly annotating it with \"translation initiation factor activity\" (GO:0003743).</p> </li> <li> <p>Representation of OMA1 activation: The model doesn't explicitly represent what activates OMA1 (mitochondrial stress or damage). Adding this upstream cause would more completely represent the pathway.</p> </li> <li> <p>Potential for adding more detailed pathway outcomes: The model connects to mitophagy but could potentially elaborate more on the downstream effects of this pathway.</p> </li> </ol>"},{"location":"reviews/6606056e00001890-Activation_of_mitophagy__in_response_to_mitochondrial_damage_via_activation_of_EIF2AK1_HRI_by_DELE1__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6606056e00001890 is a high-quality representation of the recently discovered mitochondrial stress response pathway leading to mitophagy through OMA1, DELE1, EIF2AK1/HRI, and EIF2S1. It follows GO-CAM best practices for annotation and is supported by appropriate evidence.</p> <p>The model accurately captures the current understanding of this pathway, with solid evidence from recent literature. The only minor improvements would be to use a more specific molecular function for EIF2S1 and potentially add more context around OMA1 activation and downstream effects of the pathway.</p> <p>Overall, this is a well-constructed model that provides valuable information about a relatively new and important cellular pathway involved in mitochondrial quality control.</p>"},{"location":"reviews/6606056e00002011-CD72_and_BCR_co_stimulation_by_sn_RNP_self_antigen__Human_/","title":"6606056e00002011 CD72 and BCR co stimulation by sn RNP self antigen  Human","text":"<p>Based on my review of the GO-CAM model gomodel:6606056e00002011 titled \"CD72 and BCR co-stimulation by sn/RNP self antigen (Human)\" and the relevant documentation and literature, I will now provide a comprehensive assessment of this model.</p>"},{"location":"reviews/6606056e00002011-CD72_and_BCR_co_stimulation_by_sn_RNP_self_antigen__Human_/#go-cam-review-gomodel6606056e00002011","title":"GO-CAM Review: gomodel:6606056e00002011","text":""},{"location":"reviews/6606056e00002011-CD72_and_BCR_co_stimulation_by_sn_RNP_self_antigen__Human_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:6606056e00002011) represents the interactions between CD72 and the B cell receptor (BCR) complex during co-stimulation with the sn/RNP self antigen in human cells. The model includes four key activities:</p> <ol> <li>B cell receptor (BCR) complex (CD79A/CD79B) transmembrane signaling receptor activity</li> <li>LYN protein tyrosine kinase activity </li> <li>CD72 transmembrane signaling receptor activity</li> <li>PTPN6/SHP-1 protein tyrosine phosphatase activity</li> </ol>"},{"location":"reviews/6606056e00002011-CD72_and_BCR_co_stimulation_by_sn_RNP_self_antigen__Human_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Appropriate representation of the BCR complex: The model correctly represents the BCR complex as a protein complex consisting of CD79A and CD79B. According to the \"How to annotate complexes in GO-CAM\" guide, when multiple proteins form a complex with shared activity, using a complex representation is appropriate.</p> </li> <li> <p>Correct signaling pathway relationships: The model properly uses causal relationships (RO:0002629 \"directly positively regulates\") to connect the activities in the signaling pathway, following the chain from BCR to LYN to CD72 to PTPN6.</p> </li> <li> <p>Correct cellular localization: All activities are properly annotated with their cellular locations - the receptor activities occurring at the plasma membrane (GO:0005886) and PTPN6 in the cytoplasm (GO:0005737).</p> </li> <li> <p>Appropriate biological processes: Each activity is correctly associated with relevant biological processes - BCR complex with BCR signaling pathway (GO:0050853), LYN with B cell homeostasis (GO:0001782), CD72 with negative regulation of BCR signaling (GO:0050859), and PTPN6 also with negative regulation of BCR signaling.</p> </li> <li> <p>Evidence support: The model includes appropriate evidence codes and references for the assertions, primarily using experimental evidence from relevant publications.</p> </li> </ol>"},{"location":"reviews/6606056e00002011-CD72_and_BCR_co_stimulation_by_sn_RNP_self_antigen__Human_/#areas-for-improvementconsiderations","title":"Areas for Improvement/Considerations","text":"<ol> <li> <p>Self-antigen representation: The model does not explicitly show how the sn/RNP self-antigen initiates the signaling pathway. According to the \"Signaling receptor activity annotation guidelines\", there are specific ways to represent how ligands interact with receptors. Although sn/RNP is not a protein ligand (it's a nucleoprotein complex), it would be helpful to include it in the model to show the complete picture of how CD72 and BCR are co-stimulated.</p> </li> <li> <p>Pathway completeness: The molecular functions between LYN kinase activity and CD72 receptor activity could be more explicitly detailed. The model shows LYN directly regulating CD72, but it would be valuable to include any intermediate steps if they are known.</p> </li> <li> <p>Evidence consistency: While the model does include evidence codes and references, some activities use sequence similarity evidence (ECO:0000250) with references to mouse (MGI) rather than direct experimental evidence in humans. Where possible, human-specific experimental evidence would strengthen the model.</p> </li> <li> <p>Additional downstream effects: If known, it would be beneficial to include additional downstream effects of PTPN6/SHP-1 phosphatase activity, particularly how it ultimately impacts B cell function or fate.</p> </li> </ol>"},{"location":"reviews/6606056e00002011-CD72_and_BCR_co_stimulation_by_sn_RNP_self_antigen__Human_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>Based on my review of the literature provided and the model content:</p> <ol> <li> <p>BCR Complex: The model correctly represents the BCR complex as consisting of membrane immunoglobulin associated with CD79A/CD79B heterodimers, which is consistent with current understanding of BCR structure.</p> </li> <li> <p>CD72 function: The model accurately depicts CD72 as a negative regulator of BCR signaling, which aligns with the literature showing that CD72 negatively regulates B cell responses to sn/RNP via recruitment of SHP-1/PTPN6.</p> </li> <li> <p>LYN kinase role: The model appropriately places LYN kinase as an early component of BCR signaling, which is supported by the literature describing LYN as one of the first kinases activated following BCR engagement.</p> </li> <li> <p>Negative regulation pathway: The pathway from CD72 to PTPN6/SHP-1 is accurate, as the literature confirms that CD72 recruits the phosphatase SHP-1 to negatively regulate BCR signaling.</p> </li> <li> <p>Spatial organization: The cellular locations of the activities are scientifically accurate, with receptors at the plasma membrane and downstream signaling components in the cytoplasm.</p> </li> </ol>"},{"location":"reviews/6606056e00002011-CD72_and_BCR_co_stimulation_by_sn_RNP_self_antigen__Human_/#comparison-to-go-cam-best-practices","title":"Comparison to GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Complex representation: The model correctly uses a protein complex association to represent the BCR complex, following the guidelines in the \"How to annotate complexes in GO-CAM\" document.</p> </li> <li> <p>Signaling relationships: The causal relationships between activities follow the guidelines for representing signaling pathways, using \"directly positively regulates\" (RO:0002629) appropriately.</p> </li> <li> <p>Contextual annotations: Each activity has appropriate contextual annotations (cellular component and biological process), following GO-CAM standards.</p> </li> <li> <p>Evidence codes: The model uses appropriate evidence codes, although more direct experimental evidence rather than sequence similarity would be preferred where available.</p> </li> </ol>"},{"location":"reviews/6606056e00002011-CD72_and_BCR_co_stimulation_by_sn_RNP_self_antigen__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:6606056e00002011) provides a scientifically accurate representation of CD72 and BCR co-stimulation by sn/RNP self-antigen in humans. The model follows GO-CAM best practices for representing complexes and signaling pathways, with appropriate contextual annotations and evidence.</p> <p>The model could be enhanced by explicitly representing the sn/RNP self-antigen and its interaction with both CD72 and the BCR, as well as by including additional downstream effects of PTPN6/SHP-1 activity if known. Additionally, using human-specific experimental evidence rather than evidence inferred from mouse would strengthen the model where possible.</p> <p>In summary, this is a well-constructed GO-CAM model that accurately represents key aspects of the CD72 and BCR co-stimulation pathway and its negative regulation in human B cells.</p>"},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/","title":"6606056e00002524 HIV 1 Vif protein hijacks a cullin 5 RING E3 ubiquitin protein ligase to mediate ubiquitination and degradation of APOBEC3G  Human","text":"<p>Based on my review of the GO-CAM model and relevant documentation, here is my assessment:</p>"},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/#go-cam-model-review-gomodel6606056e00002524","title":"GO-CAM Model Review: gomodel:6606056e00002524","text":""},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/#model-overview","title":"Model Overview","text":"<p>Title: HIV-1 Vif protein hijacks a cullin-5-RING E3 ubiquitin-protein ligase to mediate ubiquitination and degradation of APOBEC3G (Human).</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/#model-description","title":"Model Description","text":"<p>This GO-CAM model represents the mechanism by which HIV-1 Vif protein counteracts the host antiviral defense protein APOBEC3G by hijacking a host cullin-5-RING E3 ubiquitin-protein ligase complex. The pathway involves neddylation, ubiquitination, and ultimately leads to the degradation of APOBEC3G, which prevents its antiviral cytidine deaminase activity.</p>"},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of how HIV-1 Vif counteracts host APOBEC3G:</p> <ol> <li> <p>HIV-1 Vif (P69723) acts as a ubiquitin ligase-substrate adaptor, correctly annotated with GO:1990756.</p> </li> <li> <p>APOBEC3G (Q9HC16) is shown with its cytidine deaminase activity (GO:0004126), which is critical for its antiviral function.</p> </li> <li> <p>The model includes the key components of the E3 ubiquitin ligase complex:</p> </li> <li>CUL5 (Q93034) with ubiquitin ligase complex scaffold activity (GO:0160072)</li> <li>RNF7/RBX2 (Q9UBF6) with ubiquitin protein ligase activity (GO:0061630)</li> <li>UBE2F (Q969M7) with NEDD8 conjugating enzyme activity (GO:0061654)</li> <li> <p>ARIH2 (O95376) with ubiquitin protein ligase activity (GO:0061630)</p> </li> <li> <p>The causal relationships between activities follow the expected pathway for ubiquitin-mediated protein degradation:</p> </li> <li>UBE2F neddylation \u2192 RNF7 NEDD8 ligase activity \u2192 ARIH2 ubiquitin ligase activity</li> <li>HIV-1 Vif adaptor activity \u2192 RNF7 ubiquitin ligase activity \u2192 Negative regulation of APOBEC3G</li> </ol>"},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/#strengths","title":"Strengths","text":"<ol> <li> <p>The model accurately represents the mechanism described in the literature, particularly from the key reference (PMID:22190037).</p> </li> <li> <p>The appropriate \"part_of\" biological process annotations are used, including:</p> </li> <li>Protein neddylation (GO:0045116)</li> <li>Proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li> <p>Innate immune response (GO:0045087)</p> </li> <li> <p>The causal relationships use appropriate predicates, following the pattern described in the E3 ubiquitin ligases documentation:</p> </li> <li>RO:0002413 (provides input for)</li> <li>RO:0002629 (directly positively regulates)</li> <li>RO:0002630 (directly negatively regulates)</li> </ol>"},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/#minor-issues-and-suggestions","title":"Minor Issues and Suggestions","text":"<ol> <li> <p>Cellular location: The model includes \"host cell cytoplasm\" (GO:0030430) for HIV-1 Vif, which is correct. However, for completeness, the location of APOBEC3G could be added, as it's known to localize primarily in the cytoplasm.</p> </li> <li> <p>Additional biological process: APOBEC3G could also be annotated as part of \"defense response to virus\" (GO:0051607) in addition to \"innate immune response\" (GO:0045087), to better highlight its specific role in viral defense.</p> </li> <li> <p>Model completeness: While the main pathway is well-represented, including the CBF-beta (CBFB) component, which is hijacked by Vif and is critical for the formation of the functional E3 ligase complex as described in PMID:22190037, would enhance the model's completeness.</p> </li> </ol>"},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows the GO-CAM best practices for representing E3 ubiquitin ligase complexes:</p> <ol> <li> <p>Complex representation: The model correctly represents individual components of the E3 ligase complex with their specific activities rather than using a general complex term.</p> </li> <li> <p>E3 ligase annotation: The components follow the pattern described in the E3 ubiquitin ligases documentation, with the scaffold (CUL5), the adaptor (HIV-1 Vif), and the ligase components (RNF7, ARIH2) properly connected.</p> </li> <li> <p>Causal relationships: The model uses the recommended predicates for causal relationships between activities.</p> </li> </ol>"},{"location":"reviews/6606056e00002524-HIV_1_Vif_protein_hijacks_a_cullin_5_RING_E3_ubiquitin_protein_ligase_to_mediate_ubiquitination_and_degradation_of_APOBEC3G__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the biological process by which HIV-1 Vif counteracts host APOBEC3G. The model follows GO-CAM best practices and correctly represents the E3 ubiquitin ligase complex components and their relationships.</p> <p>The minor suggestions provided would enhance the model's completeness but do not diminish its current scientific accuracy or utility.</p>"},{"location":"reviews/66187e4700000246-The_CRL5_ASB9__complex_mediates_ubiquitination_and_degradation_of_CKB__Human__/","title":"66187e4700000246 The CRL5 ASB9  complex mediates ubiquitination and degradation of CKB  Human","text":"<p>Based on my review of this GO-CAM model and all the information I've gathered, I'll now provide my comprehensive review of gomodel:66187e4700000246.</p>"},{"location":"reviews/66187e4700000246-The_CRL5_ASB9__complex_mediates_ubiquitination_and_degradation_of_CKB__Human__/#review-of-go-cam-model-gomodel66187e4700000246","title":"Review of GO-CAM Model: gomodel:66187e4700000246","text":""},{"location":"reviews/66187e4700000246-The_CRL5_ASB9__complex_mediates_ubiquitination_and_degradation_of_CKB__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model (gomodel:66187e4700000246) describes \"The CRL5(ASB9) complex mediates ubiquitination and degradation of CKB (Human).\" It represents a specific biochemical pathway where the CRL5(ASB9) E3 ubiquitin-ligase complex targets creatine kinase B-type (CKB) for ubiquitination and subsequent proteasomal degradation in humans.</p> <p>The model shows several key activities connected through causal relationships: 1. CKB (UniProtKB:P12277) performing creatine kinase activity (GO:0004111) as part of phosphocreatine biosynthetic process (GO:0046314) 2. CUL5 (UniProtKB:Q93034) performing ubiquitin ligase complex scaffold activity (GO:0160072) as part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161) 3. ASB9 (UniProtKB:Q96DX5) performing ubiquitin-like ligase-substrate adaptor activity (GO:1990756) as part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161) 4. RNF7 (UniProtKB:Q9UBF6) performing ubiquitin protein ligase activity (GO:0061630) as part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161) 5. RNF7 also performing NEDD8 ligase activity (GO:0061663) as part of protein neddylation (GO:0045116) 6. ARIH2 (UniProtKB:O95376) performing ubiquitin protein ligase activity (GO:0061630) as part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</p> <p>The causal connections show: - CUL5 directly positively regulates (RO:0002629) ASB9's adaptor activity - ASB9 provides input for (RO:0002413) RNF7's ubiquitin ligase activity  - RNF7 directly positively regulates (RO:0002629) ARIH2's ubiquitin ligase activity - ARIH2 directly negatively regulates (RO:0002630) CKB's creatine kinase activity</p>"},{"location":"reviews/66187e4700000246-The_CRL5_ASB9__complex_mediates_ubiquitination_and_degradation_of_CKB__Human__/#evidence-and-literature-support","title":"Evidence and Literature Support","text":"<p>The model is well-supported by evidence from multiple publications: - The creatine kinase activity of CKB is supported by PMID:8186255, which established the catalytic site of creatine kinase through site-directed mutagenesis. - The ubiquitination mechanisms and complex interactions are supported by PMID:33268465, which provides detailed mechanistic insight into how NEDD8 activation of CUL5 ubiquitin E3 ligases works, particularly focusing on the ASB9-CRL E3 ligase complex and its targeting of CKB. - The NEDD8 ligase activity is supported by PMID:19250909.</p>"},{"location":"reviews/66187e4700000246-The_CRL5_ASB9__complex_mediates_ubiquitination_and_degradation_of_CKB__Human__/#biological-accuracy-and-consistency","title":"Biological Accuracy and Consistency","text":"<p>The model accurately represents the molecular mechanism discovered in the literature. It correctly shows:</p> <ol> <li>The CRL5(ASB9) complex consisting of:</li> <li>CUL5 as the scaffold</li> <li>ASB9 as the substrate recognition component</li> <li> <p>RNF7 (also known as RBX2 or SAG) as the RING component</p> </li> <li> <p>The regulatory mechanism where:</p> </li> <li>RNF7 performs protein neddylation, which is a prerequisite for the complex's activity</li> <li>ASB9 recognizes and binds to the substrate (CKB)</li> <li>ARIH2 works with the CRL5 complex to catalyze the ubiquitination of CKB</li> <li> <p>Ubiquitination of CKB leads to its degradation, effectively negatively regulating its activity</p> </li> <li> <p>The model correctly depicts that ARIH2 is essential for the complex to effectively ubiquitinate CKB, as shown in the literature. PMID:33268465 specifically demonstrates that ARIH2 is required for efficient ubiquitination of CKB by the ASB9-CRL complex.</p> </li> </ol>"},{"location":"reviews/66187e4700000246-The_CRL5_ASB9__complex_mediates_ubiquitination_and_degradation_of_CKB__Human__/#alignment-with-go-cam-best-practices","title":"Alignment with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing complexes, as outlined in the \"How to annotate complexes in GO-CAM\" document:</p> <ol> <li> <p>The activities are attributed to the specific proteins that carry them (option 1 in the guidelines), rather than to the complex as a whole, which is appropriate since the roles of the individual components are well-characterized.</p> </li> <li> <p>The scaffold activity of CUL5 is represented first, properly activating subsequent activities from other components of the complex.</p> </li> <li> <p>The causal connections follow the standard predicates correctly:</p> </li> <li>\"directly positively regulates\" (RO:0002629) is used properly to show activation relationships</li> <li>\"provides input for\" (RO:0002413) is used properly to show sequential process connections</li> <li>\"directly negatively regulates\" (RO:0002630) is used properly to show the inhibitory effect of ubiquitination on CKB</li> </ol>"},{"location":"reviews/66187e4700000246-The_CRL5_ASB9__complex_mediates_ubiquitination_and_degradation_of_CKB__Human__/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<ol> <li> <p>Additional Molecular Details: The model could potentially be expanded to include the specific E2 ubiquitin-conjugating enzymes that work with this E3 ligase complex. The literature mentions UBE2L3 and other E2s that can contribute to polyubiquitination.</p> </li> <li> <p>Ubiquitination Sites: The model could potentially annotate the specific lysine residues on CKB that are targeted for ubiquitination (K45, K101, K107, and K381) as identified in PMID:33268465.</p> </li> <li> <p>ELOB/ELOC Components: The literature describes elongin B and elongin C (ELOB/C) as components of the CRL5 complex, but these are not represented in the current model. Adding these components could provide a more complete picture of the complex.</p> </li> <li> <p>Neddylation Details: While the model includes the neddylation activity, it could potentially specify that CUL5 is neddylated at K724, which is important for the recruitment of ARIH2 (as described in PMID:33268465).</p> </li> </ol>"},{"location":"reviews/66187e4700000246-The_CRL5_ASB9__complex_mediates_ubiquitination_and_degradation_of_CKB__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the current understanding of how the CRL5(ASB9) E3 ubiquitin ligase complex targets CKB for degradation. The model effectively captures the key proteins, activities, and causal relationships involved in this process, with strong literature support for all assertions. It follows GO-CAM best practices for representing complexes and their activities.</p> <p>The model provides a valuable contribution to the GO-CAM knowledge base by representing a specific example of selective protein degradation through the ubiquitin-proteasome system, which is a fundamental cellular process with implications for numerous biological functions and disease mechanisms.</p>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/","title":"66187e4700000318 The CRL5 ASB11  complex mediates ubiquitination and degradation of BIK in response to endoplasmic reticulum stress  Human","text":"<p>Based on my review of the GO-CAM model gomodel:66187e4700000318 and the supporting literature, I'll now provide a comprehensive evaluation.</p>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#go-cam-model-review-gomodel66187e4700000318","title":"GO-CAM Model Review: gomodel:66187e4700000318","text":""},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#model-title","title":"Model Title","text":"<p>\"The CRL5(ASB11) complex mediates ubiquitination and degradation of BIK in response to endoplasmic reticulum stress (Human).\"</p>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model depicts the ubiquitination and degradation of BIK (Bcl-2-interacting killer) protein mediated by the CRL5(ASB11) E3 ubiquitin ligase complex in response to endoplasmic reticulum (ER) stress. The model shows the transcriptional induction of ASB11 by XBP1s during the adaptive phase of the unfolded protein response (UPR), and how this leads to BIK ubiquitination and subsequent degradation by the proteasome.</p>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#biological-context","title":"Biological Context","text":"<p>The model represents a mechanism for regulating cell survival during ER stress. BIK is a pro-apoptotic BH3-only protein that can trigger cell death. During the adaptive phase of the UPR, cells attempt to restore ER homeostasis rather than undergo apoptosis. The CRL5(ASB11) complex provides a mechanism to degrade BIK, thus promoting cell survival during this adaptive phase.</p>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#model-components","title":"Model Components","text":"<p>The model includes several key activities: 1. XBP1 (P17861) - DNA-binding transcription factor activity - occurring in the nucleus 2. ASB11 (Q8WXH4) - ubiquitin-like ligase-substrate adaptor activity - occurring in the ER 3. RNF7 (Q9UBF6) - ubiquitin protein ligase activity 4. CUL5 (Q93034) - ubiquitin ligase complex scaffold activity 5. VCP/p97 (P55072) - ubiquitin-modified protein reader activity 6. Proteasome core complex (GO:0005839) - endopeptidase activity - occurring in the cytoplasm</p>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#model-accuracy-review","title":"Model Accuracy Review","text":""},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#strengths","title":"Strengths:","text":"<ol> <li>Accurate molecular activities: The model correctly assigns molecular functions to each protein based on the literature:</li> <li>XBP1s as a transcription factor</li> <li>ASB11 as an adaptor protein for substrate recognition</li> <li>RNF7 as the ubiquitin ligase</li> <li>CUL5 as the scaffold protein</li> <li> <p>VCP/p97 as the recognition component for ubiquitinated proteins</p> </li> <li> <p>Well-supported by literature: The model is extensively supported by the primary literature, particularly the key paper by Chen et al. (2019), which demonstrates ASB11's role in BIK ubiquitination.</p> </li> <li> <p>Correctly represents ER stress response: The model accurately shows how ER stress leads to XBP1 activation, which then upregulates ASB11 expression.</p> </li> <li> <p>Proper causal relationships: The causal relationships between activities follow the correct biological sequence:</p> </li> <li>XBP1s activates ASB11 expression</li> <li>ASB11 directly positively regulates RNF7</li> <li>RNF7 provides input for VCP/p97</li> <li> <p>VCP/p97 provides input for proteasomal degradation</p> </li> <li> <p>Correct cellular locations: The subcellular locations (nucleus, ER, cytoplasm) are correctly assigned to each protein.</p> </li> </ol>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing complex representation: The model represents the CRL5(ASB11) complex as individual components rather than using a complex ID. According to the \"How to annotate complexes in GO-CAM\" document, if the specific activity of each subunit is known (which is the case here), this approach is acceptable. However, it might be clearer to also include the full complex representation.</p> </li> <li> <p>Incomplete BIK activity representation: BIK itself is not represented as a node in the model. While the focus is on its degradation, representing BIK's pro-apoptotic activity would provide more complete biological context about why its degradation is important for cell survival during ER stress.</p> </li> <li> <p>Missing regulation by DERL1: According to the literature (Chen et al. 2019), DERL1 plays a role in this pathway by interacting with BIK to facilitate its degradation. This interaction is not represented in the model.</p> </li> <li> <p>Incomplete representation of timing: The model doesn't fully capture the temporal aspect of the pathway - specifically that ASB11-mediated BIK degradation is transient and occurs primarily during the adaptive phase of UPR.</p> </li> <li> <p>Missing K48 polyubiquitination specificity: The model doesn't specify that the ubiquitination of BIK involves K48-linked polyubiquitin chains, which is important for proteasomal targeting.</p> </li> </ol>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The evidence used in the model is strong and well-documented: - All activities are supported by experimental evidence (ECO:0000314 - direct assay evidence used in manual assertion) - Primary literature references are provided, including PMID:31387940 (the key paper on this pathway), PMID:29033132, and others - Each annotation has appropriate provenance information</p>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add BIK as a node: Include BIK as a protein with its pro-apoptotic activity, and show how its degradation connects to cell survival outcomes.</p> </li> <li> <p>Expand on UPR context: Add more context about how this mechanism fits into the broader unfolded protein response, particularly the transition from adaptive to apoptotic phases.</p> </li> <li> <p>Include DERL1: Add DERL1 to the model and its interaction with BIK to complete the pathway representation.</p> </li> <li> <p>Add K48 ubiquitination specification: Specify the K48 linkage type for the ubiquitination, as this is key for proteasomal degradation.</p> </li> <li> <p>Consider using a complex ID: While the current representation with individual proteins is acceptable according to GO-CAM guidelines, also representing the CRL5(ASB11) complex as a whole might enhance clarity.</p> </li> </ol>"},{"location":"reviews/66187e4700000318-The_CRL5_ASB11__complex_mediates_ubiquitination_and_degradation_of_BIK_in_response_to_endoplasmic_reticulum_stress__Human__/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that accurately represents the biological process of BIK ubiquitination and degradation mediated by the CRL5(ASB11) complex during ER stress. The model effectively captures the key molecular players and their causal relationships.</p> <p>The model is consistent with GO-CAM best practices and is well-supported by experimental evidence. With minor additions and clarifications as suggested above, it could provide an even more comprehensive representation of this important regulatory mechanism in the ER stress response.</p>"},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/","title":"66187e4700001274 N6  methyladenosine modified lncRNA ARHGAP5 AS1 stabilises CSDE1 and coordinates oncogenic RNA regulons in hepatocellular carcinoma  PMID 36354136   Human","text":"<p>Now, let me review the GO-CAM model:</p>"},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#review-of-go-cam-model-gomodel66187e4700001274","title":"Review of GO-CAM Model: gomodel:66187e4700001274","text":""},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#model-overview","title":"Model Overview","text":"<p>Title: \"N6-methyladenosine-modified lncRNA ARHGAP5-AS1 stabilises CSDE1 and coordinates oncogenic RNA regulons in hepatocellular carcinoma. PMID:36354136. (Human)\"</p> <p>This model captures molecular mechanisms described in a publication about N6-methyladenosine modification of lncRNA ARHGAP5-AS1 and its role in stabilizing CSDE1 protein in hepatocellular carcinoma. The model describes how this pathway leads to ERK activation.</p>"},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#components-analysis","title":"Components Analysis","text":"<p>The model includes the following key molecular activities:</p> <ol> <li>A methyl transferase complex (GO:0036396) carrying out m6A methylation of RNAs</li> <li>IGF2BP2 functioning as an m6A RNA reader protein</li> <li>The lncRNA ARHGAP5-AS1 interacting with CSDE1 protein</li> <li>TRIM28 acting as an E3 ubiquitin ligase for CSDE1</li> <li>CSDE1 binding mRNA and regulating translation</li> <li>MAPK3/ERK1 as a downstream effector</li> </ol>"},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately captures the key molecular interactions described in the paper</li> <li>Appropriate molecular functions are assigned to each protein</li> <li>Causal relationships between activities are properly defined</li> </ol>"},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Protein Complex Representation Issue:</li> <li>The model uses <code>GO:0036396</code> (RNA N6-methyladenosine methyltransferase complex) but lists \"UniProtKB:Q86U44\" (METTL3) and \"UniProtKB:Q8N3J2\" (METTL14) as members. However, based on the paper, it's METTL14 that is specifically mentioned as the m6A writer for ARHGAP5-AS1.</li> <li>According to the annotation guidelines for complexes, when the specific subunit carrying out an activity is known, it's better to represent that specific protein rather than using the complex ID.</li> <li> <p>Recommendation: Since the paper identifies METTL14 as the primary m6A writer for ARHGAP5-AS1, consider representing METTL14 as the active enzyme rather than using the complex ID.</p> </li> <li> <p>Missing Causal Relationships:</p> </li> <li>The model shows that IGF2BP2's m6A reader activity directly positively regulates the protein binding activity of the lncRNA ARHGAP5-AS1, but there's a missing connection explaining how the m6A modification leads to stabilization of ARHGAP5-AS1.</li> <li> <p>Recommendation: Add an explicit connection showing that the m6A reader activity stabilizes the lncRNA, perhaps through an RNA stabilization process.</p> </li> <li> <p>Ubiquitin Ligase Activity Representation:</p> </li> <li>The model correctly shows TRIM28 with ubiquitin ligase activity affecting CSDE1, but the biological process associated with this activity is \"proteasome-mediated ubiquitin-dependent protein catabolic process\" (GO:0043161). This is accurate but could be more specific.</li> <li> <p>Recommendation: Consider adding the more specific process \"negative regulation of proteasomal ubiquitin-dependent protein catabolic process\" (GO:0032435) to better reflect ARHGAP5-AS1's inhibitory role.</p> </li> <li> <p>Pathway Completeness:</p> </li> <li>The model stops at MAPK3 activation but doesn't capture the downstream effects on VIM and RAC1 translation that are mentioned in the paper.</li> <li> <p>Recommendation: Consider extending the model to include these downstream effects to fully represent the pathway described in the paper.</p> </li> <li> <p>Evidence Codes:</p> </li> <li>Some of the evidence codes used are appropriate (ECO:0000315 for mutant phenotype evidence), but there could be more specific evidence codes used for some of the interactions.</li> <li>Recommendation: Review evidence codes to ensure they most accurately reflect the experimental evidence in the paper.</li> </ol>"},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#conformance-to-go-cam-guidelines","title":"Conformance to GO-CAM Guidelines","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li>\u2713 Activities are properly connected with causal relationships</li> <li>\u2713 Molecular functions are appropriately assigned to proteins</li> <li>\u2713 Biological processes are correctly associated with activities</li> <li>\u2713 Appropriate relationship types (RO terms) are used</li> <li>\u2713 The model avoids circular reasoning or redundant connections</li> </ol>"},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the key findings from the paper:</p> <ol> <li>\u2713 m6A modification of ARHGAP5-AS1 by the methyltransferase complex</li> <li>\u2713 IGF2BP2 acting as an m6A reader protein for ARHGAP5-AS1</li> <li>\u2713 ARHGAP5-AS1 inhibiting TRIM28-mediated ubiquitination of CSDE1</li> <li>\u2713 CSDE1 promoting mRNA translation</li> <li>\u2713 Activation of the ERK pathway as a downstream effect</li> </ol>"},{"location":"reviews/66187e4700001274-N6__methyladenosine_modified_lncRNA_ARHGAP5_AS1_stabilises_CSDE1_and_coordinates_oncogenic_RNA_regulons_in_hepatocellular_carcinoma__PMID_36354136___Human_/#summary-and-recommendations","title":"Summary and Recommendations","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately captures the molecular mechanisms described in the paper. The main recommendations for improvement are:</p> <ol> <li>Consider using METTL14 specifically instead of the complex ID since the paper identifies it as the primary m6A writer</li> <li>Add clearer connections showing how m6A modification leads to RNA stabilization</li> <li>Use more specific biological process terms for the TRIM28 activity</li> <li>Extend the model to include the effects on VIM and RAC1 translation</li> <li>Review evidence codes for optimal specificity</li> </ol> <p>These changes would enhance the completeness and precision of this already solid model.</p>"},{"location":"reviews/66187e4700001573-RNA_capping__GO_0036260_/","title":"66187e4700001573 RNA capping  GO 0036260","text":"<p>Based on the information gathered, I'll now provide my review of the GO-CAM model (gomodel:66187e4700001573) on RNA capping:</p>"},{"location":"reviews/66187e4700001573-RNA_capping__GO_0036260_/#review-of-go-cam-model-rna-capping-go0036260","title":"Review of GO-CAM Model: RNA capping (GO:0036260)","text":""},{"location":"reviews/66187e4700001573-RNA_capping__GO_0036260_/#model-id-gomodel66187e4700001573","title":"Model ID: gomodel:66187e4700001573","text":""},{"location":"reviews/66187e4700001573-RNA_capping__GO_0036260_/#overview","title":"Overview","text":"<p>This model represents the RNA capping pathway in Schizosaccharomyces pombe (fission yeast), specifically focusing on the 7-methylguanosine mRNA capping process (GO:0006370). The model includes four key activities performed by different proteins:</p> <ol> <li>mRNA 5'-triphosphate monophosphatase activity (Pct1)</li> <li>mRNA guanylyltransferase activity (Ceg1)</li> <li>mRNA 5'-cap (guanine-N7)-methyltransferase activity (Pcm1)</li> <li>RNA polymerase II CTD regulatory activities (Rpb1 and Mcs6)</li> </ol>"},{"location":"reviews/66187e4700001573-RNA_capping__GO_0036260_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model correctly captures the key components of the RNA capping pathway in fission yeast. In contrast to budding yeast (S. cerevisiae) where the capping machinery enzymes interact directly with each other, the literature confirms that S. pombe capping enzymes don't necessarily interact with each other but can independently interact with RNA polymerase II.</p> <p>The causal relationships between activities are supported by primary research literature, particularly: - The sequential process from Pct1 (triphosphatase) to Ceg1 (guanylyltransferase) to Pcm1 (methyltransferase) - The regulatory interactions of RNA Pol II (Rpb1) and the kinase Mcs6 in the process</p>"},{"location":"reviews/66187e4700001573-RNA_capping__GO_0036260_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several areas:</p> <ol> <li>Activity representation: Each molecular function is appropriately associated with the protein that performs it</li> <li>Causal connections: The model uses appropriate causal relationship predicates: primarily RO:0002413 (provides input for) and RO:0002629 (directly positively regulates)</li> <li>Evidence: Each assertion is backed by appropriate evidence codes and PMIDs</li> </ol>"},{"location":"reviews/66187e4700001573-RNA_capping__GO_0036260_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Subcellular localization: The model includes cellular location information for some proteins (nucleus, P-TEFb-cap methyltransferase complex) but not all. This could be completed for the remaining proteins.</p> </li> <li> <p>Evidence details: Some of the PMIDs cited couldn't be retrieved in full, making it difficult to fully verify all supporting evidence. In particular, PMID:19328067 and PMID:11139608 couldn't be examined in detail.</p> </li> <li> <p>UniProt lookup issue: I attempted to look up the UniProt entries for some of the proteins, but encountered technical issues. It would be beneficial to confirm the precise functions of each protein from their UniProt entries.</p> </li> <li> <p>Redundant evidence: For some assertions, there are multiple identical pieces of evidence with the same PMID and contributor, which appears redundant.</p> </li> </ol>"},{"location":"reviews/66187e4700001573-RNA_capping__GO_0036260_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:66187e4700001573) is a biologically accurate and well-structured representation of the RNA capping process in S. pombe. It effectively captures the unique aspects of fission yeast capping machinery, where the enzymes operate independently rather than as a complex. The model correctly represents the sequential nature of the capping process and its regulation by RNA polymerase II.</p> <p>The model adheres to GO-CAM best practices in terms of activity representation, causal relationships, and evidence citation. With minor improvements to complete subcellular localization information and consolidate redundant evidence, this would be an exemplary GO-CAM model.</p>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/","title":"66187e4700001597 The growth hormone receptor signaling pathway  Human","text":"<p>Based on my review of the GO-CAM model and the related literature, I will now provide a detailed analysis of gomodel:66187e4700001597 \"The growth hormone receptor signaling pathway (Human)\".</p>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#go-cam-review-the-growth-hormone-receptor-signaling-pathway-human","title":"GO-CAM Review: The Growth Hormone Receptor Signaling Pathway (Human)","text":""},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#summary","title":"Summary","text":"<p>This GO-CAM model (gomodel:66187e4700001597) represents the human growth hormone receptor signaling pathway, focusing on key molecular components and their causal relationships in the signaling cascade. The model includes four primary activities:</p> <ol> <li>Growth factor activity of GH1</li> <li>Growth hormone receptor activity of GHR</li> <li>Non-membrane spanning protein tyrosine kinase activity of JAK2</li> <li>DNA-binding transcription factor activity of STAT5B</li> </ol>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#overall-assessment","title":"Overall Assessment","text":"<p>The model presents a sound representation of the growth hormone signaling pathway, accurately capturing the key components and causal relationships. It adheres to GO-CAM best practices and is biologically consistent with current literature.</p>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate representation of signaling cascade: The model correctly captures the flow of signaling from the extracellular growth hormone (GH1) through the membrane receptor (GHR), to downstream kinase activation (JAK2), and ultimately to transcriptional regulation (STAT5B).</p> </li> <li> <p>Appropriate use of GO terms: The model uses appropriate GO molecular function terms for each component.</p> </li> <li> <p>Correct cellular compartmentalization: Each component is appropriately localized (GH1 in extracellular space, GHR in plasma membrane, JAK2 at the cytoplasmic side of plasma membrane, and STAT5B in the nucleus).</p> </li> <li> <p>Well-supported by evidence: Each assertion is backed by literature evidence with appropriate references.</p> </li> <li> <p>Correct causal connections: The relationships between components accurately reflect the known signaling cascade, with proper use of causal predicates.</p> </li> </ol>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#detailed-analysis","title":"Detailed Analysis","text":""},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#1-gh1-growth-hormone-activity","title":"1. GH1 (Growth Hormone) Activity","text":"<ul> <li>Function: GO:0008083 (growth factor activity)</li> <li>Location: GO:0005615 (extracellular space)</li> <li>Part of: GO:0060396 (growth hormone receptor signaling pathway)</li> <li>Evidence: ECO:0000314 (direct assay evidence used in manual assertion) from PMID:1549776</li> <li>Causal relationship: Directly positively regulates (RO:0002629) GHR activity</li> </ul> <p>This representation is accurate. Growth hormone (GH1) secreted into the extracellular space binds to its receptor on the cell surface and initiates signaling. The paper by de Vos et al. (1549776) provides strong evidence for this interaction through crystal structure analysis of the complex.</p>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#2-ghr-growth-hormone-receptor-activity","title":"2. GHR (Growth Hormone Receptor) Activity","text":"<ul> <li>Function: GO:0004903 (growth hormone receptor activity)</li> <li>Location: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0060396 (growth hormone receptor signaling pathway)</li> <li>Evidence: ECO:0000314 (direct assay evidence used in manual assertion) from PMID:2825030</li> <li>Causal relationship: Directly positively regulates (RO:0002629) JAK2 activity</li> </ul> <p>This representation is correct. GHR is properly localized to the plasma membrane, and its primary function in binding growth hormone is accurately depicted. The reference Leung et al. (2825030) provides direct evidence for GHR function and localization.</p>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#3-jak2-janus-kinase-2-activity","title":"3. JAK2 (Janus Kinase 2) Activity","text":"<ul> <li>Function: GO:0004715 (non-membrane spanning protein tyrosine kinase activity)</li> <li>Location: GO:0031234 (extrinsic component of cytoplasmic side of plasma membrane)</li> <li>Part of: GO:0060397 (growth hormone receptor signaling pathway via JAK-STAT)</li> <li>Evidence: ECO:0000314 (direct assay evidence used in manual assertion) from PMID:15690087</li> <li>Causal relationship: Provides input for (RO:0002407) STAT5B activity</li> </ul> <p>The model correctly represents JAK2 as a cytoplasmic tyrosine kinase that associates with the cytoplasmic domain of GHR. The evidence from Greenhalgh et al. (15690087) provides solid support for JAK2's role in this pathway. The subcellular localization is supported by PMID:8007942 (Mui et al.), which demonstrates that JAK2 associates with the membrane-proximal region of cytokine receptors.</p>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#4-stat5b-signal-transducer-and-activator-of-transcription-5b-activity","title":"4. STAT5B (Signal Transducer and Activator of Transcription 5B) Activity","text":"<ul> <li>Function: GO:0003700 (DNA-binding transcription factor activity)</li> <li>Location: GO:0005634 (nucleus)</li> <li>Part of: GO:0060397 (growth hormone receptor signaling pathway via JAK-STAT)</li> <li>Evidence: ECO:0000304 (author statement supported by traceable reference) from PMID:8631883</li> </ul> <p>The representation of STAT5B is accurate. Upon phosphorylation by JAK2, STAT5B dimerizes and translocates to the nucleus where it acts as a transcription factor. The evidence from PMID:8631883 (Lin et al.) supports this function. The nuclear localization is supported by PMID:29844444, which discusses the translocation of STAT5B to the nucleus in response to phosphorylation.</p>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#pathway-completeness","title":"Pathway Completeness","text":"<p>The model captures the core components of the GH signaling pathway. A few additional elements that could potentially enhance the model include:</p> <ol> <li>The dimerization of GHR upon GH binding</li> <li>Specific phosphorylation sites on JAK2 and STAT5B</li> <li>Downstream targets of STAT5B transcriptional activity</li> <li>Negative regulators of the pathway such as SOCS proteins</li> </ol>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for:</p> <ol> <li> <p>Signaling receptor activity annotation: The model correctly represents the relationship between the ligand (GH1) and its receptor (GHR), consistent with the guidelines in the \"Signaling receptor activity annotation guidelines\" document.</p> </li> <li> <p>DNA-binding transcription factor activity: The representation of STAT5B follows the guidelines specified in the \"DNA-binding transcription factor activity annotation guidelines\" document.</p> </li> <li> <p>Causal relationships: The model uses appropriate causal predicates to connect activities in the pathway.</p> </li> </ol>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Consider adding receptor dimerization: The literature (PMID:1549776) indicates that one GH molecule binds two GHR molecules, forming a 1:2 complex. This could be explicitly modeled.</p> </li> <li> <p>Include negative regulation: The pathway is regulated by negative feedback through SOCS proteins, particularly SOCS2 as indicated in PMID:15690087 and PMID:12552091. Adding these regulatory components would enhance the model's completeness.</p> </li> <li> <p>Add specific phosphorylation sites: The model could be enhanced by indicating the specific phosphorylation sites on JAK2 (Tyr1007/1008) and STAT5B (Tyr699).</p> </li> <li> <p>Include more downstream effects: The model could be expanded to include specific gene targets activated by STAT5B to provide a more complete picture of the biological outcomes of GH signaling.</p> </li> </ol>"},{"location":"reviews/66187e4700001597-The_growth_hormone_receptor_signaling_pathway__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"The growth hormone receptor signaling pathway (Human)\" (gomodel:66187e4700001597) is a scientifically accurate and well-structured representation of the core GH signaling pathway. It follows GO-CAM best practices and is supported by appropriate evidence from the literature. While a few additional components could be added to enhance completeness, the current model effectively captures the key molecular activities and causal relationships in this important signaling pathway.</p>"},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/","title":"66187e4700001644 Feedback regulation of growth hormone receptor signaling pathway via ubiquitination and degradation of GHR by the ECS SOCS2  complex  Human","text":"<p>Based on my review, I'll now provide a thorough assessment of GO-CAM model ID:66187e4700001644 titled \"Feedback regulation of growth hormone receptor signaling pathway via ubiquitination and degradation of GHR by the ECS(SOCS2) complex (Human).\"</p>"},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/#review-of-go-cam-model-gomodel66187e4700001644","title":"Review of GO-CAM Model: gomodel:66187e4700001644","text":""},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/#overview","title":"Overview","text":"<p>This GO-CAM model represents the feedback regulation mechanism of growth hormone receptor (GHR) signaling through ubiquitination and degradation by the ECS(SOCS2) E3 ubiquitin ligase complex in humans. The model illustrates a complete signaling pathway starting with growth hormone (GH) binding to its receptor, signal transduction through JAK2 and STAT5B, and the feedback inhibition mechanism via the SOCS2-containing E3 ligase complex.</p>"},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model includes:</p> <ol> <li>Growth hormone (GH1) activity as a growth factor (GO:0008083) in the extracellular space</li> <li>Growth hormone receptor (GHR) with receptor activity (GO:0004903) at the plasma membrane</li> <li>JAK2 with protein tyrosine kinase activity (GO:0004715)</li> <li>STAT5B with DNA-binding transcription factor activity (GO:0003700) in the nucleus</li> <li>SOCS2 with ubiquitin ligase-substrate adaptor activity (GO:1990756)</li> <li>CUL5 with ubiquitin ligase complex scaffold activity (GO:0160072)</li> <li>RNF7/RBX2 with ubiquitin protein ligase activity (GO:0061630)</li> </ol>"},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model accurately represents the key components of the growth hormone receptor signaling pathway and its negative feedback regulation.</li> <li>The causal relationships between activities are correctly represented, showing how GH activates GHR, which activates JAK2, which then activates both STAT5B and SOCS2, with SOCS2 ultimately feeding back to inhibit GHR.</li> <li>The E3 ligase complex (ECS) components are correctly represented with appropriate molecular functions and causal relationships.</li> <li>All activities are properly annotated with appropriate GO terms.</li> <li>Each component is correctly assigned to its subcellular location.</li> <li>Evidence for each activity and relationship is properly referenced with PMIDs.</li> </ol>"},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/#conformance-to-go-cam-guidelines","title":"Conformance to GO-CAM Guidelines","text":"<p>The model follows the E3 ubiquitin ligase annotation guidelines correctly:</p> <ol> <li>For CUL5 (scaffold protein):</li> <li>Appropriate molecular function: ubiquitin ligase complex scaffold activity (GO:0160072)</li> <li>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li> <p>Directly regulates SOCS2 (as expected for scaffold-adaptor relationship)</p> </li> <li> <p>For SOCS2 (substrate adaptor):</p> </li> <li>Appropriate molecular function: ubiquitin ligase-substrate adaptor activity (GO:1990756)</li> <li>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li>Located in cytoplasm</li> <li> <p>Directly provides input for RNF7</p> </li> <li> <p>For RNF7 (E3 ligase):</p> </li> <li>Appropriate molecular function: ubiquitin protein ligase activity (GO:0061630)</li> <li>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li>Located in cytoplasm</li> <li>Directly negatively regulates GHR (appropriate for representing the ubiquitination and degradation mechanism)</li> </ol>"},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the biological pathway based on the literature:</p> <ol> <li>The PMID:21980433 paper clearly demonstrates that SOCS2 forms a complex with Elongin B/C, Cullin5, and Rbx2 (RNF7) to ubiquitinate GHR for proteasomal degradation.</li> <li>The model correctly shows that this ubiquitination leads to decreased GHR levels and therefore provides a negative feedback mechanism for GH signaling.</li> <li>Tyrosine phosphorylation of GHR by JAK2 is correctly shown as a prerequisite for SOCS2 binding and subsequent ubiquitination.</li> <li>The spatial localization of activities (e.g., GH in extracellular space, GHR at plasma membrane, STAT5B in nucleus) is consistent with known biology.</li> </ol>"},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/#minor-issues-and-recommendations","title":"Minor Issues and Recommendations","text":"<p>While the model is generally very well constructed, I have a few minor recommendations for improvement:</p> <ol> <li> <p>Biological Process Annotation: The JAK2 activity is annotated as part of GO:0060397 (growth hormone receptor signaling pathway via JAK-STAT) which is appropriate, but it could also be useful to add a more specific process term related to receptor phosphorylation if available.</p> </li> <li> <p>Elongin Components: While the model correctly represents the key components of the ECS complex, it doesn't explicitly include Elongin B and Elongin C, which are mentioned in the PMID:21980433 paper as important for SOCS2 stability and function. Including these components could provide a more complete representation of the complex.</p> </li> <li> <p>Mechanistic Detail: The model could potentially be enhanced by representing the specific tyrosine residue on GHR (Tyr487) that is important for SOCS2 binding, as highlighted in PMID:21980433. This would add more mechanistic detail.</p> </li> </ol>"},{"location":"reviews/66187e4700001644-Feedback_regulation_of_growth_hormone_receptor_signaling_pathway_via_ubiquitination_and_degradation_of_GHR_by_the_ECS_SOCS2__complex__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model provides an accurate and comprehensive representation of the feedback regulation of growth hormone receptor signaling through the SOCS2-containing E3 ubiquitin ligase complex. It follows GO-CAM best practices for representing E3 ubiquitin ligase complexes and their activities. The model is well-supported by evidence and correctly represents the biological pathway.</p> <p>The model is an excellent example of how GO-CAM can be used to represent complex signaling pathways involving protein modifications and feedback regulation. It accurately captures the current state of knowledge about this pathway and would be useful for researchers interested in growth hormone signaling, SOCS proteins, or ubiquitin-mediated protein degradation.</p>"},{"location":"reviews/66187e4700001744-meiotic_cohesion_protection_in_anaphase_I__GO_1990813_/","title":"66187e4700001744 meiotic cohesion protection in anaphase I  GO 1990813","text":"<p>Based on my review of GO-CAM model 66187e4700001744 and the relevant documentation, I'll now provide a comprehensive review of the model.</p>"},{"location":"reviews/66187e4700001744-meiotic_cohesion_protection_in_anaphase_I__GO_1990813_/#review-of-go-cam-model-gomodel66187e4700001744","title":"Review of GO-CAM Model: gomodel:66187e4700001744","text":""},{"location":"reviews/66187e4700001744-meiotic_cohesion_protection_in_anaphase_I__GO_1990813_/#model-overview","title":"Model Overview","text":"<p>Title: \"meiotic cohesion protection in anaphase I (GO:1990813)\" Taxon: Fission yeast (NCBITaxon:4896) Status: Production Link: https://bioregistry.io/go.model:66187e4700001744</p> <p>This model represents the biological process of meiotic centromeric cohesion protection during anaphase I in fission yeast, which ensures that sister chromatids remain attached at centromeres throughout the first meiotic division.</p>"},{"location":"reviews/66187e4700001744-meiotic_cohesion_protection_in_anaphase_I__GO_1990813_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Biological accuracy: The model accurately captures the key components of the meiotic cohesion protection pathway, including Moa1, Plo1, Spc7, Shugoshin (Sgo1), PP2A phosphatase, and Rec8. The interactions represented align with current scientific understanding as evidenced in the literature.</p> </li> <li> <p>Well-connected activities: The model uses appropriate causal relations (RO:0002629 - directly positively regulates) between activities, showing clear functional connections between proteins in the pathway.</p> </li> <li> <p>Appropriate molecular functions: The molecular functions assigned to each gene product (e.g., kinetochore adaptor activity, protein serine/threonine kinase activity) are accurate and supported by evidence.</p> </li> <li> <p>Cellular context: The model correctly places activities in their appropriate cellular locations (kinetochore, condensed chromosome centromeric region).</p> </li> <li> <p>Evidence attribution: Each activity and relationship is supported by appropriate evidence codes and PMID references.</p> </li> </ol>"},{"location":"reviews/66187e4700001744-meiotic_cohesion_protection_in_anaphase_I__GO_1990813_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing occurs_in relation for some activities: Several activities in the model lack an \"occurs_in\" relation, including:</li> <li>Activity gomodel:66187e4700001744/66187e4700001974 (PomBase:SPBC16H5.07c, protein phosphatase activity)</li> <li>Activity gomodel:66187e4700001744/66187e4700001997 (PR:000050512, molecular adaptor activity)</li> <li> <p>Activity gomodel:66187e4700001744/66187e4700001845 (PomBase:SPCC1322.12c, kinase activity)</p> </li> <li> <p>Incomplete evidence for some causal associations: Some causal associations lack evidence, such as:</p> </li> <li>The relationship between PR:000050512 (Rec8) adaptor activity and Sgo1 activity</li> <li> <p>One of the causal associations from SPAC664.01c (Swi6) to SPBP35G2.03c (Sgo1)</p> </li> <li> <p>Missing key input molecules: For the molecular adaptor activity (GO:0060090) enabled by PR:000050512 (Rec8), there are no \"has input\" relations defined. According to the literature and GO-CAM best practices, adaptors should specify the molecules they bring together through \"has input\" relations.</p> </li> <li> <p>Potential simplification opportunity: The model shows two nearly identical causal associations from SPAC664.01c (Swi6) to SPBP35G2.03c (Sgo1), which appears redundant and could be consolidated.</p> </li> <li> <p>Incomplete part_of relations: Some activities are missing \"part_of\" relations to the overall biological process (GO:1990813), particularly for PR:000027566 and PR:000027557.</p> </li> </ol>"},{"location":"reviews/66187e4700001744-meiotic_cohesion_protection_in_anaphase_I__GO_1990813_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Add occurs_in relations: Add appropriate cellular component locations for all activities that are currently missing this information.</p> </li> <li> <p>Add evidence for causal associations: Provide evidence for the currently unsupported causal associations, particularly for the Rec8 adaptor activity relationships.</p> </li> <li> <p>Specify input molecules for adaptor activities: For the molecular adaptor activity (GO:0060090) enabled by PR:000050512 (Rec8), add \"has input\" relations to specify which molecules this adaptor brings together.</p> </li> <li> <p>Consolidate redundant relations: Review and consolidate the duplicate causal associations from SPAC664.01c (Swi6) to SPBP35G2.03c (Sgo1).</p> </li> <li> <p>Complete part_of relations: Ensure all activities have appropriate \"part_of\" relations to the overall biological process.</p> </li> <li> <p>Enhance molecular clarity: According to the literature, phosphorylation of Rec8 by Plo1 at S450 is a key event that promotes PP2A action. This specific mechanism could be more explicitly represented in the model.</p> </li> </ol>"},{"location":"reviews/66187e4700001744-meiotic_cohesion_protection_in_anaphase_I__GO_1990813_/#scientific-consistency","title":"Scientific Consistency","text":"<p>The model accurately represents the current understanding of meiotic cohesion protection as described in the literature. The paper by Ma et al. (2021) supports the key relationships depicted in the model, particularly the role of Moa1-Plo1 in phosphorylating Rec8, which enhances Sgo1-PP2A activity to protect centromeric cohesion.</p> <p>The model captures the hierarchical regulation where: 1. Moa1 recruits Plo1 to kinetochores 2. Plo1 phosphorylates Spc7 and Rec8 3. Phosphorylated Spc7 recruits Bub1 4. Bub1 phosphorylates histone H2A 5. Phosphorylated H2A recruits Sgo1 (Shugoshin) 6. Sgo1 brings PP2A to centromeres 7. PP2A dephosphorylates Rec8, preventing its cleavage by separase</p>"},{"location":"reviews/66187e4700001744-meiotic_cohesion_protection_in_anaphase_I__GO_1990813_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good representation of the meiotic cohesion protection pathway in fission yeast. With the suggested improvements, particularly regarding adaptor inputs and evidence for causal associations, the model would more comprehensively represent this important biological process and better adhere to GO-CAM best practices.</p>"},{"location":"reviews/66187e4700001781-silent_mating_type_cassette_heterochromatin_assembly__GO_0030466__/","title":"66187e4700001781 silent mating type cassette heterochromatin assembly  GO 0030466","text":"<p>Based on my review of the GO-CAM model 66187e4700001781 \"silent mating-type cassette heterochromatin assembly (GO:0030466)\" and relevant GO-CAM guidelines, here is my assessment:</p>"},{"location":"reviews/66187e4700001781-silent_mating_type_cassette_heterochromatin_assembly__GO_0030466__/#go-cam-model-review-gomodel66187e4700001781","title":"GO-CAM Model Review: gomodel:66187e4700001781","text":""},{"location":"reviews/66187e4700001781-silent_mating_type_cassette_heterochromatin_assembly__GO_0030466__/#overview","title":"Overview","text":"<p>This model represents the silent mating-type cassette heterochromatin assembly process in Schizosaccharomyces pombe (taxon: NCBITaxon:4896). The model includes multiple proteins and their activities involved in heterochromatin formation at the mating-type locus.</p>"},{"location":"reviews/66187e4700001781-silent_mating_type_cassette_heterochromatin_assembly__GO_0030466__/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive representation: The model includes numerous proteins and complexes involved in heterochromatin assembly, showing a well-connected causal network of activities.</p> </li> <li> <p>Proper use of cellular locations: Activities are appropriately placed in cellular locations like mating-type region heterochromatin (GO:0031934), CLRC complex (GO:0043494), etc.</p> </li> <li> <p>Well-evidenced assertions: Most activities and causal connections are supported by experimental evidence with appropriate ECO codes and PMIDs.</p> </li> <li> <p>Appropriate part_of relationships: Activities are properly modeled as part of the overall biological process (GO:0030466).</p> </li> </ol>"},{"location":"reviews/66187e4700001781-silent_mating_type_cassette_heterochromatin_assembly__GO_0030466__/#issues-identified","title":"Issues Identified","text":"<ol> <li>Duplicate causal associations: There are several instances of duplicate causal associations with the same evidence:</li> <li>In activity 663d668500002480 (arb1), there are two identical RO:0002630 connections to 663d668500002511</li> <li>In activity 66187e4700001872 (clr4), there are two identical RO:0002413 connections to 662af8fa00000979</li> <li> <p>In activity 662af8fa00001416 (dcr1), there are two identical RO:0002413 connections to 663d668500002511</p> </li> <li> <p>Missing molecular function: Several activities have GO:0003674 (molecular_function) assigned, which is a root term indicating that the specific molecular function is unknown. While this is sometimes appropriate, it would be better to specify more precise functions when known:</p> </li> <li>66187e4700002229 (raf1)</li> <li>66187e4700002222 (rik1)</li> <li>66187e4700002241 (raf2)</li> <li>66187e4700002166 (clr1)</li> <li>66187e4700002216 (cul4)</li> <li>66187e4700002204 (clr5)</li> <li> <p>665912ed00001919 (dsh1)</p> </li> <li> <p>PMID format issue: In causal association evidence for activity 66187e4700001825 (swi6), the PMID is incorrectly formatted with a space: \"PMID: 16246721\" instead of \"PMID:16246721\".</p> </li> <li> <p>Missing evidence for causal association: In activity 66187e4700002216 (cul4), there's a causal association to 66187e4700001872 without any evidence.</p> </li> <li> <p>Predicate RO:0012009: This predicate is used in two causal associations (in activities 66187e4700002229 and 665912ed00000973), but it doesn't appear in your listed standard predicates for causal associations. It should be verified whether this is an appropriate relation type for GO-CAM.</p> </li> </ol>"},{"location":"reviews/66187e4700001781-silent_mating_type_cassette_heterochromatin_assembly__GO_0030466__/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Fix duplicate causal associations: Remove duplicated causal associations that have identical predicates, targets, and evidence.</p> </li> <li> <p>Add specific molecular functions: Where possible, replace GO:0003674 (molecular_function) with more specific terms that better describe the molecular activities of the proteins.</p> </li> <li> <p>Fix PMID format: Correct the PMID format in the evidence for activity 66187e4700001825 by removing the space after \"PMID:\".</p> </li> <li> <p>Add evidence for missing causal association: Add appropriate evidence for the causal association from cul4 (66187e4700002216) to 66187e4700001872.</p> </li> <li> <p>Review non-standard predicates: Verify the appropriate use of RO:0012009 in causal associations, or replace with standard predicates (RO:0002413, RO:0002629, RO:0002630, RO:0002304, or RO:0002305).</p> </li> <li> <p>Review complex representation: Where activities occur in complexes, ensure the appropriate subunit or complex ID is used according to the \"How to annotate complexes in GO-CAM\" guidelines.</p> </li> </ol>"},{"location":"reviews/66187e4700001781-silent_mating_type_cassette_heterochromatin_assembly__GO_0030466__/#overall-assessment","title":"Overall Assessment","text":"<p>The model is generally well-constructed and represents the silent mating-type cassette heterochromatin assembly process in S. pombe comprehensively. With the recommended adjustments, it will more accurately reflect the biological process according to GO-CAM best practices.</p> <p>The model provides a good representation of how multiple proteins and complexes work together in heterochromatin formation at the mating-type locus, with appropriate causal relationships connecting the different activities.</p>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/","title":"66187e4700002082 The erythropoietin mediated signaling pathway  Human","text":"<p>Now that I have gathered all the necessary information, I'll review the GO-CAM model gomodel:66187e4700002082 \"The erythropoietin-mediated signaling pathway (Human)\".</p>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#review-of-go-cam-model-the-erythropoietin-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: The erythropoietin-mediated signaling pathway (Human)","text":""},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#gomodel66187e4700002082","title":"gomodel:66187e4700002082","text":""},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents the erythropoietin-mediated signaling pathway in humans. It captures: - Erythropoietin (EPO) acting as a cytokine in the extracellular space - EPO binding to and activating the EPO receptor (EPOR) on the plasma membrane - EPOR activation leading to JAK2 tyrosine kinase activity - JAK2 phosphorylating STAT5B, which then acts as a transcription factor in the nucleus</p>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#accuracy-and-completeness","title":"Accuracy and Completeness","text":""},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#biological-content","title":"Biological Content","text":"<p>The model correctly represents the core aspects of the EPO signaling pathway, which is well-documented in the literature:</p> <ol> <li>EPO Secretion and Location: </li> <li>EPO (UniProtKB:P01588) is correctly annotated with cytokine activity (GO:0005125)</li> <li> <p>EPO is properly located in the extracellular space (GO:0005615), which matches the UniProt entry</p> </li> <li> <p>EPOR Activity and Location:</p> </li> <li>EPOR (UniProtKB:P19235) is correctly annotated with erythropoietin receptor activity (GO:0004900)</li> <li>EPOR is appropriately located at the plasma membrane (GO:0005886)</li> <li> <p>The evidence for EPOR's membrane location (ECO:0000250) is supported by the UniProt entry</p> </li> <li> <p>JAK2 Activation:</p> </li> <li>JAK2 (UniProtKB:O60674) is correctly annotated with non-membrane spanning protein tyrosine kinase activity (GO:0004715)</li> <li>JAK2 is correctly located at the extrinsic component of cytoplasmic side of plasma membrane (GO:0031234)</li> <li> <p>The papers cited (PMID:9657743 and PMID:8007942) support that JAK2 associates with cytokine receptors and is activated by EPO</p> </li> <li> <p>STAT5B Activation and Nuclear Translocation:</p> </li> <li>STAT5B (UniProtKB:P51692) is correctly annotated with DNA-binding transcription factor activity (GO:0003700)</li> <li>STAT5B is properly located in the nucleus (GO:0005634)</li> <li>The activation pathway from JAK2 to STAT5B is supported by PMID:9657743, which shows EPO induces tyrosine phosphorylation of JAK2, STAT5A, and STAT5B</li> </ol>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#causal-relationships-in-the-model","title":"Causal Relationships in the Model","text":"<p>The causal relationships in the model accurately reflect the biological pathway:</p> <ol> <li>EPO directly positively regulates (RO:0002629) the activity of EPOR</li> <li>EPOR activity uses (RO:0002407) JAK2 activity</li> <li>JAK2 activity directly positively regulates (RO:0002629) STAT5B activity</li> </ol> <p>These relationships are consistent with the literature. According to PMID:9774108 and PMID:9657743, EPO binds to EPOR, leading to JAK2 activation, which then phosphorylates STAT5, allowing it to dimerize and translocate to the nucleus.</p>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#molecular-quality-control","title":"Molecular Quality Control","text":""},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#proper-use-of-go-terms","title":"Proper Use of GO Terms","text":"<p>The model uses appropriate GO terms for each molecule:</p> <ul> <li>EPO: Cytokine activity (GO:0005125) - Appropriate for its function</li> <li>EPOR: Erythropoietin receptor activity (GO:0004900) - Specific and accurate</li> <li>JAK2: Non-membrane spanning protein tyrosine kinase activity (GO:0004715) - Correctly describes JAK2's enzymatic function</li> <li>STAT5B: DNA-binding transcription factor activity (GO:0003700) - Accurate for its role in the nucleus</li> </ul>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#appropriate-evidence","title":"Appropriate Evidence","text":"<p>Each activity in the model is supported by experimental evidence:</p> <ul> <li>EPO cytokine activity: ECO:0000314 (direct assay) with PMID:9774108</li> <li>EPOR receptor activity: ECO:0000314 (direct assay) with PMID:2163696</li> <li>JAK2 kinase activity: ECO:0000314 (direct assay) with PMID:9657743</li> <li>STAT5B transcription factor activity: ECO:0000304 (author statement) with PMID:8631883</li> </ul> <p>The evidence codes are appropriate for the types of experimental data cited.</p>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#cellular-locations","title":"Cellular Locations","text":"<p>The cellular locations are correctly specified:</p> <ul> <li>EPO in extracellular space (GO:0005615)</li> <li>EPOR at plasma membrane (GO:0005886)</li> <li>JAK2 at cytoplasmic side of plasma membrane (GO:0031234)</li> <li>STAT5B in nucleus (GO:0005634)</li> </ul> <p>These locations accurately reflect the biology of the pathway.</p>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#conformance-to-go-cam-curation-practices","title":"Conformance to GO-CAM Curation Practices","text":"<p>The model follows GO-CAM best practices: - It uses appropriate causal relationships between activities - Each activity is assigned to the correct molecule - Cellular locations are specified - All activities are part of the erythropoietin-mediated signaling pathway (GO:0038162) - Evidence is provided for each annotation</p> <p>The model correctly handles complex representation by attributing activities to the specific proteins carrying them, rather than to the entire complex, following the guidelines in the \"How to annotate complexes in GO-CAM\" document.</p>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is scientifically accurate, there are a few areas that could be enhanced:</p> <ol> <li>Receptor Complex Formation:</li> <li>EPO binds to EPOR, causing receptor dimerization, which is a critical step for JAK2 activation. The model does not explicitly capture this dimerization event.</li> <li> <p>According to PMID:9774108, EPO imposes a specific angular relationship (120\u00b0) between two EPOR molecules, which is essential for optimal signaling.</p> </li> <li> <p>STAT5 Dimerization:</p> </li> <li>After phosphorylation by JAK2, STAT5B forms homodimers or heterodimers with STAT5A, which is an important step for DNA binding and transcriptional activity.</li> <li> <p>This dimerization and the requirement of tyrosine phosphorylation (at Tyr-699 for STAT5B) for this process are not explicitly represented.</p> </li> <li> <p>Additional Downstream Events:</p> </li> <li>The pathway could be extended to include target genes regulated by STAT5B or other downstream effectors activated by JAK2 (like PI3K/AKT pathway).</li> </ol>"},{"location":"reviews/66187e4700002082-The_erythropoietin_mediated_signaling_pathway__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66187e4700002082) accurately represents the core erythropoietin-mediated signaling pathway with appropriate annotations, evidence, and causal relationships. It correctly captures the sequence of events from EPO binding to EPOR, leading to JAK2 activation and STAT5B-mediated transcription.</p> <p>The model is appropriately concise while capturing the essential features of the pathway. The annotations are well-supported by evidence from the literature, and the causal relationships accurately reflect our understanding of EPO signaling.</p> <p>While some mechanistic details could be added to enhance the model's completeness, it provides a clear and accurate representation of this important signaling pathway.</p>"},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/","title":"66187e4700002129 Feedback regulation of erythropoietin mediated signaling via ubiquitination and degradation of EPOR by the ECS SOCS2  complex  Human","text":"<p>Now I'll review the GO-CAM model based on the information I've gathered:</p>"},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#review-of-go-cam-model-66187e4700002129","title":"Review of GO-CAM Model 66187e4700002129","text":""},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#overview-of-the-model","title":"Overview of the Model","text":"<p>The GO-CAM model gomodel:66187e4700002129 is titled \"Feedback regulation of erythropoietin-mediated signaling via ubiquitination and degradation of EPOR by the ECS(SOCS2) complex (Human).\" This model represents a molecular pathway in humans (NCBITaxon:9606) with production status.</p> <p>The model describes a negative feedback mechanism in erythropoietin (EPO) signaling where activated EPO receptors (EPOR) are targeted for degradation by the ECS(SOCS2) E3 ubiquitin ligase complex, which includes SOCS2, CUL5, and RNF7 (also known as RBX2).</p>"},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#key-components-and-activities-in-the-model","title":"Key Components and Activities in the Model","text":"<ol> <li>EPO (UniProtKB:P01588)</li> <li>Has cytokine activity (GO:0005125)</li> <li>Occurs in extracellular space (GO:0005615)</li> <li>Part of erythropoietin-mediated signaling pathway (GO:0038162)</li> <li> <p>Directly positively regulates EPOR activity</p> </li> <li> <p>EPOR (UniProtKB:P19235)</p> </li> <li>Has erythropoietin receptor activity (GO:0004900)</li> <li>Occurs in plasma membrane (GO:0005886)</li> <li>Part of erythropoietin-mediated signaling pathway (GO:0038162)</li> <li> <p>Directly positively regulates JAK2 activity</p> </li> <li> <p>JAK2 (UniProtKB:O60674)</p> </li> <li>Has non-membrane spanning protein tyrosine kinase activity (GO:0004715)</li> <li>Occurs in cytoplasmic side of plasma membrane (GO:0031234)</li> <li>Part of erythropoietin-mediated signaling pathway (GO:0038162)</li> <li>Provides input for SOCS2 activity</li> <li> <p>Has relationship with STAT5B but missing causal association predicate</p> </li> <li> <p>STAT5B (UniProtKB:P51692)</p> </li> <li>Has DNA-binding transcription factor activity (GO:0003700)</li> <li>Occurs in nucleus (GO:0005634)</li> <li> <p>Part of erythropoietin-mediated signaling pathway (GO:0038162)</p> </li> <li> <p>SOCS2 (UniProtKB:O14508)</p> </li> <li>Has ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</li> <li>Occurs in cytoplasm (GO:0005737)</li> <li>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li> <p>Directly positively regulates RNF7 activity</p> </li> <li> <p>RNF7/RBX2 (UniProtKB:Q9UBF6)</p> </li> <li>Has ubiquitin protein ligase activity (GO:0061630)</li> <li>Occurs in cytoplasm (GO:0005737)</li> <li>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li> <p>Directly negatively regulates EPOR activity</p> </li> <li> <p>CUL5 (UniProtKB:Q93034)</p> </li> <li>Has ubiquitin ligase complex scaffold activity (GO:0160072)</li> <li>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li>Directly positively regulates SOCS2 activity (though there are duplicate causal associations in the model)</li> </ol>"},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#biological-pathway-representation","title":"Biological Pathway Representation","text":"<p>The model captures a feedback regulatory pathway where:</p> <ol> <li>EPO binds to and activates its receptor EPOR in the plasma membrane</li> <li>Activated EPOR triggers JAK2 kinase activity</li> <li>JAK2 activates STAT5B (though the causal relationship isn't properly defined in the model)</li> <li>JAK2 also provides input for SOCS2 activity</li> <li>SOCS2 acts as an adaptor protein in the ECS complex with CUL5 and RNF7</li> <li>The ECS(SOCS2) complex targets activated EPOR for ubiquitination and subsequent degradation</li> <li>This creates a negative feedback loop that regulates EPO signaling</li> </ol>"},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#strengths","title":"Strengths","text":"<ol> <li> <p>Biological consistency: The model accurately represents the known EPO signaling pathway and its regulation through the ECS(SOCS2) complex as supported by the literature (PMID:9774108, PMID:11781573, etc.)</p> </li> <li> <p>Proper annotation of molecular functions: The molecular functions of each protein in the model are accurately represented with appropriate GO terms.</p> </li> <li> <p>Cellular localization: The model correctly annotates the subcellular locations where each activity occurs.</p> </li> <li> <p>Appropriate use of causal relationships: Most causal relationships use appropriate predicates according to GO-CAM guidelines (RO:0002629 for direct positive regulation, RO:0002630 for direct negative regulation, RO:0002413 for providing input).</p> </li> </ol>"},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#issues","title":"Issues","text":"<ol> <li> <p>Duplicate causal association: There are duplicate causal associations from CUL5 to SOCS2. They both use the same predicate (RO:0002629) but have different evidence attributions (one to ORCID:0000-0001-7299-6685 and another to ORCID:0000-0001-6787-2901).</p> </li> <li> <p>Missing causal relationship: There should be a clear causal relationship between JAK2 and STAT5B, but it's missing from the model. According to the literature, JAK2 directly phosphorylates and activates STAT5B in the EPO signaling pathway.</p> </li> <li> <p>STAT5B annotation: While STAT5B is included in the model, its downstream effects (e.g., transcriptional activation of target genes) are not represented.</p> </li> <li> <p>Evidence for EPOR location: The occurrence of EPOR in the plasma membrane is supported only by evidence code ECO:0000250 (sequence similarity evidence) with a reference to mouse data, rather than direct experimental evidence in humans.</p> </li> <li> <p>Clarity of ubiquitination process: While the model shows that RNF7 negatively regulates EPOR, it doesn't clearly depict the process of EPOR ubiquitination that leads to its degradation.</p> </li> </ol>"},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Remove duplicate causal association: Remove one of the duplicate causal associations from CUL5 to SOCS2.</p> </li> <li> <p>Add missing causal relationship: Add a direct positive regulation (RO:0002629) causal relationship from JAK2 to STAT5B to complete the signaling pathway.</p> </li> <li> <p>Expand STAT5B activity: Consider adding the downstream effects of STAT5B activation, such as transcriptional activation of target genes involved in erythrocyte development.</p> </li> <li> <p>Improve evidence for EPOR location: If possible, add direct experimental evidence for the plasma membrane localization of EPOR in human cells.</p> </li> <li> <p>Clarify ubiquitination process: Consider adding more detail about the ubiquitination process, such as specific ubiquitination sites on EPOR and the K48-linked polyubiquitination that typically signals for proteasomal degradation.</p> </li> <li> <p>Add temporal dimension: Consider adding annotations that reflect the temporal sequence of events in the pathway (initial activation followed by feedback inhibition).</p> </li> </ol>"},{"location":"reviews/66187e4700002129-Feedback_regulation_of_erythropoietin_mediated_signaling_via_ubiquitination_and_degradation_of_EPOR_by_the_ECS_SOCS2__complex__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, GO-CAM model 66187e4700002129 provides a good representation of the feedback regulation of EPO signaling via the ECS(SOCS2) complex. The model is biologically accurate and largely follows GO-CAM best practices. The few issues identified are relatively minor and can be addressed with the recommended improvements to create a more complete and accurate representation of this important regulatory pathway.</p>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/","title":"66187e4700002284 septation initiation signaling  GO 0031028","text":"<p>Now that I have reviewed the main GO-CAM guidelines, I'll systematically review the model \"gomodel:66187e4700002284\" which represents the \"septation initiation signaling (GO:0031028)\" in fission yeast (NCBITaxon:4896).</p>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#go-cam-model-review-septation-initiation-signaling","title":"GO-CAM Model Review: Septation Initiation Signaling","text":""},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the septation initiation signaling (SIN) pathway in fission yeast (Schizosaccharomyces pombe). The SIN is a signaling cascade essential for coordinating cell division with mitosis, ensuring that cytokinesis occurs only after chromosome segregation. </p>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#structure-and-connectivity-analysis","title":"Structure and Connectivity Analysis","text":"<p>The model has 27 activities represented, involving various proteins functioning in different cellular locations including spindle pole bodies (SPBs) and the actomyosin contractile ring. The key signaling cascade includes:</p> <ol> <li>Upstream regulators at the SPB (Plo1/Sid4/Cdc11)</li> <li>Core signaling pathway (Spg1/Cdc7/Sid1/Sid2)</li> <li>Regulatory components (GAPs like Cdc16/Byr4, phosphatases, etc.)</li> </ol>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#connectivity-strengths","title":"Connectivity strengths:","text":"<ul> <li>The model correctly represents the hierarchical structure of the SIN pathway</li> <li>Causal relationships between activities are well-documented with appropriate evidence</li> <li>The use of appropriate relation predicates (RO:0002629 \"directly positively regulates\", RO:0002630 \"directly negatively regulates\", etc.)</li> </ul>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#notable-pathway-connections","title":"Notable pathway connections:","text":"<ul> <li>Appropriate representation of Spg1 GTPase as a central switch in the pathway</li> <li>GAP proteins (Cdc16/Byr4) properly shown negatively regulating Spg1</li> <li>The downstream kinase cascade (Cdc7 \u2192 Sid1 \u2192 Sid2) follows correct biological sequence</li> </ul>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#issues-identified","title":"Issues Identified","text":"<ol> <li>Missing molecular functions: Several proteins have GO:0003674 (molecular_function) listed, which is a placeholder for \"unknown molecular function\":</li> <li>PomBase:SPAC2C4.10c (csc4)</li> <li>PomBase:SPBC3H7.13 (csc1)</li> <li>PomBase:SPBC27B12.04c (csc2)</li> <li>PomBase:SPBC1773.01 (csc3)</li> <li> <p>PomBase:SPAC1782.05 (ypa2)</p> </li> <li> <p>Missing evidence codes: Some causal associations lack evidence:</p> </li> <li>The causal association between csc4 (SPAC2C4.10c) and ppa3 (SPAC22H10.04)</li> <li>The causal association between csc2 (SPBC27B12.04c) and ppa3 (SPAC22H10.04)</li> <li> <p>The causal association between csc3 (SPBC1773.01) and ppa3 (SPAC22H10.04)</p> </li> <li> <p>Incomplete cellular context: While most activities have appropriate cellular locations, a few are missing contextual information about where the activity occurs.</p> </li> <li> <p>Evidence quality: Most associations use appropriate experimental evidence codes, but there are instances where stronger evidence could be used (like ECO:0000269 \"experimental evidence used in manual assertion\" instead of ECO:0000353 \"physical interaction evidence\").</p> </li> </ol>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#biological-consistency-review","title":"Biological Consistency Review","text":"<p>The model accurately represents the current understanding of the SIN pathway in S. pombe as documented in the literature. Key components and interactions match with published research:</p> <ol> <li>The central role of Spg1 GTPase and its regulation by Byr4/Cdc16 GAP</li> <li>The activation of Cdc7 kinase by GTP-bound Spg1</li> <li>The downstream signaling through Sid1 and Sid2 kinases</li> <li>The roles of phosphatases (Clp1, Ppa3) in regulating the pathway</li> <li>The inhibitory role of Cdc2 (CDK) on specific SIN components</li> </ol>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<ol> <li> <p>Molecular function annotations: Most proteins have appropriate molecular functions assigned (kinase activities, GTPase activities, etc.).</p> </li> <li> <p>Biological process annotations: Activities are appropriately placed within specific biological processes:</p> </li> <li>GO:0031028 (septation initiation signaling)</li> <li>GO:0031030 (negative regulation of septation initiation signaling)</li> <li> <p>GO:0031031 (positive regulation of septation initiation signaling)</p> </li> <li> <p>Cellular component annotations: Activities are correctly localized to relevant cellular structures:</p> </li> <li>GO:0044732 (mitotic spindle pole body)</li> <li>GO:0071957 (old mitotic spindle pole body)</li> <li>GO:0071958 (new mitotic spindle pole body)</li> <li> <p>GO:0110085 (mitotic actomyosin contractile ring)</p> </li> <li> <p>Evidence codes: The model generally uses appropriate evidence codes with PMIDs to support assertions.</p> </li> </ol>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Complete the missing molecular functions: For proteins currently annotated with GO:0003674, either:</li> <li>Determine specific molecular functions from literature</li> <li> <p>Note that these are likely scaffold proteins that may require specific molecular function terms</p> </li> <li> <p>Add missing evidence: Provide evidence for all causal associations.</p> </li> <li> <p>Review evidence quality: Consider strengthening evidence codes where possible (e.g., from inference to direct experimental evidence).</p> </li> <li> <p>Ensure pathway completeness: Consider if any known regulators or components of the SIN pathway are missing from the model.</p> </li> <li> <p>Check additional linkages: Consider whether the SIN pathway should be connected to other pathways, such as cell cycle regulation or actomyosin ring assembly.</p> </li> </ol>"},{"location":"reviews/66187e4700002284-septation_initiation_signaling__GO_0031028__/#summary","title":"Summary","text":"<p>Overall, this is a well-structured GO-CAM model that accurately represents the septation initiation signaling pathway in S. pombe. It contains appropriate molecular functions, biological processes, and cellular components, and most causal associations are well supported by evidence.</p> <p>The main recommendations are to complete the missing molecular functions, add evidence for all causal associations, and ensure the model represents the complete current understanding of the SIN pathway.</p> <p>Model ID: gomodel:66187e4700002284</p>"},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/","title":"66187e4700002599 SECTM1 CD7 interaction leading to cytokine production upon T cell activation  Human","text":"<p>Now let me analyze the GO-CAM model in detail based on the information gathered:</p>"},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#review-of-go-cam-model-gomodel66187e4700002599","title":"Review of GO-CAM Model: gomodel:66187e4700002599","text":""},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#model-overview","title":"Model Overview","text":"<p>Title: SECTM1-CD7 interaction leading to cytokine production upon T-cell activation (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#model-components-and-activities","title":"Model Components and Activities","text":"<p>The model consists of four main molecular activities:</p> <ol> <li>IL-2 Cytokine Activity (GO:0005125)</li> <li>Enabled by: IL-2 (UniProtKB:P60568)</li> <li>Occurs in: Extracellular space (GO:0005615)</li> <li> <p>Part of: Interleukin-2-mediated signaling pathway (GO:0038110)</p> </li> <li> <p>Transmembrane Signaling Receptor Activity (GO:0004888)</p> </li> <li>Enabled by: CD7 (UniProtKB:P09564)</li> <li>Occurs in: Plasma membrane (GO:0005886)</li> <li>Part of: Positive regulation of T cell cytokine production (GO:0002726)</li> <li> <p>Causally affects: IL-2 cytokine activity via \"has input from\" (RO:0002407)</p> </li> <li> <p>Cytokine Activity (GO:0005125)</p> </li> <li>Enabled by: IFN-gamma (UniProtKB:P01579)</li> <li>Occurs in: Extracellular space (GO:0005615)</li> <li>Part of: Type II interferon-mediated signaling pathway (GO:0060333)</li> <li> <p>Causally affects: SECTM1 receptor ligand activity via \"has input from\" (RO:0002407)</p> </li> <li> <p>Receptor Ligand Activity (GO:0048018)</p> </li> <li>Enabled by: SECTM1 (UniProtKB:Q8WVN6)</li> <li>Occurs in: Plasma membrane (GO:0005886)</li> <li>Part of: Positive regulation of T cell cytokine production (GO:0002726)</li> <li>Causally affects: CD7 transmembrane signaling receptor activity via \"directly positively regulates\" (RO:0002629)</li> </ol>"},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#causal-flow-in-the-model","title":"Causal Flow in the Model","text":"<p>The model describes a signaling pathway where:</p> <ol> <li>IFN-gamma provides input for SECTM1's receptor ligand activity</li> <li>SECTM1 directly positively regulates CD7's transmembrane signaling receptor activity</li> <li>CD7 provides input for IL-2 cytokine activity</li> </ol> <p>This creates a causal chain: IFN-gamma \u2192 SECTM1 \u2192 CD7 \u2192 IL-2</p>"},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by literature:</p> <ul> <li>SECTM1-CD7 interaction is documented in PMID:10652336, which identified CD7 as a cognate of the SECTM1 (K12) protein</li> <li>IFN-gamma regulation of SECTM1 is supported by PMID:15742156, which showed that IFN-gamma induces SECTM1 expression in thymic epithelial cells</li> <li>CD7's role in T cell activation leading to IL-2 production is documented in multiple references</li> </ul>"},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#assessment","title":"Assessment","text":""},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological Accuracy: The model correctly captures the molecular interactions between SECTM1 and CD7, and the role of IFN-gamma in regulating SECTM1 expression.</p> </li> <li> <p>Proper Use of Causal Relations: The model uses appropriate causal relationships between activities (RO:0002407 \"has input from\" and RO:0002629 \"directly positively regulates\").</p> </li> <li> <p>Evidence Support: Each component of the model is supported by published literature evidence.</p> </li> <li> <p>Anatomical Context: Cellular locations are properly specified for each activity (extracellular space for cytokines, plasma membrane for receptors).</p> </li> <li> <p>Biological Process Context: Each activity is correctly associated with relevant biological processes.</p> </li> </ol>"},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I've identified a few potential points for improvement:</p> <ol> <li> <p>Causal Relation from IFN-gamma to SECTM1: The model uses RO:0002407 \"has input from\", but based on the literature, IFN-gamma induces SECTM1 expression, which might be better represented with RO:0002304 \"causally upstream of, positive effect\".</p> </li> <li> <p>Molecular Details of CD7 Signaling: The model does not capture the downstream signaling events after CD7 activation (such as the activation of specific kinases or transcription factors that lead to IL-2 production).</p> </li> <li> <p>Temporal Aspect: The model does not explicitly represent the temporal sequence - IFN-gamma induces SECTM1, which then interacts with pre-existing CD7 on T cells.</p> </li> </ol>"},{"location":"reviews/66187e4700002599-SECTM1_CD7_interaction_leading_to_cytokine_production_upon_T_cell_activation__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:66187e4700002599 is a well-constructed representation of the SECTM1-CD7 interaction leading to cytokine production upon T-cell activation. It accurately captures the key molecular players and their interactions in this signaling pathway, with proper evidence support from the literature.</p> <p>The model correctly represents that SECTM1 is a ligand for CD7, which leads to T cell activation and IL-2 production, and that IFN-gamma induces SECTM1 expression. All protein functions are correctly annotated based on their molecular activities and cellular locations.</p> <p>This model provides a valuable contribution to understanding the mechanisms of T cell activation and cytokine production, particularly in the context of human immune responses.</p>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/","title":"66187e4700002704 Inhibition of reelin signaling via ubiquitination and degradation of DAB1 by the ECS SOCS7  complex in the cortical plate of the developing cerebral cortex  Human","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model (gomodel:66187e4700002704).</p>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#review-of-go-cam-model-gomodel66187e4700002704","title":"Review of GO-CAM Model (gomodel:66187e4700002704)","text":""},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:66187e4700002704) is titled \"Inhibition of reelin signaling via ubiquitination and degradation of DAB1 by the ECS(SOCS7) complex in the cortical plate of the developing cerebral cortex (Human).\" It represents a key pathway in neuronal development, specifically how reelin signaling is regulated through DAB1 protein degradation.</p>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#biological-pathway-represented","title":"Biological Pathway Represented","text":"<p>The model captures the reelin-mediated signaling pathway which is critical for proper neuronal migration and positioning during brain development. The pathway represented includes:</p> <ol> <li>Reelin (RELN) acting as a receptor ligand</li> <li>Activation of LRP8 (reelin receptor)</li> <li>FYN kinase activation</li> <li>Phosphorylation of DAB1 (disabled homolog 1)</li> <li>SOCS7-mediated recruitment of an E3 ubiquitin ligase complex </li> <li>Ubiquitination and degradation of DAB1 by the CUL5-RBX2-SOCS7 complex</li> </ol> <p>This pathway is crucial for proper neuronal positioning in the developing cerebral cortex, as the regulated degradation of DAB1 helps control the extent and duration of reelin signaling.</p>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#components-and-molecular-functions","title":"Components and Molecular Functions","text":"<p>The model correctly represents several key proteins and their molecular functions:</p> <ol> <li>RELN (P78509) - Reelin acts as a receptor ligand (GO:0048018)</li> <li>LRP8 (Q14114-4) - Functions as a reelin receptor (GO:0038025)</li> <li>FYN (P06241) - Protein tyrosine kinase activity (GO:0004713)</li> <li>DAB1 (O75553) - Signaling adaptor activity (GO:0035591)</li> <li>SOCS7 (O14512) - Ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</li> <li>RNF7/RBX2 (Q9UBF6) - Ubiquitin protein ligase activity (GO:0061630) </li> <li>CUL5 (Q93034) - Ubiquitin ligase complex scaffold activity (GO:0160072)</li> </ol>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#causal-relationships","title":"Causal Relationships","text":"<p>The model properly captures the following causal relationships:</p> <ol> <li>RELN directly positively regulates (RO:0002629) LRP8</li> <li>LRP8 directly positively regulates (RO:0002629) FYN</li> <li>FYN directly provides input for (RO:0002413) SOCS7 and directly positively regulates (RO:0002629) DAB1</li> <li>SOCS7 directly positively regulates (RO:0002629) RNF7</li> <li>RNF7 directly negatively regulates (RO:0002630) DAB1</li> <li>CUL5 directly positively regulates (RO:0002629) SOCS7</li> </ol>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#biological-process-context","title":"Biological Process Context","text":"<p>All the activities are correctly placed in the context of relevant biological processes:</p> <ol> <li>RELN, LRP8, FYN, and DAB1 activities are parts of the reelin-mediated signaling pathway (GO:0038026)</li> <li>CUL5, SOCS7, and RNF7 activities are parts of the proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> </ol>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by evidence:</p> <ol> <li>Most relationships are supported by experimental evidence codes, primarily ECO:0000314 (direct assay evidence used in manual assertion) or ECO:0000250 (sequence similarity evidence used in manual assertion)</li> <li>The primary reference PMID:34518685 provides strong evidence for the CUL5-ARIH2 E3-E3 ubiquitin ligase structure and mechanism, which is directly relevant to the model</li> <li>Other references include PMID:16979591 and PMID:30873003 which further support the relationships in the model</li> </ol>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#assessment-of-model-quality","title":"Assessment of Model Quality","text":""},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the reelin signaling pathway and its regulation through ubiquitination</li> <li>The causal relationships between components are biologically sound and well-supported by evidence</li> <li>The model includes appropriate molecular function annotations for each protein</li> <li>The cellular location context is properly specified (extracellular space, plasma membrane, cytoplasm)</li> <li>The model follows GO-CAM best practices for representing complexes, as proteins with known activities are represented individually rather than using a complex ID</li> </ol>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Biological Process Annotation: While the model correctly places activities in relevant biological processes, it could benefit from explicitly including GO:0021819 (layer formation in cerebral cortex) as this is the ultimate biological outcome of this pathway.</p> </li> <li> <p>Cellular Localization Precision: The model could be enhanced by specifying that these events occur specifically in the cortical plate (UBERON:0005343) of the developing cerebral cortex.</p> </li> <li> <p>Completeness of E3 Ligase Complex: The model correctly represents the CUL5-RBX2-SOCS7 (ECS-SOCS7) complex, but it could be more complete by including the Elongin B and Elongin C components, which are known to be part of the ECS complex. However, this omission is acceptable according to GO-CAM complex annotation guidelines since the key functional components with known activities are represented.</p> </li> </ol>"},{"location":"reviews/66187e4700002704-Inhibition_of_reelin_signaling_via_ubiquitination_and_degradation_of_DAB1_by_the_ECS_SOCS7__complex_in_the_cortical_plate_of_the_developing_cerebral_cortex__Human__/#conclusions","title":"Conclusions","text":"<p>Overall, the GO-CAM model (gomodel:66187e4700002704) is a high-quality representation of the inhibition of reelin signaling via ubiquitination and degradation of DAB1 by the ECS(SOCS7) complex. The model correctly captures the causal relationships between components, provides appropriate context, and is well-supported by evidence.</p> <p>The model follows good GO-CAM annotation practices by correctly representing each component's molecular function and placing them in appropriate biological processes and cellular contexts. The representation of the E3 ligase complex is in accordance with GO-CAM guidelines for complex annotation, as it includes the components with known specific activities.</p> <p>This model successfully represents a key regulatory mechanism in neuronal development and provides a valuable resource for understanding how reelin signaling is regulated through DAB1 degradation.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/","title":"66187e4700002778 The reelin signaling pathway  Human","text":"<p>Based on all the information collected, I'll now review the GO-CAM model (gomodel:66187e4700002778) that represents the reelin signaling pathway in human.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#review-of-go-cam-model-66187e4700002778-the-reelin-signaling-pathway-human","title":"Review of GO-CAM Model 66187e4700002778: The reelin signaling pathway (Human)","text":""},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:66187e4700002778) represents the reelin signaling pathway in humans. The model includes the following key players: - RELN (Reelin, UniProtKB:P78509) - LRP8 (ApoER2, UniProtKB:Q14114-4) - DAB1 (Disabled homolog 1, UniProtKB:O75553) - FYN (Tyrosine-protein kinase Fyn, UniProtKB:P06241)</p> <p>The model captures the causal relationships between these proteins in the canonical reelin signaling pathway.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#model-accuracy-and-completeness","title":"Model Accuracy and Completeness","text":""},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#components-and-activities","title":"Components and Activities","text":"<p>The model correctly identifies the core components of the reelin signaling pathway:</p> <ol> <li> <p>RELN (Reelin): Represented with receptor ligand activity (GO:0048018), which is appropriate given its role as a secreted glycoprotein that binds to receptors.</p> </li> <li> <p>LRP8 (ApoER2): Represented with reelin receptor activity (GO:0038025), which is appropriate as LRP8 is one of the primary receptors for reelin.</p> </li> <li> <p>FYN: Represented with protein tyrosine kinase activity (GO:0004713), which is correct as Fyn is a tyrosine kinase that phosphorylates DAB1.</p> </li> <li> <p>DAB1: Represented with signaling adaptor activity (GO:0035591), which is appropriate as DAB1 is an adapter protein that mediates the reelin signaling cascade.</p> </li> </ol>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#causal-relationships","title":"Causal Relationships","text":"<p>The model correctly represents the following causal relationships: - RELN directly positively regulates LRP8 (RO:0002629) - LRP8 directly positively regulates FYN (RO:0002629) - FYN directly positively regulates DAB1 (RO:0002629)</p> <p>These relationships accurately reflect the canonical reelin signaling pathway where reelin binds to its receptors (LRP8/ApoER2), leading to activation of Fyn kinase, which then phosphorylates DAB1.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#cellular-locations","title":"Cellular Locations","text":"<p>The model correctly annotates the cellular locations of the proteins: - RELN in extracellular space (GO:0005615) - LRP8 in plasma membrane (GO:0005886) - DAB1 in cytoplasm (GO:0005737)</p> <p>These localizations are consistent with the known biology of these proteins.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#quality-issues-and-recommendations","title":"Quality Issues and Recommendations","text":""},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#1-missing-component-vldlr","title":"1. Missing Component: VLDLR","text":"<p>The model lacks the very low-density lipoprotein receptor (VLDLR), which is another important receptor for reelin alongside LRP8. The PMID:30873003 paper clearly demonstrates that both ApoER2 (LRP8) and VLDLR are involved in reelin signaling and both can mediate Dab1 phosphorylation. Genetic experiments have shown that only the double knockout of both receptors recapitulates the full \"reeler phenotype\" (Trommsdorff et al.), whereas loss of either receptor alone produces distinctive phenotypes on their own.</p> <p>Recommendation: Add VLDLR to the model with reelin receptor activity (GO:0038025) and show it being regulated by RELN similarly to LRP8.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#2-receptor-oligomerization","title":"2. Receptor Oligomerization","text":"<p>As demonstrated in PMID:30873003, both LRP8 (ApoER2) and VLDLR form homo-oligomers in the absence of reelin, and full-length reelin increases the size of these clusters, which is critical for signaling. The model does not capture this clustering behavior.</p> <p>Recommendation: Consider adding appropriate annotations to capture the oligomerization of receptors and how this is enhanced by reelin binding.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#3-phosphorylation-of-dab1","title":"3. Phosphorylation of DAB1","text":"<p>The model correctly shows FYN acting on DAB1, but it doesn't specifically capture the phosphorylation event. The PMID:16979591 and other references clearly show that Fyn phosphorylates DAB1 at specific tyrosine residues, which is a critical event in the signaling cascade.</p> <p>Recommendation: Explicitly annotate the phosphorylation of DAB1 by FYN, possibly using a more specific GO term for the activity.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#4-biological-process-annotations","title":"4. Biological Process Annotations","text":"<p>While the model correctly includes the reelin-mediated signaling pathway (GO:0038026) as a biological process, it could benefit from additional biological process annotations that capture the downstream effects of this pathway, such as neuronal migration or layer formation in the cerebral cortex.</p> <p>Recommendation: Add additional biological process terms to capture the downstream effects of reelin signaling, such as \"layer formation in cerebral cortex\" (GO:0021819).</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#5-evidence-codes","title":"5. Evidence Codes","text":"<p>The model uses ECO:0000250 (sequence similarity evidence used in manual assertion) and ECO:0000314 (direct assay evidence used in manual assertion) as evidence codes, which are appropriate. However, for some assertions, more specific evidence could be provided, especially from human studies where available.</p> <p>Recommendation: Ensure all assertions have appropriate evidence codes and citations, preferably from human studies when available.</p>"},{"location":"reviews/66187e4700002778-The_reelin_signaling_pathway__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:66187e4700002778 provides a good representation of the core components and causal relationships in the reelin signaling pathway in humans. However, it could be improved by adding VLDLR as another reelin receptor, capturing receptor oligomerization, explicitly annotating the phosphorylation of DAB1, adding more specific biological process annotations, and ensuring all assertions have appropriate evidence.</p> <p>Overall, the model is scientifically sound but would benefit from these enhancements to provide a more complete and detailed representation of reelin signaling.</p>"},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/","title":"66187e4700002881 IFNA1 CR2 role in B cell ISGs induction  Human","text":"<p>Now that I have the model details and supporting information, I'll conduct a thorough review of GO-CAM model gomodel:66187e4700002881 titled \"IFNA1-CR2 role in B-cell ISGs induction (Human)\".</p>"},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/#review-of-go-cam-model-66187e4700002881-ifna1-cr2-role-in-b-cell-isgs-induction-human","title":"Review of GO-CAM Model 66187e4700002881: IFNA1-CR2 role in B-cell ISGs induction (Human)","text":""},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model describes the interaction between Interferon alpha-1 (IFNA1) and Complement receptor type 2 (CR2) in the induction of interferon-stimulated genes (ISGs) in human B-cells. The model outlines the signaling pathway from IFNA1 binding to CR2, which then activates downstream effectors (EIF2AK2/PKR and MX1) in the antiviral innate immune response.</p>"},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model consists of 4 main activity units:</p> <ol> <li>IFNA1 (P01562) with cytokine activity (GO:0005125) in the extracellular space</li> <li>CR2 (P20023) with transmembrane signaling receptor activity (GO:0004888) in the plasma membrane</li> <li>MX1 (P20591) with GTPase activity (GO:0003924) in the cytoplasm</li> <li>EIF2AK2/PKR (P19525) with kinase activity (GO:0016301) in the cytoplasm</li> </ol> <p>The model establishes causal connections using RO:0002407 (provides input for) from CR2 to both MX1 and EIF2AK2, and RO:0002629 (directly positively regulates) from IFNA1 to CR2.</p> <p>All activities are part of the type I interferon-mediated signaling pathway (GO:0060337).</p>"},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/#key-evidence-assessment","title":"Key Evidence Assessment","text":"<p>The model cites several PMIDs as evidence, primarily: - PMID:1849076 (Delcayre et al., 1991) - Documents CR2 as an interferon alpha receptor - PMID:30936491 (Review on interferon signaling) - PMID:21859714 (Interaction of MX1 with cellular RNA helicases) - PMID:21123651 (Phosphorylation of NFAR proteins by PKR) - PMID:22948139 (Role of PKR in antiviral immune response) - PMID:25930096 (MX1 role in antiviral innate immune response)</p>"},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model accurately represents a non-canonical interferon signaling pathway through CR2 (not the typical IFNAR1/2 complex), which is supported by literature.</li> <li>The molecular activities are correctly annotated with appropriate GO terms.</li> <li>The cellular locations are appropriate for each protein (extracellular for IFNA1, plasma membrane for CR2, cytoplasm for MX1 and EIF2AK2).</li> <li>The causal relationships are consistent with the biological process of type I interferon signaling.</li> <li>The evidence provided (PMIDs) supports the interactions represented in the model.</li> </ol>"},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing host cell receptor annotation: According to the GO-CAM signaling receptor activity annotation guidelines, when a ligand binds to a receptor, the relationship should be \"has input\" from the ligand to the receptor, but this is not included in the model. Currently, IFNA1 directly positively regulates CR2, which is correct, but the input relationship is missing.</p> </li> <li> <p>Receptor target specification: For the CR2 receptor, the guideline states that the receptor's input should be the effector protein it regulates, but the model does not specify CR2's direct input. Instead, it shows CR2 providing input for both downstream effectors (MX1 and EIF2AK2) which would benefit from additional mechanistic clarification.</p> </li> <li> <p>Limited ISG representation: Despite the title mentioning \"ISGs induction,\" the model only includes two ISGs (MX1 and EIF2AK2/PKR). The model would benefit from including additional relevant ISGs or at least mentioning the broader ISG induction process.</p> </li> <li> <p>Missing molecular mechanisms: The model doesn't detail the precise molecular mechanisms of how CR2 activation leads to MX1 and EIF2AK2 activation. Additional intermediate steps in this signaling pathway would strengthen the model.</p> </li> <li> <p>Evidence updates: While PMID:1849076 is a solid foundation for the IFNA1-CR2 interaction, it's from 1991. Adding more recent evidence for this interaction would strengthen the model.</p> </li> </ol>"},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add an \"has input\" relationship from IFNA1 to CR2 to properly annotate the ligand-receptor interaction according to guidelines.</p> </li> <li> <p>Consider adding the specific downstream targets of CR2 activation with appropriate evidence.</p> </li> <li> <p>Expand the model to include additional ISGs and/or the broader mechanisms of ISG induction.</p> </li> <li> <p>Add intermediate steps in the signaling pathway between CR2 and the effector proteins MX1 and EIF2AK2.</p> </li> <li> <p>Include more recent evidence for the IFNA1-CR2 interaction if available in the literature.</p> </li> <li> <p>Consider adding information on how this non-canonical signaling pathway integrates with the canonical type I interferon signaling through IFNAR1/2 complex.</p> </li> </ol>"},{"location":"reviews/66187e4700002881-IFNA1_CR2_role_in_B_cell_ISGs_induction__Human_/#conclusion","title":"Conclusion","text":"<p>The model gomodel:66187e4700002881 provides a valid representation of the IFNA1-CR2 interaction in B-cell ISG induction, supported by evidence from the literature. The causal relationships and GO annotations are appropriate, though the model could be enhanced by adding more detailed molecular mechanisms and by adhering more strictly to the signaling receptor activity annotation guidelines. With these improvements, this model would provide a more comprehensive representation of this non-canonical interferon signaling pathway in human B-cells.</p>"},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/","title":"66187e4700003043 GDP mannose biosynthetic process from glucose  Mouse","text":"<p>Based on my analysis of the GO-CAM model and the associated literature, I'll now provide a review of the model \"GDP-mannose biosynthetic process from glucose (Mouse)\" with ID gomodel:66187e4700003043.</p>"},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/#review-of-go-cam-model-gdp-mannose-biosynthetic-process-from-glucose-mouse","title":"Review of GO-CAM Model: GDP-mannose biosynthetic process from glucose (Mouse)","text":""},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the GDP-mannose biosynthetic pathway in mice, starting from glucose rather than mannose. The pathway consists of 5 connected activities performed by different mouse proteins, culminating in the production of GDP-mannose, which is an essential precursor for glycosylation processes.</p>"},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/#model-structure-and-flow","title":"Model Structure and Flow","text":"<p>The model depicts a linear pathway with the following activities connected by causal relationships:</p> <ol> <li>Hexokinase 1 (HK1, MGI:MGI:96103) - catalyzes the conversion of D-glucopyranose to alpha-D-glucose 6-phosphate in the cytosol</li> <li>Glucose-6-phosphate isomerase (GPI1, MGI:MGI:95797) - converts alpha-D-glucose 6-phosphate to beta-D-fructofuranose 6-phosphate</li> <li>Mannose-6-phosphate isomerase (MPI, MGI:MGI:97075) - converts beta-D-fructofuranose 6-phosphate to D-mannose 6-phosphate</li> <li>Phosphomannomutase 2 (PMM2, MGI:MGI:1859214) - converts D-mannose 6-phosphate to alpha-D-mannose 1-phosphate</li> <li>GDP-mannose pyrophosphorylase B (GMPPB, MGI:MGI:2660880) - uses alpha-D-mannose 1-phosphate and GTP to generate GDP-alpha-D-mannose and diphosphate</li> </ol> <p>Each activity is properly connected via the \"provides input for\" (RO:0002413) causal relationship, showing the progression of substrates through the pathway.</p>"},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Appropriate Gene Products: The model uses the correct mouse genes for each step of the pathway.</p> </li> <li> <p>Correct Substrates and Products: Each activity has the appropriate inputs and outputs, matching the enzymatic reactions described in the literature.</p> </li> <li> <p>Subcellular Location: All activities are annotated as occurring in the cytosol (GO:0005829), which is accurate for this metabolic pathway.</p> </li> <li> <p>Evidence Support: The model includes appropriate evidence codes and literature references for each assertion.</p> </li> <li> <p>Pathway Context: Each activity is appropriately linked to the GDP-mannose biosynthetic process (GO:0009298).</p> </li> </ol>"},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Complete Evidence for Locations: While the subcellular locations are properly annotated, some of the evidence references could be strengthened. For example, the evidence for HK1 being in the cytosol uses PMID:12420306, which is appropriate.</p> </li> <li> <p>Biological Process Consistency: All activities are annotated as being part of GO:0009298 (GDP-mannose biosynthetic process), which is correct. However, it would be beneficial to also include annotations to more specific processes where applicable, such as GO:0061729 (GDP-mannose biosynthetic process from fructose-6-phosphate) for the MPI activity.</p> </li> <li> <p>Evidence Specificity: Some evidence codes use sequence orthology (ECO:0000266) rather than direct experimental evidence in mice. This is acceptable when mouse-specific data is unavailable, but where possible, mouse-specific evidence would strengthen the model.</p> </li> </ol>"},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/#literature-alignment","title":"Literature Alignment","text":"<p>The model aligns well with the literature regarding the GDP-mannose biosynthetic pathway:</p> <ol> <li> <p>PMID:27053713 provides evidence for PMM2 activity in this pathway, showing how defects in this enzyme cause congenital disorders of glycosylation. This study demonstrated that PMM2 activity is responsible for the conversion of mannose-6-phosphate to mannose-1-phosphate.</p> </li> <li> <p>PMID:35006422 supports the role of GMPPB in catalyzing the formation of GDP-mannose, and its mutations lead to GMPPB-associated congenital disorders of glycosylation.</p> </li> <li> <p>PMID:12122025 provides evidence for MPI's role in converting fructose-6-phosphate to mannose-6-phosphate.</p> </li> </ol>"},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/#pathway-biology-correctness","title":"Pathway Biology Correctness","text":"<p>The model correctly represents the sequence of enzymatic activities in the GDP-mannose biosynthetic pathway starting from glucose. This pathway is essential for providing GDP-mannose, which serves as a sugar donor for various glycosylation processes including N-glycosylation, O-mannosylation, C-mannosylation, and GPI-anchor formation.</p> <p>The model correctly shows that glucose is first phosphorylated to glucose-6-phosphate, then isomerized to fructose-6-phosphate, which is then converted to mannose-6-phosphate, followed by conversion to mannose-1-phosphate, and finally to GDP-mannose.</p>"},{"location":"reviews/66187e4700003043-GDP_mannose_biosynthetic_process_from_glucose__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:66187e4700003043) is a well-constructed representation of the GDP-mannose biosynthetic pathway from glucose in mice. It includes the correct molecular activities, gene products, inputs/outputs, subcellular locations, and causal connections. The model is supported by appropriate evidence and aligns with the current understanding of this metabolic pathway.</p> <p>The model meets the GO-CAM best practices and effectively communicates the biological knowledge about this pathway in a clear and accessible manner, making it a valuable resource for understanding the GDP-mannose biosynthetic process.</p>"},{"location":"reviews/66187e4700003150-adenylate_cyclase_activating_G_protein_coupled_receptor_signaling_pathway__GO_0007189_/","title":"66187e4700003150 adenylate cyclase activating G protein coupled receptor signaling pathway  GO 0007189","text":"<p>Based on my review of the GO-CAM model (gomodel:66187e4700003150) and the GO-CAM guidelines, I'm now prepared to provide a comprehensive assessment. The model represents a G protein-coupled receptor signaling pathway in fission yeast (S. pombe).</p>"},{"location":"reviews/66187e4700003150-adenylate_cyclase_activating_G_protein_coupled_receptor_signaling_pathway__GO_0007189_/#go-cam-review-adenylate-cyclase-activating-g-protein-coupled-receptor-signaling-pathway-gomodel66187e4700003150","title":"GO-CAM Review: \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\" (gomodel:66187e4700003150)","text":""},{"location":"reviews/66187e4700003150-adenylate_cyclase_activating_G_protein_coupled_receptor_signaling_pathway__GO_0007189_/#overview","title":"Overview","text":"<p>This model represents a G protein-coupled receptor (GPCR) signaling pathway in the fission yeast Schizosaccharomyces pombe (NCBITaxon:4896), specifically focusing on the adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway (GO:0010619). The model includes receptor activation, G-protein coupling, adenylate cyclase activity, and downstream signaling events including transcriptional regulation.</p>"},{"location":"reviews/66187e4700003150-adenylate_cyclase_activating_G_protein_coupled_receptor_signaling_pathway__GO_0007189_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures the essential components of the GPCR signaling cascade, from the membrane receptor (Git3) to downstream effectors.</p> </li> <li> <p>Well-evidenced activities: Most activities are supported by appropriate experimental evidence with relevant PMIDs.</p> </li> <li> <p>Proper causal relationships: The model correctly uses causal relationship predicates (RO:0002304, RO:0002629, RO:0002630) to connect activities in the signaling cascade.</p> </li> <li> <p>Appropriate cellular components: Activities are annotated with appropriate subcellular locations (plasma membrane, cytoplasm, etc.).</p> </li> <li> <p>Molecular inputs and outputs: For enzymatic reactions like adenylate cyclase (Cyr1) and phosphodiesterase (Cgs2), the model correctly represents chemical inputs and outputs (ATP \u2192 cAMP, and cAMP \u2192 AMP).</p> </li> </ol>"},{"location":"reviews/66187e4700003150-adenylate_cyclase_activating_G_protein_coupled_receptor_signaling_pathway__GO_0007189_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing molecular function for Git7: Activity (gomodel:66187e4700003150/662af8fa00000685) for Git7 is annotated with the generic \"molecular_function\" (GO:0003674) without specific function defined, which should be replaced with a more specific term when evidence is available.</p> </li> <li> <p>Evidence gaps: Some causal associations lack evidence annotations, particularly:</p> </li> <li>The causal relationship between Git7 (SPBC36.12c) and Cyr1 (SPBC19C7.03)</li> <li> <p>Some other relationships also have limited evidence documentation</p> </li> <li> <p>G-protein complex representation: According to the \"How to annotate complexes in GO-CAM\" guidelines, the G-protein complex components (Gpa2, Git5, Git11) are appropriately represented by their individual activities, but there could be clearer annotations about how they form the heterotrimeric G-protein complex.</p> </li> <li> <p>Signaling receptor annotation: Based on the \"Signaling receptor activity annotation guidelines\", the GPCR Git3 (SPCC1753.02c) is correctly annotated with a receptor activity (GO:1990576) and occurs in the plasma membrane. However, the model could more explicitly capture the small molecule activator relationship with glucose.</p> </li> <li> <p>Biological process cohesion: While most activities are appropriately part of GO:0010619 (adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway), some activities are part of the negative regulation process (GO:0110034) but could benefit from clearer annotation of how they connect back to the main process.</p> </li> </ol>"},{"location":"reviews/66187e4700003150-adenylate_cyclase_activating_G_protein_coupled_receptor_signaling_pathway__GO_0007189_/#technical-recommendations","title":"Technical Recommendations","text":"<ol> <li> <p>Add missing molecular function: Define a specific molecular function for Git7 (SPBC36.12c) based on available literature evidence.</p> </li> <li> <p>Complete evidence documentation: Add evidence annotations for all causal relationships, particularly for Git7's effect on Cyr1.</p> </li> <li> <p>Enhance small molecule representation: Consider explicitly representing glucose as a small molecule activator of the Git3 receptor using the appropriate relationship.</p> </li> <li> <p>Review regulatory loops: The model includes negative regulation components (Cgs2, Sck1), which appear to represent a feedback mechanism. Consider reviewing this against the \"Regulation and Regulatory Processes in GO-CAM\" guidelines to ensure proper representation.</p> </li> <li> <p>Maintain consistency in evidence types: The model uses a mix of evidence codes (ECO:0000314, ECO:0000315, ECO:0000353); while this is valid, ensure that the strongest available evidence is used for each annotation.</p> </li> </ol>"},{"location":"reviews/66187e4700003150-adenylate_cyclase_activating_G_protein_coupled_receptor_signaling_pathway__GO_0007189_/#biological-assessment","title":"Biological Assessment","text":"<p>The model accurately represents what is known about GPCR signaling in fission yeast, where the Git3 receptor senses glucose leading to activation of the heterotrimeric G-protein complex (Gpa2-Git5-Git11), which then activates adenylate cyclase (Cyr1) to produce cAMP. This pathway is crucial for nutrient sensing and adaptation to glucose in fission yeast.</p> <p>The negative regulation components through phosphodiesterase (Cgs2) and PKA-mediated signaling are biologically accurate and reflect the known feedback mechanisms in this pathway.</p>"},{"location":"reviews/66187e4700003150-adenylate_cyclase_activating_G_protein_coupled_receptor_signaling_pathway__GO_0007189_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:66187e4700003150) is a well-constructed representation of the adenylate cyclase-activating G protein-coupled receptor signaling pathway in S. pombe. With some minor improvements to molecular function specificity and evidence documentation, it would be an excellent reference model for this pathway. The model follows most GO-CAM best practices and presents a biologically accurate view of GPCR signaling in fission yeast.</p>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/","title":"662af8fa00000002 BTRC is ubiquitinated and degraded by a Cul5 RING ubiquitin ligase complex  Human","text":"<p>Now that I have all the information needed, let me review the GO-CAM model \"BTRC is ubiquitinated and degraded by a Cul5-RING ubiquitin ligase complex (Human).\"</p>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#review-of-go-cam-model-gomodel662af8fa00000002","title":"Review of GO-CAM Model: gomodel:662af8fa00000002","text":""},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model (gomodel:662af8fa00000002) titled \"BTRC is ubiquitinated and degraded by a Cul5-RING ubiquitin ligase complex (Human)\" represents the ubiquitination and degradation pathway of \u03b2-TrCP1 (BTRC) protein through a Cullin5-based E3 ubiquitin ligase complex (CRL5) working with specific E2 ubiquitin-conjugating enzymes.</p>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#key-findings-from-the-review","title":"Key Findings from the Review","text":""},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#model-structure-and-connectivity","title":"Model Structure and Connectivity","text":"<p>The model correctly depicts several key molecular activities and their causal relationships:</p> <ol> <li>RNF7/RBX2/SAG (Q9UBF6) with ubiquitin protein ligase activity (GO:0061630) directly negatively regulates (\"RO:0002630\") BTRC activity</li> <li>UBE2S (Q16763) and UBE2C/UBCH10 (O00762) both have ubiquitin conjugating enzyme activity (GO:0061631) and directly positively regulate (\"RO:0002629\") RNF7's ubiquitin ligase activity</li> <li>CUL5 (Q93034) has ubiquitin ligase complex scaffold activity (GO:0160072) and provides input for (\"RO:0002407\") RNF7's activity</li> <li>BTRC (Q9Y297) has ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</li> </ol>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#evidence-and-annotations","title":"Evidence and Annotations","text":"<ul> <li>All molecular activities are supported by evidence from published literature (primarily PMID:27910872)</li> <li>The model is properly annotated with appropriate GO terms for molecular functions</li> <li>All activities are properly placed in the relevant biological processes (protein K11-linked ubiquitination, SCF-dependent proteasomal degradation)</li> </ul>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model accurately represents the findings from the primary literature source (Kuang et al., 2016), which demonstrated:</p> <ol> <li>SAG-CUL5 (but not RBX1-CUL1) promotes the ubiquitination and degradation of \u03b2-TrCP1</li> <li>This ubiquitination occurs via an atypical K11-linkage mediated by E2 enzymes UBCH10/UBE2C and UBE2S</li> <li>This establishes a cross-talk between CRL5 and CRL1 E3 ubiquitin ligase complexes</li> </ol>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model follows the GO-CAM best practices for representing complexes: - Each subunit with a known molecular activity is represented with its specific molecular function - The causal relationships between activities are appropriate for the biological process - CUL5's scaffold role is represented first, providing input for the downstream activities</p>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Mechanistic Detail: The model captures the selective E2-E3 interactions that determine ubiquitin chain specificity (K11 linkage)</li> <li>Biological Insight: It represents an important regulatory cross-talk between two E3 ligase systems (CRL5 and CRL1/SCF)</li> <li>Clear Causality: The causal relationships between activities accurately reflect the biochemical sequence of events</li> <li>Strong Evidence Base: All assertions are supported by experimental evidence from the primary literature</li> </ol>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#recommendations","title":"Recommendations","text":"<p>The model is well-constructed and accurately represents the biology described in the literature. No significant modifications are needed.</p>"},{"location":"reviews/662af8fa00000002-BTRC_is_ubiquitinated_and_degraded_by_a_Cul5_RING_ubiquitin_ligase_complex__Human__/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 662af8fa00000002 represents an accurate and well-supported depiction of the ubiquitination and degradation of BTRC by the CUL5-RNF7 ubiquitin ligase complex with UBE2C and UBE2S as E2 enzymes. The model effectively captures the novel finding that SAG/RBX2 mediates K11-linked ubiquitination through specific E2 interactions, establishing cross-talk between different E3 ubiquitin ligase complexes.</p> <p>This model provides valuable biological insight into the regulation of E3 ligase systems and protein degradation pathways, with potential implications for understanding cell cycle regulation, signaling, and disease processes associated with the NF-\u03baB pathway where BTRC plays important roles.</p>"},{"location":"reviews/662af8fa00000408-ubiquinone_metabolic_process__GO_0006743___/","title":"662af8fa00000408 ubiquinone metabolic process  GO 0006743","text":"<p>Based on my review, I'll now provide a detailed assessment of the GO-CAM model 662af8fa00000408.</p>"},{"location":"reviews/662af8fa00000408-ubiquinone_metabolic_process__GO_0006743___/#review-of-go-cam-model-gomodel662af8fa00000408","title":"Review of GO-CAM Model: gomodel:662af8fa00000408","text":""},{"location":"reviews/662af8fa00000408-ubiquinone_metabolic_process__GO_0006743___/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the ubiquinone (Coenzyme Q10) metabolic process in Schizosaccharomyces pombe (fission yeast). The model focuses on the biosynthetic pathway of CoQ10, showing the activities and relationships between multiple proteins involved in this process.</p>"},{"location":"reviews/662af8fa00000408-ubiquinone_metabolic_process__GO_0006743___/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Comprehensive pathway representation: The model effectively captures the main steps of the CoQ10 biosynthetic pathway in S. pombe, including:</li> <li>The initial steps of isoprenoid synthesis (Fps1, Spo9)</li> <li>Multiple steps of benzoquinone modification (Coq3, Coq5, Coq6, Coq7)</li> <li>The precursor transfer step (Ppt1)</li> <li> <p>The final product (CoQ10) is properly specified as the output</p> </li> <li> <p>Appropriate cellular localization: The model correctly annotates the subcellular locations of the activities:</p> </li> <li>Mitochondrial inner membrane and extrinsic components for most Coq proteins</li> <li> <p>Cytosolic location for isoprenoid synthesis enzymes</p> </li> <li> <p>Clear causal relationships: The model uses appropriate causal relationships between activities, mostly using:</p> </li> <li>RO:0002413 (provides input for) for sequential steps</li> <li> <p>RO:0002629 (directly positively regulates) for the regulatory role of Azr1</p> </li> <li> <p>Evidence support: Activities are supported by appropriate evidence codes and references, including:</p> </li> <li>Literature references (PMIDs)</li> <li>Appropriate ECO evidence codes</li> <li> <p>Reference to orthologous proteins from other organisms where applicable</p> </li> <li> <p>Regulatory aspects: The inclusion of Azr1's protein serine/threonine phosphatase activity as a regulator of CoQ10 biosynthesis aligns with the literature.</p> </li> </ol>"},{"location":"reviews/662af8fa00000408-ubiquinone_metabolic_process__GO_0006743___/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Duplicate causal relationships:    There are several instances where the same causal relationship between two activities is represented twice. For example:</li> <li>Two identical causal relationships from Fps1 to Dlp1/Dps1</li> <li>Two identical causal relationships from Spo9 to Dlp1/Dps1</li> <li>Two identical causal relationships from Azr1 to Coq7</li> </ol> <p>Recommendation: Remove duplicate causal relationships to maintain model clarity.</p> <ol> <li>Coq10 representation:    The model includes Coq10 as a molecular carrier activity that takes CoQ10 as input, but there are no causal relationships linking this activity to other parts of the pathway. Based on the literature I reviewed, Coq10 is a CoQ-binding protein that facilitates the use of CoQ in the respiratory chain.</li> </ol> <p>Recommendation: Either add appropriate causal relationships showing how Coq10 relates to the other activities, or include a note explaining its role in CoQ10 utilization rather than biosynthesis.</p> <ol> <li>Missing decarboxylation step:    According to the literature, the CoQ10 biosynthesis pathway includes a decarboxylation step that is performed by an unknown enzyme in S. pombe. This step isn't explicitly represented in the model.</li> </ol> <p>Recommendation: If possible, include this step in the pathway, even if the specific protein is unknown.</p> <ol> <li>Organization of the pathway:    While the causal relationships are accurate, the flow of activities could be more clearly organized to reflect the linear progression of the pathway from isoprenoid synthesis to final CoQ10 production.</li> </ol> <p>Recommendation: Reorganize the visual layout to better represent the sequential nature of the pathway.</p> <ol> <li>Consistency in annotation:    Some activities have extensive evidence annotations while others have minimal evidence. For example, the evidence for Coq10's role has empty evidence fields.</li> </ol> <p>Recommendation: Ensure consistent evidence annotation across all activities.</p>"},{"location":"reviews/662af8fa00000408-ubiquinone_metabolic_process__GO_0006743___/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on the literature I reviewed, the model generally represents the biological process accurately:</p> <ol> <li> <p>The model correctly shows that S. pombe produces CoQ10 with ten isoprene units, unlike S. cerevisiae which produces CoQ6.</p> </li> <li> <p>The enzyme relationships match what is known about the CoQ10 biosynthetic pathway in S. pombe.</p> </li> <li> <p>The inclusion of Azr1 as a regulatory protein is supported by literature showing that it positively regulates the ubiquinone biosynthetic process.</p> </li> <li> <p>The model correctly represents that decaprenyl diphosphate synthase in S. pombe is a heterotetramer composed of Dps1 and Dlp1, unlike in S. cerevisiae where it's a homomer.</p> </li> </ol>"},{"location":"reviews/662af8fa00000408-ubiquinone_metabolic_process__GO_0006743___/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that accurately represents the ubiquinone metabolic process in S. pombe. It captures the key proteins, their activities, and the causal relationships between them. The few issues noted are primarily related to redundant relationships and organization rather than biological accuracy.</p> <p>The model will be valuable for researchers studying coenzyme Q biosynthesis in yeast and comparing it with other organisms. It successfully integrates information from multiple published studies to provide a comprehensive view of this important metabolic pathway.</p> <p>I recommend accepting this model with minor revisions to address the duplicate causal relationships and to clarify the role of Coq10 in the pathway.</p>"},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/","title":"662af8fa00002225 Gsdmd palmitoylation by Zdhhc5 and Zdhhc9 promotes pyroptosis  Mouse","text":"<p>Based on the model details and the literature I've reviewed, I'll now provide a comprehensive review of GO-CAM model 662af8fa00002225 \"Gsdmd palmitoylation by Zdhhc5 and Zdhhc9 promotes pyroptosis (Mouse)\".</p>"},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/#review-of-go-cam-model-gomodel662af8fa00002225","title":"Review of GO-CAM Model: gomodel:662af8fa00002225","text":""},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/#summary","title":"Summary","text":"<p>This model captures the molecular pathway of GSDMD (Gasdermin D) palmitoylation by ZDHHC5 and ZDHHC9, which promotes pyroptosis in mouse. The model describes how caspase-4 cleaves GSDMD, allowing GSDMD to form pores in the plasma membrane, leading to pyroptotic cell death.</p>"},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/#structure-and-content-assessment","title":"Structure and Content Assessment","text":""},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Evidence and References: The model is well-supported with appropriate references (PMIDs: 30135078, 38530158, 27339137, etc.) and evidence codes (ECO:0000314, ECO:0000250, ECO:0000315).</p> </li> <li> <p>Causal Associations: The causal relationships between activities are logically established, showing a clear pathway from palmitoylation to pyroptosis.</p> </li> <li> <p>Cellular Compartments: Each activity has appropriate cellular compartment specifications (plasma membrane, cytosol, etc.).</p> </li> <li> <p>Process Associations: Each activity is placed in its correct biological process context.</p> </li> </ol>"},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Tax\ud800\udd4don Inconsistency: The model title specifies \"Mouse\" but the taxon field is set to \"NCBITaxon:9606\" (human). This should be corrected to \"NCBITaxon:10090\" (mouse) to match the model content, as all the proteins are mouse proteins (MGI IDs).</p> </li> <li> <p>Causal Association Evidence: Some causal associations lack explicit evidence codes and references, particularly:</p> </li> <li>The causal association between GSDMD's phosphatidylinositol-4,5-bisphosphate binding (662af8fa00002245) and wide pore channel activity (662af8fa00002249)</li> <li> <p>The causal association between Casp4's activity (662af8fa00002231) and GSDMD's binding activity (662af8fa00002245)</p> </li> <li> <p>Incomplete Predicate Use: While the model correctly uses RO:0002629 (directly positively regulates) and RO:0002304 (causally upstream of, positive effect), it also uses RO:0002407 which appears to be potentially incorrect or outdated. The intended relationship was likely one of the standard causal predicates.</p> </li> <li> <p>Pathway Completeness: Based on PMID:38530158, ROS also facilitates the palmitoylation process, but this is not captured in the model. Consider adding this aspect for completeness.</p> </li> </ol>"},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":"<ol> <li> <p>Mechanism Accuracy: The model correctly captures that ZDHHC5 and ZDHHC9 are palmitoylating GSDMD at Cys191/Cys192, which is supported by the reference (PMID:38530158).</p> </li> <li> <p>Cleavage Process: According to PMID:30135078, Caspase-4 (Casp4) cleaves GSDMD at Asp276, which is an essential step for pyroptosis. While the cleavage activity is represented, the specific cleavage site could be more explicitly captured.</p> </li> <li> <p>Pore Formation Mechanism: The sequence of events from phosphatidylinositol-4,5-bisphosphate binding to wide pore channel formation is accurately represented, aligning with the literature (PMID:27339137).</p> </li> <li> <p>NLRP3 Connection: The model includes NLRP3's signaling adaptor activity, which is connected to the pathway. This is consistent with the role of NLRP3 in pyroptosis as described in the literature.</p> </li> </ol>"},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Fix Taxon: Change the taxon from human (NCBITaxon:9606) to mouse (NCBITaxon:10090) to match the model content.</p> </li> <li> <p>Add Evidence to Causal Associations: Provide evidence codes and references for all causal associations.</p> </li> <li> <p>Review Predicates: Ensure all relationship predicates are correctly applied, especially checking RO:0002407.</p> </li> <li> <p>Consider Adding ROS Facilitation: The paper mentioned that reactive oxygen species (ROS) facilitate the palmitoylation process - this could be added to the model for completeness.</p> </li> <li> <p>Add Specificity to Cleavage Site: Consider adding information about the specific cleavage site (Asp276) in GSDMD, which is critical for its activation.</p> </li> <li> <p>Consider Adding FASN: PMID:38530158 mentions Fatty Acid Synthase (FASN) as a GSDMD-binding partner. Consider adding this interaction to the model if it provides important context.</p> </li> </ol>"},{"location":"reviews/662af8fa00002225-Gsdmd_palmitoylation_by_Zdhhc5_and_Zdhhc9_promotes_pyroptosis__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that effectively captures the molecular pathway of GSDMD palmitoylation by ZDHHC5 and ZDHHC9 leading to pyroptosis. With the suggested improvements, particularly fixing the taxon inconsistency and adding evidence to all causal associations, the model will more accurately represent the biological process and align better with GO-CAM best practices.</p>"},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/","title":"662af8fa00002332 CD28 GRB2 axis leading to  RAS activation  Human","text":"<p>Now that I have reviewed the GO-CAM model and related proteins, I'll provide a detailed review of the model.</p>"},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/#review-of-go-cam-model-cd28grb2-axis-leading-to-ras-activation-human","title":"Review of GO-CAM Model: CD28/GRB2 axis leading to RAS activation (Human)","text":""},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:662af8fa00002332) represents the CD28/GRB2 axis that leads to RAS activation in human T cells. The model describes the signaling pathway initiated by CD80/CD86 binding to CD28, which triggers a cascade through GRB2 adaptor recruitment leading to activation of guanyl-nucleotide exchange factors (GEFs) such as VAV1 and SOS1.</p>"},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model accurately represents the well-established CD28 co-stimulatory pathway that is critical for T cell activation. Key features include:</p> <ol> <li> <p>Receptor-Ligand Interactions: The model correctly shows that both CD80 (P33681) and CD86 (P42081) function as receptor ligands that positively regulate CD28's coreceptor activity. This is consistent with literature showing these molecules are primary costimulatory ligands for CD28.</p> </li> <li> <p>CD28 Signaling: CD28 (P10747) is appropriately annotated with coreceptor activity (GO:0015026) and is shown to directly positively regulate GRB2 (P62993), which is supported by multiple studies (including PMID:9784967).</p> </li> <li> <p>GRB2 Adaptor Function: GRB2 is correctly annotated with molecular adaptor activity (GO:0030674), which is its primary function in signaling cascades as documented in UniProt.</p> </li> <li> <p>GEF Activation: The model shows GRB2 directly positively regulating both VAV1 (P15498) and SOS1 (Q07889), which are both annotated with guanyl-nucleotide exchange factor activity (GO:0005085). This is consistent with the established role of GRB2 in recruiting these GEFs during T cell activation.</p> </li> </ol>"},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/#structure-and-connectivity","title":"Structure and Connectivity","text":"<p>The model has a clear and logical flow with appropriate causal relationships:</p> <ol> <li> <p>The causal relationships use proper RO terms (RO:0002629 \"directly positively regulates\") to connect activities.</p> </li> <li> <p>All activities are connected in a biologically meaningful way that reflects the signaling flow from cell surface receptors (CD80/CD86) to CD28 to GRB2 to downstream GEFs.</p> </li> <li> <p>Each protein's activity is appropriately localized: CD80, CD86, and CD28 at the plasma membrane (GO:0005886), while GRB2, VAV1, and SOS1 in the cytoplasm (GO:0005737).</p> </li> <li> <p>All activities are correctly placed in the context of T cell activation (GO:0042110) or T cell costimulation (GO:0031295) biological processes.</p> </li> </ol>"},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/#evidence-support","title":"Evidence Support","text":"<p>The model includes appropriate evidence for each assertion:</p> <ol> <li> <p>Most relationships are supported by experimental evidence codes such as ECO:0000314 (direct assay evidence) or ECO:0000304 (author statement supported by traceable reference).</p> </li> <li> <p>Key references include PMID:24845157 for CD80/CD86-CD28 interactions and PMID:7539782 for CD28-GRB2-GEF connections.</p> </li> <li> <p>All assertions include appropriate provenance information.</p> </li> </ol>"},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I've identified a few areas that could be enhanced:</p> <ol> <li> <p>Pathway Completion: The model stops at the GEF activities of VAV1 and SOS1. It could be extended to show activation of small GTPases (RAS/RAC) and subsequent MAPK cascade activation, which would complete the signaling pathway to its nuclear effects.</p> </li> <li> <p>Detailed Mechanism for CD28-GRB2 Interaction: The model could be enhanced by including the phosphorylation step of CD28 at Tyr-191, which creates the binding site for GRB2's SH2 domain. This is a critical mechanistic detail for this pathway as documented in UniProt (PMID:7568038).</p> </li> <li> <p>PI3K Pathway Branch: The model currently focuses on the RAS activation branch of CD28 signaling. Adding the parallel PI3K pathway (which is also activated by CD28-GRB2 interactions) would provide a more complete picture of CD28 costimulation effects.</p> </li> </ol>"},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li> <p>It uses the appropriate molecular function terms for each protein.</p> </li> <li> <p>Activities are properly connected using recommended causal relationship terms.</p> </li> <li> <p>Activities are appropriately contextualized with cellular component terms.</p> </li> <li> <p>Each assertion is supported by appropriate evidence.</p> </li> <li> <p>The model follows the GO-CAM guidance for representing signaling pathways, particularly in how it handles adaptor proteins like GRB2.</p> </li> </ol>"},{"location":"reviews/662af8fa00002332-CD28_GRB2_axis_leading_to__RAS_activation__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:662af8fa00002332) accurately represents the CD28/GRB2 axis leading to RAS activation in human T cells. It successfully captures the key steps in this important co-stimulatory pathway and adheres to GO-CAM best practices. The model could be enhanced by extending it to include downstream effects and by adding more mechanistic details about protein interactions, particularly the phosphorylation-dependent recruitment of GRB2 to CD28.</p> <p>The model provides a valuable resource for understanding T cell costimulation through CD28 and how it leads to activation of guanyl-nucleotide exchange factors that ultimately activate RAS signaling.</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/","title":"662af8fa00002572 Activation of the non canonical inflammasome mediated by Casp11 upon lipopolysaccharide binding can lead to blood brain barrier breakdown  Mouse","text":"<p>Based on the information gathered, I'll now review the GO-CAM model \"Activation of the non-canonical inflammasome mediated by Casp11 upon lipopolysaccharide-binding can lead to blood-brain barrier breakdown (Mouse)\".</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#go-cam-model-review-gomodel662af8fa00002572","title":"GO-CAM Model Review: gomodel:662af8fa00002572","text":""},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: Activation of the non-canonical inflammasome mediated by Casp11 upon lipopolysaccharide-binding can lead to blood-brain barrier breakdown (Mouse)</p> <p>Taxon: NCBITaxon:9606 (Human) - Note: While the title indicates mouse, the taxon is set to human</p> <p>Status: Production</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#scientific-content-review","title":"Scientific Content Review","text":""},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#model-summary","title":"Model Summary","text":"<p>This GO-CAM model represents the molecular pathway of non-canonical inflammasome activation, specifically focused on mouse Caspase-11 (Casp11), its interaction with lipopolysaccharide (LPS), and the resulting activation of Gasdermin D (Gsdmd) leading to blood-brain barrier breakdown.</p> <p>The model captures the following key steps: 1. Lipid-binding activity of Casp11 recognizing LPS 2. Cysteine-type endopeptidase activity of Casp11 (occurring in cytosol) 3. Cleavage of Gasdermin D by Casp11 4. Phosphatidylinositol-4,5-bisphosphate binding by Gsdmd 5. Formation of pores in the plasma membrane by Gsdmd (wide pore channel activity) 6. The resulting pyroptotic cell death in endothelial cells of the blood-brain barrier</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#literature-support","title":"Literature Support","text":"<p>The model is well-supported by recent scientific literature, particularly: - PMID:38632402 (2024) - Clearly establishes the role of GSDMD in blood-brain barrier breakdown during inflammatory conditions - PMID:27339137 (2016) - Explains the mechanism of Gasdermin-D p30 fragment forming pores in membranes - PMID:27383986 (2016) - Details Gasdermin D binding to phosphoinositides and membrane pore formation - PMID:25119034 (2014) - Comprehensively describes Caspase-11 as an innate immune receptor for intracellular LPS</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#accuracy-of-relationships","title":"Accuracy of Relationships","text":"<p>The causal relationships modeled accurately reflect the current scientific understanding of the pathway: 1. Casp11 binds LPS through its lipid binding activity (GO:0008289) 2. This binding triggers Casp11's cysteine-type endopeptidase activity (GO:0004197) 3. Active Casp11 cleaves Gsdmd, which leads to Gsdmd binding to phosphatidylinositol-4,5-bisphosphate (GO:0005546) 4. This enables Gsdmd to form membrane pores (GO:0022829) at the plasma membrane 5. The pore formation results in pyroptotic cell death (GO:0141201)</p> <p>The \"directly positively regulates\" (RO:0002629) causal relationships used are appropriate for representing the direct activation steps in this pathway.</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#technical-review","title":"Technical Review","text":""},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#go-term-usage","title":"GO Term Usage","text":"<p>The GO terms used appear appropriate for the activities represented: - GO:0008289 (lipid binding) - correctly used for Casp11 binding to LPS - GO:0004197 (cysteine-type endopeptidase activity) - appropriate for Casp11 protease activity - GO:0005546 (phosphatidylinositol-4,5-bisphosphate binding) - correctly used for Gsdmd membrane binding - GO:0022829 (wide pore channel activity) - appropriate for Gsdmd pore formation - GO:0141201 (pyroptotic cell death) - correctly represents the biological outcome</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#model-structure","title":"Model Structure","text":"<p>The model follows the causal flow of the non-canonical inflammasome pathway correctly. The annotations connect activities in a logical sequence that matches the molecular mechanism described in the literature.</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#protein-annotation","title":"Protein Annotation","text":"<ul> <li>MGI:MGI:107700 (Casp4 Mmus) - This appears to be correctly used to represent mouse Caspase-11, though it's labeled as Casp4. Note that mouse Casp11 is the ortholog of human CASP4/5.</li> <li>MGI:MGI:1916396 (Gsdmd Mmus) - Correctly used for mouse Gasdermin D</li> </ul>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#cellular-component","title":"Cellular Component","text":"<p>All activities are properly localized: - Casp11 activities occur in cytosol (GO:0005829) - Gsdmd pore-forming activity occurs at plasma membrane (GO:0005886)</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":""},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#issue-1-taxon-mismatch","title":"Issue 1: Taxon Mismatch","text":"<p>While the title specifies \"Mouse\" model, the taxon is set to NCBITaxon:9606 (Human). This should be corrected to NCBITaxon:10090 (Mouse).</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#issue-2-possible-clarification-of-casp11-cleavage-of-gsdmd","title":"Issue 2: Possible Clarification of Casp11 Cleavage of Gsdmd","text":"<p>The model correctly shows Casp11 cleaving Gsdmd, but could potentially benefit from explicitly representing the cleavage site (Asp276 in mouse Gsdmd) and the resulting N-terminal fragment that forms the pore.</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#issue-3-missing-input-relationship","title":"Issue 3: Missing Input Relationship","text":"<p>The \"has input\" relationship for Casp11's endopeptidase activity should include Gsdmd as the substrate.</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#issue-4-lps-origin","title":"Issue 4: LPS Origin","text":"<p>The model could benefit from clarifying whether the LPS is cytosolic (from bacterial infection) or circulating (as in sepsis), as the 2024 paper (PMID:38632402) specifically discusses both scenarios.</p>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>The model captures a contemporary understanding of the non-canonical inflammasome pathway and its role in blood-brain barrier breakdown.</p> </li> <li> <p>The causal relationships are properly constructed to show the sequence of molecular events from LPS sensing to pyroptosis.</p> </li> <li> <p>The use of appropriate GO terms and evidence codes with relevant PMIDs provides strong scientific support.</p> </li> <li> <p>The model correctly represents the dual activities of Casp11 (LPS binding and protease) and Gsdmd (lipid binding and pore formation).</p> </li> </ol>"},{"location":"reviews/662af8fa00002572-Activation_of_the_non_canonical_inflammasome_mediated_by_Casp11_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a high-quality model that accurately represents the mechanism of non-canonical inflammasome activation by Casp11 upon LPS binding and the downstream effects on Gsdmd activation leading to blood-brain barrier breakdown. The minor issues noted do not significantly impact the scientific accuracy of the model but could be addressed to further improve clarity.</p> <p>The model conforms well to GO-CAM best practices, particularly in how it handles the activities of individual proteins rather than representing the entire inflammasome complex, which is appropriate given that the specific activities of the individual proteins (Casp11 and Gsdmd) are known and documented in the literature.</p>"},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/","title":"662af8fa00002657 Activation of the non canonical inflammasome mediated by CASP4 upon lipopolysaccharide binding can lead to blood brain barrier breakdown  Human","text":"<p>Based on my review of the GO-CAM model and the supporting literature, here's my assessment:</p>"},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/#review-of-go-cam-model-gomodel662af8fa00002657","title":"Review of GO-CAM Model: gomodel:662af8fa00002657","text":""},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/#title","title":"Title","text":"<p>\"Activation of the non-canonical inflammasome mediated by CASP4 upon lipopolysaccharide-binding can lead to blood-brain barrier breakdown (Human)\"</p>"},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/#overview","title":"Overview","text":"<p>This model describes the molecular pathway of how human CASP4 (caspase-4) activation by lipopolysaccharide (LPS) leads to pyroptosis and blood-brain barrier breakdown. The model focuses on the non-canonical inflammasome pathway, where LPS directly binds to CASP4, leading to its activation, followed by GSDMD cleavage and pore formation in the plasma membrane, ultimately causing pyroptosis.</p>"},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of the non-canonical inflammasome pathway based on the literature. The key interactions are supported by multiple high-quality references, including recent publications (2020-2024) with mechanistic insights. The sequential activities in the pathway are well-characterized:</p> <ol> <li>CASP4 lipid binding to LPS in the cytosol</li> <li>CASP4 activation and cysteine-type endopeptidase activity</li> <li>CASP4-mediated cleavage of GSDMD</li> <li>GSDMD phosphatidylinositol-4,5-bisphosphate binding at the plasma membrane</li> <li>GSDMD pore formation (wide pore channel activity)</li> <li>Pyroptotic cell death</li> </ol> <p>The connection to blood-brain barrier breakdown is also well-supported by recent literature (PMID:38632402), adding important physiological context.</p>"},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/#model-structure-and-annotation","title":"Model Structure and Annotation","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li> <p>Proper activity connections: The model correctly uses the causal predicate \"RO:0002629\" (directly positively regulates) to connect sequential activities in the pathway.</p> </li> <li> <p>Molecular functions: Each activity is annotated with an appropriate molecular function term (e.g., GO:0008289 for lipid binding, GO:0004197 for cysteine-type endopeptidase activity).</p> </li> <li> <p>Cellular components: All activities are properly annotated with cellular compartments (GO:0005829 for cytosol, GO:0005886 for plasma membrane).</p> </li> <li> <p>Biological processes: Activities are placed in the context of appropriate biological processes (GO:0042742 for defense response to bacterium, GO:0051604 for protein maturation, GO:0141201 for pyroptotic cell death).</p> </li> <li> <p>Input/output annotation: The LPS input for the lipid binding activity is properly specified (CHEBI:58712).</p> </li> </ol>"},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures all key steps from LPS recognition to pyroptosis in a coherent pathway.</p> </li> <li> <p>Strong evidence basis: Each activity is supported by published literature evidence with specific references.</p> </li> <li> <p>Physiological relevance: The connection to blood-brain barrier breakdown provides important context for the pathway's relevance to disease.</p> </li> <li> <p>Molecular detail: The model includes specific molecular activities like phosphatidylinositol-4,5-bisphosphate binding that are crucial for GSDMD pore formation.</p> </li> </ol>"},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>No annotation for GSDMD cleavage site: The model does not explicitly annotate the cleavage of GSDMD by CASP4, which occurs at Asp275. This could be explicitly represented to enhance the model's detail.</p> </li> <li> <p>Missing inflammatory mediator release: The model focuses on pyroptosis but does not include the release of inflammatory mediators like IL-1\u03b2 and IL-18 through GSDMD pores, which is an important consequence of this pathway. The GSDMD-mediated release of these cytokines contributes significantly to inflammation.</p> </li> <li> <p>Missing upstream mechanisms: The model starts with LPS binding to CASP4 but does not include how LPS enters the cytosol (e.g., via bacterial infection, guanylate-binding proteins, or other mechanisms).</p> </li> <li> <p>Regulation not shown: The model does not show regulation of this pathway, such as inhibition mechanisms (e.g., by OspC3 from Shigella as described in PMID:34671164).</p> </li> </ol>"},{"location":"reviews/662af8fa00002657-Activation_of_the_non_canonical_inflammasome_mediated_by_CASP4_upon_lipopolysaccharide_binding_can_lead_to_blood_brain_barrier_breakdown__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:662af8fa00002657) provides a high-quality representation of the non-canonical inflammasome pathway activated by CASP4 in humans. It accurately captures the sequence of molecular activities from LPS recognition to pyroptotic cell death, with appropriate annotation of molecular functions, cellular components, and biological processes. The model is supported by recent literature and provides important physiological context by linking to blood-brain barrier breakdown.</p> <p>To enhance the model further, additional details on GSDMD cleavage, cytokine release mechanisms, upstream LPS entry pathways, and regulatory mechanisms could be incorporated. Nevertheless, the current model effectively communicates the core pathway and provides a valuable resource for understanding this important innate immune response mechanism.</p>"},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/","title":"662af8fa00002877 TRAIL TRAILR1 interaction leading to apoptosis","text":"<p>Based on my review of the GO-CAM model gomodel:662af8fa00002877 and related research materials, here is my assessment:</p>"},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/#go-cam-review-trailtrailr1-interaction-leading-to-apoptosis-gomodel662af8fa00002877","title":"GO-CAM Review: TRAIL/TRAILR1 interaction leading to apoptosis (gomodel:662af8fa00002877)","text":""},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/#overview-of-the-model","title":"Overview of the Model","text":"<p>The GO-CAM model gomodel:662af8fa00002877 titled \"TRAIL/TRAILR1 interaction leading to apoptosis\" describes the TRAIL-activated apoptotic signaling pathway mediated through TRAIL receptor 1 (DR4/TNFRSF10A) and the subsequent molecular events leading to apoptosis.</p>"},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model captures the following key components:</p> <ol> <li>TNFSF10 (TRAIL) with cytokine activity in the extracellular space</li> <li>TNFRSF10A (DR4) with signaling receptor activity in plasma membrane rafts </li> <li>ZDHHC3 with palmitoyltransferase activity in the Golgi apparatus</li> <li>TRADD with protein-macromolecule adaptor activity in the cytoplasm</li> <li>FADD with protein-macromolecule adaptor activity in the cytoplasm</li> <li>CASP8 with cysteine-type endopeptidase activity in the cytoplasm</li> </ol> <p>The causal connections are well-organized, representing the flow of information: 1. TRAIL \u2192 DR4 2. DR4 \u2192 TRADD 3. TRADD \u2192 FADD 4. FADD \u2192 CASP8</p>"},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model is scientifically accurate and supported by current literature. Key molecular mechanisms represented include:</p> <ol> <li> <p>DR4 Palmitoylation: The model correctly represents ZDHHC3's role in palmitoylating DR4, which is critical for its proper plasma membrane localization and function (supported by PMIDs 19090789, 22240897, 21926431).</p> </li> <li> <p>TRAIL Receptor Specificity: The model focuses correctly on the DR4/TRAIL-R1 pathway which has specific regulatory mechanisms distinct from DR5/TRAIL-R2 (supported by PMID 22240897).</p> </li> <li> <p>Death-Inducing Signaling Complex (DISC) Formation: The sequential recruitment of TRADD, FADD, and caspase-8 is correctly represented.</p> </li> <li> <p>Membrane Localization: The inclusion of DR4 localization to membrane rafts is well-supported by literature showing this is essential for efficient signaling.</p> </li> </ol>"},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Molecular Specificity: The model accurately represents the specific role of DR4/TRAIL-R1 rather than combining DR4 and DR5 pathways, which is appropriate given their different regulatory mechanisms.</p> </li> <li> <p>Post-translational Modifications: The inclusion of ZDHHC3-mediated palmitoylation of DR4 represents an important regulatory mechanism well-supported by literature.</p> </li> <li> <p>Subcellular Localization: The model correctly includes subcellular localization information, which is crucial for understanding the mechanism of this pathway.</p> </li> <li> <p>Evidence Quality: The model uses high-quality evidence with appropriate ECO codes, primarily based on direct assays (ECO:0000314) and author statements with traceable support (ECO:0000303).</p> </li> </ol>"},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Death Domain Interactions: Consider adding more detail about the specific death domain interactions between DR4, TRADD, and FADD, as these are critical for DISC formation.</p> </li> <li> <p>Caspase-8 Activation: The model could be extended to show caspase-8 activation and its downstream effects, including the cleavage of effector caspases like caspase-3.</p> </li> <li> <p>Membrane Dynamics: Given the importance of rafts in DR4 signaling, consider adding information about the role of membrane dynamics in TRAIL-DR4 signaling.</p> </li> <li> <p>Regulatory Mechanisms: Consider adding inhibitory mechanisms or feedback loops that regulate this pathway, such as FLIP inhibition of caspase-8 activation.</p> </li> </ol>"},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Molecular Functions: All activities are correctly assigned with appropriate GO terms.</p> </li> <li> <p>Causal Relationships: The \"directly positively regulates\" (RO:0002629) relationship is properly used throughout the model.</p> </li> <li> <p>Evidence Codes: Appropriate evidence codes with PMIDs are provided for each assertion.</p> </li> <li> <p>Cellular Components: Proper localization is provided for each activity.</p> </li> <li> <p>Biological Process Context: All activities are correctly assigned to the \"TRAIL-activated apoptotic signaling pathway\" (GO:0036462).</p> </li> </ol>"},{"location":"reviews/662af8fa00002877-TRAIL_TRAILR1_interaction_leading_to_apoptosis/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:662af8fa00002877 effectively represents the current understanding of TRAIL/TRAIL-R1 signaling leading to apoptosis, with special emphasis on the role of palmitoylation in DR4 function. The model is well-structured, supported by high-quality evidence, and follows GO-CAM best practices. The few suggested additions would enhance the model by providing more detailed mechanisms without changing its essential accuracy.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/","title":"663d668500000226 VIF mediated inhibition of STING by PTPN6  Human HIV","text":"<p>Based on all the information I've gathered, I'll now proceed with a comprehensive review of the GO-CAM model gomodel:663d668500000226.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#review-of-go-cam-model-gomodel663d668500000226","title":"Review of GO-CAM Model gomodel:663d668500000226","text":""},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#model-summary","title":"Model Summary","text":"<p>Title: VIF-mediated inhibition of STING by PTPN6 (Human-HIV) ID: gomodel:663d668500000226 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#overall-model-evaluation","title":"Overall Model Evaluation","text":"<p>This GO-CAM model describes a mechanism by which HIV-1 viral infectivity factor (Vif) promotes immune evasion by inhibiting the STING-mediated antiviral immune response. The model shows how Vif acts as a molecular adaptor to recruit the tyrosine phosphatase PTPN6 (SHP-1) to inhibit STING1 activity, thereby suppressing type I interferon production.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#model-strengths","title":"Model Strengths:","text":"<ol> <li>Well-supported by recent literature (PMID:34811497).</li> <li>Clear logical flow showing the causal relationships between molecular activities.</li> <li>Appropriate use of GO terms for molecular functions and biological processes.</li> <li>Properly annotated with evidence codes and PMID references.</li> </ol>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#model-structure-and-connectivity","title":"Model Structure and Connectivity:","text":"<p>The model presents five connected activities: 1. FRK kinase activity - activates Vif adaptor protein 2. Vif adaptor activity - recruits PTPN6 (SHP-1) 3. PTPN6 phosphatase activity - dephosphorylates STING 4. STING adaptor activity - inhibited by PTPN6 dephosphorylation 5. TBK1 kinase activity - downstream of STING (not directly shown)</p> <p>The causal flow is logical, with \"provides input for\" and \"directly negatively regulates\" relations correctly used according to GO-CAM best practices.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#detailed-component-analysis","title":"Detailed Component Analysis","text":""},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#1-vif-molecular-adaptor-activity","title":"1. Vif Molecular Adaptor Activity","text":"<ul> <li>MF: protein-macromolecule adaptor activity (GO:0030674)</li> <li>Enabled by: Vif protein (UniProtKB:P69723)</li> <li>Occurs in: host cell cytoplasm (GO:0030430)</li> <li>Part of: symbiont-mediated suppression of cytoplasmic pattern recognition receptor signaling pathway (GO:0039537)</li> <li>Evidence: Direct assay evidence (ECO:0000314, PMID:34811497)</li> <li>Causal connection: provides input for PTPN6 phosphatase activity</li> </ul> <p>This annotation is consistent with the documented molecular adaptor activity guidelines. According to the Wang et al. (2021) paper, Vif contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) that, when phosphorylated by FRK, recruits PTPN6/SHP-1 to inhibit STING signaling.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#2-ptpn6-phosphatase-activity","title":"2. PTPN6 Phosphatase Activity","text":"<ul> <li>MF: protein tyrosine phosphatase activity (GO:0004725)</li> <li>Enabled by: PTPN6/SHP-1 (UniProtKB:P29350)</li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li>Part of: negative regulation of innate immune response (GO:0045824)</li> <li>Evidence: Mutant phenotype evidence (ECO:0000315, PMID:17562706)</li> <li>Causal connection: directly negatively regulates STING adaptor activity</li> </ul> <p>The annotation correctly captures PTPN6's role in dephosphorylating STING, which is supported by the literature. The causal relationship is properly represented with \"directly negatively regulates\" since PTPN6 inhibits STING's function.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#3-frk-kinase-activity","title":"3. FRK Kinase Activity","text":"<ul> <li>MF: protein tyrosine kinase activity (GO:0004713)</li> <li>Enabled by: FRK (UniProtKB:P42685)</li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li>Evidence: Direct assay evidence (ECO:0000314, PMID:35723276)</li> <li>Causal connection: directly positively regulates Vif adaptor activity</li> </ul> <p>This annotation correctly represents FRK's role in phosphorylating the ITIM motif of Vif, which enables Vif to recruit PTPN6.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#4-sting-signaling-adaptor-activity","title":"4. STING Signaling Adaptor Activity","text":"<ul> <li>MF: signaling adaptor activity (GO:0035591)</li> <li>Enabled by: STING1 (UniProtKB:Q86WV6)</li> <li>Occurs in: Golgi membrane (GO:0000139)</li> <li>Part of: pattern recognition receptor signaling pathway (GO:0002221)</li> <li>Evidence: Direct assay evidence (ECO:0000314, PMID:23910378)</li> <li>Causal connection: directly positively regulates TBK1 kinase activity</li> </ul> <p>This annotation correctly captures STING's role as a signaling adaptor in the innate immune response pathway.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#5-tbk1-kinase-activity","title":"5. TBK1 Kinase Activity","text":"<ul> <li>MF: protein serine/threonine kinase activity (GO:0004674)</li> <li>Enabled by: TBK1 (UniProtKB:Q9UHD2)</li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li>Part of: cytoplasmic pattern recognition receptor signaling pathway (GO:0002753)</li> <li>Evidence: Direct assay evidence (ECO:0000314, PMID:14703513)</li> </ul> <p>TBK1 is appropriately annotated as a kinase downstream of STING in the signaling pathway.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows best practices for annotating molecular adaptors: 1. Correctly uses the 'protein-macromolecule adaptor activity' term for Vif 2. Appropriately uses 'provides input for' to connect Vif adaptor activity to PTPN6 phosphatase activity 3. Correctly uses 'directly negatively regulates' for the inhibitory effect of PTPN6 on STING 4. Properly annotates the cellular components where these activities occur 5. Documents each activity with relevant PMIDs and evidence codes</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the mechanism described in Wang et al. (2021), which demonstrates that: 1. HIV-1 Vif inhibits type I interferon production 2. FRK phosphorylates Vif's ITIM motif 3. Phosphorylated Vif recruits PTPN6 (SHP-1) 4. PTPN6 dephosphorylates STING at Tyr162 5. This inhibits STING's K63-linked ubiquitination at Lys337 6. This suppresses STING-mediated innate immune responses</p> <p>The model has effectively captured this mechanism using appropriate GO terms and relations.</p>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Complete the signaling cascade: The model could be extended to include IRF3 activation and type I interferon production downstream of TBK1.</p> </li> <li> <p>Add specific phosphorylation sites: While the model captures the key activities, it could be enhanced by including specific details about the phosphorylation sites (e.g., Vif ITIM phosphorylation by FRK and STING Tyr162 dephosphorylation by PTPN6).</p> </li> <li> <p>Include ubiquitination: The model could include the K63-linked ubiquitination of STING at Lys337, which is inhibited by PTPN6-mediated dephosphorylation.</p> </li> <li> <p>Include details on FRK inhibition: The Wang et al. paper mentions that FRK inhibitor D-65495 can block Vif phosphorylation, which could be an interesting regulatory aspect to include.</p> </li> </ol>"},{"location":"reviews/663d668500000226-VIF_mediated_inhibition_of_STING_by_PTPN6__Human_HIV_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:663d668500000226 accurately represents the mechanism of HIV-1 Vif-mediated inhibition of STING through PTPN6 recruitment. The model is well-structured, follows GO-CAM best practices for annotating molecular adaptors, and is supported by strong experimental evidence. The causal relationships between the activities are appropriately modeled using the correct relations.</p> <p>This model provides valuable insights into how HIV-1 evades host antiviral immunity through the STING signaling pathway and could be useful for developing therapeutic strategies against HIV-1 infection.</p>"},{"location":"reviews/663d668500000596-oxidative_phosphorylation__GO_0006119_/","title":"663d668500000596 oxidative phosphorylation  GO 0006119","text":"<p>Based on my review of the GO-CAM model and the relevant documentation, here is my assessment of the model gomodel:663d668500000596 on \"oxidative phosphorylation\":</p>"},{"location":"reviews/663d668500000596-oxidative_phosphorylation__GO_0006119_/#review-summary","title":"Review Summary","text":"<p>This model represents the oxidative phosphorylation process in Schizosaccharomyces pombe (fission yeast), focusing on the electron transport chain components and their relationships.</p>"},{"location":"reviews/663d668500000596-oxidative_phosphorylation__GO_0006119_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Appropriate use of protein complexes: The model correctly represents respiratory chain complexes II, III, and IV using ComplexPortal IDs and lists all constituent subunits as members, following the best practices for complex annotation.</p> </li> <li> <p>Correct molecular functions: Each complex or protein is assigned the appropriate molecular function:</p> </li> <li>Complex II (CPX-566): electron transfer activity (GO:0009055)</li> <li>Complex III (CPX-9308): ubiquinol-cytochrome-c reductase activity (GO:0008121)</li> <li>Complex IV (CPX-9641): cytochrome-c oxidase activity (GO:0004129)</li> <li>NADH dehydrogenase (ndi1): NADH dehydrogenase activity (GO:0008137)</li> <li> <p>Cytochrome c (cyc1): electron transfer activity (GO:0009055)</p> </li> <li> <p>Correct cellular localization: Components are appropriately placed in mitochondrial compartments:</p> </li> <li>Complexes II, III, IV: mitochondrial inner membrane (GO:0005743)</li> <li>NADH dehydrogenase: mitochondrial matrix (GO:0005759)</li> <li> <p>Cytochrome c: mitochondrial intermembrane space (GO:0005758)</p> </li> <li> <p>Appropriate causal relationships: The model captures the flow of electrons through the respiratory chain using the \"provides input for\" (RO:0002413) predicate.</p> </li> </ol>"},{"location":"reviews/663d668500000596-oxidative_phosphorylation__GO_0006119_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Incomplete evidence for some causal associations: I noticed several causal associations have no evidence annotations:</li> <li>The link from complex II to complex III</li> <li>The first link from cytochrome c to complex IV</li> <li> <p>The link from complex II to cytochrome c</p> </li> <li> <p>Redundant causal associations: There are duplicate causal assertions between some components:</p> </li> <li>Two identical causal associations from complex III to cytochrome c</li> <li>Two identical causal associations from cytochrome c to complex IV</li> </ol> <p>This redundancy may make the model less clear and should be eliminated by keeping only one well-evidenced association.</p> <ol> <li> <p>Missing complex I: While the model includes ndi1 (NADH dehydrogenase), there is no representation of the complete respiratory chain complex I. The comment in the model (\"Add etf1 complex\") suggests additional components are planned to be added.</p> </li> <li> <p>Model comments suggest incomplete work: The comments indicate the model is still under development:</p> </li> <li>\"Testing how a complex renders. Waiting for the other complexes to build electron transport chain\"</li> <li>\"Add etf1 complex\"</li> </ol>"},{"location":"reviews/663d668500000596-oxidative_phosphorylation__GO_0006119_/#biological-accuracy","title":"Biological Accuracy:","text":"<p>The biological flow of electrons is generally correct, matching the established path in the electron transport chain: 1. NADH dehydrogenase (ndi1) \u2192 Complex II 2. Complex II \u2192 Complex III (though there's also a direct link to cytochrome c which may be redundant) 3. Complex III \u2192 cytochrome c 4. cytochrome c \u2192 Complex IV</p> <p>The biological processes are also correctly annotated for each activity: - ndi1: mitochondrial electron transport, NADH to ubiquinone (GO:0006120) - Complex III: mitochondrial electron transport, ubiquinol to cytochrome c (GO:0006122) - Complex IV: mitochondrial electron transport, cytochrome c to oxygen (GO:0006123)</p>"},{"location":"reviews/663d668500000596-oxidative_phosphorylation__GO_0006119_/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Remove redundant causal links: Eliminate duplicate causal assertions between components.</p> </li> <li> <p>Add evidence to all causal associations: Ensure all causal links have appropriate evidence annotations.</p> </li> <li> <p>Complete the model: Add the ETF1 complex as mentioned in the comments, and consider adding ATP synthase (Complex V) to complete the oxidative phosphorylation pathway.</p> </li> <li> <p>Clean up comments: Once development is complete, update or remove the comments that indicate the model is still under development.</p> </li> <li> <p>Clarify the role of complex II: In the standard electron transport chain, NADH dehydrogenase (Complex I) typically leads to ubiquinone, which then interacts with Complex III, while Complex II (succinate dehydrogenase) is a separate input to ubiquinone. The current model shows ndi1 providing input to Complex II, which may need to be revisited for biological accuracy.</p> </li> </ol> <p>Overall, this is a mostly well-constructed model that represents the core components of oxidative phosphorylation in fission yeast, but would benefit from the improvements noted above to increase its biological accuracy and adherence to GO-CAM curation standards.</p>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/","title":"663d668500001246 Pyroptotic cell death mediated by GSDMD and NINJ1  Human","text":"<p>Now let's analyze the GO-CAM model in detail to provide a comprehensive review:</p>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#review-of-go-cam-model-gomodel663d668500001246-pyroptotic-cell-death-mediated-by-gsdmd-and-ninj1-human","title":"Review of GO-CAM Model: gomodel:663d668500001246 - \"Pyroptotic cell death mediated by GSDMD and NINJ1 (Human)\"","text":""},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#overview","title":"Overview","text":"<p>This model represents pyroptotic cell death mediated by GSDMD (Gasdermin D) and NINJ1 (Ninjurin-1) in humans. Pyroptosis is a form of inflammatory programmed cell death characterized by cell swelling, membrane pore formation, and eventual plasma membrane rupture, leading to the release of inflammatory cytokines and cellular contents.</p>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-supported by evidence: The model cites multiple recent publications as evidence for each association, enhancing its reliability. The literature referenced includes key papers about NINJ1's role in plasma membrane rupture during pyroptotic cell death.</p> </li> <li> <p>Clear pathway depiction: The model effectively captures the sequential steps in pyroptotic cell death, from caspase-1 activation to GSDMD pore formation to NINJ1-mediated membrane rupture.</p> </li> <li> <p>Appropriate use of causal connections: The model correctly uses the <code>RO:0002629</code> (directly positively regulates) predicate to connect activities in the cascade.</p> </li> <li> <p>Correct cellular locations: All activities are assigned appropriate cellular locations (cytosol for caspase, plasma membrane for GSDMD and NINJ1).</p> </li> <li> <p>Correct integration of recent research: The model accurately reflects recent discoveries about NINJ1's role in the final stage of pyroptosis (plasma membrane rupture), which was only elucidated in detail in recent years (2021-2023).</p> </li> </ol>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing input molecules: While the model shows CASP1 with cysteine-type endopeptidase activity, it doesn't include the upstream inflammasome activation that triggers CASP1 activity. Including this would provide more context about what initiates this pathway.</p> </li> <li> <p>Incomplete molecular mechanism details: The model correctly identifies that phosphatidylinositol binding activities are important for GSDMD function, but could benefit from including details about GSDMD cleavage by CASP1 to generate the active N-terminal fragment, which is mentioned in the literature you provided.</p> </li> <li> <p>Absent interleukin release: The literature indicates that the release of mature IL-1\u03b2 and IL-18 occurs through GSDMD pores, which happens before complete membrane rupture. This could be included as an additional outcome or process in the model.</p> </li> <li> <p>Missing regulation by other proteins: The studies on NINJ1 mention potential regulatory factors and conditions that affect its function, which could be added to provide a more complete picture.</p> </li> </ol>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#detailed-analysis-of-model-components","title":"Detailed Analysis of Model Components","text":""},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#1-casp1-activity","title":"1. CASP1 Activity","text":"<ul> <li>Activity: GO:0004197 (cysteine-type endopeptidase activity)</li> <li>Enabled by: UniProtKB:P29466 (CASP1 Hsap)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li>Part of: GO:0051604 (protein maturation)</li> <li>Evidence: ECO:0000314 (direct assay evidence used in manual assertion) with PMID:32109412</li> <li>Assessment: Correctly represented, but could benefit from including the inflammasome complex that activates CASP1.</li> </ul>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#2-gsdmd-activities","title":"2. GSDMD Activities","text":"<p>The model shows GSDMD with two different activities: - Activity 1: GO:0070273 (phosphatidylinositol-4-phosphate binding) - Activity 2: GO:0005546 (phosphatidylinositol-4,5-bisphosphate binding) - Both enabled by: UniProtKB:P57764 (GSDMD Hsap) - Occurs in: GO:0005886 (plasma membrane) - Part of: GO:0141201 (pyroptotic cell death) - Evidence: ECO:0000314 (direct assay evidence used in manual assertion) with PMID:36227980 - Assessment: Correctly represented, but could explicitly include the cleavage step creating GSDMD-NT fragment.</p>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#3-gsdmd-pore-formation","title":"3. GSDMD Pore Formation","text":"<ul> <li>Activity: GO:0022829 (wide pore channel activity)</li> <li>Enabled by: UniProtKB:P57764 (GSDMD Hsap)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0050729 (positive regulation of inflammatory response)</li> <li>Evidence: ECO:0000314 (direct assay evidence used in manual assertion) with PMID:33883744</li> <li>Assessment: Well represented, but could benefit from explicit connection to the release of IL-1\u03b2 and IL-18 through these pores.</li> </ul>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#4-ninj1-activity","title":"4. NINJ1 Activity","text":"<ul> <li>Activity: GO:0140912 (membrane destabilizing activity)</li> <li>Enabled by: UniProtKB:Q92982 (NINJ1 Hsap)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0141201 (pyroptotic cell death)</li> <li>Evidence: Multiple ECO:0000314 references with PMIDs: 33472215, 36468682, 37196676, 37198476</li> <li>Assessment: Well represented, supported by multiple recent publications.</li> </ul>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#5-causal-associations","title":"5. Causal Associations","text":"<p>The model correctly represents the sequential nature of the pathway: - CASP1 endopeptidase activity \u2192 GSDMD phosphatidylinositol binding activities - GSDMD phosphatidylinositol binding activities \u2192 GSDMD pore formation - GSDMD pore formation \u2192 NINJ1 membrane destabilizing activity</p> <p>All use <code>RO:0002629</code> (directly positively regulates), which is appropriate based on the literature.</p>"},{"location":"reviews/663d668500001246-Pyroptotic_cell_death_mediated_by_GSDMD_and_NINJ1__Human__/#summary-and-recommendations","title":"Summary and Recommendations","text":"<p>This GO-CAM model accurately represents the current understanding of GSDMD and NINJ1's roles in pyroptotic cell death, particularly the sequential activities leading to membrane rupture. The model is well-supported by recent scientific evidence and correctly represents the cellular locations and causal relationships between components.</p> <p>Recommendations for improvement:</p> <ol> <li> <p>Add the upstream inflammasome activation that triggers CASP1 activity, possibly including NLRP3, ASC, and other relevant components.</p> </li> <li> <p>Explicitly represent the cleavage of GSDMD by CASP1 to generate the active N-terminal fragment (GSDMD-NT).</p> </li> <li> <p>Include the release of mature IL-1\u03b2 and IL-18 through GSDMD pores as an outcome or part of the inflammatory response process.</p> </li> <li> <p>Consider adding details about oligomerization of NINJ1 and GSDMD, as described in the recent structural studies.</p> </li> <li> <p>Include additional regulatory factors that affect the activity of these proteins, as mentioned in the recent literature.</p> </li> </ol> <p>Overall, this is a high-quality model that effectively represents our current understanding of pyroptotic cell death mediated by GSDMD and NINJ1. The suggested improvements would further enhance its comprehensiveness and utility.</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/","title":"663d668500001492 TRAIL TRAILR2 interaction leading to apoptosis","text":"<p>Based on my review of the GO-CAM model \"gomodel:663d668500001492\" titled \"TRAIL/TRAILR2 interaction leading to apoptosis\", I can provide a comprehensive assessment of the model from the perspective of a GO-CAM curator.</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents the signaling pathway initiated by the interaction between TRAIL (TNF-related apoptosis-inducing ligand, UniProtKB:P50591) and its receptor TRAIL-R2 (TNFRSF10B, UniProtKB:O14763), leading to apoptosis through a cascade of molecular events. The model includes:</p> <ol> <li>TRAIL cytokine activity in the extracellular space</li> <li>TRAIL-R2 signaling receptor activity at the plasma membrane</li> <li>A cascade of adaptor proteins (TRADD, FADD) in the cytoplasm</li> <li>Activation of caspase-8, an effector protease that mediates apoptosis</li> </ol>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#go-cam-structure-and-connectivity","title":"GO-CAM Structure and Connectivity","text":"<p>The model properly represents a causal chain of molecular activities with appropriate causal relationships (RO:0002629, \"directly positively regulates\") between: - TRAIL (cytokine activity) \u2192 TRAIL-R2 (signaling receptor activity) - TRAIL-R2 \u2192 TRADD (protein-macromolecule adaptor activity) - TRADD \u2192 FADD (protein-macromolecule adaptor activity) - FADD \u2192 caspase-8 (cysteine-type endopeptidase activity)</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#evidence-quality","title":"Evidence Quality","text":"<p>Each activity and causal relationship is supported by experimental evidence with appropriate ECO codes and literature references. The model uses: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000303 (author statement without traceable support) - ECO:0000315 (mutant phenotype evidence)</p> <p>References include key papers on TRAIL signaling, with primary citations.</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":""},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#molecular-functions","title":"Molecular Functions","text":"<p>The molecular functions assigned to each protein in the model are accurate: - TRAIL (P50591): GO:0005125 (cytokine activity) - This is correct as TRAIL is a cytokine that binds to death receptors. - TRAIL-R2 (O14763): GO:0038023 (signaling receptor activity) - This is appropriate as TRAIL-R2 is a transmembrane receptor that initiates apoptotic signaling. - TRADD (Q15628): GO:0030674 (protein-macromolecule adaptor activity) - TRADD is indeed an adaptor protein that connects TRAIL-R2 to downstream signaling components. - FADD (Q13158): GO:0030674 (protein-macromolecule adaptor activity) - FADD acts as an adaptor that recruits caspase-8. - Caspase-8 (Q14790): GO:0004197 (cysteine-type endopeptidase activity) - This is the correct enzymatic activity of caspase-8.</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#subcellular-locations","title":"Subcellular Locations","text":"<p>The locations specified for each activity are biologically accurate: - TRAIL activity occurs in GO:0005615 (extracellular space) - TRAIL-R2 is located at GO:0005886 (plasma membrane) - TRADD, FADD, and caspase-8 activities occur in GO:0005737 (cytoplasm)</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#biological-process-context","title":"Biological Process Context","text":"<p>All activities are properly associated with GO:0036462 (TRAIL-activated apoptotic signaling pathway), which is the correct biological process term for this pathway.</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#comparison-with-best-practices","title":"Comparison with Best Practices","text":"<p>According to the \"How to annotate complexes in GO-CAM\" document, the model appropriately represents individual protein activities rather than complex entities. Each protein is annotated with its specific molecular function, and the causal relationships between activities form a coherent signaling cascade.</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#missing-elements-or-potential-improvements","title":"Missing Elements or Potential Improvements","text":"<p>While the model is well-constructed, I've identified a few aspects that could be improved or expanded:</p> <ol> <li> <p>Mechanism of FADD-Caspase-8 Interaction: The model shows FADD directly activating caspase-8, but it could more explicitly represent the formation of the death-inducing signaling complex (DISC). The literature (PMID:16762833) indicates that FADD recruits caspase-8 through homotypic death effector domain (DED) interactions.</p> </li> <li> <p>Caspase-8 Activation Details: The model could include the self-cleavage and dimerization of caspase-8 that is required for its activation. This is an important regulatory step in the pathway.</p> </li> <li> <p>Downstream Apoptotic Execution: The model could be extended to include downstream targets of caspase-8, such as effector caspases (caspase-3, caspase-7) or BID, which links the extrinsic and intrinsic apoptotic pathways.</p> </li> <li> <p>Regulatory Influences: The model doesn't represent negative regulators of this pathway, such as FLIP (CFLAR), which can compete with caspase-8 for binding to FADD.</p> </li> </ol>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#evidence-assessment","title":"Evidence Assessment","text":"<p>The evidence used in the model is appropriate and comes from reliable sources. The model integrates information from multiple papers that have characterized different aspects of the TRAIL signaling pathway. The papers cited (PMID:21146232, PMID:9485194, etc.) are relevant to the interactions represented.</p>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#recommendations","title":"Recommendations","text":"<p>I would recommend the following enhancements to improve this model:</p> <ol> <li> <p>Include the intermediate step of DISC formation between receptor activation and caspase-8 recruitment.</p> </li> <li> <p>Add the self-processing and oligomerization of caspase-8 as a regulatory step.</p> </li> <li> <p>Extend the model to include at least one downstream effector of caspase-8 (e.g., caspase-3 activation).</p> </li> <li> <p>Consider adding regulatory elements such as FLIP or IAPs that modulate the pathway.</p> </li> <li> <p>Include cross-talk with the intrinsic apoptotic pathway through the caspase-8-mediated cleavage of BID.</p> </li> </ol>"},{"location":"reviews/663d668500001492-TRAIL_TRAILR2_interaction_leading_to_apoptosis/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the core components of the TRAIL/TRAIL-R2 apoptotic signaling pathway. The model follows GO-CAM best practices by representing individual molecular activities and their causal relationships, supported by appropriate evidence. The suggested improvements would enhance the biological completeness of the model but are not critical deficiencies. This model provides a useful representation of TRAIL-induced apoptotic signaling for the GO-CAM knowledge base.</p>"},{"location":"reviews/663d668500001911-purine_nucleobase_metabolic_process__GO_0006144__/","title":"663d668500001911 purine nucleobase metabolic process  GO 0006144","text":"<p>Based on the information obtained, I can now provide a comprehensive review of the GO-CAM model.</p>"},{"location":"reviews/663d668500001911-purine_nucleobase_metabolic_process__GO_0006144__/#go-cam-model-review-for-gomodel663d668500001911","title":"GO-CAM Model Review for gomodel:663d668500001911","text":""},{"location":"reviews/663d668500001911-purine_nucleobase_metabolic_process__GO_0006144__/#overview","title":"Overview","text":"<p>This GO-CAM model titled \"purine nucleobase metabolic process (GO:0006144)\" represents the purine nucleotide biosynthesis and salvage pathways in Schizosaccharomyces pombe (fission yeast). It comprehensively captures both de novo biosynthetic pathways and salvage pathways for purines (adenine and guanine).</p>"},{"location":"reviews/663d668500001911-purine_nucleobase_metabolic_process__GO_0006144__/#strengths","title":"Strengths","text":"<ol> <li>Comprehensive Pathway Coverage: </li> <li>The model successfully represents both de novo purine biosynthesis and salvage pathways</li> <li>Includes transport mechanisms for purine bases across the plasma membrane</li> <li> <p>Captures conversion pathways between different purine nucleotides (IMP \u2192 AMP, IMP \u2192 GMP)</p> </li> <li> <p>Well-Evidenced Assertions:</p> </li> <li>Most activities have appropriate experimental evidence codes (ECO:0000314 - direct assay evidence)</li> <li>Key activities are supported by published literature with PMID references</li> <li> <p>Uses appropriate evidence codes for different types of assertions (direct assay, sequence similarity, etc.)</p> </li> <li> <p>Proper Molecular Function Annotations:</p> </li> <li>Enzymes are annotated with specific molecular functions matching their biochemical roles</li> <li> <p>The appropriate contexts for each activity are provided (part_of relationships)</p> </li> <li> <p>Appropriate Causal Connections:</p> </li> <li>The model uses the appropriate causal relation \"provides input for\" (RO:0002413) to connect activities in a metabolic pathway</li> <li> <p>The flow of activities follows the established biochemical pathway for purine metabolism</p> </li> <li> <p>Input/Output Annotations:</p> </li> <li>Many activities have appropriate input/output molecules specified</li> <li>Key metabolites like IMP (CHEBI:17202) and guanine (CHEBI:16235) are properly referenced</li> </ol>"},{"location":"reviews/663d668500001911-purine_nucleobase_metabolic_process__GO_0006144__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Evidence Documentation:</li> <li>One causal association from activity 663d668500001911/663d668500002065 to 663d668500001911/663d668500002073 lacks evidence annotations</li> <li> <p>Some has_input/has_output annotations could be more consistently applied across related activities</p> </li> <li> <p>Molecular Details:</p> </li> <li>The model could benefit from more systematic annotation of all inputs and outputs for each activity</li> <li> <p>Additional molecular details for some transport processes would enhance the model</p> </li> <li> <p>Completeness Check:</p> </li> <li>It would be useful to verify if the model captures all known enzymes involved in purine metabolism in S. pombe</li> <li>Potential regulatory interactions (if known) are not captured in the current model</li> </ol>"},{"location":"reviews/663d668500001911-purine_nucleobase_metabolic_process__GO_0006144__/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on the available information, the model appears to be biologically accurate and consistent with what is known about purine metabolism in yeast. The model includes key enzymes such as:</p> <ul> <li>IMP dehydrogenase (gua1, SPBC2F12.14c) for GMP biosynthesis</li> <li>Phosphoribosylaminoimidazolecarboxamide formyltransferase (ade10, SPCPB16A4.03c)</li> <li>Adenylosuccinate synthase (ade2, SPAC144.03)</li> <li>Transport proteins for adenine and guanine</li> </ul> <p>The causal flow and pathway organization match established biochemical knowledge of purine metabolism.</p>"},{"location":"reviews/663d668500001911-purine_nucleobase_metabolic_process__GO_0006144__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"gomodel:663d668500001911\" is a high-quality representation of purine nucleobase metabolic processes in S. pombe. It effectively captures the key activities, causal relationships, and molecular participants in this pathway. </p> <p>The model follows GO-CAM best practices for representing metabolic pathways, with appropriate molecular functions, biological processes, and causal connections. The model creator has made good use of available evidence codes and literature references to support the assertions.</p> <p>With minor improvements to evidence documentation and molecular details, this would be an exemplary GO-CAM model. Overall, I recommend this model for approval with only minor revisions to address the missing evidence for one causal association and to ensure consistent annotation of inputs/outputs across all activities.</p>"},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/","title":"663d668500002178 phosphatidylinositol phosphate phosphatidylinositol  biosynthetic process  GO 0006661  GO 0043647","text":"<p>Now that I've gathered essential information about the proteins involved and the inositol phosphate pathway described in this GO-CAM model, let me provide a comprehensive review:</p>"},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/#review-of-go-cam-model-gomodel663d668500002178","title":"Review of GO-CAM Model: gomodel:663d668500002178","text":""},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/#overview","title":"Overview","text":"<p>This GO-CAM model represents the phosphatidylinositol phosphate/phosphatidylinositol biosynthetic process (GO:0006661/GO:0043647) in fission yeast (Schizosaccharomyces pombe). The model illustrates the enzyme activities and pathway flow involved in inositol phosphate metabolism.</p>"},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/#pathway-structure-and-connectivity","title":"Pathway Structure and Connectivity","text":"<p>The model describes a pathway where: 1. Inositol is imported via Itr2 (PomBase:SPAC20G8.03), a myo-inositol:proton symporter 2. CDP-diacylglycerol-inositol 3-phosphatidyltransferase activity by Pis1 (PomBase:SPAC1D4.08) generates phosphatidylinositol 3. Stt4 (PomBase:SPBC577.06c) acts as a 1-phosphatidylinositol 4-kinase to generate phosphatidylinositol 4-phosphate 4. Further phosphorylation by Its3 (PomBase:SPAC19G12.14) generates phosphatidylinositol 4,5-bisphosphate 5. Plc1 (PomBase:SPAC22F8.11) acts as a phospholipase C that hydrolyzes phosphatidylinositol 4,5-bisphosphate to produce inositol 1,4,5-trisphosphate 6. Arg82 (PomBase:SPAC607.04) is an inositol-1,4,5-trisphosphate 3-kinase that phosphorylates inositol 1,4,5-trisphosphate 7. Ipk1 (PomBase:SPCC4B3.10c) acts as an inositol-1,3,4,5,6-pentakisphosphate 2-kinase 8. Kcs1 (PomBase:SPCC970.08) functions as an inositol hexakisphosphate kinase to generate inositol pyrophosphates</p>"},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/#evaluation","title":"Evaluation","text":""},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/#strengths","title":"Strengths","text":"<ol> <li> <p>Appropriately represents the key enzymes: The model includes the major enzymes involved in inositol phosphate metabolism in fission yeast, as supported by literature (specifically PMID:38133430).</p> </li> <li> <p>Uses correct causal connections: The model employs RO:0002413 \"provides input for\" appropriately to indicate how substrate output from one reaction serves as input for the next.</p> </li> <li> <p>Includes correct subcellular locations: The model correctly annotates Itr2 and Efr3 as occurring in the plasma membrane.</p> </li> <li> <p>Molecular mechanisms match literature: The model's representation of the pathway aligns with the recent publication (PMID:38133430) which describes this pathway's importance in regulating phosphate acquisition genes.</p> </li> </ol>"},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Efr3-Stt4 relationship: While the model shows Efr3 (PomBase:SPCC794.08) regulating Stt4, it doesn't clearly explain that Efr3 functions as a protein-membrane adaptor to help localize Stt4 to the plasma membrane. This relationship could be represented more precisely.</p> </li> <li> <p>Incomplete annotation of compartments: Several enzymes lack cellular compartment annotations that would enhance the model's accuracy.</p> </li> <li> <p>Incomplete representation of final inositol pyrophosphate steps: Based on the PMID:38133430 reference, the model doesn't fully represent the final steps where Asp1 converts 5-IP7 to 1,5-IP8, which is critical for the biological role of this pathway in phosphate homeostasis.</p> </li> <li> <p>Missing downstream effects: The model mentions adding \"inositol phosphate metabolic process\" to the components after plc1, but doesn't completely represent how this pathway regulates phosphate acquisition genes (pho1, pho84, and tgp1), which is a key aspect described in the literature.</p> </li> <li> <p>Incomplete evidence codes: Some of the causal associations lack sufficient evidence codes to support the connections.</p> </li> </ol>"},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Add cellular locations: Add appropriate cellular location annotations for all enzymes in the pathway.</p> </li> <li> <p>Complete the pathway: Add the final steps of inositol pyrophosphate metabolism, including Asp1's dual role as a kinase and pyrophosphatase.</p> </li> <li> <p>Include biological outcomes: Add annotations to represent how this pathway regulates gene expression of the phosphate acquisition genes.</p> </li> <li> <p>Improve causal connections: Review each \"provides input for\" causal connection to ensure all have appropriate evidence codes and references.</p> </li> <li> <p>Add chemical intermediates: The model comments mention \"add major intermediates\" - these should be incorporated to better represent the full metabolic pathway and the chemical transformations occurring between steps.</p> </li> <li> <p>Clarify Efr3 function: Better describe how Efr3 acts as a membrane adaptor for Stt4 in phosphatidylinositol 4-kinase activity.</p> </li> </ol>"},{"location":"reviews/663d668500002178-phosphatidylinositol_phosphate_phosphatidylinositol__biosynthetic_process__GO_0006661__GO_0043647___/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a useful representation of the inositol phosphate biosynthetic pathway in fission yeast. It correctly captures the major enzymatic steps and their causal relationships. However, the model could be improved by adding cellular locations for all activities, completing the final steps of the pathway, adding key intermediates, and showing the biological significance of this pathway in regulating phosphate homeostasis genes.</p> <p>The recent literature (PMID:38133430) provides important context on how this pathway functions in fission yeast to control gene expression through inositol pyrophosphate signaling, which could be better represented in the model.</p>"},{"location":"reviews/663d668500002302-canonical_glycolysis__GO_0061621_/","title":"663d668500002302 canonical glycolysis  GO 0061621","text":"<p>Based on the information I've gathered, I'll now conduct a thorough review of the GO-CAM model for canonical glycolysis (GO:0061621) in Schizosaccharomyces pombe (NCBITaxon:4896).</p>"},{"location":"reviews/663d668500002302-canonical_glycolysis__GO_0061621_/#review-of-go-cam-model-gomodel663d668500002302","title":"Review of GO-CAM Model gomodel:663d668500002302","text":""},{"location":"reviews/663d668500002302-canonical_glycolysis__GO_0061621_/#overview","title":"Overview","text":"<p>This model represents canonical glycolysis (GO:0061621) in the fission yeast Schizosaccharomyces pombe. It includes 12 activities that together form a complete glycolytic pathway, with appropriate causal relationships between activities.</p>"},{"location":"reviews/663d668500002302-canonical_glycolysis__GO_0061621_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Completeness: The model includes all canonical glycolytic enzymes and their respective activities, from hexokinase (beginning of glycolysis) to pyruvate kinase (end of glycolysis).</p> </li> <li> <p>Appropriate causality: The model correctly uses RO:0002413 (\"provides input for\") to connect the activities in the pathway in the expected sequential order, representing substrate-product relationships.</p> </li> <li> <p>Cellular localization: All activities are properly annotated as occurring in the cytosol (GO:0005829), which is the expected cellular location for glycolysis.</p> </li> <li> <p>Evidence support: Activities are supported by appropriate evidence codes, including direct assays (ECO:0000314), high throughput assays (ECO:0007005), and computational predictions based on sequence similarity (ECO:0000318, ECO:0000250).</p> </li> <li> <p>Literature references: The model cites relevant literature such as PMID:8549830 (characterizing hexokinases in S. pombe) and PMID:9790887 (pyruvate kinase characterization).</p> </li> </ol>"},{"location":"reviews/663d668500002302-canonical_glycolysis__GO_0061621_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing chemical inputs/outputs: While the model does have inputs and outputs for some activities (e.g., hexokinase has D-hexose input, and pyruvate kinase has pyruvate output), most of the intermediate reactions are missing inputs and outputs. Adding these would improve the comprehensiveness of the model.</p> </li> <li> <p>Redundant causal associations: There are several instances of duplicate causal associations between the same activities. For example:</p> </li> <li>Activity 663d668500002302/663d668500002432 (triose-phosphate isomerase) has multiple redundant causal connections to the same downstream activities.</li> <li> <p>Activity 663d668500002302/663d668500002422 (fructose-bisphosphate aldolase) has duplicate causal connections.</p> </li> <li> <p>Empty evidence fields: Some causal associations have empty evidence fields, which should be populated with appropriate evidence.</p> </li> <li> <p>Comment indicating incompleteness: The model has a comment stating \"To do, add other input chemicals and activities,\" indicating the curator's awareness that the model remains incomplete.</p> </li> <li> <p>Branch point representation: Glycolysis has a branch point where dihydroxyacetone phosphate and glyceraldehyde 3-phosphate are produced from fructose 1,6-bisphosphate. The model doesn't clearly represent this branch point and the conversion of dihydroxyacetone phosphate back to the main pathway.</p> </li> </ol>"},{"location":"reviews/663d668500002302-canonical_glycolysis__GO_0061621_/#specific-issues","title":"Specific Issues","text":"<ol> <li> <p>Activity ID 663d668500002302/663d668500002441 and 663d668500002302/663d668500002589: Both of these represent glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity (GO:0004365) enabled by different genes (PomBase:SPBC354.12 and PomBase:SPBC32F12.11). It's unusual to have two separate activities for the same function in a canonical pathway model - this should be reviewed to determine if this represents isozymes and if their inclusion is appropriate.</p> </li> <li> <p>Activity ID 663d668500002302/663d668500002626 and 663d668500002302/663d668500002636: Similarly, there are two enolase activities (GO:0004634) enabled by different genes (eno101 and eno102), which should be reviewed to determine if both are required in the model.</p> </li> <li> <p>Inputs and outputs: Key metabolites should be added as inputs and outputs of each reaction:</p> </li> <li>Glucose, glucose-6-phosphate, fructose-6-phosphate, etc. are missing from most steps.</li> </ol>"},{"location":"reviews/663d668500002302-canonical_glycolysis__GO_0061621_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Complete inputs and outputs: Add all relevant chemical inputs and outputs for each enzymatic step in the pathway.</p> </li> <li> <p>Remove redundant causal associations: Clean up duplicate causal associations between activities.</p> </li> <li> <p>Address isozymes: Either justify the inclusion of multiple enzyme isoforms for the same step or simplify to represent the canonical pathway.</p> </li> <li> <p>Add missing evidence: Ensure all causal associations have appropriate evidence fields.</p> </li> <li> <p>Represent the branch point: Clearly represent the branch at fructose 1,6-bisphosphate where dihydroxyacetone phosphate and glyceraldehyde 3-phosphate are produced, and the subsequent conversion of dihydroxyacetone phosphate.</p> </li> </ol>"},{"location":"reviews/663d668500002302-canonical_glycolysis__GO_0061621_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good representation of the canonical glycolysis pathway in S. pombe, with all key enzymatic activities represented. The activities are properly connected with causal relationships, and most have appropriate evidence and literature support. However, the model could be improved by adding chemical inputs and outputs for all steps, removing redundant causal associations, and addressing the representation of isozymes. Once these issues are addressed, the model will provide a more complete and accurate representation of glycolysis.</p>"},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/","title":"663d668500003144 TGFB1 mediated signaling pathway  Human","text":"<p>Based on my review of the GO-CAM model and its components, I'll now provide a comprehensive assessment of the model and identify any potential issues or areas for improvement.</p>"},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/#go-cam-model-review-gomodel663d668500003144","title":"GO-CAM Model Review: gomodel:663d668500003144","text":""},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>Title: TGFB1-mediated signaling pathway (Human) Taxon: Human (NCBITaxon:9606) Status: Production Model ID: gomodel:663d668500003144</p> <p>This GO-CAM represents the TGF-beta1 signaling pathway in humans, showing the interactions between the cytokine TGFB1, the receptors TGFBR1 and TGFBR2, and the downstream effector SMAD2.</p>"},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/#model-components","title":"Model Components","text":"<p>The model consists of 4 main activities:</p> <ol> <li>TGFB1 (P01137) with cytokine activity (GO:0005125) in extracellular space (GO:0005615)</li> <li>TGFBR2 (P37173) with TGF-beta receptor type II activity (GO:0005026) at plasma membrane (GO:0005886)</li> <li>TGFBR1 (P36897) with TGF-beta receptor type I activity (GO:0005025) at plasma membrane (GO:0005886)</li> <li>SMAD2 (Q15796) with DNA-binding transcription factor activity (GO:0003700) in nucleus (GO:0005634)</li> </ol>"},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model represents the following causal chain: - TGFB1 directly positively regulates (RO:0002629) TGFBR2 - TGFBR2 directly positively regulates (RO:0002629) TGFBR1 - TGFBR1 directly positively regulates (RO:0002629) SMAD2</p> <p>All activities are part of the GO:0007179 (transforming growth factor beta receptor signaling pathway).</p>"},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Biological Accuracy: The model correctly captures the canonical TGF-beta signaling pathway where the cytokine TGFB1 binds to TGFBR2, which then recruits and phosphorylates TGFBR1, leading to the activation of SMAD2.</p> </li> <li> <p>Evidence Support: Each component has appropriate evidence codes and PMID references supporting the annotations.</p> </li> <li> <p>Cellular Localization: Appropriate cellular compartments are assigned to each protein, reflecting their known localizations.</p> </li> </ol>"},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>SMAD2 Transcription Factor Activity:</li> <li>The model uses the general term \"DNA-binding transcription factor activity\" (GO:0003700) for SMAD2. According to the DNA-binding transcription factor annotation guidelines, a more specific term should be used, such as \"DNA-binding transcription activator activity, RNA polymerase II-specific\" (GO:0001228) which would be more appropriate based on SMAD2's known function.</li> <li> <p>The guideline also suggests that each transcriptional target should be captured separately, but no specific targets are indicated in this model.</p> </li> <li> <p>Missing SMAD Complex Formation:</p> </li> <li> <p>SMAD2 typically forms a complex with SMAD4 before translocating to the nucleus and activating transcription. This SMAD2-SMAD4 complex formation is not represented in the model.</p> </li> <li> <p>SMAD Phosphorylation:</p> </li> <li> <p>The activation of SMAD2 by TGFBR1 typically involves phosphorylation of SMAD2 at specific serine residues (Ser465/467), which is an important mechanistic detail that could be included in the model.</p> </li> <li> <p>Additional Regulatory Mechanisms:</p> </li> <li>The model doesn't capture negative regulators of the pathway, such as inhibitory SMADs (SMAD7) or phosphatases like PPM1A that dephosphorylate SMAD2.</li> <li> <p>It also doesn't include non-SMAD pathways activated by TGF-beta signaling.</p> </li> <li> <p>Specific Transcriptional Outputs:</p> </li> <li>No specific transcriptional targets of SMAD2 are indicated. According to the DNA-binding transcription factor annotation guidelines, the relationship between the transcription factor and the genes it regulates should be captured with \"has input\" relationships.</li> </ol>"},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li> <p>The model follows the basic GO-CAM format with activities, cellular components, and causal relationships.</p> </li> <li> <p>The use of the \"directly positively regulates\" (RO:0002629) predicate is appropriate for the signaling cascade depicted.</p> </li> <li> <p>All proteins have appropriate molecular functions and cellular components assigned.</p> </li> <li> <p>However, as noted above, the DNA-binding transcription factor activity of SMAD2 could be more specifically annotated following the transcription factor annotation guidelines.</p> </li> </ol>"},{"location":"reviews/663d668500003144-TGFB1_mediated_signaling_pathway__Human_/#recommendation","title":"Recommendation","text":"<p>The model provides a good foundation for representing the TGF-beta signaling pathway, but could be enhanced by:</p> <ol> <li>Using more specific GO terms for SMAD2's transcription factor activity</li> <li>Including SMAD4 and the formation of the SMAD2-SMAD4 complex</li> <li>Adding specific transcriptional targets of SMAD2 with \"has input\" relationships</li> <li>Including additional regulatory mechanisms such as inhibitory SMADs</li> <li>Capturing the phosphorylation of SMAD2 by TGFBR1 more explicitly</li> </ol> <p>These enhancements would make the model more comprehensive and aligned with the current understanding of TGF-beta signaling and GO-CAM best practices for annotating transcription factors.</p>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/","title":"663d668500003182 TGFB2 mediated signaling pathway  Human","text":"<p>Based on my review of the GO-CAM model and the relevant documentation, I will now provide a comprehensive review of the GO-CAM model \"gomodel:663d668500003182\" (TGFB2-mediated signaling pathway in Human).</p>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#review-of-go-cam-model-tgfb2-mediated-signaling-pathway-human","title":"Review of GO-CAM Model \"TGFB2-mediated signaling pathway (Human)\"","text":""},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:663d668500003182) represents the TGF-beta2 signaling pathway in humans, illustrating how TGF-beta2 ligand interacts with TGF-beta receptors to activate SMAD-dependent transcriptional regulation.</p>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#model-structure-and-pathway-flow","title":"Model Structure and Pathway Flow","text":"<p>The model contains four main activities arranged in a signaling cascade:</p> <ol> <li>TGF-beta2 (UniProtKB:P61812) functions as a cytokine in the extracellular space</li> <li>TGF-beta receptor type II (UniProtKB:P37173) receives the signal at the plasma membrane</li> <li>TGF-beta receptor type I (UniProtKB:P36897) is activated by TGF-beta receptor type II at the plasma membrane</li> <li>SMAD2 (UniProtKB:Q15796) acts as a DNA-binding transcription factor in the nucleus</li> </ol> <p>The causal flow follows the classic TGF-beta signaling pathway: - TGF-beta2 directly positively regulates TGF-beta receptor type II - TGF-beta receptor type II directly positively regulates TGF-beta receptor type I - TGF-beta receptor type I directly positively regulates SMAD2</p>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#evidence-and-literature-support","title":"Evidence and Literature Support","text":"<p>Each activity and association is supported by experimental evidence, primarily direct assays (ECO:0000314) with references to peer-reviewed publications: - TGF-beta2 cytokine activity is supported by computational analysis - TGF-beta receptor activity is supported by multiple publications including PMID:7774578 and PMID:8752209 - SMAD2 transcription factor activity is supported by PMID:17438144</p>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model correctly captures the core components of the canonical TGF-beta signaling pathway</li> <li>Each entity is properly localized (extracellular space, plasma membrane, nucleus)</li> <li>The causal relations use appropriate predicates (RO:0002629 - directly positively regulates)</li> <li>All activities are part of the TGF-beta receptor signaling pathway (GO:0007179)</li> <li>Evidence is provided for each assertion with appropriate references</li> </ol>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Missing SMAD Complex: According to literature, SMAD2 typically functions as part of a complex with SMAD4. The model could be enhanced by including SMAD4 and representing this complex formation.</p> </li> <li> <p>Transcriptional Target(s): Following GO-CAM guidelines for DNA-binding transcription factors, SMAD2 should have one or more specific transcriptional targets using the \"has input\" relationship, with appropriate causal relationships (indirectly positively/negatively regulates).</p> </li> <li> <p>SMAD2 Phosphorylation: The model could explicitly represent the phosphorylation of SMAD2 by TGF-beta receptor type I, as this is a crucial step in the pathway.</p> </li> <li> <p>Receptor Complex Formation: According to the signaling receptor activity guidelines, the model could better represent the formation of the TGF-beta receptor complex (type I and type II receptors).</p> </li> <li> <p>Downstream Effectors: The model currently ends with SMAD2 activation. Adding downstream target genes and their biological effects would provide a more complete picture of the pathway.</p> </li> </ol>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model generally follows GO-CAM guidelines: - The use of \"directly positively regulates\" for causal relationships is appropriate - Activities are properly contextualized with cellular locations - Each activity is part of the relevant biological process</p> <p>However, according to the DNA-binding transcription factor guidelines, the model should include specific transcriptional targets for SMAD2 with \"has input\" relationships.</p>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the core TGF-beta signaling mechanism: 1. TGF-beta2 ligand binding to the TGF-beta type II receptor 2. Recruitment and phosphorylation of the TGF-beta type I receptor 3. Activation of SMAD2 as a transcription factor</p> <p>This is consistent with the established understanding of TGF-beta signaling as documented in the UniProt entries and literature.</p>"},{"location":"reviews/663d668500003182-TGFB2_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>This model provides a good representation of the core TGF-beta2 signaling pathway in humans. It correctly captures the main components, their activities, locations, and causal relationships. To improve the model, I recommend:</p> <ol> <li>Including SMAD4 and its interaction with SMAD2</li> <li>Adding specific transcriptional targets of SMAD2</li> <li>Explicitly representing the phosphorylation of SMAD2</li> <li>Expanding the model to include downstream biological effects</li> </ol> <p>Overall, the model is biologically accurate and follows most GO-CAM guidelines, providing a valuable resource for understanding TGF-beta2 signaling.</p>"},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/","title":"663d668500003232 TGFB3 mediated signaling pathway  Human","text":"<p>Now that I have the essential information, I'll conduct a comprehensive review of the GO-CAM model gomodel:663d668500003232, which is titled \"TGFB3-mediated signaling pathway (Human)\".</p>"},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#review-of-go-cam-model-tgfb3-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: TGFB3-mediated signaling pathway (Human)","text":""},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:663d668500003232) represents the TGF-beta 3 signaling pathway in humans, focusing on the canonical pathway from ligand binding through receptor activation to transcriptional regulation. The model shows four key proteins and their interactions:</p> <ol> <li>TGFB3 (UniProtKB:P10600) - transforming growth factor beta 3, acting as a cytokine</li> <li>TGFBR2 (UniProtKB:P37173) - TGF-beta receptor type 2</li> <li>TGFBR1 (UniProtKB:P36897) - TGF-beta receptor type 1</li> <li>SMAD2 (UniProtKB:Q15796) - transcription factor activated by the pathway</li> </ol>"},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model correctly represents the canonical TGF-beta signaling pathway: - TGFB3 acts as a cytokine (GO:0005125) in the extracellular space - TGFB3 activates TGFBR2 via direct positive regulation (RO:0002629) - TGFBR2 activates TGFBR1 via direct positive regulation (RO:0002629) - TGFBR1 activates SMAD2, which then acts as a transcription factor (GO:0003700) in the nucleus</p> <p>All molecular activities in the model are supported by literature evidence, and the components are present in the correct cellular locations.</p>"},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#causal-connections","title":"Causal Connections","text":"<p>The causal connections are correctly represented: - The direction of signaling flows appropriately from extracellular TGFB3 \u2192 TGFBR2 \u2192 TGFBR1 \u2192 SMAD2 - The predicate \"directly positively regulates\" (RO:0002629) is used appropriately for these direct activation events, following GO-CAM guidelines</p>"},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>Looking at the model against the guidelines for signaling receptor activity:</p> <ol> <li>Ligand (TGFB3):</li> <li>\u2713 Correct MF: Has cytokine activity (GO:0005125), which is a child of receptor ligand activity</li> <li>\u2713 Correct location: In extracellular space (GO:0005615)</li> <li>\u2713 Correct process: Part of TGF-beta receptor signaling pathway (GO:0007179)</li> <li> <p>\u2713 Correct relation to receptor: Directly positively regulates its receptor</p> </li> <li> <p>Signaling receptor (TGFBR2):</p> </li> <li>\u2713 Correct MF: Has TGF-beta receptor type II activity (GO:0005026)</li> <li>\u2713 Correct location: Occurs in plasma membrane (GO:0005886)</li> <li>\u2713 Correct process: Part of TGF-beta receptor signaling pathway (GO:0007179)</li> <li> <p>\u2713 Correct relation: Directly positively regulates its target (TGFBR1)</p> </li> <li> <p>Type I receptor (TGFBR1):</p> </li> <li>\u2713 Correct MF: Has TGF-beta receptor type I activity (GO:0005025)</li> <li>\u2713 Correct location: Occurs in plasma membrane (GO:0005886)</li> <li>\u2713 Correct process: Part of TGF-beta receptor signaling pathway (GO:0007179)</li> <li> <p>\u2713 Correct relation: Directly positively regulates its target (SMAD2)</p> </li> <li> <p>Transcription Factor (SMAD2):</p> </li> <li>\u2713 Correct MF: Has DNA-binding transcription factor activity (GO:0003700)</li> <li>\u2713 Correct location: Occurs in nucleus (GO:0005634)</li> <li>\u2713 Correct process: Part of TGF-beta receptor signaling pathway (GO:0007179)</li> </ol>"},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#evidence-quality","title":"Evidence Quality","text":"<p>The model uses appropriate evidences: - Most assertions use direct assay evidence (ECO:0000314)  - The cytokine activity for TGFB3 uses biological aspect of ancestor evidence (ECO:0000318) - Each assertion is backed by relevant PMIDs or GO_REF IDs - The model shows good evidence coverage across all assertions</p>"},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is generally well-constructed, there are a few improvements that could be made:</p> <ol> <li> <p>Downstream effects of SMAD2: The model could be extended to show what genes SMAD2 regulates. Currently, SMAD2 is shown as a transcription factor but has no outputs, leaving the pathway incomplete.</p> </li> <li> <p>SMAD2/SMAD4 complex: According to the literature, SMAD2 typically forms a complex with SMAD4 to regulate transcription. This is not represented in the current model.</p> </li> <li> <p>Feedback mechanisms: The model could include negative feedback loops that regulate TGF-beta signaling (such as inhibitory SMADs or other regulatory proteins).</p> </li> <li> <p>Phosphorylation status: The model doesn't capture the important phosphorylation of SMAD2 by TGFBR1, which is a key regulatory mechanism for this pathway.</p> </li> </ol>"},{"location":"reviews/663d668500003232-TGFB3_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:663d668500003232) is a well-constructed representation of the TGF-beta 3 signaling pathway that follows GO-CAM best practices. The activities are properly connected and supported by evidence. It provides a parsimonious and clear representation of the canonical pathway.</p> <p>The model could be extended to show downstream effects of SMAD2 activation and include regulatory mechanisms, but as a focused representation of the core signaling pathway, it meets quality standards and is biologically accurate.</p>"},{"location":"reviews/665912ed00000015-tricarboxylic_acid_cycle__GO_0006099_/","title":"665912ed00000015 tricarboxylic acid cycle  GO 0006099","text":"<p>Based on my review of the GO-CAM model \"tricarboxylic acid cycle (GO:0006099)\" with ID gomodel:665912ed00000015, I'll provide a comprehensive analysis focusing on the model's biological content, connectivity, and adherence to GO-CAM best practices.</p>"},{"location":"reviews/665912ed00000015-tricarboxylic_acid_cycle__GO_0006099_/#overview","title":"Overview","text":"<p>This model represents the tricarboxylic acid (TCA) cycle, also known as the citric acid cycle or Krebs cycle, in Schizosaccharomyces pombe (fission yeast, taxon NCBITaxon:4896). The model includes all the major enzymes of the TCA cycle and their molecular functions, with appropriate causal connections between activities.</p>"},{"location":"reviews/665912ed00000015-tricarboxylic_acid_cycle__GO_0006099_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Complete Pathway Representation: The model captures all essential enzymes of the TCA cycle:</li> <li>Citrate synthase (cit1)</li> <li>Aconitase (aco1, aco2)</li> <li>Isocitrate dehydrogenase (idh1, idh2)</li> <li>\u03b1-Ketoglutarate dehydrogenase complex (kgd1, kgd2, kgd4, dld1)</li> <li>Succinyl-CoA ligase (sca1, lsc2)</li> <li>Succinate dehydrogenase complex (sdh1, sdh2, sdh3, tim18)</li> <li>Fumarate hydratase (fum1)</li> <li> <p>Malate dehydrogenase (mdh1)</p> </li> <li> <p>Proper Subcellular Localization: Appropriate mitochondrial locations are specified (GO:0005739, GO:0005759, GO:0005743).</p> </li> <li> <p>Causal Connectivity: Activities are connected using RO:0002413 (provides input for), creating a coherent representation of the cycle's reaction sequence.</p> </li> <li> <p>Appropriate Molecular Functions: Each enzyme is annotated with the correct molecular function term.</p> </li> <li> <p>Adaptor Protein Annotation: KGD4 is correctly represented as having a protein-macromolecule adaptor activity (GO:0030674), following the \"How to annotate complexes in GO-CAM\" guidance.</p> </li> </ol>"},{"location":"reviews/665912ed00000015-tricarboxylic_acid_cycle__GO_0006099_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Molecular Inputs/Outputs: While some activities have inputs and outputs (e.g., dihydrolipoamide for dld1, succinyl-CoA for sca1 and lsc2), many activities are missing their explicit chemical inputs/outputs, which would make the model more complete.</p> </li> <li> <p>Duplicate Causal Associations: Several activities have duplicate causal associations with the same predicate and target. For example:</p> </li> <li>kgd4 has duplicate associations to kgd1 and kgd2</li> <li> <p>Multiple activities have both evidenced and non-evidenced causal associations to the same targets</p> </li> <li> <p>Incomplete Evidence: Some activities have connections without evidence annotations.</p> </li> <li> <p>Redundant Connections: There are multiple causal paths from some activities to others. For example, aco2 has three identical causal connections to idh1 and idh2.</p> </li> <li> <p>Comment Clarity: The comment about \"directons, particularly fumerate hydratase /dehydratase\" contains a typo (\"directons\" should be \"directions\") and is unclear.</p> </li> </ol>"},{"location":"reviews/665912ed00000015-tricarboxylic_acid_cycle__GO_0006099_/#specific-technical-issues","title":"Specific Technical Issues","text":"<ol> <li> <p>KGD4 Complex Annotations: The comment about KGD4 indicates it functions as an adaptor protein in the \u03b1-ketoglutarate dehydrogenase complex, which is correctly represented. However, the causal associations from kgd4 to both kgd1 and kgd2 use RO:0012009 instead of a more specific term that would clarify its role in stabilizing the complex.</p> </li> <li> <p>Respiratory Chain Complex II: The electron transfer from SDH to ubiquinone (GO:0006121) is included, but could be better integrated with the main TCA cycle.</p> </li> <li> <p>ACO2 Annotation: The comment \"aco2 is TCA in S. cerevisiae when glucose is limiting\" is present in the model, but this statement is about S. cerevisiae while the model represents S. pombe. This may be confusing.</p> </li> </ol>"},{"location":"reviews/665912ed00000015-tricarboxylic_acid_cycle__GO_0006099_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add Missing Chemical Inputs/Outputs: For each enzymatic reaction, include all relevant chemical inputs and outputs to fully represent the transformations in the TCA cycle.</p> </li> <li> <p>Remove Duplicate Associations: Clean up duplicate causal associations that have the same predicate and target.</p> </li> <li> <p>Add Evidence for All Assertions: Ensure all causal connections have appropriate evidence annotations.</p> </li> <li> <p>Clarify Comments: Revise the comment about fumarate hydratase to make it clearer, and ensure all comments are relevant to S. pombe.</p> </li> <li> <p>Standardize Representation of Complex Subunits: For the \u03b1-ketoglutarate dehydrogenase and succinate dehydrogenase complexes, ensure consistent representation of how subunits interact.</p> </li> </ol>"},{"location":"reviews/665912ed00000015-tricarboxylic_acid_cycle__GO_0006099_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model provides a good representation of the TCA cycle in S. pombe with all essential enzymes and connections. The model follows GO-CAM best practices for complex annotation, particularly with the representation of kgd4 as an adaptor protein. With the suggested improvements, the model would be more precise and informative for users, while maintaining its parsimony and readability.</p> <p>The model is biologically accurate and consistent with standard textbook knowledge of the TCA cycle, with appropriate evidence support from both literature and orthology-based assignments.</p>"},{"location":"reviews/665912ed00000192-GPI__anchor_biosynthetic_process__GO_0006506_/","title":"665912ed00000192 GPI  anchor biosynthetic process  GO 0006506","text":"<p>Based on my review of the GO-CAM model \"GPI anchor biosynthetic process (GO:0006506)\" with ID gomodel:665912ed00000192, here's my assessment:</p>"},{"location":"reviews/665912ed00000192-GPI__anchor_biosynthetic_process__GO_0006506_/#general-review","title":"General Review","text":"<p>This model represents the GPI (glycosylphosphatidylinositol) anchor biosynthetic process in Schizosaccharomyces pombe (fission yeast), which is a complex multi-step pathway involving many enzymes that work sequentially to synthesize GPI anchors for proteins.</p>"},{"location":"reviews/665912ed00000192-GPI__anchor_biosynthetic_process__GO_0006506_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive representation: The model includes many of the key enzymes involved in GPI anchor biosynthesis, with appropriate molecular functions assigned.</p> </li> <li> <p>Proper cellular locations: The activities are correctly localized to appropriate cellular components (endoplasmic reticulum membrane, ER, GPI-anchor transamidase complex, etc.).</p> </li> <li> <p>Causal connections: Most activities are properly connected with causal relationships using the appropriate \"provides input for\" (RO:0002413) predicate to show the sequential steps in the pathway.</p> </li> <li> <p>Evidence: The model uses appropriate evidence codes, with a mix of experimental evidence, sequence similarity, and orthology-based annotations.</p> </li> </ol>"},{"location":"reviews/665912ed00000192-GPI__anchor_biosynthetic_process__GO_0006506_/#issues-identified","title":"Issues Identified","text":"<ol> <li>Duplicate causal relationships: There are several instances where the same causal relationship is represented twice between the same activities. For example:</li> <li>In activity <code>gomodel:665912ed00000192/665912ed00000210</code>, there are two identical causal associations to activity <code>665912ed00000232</code></li> <li>In activity <code>gomodel:665912ed00000192/665912ed00000396</code>, there are duplicate causal associations to activity <code>665912ed00000193</code></li> <li> <p>Several other activities have this same issue throughout the model</p> </li> <li> <p>Complex representation: The model comment mentions \"deal with 2 complexes once in complex portal,\" but it's not clear if this has been addressed. Based on the GO-CAM guidelines for representing complexes, these should be properly annotated according to whether the subunit carrying the activity is known or not.</p> </li> <li> <p>Missing molecular functions: Some activities have <code>GO:0003674</code> (molecular function) assigned, which is the root term for all molecular functions, indicating that the specific function is not known. While this is acceptable when the function is truly unknown, it should be reviewed to ensure more specific terms aren't available.</p> </li> <li> <p>Unused inputs and outputs: Some activities like <code>gomodel:665912ed00000192/665912ed00000427</code> have inputs defined (CHEBI:16749) but this input is listed twice. Activity <code>gomodel:665912ed00000192/66c7d41500001900</code> has an output defined but isn't clearly connected to the rest of the pathway.</p> </li> <li> <p>Lack of regulation clarity: The model shows several regulatory relationships (using RO:0002629 \"directly positively regulates\") but the mechanism of this regulation isn't always clear.</p> </li> </ol>"},{"location":"reviews/665912ed00000192-GPI__anchor_biosynthetic_process__GO_0006506_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Remove duplicate causal associations: Clean up the model by removing duplicate causal relationships between the same activities.</p> </li> <li> <p>Clarify complex representation: According to the best practices document, if subunits carrying specific activities are known, they should be represented directly. If not, use the complex ID. The comment about handling complexes should be addressed.</p> </li> <li> <p>Review molecular function annotations: For activities with <code>GO:0003674</code>, consider if more specific molecular function terms could be applied based on recent literature.</p> </li> <li> <p>Connect isolated activities: Ensure all activities, especially those with defined inputs/outputs like activity <code>66c7d41500001900</code> (pis1), are properly connected to the pathway.</p> </li> <li> <p>Verify evidence for regulatory relationships: Ensure that all regulatory relationships have appropriate evidence.</p> </li> <li> <p>Update comment: Once the issue with the complexes is resolved, the comment \"deal with 2 complexes once in complex portal\" should be updated or removed to reflect the current state of the model.</p> </li> </ol>"},{"location":"reviews/665912ed00000192-GPI__anchor_biosynthetic_process__GO_0006506_/#summary","title":"Summary","text":"<p>This is a comprehensive GO-CAM model of the GPI anchor biosynthetic process in S. pombe. While it accurately represents most aspects of the pathway, there are issues with duplicate causal relationships and some potential improvements in the representation of molecular functions and complexes. Addressing these issues would make the model more accurate and easier to interpret.</p>"},{"location":"reviews/665912ed00000459-dolichol_linked_oligosaccharide_biosynthetic_process__GO_0006488__/","title":"665912ed00000459 dolichol linked oligosaccharide biosynthetic process  GO 0006488","text":"<p>Let me continue with my review of GO-CAM model 665912ed00000459. This model represents the dolichol-linked oligosaccharide biosynthetic process (GO:0006488) in Schizosaccharomyces pombe (fission yeast).</p>"},{"location":"reviews/665912ed00000459-dolichol_linked_oligosaccharide_biosynthetic_process__GO_0006488__/#go-cam-review-gomodel665912ed00000459","title":"GO-CAM Review: gomodel:665912ed00000459","text":""},{"location":"reviews/665912ed00000459-dolichol_linked_oligosaccharide_biosynthetic_process__GO_0006488__/#title-and-overview","title":"Title and Overview","text":"<p>Title: \"dolichol-linked oligosaccharide biosynthetic process (GO:0006488)\" Taxon: NCBITaxon:4896 (Schizosaccharomyces pombe) Status: Production Comments: \"waiting for correct activity for dfg10, need to connect sec9, dfg10, rer2\"</p>"},{"location":"reviews/665912ed00000459-dolichol_linked_oligosaccharide_biosynthetic_process__GO_0006488__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Pathway Completeness: The model represents a comprehensive view of the dolichol-linked oligosaccharide biosynthetic pathway, including multiple sequential steps with appropriate enzymes.</li> <li>Cellular Context: Activities are properly annotated with cellular locations, primarily occurring in the endoplasmic reticulum membrane (GO:0005789).</li> <li>Causal Connections: Most activities are connected through appropriate causal relationships, forming a coherent pathway flow using RO:0002413 (provides input for).</li> <li>Evidence Support: Most activities have strong evidence codes, including experimental evidence (ECO:0000315, ECO:0000316) and literature citations.</li> </ol>"},{"location":"reviews/665912ed00000459-dolichol_linked_oligosaccharide_biosynthetic_process__GO_0006488__/#issues-identified","title":"Issues Identified","text":"<ol> <li> <p>Incomplete Connections: The model has a comment indicating that connections between sec9, dfg10, and rer2 need to be completed. This is indeed the case - these components aren't fully integrated into the pathway flow.</p> </li> <li> <p>Missing Activity: The comment mentions \"waiting for correct activity for dfg10\" - I see dfg10 (PomBase:SPAC7D4.09c) is annotated with 3-oxo-5-alpha-steroid 4-dehydrogenase activity (GO:0003865), but this may not be the most appropriate activity term based on its role in dolichol biosynthesis.</p> </li> <li> <p>Duplicate Activities: There are duplicate activities for some proteins, such as:</p> </li> <li>PomBase:SPBC11B10.01 (alg2) has two activities: GO:0004378 and GO:0102704</li> <li>PomBase:SPAC1834.05 (alg9) has two activities: GO:0052926 and GO:0052918</li> <li> <p>PomBase:SPCC330.08 (alg11) appears twice with the same activity GO:0004377</p> </li> <li> <p>Input/Output Molecules: While some activities have specified input/output molecules, there are inconsistencies:</p> </li> <li>alg7 (SPBC15D4.04) has CHEBI:16264 (UDP-N-acetyl-alpha-D-glucosamine) listed as input multiple times</li> <li> <p>Some molecular inputs and outputs are missing for key steps in the pathway</p> </li> <li> <p>Ambiguous Causal Relationships: Several activities have multiple downstream connections to the same activity, which may create confusion in pathway interpretation.</p> </li> <li> <p>Uncertain Evidence: Some associations have no evidence codes specified.</p> </li> </ol>"},{"location":"reviews/665912ed00000459-dolichol_linked_oligosaccharide_biosynthetic_process__GO_0006488__/#recommendations","title":"Recommendations","text":"<ol> <li>Complete Missing Connections:</li> <li> <p>Connect sec59 (SPCC63.10c), dfg10 (SPAC7D4.09c), and rer2 (SPAC4D7.04c) as mentioned in the comments to show the proper flow of the dolichol biosynthetic process.</p> </li> <li> <p>Resolve Duplicate Activities:</p> </li> <li>For molecules with multiple activities, determine whether these are indeed separate functions or redundant annotations, and connect them appropriately in the pathway.</li> <li> <p>For example, clarify whether alg2 (SPBC11B10.01) performs both GDP-Man:Man1GlcNAc2-PP-Dol alpha-1,3-mannosyltransferase and GDP-Man:Man2GlcNAc2-PP-dolichol alpha-1,6-mannosyltransferase activities sequentially or in different contexts.</p> </li> <li> <p>Add Missing Input/Output Molecules:</p> </li> <li> <p>Ensure all activities have their relevant input and output molecules specified to better illustrate the flow of material through the pathway.</p> </li> <li> <p>Clarify Causal Relationships:</p> </li> <li> <p>Review cases where multiple causal connections point to the same downstream activity and determine if these represent alternative pathways, redundancy, or modeling errors.</p> </li> <li> <p>Complete Evidence Documentation:</p> </li> <li> <p>Add appropriate evidence codes for any associations currently lacking them.</p> </li> <li> <p>Review Activity for dfg10:</p> </li> <li>Confirm the appropriate molecular function for dfg10 (SPAC7D4.09c). The current annotation with 3-oxo-5-alpha-steroid 4-dehydrogenase activity may need revision based on its role in dolichol biosynthesis.</li> </ol>"},{"location":"reviews/665912ed00000459-dolichol_linked_oligosaccharide_biosynthetic_process__GO_0006488__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The overall biological process represented appears accurate, modeling the dolichol-linked oligosaccharide biosynthetic pathway in fission yeast, which is a conserved pathway involved in N-linked glycosylation. The sequential arrangement of enzymes follows the known steps of this pathway, moving from early glycosylation with N-acetylglucosamine to later additions of mannose and glucose residues.</p> <p>The model connects many of the key enzymes involved including the ALG family proteins (ALG1, ALG2, ALG3, etc.) that sequentially build the lipid-linked oligosaccharide precursor. The inclusion of dolichol biosynthesis components (dfg10, rer2, sec59) is also biologically appropriate, as dolichol phosphate is a key substrate in this pathway.</p>"},{"location":"reviews/665912ed00000459-dolichol_linked_oligosaccharide_biosynthetic_process__GO_0006488__/#summary","title":"Summary","text":"<p>This GO-CAM model provides a good representation of the dolichol-linked oligosaccharide biosynthetic process in S. pombe. While the model has several strengths in terms of pathway coverage and evidence support, there are areas that need improvement, particularly in connecting dolichol biosynthesis to the main pathway, resolving duplicate activities, and ensuring consistent annotation of molecular inputs and outputs. Addressing these issues would improve the model's clarity and biological accuracy.</p>"},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/","title":"665912ed00000652 pericentric heterochromatin formation  GO 0031508","text":"<p>Now, let me review the model based on GO-CAM best practices and biological accuracy. First, I'll check for any relevant GO-CAM guidelines that might apply to this model.</p> <p>This is a detailed model representing pericentric heterochromatin formation (GO:0031508) in Schizosaccharomyces pombe (fission yeast). I'll structure my review to cover several key aspects of the model.</p>"},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:665912ed00000652) represents the molecular mechanisms involved in pericentric heterochromatin formation in fission yeast. The model includes multiple interconnected pathways involving:</p> <ol> <li>RNAi-mediated heterochromatin formation (siRNA pathway)</li> <li>Histone modification activities (methylation, deacetylation)</li> <li>Heterochromatin protein complexes (CLRC, SHREC, RITS, etc.)</li> <li>RNA processing machineries</li> </ol>"},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/#structural-assessment","title":"Structural Assessment","text":""},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/#connectivity-and-flow","title":"Connectivity and Flow","text":"<ul> <li>The model shows good connectivity between activities with appropriate causal predicates (RO:0002413 \"provides input for\", RO:0002629 \"directly positively regulates\", etc.)</li> <li>The flow follows the biological sequence from RNA processing to chromatin modification to heterochromatin formation</li> </ul>"},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/#completeness","title":"Completeness","text":"<ul> <li>The model comprehensively captures key proteins known to be involved in S. pombe heterochromatin formation</li> <li>Multiple complexes are represented with their components and functions (CLRC, SHREC, RITS, ARC, RDRC)</li> <li>Both enzymatic activities (methyltransferase, deacetylase) and binding activities are represented</li> </ul>"},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of pericentric heterochromatin formation in S. pombe:</p> <ol> <li> <p>RNAi Machinery: The model includes Dcr1 (Dicer), Ago1 (Argonaute), and the RNA-dependent RNA polymerase Rdp1, which are essential components of the RNAi pathway that initiates heterochromatin formation.</p> </li> <li> <p>Histone Modifications: The model correctly shows Clr4 as the H3K9 methyltransferase and includes deacetylases (Clr3, Sir2) that remove acetyl groups from histones to facilitate heterochromatin formation.</p> </li> <li> <p>Heterochromatin Proteins: The model includes HP1 homologs (Swi6, Chp2) that bind methylated H3K9 and contribute to heterochromatin spreading and maintenance.</p> </li> <li> <p>Adaptor Proteins: The inclusion of Stc1 as an adaptor between RNAi and chromatin modification machinery is biologically accurate.</p> </li> </ol>"},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/#evidence-and-attribution","title":"Evidence and Attribution","text":"<ul> <li>All activities have appropriate evidence codes with PMID references</li> <li>Evidence types include experimental evidence (ECO:0000269), direct assay (ECO:0000314), and mutant phenotype (ECO:0000315)</li> <li>The model has consistent attribution with ORCID identifiers</li> </ul>"},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is of high quality, I have a few minor suggestions:</p> <ol> <li> <p>Unknown Molecular Functions: Several activities (e.g., gomodel:665912ed00000652/665912ed00000704, gomodel:665912ed00000652/665912ed00000722) have \"GO:0003674\" (molecular function) as their function, indicating unknown molecular function. It would be beneficial to update these with more specific functions when the literature supports it.</p> </li> <li> <p>Missing Evidence: A few causal associations lack evidence codes, such as the causal association between Clr1 and Clr3 activities. These should be added if available in the literature.</p> </li> <li> <p>Pathway Organization: The model could potentially benefit from more explicit organization into sub-pathways (e.g., RNAi pathway, histone modification pathway) to improve readability, though this is a minor point as the connections are already clear.</p> </li> </ol>"},{"location":"reviews/665912ed00000652-pericentric_heterochromatin_formation__GO_0031508_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:665912ed00000652) is a high-quality representation of pericentric heterochromatin formation in S. pombe. It accurately captures the biological processes and molecular functions involved, with appropriate evidence and attribution. The model follows GO-CAM best practices in terms of connectivity, biological accuracy, and evidence standards.</p> <p>The model effectively represents the current understanding of how RNAi machinery, histone modifiers, and heterochromatin proteins coordinate to establish and maintain pericentric heterochromatin in fission yeast. It would serve as an excellent example for similar pathway modeling efforts.</p>"},{"location":"reviews/665912ed00001983-subtelomeric_heterochromatin_formation__GO_0031509_/","title":"665912ed00001983 subtelomeric heterochromatin formation  GO 0031509","text":"<p>Based on my review of the model and relevant documentation, I'll now provide a detailed review of GO-CAM model gomodel:665912ed00001983 on \"subtelomeric heterochromatin formation (GO:0031509)\".</p>"},{"location":"reviews/665912ed00001983-subtelomeric_heterochromatin_formation__GO_0031509_/#go-cam-model-review-subtelomeric-heterochromatin-formation-in-s-pombe","title":"GO-CAM Model Review: Subtelomeric Heterochromatin Formation in S. pombe","text":""},{"location":"reviews/665912ed00001983-subtelomeric_heterochromatin_formation__GO_0031509_/#model-overview","title":"Model Overview","text":"<p>The model gomodel:665912ed00001983 describes the process of subtelomeric heterochromatin formation in fission yeast Schizosaccharomyces pombe (NCBITaxon:4896). The model captures multiple activities involved in this complex process, including RNA processing, histone modification, protein binding, adaptor activities, and regulatory relationships between these components.</p>"},{"location":"reviews/665912ed00001983-subtelomeric_heterochromatin_formation__GO_0031509_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive coverage: The model effectively captures multiple molecular pathways involved in heterochromatin formation, including both RNAi-dependent and RNAi-independent mechanisms.</p> </li> <li> <p>Well-evidenced: Most activities and relationships are supported by appropriate experimental evidence with clear literature references.</p> </li> <li> <p>Appropriate cellular components: The model correctly localizes activities to their cellular compartments (e.g., RITS complex, SHREC complex, CLRC complex).</p> </li> <li> <p>Clear activity flow: The model generally depicts a logical flow of activities showing how different proteins contribute to heterochromatin formation.</p> </li> </ol>"},{"location":"reviews/665912ed00001983-subtelomeric_heterochromatin_formation__GO_0031509_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Duplicate causal associations: Several activities have duplicate causal associations with the same predicate and downstream activity:</li> <li>Activity gomodel:665912ed00001983/665912ed00002048 (enabled by raf1) has two identical causal associations to activity gomodel:665912ed00001983/665912ed00001995 (enabled by clr4) using RO:0002304</li> <li>Activity gomodel:665912ed00001983/665912ed00002143 (enabled by arb1) has two identical causal associations to activity gomodel:665912ed00001983/665912ed00002158 (enabled by ago1) using RO:0002630</li> <li>Activity gomodel:665912ed00001983/665912ed00002109 (enabled by dcr1) has two identical causal associations to activity gomodel:665912ed00001983/665912ed00002158 (enabled by ago1) using RO:0002413</li> <li>Activity gomodel:665912ed00001983/665912ed00002158 (enabled by ago1) has two causal associations to activity gomodel:665912ed00001983/665912ed00002173 (enabled by rdp1) using RO:0002304</li> </ol> <p>Recommendation: Remove duplicate causal associations, keeping only one instance with the strongest evidence.</p> <ol> <li>Missing molecular function terms: Several activities use \"GO:0003674\" (molecular_function) rather than specific molecular function terms:</li> <li>Activities enabled by rss1, cul4, raf1, rik1, clr1, clr2, and rad25</li> </ol> <p>Recommendation: Replace generic molecular function terms with more specific terms based on literature evidence when available.</p> <ol> <li>Feedback loops: The model shows several feedback relationships but should clarify the temporal sequence of events, especially between:</li> <li>SHREC complex components</li> <li>RITS complex and RNAi machinery</li> </ol> <p>Recommendation: Consider adding annotations to clarify temporal sequence and the biological context of feedback regulation.</p> <ol> <li>Evidence consistency: Some causal associations have strong experimental evidence while others rely on genetic interaction evidence. For example:</li> <li>The causal association between lsd1/lsd2 activities and sir2 activity is based on genetic interaction evidence</li> </ol> <p>Recommendation: For associations based on genetic evidence, consider adding notes to clarify that these may represent indirect rather than direct relationships.</p> <ol> <li>Molecular adaptor annotations: The model contains a protein with annotated adaptor activity (stc1, GO:0030674). According to GO-CAM best practices, adaptor proteins should follow the guidelines in the \"How to annotate molecular adaptors\" document.</li> </ol> <p>Recommendation: Review the annotations of adaptors to ensure they follow current best practices.</p>"},{"location":"reviews/665912ed00001983-subtelomeric_heterochromatin_formation__GO_0031509_/#technical-model-quality-issues","title":"Technical Model Quality Issues","text":"<ol> <li> <p>PMID format inconsistency: In activity gomodel:665912ed00001983/665912ed00001985, there is a malformatted PMID reference: \"PMID: 16246721\" (contains a space).</p> </li> <li> <p>Unclear evidence objects: Some evidence statements use \"with_objects\" whose relationship to the assertion isn't immediately clear.</p> </li> </ol>"},{"location":"reviews/665912ed00001983-subtelomeric_heterochromatin_formation__GO_0031509_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents current understanding of subtelomeric heterochromatin formation in S. pombe, including:</p> <ol> <li>The role of the RNAi machinery (dcr1, ago1, rdp1, hrr1) in siRNA-mediated heterochromatin formation</li> <li>The role of the CLRC complex (cul4, rik1, raf1, raf2) in directing the histone methyltransferase clr4</li> <li>The role of the SHREC complex (clr1, clr2, clr3, mit1) in histone deacetylation</li> <li>The binding of heterochromatin proteins (swi6, chp1, chp2) to methylated histones</li> <li>The demethylase activities of lsd1 and lsd2 in regulating histone methylation</li> </ol> <p>The model successfully captures both RNAi-dependent and independent pathways of heterochromatin formation, reflecting the current state of knowledge.</p>"},{"location":"reviews/665912ed00001983-subtelomeric_heterochromatin_formation__GO_0031509_/#summary","title":"Summary","text":"<p>This is a high-quality model that effectively represents the complex process of subtelomeric heterochromatin formation in S. pombe. The model integrates multiple pathways and molecular components with appropriate evidence. The main improvements needed are technical (removing duplicated causal associations) and adding more specific molecular function terms for some gene products. Overall, the model provides a comprehensive view of this important biological process, connecting histone modifications, RNA processing, and chromatin binding proteins in a coherent framework.</p>"},{"location":"reviews/665912ed00002626-nitrogen_cycle_metabolic_process__GO_0071941_/","title":"665912ed00002626 nitrogen cycle metabolic process  GO 0071941","text":"<p>Based on my review of the GO-CAM model and associated documentation, I'll now provide a comprehensive review of the GO-CAM model gomodel:665912ed00002626 for nitrogen cycle metabolic process.</p>"},{"location":"reviews/665912ed00002626-nitrogen_cycle_metabolic_process__GO_0071941_/#review-of-go-cam-model-gomodel665912ed00002626","title":"Review of GO-CAM Model: gomodel:665912ed00002626","text":""},{"location":"reviews/665912ed00002626-nitrogen_cycle_metabolic_process__GO_0071941_/#overview","title":"Overview","text":"<p>This model represents the nitrogen cycle metabolic process (GO:0071941) in Schizosaccharomyces pombe (NCBITaxon:4896), focusing on urea metabolism and the urea cycle. The model includes multiple molecular functions and causal relationships that form the pathway of nitrogen metabolism.</p>"},{"location":"reviews/665912ed00002626-nitrogen_cycle_metabolic_process__GO_0071941_/#strengths","title":"Strengths","text":"<ol> <li> <p>Comprehensive pathway representation: The model effectively captures the urea cycle and related nitrogen metabolism pathways, representing the relationships between different enzyme activities and metabolites.</p> </li> <li> <p>Evidence-based assertions: Most activities have appropriate evidence codes and references to scientific literature, such as PMID:24177583 and PMID:1313366 which provide experimental evidence for the described activities.</p> </li> <li> <p>Proper use of causal relationships: The model correctly uses the \"provides input for\" relationship (RO:0002413) to connect sequential enzymatic activities in the pathway.</p> </li> <li> <p>Detailed molecular context: The model includes inputs and outputs for many activities, using appropriate CHEBI identifiers for metabolites.</p> </li> </ol>"},{"location":"reviews/665912ed00002626-nitrogen_cycle_metabolic_process__GO_0071941_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Incomplete evidence for some causal relationships: Several causal associations lack evidence codes, including:</li> <li>The causal relationship between gomodel:665912ed00002626/665912ed00002652 and gomodel:665912ed00002626/665912ed00002676</li> <li>The causal relationship between gomodel:665912ed00002626/665912ed00002652 and gomodel:665912ed00002626/665912ed00002668</li> <li>The causal relationship between gomodel:665912ed00002626/665912ed00002657 and gomodel:665912ed00002626/665912ed00002676</li> </ol> <p>Recommendation: Add appropriate evidence codes with references to these causal relationships to strengthen the model's validity.</p> <ol> <li>CHEBI-enabled activity issue: In activity gomodel:665912ed00002626/66e382fb00001783, a chemical entity (CHEBI:36080 - protein) is listed as enabling the activity instead of a gene product. </li> </ol> <p>Recommendation: Replace this with the appropriate gene product if the specific gene is known, or consider another annotation approach if this represents a protein with unknown identity.</p> <ol> <li>Missing evidence for molecular function: The activity gomodel:665912ed00002626/66e382fb00001783 lacks evidence for its molecular function (GO:0004038 - allantoinase activity).</li> </ol> <p>Recommendation: Add appropriate evidence code and reference for this activity.</p> <ol> <li>Missing inputs/outputs: Some activities lack explicit inputs or outputs:</li> <li>Activity gomodel:665912ed00002626/665912ed00002645 (argininosuccinate synthase activity) doesn't specify its inputs/outputs</li> </ol> <p>Recommendation: Add the relevant metabolites as inputs and outputs for these activities to provide a more complete biochemical representation.</p> <ol> <li>Multiple identical causal edges: There are duplicate causal relationships between the same activities:</li> <li>Two identical edges from gomodel:665912ed00002626/665912ed00002676 to gomodel:665912ed00002626/665912ed00002637</li> </ol> <p>Recommendation: Remove redundant edges to keep the model clean and consistent.</p> <ol> <li>Metabolite redundancy: Some activities list the same output molecule twice:</li> <li>Activity gomodel:665912ed00002626/665912ed00002668 has CHEBI:16199 (urea) listed twice as output</li> <li>Activity gomodel:665912ed00002626/665912ed00002698 has CHEBI:28938 (ammonium) listed twice as output</li> </ol> <p>Recommendation: Remove duplicate metabolite entries to avoid redundancy.</p> <ol> <li>Consistency of activity representation: The model transitions between representing a pathway via sequential activities and via a more direct process, which can be confusing. For example, some parts show detailed step-by-step enzymatic reactions while others have more direct connections.</li> </ol> <p>Recommendation: Maintain a consistent level of granularity throughout the model where possible, or clearly delineate different subpathways.</p>"},{"location":"reviews/665912ed00002626-nitrogen_cycle_metabolic_process__GO_0071941_/#biological-content-validation","title":"Biological Content Validation","text":"<p>The biological content of the model is largely consistent with the literature regarding urea cycle and nitrogen metabolism in S. pombe. The key paper PMID:24177583 by Kinghorn and Fluri (1984) confirms the roles of uricase, allantoinase, allantoicase, and urease activities in the purine degradation pathway leading to nitrogen release.</p> <p>The model correctly represents these enzymes and their relationships. For example, the paper describes the ure1, ure2, ure3, and ure4 genes as encoding components of urease, which is consistent with the model's representation of urease activity.</p> <p>The model is also consistent with the arginine metabolism described in PMID:1313366, which details ornithine carbamoyltransferase in the arginine biosynthetic pathway in S. pombe.</p>"},{"location":"reviews/665912ed00002626-nitrogen_cycle_metabolic_process__GO_0071941_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for nitrogen cycle metabolic process (gomodel:665912ed00002626) is a well-constructed representation of urea metabolism and the urea cycle in S. pombe. It effectively represents the biological knowledge from the literature and mostly follows GO-CAM best practices.</p> <p>The model would benefit from the addition of missing evidence codes, removal of redundancies, and more consistent representation of inputs and outputs. Additionally, clarifying the role of the CHEBI-enabled activity would improve the model's clarity and adherence to GO-CAM standards.</p> <p>Overall, this model provides valuable information about nitrogen metabolism in S. pombe and, with the suggested improvements, would serve as an excellent resource for the research community.</p>"},{"location":"reviews/666b894f00000196-CD93_Multimerin_2_%CE%B21_integrin_complex_function_in_angiogenesis__Human_/","title":"666b894f00000196 CD93 Multimerin 2 \u03b21 integrin complex function in angiogenesis  Human","text":"<p>Based on all the information collected, I'll now review the GO-CAM model:</p>"},{"location":"reviews/666b894f00000196-CD93_Multimerin_2_%CE%B21_integrin_complex_function_in_angiogenesis__Human_/#review-of-go-cam-model-gomodel666b894f00000196","title":"Review of GO-CAM Model gomodel:666b894f00000196","text":""},{"location":"reviews/666b894f00000196-CD93_Multimerin_2_%CE%B21_integrin_complex_function_in_angiogenesis__Human_/#model-overview","title":"Model Overview","text":"<p>The model titled \"CD93/Multimerin-2/\u03b21 integrin complex function in angiogenesis (Human)\" represents the molecular interactions between three key proteins:</p> <ol> <li>MMRN2 (Multimerin-2) - An extracellular matrix protein with receptor ligand activity</li> <li>CD93 - A C-type lectin domain receptor with signaling receptor activity</li> <li>ITGB1 (Integrin \u03b21) - A coreceptor that functions in angiogenesis</li> </ol> <p>The model depicts how these proteins interact in the context of angiogenesis in humans, showing causal relationships between their molecular functions.</p>"},{"location":"reviews/666b894f00000196-CD93_Multimerin_2_%CE%B21_integrin_complex_function_in_angiogenesis__Human_/#scientific-content-assessment","title":"Scientific Content Assessment","text":"<p>The scientific basis for this model is well-supported by current literature. Recent studies, particularly by Khan et al. (2017), have established that Multimerin-2 (MMRN2) is a ligand for CD93, which is a member of the group 14 family of C-type lectins. These interactions have been shown to be important in angiogenesis. </p> <p>The model shows MMRN2 located in the extracellular space (GO:0005615) with receptor ligand activity (GO:0048018), which is consistent with its known function as a secreted ECM protein. CD93 is shown on the plasma membrane (GO:0005886) with signaling receptor activity (GO:0038023), which aligns with its established role. ITGB1 is also correctly placed on the plasma membrane with coreceptor activity (GO:0015026).</p> <p>The causal relationships showing MMRN2 directly positively regulating (RO:0002629) CD93, and CD93 directly positively regulating ITGB1 are supported by the literature. Evidence from the Khan et al. study demonstrates that MMRN2 binds to CD93, and these proteins are both involved in angiogenesis (GO:0001525). Additional evidence suggests ITGB1 functions in this pathway.</p>"},{"location":"reviews/666b894f00000196-CD93_Multimerin_2_%CE%B21_integrin_complex_function_in_angiogenesis__Human_/#model-structure-and-go-cam-standards","title":"Model Structure and GO-CAM Standards","text":"<p>The model follows GO-CAM standards for representing molecular activities and causal relationships:</p> <ol> <li>Each activity is correctly enabled by a single gene product</li> <li>Activities are appropriately localized to cellular compartments</li> <li>Activities are placed in the context of the biological process of angiogenesis</li> <li>Causal relationships are represented with the correct predicates (RO:0002629 - directly positively regulates)</li> </ol> <p>However, there is a duplication in the model that needs to be corrected:</p> <ul> <li>MMRN2's receptor ligand activity (gomodel:666b894f00000196/666b894f00000197) has two identical causal associations to CD93's signaling receptor activity (gomodel:666b894f00000196/666b894f00000204) using the same predicate (RO:0002629). This is redundant and one of these relationships should be removed.</li> </ul>"},{"location":"reviews/666b894f00000196-CD93_Multimerin_2_%CE%B21_integrin_complex_function_in_angiogenesis__Human_/#supporting-evidence","title":"Supporting Evidence","text":"<p>The model cites appropriate evidence codes and literature references:</p> <ul> <li>ECO:0000314 (direct assay evidence used in manual assertion) is used with various PMIDs</li> <li>Key references include PMID:28671670, which establishes the MMRN2-CD93 interaction</li> <li>Other citations (PMID:11559704, PMID:31138217, etc.) provide supporting evidence for cellular locations and participation in angiogenesis</li> </ul> <p>The reference PMID:23125415 provides evidence for ITGB1's coreceptor activity, which is consistent with findings about integrin \u03b21 functions.</p>"},{"location":"reviews/666b894f00000196-CD93_Multimerin_2_%CE%B21_integrin_complex_function_in_angiogenesis__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Remove the duplicate causal relationship: There are two identical causal associations from MMRN2 to CD93, one of which should be removed.</p> </li> <li> <p>Consider representing the complex: Since the document \"How to annotate complexes in GO-CAM\" suggests representing complexes when multiple proteins function together, the curator might consider explicitly modeling the CD93/MMRN2/ITGB1 complex if evidence suggests they function as a unit.</p> </li> <li> <p>Add more molecular detail if available: If there is evidence for specific signaling events downstream of CD93 activation by MMRN2, these could enrich the model.</p> </li> <li> <p>Evidence for the second causal relationship: The causal association between CD93 and ITGB1 has an empty evidence field in one case. This should be filled with appropriate evidence codes and references.</p> </li> </ol>"},{"location":"reviews/666b894f00000196-CD93_Multimerin_2_%CE%B21_integrin_complex_function_in_angiogenesis__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"CD93/Multimerin-2/\u03b21 integrin complex function in angiogenesis (Human)\" represents a scientifically accurate pathway based on current literature. It correctly depicts the roles of MMRN2, CD93, and ITGB1 in angiogenesis, with appropriate molecular functions, cellular locations, and causal relationships. </p> <p>With minor corrections (removing the duplicate causal relationship and adding missing evidence), this model will provide a valuable representation of how these three proteins interact in angiogenesis. Overall, the model is well-constructed and follows GO-CAM best practices.</p>"},{"location":"reviews/6690711d00001771-AARS1_mediates_lactylation_of_YAP1_and_TEAD1__promoting_activation_of_Hippo_signaling__Human__/","title":"6690711d00001771 AARS1 mediates lactylation of YAP1 and TEAD1  promoting activation of Hippo signaling  Human","text":"<p>Based on all the information gathered, I'll now review the GO-CAM model.</p>"},{"location":"reviews/6690711d00001771-AARS1_mediates_lactylation_of_YAP1_and_TEAD1__promoting_activation_of_Hippo_signaling__Human__/#go-cam-model-review-gomodel6690711d00001771","title":"GO-CAM Model Review: gomodel:6690711d00001771","text":""},{"location":"reviews/6690711d00001771-AARS1_mediates_lactylation_of_YAP1_and_TEAD1__promoting_activation_of_Hippo_signaling__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"AARS1 mediates lactylation of YAP1 and TEAD1, promoting activation of Hippo signaling (Human)\" represents a molecular pathway where AARS1 (alanyl-tRNA synthetase 1) acts as a lactyltransferase to modify YAP1 (Yes-associated protein 1) and TEAD1 (TEA domain family member 1), leading to activation of Hippo signaling.</p> <p>The model includes three main activities: 1. AARS1 (UniProtKB:P49588) with peptide lactyltransferase activity 2. YAP1 (UniProtKB:P46937) with transcription coregulator activity 3. TEAD1 (UniProtKB:P28347) with DNA-binding transcription factor activity</p>"},{"location":"reviews/6690711d00001771-AARS1_mediates_lactylation_of_YAP1_and_TEAD1__promoting_activation_of_Hippo_signaling__Human__/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model is based on a recent publication (PMID:38512451) that demonstrates AARS1 can function as a lactyltransferase, using lactate and ATP to catalyze the lactylation of proteins including YAP1 and TEAD1. This lactylation affects the Hippo signaling pathway, promoting YAP1's function as a transcriptional coactivator working with TEAD1.</p> <p>The causal relationships represented in the model are consistent with the literature: - AARS1's lactyltransferase activity directly positively regulates both YAP1 and TEAD1 - YAP1's coregulator activity directly positively regulates TEAD1's transcription factor activity</p> <p>These relationships align with the findings that lactylation of YAP1 at K90 and TEAD1 at K108 promotes YAP1 nuclear localization, enhances YAP1-TEAD1 interaction, and increases the transcriptional activity of this complex.</p>"},{"location":"reviews/6690711d00001771-AARS1_mediates_lactylation_of_YAP1_and_TEAD1__promoting_activation_of_Hippo_signaling__Human__/#go-cam-structure-and-compliance","title":"GO-CAM Structure and Compliance","text":"<p>The model follows GO-CAM best practices by: 1. Representing protein activities with appropriate GO molecular function terms 2. Properly representing the subcellular locations (nucleus for all activities) 3. Using appropriate causal relationships between activities (RO:0002629 \"directly positively regulates\") 4. Connecting the activities to the correct biological process (GO:0035329 \"hippo signaling\" for YAP1 and TEAD1, and GO:0035332 \"positive regulation of hippo signaling\" for AARS1)</p>"},{"location":"reviews/6690711d00001771-AARS1_mediates_lactylation_of_YAP1_and_TEAD1__promoting_activation_of_Hippo_signaling__Human__/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by evidence, with each assertion backed by appropriate reference to the primary literature (PMID:38512451, PMID:18579750, PMID:19324877). The evidence codes used (ECO:0000314 - direct assay evidence used in manual assertion) are appropriate for the experimental evidence cited.</p>"},{"location":"reviews/6690711d00001771-AARS1_mediates_lactylation_of_YAP1_and_TEAD1__promoting_activation_of_Hippo_signaling__Human__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>Overall, this is a well-constructed model that accurately captures the relationship between AARS1, YAP1, and TEAD1 in the context of Hippo signaling. However, there are a few potential enhancements that could be considered:</p> <ol> <li> <p>Additional mechanistic details: The model could be expanded to include the specific details of how lactylation affects YAP1 function, such as inhibiting its nuclear export or preventing its ubiquitination.</p> </li> <li> <p>Downstream effects: The model could be extended to include the downstream target genes of YAP1-TEAD1, such as CTGF, which was identified in the literature as an important mediator of YAP's growth-promoting function.</p> </li> <li> <p>Regulatory context: The model could include upstream regulators that influence AARS1's lactyltransferase activity, such as lactate levels which were shown to promote AARS1 nuclear translocation.</p> </li> <li> <p>Connection to phenotypic outcomes: The model could be linked to the biological outcomes of YAP1-TEAD1 activation, such as cell proliferation, EMT, or oncogenic transformation.</p> </li> </ol>"},{"location":"reviews/6690711d00001771-AARS1_mediates_lactylation_of_YAP1_and_TEAD1__promoting_activation_of_Hippo_signaling__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the molecular mechanism of AARS1-mediated lactylation of YAP1 and TEAD1 leading to Hippo pathway activation. It is well-supported by recent literature and follows GO-CAM best practices for representing molecular activities and their relationships. While there are opportunities to expand the model with additional details, the current representation serves as a solid foundation for understanding this novel regulatory mechanism.</p> <p>The model correctly focuses on the \"moonlighting\" function of AARS1 as a lactyltransferase rather than its canonical role in tRNA charging, which is appropriate given the specific biological process being modeled. The causal connections between the activities reflect the positive regulatory relationships described in the literature.</p>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/","title":"6690711d00001806 SIRT1 mediates delactylation of YAP1 and TEAD1  promoting inactivation of Hippo signaling  Human","text":"<p>Now I'll review the GO-CAM model based on my examination of the provided information. Let me start by summarizing what I understand about this model.</p>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#review-of-go-cam-model-gomodel6690711d00001806","title":"Review of GO-CAM Model: gomodel:6690711d00001806","text":""},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#model-title","title":"Model Title","text":"<p>\"SIRT1 mediates delactylation of YAP1 and TEAD1, promoting inactivation of Hippo signaling (Human).\"</p>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the relationship between SIRT1, YAP1, and TEAD1 proteins in the context of the Hippo signaling pathway, specifically focusing on the post-translational modification of lactylation and its regulation.</p>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#key-components","title":"Key Components","text":"<ol> <li>SIRT1 (UniProtKB:Q96EB6): NAD-dependent protein deacetylase/delactylase</li> <li>YAP1 (UniProtKB:P46937): Transcriptional coactivator</li> <li>TEAD1 (UniProtKB:P28347): Transcriptional enhancer factor</li> </ol>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#key-activities","title":"Key Activities","text":"<ol> <li>SIRT1 acts as a NAD-dependent protein lysine delactylase (GO:0141208)</li> <li>YAP1 functions as a transcription coregulator (GO:0003712)</li> <li>TEAD1 functions as a DNA-binding transcription factor (GO:0003700)</li> </ol>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#biological-process-context","title":"Biological Process Context","text":"<p>All activities occur within the Hippo signaling pathway (GO:0035329), with SIRT1 specifically involved in negative regulation of Hippo signaling (GO:0035331).</p>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#causal-relationships","title":"Causal Relationships","text":"<ol> <li>YAP1 directly positively regulates (RO:0002629) TEAD1</li> <li>SIRT1 directly negatively regulates (RO:0002630) both YAP1 and TEAD1</li> </ol>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#cellular-location","title":"Cellular Location","text":"<p>All activities occur in the nucleus (GO:0005634)</p>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#scientific-analysis","title":"Scientific Analysis","text":"<p>Based on the recently published research (PMID:38512451), this model captures an important regulatory mechanism of the Hippo signaling pathway through post-translational modification. The key findings are:</p> <ol> <li>YAP1 and TEAD1 can be lactylated at specific lysine residues (K90 for YAP1, K108 for TEAD1)</li> <li>Lactylation of these proteins promotes their activity and nuclear localization</li> <li>SIRT1 functions as a delactylase that removes the lactyl groups from these proteins</li> <li>This delactylation leads to decreased activity of YAP1 and TEAD1, effectively inactivating Hippo signaling</li> </ol> <p>This creates a regulatory circuit where: - Lactylation (by AARS1) \u2192 Increased YAP1-TEAD1 activity \u2192 Increased Hippo signaling target gene expression - Delactylation (by SIRT1) \u2192 Decreased YAP1-TEAD1 activity \u2192 Decreased Hippo signaling target gene expression</p>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#qc-evaluation","title":"QC Evaluation","text":""},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Evidence Support: The model is well-supported by multiple pieces of evidence, including experimental evidence (ECO:0000314) from recent publications.</li> <li>Mechanistic Detail: The model captures the specific molecular function of SIRT1 as a delactylase.</li> <li>Causal Relationships: The causal relationships between the proteins are correctly represented, with YAP1 positively regulating TEAD1 and SIRT1 negatively regulating both.</li> <li>Cellular Localization: All activities are correctly annotated to occur in the nucleus.</li> </ol>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing Context for AARS1: The model only represents the delactylation by SIRT1 but doesn't include the counteracting lactylation mechanism by AARS1, which would provide a more complete picture of the regulatory circuit.</p> </li> <li> <p>Incomplete Biological Process Representation: While the activities are connected to the Hippo signaling pathway, downstream effects on specific gene expression or cellular processes (like proliferation or apoptosis) are not included.</p> </li> <li> <p>Missing Molecular Details: </p> </li> <li>The specific lactylated residues (K90 for YAP1, K108 for TEAD1) could be annotated more explicitly</li> <li> <p>The role of NAD+ as a cofactor for SIRT1 activity is not represented</p> </li> <li> <p>Absence of Associated Phenotypes: The model doesn't capture the biological consequences of this pathway, such as impacts on cell proliferation, cancer progression, etc.</p> </li> </ol>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>Based on my review of GO-CAM documentation:</p> <ol> <li> <p>Complex Annotation: The model correctly represents the individual proteins rather than using a complex ID, which aligns with best practices when the specific subunits carrying activities are known.</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal relationship predicates (RO:0002629 for directly positively regulates and RO:0002630 for directly negatively regulates).</p> </li> <li> <p>Molecular Function Terms: The model uses appropriate molecular function terms for each protein.</p> </li> <li> <p>Evidence Codes: The model includes proper evidence codes linked to relevant publications.</p> </li> </ol>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Include AARS1 Activity: Add the counterbalancing activity of AARS1 as a lactyltransferase (GO:0141208) to provide a more complete regulatory picture.</p> </li> <li> <p>Add Downstream Effects: Include downstream transcriptional targets of the YAP1-TEAD1 complex and their biological effects.</p> </li> <li> <p>Add Specific Details: </p> </li> <li>Annotate the specific lysine residues that are lactylated/delactylated</li> <li> <p>Include NAD+ as a cofactor for SIRT1 activity</p> </li> <li> <p>Expand Biological Context: </p> </li> <li>Include the role of this pathway in cancer progression or cell proliferation</li> <li>Connect to other relevant signaling pathways that interact with Hippo signaling</li> </ol>"},{"location":"reviews/6690711d00001806-SIRT1_mediates_delactylation_of_YAP1_and_TEAD1__promoting_inactivation_of_Hippo_signaling__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:6690711d00001806) is scientifically accurate and represents an important regulatory mechanism of the Hippo signaling pathway. It correctly captures the roles of SIRT1, YAP1, and TEAD1, with appropriate causal relationships and cellular localization. The model follows GO-CAM best practices for representation of molecular activities and their connections.</p> <p>With the suggested improvements, particularly the addition of AARS1 and downstream effects, this model could provide an even more comprehensive representation of this regulatory pathway and its biological significance. Overall, this is a well-constructed model that provides valuable insights into the regulation of Hippo signaling through post-translational modifications.</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/","title":"6690711d00002607 ANG tRNA ribonuclease activity inhibits translation in response to stress  Human","text":"<p>Based on all the information I've gathered, I'll now review the GO-CAM model gomodel:6690711d00002607.</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#review-of-go-cam-model-gomodel6690711d00002607","title":"Review of GO-CAM Model gomodel:6690711d00002607","text":""},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#model-summary","title":"Model Summary","text":"<p>Title: \"ANG tRNA ribonuclease activity inhibits translation in response to stress (Human)\" Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#model-content-overview","title":"Model Content Overview","text":"<p>This model describes how angiogenin (ANG) acts to inhibit translation in response to stress in human cells. The model includes interactions between: 1. Angiogenin (ANG, UniProtKB:P03950) 2. Plexin-B2 (PLXNB2, UniProtKB:O15031) 3. Cytosolic large ribosomal subunit (GO:0022625)</p> <p>The model captures how ANG produces tRNA-derived stress-induced small RNAs (tiRNAs) in response to stress, which inhibit translation, and how this activity is regulated.</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#detailed-model-assessment","title":"Detailed Model Assessment","text":""},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#1-proteins-and-molecular-functions","title":"1. Proteins and Molecular Functions:","text":""},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#angiogenin-uniprotkbp03950","title":"Angiogenin (UniProtKB:P03950):","text":"<ul> <li>Activities in the model:</li> <li>tRNA-specific ribonuclease activity (GO:0004549)</li> <li>Receptor ligand activity (GO:0048018)</li> <li>Appropriately annotated: Yes, based on the literature evidence. ANG has dual functions: it can act as a ligand for its receptor and cleaves tRNAs when activated.</li> </ul>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#plexin-b2-uniprotkbo15031","title":"Plexin-B2 (UniProtKB:O15031):","text":"<ul> <li>Activities in the model:</li> <li>Signaling receptor activity (GO:0038023)</li> <li>Ribonuclease inhibitor activity (GO:0008428)</li> <li>Appropriately annotated: Yes, based on the literature provided. Plexin-B2 acts as a receptor for ANG and is involved in mediating ANG endocytosis and translocation.</li> </ul>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#cytosolic-large-ribosomal-subunit-go0022625","title":"Cytosolic large ribosomal subunit (GO:0022625):","text":"<ul> <li>Activities in the model:</li> <li>Structural constituent of ribosome (GO:0003735)</li> <li>Ribonuclease inhibitor activity (GO:0008428)</li> <li>Appropriately annotated: Generally yes, but with a potential issue discussed below.</li> </ul>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#2-biological-processes","title":"2. Biological Processes:","text":"<p>The model connects the molecular functions to the appropriate biological processes: - Negative regulation of translation in response to stress (GO:0032055) - Receptor-mediated endocytosis (GO:0006898) - Signal transduction (GO:0007165) - Cytoplasmic translation (GO:0002181) - Cellular response to stress (GO:0033554)</p> <p>These process annotations accurately reflect the biology depicted in the model.</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#3-cellular-components","title":"3. Cellular Components:","text":"<p>The cellular locations are well annotated: - Plasma membrane (GO:0005886) for PLXNB2 - Cytoplasm (GO:0005737) for ANG - Cytosol (GO:0005829) for ribosomal activity and inhibitor activity - Extracellular space (GO:0005615) for ANG's receptor ligand activity</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#4-causal-relationships","title":"4. Causal Relationships:","text":"<p>The causal relationships in the model appear to be correctly depicted: 1. ANG's receptor ligand activity positively regulates PLXNB2's signaling receptor activity (RO:0002304) 2. PLXNB2's signaling receptor activity positively regulates ribonuclease inhibitor activity (RO:0002629) 3. Ribonuclease inhibitor activity positively regulates ANG's tRNA ribonuclease activity (RO:0002629) 4. ANG's tRNA ribonuclease activity negatively regulates ribosomal structural activity (RO:0002630)</p> <p>These relationships accurately represent the chain of events from ANG binding to PLXNB2 to the eventual inhibition of translation.</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#issues-and-recommendations","title":"Issues and Recommendations","text":""},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#1-protein-complex-representation-and-activity-attribution","title":"1. Protein Complex Representation and Activity Attribution:","text":"<p>According to the \"How to annotate complexes in GO-CAM\" guidelines, when the specific subunit carrying an activity is not known, the GO term for the complex should be used. In this model, the ribonuclease inhibitor activity (GO:0008428) is attributed to the cytosolic large ribosomal subunit (GO:0022625), which is appropriate based on the findings in the literature.</p> <p>However, the recent paper (PMID:38718836) provides evidence that the ribosome actually activates ANG by refolding its C-terminal tail rather than acting as a ribonuclease inhibitor. The model currently depicts the ribosome as having ribonuclease inhibitor activity, which seems to contradict this finding.</p> <p>Recommendation: Consider revising the model to reflect the latest research showing that the ribosome activates ANG rather than inhibiting it. This would involve changing the molecular function attribution and possibly the causal relationships.</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#2-complex-members","title":"2. Complex Members:","text":"<p>The model represents the cytosolic large ribosomal subunit (GO:0022625) but does not specify any members of this complex. While not strictly required, it would be helpful to include at least some key ribosomal proteins if they are directly involved in the interaction with ANG.</p> <p>Recommendation: Consider adding specific ribosomal proteins that interact with ANG if this information is available from the literature.</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#3-evidence-and-references","title":"3. Evidence and References:","text":"<p>The model uses appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and references recent relevant literature (PMID:38718836, PMID:29100074, PMID:23843625, PMID:12533544). The evidence appears to be well-connected to the assertions in the model.</p>"},{"location":"reviews/6690711d00002607-ANG_tRNA_ribonuclease_activity_inhibits_translation_in_response_to_stress__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6690711d00002607 is generally well-constructed and accurately represents the current understanding of how ANG inhibits translation in response to stress through its tRNA ribonuclease activity. The model follows most GO-CAM best practices regarding representation of molecular functions, biological processes, cellular components, and causal relationships.</p> <p>The main issue is the potential misrepresentation of the ribosome's role in ANG activation based on the most recent research. Updating this aspect would make the model more accurate according to current knowledge.</p> <p>The model is parsimonious and includes the key components and relationships necessary to understand the pathway, making it accessible to human interpretation.</p>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/","title":"6690711d00002652 RNH1 inhibits the tRNA ribonuclease activity of ANG in the cytoplasm in absence of stress  Human","text":"<p>Now I'll review all the information I've gathered to provide a comprehensive review of this GO-CAM model.</p>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#review-of-go-cam-model-gomodel6690711d00002652","title":"Review of GO-CAM Model: gomodel:6690711d00002652","text":""},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"RNH1 inhibits the tRNA ribonuclease activity of ANG in the cytoplasm in absence of stress (Human)\" describes the interaction between angiogenin (ANG) and ribonuclease inhibitor 1 (RNH1) in human cells under normal (non-stress) conditions.</p>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#summary-of-the-model-content","title":"Summary of the Model Content","text":"<p>The model focuses on how RNH1 inhibits the tRNA ribonuclease activity of ANG in the cytoplasm under non-stress conditions, while ANG's receptor ligand activity in the extracellular space contributes to signaling through plexin-B2 (PLXNB2).</p> <p>The model contains the following key activities and relationships: 1. ANG (UniProtKB:P03950) has receptor ligand activity (GO:0048018) in the extracellular space 2. ANG has tRNA ribonuclease activity (GO:0004549) in the cytoplasm 3. RNH1 (UniProtKB:P13489) has ribonuclease inhibitor activity (GO:0008428) in the cytoplasm 4. PLXNB2 (UniProtKB:O15031) has signaling receptor activity (GO:0038023) on the plasma membrane 5. Large ribosomal subunit (GO:0022625) has structural constituent of ribosome activity (GO:0003735) in the cytosol</p> <p>The causal relationships show that: - ANG's receptor ligand activity directly positively regulates PLXNB2's signaling receptor activity - PLXNB2's signaling receptor activity positively regulates RNH1's ribonuclease inhibitor activity - RNH1's ribonuclease inhibitor activity directly negatively regulates ANG's tRNA ribonuclease activity - ANG's tRNA ribonuclease activity directly negatively regulates the ribosomal structural constituent activity</p>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#biological-context-assessment","title":"Biological Context Assessment","text":"<p>The model captures several key aspects of ANG and RNH1 biology that align with current scientific understanding:</p> <ol> <li>ANG as a secreted protein with dual functions:</li> <li>As a receptor ligand in the extracellular space</li> <li> <p>As a tRNA ribonuclease in the cytoplasm</p> </li> <li> <p>RNH1 as an inhibitor of ANG's ribonuclease activity:</p> </li> <li>This accurately represents RNH1's role in regulating ANG's enzymatic activity</li> <li> <p>The paper by Pizzo et al. (PMID:23843625) confirms that RNH1 controls ANG's ribonucleolytic activity in different subcellular locations</p> </li> <li> <p>PLXNB2 as the receptor for ANG:</p> </li> <li>This is supported by Yu et al. (PMID:29100074) which identified PLXNB2 as the functional receptor for ANG</li> <li> <p>The model correctly shows PLXNB2 on the plasma membrane</p> </li> <li> <p>ANG's effect on ribosomes:</p> </li> <li>Shows ANG's role in regulating translation through its ribonuclease activity</li> </ol>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#strengths","title":"Strengths","text":"<ol> <li>The model correctly uses appropriate GO terms for the activities of each protein</li> <li>The subcellular locations are accurately assigned</li> <li>The causal relationships make biological sense</li> <li>The evidence codes and references are properly attributed</li> </ol>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement","text":"<ol> <li> <p>Missing complex representation:    According to the \"How to annotate complexes in GO-CAM\" guidelines, when a complex is involved in specific activities, the representation depends on whether the specific subunit carrying the activity is known. The model could be improved by representing the ANG-RNH1 complex more explicitly, especially since their interaction is key to the biological regulation described.</p> </li> <li> <p>Missing stress condition representation:    The title explicitly mentions \"in absence of stress,\" but the model doesn't include a parallel stress condition pathway showing how the relationship between ANG and RNH1 changes under stress. This would provide a more complete biological picture.</p> </li> <li> <p>Incomplete mechanistic details:    The model shows PLXNB2 positively regulating RNH1, but the mechanistic details of how PLXNB2 signaling affects RNH1 activity are not clear from the evidence provided. The literature (Pizzo et al.) indicates that under stress, RNH1 relocates to the nucleus, allowing ANG ribonuclease activity in the cytoplasm, but this spatial regulation isn't captured in the model.</p> </li> <li> <p>PLXNB2 processing not represented:    The paper by Artigiani et al. (PMID:12533544) shows that PLXNB2 undergoes proteolytic processing by proprotein convertases to function optimally as a receptor. This processing step is not represented in the model, which could be important for understanding the regulation of the receptor's activity.</p> </li> <li> <p>Ribosome activation mechanism:    The recent paper by Loveland et al. (PMID:38718836) reveals that the ribosome is actually the activator of ANG's ribonuclease activity. This represents a significant advancement in understanding ANG's mechanism that is not captured in the current model.</p> </li> </ol>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is generally well-supported by the cited literature:</p> <ol> <li>PMID:29100074 (Yu et al., 2017) provides strong evidence for PLXNB2 as the functional receptor for ANG</li> <li>PMID:23843625 (Pizzo et al., 2013) supports the role of RNH1 in regulating ANG's subcellular localization and activity</li> <li>PMID:38718836 (Loveland et al., 2024) provides newer evidence about ribosome-mediated activation of ANG</li> </ol> <p>However, some causal relationships in the model may need additional evidence to fully support the specific directional effects indicated.</p>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add ANG-RNH1 complex: Represent the interaction between ANG and RNH1 as a complex when relevant, especially since their physical interaction is critical for the inhibition of ANG's ribonuclease activity.</p> </li> <li> <p>Include stress condition pathway: Add a parallel pathway showing how the relationships change under stress conditions, where RNH1 relocates to the nucleus, allowing ANG to perform its ribonuclease activity in the cytoplasm.</p> </li> <li> <p>Add PLXNB2 processing: Include the proteolytic processing of PLXNB2 by proprotein convertases, which affects its function as a receptor for ANG.</p> </li> <li> <p>Incorporate ribosome activation mechanism: Update the model to reflect that the ribosome directly activates ANG's ribonuclease activity, based on the recent findings from Loveland et al.</p> </li> <li> <p>Clarify directionality: Provide more mechanistic details about how PLXNB2 signaling positively regulates RNH1 activity, as this relationship is not clearly explained in the cited literature.</p> </li> </ol>"},{"location":"reviews/6690711d00002652-RNH1_inhibits_the_tRNA_ribonuclease_activity_of_ANG_in_the_cytoplasm_in_absence_of_stress__Human__/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:6690711d00002652 provides a good representation of the relationship between ANG and RNH1 under non-stress conditions. The model accurately captures the dual functionality of ANG as both a receptor ligand and a ribonuclease, as well as RNH1's role in inhibiting ANG's ribonuclease activity.</p> <p>The model could be enhanced by incorporating more detailed mechanistic information, particularly regarding PLXNB2 processing, the formation of the ANG-RNH1 complex, and the recently discovered role of ribosomes in activating ANG. Additionally, adding a parallel pathway showing the changes under stress conditions would provide a more complete biological picture.</p> <p>Overall, this is a well-constructed model that would benefit from some updates to reflect the most recent scientific findings in this area.</p>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/","title":"6690711d00002821 tryptophan biosynthetic process  GO 0000162","text":"<p>Now that I have this information, I can perform a comprehensive review of the GO-CAM model with ID 6690711d00002821.</p>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#review-of-go-cam-model-gomodel6690711d00002821","title":"Review of GO-CAM Model: gomodel:6690711d00002821","text":""},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#model-overview","title":"Model Overview","text":"<p>This model represents the tryptophan biosynthetic process (GO:0000162) in Schizosaccharomyces pombe (fission yeast). It includes the enzymes and reactions involved in the conversion of chorismate to tryptophan through several intermediate steps.</p>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#model-structure-analysis","title":"Model Structure Analysis","text":""},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#activities-and-molecular-functions","title":"Activities and Molecular Functions","text":"<p>The model includes five molecular activities: 1. Anthranilate synthase activity (GO:0004049) - performed by PomBase:SPCC1442.09 (trp3) 2. Anthranilate phosphoribosyltransferase activity (GO:0004048) - performed by PomBase:SPBC16G5.08 (trp4) 3. Phosphoribosylanthranilate isomerase activity (GO:0004640) - performed by PomBase:SPBC1539.09c (trp1) 4. Indole-3-glycerol-phosphate lyase activity (GO:0033984) - performed by PomBase:SPBC1539.09c (trp1) 5. Tryptophan synthase activity (GO:0004834) - performed by PomBase:SPAC19A8.15 (trp2)</p>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#pathway-connectivity","title":"Pathway Connectivity","text":"<p>The activities are connected through the following causal relationships: - Anthranilate synthase \u2192 Anthranilate phosphoribosyltransferase (RO:0002413 \"provides input for\") - Anthranilate phosphoribosyltransferase \u2192 Phosphoribosylanthranilate isomerase (RO:0002413 \"provides input for\") - Phosphoribosylanthranilate isomerase \u2192 Indole-3-glycerol-phosphate lyase (RO:0002413 \"provides input for\") - Indole-3-glycerol-phosphate lyase \u2192 Tryptophan synthase (RO:0002413 \"provides input for\")</p>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#cellular-location","title":"Cellular Location","text":"<p>All activities are annotated as occurring in the cytosol (GO:0005829).</p>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#inputs-and-outputs","title":"Inputs and Outputs","text":"<ul> <li>Anthranilate synthase has inputs: chorismate (CHEBI:29748) and L-glutamine (CHEBI:18050)</li> <li>Tryptophan synthase has outputs: glyceraldehyde 3-phosphate (CHEBI:17138) and tryptophan (CHEBI:27897)</li> </ul>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#scientific-content-review","title":"Scientific Content Review","text":"<p>The model correctly represents the tryptophan biosynthetic pathway in S. pombe as described in the literature. Based on the PMID:24186364 paper, we can confirm that:</p> <ol> <li> <p>The gene trp1 in S. pombe encodes activities for both phosphoribosylanthranilate isomerase and indole-3-glycerol-phosphate lyase, which is correctly represented in the model where both activities are enabled by PomBase:SPBC1539.09c.</p> </li> <li> <p>The overall pathway structure (chorismate \u2192 anthranilate \u2192 phosphoribosylanthranilate \u2192 indole-3-glycerol-phosphate \u2192 tryptophan) follows the established understanding of tryptophan biosynthesis.</p> </li> <li> <p>The evidence in the model cites relevant PMIDs and database references to support the annotations.</p> </li> </ol>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#quality-control-issues","title":"Quality Control Issues","text":"<ol> <li> <p>Model Comment Issue: The model contains the comment \"I used chatGPT for this one\" which should be removed or replaced with a more professional description of the model creation process. AI tools can be used for assistance but should not be cited as the primary source for model creation.</p> </li> <li> <p>Evidence Documentation: Some of the evidence citations are through database cross-references rather than direct experimental evidence. While this is acceptable for well-established pathways, it would be beneficial to include more primary literature references where possible.</p> </li> <li> <p>Input/Output Specification: Not all activities have explicitly defined inputs and outputs. For a complete biochemical pathway model, each reaction should specify both inputs and outputs to ensure the pathway is fully connected.</p> </li> <li> <p>Enzyme Complex Representation: The model doesn't clearly indicate whether any of these enzymes function as part of complexes. For example, anthranilate synthase in many organisms is a complex of two proteins. According to the literature (PMID:24186364), in S. pombe, the anthranilate synthase is encoded by two genes (trp1C and trp3), but this complex formation is not represented in the model.</p> </li> </ol>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Remove the \"I used chatGPT for this one\" comment and replace with a professional description of the biological process being modeled.</p> </li> <li> <p>Add specific inputs and outputs for all enzymatic reactions in the pathway to ensure complete biochemical connectivity.</p> </li> <li> <p>Clarify whether anthranilate synthase functions as a complex in S. pombe and if so, represent it according to the complex annotation guidelines.</p> </li> <li> <p>Consider adding more primary literature evidence to strengthen the model's scientific basis.</p> </li> <li> <p>Double-check the gene product identifiers with current PomBase annotations to ensure they are up-to-date.</p> </li> </ol>"},{"location":"reviews/6690711d00002821-tryptophan_biosynthetic_process__GO_0000162_/#conclusion","title":"Conclusion","text":"<p>Overall, the model correctly captures the tryptophan biosynthetic pathway in S. pombe with appropriate molecular functions and causal connections. The unique feature of trp1 encoding two enzymatic activities is properly captured. With the minor improvements suggested above, this would be a high-quality GO-CAM representation of this important metabolic pathway.</p>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/","title":"6690711d00002904 L histidine biosynthetic process  GO 0000105","text":"<p>Based on my review of the GO-CAM model 6690711d00002904 and the related information, I'll now provide a comprehensive review:</p>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#review-of-go-cam-model-6690711d00002904","title":"Review of GO-CAM Model 6690711d00002904","text":""},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:6690711d00002904) represents the \"L-histidine biosynthetic process\" (GO:0000105) in Schizosaccharomyces pombe (fission yeast). The model captures the enzymatic steps of the histidine biosynthesis pathway with multiple gene products performing specific molecular functions that are causally connected to create a coherent representation of the pathway.</p>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model includes 8 activities representing the enzymatic steps of histidine biosynthesis:</p> <ol> <li>ATP phosphoribosyltransferase (his1) - PomBase:SPAC25G10.05c (GO:0003879)</li> <li>Phosphoribosyl-ATP diphosphatase (his7) - PomBase:SPBC29A3.02c (GO:0004636)</li> <li>Phosphoribosyl-AMP cyclohydrolase (his7) - PomBase:SPBC29A3.02c (GO:0004635)</li> <li>1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino]imidazole-4-carboxamide isomerase (his6) - PomBase:SPAC3F10.09 (GO:0003949)</li> <li>Imidazoleglycerol-phosphate synthase (his4) - PomBase:SPBC418.01c (GO:0000107)</li> <li>Imidazoleglycerol-phosphate dehydratase (his5) - PomBase:SPBC21H7.07c (GO:0004424)</li> <li>Histidinol-phosphate transaminase (his3) - PomBase:SPBC11B10.02c (GO:0004400)</li> <li>Histidinol-phosphatase (SPCC1672.01) - PomBase:SPCC1672.01 (GO:0004401)</li> <li>Histidinol dehydrogenase (his2) - PomBase:SPBC1711.13 (GO:0004399)</li> </ol> <p>All of these activities are annotated to occur in the cytosol (GO:0005829) and are part of the L-histidine biosynthetic process (GO:0000105).</p>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#pathway-flow-and-causal-connections","title":"Pathway Flow and Causal Connections","text":"<p>The model effectively uses the causal relationship predicate \"provides input for\" (RO:0002413) to connect the activities in the correct sequential order, representing the flow of metabolites through the pathway:</p> <ol> <li>his1 (ATP phosphoribosyltransferase) \u2192 his7 (Phosphoribosyl-ATP diphosphatase)</li> <li>his7 (Phosphoribosyl-ATP diphosphatase) \u2192 his7 (Phosphoribosyl-AMP cyclohydrolase)</li> <li>his7 (Phosphoribosyl-AMP cyclohydrolase) \u2192 his6 (1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino]imidazole-4-carboxamide isomerase)</li> <li>his6 \u2192 his4 (Imidazoleglycerol-phosphate synthase)</li> <li>his4 \u2192 his5 (Imidazoleglycerol-phosphate dehydratase)</li> <li>his5 \u2192 his3 (Histidinol-phosphate transaminase)</li> <li>his3 \u2192 SPCC1672.01 (Histidinol-phosphatase)</li> <li>SPCC1672.01 \u2192 his2 (Histidinol dehydrogenase)</li> </ol> <p>The final product of the pathway is correctly annotated as L-histidine (CHEBI:15971).</p>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well supported by evidence:</p> <ol> <li>Multiple empirical evidence codes are used, including:</li> <li>ECO:0000316 (genetic interaction evidence)</li> <li>ECO:0000304 (author statement with traceable reference)</li> <li>ECO:0000315 (mutant phenotype evidence)</li> <li>ECO:0000266 (sequence orthology evidence)</li> <li> <p>ECO:0000318 (biological aspect of ancestor evidence)</p> </li> <li> <p>Key references include:</p> </li> <li>PMID:8299169 - Specific reference for his7 function</li> <li>PMID:8159167 - Evidence for his3 function</li> <li>PMID:16823372 - Evidence for subcellular localization in the cytosol</li> <li>PMID:15704224 - Evidence for his2 function</li> <li>PMID:17248775 - Additional evidence for his2 function</li> </ol>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Completeness: The model captures all the major steps in the histidine biosynthesis pathway with appropriate enzyme functions.</p> </li> <li> <p>Correct cellular location: All activities are properly located in the cytosol (GO:0005829), which is consistent with current knowledge about histidine biosynthesis in yeast.</p> </li> <li> <p>Appropriate causal relationships: The causal flow is well represented using the \"provides input for\" relationship (RO:0002413), correctly showing the sequential steps in the pathway.</p> </li> <li> <p>Evidence quality: The model uses appropriate evidence codes and references, including experimental evidence where available.</p> </li> <li> <p>Bifunctional enzyme representation: The bifunctional nature of the his7 gene product is correctly represented with two distinct activities (phosphoribosyl-ATP diphosphatase and phosphoribosyl-AMP cyclohydrolase).</p> </li> <li> <p>Input/output annotations: The model correctly includes the substrate input (CHEBI:73183, 1-(5-phospho-beta-D-ribosyl)-ATP) and final product (CHEBI:15971, L-histidine).</p> </li> </ol>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#minor-issues","title":"Minor Issues:","text":"<ol> <li> <p>Redundant causal connection: There appears to be a duplicated causal relationship from his4 (PomBase:SPBC418.01c) to his5 (PomBase:SPBC21H7.07c) - this redundancy should be removed to maintain model parsimony.</p> </li> <li> <p>Missing evidence: One causal association (from his3 to SPCC1672.01) lacks evidence annotation.</p> </li> <li> <p>Nomenclature consistency: Gene naming is consistent (using his1-7), but SPCC1672.01 lacks a standard gene name, which slightly reduces model clarity.</p> </li> </ol>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Remove the redundant causal relationship between his4 and his5.</p> </li> <li> <p>Add appropriate evidence for the causal association between his3 and SPCC1672.01.</p> </li> <li> <p>Verify if SPCC1672.01 has an assigned gene name (possibly his8 or his9) for consistency.</p> </li> <li> <p>Consider adding additional regulatory information if available, such as feedback inhibition of his1 by histidine, which is a common regulatory feature in histidine biosynthesis.</p> </li> </ol>"},{"location":"reviews/6690711d00002904-L_histidine_biosynthetic_process__GO_0000105_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model is a high-quality representation of the L-histidine biosynthetic process in Schizosaccharomyces pombe. It accurately captures the enzymatic steps, molecular functions, cellular locations, and pathway structure in accordance with established biological knowledge. The model demonstrates proper use of GO-CAM conventions and is well-supported by evidence. With the minor improvements suggested above, this model would serve as an excellent reference for the histidine biosynthesis pathway in fission yeast.</p>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/","title":"66a3e0bb00000156 Positive regulation of cholesterol biosynthesis by PAQR3 by anchoring SREBF1 SCAP complex to the Golgi    Human","text":"<p>Now that I have collected all the necessary information, I'll review the GO-CAM model: gomodel:66a3e0bb00000156.</p>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#review-of-go-cam-model-66a3e0bb00000156","title":"Review of GO-CAM Model: 66a3e0bb00000156","text":""},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#model-overview","title":"Model Overview","text":"<p>Title: Positive regulation of cholesterol biosynthesis by PAQR3 by anchoring SREBF1-SCAP complex to the Golgi. (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This model represents a pathway where PAQR3 positively regulates cholesterol biosynthesis by anchoring the SREBF1-SCAP complex to the Golgi apparatus. The model captures key activities involved in this process, including:</p> <ol> <li>SREBF1 (P36956) DNA-binding transcription factor activity in the nucleus</li> <li>KPNB1 (Q14974) nuclear import signal receptor activity in the cytoplasm</li> <li>INSIG1 (O15503) protein sequestering activity in the endoplasmic reticulum (ER)</li> <li>MBTPS2 (O43462) metalloendopeptidase activity in the Golgi membrane</li> <li>PAQR3 (Q6TCH7) protein-membrane adaptor activity in the Golgi membrane</li> </ol>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#detailed-component-analysis","title":"Detailed Component Analysis","text":""},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#activities-and-causal-associations","title":"Activities and Causal Associations","text":"<ol> <li> <p>SREBF1 (P36956): Functions as a DNA-binding transcription factor in the nucleus, participating in positive regulation of cholesterol biosynthetic process. This is well-supported by the literature as SREBF1 is known to be a master regulator of genes involved in cholesterol biosynthesis.</p> </li> <li> <p>KPNB1 (Q14974): Functions as a nuclear import signal receptor in the cytoplasm, participating in NLS-bearing protein import into nucleus. The model correctly establishes a causal relationship where KPNB1 positively regulates SREBF1's activity, representing the import of cleaved SREBF1 into the nucleus.</p> </li> <li> <p>INSIG1 (O15503): Functions in protein sequestering activity in the ER membrane, participating in SREBP-SCAP complex retention in the ER. The model correctly shows INSIG1 negatively regulating MBTPS2, representing how INSIG1 prevents SREBP cleavage under high cholesterol conditions.</p> </li> <li> <p>MBTPS2 (O43462): Functions as a metalloendopeptidase in the Golgi membrane, participating in protein maturation. The model correctly shows MBTPS2 positively regulating KPNB1, representing the proteolytic processing of SREBP that allows its nuclear fragment to be transported into the nucleus.</p> </li> <li> <p>PAQR3 (Q6TCH7): Functions as a protein-membrane adaptor in the Golgi membrane, participating in protein localization to Golgi apparatus. The model correctly shows PAQR3 positively regulating MBTPS2, representing how PAQR3 anchors the SREBP-SCAP complex to the Golgi where MBTPS2 can cleave it.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by published research. In particular, PMID:26311497 (Xu et al., 2015) provides extensive evidence for the role of PAQR3 in anchoring the SCAP-SREBP complex to the Golgi and thereby enhancing SREBP processing. Other references including PMID:32497488, PMID:12177166, PMID:15899885, and PMID:11163209 support various aspects of the model.</p>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#assessment-of-accuracy-and-completeness","title":"Assessment of Accuracy and Completeness","text":"<p>The model accurately represents the current understanding of how PAQR3 functions in cholesterol homeostasis according to the literature. It correctly captures:</p> <ol> <li>The role of PAQR3 as a Golgi anchor protein for the SCAP-SREBP complex</li> <li>The antagonistic relationship between INSIG1 (ER retention) and PAQR3 (Golgi anchoring)</li> <li>The sequential proteolytic processing of SREBP by proteases like MBTPS2</li> <li>The nuclear import of processed SREBP to activate cholesterol biosynthesis genes</li> </ol>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#minor-issues-and-potential-improvements","title":"Minor Issues and Potential Improvements","text":"<ol> <li> <p>Duplicate Causal Association: There appears to be a duplicate causal association from MBTPS2 to KPNB1. One of these associations has no evidence listed, which should be addressed.</p> </li> <li> <p>Cholesterol Feedback Representation: While the model represents the pathway well, it could potentially benefit from explicitly representing how cholesterol levels modulate the interactions between INSIG1, SCAP, and PAQR3, as described in PMID:26311497.</p> </li> <li> <p>SCAP Role: While SCAP (Q12770) is mentioned in the title and is essential to this pathway, it does not appear as an enabled-by component in any activity. The model could be enhanced by explicitly including SCAP's activity as an escort protein.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model follows GO-CAM guidelines in terms of: - Using appropriate GO terms for molecular functions, cellular components, and biological processes - Using appropriate causal relationship predicates - Including evidence for most assertions</p>"},{"location":"reviews/66a3e0bb00000156-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF1_SCAP_complex_to_the_Golgi____Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66a3e0bb00000156) accurately represents the positive regulation of cholesterol biosynthesis by PAQR3 through anchoring the SREBF1-SCAP complex to the Golgi apparatus. It is well-supported by the scientific literature and follows the GO-CAM guidelines. </p> <p>The model could be improved by addressing the duplicate causal association, explicitly representing SCAP's activity, and possibly expanding the representation of how cholesterol levels affect the pathway. Nevertheless, it provides a valuable representation of this important regulatory mechanism in cholesterol homeostasis.</p>"},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/","title":"66a3e0bb00000443 Positive regulation of cholesterol biosynthesis by PAQR3 by anchoring SREBF2 SCAP complex to the Golgi    Human","text":"<p>Based on my review of the GO-CAM model (gomodel:66a3e0bb00000443) and the related information I've gathered, here's my comprehensive review:</p>"},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/#go-cam-model-review-gomodel66a3e0bb00000443","title":"GO-CAM Model Review: gomodel:66a3e0bb00000443","text":""},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/#model-overview","title":"Model Overview","text":"<p>Title: \"Positive regulation of cholesterol biosynthesis by PAQR3 by anchoring SREBF2-SCAP complex to the Golgi. (Human)\" Model ID: gomodel:66a3e0bb00000443 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>This model captures a key regulatory mechanism in cholesterol homeostasis, specifically how PAQR3 (Progestin and adipoQ receptor family member 3) functions to anchor the SCAP/SREBP complex to the Golgi apparatus, which promotes SREBP processing and ultimately enhances cholesterol biosynthesis. The model accurately represents the molecular functions and causal relationships between the key players in this pathway:</p> <ol> <li>PAQR3 (UniProtKB:Q6TCH7) - Functions as a Golgi-anchored membrane protein with protein-membrane adaptor activity (GO:0043495)</li> <li>INSIG1 (UniProtKB:O15503) - Acts as a negative regulator via protein sequestering activity (GO:0140311)</li> <li>SREBF2 (UniProtKB:Q12772) - Functions as a DNA-binding transcription factor (GO:0000981)</li> <li>MBTPS2 (UniProtKB:O43462) - Acts as a metalloendopeptidase (GO:0004222)</li> <li>KPNB1 (UniProtKB:Q14974) - Functions in nuclear import (GO:0061608)</li> </ol>"},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/#assessment-of-model-structure","title":"Assessment of Model Structure","text":"<p>The model correctly represents the pathway where:</p> <ol> <li>PAQR3 tethers the SCAP/SREBP complex to the Golgi membrane</li> <li>MBTPS2 cleaves SREBP in the Golgi</li> <li>KPNB1 imports the cleaved/active SREBP into the nucleus</li> <li>SREBF2 activates transcription of genes involved in cholesterol biosynthesis</li> </ol> <p>The causal associations are appropriately used, with RO:0002304 (causally upstream of, positive effect) connecting the activities in the expected sequence.</p>"},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is well-supported by literature, particularly the paper by Xu et al. (PMID:26311497), which established PAQR3's role in anchoring the SCAP/SREBP complex to the Golgi. The model accurately captures the key findings:</p> <ul> <li>PAQR3 interacts with both SCAP and SREBP via distinct structural motifs</li> <li>PAQR3 promotes Golgi localization of SCAP/SREBP</li> <li>PAQR3 and INSIG1 have mutually exclusive interactions with SCAP, which is regulated by cholesterol levels</li> <li>PAQR3 promotes SREBP processing and subsequently enhances lipid synthesis</li> </ul>"},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Correct use of molecular functions: Each protein is appropriately annotated with its molecular function (e.g., PAQR3's protein-membrane adaptor activity)</p> </li> <li> <p>Proper subcellular localization: Activities are correctly located (e.g., PAQR3 in the Golgi membrane, SREBF2 in the nucleus)</p> </li> <li> <p>Appropriate causal connections: The model uses the appropriate causal relationships (RO:0002304 for positive regulation)</p> </li> <li> <p>Complete pathway representation: The model captures the sequence from PAQR3 anchoring to SREBP-mediated transcription</p> </li> </ol>"},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<p>While the model is solid overall, a few aspects could be enhanced:</p> <ol> <li> <p>SCAP representation: The model includes SCAP (UniProtKB:Q12770) as an object but doesn't explicitly include its activity in the pathway. Since SCAP is a critical escort protein for SREBP, its molecular function could be included in the causal chain.</p> </li> <li> <p>Evidence codes: The evidence is appropriately cited with references to primary literature, but ensuring that each causal association has explicit evidence would strengthen the model.</p> </li> <li> <p>Feedback regulation: The model captures the forward process well, but could potentially represent the feedback regulation where SREBP activation leads to PAQR3 expression changes, creating a feedback loop.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00000443-Positive_regulation_of_cholesterol_biosynthesis_by_PAQR3_by_anchoring_SREBF2_SCAP_complex_to_the_Golgi____Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66a3e0bb00000443) is a high-quality representation of PAQR3's role in cholesterol homeostasis. It accurately depicts the molecular activities, causal relationships, and cellular locations of the key players in the pathway. The model is consistent with current literature and follows GO-CAM best practices. </p> <p>The model effectively illustrates how PAQR3 functions as a Golgi anchor for the SCAP/SREBP complex, promoting SREBP processing and ultimately the positive regulation of cholesterol biosynthesis. This mechanism provides important insights into the regulation of cholesterol homeostasis in human cells.</p>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/","title":"66a3e0bb00001036 IGF1 mediated signaling via IGF1R receptor  Human","text":"<p>Based on my review of the GO-CAM model \"66a3e0bb00001036\" titled \"IGF1-mediated signaling via IGF1R receptor (Human)\", I will now provide a comprehensive analysis of the model against GO-CAM best practices.</p>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#go-cam-model-review-gomodel66a3e0bb00001036","title":"GO-CAM Model Review: gomodel:66a3e0bb00001036","text":""},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#summary","title":"Summary","text":"<p>This model represents IGF1-mediated signaling via the IGF1R receptor in humans. It includes four key activities: 1. IGF1R receptor activity (enabled by P08069/IGF1R) 2. IRS1 signaling adaptor activity (enabled by P35568/IRS1) 3. IRS2 signaling adaptor activity (enabled by Q9Y4H2/IRS2) 4. IGF1 growth factor activity (enabled by P05019/IGF1)</p>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#strengths","title":"Strengths","text":"<ul> <li>The model correctly depicts the signaling cascade from IGF1 to IGF1R to downstream adaptors (IRS1 and IRS2)</li> <li>All activities are grounded in appropriate evidence and references (PMIDs)</li> <li>The model uses appropriate causal relationships (RO:0002629 \"directly positively regulates\")</li> <li>Activities are correctly linked to appropriate cellular locations</li> <li>The model incorporates the correct biological process (GO:0048009 \"insulin-like growth factor receptor signaling pathway\")</li> </ul>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#areas-for-improvement","title":"Areas for Improvement","text":""},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#1-molecular-function-annotations","title":"1. Molecular Function Annotations","text":"<p>The signaling adaptor activities for IRS1 and IRS2 are both annotated with GO:0035591 \"signaling adaptor activity\", which is correct. However, according to the \"How to annotate molecular adaptors\" document, adaptors should have \"has input\" relationships to the molecules they bring together. In this model:</p> <ul> <li>Both IRS1 and IRS2 should have \"has input\" relationships to their binding partners</li> <li>According to the literature you provided, IRS1 and IRS2 bind to both IGF1R and downstream effectors like PI3K</li> </ul>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#2-downstream-signaling-pathway-representation","title":"2. Downstream Signaling Pathway Representation","text":"<p>The model stops at IRS1/IRS2 and doesn't represent further downstream signaling, such as: - PI3K pathway activation (mentioned in the literature) - MAPK pathway activation  - AKT signaling</p> <p>These pathways are well-established in IGF1 signaling based on the provided literature, particularly evident in PMID:16878150 and PMID:17827393.</p>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#3-igf1-and-igf1r-relationship","title":"3. IGF1 and IGF1R Relationship","text":"<p>According to the \"Signaling receptor activity annotation guidelines\", the relationship between IGF1 (ligand) and IGF1R (receptor) should be modeled as: - IGF1 \"directly positively regulates\" IGF1R (which is currently represented correctly) - IGF1 should have a GO:0048018 or child term (receptor ligand activity)   - The model correctly uses GO:0008083 \"growth factor activity\" which is appropriate for IGF1</p>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#4-additional-context","title":"4. Additional Context","text":"<p>The model could benefit from adding: - Phosphorylation events (tyrosine phosphorylation of IRS1/IRS2) - Representation of PI3K (PIK3R1) which is a key binding partner of IRS1/IRS2 - The subcellular location for IRS1 and IRS2 is cytoplasm (GO:0005737), which is correct but could be more specific based on the literature</p>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#technical-accuracy","title":"Technical Accuracy","text":"<p>The evidence codes used in the model are appropriate: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000305 (curator inference used in manual assertion) - ECO:0000250 (sequence similarity evidence used in manual assertion with UniProtKB:P35569) - ECO:0000353 (physical interaction evidence used in manual assertion)</p> <p>The overall causal flow is biologically accurate, representing: 1. IGF1 \u2192 IGF1R 2. IGF1R \u2192 IRS1 and IRS2</p>"},{"location":"reviews/66a3e0bb00001036-IGF1_mediated_signaling_via_IGF1R_receptor__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a good foundation for representing IGF1 signaling through IGF1R, IRS1, and IRS2. It captures the core interactions accurately but could be expanded to include:</p> <ol> <li>Explicit \"has input\" relationships for IRS1 and IRS2 adaptors</li> <li>Downstream signaling events (PI3K/AKT, MAPK pathways)</li> <li>Phosphorylation events that are key to this signaling cascade</li> <li>Additional binding partners like PIK3R1 (p85 subunit of PI3K)</li> </ol> <p>The model is consistent with current biological knowledge about IGF1 signaling and follows most GO-CAM best practices. With the suggested improvements, it would provide a more comprehensive representation of this important signaling pathway.</p>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/","title":"66a3e0bb00001159 Signaling by Adrenomedullin mediated by ADM ligand activating CALCRL RAMP2 receptor complex  Human","text":"<p>Based on all the information gathered, I'll now review the GO-CAM model \"Signaling by Adrenomedullin mediated by ADM ligand activating CALCRL-RAMP2 receptor complex (Human)\". Here's my comprehensive review:</p>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#go-cam-model-review-gomodel66a3e0bb00001159","title":"GO-CAM Model Review: gomodel:66a3e0bb00001159","text":""},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:66a3e0bb00001159</li> <li>Title: Signaling by Adrenomedullin mediated by ADM ligand activating CALCRL-RAMP2 receptor complex (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#overview","title":"Overview","text":"<p>This model represents the adrenomedullin receptor signaling pathway in humans. It depicts how the ADM hormone binds to and activates the CALCRL-RAMP2 receptor complex, which then activates G protein signaling through GNAS, ultimately leading to the activation of adenylate cyclase (ADCY6) and the production of cAMP.</p>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#detailed-assessment","title":"Detailed Assessment","text":""},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#activities-and-connections","title":"Activities and Connections","text":"<p>The model includes the following key activities:</p> <ol> <li> <p>ADM (P35318) - Hormone activity (GO:0005179) occurring in extracellular space (GO:0005615), which directly positively regulates the receptor activity.</p> </li> <li> <p>CALCRL (Q16602) - Adrenomedullin receptor activity (GO:0001605) occurring in plasma membrane (GO:0005886), which directly positively regulates G protein activity.</p> </li> <li> <p>RAMP2 (O60895) - Coreceptor activity (GO:0015026) occurring in plasma membrane (GO:0005886), which directly positively regulates CALCRL activity.</p> </li> <li> <p>GNAS (Q5JWF2) - G protein activity (GO:0003925) occurring in cytosol (GO:0005829), which directly positively regulates adenylate cyclase activity.</p> </li> <li> <p>ADCY6 (O43306) - Adenylate cyclase activity (GO:0004016) that has cAMP (CHEBI:17489) as output.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#conformance-to-go-cam-guidelines","title":"Conformance to GO-CAM Guidelines","text":"<ol> <li>Signaling Receptor Annotation Guidelines: </li> <li>The model follows the guidelines for protein ligand-activated signaling receptor activity.</li> <li>ADM is correctly annotated with hormone activity and localized to the extracellular space.</li> <li>CALCRL is properly annotated with receptor activity and localized to the plasma membrane.</li> <li>RAMP2 is correctly annotated with coreceptor activity and properly placed in the pathway.</li> <li> <p>The causal relation from the ligand (ADM) to the receptor (CALCRL) is correctly established as \"directly positively regulates\".</p> </li> <li> <p>Complex Annotation:</p> </li> <li>The CALCRL-RAMP2 receptor complex is correctly represented by annotating both proteins individually with their specific activities (adrenomedullin receptor activity and coreceptor activity respectively).</li> <li> <p>This is appropriate since both protein components have well-defined activities in the complex.</p> </li> <li> <p>G Protein Signaling:</p> </li> <li>The G protein (GNAS) is correctly annotated with G protein activity and shown as being regulated by the receptor (CALCRL).</li> <li> <p>The causal relationships follow the correct biological flow, with GNAS activating ADCY6.</p> </li> <li> <p>Biological Process Annotations:</p> </li> <li>ADM and RAMP2 are correctly shown as part of the \"adrenomedullin receptor signaling pathway\" (GO:1990410).</li> <li>CALCRL, GNAS, and ADCY6 are correctly shown as part of \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\" (GO:0007189).</li> <li> <p>These process annotations accurately reflect the roles of these proteins in the signaling pathway.</p> </li> <li> <p>Molecular Output:</p> </li> <li>ADCY6 is correctly shown to produce cAMP (CHEBI:17489) as its output.</li> </ol>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>All activities in the model are supported with appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and literature references:</p> <ul> <li>ADM and CALCRL activities are supported by PMID:32296767</li> <li>CALCRL localization is supported by PMID:9620797</li> <li>RAMP2 activity is supported by PMID:17916776</li> <li>GNAS activity is supported by PMID:17110384</li> <li>ADCY6 activity is supported by PMID:17916776 and PMID:23842570</li> </ul>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model accurately represents the biology of adrenomedullin signaling through its receptor complex.</li> <li>The appropriate receptor-coreceptor relationship between CALCRL and RAMP2 is well-captured.</li> <li>The complete signaling cascade from ligand binding to second messenger production is represented.</li> <li>All components are properly localized in their cellular compartments.</li> <li>All activities have appropriate evidence and literature references.</li> </ol>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, there are a few minor aspects that could be improved:</p> <ol> <li> <p>Completeness: The model could potentially include downstream effects of cAMP production, such as PKA activation, to more fully represent the signaling pathway's outcomes.</p> </li> <li> <p>Location of ADCY6: While not explicitly annotated in the model, ADCY6 is typically localized to the plasma membrane. Adding this cellular location annotation would be more precise.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001159-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP2_receptor_complex__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66a3e0bb00001159) is a high-quality representation of adrenomedullin signaling through the CALCRL-RAMP2 receptor complex. It accurately follows GO-CAM best practices for signaling receptor annotation and complex representation. The model correctly captures the biological relationship between the ligand, receptor complex, G protein, and adenylate cyclase, leading to cAMP production. The evidence supporting each activity is appropriate and well-documented.</p> <p>The model is biologically accurate and represents the current understanding of adrenomedullin receptor signaling.</p>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/","title":"66a3e0bb00001555 Signaling by Adrenomedullin mediated by ADM ligand activating CALCRL RAMP3 receptor complex  Human","text":"<p>Based on my review of the GO-CAM model gomodel:66a3e0bb00001555 \"Signaling by Adrenomedullin mediated by ADM ligand activating CALCRL-RAMP3 receptor complex (Human)\" and the supporting resources, I can now provide a comprehensive review:</p>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#go-cam-model-review-gomodel66a3e0bb00001555","title":"GO-CAM Model Review: gomodel:66a3e0bb00001555","text":""},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the adrenomedullin (ADM) signaling pathway in humans, specifically focusing on how ADM activates the CALCRL-RAMP3 receptor complex, leading to downstream G-protein signaling and adenylate cyclase activation. The model was created in 2024 by a curator with ORCID 0000-0003-1522-9900.</p>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model consists of five connected activities:</p> <ol> <li>ADM (P35318) - Hormone activity (GO:0005179) occurring in extracellular space (GO:0005615)</li> <li>RAMP3 (O60896) - Coreceptor activity (GO:0015026) occurring at plasma membrane (GO:0005886)</li> <li>CALCRL (Q16602) - Adrenomedullin receptor activity (GO:0001605) occurring at plasma membrane (GO:0005886)</li> <li>GNAS (Q5JWF2) - G protein activity (GO:0003925) occurring in cytosol (GO:0005829)</li> <li>ADCY6 (O43306) - Adenylate cyclase activity (GO:0004016) with output molecule cAMP (CHEBI:17489)</li> </ol>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#causal-flow","title":"Causal Flow","text":"<p>The model correctly represents the causal flow of the adrenomedullin signaling pathway: - ADM directly positively regulates (RO:0002629) CALCRL - RAMP3 directly positively regulates (RO:0002629) CALCRL - CALCRL directly positively regulates (RO:0002629) GNAS - GNAS directly positively regulates (RO:0002629) ADCY6 - ADCY6 produces cAMP as output</p>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#biological-process-context","title":"Biological Process Context","text":"<p>The activities are correctly contextualized within relevant biological processes: - ADM and RAMP3 are part of adrenomedullin receptor signaling pathway (GO:1990410) - CALCRL, GNAS, and ADCY6 are part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</p>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>Each assertion is supported by appropriate evidence: - ECO:0000314 (direct assay evidence used in manual assertion) is used throughout - Key publications including PMID:32296767, PMID:9620797, and PMID:17110384 are cited - The evidence is consistent with the known biology of the adrenomedullin signaling system</p>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#alignment-with-go-cam-best-practices","title":"Alignment with GO-CAM Best Practices","text":"<p>The model is consistent with signaling receptor activity annotation guidelines, which specify: 1. For protein ligands (like ADM):    - Ligand is correctly annotated with receptor ligand activity (hormone activity) occurring in extracellular space    - Receptor (CALCRL) is correctly annotated with receptor activity occurring at plasma membrane    - The causal relation between ligand and receptor is correctly represented as \"directly positively regulates\"</p> <ol> <li>For receptor-coreceptor systems:</li> <li>RAMP3 is correctly annotated with coreceptor activity</li> <li>The model correctly shows that RAMP3 directly positively regulates CALCRL, as per guidelines</li> </ol>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is well-supported by the literature: - PMID:9620797 (McLatchie et al., 1998) established that RAMPs regulate the transport and ligand specificity of CALCRL - The UniProt entries confirm that ADM functions through the CALCRL-RAMP3 receptor complex - The GO annotations for all proteins are consistent with their established functions</p>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the known biology: 1. ADM is a hormone that binds to and activates the CALCRL-RAMP3 complex 2. RAMP3 is essential for proper localization and function of CALCRL 3. When activated, the receptor complex triggers G protein (GNAS) signaling 4. GNAS activates adenylate cyclase (ADCY6), which produces cAMP 5. This signaling pathway is part of the broader adenylate cyclase-activating G protein-coupled receptor pathway</p>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#areas-of-excellence","title":"Areas of Excellence","text":"<ol> <li>Correct representation of the receptor-coreceptor relationship between CALCRL and RAMP3</li> <li>Appropriate use of cellular component annotations (plasma membrane, extracellular space, cytosol)</li> <li>Clear causal chain with appropriate relationship predicates</li> <li>Strong evidence support with relevant primary literature citations</li> </ol>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#recommendations","title":"Recommendations","text":"<p>The model is well-constructed and adheres to GO-CAM best practices. There are no significant issues to address. Minor potential enhancements could include:</p> <ol> <li> <p>Consider adding additional downstream signaling components that respond to increased cAMP levels, such as protein kinase A activation, if evidence is available.</p> </li> <li> <p>The model could potentially be expanded to include cellular responses or physiological outcomes of ADM signaling (such as vasodilation), though this may be beyond the intended scope.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001555-Signaling_by_Adrenomedullin_mediated_by_ADM_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:66a3e0bb00001555 is a high-quality representation of adrenomedullin signaling through the CALCRL-RAMP3 receptor complex. It accurately depicts the molecular mechanisms involved, is well-supported by evidence, and follows GO-CAM curation guidelines. The model provides valuable curated information about this important signaling pathway.</p>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/","title":"66a3e0bb00001633 Signaling by Adrenomedullin mediated by ADM2 ligand activating CALCRL RAMP3 receptor complex  Human","text":"<p>Based on my analysis of the GO-CAM model and the relevant resources, I'll now provide a comprehensive review of gomodel:66a3e0bb00001633:</p>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#review-of-go-cam-model-66a3e0bb00001633","title":"Review of GO-CAM Model 66a3e0bb00001633","text":""},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Signaling by Adrenomedullin mediated by ADM2 ligand activating CALCRL-RAMP3 receptor complex (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>This GO-CAM model represents a signaling pathway where ADM2 (Adrenomedullin 2, also known as Intermedin) ligand activates the CALCRL-RAMP3 receptor complex (AM2 receptor), leading to G protein (GNAS) activation, subsequent adenylate cyclase (ADCY6) activation, and production of cAMP.</p>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#structure-and-quality-assessment","title":"Structure and Quality Assessment","text":""},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#pathway-analysis","title":"Pathway Analysis","text":"<p>The model represents a canonical G-protein coupled receptor signaling pathway with the following components:</p> <ol> <li>ADM2 hormone - hormone activity (GO:0005179) occurring in extracellular space (GO:0005615)</li> <li>CALCRL-RAMP3 receptor complex - where:</li> <li>CALCRL provides adrenomedullin receptor activity (GO:0001605) on the plasma membrane (GO:0005886)</li> <li> <p>RAMP3 provides coreceptor activity (GO:0015026) on the plasma membrane</p> </li> <li> <p>G-protein component (GNAS) - G protein activity (GO:0003925) in the cytosol (GO:0005829)</p> </li> <li> <p>Adenylate cyclase (ADCY6) - adenylate cyclase activity (GO:0004016) producing cAMP (CHEBI:17489)</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model correctly uses causal relationships to show the flow of signaling: - ADM2 hormone directly positively regulates (RO:0002629) CALCRL receptor activity - RAMP3 coreceptor directly positively regulates (RO:0002629) CALCRL receptor activity - CALCRL receptor directly positively regulates (RO:0002629) GNAS G-protein activity - GNAS directly positively regulates (RO:0002629) ADCY6 adenylate cyclase activity</p>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#biological-processes","title":"Biological Processes","text":"<p>All activities are appropriately assigned to biological processes: - ADM2 hormone activity is part of adrenomedullin receptor signaling pathway (GO:1990410) - CALCRL receptor activity is part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189) - RAMP3 coreceptor activity is part of adrenomedullin receptor signaling pathway (GO:1990410) - GNAS G-protein activity is part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189) - ADCY6 adenylate cyclase activity is part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</p>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Correct implementation of signaling receptor guidelines: The model correctly follows the guidelines for signaling receptor activity annotation, including the proper representation of a receptor with a coreceptor.</p> </li> <li> <p>Appropriate cellular components: Each protein is appropriately placed in the correct cellular compartment (ADM2 in extracellular space, receptors in plasma membrane, G protein in cytosol).</p> </li> <li> <p>Biological context: The model correctly represents the roles of each component in the adenylate cyclase-activating G protein-coupled receptor signaling pathway.</p> </li> <li> <p>Evidence quality: All assertions are supported by experimental evidence with appropriate PMIDs including high-quality recent research on the structure and dynamics of adrenomedullin receptors.</p> </li> <li> <p>Molecular output: The model correctly captures cAMP as the output of ADCY6 activity.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>No evident errors: The model appears to be correctly constructed according to GO-CAM guidelines. There are no errors in causal relationships, evidence, or component specifications.</p> </li> <li> <p>Potential extension: While not a deficiency, the model could be extended to include downstream effects of cAMP production if desired, such as activation of Protein Kinase A or other cAMP-responsive elements.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#literature-support","title":"Literature Support","text":"<p>The model is well-supported by the literature. Key facts verified from the literature include:</p> <ol> <li> <p>ADM2-CALCRL-RAMP3 interaction: The 2020 paper by Liang et al. (PMID:32296767) provides structural evidence for the interaction between ADM2 (Intermedin) and the CALCRL-RAMP3 complex, forming the AM2 receptor.</p> </li> <li> <p>RAMP3 function: McLatchie et al. (PMID:9620797) described how RAMPs regulate the transport and ligand specificity of CALCRL, with RAMP3 directing CALCRL to function as an adrenomedullin receptor.</p> </li> <li> <p>G-protein coupling and adenylate cyclase activation: The model correctly represents GNAS (G\u03b1s) activating adenylate cyclase 6 (ADCY6) leading to cAMP production, supported by Gros et al. (PMID:17916776).</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001633-Signaling_by_Adrenomedullin_mediated_by_ADM2_ligand_activating_CALCRL_RAMP3_receptor_complex__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 66a3e0bb00001633 is a high-quality representation of ADM2 signaling through the CALCRL-RAMP3 (AM2) receptor complex. It adheres to GO-CAM curation best practices and accurately represents the biological relationships described in the literature. </p> <p>The model correctly implements the signaling receptor activity annotation guidelines, particularly for the case of a receptor with a coreceptor. All components are properly placed in their cellular compartments, and appropriate causal relationships are used to connect the activities.</p> <p>There are no errors or inconsistencies in the model that require correction. The model is well-supported by experimental evidence from the literature and provides a clear, accurate representation of this signaling pathway.</p>"},{"location":"reviews/66a3e0bb00001687-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/","title":"66a3e0bb00001687 Signaling by Calcitonin CGRP mediated by CALCA CGRP1 ligand activating CALCRL RAMP1 receptor complex  Human","text":"<p>Based on my review of the GO-CAM model and related information, I'll now provide a comprehensive evaluation:</p>"},{"location":"reviews/66a3e0bb00001687-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#review-of-go-cam-model-gomodel66a3e0bb00001687","title":"Review of GO-CAM Model (gomodel:66a3e0bb00001687)","text":""},{"location":"reviews/66a3e0bb00001687-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents \"Signaling by Calcitonin/CGRP mediated by CALCA/CGRP1 ligand activating CALCRL-RAMP1 receptor complex (Human)\". It models a specific G protein-coupled receptor (GPCR) signaling pathway where calcitonin gene-related peptide (CGRP) binds to a receptor complex, leading to G protein activation and ultimately to cAMP production.</p>"},{"location":"reviews/66a3e0bb00001687-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#pathway-representation-and-accuracy","title":"Pathway Representation and Accuracy","text":"<p>The model accurately represents the CGRP signaling pathway with the following sequential steps:</p> <ol> <li> <p>Hormone Activity (CALCA/CGRP1, UniProtKB:P06881-1) - The CALCA protein acts as a hormone (GO:0005179) in the extracellular space (GO:0005615), which directly positively regulates the CALCRL receptor.</p> </li> <li> <p>Coreceptor Activity (RAMP1, UniProtKB:O60894) - RAMP1 functions as a coreceptor (GO:0015026) on the plasma membrane (GO:0005886), which directly positively regulates the CALCRL receptor activity.</p> </li> <li> <p>CGRP Receptor Activity (CALCRL, UniProtKB:Q16602) - The calcitonin receptor-like receptor displays calcitonin gene-related peptide receptor activity (GO:0001635) on the plasma membrane (GO:0005886) and directly positively regulates G protein activity.</p> </li> <li> <p>G Protein Activity (GNAS, UniProtKB:Q5JWF2) - The G protein alpha subunit shows G protein activity (GO:0003925) in the cytosol (GO:0005829) and directly positively regulates adenylate cyclase activity.</p> </li> <li> <p>Adenylate Cyclase Activity (ADCY6, UniProtKB:O43306) - Adenylate cyclase converts ATP to cyclic AMP (GO:0004016), with cAMP (CHEBI:17489) as the output.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001687-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#assessment-of-model-quality","title":"Assessment of Model Quality","text":""},{"location":"reviews/66a3e0bb00001687-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Biological Accuracy: The model accurately reflects the current scientific understanding of CGRP signaling as evidenced by the literature citations (PMID:33602864, PMID:9620797, etc.).</p> </li> <li> <p>Appropriate Use of GO Terms: The molecular functions, cellular components, and biological processes are correctly assigned to each protein.</p> </li> <li> <p>Proper Causal Relationships: The model uses \"RO:0002629\" (directly positively regulates) appropriately for each step in the signaling cascade.</p> </li> <li> <p>Receptor Complex Representation: The model correctly represents the CALCRL-RAMP1 complex, where RAMP1 serves as a coreceptor that is essential for CALCRL function, consistent with the literature (PMID:9620797).</p> </li> <li> <p>Cellular Localization: Each protein activity is appropriately located in the cellular compartment where it occurs (extracellular, membrane, cytosol).</p> </li> <li> <p>Proper Evidence Coding: Each association is backed by appropriate evidence codes and literature references.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001687-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#areas-for-potential-improvement","title":"Areas for Potential Improvement:","text":"<ol> <li> <p>Complex Representation: The model represents RAMP1 and CALCRL as separate entities that regulate each other, rather than as a functional complex. According to the GO-CAM guidelines for complex annotation (\"How_to_annotate_complexes_in_GO-CAM\"), when two proteins form a functional complex where both activities are important, they can be represented as a heterodimeric receptor. However, the current representation is also valid and matches the biological reality where RAMP1 acts to transport CALCRL to the membrane and modify its ligand specificity.</p> </li> <li> <p>Temporal Aspects: The model doesn't explicitly capture the temporal aspect where RAMP1 first transports CALCRL to the plasma membrane before ligand binding occurs. However, this limitation is inherent to the GO-CAM modeling framework and not specific to this model.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001687-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a high-quality representation of CGRP signaling mediated by the CALCRL-RAMP1 receptor complex. It accurately depicts the activation of G protein signaling through adenylate cyclase, leading to cAMP production. The model is well-supported by literature evidence and follows GO-CAM best practices for representing biological pathways.</p> <p>The model is parsimonious, focusing on the key steps in the signaling pathway without unnecessary complexity, making it easy for a human to understand. All proteins are connected in a way that is consistent with the known activity flow in the CGRP signaling pathway.</p> <p>This GO-CAM model meets all the necessary quality criteria and can be approved for production use.</p>"},{"location":"reviews/66a3e0bb00001742-Signaling_by_Calcitonin_CGRP_mediated_by_CALCB_CGRP2_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/","title":"66a3e0bb00001742 Signaling by Calcitonin CGRP mediated by CALCB CGRP2 ligand activating CALCRL RAMP1 receptor complex  Human","text":"<p>Based on my review of the GO-CAM model and relevant literature, I'll now provide a comprehensive evaluation of the model:</p>"},{"location":"reviews/66a3e0bb00001742-Signaling_by_Calcitonin_CGRP_mediated_by_CALCB_CGRP2_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#review-of-go-cam-model-gomodel66a3e0bb00001742","title":"Review of GO-CAM Model: gomodel:66a3e0bb00001742","text":""},{"location":"reviews/66a3e0bb00001742-Signaling_by_Calcitonin_CGRP_mediated_by_CALCB_CGRP2_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"Signaling by Calcitonin/CGRP mediated by CALCB/CGRP2 ligand activating CALCRL-RAMP1 receptor complex (Human)\" represents the calcitonin gene-related peptide (CGRP) signaling pathway in humans. The model accurately captures the molecular mechanism by which CALCB (CGRP2) activates a receptor complex composed of CALCRL and RAMP1, leading to G protein activation, adenylyl cyclase stimulation, and cAMP production.</p>"},{"location":"reviews/66a3e0bb00001742-Signaling_by_Calcitonin_CGRP_mediated_by_CALCB_CGRP2_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate Receptor Complex Representation: The model correctly depicts the essential role of RAMP1 (O60894) as a coreceptor that partners with CALCRL (Q16602) to form a functional CGRP receptor complex. This aligns perfectly with the literature (PMID:9620797), which established that RAMPs determine the ligand specificity of CALCRL.</p> </li> <li> <p>Complete Signaling Cascade: The model captures the full signaling pathway from ligand binding to second messenger production:</p> </li> <li>CALCB (CGRP2) binding to the CALCRL-RAMP1 complex</li> <li>CALCRL-RAMP1 activation of G protein (GNAS)</li> <li>G protein activation of adenylyl cyclase (ADCY6)</li> <li> <p>cAMP production by ADCY6</p> </li> <li> <p>Correct Causal Relationships: The model uses appropriate causal predicates between activities:</p> </li> <li>CALCB <code>RO:0002629</code> (directly positively regulates) CALCRL</li> <li>RAMP1 <code>RO:0002629</code> (directly positively regulates) CALCRL</li> <li>CALCRL <code>RO:0002629</code> (directly positively regulates) GNAS</li> <li> <p>GNAS <code>RO:0002629</code> (directly positively regulates) ADCY6</p> </li> <li> <p>Proper Cellular Localization: The components are placed in appropriate cellular compartments:</p> </li> <li>CALCB in extracellular space (GO:0005615)</li> <li>CALCRL and RAMP1 at plasma membrane (GO:0005886)</li> <li>GNAS in cytosol (GO:0005829)</li> <li> <p>ADCY6 at plasma membrane (GO:0005886)</p> </li> <li> <p>Biological Process Association: Each activity is correctly connected to appropriate biological processes:</p> </li> <li>CALCB with calcitonin gene-related peptide receptor signaling pathway (GO:1990408)</li> <li>CALCRL, GNAS, and ADCY6 with adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li> <p>RAMP1 with calcitonin gene-related peptide receptor signaling pathway (GO:1990408)</p> </li> <li> <p>Evidence Basis: All assertions are supported by appropriate evidence using published literature, mainly:</p> </li> <li>PMID:9620797 (RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor)</li> <li>PMID:17916776 (Increased enzyme activity of adenylyl cyclase)</li> <li>PMID:17110384 (G protein mediated activation of adenylyl cyclase)</li> <li>PMID:32296767 (Adrenomedullin receptors structure and dynamics)</li> </ol>"},{"location":"reviews/66a3e0bb00001742-Signaling_by_Calcitonin_CGRP_mediated_by_CALCB_CGRP2_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#minor-suggestions-for-improvement","title":"Minor Suggestions for Improvement","text":"<ol> <li> <p>Functional Output: While the model shows cAMP (CHEBI:17489) as the output of ADCY6 activity, it might be beneficial to extend the model to include downstream effects of cAMP, such as activation of PKA, which would provide a more complete picture of the physiological impact of this signaling pathway.</p> </li> <li> <p>Alternative Ligands: Although the model specifically focuses on CALCB/CGRP2 signaling, it could be noted that CALCA/CGRP1 can also activate this same receptor complex with similar effects, as mentioned in the literature (PMID:9620797).</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001742-Signaling_by_Calcitonin_CGRP_mediated_by_CALCB_CGRP2_ligand_activating_CALCRL_RAMP1_receptor_complex__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66a3e0bb00001742) is a high-quality representation of the CGRP signaling pathway mediated by CALCB activation of the CALCRL-RAMP1 receptor complex. It accurately captures the molecular interactions, causal relationships, and cellular localizations of all components involved in this signaling cascade. The model properly follows the GO-CAM best practices for signaling receptor activity annotation and is well-supported by evidence from peer-reviewed literature.</p> <p>The model's representation of RAMP1 as a coreceptor that determines the ligand specificity of CALCRL is particularly accurate and important, as this is a key regulatory mechanism in this signaling system. The inclusion of the G protein (GNAS) and adenylyl cyclase (ADCY6) components completes the signaling pathway to cAMP production.</p> <p>Overall, this model serves as an excellent representation of CGRP signaling and could be valuable for researchers studying pain signaling, vasodilation, and related physiological processes where CGRP plays an important role.</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/","title":"66a3e0bb00001796 Signaling by Amylin mediated by IAPP ligand activating CALCR RAMP1  AMYR1  receptor complex  Human","text":"<p>Now let me review the GO-CAM model based on all the information gathered:</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#go-cam-model-review-for-gomodel66a3e0bb00001796","title":"GO-CAM Model Review for gomodel:66a3e0bb00001796","text":""},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Signaling by Amylin mediated by IAPP ligand activating CALCR-RAMP1 (AMYR1) receptor complex (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents the signaling pathway for amylin (IAPP) through the AMYR1 receptor complex, which consists of the calcitonin receptor (CALCR) and receptor activity-modifying protein 1 (RAMP1). The model shows how IAPP activates the CALCR-RAMP1 complex, leading to G protein (GNAS) activation, which then activates adenylate cyclase 6 (ADCY6) to produce cyclic AMP.</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#evaluation-of-model-components","title":"Evaluation of Model Components","text":""},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#1-ligand-iapp-p10997","title":"1. Ligand: IAPP (P10997)","text":"<ul> <li>MF: Hormone activity (GO:0005179)</li> <li>CC: Extracellular space (GO:0005615)</li> <li>BP: Part of amylin receptor 1 signaling pathway (GO:0150059)</li> <li>Causal relation: Directly positively regulates (RO:0002629) CALCR activity</li> <li>Evidence: ECO:0000250 (sequence similarity evidence) with reference to RGD:2854</li> </ul> <p>Assessment: The molecular function, cellular component, and biological process annotations for IAPP are appropriate. According to UniProt, IAPP is a hormone that plays a role in regulating energy homeostasis and its function is mediated by CALCR-RAMPs receptor complexes. The extracellular location is correctly annotated. The causal relation to CALCR is appropriate as IAPP activates this receptor.</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#2-receptor-calcr-p30988","title":"2. Receptor: CALCR (P30988)","text":"<ul> <li>MF: Amylin receptor activity (GO:0097643)</li> <li>CC: Plasma membrane (GO:0005886)</li> <li>BP: Part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li>Causal relation: Directly positively regulates (RO:0002629) GNAS activity</li> <li>Evidence: ECO:0000314 (direct assay) with PMID:35324283, ECO:0000303 (author statement) with PMID:7588285</li> </ul> <p>Assessment: The function of CALCR is correctly annotated as amylin receptor activity. The publication cited (PMID:35324283) confirms that CALCR in combination with RAMP1 forms the AMYR1 receptor complex. The localization in the plasma membrane and the causal relation to the G protein GNAS is also correctly represented. The biological process annotation to GO:0007189 (adenylate cyclase-activating G protein-coupled receptor signaling pathway) is appropriate.</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#3-coreceptor-ramp1-o60894","title":"3. Coreceptor: RAMP1 (O60894)","text":"<ul> <li>MF: Coreceptor activity (GO:0015026)</li> <li>CC: Plasma membrane (GO:0005886)</li> <li>BP: Part of amylin receptor 1 signaling pathway (GO:0150059)</li> <li>Causal relation: Directly positively regulates (RO:0002629) CALCR activity</li> <li>Evidence: ECO:0000314 (direct assay) with PMID:35324283, PMID:9620797</li> </ul> <p>Assessment: RAMP1 is correctly annotated with coreceptor activity. According to UniProt and PMID:35324283, RAMP1 is a coreceptor that modifies the function of the calcitonin receptor, forming the AMYR1 receptor complex. The causal relation to CALCR is correctly modeled. The cellular component (plasma membrane) and biological process annotations are appropriate.</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#4-g-protein-gnas-q5jwf2","title":"4. G Protein: GNAS (Q5JWF2)","text":"<ul> <li>MF: G protein activity (GO:0003925)</li> <li>CC: Cytosol (GO:0005829)</li> <li>BP: Part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li>Causal relation: Directly positively regulates (RO:0002629) ADCY6 activity</li> <li>Evidence: ECO:0000314 (direct assay) with PMID:17110384, PMID:12719376</li> </ul> <p>Assessment: The molecular function of GNAS as a G protein and its role in positively regulating adenylate cyclase is correctly captured. The localization in the cytosol and causal relation to ADCY6 are appropriate. The evidence is based on direct assays which is strong evidence.</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#5-adenylate-cyclase-adcy6-o43306","title":"5. Adenylate Cyclase: ADCY6 (O43306)","text":"<ul> <li>MF: Adenylate cyclase activity (GO:0004016)</li> <li>BP: Part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li>Output: 3',5'-cyclic AMP (CHEBI:17489)</li> <li>Evidence: ECO:0000314 (direct assay) with PMID:17916776, PMID:23842570, PMID:17110384</li> </ul> <p>Assessment: ADCY6 is correctly annotated with adenylate cyclase activity, which converts ATP to cyclic AMP. The output relationship to CHEBI:17489 (cAMP) is appropriate. The biological process and supporting evidence are well-documented.</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#pathway-flow-and-coherence","title":"Pathway Flow and Coherence","text":"<p>The overall flow of the pathway makes biological sense: 1. IAPP (amylin) activates the CALCR-RAMP1 receptor complex 2. This activation leads to G protein (GNAS) activation 3. GNAS activates adenylate cyclase (ADCY6) 4. ADCY6 produces cAMP</p> <p>This sequence correctly represents the canonical G protein-coupled receptor signaling cascade, specifically for the amylin receptor 1 pathway.</p>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model adheres to GO-CAM guidelines for annotating signaling receptor activity:</p> <ol> <li>Protein ligand (IAPP):</li> <li>Correctly annotated with hormone activity (a type of receptor ligand activity)</li> <li>Properly located in extracellular space</li> <li> <p>Correctly connected to its receptor via a causal relation</p> </li> <li> <p>Receptor with coreceptor:</p> </li> <li>The relationship between CALCR (receptor) and RAMP1 (coreceptor) is correctly modeled</li> <li>RAMP1 is annotated with coreceptor activity</li> <li> <p>Both are localized to the plasma membrane</p> </li> <li> <p>G protein signaling:</p> </li> <li>The cascade from receptor to G protein to adenylate cyclase is correctly represented</li> <li> <p>Causal relationships use appropriate relations (RO:0002629 - directly positively regulates)</p> </li> <li> <p>Evidence:</p> </li> <li>All annotations are supported by appropriate evidence codes</li> <li>Most relations use ECO:0000314 (direct assay evidence), which is a strong evidence type</li> </ol>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Accurately represents the amylin receptor complex (CALCR-RAMP1) based on recent literature</li> <li>Includes appropriate cellular locations for all components</li> <li>Uses strong evidence codes with recent, relevant publications</li> <li>Correctly models the complete signaling cascade from ligand to second messenger production</li> <li>Correctly uses biological process terms to provide context for each activity</li> </ol>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#opportunities-for-improvement","title":"Opportunities for Improvement","text":"<p>While the model is generally very well-constructed, here are some minor suggestions for improvement:</p> <ol> <li> <p>Cellular component for ADCY6: The model does not explicitly specify a cellular component for ADCY6. According to literature, adenylate cyclase 6 is typically membrane-bound, so adding 'plasma membrane' as the cellular location would make the model more complete.</p> </li> <li> <p>Additional downstream effects: The model could potentially be expanded to include downstream effects of cAMP production, such as activation of protein kinase A (PKA).</p> </li> </ol>"},{"location":"reviews/66a3e0bb00001796-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Signaling by Amylin mediated by IAPP ligand activating CALCR-RAMP1 (AMYR1) receptor complex (Human)\" (gomodel:66a3e0bb00001796) is of high quality and correctly represents the current understanding of amylin receptor signaling. The model adheres to GO-CAM annotation guidelines for signaling receptors and provides a clear representation of the signaling pathway with appropriate evidence.</p> <p>The representation of the CALCR-RAMP1 receptor complex and its activation by IAPP is particularly well-documented with recent literature. The model is of production quality and provides valuable information about the amylin receptor 1 signaling pathway in humans.</p>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/","title":"66a3e0bb00002104 ITPRIPL1 is a ligand of CD3E that negatively regulates TCR signaling pathway   Human","text":"<p>Now I'll review the GO-CAM model against best practices and scientific accuracy. Let me provide a comprehensive review:</p>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#review-of-go-cam-model-gomodel66a3e0bb00002104","title":"Review of GO-CAM Model: gomodel:66a3e0bb00002104","text":""},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#model-overview","title":"Model Overview","text":"<p>Title: \"ITPRIPL1 is a ligand of CD3E that negatively regulates TCR signaling pathway. (Human)\" ID: gomodel:66a3e0bb00002104 Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#content-assessment","title":"Content Assessment","text":"<p>This model captures a recently described negative regulatory mechanism in T cell receptor (TCR) signaling. According to the recent publication (PMID:38614099), ITPRIPL1 functions as a ligand for CD3E, inhibiting TCR signaling and consequently T cell activation. This appears to be a novel immunosuppressive mechanism in the tumor microenvironment.</p>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#molecular-activities-and-relationships","title":"Molecular Activities and Relationships","text":"<ol> <li>ITPRIPL1 (UniProtKB:Q6GPH6)</li> <li>MF: Receptor ligand activity (GO:0048018) - Appropriately annotated</li> <li>CC: Plasma membrane (GO:0005886) - Consistent with protein localization</li> <li>BP: Negative regulation of T cell receptor signaling pathway (GO:0050860) - Appropriate biological process</li> <li> <p>Causal relationships:</p> <ul> <li>Directly negatively regulates CD3E receptor activity</li> <li>Provides input for NCK1 sequestering activity</li> </ul> </li> <li> <p>CD3E (UniProtKB:P07766)</p> </li> <li>MF: Transmembrane signaling receptor activity (GO:0004888)</li> <li>CC: Plasma membrane (GO:0005886)</li> <li>BP: T cell receptor signaling pathway (GO:0050852)</li> <li> <p>Causal relationships:</p> <ul> <li>Directly positively regulates LCK kinase activity</li> </ul> </li> <li> <p>TCR Complex (GO:0042101)</p> </li> <li>MF: Transmembrane signaling receptor activity (GO:0004888)</li> <li>CC: Plasma membrane (GO:0005886)</li> <li>BP: T cell receptor signaling pathway (GO:0050852)</li> <li> <p>Causal relationships:</p> <ul> <li>Directly positively regulates CD3E activity</li> </ul> </li> <li> <p>NCK1 (UniProtKB:P16333)</p> </li> <li>MF: Protein sequestering activity (GO:0140311)</li> <li>CC: Cytoplasm (GO:0005737)</li> <li>BP: Negative regulation of T cell receptor signaling pathway (GO:0050860)</li> <li> <p>Causal relationships:</p> <ul> <li>Directly negatively regulates CD3E activity</li> </ul> </li> <li> <p>LCK (UniProtKB:P06239)</p> </li> <li>MF: Non-membrane spanning protein tyrosine kinase activity (GO:0004715)</li> <li>CC: Cytoplasm (GO:0005737)</li> <li>BP: T cell receptor signaling pathway (GO:0050852)</li> <li> <p>Causal relationships:</p> <ul> <li>Directly positively regulates ZAP70 activity</li> </ul> </li> <li> <p>ZAP70 (UniProtKB:P43403)</p> </li> <li>MF: Non-membrane spanning protein tyrosine kinase activity (GO:0004715)</li> <li>CC: Cytoplasm (GO:0005737)</li> <li>BP: T cell receptor signaling pathway (GO:0050852)</li> <li> <p>Causal relationships:</p> <ul> <li>Directly positively regulates LAT adaptor activity</li> </ul> </li> <li> <p>LAT (UniProtKB:O43561)</p> </li> <li>MF: Signaling adaptor activity (GO:0035591)</li> <li>CC: Plasma membrane (GO:0005886)</li> <li>BP: Positive regulation of MAPK cascade (GO:0043410)</li> </ol>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":""},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#molecular-functions","title":"Molecular Functions","text":"<ul> <li>All entities are assigned appropriate molecular functions based on their biological roles</li> <li>The use of GO:0048018 (receptor ligand activity) for ITPRIPL1 aligns with the recent paper's findings</li> <li>The use of GO:0140311 (protein sequestering activity) for NCK1 correctly captures its role in preventing CD3E-ZAP70 interaction</li> </ul>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#biological-processes","title":"Biological Processes","text":"<ul> <li>All activities are appropriately assigned to relevant biological processes</li> <li>The model correctly represents the negative regulation of TCR signaling pathway by ITPRIPL1</li> </ul>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#cellular-components","title":"Cellular Components","text":"<ul> <li>All activities have appropriate cellular component annotations</li> <li>The distinction between membrane-located and cytoplasmic activities is clear</li> </ul>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>The causal relationships correctly use appropriate relation terms:</li> <li>RO:0002630 (directly negatively regulates) for inhibitory actions</li> <li>RO:0002629 (directly positively regulates) for activating actions</li> <li>RO:0002407 (provides input for) for the connection between ITPRIPL1 and NCK1</li> </ul>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#evidence","title":"Evidence","text":"<ul> <li>All assertions are supported by evidence from the recent publication (PMID:38614099)</li> <li>The ZAP70-LAT relationship uses an older citation (PMID:9489702), which is appropriate as this is an established interaction in TCR signaling</li> </ul>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model accurately reflects the findings from the recent publication (PMID:38614099), which describes ITPRIPL1 as a novel ligand for CD3E that inhibits T cell activation. The key mechanisms represented are:</p> <ol> <li>ITPRIPL1 binding to CD3E on the cell surface</li> <li>This binding induces NCK1 recruitment to CD3E</li> <li>NCK1 prevents CD3E from interacting with ZAP70</li> <li>This disrupts the normal TCR signaling cascade (CD3E \u2192 LCK \u2192 ZAP70 \u2192 LAT \u2192 downstream signaling)</li> </ol> <p>The model correctly represents this newly discovered regulatory mechanism in a way that aligns with established knowledge of TCR signaling.</p>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, I have a few minor suggestions:</p> <ol> <li> <p>Additional Cellular Components: Consider adding more specific cellular components for activities where appropriate (e.g., immunological synapse for some of the signaling events)</p> </li> <li> <p>TCR Complex Representation: The model shows the T cell receptor complex (GO:0042101) with \"members:[]\". It might be beneficial to explicitly include the TCR complex members to provide a more complete representation.</p> </li> <li> <p>Downstream Signaling: The current model ends at LAT adaptor activity. To provide a more complete picture of the pathway, it could be extended to include some key downstream mediators of TCR signaling (e.g., PLC\u03b31, MAPK cascade components).</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002104-ITPRIPL1_is_a_ligand_of_CD3E_that_negatively_regulates_TCR_signaling_pathway___Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a high-quality GO-CAM model that effectively captures a recently discovered immunoregulatory mechanism. It is scientifically accurate, follows GO-CAM best practices, and presents a clear representation of how ITPRIPL1 negatively regulates T cell receptor signaling. The causal relationships between activities are appropriately represented, making the flow of biological information clear and interpretable.</p> <p>The model serves as an excellent representation of how ITPRIPL1 functions as an inhibitory ligand of CD3E, providing important context for understanding immune evasion mechanisms that may be relevant to cancer immunotherapy, as described in the source publication.</p>"},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/","title":"66a3e0bb00002740 TMEFF1 restricts herpes simplex virus 1  HHV 1  infection in the brain by blocking the association between NECTIN1 and the viral envelope glycoprotein D  Human","text":"<p>Let me review the information I've gathered about the GO-CAM model:</p>"},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#go-cam-model-review","title":"GO-CAM Model Review","text":""},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#model-id-gomodel66a3e0bb00002740","title":"Model ID: gomodel:66a3e0bb00002740","text":""},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#title","title":"Title:","text":"<p>TMEFF1 restricts herpes simplex virus 1 (HHV-1) infection in the brain by blocking the association between NECTIN1 and the viral envelope glycoprotein D (Human).</p>"},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#taxon","title":"Taxon:","text":"<p>Human (NCBITaxon:9606)</p>"},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#status","title":"Status:","text":"<p>Production</p>"},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#activities-in-the-model","title":"Activities in the model:","text":"<ol> <li>Activity 1 - Viral Glycoprotein D (gD)</li> <li>ID: gomodel:66a3e0bb00002740/66a3e0bb00002741</li> <li>Enabled by: UniProtKB:A1Z0Q5 (HSV-1 Envelope glycoprotein D)</li> <li>Molecular function: GO:0048018 (receptor ligand activity)</li> <li>Evidence: ECO:0000314 (direct assay evidence) from PMID:39048823 and PMID:39048830</li> <li>Occurs in: GO:0055036 (virion membrane)</li> <li>Part of: GO:0046718 (symbiont entry into host cell)</li> <li> <p>Causally associated with (RO:0002629 - directly positively regulates): Activity 3</p> </li> <li> <p>Activity 2 - TMEFF1</p> </li> <li>ID: gomodel:66a3e0bb00002740/66a3e0bb00002756</li> <li>Enabled by: UniProtKB:Q8IYR6 (Tomoregulin-1, TMEFF1)</li> <li>Molecular function: GO:0141069 (receptor ligand inhibitor activity)</li> <li>Evidence: ECO:0000314 (direct assay evidence) from PMID:39048823 and PMID:39048830</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0046597 (negative regulation of viral entry into host cell)</li> <li> <p>Causally associated with:</p> <ul> <li>RO:0002629 (directly positively regulates): Activity 1</li> <li>RO:0002630 (directly negatively regulates): Activity 1</li> </ul> </li> <li> <p>Activity 3 - NECTIN1</p> </li> <li>ID: gomodel:66a3e0bb00002740/66a3e0bb00002748</li> <li>Enabled by: UniProtKB:Q15223 (Nectin-1)</li> <li>Molecular function: GO:0001618 (virus receptor activity)</li> <li>Evidence: ECO:0000314 (direct assay evidence) from PMID:22146396</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0046718 (symbiont entry into host cell)</li> </ol>"},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#summary-of-scientific-content","title":"Summary of scientific content:","text":"<p>Based on the literature reviewed, this model represents how TMEFF1 acts as a restriction factor for HSV-1 infection in neurons. According to the recent papers (PMID:39048823 and PMID:39048830), TMEFF1 is a neuron-specific protein that blocks HSV-1 entry by interfering with the interaction between the viral glycoprotein D (gD) and its host cell receptor NECTIN1. </p> <p>The model shows that HSV-1 glycoprotein D acts as a ligand that binds to NECTIN1, which functions as a virus receptor. This interaction facilitates viral entry into host cells. TMEFF1 interferes with this process by binding to NECTIN1, preventing its association with viral gD and thereby inhibiting viral entry.</p>"},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#assessment-of-the-go-cam-model","title":"Assessment of the GO-CAM Model:","text":"<p>Let me thoroughly review this model against GO-CAM best practices and scientific accuracy.</p> <ol> <li> <p>Model structure and logical flow:     The model correctly represents the biological process of HSV-1 entry into cells and how TMEFF1 inhibits this process. The causal relationships between activities are appropriate.</p> </li> <li> <p>Molecular function annotation:</p> </li> <li> <p>The molecular function annotations are appropriate: gD as a receptor ligand, NECTIN1 as a virus receptor, and TMEFF1 as a receptor ligand inhibitor.</p> </li> <li> <p>Biological process annotation:</p> </li> <li> <p>The biological process annotations are appropriate: gD and NECTIN1 are part of \"symbiont entry into host cell\" while TMEFF1 is part of \"negative regulation of viral entry into host cell\".</p> </li> <li> <p>Cellular component annotation:</p> </li> <li>gD is correctly placed in the \"virion membrane\"</li> <li> <p>Both NECTIN1 and TMEFF1 are appropriately assigned to the \"plasma membrane\"</p> </li> <li> <p>Causal relationships:</p> </li> <li> <p>The relationships between activities are correctly represented:</p> <ul> <li>gD directly positively regulates NECTIN1's virus receptor activity</li> <li>TMEFF1 directly negatively regulates gD's ligand activity (by preventing gD-NECTIN1 interaction)</li> <li>TMEFF1 directly positively regulates gD's ligand activity (although this relationship needs closer examination)</li> </ul> </li> <li> <p>Evidence:</p> </li> <li>The model uses appropriate evidence codes (ECO:0000314 - direct assay evidence)</li> <li> <p>The evidence is based on recent publications that directly demonstrate these interactions</p> </li> <li> <p>Scientific accuracy:    The model accurately represents the biological mechanism described in the literature. The papers clearly show that TMEFF1 restricts HSV-1 infection by interfering with the interaction between gD and NECTIN1.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002740-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__infection_in_the_brain_by_blocking_the_association_between_NECTIN1_and_the_viral_envelope_glycoprotein_D__Human__/#concerns-and-recommendations","title":"Concerns and Recommendations:","text":"<ol> <li>Causal relationship between TMEFF1 and gD:</li> <li> <p>There's a potential contradiction in having TMEFF1 both positively and negatively regulate gD's ligand activity. Based on the literature, TMEFF1 should only negatively regulate the gD-NECTIN1 interaction, not positively regulate it. This should be reviewed.</p> </li> <li> <p>Cellular location for gD:</p> </li> <li> <p>gD is correctly located in the virion membrane, but for this model to show the interaction more clearly, it might be useful to also note that the interaction occurs at the host cell surface.</p> </li> <li> <p>Mechanism clarification:</p> </li> <li> <p>From the literature, TMEFF1 doesn't directly interact with gD but rather with NECTIN1, preventing gD from binding to NECTIN1. This mechanism could be more clearly represented in the model.</p> </li> <li> <p>Potential missing relationships:</p> </li> <li>The model could potentially benefit from showing a direct causal relationship between TMEFF1 and NECTIN1, since TMEFF1 physically interacts with NECTIN1.</li> </ol> <p>Based on this review, the GO-CAM model gomodel:66a3e0bb00002740 largely adheres to best practices and accurately represents the biological process. The only significant concern is the potentially contradictory causal relationship where TMEFF1 both positively and negatively regulates gD activity, which should be reviewed.</p>"},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/","title":"66a3e0bb00002776 TMEFF1 restricts herpes simplex virus 1  HHV 1  in the brain by blocking the association between MYH9 and the viral envelope glycoprotein B  Human","text":"<p>Based on all the information I've gathered, I'll now provide a thorough review of the GO-CAM model gomodel:66a3e0bb00002776.</p>"},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#review-of-go-cam-model-gomodel66a3e0bb00002776","title":"Review of GO-CAM Model gomodel:66a3e0bb00002776","text":""},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#model-overview","title":"Model Overview","text":"<p>Title: TMEFF1 restricts herpes simplex virus 1 (HHV-1) in the brain by blocking the association between MYH9 and the viral envelope glycoprotein B (Human).</p> <p>Model ID: gomodel:66a3e0bb00002776</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#model-content-and-scientific-basis","title":"Model Content and Scientific Basis","text":"<p>This GO-CAM represents how the human protein TMEFF1 (tomoregulin-1) functions as a restriction factor for herpes simplex virus 1 (HSV-1/HHV-1) in brain neurons. The model shows that TMEFF1 blocks the association between the human non-muscle myosin heavy chain 9 (MYH9/NMMHC-IIA) and the viral envelope glycoprotein B (gB), thereby preventing HSV-1 entry into cells.</p> <p>The model includes three key molecular activities:</p> <ol> <li>TMEFF1 (UniProtKB:Q8IYR6) has receptor ligand inhibitor activity (GO:0141069)</li> <li>HSV-1 gB (UniProtKB:P06436) has receptor ligand activity (GO:0048018)</li> <li>MYH9 (UniProtKB:P35579) has virus receptor activity (GO:0001618)</li> </ol> <p>The causal relationships in the model show that TMEFF1's receptor ligand inhibitor activity both positively and negatively regulates gB's receptor ligand activity, which in turn positively regulates MYH9's virus receptor activity.</p>"},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#scientific-evidence-and-literature-support","title":"Scientific Evidence and Literature Support","text":"<p>The model is based on two very recent papers from 2024 (PMID:39048823 and PMID:39048830), which identify TMEFF1 as a neuron-specific restriction factor for HSV-1. These papers demonstrate that:</p> <ol> <li>TMEFF1 is primarily expressed in neurons of the central nervous system</li> <li>TMEFF1 blocks HSV-1 entry into cells by interfering with the interaction between viral gB and cellular MYH9/NMMHC-IIA</li> <li>This mechanism restricts HSV-1 infection in the brain</li> </ol> <p>The model also references a 2010 paper (PMID:20944748) that established MYH9/NMMHC-IIA as a functional entry receptor for HSV-1 through interaction with viral gB.</p>"},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#review-comments","title":"Review Comments","text":""},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#strengths","title":"Strengths","text":"<ol> <li> <p>Timely and relevant representation: The model captures very recent scientific findings published in 2024 about a novel restriction factor for HSV-1 infection.</p> </li> <li> <p>Clear causal relationships: The model properly uses causal relations (RO:0002629 and RO:0002630) to show how TMEFF1 regulates the interaction between viral gB and cellular MYH9.</p> </li> <li> <p>Proper biological context: The model correctly places TMEFF1's activity in the plasma membrane (GO:0005886) and as part of the negative regulation of viral entry into host cell (GO:0046597) process, while also placing MYH9's activity on the cell surface (GO:0009986) and gB's activity in the virion membrane (GO:0055036).</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Dual regulation paradox: The model shows TMEFF1 both positively and negatively regulating gB's activity. Based on the literature, TMEFF1 should only negatively regulate this interaction, so the positive regulation causal relationship (<code>RO:0002629</code>) from TMEFF1's activity to gB's activity appears incorrect.</p> </li> <li> <p>Duplicate causal associations: There are two identical causal associations from gB's activity to MYH9's activity (both using <code>RO:0002629</code>), which is redundant and potentially confusing.</p> </li> <li> <p>Missing molecular interactions: The literature indicates that TMEFF1 interacts with NECTIN-1 (another HSV-1 receptor), but this interaction is not represented in the model. While this may be beyond the current scope, it would provide a more complete picture of TMEFF1's restriction mechanism.</p> </li> <li> <p>Cellular context specificity: The model could benefit from more specific cellular context annotations indicating that this mechanism is specific to neurons, perhaps by including a cell type annotation (e.g., CL:0000540 for neuron).</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Remove duplicate causal association: One of the two identical causal associations from gB to MYH9 should be removed.</p> </li> <li> <p>Correct causal relationships: Revise the causal relationship from TMEFF1 to gB to only use the negative regulation predicate (<code>RO:0002630</code>), removing the positive regulation (<code>RO:0002629</code>).</p> </li> <li> <p>Add cell type context: Consider adding CL:0000540 (neuron) as an additional context annotation to provide information about the cell-type specificity of this mechanism.</p> </li> <li> <p>Consider expanding the model: If appropriate, consider expanding the model to include other known interactions, such as TMEFF1's interaction with NECTIN-1, to provide a more comprehensive representation of the mechanism.</p> </li> <li> <p>Clarify molecular mechanism: The model could potentially benefit from annotations that better explain the molecular mechanism by which TMEFF1 inhibits the gB-MYH9 interaction (e.g., by adding information about TMEFF1's domains involved in this inhibition).</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002776-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH9_and_the_viral_envelope_glycoprotein_B__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model effectively represents a novel and important mechanism for the restriction of HSV-1 infection in neurons, based on very recent scientific literature. With a few minor corrections and potential enhancements, it will provide an accurate and valuable representation of this biological process. The model highlights the role of TMEFF1 as a neuron-specific HSV-1 restriction factor, which has significant implications for understanding the brain's intrinsic immunity against viral infections.</p>"},{"location":"reviews/66a3e0bb00002793-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH10_and_the_viral_envelope_glycoprotein_B__Human__/","title":"66a3e0bb00002793 TMEFF1 restricts herpes simplex virus 1  HHV 1  in the brain by blocking the association between MYH10 and the viral envelope glycoprotein B  Human","text":"<p>Based on the thorough review of this GO-CAM model and the related information, I can now provide a comprehensive assessment of GO-CAM model:66a3e0bb00002793.</p>"},{"location":"reviews/66a3e0bb00002793-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH10_and_the_viral_envelope_glycoprotein_B__Human__/#review-of-go-cam-model66a3e0bb00002793","title":"Review of GO-CAM model:66a3e0bb00002793","text":""},{"location":"reviews/66a3e0bb00002793-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH10_and_the_viral_envelope_glycoprotein_B__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model (gomodel:66a3e0bb00002793) represents a molecular interaction pathway describing how TMEFF1 restricts herpes simplex virus 1 (HSV-1) in the brain by blocking the association between MYH10 (non-muscle myosin heavy chain IIB) and the viral envelope glycoprotein B. The model consists of three main activities with causal associations between them.</p>"},{"location":"reviews/66a3e0bb00002793-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH10_and_the_viral_envelope_glycoprotein_B__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological coherence: The model accurately represents recently published scientific literature (PMID:39048823 and PMID:39048830) showing TMEFF1's role as a neuron-specific restriction factor for HSV-1.</p> </li> <li> <p>Appropriate connectivity: The causal flow from TMEFF1's receptor ligand inhibitor activity to glycoprotein B's receptor ligand activity and finally to MYH10's virus receptor activity follows a logical pathway consistent with the mechanism described in the literature.</p> </li> <li> <p>Proper cellular compartmentalization: Each activity is correctly annotated with its cellular location: TMEFF1 at the plasma membrane, glycoprotein B at the virion membrane, and MYH10 at the cell surface.</p> </li> <li> <p>Appropriate biological context: All activities are properly contextualized within the biological process of \"symbiont entry into host cell\" (GO:0046718), and for TMEFF1, additionally with \"negative regulation of viral entry into host cell\" (GO:0046597).</p> </li> <li> <p>Well-evidenced associations: Each activity and causal relationship is supported by appropriate evidence codes and references to primary literature.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002793-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH10_and_the_viral_envelope_glycoprotein_B__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Possible redundancy in causal associations: There are two identical causal associations from gB to MYH10 with the same predicate (RO:0002629) and the same evidence. This appears redundant and could be consolidated into a single association.</li> </ol> <pre><code>\"causal_associations\":[\n  {\"type\":\"CausalAssociation\",\"evidence\":[{\"term\":\"ECO:0000314\",\"reference\":\"PMID:20944748\",\"provenances\":[{\"contributor\":\"https://orcid.org/0000-0001-7299-6685\",\"date\":\"2024-08-08\"}]}],\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:66a3e0bb00002793/66a3e0bb00002794\"},\n  {\"type\":\"CausalAssociation\",\"evidence\":[{\"term\":\"ECO:0000314\",\"reference\":\"PMID:20944748\",\"provenances\":[{\"contributor\":\"https://orcid.org/0000-0001-7299-6685\",\"date\":\"2024-08-07\"}]}],\"predicate\":\"RO:0002629\",\"downstream_activity\":\"gomodel:66a3e0bb00002793/66a3e0bb00002794\"}\n]\n</code></pre> <ol> <li>Evidence code detail: While the model uses appropriate evidence codes, for some associations such as TMEFF1's occurrence in the plasma membrane (GO:0005886), the reference cited is PMID:39048830, but it might be beneficial to add more specific evidence beyond just the paper reference (e.g., specific figure or section of the paper that demonstrates this localization).</li> </ol>"},{"location":"reviews/66a3e0bb00002793-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH10_and_the_viral_envelope_glycoprotein_B__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li> <p>Complex annotation: The model appropriately represents activities of individual proteins rather than complexes, which is consistent with GO-CAM guidelines for cases where the specific subunits carrying the activities are known.</p> </li> <li> <p>Causal relationships: The model uses appropriate causal relationship predicates:</p> </li> <li>RO:0002630 \"directly negatively regulates\" from TMEFF1 to gB</li> <li> <p>RO:0002629 \"directly positively regulates\" from gB to MYH10</p> </li> <li> <p>Evidence codes: The model uses ECO:0000314 \"direct assay evidence used in manual assertion\" for molecular functions and causal associations, which is appropriate for these experimental findings.</p> </li> <li> <p>Location annotation: Each activity is appropriately annotated with its cellular location.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002793-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH10_and_the_viral_envelope_glycoprotein_B__Human__/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li> <p>Remove redundant causal association: The duplicate causal association from gB to MYH10 should be removed to maintain model parsimony.</p> </li> <li> <p>Consider adding sequence similarity evidence details: For gB's occurrence in \"virion membrane\" (GO:0055036), the evidence is listed as ECO:0000250 \"sequence similarity evidence used in manual assertion\" with reference to UniProt:P10211, but it might be helpful to provide additional context for this inference.</p> </li> <li> <p>Consider enhancing the model with additional interactions: Based on the literature (PMID:39048823), TMEFF1 also interacts with NECTIN-1, which is another HSV-1 receptor. This additional interaction could be incorporated into the model to provide a more complete representation of TMEFF1's mechanism of action in restricting HSV-1 entry.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002793-TMEFF1_restricts_herpes_simplex_virus_1__HHV_1__in_the_brain_by_blocking_the_association_between_MYH10_and_the_viral_envelope_glycoprotein_B__Human__/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model is well-constructed and faithfully represents the biological pathway of TMEFF1-mediated restriction of HSV-1 entry into neurons via inhibition of the interaction between viral glycoprotein B and MYH10. The model follows GO-CAM best practices for representing molecular activities and causal relationships. The minor issues identified, particularly the redundant causal association, could be addressed to further improve the model's quality and clarity.</p> <p>The model effectively captures the recent findings on TMEFF1's role as a neuron-specific restriction factor for HSV-1, making it a valuable resource for understanding viral entry mechanisms and host defense in the central nervous system.</p>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/","title":"66a3e0bb00002890 Thrombopoeitin mediated signaling pathway  Human","text":"<p>Based on my review of the GO-CAM model gomodel:66a3e0bb00002890 and related information, I can provide the following quality control assessment:</p>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#go-cam-model-review-gomodel66a3e0bb00002890","title":"GO-CAM Model Review: gomodel:66a3e0bb00002890","text":""},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#overview","title":"Overview","text":"<ul> <li>Title: Thrombopoietin-mediated signaling pathway (Human)</li> <li>Taxon: Homo sapiens (NCBITaxon:9606)</li> <li>Status: Production</li> <li>ID: gomodel:66a3e0bb00002890</li> </ul>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the thrombopoietin (TPO) signaling pathway in humans through the TPO receptor (MPL), illustrating a canonical cytokine signaling cascade through JAK2 and STAT5A. The model captures a linear causal sequence from TPO binding to its receptor, subsequent activation of JAK2 kinase, and ultimately STAT5A-mediated transcriptional regulation.</p>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model consists of 4 key molecular activities, all part of the thrombopoietin-mediated signaling pathway (GO:0038163):</p> <ol> <li>TPO (UniProtKB:P40225) - cytokine activity (GO:0005125)</li> <li>Occurs in: extracellular space (GO:0005615)</li> <li> <p>Causal relation: directly positively regulates MPL activity</p> </li> <li> <p>MPL/TPO Receptor (UniProtKB:P40238) - thrombopoietin receptor activity (GO:0038164)</p> </li> <li>Occurs in: plasma membrane (GO:0005886)</li> <li> <p>Causal relation: directly positively regulates JAK2 activity</p> </li> <li> <p>JAK2 (UniProtKB:O60674) - protein tyrosine kinase activity (GO:0004713)</p> </li> <li>Occurs in: cytoplasm (GO:0005737)</li> <li> <p>Causal relation: directly positively regulates STAT5A activity</p> </li> <li> <p>STAT5A (UniProtKB:P42229) - DNA-binding transcription factor activity (GO:0003700)</p> </li> <li>Occurs in: nucleus (GO:0005634)</li> </ol>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Correct biological pathway: The model accurately represents the canonical TPO signaling pathway with appropriate causal connections between TPO, its receptor MPL, JAK2, and STAT5A.</p> </li> <li> <p>Proper localization: All components have appropriate cellular locations (TPO in extracellular space, MPL at the plasma membrane, JAK2 in cytoplasm, and STAT5A in the nucleus).</p> </li> <li> <p>Appropriate causal relationships: The model uses \"directly positively regulates\" (RO:0002629) relations correctly to show the direct activation sequence.</p> </li> <li> <p>Evidential support: Each activity has appropriate evidence codes and literature references.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#potential-improvements","title":"Potential Improvements","text":"<ol> <li> <p>Inclusion of receptor dimerization: The current model does not explicitly capture the dimerization of MPL receptors, which is a critical mechanistic step in receptor activation. The latest research (PMID:37633268) shows that TPO bridges two MPL chains via high and low-affinity interfaces, which is important for signal transduction.</p> </li> <li> <p>JAK2 autophosphorylation: The model doesn't explicitly represent JAK2 autophosphorylation, which is a key step in JAK2 activation following receptor dimerization.</p> </li> <li> <p>STAT5 dimerization: STAT5 factors form dimers after phosphorylation by JAK2, before translocation to the nucleus. This step is not explicitly represented in the model.</p> </li> <li> <p>Missing complementary signaling pathways: TPO-MPL signaling activates multiple downstream pathways in addition to JAK-STAT, including MAPK/ERK and PI3K/AKT pathways (as evidenced in PMID:25538044), which contribute to the biological responses but aren't represented in this model.</p> </li> <li> <p>Complex representation: According to GO-CAM best practices for representing complexes, the model could potentially benefit from indicating whether activities are carried out by specific subunits or by the complex as a whole.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#literature-and-evidence-consistency","title":"Literature and Evidence Consistency","text":"<p>The model is well-supported by the cited literature: - PMID:25538044 confirms TPO interaction with MPL and downstream signaling - PMID:8007942 validates JAK2's tyrosine kinase activity in this pathway - PMID:10502458 confirms JAK2's cytoplasmic localization - PMID:9122198 supports involvement in the TPO signaling pathway - PMID:9516478 confirms STAT5A nuclear localization - PMID:10919676 validates STAT5A's role in cytokine signaling</p> <p>Recent literature (PMID:37633268) provides additional structural insights into TPO-MPL complex formation that could enhance the model.</p>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add receptor dimerization: Consider representing the TPO-induced dimerization of MPL receptors based on recent structural insights (PMID:37633268).</p> </li> <li> <p>Include additional signaling branches: Add parallel signaling cascades activated by TPO-MPL, particularly the PI3K/AKT and MAPK pathways, which play important roles in TPO-mediated megakaryopoiesis and stem cell maintenance.</p> </li> <li> <p>Represent protein modifications: Include phosphorylation events of JAK2 and STAT5A as these are critical for signal transduction.</p> </li> <li> <p>Add STAT5 dimerization: Include the dimerization of STAT5 after phosphorylation by JAK2.</p> </li> <li> <p>Consider biological outcomes: Add connections to biological processes that result from this signaling pathway, such as megakaryocyte differentiation or platelet production.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002890-Thrombopoeitin_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:66a3e0bb00002890 provides a good representation of the core TPO signaling pathway. It captures the essential components and causal relationships accurately with appropriate evidence. The model could be enhanced by incorporating more detailed mechanistic steps like receptor dimerization, protein modifications, and additional signaling branches to provide a more comprehensive representation of TPO signaling and its biological outcomes.</p>"},{"location":"reviews/66a3e0bb00002988-pteridine_containing_compound_metabolic_process__GO_0042558_/","title":"66a3e0bb00002988 pteridine containing compound metabolic process  GO 0042558","text":"<p>Based on the available documentation and my review, here's my assessment regarding GO-CAM best practices:</p>"},{"location":"reviews/66a3e0bb00002988-pteridine_containing_compound_metabolic_process__GO_0042558_/#assessment-according-to-go-cam-best-practices","title":"Assessment According to GO-CAM Best Practices:","text":"<ol> <li> <p>Molecular Activity Representation: The model correctly represents molecular activities linked to specific gene products, with appropriate GO molecular function terms.</p> </li> <li> <p>Complex Representation: The model appears to follow best practices by assigning molecular activities to specific gene products rather than complexes. However, one annotation (CHEBI:36080 \"protein\") should be replaced with a specific gene product or complex ID if possible.</p> </li> <li> <p>Causal Relationships: The model correctly uses the RO:0002413 (provides input for) relationship for metabolic pathways, showing the flow of activities and metabolites.</p> </li> <li> <p>Cellular Context: The model properly includes cellular context for activities (GO:0005737, GO:0005739, GO:0005829).</p> </li> <li> <p>Part_of Relationships: Each activity is properly associated with a biological process using part_of relationships.</p> </li> <li> <p>Evidence Codes: The model generally uses appropriate evidence codes, though there's room for improvement with more direct experimental evidence.</p> </li> </ol>"},{"location":"reviews/66a3e0bb00002988-pteridine_containing_compound_metabolic_process__GO_0042558_/#final-recommendations","title":"Final Recommendations:","text":"<ol> <li> <p>Address Missing Evidence: Add evidence to the activity for 6-pyruvoyltetrahydropterin synthase (GO:0003874).</p> </li> <li> <p>Specific Gene Product Assignment: Replace the generic \"protein\" (CHEBI:36080) annotation with a specific gene product if known.</p> </li> <li> <p>Additional Literature Support: Where possible, add more direct experimental evidence (PMIDs) to strengthen the model beyond orthology and sequence similarity evidence.</p> </li> <li> <p>Pathway Verification: Verify that the tetrahydrobiopterin pathway branch is accurately represented with all necessary intermediates and enzymes.</p> </li> <li> <p>Documentation: Consider adding a brief description or notes about the model to help users understand the biological significance of this pathway in S. pombe.</p> </li> </ol> <p>Overall, this is a well-structured GO-CAM model that effectively represents the pteridine-containing compound metabolic processes in fission yeast. With the minor improvements suggested above, it would be even more valuable to the scientific community.</p>"},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/","title":"66b5638000000056 GDP L fucose salvage   Mouse","text":"<p>Based on my review of the GO-CAM model for \"GDP-L-fucose salvage (Mouse)\" (gomodel:66b5638000000056), I'll provide a comprehensive QC assessment:</p>"},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/#go-cam-review-gdp-l-fucose-salvage-pathway-mouse","title":"GO-CAM Review: GDP-L-fucose Salvage Pathway (Mouse)","text":""},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/#model-id-gomodel66b5638000000056","title":"Model ID: gomodel:66b5638000000056","text":""},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model represents the GDP-L-fucose salvage pathway in mouse, showing how free fucose is taken up, phosphorylated, and converted to GDP-L-fucose for use in glycosylation. The model captures the key enzymes and transport steps in this pathway.</p>"},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model accurately represents the GDP-L-fucose salvage pathway as described in the literature, particularly in reference PMID:14686921, which describes the cloning and expression of murine L-fucokinase and GDP-L-fucose pyrophosphorylase. The specific sequence is well-supported:</p> <ol> <li>Fucose transport: SLC2A1 (GLUT1) transports L-fucose across the plasma membrane (based on PMID:36423686)</li> <li>Fucokinase activity: FCSK phosphorylates L-fucose to L-fucose-1-phosphate</li> <li>GDP-L-fucose pyrophosphorylase activity: FPGT converts L-fucose-1-phosphate to GDP-L-fucose </li> <li>GDP-L-fucose transport: SLC35C1 transports GDP-L-fucose to the Golgi apparatus</li> </ol> <p>The model also correctly includes FUOM (fucose mutarotase), which catalyzes the conversion of \u03b1-L-fucose to \u03b2-L-fucose, providing substrate for FCSK.</p>"},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li>Proper causal connections: The model uses RO:0002413 (\"provides input for\") appropriately to connect the activities in the pathway.</li> <li>Proper cellular component annotation: Each activity is annotated with the correct cellular component (cytosol, Golgi membrane, plasma membrane).</li> <li>Evidence codes: Appropriate evidence codes are used, including ECO:0000314 (direct assay) and ECO:0000315 (mutant phenotype).</li> <li>Input/output annotations: The chemical inputs and outputs are properly annotated for each reaction.</li> </ol>"},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, I identified a few areas for improvement:</p> <ol> <li> <p>Missing evidence for some inputs/outputs: Some of the molecular associations (for input/output molecules) lack evidence annotations. For example, in the FCSK activity (gomodel:66b5638000000056/66b5638000000080), inputs CHEBI:42589 and CHEBI:30616 have no evidence annotations.</p> </li> <li> <p>Missing cellular component annotation: The FPGT activity (gomodel:66b5638000000056/66b5638000000078) has a cellular component (GO:0005829 - cytosol) but lacks evidence annotation for this assertion.</p> </li> <li> <p>Suggestion for improved pathway flow: The model could be enhanced by explicitly connecting the initial transport activity (SLC2A1) to subsequent enzymes. Currently, SLC2A1 (GLUT1) is shown positively regulating FCSK, which is correct, but a clearer representation of how extracellular fucose enters the metabolic pathway might be beneficial.</p> </li> <li> <p>Complete the cycle: The model could potentially be expanded to show what happens to GDP-L-fucose after it's transported into the Golgi - i.e., its incorporation into glycoproteins and glycolipids.</p> </li> </ol>"},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/#literature-support","title":"Literature Support","text":"<p>The biological content of the model is well-supported by multiple publications:</p> <ul> <li>PMID:14686921 establishes the key enzymes of the salvage pathway</li> <li>PMID:36423686 documents SLC2A1 (GLUT1) as an L-fucose transporter</li> <li>PMID:17602138 and PMID:19524593 support the role of FUOM in the pathway</li> <li>PMID:17276979 supports the SLC35C1 GDP-fucose transporter function</li> </ul>"},{"location":"reviews/66b5638000000056-GDP_L_fucose_salvage___Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the GDP-L-fucose salvage pathway in mouse. It captures the key molecular activities, their correct sequence, and appropriate cellular locations. With minor improvements to evidence annotations and component locations, this would be an exemplary GO-CAM model for a metabolic pathway.</p> <p>The model successfully captures the conversion of extracellular L-fucose to intracellular GDP-L-fucose for use in glycosylation, with each step represented by the appropriate enzyme and molecular function.</p>"},{"location":"reviews/66b5638000000102-PVR_CD226_mediated_NK_cell_cytotoxicity__Human_/","title":"66b5638000000102 PVR CD226 mediated NK cell cytotoxicity  Human","text":"<p>Based on all the information gathered, I'll now review the GO-CAM model with ID gomodel:66b5638000000102.</p>"},{"location":"reviews/66b5638000000102-PVR_CD226_mediated_NK_cell_cytotoxicity__Human_/#review-of-go-cam-model-gomodel66b5638000000102-pvr-cd226-mediated-nk-cell-cytotoxicity-human","title":"Review of GO-CAM Model: gomodel:66b5638000000102 - \"PVR-CD226 mediated NK-cell cytotoxicity (Human)\"","text":""},{"location":"reviews/66b5638000000102-PVR_CD226_mediated_NK_cell_cytotoxicity__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>The model describes the PVR (CD155)-CD226 signaling pathway involved in natural killer (NK) cell cytotoxicity in humans. This signaling cascade is important for immune surveillance, particularly against tumor cells. The model captures:</p> <ol> <li>The interaction between PVR (CD155) on target cells and CD226 (DNAM-1) on NK cells</li> <li>The subsequent activation of GRB2 as a molecular adaptor</li> <li>GRB2's activation of VAV1, which functions as a guanyl-nucleotide exchange factor</li> <li>All these events occurring as part of natural killer cell-mediated cytotoxicity</li> </ol>"},{"location":"reviews/66b5638000000102-PVR_CD226_mediated_NK_cell_cytotoxicity__Human_/#detailed-review","title":"Detailed Review","text":""},{"location":"reviews/66b5638000000102-PVR_CD226_mediated_NK_cell_cytotoxicity__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the established molecular interactions in this pathway:</p> <ol> <li>PVR (P15151) functioning as a receptor ligand on target cells:</li> <li>PVR/CD155 is correctly annotated with receptor ligand activity (GO:0048018)</li> <li> <p>According to UniProt data, PVR indeed mediates NK cell adhesion and triggers NK cell effector functions by binding to CD226</p> </li> <li> <p>CD226 (Q15762) as the signaling receptor:</p> </li> <li>CD226/DNAM-1 is correctly annotated with signaling receptor activity (GO:0038023)</li> <li>CD226 is known to be an activation receptor on NK cells that binds PVR/CD155</li> <li> <p>The literature supports this interaction (PMID:15039383)</p> </li> <li> <p>GRB2 (P62993) as the adaptor protein:</p> </li> <li>GRB2 is correctly annotated with protein-macromolecule adaptor activity (GO:0030674)</li> <li>GRB2 is known to function downstream of CD226 activation</li> <li> <p>Its role in nucleating signaling complexes (PMID:25870599) aligns with its representation in the model</p> </li> <li> <p>VAV1 (P15498) as a GEF downstream of GRB2:</p> </li> <li>VAV1 is correctly annotated with guanyl-nucleotide exchange factor activity (GO:0005085)</li> <li> <p>VAV1 is known to be activated downstream of GRB2 in NK cell activation pathways</p> </li> <li> <p>Causal relationships:</p> </li> <li>The causal relationships using RO:0002629 (directly positively regulates) properly connect the activity flow from PVR to CD226 to GRB2 to VAV1</li> <li>This accurately represents the directional signal flow in the pathway</li> </ol>"},{"location":"reviews/66b5638000000102-PVR_CD226_mediated_NK_cell_cytotoxicity__Human_/#structural-review","title":"Structural Review","text":"<p>The model follows GO-CAM best practices for signaling pathways:</p> <ol> <li> <p>Enabled by associations: Each activity is correctly associated with the proteins that enable them</p> </li> <li> <p>Part of associations: All activities are appropriately designated as part of \"natural killer cell mediated cytotoxicity\" (GO:0042267)</p> </li> <li> <p>Occurs in associations: Proper cellular compartments are specified:</p> </li> <li>PVR and CD226 at the plasma membrane (GO:0005886)</li> <li> <p>GRB2 and VAV1 in the cytoplasm (GO:0005737)</p> </li> <li> <p>Causal associations: The direct positive regulation (RO:0002629) is correctly used to connect sequential activities in the pathway</p> </li> <li> <p>Evidence codes: Appropriate evidence codes are used with relevant PMIDs for each assertion</p> </li> </ol>"},{"location":"reviews/66b5638000000102-PVR_CD226_mediated_NK_cell_cytotoxicity__Human_/#suggested-improvements","title":"Suggested Improvements","text":"<p>While the model is generally well-constructed, I have the following suggestions for improvement:</p> <ol> <li>More detailed mechanistic representation:</li> <li> <p>Consider representing the phosphorylation events involved. Based on the literature, CD226 engagement leads to tyrosine phosphorylation and recruitment of GRB2. This molecular detail could be added.</p> </li> <li> <p>Additional pathway components:</p> </li> <li>The role of LFA-1, which cooperates with CD226 in triggering cytotoxicity (as mentioned in PMID:15039383), could be incorporated.</li> <li> <p>The connection to downstream effector mechanisms of NK cell cytotoxicity (perforin/granzyme release) could be added to make the model more complete.</p> </li> <li> <p>Complex formation:</p> </li> <li>According to the \"How to annotate complexes in GO-CAM\" document, if specific activities are carried out by a complex (rather than individual proteins), this should be represented. </li> <li> <p>The literature suggests that CD226 forms complexes with other molecules upon activation, which could be captured.</p> </li> <li> <p>Downstream consequences:</p> </li> <li>The model could be extended to include the ultimate outcomes of this pathway, such as target cell lysis or cytokine production.</li> </ol>"},{"location":"reviews/66b5638000000102-PVR_CD226_mediated_NK_cell_cytotoxicity__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"PVR-CD226 mediated NK-cell cytotoxicity (Human)\" (gomodel:66b5638000000102) provides an accurate representation of the core signaling pathway from PVR-CD226 interaction to VAV1 activation in NK cell-mediated cytotoxicity. The model adheres to GO-CAM best practices and is well-supported by scientific literature.</p> <p>The model could be enhanced by adding more molecular details of the activation events, representing relevant protein complexes, and extending the pathway to include additional cooperating receptors and downstream effects. Nevertheless, in its current form, it provides a valuable representation of this important immune surveillance pathway.</p>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/","title":"66b5638000000624 Activation of the integrated stress response via activation of EIF2AK3 PERK in response to unfolded protein response  Human","text":"<p>Based on my review of the GO-CAM model and supporting literature, I will now provide a comprehensive assessment of this model.</p>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#review-of-go-cam-model-gomodel66b5638000000624","title":"Review of GO-CAM Model: gomodel:66b5638000000624","text":""},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#model-overview","title":"Model Overview","text":"<p>Title: Activation of the integrated stress response via activation of EIF2AK3/PERK in response to unfolded protein response (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents the PERK-mediated unfolded protein response (UPR) pathway, a branch of the integrated stress response (ISR). The model depicts how endoplasmic reticulum (ER) stress activates EIF2AK3/PERK, which then phosphorylates and inhibits eIF2\u03b1 (EIF2S1), leading to the translation of specific stress-responsive mRNAs including ATF4, which functions as a transcription factor in the nucleus to activate stress response genes.</p>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model accurately captures the key molecular events in the PERK-mediated UPR pathway.</li> <li>The causal relationships between activities are appropriately represented with the correct predicates.</li> <li>The model is well-supported by the scientific literature (PMIDs).</li> <li>All activities are localized to the correct cellular compartments.</li> <li>The model clearly indicates the biological processes each molecular function is part of.</li> </ol>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#components-of-the-model","title":"Components of the Model","text":"<p>The model includes four key molecular activities:</p> <ol> <li> <p>EIF2AK3/PERK kinase activity (GO:0004694) enabled by UniProtKB:Q9NZJ5, occurring in the ER membrane (GO:0005789), part of the PERK-mediated UPR (GO:0036499).</p> </li> <li> <p>EIF2S1/eIF2\u03b1 translation initiation factor activity (GO:0003743) enabled by UniProtKB:P05198, occurring in the cytosol (GO:0005829), part of translational initiation (GO:0006413). This appears in two instances in the model - one active and one inhibited.</p> </li> <li> <p>ATF4 transcription factor activity (GO:0003700) enabled by UniProtKB:P18848, occurring in the nucleus (GO:0005634), part of the PERK-mediated UPR (GO:0036499).</p> </li> </ol>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#causal-relationships","title":"Causal Relationships","text":"<p>The model uses appropriate causal predicates: - PERK (EIF2AK3) directly positively regulates (RO:0002629) EIF2S1/eIF2\u03b1 - PERK (EIF2AK3) directly negatively regulates (RO:0002630) EIF2S1/eIF2\u03b1 - EIF2S1/eIF2\u03b1 indirectly provides input for (RO:0002407) ATF4 transcription factor activity</p>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#conformance-to-go-cam-best-practices","title":"Conformance to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li>Using appropriate activity terms for each protein</li> <li>Correctly representing the cellular locations of each activity</li> <li>Using the appropriate causal predicates for signaling relationships</li> <li>Including supporting evidence from the literature for each assertion</li> <li>Properly connecting activities to the relevant biological processes</li> </ol>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Clarify Dual Regulation of EIF2S1: The model shows PERK both positively and negatively regulating EIF2S1. While this reflects the biological reality (PERK phosphorylates eIF2\u03b1, which inhibits general translation but selectively enhances translation of specific mRNAs like ATF4), it might be clearer to annotate these distinct activities more explicitly. The model shows two EIF2S1 nodes with the same GO term (GO:0003743), but perhaps these could be annotated differently to better distinguish between the two states or activities.</p> </li> <li> <p>Expand Downstream Effects: The model could be expanded to include more downstream effects of ATF4 activation, such as the transcriptional activation of specific target genes (e.g., CHOP/DDIT3, GADD34/PPP1R15A) that are important in the integrated stress response.</p> </li> <li> <p>Include Regulatory Mechanisms: The model could include more detail about how PERK itself is activated, such as its dimerization/oligomerization and autophosphorylation in response to ER stress, as well as its regulation by BiP/GRP78.</p> </li> <li> <p>Connection to Other UPR Branches: The model focuses on the PERK branch of the UPR, but connections to the other branches (IRE1 and ATF6) could be included to provide a more comprehensive view of the UPR.</p> </li> </ol>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#accuracy-of-the-biology","title":"Accuracy of the Biology","text":"<p>The model accurately reflects the current understanding of the PERK-mediated UPR pathway as described in the literature:</p> <ol> <li>PERK is correctly shown as a kinase activated by ER stress</li> <li>PERK phosphorylates eIF2\u03b1, which both inhibits general protein translation and selectively enhances translation of specific mRNAs like ATF4</li> <li>ATF4 is accurately depicted as a transcription factor that operates in the nucleus to activate stress response genes</li> <li>The cellular locations of these activities are accurate: PERK in the ER membrane, eIF2\u03b1 in the cytosol, and ATF4 in the nucleus</li> </ol> <p>The evidence cited (PMIDs 16289705, 10026192, 11960987, 15109498, 23123191, 31023583, and 32132707) provides strong support for the relationships depicted in the model.</p>"},{"location":"reviews/66b5638000000624-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response__Human__/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:66b5638000000624 is a high-quality representation of the PERK-mediated unfolded protein response pathway. It accurately captures the key molecular events, their causal relationships, and cellular locations. The model is well-supported by scientific evidence and conforms to GO-CAM best practices. While there are opportunities to expand the model to include more details and connections, the current model provides a clear and accurate representation of this important stress response pathway.</p>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/","title":"66b5638000000739 Inhibition of the PERK mediated unfolded protein response by HSPA5 BiP in absence of stress  Human","text":"<p>Based on the information gathered, I'll now provide a detailed review of the GO-CAM model gomodel:66b5638000000739.</p>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#review-of-go-cam-model-66b5638000000739","title":"Review of GO-CAM Model: 66b5638000000739","text":""},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#model-overview","title":"Model Overview","text":"<p>Title: \"Inhibition of the PERK-mediated unfolded protein response by HSPA5/BiP in absence of stress (Human).\"</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>Link to model</p>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#biological-process-context","title":"Biological Process Context","text":"<p>This model represents the inhibition of the PERK-mediated unfolded protein response by HSPA5/BiP (Binding immunoglobulin Protein, also known as GRP78) in the absence of stress in humans. The PERK-mediated unfolded protein response is a critical cellular pathway that responds to endoplasmic reticulum (ER) stress by phosphorylating eIF2\u03b1 to attenuate general protein translation while upregulating specific stress-response genes.</p>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#components-and-activities-in-the-model","title":"Components and Activities in the Model","text":"<p>The model captures five main molecular activities and their causal relationships:</p> <ol> <li>HSPA5/BiP (P11021) - Protein serine/threonine kinase inhibitor activity</li> <li>Occurs in: Cytosol (GO:0005829)</li> <li>Part of: Negative regulation of PERK-mediated unfolded protein response (GO:1903898)</li> <li> <p>Causal relationship: Directly negatively regulates (RO:0002630) EIF2AK3/PERK kinase activity</p> </li> <li> <p>EIF2AK3/PERK (Q9NZJ5) - Eukaryotic translation initiation factor 2alpha kinase activity</p> </li> <li>Occurs in: Endoplasmic reticulum membrane (GO:0005789)</li> <li>Part of: PERK-mediated unfolded protein response (GO:0036499)</li> <li> <p>Causal relationships:</p> <ul> <li>Directly positively regulates (RO:0002629) EIF2S1/eIF-2-alpha active form</li> <li>Directly negatively regulates (RO:0002630) EIF2S1/eIF-2-alpha inactive form</li> </ul> </li> <li> <p>EIF2S1/eIF-2-alpha (P05198) - Translation initiation factor activity (inactive form)</p> </li> <li>Occurs in: Cytosol (GO:0005829)</li> <li> <p>Part of: Translational initiation (GO:0006413)</p> </li> <li> <p>EIF2S1/eIF-2-alpha (P05198) - Translation initiation factor activity (active form)</p> </li> <li>Occurs in: Cytosol (GO:0005829)</li> <li>Part of: Translational initiation (GO:0006413)</li> <li> <p>Causal relationship: Provides input for (RO:0002407) ATF4 transcription factor activity</p> </li> <li> <p>ATF4 (P18848) - DNA-binding transcription factor activity</p> </li> <li>Occurs in: Nucleus (GO:0005634)</li> <li>Part of: PERK-mediated unfolded protein response (GO:0036499)</li> </ol>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#assessment-of-model-accuracy","title":"Assessment of Model Accuracy","text":""},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#1-biological-content-accuracy","title":"1. Biological Content Accuracy","text":"<p>The model accurately represents the established mechanism of PERK regulation by BiP/HSPA5 in the absence of stress. The literature and UniProt entries confirm that:</p> <ul> <li>HSPA5/BiP interacts with and inhibits PERK in the absence of stress (verified in UniProt P11021 and PMID:11907036)</li> <li>When ER stress occurs, HSPA5/BiP dissociates from PERK, allowing PERK activation (autophosphorylation and dimerization)</li> <li>Activated PERK phosphorylates eIF2\u03b1 at Ser-52</li> <li>Phosphorylated eIF2\u03b1 reduces general translation but selectively enhances translation of specific mRNAs including ATF4</li> <li>ATF4 activates genes involved in the unfolded protein response</li> </ul> <p>The model correctly shows BiP as a negative regulator of PERK in unstressed conditions, and the downstream consequences through eIF2\u03b1 phosphorylation to ATF4 activation.</p>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#2-go-cam-best-practices-compliance","title":"2. GO-CAM Best Practices Compliance","text":"<p>The model follows GO-CAM best practices:</p> <ul> <li>Molecular Functions: Each protein has appropriate molecular functions assigned</li> <li>Causal Relationships: The model uses appropriate causal relationship predicates:</li> <li>\"Directly negatively regulates\" (RO:0002630) for BiP inhibition of PERK</li> <li>\"Directly positively regulates\" (RO:0002629) for PERK activation of eIF2\u03b1</li> <li>\"Provides input for\" (RO:0002407) for eIF2\u03b1's effect on ATF4</li> <li>Cellular Locations: Activities are assigned to correct cellular compartments:</li> <li>PERK at the ER membrane</li> <li>eIF2\u03b1 in the cytosol</li> <li>ATF4 in the nucleus</li> <li>BiP in the cytosol (though BiP is primarily an ER protein, it can be found in the cytosol where it would interact with the cytosolic domain of PERK)</li> <li>Biological Processes: Activities are correctly associated with relevant biological processes</li> </ul>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#3-activity-flow-and-connectivity","title":"3. Activity Flow and Connectivity","text":"<p>The activity flow is logically connected and follows the established sequence of events in the PERK pathway:</p> <ol> <li>BiP inhibits PERK activity (under unstressed conditions)</li> <li>PERK, when active, phosphorylates eIF2\u03b1 (not shown during unstressed conditions)</li> <li>Phosphorylated eIF2\u03b1 leads to ATF4 translation and transcriptional activity</li> </ol>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#4-evidence-support","title":"4. Evidence Support","text":"<p>Each activity and causal relationship is supported by appropriate evidence and literature references:</p> <ul> <li>PMID:10026192 and PMID:10677345 are cited for PERK kinase activity</li> <li>PMID:11907036 is cited for BiP inhibition of PERK</li> <li>PMID:16289705 is cited for eIF2\u03b1's role in translation initiation</li> <li>PMID:11960987, PMID:15109498, PMID:23123191, and PMID:32132707 are cited for ATF4's transcription factor activity</li> </ul>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<ol> <li> <p>Representation of Stress Conditions: Since this model focuses on the unstressed state, it might be valuable to create a companion model showing the pathway under ER stress conditions. This would provide a complete picture of the PERK-mediated UPR.</p> </li> <li> <p>Additional Molecular Details: </p> </li> <li>The model could include the role of PERK dimerization and autophosphorylation in its activation</li> <li>The phosphorylation site on eIF2\u03b1 (Ser-52) could be explicitly noted</li> <li> <p>The mediating role of eIF2B in the translation initiation process could be included</p> </li> <li> <p>Downstream Effects: </p> </li> <li>The model could be extended to include specific genes activated by ATF4 during UPR</li> <li> <p>The feedback mechanism involving GADD34 (PPP1R15A) could be included to show pathway attenuation</p> </li> <li> <p>BiP Location: While BiP is shown in the cytosol, it is primarily an ER lumen protein that interacts with the luminal domain of PERK. The model could better specify that BiP is binding to the luminal domain of PERK.</p> </li> </ol>"},{"location":"reviews/66b5638000000739-Inhibition_of_the_PERK_mediated_unfolded_protein_response_by_HSPA5_BiP_in_absence_of_stress__Human__/#final-assessment","title":"Final Assessment","text":"<p>This GO-CAM model (gomodel:66b5638000000739) provides an accurate representation of the regulatory relationship between BiP/HSPA5 and the PERK-mediated unfolded protein response under unstressed conditions. It correctly captures the key molecular functions, causal relationships, and cellular locations of the involved proteins.</p> <p>The model is well-supported by evidence from the literature and follows GO-CAM best practices. It presents a clear, parsimonious view of this important regulatory mechanism that would be understandable to researchers in the field.</p> <p>For a complete understanding of the PERK pathway, I would recommend creating a complementary model showing the pathway's behavior under ER stress conditions, which would highlight the dynamic nature of this stress response pathway and its regulation.</p>"},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/","title":"66b5638000000808 Ubiquitination and degradation of NFE2L2 NRF2 by KEAP1 in absence of stress  Human","text":"<p>Now let me review the GO-CAM model gomodel:66b5638000000808 and check if it follows GO-CAM best practices.</p>"},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#go-cam-model-review-gomodel66b5638000000808","title":"GO-CAM Model Review: gomodel:66b5638000000808","text":""},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:66b5638000000808</li> <li>Title: Ubiquitination and degradation of NFE2L2/NRF2 by KEAP1 in absence of stress (Human).</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the ubiquitination and degradation pathway of the NFE2L2/NRF2 transcription factor mediated by the KEAP1-CUL3-RBX1 E3 ubiquitin ligase complex under non-stress conditions in humans. The model includes four key proteins involved in this pathway:</p> <ol> <li>KEAP1 (UniProtKB:Q14145) - acts as a ubiquitin-like ligase-substrate adaptor</li> <li>CUL3 (UniProtKB:Q13618) - provides ubiquitin ligase complex scaffold activity</li> <li>RBX1 (UniProtKB:P62877) - provides E3 ubiquitin-protein ligase activity</li> <li>NFE2L2/NRF2 (UniProtKB:Q16236) - the target transcription factor being regulated</li> </ol>"},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the known biological process of NFE2L2/NRF2 regulation:</p> <ul> <li>Under non-stress conditions, KEAP1 binds to NFE2L2/NRF2 and targets it for ubiquitination and degradation through the CUL3-RBX1 E3 ubiquitin ligase complex</li> <li>The model properly captures the repressive effect of this complex on NFE2L2/NRF2 DNA-binding transcription factor activity</li> <li>All interactions are supported by evidence from literature (primarily PMID:15601839)</li> </ul>"},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#go-cam-structure-and-connections","title":"GO-CAM Structure and Connections","text":"<p>The model follows the GO-CAM best practices for representing protein complexes:</p> <ol> <li>Appropriate representation of complex components:</li> <li>Each component of the BCR(KEAP1) complex has a defined and precise molecular function</li> <li> <p>The model correctly represents individual components rather than using a complex GO ID, which aligns with best practice #1 from the complex annotation guidelines</p> </li> <li> <p>Causal connections:</p> </li> <li>The causal flow is properly represented: KEAP1 activity \u2192 RBX1 activity \u2192 negative regulation of NFE2L2 activity</li> <li> <p>The model uses appropriate causal relationship predicates:</p> <ul> <li><code>RO:0002629</code> (directly positively regulates) from KEAP1 to RBX1</li> <li><code>RO:0002630</code> (directly negatively regulates) from RBX1 to NFE2L2</li> </ul> </li> <li> <p>Cellular context:</p> </li> <li>All activities are correctly annotated with their cellular locations</li> <li>KEAP1 and RBX1 activities occur in the cytoplasm (GO:0005737)</li> <li> <p>NFE2L2 activity occurs in the nucleus (GO:0005634)</p> </li> <li> <p>Biological process context:</p> </li> <li>KEAP1 and RBX1 activities are part of the proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</li> <li>NFE2L2 activity is part of the response to oxidative stress (GO:0006979)</li> </ol>"},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#evidence-and-provenance","title":"Evidence and Provenance","text":"<p>All assertions in the model are supported with appropriate evidence and provenance:</p> <ul> <li>All activities and relationships cite direct experimental evidence (ECO:0000314)</li> <li>The primary reference (PMID:15601839) supports the key interactions</li> <li>Additional references provide supporting evidence for specific activities</li> <li>All annotations include proper provenance information with contributor ORCID</li> </ul>"},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#recommendations","title":"Recommendations","text":"<p>The model is well-constructed and follows GO-CAM best practices. There are no significant issues that require correction. Here are some minor suggestions for potential enhancement:</p> <ol> <li> <p>Possible addition: The model could be expanded to include the mechanism of NFE2L2/NRF2 stabilization under stress conditions, which would provide a more complete picture of this regulatory pathway.</p> </li> <li> <p>More detailed cellular location: While the current cellular locations are correct, more specific subcellular locations could be considered if supported by evidence.</p> </li> </ol>"},{"location":"reviews/66b5638000000808-Ubiquitination_and_degradation_of_NFE2L2_NRF2_by_KEAP1_in_absence_of_stress__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:66b5638000000808 accurately represents the KEAP1-mediated ubiquitination and degradation of NFE2L2/NRF2 in the absence of stress. The model follows GO-CAM best practices for:</p> <ol> <li>Representing complex components with their individual molecular functions</li> <li>Using appropriate causal relationships</li> <li>Including cellular context</li> <li>Providing biological process context</li> <li>Supporting assertions with appropriate evidence</li> </ol> <p>The model is of high quality and provides a clear representation of this important regulatory pathway. It correctly shows how the KEAP1-CUL3-RBX1 complex regulates NFE2L2/NRF2 activity and provides valuable information about this critical pathway involved in the cellular response to oxidative stress.</p>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/","title":"66b5638000000873 EIF2AK3 PERK phosphorylates NFE2L2 NRF2 in response to unfolded protein response  preventing the ubiquitination of NFE2L2 NRF2 by KEAP1  Human","text":"<p>Now that I've gathered the necessary information, I'll review the GO-CAM model gomodel:66b5638000000873.</p>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#review-of-go-cam-model-66b5638000000873","title":"Review of GO-CAM Model: 66b5638000000873","text":""},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#model-overview","title":"Model Overview","text":"<p>Title: EIF2AK3/PERK phosphorylates NFE2L2/NRF2 in response to unfolded protein response, preventing the ubiquitination of NFE2L2/NRF2 by KEAP1 (Human).</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM represents a pathway where EIF2AK3/PERK (pancreatic eIF-2\u03b1 kinase) phosphorylates NFE2L2/NRF2 during the unfolded protein response, which prevents NFE2L2/NRF2 from being ubiquitinated by the KEAP1-RBX1 complex. This allows NFE2L2/NRF2 to translocate to the nucleus where it can function as a DNA-binding transcription factor involved in the response to oxidative stress.</p>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#components-and-activities-in-the-model","title":"Components and Activities in the Model","text":"<p>The model describes four main activities:</p> <ol> <li>EIF2AK3 (UniProtKB:Q9NZJ5) - Protein serine/threonine kinase activity (GO:0004674)</li> <li>Part of the PERK-mediated unfolded protein response (GO:0036499)</li> <li> <p>Evidence: Sequence similarity evidence (ECO:0000250) with mouse gene (MGI:1341830)</p> </li> <li> <p>KEAP1 (UniProtKB:Q14145) - Ubiquitin-like ligase-substrate adaptor activity (GO:1990756)</p> </li> <li>Occurs in the cytoplasm (GO:0005737)</li> <li> <p>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</p> </li> <li> <p>RBX1 (UniProtKB:P62877) - Ubiquitin protein ligase activity (GO:0061630)</p> </li> <li>Occurs in the cytoplasm (GO:0005737)</li> <li> <p>Part of proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)</p> </li> <li> <p>NFE2L2/NRF2 (UniProtKB:Q16236) - DNA-binding transcription factor activity (GO:0003700)</p> </li> <li>Occurs in the nucleus (GO:0005634)</li> <li>Part of response to oxidative stress (GO:0006979)</li> </ol>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#causal-relationships","title":"Causal Relationships","text":"<ol> <li> <p>EIF2AK3 \u2192 KEAP1: EIF2AK3 phosphorylation activity [RO:0012010] enables KEAP1's ubiquitin-like ligase-substrate adaptor activity.</p> </li> <li> <p>KEAP1 \u2192 RBX1: KEAP1 directly positively regulates [RO:0002629] RBX1's ubiquitin protein ligase activity.</p> </li> <li> <p>RBX1 \u2192 NFE2L2: RBX1 directly negatively regulates [RO:0002630] NFE2L2's DNA-binding transcription factor activity.</p> </li> </ol>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#evidence-and-references","title":"Evidence and References","text":"<p>The model is supported by several primary research articles: - PMID:10026192 - Characterization of PERK and its functions in pancreatic islets - PMID:15601839 - KEAP1 targeting NRF2 for ubiquitination - PMID:27708159 - Subcellular localization information - PMID:36075446 - NRF2's role in oxidative stress response - PMID:20452972 - Additional information on the NRF2 pathway</p>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#model-quality-assessment","title":"Model Quality Assessment","text":""},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#strengths","title":"Strengths:","text":"<ol> <li>Appropriate evidence usage: The model uses appropriate evidence codes and references for each assertion.</li> <li>Cellular compartments: The model correctly captures the relevant cellular locations for each protein (cytoplasm for KEAP1/RBX1 and nucleus for NFE2L2).</li> <li>Biological accuracy: The representation of PERK-mediated NFE2L2 activation is consistent with the literature. Under ER stress, PERK phosphorylates NFE2L2, preventing its degradation by the KEAP1-CUL3-RBX1 complex.</li> <li>Correct use of causal relationships: The model uses appropriate relationship predicates to represent the regulatory connections.</li> </ol>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Additional upstream regulators: The model could benefit from including what activates EIF2AK3/PERK initially (unfolded proteins in the ER).</li> <li>Missing CUL3 component: The BCR(KEAP1) complex typically includes CUL3 as a core component along with KEAP1 and RBX1, but CUL3 is not included in this model.</li> <li>Missing downstream targets: The model ends with NFE2L2's transcription factor activity but doesn't include its downstream target genes that are involved in the antioxidant response.</li> <li>Regulatory detail: The model doesn't specify the mechanism by which PERK phosphorylation of NFE2L2 prevents KEAP1-mediated ubiquitination.</li> </ol>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#conformity-with-go-cam-best-practices","title":"Conformity with GO-CAM Best Practices","text":"<p>The model follows key best practices by: - Using appropriate GO terms for molecular functions - Connecting activities with causal relationships - Including cellular compartment information - Providing proper evidence codes and references</p>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#biological-consistency","title":"Biological Consistency","text":"<p>The model accurately represents the known biology of the PERK-NFE2L2-KEAP1 pathway: 1. The PERK kinase is activated during the unfolded protein response. 2. PERK phosphorylates NFE2L2, which prevents its degradation by the KEAP1-RBX1 ubiquitin ligase complex. 3. This allows NFE2L2 to accumulate and translocate to the nucleus where it functions as a transcription factor involved in the oxidative stress response.</p> <p>The relationship between EIF2AK3 and NFE2L2 is biologically consistent with literature showing that PERK activation during ER stress leads to NFE2L2 phosphorylation and subsequent activation.</p>"},{"location":"reviews/66b5638000000873-EIF2AK3_PERK_phosphorylates_NFE2L2_NRF2_in_response_to_unfolded_protein_response__preventing_the_ubiquitination_of_NFE2L2_NRF2_by_KEAP1__Human__/#conclusions-and-recommendations","title":"Conclusions and Recommendations","text":"<p>This is a solid GO-CAM model representing the PERK-NFE2L2-KEAP1 pathway in humans. It accurately captures the core components and relationships in this pathway, which is important for the cellular response to both ER stress and oxidative stress.</p> <p>Recommendations for improvement: 1. Add CUL3 as a component of the BCR(KEAP1) complex for a more complete representation. 2. Include some downstream target genes of NFE2L2 to better represent the antioxidant response. 3. Specify the phosphorylation sites on NFE2L2 targeted by PERK if known. 4. Add more detailed information about the cellular conditions that activate PERK (accumulation of unfolded proteins in the ER).</p> <p>Overall, this model effectively represents an important pathway involved in the cellular stress response and has a good foundation that can be expanded to include additional regulatory details and downstream effectors.</p>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/","title":"66b5638000001291 NECTIN2 CD226 mediated NK cell cytotoxicity  Human","text":"<p>Now that I have gathered all the necessary information, I will conduct a comprehensive review of the GO-CAM model <code>gomodel:66b5638000001291</code>.</p>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#review-of-go-cam-model-gomodel66b5638000001291","title":"Review of GO-CAM Model: gomodel:66b5638000001291","text":""},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#model-overview","title":"Model Overview","text":"<p>Title: NECTIN2-CD226 mediated NK-cell cytotoxicity (Human) Taxon: Human (NCBITaxon:9606) Status: Production Model ID: gomodel:66b5638000001291</p> <p>This model describes the molecular interactions involved in natural killer (NK) cell-mediated cytotoxicity through the NECTIN2 (CD112) and CD226 (DNAM-1) receptor-ligand pathway, leading to GRB2 adaptor protein recruitment and subsequent VAV1 activation.</p>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#components-of-the-model","title":"Components of the Model","text":"<p>The model consists of four main molecular activities:</p> <ol> <li>NECTIN2 (Q92692): Receptor ligand activity (GO:0048018)</li> <li>CD226 (Q15762): Signaling receptor activity (GO:0038023)</li> <li>GRB2 (P62993): Protein-macromolecule adaptor activity (GO:0030674)</li> <li>VAV1 (P15498): Guanyl-nucleotide exchange factor activity (GO:0005085)</li> </ol> <p>All these components participate in the biological process of natural killer cell-mediated cytotoxicity (GO:0042267).</p>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The model shows three causal relationships with \"directly positively regulates\" (RO:0002629) predicate: 1. NECTIN2 (receptor ligand) \u2192 CD226 (signaling receptor) 2. CD226 (signaling receptor) \u2192 GRB2 (adaptor protein) 3. GRB2 (adaptor protein) \u2192 VAV1 (guanyl-nucleotide exchange factor)</p> <p>This creates a linear signaling cascade where NECTIN2 binding to CD226 triggers downstream adaptor protein recruitment and eventual activation of VAV1.</p>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#cellular-locations","title":"Cellular Locations","text":"<ul> <li>NECTIN2 activity occurs at the plasma membrane (GO:0005886)</li> <li>CD226 activity occurs at the plasma membrane (GO:0005886)</li> <li>GRB2 activity occurs in the cytoplasm (GO:0005737)</li> <li>VAV1 activity occurs in the cytoplasm (GO:0005737)</li> </ul>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>Each activity and causal relationship is supported by experimental evidence:</p> <ul> <li>The NECTIN2-CD226 interaction is supported by direct assay evidence (ECO:0000314) from PMID:15607800</li> <li>CD226's signaling activity is supported by direct assay evidence (ECO:0000314) from PMID:15039383</li> <li>GRB2's adaptor function is supported by direct assay evidence (ECO:0000314) from PMID:25870599</li> <li>VAV1's GEF activity is supported by direct assay evidence (ECO:0000314) from PMID:8990121</li> </ul>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#biological-significance","title":"Biological Significance","text":"<p>This model captures an important biological pathway in NK cell activation. When NECTIN2 (CD112) on a target cell binds to CD226 (DNAM-1) on an NK cell, it triggers a signaling cascade that contributes to natural killer cell-mediated cytotoxicity. This interaction is particularly important in immune surveillance against tumor cells that express NECTIN2.</p>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#model-quality-assessment","title":"Model Quality Assessment","text":""},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the signaling pathway from NECTIN2-CD226 binding to VAV1 activation.</li> <li>Each component and relationship is supported by published experimental evidence.</li> <li>Cellular locations are correctly annotated for all molecules.</li> <li>The biological process (NK cell cytotoxicity) is correctly associated with all activities.</li> </ol>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing Protein Relationships: The literature indicates that CD226 can also interact with PVR (CD155) as another ligand. While the model focuses specifically on the NECTIN2-CD226 pathway, a note about this alternative pathway could be useful for completeness.</p> </li> <li> <p>Downstream Signaling: The model stops at VAV1 activation, but the literature indicates further downstream effects through the RAS/MAPK pathway. Extending the model to include these downstream effects would provide a more complete picture of the signaling cascade.</p> </li> <li> <p>Alternative Downstream Pathways: The literature suggests that CD226 signaling can also lead to PI3K/AKT pathway activation, which is not represented in this model.</p> </li> <li> <p>Molecular Details: The model doesn't capture the details of how CD226 activates GRB2. According to the literature, CD226 must be phosphorylated by Src family kinases to recruit GRB2, which then leads to activation of VAV1.</p> </li> <li> <p>Timing and Context: The model doesn't capture the context in which this pathway is activated, such as the presence of other co-stimulatory or inhibitory signals that might modulate NK cell activation.</p> </li> </ol>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#recommendations-for-model-improvement","title":"Recommendations for Model Improvement","text":"<ol> <li> <p>Consider adding details about the phosphorylation of CD226 by Src family kinases before GRB2 recruitment.</p> </li> <li> <p>Include a note or representation of the alternative ligand PVR (CD155) that can also bind to CD226.</p> </li> <li> <p>Extend the model to include downstream effects of VAV1 activation, particularly the activation of small GTPases like RAC1 that lead to cytoskeletal reorganization and NK cell activation.</p> </li> <li> <p>Consider adding parallel pathways that might be activated by CD226 signaling, such as the PI3K/AKT pathway.</p> </li> <li> <p>Add information about how this pathway intersects with other pathways in NK cell activation to provide a more comprehensive view of NK cell cytotoxicity.</p> </li> </ol>"},{"location":"reviews/66b5638000001291-NECTIN2_CD226_mediated_NK_cell_cytotoxicity__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model <code>gomodel:66b5638000001291</code> accurately represents the core pathway of NECTIN2-CD226 mediated NK cell cytotoxicity from ligand binding to VAV1 activation. Each component and relationship is well-supported by experimental evidence. While there are opportunities to expand the model to include additional details and downstream events, the current model provides a solid foundation for understanding this important immune pathway.</p>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/","title":"66b5638000001589 Activation of the integrated stress response via activation of EIF2AK3 PERK in response to unfolded protein response promotes expression of COX7A2L SCAF1  increasing formation of respiratory chain supercomplexes  Human","text":"<p>Based on my thorough review of the GO-CAM model with ID 66b5638000001589 and the supporting information, I'll now provide a comprehensive assessment:</p>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#go-cam-model-review-gomodel66b5638000001589","title":"GO-CAM Model Review: gomodel:66b5638000001589","text":""},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#overview","title":"Overview","text":"<p>This GO-CAM model represents a pathway depicting how endoplasmic reticulum (ER) stress activates the PERK/eIF2alpha/ATF4 signaling axis to promote the expression of COX7A2L/SCAF1, which increases the formation of respiratory chain supercomplexes in human cells.</p>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#model-title","title":"Model Title","text":"<p>\"Activation of the integrated stress response via activation of EIF2AK3/PERK in response to unfolded protein response promotes expression of COX7A2L/SCAF1, increasing formation of respiratory chain supercomplexes (Human).\"</p>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model consists of four primary activities connected through causal relationships:</p> <ol> <li>EIF2AK3/PERK Activity:</li> <li>Enabled by: UniProtKB:Q9NZJ5 (EIF2AK3/PERK)</li> <li>Molecular function: GO:0004694 (eukaryotic translation initiation factor 2alpha kinase activity)</li> <li>Occurs in: GO:0005789 (endoplasmic reticulum membrane)</li> <li> <p>Part of: GO:0036499 (PERK-mediated unfolded protein response)</p> </li> <li> <p>EIF2S1 Activity #1:</p> </li> <li>Enabled by: UniProtKB:P05198 (EIF2S1/eIF2-alpha)</li> <li>Molecular function: GO:0003743 (translation initiation factor activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li> <p>Part of: GO:0006413 (translational initiation)</p> </li> <li> <p>EIF2S1 Activity #2:</p> </li> <li>Enabled by: UniProtKB:P05198 (EIF2S1/eIF2-alpha)</li> <li>Molecular function: GO:0003743 (translation initiation factor activity)</li> <li>Occurs in: GO:0005829 (cytosol)</li> <li> <p>Part of: GO:0006413 (translational initiation)</p> </li> <li> <p>ATF4 Activity:</p> </li> <li>Enabled by: UniProtKB:P18848 (ATF4)</li> <li>Molecular function: GO:0003700 (DNA-binding transcription factor activity)</li> <li>Occurs in: GO:0005634 (nucleus)</li> <li> <p>Part of: GO:0036499 (PERK-mediated unfolded protein response)</p> </li> <li> <p>COX7A2L Activity:</p> </li> <li>Enabled by: UniProtKB:O14548 (COX7A2L/SCAF1)</li> <li>Molecular function: GO:0030674 (protein-macromolecule adaptor activity)</li> <li>Occurs in: GO:0005743 (mitochondrial inner membrane)</li> <li>Part of: GO:0097250 (mitochondrial respirasome assembly)</li> </ol>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes the following causal relationships: 1. EIF2AK3/PERK directly negatively regulates EIF2S1 Activity #1 (RO:0002630) 2. EIF2AK3/PERK directly positively regulates EIF2S1 Activity #2 (RO:0002629) 3. EIF2S1 Activity #2 directly provides input for ATF4 Activity (RO:0002407) 4. ATF4 directly provides input for COX7A2L Activity (RO:0002407)</p>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate Representation of Signaling Cascade: The model correctly depicts the PERK-eIF2alpha-ATF4 signaling axis that is activated in response to ER stress. This is supported by the primary literature citing how PERK activation phosphorylates eIF2alpha, which leads to selective translation of ATF4.</p> </li> <li> <p>Correct Molecular Functions: The molecular functions assigned to each protein are appropriate. PERK is correctly annotated with kinase activity, eIF2alpha with translation initiation factor activity, ATF4 with transcription factor activity, and COX7A2L with protein-macromolecule adaptor activity.</p> </li> <li> <p>Appropriate Cellular Localization: Each protein is accurately localized within the cell: PERK at the ER membrane, eIF2alpha in the cytosol, ATF4 in the nucleus, and COX7A2L at the mitochondrial inner membrane.</p> </li> <li> <p>Well-Supported Pathway: The pathway described is well-supported by the primary literature, particularly the paper by Balsa et al. (2019) which demonstrates that PERK activation leads to ATF4-mediated transcription of COX7A2L/SCAF1, promoting respiratory supercomplex formation.</p> </li> <li> <p>Proper Causal Relationships: The causal relationships between the activities are accurately represented. PERK has a dual effect on eIF2alpha (negatively regulating general translation but promoting specific translation of stress response genes), which is correctly captured by the two separate arrows (RO:0002630 and RO:0002629).</p> </li> </ol>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Dual EIF2S1 Activities: While the model correctly represents that PERK both negatively and positively regulates eIF2alpha, having two separate EIF2S1 activities with identical annotations might be confusing. This dual representation is attempting to capture how phosphorylated eIF2alpha inhibits global translation (Activity #1) while promoting translation of specific mRNAs like ATF4 (Activity #2). A more precise annotation might differentiate these activities more clearly, perhaps by adding state information to the activities or annotations.</p> </li> <li> <p>Missing Environmental Context: The model doesn't explicitly represent the initial environmental stimulus (ER stress) that activates PERK. Adding this context would provide a more complete representation of the pathway.</p> </li> <li> <p>Additional Detail on COX7A2L Function: The model could be enhanced with more detail on how COX7A2L/SCAF1 specifically promotes respiratory supercomplex formation. From the paper by Perez-Perez et al. (2016), SCAF1 functions as an adaptor that mediates the association between complexes III and IV. This mechanistic detail could be included.</p> </li> <li> <p>Missing Intermediate Steps: The model simplifies the mechanism by which ATF4 regulates COX7A2L. Adding the transcriptional activation step explicitly would make the model more complete.</p> </li> <li> <p>Molecular Complexes Representation: According to the \"How to annotate complexes in GO-CAM\" document, when a protein like COX7A2L serves as an adaptor between complexes, it might be valuable to represent the actual respiratory complexes (III and IV) in the model to show how SCAF1 mediates their interaction.</p> </li> </ol>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by primary literature, particularly:</p> <ol> <li> <p>The PMID:31023583 (Balsa et al., 2019) which directly shows the PERK-eIF2alpha-ATF4 axis promoting COX7A2L expression and supercomplex formation.</p> </li> <li> <p>The PMID:27545886 (Perez-Perez et al., 2016) which characterizes COX7A2L/SCAF1 as a protein that stabilizes the III2+IV supercomplex.</p> </li> </ol> <p>Each activity has appropriate evidence codes and references to primary literature.</p>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model follows GO-CAM curation guidelines in terms of: - Using appropriate molecular functions, cellular components, and biological processes - Properly representing causal relationships between activities - Attributing activities to the correct gene products</p> <p>The model could better follow guidelines regarding complex representation as mentioned in \"How to annotate complexes in GO-CAM,\" especially when dealing with macromolecular adaptors like COX7A2L.</p>"},{"location":"reviews/66b5638000001589-Activation_of_the_integrated_stress_response_via_activation_of_EIF2AK3_PERK_in_response_to_unfolded_protein_response_promotes_expression_of_COX7A2L_SCAF1__increasing_formation_of_respiratory_chain_supercomplexes__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 66b5638000001589 provides a clear and scientifically accurate representation of how PERK activation leads to increased respiratory supercomplex formation via ATF4-mediated expression of COX7A2L/SCAF1. The model correctly captures the cellular locations, molecular functions, and causal relationships between the components of this pathway.</p> <p>While there are some areas for potential refinement, particularly in the representation of dual eIF2alpha activities and in providing more mechanistic detail for how COX7A2L promotes supercomplex formation, the model successfully conveys the key aspects of this signaling pathway in a manner that aligns with GO-CAM best practices.</p> <p>This pathway represents an important mechanism by which cells adapt to ER stress by enhancing mitochondrial respiratory efficiency, highlighting the integration between cellular stress responses and energy metabolism.</p>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/","title":"66b5638000001665 Signaling by Calcitonin mediated by CALCA CT ligand activating CALCR RAMP2   AMYR2  receptor complex  Human","text":"<p>Now I'll thoroughly review the GO-CAM model with ID gomodel:66b5638000001665 based on the information I've gathered.</p>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#review-of-go-cam-model-gomodel66b5638000001665","title":"Review of GO-CAM Model: gomodel:66b5638000001665","text":""},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#model-overview","title":"Model Overview:","text":"<p>Title: \"Signaling by Calcitonin mediated by CALCA/CT ligand activating CALCR-RAMP2 (AMYR2) receptor complex (Human)\" Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#model-structure-and-components","title":"Model Structure and Components:","text":"<p>The model represents the calcitonin signaling pathway via the AMYR2 receptor complex (CALCR-RAMP2). It includes:</p> <ol> <li>Hormone activity (P01258/CALCA)</li> <li>Function: GO:0005179 \"hormone activity\"</li> <li>Location: GO:0005615 \"extracellular space\"</li> <li>Part of: GO:0150060 \"amylin receptor 2 signaling pathway\"</li> <li> <p>Causal association: Directly positively regulates CALCR's calcitonin family receptor activity</p> </li> <li> <p>Coreceptor activity (O60895/RAMP2)</p> </li> <li>Function: GO:0015026 \"coreceptor activity\"</li> <li>Location: GO:0005886 \"plasma membrane\"</li> <li>Part of: GO:0150060 \"amylin receptor 2 signaling pathway\"</li> <li> <p>Causal association: Directly positively regulates CALCR's calcitonin family receptor activity</p> </li> <li> <p>Receptor activity (P30988/CALCR)</p> </li> <li>Function: GO:0097642 \"calcitonin family receptor activity\"</li> <li>Location: GO:0005886 \"plasma membrane\"</li> <li>Part of: GO:0007189 \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\"</li> <li> <p>Causal association: Directly positively regulates G protein activity</p> </li> <li> <p>G protein activity (Q5JWF2/GNAS)</p> </li> <li>Function: GO:0003925 \"G protein activity\"</li> <li>Location: GO:0005829 \"cytosol\"</li> <li>Part of: GO:0007189 \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\"</li> <li> <p>Causal association: Directly positively regulates adenylate cyclase activity</p> </li> <li> <p>Adenylate cyclase activity (O43306/ADCY6)</p> </li> <li>Function: GO:0004016 \"adenylate cyclase activity\"</li> <li>Part of: GO:0007189 \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\"</li> <li>Output: CHEBI:17489 \"3',5'-cyclic AMP\"</li> </ol>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#assessment-against-go-cam-standards","title":"Assessment Against GO-CAM Standards:","text":""},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#1-overall-structure-and-signal-flow","title":"1. Overall Structure and Signal Flow","text":"<p>The model correctly represents a GPCR signaling pathway with appropriate causal relationships: - CALCA (ligand) positively regulates CALCR (receptor) - RAMP2 (coreceptor) positively regulates CALCR (receptor) - CALCR positively regulates GNAS (G protein) - GNAS positively regulates ADCY6 (adenylate cyclase) - ADCY6 has output of cAMP</p> <p>This flow aligns with canonical GPCR signaling pathways and uses appropriate predicates for causal associations (RO:0002629 \"directly positively regulates\").</p>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#2-receptor-complex-representation","title":"2. Receptor Complex Representation","text":"<p>The model correctly represents the AMYR2 receptor complex as recommended in the GO-CAM guidelines. CALCR and RAMP2 are represented separately with their respective activities, with RAMP2 having coreceptor activity that directly positively regulates CALCR's receptor activity. This is consistent with the guidelines for annotating complexes and receptor/coreceptor relationships.</p>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#3-cellular-localization","title":"3. Cellular Localization","text":"<p>Appropriate cellular components are assigned: - CALCA is located in the extracellular space (GO:0005615) - CALCR and RAMP2 are located in the plasma membrane (GO:0005886) - GNAS is located in the cytosol (GO:0005829)</p> <p>These locations are consistent with the biological roles of these proteins in signaling.</p>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#4-biological-process-context","title":"4. Biological Process Context","text":"<p>The model appropriately places: - CALCA and RAMP2 in the \"amylin receptor 2 signaling pathway\" (GO:0150060) - CALCR, GNAS, and ADCY6 in the \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\" (GO:0007189)</p> <p>This correctly represents the nested pathway structure in GPCR signaling.</p>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#5-evidence-support","title":"5. Evidence Support","text":"<p>All activities in the model are supported by experimental evidence codes (primarily ECO:0000314 \"direct assay evidence used in manual assertion\") and referenced to primary literature (PMIDs).</p>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#consistency-with-current-knowledge","title":"Consistency with Current Knowledge:","text":"<p>The model accurately reflects current knowledge about calcitonin signaling through the AMYR2 receptor complex:</p> <ol> <li> <p>CALCR-RAMP2 complex formation: The interaction between CALCR and RAMP2 to form the AMYR2 receptor complex is well-established in the literature (supported by PMID:35324283).</p> </li> <li> <p>Ligand specificity: The model correctly shows calcitonin (CALCA) as a ligand for the AMYR2 complex, which is supported by recent structural biology studies (PMID:35324283).</p> </li> <li> <p>Downstream signaling: The activation of G protein (GNAS) and subsequent stimulation of adenylate cyclase (ADCY6) leading to cAMP production is consistent with the canonical signaling pathway for this receptor type.</p> </li> <li> <p>Biological process annotation: The placement of the receptor complex components in the \"amylin receptor 2 signaling pathway\" is appropriate, as the CALCR-RAMP2 complex is known to respond to both calcitonin and amylin.</p> </li> </ol>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#minor-points-for-additional-consideration","title":"Minor Points for Additional Consideration:","text":"<ol> <li> <p>The model does not include downstream signaling events from cAMP (such as PKA activation), which could potentially be added in future expansions of the model.</p> </li> <li> <p>The specific isoform of GNAS being used could potentially be clarified if known, as multiple isoforms exist with different functions.</p> </li> </ol>"},{"location":"reviews/66b5638000001665-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_RAMP2___AMYR2__receptor_complex__Human_/#conclusion","title":"Conclusion:","text":"<p>The GO-CAM model gomodel:66b5638000001665 is a well-constructed representation of calcitonin signaling through the AMYR2 receptor complex. It adheres to GO-CAM best practices for representing receptor-ligand interactions, complex formation, and GPCR signaling. The model includes appropriate molecular functions, cellular locations, and biological processes for all components, with evidence-supported causal relationships that correctly depict the flow of signaling information.</p> <p>The model is consistent with current scientific understanding of calcitonin signaling and appropriately represents the roles of CALCR and RAMP2 in forming the AMYR2 receptor complex. All activities are well-supported by primary literature references and appropriate evidence codes.</p> <p>Overall, this is a high-quality model that effectively captures the key components and relationships in calcitonin signaling through the AMYR2 receptor complex in human.</p>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/","title":"66b5638000001719 AKT1 inhibits EIF2AK3 PERK   Human","text":"<p>After reviewing all the documentation and relevant information, I'll now provide a detailed review of the GO-CAM model (gomodel:66b5638000001719) titled \"AKT1 inhibits EIF2AK3/PERK (Human)\":</p>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#review-of-gomodel-66b5638000001719-akt1-inhibits-eif2ak3perk-human","title":"Review of GOModel: 66b5638000001719 - \"AKT1 inhibits EIF2AK3/PERK (Human)\"","text":""},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:66b5638000001719) represents the regulatory relationship between AKT1 (protein kinase B) and EIF2AK3 (also known as PERK), which is a key component of the unfolded protein response (UPR) pathway. The model is focused on human proteins (NCBITaxon:9606) and depicts how AKT1 negatively regulates the PERK-mediated UPR.</p>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#model-components","title":"Model Components","text":"<p>The model contains 5 molecular activities:</p> <ol> <li>AKT1 (UniProtKB:P31749) - protein serine/threonine kinase activity (GO:0004674)</li> <li>Part of negative regulation of PERK-mediated UPR (GO:1903898)</li> <li> <p>Directly negatively regulates PERK/EIF2AK3 (RO:0002630)</p> </li> <li> <p>PERK/EIF2AK3 (UniProtKB:Q9NZJ5) - eukaryotic translation initiation factor 2alpha kinase activity (GO:0004694)</p> </li> <li>Located in endoplasmic reticulum membrane (GO:0005789)</li> <li>Part of PERK-mediated UPR (GO:0036499)</li> <li>Directly negatively regulates EIF2S1/eIF-2-alpha translational activity (RO:0002630)</li> <li> <p>Directly positively regulates ATF4 (RO:0002629)</p> </li> <li> <p>EIF2S1/eIF-2-alpha (UniProtKB:P05198) - translation initiation factor activity (GO:0003743)</p> </li> <li>Located in cytosol (GO:0005829)</li> <li> <p>Part of translational initiation (GO:0006413)</p> </li> <li> <p>ATF4 (UniProtKB:P18848) - DNA-binding transcription factor activity (GO:0003700)</p> </li> <li>Located in nucleus (GO:0005634)</li> <li> <p>Part of PERK-mediated UPR (GO:0036499)</p> </li> <li> <p>EIF2S1/eIF-2-alpha (UniProtKB:P05198) - translation initiation factor activity (GO:0003743)</p> </li> <li>Located in cytosol (GO:0005829)</li> <li>Part of translational initiation (GO:0006413)</li> <li>Causally related to ATF4 transcription factor activity (RO:0002407)</li> </ol>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>The model accurately captures the core regulatory relationship where AKT1 inhibits PERK/EIF2AK3 kinase activity.</p> </li> <li> <p>It correctly depicts the PERK pathway where PERK activation leads to EIF2S1 phosphorylation, which inhibits general translation while promoting ATF4 translation.</p> </li> <li> <p>The model uses appropriate GO terms for activities, cellular components, and biological processes.</p> </li> <li> <p>The causal relationships are correctly represented using appropriate relationship ontology (RO) terms.</p> </li> <li> <p>The evidence provided for each association is robust, with multiple primary literature references.</p> </li> </ol>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Phosphorylation Sites Representation: The model doesn't explicitly indicate that AKT1 phosphorylates PERK at Thr-802, which is the mechanism by which it inhibits PERK activity (as described in the UniProt entry for PERK). Adding this molecular detail would enhance the model.</p> </li> <li> <p>Representation of EIF2S1 Phosphorylation: While the model shows PERK negatively regulating EIF2S1, it would be more precise to indicate that PERK phosphorylates EIF2S1 at Ser-52, which then leads to translational inhibition.</p> </li> <li> <p>Upstream Activators: The model doesn't include what activates AKT1 in the context of ER stress. Adding this context would provide a more complete picture.</p> </li> <li> <p>Missing Pathway Components: The model doesn't include some important components of the PERK pathway such as:</p> </li> <li>GADD34/PPP1R15A which provides negative feedback</li> <li> <p>CHOP/DDIT3 which is induced by ATF4 and involved in ER stress-induced apoptosis</p> </li> <li> <p>ATF4 Transcriptional Targets: The model stops at ATF4 activation but doesn't show any of its downstream targets such as SCAF1/COX7A2L (as described in the paper by Balsa et al., 2019), which would provide more context about the biological outcome.</p> </li> <li> <p>Integrated Stress Response Context: The model doesn't fully contextualize that PERK is part of the broader integrated stress response (ISR), which can be activated by multiple stressors beyond ER stress.</p> </li> <li> <p>Potential Duplication: There are two identical activities for EIF2S1 (entries #3 and #5 in the components list), which seems redundant unless they represent different instances/populations of the same protein.</p> </li> </ol>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model is biologically accurate in depicting the core regulatory relationship between AKT1 and PERK. The evidence provided comes from multiple peer-reviewed publications, strengthening the model's validity. The relationships shown align with current understanding of the PERK branch of the UPR pathway.</p> <p>However, as noted above, including more molecular details (such as specific phosphorylation sites) and extending the model to include more downstream components would improve its comprehensiveness.</p>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#go-cam-modeling-guidelines-compliance","title":"GO-CAM Modeling Guidelines Compliance","text":"<p>The model generally follows GO-CAM modeling guidelines:</p> <ol> <li>It uses appropriate molecular function GO terms for each protein.</li> <li>It accurately represents cellular locations.</li> <li>It uses appropriate causal relationship predicates (RO terms).</li> <li>It includes proper evidence for each assertion.</li> </ol> <p>However, regarding how complexes are annotated, since the model doesn't explicitly represent any protein complexes, it doesn't fully leverage the guidance provided in the \"How to annotate complexes in GO-CAM\" document. For a more comprehensive representation, it might be worth considering if any of the proteins act as part of complexes (e.g., eIF2 is typically a complex of alpha, beta, and gamma subunits).</p>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#recommendations","title":"Recommendations","text":"<p>To enhance this GO-CAM model, I recommend:</p> <ol> <li> <p>Add Phosphorylation Details: Specify that AKT1 phosphorylates PERK at Thr-802 and that PERK phosphorylates EIF2S1 at Ser-52.</p> </li> <li> <p>Resolve the Duplication: Remove or distinguish between the two identical EIF2S1 activities.</p> </li> <li> <p>Extend the Pathway: Consider adding:</p> </li> <li>Upstream regulators of AKT1 in the context of ER stress</li> <li>Downstream targets of ATF4 (especially SCAF1/COX7A2L)</li> <li> <p>The negative feedback loop involving GADD34/PPP1R15A</p> </li> <li> <p>Consider Complex Representation: Evaluate if representing eIF2 as a complex would be more appropriate than just showing the alpha subunit.</p> </li> <li> <p>Add Physiological Context: Include annotations that connect this regulatory pathway to its physiological outcomes, such as how AKT1-mediated inhibition of PERK affects cell survival during ER stress.</p> </li> </ol>"},{"location":"reviews/66b5638000001719-AKT1_inhibits_EIF2AK3_PERK___Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:66b5638000001719 \"AKT1 inhibits EIF2AK3/PERK (Human)\" is a valuable representation of a key regulatory relationship in the PERK branch of the UPR pathway. While it accurately captures the core elements of this regulation, adding more molecular details and extending the pathway representation would enhance its comprehensiveness and utility for the scientific community.</p>"},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/","title":"66b5638000001772 Signaling by Calcitonin mediated by CALCA CT ligand activating CALCR receptor  Human","text":"<p>Let's now check the GO-CAM model for its conformance to best practices and scientific accuracy. Based on my review of the model (<code>gomodel:66b5638000001772</code>) and the available information, I'll provide a comprehensive assessment:</p>"},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#go-cam-model-review-signaling-by-calcitonin-mediated-by-calcact-ligand-activating-calcr-receptor-human","title":"GO-CAM Model Review: Signaling by Calcitonin mediated by CALCA/CT ligand activating CALCR receptor (Human)","text":""},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#model-summary","title":"Model Summary","text":"<p>This GO-CAM (ID: gomodel:66b5638000001772) represents the calcitonin signaling pathway in humans, specifically showing how calcitonin hormone (CALCA) activates its receptor (CALCR), which then signals through a G protein (GNAS) to activate adenylate cyclase (ADCY6), ultimately producing cAMP as a signaling molecule.</p>"},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#structure-of-the-model","title":"Structure of the Model","text":"<p>The model consists of four main activities:</p> <ol> <li>Hormone activity (GO:0005179) - enabled by CALCA (P01258) occurring in extracellular space (GO:0005615)</li> <li>Calcitonin receptor activity (GO:0004948) - enabled by CALCR (P30988) occurring in plasma membrane (GO:0005886)</li> <li>G protein activity (GO:0003925) - enabled by GNAS (Q5JWF2) occurring in cytosol (GO:0005829)</li> <li>Adenylate cyclase activity (GO:0004016) - enabled by ADCY6 (O43306) producing cAMP (CHEBI:17489)</li> </ol> <p>The causal flow follows: - CALCA directly positively regulates CALCR - CALCR directly positively regulates GNAS - GNAS directly positively regulates ADCY6</p>"},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#assessment-against-go-cam-guidelines","title":"Assessment Against GO-CAM Guidelines","text":""},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#1-model-structure-and-organization","title":"1. Model Structure and Organization","text":"<p>\u2705 Correctly structured signal transduction pathway: The model properly represents a hormone signaling pathway with appropriate causal connections.</p> <p>\u2705 Appropriate molecular functions: Each protein is annotated with an appropriate molecular function term.</p> <p>\u2705 Proper cellular components: Subcellular locations are correctly specified for each activity.</p> <p>\u2705 Biological process annotation: All activities are appropriately annotated with \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\" (GO:0007189).</p>"},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#2-representation-of-receptor-signaling","title":"2. Representation of Receptor Signaling","text":"<p>\u2705 Hormone-receptor relationship: The model correctly represents CALCA as a hormone ligand that activates the CALCR receptor.</p> <p>\u2705 GPCR signal transduction: The flow from receptor to G protein to effector enzyme adheres to established GPCR signaling mechanisms.</p> <p>\u2705 Evidence sources: Each activity and causal relationship is supported by evidence from scientific literature.</p>"},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#3-scientific-accuracy","title":"3. Scientific Accuracy","text":"<p>\u2705 Biological accuracy: The model accurately represents the known mechanism of calcitonin signaling based on literature evidence.</p> <p>\u2705 Protein functions: All proteins are annotated with molecular functions that match their known biological roles according to UniProt entries.</p> <p>\u2705 Subcellular locations: The cellular components are consistent with the known localizations of these proteins.</p>"},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#4-areas-for-improvement","title":"4. Areas for Improvement","text":"<p>While the model is generally well-constructed, there are some potential areas for improvement:</p> <ol> <li> <p>Additional downstream effects: The model could be extended to include downstream effects of cAMP, such as activation of protein kinase A (PKA).</p> </li> <li> <p>Regulatory feedback mechanisms: If relevant, the model could include negative feedback mechanisms that regulate this signaling pathway.</p> </li> <li> <p>Specific biological outcome: The model could potentially include the physiological outcome of this signaling pathway (e.g., effects on calcium homeostasis, bone resorption).</p> </li> </ol>"},{"location":"reviews/66b5638000001772-Signaling_by_Calcitonin_mediated_by_CALCA_CT_ligand_activating_CALCR_receptor__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (<code>gomodel:66b5638000001772</code>) correctly represents the calcitonin signaling pathway through CALCR receptor, G protein activation, and adenylate cyclase stimulation leading to cAMP production. The model follows GO-CAM curation guidelines appropriately and represents the biological process accurately according to current knowledge.</p> <p>The model is well-annotated with appropriate GO terms for molecular functions, cellular components, and biological processes. All causal relationships are properly specified and supported by evidence from the literature. Overall, this appears to be a high-quality GO-CAM model that represents the calcitonin signaling pathway accurately and according to best practices.</p>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/","title":"66b5638000001825 Signaling by Amylin mediated by IAPP ligand activating CALCR  receptor  Human","text":"<p>Now, I will systematically review the GO-CAM model based on all the information I've gathered:</p>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#review-of-go-cam-model-gomodel66b5638000001825","title":"Review of GO-CAM Model: gomodel:66b5638000001825","text":""},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Signaling by Amylin mediated by IAPP ligand activating CALCR receptor (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>This model represents the signaling pathway where amylin (IAPP) activates the calcitonin receptor (CALCR), which then signals through G proteins (GNAS) and adenylate cyclase (ADCY6) to produce cAMP as part of the amylin receptor signaling pathway.</p>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#components-evaluation","title":"Components Evaluation","text":""},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#1-iapp-amylin-as-ligand","title":"1. IAPP (Amylin) as Ligand","text":"<ul> <li>MF: hormone activity (GO:0005179) - correctly annotated</li> <li>CC: occurs_in extracellular space (GO:0005615) - correctly annotated</li> <li>BP: part_of amylin receptor signaling pathway (GO:0097647) - correctly annotated</li> <li>Causal Association: directly positively regulates (RO:0002629) CALCR receptor activity - correctly annotated</li> </ul> <p>IAPP ligand annotation follows the GO-CAM guidelines for a protein ligand activating a receptor. The islet amylin polypeptide (IAPP) is correctly annotated with hormone activity which is a child term of receptor ligand activity.</p>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#2-calcr-as-receptor","title":"2. CALCR as Receptor","text":"<ul> <li>MF: amylin receptor activity (GO:0097643) - correctly annotated</li> <li>CC: occurs_in plasma membrane (GO:0005886) - correctly annotated</li> <li>BP: part_of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189) - correctly annotated</li> <li>Causal Association: directly positively regulates (RO:0002629) GNAS G protein activity - correctly annotated</li> </ul> <p>The CALCR receptor is correctly annotated according to GO-CAM guidelines. CALCR forms the core of the amylin receptor and is appropriately shown as part of the adenylate cyclase-activating G protein-coupled receptor signaling pathway, which is consistent with the literature showing CALCR signaling through Gs proteins.</p>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#3-gnas-as-g-protein","title":"3. GNAS as G Protein","text":"<ul> <li>MF: G protein activity (GO:0003925) - correctly annotated</li> <li>CC: occurs_in cytosol (GO:0005829) - correctly annotated</li> <li>BP: part_of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189) - correctly annotated</li> <li>Causal Association: directly positively regulates (RO:0002629) ADCY6 adenylate cyclase activity - correctly annotated</li> </ul> <p>The G protein (GNAS) is correctly annotated as an intermediate signaling component that is activated by the receptor and in turn activates adenylate cyclase. This is consistent with the canonical G protein signaling pathway.</p>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#4-adcy6-as-effector-enzyme","title":"4. ADCY6 as Effector Enzyme","text":"<ul> <li>MF: adenylate cyclase activity (GO:0004016) - correctly annotated</li> <li>BP: part_of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189) - correctly annotated</li> <li>Output: has_output CHEBI:17489 (3',5'-cyclic AMP) - correctly annotated</li> </ul> <p>The adenylate cyclase (ADCY6) is correctly shown as producing cAMP in response to G protein activation, which is the expected downstream effect of this signaling pathway.</p>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the amylin receptor signaling pathway according to current literature:</p> <ol> <li> <p>The model correctly shows IAPP (amylin) as the ligand activating CALCR, which is consistent with the literature describing amylin's binding to calcitonin receptors.</p> </li> <li> <p>The research from PMID:35324283 confirms that CALCR can function as an amylin receptor, and that IAPP can activate CALCR to trigger intracellular signaling.</p> </li> <li> <p>The downstream signaling through G proteins (GNAS) and adenylate cyclase (ADCY6) to produce cAMP is consistent with the literature on GPCR signaling pathways, particularly PMID:17110384 which describes adenylate cyclase activation by G proteins.</p> </li> <li> <p>The localization of components is appropriate: IAPP in extracellular space, CALCR at the plasma membrane, GNAS in the cytosol, and ADCY6 properly annotated.</p> </li> </ol>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#connectivity-and-structure","title":"Connectivity and Structure","text":"<ol> <li>The causal connections between activities are correctly established using appropriate relationships:</li> <li>IAPP hormone activity directly positively regulates CALCR amylin receptor activity</li> <li>CALCR amylin receptor activity directly positively regulates GNAS G protein activity</li> <li> <p>GNAS G protein activity directly positively regulates ADCY6 adenylate cyclase activity</p> </li> <li> <p>All components are properly connected in a biologically accurate sequence representing the flow of information from extracellular ligand to intracellular signaling and second messenger production (cAMP).</p> </li> </ol>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by appropriate evidence citations:</p> <ol> <li>PMID:35324283 - A structural basis for amylin receptor phenotype (2022)</li> <li>Supports the role of IAPP in activating CALCR</li> <li> <p>Supports the biological process annotation of amylin receptor signaling pathway</p> </li> <li> <p>PMID:32296767 - (Not fully retrievable but pertains to amylin/IAPP activation of CALCR)</p> </li> <li> <p>PMID:37963465 - Related to signaling mechanisms but not directly to this pathway</p> </li> <li> <p>PMID:17110384 - Conditional stimulation of adenylyl cyclases by G protein beta/gamma subunits</p> </li> <li> <p>Supports the G protein activation of adenylate cyclase</p> </li> <li> <p>PMID:17916776 - Supporting ADCY6 function in cAMP production</p> </li> <li> <p>Confirms the role of adenylate cyclase in generating cAMP</p> </li> <li> <p>PMID:7588285 - Early characterization of the calcitonin receptor</p> </li> <li>Supports the localization of CALCR to the plasma membrane</li> </ol> <p>All evidence is appropriately matched to the corresponding assertions in the model.</p>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Completeness of the Model: While the core signaling pathway is well represented, the model could potentially be enhanced by including:</li> <li>The role of RAMP proteins (Receptor Activity Modifying Proteins), which are known to form complexes with CALCR to create functional amylin receptors (AMY1R, AMY2R, and AMY3R) as described in PMID:35324283.</li> <li> <p>Downstream effects of cAMP production, such as activation of PKA and subsequent cellular responses.</p> </li> <li> <p>Additional Evidence: Some additional citations could strengthen certain aspects of the model:</p> </li> <li>Evidence specifically supporting the GNAS to ADCY6 activation in the context of amylin signaling would strengthen the model.</li> </ol>"},{"location":"reviews/66b5638000001825-Signaling_by_Amylin_mediated_by_IAPP_ligand_activating_CALCR__receptor__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Signaling by Amylin mediated by IAPP ligand activating CALCR receptor (Human)\" (gomodel:66b5638000001825) is scientifically accurate, follows GO-CAM best practices, and is well-supported by appropriate evidence. The model correctly captures the core components and connections of the amylin receptor signaling pathway.</p> <p>The model is parsimonious, focusing on the essential components of the signaling pathway without unnecessary complexity. It provides a clear representation of how amylin activates the calcitonin receptor to trigger G protein-mediated activation of adenylate cyclase, resulting in cAMP production.</p> <p>While there are minor opportunities for enhancement by adding RAMP proteins or downstream signaling components, the current model is valid, biologically accurate, and meets the standards for a GO-CAM representation of a receptor signaling pathway.</p>"},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/","title":"66b5638000001968 PVR TIGIT pair inhibits NK cell mediated cytotoxicity  Human","text":"<p>Based on my review of the GO-CAM model (gomodel:66b5638000001968) titled \"PVR-TIGIT pair inhibits NK cell mediated cytotoxicity (Human)\", I'll provide a comprehensive assessment of this model and its biological representation.</p>"},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/#go-cam-review-pvr-tigit-pair-inhibits-nk-cell-mediated-cytotoxicity-human","title":"GO-CAM Review: \"PVR-TIGIT pair inhibits NK cell mediated cytotoxicity (Human)\"","text":""},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the inhibitory signaling pathway in which the interaction between Poliovirus Receptor (PVR/CD155) and T-cell immunoglobulin and ITIM domain (TIGIT) suppresses natural killer (NK) cell-mediated cytotoxicity. The pathway involves multiple molecular functions including receptor ligand activity, signaling receptor activity, molecular adaptor activity, phosphatase activity, and kinase activity connected through a causal chain.</p>"},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The biological content of the model is well-supported by the literature:</p> <ol> <li> <p>The TIGIT-PVR interaction as an inhibitory axis in NK cells is accurately depicted, consistent with the PMID:23154388 study which demonstrates that this interaction \"suppresses granule polarization and cytotoxicity of NK cells.\"</p> </li> <li> <p>The recruitment of Grb2 (P62993) by TIGIT as a molecular adaptor is correctly represented, as the literature shows the ITT-like motif of TIGIT is phosphorylated at Tyr225 and binds to Grb2.</p> </li> <li> <p>The subsequent recruitment of SHIP1 (INPP5D/Q92835) through Grb2 and its inositol-polyphosphate 5-phosphatase activity is correctly depicted as the mechanism that prematurely terminates PI3K signaling.</p> </li> <li> <p>The inclusion of PIK3CB (P42338) and its 1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity in natural killer cell mediated cytotoxicity is well-supported by PMID:36248894.</p> </li> </ol>"},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/#model-structure-and-connectivity","title":"Model Structure and Connectivity","text":"<p>The causal flow of the model follows this pathway: 1. PVR (P15151) provides receptor ligand activity (GO:0048018) that directly positively regulates TIGIT (Q495A1) signaling receptor activity (GO:0038023) 2. TIGIT signaling receptor activity directly positively regulates GRB2 (P62993) protein-macromolecule adaptor activity (GO:0030674) 3. GRB2 adaptor activity directly positively regulates INPP5D/SHIP1 (Q92835) inositol-polyphosphate 5-phosphatase activity (GO:0004445) 4. INPP5D/SHIP1 directly negatively regulates PIK3CB (P42338) 1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity (GO:0046934)</p> <p>This causal chain correctly represents the negative regulation of PI3K-mediated NK cell cytotoxicity by the TIGIT-PVR interaction.</p>"},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/#ontology-and-evidence-usage","title":"Ontology and Evidence Usage","text":"<p>The model appropriately uses: - Molecular functions from GO (e.g., receptor ligand activity, signaling receptor activity) - Cellular locations (plasma membrane, cytoplasm) - Proper causal relationships (directly positively regulates, directly negatively regulates) - Evidence codes with proper literature citations (ECO:0000314 - direct assay evidence used in manual assertion)</p>"},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model follows GO-CAM practices: 1. Each activity is properly connected in a causal chain 2. Entities are appropriately enabled by the correct gene products 3. Cellular locations are specified for each activity 4. Activities are part of appropriate biological processes 5. Each assertion has evidence with appropriate citations</p>"},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/#specific-improvements-or-suggestions","title":"Specific Improvements or Suggestions","text":"<ol> <li> <p>Complex Representation: While the model doesn't explicitly represent complexes, this follows GO-CAM guidelines as each protein's individual molecular function is known and represented. According to the document \"How to annotate complexes in GO-CAM\", this is the correct approach when the subunits carrying specific activities are known.</p> </li> <li> <p>Activity Completeness: The model could be expanded to represent additional downstream effectors of the PI3K pathway in NK cells or additional regulatory interactions of SHIP1.</p> </li> <li> <p>Evidence Diversity: While the model uses appropriate direct evidence, it could be strengthened by including additional supporting evidence from more publications.</p> </li> </ol>"},{"location":"reviews/66b5638000001968-PVR_TIGIT_pair_inhibits_NK_cell_mediated_cytotoxicity__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66b5638000001968) effectively represents the TIGIT-PVR inhibitory signaling pathway in NK cells with accurate biological content, proper causal connectivity, and appropriate use of GO terms and evidence. The model clearly captures how PVR binding to TIGIT initiates a signaling cascade that recruits Grb2 and SHIP1, ultimately inhibiting PI3K activity and suppressing NK cell cytotoxicity.</p> <p>The model is parsimonious and well-structured, making it easy to understand the inhibitory pathway involved in natural killer cell-mediated cytotoxicity regulation. It properly implements GO-CAM curation best practices and effectively represents the biological mechanism described in the literature.</p>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/","title":"66b5638000002273 GRIM1 activates GRID2 via GNAQ in Purkinje cells  Human","text":"<p>Now, let me review the GO-CAM model with ID 66b5638000002273 based on all the information I've gathered.</p>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#review-of-go-cam-model-66b5638000002273","title":"Review of GO-CAM Model 66b5638000002273","text":""},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#model-information","title":"Model Information","text":"<ul> <li>Model ID: gomodel:66b5638000002273</li> <li>Title: \"GRIM1 activates GRID2 via GNAQ in Purkinje cells (Human)\"</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#overview-of-model-content","title":"Overview of Model Content","text":"<p>This GO-CAM model describes a signaling pathway in human Purkinje cells where GRM1 (metabotropic glutamate receptor 1) activates GRID2 (glutamate receptor ionotropic delta-2) via GNAQ (G protein subunit alpha q) signaling. The model captures the molecular function, cellular location, and biological process of each component, as well as the causal relationships between them.</p>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#model-components-and-activities","title":"Model Components and Activities","text":""},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#1-grm1-uniprotkbq13255","title":"1. GRM1 (UniProtKB:Q13255)","text":"<ul> <li>Molecular Function: GO:0099530 - G protein-coupled receptor activity involved in regulation of postsynaptic membrane potential</li> <li>Cellular Component: GO:0098839 - postsynaptic density membrane</li> <li>Biological Process: GO:0007200 - phospholipase C-activating G protein-coupled receptor signaling pathway</li> <li>Causal Relationship: Directly positively regulates GNAQ (RO:0002629)</li> </ul>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#2-gnaq-uniprotkbp50148","title":"2. GNAQ (UniProtKB:P50148)","text":"<ul> <li>Molecular Function: GO:0003925 - G protein activity</li> <li>Cellular Component: GO:0099524 - postsynaptic cytosol</li> <li>Biological Process: GO:0007200 - phospholipase C-activating G protein-coupled receptor signaling pathway</li> <li>Causal Relationship: Directly positively regulates PLCB3 (RO:0002629)</li> </ul>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#3-plcb3-uniprotkbq01970","title":"3. PLCB3 (UniProtKB:Q01970)","text":"<ul> <li>Molecular Function: GO:0004435 - phosphatidylinositol phospholipase C activity</li> <li>Cellular Component: GO:0099524 - postsynaptic cytosol</li> <li>Biological Process: GO:0007200 - phospholipase C-activating G protein-coupled receptor signaling pathway</li> <li>Outputs: CHEBI:17815 (1,2-diacyl-sn-glycerol) and CHEBI:203600 (1D-myo-inositol 1,4,5-trisphosphate)</li> </ul>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#4-prkcg-uniprotkbp05129","title":"4. PRKCG (UniProtKB:P05129)","text":"<ul> <li>Molecular Function: GO:0004698 - calcium,diacylglycerol-dependent serine/threonine kinase activity</li> <li>Cellular Component: GO:0099524 - postsynaptic cytosol</li> <li>Biological Process: GO:0007200 - phospholipase C-activating G protein-coupled receptor signaling pathway</li> <li>Causal Relationship: Provides input for GRID2 (RO:0002407)</li> </ul>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#5-grid2-uniprotkbo43424","title":"5. GRID2 (UniProtKB:O43424)","text":"<ul> <li>Molecular Function: GO:1904315 - transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential</li> <li>Cellular Component: GO:0098839 - postsynaptic density membrane</li> <li>Biological Process: GO:0099538 - synaptic signaling via neuropeptide</li> </ul>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#analysis-of-causal-relationships","title":"Analysis of Causal Relationships","text":"<p>The model represents a signaling cascade where: 1. GRM1 activates GNAQ 2. GNAQ activates PLCB3 3. PLCB3 generates second messengers (IP3 and DAG) 4. PRKCG (activated by DAG and calcium) provides input for GRID2</p> <p>This pathway accurately represents the canonical phospholipase C-activating G protein-coupled receptor signaling pathway, where GRM1 (mGlu1) activates GRID2 via the GNAQ-PLC-PKC pathway, as supported by the literature (particularly PMID:27276689).</p>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate molecular functions: Each protein is assigned appropriate molecular functions based on current knowledge.</p> </li> <li> <p>Correct subcellular localization: The subcellular locations are accurately represented, with GRM1 and GRID2 at the postsynaptic density membrane, and GNAQ, PLCB3, and PRKCG in the postsynaptic cytosol.</p> </li> <li> <p>Complete signaling pathway: The model captures the entire signaling cascade from receptor activation to the final effector.</p> </li> <li> <p>Evidence-based annotations: The annotations are supported by published literature, including experimental evidence from PMIDs 24357660, 27276689, 37991948, and 23115168.</p> </li> <li> <p>Correct causal relationships: The causal relationships between components are accurately represented using appropriate relationship ontology terms.</p> </li> </ol>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>IP3 effect could be expanded: The model doesn't explicitly show the effect of IP3 on calcium release, which is part of the PKC activation mechanism. This could be included to make the model more complete.</p> </li> <li> <p>Molecular complex representation: The model does not represent any protein complexes. While this is appropriate based on the current evidence, if future research identifies specific complexes involved in this pathway, they could be included according to GO-CAM complex annotation guidelines.</p> </li> <li> <p>Feedback mechanisms: The model doesn't include any feedback mechanisms that might regulate this signaling pathway, which could be added if supported by evidence.</p> </li> </ol>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li>Using appropriate GO terms for molecular functions, cellular components, and biological processes</li> <li>Using correct relationship ontology terms for causal relationships</li> <li>Including evidence codes and references for annotations</li> <li>Maintaining consistency between molecular functions and their biological context</li> </ol>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#biological-accuracy-and-significance","title":"Biological Accuracy and Significance","text":"<p>This model accurately captures the current understanding of how mGluR1 (GRM1) activates GRID2 via the GNAQ-PLC-PKC signaling pathway in Purkinje cells. The literature supports that:</p> <ol> <li>GRM1 activation stimulates GNAQ (PMID:27276689)</li> <li>GNAQ activates PLCB3, leading to production of IP3 and DAG (PMID:37991948)</li> <li>DAG and calcium activate PRKCG (PMID:23115168)</li> <li>PRKCG contributes to GRID2 channel activation (PMIDs:24357660, 27276689)</li> </ol> <p>The model is particularly significant because it explains the shared cerebellar motor phenotype observed in mutants of the mGluR1 and GluR\u03b42 signaling pathways, as indicated in PMID:23115168.</p>"},{"location":"reviews/66b5638000002273-GRIM1_activates_GRID2_via_GNAQ_in_Purkinje_cells__Human__/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 66b5638000002273 is a high-quality representation of the GRM1-GNAQ-PLCB3-PRKCG-GRID2 signaling pathway in human Purkinje cells. It accurately captures the molecular functions, cellular locations, biological processes, and causal relationships between components based on current evidence. The model provides valuable insights into the mechanism by which metabotropic glutamate receptor signaling regulates ionotropic glutamate receptor function in the cerebellum, which is critical for proper motor coordination.</p> <p>The model could potentially be enhanced by including additional details about calcium signaling and feedback mechanisms, but as it stands, it represents a scientifically accurate and useful resource for understanding this important neuronal signaling pathway.</p>"},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/","title":"66b5638000002528 GRIM1 activates GRID1 via GNAQ in dopamine neurons  Mouse","text":"<p>Based on my analysis of the model and relevant research, here is my review of GO-CAM model gomodel:66b5638000002528:</p>"},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/#go-cam-model-review-grim1-activates-grid1-via-gnaq-in-dopamine-neurons-mouse","title":"GO-CAM Model Review: \"GRIM1 activates GRID1 via GNAQ in dopamine neurons (Mouse)\"","text":""},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/#overview","title":"Overview","text":"<p>This GO-CAM model describes a signaling pathway in which GRIM1 (metabotropic glutamate receptor 1, GRM1/Grm1) activates GRID1 via GNAQ (Gq) in dopamine neurons in mouse. The model shows how dopamine neurons employ a metabotropic glutamate receptor signaling pathway to regulate glutamate receptor delta-1 channel activity.</p>"},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/#model-components","title":"Model Components","text":"<p>The model contains four main activities: 1. MGI:MGI:1351338 (Grm1) with GO:0099530 (G protein-coupled receptor activity involved in regulation of postsynaptic membrane potential) 2. MGI:MGI:95776 (Gnaq) with GO:0003925 (G protein activity) 3. MGI:MGI:104778 (Plcb3) with GO:0004435 (phosphatidylinositol phospholipase C activity) 4. MGI:MGI:97597 (Prkcg) with GO:0004698 (calcium,diacylglycerol-dependent serine/threonine kinase activity) 5. MGI:MGI:95812 (Grid1) with GO:1904315 (transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential)</p>"},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/#strengths","title":"Strengths","text":"<ol> <li>The model accurately represents the molecular function and causal relationships between key signaling components based on recent literature.</li> <li>The cellular components are correctly annotated, with most activities occurring in the postsynaptic compartment.</li> <li>The causal relationships follow the canonical signaling pathway from GPCR activation to channel opening.</li> <li>The model is grounded in evidence from multiple published studies, with each relationship having supporting evidence.</li> </ol>"},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Inconsistent cellular localization: While the model specifies postsynaptic cytosol (GO:0099524) for most components, it would be more accurate to place GRID1 in the postsynaptic density membrane (GO:0098839) where it functions, which is noted for some activities but not all.</p> </li> <li> <p>Biological process annotation: The model shows Grm1 and Gnaq being part of GO:0007200 (phospholipase C-activating G protein-coupled receptor signaling pathway), which is appropriate. However, Grid1 is annotated as part of GO:0099538 (synaptic signaling via neuropeptide), which doesn't seem as precise as possible for this pathway. A term more related to glutamatergic signaling would be more appropriate.</p> </li> <li> <p>Input-output relationships: The model shows outputs from Plcb3 activity (CHEBI:203600 - inositol triphosphate and CHEBI:17815 - diacylglycerol), but doesn't explicitly connect these outputs as inputs to the downstream Prkcg (PKC) activity, which would improve the model connectivity.</p> </li> <li> <p>Missing intermediates: The research suggests that additional components might be involved in complex formation (such as TRPC3), but these are not represented in the model.</p> </li> </ol>"},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/#scientific-accuracy","title":"Scientific Accuracy","text":"<ol> <li> <p>Signaling pathway: The model correctly represents the G protein-coupled receptor mGluR1 (Grm1) activating Gq (Gnaq), which activates PLC-beta3 (Plcb3), leading to PKC-gamma (Prkcg) activation and ultimately the regulation of the GluD1 (Grid1) channel.</p> </li> <li> <p>Causal relationships: The model accurately represents directionality using appropriate predicates. The causal flow from Grm1 \u2192 Gnaq \u2192 Plcb3 \u2192 Prkcg \u2192 Grid1 is supported by the literature, particularly the papers by Dadak et al. (2016) and Ady et al. (2014).</p> </li> <li> <p>Localization: The model correctly places these interactions in the postsynaptic compartment of dopamine neurons, which aligns with the expression patterns described in the literature.</p> </li> <li> <p>Evidence: The model appropriately cites primary literature for each relationship, including PMID:27276689, PMID:28696429, and PMID:23115168.</p> </li> </ol>"},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Update cellular location for GRID1: Ensure consistency in cellular annotations for GRID1, which should be in the postsynaptic density membrane (GO:0098839).</p> </li> <li> <p>Add second messenger relationships: The model could explicitly show how the second messengers (IP3 and DAG) connect to PKC activation.</p> </li> <li> <p>Consider adding TRPC3: Based on the literature (PMID:23115168), TRPC3 appears to be part of the complex with mGluR1 and GluD1. Including this protein would enhance the model's completeness.</p> </li> <li> <p>Revise biological process annotation for GRID1: Consider replacing GO:0099538 (synaptic signaling via neuropeptide) with a more appropriate term related to glutamate signaling.</p> </li> <li> <p>Add specific phosphorylation targets: If the literature supports it, the model could be enhanced by specifying the phosphorylation targets of PKC on GRID1.</p> </li> </ol>"},{"location":"reviews/66b5638000002528-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Mouse__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively captures the G protein-coupled receptor signaling pathway by which mGluR1 activates GluD1 channels in dopamine neurons, a pathway that appears important for neuronal firing patterns. The model is scientifically sound and well-supported by evidence. With the suggested minor improvements, it would provide an even more comprehensive representation of this signaling pathway that plays an important role in dopamine neuron function and potentially in disorders like schizophrenia, where GRID1 mutations have been implicated.</p>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/","title":"66b5638000002630 GRIM1 activates GRID1 via GNAQ in dopamine neurons  Human","text":"<p>Now, let me review the GO-CAM model gomodel:66b5638000002630. I'll analyze the structure, content, and quality of this model based on GO-CAM best practices.</p>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#review-of-go-cam-model-gomodel66b5638000002630","title":"Review of GO-CAM Model: gomodel:66b5638000002630","text":""},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#model-overview","title":"Model Overview","text":"<p>Title: GRIM1 activates GRID1 via GNAQ in dopamine neurons (Human).</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p> <p>URL: https://bioregistry.io/go.model:66b5638000002630</p>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#model-structure-summary","title":"Model Structure Summary","text":"<p>This model describes a signaling pathway in dopamine neurons involving: 1. GRID1 (Glutamate receptor ionotropic, delta-1) - UniProtKB:Q9ULK0 2. GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha) - UniProtKB:P50148 3. PLCB3 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3) - UniProtKB:Q01970 4. PRKCG (Protein kinase C gamma type) - UniProtKB:P05129</p> <p>The model represents a causal pathway where: - GRID1 has a G protein-coupled receptor activity that directly positively regulates GNAQ - GNAQ has G protein activity that directly positively regulates PLCB3 - PLCB3 has phosphatidylinositol phospholipase C activity, producing 1D-myo-inositol 1,4,5-trisphosphate and 1,2-diacyl-sn-glycerol - PRKCG has calcium,diacylglycerol-dependent serine/threonine kinase activity and appears to regulate GRID1</p>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#detailed-analysis","title":"Detailed Analysis","text":""},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#1-molecular-function-and-evidence-quality","title":"1. Molecular Function and Evidence Quality","text":""},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#grid1-uniprotkbq9ulk0","title":"GRID1 (UniProtKB:Q9ULK0):","text":"<ul> <li>Two activities are represented:</li> <li>GO:1904315 (transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential) with evidence ECO:0000250 (sequence similarity evidence)</li> <li> <p>GO:0099530 (G protein-coupled receptor activity involved in regulation of postsynaptic membrane potential) with evidence ECO:0000314 (direct assay)</p> </li> <li> <p>The annotation is well supported by recent literature (PMID:27276689) which directly shows GRID1 (GluD1) functioning as a G protein-coupled receptor.</p> </li> <li>The model correctly places GRID1 in postsynaptic density membrane (GO:0098839).</li> </ul>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#gnaq-uniprotkbp50148","title":"GNAQ (UniProtKB:P50148):","text":"<ul> <li>Annotated with GO:0003925 (G protein activity)</li> <li>Evidence is solid (ECO:0000314 with PMID:37991948)</li> <li>The subcellular location in postsynaptic cytosol (GO:0099524) is appropriate</li> </ul>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#plcb3-uniprotkbq01970","title":"PLCB3 (UniProtKB:Q01970):","text":"<ul> <li>Annotated with GO:0004435 (phosphatidylinositol phospholipase C activity)</li> <li>Evidence is solid (ECO:0000314 with PMID:9188725)</li> <li>Produces appropriate outputs: CHEBI:203600 (1D-myo-inositol 1,4,5-trisphosphate) and CHEBI:17815 (1,2-diacyl-sn-glycerol)</li> <li>The subcellular location in postsynaptic cytosol (GO:0099524) is appropriate</li> </ul>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#prkcg-uniprotkbp05129","title":"PRKCG (UniProtKB:P05129):","text":"<ul> <li>Annotated with GO:0004698 (calcium,diacylglycerol-dependent serine/threonine kinase activity)</li> <li>Evidence is solid (ECO:0000314 with PMID:23115168)</li> <li>The subcellular location in postsynaptic cytosol (GO:0099524) is appropriate</li> </ul>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#2-causal-relationships","title":"2. Causal Relationships","text":"<p>The causal relationships in the model follow logical pathways and are supported by the literature:</p> <ol> <li> <p>GRID1 \u2192 GNAQ: Uses RO:0002629 (directly positively regulates), which is appropriate for a receptor activating a G protein.</p> </li> <li> <p>GNAQ \u2192 PLCB3: Uses RO:0002629 (directly positively regulates), which is appropriate for G protein regulation of phospholipase C activity.</p> </li> <li> <p>PRKCG \u2192 GRID1: Uses RO:0002407 (indirectly activates), which seems appropriate based on literature that shows PKC activation can modulate ionotropic glutamate receptor function.</p> </li> </ol>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#3-biological-process-context","title":"3. Biological Process Context","text":"<p>Each activity is appropriately placed in the phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200), which is consistent with the model's content. For GRID1's ion channel activity, it's also placed in synaptic signaling via neuropeptide (GO:0099538).</p>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#4-cellular-localization","title":"4. Cellular Localization","text":"<p>All activities are appropriately localized in relevant cellular compartments: - GRID1 in postsynaptic density membrane (GO:0098839) - GNAQ, PLCB3, and PRKCG in postsynaptic cytosol (GO:0099524)</p>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#5-quality-of-evidence","title":"5. Quality of Evidence","text":"<p>Most evidence uses: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000250 (sequence similarity evidence used in manual assertion) - ECO:0000318 (biological aspect of ancestor evidence used in manual assertion)</p> <p>These are appropriate evidence codes, and each annotation is linked to relevant primary literature or appropriate GO references.</p>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#evaluative-comments","title":"Evaluative Comments","text":""},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model effectively captures the signaling cascade from receptor activation through G protein signaling to downstream effectors.</p> </li> <li> <p>Appropriate use of causal relations: The model uses the correct predicates to represent the causal relationships between activities.</p> </li> <li> <p>Well-supported by evidence: Most annotations are backed by direct experimental evidence and appropriate literature references.</p> </li> <li> <p>Proper cellular context: The activities are correctly localized in appropriate cellular compartments.</p> </li> <li> <p>Logical molecular outputs: The model correctly represents the products of PLCB3 activity.</p> </li> </ol>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<ol> <li> <p>Complex representation: While this model doesn't explicitly represent any protein complexes, it correctly follows the GO-CAM guidelines for representing the individual proteins carrying specific activities rather than representing the complex as a whole.</p> </li> <li> <p>Feedback loops: The model could potentially be enhanced by including any feedback mechanisms that might exist in this signaling pathway.</p> </li> <li> <p>Downstream effects: The model could be extended to show how PKC activation ultimately affects cellular processes beyond regulation of GRID1.</p> </li> <li> <p>Alternative evidence for GRID1 channel activity: The ion channel activity of GRID1 is supported only by sequence similarity evidence. According to the UniProt entry for GRID1 (Q9ULK0), there is now controversy about this activity (noted under CAUTION: \"The ligand-gated cation channel activity triggered by glycine and D-serine, first reported in an article, has been a subject of controversy\"). Recent research (PubMed:39052831) has disputed this ligand-gated cation channel activity.</p> </li> </ol>"},{"location":"reviews/66b5638000002630-GRIM1_activates_GRID1_via_GNAQ_in_dopamine_neurons__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"GRIM1 activates GRID1 via GNAQ in dopamine neurons (Human)\" (gomodel:66b5638000002630) is a well-constructed, evidence-based representation of a G protein-coupled receptor signaling pathway in dopamine neurons. The model follows GO-CAM best practices for representing molecular functions, cellular components, and causal relationships.</p> <p>The model successfully captures a signaling cascade from GRID1 receptor activation, through GNAQ G protein function, to phospholipase C activation and subsequent second messenger generation, with protein kinase C serving as a feedback regulator.</p> <p>The evidence used to support the annotations is strong, with most activities supported by direct experimental evidence. While there could be some potential updates regarding the controversy around GRID1's ion channel activity, the overall structure of the model is sound.</p> <p>In summary, this is a high-quality GO-CAM model that effectively represents the current understanding of GRID1-mediated signaling through GNAQ in dopamine neurons.</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/","title":"66b5638000002701 IL13RA2 mediated alternative IL13 pathway leading to TGFB1 production  Human","text":"<p>After gathering and reviewing all the necessary information about the GO-CAM model, let me provide a comprehensive review:</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#review-of-go-cam-model-66b5638000002701","title":"Review of GO-CAM Model: 66b5638000002701","text":""},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model gomodel:66b5638000002701 is titled \"IL13RA2-mediated alternative IL13 pathway leading to TGFB1 production (Human)\" and describes a signaling pathway in humans (NCBITaxon:9606) where IL-13 signals through the IL-13R\u03b12 receptor to ultimately lead to TGF-\u03b21 production.</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model includes four main activities:</p> <ol> <li>IL-13 cytokine activity (enabled by UniProtKB:P35225)</li> <li>IL-13R\u03b12 cytokine receptor activity (enabled by UniProtKB:Q14627)</li> <li>AP-1 transcription factor activity (enabled by a complex of UniProtKB:P05412/UniProtKB:P15408)</li> <li>TGF-\u03b21 cytokine activity (enabled by UniProtKB:P01137)</li> </ol> <p>The causal relationships in the model are: - IL-13 directly positively regulates IL-13R\u03b12 - IL-13R\u03b12 directly positively regulates the AP-1 complex and has input into the AP-1 complex - AP-1 complex has target response element activity toward the TGF-\u03b21 protein</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#evidence-and-literature-support","title":"Evidence and Literature Support","text":"<p>The model is well-supported by the literature. The primary citation (PMID:16327802) provides detailed experimental evidence showing that IL-13 signaling through IL-13R\u03b12 activates an AP-1 complex (containing c-Jun and Fra-2) which then activates TGF-\u03b21 production. This finding was significant because IL-13R\u03b12 was previously considered only a decoy receptor.</p> <p>Additional citations support individual steps in the model: - PMID:8096327 for IL-13 cytokine activity - PMID:18694590 for IL-13R\u03b12 localization - PMID:32644293 for TGF-\u03b21 cytokine activity</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#cellular-location-accuracy","title":"Cellular Location Accuracy","text":"<p>The model correctly places: - IL-13 in the extracellular space (GO:0005615) - IL-13R\u03b12 at the plasma membrane (GO:0005886) - AP-1 complex in the nucleus (GO:0005634) - TGF-\u03b21 in the extracellular space (GO:0005615)</p> <p>These localizations are consistent with the known biology of these proteins and the signaling pathway.</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#molecular-function-annotation","title":"Molecular Function Annotation","text":"<p>The molecular functions assigned to each component are appropriate: - IL-13: cytokine activity (GO:0005125) - IL-13R\u03b12: cytokine receptor activity (GO:0004896) - AP-1 complex: DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981) - TGF-\u03b21: cytokine activity (GO:0005125)</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#biological-process-annotation","title":"Biological Process Annotation","text":"<p>The model appropriately connects the activities to relevant biological processes: - IL-13 and IL-13R\u03b12 activities are part of the interleukin-13-mediated signaling pathway (GO:0035772) - AP-1 complex activity is part of transforming growth factor beta1 production (GO:0032905) - TGF-\u03b21 activity is part of the transforming growth factor beta receptor signaling pathway (GO:0007179)</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships in the model accurately reflect the biology described in the literature: - IL-13 directly positively regulates (RO:0002629) IL-13R\u03b12 activity - IL-13R\u03b12 directly positively regulates (RO:0002629) and directly provides input for (RO:0002409) the AP-1 complex - AP-1 complex has target response element activity toward (RO:0002407) TGF-\u03b21</p> <p>This matches the mechanism described by Fichtner-Feigl et al. (2006), who demonstrated that IL-13 signals through IL-13R\u03b12 to activate an AP-1 complex containing c-Jun and Fra-2, which then activates the TGFB1 promoter.</p>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate representation of a novel signaling pathway: The model correctly captures the alternative pathway of IL-13 signaling through IL-13R\u03b12, which was a significant discovery showing that IL-13R\u03b12 is not just a decoy receptor but has signaling capabilities.</p> </li> <li> <p>Appropriate protein complex formation: The AP-1 transcription factor is correctly modeled as a complex comprising c-Jun (P05412) and Fra-2 (P15408), as identified in the research paper.</p> </li> <li> <p>Well-supported by experimental evidence: Each component and relationship in the model is supported by published experimental evidence.</p> </li> <li> <p>Correct cellular locations: All proteins are placed in their correct cellular compartments.</p> </li> <li> <p>Biologically meaningful connections: The model makes biologically meaningful connections between IL-13 signaling and TGF-\u03b21 production, with implications for fibrosis.</p> </li> </ol>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#minor-suggestions-for-improvement","title":"Minor Suggestions for Improvement","text":"<ol> <li> <p>Additional context on TNF-\u03b1 role: Although outside the direct scope of this pathway, the primary reference indicates that TNF-\u03b1 is required for the induction of IL-13R\u03b12 expression before IL-13 can signal through it. This could be noted in model annotations for a more complete understanding of the pathway's context.</p> </li> <li> <p>Biological outcomes: The model could potentially benefit from extending to include the biological outcomes of TGF-\u03b21 production, such as fibrosis, which was a key finding in the research papers.</p> </li> </ol>"},{"location":"reviews/66b5638000002701-IL13RA2_mediated_alternative_IL13_pathway_leading_to_TGFB1_production__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:66b5638000002701 is a high-quality representation of the IL-13R\u03b12-mediated alternative IL-13 pathway leading to TGF-\u03b21 production. It accurately captures the biological mechanism described in the literature with appropriate molecular functions, cellular locations, and causal relationships. The model is well-supported by experimental evidence and follows GO-CAM best practices for representing signaling pathways and transcription factor activities.</p> <p>This model is particularly valuable because it represents a significant advancement in understanding IL-13 signaling - the finding that IL-13R\u03b12, previously thought to function only as a decoy receptor, actually has signaling capabilities that lead to TGF-\u03b21 production. This pathway has important implications for understanding fibrosis in various inflammatory conditions.</p>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/","title":"66c7d41500000163 Signaling by Calcitonin CGRP mediated by CALCA CGRP1 ligand activating CALCR RAMP1  AMYR1  receptor complex  Human","text":"<p>After reviewing all the information, I'll now provide a detailed review of the GO-CAM model with ID gomodel:66c7d41500000163, titled \"Signaling by Calcitonin/CGRP mediated by CALCA/CGRP1 ligand activating CALCR-RAMP1 (AMYR1) receptor complex (Human)\".</p>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#go-cam-review-gomodel66c7d41500000163","title":"GO-CAM Review: gomodel:66c7d41500000163","text":""},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#overview","title":"Overview","text":"<p>This model represents the signaling pathway of Calcitonin Gene-Related Peptide (CGRP) via the Amylin 1 Receptor (AMYR1), which is formed by the calcitonin receptor (CALCR) and receptor activity-modifying protein 1 (RAMP1). The model shows how CGRP (CALCA) activates this receptor complex, leading to G protein activation, adenylate cyclase activity, and production of cyclic AMP as a second messenger.</p>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#model-structure-evaluation","title":"Model Structure Evaluation","text":""},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#proteins-and-activities-represented","title":"Proteins and Activities Represented:","text":"<ol> <li>CALCA (P06881-1): Hormone activity (GO:0005179) in extracellular space</li> <li>RAMP1 (O60894): Coreceptor activity (GO:0015026) at plasma membrane </li> <li>CALCR (P30988): Calcitonin gene-related peptide receptor activity (GO:0001635) at plasma membrane</li> <li>GNAS (Q5JWF2): G protein activity (GO:0003925) in cytosol</li> <li>ADCY6 (O43306): Adenylate cyclase activity (GO:0004016) producing cAMP</li> </ol>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#causal-connections","title":"Causal Connections:","text":"<ul> <li>CALCA directly positively regulates CALCR</li> <li>RAMP1 directly positively regulates CALCR</li> <li>CALCR directly positively regulates GNAS</li> <li>GNAS directly positively regulates ADCY6</li> </ul>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#biological-process-contexts","title":"Biological Process Contexts:","text":"<ul> <li>CALCA is part of amylin receptor 1 signaling pathway (GO:0150059)</li> <li>RAMP1 is part of amylin receptor 1 signaling pathway (GO:0150059)</li> <li>CALCR is part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li>GNAS is part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li>ADCY6 is part of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> </ul>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Scientific Accuracy: The model is consistent with the latest research on CGRP receptor interactions, as evidenced by publications like PMID:38603770, which describes the cryo-EM structure of the AMYR1 receptor complex with CGRP.</p> </li> <li> <p>Complete Pathway Representation: The model captures the entire signaling cascade from ligand binding through receptor activation, G protein coupling, and second messenger generation.</p> </li> <li> <p>Proper Evidence: Each activity and relationship is supported by appropriate evidence with specific PMIDs.</p> </li> <li> <p>Appropriate Use of GO Terms: The molecular functions, biological processes, and cellular components used are all appropriate for the proteins in the model.</p> </li> <li> <p>Correct Causal Relationships: The model uses the appropriate causal relationship \"directly positively regulates\" (RO:0002629) between activities.</p> </li> </ol>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>RAMP1 Representation: According to the signaling receptor activity annotation guidelines, the input of a coreceptor should be the signaling receptor it regulates. However, in this model, RAMP1 directly regulates CALCR, which is consistent with its biological role but could be clarified with a more specific annotation about their complex formation.</p> </li> <li> <p>Complex Representation: While the title mentions the CALCR-RAMP1 (AMYR1) receptor complex, the model represents CALCR and RAMP1 as separate proteins with separate activities rather than as a complex. According to the \"How to annotate complexes in GO-CAM\" document, when two proteins form a heterodimeric receptor where both activities are important (as is the case with CALCR and RAMP1), there are specific ways to represent this. The current approach is valid but could potentially benefit from clearer complex notation.</p> </li> <li> <p>Biological Process Annotation: While the activities are appropriately placed in biological processes, the model would benefit from showing more explicitly how these processes relate to each other.</p> </li> </ol>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#conclusion-and-recommendations","title":"Conclusion and Recommendations","text":"<p>This GO-CAM model accurately represents the CGRP signaling pathway through the AMYR1 receptor complex. The model follows GO-CAM best practices in most respects, including the use of appropriate molecular functions, biological processes, cellular components, and causal relationships.</p>"},{"location":"reviews/66c7d41500000163-Signaling_by_Calcitonin_CGRP_mediated_by_CALCA_CGRP1_ligand_activating_CALCR_RAMP1__AMYR1__receptor_complex__Human_/#recommended-improvements","title":"Recommended Improvements:","text":"<ol> <li> <p>Consider Complex Representation: While representing CALCR and RAMP1 as separate entities with their own activities is valid, the model might benefit from more explicitly showing their functional relationship as a complex. This could potentially be done by adding an annotation that clarifies their heterodimeric nature.</p> </li> <li> <p>RAMP1 Relationship with CALCR: Consider clarifying the relationship between RAMP1 and CALCR to better align with the guidelines for annotating coreceptor activities, by specifying that RAMP1 enables the trafficking and ligand specificity of CALCR.</p> </li> <li> <p>PMIDs: While most references are correctly cited, some PMID citations need formatting corrections (e.g., \"PMID: 2408883\" has a space that should be removed).</p> </li> </ol> <p>Overall, this is a well-constructed GO-CAM model that accurately represents the current scientific understanding of CGRP signaling through the AMYR1 receptor. The minor suggestions for improvement would enhance clarity but don't detract from the model's scientific accuracy.</p>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/","title":"66c7d41500000427 Zika virus NS5 inhibition of STAT2 signaling via ZSWIM8  Human","text":"<p>Based on my review of the GO-CAM model and the relevant scientific literature, I'll now provide a comprehensive review of gomodel:66c7d41500000427 \"Zika virus NS5 inhibition of STAT2 signaling via ZSWIM8 (Human)\".</p>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#go-cam-model-review-gomodel66c7d41500000427","title":"GO-CAM Model Review: gomodel:66c7d41500000427","text":""},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#model-summary","title":"Model Summary","text":"<p>Title: Zika virus NS5 inhibition of STAT2 signaling via ZSWIM8 (Human) Taxon: NCBITaxon:9606 (Human) Status: Production ID: gomodel:66c7d41500000427</p>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the mechanism by which Zika virus NS5 protein inhibits interferon signaling by targeting the STAT2 protein for degradation via the ZSWIM8-containing Cullin-RING E3 ubiquitin ligase complex. The model illustrates a key viral immune evasion strategy that helps Zika virus overcome host antiviral defenses.</p>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#biological-content-evaluation","title":"Biological Content Evaluation","text":"<p>The model accurately represents a well-documented mechanism of viral immune evasion based on current literature. The key molecular players include:</p> <ol> <li>ZSWIM8 (UniProtKB:A7E2V4) - Functions as a ubiquitin-like ligase-substrate adaptor</li> <li>Zika virus NS5 (UniProtKB:Q32ZE1) - Acts as a protein-macromolecule adaptor</li> <li>CUL3 (UniProtKB:Q13618) - Functions as ubiquitin ligase complex scaffold</li> <li>STAT2 (UniProtKB:P52630) - The target transcription factor that gets degraded</li> </ol>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#activity-flow-assessment","title":"Activity Flow Assessment","text":"<p>The model correctly captures the causal flow of activities:</p> <ol> <li> <p>Zika virus NS5 (GO:0030674 - protein-macromolecule adaptor activity) provides input for the ZSWIM8 activity. This is supported by PMID:39145933, which shows that NS5 acts as a scaffold protein connecting the ZSWIM8-CUL3 E3 ligase complex to STAT2.</p> </li> <li> <p>ZSWIM8 (GO:1990756 - ubiquitin-like ligase-substrate adaptor activity) negatively regulates, through direct negative regulation (RO:0002409), the STAT2 activity. This is well supported by PMID:33184234.</p> </li> <li> <p>CUL3 (GO:0160072 - ubiquitin ligase complex scaffold activity) directly positively regulates (RO:0002629) the activity of ZSWIM8. This is supported by PMID:23453970.</p> </li> <li> <p>The degradation of STAT2 prevents its DNA-binding transcription factor activity (GO:0003700), which would normally function in the type I interferon-mediated signaling pathway (GO:0060337).</p> </li> </ol>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#evidence-evaluation","title":"Evidence Evaluation","text":"<p>The model is well-supported by multiple recent scientific publications:</p> <ul> <li>PMID:33184234 (2020) - Identifies ZSWIM8 as a key component in the ubiquitin ligase complex</li> <li>PMID:39145933 (2023) - Specifically demonstrates how Zika virus NS5 protein inhibits type I interferon signaling via CRL3 E3 ubiquitin ligase-mediated degradation of STAT2</li> <li>PMID:23453970 (2013) - Establishes the role of CUL3 in the ubiquitin ligase complex</li> <li>PMID:31127039 (2019) - Documents STAT2's role as a DNA-binding transcription factor</li> <li>PMID:23391734 (2013) - Describes the function of STAT2 in type I interferon signaling pathway</li> </ul> <p>All evidence types are appropriate, primarily using ECO:0000314 (direct assay evidence used in manual assertion).</p>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#cellular-location-accuracy","title":"Cellular Location Accuracy","text":"<p>The model correctly represents the cellular locations:</p> <ul> <li>ZSWIM8 activity occurs in the cytosol (GO:0005829)</li> <li>Zika virus NS5 is correctly shown in the host cell cytoplasm (GO:0030430)</li> <li>CUL3 is shown in the cytoplasm (GO:0005737)</li> <li>STAT2 is shown in the nucleus (GO:0005634), which is appropriate since that's where it would function as a transcription factor (when not degraded)</li> </ul>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#alignment-with-go-cam-best-practices","title":"Alignment with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Appropriate GO terms: The molecular functions, cellular components, and biological processes are all appropriately selected.</p> </li> <li> <p>Correct causal relationships: The model uses appropriate causal predicates:</p> </li> <li>RO:0002413 (provides input for) for NS5 to ZSWIM8</li> <li>RO:0002409 (negatively regulated by) for ZSWIM8 to STAT2</li> <li> <p>RO:0002629 (directly positively regulates) for CUL3 to ZSWIM8</p> </li> <li> <p>Proper evidence documentation: Each association includes evidence codes, reference citations, and contributor information.</p> </li> <li> <p>Species specificity: The model clearly indicates it represents the human system.</p> </li> </ol>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#parsimony-and-clarity","title":"Parsimony and Clarity","text":"<p>The model is parsimonious and clear: - It focuses on the core mechanism of STAT2 degradation without unnecessary complexity - The causal flow is logical and easy to follow - It correctly represents the roles of all four key proteins in the process - It accurately captures the immune evasion strategy of Zika virus</p>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#recommendations","title":"Recommendations","text":"<p>The model is scientifically accurate and well-constructed. Some minor potential enhancements could include:</p> <ol> <li> <p>Expanding upstream regulators: Consider adding information on what activates the CUL3 complex in this context (if known).</p> </li> <li> <p>Downstream effects: The model could potentially be expanded to show the specific genes whose expression is affected by the loss of STAT2 activity.</p> </li> <li> <p>Temporal aspects: If temporal data is available about when during infection this mechanism is most active, this could be added as annotation.</p> </li> </ol>"},{"location":"reviews/66c7d41500000427-Zika_virus_NS5_inhibition_of_STAT2_signaling_via_ZSWIM8__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model accurately represents the current scientific understanding of how Zika virus NS5 inhibits STAT2 signaling via ZSWIM8. It is well-supported by recent literature, follows GO-CAM best practices, and clearly illustrates an important viral immune evasion mechanism. The model is biologically accurate, properly connects activities in a meaningful causal flow, and is built with appropriate evidence.</p> <p>The model makes a valuable contribution to understanding how Zika virus evades the host immune response and could be useful for researchers studying viral pathogenesis and host-pathogen interactions.</p>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/","title":"66c7d41500000544 CAAX box protein maturation 1  Mouse","text":"<p>Based on my comprehensive review of the GO-CAM model with ID gomodel:66c7d41500000544, here's my assessment:</p>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#review-of-go-cam-model-caax-box-protein-maturation-1-mouse","title":"Review of GO-CAM Model: CAAX-box protein maturation 1 (Mouse)","text":"<p>Model ID: gomodel:66c7d41500000544</p>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#general-overview","title":"General Overview","text":"<p>This GO-CAM model represents the CAAX-box protein maturation pathway in mice (NCBITaxon:10090). The model is in production status and illustrates the enzymatic cascade involved in post-translational processing of proteins containing a CAAX-box motif, which is an important process for proper membrane localization and function of many proteins including members of the RHO family.</p>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#pathway-structure","title":"Pathway Structure","text":"<p>The model effectively captures the sequential steps in CAAX-box protein maturation:</p> <ol> <li> <p>The initial step involves the CAAX-protein geranylgeranyltransferase complex (GO:0005953), composed of Fnta (MGI:MGI:104683) and Pggt1b (MGI:MGI:1917514), which adds a geranylgeranyl group to the cysteine residue of the CAAX motif.</p> </li> <li> <p>This is followed by Rce1 (MGI:MGI:1336895) which performs endopeptidase activity to remove the -AAX portion of the motif.</p> </li> <li> <p>Finally, Icmt (MGI:MGI:1888594) performs the methylation of the C-terminal prenylated cysteine residue.</p> </li> <li> <p>The model also includes a regulatory component where Musk (MGI:MGI:103581) positively regulates the initial geranylgeranyltransferase activity.</p> </li> </ol>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#evidence-support","title":"Evidence Support","text":"<p>The model is well-supported by experimental evidence: - Most associations are backed by mutant phenotype evidence (ECO:0000315) or direct assay evidence (ECO:0000314) - The references cited (e.g., PMID:14622576, PMID:10085069, PMID:10747846) are appropriate for the process described - The reviewed papers support the connections between components, particularly the paper by Luo et al. (PMID:14622576) which provides solid evidence for the regulatory role of Musk in geranylgeranyltransferase activity</p>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal relationships are accurately represented using appropriate predicates: - RO:0002413 (provides input for) is used correctly to connect the sequential enzymatic activities in the pathway - RO:0002629 (directly positively regulates) properly represents Musk's regulatory role on the geranylgeranyltransferase complex</p>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#chemical-entities","title":"Chemical Entities","text":"<p>The model properly includes the relevant chemical entities: - CHEBI:57533 (geranylgeranyl diphosphate) as input to the first enzyme - CHEBI:86021 (S-geranylgeranyl-L-cysteine residue) as output of the first enzyme/input to the next - CHEBI:59789 (S-adenosyl-L-methionine) as a cofactor for methylation - CHEBI:57856 (S-adenosyl-L-homocysteine) as a byproduct - CHEBI:87167 (S-[(2E,6E)-farnesyl]-L-cysteine methyl ester) as the final product</p>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#best-practices-compliance","title":"Best Practices Compliance","text":"<p>The model follows GO-CAM best practices: - Activities have appropriate molecular functions, cellular components (when relevant), and biological process associations - Causal connections are biologically meaningful and correctly represent the pathway flow - The protein complex (GGTase-I) is correctly modeled with its component subunits</p>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#parsimony-and-clarity","title":"Parsimony and Clarity","text":"<ul> <li>The model effectively represents the essential steps in CAAX-box protein maturation without unnecessary complexity</li> <li>The structure is clear and would be easily understandable by biologists familiar with protein prenylation</li> </ul>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<ul> <li>The model aligns well with the key papers cited, particularly Luo et al. (PMID:14622576), which describes the role of geranylgeranyltransferase in synapse formation</li> <li>The biological roles of these enzymes are consistent with the current understanding of CAAX-box protein processing</li> </ul>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#recommendations","title":"Recommendations","text":"<p>The model is generally well-constructed, but I have a few minor recommendations:</p> <ol> <li> <p>Subcellular Location: The Icmt activity (protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase) is correctly annotated as occurring in the endoplasmic reticulum membrane (GO:0005789), but the other activities could also benefit from cellular location annotations for completeness.</p> </li> <li> <p>Biological Context: While the model accurately represents the enzymatic pathway, adding some additional context about the biological significance of this process in mice might enhance the model's value (though this is optional).</p> </li> <li> <p>Additional Evidence: For a few of the \"has_input\" and \"has_output\" associations, there isn't specific evidence listed. Adding evidence for these relationships would strengthen the model further.</p> </li> </ol>"},{"location":"reviews/66c7d41500000544-CAAX_box_protein_maturation_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a well-constructed representation of CAAX-box protein maturation in mice. It effectively captures the essential enzymatic steps, regulatory mechanisms, and chemical transformations involved in this process. The evidence is well-documented and the causal connections are biologically meaningful. With the minor enhancements suggested above, this would be an exemplary GO-CAM model for this important post-translational modification pathway.</p>"},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/","title":"66c7d41500000715 CLEC12A acts as an inhibitor of neutrophil activation  Human","text":"<p>Let me review the GO-CAM model with ID gomodel:66c7d41500000715 based on the information I've retrieved and the GO-CAM best practices.</p>"},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#go-cam-review-gomodel66c7d41500000715","title":"GO-CAM Review: gomodel:66c7d41500000715","text":""},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#model-overview","title":"Model Overview","text":"<p>Title: \"CLEC12A acts as an inhibitor of neutrophil activation (Human)\"</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#model-structure-and-content","title":"Model Structure and Content","text":"<p>This GO-CAM describes how CLEC12A (also known as MICL, Myeloid Inhibitory C-type Lectin-like receptor) functions as an inhibitory receptor to regulate neutrophil activation through a signaling cascade involving several key proteins. The model includes the following activities and their causal relationships:</p> <ol> <li> <p>CLEC12A (Q5QGZ9) - Functions as a transmembrane signaling receptor (GO:0004888) at the plasma membrane (GO:0005886), participating in negative regulation of neutrophil activation (GO:1902564)</p> </li> <li> <p>SRC (P12931) - Exhibits protein tyrosine kinase activity (GO:0004713) in the negative regulation of neutrophil activation pathway, acts upstream of PTPN6 and PTPN11 through causal relationship (RO:0012010 - \"causally upstream of, positive effect\")</p> </li> <li> <p>PTPN6/SHP-1 (P29350) - Shows protein tyrosine phosphatase activity (GO:0004725) in the negative regulation of neutrophil activation process, acts to directly negatively regulate (RO:0002630) SYK activity </p> </li> <li> <p>PTPN11/SHP-2 (Q06124) - Exhibits protein tyrosine phosphatase activity (GO:0004725) in the negative regulation of neutrophil activation process, and like PTPN6, also directly negatively regulates (RO:0002630) SYK activity</p> </li> <li> <p>SYK (P43405) - Displays protein tyrosine kinase activity (GO:0004713) in neutrophil activation involved in immune response (GO:0002283)</p> </li> </ol>"},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#assessment-of-the-model","title":"Assessment of the Model","text":""},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of CLEC12A's role in neutrophil regulation as supported by literature:</p> <ol> <li> <p>The PMID:34234773 paper clearly establishes CLEC12A as an inhibitory receptor that negatively regulates neutrophil activation through pathways involving SRC and phosphatases</p> </li> <li> <p>PMID:33782605 provides evidence for SYK's role in neutrophil activation in immune responses</p> </li> <li> <p>PMID:39143217 further validates CLEC12A's role as a transmembrane signaling receptor that regulates neutrophil activation</p> </li> </ol> <p>The model correctly depicts the cascade where CLEC12A engagement leads to SRC activation, which then activates the phosphatases PTPN6 and PTPN11, which in turn negatively regulate SYK, a key kinase involved in neutrophil activation.</p>"},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model adheres to GO-CAM best practices:</p> <ol> <li> <p>Proper use of evidence codes: The model uses appropriate evidence codes for each assertion (ECO:0000314 for direct assay evidence, ECO:0000315 for mutant phenotype evidence)</p> </li> <li> <p>Appropriate causal relationships: The causal relationships use proper predicates (RO:0012010 for \"causally upstream of, positive effect\" and RO:0002630 for \"directly negatively regulates\")</p> </li> <li> <p>Cellular locations: When relevant, cellular locations are specified (plasma membrane for CLEC12A)</p> </li> <li> <p>Biological process context: Each molecular function is appropriately situated within a biological process context</p> </li> <li> <p>Protein annotation: Proteins are identified by UniProtKB accessions, which is the correct practice</p> </li> </ol>"},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#completeness-and-parsimony","title":"Completeness and Parsimony","text":"<p>The model is both:</p> <ol> <li> <p>Complete: It captures the key players and relationships in this specific inhibitory pathway</p> </li> <li> <p>Parsimonious: It includes the essential components without unnecessary complexity</p> </li> </ol>"},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is of high quality, a few potential enhancements could be considered:</p> <ol> <li> <p>Additional contextual information: The model could potentially include more specific details about when and how CLEC12A is activated, such as its interaction with NETs (neutrophil extracellular traps) as mentioned in PMID:39143217</p> </li> <li> <p>Connection to downstream effects: The model could be expanded to show downstream effects of inhibited neutrophil activation</p> </li> </ol>"},{"location":"reviews/66c7d41500000715-CLEC12A_acts_as_an_inhibitor_of_neutrophil_activation__Human__/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:66c7d41500000715 is a high-quality representation of CLEC12A's role as an inhibitor of neutrophil activation. It accurately captures the molecular interactions, causal relationships, and biological context based on current literature. The model adheres to GO-CAM best practices and effectively conveys how this inhibitory pathway functions in human neutrophils.</p> <p>The model effectively communicates the signaling cascade from the inhibitory receptor CLEC12A to the downstream effector SYK, showing how phosphatases PTPN6 and PTPN11 mediate this inhibitory signal. This provides valuable insight into mechanisms regulating neutrophil activation, which is critical for immune homeostasis and preventing excessive inflammation.</p>"},{"location":"reviews/66c7d41500000841-heme_biosynthetic_process__GO_0006783_/","title":"66c7d41500000841 heme biosynthetic process  GO 0006783","text":"<p>Based on my review of the GO-CAM model and checking against best practices, here's my assessment:</p>"},{"location":"reviews/66c7d41500000841-heme_biosynthetic_process__GO_0006783_/#review-summary-for-go-cam-model-gomodel66c7d41500000841","title":"Review Summary for GO-CAM Model gomodel:66c7d41500000841","text":""},{"location":"reviews/66c7d41500000841-heme_biosynthetic_process__GO_0006783_/#positive-aspects","title":"Positive Aspects","text":"<ol> <li> <p>Complete Pathway Representation: The model successfully captures the full heme biosynthetic pathway from 5-aminolevulinate synthase through ferrochelatase, as well as the branching pathways to heme A and siroheme.</p> </li> <li> <p>Appropriate Evidence: All activities have appropriate evidence codes (ECO terms) and references (PMID or GO_REF).</p> </li> <li> <p>Correct Causal Relationships: The activities are properly connected using the \"provides input for\" predicate (RO:0002413), showing the flow of the pathway.</p> </li> <li> <p>Proper Cellular Localization: Correct cellular compartments are specified for relevant enzymes.</p> </li> <li> <p>Input/Output Molecules: The model appropriately includes substrate and product molecules for enzymatic reactions.</p> </li> </ol>"},{"location":"reviews/66c7d41500000841-heme_biosynthetic_process__GO_0006783_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li>Missing Has_Input Annotations: Some activities are missing explicit has_input annotations that would clarify the substrate-product relationships. For example:</li> <li>The ferrochelatase activity (SPCC320.09/hem15) is missing its iron input</li> <li> <p>Some intermediate steps are missing explicit input molecules</p> </li> <li> <p>Complex Handling: The model doesn't include any protein complexes, but it should be verified if any of these enzymes function as complexes in S. pombe. </p> </li> <li> <p>Potential Regulatory Relationships: The model exclusively uses the \"provides input for\" causal relationship (RO:0002413). If any direct regulatory relationships exist (such as feedback inhibition that is common in biosynthetic pathways), these could be captured using regulatory relationships like \"directly positively regulates\" (RO:0002629) or \"directly negatively regulates\" (RO:0002630).</p> </li> <li> <p>Branch Points Clarity: The branching of the pathway to siroheme biosynthesis from uroporphyrinogen III is correctly shown, but the clarity of this branch point could be improved by adding more explicit annotations about the branching relationship.</p> </li> <li> <p>Connectivity Check: I notice that the ferrochelatase (hem15) appears to be an endpoint without showing connections to how heme b is further processed to heme a. The connection between the main heme synthesis path and the heme A biosynthesis branch could be made more explicit.</p> </li> </ol>"},{"location":"reviews/66c7d41500000841-heme_biosynthetic_process__GO_0006783_/#additional-recommendations","title":"Additional Recommendations","text":"<ol> <li> <p>Pathway Completeness Verification: Check literature to ensure all known regulatory mechanisms of the pathway in S. pombe are included.</p> </li> <li> <p>Human Readability: While the model captures the pathway steps accurately, consider if the layout and organization optimize human understanding of the overall pathway flow.</p> </li> <li> <p>Species-Specific Details: Verify that any known S. pombe-specific aspects of heme biosynthesis are accurately captured, as there can be species-specific variations in this pathway.</p> </li> </ol>"},{"location":"reviews/66c7d41500000841-heme_biosynthetic_process__GO_0006783_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that effectively represents the heme biosynthetic pathway in S. pombe. The model follows most GO-CAM best practices and provides valuable information about the molecular functions, their cellular locations, and the overall pathway organization. The suggested improvements are relatively minor and would mainly enhance the completeness and clarity of the model rather than correct any significant errors.</p>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/","title":"66c7d41500002088 ergosterol biosynthetic process","text":"<p>Now, let me review this GO-CAM model in detail.</p>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#go-cam-review-ergosterol-biosynthetic-process-model-gomodel66c7d41500002088","title":"GO-CAM Review: Ergosterol Biosynthetic Process Model (gomodel:66c7d41500002088)","text":""},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the ergosterol biosynthetic process (GO:0006696) in Schizosaccharomyces pombe (NCBITaxon:4896). The model illustrates a comprehensive pathway of ergosterol biosynthesis with multiple enzymes, their molecular functions, cellular locations, and causal relationships between activities.</p>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#model-structure","title":"Model Structure","text":"<p>The model includes 15 different gene products (proteins) from S. pombe, each with defined: - Molecular functions (specific enzymatic activities) - Cellular locations (primarily in the endoplasmic reticulum or ER membrane) - Participation in the ergosterol biosynthetic process - Causal connections showing the flow of the pathway</p>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#key-components","title":"Key Components","text":""},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#1-enzymes-and-activities","title":"1. Enzymes and Activities:","text":"<ul> <li>The pathway begins with squalene synthesis (Erg9)</li> <li>Involves multiple sterol modification enzymes (Erg1, Erg7, Erg11, etc.)</li> <li>Includes desaturases, reductases, isomerases, and transferases</li> <li>Ends with ergosterol as the final product</li> </ul>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#2-cellular-localization","title":"2. Cellular Localization:","text":"<ul> <li>All activities occur in the endoplasmic reticulum (GO:0005783) or more specifically in the ER membrane (GO:0005789)</li> <li>This is consistent with what we know about sterol biosynthesis</li> </ul>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#3-evidence","title":"3. Evidence:","text":"<ul> <li>Most annotations are supported by sequence similarity evidence (ECO:0000250), biological aspect of ancestor evidence (ECO:0000318), or direct experimental evidence</li> <li>References to PMID literature and orthology to known proteins in other species (especially S. cerevisiae)</li> </ul>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#pathway-flow-analysis","title":"Pathway Flow Analysis","text":"<p>The pathway is well-structured with clear \"provides input for\" (RO:0002413) relationships between sequential steps:</p> <ol> <li>Isoprenoid synthesis \u2192 Squalene synthesis (Erg9)</li> <li>Squalene oxidation (Erg1) \u2192 Lanosterol synthesis (Erg7)</li> <li>Lanosterol modification (Erg11) \u2192 Multiple sterol intermediates</li> <li>Sequential sterol modifications through multiple enzymes</li> <li>Final steps leading to ergosterol formation</li> </ol>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#quality-control-review","title":"Quality Control Review","text":""},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#strengths","title":"Strengths:","text":"<ol> <li>Biological completeness: The model captures the complete ergosterol biosynthesis pathway.</li> <li>Molecular specificity: Appropriate molecular functions assigned to each gene product.</li> <li>Causal relationships: Clear \"provides input for\" relationships between sequential activities.</li> <li>Cellular context: Correct subcellular localization in the ER and ER membrane.</li> <li>Evidence quality: Good use of multiple evidence codes and references.</li> </ol>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#minor-issues","title":"Minor issues:","text":"<ol> <li>Duplicate causal relationships: Some activities have duplicate causal associations with the same predicate and target, one with evidence and one without. For example:</li> <li>Between SPBC3F6.02c (Erg26) \u2192 SPBC1709.07 (Erg27)</li> <li> <p>Between SPBC16E9.05 (Erg6) \u2192 SPBC20G8.07c (Erg2)</p> </li> <li> <p>Molecular inputs/outputs: While some activities have specific chemical inputs/outputs defined (e.g., lanosterol, ergosterol), not all intermediate metabolites are explicitly defined.</p> </li> <li> <p>Regulatory connections: One positive regulation relationship exists (Ccr1 directly positively regulates Erg11), but the model could potentially benefit from additional regulatory relationships if biologically relevant.</p> </li> </ol>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#literature-consistency","title":"Literature Consistency","text":"<p>The model uses multiple literature references (PMID:18310029, PMID:23145048, PMID:23737303, PMID:16823372) that support the ergosterol biosynthetic process in S. pombe. The enzyme functions and pathway organization are consistent with established knowledge of fungal sterol biosynthesis.</p>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing biochemical pathways: - Each activity is enabled by a specific gene product - Activities are connected with appropriate causal predicates - Cellular components are specified - The biological process context is provided - Evidence is provided for most assertions</p>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#parsimony-and-human-understanding","title":"Parsimony and Human Understanding","text":"<p>The model is well-organized and represents the pathway in a way that would be clear to users familiar with sterol biosynthesis. The linear flow through sterol modifications is logically presented.</p>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#recommendations","title":"Recommendations","text":"<ol> <li>Remove duplicate causal relationships: The duplicate causal associations without evidence should be removed.</li> <li>Add metabolite details: Consider adding all intermediate metabolites as inputs/outputs for a more complete representation.</li> <li>Verify consistency of enzyme order: Confirm that the sequence of enzyme activities matches the accepted ergosterol biosynthetic pathway in fungi.</li> </ol>"},{"location":"reviews/66c7d41500002088-ergosterol_biosynthetic_process_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66c7d41500002088) provides a comprehensive and scientifically accurate representation of the ergosterol biosynthetic process in S. pombe. With minor improvements to remove duplicate relationships and possibly add more metabolite details, it would be an excellent reference model for fungal sterol biosynthesis. The model is biologically sound, supported by appropriate evidence, and follows GO-CAM best practices.</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/","title":"66c7d41500002513 DDX39A inhibition of immune related RNA export to the cytoplasm  Human","text":"<p>Now I have a better understanding of how these components should be represented in GO-CAM models. Let me review the model in detail:</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#go-cam-model-review-ddx39a-inhibition-of-immune-related-rna-export-to-the-cytoplasm-human","title":"GO-CAM Model Review: DDX39A inhibition of immune related RNA export to the cytoplasm (Human)","text":"<p>GO-CAM Model: gomodel:66c7d41500002513</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the pathway by which DDX39A inhibits immune-related RNA export to the cytoplasm in humans. The model includes:</p> <ol> <li>DDX39A (RNA helicase) with RNA binding activity and its role in the negative regulation of RNA export from the nucleus</li> <li>RANBP2 (E3 SUMO-protein ligase) and its SUMO ligase activity's effect on DDX39A</li> <li>TRAF3 (E3 ubiquitin ligase) and its role in toll-like receptor signaling</li> <li>MAVS (signaling adaptor) in the mitochondrial outer membrane</li> <li>TRAF6 (E3 ubiquitin ligase) and its role in cytoplasmic pattern recognition receptor signaling</li> </ol>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#structure-of-the-model","title":"Structure of the Model","text":"<p>The model depicts the following causal pathway: - RANBP2 directly negatively regulates DDX39A through SUMOylation - DDX39A RNA binding activity serves as a checkpoint, providing input for:   - TRAF3 ubiquitin ligase activity in the endosome   - TRAF6 ubiquitin ligase activity in the cytoplasm   - MAVS signaling adaptor activity in the mitochondrial outer membrane</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#molecular-details-assessment","title":"Molecular Details Assessment","text":""},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#ddx39a-o00148","title":"DDX39A (O00148)","text":"<ul> <li>Molecular Function: RNA binding (GO:0003723)</li> <li>Biological Process: Negative regulation of RNA export from the nucleus (GO:0046832)</li> <li>Cellular Component: Nucleus (GO:0005634)</li> </ul> <p>This appears to be appropriate based on the UniProt data, which confirms DDX39A functions in mRNA export and plays a role in negative regulation of type I IFN production by increasing nuclear retention of antiviral transcripts.</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#ranbp2-p49792","title":"RANBP2 (P49792)","text":"<ul> <li>Molecular Function: SUMO ligase activity (GO:0061665)</li> <li>Biological Process: Protein sumoylation (GO:0016925)</li> <li>Cellular Component: Nucleus (GO:0005634)</li> </ul> <p>This annotation is appropriate since RANBP2 is an E3 SUMO-protein ligase that facilitates SUMO1 and SUMO2 conjugation, and is located at the nuclear pore complex.</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#traf3-q13114","title":"TRAF3 (Q13114)","text":"<ul> <li>Molecular Function: Ubiquitin protein ligase activity (GO:0061630)</li> <li>Biological Process: Toll-like receptor signaling pathway (GO:0002224)</li> <li>Cellular Component: Endosome (GO:0005768)</li> </ul> <p>This is appropriate as TRAF3 is a cytoplasmic E3 ubiquitin ligase that regulates various signaling pathways including TLR signaling, and UniProt data confirms it can be localized to endosomes.</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#traf6-q9y4k3","title":"TRAF6 (Q9Y4K3)","text":"<ul> <li>Molecular Function: Ubiquitin protein ligase activity (GO:0061630)</li> <li>Biological Process: Cytoplasmic pattern recognition receptor signaling pathway (GO:0002753)</li> <li>Cellular Component: Cytoplasm (GO:0005737)</li> </ul> <p>This is appropriate based on TRAF6's known role in pattern recognition receptor signaling.</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#mavs-q7z434","title":"MAVS (Q7Z434)","text":"<ul> <li>Molecular Function: Signaling adaptor activity (GO:0035591)</li> <li>Biological Process: Cytoplasmic pattern recognition receptor signaling pathway (GO:0002753)</li> <li>Cellular Component: Mitochondrial outer membrane (GO:0005741)</li> </ul> <p>This is appropriate as MAVS is a mitochondrial antiviral signaling protein that functions as an adaptor in innate immune response pathways.</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#causal-relations-assessment","title":"Causal Relations Assessment","text":"<p>The model shows that DDX39A's RNA binding activity \"provides input for\" (RO:0002409) several downstream signaling components involved in immune response: - MAVS signaling adaptor activity - TRAF3 ubiquitin ligase activity - TRAF6 ubiquitin ligase activity</p> <p>Based on the available literature, this appears to represent DDX39A's role in binding and controlling the export of specific mRNAs, including those encoding immune response components.</p> <p>The causal relationship between RANBP2 and DDX39A (\"directly negatively regulates\", RO:0002630) represents the SUMOylation of DDX39A by RANBP2, which is known to alter DDX39A's RNA binding ability.</p>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately captures the pathway described in the scientific literature:</p> <ol> <li>DDX39A functions as a negative regulator of innate immune signaling by binding to and sequestering immune-related transcripts in the nucleus.</li> <li>SUMOylation of DDX39A by RANBP2 alters its binding specificity and export activity, which impacts the immune response.</li> <li>The mRNAs affected include those encoding key immune signaling components like TRAF3, TRAF6, and MAVS.</li> </ol>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#go-cam-best-practices-review","title":"GO-CAM Best Practices Review","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Activity representation: Each gene product is annotated with a specific molecular function that it enables.</li> <li>Contextual annotation: All activities are annotated with both biological process and cellular component contexts.</li> <li>Causal relationships: Appropriate causal predicates are used to connect the activities.</li> </ol>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#minor-issues-and-recommendations","title":"Minor Issues and Recommendations","text":"<ol> <li> <p>Additional evidence: While the model includes reference PMIDs for each annotation, additional mechanistic details from the papers would strengthen the model.</p> </li> <li> <p>Clarification of mechanism: The model could be enhanced by specifying the exact mechanism of how SUMOylation of DDX39A alters its RNA binding properties. The model uses \"directly negatively regulates\" but this could be further clarified with mRNA targets specified.</p> </li> <li> <p>Connection to downstream effects: The model shows DDX39A providing input for MAVS, TRAF3, and TRAF6 activities, but doesn't show how these components further affect innate immune responses. Extending the model to include downstream effects on type I IFN production would make the biological significance clearer.</p> </li> </ol>"},{"location":"reviews/66c7d41500002513-DDX39A_inhibition_of_immune_related_RNA_export_to_the_cytoplasm__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model adequately represents the pathway by which DDX39A, when SUMOylated by RANBP2, regulates the export of immune-related transcripts from the nucleus to the cytoplasm. The model follows GO-CAM best practices and accurately captures the biological knowledge from the literature.</p> <p>The model effectively depicts how DDX39A functions as a negative regulator of innate immune responses by controlling the nuclear export of mRNAs encoding immune signaling components (TRAF3, TRAF6, and MAVS), and how this function is regulated by RANBP2-mediated SUMOylation.</p>"},{"location":"reviews/66e382fb00000178-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR1_receptor__Human_/","title":"66e382fb00000178 Signaling by Vasoactive Intestinal Peptide VIP mediated by VIPR1 receptor  Human","text":"<p>Based on my review of the GO-CAM model, UniProt entries, and relevant literature, I will now provide my evaluation of the model \"Signaling by Vasoactive Intestinal Peptide/VIP mediated by VIPR1 receptor (Human)\".</p>"},{"location":"reviews/66e382fb00000178-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR1_receptor__Human_/#review-of-go-cam-model-gomodel66e382fb00000178","title":"Review of GO-CAM Model: gomodel:66e382fb00000178","text":""},{"location":"reviews/66e382fb00000178-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR1_receptor__Human_/#general-overview","title":"General Overview","text":"<p>This GO-CAM model titled \"Signaling by Vasoactive Intestinal Peptide/VIP mediated by VIPR1 receptor (Human)\" represents a G protein-coupled receptor (GPCR) signaling pathway in humans. The model depicts how VIP (Vasoactive Intestinal Peptide) binds to and activates the VIPR1 receptor, leading to G protein (GNAS) activation, which then activates adenylate cyclase (ADCY6), resulting in the production of cAMP.</p>"},{"location":"reviews/66e382fb00000178-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR1_receptor__Human_/#model-components","title":"Model Components","text":"<p>The model consists of four main activities: 1. VIP (P01282) with neuropeptide hormone activity (GO:0005184) 2. VIPR1 receptor (P32241) with vasoactive intestinal polypeptide receptor activity (GO:0004999) 3. GNAS (Q5JWF2) with G protein activity (GO:0003925) 4. ADCY6 (O43306) with adenylate cyclase activity (GO:0004016)</p>"},{"location":"reviews/66e382fb00000178-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR1_receptor__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Appropriate cellular locations: The model correctly represents the cellular locations of each component. VIP is located in the extracellular space (GO:0005615), VIPR1 is in the plasma membrane (GO:0005886), GNAS is in the cytosol (GO:0005829), and ADCY6 properly functions at the membrane.</p> </li> <li> <p>Correct biological process: All activities are appropriately part of the adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189).</p> </li> <li> <p>Correct causal connections: The model properly shows the causal flow:</p> </li> <li>VIP directly positively regulates VIPR1 (RO:0002629)</li> <li>VIPR1 directly positively regulates GNAS (RO:0002629)</li> <li> <p>GNAS directly positively regulates ADCY6 (RO:0002629)</p> </li> <li> <p>Correct molecular output: The model correctly shows that ADCY6 produces cAMP (CHEBI:17489)</p> </li> <li> <p>Appropriate evidence: Each activity and causal connection includes evidence codes and PMID references.</p> </li> </ol>"},{"location":"reviews/66e382fb00000178-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR1_receptor__Human_/#minor-issues","title":"Minor Issues","text":"<ol> <li> <p>Missing G\u03b2\u03b3 subunits: While the model correctly shows GNAS (G\u03b1 subunit) activation, it doesn't represent the G\u03b2 and G\u03b3 subunits that form the complete heterotrimeric G protein complex. According to the paper PMID:17110384, ADCY6 interacts with GNB1 and GNG2 (G\u03b2 and G\u03b3 subunits). However, the omission is reasonable as GNAS is the primary activator of ADCY6.</p> </li> <li> <p>Simplified mechanism: The model doesn't represent some details of the activation mechanism, such as the specific conformational changes that occur when VIP binds to VIPR1 or when GNAS activates ADCY6. However, this level of detail is not typically required in GO-CAM models.</p> </li> </ol>"},{"location":"reviews/66e382fb00000178-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR1_receptor__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is well-supported by the literature:</p> <ol> <li> <p>The UniProt entries for VIP (P01282), VIPR1 (P32241), GNAS (Q5JWF2), and ADCY6 (O43306) confirm the functions and interactions depicted in the model.</p> </li> <li> <p>PMID:36385145 provides detailed structural information about VIP binding to VIPR1 and confirms the direct activation mechanism.</p> </li> <li> <p>PMID:17110384 and PMID:17916776 provide evidence for GNAS activation of ADCY6 and its role in producing cAMP.</p> </li> <li> <p>PMID:3456568 supports the function of VIP as a neuropeptide hormone.</p> </li> <li> <p>From PMID:36385145, we know that \"VIP is a neuropeptide involved in a diverse array of physiological processes through activating the PACAP subfamily of class B1 G protein-coupled receptors: VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2).\"</p> </li> </ol>"},{"location":"reviews/66e382fb00000178-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR1_receptor__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the VIP-VIPR1-GNAS-ADCY6 signaling pathway. It follows GO-CAM best practices for representing molecular activities, their locations, and causal relationships. The model is well-supported by the literature and provides a clear, concise representation of this important signaling pathway.</p> <p>The model is particularly strong in its representation of: 1. The correct binding relationship between VIP and VIPR1 2. The G protein-mediated signal transduction from VIPR1 to ADCY6 3. The production of cAMP as the key second messenger output</p> <p>The model appropriately represents a canonical GPCR signaling pathway and follows GO-CAM best practices. It provides a valuable resource for understanding VIP-mediated signaling through VIPR1 receptor in humans.</p>"},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/","title":"66e382fb00000254 Signaling by Vasoactive Intestinal Peptide VIP mediated by VIPR2 receptor  Human","text":"<p>Now I can provide a comprehensive review of the GO-CAM model \"gomodel:66e382fb00000254\".</p>"},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#review-of-go-cam-model-signaling-by-vasoactive-intestinal-peptidevip-mediated-by-vipr2-receptor-human","title":"Review of GO-CAM Model: Signaling by Vasoactive Intestinal Peptide/VIP mediated by VIPR2 receptor (Human)","text":""},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#model-id-gomodel66e382fb00000254","title":"Model ID: gomodel:66e382fb00000254","text":""},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the VIP (Vasoactive Intestinal Peptide) signaling pathway through the VIPR2 receptor in humans. The model shows the signaling cascade from VIP ligand binding to VIPR2 receptor, G protein activation, adenylate cyclase stimulation, and ultimately cAMP production.</p>"},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#components-and-activities","title":"Components and Activities","text":"<ol> <li>VIP (UniProtKB:P01282)</li> <li>Molecular Function: neuropeptide hormone activity (GO:0005184)</li> <li>Occurs in: extracellular space (GO:0005615)</li> <li>Part of: adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li> <p>Causal relationship: directly positively regulates VIPR2 receptor activity</p> </li> <li> <p>VIPR2 (UniProtKB:P41587)</p> </li> <li>Molecular Function: vasoactive intestinal polypeptide receptor activity (GO:0004999)</li> <li>Occurs in: plasma membrane (GO:0005886)</li> <li>Part of: adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li> <p>Causal relationship: directly positively regulates G protein activity</p> </li> <li> <p>G protein - GNAS (UniProtKB:Q5JWF2)</p> </li> <li>Molecular Function: G protein activity (GO:0003925)</li> <li>Occurs in: cytosol (GO:0005829)</li> <li>Part of: adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li> <p>Causal relationship: directly positively regulates adenylate cyclase activity</p> </li> <li> <p>Adenylate cyclase 6 (UniProtKB:O43306)</p> </li> <li>Molecular Function: adenylate cyclase activity (GO:0004016)</li> <li>Part of: adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</li> <li>Has output: 3',5'-cyclic AMP (CHEBI:17489)</li> </ol>"},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#evaluation","title":"Evaluation","text":""},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#biological-content-assessment","title":"Biological Content Assessment","text":"<ol> <li>Accuracy of the signaling pathway:</li> <li>The model correctly represents VIP signaling through VIPR2 receptor, which is a G protein-coupled receptor known to activate adenylate cyclase.</li> <li>The literature evidence supports VIP binding to VIPR2 receptor with high affinity (PMID:8933357).</li> <li>The G protein activation and subsequent adenylate cyclase stimulation is accurate according to PMID:17110384.</li> <li> <p>The production of cAMP as the output of adenylate cyclase activity is correctly represented.</p> </li> <li> <p>Completeness of the pathway:</p> </li> <li>The model captures the essential components of the VIP-VIPR2 signaling pathway.</li> <li>The sequence of events (ligand binding \u2192 receptor activation \u2192 G protein activation \u2192 adenylate cyclase stimulation \u2192 cAMP production) is logical and supported by the literature.</li> </ol>"},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#go-cam-best-practices-assessment","title":"GO-CAM Best Practices Assessment","text":"<ol> <li>Signaling Receptor Activity Annotation:</li> <li>The model follows the GO-CAM guidelines for protein ligand-activated signaling receptor activity.</li> <li>VIP is correctly annotated with \"neuropeptide hormone activity\" which is a child term of \"receptor ligand activity\".</li> <li>VIPR2 is correctly annotated with \"vasoactive intestinal polypeptide receptor activity\" which is a child term of \"signaling receptor activity\".</li> <li> <p>The causal relationship between VIP and VIPR2 is correctly annotated as \"directly positively regulates\" (RO:0002629).</p> </li> <li> <p>G Protein and Adenylate Cyclase Annotation:</p> </li> <li>GNAS is correctly annotated with \"G protein activity\".</li> <li>The connection between VIPR2 receptor and GNAS is correctly annotated as \"directly positively regulates\".</li> <li>ADCY6 (adenylate cyclase 6) is correctly annotated with \"adenylate cyclase activity\".</li> <li>The connection between GNAS and ADCY6 is correctly annotated as \"directly positively regulates\".</li> <li> <p>The output of ADCY6 is correctly annotated as \"3',5'-cyclic AMP\".</p> </li> <li> <p>Cellular Locations:</p> </li> <li>VIP is correctly localized to the extracellular space.</li> <li>VIPR2 receptor is correctly localized to the plasma membrane.</li> <li>GNAS is correctly localized to the cytosol.</li> <li> <p>The cellular location for ADCY6 is not specified, which could be improved by adding this information (typically would be plasma membrane).</p> </li> <li> <p>Process Annotations:</p> </li> <li>All components are correctly annotated as part of the \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\".</li> </ol>"},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#evidential-support","title":"Evidential Support","text":"<ol> <li>Evidence Quality:</li> <li>All annotations are supported by experimental evidence (ECO:0000314 - direct assay evidence used in manual assertion).</li> <li> <p>Multiple references are provided for key activities (e.g., PMID:17916776 and PMID:23842570 for adenylate cyclase activity).</p> </li> <li> <p>Literature Consistency:</p> </li> <li>The model is consistent with the referenced literature.</li> <li>PMID:8933357 supports VIP binding to VIPR2 and activation of adenylate cyclase.</li> <li>PMID:3456568 supports VIP's neuropeptide hormone activity.</li> <li>PMID:17110384 supports G protein-mediated activation of adenylate cyclase.</li> </ol>"},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add cellular location for adenylate cyclase: The model should specify the cellular location for ADCY6, which is typically the plasma membrane.</p> </li> <li> <p>Consider adding downstream effects of cAMP: While not necessary, the model could be expanded to include downstream effects of cAMP, such as activation of protein kinase A (PKA).</p> </li> <li> <p>Consider adding regulatory information: Information about how this pathway is regulated (e.g., desensitization mechanisms) could enhance the biological context.</p> </li> </ol>"},{"location":"reviews/66e382fb00000254-Signaling_by_Vasoactive_Intestinal_Peptide_VIP_mediated_by_VIPR2_receptor__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"gomodel:66e382fb00000254\" accurately represents the VIP signaling pathway mediated by VIPR2 receptor in humans. It follows the GO-CAM best practices for modeling signaling pathways and is supported by appropriate experimental evidence. The model effectively captures the key molecular functions, biological processes, cellular components, and causal relationships of this signaling pathway. With minor enhancements as suggested above, this model could serve as an excellent reference for representing G protein-coupled receptor signaling pathways in GO-CAM.</p>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/","title":"66e382fb00000408 Signaling by PACAP ADCYAP1 mediated by VIPR1 receptor  Human","text":"<p>Based on my thorough review of the GO-CAM model (gomodel:66e382fb00000408), protein information, relevant literature, and GO-CAM annotation guidelines, I can now provide a comprehensive review.</p>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#review-of-go-cam-model-gomodel66e382fb00000408","title":"Review of GO-CAM Model: gomodel:66e382fb00000408","text":""},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Signaling by PACAP/ADCYAP1 mediated by VIPR1 receptor (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>This model represents the signaling pathway where the neuropeptide PACAP/ADCYAP1 (Pituitary adenylate cyclase-activating polypeptide) activates VIPR1 receptors (Vasoactive intestinal peptide receptor 1), leading to G protein activation and subsequent adenylate cyclase activity, resulting in cAMP production.</p> <p>The model contains four key activities:</p> <ol> <li>ADCYAP1 (P18509) - Functions as a neuropeptide hormone (GO:0005184) in the extracellular space</li> <li>VIPR1 (P32241) - Acts as a PACAP receptor (GO:0001634) in the plasma membrane</li> <li>GNAS (Q5JWF2) - Performs G protein activity (GO:0003925) in the cytosol</li> <li>ADCY6 (O43306) - Exhibits adenylate cyclase activity (GO:0004016) producing cAMP</li> </ol>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#pathway-logic-and-evidence-assessment","title":"Pathway Logic and Evidence Assessment","text":"<p>The model correctly captures the following signaling cascade: - ADCYAP1 (PACAP) binding to VIPR1 receptor (directly positively regulates) - VIPR1 activation of the G protein GNAS (directly positively regulates) - GNAS activation of adenylate cyclase ADCY6 (directly positively regulates) - ADCY6 producing cAMP (has output CHEBI:17489)</p> <p>All activities are part of the adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189), which is appropriate for this model.</p>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#evidence-quality","title":"Evidence Quality","text":"<p>The model includes high-quality evidence for each activity: - All assertions use direct assay evidence (ECO:0000314) - Evidence is supported by appropriate literature references (PMID:36385145, PMID:17110384, PMID:17916776, etc.) - All activities have proper contributor information and recent dates (2024-09-17)</p>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate Molecular Representation: The model correctly captures the GPCR signaling cascade from ligand binding through G protein activation to second messenger production.</p> </li> <li> <p>Appropriate Cellular Localization: Each component is correctly localized to its appropriate cellular compartment (extracellular space for PACAP, plasma membrane for VIPR1, cytosol for GNAS).</p> </li> <li> <p>Strong Evidence Base: The model is well-supported by recent scientific literature, particularly PMID:36385145, which provides detailed structural information on VPAC receptor family peptide binding and selectivity.</p> </li> <li> <p>Consistent with Current Knowledge: The model accurately represents the known signaling pathway for PACAP activating VIPR1 receptors, leading to G protein (Gs) activation and adenylate cyclase stimulation.</p> </li> </ol>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#improvement-opportunities","title":"Improvement Opportunities","text":"<ol> <li> <p>Consideration of Multiple AC Isoforms: Based on PMID:23842570, there appears to be specificity in which adenylate cyclase isoforms are activated. The model currently only includes ADCY6, but the literature suggests that multiple AC isoforms may be involved in PACAP-VIPR1 signaling. Consider adding a note about potential involvement of other AC isoforms.</p> </li> <li> <p>Downstream Signaling: The model currently ends at cAMP production. Consider extending the model to include downstream effects of cAMP production, such as PKA activation, which would provide a more complete representation of the pathway.</p> </li> <li> <p>Receptor Selectivity: PMID:36385145 discusses the selectivity of PACAP for different receptor types (VPAC1R vs PAC1R). The model could potentially note that PACAP can also activate other receptor types (particularly PAC1R) with different affinities.</p> </li> <li> <p>G Protein Subunit Specification: The model correctly shows GNAS (G\u03b1s) but could potentially include information about the \u03b2\u03b3 subunits, which according to PMID:17110384 also play a role in adenylate cyclase regulation.</p> </li> </ol>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM annotation guidelines for signaling receptor activity: - ADCYAP1 correctly enables neuropeptide hormone activity (GO:0005184) - VIPR1 correctly enables PACAP receptor activity (GO:0001634) - The causal relations use appropriate predicates (RO:0002629 - directly positively regulates) - Cellular locations are appropriate for each component</p> <p>According to the \"Signaling receptor activity annotation guidelines,\" this model correctly represents a protein ligand-activated signaling receptor pathway.</p>"},{"location":"reviews/66e382fb00000408-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR1_receptor__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:66e382fb00000408) is a high-quality representation of PACAP signaling through VIPR1 receptors leading to adenylate cyclase activation and cAMP production. The model is well-supported by scientific evidence, follows GO-CAM annotation guidelines, and accurately represents the known biology of this signaling pathway.</p> <p>The model is ready for continued use in production, with minor suggestions for potential enhancements that could provide a more comprehensive view of the signaling cascade.</p>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/","title":"66e382fb00000449 Signaling by PACAP ADCYAP1 mediated by VIPR2 receptor  Human","text":"<p>Based on my review of the GO-CAM model, the protein information, and the relevant guidelines, I will now provide a thorough review of the GO-CAM model with ID 66e382fb00000449, titled \"Signaling by PACAP/ADCYAP1 mediated by VIPR2 receptor (Human)\".</p>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#go-cam-review-signaling-by-pacapadcyap1-mediated-by-vipr2-receptor-human","title":"GO-CAM Review: Signaling by PACAP/ADCYAP1 mediated by VIPR2 receptor (Human)","text":""},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#model-summary","title":"Model Summary","text":"<p>This GO-CAM model (gomodel:66e382fb00000449) represents the signaling cascade initiated by PACAP (Pituitary adenylate cyclase-activating polypeptide, or ADCYAP1) through the VIPR2 receptor (Vasoactive intestinal polypeptide receptor 2), leading to activation of G-protein signaling and adenylate cyclase, ultimately resulting in cAMP production. The model describes a key G protein-coupled receptor (GPCR) signaling pathway in human cells.</p>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the established PACAP/VIPR2 signaling pathway:</p> <ol> <li>ADCYAP1 (PACAP) acts as a neuropeptide hormone in the extracellular space</li> <li>VIPR2 is correctly represented as a PACAP receptor located in the plasma membrane</li> <li>GNAS (G protein) activation follows receptor activation</li> <li>ADCY6 (adenylate cyclase 6) is appropriately shown as producing cAMP</li> </ol> <p>The molecular components and their relationships align with current knowledge from literature. The evidence is well-cited with appropriate PMID references, particularly the detailed structural basis from the cryo-EM study (PMID:35477937) showing how PACAP27 binds to VIPR2 and activates G protein signaling.</p>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#go-cam-annotation-practices","title":"GO-CAM Annotation Practices","text":""},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#molecular-functions","title":"Molecular Functions","text":"<p>The molecular functions are correctly annotated and appropriate for each protein:</p> <ol> <li>ADCYAP1 (P18509): Annotated with \"neuropeptide hormone activity\" (GO:0005184) - correct for a secreted signaling peptide</li> <li>VIPR2 (P41587): Annotated with \"pituitary adenylate cyclase-activating polypeptide receptor activity\" (GO:0001634) - specific and appropriate</li> <li>GNAS (Q5JWF2): Annotated with \"G protein activity\" (GO:0003925) - correct for this G-alpha subunit</li> <li>ADCY6 (O43306): Annotated with \"adenylate cyclase activity\" (GO:0004016) - appropriate for its enzymatic function</li> </ol>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#cellular-location","title":"Cellular Location","text":"<p>Cellular locations are correctly specified:</p> <ol> <li>ADCYAP1: Extracellular space (GO:0005615) - correct for a secreted neuropeptide</li> <li>VIPR2: Plasma membrane (GO:0005886) - appropriate for a membrane-bound receptor</li> <li>GNAS: Cytosol (GO:0005829) - proper location for G protein signaling</li> <li>ADCY6: Not explicitly annotated with cellular location, which is a minor omission as it should be plasma membrane-associated</li> </ol>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#biological-process","title":"Biological Process","text":"<p>All activities are appropriately annotated as part of the \"adenylate cyclase-activating G protein-coupled receptor signaling pathway\" (GO:0007189), which is the correct classification for this pathway.</p>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#causal-relationships","title":"Causal Relationships","text":"<p>The causal flow through the pathway is well-represented:</p> <ol> <li>ADCYAP1 \u2192 VIPR2: \"directly positively regulates\" (RO:0002629) - correct for ligand activation of receptor</li> <li>VIPR2 \u2192 GNAS: \"directly positively regulates\" (RO:0002629) - appropriate for receptor activation of G protein</li> <li>GNAS \u2192 ADCY6: \"directly positively regulates\" (RO:0002629) - correct for G protein stimulation of adenylate cyclase</li> <li>ADCY6 has CHEBI:17489 (3',5'-cyclic AMP) as output - correctly representing the product of the enzymatic reaction</li> </ol> <p>These relationships follow the GO-CAM guidelines for representing GPCR signaling pathways.</p>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#evidence-quality","title":"Evidence Quality","text":"<p>Each annotation is supported by appropriate evidence:</p> <ol> <li>Direct assay evidence (ECO:0000314) and mutant phenotype evidence (ECO:0000315) from published literature</li> <li>Use of multiple PMIDs provides strong support for the model</li> <li>Key references include structural studies (PMID:35477937) showing the PACAP-VIPR2-G protein complex</li> </ol>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While this is a well-constructed GO-CAM model, I have a few minor suggestions for improvement:</p> <ol> <li> <p>Add cellular location for ADCY6: Explicitly annotate ADCY6 with \"plasma membrane\" (GO:0005886) as its cellular location, as adenylate cyclase 6 is a membrane-bound enzyme.</p> </li> <li> <p>Consider expanding pathway context: The model could be expanded to include downstream effects of cAMP production, such as activation of protein kinase A (PKA) or effects on ion channels, which would provide more biological context.</p> </li> <li> <p>Include small molecule regulators: The model could be enhanced by including known pharmacological regulators of this pathway, such as forskolin (an adenylate cyclase activator).</p> </li> <li> <p>Add tissue specificity information: Contextual information about where this signaling is most relevant (e.g., neural tissue, immune cells) would enhance the biological relevance of the model.</p> </li> </ol>"},{"location":"reviews/66e382fb00000449-Signaling_by_PACAP_ADCYAP1_mediated_by_VIPR2_receptor__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Signaling by PACAP/ADCYAP1 mediated by VIPR2 receptor (Human)\" is accurate, well-evidenced, and follows GO-CAM annotation best practices. It correctly represents the signaling cascade from PACAP activation of VIPR2 through G protein-mediated activation of adenylate cyclase and production of cAMP. The model provides a clear view of this important signaling pathway and could serve as a useful reference for researchers studying GPCR signaling, particularly in the context of PACAP/VIP signaling systems.</p>"},{"location":"reviews/66e382fb00000583-Signaling_by_PACAP_ADCYAP1_mediated_by_PAC1R_ADCYAP1R1_receptor__Human_/","title":"66e382fb00000583 Signaling by PACAP ADCYAP1 mediated by PAC1R ADCYAP1R1 receptor  Human","text":"<p>Based on the review of the above model, literature, and GO-CAM guidelines, I will now provide a detailed review of GO-CAM model \"gomodel:66e382fb00000583\" (Signaling by PACAP/ADCYAP1 mediated by PAC1R/ADCYAP1R1 receptor in Human).</p>"},{"location":"reviews/66e382fb00000583-Signaling_by_PACAP_ADCYAP1_mediated_by_PAC1R_ADCYAP1R1_receptor__Human_/#review-of-go-cam-model-gomodel66e382fb00000583","title":"Review of GO-CAM Model: gomodel:66e382fb00000583","text":""},{"location":"reviews/66e382fb00000583-Signaling_by_PACAP_ADCYAP1_mediated_by_PAC1R_ADCYAP1R1_receptor__Human_/#model-summary","title":"Model Summary","text":"<p>The model represents \"Signaling by PACAP/ADCYAP1 mediated by PAC1R/ADCYAP1R1 receptor (Human)\" and describes the signaling pathway where pituitary adenylate cyclase-activating polypeptide (PACAP/ADCYAP1) activates its receptor PAC1R/ADCYAP1R1, leading to G protein (GNAS) activation and subsequent stimulation of adenylate cyclase (ADCY6), resulting in cAMP production.</p>"},{"location":"reviews/66e382fb00000583-Signaling_by_PACAP_ADCYAP1_mediated_by_PAC1R_ADCYAP1R1_receptor__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Appropriate Molecular Functions:</li> <li>ADCYAP1 (P18509) is correctly annotated with neuropeptide hormone activity (GO:0005184)</li> <li>PAC1R/ADCYAP1R1 (P41586) uses appropriate pituitary adenylate cyclase-activating polypeptide receptor activity (GO:0001634)</li> <li>GNAS (Q5JWF2) uses G protein activity (GO:0003925)</li> <li> <p>ADCY6 (O43306) uses adenylate cyclase activity (GO:0004016)</p> </li> <li> <p>Biological Process Context:</p> </li> <li> <p>All activities are correctly part of the adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)</p> </li> <li> <p>Cellular Component Context:</p> </li> <li> <p>Appropriate cellular locations used: ADCYAP1 in extracellular space (GO:0005615), PAC1R in plasma membrane (GO:0005886), GNAS in cytosol (GO:0005829)</p> </li> <li> <p>Causal Relationships:</p> </li> <li> <p>The model correctly represents the signaling cascade:</p> <ul> <li>ADCYAP1 directly positively regulates PAC1R (RO:0002629)</li> <li>PAC1R directly positively regulates GNAS (RO:0002629)</li> <li>GNAS directly positively regulates ADCY6 (RO:0002629)</li> </ul> </li> <li> <p>Evidence:</p> </li> <li>Each activity is well supported by primary research articles with appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion)</li> </ol>"},{"location":"reviews/66e382fb00000583-Signaling_by_PACAP_ADCYAP1_mediated_by_PAC1R_ADCYAP1R1_receptor__Human_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li>Product of Adenylate Cyclase Activity:</li> <li> <p>The model correctly shows ADCY6 producing cAMP (CHEBI:17489) as output, but this could be enhanced by adding a subsequent step showing cAMP's role in activating protein kinase A, which would make the functional outcome of the pathway clearer.</p> </li> <li> <p>Potential Missing Component:</p> </li> <li> <p>The model doesn't explicitly represent the G\u03b2\u03b3 subunits of the heterotrimeric G protein complex. While the paper by Gao et al. (2017) mentioned in evidence suggests interactions between ADCY6 and GNB1/GNG2, these aren't included in the model. Consider adding these if there's sufficient evidence for their specific role in this signaling pathway.</p> </li> <li> <p>Additional Regulatory Elements:</p> </li> <li>Based on the UniProt entries, calcium ions inhibit ADCY6 at micromolar concentrations. If supported by evidence, this regulatory mechanism could be added to provide a more complete picture of the signaling pathway regulation.</li> </ol>"},{"location":"reviews/66e382fb00000583-Signaling_by_PACAP_ADCYAP1_mediated_by_PAC1R_ADCYAP1R1_receptor__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<ol> <li>Receptor Signaling Guidelines:</li> <li> <p>The model follows the guidelines for protein ligand-activated signaling receptor activity:</p> <ul> <li>ADCYAP1 is correctly annotated with neuropeptide hormone activity (a descendant of receptor ligand activity)</li> <li>It occurs in the extracellular space</li> <li>It directly positively regulates the receptor activity of PAC1R</li> <li>PAC1R is correctly annotated with PACAP receptor activity</li> <li>PAC1R occurs in the plasma membrane</li> <li>The causal relations between components follow the appropriate pattern</li> </ul> </li> <li> <p>G Protein Signaling:</p> </li> <li>The G protein (GNAS) activity is appropriately represented as mediating between the receptor and adenylate cyclase</li> <li>The model correctly shows GNAS positively regulating ADCY6 (adenylate cyclase)</li> </ol>"},{"location":"reviews/66e382fb00000583-Signaling_by_PACAP_ADCYAP1_mediated_by_PAC1R_ADCYAP1R1_receptor__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<ol> <li>Consistency with Literature:</li> <li>The model accurately represents the well-established PACAP signaling pathway as described in the literature</li> <li>The cryo-EM structure of PAC1R (PMID:36385145) confirms the interaction between PACAP and PAC1R</li> <li> <p>The functional studies (PMID:17916776) support the role of ADCY6 in the pathway</p> </li> <li> <p>Species Specificity:</p> </li> <li>The model appropriately specifies human proteins and the human context (NCBITaxon:9606)</li> </ol>"},{"location":"reviews/66e382fb00000583-Signaling_by_PACAP_ADCYAP1_mediated_by_PAC1R_ADCYAP1R1_receptor__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66e382fb00000583) is well-constructed and accurately represents the PACAP/ADCYAP1 signaling pathway through PAC1R/ADCYAP1R1, GNAS, and ADCY6. It follows GO-CAM best practices for representing receptor signaling pathways and is supported by appropriate evidence.</p> <p>The model could potentially be enhanced by including downstream effects of cAMP production and possibly including additional regulatory mechanisms, but as it stands, it provides a clear and accurate representation of this signaling pathway.</p>"},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/","title":"66e382fb00002105 BMP8A role in spermatogenesis via SMAD1  SMAD5 and SMAD9  Human","text":"<p>Based on my review of the model and the supporting literature, I'll now provide a comprehensive review of GO-CAM model 66e382fb00002105.</p>"},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/#review-of-go-cam-model-66e382fb00002105","title":"Review of GO-CAM Model: 66e382fb00002105","text":""},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/#model-overview","title":"Model Overview","text":"<p>Title: BMP8A role in spermatogenesis via SMAD1, SMAD5 and SMAD9 (Human)</p> <p>Taxon: Human (NCBITaxon:9606)</p> <p>Status: Production</p>"},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/#model-architecture-summary","title":"Model Architecture Summary","text":"<p>This GO-CAM model represents the BMP signaling pathway focusing on BMP8A's role in spermatogenesis, specifically how BMP8A activates its receptors and downstream SMAD signaling. The model includes:</p> <ol> <li>BMP8A (UniProtKB:Q7Z5Y6) with cytokine activity</li> <li>BMP receptors (BMPR2 and BMPR1A)</li> <li>Downstream SMAD transcription factors (SMAD1, SMAD5, SMAD9)</li> <li>Appropriate causal connections between these components</li> <li>Cellular locations for each activity</li> </ol>"},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/#strong-points","title":"Strong Points","text":"<ol> <li>Accurate biological pathway representation: The model correctly depicts the canonical BMP signaling pathway where:</li> <li>BMP8A has cytokine activity in the extracellular space</li> <li>BMPR2 acts as the type II receptor</li> <li>BMPR1A functions as the type I receptor</li> <li> <p>SMAD1/5/9 are activated by BMPR1A phosphorylation and translocate to the nucleus</p> </li> <li> <p>Well-supported evidence: The model uses appropriate evidence codes and citations, including:</p> </li> <li>Direct assay evidence (ECO:0000314) from primary literature sources</li> <li>Mutant phenotype evidence (ECO:0000315)</li> <li> <p>Appropriate localization of activities in relevant cellular compartments</p> </li> <li> <p>Causal relationships: The model properly represents the causal cascade using the recommended relationships:</p> </li> <li>BMP8A directly positively regulates (RO:0002629) BMPR2</li> <li>BMPR2 directly positively regulates (RO:0002629) BMPR1A</li> <li> <p>BMPR1A directly positively regulates (RO:0002629) SMAD1/5/9</p> </li> <li> <p>Molecular Function Details: The model appropriately assigns molecular functions to each protein:</p> </li> <li>BMP8A: cytokine activity (GO:0005125)</li> <li>BMPR2: activin receptor activity, type II (GO:0016362)</li> <li>BMPR1A: transforming growth factor beta receptor activity, type I (GO:0005025)</li> <li> <p>SMAD1/5/9: DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981)</p> </li> <li> <p>Cellular Compartmentalization: Each protein activity is correctly placed in its cellular compartment:</p> </li> <li>BMP8A in extracellular space (GO:0005615)</li> <li>Receptors at plasma membrane (GO:0005886)</li> <li>SMAD proteins in nucleus (GO:0005634)</li> </ol>"},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Receptor Complex Representation: </li> <li> <p>The model separately represents BMPR1A and BMPR2, which is technically correct, but it might be worth considering representing the active receptor complex in line with how BMP receptors function. According to the complexes guidance document, since the individual subunits have known activities, the current approach is acceptable.</p> </li> <li> <p>SMAD Nuclear Translocation: </p> </li> <li> <p>While the model places SMAD1/5/9 activities in the nucleus, it could more explicitly represent how phosphorylation by BMPR1A leads to their nuclear translocation.</p> </li> <li> <p>SMAD Oligomerization: </p> </li> <li> <p>The model doesn't capture the formation of SMAD complexes (with SMAD4/co-SMAD), which is an important step in the canonical BMP signaling pathway. Based on the literature (Kretzschmar et al., 1997), SMAD phosphorylation by the type I receptor leads to association with SMAD4/DPC4 and nuclear accumulation.</p> </li> <li> <p>Downstream Targets: </p> </li> <li> <p>The model focuses on the core signaling pathway but doesn't include the downstream targets of SMAD transcriptional activity relevant to spermatogenesis.</p> </li> <li> <p>Biological Process Context: </p> </li> <li>While the model's title mentions spermatogenesis, there could be more specific annotation to relate the activities to specific processes in spermatogenesis.</li> </ol>"},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/#scientific-validity","title":"Scientific Validity","text":"<p>The model is scientifically valid and well-supported by the literature. The BMP8A signaling through BMPR2/BMPR1A to activate SMAD1/5/9 is consistent with what is known about BMP signaling pathways. Based on the UniProt entry for BMP8A (Q7Z5Y6), it plays a role in spermatogenesis and initiates the canonical BMP signaling cascade by associating with type I receptor BMPR1A and type II receptor BMPR2. The primary literature evidence (PMID:9136927) clearly supports the phosphorylation of SMAD1 by BMP type I receptors and the resulting nuclear translocation and transcriptional activity.</p>"},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Consider adding SMAD4: The model could be enhanced by including SMAD4/DPC4, which forms complexes with phosphorylated SMAD1/5/9 as demonstrated in the Kretzschmar paper.</p> </li> <li> <p>Include specific spermatogenesis-related processes: Add specific biological processes related to spermatogenesis that are regulated by this pathway.</p> </li> <li> <p>Add Id1/Id2 target genes: The PMID:15657086 and PMID:17992660 papers discuss downstream targets of BMP signaling such as Id1 and Id2, which could be added to make the model more comprehensive.</p> </li> <li> <p>Consider adding negative regulators: The pathway is also regulated by negative regulators like Smurf1 and noggin, which could be included to provide a more complete picture of BMP signaling regulation.</p> </li> </ol>"},{"location":"reviews/66e382fb00002105-BMP8A_role_in_spermatogenesis_via_SMAD1__SMAD5_and_SMAD9__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the core BMP8A signaling pathway through its receptors to SMAD transcription factors. It follows GO-CAM best practices regarding the representation of activities, causal relationships, and cellular locations. The model is well-supported by literature evidence and provides a solid representation of this important developmental signaling pathway. With the suggested enhancements, it could provide an even more comprehensive view of BMP8A's role in spermatogenesis.</p>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/","title":"66e382fb00002243 BMP8B role in adipocyte differentiation inhibition  Human","text":"<p>Now I have a better understanding of the model and the proteins involved. Let me provide a comprehensive review.</p>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#go-cam-model-review-bmp8b-role-in-adipocyte-differentiation-inhibition-human","title":"GO-CAM Model Review: BMP8B role in adipocyte differentiation inhibition (Human)","text":""},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#model-id-gomodel66e382fb00002243","title":"Model ID: gomodel:66e382fb00002243","text":""},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the molecular mechanisms by which BMP8B (Bone Morphogenetic Protein 8B) inhibits adipocyte differentiation in humans. The model captures a signaling cascade from the extracellular BMP8B protein through the ACVR1B receptor to SMAD2 and SMAD3 transcription factors, which ultimately leads to the negative regulation of cell differentiation.</p>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#model-components","title":"Model Components","text":"<ol> <li>BMP8B (UniProtKB:P34820)</li> <li>Annotated with cytokine activity (GO:0005125)</li> <li>Located in extracellular space (GO:0005615)</li> <li>Part of negative regulation of cell differentiation (GO:0045596)</li> <li> <p>Provides input for ACVR1B's activin receptor activity</p> </li> <li> <p>ACVR1B (UniProtKB:P36896)</p> </li> <li>Annotated with activin receptor activity, type I (GO:0016361)</li> <li>Located in plasma membrane (GO:0005886)</li> <li>Part of negative regulation of cell differentiation (GO:0045596)</li> <li> <p>Directly positively regulates both SMAD2 and SMAD3 transcription factors</p> </li> <li> <p>SMAD2 (UniProtKB:Q15796)</p> </li> <li>Annotated with DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228)</li> <li>Located in nucleus (GO:0005634)</li> <li> <p>Part of negative regulation of cell differentiation (GO:0045596)</p> </li> <li> <p>SMAD3 (UniProtKB:P84022)</p> </li> <li>Annotated with DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228)</li> <li>Located in nucleus (GO:0005634)</li> <li>Part of negative regulation of cell differentiation (GO:0045596)</li> </ol>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#causal-flow","title":"Causal Flow","text":"<p>The model represents a clear causal flow from extracellular signaling to transcriptional regulation: 1. BMP8B in the extracellular space provides input for ACVR1B receptor at the plasma membrane 2. ACVR1B directly positively regulates SMAD2 and SMAD3  3. SMAD2 and SMAD3 function as transcriptional activators in the nucleus 4. All components are part of the negative regulation of cell differentiation</p>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#literature-support","title":"Literature Support","text":"<p>The model is supported by several publications cited in the annotations: - PMID:24378993 supports the role of SMAD3 as a DNA-binding transcription activator  - PMID:9892009 supports ACVR1B's direct positive regulation of SMAD2 and SMAD3 - PMID:9032295 supports ACVR1B localization in the plasma membrane - PMID:21145499 supports SMAD2 nuclear localization</p>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#qc-assessment","title":"QC Assessment","text":""},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Biological Accuracy: The model correctly represents the established pathway by which BMP signaling through ACVR1B leads to SMAD2/3 activation and nuclear localization to regulate transcription.</p> </li> <li> <p>Correct GO Terms: The molecular functions (cytokine activity, receptor activity, transcription activator activity) are appropriately chosen for each protein.</p> </li> <li> <p>Appropriate Causal Relations: The causal relations (RO:0002409 for \"provides input for\" and RO:0002629 for \"directly positively regulates\") accurately depict the flow of information through this signaling pathway.</p> </li> <li> <p>Subcellular Localization: The model correctly annotates proteins with their proper cellular compartments (extracellular for BMP8B, plasma membrane for ACVR1B, and nucleus for SMAD2/3).</p> </li> <li> <p>Evidence Support: Each assertion is backed by appropriate literature evidence with relevant PMIDs.</p> </li> </ol>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Adipocyte Context: While the title specifies \"BMP8B role in adipocyte differentiation inhibition,\" there is no explicit annotation to XAO:0006041 (adipocyte) in the activity components, despite it being listed in the objects. This cellular context should be included to better align with the model's title.</p> </li> <li> <p>Mechanistic Detail: The model doesn't capture the phosphorylation of SMAD2/3 by ACVR1B, which is a critical mechanistic detail of this pathway. Based on PMID:9892009, ACVR1B phosphorylates SMAD2/3 to enable their nuclear translocation.</p> </li> <li> <p>SMAD Complex Formation: While individual SMAD proteins are represented, the formation of SMAD2/3-SMAD4 complexes, which is essential for their transcriptional activity, is not included. According to the literature (PMID:21145499), activated SMADs form complexes that regulate transcription.</p> </li> <li> <p>Downstream Target Genes: The model doesn't include specific target genes whose expression is regulated by SMAD2/3 to inhibit adipocyte differentiation.</p> </li> <li> <p>Completeness of Pathway: BMP8B is shown interacting directly with ACVR1B, but BMPs typically require both Type I and Type II receptors for signaling. The model doesn't include a Type II receptor component.</p> </li> </ol>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Add Adipocyte Context: Include the adipocyte term (XAO:0006041) as the \"occurs_in\" location for relevant activities to make the cellular context explicit.</p> </li> <li> <p>Include SMAD4: Add SMAD4 and represent the formation of SMAD complexes, which are crucial for transcriptional regulation.</p> </li> <li> <p>Add Phosphorylation Mechanism: Include annotations that capture the phosphorylation of SMAD2/3 by ACVR1B.</p> </li> <li> <p>Include Type II Receptor: BMP signaling typically requires both Type I and Type II receptors. Consider adding a Type II BMP receptor to complete the receptor complex.</p> </li> <li> <p>Add Target Genes: If known, include specific target genes regulated by SMAD2/3 that affect adipocyte differentiation.</p> </li> </ol>"},{"location":"reviews/66e382fb00002243-BMP8B_role_in_adipocyte_differentiation_inhibition__Human_/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model accurately represents the core signaling cascade through which BMP8B inhibits adipocyte differentiation via ACVR1B and SMAD2/3 activation. While the fundamental pathway is correct, additional molecular details would strengthen the model's biological completeness. The model aligns with current literature on BMP signaling through SMAD transcription factors and provides a valuable resource for understanding BMP8B's role in the negative regulation of cell differentiation.</p>"},{"location":"reviews/66e382fb00002293-Signaling_by_Secretin_SCT_mediated_by_SCTR_receptor__Human_/","title":"66e382fb00002293 Signaling by Secretin SCT mediated by SCTR receptor  Human","text":"<p>Based on my review of the GO-CAM model \"Signaling by Secretin/SCT mediated by SCTR receptor (Human)\" and related documents, I'll provide a comprehensive QC review.</p>"},{"location":"reviews/66e382fb00002293-Signaling_by_Secretin_SCT_mediated_by_SCTR_receptor__Human_/#go-cam-review-signaling-by-secretinsct-mediated-by-sctr-receptor-human-gomodel66e382fb00002293","title":"GO-CAM Review: Signaling by Secretin/SCT mediated by SCTR receptor (Human) gomodel:66e382fb00002293","text":""},{"location":"reviews/66e382fb00002293-Signaling_by_Secretin_SCT_mediated_by_SCTR_receptor__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the signaling pathway initiated by the binding of secretin (SCT) to its receptor (SCTR), leading to G protein activation, adenylyl cyclase stimulation, and cAMP production in human cells. The model captures a canonical G protein-coupled receptor (GPCR) signaling pathway with appropriate molecular activities, cellular locations, and causal relationships.</p>"},{"location":"reviews/66e382fb00002293-Signaling_by_Secretin_SCT_mediated_by_SCTR_receptor__Human_/#strengths","title":"Strengths","text":"<ol> <li> <p>Adherence to GO-CAM Structure: The model appropriately represents a complete signaling pathway from ligand binding through second messenger production.</p> </li> <li> <p>Appropriate Molecular Functions: </p> </li> <li>SCT has hormone activity (GO:0005179)</li> <li>SCTR has secretin receptor activity (GO:0015055)</li> <li>GNAS has G protein activity (GO:0003925)</li> <li> <p>ADCY6 has adenylate cyclase activity (GO:0004016)</p> </li> <li> <p>Correct Cellular Locations:</p> </li> <li>SCT is correctly located in extracellular space (GO:0005615)</li> <li>SCTR is correctly located in plasma membrane (GO:0005886)</li> <li> <p>GNAS is correctly located in cytosol (GO:0005829)</p> </li> <li> <p>Accurate Biological Process: All activities are part of the adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189).</p> </li> <li> <p>Complete Causal Chain: The model includes appropriate causal relationships using \"directly positively regulates\" (RO:0002629) between activities:</p> </li> <li>SCT hormone activity \u2192 SCTR receptor activity</li> <li>SCTR receptor activity \u2192 GNAS G protein activity</li> <li> <p>GNAS G protein activity \u2192 ADCY6 adenylate cyclase activity</p> </li> <li> <p>Appropriate Output: ADCY6 adenylate cyclase activity has the output of 3',5'-cyclic AMP (CHEBI:17489).</p> </li> </ol>"},{"location":"reviews/66e382fb00002293-Signaling_by_Secretin_SCT_mediated_by_SCTR_receptor__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li>Evidence Quality: The model uses a mix of evidence types:</li> <li>Direct assay evidence (ECO:0000314) for most critical relationships</li> <li>Sequence similarity evidence (ECO:0000250) for some aspects of SCT and SCTR</li> </ol> <p>This is appropriate, but it would be beneficial to ensure the most direct experimental evidence is used when available.</p> <ol> <li>Model Completeness: The model could potentially be expanded to include:</li> <li>Downstream effects of cAMP production (e.g., PKA activation)</li> <li>Additional regulatory relationships that may modulate the pathway</li> <li> <p>Potential cross-talk with other signaling pathways</p> </li> <li> <p>GNAS Representation: The model uses UniProtKB:Q5JWF2 (GNAS1_HUMAN) for the G protein alpha subunit, which represents the XLas isoform. While this is technically correct as it can couple to SCTR, the more commonly referenced isoform in GPCR signaling literature is P63092 (GNAS2). Both are functional, so this is not incorrect.</p> </li> </ol>"},{"location":"reviews/66e382fb00002293-Signaling_by_Secretin_SCT_mediated_by_SCTR_receptor__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<ol> <li> <p>Secretin Function: The model correctly represents secretin's role as a hormone that binds to the secretin receptor. According to UniProt data, secretin (SCT) is involved in regulating pH of duodenal content, food intake, and water homeostasis, which aligns with the signaling pathway represented.</p> </li> <li> <p>Receptor-G Protein Coupling: SCTR is appropriately shown to couple to Gs (GNAS), which is consistent with literature showing that secretin receptor activates adenylyl cyclase through Gs.</p> </li> <li> <p>Downstream Signaling: The production of cAMP by adenylyl cyclase 6 (ADCY6) as a result of G protein activation is biologically accurate.</p> </li> </ol>"},{"location":"reviews/66e382fb00002293-Signaling_by_Secretin_SCT_mediated_by_SCTR_receptor__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li>Signaling Receptor Guidelines: The model follows the guidelines for signaling receptor activity annotation by:</li> <li>Correctly representing the hormone (ligand) activity with its \"directly positively regulates\" relationship to the receptor</li> <li>Properly locating the hormone in extracellular space and the receptor in plasma membrane</li> <li> <p>Situating all activities within the appropriate biological process</p> </li> <li> <p>Complex Annotation: The model appropriately annotates individual proteins rather than complexes, which is the recommended approach when the specific protein carrying the activity is known.</p> </li> <li> <p>Causal Relations: The model correctly uses \"directly positively regulates\" for the causal chain, which is appropriate for these direct molecular interactions.</p> </li> </ol>"},{"location":"reviews/66e382fb00002293-Signaling_by_Secretin_SCT_mediated_by_SCTR_receptor__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Signaling by Secretin/SCT mediated by SCTR receptor (Human)\" is a well-constructed representation of the secretin signaling pathway. It follows GO-CAM best practices for signaling pathway annotation and accurately represents the biological process with appropriate molecular functions, cellular locations, and causal relationships.</p> <p>The model correctly captures the key molecular steps in secretin signaling from hormone-receptor binding through G protein activation to adenylyl cyclase stimulation and cAMP production. The evidence used to support the model is appropriate, with direct experimental evidence cited for most key relationships.</p> <p>This model provides a valuable resource for understanding secretin signaling and serves as a good template for other GPCR signaling pathways.</p>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/","title":"66f5faaa00000112 TRAF6 and HUWE1 catalyze branched linked polyubiquitination that promote NF kappa B signaling  Human","text":"<p>Based on my review of the GO-CAM model and the documentation, I'll now provide a thorough review of model gomodel:66f5faaa00000112.</p>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#review-of-go-cam-model-gomodel66f5faaa00000112","title":"Review of GO-CAM Model: gomodel:66f5faaa00000112","text":""},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#model-overview","title":"Model Overview","text":"<p>Title: \"TRAF6 and HUWE1 catalyze branched-linked polyubiquitination that promote NF-kappa-B signaling (Human).\" Taxon: Human (NCBITaxon:9606) Status: production</p>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#model-content-and-structure","title":"Model Content and Structure","text":"<p>This model represents a pathway involving branched-linked polyubiquitination that promotes NF-kappa-B signaling, with a focus on the roles of TRAF6 and HUWE1. The model consists of 8 activities that are causally connected to represent signaling events.</p>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#main-components","title":"Main Components","text":"<ol> <li>CYLD (Q9NQC7) - K63-linked deubiquitinase activity</li> <li>TAB2 (Q9NYJ8) - K63-linked polyubiquitin modification-dependent protein binding</li> <li>MAP3K7/TAK1 (O43318) - protein serine/threonine kinase activity</li> <li>IKBKB (O14920) - IkappaB kinase activity</li> <li>NFKBIA/I\u03baB\u03b1 (P25963) - protein sequestering activity</li> <li>RELA/p65 (Q04206) &amp; NFKB1/p50 (P19838) - DNA-binding transcription factor activity</li> <li>TRAF6 (Q9Y4K3) - ubiquitin-ubiquitin ligase activity</li> <li>HUWE1 (Q7Z6Z7) - ubiquitin protein ligase activity</li> </ol>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#pathway-logic-analysis","title":"Pathway Logic Analysis","text":"<p>The model depicts the following pathway:</p> <ol> <li>TRAF6 catalyzes K63-linked ubiquitination (GO:0070534)</li> <li>HUWE1 adds K48-linked ubiquitin branches to TRAF6-created K63-linked chains (GO:0070936)</li> <li>These branched chains are recognized by TAB2 (K63-linked polyubiquitin modification-dependent protein binding)</li> <li>This activates MAP3K7/TAK1 (protein serine/threonine kinase activity)</li> <li>MAP3K7 activates IKBKB (IkappaB kinase activity)</li> <li>IKBKB leads to inactivation of NFKBIA (protein sequestering activity)</li> <li>This relieves inhibition of NF-kappa-B transcription factors RELA and NFKB1</li> <li>CYLD acts as a negative regulator by deubiquitinating K63-linked chains</li> </ol> <p>The model properly shows that CYLD deubiquitinase (GO:0061578) negatively regulates NF-kappa-B signaling (GO:0043124) through removal of K63-linked ubiquitin chains, but the branched K48/K63 ubiquitin chains created by TRAF6 and HUWE1 are protected from CYLD's activity, allowing signaling to proceed.</p>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#evaluation-of-model-quality","title":"Evaluation of Model Quality","text":""},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#strengths","title":"Strengths","text":"<ol> <li> <p>Accurate molecular mechanisms: The model correctly represents the branched-linked polyubiquitination mechanism as described in the literature (Ohtake et al., 2016, Mol Cell).</p> </li> <li> <p>Proper causal relationships: The causal relationships are represented appropriately with the correct predicates:</p> </li> <li>\"RO:0002413\" (provides input for) between TRAF6 and HUWE1</li> <li>\"RO:0012010\" (ubiquitinates) between HUWE1 and CYLD</li> <li>\"RO:0012010\" (ubiquitinates) between HUWE1 and TAB2</li> <li>\"RO:0002629\" (directly positively regulates) between TAB2 and MAP3K7</li> <li>\"RO:0002629\" (directly positively regulates) between MAP3K7 and IKBKB</li> <li>\"RO:0002409\" (indirectly upstream of, positive effect) between IKBKB and NFKBIA</li> <li> <p>\"RO:0002630\" (directly negatively regulates) between NFKBIA and transcription factors</p> </li> <li> <p>Appropriate BP annotations: Each activity is properly annotated with the relevant biological process:</p> </li> <li>TRAF6: protein K63-linked ubiquitination (GO:0070534)</li> <li>HUWE1: protein K48-linked ubiquitination (GO:0070936)</li> <li>CYLD: negative regulation of canonical NF-kappaB signal transduction (GO:0043124)</li> <li>TAB2, MAP3K7, IKBKB: positive regulation of canonical NF-kappaB signal transduction (GO:0043123)</li> <li>NFKBIA: negative regulation of canonical NF-kappaB signal transduction (GO:0043124)</li> <li> <p>RELA and NFKB1: canonical NF-kappaB signal transduction (GO:0007249)</p> </li> <li> <p>Evidence: Each activity and causal relationship is supported by evidence with appropriate ECO codes and literature references.</p> </li> </ol>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing participants: While the model represents the core pathway accurately, it doesn't include upstream activators like cytokine receptors or TLR signaling that would initiate the TRAF6 activity.</p> </li> <li> <p>Subcellular location: Only NFKBIA, RELA, and NFKB1 have subcellular location annotations (chromatin for RELA/NFKB1, cytoplasm for IKBKB). Adding subcellular location information for other proteins would enhance the model.</p> </li> <li> <p>Missing IKK complex components: The model only includes IKBKB, but the IKK complex typically consists of IKBKA, IKBKB, and IKBKG/NEMO. Including these additional components would make the model more complete.</p> </li> <li> <p>Missing feedback mechanisms: NF-kappa-B signaling often involves feedback mechanisms, such as NF-kappa-B-dependent transcription of inhibitors like NFKBIA, which are not represented in the model.</p> </li> </ol>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices as outlined in the available documentation:</p> <ol> <li> <p>E3 ubiquitin ligase annotation: Both TRAF6 and HUWE1 are properly annotated with the correct molecular functions and biological processes as per the \"E3 ubiquitin ligases\" guidelines.</p> </li> <li> <p>Causal relationships: The causal relationships follow the recommended predicates for different types of regulatory relationships.</p> </li> <li> <p>Evidence codes: Appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) are used throughout.</p> </li> </ol>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#suggestions-for-enhancement","title":"Suggestions for Enhancement","text":"<ol> <li> <p>Include upstream activators: Add the initiating events, such as cytokine receptor activation or TLR signaling.</p> </li> <li> <p>Add subcellular locations: Annotate all activities with their appropriate subcellular locations.</p> </li> <li> <p>Include IKK complex components: Add IKBKA and IKBKG/NEMO to represent the complete IKK complex.</p> </li> <li> <p>Represent feedback mechanisms: Include the feedback regulation of NF-kappa-B signaling, such as the transcriptional activation of inhibitors.</p> </li> <li> <p>Include substrates or targets: For key enzymes like TRAF6, HUWE1, CYLD, and IKBKB, consider annotating specific substrates where known.</p> </li> </ol>"},{"location":"reviews/66f5faaa00000112-TRAF6_and_HUWE1_catalyze_branched_linked_polyubiquitination_that_promote_NF_kappa_B_signaling__Human__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:66f5faaa00000112) accurately represents the mechanism of branched-linked polyubiquitination in NF-kappa-B signaling mediated by TRAF6 and HUWE1, with negative regulation by CYLD. The model follows GO-CAM best practices and includes appropriate causal relationships and evidence. While there are areas for potential enhancement, the core biological pathway is well-captured and the model provides a valuable representation of this important signaling mechanism.</p>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/","title":"66f5faaa00001204 Retinoid Metabolic Process 1  Mouse","text":"<p>Now that I have a better understanding of the model and the biological context, I'll provide a comprehensive review of GO-CAM model gomodel:66f5faaa00001204 (Retinoid Metabolic Process 1 in Mouse).</p>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#review-of-go-cam-model-retinoid-metabolic-process-1-mouse","title":"Review of GO-CAM Model: Retinoid Metabolic Process 1 (Mouse)","text":""},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#model-id-gomodel66f5faaa00001204","title":"Model ID: gomodel:66f5faaa00001204","text":""},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model represents retinoid (vitamin A) metabolic processes in mouse. It includes key enzymes involved in retinoid transport, binding, metabolism, and storage. The model captures the flow of retinol metabolism through various activities including hydrolysis, transport, oxidation, and esterification within the retinoid metabolic pathway.</p>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#strengths","title":"Strengths","text":"<ol> <li> <p>The model correctly represents \"retinoid metabolic process\" (GO:0001523) as the overarching biological process, with individual molecular activities properly identified as part of this process.</p> </li> <li> <p>The causal connections between activities use appropriate predicates, generally following the flow of the retinoid metabolic pathway.</p> </li> <li> <p>Molecular function assignments are well-supported by literature evidence (ECO codes are appropriate and include references to primary literature).</p> </li> <li> <p>The model correctly represents cellular localization of different activities (e.g., extracellular region, plasma membrane, endoplasmic reticulum membrane, cytosol).</p> </li> <li> <p>Chemical entities (CHEBI terms) are appropriately used to represent the molecular inputs and outputs of the different enzymatic reactions.</p> </li> </ol>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#issues-and-recommendations","title":"Issues and Recommendations","text":""},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#1-complex-annotation","title":"1. Complex Annotation","text":"<p>The model includes GO:0042627 (chylomicron) as a protein complex enabling the retinoid binding activity (GO:0005501), but no members of this complex are specified:</p> <pre><code>\"id\":\"gomodel:66f5faaa00001204/66f5faaa00001265\",\n\"enabled_by\":{\"type\":\"EnabledByProteinComplexAssociation\",\"term\":\"GO:0042627\",\"members\":[]}\n</code></pre> <p>According to \"How to annotate complexes in GO-CAM,\" when a complex is used, it should either include the subunits that carry the activity (if known) or use the GO complex term if the specific protein carrying the activity is not known. In this case, the specific proteins in the chylomicron that bind retinoids should be specified if known, or a note should be included explaining why the complex is used without specified members.</p>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#2-molecular-carrier-activity","title":"2. Molecular Carrier Activity","text":"<p>The model correctly uses molecular carrier activity (GO:0140104) for Rbp2 (MGI:MGI:97877), but this should be carefully reviewed to ensure it follows the guidelines for molecular carrier activity:</p> <ul> <li>The model correctly uses \"has_primary_input\" to indicate all-trans-retinol (CHEBI:17336), but it's not clear if appropriate downstream connections are made to show where the carried molecule is delivered.</li> </ul>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#3-completeness-of-evidence","title":"3. Completeness of Evidence","text":"<p>Some activities lack evidence codes or citations: - The chylomicron retinoid binding activity (gomodel:66f5faaa00001204/66f5faaa00001265) lacks evidence annotations. - Several causal associations lack evidence codes.</p> <p>I recommend adding evidence codes and references for all assertions to strengthen the model's validity.</p>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#4-biological-completeness","title":"4. Biological Completeness","text":"<p>While the model captures key aspects of retinoid metabolism, some known components of the pathway might be missing: - Cellular retinol-binding protein (CRBP) and cellular retinoic acid-binding protein (CRABP) which are important intracellular carriers are not explicitly represented. - The conversion of retinol to retinoic acid (via retinal) is represented but could be more detailed with the specific steps and enzymes involved.</p>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#5-causal-association-and-activity-flow","title":"5. Causal Association and Activity Flow","text":"<p>Some improvements could be made in the representation of causal relationships: - The model has both Rbp1 (MGI:MGI:97876) activities (gomodel:66f5faaa00001204/66f5faaa00001280 and gomodel:66f5faaa00001204/66f5faaa00001307) inhibiting Adh1 (MGI:MGI:87921) retinol dehydrogenase activity. Based on the PMID:15193143 reference, this appears to represent the opposing actions of CRBP1 (Rbp1) and ADH1 in regulating the balance between retinyl ester formation and retinol oxidation. This is biologically accurate and well-represented.</p> <ul> <li>The causal relationships across the entire model create a coherent flow that aligns with the known retinoid metabolic pathway.</li> </ul>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#specific-entity-reviews","title":"Specific Entity Reviews","text":""},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#enzymes-and-their-functions","title":"Enzymes and Their Functions","text":"<ol> <li> <p>Lpl (MGI:MGI:96820) - Lipoprotein lipase activity: Correctly represented as participating in retinoid metabolic process and occurring in extracellular region.</p> </li> <li> <p>Lrat (MGI:MGI:1891259) - O-palmitoyltransferase and phosphatidylcholine-retinol O-acyltransferase activities: Both activities are correctly represented as occurring in ER membrane.</p> </li> <li> <p>Rbp1 (MGI:MGI:97876) and Rbp2 (MGI:MGI:97877) - Retinol binding and molecular carrier activities: Appropriately represented with their respective molecular functions.</p> </li> <li> <p>Pnlip (MGI:MGI:97722) - Retinyl-palmitate esterase activity: Correctly shown occurring in the extracellular region with appropriate inputs and outputs.</p> </li> <li> <p>Adh1 (MGI:MGI:87921) - Retinol dehydrogenase activity: Properly represented with appropriate regulation by Rbp1.</p> </li> </ol>"},{"location":"reviews/66f5faaa00001204-Retinoid_Metabolic_Process_1__Mouse__/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model provides a good representation of the retinoid metabolic process in mouse. It captures the key activities and relationships in the pathway, with strong evidence support. The model would benefit from a few clarifications around complex representation and the addition of evidence codes for all assertions. The biological content is accurate and consistent with the literature. The connections between activities represent the known flow of the retinoid metabolic pathway reasonably well.</p> <p>The model is parsimonious and focused on the core aspects of retinoid metabolism, making it accessible and understandable while still being comprehensive. With the minor improvements suggested, this would be an excellent curated model of retinoid metabolism.</p>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/","title":"67086be200000363 cardiolipin metabolic process  GO 0032048   Spom","text":"<p>Now, let me review the GO-CAM model gomodel:67086be200000363.</p>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#go-cam-model-review-gomodel67086be200000363-cardiolipin-metabolic-process-in-s-pombe","title":"GO-CAM Model Review: gomodel:67086be200000363 (cardiolipin metabolic process in S. pombe)","text":""},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:67086be200000363) represents the cardiolipin biosynthetic pathway in fission yeast (Schizosaccharomyces pombe). The model details the enzymatic steps involved in the synthesis of cardiolipin, a unique phospholipid found in mitochondrial membranes that is essential for mitochondrial function.</p>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#model-content-and-structure","title":"Model Content and Structure","text":"<p>The model includes four key activities connected in a causal pathway:</p> <ol> <li>Phosphatidate cytidylyltransferase activity (GO:0004605)</li> <li>Enabled by: PomBase:SPBC1A4.06c (tam41)</li> <li>Occurs in: Mitochondrial matrix (GO:0005759)</li> <li>Part of: CDP-diacylglycerol biosynthetic process (GO:0016024)</li> <li>Has output: CDP-diacylglycerol (CHEBI:17962)</li> <li> <p>Causally upstream of: CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase activity</p> </li> <li> <p>CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase activity (GO:0008444)</p> </li> <li>Enabled by: PomBase:SPBP18G5.02 (pgs1)</li> <li>Occurs in: Mitochondrial matrix (GO:0005759)</li> <li>Part of: Cardiolipin biosynthetic process (GO:0032049)</li> <li>Has input: CDP-diacylglycerol (CHEBI:17962)</li> <li> <p>Causally upstream of: Phosphatidylglycerophosphatase activity</p> </li> <li> <p>Phosphatidylglycerophosphatase activity (GO:0008962)</p> </li> <li>Enabled by: PomBase:SPCC645.02 (gep4)</li> <li>Occurs in: Mitochondrial matrix (GO:0005759)</li> <li>Part of: Cardiolipin biosynthetic process (GO:0032049)</li> <li> <p>Causally upstream of: Cardiolipin synthase (CMP-forming) activity</p> </li> <li> <p>Cardiolipin synthase (CMP-forming) activity (GO:0043337)</p> </li> <li>Enabled by: PomBase:SPAC22A12.08c (crd1)</li> <li>Occurs in: Mitochondrial membrane (GO:0031966)</li> <li>Part of: Cardiolipin biosynthetic process (GO:0032049)</li> <li>Has output: Cardiolipin(2-) (CHEBI:62237)</li> </ol>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported by evidence: - Most activities are backed by direct experimental evidence (ECO:0000314) or sequence orthology evidence (ECO:0000266) - Key evidential support comes from PMID:31178220, PMID:9468529, and PMID:29958934 - From the literature (PMID:29958934) I was able to verify that SPAC22A12.08c indeed encodes the cardiolipin synthase in S. pombe, confirming a key element of the model</p>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#evaluation-of-causal-connections","title":"Evaluation of Causal Connections","text":"<p>The causal flow is well-represented: - All activities are appropriately connected using the \"provides input for\" (RO:0002413) predicate - The connections accurately represent the sequential enzymatic steps in cardiolipin biosynthesis - The inputs and outputs of reactions (specifically CDP-diacylglycerol and cardiolipin) are properly annotated</p>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#anatomical-context","title":"Anatomical Context","text":"<p>The model correctly localizes: - Most activities to the mitochondrial matrix (GO:0005759) - The final cardiolipin synthase activity to the mitochondrial membrane (GO:0031966)</p> <p>This is consistent with the known localization of cardiolipin biosynthesis enzymes.</p>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#issues-identified","title":"Issues Identified","text":"<ol> <li> <p>Minor redundancy issue: There is a duplicate \"has_input\" association for CHEBI:17962 (CDP-diacylglycerol) in the PomBase:SPBP18G5.02 activity node. One of these inputs lacks evidence information.</p> </li> <li> <p>Missing intermediate molecule: The model doesn't explicitly represent phosphatidylglycerol as an output of the phosphatidylglycerophosphatase activity and input to the cardiolipin synthase activity. This intermediate molecule should be included for complete pathway representation.</p> </li> <li> <p>Evidence consistency: There's inconsistent evidence attribution for some of the connections. For example, one of the \"has_input\" connections for CDP-diacylglycerol has no evidence indicated.</p> </li> </ol>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Remove redundant input: Remove the duplicate input annotation for CDP-diacylglycerol or add appropriate evidence information.</p> </li> <li> <p>Add missing intermediate molecule: Add phosphatidylglycerol (PG) as:</p> </li> <li>An output of the phosphatidylglycerophosphatase activity (PomBase:SPCC645.02)</li> <li> <p>An input to the cardiolipin synthase activity (PomBase:SPAC22A12.08c)</p> </li> <li> <p>Ensure complete evidence: Add evidence information to all associations, particularly the missing evidence for one of the CDP-diacylglycerol inputs.</p> </li> </ol>"},{"location":"reviews/67086be200000363-cardiolipin_metabolic_process__GO_0032048___Spom_/#overall-assessment","title":"Overall Assessment","text":"<p>The model is generally well-constructed and accurately represents the cardiolipin biosynthetic pathway in S. pombe with good evidence support. It correctly identifies the key enzymatic steps, their causal relationships, and subcellular localization. The minor issues identified don't significantly affect the biological accuracy of the model but addressing them would improve its completeness and consistency.</p> <p>The flow of the pathway is logical and follows the established understanding of cardiolipin biosynthesis, starting with the conversion of phosphatidic acid to CDP-diacylglycerol, then to phosphatidylglycerol phosphate, phosphatidylglycerol, and finally to cardiolipin. The evidence from published literature supports this representation.</p>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/","title":"67086be200001578 Negative regulation of BNIP3 and BNIP3L via PPTC7 and FBXL4  Human","text":"<p>Based on my comprehensive review of the GO-CAM model and related literature, I will now provide a detailed assessment of the model:</p>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#go-cam-model-review-gomodel67086be200001578","title":"GO-CAM Model Review: gomodel:67086be200001578","text":""},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#model-overview","title":"Model Overview","text":"<p>This model, titled \"Negative regulation of BNIP3 and BNIP3L via PPTC7 and FBXL4 (Human)\", represents a biological pathway that negatively regulates mitophagy through the controlled degradation of the mitophagy receptors BNIP3 and BNIP3L/NIX via the PPTC7-FBXL4-RBX1 axis.</p>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#scientific-content-assessment","title":"Scientific Content Assessment","text":"<p>The model accurately represents a recently discovered mechanism described in PMID:38992176, where PPTC7 acts as a molecular adaptor between the mitophagy receptors BNIP3/NIX and the SCFFBXL4 E3 ubiquitin ligase complex to facilitate the ubiquitination and subsequent degradation of these receptors, thereby suppressing mitophagy.</p> <p>The key molecular interactions represented in the model are: 1. PPTC7 (Q8NI37) functioning as a protein-macromolecule adaptor (GO:0030674) 2. FBXL4 (Q9UKA2) serving as a ubiquitin ligase-substrate adaptor (GO:1990756) 3. RBX1 (P62877) acting as an E3 ubiquitin protein ligase (GO:0061630) 4. BNIP3 (Q12983) functioning as a mitochondrion autophagosome adaptor (GO:0140580)</p> <p>All of these activities are correctly located at the mitochondrial outer membrane (GO:0005741), consistent with the published literature.</p>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#model-structure-and-connections","title":"Model Structure and Connections","text":"<p>The model correctly depicts the flow of activities using appropriate causal connections: 1. PPTC7's adaptor activity provides input for (RO:0002413) FBXL4's adaptor activity 2. FBXL4's adaptor activity provides input for (RO:0002413) RBX1's ubiquitin ligase activity 3. RBX1's ubiquitin ligase activity directly negatively regulates (RO:0002630) BNIP3's mitophagy receptor activity</p> <p>This structure accurately reflects the mechanism where PPTC7 facilitates the recognition of BNIP3/NIX by FBXL4, leading to their ubiquitination by the SCF complex and subsequent degradation, thereby inhibiting mitophagy.</p>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model appropriately cites the primary research article (PMID:38992176) for most of the assertions, using the correct evidence code ECO:0000314 (direct assay evidence used in manual assertion). A secondary citation (PMID:22505714) supports BNIP3's role in mitophagy with appropriate evidence code ECO:0000315 (mutant phenotype evidence).</p>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#conformance-to-go-cam-best-practices","title":"Conformance to GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing molecular adaptors and E3 ubiquitin ligase complexes:</p> <ol> <li> <p>Molecular Adaptor Representation: PPTC7 is correctly annotated with \"protein-macromolecule adaptor activity\" (GO:0030674), which aligns with the guidelines in the \"Molecular_adaptor_activity\" document.</p> </li> <li> <p>E3 Ubiquitin Ligase Representation: The model correctly depicts the SCF complex components:</p> </li> <li>FBXL4 as the substrate adaptor with \"ubiquitin ligase-substrate adaptor activity\" (GO:1990756)</li> <li>RBX1 with \"ubiquitin protein ligase activity\" (GO:0061630)</li> </ol> <p>This follows the pattern described in the \"E3_ubiquitin_ligases\" document for \"When only substrate adaptor and substrate are known.\"</p> <ol> <li> <p>Part_of Relationships: All activities are appropriately indicated as being \"part_of\" the biological process \"negative regulation of mitophagy\" (GO:1901525).</p> </li> <li> <p>Occurs_in Relationships: The cellular location is correctly specified for each activity, with PPTC7, FBXL4, and BNIP3 activities occurring in the mitochondrial outer membrane (GO:0005741) and RBX1's activity in the cytoplasm (GO:0005737).</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal relationships between activities:</p> </li> <li>\"provides input for\" (RO:0002413) between adaptor activities</li> <li>\"directly negatively regulates\" (RO:0002630) for the effect on BNIP3/NIX</li> </ol>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#suggested-improvements","title":"Suggested Improvements","text":"<p>While the model is largely accurate and follows GO-CAM best practices, there are a few potential improvements:</p> <ol> <li> <p>Missing Component: The model doesn't explicitly include other components of the SCF complex such as SKP1 and CUL1. According to the E3 ubiquitin ligases guidelines, these could be included for a more complete representation.</p> </li> <li> <p>BNIP3L/NIX Representation: Although the model title mentions both BNIP3 and BNIP3L/NIX, only BNIP3 is explicitly represented in the model. Since both proteins are regulated in the same manner according to PMID:38992176, BNIP3L/NIX (UniProtKB:O60238) could be added with the same relationships and activities.</p> </li> <li> <p>Additional Evidence: While most assertions have appropriate evidence, there is a second causal association between RBX1 and BNIP3 that lacks evidence codes. This should be remedied by adding the appropriate evidence codes and references.</p> </li> </ol>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model faithfully represents the current understanding of this pathway as described in the primary literature. The discovery that PPTC7 acts as an adaptor between BNIP3/NIX and the SCFFBXL4 E3 ubiquitin ligase complex is a recent finding (PMID:38992176) and the model accurately captures this mechanism.</p> <p>The model correctly indicates that this process occurs at the mitochondrial outer membrane and ultimately leads to the negative regulation of mitophagy, which aligns with the biological understanding presented in the literature.</p>"},{"location":"reviews/67086be200001578-Negative_regulation_of_BNIP3_and_BNIP3L_via_PPTC7_and_FBXL4__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Negative regulation of BNIP3 and BNIP3L via PPTC7 and FBXL4 (Human)\" is a high-quality representation of the recently discovered pathway regulating mitophagy. It follows GO-CAM best practices and accurately represents the biological mechanism with appropriate evidence.</p> <p>The suggested improvements would enhance the model's completeness but do not detract from its current accuracy. The model provides a valuable contribution to our understanding of mitophagy regulation and would be useful for researchers in this field.</p>"},{"location":"reviews/67086be200001601-Fertilization_complex_allows_sperm_egg_recognition_during_fertilization___Human_/","title":"67086be200001601 Fertilization complex allows sperm egg recognition during fertilization   Human","text":"<p>Based on my review of the model, the proteins involved, and the relevant best practices, I can now provide a comprehensive review of GO-CAM model gomodel:67086be200001601.</p>"},{"location":"reviews/67086be200001601-Fertilization_complex_allows_sperm_egg_recognition_during_fertilization___Human_/#review-of-go-cam-model-gomodel67086be200001601","title":"Review of GO-CAM Model: gomodel:67086be200001601","text":""},{"location":"reviews/67086be200001601-Fertilization_complex_allows_sperm_egg_recognition_during_fertilization___Human_/#model-overview","title":"Model Overview","text":"<p>Title: Fertilization complex allows sperm-egg recognition during fertilization. (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/67086be200001601-Fertilization_complex_allows_sperm_egg_recognition_during_fertilization___Human_/#summary","title":"Summary","text":"<p>This model describes the molecular functions and interactions involved in sperm-egg recognition during fertilization in humans. The model involves four key proteins: 1. IZUMO1 (UniProtKB:Q8IYV9) - Sperm protein with receptor ligand activity 2. IZUMO1R/JUNO (UniProtKB:A6ND01) - Egg protein with signaling receptor activity 3. SPACA6 (UniProtKB:W5XKT8) - Sperm protein with protein-macromolecule adaptor activity 4. TMEM81 (UniProtKB:Q6P7N7) - Sperm protein with protein-macromolecule adaptor activity</p> <p>All activities are part of the biological process of sperm-egg recognition (GO:0035036) and occur at the plasma membrane (GO:0005886).</p>"},{"location":"reviews/67086be200001601-Fertilization_complex_allows_sperm_egg_recognition_during_fertilization___Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Recent Evidence Base: The model is well-supported by a recent publication (PMID:39423812, 2024) that demonstrates the formation of a conserved fertilization complex involving IZUMO1, SPACA6, and TMEM81.</p> </li> <li> <p>Appropriate Molecular Functions: The molecular functions assigned to each protein appear accurate:</p> </li> <li>IZUMO1 as receptor ligand (GO:0048018)</li> <li>IZUMO1R/JUNO as signaling receptor (GO:0038023)</li> <li> <p>SPACA6 and TMEM81 as protein-macromolecule adaptors (GO:0030674)</p> </li> <li> <p>Correct Causal Relationships: The model correctly shows SPACA6 and TMEM81 directly positively regulating (RO:0002629) IZUMO1's receptor ligand activity, followed by IZUMO1 directly positively regulating IZUMO1R/JUNO's signaling receptor activity.</p> </li> <li> <p>Consistent Cellular Location: All activities appropriately occur at the plasma membrane (GO:0005886).</p> </li> </ol>"},{"location":"reviews/67086be200001601-Fertilization_complex_allows_sperm_egg_recognition_during_fertilization___Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex Representation: Based on the \"How to annotate complexes in GO-CAM\" guidelines, since the model is representing a complex (IZUMO1, SPACA6, and TMEM81), it may be appropriate to consider if a GO complex ID could be used. However, since the individual roles of each protein are well-defined and supported by evidence, the current representation with individual proteins is also valid.</p> </li> <li> <p>Biological Completeness: While the model accurately represents the interaction between the sperm proteins and the egg receptor, it could be expanded to show the downstream effects following receptor activation. According to the UniProt entry for IZUMO1R/JUNO, the receptor is rapidly cleaved following fertilization to block polyspermy. This could be represented as a downstream event.</p> </li> <li> <p>Evidence Codes: The model correctly uses ECO:0000250 (sequence similarity evidence) with references to mouse orthologs for some interactions, and ECO:0000314 (direct assay evidence) with the PMID reference for others. This is appropriate based on the available evidence.</p> </li> <li> <p>MAIA/FCRL3 Consideration: Recent evidence (PMID:36070373) suggests that in humans, FCRL3/MAIA replaces IZUMO1R/JUNO as the IZUMO1 receptor after initial sperm-egg adhesion. This subsequent interaction could potentially be included in an expanded version of the model to provide a more complete picture of the fertilization process in humans.</p> </li> </ol>"},{"location":"reviews/67086be200001601-Fertilization_complex_allows_sperm_egg_recognition_during_fertilization___Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:67086be200001601 is well-constructed and accurately represents current knowledge about the sperm-egg recognition process during human fertilization. The model is appropriately parsimonious while capturing the key molecular functions and causal relationships involved in this process. It is supported by recent scientific evidence, particularly PMID:39423812, which provides direct experimental evidence for the interactions represented.</p> <p>The model correctly applies GO-CAM best practices regarding the representation of complex interactions and is consistent with what is known about the proteins involved based on their UniProt entries. The causal relationships between the proteins accurately reflect the molecular mechanisms described in the literature.</p> <p>In summary, this model is of high quality and provides a clear, evidence-supported representation of the sperm-egg recognition process in humans.</p>"},{"location":"reviews/67086be200002266-sphingolipid_biosynthetic_process__GO_0030148_/","title":"67086be200002266 sphingolipid biosynthetic process  GO 0030148","text":"<p>Based on my review of the GO-CAM model titled \"sphingolipid biosynthetic process (GO:0030148)\" (model ID: gomodel:67086be200002266), here is my assessment:</p>"},{"location":"reviews/67086be200002266-sphingolipid_biosynthetic_process__GO_0030148_/#overall-assessment","title":"Overall Assessment","text":"<p>This model represents the sphingolipid biosynthetic pathway in Schizosaccharomyces pombe (fission yeast, taxon NCBITaxon:4896) and appears to be a comprehensive representation of the pathway components and their relationships. The model includes proteins involved in sphingolipid synthesis from initial steps (serine palmitoyltransferase activity) through ceramide synthesis and further modifications.</p>"},{"location":"reviews/67086be200002266-sphingolipid_biosynthetic_process__GO_0030148_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Comprehensive pathway representation: The model covers multiple aspects of sphingolipid biosynthesis including:</li> <li>Sphingosine biosynthesis</li> <li>Ceramide biosynthesis</li> <li>Inositol phosphoceramide synthesis</li> <li> <p>Mannosylinositol phosphorylceramide synthesis</p> </li> <li> <p>Well-defined molecular functions: Each activity has appropriately assigned molecular functions with proper evidence codes.</p> </li> <li> <p>Cellular localization: Proper annotations for subcellular locations (primarily endoplasmic reticulum and Golgi) are included.</p> </li> <li> <p>Causal connections: The model uses appropriate causal relationships (RO:0002413 \"provides input for\") to link activities in the pathway.</p> </li> <li> <p>Input/output annotations: Chemical entities are properly linked as inputs and outputs of enzymatic activities.</p> </li> </ol>"},{"location":"reviews/67086be200002266-sphingolipid_biosynthetic_process__GO_0030148_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Complex representation:    The model comment states: \"Orm1, Sac11 and Sac12 are part of the Serine palmitoyltransferase complex, function unknown\". However, these proteins are modeled individually without explicit representation of the complex. According to GO-CAM guidelines, if these form a functional complex but their specific activities are unknown, it might be better to use a GO complex ID to represent this. </p> </li> <li> <p>Undefined molecular function:    Several proteins (SPAC3C7.01c/sac12, SPBC119.09c/orm1, SPBC36B7.02/svf2) have \"GO:0003674\" (molecular_function) as their activity, indicating unknown molecular function. This is acceptable given evidence limitations, but when possible, specific functions should be determined.</p> </li> <li> <p>Evidence consistency:    Most activities have appropriate evidence codes, but there are a few instances of empty evidence lists (e.g., in causal_associations for activities gomodel:67086be200002266/67086be200002288, gomodel:67086be200002266/67086be200002404). These should be completed with appropriate evidence.</p> </li> <li> <p>Consistency in input/output:    In some cases, like for activity gomodel:67086be200002266/67086be200002533 (SPAC17G8.11c/imt3), there are duplicate outputs (CHEBI:25168 mannosylinositol phosphorylceramide) and one output lacks evidence. This redundancy should be resolved.</p> </li> <li> <p>Potentially erroneous evidence:    In gomodel:67086be200002266/67086be200002476 (SPBC36B7.02/svf2), there are evidence codes with \"with_objects\" references to \"PomBa\", \"PomBas\", and \"PomBase\" which appear to be incomplete or incorrect entries. These should be corrected to proper database references.</p> </li> <li> <p>Protein without specific annotation:    The model includes a generic protein (CHEBI:36080) with N-acylsphingosine amidohydrolase activity (GO:0017040) but without evidence codes. This should be replaced with a specific protein if possible, or evidence should be added.</p> </li> </ol>"},{"location":"reviews/67086be200002266-sphingolipid_biosynthetic_process__GO_0030148_/#technical-consistency","title":"Technical Consistency","text":"<ol> <li> <p>The causal flow is generally well-represented with appropriate use of RO:0002413 (provides input for) and RO:0002629 (directly positively regulates) predicates.</p> </li> <li> <p>The usage of evidence codes is generally appropriate, with many annotations supported by experimental evidence (ECO:0000269), sequence orthology (ECO:0000266), and biological aspect of ancestor evidence (ECO:0000318).</p> </li> </ol>"},{"location":"reviews/67086be200002266-sphingolipid_biosynthetic_process__GO_0030148_/#biological-consistency","title":"Biological Consistency","text":"<p>The model accurately represents the sphingolipid biosynthetic pathway according to current knowledge: - Initial synthesis of 3-ketosphinganine from serine and palmitoyl-CoA - Reduction to sphinganine - Conversion to ceramides - Further modification of ceramides with inositol phosphate - Mannosylation of inositol phosphoceramides</p> <p>The pathway flow is biologically consistent, and the localization of activities to appropriate subcellular compartments (ER and Golgi) matches known biology.</p>"},{"location":"reviews/67086be200002266-sphingolipid_biosynthetic_process__GO_0030148_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Consider using a GO complex term to represent the Serine palmitoyltransferase complex mentioned in the comments.</p> </li> <li> <p>Complete the missing evidence annotations for causal relationships.</p> </li> <li> <p>Remove duplicate chemical entity listings and ensure all have appropriate evidence.</p> </li> <li> <p>Fix the incorrect evidence with_objects references (PomBa, PomBas).</p> </li> <li> <p>Replace the generic protein (CHEBI:36080) with a specific protein if possible.</p> </li> <li> <p>Review and specify molecular functions for proteins currently annotated with GO:0003674 (molecular_function) if literature supports more specific activities.</p> </li> </ol> <p>Overall, this is a high-quality model that provides a comprehensive representation of sphingolipid biosynthesis in fission yeast, with only minor issues that should be addressed for completeness and consistency.</p>"},{"location":"reviews/67086be200002592-Retinoid_Metabolic_Process_3__Mouse__/","title":"67086be200002592 Retinoid Metabolic Process 3  Mouse","text":"<p>Based on my review of the model and the available guidelines, I'll now provide a comprehensive review of GO-CAM model gomodel:67086be200002592.</p>"},{"location":"reviews/67086be200002592-Retinoid_Metabolic_Process_3__Mouse__/#go-cam-model-review-retinoid-metabolic-process-3-mouse","title":"GO-CAM Model Review: \"Retinoid Metabolic Process 3 (Mouse)\"","text":""},{"location":"reviews/67086be200002592-Retinoid_Metabolic_Process_3__Mouse__/#model-overview","title":"Model Overview","text":"<p>This model represents retinoid metabolic processes in mouse, including various enzymatic activities and molecular functions involved in processing and transporting retinoids. The model includes 8 activities centered around the retinoid metabolic process (GO:0001523).</p>"},{"location":"reviews/67086be200002592-Retinoid_Metabolic_Process_3__Mouse__/#strengths","title":"Strengths","text":"<ol> <li>Appropriate biological process annotation: All activities are correctly annotated as \"part of\" retinoid metabolic process (GO:0001523).</li> <li>Evidence support: Each activity has appropriate evidence codes with PMID references.</li> <li>Causal connections: The model appropriately uses RO:0002413 (provides input for) and RO:0002629 (directly positively regulates) to connect related activities.</li> <li>Cellular components: Appropriate cellular locations are specified for most activities.</li> <li>Use of molecular carrier activity: Rbp2 (MGI:MGI:97877) is correctly annotated with molecular carrier activity (GO:0140104) following the guidelines.</li> </ol>"},{"location":"reviews/67086be200002592-Retinoid_Metabolic_Process_3__Mouse__/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Missing members in protein complex:</li> <li>The chylomicron (GO:0042627) protein complex is annotated without any members. According to the complex annotation guidelines, either specific proteins should be included or a GO complex term should be used when the specific subunits are not known.</li> <li> <p>Recommendation: Add the specific protein members of the chylomicron complex if they are known.</p> </li> <li> <p>Incomplete input/output annotations:</p> </li> <li>Some activities are missing has_input/has_output annotations, making it difficult to track the flow of molecules through the pathway.</li> <li> <p>Recommendation: Add appropriate input/output annotations for each activity to fully specify the molecular conversions.</p> </li> <li> <p>Cellular component annotations:</p> </li> <li>Activity gomodel:67086be200002592/67086be200002630 (Clps) is missing a cellular component annotation.</li> <li> <p>Recommendation: Add the appropriate cellular location for this activity.</p> </li> <li> <p>Activity flow considerations:</p> </li> <li>While the model shows Rbp2 (molecular carrier) providing input for Lrat (phosphatidylcholine-retinol O-acyltransferase activity), additional connections between other activities could enhance the model's clarity.</li> <li> <p>Recommendation: Consider adding more causal connections between activities to better represent the complete pathway.</p> </li> <li> <p>Complex model readability:</p> </li> <li>The model includes many proteins and activities but could benefit from clearer grouping or organization.</li> <li> <p>Recommendation: Consider organizing related activities in a more structured manner to improve readability.</p> </li> <li> <p>Validation of enzymatic reactions:</p> </li> <li>Some enzymatic reactions like retinyl-palmitate esterase activity (GO:0050253) could benefit from additional literature validation.</li> <li>Recommendation: Additional evidence references for key enzymatic steps would strengthen the model.</li> </ol>"},{"location":"reviews/67086be200002592-Retinoid_Metabolic_Process_3__Mouse__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Retinoid Metabolic Process 3 (Mouse)\" is generally well-constructed and follows GO-CAM best practices. It effectively represents the flow of retinoid metabolism from molecular carrier activities through various enzymatic processes. With the minor improvements suggested above, particularly regarding the protein complex membership and complete input/output annotations, this model would provide an even clearer representation of retinoid metabolism.</p> <p>The model successfully captures the key players in retinoid metabolism and uses appropriate causal connections to show the relationships between different activities. It effectively demonstrates how GO-CAM can be used to model complex metabolic pathways.</p>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/","title":"67086be200002705 Retinoid Metabolic Process 4  Mouse","text":"<p>Let me now examine the key aspects of the GO-CAM model I'm reviewing:</p>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#review-of-go-cam-model-gomodel67086be200002705-retinoid-metabolic-process-4-mouse","title":"Review of GO-CAM Model: gomodel:67086be200002705 \"Retinoid Metabolic Process 4 (Mouse)\"","text":""},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#overview","title":"Overview","text":"<p>This model represents the retinoid metabolic process in mouse, focusing on the mechanisms by which retinoids (vitamin A and its derivatives) are processed, transported, and metabolized. The model includes various proteins involved in this pathway, such as lipoprotein lipase (Lpl), retinol binding proteins (Rbp1, Rbp2), alcohol dehydrogenase (Adh1), lecithin retinol acyltransferase (Lrat), and other enzymes that participate in retinoid metabolism.</p>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#strengths","title":"Strengths","text":"<ol> <li>Appropriate evidence citations: The model includes evidence from peer-reviewed literature with proper citation of PMIDs.</li> <li>Detailed molecular activities: The model captures specific molecular activities like lipoprotein lipase activity, retinol binding, retinol dehydrogenase activity, and retinyl-palmitate hydrolase activity.</li> <li>Appropriate causal connections: The model shows appropriate causal relationships using relation predicates like \"provides input for\" (RO:0002413) and \"directly negatively regulates\" (RO:0002630).</li> <li>Proper context annotations: Activities are properly contextualized with cellular locations (e.g., occurs_in GO:0005576 - extracellular region, GO:0005829 - cytosol) and biological processes (part_of GO:0001523 - retinoid metabolic process).</li> </ol>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":""},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#1-complex-representation","title":"1. Complex Representation","text":"<p>In the model, there is a chylomicron complex (GO:0042627) that enables retinoid binding. According to the \"How to annotate complexes in GO-CAM\" guidelines, when the specific subunit carrying the activity is not known, using the GO complex term is appropriate. However, the complex is represented with \"members: []\" - an empty list. It would be helpful to annotate the known components of this complex if available.</p>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#2-molecular-carrier-activities","title":"2. Molecular Carrier Activities","text":"<p>The model includes several proteins involved in retinol binding and transport. According to the \"Molecular carrier activity\" guidelines, carrier proteins that transport small molecules should use: - \"has input\" relation for the transported molecule - \"has output\" relation so the small molecule can be input for the next reaction</p> <p>While some of these relationships are present, others could be more clearly defined. For instance, the model shows Rbp1 (MGI:MGI:97876) with all-trans-retinol binding activity, but the complete carrier pathway could be more explicitly modeled.</p>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#3-inputoutput-relationships","title":"3. Input/Output Relationships","text":"<p>Some molecular functions have inputs or outputs specified, but others do not. For complete pathway modeling, it would be beneficial to ensure all relevant inputs and outputs are captured. For example: - Activity 67086be200002723 has appropriate input (CHEBI:17336 - all-trans-retinol) - Activity 67086be200002729 has primary input as CHEBI:17898 (all-trans-retinal) - However, some intermediary activities could have more clearly defined inputs/outputs</p>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#4-evidence-base","title":"4. Evidence Base","text":"<p>While the model uses evidence from multiple PMIDs, examining one of the key papers (PMID:23362116) reveals important mechanistic details about the role of cellular retinol-binding protein (CRBP1/Rbp1) in regulating retinoid metabolism. These mechanistic details from the literature support the model but could be more completely captured in some of the relationships.</p>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#biological-consistency-check","title":"Biological Consistency Check","text":"<p>The model represents retinoid metabolism from the initial processing of retinoids by lipoprotein lipase, through binding by carrier proteins, to conversion between different retinoid forms (retinol, retinal, retinoic acid) by appropriate enzymes. This is consistent with what is known about retinoid metabolism:</p> <ol> <li>Retinoids are transported in circulation as retinyl esters in chylomicrons</li> <li>Retinyl esters can be hydrolyzed to retinol</li> <li>Retinol is bound by cellular retinol binding proteins</li> <li>Retinol can be oxidized to retinal by retinol dehydrogenases</li> <li>Retinal can be further oxidized to retinoic acid</li> <li>Retinol can also be esterified for storage</li> </ol> <p>These key steps are included in the model, supporting its biological accuracy.</p>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#recommendations","title":"Recommendations","text":"<ol> <li>Consider adding more detail to the chylomicron complex representation if component information is available.</li> <li>Review and ensure all carrier activities follow the molecular carrier activity guidelines, with clear input/output relationships.</li> <li>Complete any missing input/output annotations for intermediate steps in the pathway.</li> <li>Consider adding more detailed annotations about the role of Rbp1 in regulating retinoid homeostasis, as supported by the literature evidence.</li> </ol>"},{"location":"reviews/67086be200002705-Retinoid_Metabolic_Process_4__Mouse__/#conclusion","title":"Conclusion","text":"<p>Overall, the model \"Retinoid Metabolic Process 4 (Mouse)\" (gomodel:67086be200002705) is a well-constructed representation of retinoid metabolism that follows most GO-CAM best practices. With the suggested improvements, particularly in complex representation and carrier protein modeling, the model could provide an even more complete picture of retinoid metabolism.</p> <p>The model correctly captures the flow of retinoids from extracellular transport to cellular processing and metabolism, with appropriate causal connections between activities, making it a valuable resource for understanding retinoid metabolism in mouse.</p>"},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/","title":"MGI MGI 109482 Cacna1a  MGI MGI 109482","text":"<p>Based on my review of the GO-CAM model for MGI_MGI_109482 and the relevant guidelines and related information, I'll now provide a detailed review of the model.</p>"},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/#go-cam-model-review-cacna1a-mgimgi109482","title":"GO-CAM Model Review: Cacna1a (MGI:MGI:109482)","text":""},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/#summary","title":"Summary","text":"<p>This GO-CAM model (gomodel:MGI_MGI_109482) represents the mouse Cacna1a gene, which encodes a voltage-dependent P/Q-type calcium channel subunit alpha-1A. The model primarily documents the molecular activities of this calcium channel, its cellular locations, and some causal relationships with other proteins.</p>"},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/#model-overview","title":"Model Overview","text":"<p>The model describes the Cacna1a protein's primary function as a voltage-gated calcium channel (GO:0005245) and high voltage-gated calcium channel (GO:0008331), occurring in various neuronal cell types. It also shows some causal relationships between Cacna1a and other proteins in signaling pathways.</p>"},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/#strengths","title":"Strengths","text":"<ol> <li>Comprehensive molecular function annotation: The model appropriately captures the primary molecular function of Cacna1a as a voltage-gated calcium channel.</li> <li>Detailed cellular location information: The model includes annotations for cellular locations where Cacna1a functions, including specific neuron types like Purkinje cells (CL:0000121) and granule cells (CL:0000120).</li> <li>Evidence-based assertions: Each annotation is supported by literature evidence with appropriate ECO codes and PubMed references.</li> <li>Some causal relationships: The model includes some causal relationships showing how Cacna1a activity affects other proteins in signaling pathways.</li> </ol>"},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Redundant annotations: There are many redundant annotations for the same molecular function (GO:0003674 - molecular_function) with different evidence codes. These should be consolidated to improve model clarity.</p> </li> <li> <p>Limited causal relationships: Given the importance of this calcium channel in various signaling pathways, the model would benefit from more detailed causal relationships showing how its activity connects to downstream processes.</p> </li> <li> <p>Pathway context: While the model shows some relationships with Penk (MGI:MGI:104629), Sst (MGI:MGI:98326), and Cck (MGI:MGI:88297), the broader biological pathway context could be more clearly defined.</p> </li> <li> <p>Complex representation: As a voltage-gated calcium channel, Cacna1a typically functions as part of a multi-subunit complex. According to the UniProt entry, \"Voltage-dependent calcium channels are multisubunit complexes, consisting of alpha-1, alpha-2, beta and delta subunits in a 1:1:1:1 ratio.\" The model would benefit from representing these interactions according to the guidelines for representing complexes in GO-CAM.</p> </li> <li> <p>Molecular mechanism details: The model could include more details about how the channel functions mechanistically (e.g., voltage sensing, conformational changes) based on the UniProt information about the S4 segments functioning as voltage sensors.</p> </li> <li> <p>Biological process context: While there are some part_of relationships to biological processes, the model would benefit from more explicit connections to the various biological processes listed in UniProt (e.g., calcium ion transport, neurotransmitter release, etc.).</p> </li> </ol>"},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/#specific-causal-relationship-review","title":"Specific Causal Relationship Review","text":"<p>The model includes three causal relationship instances:</p> <ol> <li>Cacna1a (GO:0008331) -[RO:0002305]\u2192 Cck (GO:0048018)</li> <li> <p>This represents a negative causal relationship where Cacna1a activity negatively affects Cck receptor ligand activity.</p> </li> <li> <p>Cacna1a (GO:0008331) -[RO:0002305]\u2192 Sst (GO:0048018)</p> </li> <li> <p>This represents a negative causal relationship where Cacna1a activity negatively affects Sst receptor ligand activity.</p> </li> <li> <p>Cacna1a (GO:0008331) -[RO:0002305]\u2192 Penk (GO:0048018)</p> </li> <li>This represents a negative causal relationship where Cacna1a activity negatively affects Penk receptor ligand activity.</li> </ol> <p>Additionally, there's a causal relationship with Cstl1 (GO:0008234) -[RO:0002629]\u2192 Penk (GO:0048018), showing how Cstl1 peptidase activity directly positively regulates Penk activity.</p> <p>These causal relationships use appropriate relation ontology terms but would benefit from more context and intermediate steps to better describe the complete signaling pathways.</p>"},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Consolidate redundant annotations: Remove duplicate GO:0003674 annotations and keep only the most specific molecular function terms with the strongest evidence.</p> </li> <li> <p>Enhance complex representation: Add representations of the other subunits of the calcium channel complex and their interactions with Cacna1a.</p> </li> <li> <p>Expand causal relationships: Add more detail to the existing causal relationships and include additional ones that reflect the diverse roles of this calcium channel in neuronal signaling.</p> </li> <li> <p>Add biological process context: Create more explicit connections to biological processes such as calcium ion transport, neurotransmitter release, and synaptic transmission.</p> </li> <li> <p>Include cellular component information: Add information about the localization of the channel to specific neuronal structures such as synapses and dendrites as mentioned in UniProt.</p> </li> <li> <p>Review pathway completeness: Ensure that the signaling pathways involving Penk, Sst, and Cck are completely represented with all intermediate steps.</p> </li> </ol>"},{"location":"reviews/MGI_MGI_109482-Cacna1a__MGI_MGI_109482_/#conclusion","title":"Conclusion","text":"<p>The current GO-CAM model for Cacna1a provides a solid foundation but would benefit from additional details about its molecular interactions, complex formation, and role in broader biological processes. By addressing the recommendations above, the model would provide a more comprehensive and informative representation of Cacna1a's functions and would better follow GO-CAM best practices.</p>"},{"location":"reviews/YeastPathways_GLUCONEO-PWY-1-gluconeogenesis_I___imported_from__Saccharomyces_Genome_Database/","title":"YeastPathways GLUCONEO PWY 1 gluconeogenesis I   imported from  Saccharomyces Genome Database","text":"<p>Now, let me review the Yeast Gluconeogenesis GO-CAM model (gomodel:YeastPathways_GLUCONEO-PWY-1) based on the available information. Here's my evaluation:</p>"},{"location":"reviews/YeastPathways_GLUCONEO-PWY-1-gluconeogenesis_I___imported_from__Saccharomyces_Genome_Database/#go-cam-model-review-yeast-gluconeogenesis-pathway-gomodelyeastpathways_gluconeo-pwy-1","title":"GO-CAM Model Review: Yeast Gluconeogenesis Pathway (gomodel:YeastPathways_GLUCONEO-PWY-1)","text":""},{"location":"reviews/YeastPathways_GLUCONEO-PWY-1-gluconeogenesis_I___imported_from__Saccharomyces_Genome_Database/#general-model-information","title":"General Model Information","text":"<ul> <li>Title: \"gluconeogenesis I - imported from: Saccharomyces Genome Database\"</li> <li>Taxon: NCBITaxon:559292 (Saccharomyces cerevisiae S288C)</li> <li>Status: Production</li> <li>Source: Imported from Saccharomyces Genome Database (SGD)</li> </ul>"},{"location":"reviews/YeastPathways_GLUCONEO-PWY-1-gluconeogenesis_I___imported_from__Saccharomyces_Genome_Database/#model-structure-assessment","title":"Model Structure Assessment","text":""},{"location":"reviews/YeastPathways_GLUCONEO-PWY-1-gluconeogenesis_I___imported_from__Saccharomyces_Genome_Database/#strengths","title":"Strengths:","text":"<ol> <li> <p>Comprehensive Pathway Coverage: The model represents the entire gluconeogenesis pathway with 16 activity nodes, covering all major enzymatic steps from pyruvate to glucose-6-phosphate.</p> </li> <li> <p>Proper Cellular Compartmentalization: Activities are correctly localized, with most occurring in the cytosol (GO:0005829) and some in mitochondria (GO:0005739) where appropriate.</p> </li> <li> <p>Complete Information for Reactions: Each enzyme activity includes appropriate inputs (substrates) and outputs (products), with all molecular entities properly identified with ChEBI terms.</p> </li> <li> <p>Process Annotation: All activities are correctly annotated as part of the gluconeogenesis process (GO:0006094).</p> </li> <li> <p>Gene Product Specificity: Each activity is enabled by specific yeast gene products with SGD identifiers.</p> </li> </ol>"},{"location":"reviews/YeastPathways_GLUCONEO-PWY-1-gluconeogenesis_I___imported_from__Saccharomyces_Genome_Database/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Limited Causal Connectivity: </li> <li>Issue: Most enzymatic steps lack causal relationships (RO:0002413 \"provides input for\") connecting them in the proper sequence. Only a few activities have causal connections.</li> <li> <p>Recommendation: Add causal relationships between all sequential steps to properly represent the flow of the pathway from pyruvate to glucose-6-phosphate.</p> </li> <li> <p>Redundant Activity Representations:</p> </li> <li>Issue: Several enzymes are represented multiple times with identical functions (e.g., three instances of GAPOXNPHOSPHN-RXN for glyceraldehyde-3-phosphate dehydrogenase with different gene products).</li> <li> <p>Recommendation: Consider using protein complexes where appropriate or at least link the redundant activities to show they catalyze the same step.</p> </li> <li> <p>Inconsistent Evidence Documentation:</p> </li> <li>Issue: All evidence is cited as ECO:0000313 (imported information) without specific literature references beyond the SGD pathway.</li> <li> <p>Recommendation: Add primary literature citations where possible to strengthen the evidence basis.</p> </li> <li> <p>Mitochondrial Malate Dehydrogenase Connectivity:</p> </li> <li>Issue: There are two representations of L-malate dehydrogenase (NAD+) activity (MAE1 - both in the mitochondrion), but their connectivity to the rest of the pathway isn't fully established.</li> <li> <p>Recommendation: Clarify the role of mitochondrial activities in the pathway by adding appropriate transporters and causal relationships.</p> </li> <li> <p>Missing Regulatory Information:</p> </li> <li>Issue: The model lacks any regulatory information about the pathway.</li> <li>Recommendation: Consider adding key regulatory influences on gluconeogenesis, such as inhibition by insulin signaling or activation during fasting states.</li> </ol>"},{"location":"reviews/YeastPathways_GLUCONEO-PWY-1-gluconeogenesis_I___imported_from__Saccharomyces_Genome_Database/#comparison-with-mouse-gluconeogenesis-model","title":"Comparison with Mouse Gluconeogenesis Model","text":"<p>The mouse model (gomodel:61e0e55600001225) has several features that could enhance the yeast model:</p> <ol> <li> <p>Complete Causal Connectivity: The mouse model fully connects all activities with causal relationships, clearly showing the pathway flow.</p> </li> <li> <p>Transport Mechanisms: The mouse model includes transport mechanisms between compartments (e.g., malate transport across mitochondrial membrane).</p> </li> <li> <p>Stronger Evidence Base: The mouse model includes diverse evidence codes with specific PMID references for each activity.</p> </li> </ol>"},{"location":"reviews/YeastPathways_GLUCONEO-PWY-1-gluconeogenesis_I___imported_from__Saccharomyces_Genome_Database/#overall-assessment","title":"Overall Assessment","text":"<p>The Yeast Gluconeogenesis GO-CAM model is scientifically accurate in terms of the enzymes, substrates, products, and cellular locations. It provides a good representation of the pathway components but falls short in representing the pathway structure and flow. The model would benefit significantly from adding causal connections between the enzymatic steps to properly represent the sequential nature of gluconeogenesis.</p> <p>The model appears to be an automated import from SGD rather than a manually curated model, which explains some of its limitations. For it to be maximally useful, manual curation to add causal relationships and consolidate redundant activities would greatly enhance its utility as a knowledge representation.</p>"},{"location":"reviews/YeastPathways_P4-PWY-1-superpathway_of_threonine_and_methionine_biosynthesis___imported_from__Saccharomyces_Genome_Database/","title":"YeastPathways P4 PWY 1 superpathway of threonine and methionine biosynthesis   imported from  Saccharomyces Genome Database","text":"<p>Based on my review of the GO-CAM model \"gomodel:YeastPathways_P4-PWY-1\" for the superpathway of threonine and methionine biosynthesis, here is my evaluation:</p>"},{"location":"reviews/YeastPathways_P4-PWY-1-superpathway_of_threonine_and_methionine_biosynthesis___imported_from__Saccharomyces_Genome_Database/#go-cam-review-superpathway-of-threonine-and-methionine-biosynthesis","title":"GO-CAM Review: Superpathway of threonine and methionine biosynthesis","text":""},{"location":"reviews/YeastPathways_P4-PWY-1-superpathway_of_threonine_and_methionine_biosynthesis___imported_from__Saccharomyces_Genome_Database/#model-overview","title":"Model Overview:","text":"<p>This model (gomodel:YeastPathways_P4-PWY-1) represents the superpathway of threonine and methionine biosynthesis in yeast (Saccharomyces cerevisiae). It was imported from the Saccharomyces Genome Database (SGD) and contains 11 activities with 52 objects.</p>"},{"location":"reviews/YeastPathways_P4-PWY-1-superpathway_of_threonine_and_methionine_biosynthesis___imported_from__Saccharomyces_Genome_Database/#strengths","title":"Strengths:","text":"<ol> <li>Comprehensive pathway representation: The model includes key enzymes involved in threonine and methionine biosynthesis with appropriate genes enabling the activities.</li> <li>Detailed molecular inputs/outputs: Each enzyme activity has clearly defined inputs (substrates) and outputs (products), following biochemical principles.</li> <li>Cellular localization: All activities are correctly annotated as occurring in the cytosol (GO:0005829), which is appropriate for this pathway in yeast.</li> <li>Consistent biological process annotation: All activities are annotated as part of threonine metabolic process (GO:0006566).</li> <li>Proper evidence codes: All annotations use ECO:0000313 (imported information used in automatic assertion) with appropriate references.</li> </ol>"},{"location":"reviews/YeastPathways_P4-PWY-1-superpathway_of_threonine_and_methionine_biosynthesis___imported_from__Saccharomyces_Genome_Database/#issues-identified","title":"Issues Identified:","text":"<ol> <li>Causal connectivity is incomplete: While some activities have causal connections using RO:0002411 (\"functionally upstream of\"), many activities in the pathway lack these connections. For example:</li> <li>ASPARTATE-SEMIALDEHYDE-DEHYDROGENASE-RXN should be causally connected to HOMOSERDEHYDROG-RXN</li> <li>HOMOSERDEHYDROG-RXN should be causally connected to HOMOSERINE-O-ACETYLTRANSFERASE-RXN or HOMOSERKIN-RXN depending on the branch</li> <li> <p>THRESYN-RXN lacks causal connections to upstream reactions</p> </li> <li> <p>Duplicate annotation: There are two instances of ASPAMINOTRANS-RXN (aspartate aminotransferase) with identical functions but enabled by different gene products (SGD:S000004017/AAT2 and SGD:S000001589/AAT1). While both enzymes exist, their redundant representation without differentiation (e.g., in subcellular localization or regulation) may confuse users about their biological roles.</p> </li> <li> <p>Missing pathway branch annotation: While the model has \"superpathway of threonine and methionine biosynthesis\" in the title, the activities are all annotated to \"threonine metabolic process\" (GO:0006566) rather than also including methionine metabolic process (GO:0006555) for the methionine branch.</p> </li> <li> <p>Predicate usage: The model uses RO:0002411 (\"functionally upstream of\") for causal connections, but according to GO-CAM guidelines, pathway steps should preferably use RO:0002413 (\"provides input for\") to represent direct substrate-product relationships.</p> </li> <li> <p>Pathway context: While this is a \"superpathway,\" it would benefit from higher-level process annotations that connect this pathway to larger cellular metabolic networks or biological processes.</p> </li> </ol>"},{"location":"reviews/YeastPathways_P4-PWY-1-superpathway_of_threonine_and_methionine_biosynthesis___imported_from__Saccharomyces_Genome_Database/#recommendations","title":"Recommendations:","text":"<ol> <li> <p>Complete causal connections: Add missing causal links between activities to represent the complete pathway flow. Use RO:0002413 (\"provides input for\") to connect sequential enzymatic reactions.</p> </li> <li> <p>Distinguish duplicate enzymes: For the duplicate ASPAMINOTRANS-RXN activities, add additional annotations to differentiate their roles (e.g., different regulatory contexts or expression patterns).</p> </li> <li> <p>Add methionine process annotation: Activities in the methionine biosynthesis branch should also be annotated with GO:0006555 (methionine metabolic process).</p> </li> <li> <p>Add pathway context: Consider adding higher-level process annotations to relate this pathway to amino acid biosynthesis generally or to cellular responses like amino acid starvation.</p> </li> <li> <p>Consider pathway branching: Make the branching of the pathway (into threonine and methionine branches) more explicit through additional annotations or comments.</p> </li> </ol>"},{"location":"reviews/YeastPathways_P4-PWY-1-superpathway_of_threonine_and_methionine_biosynthesis___imported_from__Saccharomyces_Genome_Database/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model provides a good representation of the threonine and methionine biosynthesis pathway but would benefit from more complete causal connections between activities and clearer process annotations to distinguish the different branches of the pathway. The model follows most GO-CAM guidelines but could be improved for increased biological clarity and utility.</p>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/","title":"YeastPathways PWY 5084 2 oxoglutarate decarboxylation to succinyl CoA   imported from  Saccharomyces Genome Database","text":"<p>Now that I have gathered relevant information about the GO-CAM model for \"2-oxoglutarate decarboxylation to succinyl-CoA\" (gomodel:YeastPathways_PWY-5084), I'll review it comprehensively based on GO-CAM best practices.</p>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#review-of-go-cam-model-yeastpathways_pwy-5084","title":"Review of GO-CAM Model: YeastPathways_PWY-5084","text":""},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the 2-oxoglutarate decarboxylation to succinyl-CoA pathway in Saccharomyces cerevisiae (baker's yeast). The model was imported from the Saccharomyces Genome Database (SGD) and depicts three key activities involved in this fundamental biochemical process in the TCA cycle.</p>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#model-structure-and-connections","title":"Model Structure and Connections","text":"<p>The model contains three main activities carried out by the following gene products: 1. KGD1 (SGD:S000001387) - oxoglutarate dehydrogenase activity (GO:0004591) 2. KGD2 (SGD:S000002555) - dihydrolipoyllysine-residue succinyltransferase activity (GO:0004149) 3. LPD1 (SGD:S000001876) - dihydrolipoyl dehydrogenase activity (GO:0004148)</p> <p>These activities are properly connected through causal associations using the predicate RO:0002411 (causally upstream of), forming a logical biochemical cascade: - KGD1 activity is causally upstream of KGD2 - KGD2 activity is causally upstream of LPD1</p>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#annotation-quality","title":"Annotation Quality","text":"<ul> <li>Evidence codes: Appropriate evidence codes are used (ECO:0000313 for imported information, ECO:0000315 for mutant phenotype evidence, ECO:0000304 for author statements, and ECO:0007005 for high-throughput assays)</li> <li>Literature support: Multiple PMID references are cited (3528755, 2115121, 9175438, 16823961)</li> <li>Cellular location: All activities are correctly annotated to occur in the mitochondrion (GO:0005739)</li> <li>Biological process association: All activities are part of cellular respiration (GO:0045333)</li> </ul>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#molecular-inputs-and-outputs","title":"Molecular Inputs and Outputs","text":"<p>The model properly captures the substrate-product relationships with inputs and outputs for each activity:</p> <ol> <li>2OXOGLUTDECARB-RXN (KGD1):</li> <li>Inputs: hydron (CHEBI:15378), 2-oxoglutarate (CHEBI:16810), chemical entity (CHEBI:24431)</li> <li> <p>Outputs: chemical entity (CHEBI:24431), carbon dioxide (CHEBI:16526)</p> </li> <li> <p>RXN0-1147 (KGD2):</p> </li> <li>Inputs: coenzyme A (CHEBI:57287), chemical entity (CHEBI:24431)</li> <li> <p>Outputs: chemical entity (CHEBI:24431), succinyl-CoA (CHEBI:57292)</p> </li> <li> <p>RXN-7716 (LPD1):</p> </li> <li>Inputs: NAD (CHEBI:57540), chemical entity (CHEBI:24431)</li> <li>Outputs: hydron (CHEBI:15378), NADH (CHEBI:57945), chemical entity (CHEBI:24431)</li> </ol>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#biological-assessment","title":"Biological Assessment","text":"<p>This model accurately represents the 2-oxoglutarate dehydrogenase complex (OGDC), a critical multienzyme complex in the TCA cycle. Based on the referenced literature:</p> <ol> <li> <p>The three-step enzymatic reaction is properly represented with the correct enzymes in the appropriate order.</p> </li> <li> <p>Based on PMID:3528755, LPD1 is correctly identified as the lipoamide dehydrogenase component, which affects both 2-oxoglutarate dehydrogenase and pyruvate dehydrogenase activities. The paper demonstrates that mutation in LPD1 abolishes the activities of both enzymes.</p> </li> <li> <p>Based on PMID:2115121, KGD2 is correctly identified as the dihydrolipoyl transsuccinylase component (E2) of the complex.</p> </li> <li> <p>Based on PMID:9175438, KGD1 is correctly identified as the oxoglutarate dehydrogenase component.</p> </li> <li> <p>The mitochondrial localization of all three components is well-supported by PMID:16823961, which includes these proteins in the mitochondrial proteome.</p> </li> <li> <p>All activities are correctly annotated as part of cellular respiration (GO:0045333).</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>Based on the GO-CAM annotation guidelines, this model follows best practices:</p> <ol> <li> <p>Causal connections: The activities are properly connected using appropriate causal predicates.</p> </li> <li> <p>Evidence and references: Each assertion includes appropriate evidence codes and is linked to published literature.</p> </li> <li> <p>Cellular context: The activities are properly localized to the mitochondrion.</p> </li> <li> <p>Inputs and outputs: Each activity has properly annotated inputs and outputs.</p> </li> <li> <p>Complex annotation: The model follows the guideline for complexes where each subunit of the 2-oxoglutarate dehydrogenase complex has a defined activity. Rather than representing the complex as a whole, each component is represented with its specific molecular function, which is the preferred approach when individual activities are known (as specified in \"How to annotate complexes in GO-CAM\").</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is scientifically accurate and well-structured, a few minor improvements could be considered:</p> <ol> <li> <p>Chemical entity annotation: The generic \"chemical entity\" (CHEBI:24431) appears as both input and output in all activities, which is somewhat vague. This could potentially be replaced with more specific chemical entities if the exact cofactors or intermediate metabolites are known.</p> </li> <li> <p>Biological process annotation: While cellular respiration is correct, it might be helpful to also annotate these activities to the more specific \"tricarboxylic acid cycle\" (GO:0006099) biological process.</p> </li> <li> <p>Additional complex information: While the model correctly follows the guideline for annotating complexes with known activities for each subunit, it might be helpful to explicitly note that these three proteins form the 2-oxoglutarate dehydrogenase complex.</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY-5084-2_oxoglutarate_decarboxylation_to_succinyl_CoA___imported_from__Saccharomyces_Genome_Database/#conclusion","title":"Conclusion","text":"<p>Overall, the GO-CAM model \"YeastPathways_PWY-5084\" is scientifically accurate, well-structured, and follows GO-CAM best practices. It correctly represents the 2-oxoglutarate decarboxylation to succinyl-CoA pathway with appropriate relationships between activities, proper evidence codes, and accurate biochemical inputs and outputs. The three enzymes of the 2-oxoglutarate dehydrogenase complex are properly represented with their specific activities, following the guideline for annotating complexes where the activity of each subunit is known.</p> <p>The model is supported by multiple literature references that confirm both the enzymatic functions and the mitochondrial localization of these proteins, making it a reliable representation of this important biochemical pathway in yeast.</p>"},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/","title":"YeastPathways PWY3O 20 folate polyglutamylation   imported from  Saccharomyces Genome Database","text":"<p>Based on my review of the GO-CAM model \"gomodel:YeastPathways_PWY3O-20\" representing folate polyglutamylation in Saccharomyces cerevisiae, I'll now provide a comprehensive assessment of the model's quality and adherence to GO-CAM best practices.</p>"},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/#go-cam-review-folate-polyglutamylation-gomodelyeastpathways_pwy3o-20","title":"GO-CAM Review: Folate Polyglutamylation (gomodel:YeastPathways_PWY3O-20)","text":""},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/#overview","title":"Overview","text":"<p>The model represents the folate polyglutamylation pathway in yeast (Saccharomyces cerevisiae), which is important for one-carbon metabolism. This pathway involves the addition of multiple glutamate molecules to folate derivatives, making them more effective coenzymes and preventing their efflux from cells.</p>"},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/#model-structure-assessment","title":"Model Structure Assessment","text":""},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/#strengths","title":"Strengths:","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures the key enzymatic activities in the folate polyglutamylation pathway, including dihydrofolate synthase (Fol3p/FOL3), dihydrofolate reductase (Dfr1p/DFR1), and folylpolyglutamate synthase (Met7p/MET7).</p> </li> <li> <p>Molecular details: The model appropriately includes input and output molecules for each reaction, including ATP, folate derivatives, glutamate, and other relevant metabolites.</p> </li> <li> <p>Subcellular localization: All activities are correctly annotated as occurring in the cytosol (GO:0005829), which is consistent with known folate metabolism in yeast.</p> </li> <li> <p>Biological process annotation: All activities are appropriately linked to the folate metabolic process (GO:0046655).</p> </li> <li> <p>Evidence capture: Each annotation includes evidence codes (ECO:0000313) and references to the source pathway (SGD_PWY:PWY3O-20).</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Limited causal relationships: Only two activities (dihydrofolate synthase and dihydrofolate reductase) have causal relationships defined using RO:0002411 (causally upstream of). The model would better represent the pathway flow if causal relationships were added between all sequential steps.</p> </li> <li> <p>Missing activity connections: Several enzymatic steps are not causally linked, making it difficult to interpret the flow of the pathway. For example, there are no causal connections between many of the folylpolyglutamate synthase (Met7p) activities.</p> </li> <li> <p>Redundant activity annotations: The model contains multiple instances of the same enzyme activities (e.g., multiple nodes for folylpolyglutamate synthase activity by MET7/SGD:S000005767) that appear to represent different reaction instances but aren't clearly distinguished in their roles.</p> </li> <li> <p>No regulatory relationships: The model lacks any regulatory relationships (using RO:0002629 or RO:0002630), which might be important for understanding pathway control.</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/#technical-content-assessment","title":"Technical Content Assessment","text":"<ol> <li> <p>Gene product annotation: The model correctly uses SGD identifiers for yeast proteins (e.g., SGD:S000005767 for Met7p).</p> </li> <li> <p>Chemical entities: The model uses appropriate ChEBI identifiers for all small molecules.</p> </li> <li> <p>Evidence codes: The model consistently uses ECO:0000313 (imported information used in automatic assertion) with appropriate provenance tracking.</p> </li> <li> <p>Biological alignment: The enzymatic activities in the model align with the known biochemistry of folate polyglutamylation in yeast, as confirmed by literature and SGD pathway resources.</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add causal connections: Connect all activities in the pathway with appropriate causal relationships (RO:0002411 - causally upstream of) to show the flow of the pathway.</p> </li> <li> <p>Clarify redundant activities: Either consolidate redundant activities or clearly differentiate their specific roles in the pathway (e.g., different substrates or products).</p> </li> <li> <p>Consider adding regulatory relationships: If known from literature, include any regulatory relationships that affect the pathway.</p> </li> <li> <p>Add more specific evidence: Consider strengthening evidence by including specific experimental references beyond the general pathway citation.</p> </li> <li> <p>Improve model parsimony: The current model has some redundancy in representation. A more streamlined model with clearer causal connections would improve human readability while maintaining biological accuracy.</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY3O-20-folate_polyglutamylation___imported_from__Saccharomyces_Genome_Database/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"gomodel:YeastPathways_PWY3O-20\" provides a good representation of the folate polyglutamylation pathway in yeast. It includes the key enzymatic activities, molecular inputs/outputs, and correct subcellular localization. The main areas for improvement involve enhancing the causal connections between activities to better represent pathway flow and reducing redundancy in activity representation. With these improvements, the model would provide a more complete and easier-to-interpret representation of this important metabolic pathway.</p>"},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/","title":"YeastPathways PWY3O 4158 superpathway of NAD biosynthesis   imported from  Saccharomyces Genome Database","text":"<p>Now let me review this GO-CAM model. The model represents the superpathway of NAD biosynthesis in yeast (Saccharomyces cerevisiae). I'll assess various aspects of the model according to GO-CAM best practices and biological accuracy.</p>"},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/#model-overview","title":"Model Overview","text":"<p>Title: \"superpathway of NAD biosynthesis - imported from: Saccharomyces Genome Database\" ID: gomodel:YeastPathways_PWY3O-4158 Taxon: NCBITaxon:559292 (Saccharomyces cerevisiae S288C) Status: production Source: Imported from Saccharomyces Genome Database (SGD)</p>"},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/#quality-control-review","title":"Quality Control Review","text":""},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/#1-completeness-and-biological-accuracy","title":"1. Completeness and Biological Accuracy","text":"<ul> <li>The model captures the NAD biosynthesis pathway from multiple precursors including the de novo pathway (from tryptophan) and salvage pathways (from nicotinamide, nicotinic acid, and nicotinamide riboside).</li> <li>All activities are properly associated with the general biological process GO:0009435 (NAD biosynthetic process).</li> <li>All activities are correctly located in GO:0005829 (cytosol).</li> <li>Each gene product is associated with appropriate molecular functions that match their known biochemical roles.</li> <li>Input and output molecules are properly specified for each reaction with appropriate CHEBI identifiers.</li> </ul>"},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/#2-compliance-with-go-cam-best-practices","title":"2. Compliance with GO-CAM Best Practices","text":"<ul> <li>Gene Product Representation: Each activity is enabled by a specific gene product from SGD.</li> <li>Molecular Functions: Appropriate molecular function terms are used (e.g., GO:0004516 for nicotinate phosphoribosyltransferase activity).</li> <li>Evidence: All associations have evidence codes (ECO:0000313 - imported information used in automatic assertion) with appropriate references to the source pathway.</li> <li>Provenance: Attribution is provided with contributor information (GOC:sgd_curators).</li> </ul>"},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/#3-model-structure-and-connectivity","title":"3. Model Structure and Connectivity","text":"<ul> <li>There are several causal associations that indicate reaction order in the pathway, using RO:0002411 (causally upstream of) predicate.</li> <li>However, many expected causal connections between activities are missing. The model would benefit from additional causal links to better represent the flow of the pathway.</li> <li>Some activities appear to be duplicated (e.g., gomodel:2.7.7.1-RXN appears twice with different gene products), which may be confusing.</li> </ul>"},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/#4-issues-identified","title":"4. Issues Identified","text":"<ol> <li> <p>Missing Causal Connections: Many expected causal connections between sequential enzymatic steps are not specified.</p> </li> <li> <p>Duplicated Activity IDs: The same activity ID (e.g., gomodel:2.7.7.1-RXN, gomodel:ARYLFORMAMIDASE-RXN, gomodel:NICONUCADENYLYLTRAN-RXN) is used for different gene products, which is potentially confusing.</p> </li> <li> <p>Duplicate Output Molecules: Some activities list the same molecule twice in their outputs (e.g., CHEBI:32544 appears twice as output of gomodel:NICOTINAMID-RXN).</p> </li> <li> <p>Self-referential Causal Association: There is a case where an activity is causally upstream of itself (gomodel:NAD-SYNTH-GLN-RXN), which appears erroneous.</p> </li> <li> <p>Reaction Identifiers: The model uses reaction identifiers (e.g., RXN-8441) as activity IDs rather than more descriptive IDs, which makes the model harder to interpret without additional context.</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add Missing Causal Connections: Complete the causal connections between sequential reactions to better represent the pathway flow.</p> </li> <li> <p>Fix Duplicate Activity IDs: Use unique IDs for each activity instance, even if they represent similar reactions.</p> </li> <li> <p>Remove Duplicate Molecules: Ensure each molecule appears only once in input/output lists.</p> </li> <li> <p>Fix Self-referential Causality: Remove or correct the self-referential causal association in gomodel:NAD-SYNTH-GLN-RXN.</p> </li> <li> <p>Better Document Reaction Steps: Consider adding comments to clarify the different branches of the NAD biosynthesis pathway.</p> </li> <li> <p>Check for Completeness: Verify that all known enzymatic steps in the NAD biosynthesis pathway in yeast are represented.</p> </li> </ol>"},{"location":"reviews/YeastPathways_PWY3O-4158-superpathway_of_NAD_biosynthesis___imported_from__Saccharomyces_Genome_Database/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for the superpathway of NAD biosynthesis from SGD provides a comprehensive representation of the biochemical reactions involved in NAD biosynthesis in yeast. While the model captures the essential components (gene products, molecular functions, cellular locations, and chemical entities), it could be improved by better representing the causal flow of the pathway and addressing the issues with duplicate identifiers and molecule listings.</p> <p>Overall, the model is biologically accurate and follows most GO-CAM best practices, but the connectivity and organizational issues should be addressed to improve its clarity and usefulness.</p>"},{"location":"reviews/YeastPathways_TCA-EUK-PWY-TCA_cycle__aerobic_respiration___imported_from__Saccharomyces_Genome_Database/","title":"YeastPathways TCA EUK PWY TCA cycle  aerobic respiration   imported from  Saccharomyces Genome Database","text":"<p>Let me now provide a detailed review of the GO-CAM model for the yeast TCA cycle (YeastPathways_TCA-EUK-PWY):</p>"},{"location":"reviews/YeastPathways_TCA-EUK-PWY-TCA_cycle__aerobic_respiration___imported_from__Saccharomyces_Genome_Database/#go-cam-review-tca-cycle-yeastpathways_tca-euk-pwy","title":"GO-CAM Review: TCA Cycle (YeastPathways_TCA-EUK-PWY)","text":""},{"location":"reviews/YeastPathways_TCA-EUK-PWY-TCA_cycle__aerobic_respiration___imported_from__Saccharomyces_Genome_Database/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (https://bioregistry.io/go.model:YeastPathways_TCA-EUK-PWY) represents the TCA cycle (tricarboxylic acid cycle, also known as citric acid cycle or Krebs cycle) in Saccharomyces cerevisiae. It was imported from the Saccharomyces Genome Database (SGD) and models the aerobic respiration process (GO:0009060).</p>"},{"location":"reviews/YeastPathways_TCA-EUK-PWY-TCA_cycle__aerobic_respiration___imported_from__Saccharomyces_Genome_Database/#strengths","title":"Strengths","text":"<ol> <li>Comprehensive representation: The model captures all key enzymatic steps of the TCA cycle with appropriate gene products, molecular functions, inputs, and outputs.</li> <li>Cellular localization: Most activities are correctly annotated to occur in the mitochondrion (GO:0005739), which is the correct subcellular location for the TCA cycle.</li> <li>Complex representation: Protein complexes (e.g., succinate dehydrogenase, isocitrate dehydrogenase) are correctly represented according to GO-CAM guidelines, with their component subunits listed.</li> <li>Complete chemical transformations: Each reaction includes appropriate substrate and product molecules with their CHEBI identifiers.</li> </ol>"},{"location":"reviews/YeastPathways_TCA-EUK-PWY-TCA_cycle__aerobic_respiration___imported_from__Saccharomyces_Genome_Database/#issues-identified","title":"Issues Identified","text":"<ol> <li>Inconsistent Causal Relationships:</li> <li>Only a few causal relationships (RO:0002411 \"directly provides input for\") are established between reactions, specifically:<ul> <li>Aconitate hydratase (ACO1) to aconitate dehydratase (ACO2)</li> <li>Succinate-CoA ligase to succinate dehydrogenase</li> <li>2-oxoglutarate dehydrogenase to isocitrate dehydrogenase</li> </ul> </li> <li> <p>The majority of reactions lack causal connections, making it difficult to follow the complete cycle flow.</p> </li> <li> <p>Duplicate Entries:</p> </li> <li>There are duplicate entries for some reactions:<ul> <li>Three separate citrate synthase activities (enabled by CIT1, CIT2, CIT3)</li> <li>Two separate malate dehydrogenase activities (enabled by MDH1, MAE1)</li> <li>Two separate aconitate hydratase activities (enabled by ACO1, ACO2)</li> <li>Two separate pyruvate carboxylase activities (enabled by PYC1, PYC2)</li> </ul> </li> <li> <p>While these may represent isozymes, they are disconnected and not shown as alternative paths in the pathway.</p> </li> <li> <p>Conflicting Cellular Locations:</p> </li> <li>Some TCA cycle enzymes are annotated to the cytosol (GO:0005829) rather than mitochondrion:<ul> <li>Aconitate hydratase (ACO1, ACO2) - in cytosol</li> <li>Pyruvate carboxylase (PYC1, PYC2) - in cytosol</li> </ul> </li> <li> <p>This is inconsistent with the canonical TCA cycle location (mitochondria).</p> </li> <li> <p>Inconsistent Complex Representation:</p> </li> <li>Succinate dehydrogenase complex has two representations with different subunit compositions:<ul> <li>One with SGD:S000218027 (proper complex ID) containing SDH1, SDH2, SDH3, SDH4</li> <li>Another with GO:0032991 (generic complex) containing SDH2, SDH3, SDH4, SDH9</li> </ul> </li> <li> <p>This inconsistency creates confusion about the actual complex composition.</p> </li> <li> <p>Incomplete Activity Flow:</p> </li> <li>The model does not completely represent the cyclic nature of the TCA cycle.</li> <li>Many reactions that should be connected are isolated (e.g., citrate synthase to aconitase).</li> </ol>"},{"location":"reviews/YeastPathways_TCA-EUK-PWY-TCA_cycle__aerobic_respiration___imported_from__Saccharomyces_Genome_Database/#recommendations","title":"Recommendations","text":"<ol> <li>Complete the causal relationships:</li> <li>Add \"directly provides input for\" (RO:0002411) relationships between all consecutive reactions to represent the cycle properly.</li> <li> <p>Ensure the cycle is closed by connecting malate dehydrogenase to citrate synthase.</p> </li> <li> <p>Consolidate duplicate entries:</p> </li> <li>If different isozymes perform the same reaction in the same compartment, use causal relationships to indicate they are alternatives.</li> <li> <p>Alternatively, document in comments why multiple instances of the same reaction are represented.</p> </li> <li> <p>Correct subcellular localization:</p> </li> <li>Review and correct the cellular location annotations to ensure all TCA cycle enzymes are properly localized.</li> <li> <p>If some reactions genuinely occur in the cytosol (e.g., in alternate pathways), this should be clearly documented.</p> </li> <li> <p>Standardize complex representation:</p> </li> <li>Resolve the inconsistency in the succinate dehydrogenase complex representation by using a single consistent complex ID with the correct subunits.</li> <li> <p>Follow the GO-CAM guidelines for complexes (option 1 or 2 from the document).</p> </li> <li> <p>Add biological context:</p> </li> <li>Include additional annotations or comments to explain the biological relevance of certain features (e.g., why some enzymes are in the cytosol).</li> </ol>"},{"location":"reviews/YeastPathways_TCA-EUK-PWY-TCA_cycle__aerobic_respiration___imported_from__Saccharomyces_Genome_Database/#summary","title":"Summary","text":"<p>The GO-CAM model for the yeast TCA cycle provides a valuable representation of this critical metabolic pathway. While it captures most enzymatic steps correctly, it would benefit from improved causal connections between reactions, consistent subcellular localizations, and standardized complex representations. These improvements would make the model more accurate and easier to interpret, especially for researchers unfamiliar with the TCA cycle.</p> <p>The model is consistent with known biochemistry of the TCA cycle but requires refinement in how the enzymes and reactions are connected to fully represent the cycle's flow and compartmentalization.</p>"}]}